PMID-sentid Pub_year Sent_text comp_official_name comp_offset protein_name organism prot_offset 34658963-7 2021 Of the nine groups of treatments included, adjunctive aripiprazole (<5 mg/day) was associated with the most significant reduction in prolactin levels compared to placebo (posterior MD = -65.52, 95% CI = -104.91, -24.08) and the other eight treatment groups. Aripiprazole 54-66 prolactin Homo sapiens 133-142 34658963-9 2021 In addition, when risperidone, amisulpride, and olanzapine were the primary AP medications, adjunctive paeoniae/glycyrrhiza = 1:1, aripiprazole <5 mg/day, and aripiprazole >10 mg/day were the most effective treatments in reducing the prolactin levels, respectively. Risperidone 18-29 prolactin Homo sapiens 234-243 34658963-9 2021 In addition, when risperidone, amisulpride, and olanzapine were the primary AP medications, adjunctive paeoniae/glycyrrhiza = 1:1, aripiprazole <5 mg/day, and aripiprazole >10 mg/day were the most effective treatments in reducing the prolactin levels, respectively. Amisulpride 31-42 prolactin Homo sapiens 234-243 34658963-9 2021 In addition, when risperidone, amisulpride, and olanzapine were the primary AP medications, adjunctive paeoniae/glycyrrhiza = 1:1, aripiprazole <5 mg/day, and aripiprazole >10 mg/day were the most effective treatments in reducing the prolactin levels, respectively. Olanzapine 48-58 prolactin Homo sapiens 234-243 34658963-9 2021 In addition, when risperidone, amisulpride, and olanzapine were the primary AP medications, adjunctive paeoniae/glycyrrhiza = 1:1, aripiprazole <5 mg/day, and aripiprazole >10 mg/day were the most effective treatments in reducing the prolactin levels, respectively. Aripiprazole 131-143 prolactin Homo sapiens 234-243 34658963-9 2021 In addition, when risperidone, amisulpride, and olanzapine were the primary AP medications, adjunctive paeoniae/glycyrrhiza = 1:1, aripiprazole <5 mg/day, and aripiprazole >10 mg/day were the most effective treatments in reducing the prolactin levels, respectively. Aripiprazole 159-171 prolactin Homo sapiens 234-243 34611474-8 2021 Treatment with Imipridones decreased CCL3/MIP-1 alpha, VEGF, CXCL14/BRAK, IL-8/CXCL8, and Prolactin and increased CXCL5/ENA-78. imipridones 15-26 prolactin Homo sapiens 90-99 34540295-0 2021 Prolactin-Secreting Leiomyoma Causing Hyperprolactinaemia Unresponsive to Dopamine Agonist Therapy and Resolution following Myomectomy. Dopamine 74-82 prolactin Homo sapiens 0-9 34089536-7 2021 Patients treated with cabergoline (n = 26) showed a significant increase in LH levels (p = .003) and a significant decrease in prolactin levels (p = .003). Cabergoline 22-33 prolactin Homo sapiens 127-136 34164806-4 2021 Simazine treated corn area was computed as the total simazine load (g) divided by total atrazine load (g ha-1 ), on a treated area basis; atrazine was used as surrogate in the absence of treated area simazine load data. Simazine 0-8 prolactin Homo sapiens 103-109 34106485-7 2021 Atremorine also influences the levels of other neurotransmitters (adrenaline, noradrenaline) and hormones which are regulated by DA (e.g., prolactin, PRL), with no effect on serotonin or histamine. Dopamine 129-131 prolactin Homo sapiens 139-148 34106485-7 2021 Atremorine also influences the levels of other neurotransmitters (adrenaline, noradrenaline) and hormones which are regulated by DA (e.g., prolactin, PRL), with no effect on serotonin or histamine. Dopamine 129-131 prolactin Homo sapiens 150-153 34446277-5 2021 However, the physiologic decline of prolactin levels during menopause and the lack of fertility concerns, which represent specific indications for medical treatment with dopamine agonists, might require a careful reassessment of therapeutic management in such patients. Dopamine 170-178 prolactin Homo sapiens 36-45 34189861-1 2021 AIM: Several reports have shown that risperidone increases prolactin concentrations, while aripiprazole decreases prolactin concentrations. Risperidone 37-48 prolactin Homo sapiens 59-68 34189861-1 2021 AIM: Several reports have shown that risperidone increases prolactin concentrations, while aripiprazole decreases prolactin concentrations. Aripiprazole 91-103 prolactin Homo sapiens 114-123 34189861-6 2021 We compared the prolactin and testosterone levels in patients receiving risperidone or paliperidone and patients receiving aripiprazole. Risperidone 72-83 prolactin Homo sapiens 16-25 34189861-6 2021 We compared the prolactin and testosterone levels in patients receiving risperidone or paliperidone and patients receiving aripiprazole. Paliperidone Palmitate 87-99 prolactin Homo sapiens 16-25 34189861-7 2021 RESULTS: The average serum prolactin concentration was 27.5 +- 13.1 ng/mL for the risperidone group and 3.9 +- 3.5 ng/mL for the aripiprazole group, and the concentrations were significantly different (P < .001). Risperidone 82-93 prolactin Homo sapiens 27-36 34189861-7 2021 RESULTS: The average serum prolactin concentration was 27.5 +- 13.1 ng/mL for the risperidone group and 3.9 +- 3.5 ng/mL for the aripiprazole group, and the concentrations were significantly different (P < .001). Aripiprazole 129-141 prolactin Homo sapiens 27-36 34189861-9 2021 A positive correlation between prolactin levels and the risperidone daily dose was found, whereas a negative correlation between prolactin levels and the aripiprazole daily dose was observed. Risperidone 56-67 prolactin Homo sapiens 31-40 34189861-9 2021 A positive correlation between prolactin levels and the risperidone daily dose was found, whereas a negative correlation between prolactin levels and the aripiprazole daily dose was observed. Aripiprazole 154-166 prolactin Homo sapiens 129-138 34189861-10 2021 In the risperidone group, total testosterone concentrations were correlated with age, while free testosterone concentrations were inversely correlated with age and prolactin levels. Risperidone 7-18 prolactin Homo sapiens 164-173 34189861-10 2021 In the risperidone group, total testosterone concentrations were correlated with age, while free testosterone concentrations were inversely correlated with age and prolactin levels. Testosterone 97-109 prolactin Homo sapiens 164-173 34189861-12 2021 Testosterone concentrations were associated with elevated prolactin levels in patients receiving risperidone or paliperidone. Testosterone 0-12 prolactin Homo sapiens 58-67 34189861-12 2021 Testosterone concentrations were associated with elevated prolactin levels in patients receiving risperidone or paliperidone. Risperidone 97-108 prolactin Homo sapiens 58-67 34189861-12 2021 Testosterone concentrations were associated with elevated prolactin levels in patients receiving risperidone or paliperidone. Paliperidone Palmitate 112-124 prolactin Homo sapiens 58-67 34334349-4 2021 His plasma prolactin level (PRL) dropped after treatment with bromocriptine, and so did his weight. Bromocriptine 62-75 prolactin Homo sapiens 11-20 34334349-4 2021 His plasma prolactin level (PRL) dropped after treatment with bromocriptine, and so did his weight. Bromocriptine 62-75 prolactin Homo sapiens 28-31 34512411-9 2021 AIHP reduction efficacy of vB6 was associated with baseline prolactin and triglyceride levels, total vB6 dosage, and education level. aihp 0-4 prolactin Homo sapiens 60-69 34408155-9 2021 Prolactin levels were higher in women than in men, especially for amisulpride (p < 0.001). Amisulpride 66-77 prolactin Homo sapiens 0-9 34444905-9 2021 Caution is advised for pregnant and lactating women since GABA can affect neurotransmitters and the endocrine system, i.e., increases in growth hormone and prolactin levels. gamma-Aminobutyric Acid 58-62 prolactin Homo sapiens 156-165 34241933-11 2021 Our data fit a speculative model in which elevated maternal stress increases cortisol, which suppresses T3, leading to decreased PRL. Hydrocortisone 77-85 prolactin Homo sapiens 129-132 34438820-8 2021 PRL was negatively correlated with T in both sexes and with P4 and E2 in female geese. propiverine 60-62 prolactin Homo sapiens 0-3 34438820-8 2021 PRL was negatively correlated with T in both sexes and with P4 and E2 in female geese. Estradiol 67-69 prolactin Homo sapiens 0-3 34421613-1 2021 The aim of the study was to assess the relationship between prolactin levels and sexual dysfunction in patients with schizophrenia who use olanzapine medication. Olanzapine 139-149 prolactin Homo sapiens 60-69 34148244-5 2021 AIMS: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics (effect on prolactin and gastric function) of twice-daily trazpiroben (5, 25 and 100 mg) in participants with gastroparesis. Trazpiroben 140-151 prolactin Homo sapiens 93-102 34148244-10 2021 All trazpiroben doses were rapidly absorbed and eliminated (t1/2z 4-5 hours), and D2 /D3 receptor target engagement confirmed by increased serum prolactin (peaking at trazpiroben 25 mg). Trazpiroben 4-15 prolactin Homo sapiens 145-154 34118485-9 2021 In this post hoc analysis, the high levels of prolactin observed at screening decreased during AL treatment, and modest improvements in sexual side effects were evident in patients with schizophrenia. aripiprazole lauroxil 95-97 prolactin Homo sapiens 46-55 34439942-8 2021 We observed decreased levels of prolactin (11.9 ng/mL) and cortisol (87.4 mug/mL) in patients under tacrolimus-based therapy. Tacrolimus 100-110 prolactin Homo sapiens 32-41 34307410-7 2021 However, following a brief period where the patient resumed cabergoline (of her own volition), there was a decrease in serum prolactin with a corresponding decrease in visual ability and increase in radial diffusivity (p < 0.001). Cabergoline 60-71 prolactin Homo sapiens 125-134 34188118-1 2021 In breast cancer, prolactin-induced activation of the transcription factor STAT5a results from the phosphorylation of STAT5a tyrosine residue 694. Tyrosine 125-133 prolactin Homo sapiens 18-27 34200394-7 2021 In turn, Zn2+ added to Biolasol + PRL (PRL: 0.1 microg/L) acted as a prolactin inhibitor. Zinc 9-13 prolactin Homo sapiens 34-37 34200394-7 2021 In turn, Zn2+ added to Biolasol + PRL (PRL: 0.1 microg/L) acted as a prolactin inhibitor. Zinc 9-13 prolactin Homo sapiens 39-56 34200394-7 2021 In turn, Zn2+ added to Biolasol + PRL (PRL: 0.1 microg/L) acted as a prolactin inhibitor. Zinc 9-13 prolactin Homo sapiens 69-78 34200394-7 2021 In turn, Zn2+ added to Biolasol + PRL (PRL: 0.1 microg/L) acted as a prolactin inhibitor. biolasol 23-31 prolactin Homo sapiens 34-37 34200394-7 2021 In turn, Zn2+ added to Biolasol + PRL (PRL: 0.1 microg/L) acted as a prolactin inhibitor. biolasol 23-31 prolactin Homo sapiens 39-56 34200394-7 2021 In turn, Zn2+ added to Biolasol + PRL (PRL: 0.1 microg/L) acted as a prolactin inhibitor. biolasol 23-31 prolactin Homo sapiens 69-78 35243671-4 2022 One of the causes of delayed ejaculation may be elevated prolactin levels, which may be increased by psychosocial stress, pituitary disorders or also treatment with selective serotonin reuptake inhibitors in the treatment of depression. Serotonin 175-184 prolactin Homo sapiens 57-66 34095489-3 2021 Moreover, high prolactin levels lead to decreased testosterone production by disrupting 17-b-estradiol synthesis. Testosterone 50-62 prolactin Homo sapiens 15-24 34095489-3 2021 Moreover, high prolactin levels lead to decreased testosterone production by disrupting 17-b-estradiol synthesis. 17-b-estradiol 88-102 prolactin Homo sapiens 15-24 35525260-6 2022 Preference is given to cabergoline at the lowest possible dose that normalizes PRL, restoring fertility in the vast majority of cases. Cabergoline 23-34 prolactin Homo sapiens 79-82 35123968-10 2022 Based on NCS models, we observed U-shaped associations of urinary DCAA with serum PRGE and PRL; each ln-unit increment in urinary DCAA concentrations above 3.61 mug/L and 6.30 mug/L was associated with 18.9% (95% CI: 4.8%, 34.7%) and 23.3% (95% CI: -0.92%, 53.5%) increase in serum PRGE and PRL, respectively. Dichloroacetic Acid 66-70 prolactin Homo sapiens 91-94 35123968-10 2022 Based on NCS models, we observed U-shaped associations of urinary DCAA with serum PRGE and PRL; each ln-unit increment in urinary DCAA concentrations above 3.61 mug/L and 6.30 mug/L was associated with 18.9% (95% CI: 4.8%, 34.7%) and 23.3% (95% CI: -0.92%, 53.5%) increase in serum PRGE and PRL, respectively. Dichloroacetic Acid 66-70 prolactin Homo sapiens 291-294 35123968-10 2022 Based on NCS models, we observed U-shaped associations of urinary DCAA with serum PRGE and PRL; each ln-unit increment in urinary DCAA concentrations above 3.61 mug/L and 6.30 mug/L was associated with 18.9% (95% CI: 4.8%, 34.7%) and 23.3% (95% CI: -0.92%, 53.5%) increase in serum PRGE and PRL, respectively. Dichloroacetic Acid 130-134 prolactin Homo sapiens 91-94 35123968-10 2022 Based on NCS models, we observed U-shaped associations of urinary DCAA with serum PRGE and PRL; each ln-unit increment in urinary DCAA concentrations above 3.61 mug/L and 6.30 mug/L was associated with 18.9% (95% CI: 4.8%, 34.7%) and 23.3% (95% CI: -0.92%, 53.5%) increase in serum PRGE and PRL, respectively. Dichloroacetic Acid 130-134 prolactin Homo sapiens 291-294 35143036-8 2022 After commencing cabergoline treatment, prolactin concentrations decreased in 5 months and normalized 18 months later, while significant shrinkage of the tumor was observed. Cabergoline 17-28 prolactin Homo sapiens 40-49 35477330-4 2022 In addition to genetic factors, dose, duration and drug-drug interactions of risperidone might also increase the serum prolactin level. Risperidone 77-88 prolactin Homo sapiens 119-128 35622138-0 2022 Effect of different iodine levels on the DNA methylation of PRKAA2, ITGA6, THEM4 and PRL genes in PI3K-AKT signaling pathway and population-based validation from autoimmune thyroiditis patients. Iodine 20-26 prolactin Homo sapiens 85-88 35620917-6 2022 RESULTS: Meta-analysis showed significant decline of total testosterone, free testosterone, dehydroepiandrosterone sulphate, androstenedione, luteinizing hormone (LH), LH to follicle-stimulating hormone (FSH) ratio, and prolactin in statin group. Testosterone 59-71 prolactin Homo sapiens 220-229 35620917-6 2022 RESULTS: Meta-analysis showed significant decline of total testosterone, free testosterone, dehydroepiandrosterone sulphate, androstenedione, luteinizing hormone (LH), LH to follicle-stimulating hormone (FSH) ratio, and prolactin in statin group. Testosterone 78-90 prolactin Homo sapiens 220-229 35591886-0 2022 Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia. cariprazine 19-30 prolactin Homo sapiens 34-43 35591886-2 2022 The effects of cariprazine, a dopamine D3/D2 receptor partial agonist, on prolactin levels in patients with schizophrenia or bipolar I disorder were evaluated. cariprazine 15-26 prolactin Homo sapiens 74-83 35591886-6 2022 Results: In patients with schizophrenia (male, n = 1377; female, n = 558), median prolactin changes were -1.2 for males and -7.4 for females on placebo, and ranged from -4.2 to -3.6 for males and -12.4 to +0.2 for females in the cariprazine-treatment groups. cariprazine 229-240 prolactin Homo sapiens 82-91 35591886-7 2022 In patients with bipolar mania (male, n = 570; female, n = 395), median prolactin changes were -0.2 for males and -1.1 for females on placebo and ranged from -2.1 to -3.0 for males and 0 to +1.8 for females in the cariprazine-treatment groups. cariprazine 214-225 prolactin Homo sapiens 72-81 35591886-9 2022 In patients with bipolar depression (male, n = 485; female, n = 780), median prolactin changes were +0.3 for males and +0.7 for females on placebo and ranged from +0.4 to +0.5 for males and +3.0 to +3.1 for females in the cariprazine-treatment groups. cariprazine 222-233 prolactin Homo sapiens 77-86 35521048-1 2022 Cabergoline is routinely prescribed in the management of prolactin excreting adenomas and is associated with low risk of congenital malformations and teratogenicity. Cabergoline 0-11 prolactin Homo sapiens 57-66 35509763-2 2022 This study aims to compare the serum PRL levels between type 2 diabetes mellitus (T2DM) patients and normoglycaemic volunteers and correlate the serum PRL level with fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated haemoglobin (HbA1c) levels, and the lipid profile in the study population. Glucose 181-188 prolactin Homo sapiens 151-154 35470768-9 2022 Thirdly, if sexolytic compounds cannot be dismissed, such as first-generation antipsychotics, risperidone, paliperidone, or amisulpride, then aripiprazole 5-20 mg/day adjunctive therapy has proven to be most effective in normalizing prolactin levels and consequently treating antipsychotic-induced SD. Aripiprazole 142-154 prolactin Homo sapiens 233-242 35358514-5 2022 We incubated ESCs with cAMP to induce decidualization, and knocked down PPARGC1A to inhibit cAMP-induced expression of IGFBP-1 and PRL. Cyclic AMP 92-96 prolactin Homo sapiens 131-134 35358514-6 2022 We found cAMP increased the recruitment of PGC-1alpha and p300 to C/EBPbeta binding sites in the promoter and enhancer regions of IGFBP1 and PRL, corresponding with increases in H3K27ac. Cyclic AMP 9-13 prolactin Homo sapiens 141-144 35192840-0 2022 Architecture of the two metal-binding sites in prolactin. Metals 24-29 prolactin Homo sapiens 47-56 35192840-3 2022 Here, we investigate metal binding by a GH family member prolactin (PRL) using paramagnetic metal titration and chelation experiments. Metals 21-26 prolactin Homo sapiens 57-66 35192840-3 2022 Here, we investigate metal binding by a GH family member prolactin (PRL) using paramagnetic metal titration and chelation experiments. Metals 21-26 prolactin Homo sapiens 68-71 35192840-3 2022 Here, we investigate metal binding by a GH family member prolactin (PRL) using paramagnetic metal titration and chelation experiments. Metals 92-97 prolactin Homo sapiens 57-66 35192840-3 2022 Here, we investigate metal binding by a GH family member prolactin (PRL) using paramagnetic metal titration and chelation experiments. Metals 92-97 prolactin Homo sapiens 68-71 35192840-4 2022 Cu2+-mediated paramagnetic relaxation enhancement measurements identified two partial metal-binding sites on the opposite faces of PRL composed of residues H30/H180 and E93/H97, respectively. cupric ion 0-4 prolactin Homo sapiens 131-134 35192840-4 2022 Cu2+-mediated paramagnetic relaxation enhancement measurements identified two partial metal-binding sites on the opposite faces of PRL composed of residues H30/H180 and E93/H97, respectively. Metals 86-91 prolactin Homo sapiens 131-134 35192840-5 2022 Coordination of metal ions by these two sites causes formation of inter-molecular bridges between the PRL protomers and enables formation of reversible higher aggregates. Metals 16-21 prolactin Homo sapiens 102-105 35192840-7 2022 The proposed mechanism of metal-promoted PRL aggregation lends insight and support to the previously suggested role of metal coordination in secretory granule formation by GH proteins. Metals 26-31 prolactin Homo sapiens 41-44 35192840-7 2022 The proposed mechanism of metal-promoted PRL aggregation lends insight and support to the previously suggested role of metal coordination in secretory granule formation by GH proteins. Metals 119-124 prolactin Homo sapiens 41-44 35064296-7 2022 PRL-adjusted ACTH IPS/P ratios were > 1.3 in all patients with proven CD; it was 0.7 in the patient with EAS. Phosphorus 22-23 prolactin Homo sapiens 0-3 35064296-9 2022 CONCLUSION: Although PRL-adjusted ACTH IPS/P ratios can be helpful to improve the accuracy of results during IPSS procedures, a prolactin intersinus gradient towards the ACTH-dominant side in patients with CD may invalidate PRL as an indicator of pituitary venous outflow. Phosphorus 43-44 prolactin Homo sapiens 21-24 35526163-0 2022 Effect of the Prolactin Inhibitor Cabergoline and the Gonadotropin Releasing-Hormone Agonist Deslorelin in the Suppression of Plasma Prolactin Concentrations and Egg Laying in Quail (Coturnix japonica). Cabergoline 34-45 prolactin Homo sapiens 14-23 35526163-0 2022 Effect of the Prolactin Inhibitor Cabergoline and the Gonadotropin Releasing-Hormone Agonist Deslorelin in the Suppression of Plasma Prolactin Concentrations and Egg Laying in Quail (Coturnix japonica). Cabergoline 34-45 prolactin Homo sapiens 133-142 35526163-4 2022 The objective of this study was to investigate whether the prolactin inhibitor cabergoline suppresses ovulation and whether it could be used to bridge the time until the onset of effect by the deslorelin implant. Cabergoline 79-90 prolactin Homo sapiens 59-68 35526163-9 2022 Treatment with the deslorelin implant (P < .001) and with cabergoline (P = .04) had a significant (negative) influence on plasma prolactin concentrations compared with the baseline. Cabergoline 58-69 prolactin Homo sapiens 129-138 35526163-11 2022 These results show that daily oral cabergoline has no significant influence on egg laying and only a minor biologically nonsignificant effect on lowering the relative plasma prolactin concentrations in quail. Cabergoline 35-46 prolactin Homo sapiens 174-183 35447036-18 2022 It is vital to assess PRL level and reduce PRL to normal in patients with GM. gm 74-76 prolactin Homo sapiens 22-25 35447036-18 2022 It is vital to assess PRL level and reduce PRL to normal in patients with GM. gm 74-76 prolactin Homo sapiens 43-46 35465073-10 2022 In addition, our findings proved that paeoniflorin increased the absorbance values of ALP-positive cells and the areas of alizarin red S (ARS) deposition compared to those in the prolactin group, suggesting that paeoniflorin reversed the PRL-induced reduction in osteoblast differentiation. peoniflorin 38-50 prolactin Homo sapiens 238-241 35465073-10 2022 In addition, our findings proved that paeoniflorin increased the absorbance values of ALP-positive cells and the areas of alizarin red S (ARS) deposition compared to those in the prolactin group, suggesting that paeoniflorin reversed the PRL-induced reduction in osteoblast differentiation. peoniflorin 212-224 prolactin Homo sapiens 238-241 35465073-11 2022 The PRL-induced activation of nuclear factor kappa B (NF-kappaB) was significantly reversed by paeoniflorin, indicating that paeoniflorin promoted osteoblast function by inhibiting the NF-kappaB signaling pathway. peoniflorin 125-137 prolactin Homo sapiens 4-7 35509763-8 2022 Serum PRL levels were inversely correlated with serum total cholesterol, low-density lipoprotein cholesterol, and triglycerides, but not with high-density lipoprotein cholesterol. Cholesterol 60-71 prolactin Homo sapiens 6-9 35509763-8 2022 Serum PRL levels were inversely correlated with serum total cholesterol, low-density lipoprotein cholesterol, and triglycerides, but not with high-density lipoprotein cholesterol. Triglycerides 114-127 prolactin Homo sapiens 6-9 35509763-2 2022 This study aims to compare the serum PRL levels between type 2 diabetes mellitus (T2DM) patients and normoglycaemic volunteers and correlate the serum PRL level with fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated haemoglobin (HbA1c) levels, and the lipid profile in the study population. Glucose 216-223 prolactin Homo sapiens 151-154 35509763-2 2022 This study aims to compare the serum PRL levels between type 2 diabetes mellitus (T2DM) patients and normoglycaemic volunteers and correlate the serum PRL level with fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated haemoglobin (HbA1c) levels, and the lipid profile in the study population. ppg 225-228 prolactin Homo sapiens 151-154 35220156-13 2022 The increase in prolactin after her NGSOs indicate that they induce the same physiological changes as GSOs and result from "top-down" processing in the brain. gsos 102-106 prolactin Homo sapiens 16-25 35368902-6 2022 Significant reductions in serum levels of PRL, IGF-1, and GH were observed in both groups after treatment, whereas the combined group treated with radiotherapy and TMZ resulted in significantly lower levels compared with the control group (p < 0.05). Temozolomide 164-167 prolactin Homo sapiens 42-45 35350016-8 2022 Furthermore, a maternal uncle was diagnosed with biochemical CCH at 34 years of age, despite having few symptoms, and a complete work-up revealed prolactin deficiency and macroorchidism. 1-acetyl-2-(coumariniminecarboxamide-3-yl)hydrazine 61-64 prolactin Homo sapiens 146-155 35173685-8 2022 Furthermore, ESCs of the Rapamycin-treated group showed significant decidual-like changes with significantly increased decidual prolactin level at 72 h after in vitro decidualization. Sirolimus 25-34 prolactin Homo sapiens 128-137 35356252-1 2022 Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. Temozolomide 68-80 prolactin Homo sapiens 165-174 35356252-1 2022 Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. Temozolomide 68-80 prolactin Homo sapiens 176-179 35356252-1 2022 Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. Temozolomide 82-85 prolactin Homo sapiens 165-174 35356252-1 2022 Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. Temozolomide 82-85 prolactin Homo sapiens 176-179 35360427-10 2022 Moreover, prolactin (PRL) and cortisol 8AM were found to be correlated with the volume of the tumor and the hematoma, respectively. Prolactin 21-24 prolactin Homo sapiens 10-19 35085394-8 2022 PRL secretion was promoted by various prolactin secretagogues such as thyrotropin-releasing hormone, vasoactive intestinal peptide, and prolactin-releasing peptide, and inhibited by bromocriptine. Bromocriptine 182-195 prolactin Homo sapiens 0-3 35242209-0 2022 Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets. Amisulpride 140-151 prolactin Homo sapiens 34-43 35242209-0 2022 Changes of Mental State and Serum Prolactin Levels in Patients with Schizophrenia and Depression after Receiving the Combination Therapy of Amisulpride and Chloroprothixol Tablets. chloroprothixol 156-171 prolactin Homo sapiens 34-43 35242209-1 2022 Objective: To investigate the changes in mental state and serum prolactin levels in patients with schizophrenia and depression after receiving the combination therapy of amisulpride and chloroprothixol tablets. Amisulpride 170-181 prolactin Homo sapiens 64-73 35242209-1 2022 Objective: To investigate the changes in mental state and serum prolactin levels in patients with schizophrenia and depression after receiving the combination therapy of amisulpride and chloroprothixol tablets. chloroprothixol 186-201 prolactin Homo sapiens 64-73 35356252-0 2022 Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone. Capecitabine 16-28 prolactin Homo sapiens 126-135 35356252-0 2022 Chemotherapy of Capecitabine plus Temozolomide for Refractory Pituitary Adenoma after Tumor Resection and Its Impact on Serum Prolactin, IGF-1, and Growth Hormone. Temozolomide 34-46 prolactin Homo sapiens 126-135 34864772-1 2022 PURPOSE/BACKGROUND: Antipsychotic drugs are well established to alter circulating prolactin levels by blocking dopamine D2 receptors in the pituitary. Dopamine 111-119 prolactin Homo sapiens 82-91 35356252-1 2022 Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. Capecitabine 44-56 prolactin Homo sapiens 165-174 35356252-1 2022 Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. Capecitabine 44-56 prolactin Homo sapiens 176-179 35356252-1 2022 Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. Capecitabine 58-61 prolactin Homo sapiens 165-174 35356252-1 2022 Objective: To investigate the efficiency of capecitabine (CAP) plus temozolomide (TEM) in refractory pituitary adenoma after tumor resection and its impact on serum prolactin (PRL), insulin-like growth factor 1 (IGF-1), and growth hormone (GH) levels. Capecitabine 58-61 prolactin Homo sapiens 176-179 35093063-9 2022 The withdrawal akathisia disappeared over 2 weeks after switching to aripiprazole (10 mg/day) with propranolol (40 mg/day) and the patient"s prolactin levels had normalized after 6 months of aripiprazole monotherapy. Aripiprazole 191-203 prolactin Homo sapiens 141-150 35232561-11 2022 To create a consensus document that standardizes the reporting of prolactin results after precipitation with PEG to minimize errors in the interpretation of the results, in line with international standards. Polyethylene Glycols 109-112 prolactin Homo sapiens 66-75 35611427-14 2022 Cabergoline (0.5 mg/ twice weekly) was initiated to decrease PRL levels and reduce galactorrhea. Cabergoline 0-11 prolactin Homo sapiens 61-64 35022283-7 2022 On a fixed thyroxine supplement for each patient, significant decrease in levels of anti-TPO, anti-TG, TSH, prolactin, and erythrocyte sedi-mentation rate (ESR) occurred. Thyroxine 11-20 prolactin Homo sapiens 108-117 35355922-10 2021 Results: Among patients in whom cabergoline was stopped during pregnancy (n = 24), 41.6% (n = 10) had prolactin in normal range (achieved remission) after pregnancy and/or lactation. Cabergoline 32-43 prolactin Homo sapiens 102-111 35355923-1 2021 Cabergoline has long been used in the medical management of prolactin-secreting pituitary adenomas. Cabergoline 0-11 prolactin Homo sapiens 60-69 2511222-8 1989 The mean decrement in serum PRL level after L-dopa ingestion was greater in group 1 than in group 3 (P less than 0.05). Levodopa 44-50 prolactin Homo sapiens 28-31 2559587-0 1989 Sex-linked differences in cortisol, ACTH and prolactin responses to 5-hydroxy-tryptophan in healthy controls and minor and major depressed patients. 5-Hydroxytryptophan 68-88 prolactin Homo sapiens 45-54 2575440-3 1989 It has been suggested that the stimulation of the secretion of PRL by the alpha 2 adrenergic receptor antagonists (yohimbine, piperoxane) results from blockade of an inhibitory influence imposed on PRL release by the central alpha 2 receptors (7, 15). Yohimbine 115-124 prolactin Homo sapiens 63-66 2575440-3 1989 It has been suggested that the stimulation of the secretion of PRL by the alpha 2 adrenergic receptor antagonists (yohimbine, piperoxane) results from blockade of an inhibitory influence imposed on PRL release by the central alpha 2 receptors (7, 15). Yohimbine 115-124 prolactin Homo sapiens 198-201 2575440-3 1989 It has been suggested that the stimulation of the secretion of PRL by the alpha 2 adrenergic receptor antagonists (yohimbine, piperoxane) results from blockade of an inhibitory influence imposed on PRL release by the central alpha 2 receptors (7, 15). Piperoxan 126-136 prolactin Homo sapiens 63-66 2575440-3 1989 It has been suggested that the stimulation of the secretion of PRL by the alpha 2 adrenergic receptor antagonists (yohimbine, piperoxane) results from blockade of an inhibitory influence imposed on PRL release by the central alpha 2 receptors (7, 15). Piperoxan 126-136 prolactin Homo sapiens 198-201 2575440-5 1989 RAU was more effective in activation of PRL secretion than either YOH or Wy 26392 although it had a similar alpha 2 antagonist activity, while IDAZ, the most potent alpha 2 blocker among the four compounds, did not stimulate PRL secretion. Yohimbine 0-3 prolactin Homo sapiens 40-43 2575440-6 1989 2) The PRL-releasing effect of YOH or Wy 26392 was reversed by the alpha 2 agonist clonidine but the same effect of RAU was not, speaking against a common alpha 2-mediated mechanism of action of the three antagonists. Yohimbine 31-34 prolactin Homo sapiens 7-10 2575440-6 1989 2) The PRL-releasing effect of YOH or Wy 26392 was reversed by the alpha 2 agonist clonidine but the same effect of RAU was not, speaking against a common alpha 2-mediated mechanism of action of the three antagonists. Wy 26392 38-46 prolactin Homo sapiens 7-10 2575440-6 1989 2) The PRL-releasing effect of YOH or Wy 26392 was reversed by the alpha 2 agonist clonidine but the same effect of RAU was not, speaking against a common alpha 2-mediated mechanism of action of the three antagonists. Clonidine 83-92 prolactin Homo sapiens 7-10 2575440-7 1989 3) The PRL-stimulating effect of YOH, RAU or Wy 26392 persisted following inhibition of NE synthesis and presumably release with FLA 63, DDC or combination of reserpine and DDC. Yohimbine 33-36 prolactin Homo sapiens 7-10 2575440-7 1989 3) The PRL-stimulating effect of YOH, RAU or Wy 26392 persisted following inhibition of NE synthesis and presumably release with FLA 63, DDC or combination of reserpine and DDC. Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide 129-135 prolactin Homo sapiens 7-10 2575440-7 1989 3) The PRL-stimulating effect of YOH, RAU or Wy 26392 persisted following inhibition of NE synthesis and presumably release with FLA 63, DDC or combination of reserpine and DDC. Zalcitabine 137-140 prolactin Homo sapiens 7-10 2575440-7 1989 3) The PRL-stimulating effect of YOH, RAU or Wy 26392 persisted following inhibition of NE synthesis and presumably release with FLA 63, DDC or combination of reserpine and DDC. Reserpine 159-168 prolactin Homo sapiens 7-10 2575440-7 1989 3) The PRL-stimulating effect of YOH, RAU or Wy 26392 persisted following inhibition of NE synthesis and presumably release with FLA 63, DDC or combination of reserpine and DDC. Zalcitabine 173-176 prolactin Homo sapiens 7-10 2692640-6 1989 However, reduced neuroendocrine (i.e. prolactin) responses to fenfluramine, a 5-HT uptake inhibitor/releaser, which activates both pre- and post-synaptic sides of the 5-HT synapse, strongly suggest that overall central 5-HT activity is reduced in mood and/or personality disorder patients with history of suicidal and/or impulsive aggressive behaviour. Fenfluramine 62-74 prolactin Homo sapiens 38-47 2479529-0 1989 Regulation of prolactin secretion in the human B-lymphoblastoid cell line IM-9-P3 by dexamethasone but not other regulators of pituitary prolactin secretion. Dexamethasone 85-98 prolactin Homo sapiens 14-23 2479529-2 1989 We demonstrate that PRL secretion in this cell line is regulated by dexamethasone but not by other hormones known to modulate PRL secretion in the pituitary or decidua. Dexamethasone 68-81 prolactin Homo sapiens 20-23 2479529-3 1989 Dexamethasone caused a reduction of secretion rates to 30% of control values after 3 day paralleled by a decrease in hPRL mRNA levels, without affecting cell viability. Dexamethasone 0-13 prolactin Homo sapiens 117-121 2479529-4 1989 Half-life determinations of hPRL mRNA in control and dexamethasone-treated cells revealed a reduction of t1/2 from 16 to 4 h. PRL secreted by IM-9-P3 cells did not control its own secretion in an autocrine loop, nor did it serve as an autocrine growth factor. Dexamethasone 53-66 prolactin Homo sapiens 28-32 2479529-4 1989 Half-life determinations of hPRL mRNA in control and dexamethasone-treated cells revealed a reduction of t1/2 from 16 to 4 h. PRL secreted by IM-9-P3 cells did not control its own secretion in an autocrine loop, nor did it serve as an autocrine growth factor. Dexamethasone 53-66 prolactin Homo sapiens 29-32 2584353-3 1989 A study was performed on 94 women delivering at 34-44 weeks gestation, whose pregnancies were uncomplicated to determine the role of PRL in human fetal and neonatal salt and water conservation. Salts 165-169 prolactin Homo sapiens 133-136 2584360-10 1989 Cocaine-induced hyperprolactinemia may contribute to disorders of sexual and reproductive function in men who abuse the drug, and recent reports that PRL modulates immune function suggest that cocaine-induced derangements of PRL secretion may also contribute to cocaine-related comorbidity in infectious disease. Cocaine 193-200 prolactin Homo sapiens 150-153 2584360-10 1989 Cocaine-induced hyperprolactinemia may contribute to disorders of sexual and reproductive function in men who abuse the drug, and recent reports that PRL modulates immune function suggest that cocaine-induced derangements of PRL secretion may also contribute to cocaine-related comorbidity in infectious disease. Cocaine 193-200 prolactin Homo sapiens 225-228 2584360-10 1989 Cocaine-induced hyperprolactinemia may contribute to disorders of sexual and reproductive function in men who abuse the drug, and recent reports that PRL modulates immune function suggest that cocaine-induced derangements of PRL secretion may also contribute to cocaine-related comorbidity in infectious disease. Cocaine 262-269 prolactin Homo sapiens 150-153 2584360-10 1989 Cocaine-induced hyperprolactinemia may contribute to disorders of sexual and reproductive function in men who abuse the drug, and recent reports that PRL modulates immune function suggest that cocaine-induced derangements of PRL secretion may also contribute to cocaine-related comorbidity in infectious disease. Cocaine 262-269 prolactin Homo sapiens 225-228 2584360-11 1989 Since cocaine users with hyperprolactinemia had a higher mean valley as well as a higher peak pulse PRL height than control subjects, but did not have greater PRL pulse frequencies, we conclude that hyperprolactinemia in these men may be due to a cocaine-induced derangement of dopaminergic inhibition of basal PRL secretion. Cocaine 6-13 prolactin Homo sapiens 100-103 2813443-2 1989 The PKC activator 12-O-tetradeconylphorbol-13-acetate (TPA) at certain concentrations has been shown to potentiate the mitogenic effect of PRL, whereas at higher concentrations, TPA inhibits the PRL response. 12-o-tetradeconylphorbol-13-acetate 18-53 prolactin Homo sapiens 139-142 2516707-10 1989 During treatment, median plasma PRL levels were significantly decreased only in bromocriptine-treated patients (10.8 vs 7.3 ng/ml). Bromocriptine 80-93 prolactin Homo sapiens 32-35 2559014-3 1989 The administration of L-dopa produced a decrease of serum prolactin in all. Levodopa 22-28 prolactin Homo sapiens 58-67 2590229-2 1989 Using high performance liquid chromatography and other protein isolation techniques we have demonstrated that a glycosylated prolactin species is linked to immunoglobulin by disulfide bonds in amniotic fluid. Disulfides 174-183 prolactin Homo sapiens 125-134 2589434-6 1989 We conclude that estradiol selectively augments the amplitude of episodic prolactin pulsatility, amplifies ultradian rhythms, and increases the mass of prolactin released per secretory burst. Estradiol 17-26 prolactin Homo sapiens 74-83 2589434-6 1989 We conclude that estradiol selectively augments the amplitude of episodic prolactin pulsatility, amplifies ultradian rhythms, and increases the mass of prolactin released per secretory burst. Estradiol 17-26 prolactin Homo sapiens 152-161 2612065-4 1989 THIP, a GABAmimetic, per se produced an analgesic effect and potentiated the analgesic effect of prolactin and morphine. gaboxadol 0-4 prolactin Homo sapiens 97-106 2612065-6 1989 Bicuculline, in subconvulsive doses, per se did not alter the number of writhings, while it attenuated the analgesic effect of prolactin. Bicuculline 0-11 prolactin Homo sapiens 127-136 2612065-10 1989 Since THIP resembles morphine and because prolactin possesses several other morphine-like functions, it is possible that the role played by GABA may be an opioid-related one. Morphine 76-84 prolactin Homo sapiens 42-51 2612065-10 1989 Since THIP resembles morphine and because prolactin possesses several other morphine-like functions, it is possible that the role played by GABA may be an opioid-related one. gamma-Aminobutyric Acid 140-144 prolactin Homo sapiens 42-51 2627752-6 1989 Octreotide induced a decrease in plasma PRL in three out of seven patients. Octreotide 0-10 prolactin Homo sapiens 40-43 2627752-8 1989 In addition, acromegalic patients did not exhibit the PRL and TSH-releasing activity of calcitonin found in normal subjects, while octreotide inhibited PRL secretion in some acromegalic patients. Octreotide 131-141 prolactin Homo sapiens 152-155 2531718-3 1989 Alpha-hANP administration was followed by a significant fall of prolactin plasma levels but did not influence TRH-induced prolactin response. NPPA protein, human 0-10 prolactin Homo sapiens 64-73 2531718-4 1989 Nevertheless, sulpiride-induced prolactin secretion was significantly lower after Alpha-hANP administration than after placebo pre-treatment (p values ranging between 0.01 and 0.001). Sulpiride 14-23 prolactin Homo sapiens 32-41 2531718-4 1989 Nevertheless, sulpiride-induced prolactin secretion was significantly lower after Alpha-hANP administration than after placebo pre-treatment (p values ranging between 0.01 and 0.001). NPPA protein, human 82-92 prolactin Homo sapiens 32-41 2516347-3 1989 In order to evaluate the possible effect of GH-RH over seric levels of PRL in uremic patients we carried out a study in a group of ten male patients on hemodialysis (HD), who were given an acute stimulus of GH-RH (an IV 50 mcg. seric 55-60 prolactin Homo sapiens 71-74 2516707-6 1989 Dopamine caused a 50.2% and 60.4% MD in prolactin (PRL) in the PCOS and control groups, respectively, the difference being statistically non-significant. Dopamine 0-8 prolactin Homo sapiens 51-54 2516707-7 1989 Metoclopramide increased PRL levels by 1261.0% and 1832.0% in the PCOS and control groups, respectively (not significant). Metoclopramide 0-14 prolactin Homo sapiens 25-28 2813443-2 1989 The PKC activator 12-O-tetradeconylphorbol-13-acetate (TPA) at certain concentrations has been shown to potentiate the mitogenic effect of PRL, whereas at higher concentrations, TPA inhibits the PRL response. 12-o-tetradeconylphorbol-13-acetate 18-53 prolactin Homo sapiens 195-198 2813443-2 1989 The PKC activator 12-O-tetradeconylphorbol-13-acetate (TPA) at certain concentrations has been shown to potentiate the mitogenic effect of PRL, whereas at higher concentrations, TPA inhibits the PRL response. Tetradecanoylphorbol Acetate 55-58 prolactin Homo sapiens 139-142 2813443-2 1989 The PKC activator 12-O-tetradeconylphorbol-13-acetate (TPA) at certain concentrations has been shown to potentiate the mitogenic effect of PRL, whereas at higher concentrations, TPA inhibits the PRL response. Tetradecanoylphorbol Acetate 55-58 prolactin Homo sapiens 195-198 2813443-2 1989 The PKC activator 12-O-tetradeconylphorbol-13-acetate (TPA) at certain concentrations has been shown to potentiate the mitogenic effect of PRL, whereas at higher concentrations, TPA inhibits the PRL response. Tetradecanoylphorbol Acetate 178-181 prolactin Homo sapiens 139-142 2813443-2 1989 The PKC activator 12-O-tetradeconylphorbol-13-acetate (TPA) at certain concentrations has been shown to potentiate the mitogenic effect of PRL, whereas at higher concentrations, TPA inhibits the PRL response. Tetradecanoylphorbol Acetate 178-181 prolactin Homo sapiens 195-198 2813443-7 1989 On long-term exposure (3 days), high concentrations of TPA down-regulate the PKC enzyme; this down-regulation likely accounts for the inhibitory effect of high concentrations of TPA on the PRL stimulation of cell division. Tetradecanoylphorbol Acetate 55-58 prolactin Homo sapiens 189-192 2813443-7 1989 On long-term exposure (3 days), high concentrations of TPA down-regulate the PKC enzyme; this down-regulation likely accounts for the inhibitory effect of high concentrations of TPA on the PRL stimulation of cell division. Tetradecanoylphorbol Acetate 178-181 prolactin Homo sapiens 189-192 2813443-8 1989 In further studies, the PKC inhibitors H-7 and gossypol were shown to inhibit the PRL stimulation of cell division in a concentration-dependent fashion. 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine 39-42 prolactin Homo sapiens 82-85 2813443-8 1989 In further studies, the PKC inhibitors H-7 and gossypol were shown to inhibit the PRL stimulation of cell division in a concentration-dependent fashion. Gossypol 47-55 prolactin Homo sapiens 82-85 2553110-5 1989 Amiloride was also found to inhibit the prolactin stimulation of DNA, RNA and protein synthesis, thus suggesting that the initial regulation of the Na+/H+ antiporter may initiate these responses as well as the mitogenic effect of prolactin. Amiloride 0-9 prolactin Homo sapiens 230-239 2514354-7 1989 During long-term treatment with a dopaminergic drug the elevated prolactin levels decreased to the normal range and testicular function normalized as shown by growth of the testes and increasing testosterone levels. Testosterone 195-207 prolactin Homo sapiens 65-74 2480873-3 1989 We examined six methylatable cytosine residues (5, -CCGG- and 1, -GCGC-) within the 30-kb region of the PRL gene in these subclones. Cytosine 29-37 prolactin Homo sapiens 104-107 2480873-5 1989 Furthermore, the inhibition of PRL gene expression in GH(1)2C1 was reversed by short-term treatment of the cells with a sublethal concentration of azacytidine (AzaC), an inhibitor of DNA methylation. Azacitidine 147-158 prolactin Homo sapiens 31-34 2480873-5 1989 Furthermore, the inhibition of PRL gene expression in GH(1)2C1 was reversed by short-term treatment of the cells with a sublethal concentration of azacytidine (AzaC), an inhibitor of DNA methylation. Azacitidine 160-164 prolactin Homo sapiens 31-34 2480873-6 1989 The reversion of PRL gene expression by AzaC was correlated with the concurrent demethylation of the same -CCGG- sequences in the transcribed region of PRL gene. Azacitidine 40-44 prolactin Homo sapiens 17-20 2480873-6 1989 The reversion of PRL gene expression by AzaC was correlated with the concurrent demethylation of the same -CCGG- sequences in the transcribed region of PRL gene. Azacitidine 40-44 prolactin Homo sapiens 152-155 2480873-8 1989 The DNase I sensitivity of these regions of the PRL gene in PRL+, PRL-, and AzaC-treated cells was also consistent with an inverse relationship between methylation state, a higher order of structural modification, and gene expression. Azacitidine 76-80 prolactin Homo sapiens 48-51 2806601-5 1989 We conclude that bromocriptine, given before anesthesia, can suppress transient, anesthesia-induced hyperprolactinemia and dramatically alter follicular fluid concentrations of PRL and E2. Bromocriptine 17-30 prolactin Homo sapiens 177-180 2676994-0 1989 Relation of serum molindone levels to serum prolactin levels and antipsychotic response. Molindone 18-27 prolactin Homo sapiens 44-53 2676994-7 1989 Serum molindone and prolactin levels might help assess resistance to molindone treatment. Molindone 69-78 prolactin Homo sapiens 20-29 2553110-2 1989 In time sequence studies the onset of the prolactin stimulation of the incorporation of radiolabeled precursors into these macromolecules was found to be 0.5-1 h for [3H]uridine incorporation into RNA, 1-2 h for [3H]leucine incorporation into protein, and 4-8 h for [3H]thymidine incorporation into DNA. Tritium 167-169 prolactin Homo sapiens 42-51 2553110-2 1989 In time sequence studies the onset of the prolactin stimulation of the incorporation of radiolabeled precursors into these macromolecules was found to be 0.5-1 h for [3H]uridine incorporation into RNA, 1-2 h for [3H]leucine incorporation into protein, and 4-8 h for [3H]thymidine incorporation into DNA. Uridine 170-177 prolactin Homo sapiens 42-51 2553110-2 1989 In time sequence studies the onset of the prolactin stimulation of the incorporation of radiolabeled precursors into these macromolecules was found to be 0.5-1 h for [3H]uridine incorporation into RNA, 1-2 h for [3H]leucine incorporation into protein, and 4-8 h for [3H]thymidine incorporation into DNA. Tritium 213-215 prolactin Homo sapiens 42-51 2553110-2 1989 In time sequence studies the onset of the prolactin stimulation of the incorporation of radiolabeled precursors into these macromolecules was found to be 0.5-1 h for [3H]uridine incorporation into RNA, 1-2 h for [3H]leucine incorporation into protein, and 4-8 h for [3H]thymidine incorporation into DNA. Leucine 216-223 prolactin Homo sapiens 42-51 2553110-2 1989 In time sequence studies the onset of the prolactin stimulation of the incorporation of radiolabeled precursors into these macromolecules was found to be 0.5-1 h for [3H]uridine incorporation into RNA, 1-2 h for [3H]leucine incorporation into protein, and 4-8 h for [3H]thymidine incorporation into DNA. Tritium 213-215 prolactin Homo sapiens 42-51 2553110-4 1989 Amiloride, an inhibitor of the plasma-membrane-bound Na+/H+ antiporter, was found to inhibit the mitogenic effects of prolactin. Amiloride 0-9 prolactin Homo sapiens 118-127 2553110-5 1989 Amiloride was also found to inhibit the prolactin stimulation of DNA, RNA and protein synthesis, thus suggesting that the initial regulation of the Na+/H+ antiporter may initiate these responses as well as the mitogenic effect of prolactin. Amiloride 0-9 prolactin Homo sapiens 40-49 2518665-2 1989 The study aimed at measuring blood serum level of TSH and PRL after THR loading in 10 ALS patients and in the 10 healthy individuals. Threonine 68-71 prolactin Homo sapiens 58-61 2576397-1 1989 CV 205-502 (Sandoz), an octahydrobenzol [g]quinoline, is a long-acting dopamine agonist which inhibits prolactin secretion. octahydrobenzol [g]quinoline 24-52 prolactin Homo sapiens 103-112 2576397-1 1989 CV 205-502 (Sandoz), an octahydrobenzol [g]quinoline, is a long-acting dopamine agonist which inhibits prolactin secretion. Dopamine 71-79 prolactin Homo sapiens 103-112 2509249-5 1989 During the metoclopramide infusion prolactin (PRL) increased in all subjects, with a slightly higher increase in PRL in the eumenorrheic swimmers. Metoclopramide 11-25 prolactin Homo sapiens 46-49 2570790-1 1989 Cabergoline (CAB) is a new oral dopaminergic compound showing a very long-lasting PRL-lowering activity and reported to be well tolerated. Cabergoline 0-11 prolactin Homo sapiens 82-85 2570790-1 1989 Cabergoline (CAB) is a new oral dopaminergic compound showing a very long-lasting PRL-lowering activity and reported to be well tolerated. Cabergoline 13-16 prolactin Homo sapiens 82-85 2570790-3 1989 In a group of 10 patients who received CAB (0.8 mg once weekly or 0.4 mg twice weekly) for 8 weeks PRL levels normalized while on treatment and remained normal (8 patients) or greatly reduced (1 patient) for 1-2 months after discontinuation of the drug. Cabergoline 39-42 prolactin Homo sapiens 99-102 2482208-0 1989 Phorbol ester stimulates prolactin release but reduces prolactin mRNA in the human B-lymphoblastoid cell line IM-9-P3. Phorbol Esters 0-13 prolactin Homo sapiens 25-34 2482208-5 1989 The addition of dibutyryl cAMP caused a minor transient increase in hPRL secretion by 35% after 1 h. Bucladesine 16-30 prolactin Homo sapiens 68-72 2798438-0 1989 Effects of mezerein and diglycerides on the PRL stimulation of cell replication in Nb2 node lymphoma cells. mezerein 11-19 prolactin Homo sapiens 44-47 2798438-0 1989 Effects of mezerein and diglycerides on the PRL stimulation of cell replication in Nb2 node lymphoma cells. Diglycerides 24-36 prolactin Homo sapiens 44-47 2798438-2 1989 The diterpene mezerein is shown to potentiate the mitogenic effect of PRL at a hormone concentration which elicits a less than maximum response. diterpene mezerein 4-22 prolactin Homo sapiens 70-73 2794103-0 1989 Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety. Buspirone 0-9 prolactin Homo sapiens 22-31 2636025-3 1989 When phenol red, which is a weak estrogen agonist, is also eliminated from the medium, the cells respond to prolactin to the same extent. Phenolsulfonphthalein 5-15 prolactin Homo sapiens 108-117 2636025-4 1989 When cells are grown for two generations in the presence of lactogen free, phenol red free, charcoal stripped serum, the prolactin induced response is even greater. Phenolsulfonphthalein 75-85 prolactin Homo sapiens 121-130 2482208-0 1989 Phorbol ester stimulates prolactin release but reduces prolactin mRNA in the human B-lymphoblastoid cell line IM-9-P3. Phorbol Esters 0-13 prolactin Homo sapiens 55-64 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Phorbol Esters 4-17 prolactin Homo sapiens 72-81 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Phorbol Esters 4-17 prolactin Homo sapiens 83-86 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Phorbol Esters 4-17 prolactin Homo sapiens 105-108 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Phorbol Esters 4-17 prolactin Homo sapiens 105-108 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Tetradecanoylphorbol Acetate 18-54 prolactin Homo sapiens 72-81 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Tetradecanoylphorbol Acetate 18-54 prolactin Homo sapiens 83-86 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Tetradecanoylphorbol Acetate 18-54 prolactin Homo sapiens 105-108 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Tetradecanoylphorbol Acetate 18-54 prolactin Homo sapiens 105-108 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Tetradecanoylphorbol Acetate 56-59 prolactin Homo sapiens 72-81 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Tetradecanoylphorbol Acetate 56-59 prolactin Homo sapiens 83-86 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Tetradecanoylphorbol Acetate 56-59 prolactin Homo sapiens 105-108 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. Tetradecanoylphorbol Acetate 56-59 prolactin Homo sapiens 105-108 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. im-9-p3 152-159 prolactin Homo sapiens 72-81 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. im-9-p3 152-159 prolactin Homo sapiens 83-86 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. im-9-p3 152-159 prolactin Homo sapiens 105-108 2482208-1 1989 The phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) stimulated prolactin (PRL) release from the PRL producing human B-lymphoblastoid cell line IM-9-P3 within 30 min with an EC50 of 5 x 10(-9) M. Increased release was entirely attributable to a loss from intracellular PRL pools. im-9-p3 152-159 prolactin Homo sapiens 105-108 2482208-3 1989 Prolonged exposure of the cells to 2 x 10(-7) M TPA, however, led to a maximal reduction of hPRL mRNA levels after 24 h and a subsequent recovery by 72 h. Secretory rates followed a corresponding kinetic. Tetradecanoylphorbol Acetate 48-51 prolactin Homo sapiens 92-96 2689208-3 1989 Bromocriptine is a dopamine agonist, dopamine being a natural inhibitor of PRL-secretion. Bromocriptine 0-13 prolactin Homo sapiens 75-78 2689208-3 1989 Bromocriptine is a dopamine agonist, dopamine being a natural inhibitor of PRL-secretion. Dopamine 37-45 prolactin Homo sapiens 75-78 2689208-7 1989 In the postpubertal animals PRL is a melatonin antagonist in the dark time but LH synergist at the exposure to light. Melatonin 37-46 prolactin Homo sapiens 28-31 2689208-8 1989 A high PRL concentration inhibits gonadoliberin formation, LH secretion; testosterone concentration and especially dihydrotestosterone concentration decrease (or do not change) with an elevation of estradiol level that on the whole results in feminization. Luteinizing Hormone 59-61 prolactin Homo sapiens 7-10 2689208-8 1989 A high PRL concentration inhibits gonadoliberin formation, LH secretion; testosterone concentration and especially dihydrotestosterone concentration decrease (or do not change) with an elevation of estradiol level that on the whole results in feminization. Testosterone 73-85 prolactin Homo sapiens 7-10 2689208-8 1989 A high PRL concentration inhibits gonadoliberin formation, LH secretion; testosterone concentration and especially dihydrotestosterone concentration decrease (or do not change) with an elevation of estradiol level that on the whole results in feminization. Dihydrotestosterone 115-134 prolactin Homo sapiens 7-10 2689208-8 1989 A high PRL concentration inhibits gonadoliberin formation, LH secretion; testosterone concentration and especially dihydrotestosterone concentration decrease (or do not change) with an elevation of estradiol level that on the whole results in feminization. Estradiol 198-207 prolactin Homo sapiens 7-10 2570719-0 1989 Reduction in the size of prolactin-producing pituitary tumor after Cabergoline administration. Cabergoline 67-78 prolactin Homo sapiens 25-34 2695151-0 1989 Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia. Bromocriptine 44-57 prolactin Homo sapiens 24-33 2570719-4 1989 Cabergoline induced marked inhibition of PRL secretion in conjunction with a CT demonstration of reduction in the pituitary tumor size in all patients. Cabergoline 0-11 prolactin Homo sapiens 41-44 2695151-0 1989 Controlled trial of the prolactin inhibitor bromocriptine (Parlodel) in the treatment of severe cyclical mastalgia. Bromocriptine 59-67 prolactin Homo sapiens 24-33 2695151-5 1989 Bromocriptine, compared with placebo, caused a significant (p less than 0.01) and sustained improvement in breast pain, tenderness and nodularity together with a reduction in serum prolactin levels (p less than 0.01). Bromocriptine 0-13 prolactin Homo sapiens 181-190 2570719-5 1989 The potent, long-lasting PRL inhibitory effect of Cabergoline and the absence of side effects typical of dopaminergic compounds suggest that the use of this drug is advantageous over others in the medical treatment of hyperprolactinemia. Cabergoline 50-61 prolactin Homo sapiens 25-28 2531771-1 1989 The purpose of the present investigation was to verify possible positive correlations between prolactin secretion and dehydroepiandrosterone sulphate levels in plasma of women with benign breast disease. Dehydroepiandrosterone Sulfate 118-149 prolactin Homo sapiens 94-103 2512340-7 1989 On days 30-90 PRL pulses were sporadically concomitant with LHRH-induced LH pulses. Luteinizing Hormone 60-62 prolactin Homo sapiens 14-17 2608067-1 1989 During lactation, a dramatic rise in serum PRL stimulates milk production, resulting in a substantial rise in calcium mobilization from gut and bone. Calcium 110-117 prolactin Homo sapiens 43-46 2512340-9 1989 A significant positive (p less than 0.01) correlation was observed between testosterone and PRL levels during LHRH therapy. Testosterone 75-87 prolactin Homo sapiens 92-95 2608067-2 1989 We found that the production of a newly characterized calcium-mobilizing PTH-like peptide (PTH-LP) by mammary tissue was tightly linked to lactation, suggesting a possible role for PRL in the expression of PTH-LP. Calcium 54-61 prolactin Homo sapiens 181-184 2555427-7 1989 There was a statistically significant inverse relationship between PRL and NE (r = -0.392, p less than 0.001) and between PRL and PGF2 alpha (r = -0.523, p less than 0.001) during labor, but there was no statistical correlation among PRL, DOPA and DOPAC. Dinoprost 130-134 prolactin Homo sapiens 122-125 2555427-7 1989 There was a statistically significant inverse relationship between PRL and NE (r = -0.392, p less than 0.001) and between PRL and PGF2 alpha (r = -0.523, p less than 0.001) during labor, but there was no statistical correlation among PRL, DOPA and DOPAC. Dinoprost 130-134 prolactin Homo sapiens 122-125 2555427-8 1989 In conclusion, these data suggest that the dopaminergic activity in the maternal circulation increases before the onset of labor, and the PRL release from the maternal pituitary gland during labor is probably not controlled primarily by dopaminergic neurons and may be suppressed by other mechanisms, such as the stress of labor and/or the influence of PGF2 alpha. Dinoprost 353-357 prolactin Homo sapiens 138-141 2503796-14 1989 Administration of L-dopa decreased the serum PRL of subject 1 from 33 to 7 ng/mL, but had no clinically significant effect in subject 2. Levodopa 18-24 prolactin Homo sapiens 45-48 2595862-2 1989 The findings demonstrated the increased levels of prolactin (249.09 +/- 39.6 mu/U/ml), significantly exceeding the normal (132.6 +/- 32.4 mu/U/ml), a tendency towards a decrease in the levels of FSH and testosterone (up to 7.01 +/- 0.70 nmol/l versus 12.57 +/- 0.39 nmol/l in health) and manifest elevation of estradiol levels (up to 634.71 +/- 29.16 nmol/l versus 205.02 +/- 18.60 nmol/l), as well as its ratio to the testosterone levels. Testosterone 203-215 prolactin Homo sapiens 50-59 2608067-4 1989 Bromocriptine, a potent inhibitor of PRL secretion, blocked the suckling-associated rise in serum PRL and the subsequent induction of PTH-LP mRNA in mammary gland. Bromocriptine 0-13 prolactin Homo sapiens 37-40 2608067-4 1989 Bromocriptine, a potent inhibitor of PRL secretion, blocked the suckling-associated rise in serum PRL and the subsequent induction of PTH-LP mRNA in mammary gland. Bromocriptine 0-13 prolactin Homo sapiens 98-101 2608067-6 1989 Thus, the correlation between serum levels of PRL and the expression of PTH-LP mRNA in mammary tissue extends the role of PRL in milk production and suggests a possible mechanism for the PRL effects on calcium metabolism. Calcium 202-209 prolactin Homo sapiens 46-49 2595862-2 1989 The findings demonstrated the increased levels of prolactin (249.09 +/- 39.6 mu/U/ml), significantly exceeding the normal (132.6 +/- 32.4 mu/U/ml), a tendency towards a decrease in the levels of FSH and testosterone (up to 7.01 +/- 0.70 nmol/l versus 12.57 +/- 0.39 nmol/l in health) and manifest elevation of estradiol levels (up to 634.71 +/- 29.16 nmol/l versus 205.02 +/- 18.60 nmol/l), as well as its ratio to the testosterone levels. Estradiol 310-319 prolactin Homo sapiens 50-59 2595862-2 1989 The findings demonstrated the increased levels of prolactin (249.09 +/- 39.6 mu/U/ml), significantly exceeding the normal (132.6 +/- 32.4 mu/U/ml), a tendency towards a decrease in the levels of FSH and testosterone (up to 7.01 +/- 0.70 nmol/l versus 12.57 +/- 0.39 nmol/l in health) and manifest elevation of estradiol levels (up to 634.71 +/- 29.16 nmol/l versus 205.02 +/- 18.60 nmol/l), as well as its ratio to the testosterone levels. Testosterone 419-431 prolactin Homo sapiens 50-59 2484316-4 1989 Bromocriptine in a daily doses ranging from 5.0 to 7.5 mg decreases prolactin levels in the recurrent chromophobe pituitary adenomas and does not affect their proliferation. Bromocriptine 0-13 prolactin Homo sapiens 68-77 2476350-3 1989 The effects of forskolin (10 microM) and cholera toxin (1 microgram/ml) were potentiated by PRL (10 micrograms/ml). Colforsin 15-24 prolactin Homo sapiens 92-95 2775278-0 1989 Cell swelling induced by the permeant molecules urea or glycerol induces immediate high amplitude thyrotropin and prolactin secretion by perifused adenohypophyseal cells. Urea 48-52 prolactin Homo sapiens 114-123 2775278-0 1989 Cell swelling induced by the permeant molecules urea or glycerol induces immediate high amplitude thyrotropin and prolactin secretion by perifused adenohypophyseal cells. Glycerol 56-64 prolactin Homo sapiens 114-123 2775278-1 1989 The permeant molecules, urea and glycerol, evoked a prompt secretory burst of TSH and PRL when added to the extracellular medium of acutely dispersed anterior pituitary cells. Urea 24-28 prolactin Homo sapiens 86-89 2775278-1 1989 The permeant molecules, urea and glycerol, evoked a prompt secretory burst of TSH and PRL when added to the extracellular medium of acutely dispersed anterior pituitary cells. Glycerol 33-41 prolactin Homo sapiens 86-89 2756933-5 1989 Biotinylated oligonucleotide probes for other mRNAs present in high abundance such as adrenocorticotroipic hormone (ACTH), prolactin, and growth hormone also detected the respective mRNAs in pituitary tissues. Oligonucleotides 13-28 prolactin Homo sapiens 123-132 2753986-5 1989 Hydergine induced a significant (P less than 0.01) decrease in the serum PRL level, compared with placebo, in both groups. Ergoloid Mesylates 0-9 prolactin Homo sapiens 73-76 2753986-6 1989 The fall in mean serum PRL in group A was significant (P less than 0.05) 300 min after hydergine administration, and the concentration remained low at 480 min, at 45.5% of the mean baseline value. Ergoloid Mesylates 87-96 prolactin Homo sapiens 23-26 2753986-9 1989 In group B, also, hydergine administration significantly (P less than 0.01) reduced the mean serum PRL concentration within 240 min, and it declined further to within the normal range. Ergoloid Mesylates 18-27 prolactin Homo sapiens 99-102 2753986-14 1989 These data indicate that hydergine has PRL inhibitory activity and is useful in the treatment of hyperprolactinemic anovulatory patients whose basal serum PRL concentrations are below 100 micrograms/L. Ergoloid Mesylates 25-34 prolactin Homo sapiens 39-42 2753986-14 1989 These data indicate that hydergine has PRL inhibitory activity and is useful in the treatment of hyperprolactinemic anovulatory patients whose basal serum PRL concentrations are below 100 micrograms/L. Ergoloid Mesylates 25-34 prolactin Homo sapiens 155-158 2736489-10 1989 The abnormal concentrations of PRL and TSH in these patients could be due to a depressed melatonin peak normally serving as a central circadian synchronizer and modulator of the secretion of adenohypophysial hormones. Melatonin 89-98 prolactin Homo sapiens 31-34 2585752-2 1989 Prolactin levels in the maternal, fetal and amniotic compartments were measured by radio-immunoassay in patients with anencephalic fetuses, and patients treated with bromocriptine during pregnancy. Bromocriptine 166-179 prolactin Homo sapiens 0-9 2585752-3 1989 Bromocriptine or an active metabolite(s) passed through the term placenta and suppressed prolactin secretion by the fetal pituitary gland. Bromocriptine 0-13 prolactin Homo sapiens 89-98 2546831-0 1989 Effects of pretreatment with tetradecanoyl phorbol acetate on regulation of growth hormone and prolactin secretion from ovine anterior pituitary cells. Tetradecanoylphorbol Acetate 29-58 prolactin Homo sapiens 95-104 2546831-1 1989 Tetradecanoyl phorbol acetate (TPA) stimulates growth hormone (GH) and prolactin secretion from ovine anterior pituitary cells. Tetradecanoylphorbol Acetate 0-29 prolactin Homo sapiens 71-80 2546831-1 1989 Tetradecanoyl phorbol acetate (TPA) stimulates growth hormone (GH) and prolactin secretion from ovine anterior pituitary cells. Tetradecanoylphorbol Acetate 31-34 prolactin Homo sapiens 71-80 2735812-3 1989 To evaluate central serotonergic function in relation to these variables, prolactin responses to a single-dose challenge with fenfluramine hydrochloride (60 mg orally), a serotonin releasing/uptake-inhibiting agent, were examined in 45 male patients with clearly defined major affective (n = 25) and/or personality disorder (n = 20) and in 18 normal male control patients. Fenfluramine 126-152 prolactin Homo sapiens 74-83 2735812-4 1989 Prolactin responses to fenfluramine among all patients were reduced compared with responses of controls. Fenfluramine 23-35 prolactin Homo sapiens 0-9 2735812-5 1989 Reduced prolactin responses to fenfluramine were correlated with history of suicide attempt in all patients but with clinician and self-reported ratings of impulsive aggression in patients with personality disorder only; there was no correlation with depression. Fenfluramine 31-43 prolactin Homo sapiens 8-17 2526730-8 1989 The PRL response to MC was higher after CBZ treatment than before. Metoclopramide 20-22 prolactin Homo sapiens 4-7 2526730-8 1989 The PRL response to MC was higher after CBZ treatment than before. Carbamazepine 40-43 prolactin Homo sapiens 4-7 2663550-3 1989 The mean prolactin (PRL) response following metoclopramide was significantly higher in the constitutional delay of puberty group when compared with the hypogonadotropic hypogonadism patients (P less than 0.01 at 15, 30, 45, and 60 minutes); all patients with constitutional delay of puberty increased their PRL level to greater than or equal to 60 ng/ml, except one who had a peak PRL level of 38 ng/ml. Metoclopramide 44-58 prolactin Homo sapiens 20-23 2544414-3 1989 Dopamine (DA) attenuated IL6-induced PRL release. Dopamine 0-8 prolactin Homo sapiens 37-40 2544414-3 1989 Dopamine (DA) attenuated IL6-induced PRL release. Dopamine 10-12 prolactin Homo sapiens 37-40 2744187-2 1989 During bromocriptine treatment, the serum prolactin (PRL) concentration significantly decreased, and consequently the serum estradiol (E2) concentration was significantly higher than in the controls on cycle day 9, and the ratio of testosterone (T) to E2 was decreased from cycle day 8 through day 10. Bromocriptine 7-20 prolactin Homo sapiens 42-51 2744187-0 1989 Prolactin suppression by bromocriptine stimulates aromatization of testosterone to estradiol in women. Bromocriptine 25-38 prolactin Homo sapiens 0-9 2744187-0 1989 Prolactin suppression by bromocriptine stimulates aromatization of testosterone to estradiol in women. Testosterone 67-79 prolactin Homo sapiens 0-9 2744187-0 1989 Prolactin suppression by bromocriptine stimulates aromatization of testosterone to estradiol in women. Estradiol 83-92 prolactin Homo sapiens 0-9 2544811-1 1989 Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans. Chlormethiazole 0-13 prolactin Homo sapiens 104-113 2544811-1 1989 Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans. Chlormethiazole 0-13 prolactin Homo sapiens 115-118 2544811-1 1989 Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans. Chlormethiazole 15-19 prolactin Homo sapiens 104-113 2544811-1 1989 Clomethiazole (CLOM) is known to be an anticonvulsant drug and has been also reported to decrease serum prolactin (PRL) in humans. Chlormethiazole 15-19 prolactin Homo sapiens 115-118 2774848-6 1989 These lower midsleep PRL concentrations were associated with a significant increase in the amount of time spent awake during the same period. midsleep 12-20 prolactin Homo sapiens 21-24 2560316-0 1989 Enalapril decreases plasma prolactin levels in hypertensive patients. Enalapril 0-9 prolactin Homo sapiens 27-36 2560316-3 1989 We studied the effect of enalapril, a potent converting enzyme inhibitor, on baseline prolactin levels in nine hypertensive postmenopausal women. Enalapril 25-34 prolactin Homo sapiens 86-95 2560316-4 1989 The results indicate that 15-day inhibition of ACE by enalapril reduced prolactinaemia, suggesting that angiotensin II plays a role in the control of prolactin secretion in hypertensives. Enalapril 54-63 prolactin Homo sapiens 72-81 2678928-1 1989 We have developed a two-site immunoassay for human prolactin using two monoclonal antibodies: one of them immobilized on the solid phase and the other labelled with biotin. Biotin 165-171 prolactin Homo sapiens 51-60 2732299-5 1989 Of the single amino acids tested, phenylalanine and tyrosine were the most potent stimulators of PRL secretion and can account for most, if not all, of the PRL-releasing activity of the mixed meal. Phenylalanine 34-47 prolactin Homo sapiens 97-100 2732299-5 1989 Of the single amino acids tested, phenylalanine and tyrosine were the most potent stimulators of PRL secretion and can account for most, if not all, of the PRL-releasing activity of the mixed meal. Phenylalanine 34-47 prolactin Homo sapiens 156-159 2732299-5 1989 Of the single amino acids tested, phenylalanine and tyrosine were the most potent stimulators of PRL secretion and can account for most, if not all, of the PRL-releasing activity of the mixed meal. Tyrosine 52-60 prolactin Homo sapiens 97-100 2732299-5 1989 Of the single amino acids tested, phenylalanine and tyrosine were the most potent stimulators of PRL secretion and can account for most, if not all, of the PRL-releasing activity of the mixed meal. Tyrosine 52-60 prolactin Homo sapiens 156-159 2602354-1 1989 The properties of a previously isolated disulfide form of pituitary porcine prolactin (pPRL) were studied. Disulfides 40-49 prolactin Homo sapiens 76-85 2730278-4 1989 Significant and similar increases in plasma prolactin and cortisol levels were found in both patients with Alzheimer"s disease and controls following the administration of mCPP vs placebo. 1-(3-chlorophenyl)piperazine 172-176 prolactin Homo sapiens 44-53 2512041-1 1989 There have been no detailed in-vitro studies of PRL secretion by human macroprolactinoma cells exposed to bromocriptine (BC) to within a few days of surgical removal. Bromocriptine 106-119 prolactin Homo sapiens 48-51 2512041-5 1989 During perifusion with dopamine (DA, 5 mumol/l) untreated prolactinomas had a higher PRL secretion rate (19.3 +/- 2.7 microU/mg tissue/min, mean +/- SEM) than BC-treated (3.9 +/- 0.7, P = 0.005). Dopamine 23-31 prolactin Homo sapiens 85-88 2512041-5 1989 During perifusion with dopamine (DA, 5 mumol/l) untreated prolactinomas had a higher PRL secretion rate (19.3 +/- 2.7 microU/mg tissue/min, mean +/- SEM) than BC-treated (3.9 +/- 0.7, P = 0.005). Dopamine 33-35 prolactin Homo sapiens 85-88 2512041-8 1989 TRH (10 ng/ml), without DA, provoked increased PRL release from both untreated (266% basal secretion, n = 3) and BC-treated (298%, n = 3) tumours; this effect was completely inhibited by DA (5 mumol/l). Bromocriptine 113-115 prolactin Homo sapiens 47-50 2663475-4 1989 Bromocriptine can lower serum prolactin, reduce tumor size, and restore fertility in those patients during pregnancy. Bromocriptine 0-13 prolactin Homo sapiens 30-39 2510462-1 1989 Prolactin levels were measured in 71 menopausal women before treatment and 32 treated with steroid implants. Steroids 91-98 prolactin Homo sapiens 0-9 2510463-5 1989 Temporary administration of bromocriptine decreased prolactin levels, caused cessation of lactation and restored ovulatory cycles. Bromocriptine 28-41 prolactin Homo sapiens 52-61 2777190-6 1989 DA infusion caused a significant reduction in serum prolactin (PRL) levels both in hyperprolactinaemic patients (P less than 0.001) and normal women (P less than 0.02), but the PRL suppression was significantly (P less than 0.05) less pronounced in the hyperprolactinaemic patients, compared to normal women. Dopamine 0-2 prolactin Homo sapiens 63-66 2777190-6 1989 DA infusion caused a significant reduction in serum prolactin (PRL) levels both in hyperprolactinaemic patients (P less than 0.001) and normal women (P less than 0.02), but the PRL suppression was significantly (P less than 0.05) less pronounced in the hyperprolactinaemic patients, compared to normal women. Dopamine 0-2 prolactin Homo sapiens 177-180 2656736-1 1989 Cabergoline, a new orally active dopaminergic drug with an extremely long-lasting PRL-lowering effect, was given to 48 hyperprolactinemic women for 3-18 months (median, 8 months) at doses varying between 0.2-3 mg/week administered one to three times weekly. Cabergoline 0-11 prolactin Homo sapiens 82-85 2656736-9 1989 All 3 cabergoline schedules, but not placebo, induced significant reductions in serum PRL concentrations during the 8-week treatment period. Cabergoline 6-17 prolactin Homo sapiens 86-89 2666829-10 1989 The large variety of functions of PRL, in particular the regulation of the transport of sodium and chloride across epithelial membranes, and the regulation of mucus production, can be matched to the major disease symptomatology. Sodium 88-94 prolactin Homo sapiens 34-37 2666829-10 1989 The large variety of functions of PRL, in particular the regulation of the transport of sodium and chloride across epithelial membranes, and the regulation of mucus production, can be matched to the major disease symptomatology. Chlorides 99-107 prolactin Homo sapiens 34-37 2666829-19 1989 We conclude by postulating that PRL acts at the level of the target cell by triggering (in conjunction with a steroid) the gene expression of unique proteins; these act as intermediaries of PRL activity; two or more abnormalities of these proteins when present in an individual produce CF; the protein abnormalities are the consequence of nutritional and ecological pressure. Steroids 110-117 prolactin Homo sapiens 32-35 2759338-4 1989 The size difference persisted after removal of the 3" end poly(A) tract, whereas the PRL precursors synthesized in a cell-free translation system using mRNAs from the three tissues showed identical apparent molecular weights upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Sodium Dodecyl Sulfate 230-252 prolactin Homo sapiens 85-88 2759338-4 1989 The size difference persisted after removal of the 3" end poly(A) tract, whereas the PRL precursors synthesized in a cell-free translation system using mRNAs from the three tissues showed identical apparent molecular weights upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis. polyacrylamide 253-267 prolactin Homo sapiens 85-88 2811781-3 1989 Our results show that thiopental, ketamine and dehydrobenzperidine increase PRL levels significantly (p less than 0.05-0.0025) while fentanyl and diazepam do not alter basal PRL values (p greater than 0.10). Thiopental 22-32 prolactin Homo sapiens 76-79 2811781-3 1989 Our results show that thiopental, ketamine and dehydrobenzperidine increase PRL levels significantly (p less than 0.05-0.0025) while fentanyl and diazepam do not alter basal PRL values (p greater than 0.10). Ketamine 34-42 prolactin Homo sapiens 76-79 2811781-3 1989 Our results show that thiopental, ketamine and dehydrobenzperidine increase PRL levels significantly (p less than 0.05-0.0025) while fentanyl and diazepam do not alter basal PRL values (p greater than 0.10). dehydrobenzperidine 47-66 prolactin Homo sapiens 76-79 2811781-5 1989 Atropine reduces the increase in PRL levels caused by thiopental and ketamine, while it does not affect PRL high levels induced by dehydrobenzperidine. Atropine 0-8 prolactin Homo sapiens 33-36 2811781-5 1989 Atropine reduces the increase in PRL levels caused by thiopental and ketamine, while it does not affect PRL high levels induced by dehydrobenzperidine. Thiopental 54-64 prolactin Homo sapiens 33-36 2811781-5 1989 Atropine reduces the increase in PRL levels caused by thiopental and ketamine, while it does not affect PRL high levels induced by dehydrobenzperidine. Ketamine 69-77 prolactin Homo sapiens 33-36 2811781-6 1989 TSH levels remain unaffected by all drugs, though ketamine shows a statistically indicative mild tendency to increase PRL levels (p less than 0.10). Ketamine 50-58 prolactin Homo sapiens 118-121 2756161-2 1989 On clinical studies, we investigated change of serum prolactin level during the menstrual cycle and relationship to other hormones (LH, FSH, estradiol, progesterone). Estradiol 141-150 prolactin Homo sapiens 53-62 2756161-2 1989 On clinical studies, we investigated change of serum prolactin level during the menstrual cycle and relationship to other hormones (LH, FSH, estradiol, progesterone). Progesterone 152-164 prolactin Homo sapiens 53-62 2756161-4 1989 We conclude that change of prolactin level during the menstrual cycle is related with change of estradiol level. Estradiol 96-105 prolactin Homo sapiens 27-36 2525805-3 1989 Two other groups of hypertensive (n = 10) and normotensive (n = 11) subjects received 10 mg of the dopamine antagonist metoclopramide intravenously, upon which serum prolactin concentration increased 10-fold. Metoclopramide 119-133 prolactin Homo sapiens 166-175 2524947-0 1989 Role of prolactin in age-related change in serum dehydroepiandrosterone sulphate concentrations. Dehydroepiandrosterone Sulfate 49-80 prolactin Homo sapiens 8-17 2803131-6 1989 All patients in the study were treated with bromocriptine (2.5-10 mg) to normalize serum prolactin or to achieve a pregnancy. Bromocriptine 44-57 prolactin Homo sapiens 89-98 2651165-0 1989 Prolactin and its response to the luteinizing hormone-releasing hormone thyrotropin-releasing hormone test in patients with endometriosis before, during, and after treatment with danazol. Danazol 179-186 prolactin Homo sapiens 0-9 2707462-0 1989 Metoclopramide-mediated prolactin secretion in patients with idiopathic hypogonadotropic hypogonadism: effect of testosterone therapy. Metoclopramide 0-14 prolactin Homo sapiens 24-33 2707462-1 1989 The secretion of prolactin (PRL) after intravenous metoclopramide was evaluated in six prepubertal subjects with idiopathic isolated hypogonadotropic hypogonadism before and after repeated testosterone (T) injections. Metoclopramide 51-65 prolactin Homo sapiens 17-26 2707462-2 1989 The PRL response to metoclopramide was markedly blunted before T treatment, but both the basal and metoclopramide-stimulated PRL secretion became normal after 4 to 15 months of intramuscular T enanthate, although in three of the subjects, serum T was low at the time of the repeat study. Metoclopramide 20-34 prolactin Homo sapiens 4-7 2707462-2 1989 The PRL response to metoclopramide was markedly blunted before T treatment, but both the basal and metoclopramide-stimulated PRL secretion became normal after 4 to 15 months of intramuscular T enanthate, although in three of the subjects, serum T was low at the time of the repeat study. Metoclopramide 99-113 prolactin Homo sapiens 125-128 2526151-0 1989 Long-term effects of progestin and RU 486 on prolactin production and synthesis in human endometrial stromal cells. Mifepristone 35-41 prolactin Homo sapiens 45-54 2526151-1 1989 Previous studies have shown that the production of prolactin (PRL) is increased in human endometrial stromal cells cultured with medroxyprogesterone acetate (MPA) for 3-5 days. Medroxyprogesterone Acetate 129-156 prolactin Homo sapiens 51-60 2526151-1 1989 Previous studies have shown that the production of prolactin (PRL) is increased in human endometrial stromal cells cultured with medroxyprogesterone acetate (MPA) for 3-5 days. Medroxyprogesterone Acetate 129-156 prolactin Homo sapiens 62-65 2526151-1 1989 Previous studies have shown that the production of prolactin (PRL) is increased in human endometrial stromal cells cultured with medroxyprogesterone acetate (MPA) for 3-5 days. Medroxyprogesterone Acetate 158-161 prolactin Homo sapiens 51-60 2526151-1 1989 Previous studies have shown that the production of prolactin (PRL) is increased in human endometrial stromal cells cultured with medroxyprogesterone acetate (MPA) for 3-5 days. Medroxyprogesterone Acetate 158-161 prolactin Homo sapiens 62-65 2526151-7 1989 However, the production of PRL was increased by MPA in stromal cells pretreated with RU 486 indicating that the effect of RU 486 is reversible. Mifepristone 85-91 prolactin Homo sapiens 27-30 2526151-7 1989 However, the production of PRL was increased by MPA in stromal cells pretreated with RU 486 indicating that the effect of RU 486 is reversible. Mifepristone 122-128 prolactin Homo sapiens 27-30 2526151-8 1989 When stromal cells were treated with MPA and RU 486 sequentially, RU 486 stimulated the PRL production (approximately 2-fold over the MPA-treated cells) for 2-3 days and then reduced to basal levels over a 5-day period. Mifepristone 45-51 prolactin Homo sapiens 88-91 2526151-8 1989 When stromal cells were treated with MPA and RU 486 sequentially, RU 486 stimulated the PRL production (approximately 2-fold over the MPA-treated cells) for 2-3 days and then reduced to basal levels over a 5-day period. Mifepristone 66-72 prolactin Homo sapiens 88-91 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Mifepristone 42-48 prolactin Homo sapiens 52-55 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Mifepristone 42-48 prolactin Homo sapiens 156-159 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Mifepristone 42-48 prolactin Homo sapiens 156-159 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Mifepristone 42-48 prolactin Homo sapiens 156-159 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Sulfur-35 208-211 prolactin Homo sapiens 52-55 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Sulfur-35 208-211 prolactin Homo sapiens 156-159 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Sulfur-35 208-211 prolactin Homo sapiens 156-159 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Sulfur-35 208-211 prolactin Homo sapiens 156-159 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Methionine 212-222 prolactin Homo sapiens 52-55 2526151-9 1989 The stimulatory and inhibitory effects of RU 486 on PRL production in stromal cells pretreated with progestin was also observed in the rate of synthesis of PRL estimated by incubating the stromal cells with [35S]methionine and immuno-isolating the [35S]PRL with anti-PRL. Sulfur-35 249-252 prolactin Homo sapiens 52-55 2745669-4 1989 During bromocriptine treatment the serum prolactin levels declined and serum oestradiol levels were higher on day 9 of the cycle. Bromocriptine 7-20 prolactin Homo sapiens 41-50 2549113-0 1989 Effects of the antidopaminergic drug veralipride on LH and PRL secretion in postmenopausal women. veralipride 37-48 prolactin Homo sapiens 59-62 2549113-3 1989 Mean plasma LH levels were significantly blunted (p less than 0.05) and mean plasma PRL levels were significantly increased (p less than 0.001) by veralipride administration. veralipride 147-158 prolactin Homo sapiens 84-87 2549113-4 1989 The frequency of both LH and PRL secretory pulses was not modified, while the mean pulse amplitude of both hormones was significantly increased (p less than 0.05 for LH; p less than 0.001 for PRL) by veralipride administration. veralipride 200-211 prolactin Homo sapiens 192-195 2549113-8 1989 In untreated postmenopausal women, the percentage of concomitant PRL and LH pulses was significantly higher (p less than 0.001) during naloxone than during saline infusion, and this effect was amplified by veralipride administration (p less than 0.01). Naloxone 135-143 prolactin Homo sapiens 65-68 2549113-8 1989 In untreated postmenopausal women, the percentage of concomitant PRL and LH pulses was significantly higher (p less than 0.001) during naloxone than during saline infusion, and this effect was amplified by veralipride administration (p less than 0.01). Sodium Chloride 156-162 prolactin Homo sapiens 65-68 2715295-6 1989 Two additional pregnant women, one with a bromocriptine-treated PRL-secreting adenoma (subject C), and a normal woman (subject D) were studied. Bromocriptine 42-55 prolactin Homo sapiens 64-67 2601863-5 1989 L-sulpiride is an antagonist of dopamine on D2 receptors therefore inhibits the action of dopamine increasing the secretion of prolactin. levosulpiride 0-11 prolactin Homo sapiens 127-136 2601863-5 1989 L-sulpiride is an antagonist of dopamine on D2 receptors therefore inhibits the action of dopamine increasing the secretion of prolactin. Dopamine 32-40 prolactin Homo sapiens 127-136 2601863-5 1989 L-sulpiride is an antagonist of dopamine on D2 receptors therefore inhibits the action of dopamine increasing the secretion of prolactin. Dopamine 90-98 prolactin Homo sapiens 127-136 2601863-7 1989 Together with the increment of catecholamines, high concentration of prolactin can evoke arrhythmias. Catecholamines 31-45 prolactin Homo sapiens 69-78 2601863-8 1989 In view of this possibility we studied the time course of the administration of the two doses of L-sulpiride and of droperidol on prolactin secretion. Droperidol 116-126 prolactin Homo sapiens 130-139 2601863-10 1989 Droperidol-induced increase in prolactin secretion was significant already at ten minutes after the administration reaching the peak after 20 minutes. Droperidol 0-10 prolactin Homo sapiens 31-40 2601863-11 1989 L-sulpiride increased prolactin secretion reaching the maximum increase 20 minutes after the administration of 50 mg of the drug, and 30 minutes after the administration of 100 mg doses. levosulpiride 0-11 prolactin Homo sapiens 22-31 2780875-1 1989 Intracranial injections of prolactin (PRL) have been previously shown to elevate food and water intake in ring doves. Water 90-95 prolactin Homo sapiens 27-36 2780875-1 1989 Intracranial injections of prolactin (PRL) have been previously shown to elevate food and water intake in ring doves. Water 90-95 prolactin Homo sapiens 38-41 2780875-3 1989 PRL increased food consumption by 35-50% over baseline levels in water deprived and nondeprived doves, although response latencies (10 hr) and durations (greater than 24 hr) were considerably longer than those reported for other orexigenic peptides. Water 65-70 prolactin Homo sapiens 0-3 2780875-5 1989 In contrast to this pattern, water intake remained unchanged in food deprived doves and was only marginally increased in nondeprived doves following PRL treatment. Water 29-34 prolactin Homo sapiens 149-152 2748770-2 1989 We studied the plasma prolactin response to infusion of 0.5 molar sodium lactate in 38 patients with panic disorder or agoraphobia with panic attacks, and 16 normal controls. Sodium Lactate 66-80 prolactin Homo sapiens 22-31 2748770-4 1989 However, the males who experienced lactate-induced panic had significantly elevated baseline prolactin levels compared to male nonpanickers and controls. Lactic Acid 35-42 prolactin Homo sapiens 93-102 2748770-5 1989 Prolactin levels increased in all groups during lactate infusion, which may reflect osmotic effects, but were blunted in the late panickers compared to nonpanickers and controls. Lactic Acid 48-55 prolactin Homo sapiens 0-9 2720017-5 1989 When adjusted for the baseline, PRL and cortisol responses 180 min after fenfluramine administration were significantly elevated in subjects with higher levels of aggressiveness and impulsivity. Fenfluramine 73-85 prolactin Homo sapiens 32-35 2658666-7 1989 A significantly reduced prolactin response to alcohol in HR subjects could not be confirmed. Alcohols 46-53 prolactin Homo sapiens 24-33 2598475-0 1989 Effect of morphine on cortisol and prolactin secretion in anorexia nervosa and depression. Morphine 10-18 prolactin Homo sapiens 35-44 2598475-2 1989 To investigate further this hypothesis, we conducted a placebo-controlled study of the effect of the opiate alkaloid morphine on cortisol and prolactin secretion in six patients with anorexia nervosa and six age-matched healthy volunteers, and compared the results with those obtained in nine depressed patients. Morphine 117-125 prolactin Homo sapiens 142-151 2598475-5 1989 The prolactin response to morphine was attenuated significantly in patients with depression. Morphine 26-34 prolactin Homo sapiens 4-13 2598475-7 1989 However, the decreased prolactin response to morphine in depressed patients remains compatible with this hypothesis. Morphine 45-53 prolactin Homo sapiens 23-32 2506003-2 1989 The effect of an acute increase in serum PRL induced by thyrotropin releasing hormone (TRH) or metoclopramide (MCP) on the serum immunoreactive EGF concentration was examined in nine hyperprolactinemic patients and eight normoprolactinemic women. Metoclopramide 95-109 prolactin Homo sapiens 41-44 2506003-4 1989 The serum EGF concentration was decreased to 40-50% of the basal level after the abrupt increase in serum PRL induced by the injection of TRH or MCP in normoprolactinemic subjects, but no significant change in serum EGF occurred in hyperprolactinemic patients after MCP injection, in spite of a significant increase in PRL. Metoclopramide 145-148 prolactin Homo sapiens 106-109 2721367-5 1989 Footprinting competition experiments and gel retardation assays with synthetic oligonucleotides suggest that a single factor is responsible for the pituitary-specific footprints seen on the human Prl, CS, and GH genes. Oligonucleotides 79-95 prolactin Homo sapiens 196-199 2497097-6 1989 Basal serum PRL increased after 3, 6 and 9 wk of MC treatment (58.1 vs 5.4, 46.0 vs 12.0 and 50.8 vs 16.9 ng/ml, MC vs sucrose, respectively). Metoclopramide 49-51 prolactin Homo sapiens 12-15 2497097-6 1989 Basal serum PRL increased after 3, 6 and 9 wk of MC treatment (58.1 vs 5.4, 46.0 vs 12.0 and 50.8 vs 16.9 ng/ml, MC vs sucrose, respectively). Metoclopramide 113-115 prolactin Homo sapiens 12-15 2497097-6 1989 Basal serum PRL increased after 3, 6 and 9 wk of MC treatment (58.1 vs 5.4, 46.0 vs 12.0 and 50.8 vs 16.9 ng/ml, MC vs sucrose, respectively). Sucrose 119-126 prolactin Homo sapiens 12-15 2723127-0 1989 Naloxone suppresses buprenorphine stimulation of plasma prolactin. Naloxone 0-8 prolactin Homo sapiens 56-65 2723127-0 1989 Naloxone suppresses buprenorphine stimulation of plasma prolactin. Buprenorphine 20-33 prolactin Homo sapiens 56-65 2723127-3 1989 Simultaneous injection of buprenorphine 0.3 mg and saline resulted in an average increase in plasma prolactin above baseline levels of approximately 10 and 25 ng/ml, 30 and 55 minutes after injection. Buprenorphine 26-39 prolactin Homo sapiens 100-109 2723127-3 1989 Simultaneous injection of buprenorphine 0.3 mg and saline resulted in an average increase in plasma prolactin above baseline levels of approximately 10 and 25 ng/ml, 30 and 55 minutes after injection. Sodium Chloride 51-57 prolactin Homo sapiens 100-109 2723127-4 1989 Buprenorphine-induced stimulation of plasma prolactin levels was statistically significantly greater than basal prolactin values (p less than 0.01). Buprenorphine 0-13 prolactin Homo sapiens 44-53 2723127-5 1989 When 0.6 mg of naloxone was simultaneously injected with 0.3 mg buprenorphine, peak plasma prolactin levels were significantly lower (p less than 0.05) than prolactin values after administration of 0.3 mg buprenorphine and saline. Naloxone 15-23 prolactin Homo sapiens 91-100 2723127-5 1989 When 0.6 mg of naloxone was simultaneously injected with 0.3 mg buprenorphine, peak plasma prolactin levels were significantly lower (p less than 0.05) than prolactin values after administration of 0.3 mg buprenorphine and saline. Naloxone 15-23 prolactin Homo sapiens 157-166 2723127-5 1989 When 0.6 mg of naloxone was simultaneously injected with 0.3 mg buprenorphine, peak plasma prolactin levels were significantly lower (p less than 0.05) than prolactin values after administration of 0.3 mg buprenorphine and saline. Buprenorphine 64-77 prolactin Homo sapiens 91-100 2723127-6 1989 Simultaneous injection of 0.45 mg naloxone and 0.3 mg buprenorphine also resulted in a significant attenuation (p less than 0.05) of buprenorphine-stimulated prolactin levels. Naloxone 34-42 prolactin Homo sapiens 158-167 2723127-6 1989 Simultaneous injection of 0.45 mg naloxone and 0.3 mg buprenorphine also resulted in a significant attenuation (p less than 0.05) of buprenorphine-stimulated prolactin levels. Buprenorphine 54-67 prolactin Homo sapiens 158-167 2723127-6 1989 Simultaneous injection of 0.45 mg naloxone and 0.3 mg buprenorphine also resulted in a significant attenuation (p less than 0.05) of buprenorphine-stimulated prolactin levels. Buprenorphine 133-146 prolactin Homo sapiens 158-167 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Naloxone 62-70 prolactin Homo sapiens 127-136 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Naloxone 62-70 prolactin Homo sapiens 199-208 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 174-187 prolactin Homo sapiens 127-136 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 174-187 prolactin Homo sapiens 199-208 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Naloxone 387-395 prolactin Homo sapiens 127-136 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Naloxone 387-395 prolactin Homo sapiens 199-208 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 405-418 prolactin Homo sapiens 127-136 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 405-418 prolactin Homo sapiens 199-208 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 405-418 prolactin Homo sapiens 127-136 2723127-8 1989 These findings demonstrate a dose-effect relationship between naloxone concentration and suppression of the increase in plasma prolactin levels produced by administration of buprenorphine 0.3 mg. As prolactin stimulation occurs shortly after opioid agonist administration and is temporally concordant with the rapid induction of pharmacologic reinforcement associated with opiate abuse, naloxone added to buprenorphine parenteral preparations may reduce the abuse potential of buprenorphine. Buprenorphine 405-418 prolactin Homo sapiens 199-208 2723131-0 1989 Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety. Buspirone 0-9 prolactin Homo sapiens 22-31 2723131-4 1989 A drug effect upon serotonin-modulated prolactin release or on the tubero-infundibular dopamine axis (prolactin; growth hormone) was negligible at clinically effective dosages of buspirone. Serotonin 19-28 prolactin Homo sapiens 39-48 2723131-4 1989 A drug effect upon serotonin-modulated prolactin release or on the tubero-infundibular dopamine axis (prolactin; growth hormone) was negligible at clinically effective dosages of buspirone. Dopamine 87-95 prolactin Homo sapiens 102-111 2744187-2 1989 During bromocriptine treatment, the serum prolactin (PRL) concentration significantly decreased, and consequently the serum estradiol (E2) concentration was significantly higher than in the controls on cycle day 9, and the ratio of testosterone (T) to E2 was decreased from cycle day 8 through day 10. Bromocriptine 7-20 prolactin Homo sapiens 53-56 2923932-0 1989 Prolactin response to fentanyl in depression. Fentanyl 22-30 prolactin Homo sapiens 0-9 2923932-3 1989 Repeated measures Analysis of Variance yielded a significant effect of fentanyl administration on prolactin secretion (p less than 0.0001), and there were elevated hormone responses in the evening (p less than 0.005). Fentanyl 71-79 prolactin Homo sapiens 98-107 2494827-5 1989 Each TRH administration stimulated PRL release in acromegalic patients, though the nAUC of PRL was significantly higher after the first (1260 +/- 249 micrograms.min.l-1) than after the second and the third TRH administration (478 +/- 195 and 615 +/- 117 micrograms.min.l-1, respectively; P less than 0.01). nauc 83-87 prolactin Homo sapiens 91-94 2574083-0 1989 Effect of subacute cabergoline treatment on prolactin, thyroid stimulating hormone and growth hormone response to simultaneous administration of thyrotrophin-releasing hormone and growth hormone-releasing hormone in hyperprolactinaemic women. Cabergoline 19-30 prolactin Homo sapiens 44-53 2714509-6 1989 Furthermore, the effect of bromocriptine on the serum PRL level in patients with prolactinoma, and the change in the serum PRL level after metoclopramide loading could be determined using this kit. Bromocriptine 27-40 prolactin Homo sapiens 54-57 2545768-4 1989 In 4 out of 7 patients basal serum PRL concentrations in the inferior petrosal sinus ipsilateral to the tumor were higher than in the contralateral; only two out of 4 showed an increase in PRL levels after oCRH injection. Corticorelin ovine 206-210 prolactin Homo sapiens 189-192 2924745-4 1989 During the naloxone infusion night, mean nocturnal plasma prolactin (PRL) concentrations in this group of patients showed significant elevation, which was correlated with increased density of FIEDs. Naloxone 11-19 prolactin Homo sapiens 58-67 2494621-2 1989 Because elevated serum prolactin (PRL) has several adverse effects on female reproductive function, this event has been implicated as a factor to explain the difference between ovulation and pregnancy rates in hMG/hCG treatment cycles. Menotropins 210-213 prolactin Homo sapiens 23-32 2564008-14 1989 The residual PRL responses were negatively correlated with free triiodothyronine levels and positively with serotonergic variables, i.e., 5-hydroxyindoleacetic acid in 24-h urine and the ratio L-tryptophan/competing amino acids. Triiodothyronine 64-80 prolactin Homo sapiens 13-16 2564008-13 1989 There was a significant negative correlation between basal PRL and follicle stimulating hormone levels, age and post-dexamethasone cortisol values. Dexamethasone 117-130 prolactin Homo sapiens 59-62 2564008-14 1989 The residual PRL responses were negatively correlated with free triiodothyronine levels and positively with serotonergic variables, i.e., 5-hydroxyindoleacetic acid in 24-h urine and the ratio L-tryptophan/competing amino acids. Hydroxyindoleacetic Acid 138-164 prolactin Homo sapiens 13-16 2564008-14 1989 The residual PRL responses were negatively correlated with free triiodothyronine levels and positively with serotonergic variables, i.e., 5-hydroxyindoleacetic acid in 24-h urine and the ratio L-tryptophan/competing amino acids. Tryptophan 193-205 prolactin Homo sapiens 13-16 2714509-6 1989 Furthermore, the effect of bromocriptine on the serum PRL level in patients with prolactinoma, and the change in the serum PRL level after metoclopramide loading could be determined using this kit. Metoclopramide 139-153 prolactin Homo sapiens 123-126 2666885-3 1989 When treatment with bromocriptine was instituted (10 mg/daily) mean serum prolactin concentration fell from 490 ng/ml to 108 ng/ml. Bromocriptine 20-33 prolactin Homo sapiens 74-83 2666885-8 1989 Bromocriptine can cause not only a decrease in serum prolactin levels but also a regression in the size of prolactinomas in hyperprolactinemic women. Bromocriptine 0-13 prolactin Homo sapiens 53-62 2927618-1 1989 Four patients with macroprolactinomas treated with bromocriptine had tumor growth and visual loss despite marked reduction in their serum prolactin levels. Bromocriptine 51-64 prolactin Homo sapiens 24-33 2493039-2 1989 In this study we measured basal and TRH-stimulated serum TSH and PRL levels in 15 women with PMS and in 19 age-matched normal women. Thyrotropin-Releasing Hormone 36-39 prolactin Homo sapiens 65-68 2493039-5 1989 After TRH administration, peak serum PRL and TSH levels were reached at 15 and 30 min, respectively, and the response curves were virtually identical in the 2 groups in both phases of the cycle. Thyrotropin-Releasing Hormone 6-9 prolactin Homo sapiens 37-40 2537637-3 1989 A one second pulse of 100 mM KCl caused an increase in [Ca2+]c with a half peak width of about 18 seconds and an almost coincident increase in prolactin secretion. Potassium Chloride 29-32 prolactin Homo sapiens 143-152 2537637-4 1989 Subsequent pulses of KCl each caused increases in [Ca2+]c and prolactin release that were the same as the first, up to a pulse frequency of one every two minutes. Potassium Chloride 21-24 prolactin Homo sapiens 62-71 2612015-4 1989 All were treated with bromocriptine (7.5-60 mg/day) which lowered prolactin substantially in all and into the normal range in 11 (range less than 60-3090, median 105 mU/l). Bromocriptine 22-35 prolactin Homo sapiens 66-75 2912773-6 1989 In all patients there was a dramatic initial reduction in PRL in response to a single 2.5 mg dose of bromocriptine. Bromocriptine 101-114 prolactin Homo sapiens 58-61 2722134-2 1989 The chromatographic profile by Sephadex G-100 showed that the percentage of immunoreactive big-big hPRL was 10.7% in case 1 and 64.1% in case 2. sephadex 31-45 prolactin Homo sapiens 99-103 2722134-3 1989 On Sephadex G-200 and TSK G3000SW columns, the molecular weight of big-big hPRL was estimated to be more than 500,000 daltons (big-big1 hPRL) in case 1 and approximately 250,000-300,000 daltons (big-big2 hPRL) in case 2. sephadex 3-11 prolactin Homo sapiens 75-79 2722134-4 1989 Big-big1 hPRL in case 1 was converted to big and little hPRLs when the serum was treated with 2-mercaptoethanol (2-ME), but part of the big-big2 hPRL in case 2 was converted to a larger molecule. Mercaptoethanol 94-111 prolactin Homo sapiens 9-13 2722134-4 1989 Big-big1 hPRL in case 1 was converted to big and little hPRLs when the serum was treated with 2-mercaptoethanol (2-ME), but part of the big-big2 hPRL in case 2 was converted to a larger molecule. Mercaptoethanol 113-117 prolactin Homo sapiens 9-13 2722134-5 1989 Radioactive big-big hPRL generated by mixing labeled hPRL with the serum from case 1 was eluted with the void volume on Sephadex G-100 column and was not converted to the other molecular forms after 2-ME treatment. sephadex 120-134 prolactin Homo sapiens 20-24 2722134-5 1989 Radioactive big-big hPRL generated by mixing labeled hPRL with the serum from case 1 was eluted with the void volume on Sephadex G-100 column and was not converted to the other molecular forms after 2-ME treatment. sephadex 120-134 prolactin Homo sapiens 53-57 2722134-5 1989 Radioactive big-big hPRL generated by mixing labeled hPRL with the serum from case 1 was eluted with the void volume on Sephadex G-100 column and was not converted to the other molecular forms after 2-ME treatment. Mercaptoethanol 199-203 prolactin Homo sapiens 20-24 2920849-4 1989 Serum PRL was higher in azoospermia and also in subjects with lower levels of seminal citric acid. Citric Acid 86-97 prolactin Homo sapiens 6-9 2920849-6 1989 Seminal PRL was increased in subjects with higher levels of seminal citric acid and decreased in subjects with lower levels of corrected seminal fructose. Citric Acid 68-79 prolactin Homo sapiens 8-11 2920849-6 1989 Seminal PRL was increased in subjects with higher levels of seminal citric acid and decreased in subjects with lower levels of corrected seminal fructose. Fructose 145-153 prolactin Homo sapiens 8-11 2669670-3 1989 The high serum prolactin levels detected initially decreased under bromocriptine to ward normal levels and was not modified after surgery, while gonadotropin production remain scarce. Bromocriptine 67-80 prolactin Homo sapiens 15-24 2910219-4 1989 The prolactin response to tryptophan was significantly enhanced after short-term lithium treatment; long-term lithium treatment had no effect. Tryptophan 26-36 prolactin Homo sapiens 4-13 2910219-4 1989 The prolactin response to tryptophan was significantly enhanced after short-term lithium treatment; long-term lithium treatment had no effect. Lithium 81-88 prolactin Homo sapiens 4-13 2910219-5 1989 Other studies have shown that the prolactin response to tryptophan is also enhanced after long-term tricyclic antidepressant treatment in depressed patients and after short- and long-term lithium treatment in healthy subjects. Tryptophan 56-66 prolactin Homo sapiens 34-43 2910219-5 1989 Other studies have shown that the prolactin response to tryptophan is also enhanced after long-term tricyclic antidepressant treatment in depressed patients and after short- and long-term lithium treatment in healthy subjects. Lithium 188-195 prolactin Homo sapiens 34-43 2910220-7 1989 As anticipated, metergoline lowered plasma prolactin concentrations (providing evidence of physiologically significant 5-HT antagonism) but did not alter plasma clomipramine concentrations. Metergoline 16-27 prolactin Homo sapiens 43-52 2506942-0 1989 Prolactin response to dopamine and valproate administration in breast cancer patients. Dopamine 22-30 prolactin Homo sapiens 0-9 2506942-0 1989 Prolactin response to dopamine and valproate administration in breast cancer patients. Valproic Acid 35-44 prolactin Homo sapiens 0-9 2650930-3 1989 A significant (p less than 0.05) slight decrease in mean values of PRL was observed in normals after the CWT but no change was found in hypertensives. CWT 105-108 prolactin Homo sapiens 67-70 2927618-3 1989 Patients treated with bromocriptine require periodic examination by computed tomographic scan or magnetic resonance imaging and neuro-ophthalmological evaluation in addition to monitoring of serum prolactin. Bromocriptine 22-35 prolactin Homo sapiens 197-206 11941005-0 1989 Prolactin Response to Pentylenetetrazol (Cardiazol) Convulsive Therapy. Pentylenetetrazole 22-39 prolactin Homo sapiens 0-9 11941005-0 1989 Prolactin Response to Pentylenetetrazol (Cardiazol) Convulsive Therapy. Pentylenetetrazole 41-50 prolactin Homo sapiens 0-9 11941005-2 1989 Similar prolactin response has been demonstrated following pentylenetetrazol (Cardiazol)-induced seizures in two schizophrenic female patients. Pentylenetetrazole 59-76 prolactin Homo sapiens 8-17 11941005-2 1989 Similar prolactin response has been demonstrated following pentylenetetrazol (Cardiazol)-induced seizures in two schizophrenic female patients. Pentylenetetrazole 78-87 prolactin Homo sapiens 8-17 2492224-5 1989 Nevertheless, the mean basal concentration of serum prolactin (PRL) was lower and the response of PRL to TRH was higher in male patients treated with CBZ. Carbamazepine 150-153 prolactin Homo sapiens 52-61 2912716-2 1989 We studied the effects of administration of high-dose naloxone, an opiate antagonist, on postictal prolactin levels, seizure duration, and postictal behavior, using patients undergoing electroconvulsive therapy (ECT) as a seizure model. Naloxone 54-62 prolactin Homo sapiens 99-108 2499519-1 1989 The main aim of this study was to evaluate the effect of dopamine infusion on plasma luteinizing hormone (LH), follicle-stimulating hormone, (FSH) and prolactin (PRL) after acute (1 week postovariectomy) and chronic (postmenopausal women) estrogen withdrawal. Dopamine 57-65 prolactin Homo sapiens 151-160 2499519-1 1989 The main aim of this study was to evaluate the effect of dopamine infusion on plasma luteinizing hormone (LH), follicle-stimulating hormone, (FSH) and prolactin (PRL) after acute (1 week postovariectomy) and chronic (postmenopausal women) estrogen withdrawal. Dopamine 57-65 prolactin Homo sapiens 162-165 2499519-5 1989 In all groups of patients, dopamine significantly inhibited plasma PRL levels. Dopamine 27-35 prolactin Homo sapiens 67-70 2499519-7 1989 Plasma FSH levels did not change in any group and PRL levels increased after metoclopramide administration in all subjects. Metoclopramide 77-91 prolactin Homo sapiens 50-53 2737544-0 1989 Studies on amniotic prolactin: chromatographic pattern and correlation with the lecithin content. Lecithins 80-88 prolactin Homo sapiens 20-29 2737544-2 1989 Prolactin is present totally as a low-molecular-weight form, "little" prolactin, and appears to correlate negatively with lecithin during the 2nd and positively during the 3rd trimester. Lecithins 122-130 prolactin Homo sapiens 0-9 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 53-61 prolactin Homo sapiens 17-26 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 53-61 prolactin Homo sapiens 28-31 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 53-61 prolactin Homo sapiens 116-119 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 66-74 prolactin Homo sapiens 17-26 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 66-74 prolactin Homo sapiens 28-31 2722137-1 1989 In most of human prolactin (PRL)-secreting adenomas, dopamine and dopamine agonists normally suppress the excessive PRL secretion. Dopamine 66-74 prolactin Homo sapiens 116-119 2722137-4 1989 Culture studies of these adenoma cells showed that: (1) 10(-8) M bromocriptine produced a 32 +/- 16% inhibition of PRL release versus 65 +/- 12% obtained in the same conditions with normal human pituitary cells; (2) sulpiride (10(-6) M) reversed the inhibitory effects of bromocriptine, and (3) the bacterial endotoxins, cholera toxin (10(-11) M) and pertussis toxin (250 ng/ml), respectively, produced a 45-500% increase and a total abolition of bromocriptine-induced PRL inhibition. Bromocriptine 65-78 prolactin Homo sapiens 115-118 2722137-4 1989 Culture studies of these adenoma cells showed that: (1) 10(-8) M bromocriptine produced a 32 +/- 16% inhibition of PRL release versus 65 +/- 12% obtained in the same conditions with normal human pituitary cells; (2) sulpiride (10(-6) M) reversed the inhibitory effects of bromocriptine, and (3) the bacterial endotoxins, cholera toxin (10(-11) M) and pertussis toxin (250 ng/ml), respectively, produced a 45-500% increase and a total abolition of bromocriptine-induced PRL inhibition. Bromocriptine 65-78 prolactin Homo sapiens 469-472 2531773-13 1989 Plasma levels of prolactin increased transiently after raclopride intake to a maximum of up to 80 and 130 ng/ml in male and female patients respectively. Raclopride 55-65 prolactin Homo sapiens 17-26 2536765-1 1989 A single dose of 80 mg fluoxetine induced a slight increase in cortisol secretion when compared to placebo in an acute endocrine challenge test including assessment of prolactin, growth hormone, luteinizing hormone, follicle stimulating hormone, testosterone. Fluoxetine 23-33 prolactin Homo sapiens 168-177 2485823-2 1989 In this communication, evidence is presented to suggest that the striatal dopamine receptor supersensitivity in TS may be mediated by alterations in the release and function of dopamine supersensitive factors including prolactin, estrogens, beta-endorphin, melanocyte stimulating hormone (MSH), and adrenal corticotrophic hormone (ACTH). Dopamine 74-82 prolactin Homo sapiens 219-228 2485823-2 1989 In this communication, evidence is presented to suggest that the striatal dopamine receptor supersensitivity in TS may be mediated by alterations in the release and function of dopamine supersensitive factors including prolactin, estrogens, beta-endorphin, melanocyte stimulating hormone (MSH), and adrenal corticotrophic hormone (ACTH). Dopamine 177-185 prolactin Homo sapiens 219-228 2521644-0 1989 Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. Imipramine 10-20 prolactin Homo sapiens 38-47 2521644-0 1989 Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. Fenfluramine 60-72 prolactin Homo sapiens 38-47 2521644-1 1989 As an index of central serotonergic function, plasma prolactin response to fenfluramine (60 mg orally) and placebo challenge was examined in 10 depressed patients before and after treatment with imipramine 200 mg/day for 3 weeks. Fenfluramine 75-87 prolactin Homo sapiens 53-62 2521644-2 1989 Although baseline prolactin levels were not altered by imipramine, the prolactin response to fenfluramine was significantly (P = 0.01) increased compared to the response in the untreated state. Fenfluramine 93-105 prolactin Homo sapiens 71-80 2909550-1 1989 High serum PRL and low zinc (Zn) levels are common findings in patients with chronic renal failure (CRF); in such patients serum Zn concentrations have been reported to be inversely correlated to serum PRL levels. Zinc 129-131 prolactin Homo sapiens 11-14 2909550-1 1989 High serum PRL and low zinc (Zn) levels are common findings in patients with chronic renal failure (CRF); in such patients serum Zn concentrations have been reported to be inversely correlated to serum PRL levels. Zinc 129-131 prolactin Homo sapiens 202-205 2654270-8 1989 Prolactin exerts a direct stimulating effect on the growth of prostatic cells working synergistically with testosterone through specific prolactin receptors. Testosterone 107-119 prolactin Homo sapiens 0-9 2654270-8 1989 Prolactin exerts a direct stimulating effect on the growth of prostatic cells working synergistically with testosterone through specific prolactin receptors. Testosterone 107-119 prolactin Homo sapiens 137-146 2732638-8 1989 The increased brain serotonin synthesis as the associated pathology of X-linked congenital adrenal hypoplasia was proposed on the basis of elevated basal plasma GH and PRL levels in the reported cases, taken together with an incidence of congenital LH deficiency and persistent ACTH hypersecretion in corticosteroid treated patients reported elsewhere. Serotonin 20-29 prolactin Homo sapiens 168-171 2709304-0 1989 Plasma prolactin concentrations in pinealectomized ewes receiving melatonin treatment and in pineal intact ewes maintained under a non-24-hour photoperiod. Melatonin 66-75 prolactin Homo sapiens 7-16 2533954-5 1989 There was a tendency to lower levels of DHEAS in the infected group by comparison with controls (54.92 +/- 37.34 micrograms/dl vs 66.80 +/- 47.18 micrograms/dl) while in the same infected group more subjects had higher levels of prolactin by comparison with the control group (10.85 +/- 14.16 ng/ml vs 9.80 +/- 5.56 ng/ml). Dehydroepiandrosterone Sulfate 40-45 prolactin Homo sapiens 229-238 2776353-5 1989 Hyperprolactinaemia (greater than 350 mIU/l) was present in hypothyroid cretins only (13 of 26; 50%) and serum PRL showed a curvilinear relation with serum TSH levels (r = 0.7, P less than 0.0001). Thyrotropin 156-159 prolactin Homo sapiens 111-114 2497396-0 1989 Role of hypothalamic catecholamines in the regulation of luteinizing hormone and prolactin secretion in the ewe during seasonal anestrus. Catecholamines 21-35 prolactin Homo sapiens 81-90 2497396-8 1989 Plasma prolactin levels were significantly reduced by 6OH-DA treatment. Oxidopamine 54-60 prolactin Homo sapiens 7-16 2561010-1 1989 In the past, some researchers found increased cortisol and prolactin responses to the administration of fenfluramine in major-depressed patients. Fenfluramine 104-116 prolactin Homo sapiens 59-68 2561010-8 1989 There was a significant (p = 0.02) effect for fenfluramine treatment on prolactin. Fenfluramine 46-58 prolactin Homo sapiens 72-81 2615927-3 1989 The main findings were (1) sex differences in the growth hormone and cortisol response to desipramine and (2) a significant genetic component of the prolactin and cortisol response to desipramine as indicated by significantly (p less than 0.05) lower within-pair than between-pair variance in the sibling pairs but not random pairs of the experimental subjects. Desipramine 184-195 prolactin Homo sapiens 149-158 2594732-2 1989 It was shown that CD + LD resulted in minimal suppression of serum PRL (18.4 +/- 3.4%) in tumor patients, with this being significantly less than that in normal women (80.7 +/- 4.6%). Cadmium 18-22 prolactin Homo sapiens 67-70 2508166-0 1989 Lithium increases 5-HT-mediated prolactin release. Lithium 0-7 prolactin Homo sapiens 32-41 2508166-1 1989 The effects of short-term (3-4 days) lithium treatment on the prolactin responses to intravenous clomipramine (0.1 mg/kg), metoclopramide (5 micrograms/kg) and haloperidol (2.5-5 micrograms/kg) were assessed in male volunteers. Lithium 37-44 prolactin Homo sapiens 62-71 2508166-1 1989 The effects of short-term (3-4 days) lithium treatment on the prolactin responses to intravenous clomipramine (0.1 mg/kg), metoclopramide (5 micrograms/kg) and haloperidol (2.5-5 micrograms/kg) were assessed in male volunteers. Clomipramine 97-109 prolactin Homo sapiens 62-71 2508166-1 1989 The effects of short-term (3-4 days) lithium treatment on the prolactin responses to intravenous clomipramine (0.1 mg/kg), metoclopramide (5 micrograms/kg) and haloperidol (2.5-5 micrograms/kg) were assessed in male volunteers. Metoclopramide 123-137 prolactin Homo sapiens 62-71 2508166-2 1989 Prolactin responses to clomipramine were significantly enhanced by lithium while those following administration of haloperidol and metoclopramide were not significantly altered. Clomipramine 23-35 prolactin Homo sapiens 0-9 2508166-2 1989 Prolactin responses to clomipramine were significantly enhanced by lithium while those following administration of haloperidol and metoclopramide were not significantly altered. Lithium 67-74 prolactin Homo sapiens 0-9 2508166-4 1989 The results suggest that lithium may selectively enhance 5-HT mediated prolactin release. Lithium 25-32 prolactin Homo sapiens 71-80 3234595-0 1988 Effect of dopamine on plasma growth hormone and prolactin concentrations under anaesthesia. Dopamine 10-18 prolactin Homo sapiens 48-57 2573106-2 1989 Compared to classical neuroleptics, clozapine causes only a short-lasting elevation of plasma prolactin levels, elevates both striatal homovanillic acid and dopamine content, is devoid of marked apomorphine-inhibitory or cataleptogenic activity and fails to induce supersensitivity of striatal dopaminergic systems after chronic administration. Clozapine 36-45 prolactin Homo sapiens 94-103 2574481-2 1989 The PET-estimated occupation was highly significantly correlated in a sigmoid-like fashion to the logarithm of the chlorpromazine-equivalent dose of oral neuroleptics (suggesting a strict dose-occupation relationship during oral neuroleptic treatment and supporting the D2-mediated hypothesis of neuroleptic action), while PRL was weakly related to daily dosage. Chlorpromazine 115-129 prolactin Homo sapiens 323-326 2977175-5 1988 Before ibopamine metoclopramide induced the expected, marked increases in aldosterone and in prolactin, but only minimal, non-significant decreases in ANF. ibopamine metoclopramide 7-31 prolactin Homo sapiens 93-102 2977175-7 1988 After ibopamine treatment, which caused a transient natriuretic effect, the responses of aldosterone and of ANF to metoclopramide were similar to those observed in control studies, whereas that of prolactin was enhanced. ibopamine 6-15 prolactin Homo sapiens 197-206 3067061-6 1988 The densities of these receptors are increased in hypothyroidism and they exert control over release of prolactin and other hormones, including melatonin at multiple sites in the hypothalamic--pituitary axis. Melatonin 144-153 prolactin Homo sapiens 104-113 3149403-10 1988 The same was shown in vitro: Pituitary cells cultured in vitro with 10(-6) M dopamine showed an increase of prolactin secretion after coincubation with 10(-7) M TRH. Dopamine 77-85 prolactin Homo sapiens 108-117 3149403-11 1988 There was a linear increase of the prolactin concentration during the incubation period in dopamine-free cell cultures. Dopamine 91-99 prolactin Homo sapiens 35-44 3149403-13 1988 The in vivo and in vitro results are in agreement with the hypothesis of a rapid, dopamine-independent effect of TRH on the secretion of stored prolactin in the pituitary. Dopamine 82-90 prolactin Homo sapiens 144-153 3187541-2 1988 Most of the methylated adenosine residues in prolactin mRNA are in the 3" untranslated region. Adenosine 23-32 prolactin Homo sapiens 45-54 3065095-12 1988 MCP induced a definite rise in PAC and PRL in all subjects under both dietary conditions (p less than 0.01), while plasma E and PRA remained unchanged after MCP challenge. Metoclopramide 0-3 prolactin Homo sapiens 39-42 3142197-3 1988 In this study, we tested CQP 201-403 m healthy male volunteers in order to assess its PRL suppression action and other hormonal effects as well as its duration of action and tolerability. cqp 25-28 prolactin Homo sapiens 86-89 2908102-4 1988 Cabergoline induced a marked fall in serum PRL level, starting within 3 h and continuing for 7 days after administering 0.3 mg, and for 14 days after 0.6 mg. Cabergoline 0-11 prolactin Homo sapiens 43-46 2908102-11 1988 These data indicate that a single dose of 0.6 mg of cabergoline inhibits GH as well as PRL secretion in dopamine-responsive acromegalic patients and suggests that doses of 0.3-0.6 mg once to three times a week may prove suitable for treatment of this condition. Cabergoline 52-63 prolactin Homo sapiens 87-90 3069753-3 1988 In an uncontrolled trial of 25 heavy cocaine users, measurements of pre- and post-bromocriptine serum prolactin levels-as indicators of inhibitory dopaminergic control-did not suggest dopamine depletion. Bromocriptine 82-95 prolactin Homo sapiens 102-111 3192504-9 1988 In 5 nM cortisol medium, the number of GH-IR cells decreased and PRL-IR cells increased or appeared. cortisol medium 8-23 prolactin Homo sapiens 65-68 2682729-3 1989 These PRL results are consistent with the observation that clozapine may increase DA release. Clozapine 59-68 prolactin Homo sapiens 6-9 2682729-3 1989 These PRL results are consistent with the observation that clozapine may increase DA release. Dopamine 82-84 prolactin Homo sapiens 6-9 2682729-6 1989 We hypothesize that antagonism of D-2 and 5-HT2 receptors and enhancement of DA and 5-HT release are critical elements in the action of clozapine to minimize both positive and negative symptoms without producing significant extrapyramidal symptoms or plasma PRL increases. Clozapine 136-145 prolactin Homo sapiens 258-261 2675278-4 1989 Prolactin secretion is regulated by both an inhibitory hormone (dopamine), and by one or more releasing factors. Dopamine 64-72 prolactin Homo sapiens 0-9 2675278-6 1989 All factors except for the prolactin inhibitory hormone (which is a biogenic amine) are peptides, all synthesized as part of large prohormones. Amines 77-82 prolactin Homo sapiens 27-36 2517609-4 1989 In the past decade, many studies in neuroendocrinology revealed that Tubero-infundibular dopamine (TIDA) neurons of hypothalamus play a major modulating role in PRL secretion. Dopamine 89-97 prolactin Homo sapiens 161-164 2517609-4 1989 In the past decade, many studies in neuroendocrinology revealed that Tubero-infundibular dopamine (TIDA) neurons of hypothalamus play a major modulating role in PRL secretion. tida 99-103 prolactin Homo sapiens 161-164 2517609-8 1989 The GABA has dual actions on PRL secretion: central action is stimulatory, but inhibitory on pituitary directly Using agonist or antagonist of central neurotransmitter as well as its biosynthesis blocker etc., this paper mainly observed the possible role of catecholamine and r-aminobutyric acid in prolactin-elevating effect of acupuncture. gamma-Aminobutyric Acid 4-8 prolactin Homo sapiens 29-32 2517609-8 1989 The GABA has dual actions on PRL secretion: central action is stimulatory, but inhibitory on pituitary directly Using agonist or antagonist of central neurotransmitter as well as its biosynthesis blocker etc., this paper mainly observed the possible role of catecholamine and r-aminobutyric acid in prolactin-elevating effect of acupuncture. gamma-Aminobutyric Acid 4-8 prolactin Homo sapiens 299-308 3201880-0 1988 Effects of a four-day nocturnal melatonin treatment on the 24 h plasma melatonin, cortisol and prolactin profiles in humans. Melatonin 32-41 prolactin Homo sapiens 95-104 3207131-1 1988 We evaluated the effect of preovulatory concentrations of estradiol on the 24-hour profile of prolactin secretion in women with regular menstrual cycles. Estradiol 58-67 prolactin Homo sapiens 94-103 3207131-3 1988 Estradiol benzoate, 1 mg intramuscularly, was administered for 7 days to achieve estradiol concentrations just above preovulatory levels (424 +/- 54 pg/ml); 24-hour mean prolactin concentrations increased threefold (14.0 +/- 2.1 to 40.6 +/- 7.1 ng/ml). estradiol 3-benzoate 0-18 prolactin Homo sapiens 170-179 3207131-4 1988 Prolactin pulse frequency increased significantly (p less than 0.001) during waking hours after estradiol benzoate administration. estradiol 3-benzoate 96-114 prolactin Homo sapiens 0-9 3207131-5 1988 The diurnal pattern of prolactin secretion was maintained with estradiol benzoate, although the sleep acrophase often reached high concentrations (86 +/- 11 ng/ml). estradiol 3-benzoate 63-81 prolactin Homo sapiens 23-32 3207131-6 1988 These results suggest in women with regular menstrual cycles: (1) that estrogen administration that achieves slightly greater than preovulatory estradiol concentrations can stimulate prolactin release, (2) that estradiol may elevate prolactin by increasing its pulsatile secretion, (3) that estradiol does not alter the diurnal pattern of prolactin secretion, (4) that estradiol concentrations just above preovulatory levels can be associated with markedly elevated prolactin concentrations. Estradiol 144-153 prolactin Homo sapiens 183-192 3207131-6 1988 These results suggest in women with regular menstrual cycles: (1) that estrogen administration that achieves slightly greater than preovulatory estradiol concentrations can stimulate prolactin release, (2) that estradiol may elevate prolactin by increasing its pulsatile secretion, (3) that estradiol does not alter the diurnal pattern of prolactin secretion, (4) that estradiol concentrations just above preovulatory levels can be associated with markedly elevated prolactin concentrations. Estradiol 211-220 prolactin Homo sapiens 183-192 3207131-6 1988 These results suggest in women with regular menstrual cycles: (1) that estrogen administration that achieves slightly greater than preovulatory estradiol concentrations can stimulate prolactin release, (2) that estradiol may elevate prolactin by increasing its pulsatile secretion, (3) that estradiol does not alter the diurnal pattern of prolactin secretion, (4) that estradiol concentrations just above preovulatory levels can be associated with markedly elevated prolactin concentrations. Estradiol 211-220 prolactin Homo sapiens 233-242 3207131-6 1988 These results suggest in women with regular menstrual cycles: (1) that estrogen administration that achieves slightly greater than preovulatory estradiol concentrations can stimulate prolactin release, (2) that estradiol may elevate prolactin by increasing its pulsatile secretion, (3) that estradiol does not alter the diurnal pattern of prolactin secretion, (4) that estradiol concentrations just above preovulatory levels can be associated with markedly elevated prolactin concentrations. Estradiol 211-220 prolactin Homo sapiens 233-242 3207131-6 1988 These results suggest in women with regular menstrual cycles: (1) that estrogen administration that achieves slightly greater than preovulatory estradiol concentrations can stimulate prolactin release, (2) that estradiol may elevate prolactin by increasing its pulsatile secretion, (3) that estradiol does not alter the diurnal pattern of prolactin secretion, (4) that estradiol concentrations just above preovulatory levels can be associated with markedly elevated prolactin concentrations. Estradiol 211-220 prolactin Homo sapiens 233-242 3229037-1 1988 In order to evaluate the dopaminergic control of the lactotroph, we examined the plasma prolactin response to metoclopramide (a dopamine receptor blocker, 10 mg iv bolus) and to dopamine (1 microgram/Kg/min iv infusion for 120 min) in 52 hyperprolactinemic female patients and 19 healthy volunteer women. Metoclopramide 110-124 prolactin Homo sapiens 88-97 3229037-3 1988 Patients from all groups showed a marked blunting of the prolactin response to metoclopramide as compared to the prolactin rise in normal women (p less than 0.001). Metoclopramide 79-93 prolactin Homo sapiens 57-66 3229037-5 1988 The magnitude of the prolactin response to metoclopramide (percent of baseline level) correlated negatively with the level of basal prolactin in each group except for macroadenoma patients. Metoclopramide 43-57 prolactin Homo sapiens 21-30 3229037-5 1988 The magnitude of the prolactin response to metoclopramide (percent of baseline level) correlated negatively with the level of basal prolactin in each group except for macroadenoma patients. Metoclopramide 43-57 prolactin Homo sapiens 132-141 3229037-6 1988 Dopamine infusion significantly (p = 0.015) reduced the mean plasma prolactin levels in hyperprolactinemic patients and normal women. Dopamine 0-8 prolactin Homo sapiens 68-77 3229037-10 1988 They also suggest that in these patients, the decrease in prolactin response to metoclopramide may be explained by the relative refractoriness to endogenous dopamine. Metoclopramide 80-94 prolactin Homo sapiens 58-67 3229037-10 1988 They also suggest that in these patients, the decrease in prolactin response to metoclopramide may be explained by the relative refractoriness to endogenous dopamine. Dopamine 157-165 prolactin Homo sapiens 58-67 2973977-5 1988 IGF-I-mediated effects were inhibited by cycloheximide (3.6 microM), suggesting that the increase in PRL was the result of newly synthesized hormone. Cycloheximide 41-54 prolactin Homo sapiens 101-104 3203763-5 1988 Progesterone (P) induces PRL secretion in anovulatory monkeys after estrogen priming with a time delay of several days, indicating probable de novo synthesis. Progesterone 0-12 prolactin Homo sapiens 25-28 2851518-0 1988 Participation of GABA B binding sites on the control of prolactin, but not gonadotropin secretion in humans. gaba b 17-23 prolactin Homo sapiens 56-65 3225400-1 1988 Cimetidine, an H2 receptor antagonist, is a potent stimulant of PRL secretion in normal women. Cimetidine 0-10 prolactin Homo sapiens 64-67 3225400-2 1988 In the present study, the PRL response to cimetidine was studied in 34 normal pregnant women and their fetuses during labor. Cimetidine 42-52 prolactin Homo sapiens 26-29 3225400-3 1988 Serum maternal PRL levels increased significantly after the acute iv injection of 400 mg cimetidine 30-45 min before delivery (10 women) as compared to 7 control women given saline. Cimetidine 89-99 prolactin Homo sapiens 15-18 3225400-5 1988 Similar results concerning PRL levels in umbilical vein and artery serum were obtained when cimetidine was injected 10-20 min (8 women), 60-75 min (8 women) and 90-120 min (8 women) before delivery. Cimetidine 92-102 prolactin Homo sapiens 27-30 3148791-2 1988 In one amenorrheic alcohol-dependent monkey, prolactin levels increased from 16.5 to 63 ng/ml during chronic, high-dose alcohol self-administration (3.4 g/kg/day) and immunocytochemical examination of the anterior pituitary showed apparent hyperplasia of the lactotrophs. Alcohols 19-26 prolactin Homo sapiens 45-54 3148791-2 1988 In one amenorrheic alcohol-dependent monkey, prolactin levels increased from 16.5 to 63 ng/ml during chronic, high-dose alcohol self-administration (3.4 g/kg/day) and immunocytochemical examination of the anterior pituitary showed apparent hyperplasia of the lactotrophs. Alcohols 120-127 prolactin Homo sapiens 45-54 3148791-8 1988 There was a negative correlation between daily alcohol dose and prolactin levels (p less than .01). Alcohols 47-54 prolactin Homo sapiens 64-73 3148791-9 1988 High-dose alcohol self-administration was often associated with low normal prolactin levels, but a relative fall in alcohol dose was usually associated with elevated prolactin levels. Alcohols 10-17 prolactin Homo sapiens 75-84 3148791-9 1988 High-dose alcohol self-administration was often associated with low normal prolactin levels, but a relative fall in alcohol dose was usually associated with elevated prolactin levels. Alcohols 116-123 prolactin Homo sapiens 166-175 3148791-10 1988 These data suggest that both alcohol intoxication and relative alcohol withdrawal may alter basal prolactin levels. Alcohols 29-36 prolactin Homo sapiens 98-107 3221879-1 1988 PRL synthesis by GH cells in culture has previously been shown to increase when calcium is added to cultures grown in calcium-depleted medium or when cultures are treated for 18 h or longer with the dihydropyridine calcium channel agonist BAY K8644, whereas the antagonist nimodipine inhibits PRL. Calcium 80-87 prolactin Homo sapiens 0-3 3221879-1 1988 PRL synthesis by GH cells in culture has previously been shown to increase when calcium is added to cultures grown in calcium-depleted medium or when cultures are treated for 18 h or longer with the dihydropyridine calcium channel agonist BAY K8644, whereas the antagonist nimodipine inhibits PRL. Calcium 80-87 prolactin Homo sapiens 293-296 3221879-1 1988 PRL synthesis by GH cells in culture has previously been shown to increase when calcium is added to cultures grown in calcium-depleted medium or when cultures are treated for 18 h or longer with the dihydropyridine calcium channel agonist BAY K8644, whereas the antagonist nimodipine inhibits PRL. Calcium 118-125 prolactin Homo sapiens 0-3 3221879-1 1988 PRL synthesis by GH cells in culture has previously been shown to increase when calcium is added to cultures grown in calcium-depleted medium or when cultures are treated for 18 h or longer with the dihydropyridine calcium channel agonist BAY K8644, whereas the antagonist nimodipine inhibits PRL. Nimodipine 273-283 prolactin Homo sapiens 0-3 3221879-2 1988 The experiments described here were designed to test whether differences in PRL synthesis caused by the dihydropyridines are due to changes in PRL mRNA levels, whether structurally different classes of calcium channel blockers alter PRL production, and whether long term treatment with calcium channel agonists and antagonists alters intracellular free calcium, [Ca2+]i. Dihydropyridines 104-120 prolactin Homo sapiens 76-79 3221879-3 1988 PRL synthesis and PRL mRNA levels were increased similarly by BAY K8644 and decreased in parallel by the dihydropyridine antagonist nimodipine, while overall protein and RNA synthesis were not changed by either the agonist or antagonist. k8644 66-71 prolactin Homo sapiens 0-3 3221879-3 1988 PRL synthesis and PRL mRNA levels were increased similarly by BAY K8644 and decreased in parallel by the dihydropyridine antagonist nimodipine, while overall protein and RNA synthesis were not changed by either the agonist or antagonist. k8644 66-71 prolactin Homo sapiens 18-21 3221879-3 1988 PRL synthesis and PRL mRNA levels were increased similarly by BAY K8644 and decreased in parallel by the dihydropyridine antagonist nimodipine, while overall protein and RNA synthesis were not changed by either the agonist or antagonist. 1,4-dihydropyridine 105-120 prolactin Homo sapiens 0-3 3221879-3 1988 PRL synthesis and PRL mRNA levels were increased similarly by BAY K8644 and decreased in parallel by the dihydropyridine antagonist nimodipine, while overall protein and RNA synthesis were not changed by either the agonist or antagonist. Nimodipine 132-142 prolactin Homo sapiens 0-3 3221879-3 1988 PRL synthesis and PRL mRNA levels were increased similarly by BAY K8644 and decreased in parallel by the dihydropyridine antagonist nimodipine, while overall protein and RNA synthesis were not changed by either the agonist or antagonist. Nimodipine 132-142 prolactin Homo sapiens 18-21 3221879-4 1988 Two calcium channel blockers which act at different sites on L-type channels than the dihydropyridines also inhibited PRL synthesis without affecting GH; 5 microM verapamil reduced PRL by 64% and 15 microM diltiazem by 89%. Dihydropyridines 86-102 prolactin Homo sapiens 118-121 3221879-4 1988 Two calcium channel blockers which act at different sites on L-type channels than the dihydropyridines also inhibited PRL synthesis without affecting GH; 5 microM verapamil reduced PRL by 64% and 15 microM diltiazem by 89%. Verapamil 163-172 prolactin Homo sapiens 118-121 3221879-4 1988 Two calcium channel blockers which act at different sites on L-type channels than the dihydropyridines also inhibited PRL synthesis without affecting GH; 5 microM verapamil reduced PRL by 64% and 15 microM diltiazem by 89%. Verapamil 163-172 prolactin Homo sapiens 181-184 3221879-5 1988 Partial depolarization with 5-25 mM KCl increased PRL synthesis up to 2-fold. Potassium Chloride 36-39 prolactin Homo sapiens 50-53 3173919-0 1988 Vaginal bromocriptine: pharmacology and effect on serum prolactin in normal women. Bromocriptine 8-21 prolactin Homo sapiens 56-65 2908364-6 1988 The in vitro potency of EGYT-2509 to block dopamine-mediated inhibition of prolactin release was weaker by three orders of magnitude than that of haloperidol. EGYT 2509 24-33 prolactin Homo sapiens 75-84 2908364-6 1988 The in vitro potency of EGYT-2509 to block dopamine-mediated inhibition of prolactin release was weaker by three orders of magnitude than that of haloperidol. Dopamine 43-51 prolactin Homo sapiens 75-84 3154528-3 1988 The prolactin (PRL) response to fenfluramine was significantly blunted in the schizophrenic subjects. Fenfluramine 32-44 prolactin Homo sapiens 4-13 3154528-3 1988 The prolactin (PRL) response to fenfluramine was significantly blunted in the schizophrenic subjects. Fenfluramine 32-44 prolactin Homo sapiens 15-18 3140665-6 1988 All doses of dopamine achieved some degree of prolactin suppression, but doses that achieved nanomolar circulating concentrations did not significantly affect luteinizing hormone secretion. Dopamine 13-21 prolactin Homo sapiens 46-55 3178385-4 1988 An unstimulated prolactin level was 187 micrograms/L and returned to normal with levothyroxine therapy. Thyroxine 81-94 prolactin Homo sapiens 16-25 3071396-1 1988 This study examined the hypothesis that human chorionic gonadotrophin (hCG) increases prolactin (PRL) stimulation of the utilization of lipoprotein-borne cholesterol by pig luteinized granulosa cells in culture. lipoprotein-borne cholesterol 136-165 prolactin Homo sapiens 86-95 2976743-10 1988 The influence of physical stress upon the pattern of testosterone may be mediated mainly by inhibition of testicular steroidogenesis by elevated cortisol and/or prolactin levels, rather than by decreased gonadotrophic stimulation or by alterations in binding to SHBG. Testosterone 53-65 prolactin Homo sapiens 161-170 2465437-5 1988 Prolactin levels decreased slightly (4.1 +/- 3.0 vs. 3.7 +/- 2.9 ng/ml, p less than 0.05) during ketanserin therapy when measured 12 h after dosing. Ketanserin 97-107 prolactin Homo sapiens 0-9 3417848-11 1988 In the case of PRL-secreting cells, which are tonically inhibited by the hypothalamic hormone dopamine, this would result in hypertrophy, hyperplasia, and possibly tumorigenesis. Dopamine 94-102 prolactin Homo sapiens 15-18 3414852-4 1988 These findings suggest that persistent elevation of plasma prolactin levels after cocaine withdrawal may reflect a chronic cocaine-induced derangement in neural dopaminergic regulatory systems. Cocaine 123-130 prolactin Homo sapiens 59-68 2908233-0 1988 Actions of pertussis toxin on the inhibitory effects of dopamine and somatostatin on prolactin and growth hormone release from ovine anterior pituitary cells. Dopamine 56-64 prolactin Homo sapiens 85-94 2908233-1 1988 Forskolin and the phorbol ester 12-O-tetradecanoylphorbol 13-acetate stimulate prolactin and GH release from ovine anterior pituitary cells cultured in vitro. Colforsin 0-9 prolactin Homo sapiens 79-88 2908233-1 1988 Forskolin and the phorbol ester 12-O-tetradecanoylphorbol 13-acetate stimulate prolactin and GH release from ovine anterior pituitary cells cultured in vitro. Phorbol Esters 18-31 prolactin Homo sapiens 79-88 2908233-1 1988 Forskolin and the phorbol ester 12-O-tetradecanoylphorbol 13-acetate stimulate prolactin and GH release from ovine anterior pituitary cells cultured in vitro. Tetradecanoylphorbol Acetate 32-68 prolactin Homo sapiens 79-88 2908233-2 1988 Dopamine and somatostatin inhibit release of prolactin and GH respectively, after stimulation by these agents, but without effects on intracellular cyclic AMP concentrations. Dopamine 0-8 prolactin Homo sapiens 45-54 2475126-5 1988 We describe ESTA systems for GH, prolactin, thyroid stimulators and human chorionic gonadotrophin which utilize the reduction of a tetrazolium salt to a formazan by intracellular dehydrogenase as the cytochemical system. Tetrazolium Salts 131-147 prolactin Homo sapiens 33-42 2475126-5 1988 We describe ESTA systems for GH, prolactin, thyroid stimulators and human chorionic gonadotrophin which utilize the reduction of a tetrazolium salt to a formazan by intracellular dehydrogenase as the cytochemical system. Formazans 153-161 prolactin Homo sapiens 33-42 3251504-1 1988 The prolactin (PRL) and thyrotropin (TSH) secretory response to the opioid agonist fentanyl (0.1 mg IV) was investigated with serial blood sampling in ten healthy women at 9 AM and 9 PM on different days. Fentanyl 83-91 prolactin Homo sapiens 4-13 3237541-1 1988 Among 14 patients with prolactinomas a single injection of 50 mg bromocriptine in a retard preparation resulted in a decrease of the initially elevated serum prolactin levels (to 4-62% of the initial value) in 12 cases and in a tumor shrinkage in 9 patients. Bromocriptine 65-78 prolactin Homo sapiens 23-32 3237544-2 1988 The use of oligonucleotide probes for hPRL and hGH labeled with 35S allowed detection of a specific messenger RNA in frozen and paraffin sections. Oligonucleotides 11-26 prolactin Homo sapiens 38-42 3237544-2 1988 The use of oligonucleotide probes for hPRL and hGH labeled with 35S allowed detection of a specific messenger RNA in frozen and paraffin sections. Paraffin 128-136 prolactin Homo sapiens 38-42 3044115-4 1988 Correlations of amniotic fluid prolactin levels with both lecithin phosphorus and insulin levels were not statistically significant in any of the groups. lecithin phosphorus 58-77 prolactin Homo sapiens 31-40 3180518-3 1988 The MANOVA analysis (multivariate analysis of variance) showed that all 3 considered factors (sex, age, creatinine) have a systematic effect on PRL values, that of creatinine being the most prominent. Creatinine 104-114 prolactin Homo sapiens 144-147 3180518-3 1988 The MANOVA analysis (multivariate analysis of variance) showed that all 3 considered factors (sex, age, creatinine) have a systematic effect on PRL values, that of creatinine being the most prominent. Creatinine 164-174 prolactin Homo sapiens 144-147 3045111-8 1988 Serotonin stimulated release of prolactin and growth hormone, although the prolactin response was less marked in depression. Serotonin 0-9 prolactin Homo sapiens 32-41 3227043-0 1988 The psychopharmacologic and prolactin response after large doses of naloxone in man. Naloxone 68-76 prolactin Homo sapiens 28-37 3227043-2 1988 Plasma prolactin responses after naloxone 210 mg and placebo were compared. Naloxone 33-41 prolactin Homo sapiens 7-16 3146515-4 1988 The change of central dopaminergic activity by the salt load was evaluated by the decrement of plasma prolactin (PRL) response to small dosage (25 micrograms) of thyrotropin releasing hormone. Salts 51-55 prolactin Homo sapiens 102-111 3146515-4 1988 The change of central dopaminergic activity by the salt load was evaluated by the decrement of plasma prolactin (PRL) response to small dosage (25 micrograms) of thyrotropin releasing hormone. Salts 51-55 prolactin Homo sapiens 113-116 3146515-5 1988 The mean percent change of PRL response by the salt load in the SS group was -6.5 +/- 8.3% (mean +/- SEM), which was significantly lower than 26.8 +/- 5.5% in the NSS group (p less than 0.01). Salts 47-51 prolactin Homo sapiens 27-30 3146515-5 1988 The mean percent change of PRL response by the salt load in the SS group was -6.5 +/- 8.3% (mean +/- SEM), which was significantly lower than 26.8 +/- 5.5% in the NSS group (p less than 0.01). H-SER-SER-OH 64-66 prolactin Homo sapiens 27-30 3146515-6 1988 There was a significant negative correlation between the percent changes of PRL response and the percent changes of MBP by the salt load (r = -0.448, p less than 0.05). Salts 127-131 prolactin Homo sapiens 76-79 3060191-12 1988 Treatment with haloperidol increased plasma prolactin moderately whilst nalbuphine raised it markedly 1 and 2.5 h post injection. Haloperidol 15-26 prolactin Homo sapiens 44-53 2898361-4 1988 Studies of the de novo synthesis of [35S]methionyl PRL indicated that the increase in PRL release after the first few hours of exposure to PRL-RF was secondary to an increase in PRL synthesis. Sulfur-35 37-40 prolactin Homo sapiens 51-54 2898361-4 1988 Studies of the de novo synthesis of [35S]methionyl PRL indicated that the increase in PRL release after the first few hours of exposure to PRL-RF was secondary to an increase in PRL synthesis. Sulfur-35 37-40 prolactin Homo sapiens 86-89 2898361-4 1988 Studies of the de novo synthesis of [35S]methionyl PRL indicated that the increase in PRL release after the first few hours of exposure to PRL-RF was secondary to an increase in PRL synthesis. Sulfur-35 37-40 prolactin Homo sapiens 86-89 2898361-4 1988 Studies of the de novo synthesis of [35S]methionyl PRL indicated that the increase in PRL release after the first few hours of exposure to PRL-RF was secondary to an increase in PRL synthesis. Sulfur-35 37-40 prolactin Homo sapiens 86-89 2898361-4 1988 Studies of the de novo synthesis of [35S]methionyl PRL indicated that the increase in PRL release after the first few hours of exposure to PRL-RF was secondary to an increase in PRL synthesis. methionyl 41-50 prolactin Homo sapiens 86-89 2898361-4 1988 Studies of the de novo synthesis of [35S]methionyl PRL indicated that the increase in PRL release after the first few hours of exposure to PRL-RF was secondary to an increase in PRL synthesis. methionyl 41-50 prolactin Homo sapiens 86-89 2898361-4 1988 Studies of the de novo synthesis of [35S]methionyl PRL indicated that the increase in PRL release after the first few hours of exposure to PRL-RF was secondary to an increase in PRL synthesis. methionyl 41-50 prolactin Homo sapiens 86-89 2898361-6 1988 On the other hand, cycloheximide (20 microM) completely inhibited the secondary increase in PRL release in response to PRL-RF but had no effect on the acute release. Cycloheximide 19-32 prolactin Homo sapiens 92-95 2898361-6 1988 On the other hand, cycloheximide (20 microM) completely inhibited the secondary increase in PRL release in response to PRL-RF but had no effect on the acute release. Cycloheximide 19-32 prolactin Homo sapiens 119-122 3410298-6 1988 The concentration of HE that induced the first significant increase in the release of PRL or LH above that of basal levels also varied with the reproductive stage of the donor hens. Helium 21-23 prolactin Homo sapiens 86-89 3139701-0 1988 Prolactin and gonadotrophin interactions on progesterone formation in cultured human granulosa cells. Progesterone 44-56 prolactin Homo sapiens 0-9 3139701-5 1988 In cells derived from clomiphene-HMG-HCG stimulated cycles, prolactin per se did not influence basal P formation but reduced the stimulatory effect of HCG. clomiphene-hmg-hcg 22-40 prolactin Homo sapiens 60-69 3183301-4 1988 The serum prolactin levels of 51-100 ng/ml in 11 subjects may have been induced by drugs (sulpiride) or unknown factors. Sulpiride 90-99 prolactin Homo sapiens 10-19 3078204-0 1988 [Studies of the effect of bromocriptine on the serum prolactin, aldosterone and cortisol levels and plasma renin activity in patients with essential hypertension]. Bromocriptine 26-39 prolactin Homo sapiens 53-62 3369564-0 1988 Prolactin response to tryptophan during mianserin treatment. Tryptophan 22-32 prolactin Homo sapiens 0-9 3369564-0 1988 Prolactin response to tryptophan during mianserin treatment. Mianserin 40-49 prolactin Homo sapiens 0-9 2836165-5 1988 IM-9-P PRL was immunoaffinity purified from conditioned medium and found to be identical in mol wt by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to human pituitary PRL. im-9-p 0-6 prolactin Homo sapiens 7-10 2836165-5 1988 IM-9-P PRL was immunoaffinity purified from conditioned medium and found to be identical in mol wt by sodium dodecyl sulfate-polyacrylamide gel electrophoresis to human pituitary PRL. im-9-p 0-6 prolactin Homo sapiens 179-182 2836165-10 1988 The PRL-producing IM-9-P line was cloned by limiting dilution, and a high PRL-producing clone IM-9-P3 and a non-PRL producer IM-9-P6 were isolated for further analysis. im-9-p 18-24 prolactin Homo sapiens 4-7 2836165-10 1988 The PRL-producing IM-9-P line was cloned by limiting dilution, and a high PRL-producing clone IM-9-P3 and a non-PRL producer IM-9-P6 were isolated for further analysis. im-9-p3 94-101 prolactin Homo sapiens 74-77 2836165-10 1988 The PRL-producing IM-9-P line was cloned by limiting dilution, and a high PRL-producing clone IM-9-P3 and a non-PRL producer IM-9-P6 were isolated for further analysis. im-9-p3 94-101 prolactin Homo sapiens 74-77 3131120-4 1988 The combination of polyacrylamide gel electrophoresis and immunoblotting techniques using a [125I]anti-hPRL monoclonal antibody allowed qualitative and quantitative analysis of the hPRL variants. polyacrylamide 19-33 prolactin Homo sapiens 181-185 3131120-8 1988 G-hPRL appeared fully sensitive to endoglycosidase F digestion, further supporting the presence of a freely accessible N-linked carbohydrate chain. n-linked carbohydrate 119-140 prolactin Homo sapiens 2-6 3045032-1 1988 Equine prolactin was determined to be a single chain protein of 199 amino acid containing two tryptophan and six cysteine residues, as found in other mammalian prolactins. Tryptophan 94-104 prolactin Homo sapiens 7-16 3045032-1 1988 Equine prolactin was determined to be a single chain protein of 199 amino acid containing two tryptophan and six cysteine residues, as found in other mammalian prolactins. Cysteine 113-121 prolactin Homo sapiens 7-16 3410636-2 1988 The alpha-amino group of ovine prolactin (oPRL) and human growth hormone (hGH) was selectively modified by transamination with glyoxylic acid. glyoxylic acid 127-141 prolactin Homo sapiens 31-40 3372677-8 1988 Bromocriptine therapy (3 patients) reduced serum PRL levels to normal, but failed to halt tumor growth. Bromocriptine 0-13 prolactin Homo sapiens 49-52 3171320-0 1988 Human follicular fluid: prolactin is biologically active and ovum fertilization correlates with estradiol concentration. Estradiol 96-105 prolactin Homo sapiens 24-33 3045725-2 1988 In a case report a patient with metastatic breast cancer, who had chemotherapy resistance and hyperprolactinemia, showed a tumor remission following suppression of elevated prolactin levels with bromocriptine. Bromocriptine 195-208 prolactin Homo sapiens 99-108 3401716-0 1988 Role of prolactin on neural and glial cellular enzymes involved in carbohydrate metabolism. Carbohydrates 67-79 prolactin Homo sapiens 8-17 3401716-3 1988 The influence of prolactin (Prl) and bromocriptine on the specific activities of neural and glial cellular enzymes involved in carbohydrate metabolism in cerebral cortex, hypothalamus, cerebellum and pons-medulla was studied. Carbohydrates 127-139 prolactin Homo sapiens 17-26 3401716-9 1988 Thus, the present study suggests that Prl has a differential effect on the activities of enzymes involved in Embden-Meyerhoff pathway (EMP) and hexosemonophosphate shunt (HMP) in the neural and glial cells of immature male bonnet monkeys. hexosemonophosphate 144-163 prolactin Homo sapiens 38-41 3404163-0 1988 Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis. Bromocriptine 10-23 prolactin Homo sapiens 52-61 3416226-1 1988 Porcine granulosa cells cultured under serum free conditions responded by increased progesterone secretion to the addition of the leuteotropic hormones, LH, prolactin, and estradiol. Progesterone 84-96 prolactin Homo sapiens 157-166 3416226-3 1988 Estradiol, LH, and prolactin all greatly increased progesterone accumulation in the presence of either high or low density lipoproteins. Progesterone 51-63 prolactin Homo sapiens 19-28 3416226-5 1988 Pre-exposure of granulosa cell cultures to estradiol increased the subsequent stimulatory effect of prolactin on lipoprotein utilization. Estradiol 43-52 prolactin Homo sapiens 100-109 3365458-0 1988 Stimulation of serum cortisol and prolactin secretion in humans by MK-212, a centrally active serotonin agonist. 6-chloro-2-(1-piperazinyl)pyrazine 67-73 prolactin Homo sapiens 34-43 3365458-5 1988 The cortisol and prolactin responses to the 40-mg dose of MK-212 were positively correlated (rho = + 0.85, p less than 0.02). 6-chloro-2-(1-piperazinyl)pyrazine 58-64 prolactin Homo sapiens 17-26 3365458-8 1988 MK-212 may stimulate the secretion of cortisol and prolactin in humans via a serotonin (5-HT2) receptor mechanism and may be a valuable tool with which to study 5-HT receptor sensitivity in humans. 6-chloro-2-(1-piperazinyl)pyrazine 0-6 prolactin Homo sapiens 51-60 3136040-8 1988 In conclusion we have found that PCO is associated with high level and pulse amplitude of LH and testosterone, with high frequency and low amplitude of PRL, and bromocriptine administration can blunt LH, PRL and testosterone secretion, suggesting a hypothalamic intervention in gonadotropic regulation in patient with PCO. Bromocriptine 161-174 prolactin Homo sapiens 204-207 3404163-0 1988 Effect of bromocriptine and metoclopramide on serum prolactin levels in patients with amyotrophic lateral sclerosis. Metoclopramide 28-42 prolactin Homo sapiens 52-61 3404163-1 1988 Secretion of prolactin in nine patients with amyotrophic lateral sclerosis and in seven healthy men was investigated with the use of metoclopramide stimulation and bromocriptine inhibition tests. Metoclopramide 133-147 prolactin Homo sapiens 13-22 3404163-1 1988 Secretion of prolactin in nine patients with amyotrophic lateral sclerosis and in seven healthy men was investigated with the use of metoclopramide stimulation and bromocriptine inhibition tests. Bromocriptine 164-177 prolactin Homo sapiens 13-22 3404163-2 1988 Blood serum prolactin concentration was determined in the basal state and 30, 60 and 120 minutes after oral administration of 10 mg metoclopramide or 2.5 mg bromocriptine. Bromocriptine 157-170 prolactin Homo sapiens 12-21 3404163-6 1988 In the bromocriptine inhibition test the mean value of maximal prolactin percentage decrement was 50.4% (SD 6.1) in amyotrophic lateral sclerosis and 66.5% (SD 5.3) in the controls and this difference was statistically insignificant. Bromocriptine 7-20 prolactin Homo sapiens 63-72 3404163-7 1988 These data suggest that exaggerated prolactin response to metoclopramide in amyotrophic lateral sclerosis may be a result of a decreased activity of central dopaminergic neurons. Metoclopramide 58-72 prolactin Homo sapiens 36-45 3291529-4 1988 Fasting prolactin levels measured on day 7 was significantly decreased when compared with day 1 (P less than 0.05) in all CQP groups, to 78% with 0.005 mg daily, to 40% with 0.015 mg daily, and to 27% with 0.025 mg CQP per day for one week. cqp 122-125 prolactin Homo sapiens 8-17 3291529-4 1988 Fasting prolactin levels measured on day 7 was significantly decreased when compared with day 1 (P less than 0.05) in all CQP groups, to 78% with 0.005 mg daily, to 40% with 0.015 mg daily, and to 27% with 0.025 mg CQP per day for one week. cqp 215-218 prolactin Homo sapiens 8-17 3291529-6 1988 The area under the curve of the prolactin day curve (1-8 h after drug administration) decreased significantly (P less than 0.05) at all doses when day 7 was compared with day 1, to 77% with 0.005 mg, to 51% with 0.015 mg, and to 37% with 0.025 mg CQP. cqp 247-250 prolactin Homo sapiens 32-41 3291529-9 1988 CQP 201-403 lowers prolactin levels in hyperprolactinemic women at all doses employed. cqp 0-3 prolactin Homo sapiens 19-28 3137253-8 1988 A relative dopamine deficiency might cause hypersecretion of PRL and LH in patients with PCOS and hyperprolactinemia. Dopamine 11-19 prolactin Homo sapiens 61-64 3346363-5 1988 Treatment with bromocriptine was associated with normalization of plasma PRL levels, elevation of plasma gonadotropin levels, and the onset of menopausal hot flashes in both patients. Bromocriptine 15-28 prolactin Homo sapiens 73-76 3346364-5 1988 Compared with the placebo group, which had the expected postpartum plasma PRL decline, the sulpiride-treated women maintained significantly elevated basal plasma PRL values up to the 90th postpartum day. Sulpiride 91-100 prolactin Homo sapiens 74-77 3346364-5 1988 Compared with the placebo group, which had the expected postpartum plasma PRL decline, the sulpiride-treated women maintained significantly elevated basal plasma PRL values up to the 90th postpartum day. Sulpiride 91-100 prolactin Homo sapiens 162-165 2894547-4 1988 Bromocriptine-treated patients showed significant reductions in prolactin levels and in S-phase fraction of tumour cells within the primary infiltrating carcinoma. Bromocriptine 0-13 prolactin Homo sapiens 64-73 3147572-2 1988 A multifactorial analysis of variance showed that, in addition to the well-established increases of gonadotropins at midcycle and melatonin and prolactin at night, there was a significant effect of season on the serum levels of melatonin and LH. Melatonin 228-237 prolactin Homo sapiens 144-153 3133960-0 1988 Testicular function and prolactin responsiveness to TRH and cimetidine after renal transplantation. Cimetidine 60-70 prolactin Homo sapiens 24-33 3344852-1 1988 In four depressed patients with abnormal dexamethasone suppression test results before treatment, plasma prolactin levels significantly increased after successful amitriptyline therapy. Dexamethasone 41-54 prolactin Homo sapiens 105-114 3344852-1 1988 In four depressed patients with abnormal dexamethasone suppression test results before treatment, plasma prolactin levels significantly increased after successful amitriptyline therapy. Amitriptyline 163-176 prolactin Homo sapiens 105-114 3179506-0 1988 Prolactin receptors on large granular lymphocytes: dual regulation by cyclosporin A. Cyclosporine 70-83 prolactin Homo sapiens 0-9 3422553-6 1988 Results of a search for independent factors in the cluster of test scores after ethanol using a principal components analysis were consistent with the discriminant analysis, indicating the possibility of three overlapping domains of the ethanol response, including subjective feelings after the high-dose ethanol challenge (explaining 46% of the variance), hormonal changes after high-dose ethanol along with body sway items (14% of variance), and prolactin changes after low-dose ethanol (9% of variance). Ethanol 237-244 prolactin Homo sapiens 448-457 3422553-6 1988 Results of a search for independent factors in the cluster of test scores after ethanol using a principal components analysis were consistent with the discriminant analysis, indicating the possibility of three overlapping domains of the ethanol response, including subjective feelings after the high-dose ethanol challenge (explaining 46% of the variance), hormonal changes after high-dose ethanol along with body sway items (14% of variance), and prolactin changes after low-dose ethanol (9% of variance). Ethanol 237-244 prolactin Homo sapiens 448-457 3422553-6 1988 Results of a search for independent factors in the cluster of test scores after ethanol using a principal components analysis were consistent with the discriminant analysis, indicating the possibility of three overlapping domains of the ethanol response, including subjective feelings after the high-dose ethanol challenge (explaining 46% of the variance), hormonal changes after high-dose ethanol along with body sway items (14% of variance), and prolactin changes after low-dose ethanol (9% of variance). Ethanol 237-244 prolactin Homo sapiens 448-457 3422553-6 1988 Results of a search for independent factors in the cluster of test scores after ethanol using a principal components analysis were consistent with the discriminant analysis, indicating the possibility of three overlapping domains of the ethanol response, including subjective feelings after the high-dose ethanol challenge (explaining 46% of the variance), hormonal changes after high-dose ethanol along with body sway items (14% of variance), and prolactin changes after low-dose ethanol (9% of variance). Ethanol 237-244 prolactin Homo sapiens 448-457 3280589-6 1988 DMP administration before exercise caused a significant increase in plasma PRL (P = 0.0009), a greater increase in plasma NE at the end of the exercise (P = 0.002), and an overall increase in plasma E (P = 0.02) and FFA (P = 0.02) concentrations. Domperidone 0-3 prolactin Homo sapiens 75-78 3279350-5 1988 Prolactin, LH/FSH ratio, testosterone, and E1 showed a significant drop with bromocriptine, whereas E2 significantly increased. Bromocriptine 77-90 prolactin Homo sapiens 0-9 3279351-0 1988 Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline. Cabergoline 104-115 prolactin Homo sapiens 77-86 3279351-8 1988 Plasma PRL concentrations were significantly reduced starting from one day after Cabergoline administration, however, and the amount of inhibition of PRL secretion induced by different doses of the drug was not statistically different. Cabergoline 81-92 prolactin Homo sapiens 7-10 2855317-0 1988 Influence of the interaction of calcitonin and 1,25(OH)2-vitamin D3 on prolactin secretion. Calcitriol 47-67 prolactin Homo sapiens 71-80 2855317-1 1988 Calcitonin inhibits and 1,25(OH)2-Vitamin D3 (1,25(OH)2D3) stimulates prolactin and thyrotropin secretion. Calcitriol 24-44 prolactin Homo sapiens 70-79 2855317-1 1988 Calcitonin inhibits and 1,25(OH)2-Vitamin D3 (1,25(OH)2D3) stimulates prolactin and thyrotropin secretion. Calcitriol 46-57 prolactin Homo sapiens 70-79 3342895-2 1988 Bromocriptine decreased serum and follicular fluid prolactin (PRL), accelerated ovarian follicle growth, increased serum and follicular fluid estradiol, lowered luteal phase progesterone, and shortened the luteal phase length of the cycle. Bromocriptine 0-13 prolactin Homo sapiens 51-60 3342895-2 1988 Bromocriptine decreased serum and follicular fluid prolactin (PRL), accelerated ovarian follicle growth, increased serum and follicular fluid estradiol, lowered luteal phase progesterone, and shortened the luteal phase length of the cycle. Bromocriptine 0-13 prolactin Homo sapiens 62-65 3140590-2 1988 GnRH-analog treatment lowered the maximal PRL responses to TRH and MC stimulation in the luteal phase, compared to those of 8 normally menstruating control patients. Metoclopramide 67-69 prolactin Homo sapiens 42-45 3140590-4 1988 Antiestrogen administration during GnRH-analog treatment further reduced the capacity of pituitary lactotropes to secrete PRL in TRH and MC tests, and it increased the LH response but not the FSH response to GnRH stimulation. Metoclopramide 137-139 prolactin Homo sapiens 122-125 3126284-6 1988 Improvement of testosterone secretion followed decreasing prolactin levels with bromocriptine administration, suggesting an inhibitory effect of prolactin on luteinizing hormone action at the Leydig cell. Bromocriptine 80-93 prolactin Homo sapiens 145-154 3179506-3 1988 The calculated receptor number was 660 per cell and the dissociation constant (Kd) was 3.0 X 10(-10) M. Since previous studies have reported that cyclosporin (CsA), an immunosuppressive agent used in organ transplant patients, affects the binding of PRL to T and B lymphocytes, but not to rabbit mammary gland cells, we investigated whether this compound could alter the binding of the hormone to LGL. Cyclosporine 146-157 prolactin Homo sapiens 250-253 3179506-3 1988 The calculated receptor number was 660 per cell and the dissociation constant (Kd) was 3.0 X 10(-10) M. Since previous studies have reported that cyclosporin (CsA), an immunosuppressive agent used in organ transplant patients, affects the binding of PRL to T and B lymphocytes, but not to rabbit mammary gland cells, we investigated whether this compound could alter the binding of the hormone to LGL. Cyclosporine 159-162 prolactin Homo sapiens 250-253 3179506-4 1988 At concentrations from 10(-7) to 10(-6), corresponding to the therapeutical range, CsA induced a complete inhibition of the PRL binding. Cyclosporine 83-86 prolactin Homo sapiens 124-127 3179506-5 1988 By contrast, concentrations of CsA ranging from 10(-11) to 10(-9) increased the PRL binding to more than 100% of control levels. Cyclosporine 31-34 prolactin Homo sapiens 80-83 3179506-7 1988 The finding that CsA can differently affect PRL-receptor expression on LGL points to an involvement of CsA--PRL interactions in determining the output of these immune responses. Cyclosporine 17-20 prolactin Homo sapiens 44-47 3179506-7 1988 The finding that CsA can differently affect PRL-receptor expression on LGL points to an involvement of CsA--PRL interactions in determining the output of these immune responses. Cyclosporine 17-20 prolactin Homo sapiens 108-111 3179506-7 1988 The finding that CsA can differently affect PRL-receptor expression on LGL points to an involvement of CsA--PRL interactions in determining the output of these immune responses. Cyclosporine 103-106 prolactin Homo sapiens 44-47 2830786-2 1988 Prolactin (PRL) secretory dynamics were evaluated by several stimulation (thyrotropin-releasing hormone [TRH], sulpiride) and suppression (L-dopa) tests. Sulpiride 111-120 prolactin Homo sapiens 0-9 3355513-1 1988 Lactogenic receptors were analysed with the use of the cross-linking agent disuccinimidyl suberate to attach covalently 125I-labelled ovine prolactin or human growth hormone to binding sites from (1) liver from pregnant rats and (2) the rat-derived Nb2 lymphoma cell line. disuccinimidyl 75-89 prolactin Homo sapiens 140-149 3132791-0 1988 Suppressed plasma prolactin response to thyrotropin-releasing hormone in hyperthyroidism reproduced by thyroxine but not by triiodothyronine administration to normal subjects. Thyroxine 103-112 prolactin Homo sapiens 18-27 2830786-2 1988 Prolactin (PRL) secretory dynamics were evaluated by several stimulation (thyrotropin-releasing hormone [TRH], sulpiride) and suppression (L-dopa) tests. Levodopa 139-145 prolactin Homo sapiens 0-9 3139336-6 1988 In the FSH cycles without an LH surge, PRL levels increased as long as FSH administration was continued and showed a significant positive correlation with the increasing serum oestradiol levels (r = 0.77). Estradiol 176-186 prolactin Homo sapiens 39-42 2830786-3 1988 Before glucocorticoid replacement therapy, both TRH and sulpiride administration resulted in PRL hyper-responsiveness. Sulpiride 56-65 prolactin Homo sapiens 93-96 2830786-4 1988 The sulpiride-induced PRL increase was higher than that induced by TRH. Sulpiride 4-13 prolactin Homo sapiens 22-25 2830786-5 1988 L-dopa administration resulted in normal PRL suppression. Levodopa 0-6 prolactin Homo sapiens 41-44 2830786-6 1988 Following glucocorticoid replacement therapy, the elevated basal PRL level returned to normal, and PRL hyper-responsiveness to TRH or sulpiride also returned to normal. Sulpiride 134-143 prolactin Homo sapiens 99-102 3341510-3 1988 The second patient, who also had bilateral ectasia, had a prolactin-producing pituitary adenoma for which bromocriptine was prescribed. Bromocriptine 106-119 prolactin Homo sapiens 58-67 3345539-3 1988 Following the reaction with the second antibody (goat antirabbit IgG) for 1 h at room temperature, prolactin was localized using peroxidase anti-peroxidase and 3.3"-diaminobenzidine as the chromogen. 3,3'-Diaminobenzidine 160-181 prolactin Homo sapiens 99-108 3132404-4 1988 The PRL responsiveness to TRH, evaluated by % delta PRL (peak PRL - basal PRL/basal PRL X 100), tended to be high in ADCS and DIG (group after discontinuation of drugs) compared with those of normal subjects (n = 12) and patients with primary hypothyroidism (n = 21). digitoxose 126-129 prolactin Homo sapiens 4-7 3276562-5 1988 Bio-PRL and immuno-PRL increased after GnRH in PCO, but not controls, and these responses were inhibited by disulfiram. Disulfiram 108-118 prolactin Homo sapiens 4-7 3276562-5 1988 Bio-PRL and immuno-PRL increased after GnRH in PCO, but not controls, and these responses were inhibited by disulfiram. Disulfiram 108-118 prolactin Homo sapiens 19-22 2832191-0 1988 Evidence for a differential interaction of buprenorphine with opiate receptor subtypes controlling prolactin secretion. Buprenorphine 43-56 prolactin Homo sapiens 99-108 2832191-1 1988 We studied the effects of various doses of the opiate derivative buprenorphine on serum prolactin levels and whether these effects could be counteracted by pretreatment with the opiate receptor blocker naloxone. Opiate Alkaloids 47-53 prolactin Homo sapiens 88-97 3132404-4 1988 The PRL responsiveness to TRH, evaluated by % delta PRL (peak PRL - basal PRL/basal PRL X 100), tended to be high in ADCS and DIG (group after discontinuation of drugs) compared with those of normal subjects (n = 12) and patients with primary hypothyroidism (n = 21). digitoxose 126-129 prolactin Homo sapiens 52-55 2832191-1 1988 We studied the effects of various doses of the opiate derivative buprenorphine on serum prolactin levels and whether these effects could be counteracted by pretreatment with the opiate receptor blocker naloxone. Buprenorphine 65-78 prolactin Homo sapiens 88-97 2832191-2 1988 The administration of increasing doses of buprenorphine exerted a dual effect on serum prolactin levels. Buprenorphine 42-55 prolactin Homo sapiens 87-96 3132404-4 1988 The PRL responsiveness to TRH, evaluated by % delta PRL (peak PRL - basal PRL/basal PRL X 100), tended to be high in ADCS and DIG (group after discontinuation of drugs) compared with those of normal subjects (n = 12) and patients with primary hypothyroidism (n = 21). digitoxose 126-129 prolactin Homo sapiens 52-55 2832191-5 1988 Naloxone (30 mg/kg) decreased serum prolactin levels and reversed both the stimulatory and the inhibitory action of buprenorphine. Naloxone 0-8 prolactin Homo sapiens 36-45 3132404-4 1988 The PRL responsiveness to TRH, evaluated by % delta PRL (peak PRL - basal PRL/basal PRL X 100), tended to be high in ADCS and DIG (group after discontinuation of drugs) compared with those of normal subjects (n = 12) and patients with primary hypothyroidism (n = 21). digitoxose 126-129 prolactin Homo sapiens 52-55 2832191-6 1988 These data are compatible with the hypothesis that buprenorphine could interfere with two different, but inter-dependent receptors: at low doses the oripavine derivative could act at one receptor site to cause an increase of serum prolactin, whereas at higher doses it could interact with a second site of lower affinity that is responsible for the inhibition of prolactin secretion. Buprenorphine 51-64 prolactin Homo sapiens 231-240 3132404-4 1988 The PRL responsiveness to TRH, evaluated by % delta PRL (peak PRL - basal PRL/basal PRL X 100), tended to be high in ADCS and DIG (group after discontinuation of drugs) compared with those of normal subjects (n = 12) and patients with primary hypothyroidism (n = 21). digitoxose 126-129 prolactin Homo sapiens 52-55 2832191-6 1988 These data are compatible with the hypothesis that buprenorphine could interfere with two different, but inter-dependent receptors: at low doses the oripavine derivative could act at one receptor site to cause an increase of serum prolactin, whereas at higher doses it could interact with a second site of lower affinity that is responsible for the inhibition of prolactin secretion. Buprenorphine 51-64 prolactin Homo sapiens 363-372 2832191-6 1988 These data are compatible with the hypothesis that buprenorphine could interfere with two different, but inter-dependent receptors: at low doses the oripavine derivative could act at one receptor site to cause an increase of serum prolactin, whereas at higher doses it could interact with a second site of lower affinity that is responsible for the inhibition of prolactin secretion. oripavine 149-158 prolactin Homo sapiens 231-240 3167163-6 1988 These preparations were exposed to 3 M MgCl2, which dissociates the endogenous-bound PRL from the hormone-receptor complex and allows the characterization of the "total" PRL receptors. Magnesium Chloride 39-44 prolactin Homo sapiens 85-88 2832191-6 1988 These data are compatible with the hypothesis that buprenorphine could interfere with two different, but inter-dependent receptors: at low doses the oripavine derivative could act at one receptor site to cause an increase of serum prolactin, whereas at higher doses it could interact with a second site of lower affinity that is responsible for the inhibition of prolactin secretion. oripavine 149-158 prolactin Homo sapiens 363-372 3250231-8 1988 The parallel effects of phorbol ester tumor promoters and PRL on cell cycle progression in Nb2 lymphoma cells and in hepatic proliferation suggest that PRL may likewise mediate proliferation in aberrant growth conditions such as neoplasia. Phorbol Esters 24-37 prolactin Homo sapiens 152-155 3250231-14 1988 In the Nb2 lymphoma cell model, tumor promoting phorbol esters mimic the effects of PRL. Phorbol Esters 48-62 prolactin Homo sapiens 84-87 3250231-15 1988 Similarly, PRL-stimulated enzyme induction in liver is mirrored by phorbol ester treatment, and inhibitors of PKC block PRL-stimulated mitogenesis in Nb2 cells. Phorbol Esters 67-80 prolactin Homo sapiens 11-14 3122579-1 1988 Bromocriptine treatment of the amenorrhea-galactorrhea syndrome with elevated prolactin levels is well recognized. Bromocriptine 0-13 prolactin Homo sapiens 78-87 3122579-3 1988 Lowering of both prolactin and follicle-stimulating hormone levels was found to occur after bromocriptine therapy. Bromocriptine 92-105 prolactin Homo sapiens 17-26 3245713-5 1988 Treatment with bromocriptine markedly reduced the level of serum prolactin together with improvement of sexual libido and potency. Bromocriptine 15-28 prolactin Homo sapiens 65-74 3383612-0 1988 The role of prolactin in luteal inadequacy: treatment of hyperprolactinaemia with bromocriptine. Bromocriptine 82-95 prolactin Homo sapiens 12-21 3203697-4 1988 A significant increase in serum PRL values was also found in 10 patients who were treated with chlorpromazine (100 mg t.i.d., p.o.) Chlorpromazine 95-109 prolactin Homo sapiens 32-35 3203697-7 1988 Following chlorpromazine treatment with or without concomitant administration of trihexyphenidyl, 20 patients showed a significant increase in serum PRL levels and a significant decrease in serum LH and T levels. Chlorpromazine 10-24 prolactin Homo sapiens 149-152 3203697-7 1988 Following chlorpromazine treatment with or without concomitant administration of trihexyphenidyl, 20 patients showed a significant increase in serum PRL levels and a significant decrease in serum LH and T levels. Trihexyphenidyl 81-96 prolactin Homo sapiens 149-152 3203713-0 1988 Effect of methyldopa on prolactin serum concentration. Methyldopa 10-20 prolactin Homo sapiens 24-33 3203713-2 1988 In a group of ten hypertensive patients, the effects of methyldopa administration in two different formulations on serum prolactin (PRL) were studied. Methyldopa 56-66 prolactin Homo sapiens 121-130 3203713-2 1988 In a group of ten hypertensive patients, the effects of methyldopa administration in two different formulations on serum prolactin (PRL) were studied. Methyldopa 56-66 prolactin Homo sapiens 132-135 3203713-3 1988 A single oral dose of normal release methyldopa significantly increased serum prolactin levels, peak concentrations occurring 3 to 6 h after drug administration. Methyldopa 37-47 prolactin Homo sapiens 78-87 3203713-4 1988 On the contrary, administration of sustained release methyldopa at the same dose was only followed by slight and not significant fluctuations in prolactin plasma levels. Methyldopa 53-63 prolactin Homo sapiens 145-154 2900188-0 1988 Size changes of a growth hormone- and prolactin-producing adenoma during and after sandostatin treatment. Octreotide 83-94 prolactin Homo sapiens 38-47 3397041-7 1988 In contrast, prolactin was suppressed by bromocriptine and did not rise in response to exercise or heat exposure. Bromocriptine 41-54 prolactin Homo sapiens 13-22 21927277-3 1988 Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Dopamine 89-97 prolactin Homo sapiens 0-9 21927277-3 1988 Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Dopamine 89-97 prolactin Homo sapiens 11-14 2839820-3 1988 The use of L-dopa reducing the levels of ACTH and prolactin led to the improvement of indices of cellular immunity and the patients" clinical status. Levodopa 11-17 prolactin Homo sapiens 50-59 2839820-4 1988 On the contrary, haloperidol increasing prolactin and ACTH secretion and suppressing STH secretion resulted in the deterioration of indices of cellular immunity and the patients" clinical status. Haloperidol 17-28 prolactin Homo sapiens 40-49 3168303-0 1988 Prolactin response to metoclopramide does not distinguish patients with hypogonadotrophic hypogonadism from delayed puberty. Metoclopramide 22-36 prolactin Homo sapiens 0-9 3168303-1 1988 The prolactin response to metoclopramide (MCP) was studied in 23 sexually immature males, 14 with isolated hypogonadotrophic hypogonadism (IHH) and nine with constitutional delayed puberty. Metoclopramide 26-40 prolactin Homo sapiens 4-13 3168303-3 1988 We also measured the prolactin response to chlorpromazine (CPZ) in the untreated IHH men. Chlorpromazine 43-57 prolactin Homo sapiens 21-30 3168303-3 1988 We also measured the prolactin response to chlorpromazine (CPZ) in the untreated IHH men. Chlorpromazine 59-62 prolactin Homo sapiens 21-30 3145217-3 1988 It has been found, that PRL and GH released into the media in normal KRB solution revealed nearly two times higher concentration than in the presence of high Mg2+. krb 69-72 prolactin Homo sapiens 24-27 3145217-3 1988 It has been found, that PRL and GH released into the media in normal KRB solution revealed nearly two times higher concentration than in the presence of high Mg2+. magnesium ion 158-162 prolactin Homo sapiens 24-27 3145217-5 1988 The incorporation of 4.5-3H-leucine into the prolactin and growth hormone demonstrate a significant decrease in the presence of high Mg2+ indicating that the ion is able to inhibit the secretion of newly synthesized PRL an GH. 4.5-3h-leucine 21-35 prolactin Homo sapiens 216-219 3145217-5 1988 The incorporation of 4.5-3H-leucine into the prolactin and growth hormone demonstrate a significant decrease in the presence of high Mg2+ indicating that the ion is able to inhibit the secretion of newly synthesized PRL an GH. magnesium ion 133-137 prolactin Homo sapiens 216-219 2975630-5 1988 Diclofenac resulted in a significant and sustained decrease in plasma level of prolactin (p less than 0.005). Diclofenac 0-10 prolactin Homo sapiens 79-88 2975630-7 1988 These data suggest that administration of a prostaglandin synthesis inhibitor, such as diclofenac, selectively alters basal pituitary secretion of prolactin in humans without a detectable effect on plasma levels of other pituitary hormones. Prostaglandins 44-57 prolactin Homo sapiens 147-156 2975630-7 1988 These data suggest that administration of a prostaglandin synthesis inhibitor, such as diclofenac, selectively alters basal pituitary secretion of prolactin in humans without a detectable effect on plasma levels of other pituitary hormones. Diclofenac 87-97 prolactin Homo sapiens 147-156 2975630-8 1988 This study supports the hypothesis that prostaglandins are necessary for maintaining basal level of prolactin secretion in man. Prostaglandins 40-54 prolactin Homo sapiens 100-109 3275684-0 1988 Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. Cabergoline 85-96 prolactin Homo sapiens 0-9 3275684-1 1988 To further evaluate the potency and time course of the PRL-lowering effect of single oral doses of cabergoline, two doses of the drug were given to 51 hyperprolactinemic patients who also received 2.5 mg bromocriptine according to a randomized cross-over design. Cabergoline 99-110 prolactin Homo sapiens 55-58 3275684-3 1988 Both cabergoline doses induced a significant fall in serum PRL levels, which lasted, on the average, from 3 h to 5 days after 0.3 mg and from 3 h to 14 days after 0.6 mg; the mean maximum decrease after 0.3 mg was -65 +/-4% (+/- SEM), significantly (P less than 0.05) less than that after bromocriptine (group mean, -73 +/- 4%), and it was -76 +/- 3% after 0.6 mg, not significantly different from that induced by bromocriptine (group mean, -71 +/- 4%). Cabergoline 5-16 prolactin Homo sapiens 59-62 3275684-3 1988 Both cabergoline doses induced a significant fall in serum PRL levels, which lasted, on the average, from 3 h to 5 days after 0.3 mg and from 3 h to 14 days after 0.6 mg; the mean maximum decrease after 0.3 mg was -65 +/-4% (+/- SEM), significantly (P less than 0.05) less than that after bromocriptine (group mean, -73 +/- 4%), and it was -76 +/- 3% after 0.6 mg, not significantly different from that induced by bromocriptine (group mean, -71 +/- 4%). Bromocriptine 289-302 prolactin Homo sapiens 59-62 3275684-3 1988 Both cabergoline doses induced a significant fall in serum PRL levels, which lasted, on the average, from 3 h to 5 days after 0.3 mg and from 3 h to 14 days after 0.6 mg; the mean maximum decrease after 0.3 mg was -65 +/-4% (+/- SEM), significantly (P less than 0.05) less than that after bromocriptine (group mean, -73 +/- 4%), and it was -76 +/- 3% after 0.6 mg, not significantly different from that induced by bromocriptine (group mean, -71 +/- 4%). Bromocriptine 414-427 prolactin Homo sapiens 59-62 3275684-6 1988 Serum PRL levels fell significantly by the first week and reached a plateau after 2 doses in the 0.6 mg cabergoline-treated group and after 5 doses in the 0.3 mg-treated group; the absolute PRL decrease was greater in the former. Cabergoline 104-115 prolactin Homo sapiens 6-9 3275684-6 1988 Serum PRL levels fell significantly by the first week and reached a plateau after 2 doses in the 0.6 mg cabergoline-treated group and after 5 doses in the 0.3 mg-treated group; the absolute PRL decrease was greater in the former. Cabergoline 104-115 prolactin Homo sapiens 190-193 2965754-1 1988 SKF 38393, a selective D-1 dopamine receptor agonist, elevated plasma prolactin levels in eight patients with various neurological disorders. 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine 0-9 prolactin Homo sapiens 70-79 21927277-3 1988 Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Dopamine 99-101 prolactin Homo sapiens 0-9 21927277-3 1988 Prolactin (PRL), Lutenising hormone (LH) and Growth hormone (GH) have definite link with Dopamine (DA), the latter being implicated in the pathogenesis of schizophrenia. Dopamine 99-101 prolactin Homo sapiens 11-14 3422092-2 1988 A possible mechanism for this incidental finding is elevated prolactin levels, as other causes of gallium breast uptake such as drug therapy, and intrinsic breast disease, were not present. Gallium 98-105 prolactin Homo sapiens 61-70 3367257-0 1988 Positive relationship between the nocturnal concentrations of melatonin and prolactin, and a stimulation of prolactin after melatonin administration in young men. Melatonin 62-71 prolactin Homo sapiens 76-85 3367257-0 1988 Positive relationship between the nocturnal concentrations of melatonin and prolactin, and a stimulation of prolactin after melatonin administration in young men. Melatonin 62-71 prolactin Homo sapiens 108-117 3140587-2 1987 Randomized double-blind treatment with bromocriptine 5 mg daily (leading to adequate prolactin suppression) or matching placebo, each for 4 cycles, resulted in a cumulative rate after 4 months of 14.3 +/- 10.6% (SE) in both groups. Bromocriptine 39-52 prolactin Homo sapiens 85-94 3692700-3 1987 Serum prolactin levels fell approximately four months prior to onset of the psychotic episode and thus may have provided a predictive indicator of changing dopamine activity in both the tubero-infundibular and the mesolimbic-mesocortical dopaminergic systems. Dopamine 156-164 prolactin Homo sapiens 6-15 3361075-1 1988 The aim of the present study was to investigate the effect of a new galenic injectable form of bromocriptine (Parlodel LA), characterized by sustained release of bromocriptine for 4-6 weeks, in 3 patients with prolactin-secreting macroadenomas through a 42-day follow-up. Bromocriptine 95-108 prolactin Homo sapiens 210-219 3139830-0 1988 Flunarizine increases PRL secretion in normal and in migraineous women. Flunarizine 0-11 prolactin Homo sapiens 22-25 3139830-5 1988 A significance increase of serum PRL levels was found after FLU administration, but not after placebo. Flunarizine 60-63 prolactin Homo sapiens 33-36 3367257-0 1988 Positive relationship between the nocturnal concentrations of melatonin and prolactin, and a stimulation of prolactin after melatonin administration in young men. Melatonin 124-133 prolactin Homo sapiens 108-117 3367257-1 1988 The relationship between the concentrations of melatonin and prolactin over the 24-h cycle has been investigated in a group of young men at three times in the year. Melatonin 47-56 prolactin Homo sapiens 61-70 3367257-5 1988 Melatonin concentrations increased before prolactin during the evening and decreased before prolactin in the morning. Melatonin 0-9 prolactin Homo sapiens 42-51 3367257-6 1988 Oral administration of 6 mg melatonin significantly stimulated prolactin release above concentrations measured after placebo administration, in both the morning (P less than 0.05) and evening (P less than 0.01) time periods; the prolactin response being greater in the evening. Melatonin 28-37 prolactin Homo sapiens 63-72 3367257-6 1988 Oral administration of 6 mg melatonin significantly stimulated prolactin release above concentrations measured after placebo administration, in both the morning (P less than 0.05) and evening (P less than 0.01) time periods; the prolactin response being greater in the evening. Melatonin 28-37 prolactin Homo sapiens 229-238 3367257-7 1988 These results provide evidence for melatonin controlling the nocturnal increase of prolactin via its ability to stimulate prolactin release. Melatonin 35-44 prolactin Homo sapiens 83-92 3367257-7 1988 These results provide evidence for melatonin controlling the nocturnal increase of prolactin via its ability to stimulate prolactin release. Melatonin 35-44 prolactin Homo sapiens 122-131 3221620-0 1988 [Effect of bromocriptine on arterial blood pressure and serum prolactin level in patients with essential arterial hypertension]. Bromocriptine 11-24 prolactin Homo sapiens 62-71 3398697-3 1988 In both EF women and PMW, a prompt (within 90 min, p less than 0.001) and sustained (greater than 45 micrograms/L, p less than 0.001) release of PRL was induced by MCP infusions. Metoclopramide 164-167 prolactin Homo sapiens 145-148 3136392-13 1988 Findings obtained in this study suggest that cocaine-related derangements in prolactin secretion may be a biologic marker of a protracted cocaine abstinence syndrome. Cocaine 45-52 prolactin Homo sapiens 77-86 3336541-0 1988 Prolactin stimulation tests: different response patterns after bromocriptine, lisuride, and metergoline treatment of puerperal women. Bromocriptine 63-76 prolactin Homo sapiens 0-9 3336541-0 1988 Prolactin stimulation tests: different response patterns after bromocriptine, lisuride, and metergoline treatment of puerperal women. Lisuride 78-86 prolactin Homo sapiens 0-9 3336541-0 1988 Prolactin stimulation tests: different response patterns after bromocriptine, lisuride, and metergoline treatment of puerperal women. Metergoline 92-103 prolactin Homo sapiens 0-9 3336541-1 1988 To elucidate different mechanisms by which bromocriptine, lisuride, and metergoline may inhibit prolactin (PRL) secretion and lactation in puerperal women, the PRL secretion patterns were examined by means of a stimulation test using an intravenous bolus of metoclopramide. Bromocriptine 43-56 prolactin Homo sapiens 96-105 3336541-1 1988 To elucidate different mechanisms by which bromocriptine, lisuride, and metergoline may inhibit prolactin (PRL) secretion and lactation in puerperal women, the PRL secretion patterns were examined by means of a stimulation test using an intravenous bolus of metoclopramide. Bromocriptine 43-56 prolactin Homo sapiens 107-110 3336541-1 1988 To elucidate different mechanisms by which bromocriptine, lisuride, and metergoline may inhibit prolactin (PRL) secretion and lactation in puerperal women, the PRL secretion patterns were examined by means of a stimulation test using an intravenous bolus of metoclopramide. Lisuride 58-66 prolactin Homo sapiens 96-105 3336541-1 1988 To elucidate different mechanisms by which bromocriptine, lisuride, and metergoline may inhibit prolactin (PRL) secretion and lactation in puerperal women, the PRL secretion patterns were examined by means of a stimulation test using an intravenous bolus of metoclopramide. Metergoline 72-83 prolactin Homo sapiens 96-105 3336541-1 1988 To elucidate different mechanisms by which bromocriptine, lisuride, and metergoline may inhibit prolactin (PRL) secretion and lactation in puerperal women, the PRL secretion patterns were examined by means of a stimulation test using an intravenous bolus of metoclopramide. Metergoline 72-83 prolactin Homo sapiens 107-110 3336541-3 1988 However, women subjected to metergoline treatment had significantly higher responses of PRL to metoclopramide as compared with those treated with either bromocriptine or lisuride. Metergoline 28-39 prolactin Homo sapiens 88-91 3336541-3 1988 However, women subjected to metergoline treatment had significantly higher responses of PRL to metoclopramide as compared with those treated with either bromocriptine or lisuride. Metoclopramide 95-109 prolactin Homo sapiens 88-91 3336541-4 1988 Thus, the PRL-lowering mechanism of metergoline appears to be different from those of bromocriptine and lisuride. Metergoline 36-47 prolactin Homo sapiens 10-13 2453860-0 1988 Prolactin effect on the permeability of human benign hyperplastic prostate to testosterone. Testosterone 78-90 prolactin Homo sapiens 0-9 2834764-6 1988 In other words, bulimic subjects who developed an increased plasma TRP ratio during bingeing and vomiting had fewer cycles of bingeing and vomiting and a greater increase in plasma PRL than did subjects who did not develop an increase in the plasma TRP ratio. Tryptophan 67-70 prolactin Homo sapiens 181-184 2906441-0 1988 Plasma prolactin response to gonadotropin-releasing hormone during benzodiazepine treatment. Benzodiazepines 67-81 prolactin Homo sapiens 7-16 2906441-4 1988 In six premenopausal women treated with benzodiazepines, basal PRL concentrations were not influenced by the drug in four subjects (range 4.0-15.7 ng/ml) and were slightly elevated in two subjects (23 and 30 ng/ml). Benzodiazepines 40-55 prolactin Homo sapiens 63-66 3148149-0 1988 Prolactin response to sodium valproate in schizophrenics with and without tardive dyskinesia. Valproic Acid 22-38 prolactin Homo sapiens 0-9 3148149-3 1988 Sodium valproate decreased plasma prolactin levels in healthy subjects (P less than 0.001) and in schizophrenic patients with TD (P less than 0.001), but not in chronic schizophrenics without TD. Valproic Acid 0-16 prolactin Homo sapiens 34-43 3148149-5 1988 Although the neural or biochemical substrate underlying the different responses of plasma prolactin to sodium valproate in schizophrenics with and without TD remains unclear, these results provide the first neuroendocrine evidence able to differentiate dyskinetic subjects from those without TD within a schizophrenic population. Valproic Acid 103-119 prolactin Homo sapiens 90-99 3237947-0 1988 Prolactin responses to haloperidol in normal young women. Haloperidol 23-34 prolactin Homo sapiens 0-9 3237947-1 1988 The prolactin (PRL) responses to intramuscular haloperidol (HPD) (0.5, 1.0, and 1.5 mg) were evaluated in six normal premenopausal women during the follicular and luteal phases of their menstrual cycles. Haloperidol 47-58 prolactin Homo sapiens 4-13 3406324-7 1988 Dexamethasone significantly enhanced the prolactin response to meals among both bulimics (at 90 min post onset of eating) and normals (at 60, 75 and 90 min post onset of eating). Dexamethasone 0-13 prolactin Homo sapiens 41-50 3406324-8 1988 This enhancement of the prolactin response to meals by dexamethasone is opposite to the inhibitory effect of dexamethasone on stress-induced prolactin release and suggesting that stress-induced and meal-induced prolactin release involve different neuroendocrine mechanisms. Dexamethasone 55-68 prolactin Homo sapiens 24-33 3406324-8 1988 This enhancement of the prolactin response to meals by dexamethasone is opposite to the inhibitory effect of dexamethasone on stress-induced prolactin release and suggesting that stress-induced and meal-induced prolactin release involve different neuroendocrine mechanisms. Dexamethasone 109-122 prolactin Homo sapiens 141-150 3406324-8 1988 This enhancement of the prolactin response to meals by dexamethasone is opposite to the inhibitory effect of dexamethasone on stress-induced prolactin release and suggesting that stress-induced and meal-induced prolactin release involve different neuroendocrine mechanisms. Dexamethasone 109-122 prolactin Homo sapiens 141-150 3176736-2 1988 application of Sulproston for induction of abortion was examined on the serum levels of PRL, HCG, HPL, estradiol and progesterone in 8 primigravidae during the first trimenon. sulprostone 15-25 prolactin Homo sapiens 88-91 2961251-6 1987 However, for nonvegetarians, prolactin levels were positively correlated with dietary energy, protein, total and saturated fatty acids, and oleic acid. Fatty Acids 113-134 prolactin Homo sapiens 29-38 2961251-6 1987 However, for nonvegetarians, prolactin levels were positively correlated with dietary energy, protein, total and saturated fatty acids, and oleic acid. Oleic Acid 140-150 prolactin Homo sapiens 29-38 3322022-4 1987 However, the MtT/F4 tumor had significantly more prolactin (PRL)-secreting cells. monooxyethylene trimethylolpropane tristearate 13-16 prolactin Homo sapiens 49-58 3322022-4 1987 However, the MtT/F4 tumor had significantly more prolactin (PRL)-secreting cells. monooxyethylene trimethylolpropane tristearate 13-16 prolactin Homo sapiens 60-63 3500688-1 1987 A double-blind random-ordered comparison of the effects of placebo and 5-hydroxytryptophan (200 mg, orally) in ten depressed patients with seasonal affective disorder (SAD) and ten controls disclosed slightly but significantly higher basal levels of serum prolactin and a trend toward higher basal levels of serum cortisol in the patients with SAD compared with controls. 5-Hydroxytryptophan 71-90 prolactin Homo sapiens 256-265 3500688-2 1987 After administration of 5-HTP, the cortisol level significantly increased and the prolactin level significantly decreased in both patients and controls. 5-Hydroxytryptophan 24-29 prolactin Homo sapiens 82-91 2960516-5 1987 Bio-Gel elution pattern and mol wt analysis on sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting showed that PRL produced by stromal cells had properties identical to those of pituitary PRL. Sodium Dodecyl Sulfate 47-69 prolactin Homo sapiens 144-147 2960516-5 1987 Bio-Gel elution pattern and mol wt analysis on sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting showed that PRL produced by stromal cells had properties identical to those of pituitary PRL. polyacrylamide 70-84 prolactin Homo sapiens 144-147 2960516-16 1987 A potent progestin antagonist, RU486, inhibited PRL production in stromal cells treated with MPA, MPA and E2, or MPA and RLX. Mifepristone 31-36 prolactin Homo sapiens 48-51 2960516-17 1987 These results indicate that endometrial PRL production is regulated by the combined effects of steroid hormones (progestin and estrogen) and a peptide hormone (relaxin). Steroids 95-111 prolactin Homo sapiens 40-43 3680476-2 1987 The PRL was immunoprecipitated from 100-microL aliquots of serum, and the precipitates were subjected to gel electrophoresis in the presence of sodium dodecyl sulfate, electrotransferred to nitrocellulose paper, immunoblotted with anti-hPRL serum and [125I]protein-A, and autoradiographed. Sodium Dodecyl Sulfate 144-166 prolactin Homo sapiens 4-7 3430186-0 1987 Intraventricular morphine produces pain relief, hypothermia, hyperglycaemia and increased prolactin and growth hormone levels in patients with cancer pain. Morphine 17-25 prolactin Homo sapiens 90-99 3430186-6 1987 Further, 10 to 20 min after intraventricular administration of morphine, the blood levels of prolactin, growth hormone and glucose were elevated in these patients. Morphine 63-71 prolactin Homo sapiens 93-102 3681421-0 1987 Prolactin-secreting adenomas: the preoperative response to bromocriptine treatment and surgical outcome. Bromocriptine 59-72 prolactin Homo sapiens 0-9 3681421-9 1987 A response to preoperative bromocriptine therapy was defined as a return of the basal prolactin level to normal: 18 patients were responders and 29 were hyporesponders; in eight the data were not available. Bromocriptine 27-40 prolactin Homo sapiens 86-95 3328132-3 1987 The treatment of high prolactin levels is mainly based on the clinical findings, but in most of the instances, a medical approach utilizing bromocriptine appears to be advantageous. Bromocriptine 140-153 prolactin Homo sapiens 22-31 2824954-1 1987 The control of prolactin secretion by Ca calmodulin and cyclic AMP was studied. Cyclic AMP 56-66 prolactin Homo sapiens 15-24 2824954-2 1987 Ca++ ionophore A23187 stimulated both cyclic AMP accumulation and prolactin release by primary culture of anterior pituitary cells in vitro. Calcimycin 15-21 prolactin Homo sapiens 66-75 2824954-3 1987 The increase of cyclic AMP formation by A23187 preceded that of prolactin release. Cyclic AMP 16-26 prolactin Homo sapiens 64-73 2824954-3 1987 The increase of cyclic AMP formation by A23187 preceded that of prolactin release. Calcimycin 40-46 prolactin Homo sapiens 64-73 2824954-5 1987 W7 dose dependently inhibited both basal or A23187 stimulated cyclic AMP accumulation and prolactin secretion. Calcimycin 44-50 prolactin Homo sapiens 90-99 3447105-0 1987 [Effect of metoclopramide on prolactin secretion in amyotrophic lateral sclerosis]. Metoclopramide 11-25 prolactin Homo sapiens 29-38 3435630-0 1987 The effect of ethanol on prolactin release from pituitary cells in vitro. Ethanol 14-21 prolactin Homo sapiens 25-34 3435630-2 1987 Since elevated levels of prolactin will interfere with normal functioning of the hypothalamic-pituitary-gonadal axis, and since ethanol has been shown by others to lead to increased prolactin secretion in vivo, the present in vitro study was undertaken to determine whether there is a direct effect of ethanol (ETOH) on prolactin release. Ethanol 128-135 prolactin Homo sapiens 182-191 3435630-2 1987 Since elevated levels of prolactin will interfere with normal functioning of the hypothalamic-pituitary-gonadal axis, and since ethanol has been shown by others to lead to increased prolactin secretion in vivo, the present in vitro study was undertaken to determine whether there is a direct effect of ethanol (ETOH) on prolactin release. Ethanol 128-135 prolactin Homo sapiens 182-191 3435630-4 1987 Ethanol added directly to pituitary cells stimulated prolactin release at all time points examined. Ethanol 0-7 prolactin Homo sapiens 53-62 3435630-7 1987 Thus, the effect of ethanol on prolactin secretion is mediated, at least in part, at the anterior pituitary level. Ethanol 20-27 prolactin Homo sapiens 31-40 3675135-3 1987 The increases in the prolactin level following intravenous infusion of tryptophan and in response to protirelin were also determined. Tryptophan 71-81 prolactin Homo sapiens 21-30 3675135-6 1987 In male subjects, prolactin responses to tryptophan and protirelin were not increased by dieting. Tryptophan 41-51 prolactin Homo sapiens 18-27 3675135-7 1987 In females, the prolactin response to protirelin was similarly not increased, but the prolactin response to tryptophan was markedly enhanced. Tryptophan 108-118 prolactin Homo sapiens 86-95 3675136-1 1987 The increases in plasma levels of prolactin (PRL) and growth hormone (GH) following intravenous administration of the 5-hydroxytryptamine precursor tryptophan (100 mg/kg) were assessed in 30 depressed patients and 30 control subjects. Serotonin 118-137 prolactin Homo sapiens 34-43 3675136-1 1987 The increases in plasma levels of prolactin (PRL) and growth hormone (GH) following intravenous administration of the 5-hydroxytryptamine precursor tryptophan (100 mg/kg) were assessed in 30 depressed patients and 30 control subjects. Tryptophan 148-158 prolactin Homo sapiens 34-43 3675136-5 1987 Prolactin, but not GH, responses correlated significantly with the postdexamethasone plasma cortisol concentration; however, an apparent relationship between GH and PRL responses and suicidal behavior was probably due to the common factor of weight loss. postdexamethasone 67-84 prolactin Homo sapiens 0-9 3675136-5 1987 Prolactin, but not GH, responses correlated significantly with the postdexamethasone plasma cortisol concentration; however, an apparent relationship between GH and PRL responses and suicidal behavior was probably due to the common factor of weight loss. Hydrocortisone 92-100 prolactin Homo sapiens 0-9 3678052-0 1987 Calcitonin and prolactin serum levels in heroin addicts: study on a methadone treated group. Methadone 68-77 prolactin Homo sapiens 15-24 3121569-3 1987 Administration in the dopamine receptor blocker, metoclopramide (25 or 100 mg, im), rapidly increased serum prolactin, and the response was dependent on dose administered (total prolactin measured for 420 min was 3,362.7 +/- 182.1 ng for 25 mg, and 4,485.7 +/- 212.6 ng for 100 mg administered im; P less than .05), but not on route of injection (3,026.3 +/- 492.3 ng prolactin with 25 mg, iv; P less than .05). Metoclopramide 49-63 prolactin Homo sapiens 108-117 3429330-1 1987 The concentration of serum prolactin in response to a standard MVO2 treadmill stress test to self-perceived exhaustion was investigated in 19 normal healthy males. mvo2 63-67 prolactin Homo sapiens 27-36 3438224-0 1987 Meptazinol and pentazocine: effects on prolactin, growth hormone and vasopressin levels in plasma. Meptazinol 0-10 prolactin Homo sapiens 39-48 3432453-0 1987 Diminished prolactin responses to repeated fenfluramine challenge in man. Fenfluramine 43-55 prolactin Homo sapiens 11-20 3121569-3 1987 Administration in the dopamine receptor blocker, metoclopramide (25 or 100 mg, im), rapidly increased serum prolactin, and the response was dependent on dose administered (total prolactin measured for 420 min was 3,362.7 +/- 182.1 ng for 25 mg, and 4,485.7 +/- 212.6 ng for 100 mg administered im; P less than .05), but not on route of injection (3,026.3 +/- 492.3 ng prolactin with 25 mg, iv; P less than .05). Metoclopramide 49-63 prolactin Homo sapiens 178-187 3121569-3 1987 Administration in the dopamine receptor blocker, metoclopramide (25 or 100 mg, im), rapidly increased serum prolactin, and the response was dependent on dose administered (total prolactin measured for 420 min was 3,362.7 +/- 182.1 ng for 25 mg, and 4,485.7 +/- 212.6 ng for 100 mg administered im; P less than .05), but not on route of injection (3,026.3 +/- 492.3 ng prolactin with 25 mg, iv; P less than .05). Metoclopramide 49-63 prolactin Homo sapiens 178-187 3121569-4 1987 Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10). Sulpiride 11-20 prolactin Homo sapiens 84-93 3660204-1 1987 Two cases of human prolactinomas after short-term treatment with bromocriptine were studied by means of immunohistochemistry for prolactin, electron microscopy, and morphometry at the ultrastructural level. Bromocriptine 65-78 prolactin Homo sapiens 19-28 3660204-3 1987 These findings strongly suggest that the effects of short-term bromocriptine treatment for lowering serum prolactin levels did not inhibit protein and secretory granule synthesis but rather caused a disturbance in the secretion of prolactin granules. Bromocriptine 63-76 prolactin Homo sapiens 106-115 3660204-3 1987 These findings strongly suggest that the effects of short-term bromocriptine treatment for lowering serum prolactin levels did not inhibit protein and secretory granule synthesis but rather caused a disturbance in the secretion of prolactin granules. Bromocriptine 63-76 prolactin Homo sapiens 231-240 3121569-4 1987 Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10). Sulpiride 11-20 prolactin Homo sapiens 165-174 3121569-4 1987 Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10). Sulpiride 11-20 prolactin Homo sapiens 165-174 3121569-4 1987 Similarly, sulpiride, a D-2 dopamine receptor blocker, induced an increase in serum prolactin, which appeared to be maximal at a dose of 25 mg (6,556.3 +/- 636.9 ng prolactin/420 min compared with 6,594.5 +/- 169.3 ng prolactin/420 min with 100 mg sulpiride; P less than .10). Sulpiride 248-257 prolactin Homo sapiens 84-93 3121569-5 1987 Finally, bromocriptine, a dopamine agonist, decreased serum prolactin compared with vehicle-injected controls, but the inhibitory effect was found only when basal levels of serum prolactin were highest (in May). Bromocriptine 9-22 prolactin Homo sapiens 60-69 3121569-5 1987 Finally, bromocriptine, a dopamine agonist, decreased serum prolactin compared with vehicle-injected controls, but the inhibitory effect was found only when basal levels of serum prolactin were highest (in May). Bromocriptine 9-22 prolactin Homo sapiens 179-188 3116800-9 1987 Dopamine agonist therapy led to suppression of serum PRL with few exceptions in patients with PRL-positive and -negative tumours, whereas shrinkage was only observed in PRL-immunostainable tumours with high serum PRL levels (over 18,000 mU/l). Dopamine 0-8 prolactin Homo sapiens 53-56 3661064-4 1987 Serum prolactin was normalized in 4 patients during dopamine, and in 6 patients 12-48 h following depot bromocriptine. Dopamine 52-60 prolactin Homo sapiens 6-15 3661064-4 1987 Serum prolactin was normalized in 4 patients during dopamine, and in 6 patients 12-48 h following depot bromocriptine. Bromocriptine 104-117 prolactin Homo sapiens 6-15 3502750-4 1987 At rest higher HRS scores were related to increased acute psychosomatic symptom scores and higher JAS scores to higher prolactin levels. JAS 98-101 prolactin Homo sapiens 119-128 2820700-5 1987 In the presence of hPRL, the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA), known to activate the Na+/H+ antiporter as well as protein kinase C in other cell systems, enhanced the hPRL-stimulated Nb2 cell mitogenesis. Tetradecanoylphorbol Acetate 44-81 prolactin Homo sapiens 19-23 2820700-5 1987 In the presence of hPRL, the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA), known to activate the Na+/H+ antiporter as well as protein kinase C in other cell systems, enhanced the hPRL-stimulated Nb2 cell mitogenesis. Tetradecanoylphorbol Acetate 44-81 prolactin Homo sapiens 193-197 2820700-5 1987 In the presence of hPRL, the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA), known to activate the Na+/H+ antiporter as well as protein kinase C in other cell systems, enhanced the hPRL-stimulated Nb2 cell mitogenesis. Tetradecanoylphorbol Acetate 83-86 prolactin Homo sapiens 19-23 2820700-5 1987 In the presence of hPRL, the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA), known to activate the Na+/H+ antiporter as well as protein kinase C in other cell systems, enhanced the hPRL-stimulated Nb2 cell mitogenesis. Tetradecanoylphorbol Acetate 83-86 prolactin Homo sapiens 193-197 2820701-2 1987 Human PRL (hPRL) stimulated an amiloride-sensitive Na+/H+ exchange system, measured as extracellular acidification or rate of H+ efflux, uptake of 22Na+, and intracellular alkalinization (pHi) in rat Nb2 node lymphoma cells. Amiloride 31-40 prolactin Homo sapiens 11-15 2820701-6 1987 Complete replacement of Na+ by choline chloride gave a marginal increase in the rate of H+ efflux upon addition of hPRL. Choline 31-47 prolactin Homo sapiens 115-119 2820701-7 1987 At a maximum noncytotoxic concentration (25 microM), the potent amiloride analog, 5-(N-ethyl-N-isopropyl)amiloride (EP-Am), decreased but did not abolish, the stimulatory effect of hPRL. ethylisopropylamiloride 82-114 prolactin Homo sapiens 181-185 2820701-7 1987 At a maximum noncytotoxic concentration (25 microM), the potent amiloride analog, 5-(N-ethyl-N-isopropyl)amiloride (EP-Am), decreased but did not abolish, the stimulatory effect of hPRL. ethylisopropylamiloride 116-121 prolactin Homo sapiens 181-185 2820701-8 1987 The hPRL-stimulated increase in H+ efflux rate was accompanied by an EP-Am-sensitive uptake of 22Na+ in acid-loaded (pHi = 6.2) Nb2 cells as well as EP-Am sensitive and extracellular Na+-dependent increase in pHi. ethylisopropylamiloride 69-74 prolactin Homo sapiens 4-8 2820701-8 1987 The hPRL-stimulated increase in H+ efflux rate was accompanied by an EP-Am-sensitive uptake of 22Na+ in acid-loaded (pHi = 6.2) Nb2 cells as well as EP-Am sensitive and extracellular Na+-dependent increase in pHi. Sodium-22 95-100 prolactin Homo sapiens 4-8 2820701-8 1987 The hPRL-stimulated increase in H+ efflux rate was accompanied by an EP-Am-sensitive uptake of 22Na+ in acid-loaded (pHi = 6.2) Nb2 cells as well as EP-Am sensitive and extracellular Na+-dependent increase in pHi. ethylisopropylamiloride 149-154 prolactin Homo sapiens 4-8 2820701-12 1987 The hPRL-stimulated increase in pHi was abolished in Nb2 cells preincubated for 5-10 min with EP-Am (25 microM) before the addition of the hormone. ethylisopropylamiloride 94-99 prolactin Homo sapiens 4-8 3436304-7 1987 The addition of triton X-100 to PBS (pH 7) at 0.1% resulted in the maximum extraction of glycoprotein hormones with homogenization and F-T, but further sonication was necessary for GH and PRL. Octoxynol 16-28 prolactin Homo sapiens 188-191 3436304-7 1987 The addition of triton X-100 to PBS (pH 7) at 0.1% resulted in the maximum extraction of glycoprotein hormones with homogenization and F-T, but further sonication was necessary for GH and PRL. Lead 32-35 prolactin Homo sapiens 188-191 3436304-8 1987 When the anterior pituitaries were homogenized and frozen-thawed in PBS (pH 7) containing 1 M urea, yields of PRL, GH, LH, FSH, and TSH were maximum, and sonication did not cause any additional extraction, indicating that this procedure, i.e. homogenization and F-T in 1 M urea-PBS, would be the best for the simultaneous estimation of these anterior pituitary hormones. Urea 94-98 prolactin Homo sapiens 110-113 3680491-0 1987 Relationship between intrafollicular levels of prolactin and sex steroids and in-vitro fertilization of human oocytes. Steroids 65-73 prolactin Homo sapiens 47-56 2828458-1 1987 We evaluated the effect of a single oral administration of 100 mg melatonin (MT) vs placebo (PL) on the pituitary release of LH, FSH, TSH and prolactin (PRL) after GnRH + TRH and on the adrenocortical release of cortisol, aldosterone and progesterone after ACTH in healthy adult males. Melatonin 66-75 prolactin Homo sapiens 142-151 3310494-3 1987 When cells were incubated with dopamine (10 nmol/l), a significant inhibition in PRL secretion was observed in all the experiments, which was blocked by co-incubation with haloperidol. Dopamine 31-39 prolactin Homo sapiens 81-84 3310494-3 1987 When cells were incubated with dopamine (10 nmol/l), a significant inhibition in PRL secretion was observed in all the experiments, which was blocked by co-incubation with haloperidol. Haloperidol 172-183 prolactin Homo sapiens 81-84 3310494-4 1987 In mixed GH- and PRL-secreting adenoma cells, dopamine likewise decreased GH secretion. Dopamine 46-54 prolactin Homo sapiens 17-20 3332537-0 1987 Modulation of prolactin responses to gonadotropin releasing hormone by acute testosterone infusions in normal women. Testosterone 77-89 prolactin Homo sapiens 14-23 3332537-2 1987 This study addresses whether testosterone may modulate the release of PRL with GnRH during the early follicular phase when this stimulatory effect is not usually observed. Testosterone 29-41 prolactin Homo sapiens 70-73 3332537-8 1987 PRL did not increase significantly after GnRH before testosterone infusion but showed a significant increase after testosterone as well as after testosterone with testolactone. Testosterone 53-65 prolactin Homo sapiens 0-3 3332537-8 1987 PRL did not increase significantly after GnRH before testosterone infusion but showed a significant increase after testosterone as well as after testosterone with testolactone. Testosterone 115-127 prolactin Homo sapiens 0-3 3332537-8 1987 PRL did not increase significantly after GnRH before testosterone infusion but showed a significant increase after testosterone as well as after testosterone with testolactone. Testosterone 115-127 prolactin Homo sapiens 0-3 3332537-8 1987 PRL did not increase significantly after GnRH before testosterone infusion but showed a significant increase after testosterone as well as after testosterone with testolactone. Testolactone 163-175 prolactin Homo sapiens 0-3 3618680-3 1987 Since tamoxifen citrate administration also suppressed prolactin levels, it was suggested that a low but sustained serum level of estradiol and consequently continuous estrogenic stimulation may be an important causative factor in the development of hyperprolactinemic anovulation. Tamoxifen 6-23 prolactin Homo sapiens 55-64 3618680-3 1987 Since tamoxifen citrate administration also suppressed prolactin levels, it was suggested that a low but sustained serum level of estradiol and consequently continuous estrogenic stimulation may be an important causative factor in the development of hyperprolactinemic anovulation. Estradiol 130-139 prolactin Homo sapiens 55-64 3673636-0 1987 Prolactin response to dexamethasone: a study on normal controls and depressed patients. Dexamethasone 22-35 prolactin Homo sapiens 0-9 3673636-2 1987 Dexamethasone had a suppressive effect on prolactin levels, which was expressed more in normal controls and in non-endogenous depressive patients than in endogenous depression. Dexamethasone 0-13 prolactin Homo sapiens 42-51 3673636-3 1987 A "prolactin suppression test" by dexamethasone was constructed and provided comparable results to the usual DST. Dexamethasone 34-47 prolactin Homo sapiens 3-12 3437926-2 1987 Because bromocriptine not only decreases the levels of serum prolactin but also reduces the tumor size. Bromocriptine 8-21 prolactin Homo sapiens 61-70 3125045-7 1987 These results indicate that hypersecretion of PRL induced by SLP has a direct effect on ovary by inhibiting follicular rupture induced by hCG and this inhibitory effect was partly due to the suppression of progesterone secretion during the course of ovulation. Progesterone 206-218 prolactin Homo sapiens 46-49 3432986-2 1987 Human purified Prl (NIAMDD-hPrl-16) was labelled with 125I by the Chloramine-T or alternatively by the lactoperoxidase method. chloramine-T 66-78 prolactin Homo sapiens 15-18 3432986-6 1987 The prolactin was measured in the human sera and in our hPrl preparations by a double antibody radioimmunoassay (RIA) system using the NIAMDD reagents. niamdd 135-141 prolactin Homo sapiens 4-13 3436300-0 1987 Decrease in serum prolactin during bromocriptine-induced pregnancy and subsequent restoration of reproductive function in some hyperprolactinemic women. Bromocriptine 35-48 prolactin Homo sapiens 18-27 3436300-7 1987 In 11 of the 22 patients, PRL levels were serially determined during bromocriptine-induced pregnancies. Bromocriptine 69-82 prolactin Homo sapiens 26-29 3436304-2 1987 Ethanolic media (60% EtOH) gave high yields of PRL at neutral to alkaline pH, but poor extraction of GH accompanied by a marked loss of its immunoreactivity during storage. ethanolic media 0-15 prolactin Homo sapiens 47-50 3653413-0 1987 Prolactin secretion and menstrual function after long-term bromocriptine treatment. Bromocriptine 59-72 prolactin Homo sapiens 0-9 3653413-9 1987 Long-term bromocriptine treatment seems to induce long-standing normalization of prolactin secretion in patients with hyperprolactinemia. Bromocriptine 10-23 prolactin Homo sapiens 81-90 3653414-0 1987 The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women. Ergolines 18-26 prolactin Homo sapiens 53-62 3653414-0 1987 The effect of the ergoline derivative, CU 32-085, on prolactin secretion in hyperprolactinemic women. Copper 39-41 prolactin Homo sapiens 53-62 3653414-3 1987 Significant declines of serum PRL occurred with total daily doses of CU 32-085 of 0.1 to 0.5 mg (P less than 0.001). Copper 69-71 prolactin Homo sapiens 30-33 3653414-8 1987 The results of this study demonstrate that CU 32-085 exhibits a clinically significant dopaminomimetic action on PRL secretion in hyperprolactinemic women. Copper 43-45 prolactin Homo sapiens 113-116 3116029-1 1987 The precise patterns of LH, FSH, and PRL secretion and their correlation with estradiol (E2) and progesterone (P) secretion during the entire luteal phase have not been elucidated. Progesterone 97-109 prolactin Homo sapiens 37-40 3116032-2 1987 After acute administration of 5 mg DHECP, orally, serum PRL decreased by 61 +/- 18% (+/- SD); only 1 patient was unresponsive. Dihydroergocryptine 35-40 prolactin Homo sapiens 56-59 3116032-4 1987 Long term treatment with increasing DHECP doses caused a progressive PRL fall from 125 +/- 142 (+/- SD) to 81 +/- 159 micrograms/L after 1 week of a 3 mg twice daily regimen, to 64 +/- 88 micrograms/L after 1 week of 5 mg twice daily, 46 +/- 57 micrograms/L after 1 week of 10 mg twice daily, and 28 +/- 34 to 33 +/- 45 micrograms/L throughout 9 months of treatment with 10 mg DHECP 3 times daily. Dihydroergocryptine 36-41 prolactin Homo sapiens 69-72 3116797-6 1987 All had normal basal PRL levels, but in 14 of the 18 boys the metoclopramide-releasable PRL levels were subnormal. Metoclopramide 62-76 prolactin Homo sapiens 88-91 3322467-8 1987 Plasma neuroleptic and prolactin levels, week-by-week systemic drug availability and Parkinsonism showed less variation between injections with haloperidol than with fluphenazine. Haloperidol 144-155 prolactin Homo sapiens 23-32 3658111-0 1987 Vasoactive intestinal polypeptide and dopamine: effect on prolactin secretion in normal women and patients with microprolactinomas. Dopamine 38-46 prolactin Homo sapiens 58-67 3658111-1 1987 In order to investigate the influence of dopamine (DA) in modulating prolactin (PRL) response to vasoactive intestinal polypeptide (VIP), VIP (75 micrograms i.v. Dopamine 51-53 prolactin Homo sapiens 69-78 3658111-1 1987 In order to investigate the influence of dopamine (DA) in modulating prolactin (PRL) response to vasoactive intestinal polypeptide (VIP), VIP (75 micrograms i.v. Dopamine 51-53 prolactin Homo sapiens 80-83 3658111-4 1987 DA infusion lowered serum PRL by 67 and 58.2% at 120 min in normal women and in patients with microprolactinomas, respectively, and abolished VIP-induced PRL response in normal women without influencing PRL response in patients with microprolactinomas. Dopamine 0-2 prolactin Homo sapiens 26-29 3658111-4 1987 DA infusion lowered serum PRL by 67 and 58.2% at 120 min in normal women and in patients with microprolactinomas, respectively, and abolished VIP-induced PRL response in normal women without influencing PRL response in patients with microprolactinomas. Dopamine 0-2 prolactin Homo sapiens 154-157 3658111-4 1987 DA infusion lowered serum PRL by 67 and 58.2% at 120 min in normal women and in patients with microprolactinomas, respectively, and abolished VIP-induced PRL response in normal women without influencing PRL response in patients with microprolactinomas. Dopamine 0-2 prolactin Homo sapiens 154-157 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Levodopa 49-55 prolactin Homo sapiens 11-14 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Bromocriptine 57-63 prolactin Homo sapiens 11-14 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Dopamine 28-36 prolactin Homo sapiens 11-14 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Levodopa 138-144 prolactin Homo sapiens 11-14 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Bromocriptine 207-213 prolactin Homo sapiens 11-14 3123284-5 1987 The plasma PRL responses to dopaminergic agents (L-dopa, CB-154, dopamine) were greater in responders than in non-responders (% of basal: L-dopa, 33.7 +/- 3.7% vs 51.6 +/- 5.6% at 150 min, P less than 0.05; CB-154, 16.5 +/- 2.6% vs 30.9 +/- 2.8% at 6 hr, P less than 0.05; dopamine, 31.7 +/- 5.6% vs 44.9 +/- 4.3% at 90 min, P less than 0.05). Dopamine 65-73 prolactin Homo sapiens 11-14 3123284-8 1987 During the short term CB-154 treatment (7.5mg/day for 3 approximately 5 weeks) in 8 responders and 15 non-responders, all responder patients showed normalization of plasma PRL levels, while such normalization was observed in only 6 non-responder patients. Bromocriptine 22-28 prolactin Homo sapiens 172-175 3116800-9 1987 Dopamine agonist therapy led to suppression of serum PRL with few exceptions in patients with PRL-positive and -negative tumours, whereas shrinkage was only observed in PRL-immunostainable tumours with high serum PRL levels (over 18,000 mU/l). Dopamine 0-8 prolactin Homo sapiens 94-97 3116800-9 1987 Dopamine agonist therapy led to suppression of serum PRL with few exceptions in patients with PRL-positive and -negative tumours, whereas shrinkage was only observed in PRL-immunostainable tumours with high serum PRL levels (over 18,000 mU/l). Dopamine 0-8 prolactin Homo sapiens 94-97 3116800-9 1987 Dopamine agonist therapy led to suppression of serum PRL with few exceptions in patients with PRL-positive and -negative tumours, whereas shrinkage was only observed in PRL-immunostainable tumours with high serum PRL levels (over 18,000 mU/l). Dopamine 0-8 prolactin Homo sapiens 94-97 3116800-10 1987 All patients with PRL-negative tumours showed no change or even growth of the tumour despite dopamine agonist therapy. Dopamine 93-101 prolactin Homo sapiens 18-21 3116800-12 1987 Dopamine agonist therapy is effective in PRL suppression and tumour shrinkage in most of these patients. Dopamine 0-8 prolactin Homo sapiens 41-44 3597709-4 1987 In five normal men whose endogenous PRL secretion was suppressed by dopamine, a loading dose of hPRL (70-90 micrograms) followed by a constant infusion (1.39-2.9 ng/min) produced steady state serum PRL levels of 15.2-25.4 ng/mL by 30-60 min. Dopamine 68-76 prolactin Homo sapiens 96-100 3620290-0 1987 Prolactin response to low dose sulpiride. Sulpiride 31-40 prolactin Homo sapiens 0-9 3115863-1 1987 Dopamine has already been recognized as an inhibiting factor of prolactin. Dopamine 0-8 prolactin Homo sapiens 64-73 3609333-0 1987 The temporal relationship between melatonin and prolactin in women. Melatonin 34-43 prolactin Homo sapiens 48-57 3609333-1 1987 The relationship between the concentrations of melatonin and prolactin (PRL) over 24 hours has been investigated. Melatonin 47-56 prolactin Homo sapiens 61-70 3119696-0 1987 Acute effects of L-dopa and bromocriptine on serum PRL, LH and FSH levels in patients with hyperprolactinemic and normoprolactinemic polycystic ovary syndrome. Bromocriptine 28-41 prolactin Homo sapiens 51-54 3119696-1 1987 We have investigated the importance of the dopaminergic control of gonadotropin secretion by studying LH, FSH and PRL responses to L-dopa and bromocriptine in patients with polycystic ovary syndrome (PCOS). Levodopa 131-137 prolactin Homo sapiens 114-117 3119696-5 1987 Prolactin sensitivity to the inhibitory effect of bromocriptine and L-dopa showed a significant correlation with the basal PRL level (p less than 0.01). Bromocriptine 50-63 prolactin Homo sapiens 123-126 3597709-4 1987 In five normal men whose endogenous PRL secretion was suppressed by dopamine, a loading dose of hPRL (70-90 micrograms) followed by a constant infusion (1.39-2.9 ng/min) produced steady state serum PRL levels of 15.2-25.4 ng/mL by 30-60 min. Dopamine 68-76 prolactin Homo sapiens 97-100 3114114-2 1987 Enhanced GABA activity may either reduce basal prolactin levels whilst allowing a normal pituitary response to TRH stimulation, or may overcome the inhibitory effects of dopamine on pituitary prolactin release. gamma-Aminobutyric Acid 9-13 prolactin Homo sapiens 47-56 3119696-5 1987 Prolactin sensitivity to the inhibitory effect of bromocriptine and L-dopa showed a significant correlation with the basal PRL level (p less than 0.01). Levodopa 68-74 prolactin Homo sapiens 123-126 3119696-7 1987 These results suggest that a reduction of an inhibitory influence of hypothalamic dopamine might be a cause of inappropriately elevated LH and PRL levels found in patients with polycystic ovary syndrome and hyperprolactinemia. Dopamine 82-90 prolactin Homo sapiens 143-146 3300328-13 1987 Both PRL and GH antibodies elicited numerous bands of high Mr by the technique employed, far more than ever observed by Sephadex chromatography. sephadex 120-128 prolactin Homo sapiens 5-8 3595910-3 1987 In vitro treatment with human PRL (100 ng/ml) reduced by 57% the specific binding of luteinizing hormone (LH) to follicle-stimulating hormone(FSH)-primed cultured rat granulosa cells, an effect associated with a 2.6-fold diminution of human chorionic gonadotropin (hCG; 10 ng/ml)-stimulated progesterone biosynthesis. Progesterone 291-303 prolactin Homo sapiens 30-33 3595910-5 1987 Inasmuch as the acquisition of LH receptors and progesterone (P) biosynthetic capacity are acceptable as criteria of granulosa cell luteinization, the authors" findings indicate that PRL, acting at concentrations achievable in vivo within the ovarian FF, may account, if only in part, for physiologically encountered LI-like activity. Progesterone 48-60 prolactin Homo sapiens 183-186 3693868-5 1987 Prolactin at haloperidol steady state was significantly related to global outcome at 10 days in the males. Haloperidol 13-24 prolactin Homo sapiens 0-9 3112295-4 1987 1) The plasma PRL levels increased significantly after the injection of MCP, TRH and cimetidine. Cimetidine 85-95 prolactin Homo sapiens 14-17 3112295-5 1987 The peak values of delta PRL levels were 447.0 +/- 62.3 ng/ml after MCP, 278.3 +/- 65.1 ng/ml after TRH and 86.5 +/- 27.3 ng/ml after cimetidine. Cimetidine 134-144 prolactin Homo sapiens 25-28 3112295-6 1987 2) This PRL increase after the injection of MCP and cimetidine was suppressed significantly by pretreatment with BRC. Cimetidine 52-62 prolactin Homo sapiens 8-11 3112295-8 1987 3) Naloxone had no significant effect on PRL response to MCP and TRH, since the plasma PRL levels rose significantly after the injection of MCP and TRH in the naloxone-treated group. Naloxone 159-167 prolactin Homo sapiens 87-90 3114654-5 1987 Patients with epileptic seizures due to alcohol withdrawal showed an elevated prolactin concentration in only 45% of cases. Alcohols 40-47 prolactin Homo sapiens 78-87 3603722-0 1987 Correlation between changes in prolactin and melatonin serum levels after radical mastectomy. Melatonin 45-54 prolactin Homo sapiens 31-40 3035307-0 1987 Effects of acute and chronic methylphenidate administration on beta-endorphin, growth hormone, prolactin and cortisol in children with attention deficit disorder and hyperactivity. Methylphenidate 29-44 prolactin Homo sapiens 95-104 3035307-2 1987 methylphenidate (MPH) challenge on beta-endorphin (beta-EP), growth hormone (GH), prolactin (Prl) and cortisol was investigated in 16 children suffering from attention deficit disorder with hyperactivity (ADDH) before and after 4 weeks MPH treatment. Methylphenidate 0-15 prolactin Homo sapiens 82-91 3035307-2 1987 methylphenidate (MPH) challenge on beta-endorphin (beta-EP), growth hormone (GH), prolactin (Prl) and cortisol was investigated in 16 children suffering from attention deficit disorder with hyperactivity (ADDH) before and after 4 weeks MPH treatment. Methylphenidate 0-15 prolactin Homo sapiens 93-96 3595894-3 1987 Reduction of serum PRL levels followed by menarche can be anticipated within a few months of starting bromocriptine therapy in the majority of cases. Bromocriptine 102-115 prolactin Homo sapiens 19-22 3620290-1 1987 1 Prolactin levels in response to sulpiride were studied in healthy volunteers. Sulpiride 34-43 prolactin Homo sapiens 2-11 3620290-5 1987 6 These results indicate that sulpiride retains its potent ability to produce prolactin release even at the low doses studied here. Sulpiride 30-39 prolactin Homo sapiens 78-87 3114663-0 1987 A pharmacological dose of melatonin increases PRL levels in males without altering those of GH, LH, FSH, TSH, testosterone or cortisol. Melatonin 26-35 prolactin Homo sapiens 46-49 3628621-2 1987 An acute dose of diazepam (15 mg) significantly attenuated the prolactin and growth hormone responses to intravenous L-tryptophan. Diazepam 17-25 prolactin Homo sapiens 63-72 3628621-2 1987 An acute dose of diazepam (15 mg) significantly attenuated the prolactin and growth hormone responses to intravenous L-tryptophan. Tryptophan 117-129 prolactin Homo sapiens 63-72 3605397-1 1987 The authors evaluated changes in serum prolactin levels as a measure of differences in response to ethanol between 30 healthy, drinking, young adult sons of alcoholics and 30 matched control subjects with no family history of psychiatric or substance abuse problems. Ethanol 99-106 prolactin Homo sapiens 39-48 3605397-4 1987 Controlling for baseline prolactin measures and hormonal changes after placebo, the authors found that the sons of alcoholics had significantly lower prolactin levels in response to the high-dose ethanol challenge. Ethanol 196-203 prolactin Homo sapiens 150-159 3595069-0 1987 Intravenous medroxalol stimulates prolactin secretion in normal and hypertensive subjects. medroxalol 12-22 prolactin Homo sapiens 34-43 3595069-1 1987 This study evaluated the effects of medroxalol on prolactin secretion. medroxalol 36-46 prolactin Homo sapiens 50-59 3595069-3 1987 Integrated prolactin secretion during the 3 hours after medroxalol injection was significantly increased as compared with dextrose (P less than 0.001). medroxalol 56-66 prolactin Homo sapiens 11-20 3595069-4 1987 Intravenous administration of medroxalol, 2 mg/kg, to 10 hypertensive subjects resulted in significant elevation of mean prolactin levels above basal levels at all time intervals measured from 30 to 240 minutes after injection. medroxalol 30-40 prolactin Homo sapiens 121-130 3595069-7 1987 In conclusion, intravenous medroxalol stimulates prolactin secretion in both normal and hypertensive subjects. medroxalol 27-37 prolactin Homo sapiens 49-58 3666000-0 1987 The clinical significance of melatonin serum determination in oncological patients and its correlations with GH and PRL blood levels. Melatonin 29-38 prolactin Homo sapiens 116-119 2889675-2 1987 PRL secretion is undoubtedly influenced by many substances, which can be variously altered in uremia: monoamines, endogenous opiates and PTH. monoamines 102-112 prolactin Homo sapiens 0-3 2889675-2 1987 PRL secretion is undoubtedly influenced by many substances, which can be variously altered in uremia: monoamines, endogenous opiates and PTH. Opiate Alkaloids 125-132 prolactin Homo sapiens 0-3 2889675-4 1987 PRL derangements could be due in mild renal failure, to unknown factors (GABA? gamma-Aminobutyric Acid 73-77 prolactin Homo sapiens 0-3 3665123-0 1987 Remission of hypoparathyroidism during lactation: evidence for a physiological role for prolactin in the regulation of vitamin D metabolism. Vitamin D 119-128 prolactin Homo sapiens 88-97 3114114-2 1987 Enhanced GABA activity may either reduce basal prolactin levels whilst allowing a normal pituitary response to TRH stimulation, or may overcome the inhibitory effects of dopamine on pituitary prolactin release. gamma-Aminobutyric Acid 9-13 prolactin Homo sapiens 192-201 3114114-2 1987 Enhanced GABA activity may either reduce basal prolactin levels whilst allowing a normal pituitary response to TRH stimulation, or may overcome the inhibitory effects of dopamine on pituitary prolactin release. Dopamine 170-178 prolactin Homo sapiens 192-201 2885345-0 1987 Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. Remoxipride 33-44 prolactin Homo sapiens 96-105 2437140-5 1987 Oral administration of bromocriptine (5 mg), on the other hand, consistently decreased serum alpha-subunit and PRL levels in 2 patients with prolactinoma and alpha-subunit and GH levels in 1 acromegalic patient. Bromocriptine 23-36 prolactin Homo sapiens 111-114 3106986-3 1987 Quinacrine at concentrations of 1-5 microM attenuated the magnitude of the PRL stimulation of cell division; at concentrations of 10 microM and above quinacrine abolished the PRL response. Quinacrine 0-10 prolactin Homo sapiens 75-78 3040850-0 1987 Treatment of pituitary macroadenomas secreting PRL, HGH or ACTH with long-acting bromocriptine. Bromocriptine 81-94 prolactin Homo sapiens 47-50 3106726-7 1987 Chlorpromazine injections failed to elevate serum prolactin in all patients, and administration of levodopa caused a partial reduction in serum prolactin; thus, the hypothalamus may be an important locus of endocrine malfunction in these patients. Levodopa 99-107 prolactin Homo sapiens 144-153 3106986-3 1987 Quinacrine at concentrations of 1-5 microM attenuated the magnitude of the PRL stimulation of cell division; at concentrations of 10 microM and above quinacrine abolished the PRL response. Quinacrine 150-160 prolactin Homo sapiens 175-178 3106986-4 1987 BPB at concentrations of 1-10 microM also inhibited the mitogenic effect of PRL in a concentration response fashion. bpb 0-3 prolactin Homo sapiens 76-79 3578141-3 1987 Phenothiazines have been demonstrated to cause elevated serum prolactin levels. Phenothiazines 0-14 prolactin Homo sapiens 62-71 3665121-0 1987 Role of gonadal steroids in the serotoninergic control of prolactin secretion in men. Steroids 16-24 prolactin Homo sapiens 58-67 3665121-1 1987 The physiological regulation of PRL secretion seems to involve the central serotonin system, since plasma PRL levels are enhanced by serotoninergic agonists and serotonin re-uptake blockers. Serotonin 75-84 prolactin Homo sapiens 32-35 3665121-1 1987 The physiological regulation of PRL secretion seems to involve the central serotonin system, since plasma PRL levels are enhanced by serotoninergic agonists and serotonin re-uptake blockers. Serotonin 75-84 prolactin Homo sapiens 106-109 3665121-1 1987 The physiological regulation of PRL secretion seems to involve the central serotonin system, since plasma PRL levels are enhanced by serotoninergic agonists and serotonin re-uptake blockers. Serotonin 133-142 prolactin Homo sapiens 32-35 3665121-1 1987 The physiological regulation of PRL secretion seems to involve the central serotonin system, since plasma PRL levels are enhanced by serotoninergic agonists and serotonin re-uptake blockers. Serotonin 133-142 prolactin Homo sapiens 106-109 3665121-2 1987 The aim of this study was to evaluate whether the influence of oestrogens on PRL is mediated by the hypothalamic serotonin system. Serotonin 113-122 prolactin Homo sapiens 77-80 3665121-3 1987 The PRL response to fenfluramine, a serotonin agonist that releases the amine and inhibits its re-uptake, was assessed in 10 normal men (aged 18-25 years) and in six castrated men (aged 18-24 years). Fenfluramine 20-32 prolactin Homo sapiens 4-7 3665121-3 1987 The PRL response to fenfluramine, a serotonin agonist that releases the amine and inhibits its re-uptake, was assessed in 10 normal men (aged 18-25 years) and in six castrated men (aged 18-24 years). Amines 27-32 prolactin Homo sapiens 4-7 3665121-4 1987 In both groups, the effect of fenfluramine on PRL secretion was also evaluated on the sixth day after receiving clomiphene citrate, an oestrogen antagonist and partial agonist. Fenfluramine 30-42 prolactin Homo sapiens 46-49 3665121-7 1987 Our results demonstrate that in normal men fenfluramine treatment significantly enhances plasma PRL levels, and clomiphene citrate treatment significantly reduces this effect. Fenfluramine 43-55 prolactin Homo sapiens 96-99 3665121-8 1987 In castrated men, fenfluramine is also able to enhance PRL secretion but to a lesser extent; after clomiphene citrate treatment the increase of plasma PRL levels induced by fenfluramine rises to the normal range. Fenfluramine 18-30 prolactin Homo sapiens 55-58 3665121-8 1987 In castrated men, fenfluramine is also able to enhance PRL secretion but to a lesser extent; after clomiphene citrate treatment the increase of plasma PRL levels induced by fenfluramine rises to the normal range. Clomiphene 99-117 prolactin Homo sapiens 151-154 3665121-8 1987 In castrated men, fenfluramine is also able to enhance PRL secretion but to a lesser extent; after clomiphene citrate treatment the increase of plasma PRL levels induced by fenfluramine rises to the normal range. Fenfluramine 173-185 prolactin Homo sapiens 151-154 2885281-0 1987 Prolactin response to clomiphene citrate is different in hyperprolactinemic polycystic ovary syndrome and idiopathic hyperprolactinemia. Clomiphene 22-40 prolactin Homo sapiens 0-9 3108440-10 1987 Binding of 125I-labelled hPRL to human luteal homogenates was increased by Mg2+ and was specific for lactogenic hormones (human prolactin, human growth hormone and ovine prolactin). Iodine-125 11-15 prolactin Homo sapiens 25-29 3108440-10 1987 Binding of 125I-labelled hPRL to human luteal homogenates was increased by Mg2+ and was specific for lactogenic hormones (human prolactin, human growth hormone and ovine prolactin). Iodine-125 11-15 prolactin Homo sapiens 128-137 3108440-10 1987 Binding of 125I-labelled hPRL to human luteal homogenates was increased by Mg2+ and was specific for lactogenic hormones (human prolactin, human growth hormone and ovine prolactin). Iodine-125 11-15 prolactin Homo sapiens 170-179 3108440-10 1987 Binding of 125I-labelled hPRL to human luteal homogenates was increased by Mg2+ and was specific for lactogenic hormones (human prolactin, human growth hormone and ovine prolactin). magnesium ion 75-79 prolactin Homo sapiens 25-29 3569491-1 1987 Reductions of prolactin secretion by bromocriptine treatment for 24 days reduced fat stores (abdominal and epididymal fat depots) in hamsters by 25-49% compared with control animals. Bromocriptine 37-50 prolactin Homo sapiens 14-23 3109998-2 1987 Since prolactin (PRL), being an aromatase inhibitor, can interfere with follicular fluid steroid metabolism, we examined the influence of high serum PRL levels on the endocrine response and fertilisation rate of oocytes. Steroids 89-96 prolactin Homo sapiens 6-15 3109998-2 1987 Since prolactin (PRL), being an aromatase inhibitor, can interfere with follicular fluid steroid metabolism, we examined the influence of high serum PRL levels on the endocrine response and fertilisation rate of oocytes. Steroids 89-96 prolactin Homo sapiens 17-20 3111873-0 1987 The prolactin response to TRH and domperidone does not differentiate male hypothalamic hypogonadism and constitutional delay of puberty. Domperidone 34-45 prolactin Homo sapiens 4-13 3111873-10 1987 Successful treatment of a patient with IHH did not change the response of prolactin to TRH, but increased prolactin response to domperidone possibly due to altered steroid milieu. Domperidone 128-139 prolactin Homo sapiens 106-115 3111873-10 1987 Successful treatment of a patient with IHH did not change the response of prolactin to TRH, but increased prolactin response to domperidone possibly due to altered steroid milieu. Steroids 164-171 prolactin Homo sapiens 106-115 3298648-4 1987 The high basal serum prolactin (PRL) levels observed in these patients with SLE is a novel finding not previously reported that could explain why serum T and DHT levels are low in this syndrome. Dihydrotestosterone 158-161 prolactin Homo sapiens 21-30 3298648-4 1987 The high basal serum prolactin (PRL) levels observed in these patients with SLE is a novel finding not previously reported that could explain why serum T and DHT levels are low in this syndrome. Dihydrotestosterone 158-161 prolactin Homo sapiens 32-35 3037356-0 1987 [Decrease of plasma prolactin in valproate therapy--expression of an increase in the activity of the central GABAergic system]. Valproic Acid 33-42 prolactin Homo sapiens 20-29 3037356-1 1987 The effect of Valproat on plasma prolactin level in epileptic children with long term medication was investigated. valproat 14-22 prolactin Homo sapiens 33-42 3154353-0 1987 [The effect of nomifensine on prolactin secretion in the puerperium and its aftereffect on lactation]. Nomifensine 15-26 prolactin Homo sapiens 30-39 3474160-1 1987 We have examined the effects of prolactin (PRL) on progesterone (P) and estradiol (E2) synthesis by cells obtained from human corpora lutea of early and midluteal phases. Progesterone 51-63 prolactin Homo sapiens 43-46 3474160-7 1987 The high dose of PRL also inhibited prostaglandin E2 but not 8-bromoadenosine 3":5"-cyclic monophosphate-stimulated P and E2 synthesis. Dinoprostone 36-52 prolactin Homo sapiens 17-20 3474160-7 1987 The high dose of PRL also inhibited prostaglandin E2 but not 8-bromoadenosine 3":5"-cyclic monophosphate-stimulated P and E2 synthesis. 5"-cyclic monophosphate 81-104 prolactin Homo sapiens 17-20 3327498-13 1987 The prolactin rise is brought about by either a decrease in dopamine activity, an increased secretion of a hypothetical PRF, or by both mechanisms. Dopamine 60-68 prolactin Homo sapiens 4-13 3032694-3 1987 Initial bromocriptine therapy resulted in cessation of amenorrhea-galactorrhea and normalization of PRL levels. Bromocriptine 8-21 prolactin Homo sapiens 100-103 3297633-2 1987 Different neurotransmitters (Dopamine, serotonin, GABA...) and hormones (TRH, oestrogenes...) are involved in the central regulation of prolactin synthesis and release. Dopamine 29-37 prolactin Homo sapiens 136-145 3297633-2 1987 Different neurotransmitters (Dopamine, serotonin, GABA...) and hormones (TRH, oestrogenes...) are involved in the central regulation of prolactin synthesis and release. Serotonin 39-48 prolactin Homo sapiens 136-145 3297633-2 1987 Different neurotransmitters (Dopamine, serotonin, GABA...) and hormones (TRH, oestrogenes...) are involved in the central regulation of prolactin synthesis and release. gamma-Aminobutyric Acid 50-54 prolactin Homo sapiens 136-145 3297633-5 1987 Different research paradigms are presently reviewed: measurement of plasma levels of prolactin under basal conditions, in a circadian pattern or after pharmacological challenge with TRH and/or morphine (stimulation), L-dopa and/or dexamethasone (inhibition) and its response to antidepressant drugs. Morphine 193-201 prolactin Homo sapiens 85-94 3569115-11 1987 Furthermore, vascular injections of [125I]iodo-PRL administered with a range of concentrations of unlabeled oPRL revealed a dose-response inhibition in the transport of [125I]iodo-PRL from blood to CSF. Iodine-125 36-41 prolactin Homo sapiens 47-50 3569115-11 1987 Furthermore, vascular injections of [125I]iodo-PRL administered with a range of concentrations of unlabeled oPRL revealed a dose-response inhibition in the transport of [125I]iodo-PRL from blood to CSF. Iodine-125 36-41 prolactin Homo sapiens 109-112 3577589-2 1987 The specific [3H]spiperone binding sites on prolactin (PRL)-secreting adenoma membranes were recognized as a dopamine receptor, based upon the data showing high affinity binding, saturability, specificity, temperature dependence, and reversibility. Tritium 14-16 prolactin Homo sapiens 44-53 3577589-2 1987 The specific [3H]spiperone binding sites on prolactin (PRL)-secreting adenoma membranes were recognized as a dopamine receptor, based upon the data showing high affinity binding, saturability, specificity, temperature dependence, and reversibility. Spiperone 17-26 prolactin Homo sapiens 44-53 3567264-0 1987 The prolactin response to metoclopramide is increased in depression and in euthymic rapid cycling bipolar patients. Metoclopramide 26-40 prolactin Homo sapiens 4-13 3106094-1 1987 Infertile women with normal serum prolactin (PRL) levels have been known to establish a pregnancy after the use of bromocriptine, a dopamine agonist. Bromocriptine 115-128 prolactin Homo sapiens 34-43 3106094-1 1987 Infertile women with normal serum prolactin (PRL) levels have been known to establish a pregnancy after the use of bromocriptine, a dopamine agonist. Bromocriptine 115-128 prolactin Homo sapiens 45-48 3106094-1 1987 Infertile women with normal serum prolactin (PRL) levels have been known to establish a pregnancy after the use of bromocriptine, a dopamine agonist. Dopamine 132-140 prolactin Homo sapiens 45-48 2980713-0 1987 Light microscopical morphometry of prolactin secreting adenomas under treatment with dopamine agonists. Dopamine 85-93 prolactin Homo sapiens 35-44 3653746-0 1987 [Evaluation of FSH, LH and prolactin levels in women with secondary amenorrhea in relation to the reaction to progesterone and duration of the disorder]. Progesterone 110-122 prolactin Homo sapiens 27-36 3102546-12 1987 Along with the rise of estradiol levels an increase of sex hormone-binding globulin and PRL levels occurred. Estradiol 23-32 prolactin Homo sapiens 88-91 3818900-0 1987 Angiotensin II promotes prolactin release from normal human anterior pituitary cell cultures in a calcium-dependent manner. Calcium 98-105 prolactin Homo sapiens 24-33 2884239-1 1987 An open-label reversal drug study was undertaken on 10 neuroleptic-treated schizophrenic inpatients to assess the impact of amantadine hydrochloride on presumed prolactin-mediated neuroendocrine side effects. Amantadine 124-148 prolactin Homo sapiens 161-170 2884239-3 1987 Significant reduction with amantadine was observed on all six indices of neuroendocrine side effects: serum prolactin levels, body weight, gynecomastia/galactorrhea, breast tenderness, decreased libido, and amenorrhea. Amantadine 27-37 prolactin Homo sapiens 108-117 3035002-0 1987 Naloxone increases the response of growth hormone and prolactin to stimuli in obese humans. Naloxone 0-8 prolactin Homo sapiens 54-63 3035002-1 1987 Opiates stimulate the growth hormone and prolactin responses to stimuli in non-obese humans. Opiate Alkaloids 0-7 prolactin Homo sapiens 41-50 3035002-3 1987 We therefore investigated the effect of the opiate antagonist naloxone on the stimulated growth hormone and prolactin secretions in a controlled double-blind study in obese patients. Naloxone 62-70 prolactin Homo sapiens 108-117 3035002-7 1987 The TRH- and arginine-induced increases in prolactin and growth hormone were significantly greater after administration of naloxone (p less than 0.05). Arginine 13-21 prolactin Homo sapiens 43-52 3035002-7 1987 The TRH- and arginine-induced increases in prolactin and growth hormone were significantly greater after administration of naloxone (p less than 0.05). Naloxone 123-131 prolactin Homo sapiens 43-52 3035002-10 1987 The effect of naloxone on growth hormone and prolactin secretions in obese humans can thus be regarded as a partial normalization. Naloxone 14-22 prolactin Homo sapiens 45-54 3035002-11 1987 We therefore conclude that the hypothalamic regulatory disturbance of growth hormone and prolactin secretions in the obese could be caused by raised opiate levels. Opiate Alkaloids 149-155 prolactin Homo sapiens 89-98 3108355-8 1987 In the first protocol, PRL showed a significant increase (peak values at 30 min) after SUL administration in both phases (phase A: 54.8 +/- 5.6 ng/ml, mean +/- SE vs 6.4 +/- 0.3, p less than 0.001. Sulpiride 87-90 prolactin Homo sapiens 23-26 3108355-11 1987 Also in the second protocol, SUL alone induced a significant PRL increase (peak values at 30 min: 47.1 +/- 7.2 vs 4.2 +/- 0.5, p less than 0.005). Sulpiride 29-32 prolactin Homo sapiens 61-64 3584856-1 1987 Recently, a new long-acting form of bromocriptine (Parlodel LA, Sandoz) has been developed and it has already been found to be effective in lowering plasma PRL levels in normal volunteers and postpartum women. Bromocriptine 36-49 prolactin Homo sapiens 156-159 3593602-1 1987 Bromocriptine (CB) not only lowers serum prolactin (PRL) levels but also reduces tumor size of human prolactinomas. Bromocriptine 0-13 prolactin Homo sapiens 41-50 3593602-1 1987 Bromocriptine (CB) not only lowers serum prolactin (PRL) levels but also reduces tumor size of human prolactinomas. Bromocriptine 0-13 prolactin Homo sapiens 52-55 3602989-1 1987 Clomipramine in therapeutic dose was associated with nonpuerperal lactation and an elevated plasma prolactin. Clomipramine 0-12 prolactin Homo sapiens 99-108 2889495-10 1987 Pimozide produced greater elevation of plasma prolactin. Pimozide 0-8 prolactin Homo sapiens 46-55 3593430-1 1987 Cyanogen bromide and chymotryptic fragments both containing a carbohydrate chain were obtained from the glycosylated form of porcine prolactin. Carbohydrates 62-74 prolactin Homo sapiens 133-142 3593430-0 1987 [Structure of the carbohydrate chain of glycosylated porcine prolactin]. Carbohydrates 18-30 prolactin Homo sapiens 61-70 3593430-1 1987 Cyanogen bromide and chymotryptic fragments both containing a carbohydrate chain were obtained from the glycosylated form of porcine prolactin. Cyanogen Bromide 0-16 prolactin Homo sapiens 133-142 3107837-0 1987 Prolactin in cluster headache: diurnal secretion, response to thyrotropin-releasing hormone, and relation to sex steroids and gonadotropins. Steroids 113-121 prolactin Homo sapiens 0-9 3816084-3 1987 Prolactin responsiveness to metoclopramide was reduced in the patients as compared with the controls, such being considered characteristic of a prolactinoma. Metoclopramide 28-42 prolactin Homo sapiens 0-9 3816084-7 1987 One explanation for these results is that prolactin can directly or indirectly modulate the aldosterone response to metoclopramide. Aldosterone 92-103 prolactin Homo sapiens 42-51 3816084-7 1987 One explanation for these results is that prolactin can directly or indirectly modulate the aldosterone response to metoclopramide. Metoclopramide 116-130 prolactin Homo sapiens 42-51 3816709-5 1987 The PRL levels in the CSF correlated negatively to the HVA levels in CSF in the patient group only. Homovanillic Acid 55-58 prolactin Homo sapiens 4-7 3569359-0 1987 Increased serum prolactin but normal TSH during prolonged domperidone treatment in children. Domperidone 58-69 prolactin Homo sapiens 16-25 3104097-3 1987 The maximal response of PRL to the dopamine antagonist metoclopramide was increased (P less than 0.01), whereas the maximal responses of luteinizing hormone (P less than 0.025) and follicle-stimulating hormone (P less than 0.001) to gonadotropin-releasing hormone were lowered in the treatment cycles. Dopamine 35-43 prolactin Homo sapiens 24-27 3104097-3 1987 The maximal response of PRL to the dopamine antagonist metoclopramide was increased (P less than 0.01), whereas the maximal responses of luteinizing hormone (P less than 0.025) and follicle-stimulating hormone (P less than 0.001) to gonadotropin-releasing hormone were lowered in the treatment cycles. Metoclopramide 55-69 prolactin Homo sapiens 24-27 3569359-1 1987 The influence of the dopamine receptor blocking agent domperidone on prolactin and TSH secretion was studied in 16 infants, aged 10-360 days, who were treated for gastroesophageal reflux. Domperidone 54-65 prolactin Homo sapiens 69-78 3569359-3 1987 During treatment with domperidone a significant increase in prolactin level was observed on days 1, 4 and 21-28, the mean values on these three days not being statistically different. Domperidone 22-33 prolactin Homo sapiens 60-69 3595729-1 1987 The authors have evaluated the secretion of prolactin after dopaminergic blockade with metoclopramide in female patients revealing hyperostosis frontalis. Metoclopramide 87-101 prolactin Homo sapiens 44-53 2880862-8 1987 In neither of those groups was a significant correlation found between the plasma LH response to naloxone and basal plasma PRL levels. Naloxone 97-105 prolactin Homo sapiens 123-126 2438170-0 1987 Cyclic AMP inhibits the synthesis and release of prolactin from human decidual cells. Cyclic AMP 0-10 prolactin Homo sapiens 49-58 2438170-1 1987 Exposure of human decidual cells for 0.5 h to dibutyryl cAMP, isobutyl-methylxanthine (IBMX), cholera toxin or forskolin caused a dose-dependent inhibition of prolactin release with maximal inhibition by each agent of 50-60%. Bucladesine 46-60 prolactin Homo sapiens 159-168 2438170-1 1987 Exposure of human decidual cells for 0.5 h to dibutyryl cAMP, isobutyl-methylxanthine (IBMX), cholera toxin or forskolin caused a dose-dependent inhibition of prolactin release with maximal inhibition by each agent of 50-60%. 1-Methyl-3-isobutylxanthine 62-85 prolactin Homo sapiens 159-168 2438170-1 1987 Exposure of human decidual cells for 0.5 h to dibutyryl cAMP, isobutyl-methylxanthine (IBMX), cholera toxin or forskolin caused a dose-dependent inhibition of prolactin release with maximal inhibition by each agent of 50-60%. 1-Methyl-3-isobutylxanthine 87-91 prolactin Homo sapiens 159-168 2438170-1 1987 Exposure of human decidual cells for 0.5 h to dibutyryl cAMP, isobutyl-methylxanthine (IBMX), cholera toxin or forskolin caused a dose-dependent inhibition of prolactin release with maximal inhibition by each agent of 50-60%. Colforsin 111-120 prolactin Homo sapiens 159-168 2438170-2 1987 Dibutyryl cAMP (5 mM), IBMX (0.5 mM), and cholera toxin (10 micrograms/ml) also inhibited prolactin synthesis to the same extent as prolactin release. dibutyryl 0-9 prolactin Homo sapiens 90-99 2438170-2 1987 Dibutyryl cAMP (5 mM), IBMX (0.5 mM), and cholera toxin (10 micrograms/ml) also inhibited prolactin synthesis to the same extent as prolactin release. dibutyryl 0-9 prolactin Homo sapiens 132-141 2438170-2 1987 Dibutyryl cAMP (5 mM), IBMX (0.5 mM), and cholera toxin (10 micrograms/ml) also inhibited prolactin synthesis to the same extent as prolactin release. Cyclic AMP 10-14 prolactin Homo sapiens 90-99 2438170-2 1987 Dibutyryl cAMP (5 mM), IBMX (0.5 mM), and cholera toxin (10 micrograms/ml) also inhibited prolactin synthesis to the same extent as prolactin release. 1-Methyl-3-isobutylxanthine 23-27 prolactin Homo sapiens 90-99 2438170-2 1987 Dibutyryl cAMP (5 mM), IBMX (0.5 mM), and cholera toxin (10 micrograms/ml) also inhibited prolactin synthesis to the same extent as prolactin release. 1-Methyl-3-isobutylxanthine 23-27 prolactin Homo sapiens 132-141 3588662-6 1987 Bromocriptine slowed the alpha activity of the resting EEG power spectrum, depressed subjective mental and emotional states, lowered blood pressure, and reduced prolactin secretion. Bromocriptine 0-13 prolactin Homo sapiens 161-170 3031644-4 1987 In cultured human ovarian granulosa cells, follicle-stimulating hormone, human chorionic gonadotropin, and dibutyryl cAMP increased IGF-II mRNA, but corticotropin [adrenocorticotropic hormone (ACTH)], chorionic somatomammotropin, growth hormone, prolactin, dexamethasone, estradiol, and progesterone had no effect. Cyclic AMP 117-121 prolactin Homo sapiens 246-255 3817155-3 1987 Concanavalin A-Sepharose 4B chromatography revealed that the 25 kDa form was a glycosylated variant of PRL. Sepharose 15-24 prolactin Homo sapiens 103-106 3812533-1 1987 Several investigators have suggested that prolactin secretion in some subjects with hyperprolactinemia associated with pituitary macroadenomas may have a resistance to the prolactin inhibitory hormone, dopamine. Dopamine 202-210 prolactin Homo sapiens 42-51 3812533-2 1987 This report describes a male subject with a prolactinoma whose preoperative evaluation demonstrated a resistance of prolactin release to inhibition by dopamine. Dopamine 151-159 prolactin Homo sapiens 44-53 3812533-3 1987 Evaluation of prolactin secretion from monolayer culture of his tumor also revealed a resistance to inhibition by dopamine. Dopamine 114-122 prolactin Homo sapiens 14-23 3812533-4 1987 Four months postoperatively, normal serum prolactin levels and a normal maximal inhibition of prolactin to a dopamine infusion of 0.04 microgram/kg/minute suggested surgical cure. Dopamine 109-117 prolactin Homo sapiens 94-103 3812533-5 1987 However, a 24-hour prolactin sampling revealed blunted nocturnal augmentation of prolactin release, an early escape of inhibition of prolactin release at 150 minutes from a 0.04 microgram/kg/minute dopamine infusion, and abnormal prolactin response to a low-dose (0.004 microgram/kg/minute) dopamine infusion. Dopamine 198-206 prolactin Homo sapiens 81-90 3594320-2 1987 This study describes the inhibitory influence of an acute exposure to hypoxia (14.5% O2) on the blood PRL response induced by graded maximal exercise in eight trained male subjects. Oxygen 85-87 prolactin Homo sapiens 102-105 3665115-5 1987 After bromocriptine therapy for 4 months serum PRL had fallen to 90 mU/l and the tumour was not visible on repeat computerized tomography. Bromocriptine 6-19 prolactin Homo sapiens 47-50 3812533-5 1987 However, a 24-hour prolactin sampling revealed blunted nocturnal augmentation of prolactin release, an early escape of inhibition of prolactin release at 150 minutes from a 0.04 microgram/kg/minute dopamine infusion, and abnormal prolactin response to a low-dose (0.004 microgram/kg/minute) dopamine infusion. Dopamine 198-206 prolactin Homo sapiens 81-90 3812533-5 1987 However, a 24-hour prolactin sampling revealed blunted nocturnal augmentation of prolactin release, an early escape of inhibition of prolactin release at 150 minutes from a 0.04 microgram/kg/minute dopamine infusion, and abnormal prolactin response to a low-dose (0.004 microgram/kg/minute) dopamine infusion. Dopamine 198-206 prolactin Homo sapiens 81-90 3812533-8 1987 Thus, resistance of prolactin secretion to inhibition by dopamine was present in this patient with a prolactinoma. Dopamine 57-65 prolactin Homo sapiens 20-29 3812533-9 1987 Additionally, an abnormal prolactin response to dopamine was noted to precede the development of hyperprolactinemia with tumor recurrence. Dopamine 48-56 prolactin Homo sapiens 26-35 3098774-5 1987 During normal menstrual cycles and after iv GnRH, TRH, metoclopramide, and insulin tolerance tests, serum PRL was only rarely detectable by RIA, at very low concentrations. Metoclopramide 55-69 prolactin Homo sapiens 106-109 2438170-5 1987 The demonstration that agents which increase intracellular cAMP levels inhibit the synthesis and release of decidual prolactin strongly implicates cAMP as a second messenger in the regulation of the synthesis and release of the hormone. Cyclic AMP 59-63 prolactin Homo sapiens 117-126 2438170-5 1987 The demonstration that agents which increase intracellular cAMP levels inhibit the synthesis and release of decidual prolactin strongly implicates cAMP as a second messenger in the regulation of the synthesis and release of the hormone. Cyclic AMP 147-151 prolactin Homo sapiens 117-126 2438170-6 1987 The inhibitory effect of cAMP on prolactin release appears to be on the release from a rapidly releasable, newly synthesized intracellular prolactin pool. Cyclic AMP 25-29 prolactin Homo sapiens 33-42 2438170-6 1987 The inhibitory effect of cAMP on prolactin release appears to be on the release from a rapidly releasable, newly synthesized intracellular prolactin pool. Cyclic AMP 25-29 prolactin Homo sapiens 139-148 3793856-2 1987 This report documents exacerbation of a PRL-secreting tumor after two separate 200-mg testosterone enanthate (T) injections despite continued bromocriptine (BRC) therapy. testosterone enanthate 86-108 prolactin Homo sapiens 40-43 3598074-4 1987 Chronic treatment (4-12 months) with an oral single evening dose of bromocriptine is able to control plasma PRL at least as well as the traditional tid regimen (2.8-21.6 ng/ml vs 1.2-31.8 ng/ml). Bromocriptine 68-81 prolactin Homo sapiens 108-111 3819638-6 1987 Daily injections of 2500 micrograms corticosterone/kg body weight, in both lines, depressed mean concentrations of plasma prolactin, T3 and somatomedin C and body weight. Corticosterone 36-50 prolactin Homo sapiens 122-131 3793856-2 1987 This report documents exacerbation of a PRL-secreting tumor after two separate 200-mg testosterone enanthate (T) injections despite continued bromocriptine (BRC) therapy. Bromocriptine 142-155 prolactin Homo sapiens 40-43 3587524-0 1987 Effect of prolactin on tolerance and dependence to acute administration of morphine. Morphine 75-83 prolactin Homo sapiens 10-19 3560070-0 1987 Metergoline as an inhibitor of prolactin release. Metergoline 0-11 prolactin Homo sapiens 31-40 3099198-5 1987 A significant decrease was seen, however, in basal and perphenazine-stimulated levels of prolactin after pregnancy in both the younger and older first-pregnancy groups but not in the controls. Perphenazine 55-67 prolactin Homo sapiens 89-98 3574600-6 1987 Brain cortex-phosphatidylserine (BC-PS), a pharmacologically active purified phospholipid, capable of stimulating the dopaminergic system in the hypothalamus and of decreasing prolactin secretion both in humans and rats in vitro and in vivo, inhibited the incorporation of labeled phosphate into PI of pituitary glands from either young or old rats, but did not alter the prolactin secretion from the glands incubated in vitro. Phospholipids 77-89 prolactin Homo sapiens 176-185 3587524-1 1987 The effect of exogenous prolactin on the development of acute tolerance to and dependence on morphine was studied. Morphine 93-101 prolactin Homo sapiens 24-33 3587524-3 1987 Pretreatment with prolactin enhanced the development of tolerance to analgesia induced by morphine while it effectively suppressed the withdrawal symptoms. Morphine 90-98 prolactin Homo sapiens 18-27 3321867-7 1987 Plasma prolactin levels were significantly reduced by bromocriptine administration. Bromocriptine 54-67 prolactin Homo sapiens 7-16 3115024-1 1987 Lisuride is a potent direct Dopamine agonist and has an effective Prolactin-lowering effect. Lisuride 0-8 prolactin Homo sapiens 66-75 3103387-0 1987 Dopamine receptor function in Parkinson"s disease--in vivo studies with prolactin responses. Dopamine 0-8 prolactin Homo sapiens 72-81 3324676-0 1987 Role of prolactin in the regulation of sensitivity of the hypothalamic-pituitary system to steroid feedback. Steroids 91-98 prolactin Homo sapiens 8-17 3324676-6 1987 We propose that PRL is one of the factors which regulate the sensitivity of gonadotropin release to gonadal steroid feedback. Steroids 108-115 prolactin Homo sapiens 16-19 3324676-11 1987 In this species, pharmacologic suppression of PRL release leads to increased responsiveness of plasma gonadotropin levels to negative feedback effects of testosterone, while PRL-secreting ectopic pituitary transplants exert an opposite effect. Testosterone 154-166 prolactin Homo sapiens 46-49 3324676-13 1987 In immature animals, the amount of cytoplasmic androgen receptors in the anterior pituitary was decreased by mild hyperprolactinemia and increased by treatment with bromocriptine, an inhibitor of PRL release. Bromocriptine 165-178 prolactin Homo sapiens 196-199 2891536-0 1987 Effect of 6-hourly intermittent intravenous boluses of oxmetidine and ranitidine on gastric acidity and serum prolactin. oxmetidine 55-65 prolactin Homo sapiens 110-119 3324676-15 1987 These findings would imply that PRL modulates the responsiveness to negative steroid feedback at the pituitary level. Steroids 77-84 prolactin Homo sapiens 32-35 3324681-2 1987 Prolactin may be important in the regulation of water and ion transport across the amnion, the production of surfactant by the fetal lung, and the immune response during pregnancy. Water 48-53 prolactin Homo sapiens 0-9 3799691-6 1987 If the serum prolactin concentration is less than 3,000 mU/liter in the presence of significant pituitary enlargement, surgical removal is essential for both diagnosis and treatment since only prolactin-secreting adenomas are likely to shrink with dopamine agonist therapy. Dopamine 248-256 prolactin Homo sapiens 13-22 3815388-8 1987 Transdihydrolisuride caused prolonged inhibition of prolactin release, but unlike levodopa did not elevate plasma growth hormone levels. dironyl 0-20 prolactin Homo sapiens 52-61 3119290-0 1987 Prolactin, renin, growth hormone, lipoproteins and glucose under guanfacine treatment. Guanfacine 65-75 prolactin Homo sapiens 0-9 2891536-0 1987 Effect of 6-hourly intermittent intravenous boluses of oxmetidine and ranitidine on gastric acidity and serum prolactin. Ranitidine 70-80 prolactin Homo sapiens 110-119 2896146-7 1987 The absence of liability to dependence with prolactin strengthens the contention that prolactin may be a potential drug for combatting opiate dependence. Opiate Alkaloids 135-141 prolactin Homo sapiens 86-95 2888653-7 1987 Chronic treatment with drugs affecting dopamine transmission had a profound effect on PRL secretion, and a dose-dependent significant increase in PRL with neuroleptics was observed. Dopamine 39-47 prolactin Homo sapiens 86-89 2888653-7 1987 Chronic treatment with drugs affecting dopamine transmission had a profound effect on PRL secretion, and a dose-dependent significant increase in PRL with neuroleptics was observed. Dopamine 39-47 prolactin Homo sapiens 146-149 3106183-0 1987 Possible direct effect of serotonin on pituitary prolactin secretion: in vivo and in vitro studies. Serotonin 26-35 prolactin Homo sapiens 49-58 3108134-0 1987 TSH and PRL responses to domperidone and TRH in men with insulin-dependent diabetes mellitus of different duration. Domperidone 25-36 prolactin Homo sapiens 8-11 3108134-1 1987 The effect of domperidone, a specific blocker of dopamine receptors, on serum TSH and PRL levels was evaluated in 16 euthyroid men affected by insulin-dependent diabetes mellitus (IDDM) of different duration and in 7 age-matched normal controls. Domperidone 14-25 prolactin Homo sapiens 86-89 3108134-5 1987 When all 16 diabetics were studied together, a significant negative correlation was found between mean maximal peaks of TSH and PRL responses to domperidone and duration of diabetes. Domperidone 145-156 prolactin Homo sapiens 128-131 3108134-7 1987 Dopamine infusion induced parallel decreases in TSH and PRL concentrations, without modifying hormonal secretory patterns in response to domperidone. Dopamine 0-8 prolactin Homo sapiens 56-59 3108134-8 1987 These data suggested that the reduced TSH and PRL responses to domperidone in diabetics were not due to alterations of the dopaminergic control of pituitary function but to a defect at the pituitary level. Domperidone 63-74 prolactin Homo sapiens 46-49 3121487-0 1987 Role of aging on growth hormone and prolactin release after growth hormone-releasing hormone and domperidone in man. Domperidone 97-108 prolactin Homo sapiens 36-45 3121487-1 1987 Growth hormone (GH) and prolactin (PRL) secretion after GH-releasing hormone (GHRH) and domperidone (DOM), an antidopaminergic drug which does not cross the blood-brain barrier (BBB), was evaluated in 8 healthy elderly men (65-91 years) and in 7 young adults (23-40 years). Domperidone 88-99 prolactin Homo sapiens 24-33 3436616-0 1987 Effect of fenfluramine on growth hormone and prolactin secretion in obese subjects. Fenfluramine 10-22 prolactin Homo sapiens 45-54 2880822-1 1987 Seventy-one hyperprolactinemic women were analyzed for medical history, gonadotropin and ovarian hormonal levels, and prolactin (PRL) responsiveness to benserazide. Benserazide 152-163 prolactin Homo sapiens 129-132 2880822-5 1987 The benserazide test for PRL release had yielded abnormal results since the beginning in all the 44 women with final roentgenographic evidence of pituitary adenoma, and in about half of the patients with persistently normal aspect of the sella; autoantibodies towards the pituitary gland, the thyroid gland, and gastric parietal cells were found in 3, 2, and 3 patients, respectively. Benserazide 4-15 prolactin Homo sapiens 25-28 3582865-0 1987 [Effect of nomifensine on the secretion of prolactin in the puerperium and its impact on lactation]. Nomifensine 11-22 prolactin Homo sapiens 43-52 3782429-5 1987 In contrast, the alcohol users had increased PRL levels during the 16-24th weeks of pregnancy compared with those in the abstinent women, but this rise was not related to the FAS. Alcohols 17-24 prolactin Homo sapiens 45-48 3782429-7 1987 Thus, heavy maternal abuse of alcohol resulting in FAS is accompanied, primarily or secondarily, by reduced estrogen concentrations throughout pregnancy and increased PRL levels during the 16-24th weeks of pregnancy. Alcohols 30-37 prolactin Homo sapiens 167-170 3683686-6 1987 By contrast, metoclopramide stimulated prolactin secretion in both normokalemic and hyperkalemic chronic renal failure patients. Metoclopramide 13-27 prolactin Homo sapiens 39-48 3583091-3 1987 Among hypothalamic neurotransmitters regulating the anterior pituitary function, dopamine (DA) is currently considered to correspond to the PRL-inhibiting factor. Dopamine 81-89 prolactin Homo sapiens 140-143 3583091-3 1987 Among hypothalamic neurotransmitters regulating the anterior pituitary function, dopamine (DA) is currently considered to correspond to the PRL-inhibiting factor. Dopamine 91-93 prolactin Homo sapiens 140-143 3822068-3 1987 As the effect of bromocriptine therapy was partial in tumor size reduction and decrease of serum PRL level and it could not be gained further improvement except for the well recovered visual acuity, tamoxifen was used together with bromocriptine resulting further reduction of tumor size and normalization of serum PRL level. Bromocriptine 17-30 prolactin Homo sapiens 97-100 3822068-3 1987 As the effect of bromocriptine therapy was partial in tumor size reduction and decrease of serum PRL level and it could not be gained further improvement except for the well recovered visual acuity, tamoxifen was used together with bromocriptine resulting further reduction of tumor size and normalization of serum PRL level. Bromocriptine 17-30 prolactin Homo sapiens 315-318 3822068-3 1987 As the effect of bromocriptine therapy was partial in tumor size reduction and decrease of serum PRL level and it could not be gained further improvement except for the well recovered visual acuity, tamoxifen was used together with bromocriptine resulting further reduction of tumor size and normalization of serum PRL level. Tamoxifen 199-208 prolactin Homo sapiens 97-100 3822068-3 1987 As the effect of bromocriptine therapy was partial in tumor size reduction and decrease of serum PRL level and it could not be gained further improvement except for the well recovered visual acuity, tamoxifen was used together with bromocriptine resulting further reduction of tumor size and normalization of serum PRL level. Tamoxifen 199-208 prolactin Homo sapiens 315-318 3102662-0 1987 Changes in plasma concentrations of LH, FSH and prolactin in ewes receiving melatonin and short-photoperiod treatments to induce early onset of breeding activity. Melatonin 76-85 prolactin Homo sapiens 48-57 3102662-5 1987 Plasma prolactin levels were significantly reduced immediately following the start of the melatonin (implant and oral) and short-photoperiod treatments but "rebounded" to levels greater than control values. Melatonin 90-99 prolactin Homo sapiens 7-16 3114361-1 1987 Bromocriptine, a dopamine agonist, is well known for its inhibitory action on prolactin secretion. Bromocriptine 0-13 prolactin Homo sapiens 78-87 3114361-1 1987 Bromocriptine, a dopamine agonist, is well known for its inhibitory action on prolactin secretion. Dopamine 17-25 prolactin Homo sapiens 78-87 3613693-0 1987 Serum prolactin levels after buspirone in man. Buspirone 29-38 prolactin Homo sapiens 6-15 3613693-2 1987 Sulpiride (200 mg) was used as a control drug; it raised PRL by almost 800%. Sulpiride 0-9 prolactin Homo sapiens 57-60 3613693-3 1987 Buspirone (25, 50 and 100 mg) raised serum PRL dose-dependently; the greatest increases (30, 70, and 320% from baseline, respectively) were seen 1 h after each dose. Buspirone 0-9 prolactin Homo sapiens 43-46 3099236-2 1987 The absence of PRL secretory response to dopamine or TRH in prolactinoma patients also may be an effect of the disease. Dopamine 41-49 prolactin Homo sapiens 15-18 3099236-4 1987 Basal PRL levels decreased after surgery and bromocriptine treatment. Bromocriptine 45-58 prolactin Homo sapiens 6-9 3099236-5 1987 At the time of the follow-up study, PRL levels were elevated in six of the 15 surgically treated patients and in six of the 11 treated with bromocriptine. Bromocriptine 140-153 prolactin Homo sapiens 36-39 3099236-6 1987 Thyrotropin-releasing hormone, nomifensine, and domperidone produced standard PRL responses in normoprolactinemic patients but not in hyperprolactinemic patients. Nomifensine 31-42 prolactin Homo sapiens 78-81 3099236-6 1987 Thyrotropin-releasing hormone, nomifensine, and domperidone produced standard PRL responses in normoprolactinemic patients but not in hyperprolactinemic patients. Domperidone 48-59 prolactin Homo sapiens 78-81 3099236-7 1987 These results indicate that the alteration of TRH or dopaminergic receptors in the regulation of PRL secretion in prolactinoma is related to the disease and disappears when the tumor is removed or treated successfully with bromocriptine. Bromocriptine 223-236 prolactin Homo sapiens 97-100 2887003-1 1987 The growth hormone (GH) and prolactin (PRL) responses to intravenous L-tryptophan (LTP) were measured in 20 schizophrenics receiving long-term treatment with neuroleptics and 20 unmedicated control subjects. Tryptophan 69-81 prolactin Homo sapiens 39-42 2892222-6 1987 There was a positive correlation between serum neuroleptic and prolactin concentrations for the patients taking haloperidol (r = 0.620, P less than 0.001) or thioridazine (r = 0.542, P less than 0.001). Haloperidol 112-123 prolactin Homo sapiens 63-72 2892222-6 1987 There was a positive correlation between serum neuroleptic and prolactin concentrations for the patients taking haloperidol (r = 0.620, P less than 0.001) or thioridazine (r = 0.542, P less than 0.001). Thioridazine 158-170 prolactin Homo sapiens 63-72 2892222-7 1987 In patients taking a constant dose of haloperidol or thioridazine for up to 1 year serum neuroleptic activity remained stable, suggesting the absence of metabolic tolerance; the observation of a decrease of 38 +/- 16% (mean +/- SD) in serum prolactin concentrations in patients treated with haloperidol but no prolactin decrease with thioridazine suggests that under certain neuroleptic treatment conditions a functional tolerance develops in the tuberoinfundibular dopamine system. Haloperidol 38-49 prolactin Homo sapiens 241-250 2892222-7 1987 In patients taking a constant dose of haloperidol or thioridazine for up to 1 year serum neuroleptic activity remained stable, suggesting the absence of metabolic tolerance; the observation of a decrease of 38 +/- 16% (mean +/- SD) in serum prolactin concentrations in patients treated with haloperidol but no prolactin decrease with thioridazine suggests that under certain neuroleptic treatment conditions a functional tolerance develops in the tuberoinfundibular dopamine system. Haloperidol 38-49 prolactin Homo sapiens 310-319 3114793-0 1987 The effect of bupropion on prolactin in a patient with a pituitary microadenoma. Bupropion 14-23 prolactin Homo sapiens 27-36 2827235-6 1987 Procaine stimulates ACTH-cortisol and prolactin, but not growth hormone secretion. Procaine 0-8 prolactin Homo sapiens 38-47 3588810-5 1987 Morphine strongly stimulated PRL secretion, which was found to be significantly smaller in patients than in controls, but no difference was seen between depressed and nondepressed subjects. Morphine 0-8 prolactin Homo sapiens 29-32 3103591-0 1986 The acute effects of antidepressants, maprotiline and amoxapine on serum prolactin and gonadotropin levels in normal women. Amoxapine 54-63 prolactin Homo sapiens 73-82 3602261-4 1987 The concentrations of melatonin correlated positively with those of prolactin (r = 0.56, p less than 0.05 for men and r = 0.58, p less than 0.001 for women) and thyrotropin (r = 0.62, p less than 0.001 for all subjects), but not with those of cortisol (r = 0.004, p greater than 0.05). Melatonin 22-31 prolactin Homo sapiens 68-77 3780532-1 1986 The purpose of this study was to determine whether the availability of PRL modulates the chloride concentration of human sweat. Chlorides 89-97 prolactin Homo sapiens 71-74 3780532-14 1986 We conclude that depletion of PRL increases the concentration of chloride in human sweat. Chlorides 65-73 prolactin Homo sapiens 30-33 3124174-1 1987 A previous study has shown that acute administration of the 5-HT2 receptor antagonist ritanserin doubles Slow Wave Sleep (SWS) and increases the prolactin (PRL) response to L-tryptophan (LTP). Ritanserin 86-96 prolactin Homo sapiens 145-154 3124174-1 1987 A previous study has shown that acute administration of the 5-HT2 receptor antagonist ritanserin doubles Slow Wave Sleep (SWS) and increases the prolactin (PRL) response to L-tryptophan (LTP). Tryptophan 173-185 prolactin Homo sapiens 145-154 3126515-3 1987 PRL levels increased following GnRH and administration of both ethanol and ethanol placebo. Ethanol 63-70 prolactin Homo sapiens 0-3 3126515-3 1987 PRL levels increased following GnRH and administration of both ethanol and ethanol placebo. Ethanol 75-82 prolactin Homo sapiens 0-3 3566845-6 1986 There was a tendency for the prolactin-lowering effect of lisuride to last longer upon cessation of therapy which might be related to the higher receptor affinity of both drugs. Lisuride 58-66 prolactin Homo sapiens 29-38 3828431-6 1986 Serum PRL concentrations averaged 8.6 +/- 0.7 ng/ml and 7.6 +/- 0.6 ng/ml in EF and LF gilts, respectively, prior to NAL treatment, and decreased (p less than 0.05) to an average of 4.1 +/- 0.2 ng/ml and 5.6 +/- 0.4 ng/ml in EF and LF gilts, respectively, during the fourth h after NAL. Naloxone 117-120 prolactin Homo sapiens 6-9 3546358-2 1986 The use of ergoline derivatives is described to correct prolactin levels, restore reproductive dysfunctions and reduce the size of prolactinomas. Ergolines 11-19 prolactin Homo sapiens 56-65 3546358-5 1986 The authors recommend that dopaminergic drugs should be the primary therapies for prolactin-secreting adenomas and idiopathic hyperprolactinaemia, and surgery should be reserved for dopamine-resistant conditions. Dopamine 27-35 prolactin Homo sapiens 82-91 3100711-3 1986 Prolactin responses to either a stressful stimulus or the dopaminergic antagonists metoclopramide (20 mg i.v.) Metoclopramide 83-97 prolactin Homo sapiens 0-9 3096790-3 1986 Daily administration of sulpiride (150 mg orally) significantly elevated serum prolactin (PRL) levels in all six women. Sulpiride 24-33 prolactin Homo sapiens 79-88 3096790-3 1986 Daily administration of sulpiride (150 mg orally) significantly elevated serum prolactin (PRL) levels in all six women. Sulpiride 24-33 prolactin Homo sapiens 90-93 3571850-0 1986 The relationship between plasma prolactin and testosterone levels in male hypogonadism. Testosterone 46-58 prolactin Homo sapiens 32-41 3556418-0 1986 Stimulatory effect of pentagastrin on growth hormone and prolactin secretion in normal subjects. Pentagastrin 22-34 prolactin Homo sapiens 57-66 3556418-3 1986 As small gastrin-like peptides may also play a role in the regulation of anterior pituitary hormones, the present study deals with the in vivo effect of pentagastrin on the release of growth hormone (GH) and prolactin (PRL). Pentagastrin 153-165 prolactin Homo sapiens 208-217 3777265-0 1986 Reduction in plasma prolactin levels in depressed women after homatropine administration. homatropine 62-73 prolactin Homo sapiens 20-29 3795197-0 1986 Prolactin response to perphenazine. Perphenazine 22-34 prolactin Homo sapiens 0-9 3795197-3 1986 We compared serial prolactin levels following perphenazine stimulation in 20 women with histologically documented tumors to those in 22 normal controls. Perphenazine 46-58 prolactin Homo sapiens 19-28 3102292-0 1986 Effect of ouabain and bumetanide on the basal and the osmolality-affected prolactin secretion from human decidual cells in vitro. Ouabain 10-17 prolactin Homo sapiens 74-83 3102292-0 1986 Effect of ouabain and bumetanide on the basal and the osmolality-affected prolactin secretion from human decidual cells in vitro. Bumetanide 22-32 prolactin Homo sapiens 74-83 2898444-5 1986 Following hMG stimulation, the serum E2 increment (delta E2) from basal E2 levels in the control group (491 +/- 91 pg/mL) was significantly higher than the increment in the hyperprolactinemic group (182 +/- 48 pg/mL, P less than .01), and a significant negative correlation was observed between basal serum hPRL levels and the logarithm of delta E2 (r = -.4744, P less than .05). Menotropins 10-13 prolactin Homo sapiens 307-311 3752759-3 1986 Plasma testosterone was low (130 ng/dL; normal, 300 to 1000 ng/dL) with marked elevation of serum prolactin (590 ng/mL; normal, 0 to 15 ng/mL). Testosterone 7-19 prolactin Homo sapiens 98-107 3769872-7 1986 On the other hand, PTH-(1-34), human PRL, and lysine vasopressin all activate mononuclear leukocytes, as determined by [3H]thymidine incorporation. Tritium 120-122 prolactin Homo sapiens 37-40 3769872-7 1986 On the other hand, PTH-(1-34), human PRL, and lysine vasopressin all activate mononuclear leukocytes, as determined by [3H]thymidine incorporation. Thymidine 123-132 prolactin Homo sapiens 37-40 3781474-2 1986 The binding of 125I-labelled, highly purified pituitary human prolactin was specific for lactogenic hormones and depending on time, temperature, and concentration of receptor protein. Iodine-125 15-19 prolactin Homo sapiens 62-71 3756269-0 1986 Hydergine effect on prolactin and reaction time in dementia. Ergoloid Mesylates 0-9 prolactin Homo sapiens 20-29 3122863-1 1986 Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration. Sulpiride 49-58 prolactin Homo sapiens 7-16 3122863-1 1986 Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration. Levodopa 60-66 prolactin Homo sapiens 7-16 3122863-1 1986 Plasma prolactin and GH responses following TRH, sulpiride, L-dopa, and bromocriptine administration. Bromocriptine 72-85 prolactin Homo sapiens 7-16 3830075-3 1986 In group I, TSH level rose from 1.96 +/- 0.42 mu u/ml (mean +/- SEM) to 2.52 +/- 0.30 mu u/ml (p less than 0.01), and PRL levels rose from 11.0 +/- 2.0 ng/ml to 19.0 +/- 5.2 ng/ml (p less than 0.01). Thyrotropin 12-15 prolactin Homo sapiens 118-121 3745401-3 1986 Terguride, given for at least 6 months in divided doses ranging from 0.25-1.50 mg/day to group A patients, resulted in normal (11 patients) or markedly reduced plasma PRL levels. dironyl 0-9 prolactin Homo sapiens 167-170 3540081-5 1986 Furthermore, we also measured the plasma prolactin levels, to see whether the specific and well known effect of domperidone on prolactin release matches with the effect on beta-cell function. Domperidone 112-123 prolactin Homo sapiens 127-136 3540081-6 1986 As far as prolactin is concerned, we observed a dose response effect of domperidone infusion, with a detectable elevation of prolactin at infusion rate of 0.25 microgram/kg/min. Domperidone 72-83 prolactin Homo sapiens 10-19 3540081-6 1986 As far as prolactin is concerned, we observed a dose response effect of domperidone infusion, with a detectable elevation of prolactin at infusion rate of 0.25 microgram/kg/min. Domperidone 72-83 prolactin Homo sapiens 125-134 3093797-5 1986 In one group (group I, n = 65), patients had greater than 100% rise in serum PRL following TRH or perphenazine (Pz) administration. Perphenazine 98-110 prolactin Homo sapiens 77-80 3792440-0 1986 Nafazatrom, an arachidonate metabolism inhibitor, decreases prolactin and GH release. nafazatrom 0-10 prolactin Homo sapiens 60-69 3763270-1 1986 Metoclopramide treatment has been shown to augment milk production by stimulating prolactin secretion in women in whom lactational insufficiency develops after a full-term pregnancy. Metoclopramide 0-14 prolactin Homo sapiens 82-91 3750191-11 1986 On the other hand, in patients with macroprolactinomas who manifest high levels of serum prolactin, initial treatment with bromocriptine should be considered because there is little hope for surgical cure and postoperative bromocriptine treatment might be necessary. Bromocriptine 123-136 prolactin Homo sapiens 41-50 3792440-1 1986 Nafazatrom, an inhibitor of arachidonate metabolism by the lipoxygenase enzymes, decreases basal prolactin and growth hormone release in a concentration-dependent manner without significantly affecting the synthesis of either hormone. nafazatrom 0-10 prolactin Homo sapiens 97-106 3792440-3 1986 These data suggest that the lipoxygenase products of arachidonate metabolism may be important mediators in basal and secretagogue-induced release of prolactin and growth hormone. Arachidonic Acid 53-65 prolactin Homo sapiens 149-158 3099670-1 1986 The effect of calcium chloride and nifedipine on prolactin-(PRL) induced analgesia was studied by chemical assay and compared with other analgesics like morphine, thyrotrophin-releasing hormone (TRH) and clonidine. Calcium Chloride 14-30 prolactin Homo sapiens 60-63 3734040-2 1986 The effects of human PRL (hPRL) and oxytocin on the kinetics of the hydrolysis of estrone sulfate were determined in decidual cells prepared from tissue obtained before and after the onset of labor. estrone sulfate 82-97 prolactin Homo sapiens 21-24 3734040-2 1986 The effects of human PRL (hPRL) and oxytocin on the kinetics of the hydrolysis of estrone sulfate were determined in decidual cells prepared from tissue obtained before and after the onset of labor. estrone sulfate 82-97 prolactin Homo sapiens 26-30 3755791-2 1986 The secretion of prolactin (PRL) and growth hormone (GH) was increased after metoclopramide. Metoclopramide 77-91 prolactin Homo sapiens 17-26 3755791-2 1986 The secretion of prolactin (PRL) and growth hormone (GH) was increased after metoclopramide. Metoclopramide 77-91 prolactin Homo sapiens 28-31 3099670-1 1986 The effect of calcium chloride and nifedipine on prolactin-(PRL) induced analgesia was studied by chemical assay and compared with other analgesics like morphine, thyrotrophin-releasing hormone (TRH) and clonidine. Nifedipine 35-45 prolactin Homo sapiens 60-63 3016630-2 1986 Gonadotropin and prolactin levels were compatible with estrogen-progesterone synergy on hypothalamic pituitary function. Progesterone 64-76 prolactin Homo sapiens 17-26 3099670-2 1986 Nifedipine potentiated the analgesic effect of PRL similar to morphine while that of clonidine and TRH remained unaltered. Nifedipine 0-10 prolactin Homo sapiens 47-50 3099670-3 1986 Further, calcium chloride administration antagonized the analgesic effect of PRL and of morphine. Calcium Chloride 9-25 prolactin Homo sapiens 77-80 3099670-4 1986 These data suggest that PRL, similar to morphine, may alter calcium movements across the membrane to produce analgesia. Calcium 60-67 prolactin Homo sapiens 24-27 3776529-0 1986 Ultrastructural localization of prolactin in the human pituitary prolactinomas and its changes by bromocriptine treatment. Bromocriptine 98-111 prolactin Homo sapiens 32-41 3740256-3 1986 sn-1,2-Dioctanoylglycerol (diC8), which is known to stimulate protein kinase C in other systems, inhibited prolactin release in a dose-dependent manner with maximal inhibition of 53.1% (P less than 0.01) at 100 microM. 1,2-dioctanoylglycerol 0-25 prolactin Homo sapiens 107-116 3740256-3 1986 sn-1,2-Dioctanoylglycerol (diC8), which is known to stimulate protein kinase C in other systems, inhibited prolactin release in a dose-dependent manner with maximal inhibition of 53.1% (P less than 0.01) at 100 microM. 1,2-dioctanoylglycerol 27-31 prolactin Homo sapiens 107-116 3740256-4 1986 Diolein (100 microM), which also stimulates protein kinase C activity in some systems, inhibited prolactin release by 21.3% (P less than 0.05). diolein 0-7 prolactin Homo sapiens 97-106 3740256-6 1986 Phorbol 12-myristate 13-acetate (PMA), phorbol 12,13-didecanoate, and 4 beta-phorbol 12,13-dibutyrate, which activate protein kinase C in other systems, also inhibited the release of prolactin, while the protein kinase C inactivate 4 alpha-phorbol-12,13-didecanoate was without effect. Tetradecanoylphorbol Acetate 0-31 prolactin Homo sapiens 183-192 3740256-6 1986 Phorbol 12-myristate 13-acetate (PMA), phorbol 12,13-didecanoate, and 4 beta-phorbol 12,13-dibutyrate, which activate protein kinase C in other systems, also inhibited the release of prolactin, while the protein kinase C inactivate 4 alpha-phorbol-12,13-didecanoate was without effect. Tetradecanoylphorbol Acetate 33-36 prolactin Homo sapiens 183-192 3740256-6 1986 Phorbol 12-myristate 13-acetate (PMA), phorbol 12,13-didecanoate, and 4 beta-phorbol 12,13-dibutyrate, which activate protein kinase C in other systems, also inhibited the release of prolactin, while the protein kinase C inactivate 4 alpha-phorbol-12,13-didecanoate was without effect. phorbol-12,13-didecanoate 39-64 prolactin Homo sapiens 183-192 3740256-6 1986 Phorbol 12-myristate 13-acetate (PMA), phorbol 12,13-didecanoate, and 4 beta-phorbol 12,13-dibutyrate, which activate protein kinase C in other systems, also inhibited the release of prolactin, while the protein kinase C inactivate 4 alpha-phorbol-12,13-didecanoate was without effect. 4 beta-phorbol 12,13-dibutyrate 70-101 prolactin Homo sapiens 183-192 3740256-6 1986 Phorbol 12-myristate 13-acetate (PMA), phorbol 12,13-didecanoate, and 4 beta-phorbol 12,13-dibutyrate, which activate protein kinase C in other systems, also inhibited the release of prolactin, while the protein kinase C inactivate 4 alpha-phorbol-12,13-didecanoate was without effect. alpha-phorbol-12,13-didecanoate 234-265 prolactin Homo sapiens 183-192 3740256-8 1986 The amounts of prolactin synthesized by cells exposed to diC8 (300 microM) or PMA (10(-7) M) for 30 min were 56.3 and 50.0% less than that synthesized by control cells (P less than 0.01 in each instance). 1,2-dioctanoylglycerol 57-61 prolactin Homo sapiens 15-24 3740256-8 1986 The amounts of prolactin synthesized by cells exposed to diC8 (300 microM) or PMA (10(-7) M) for 30 min were 56.3 and 50.0% less than that synthesized by control cells (P less than 0.01 in each instance). Tetradecanoylphorbol Acetate 78-81 prolactin Homo sapiens 15-24 2878748-2 1986 In the present study it was investigated whether PRL release in prolactinoma and acromegalic patients might also be sensitive to SMS 201-995 and whether co-secretion of PRL in acromegaly plays a role in determining the sensitivity of GH secretion to SMS 201-995. Samarium 129-132 prolactin Homo sapiens 49-52 3776529-8 1986 In a case which was resistant to the bromocriptine treatment, most tumor cells were similar in ultrastructural localization of PRL to those cells in the untreated cases and this might suggest the lack of dopamine receptor. Bromocriptine 37-50 prolactin Homo sapiens 127-130 3776530-8 1986 The experiment with bromocriptine treatment for 24 hours supported the proposed mechanism that bromocriptine evokes inhibition of exocytosis followed by continuous granule formation in Golgi complexes and subsequently lowers synthesis of PRL. Bromocriptine 20-33 prolactin Homo sapiens 238-241 3776530-8 1986 The experiment with bromocriptine treatment for 24 hours supported the proposed mechanism that bromocriptine evokes inhibition of exocytosis followed by continuous granule formation in Golgi complexes and subsequently lowers synthesis of PRL. Bromocriptine 95-108 prolactin Homo sapiens 238-241 3771097-9 1986 The third form of hormone (Mr 50,000) was shown to be a disulphide linked prolactin dimer. disulphide 56-66 prolactin Homo sapiens 74-83 3489596-3 1986 After Sephadex G-100 column chromatography, 7 samples contained a protein fraction which bound human prolactin. sephadex 6-20 prolactin Homo sapiens 101-110 3758928-0 1986 Dissociation of the central and peripheral effects of naloxone on PRL secretion. Naloxone 54-62 prolactin Homo sapiens 66-69 3788410-4 1986 These peripheral steroid patterns might affect gonadotropin and PRL secretions as well; nevertheless an interference with the metabolism of cerebral neurotransmitters, perhaps related to a nutritional component (impaired glucose tolerance), cannot be completely excluded. Steroids 17-24 prolactin Homo sapiens 64-67 3722328-1 1986 We performed a quantitative study using a point-counting technique at the light microscope level of the fibrous tissue content of PRL-secreting and nonfunctioning pituitary macroadenomas from patients treated or untreated with bromocriptine (BC) before surgery. Bromocriptine 227-240 prolactin Homo sapiens 130-133 3755608-0 1986 Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model. Dopamine 74-82 prolactin Homo sapiens 38-47 3755608-0 1986 Description of the time course of the prolactin suppressant effect of the dopamine agonist CQP201-403 by an integrated pharmacokinetic-pharmacodynamic model. cqp201 91-97 prolactin Homo sapiens 38-47 3792121-0 1986 Chronobiologic quantification of nocturnal low-dose dopamine effect on circadian rhythms of thyroid-related hormones and prolactin (PRL). Dopamine 52-60 prolactin Homo sapiens 132-135 3521942-0 1986 Laser-excited immunofluorometric assay of prolactin, with use of antibodies coupled to lanthanide-labeled diethylenetriaminepentaacetic acid. Lanthanoid Series Elements 87-97 prolactin Homo sapiens 42-51 3521942-0 1986 Laser-excited immunofluorometric assay of prolactin, with use of antibodies coupled to lanthanide-labeled diethylenetriaminepentaacetic acid. Pentetic Acid 106-140 prolactin Homo sapiens 42-51 3521942-1 1986 We describe an immunofluorometric assay for prolactin based on lanthanide labeling of a monoclonal antibody and measuring time-resolved fluorescence. Lanthanoid Series Elements 63-73 prolactin Homo sapiens 44-53 3757769-0 1986 Serum prolactin correlates with depressed mood during alcohol withdrawal. Alcohols 54-61 prolactin Homo sapiens 6-15 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 72-80 prolactin Homo sapiens 20-29 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 72-80 prolactin Homo sapiens 31-34 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 96-104 prolactin Homo sapiens 20-29 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 96-104 prolactin Homo sapiens 31-34 3757769-3 1986 In this study serum prolactin (PRL) was used as an indicator of central dopamine activity since dopamine is the most important factor in the control of prolactin secretion from the pituitary. Dopamine 96-104 prolactin Homo sapiens 152-161 3757769-4 1986 Increased serum PRL levels were found during alcohol withdrawal and they correlated significantly with high scores on the Hamilton Depression Rating Scale (HDRS). Alcohols 45-52 prolactin Homo sapiens 16-19 3720978-2 1986 We have evaluated the effects of several doses of PRL on the secretion of progesterone (P) and estradiol (E2) by human granulosa cells from preovulatory follicles of gonadotropin-stimulated women. Progesterone 74-86 prolactin Homo sapiens 50-53 3086358-1 1986 Contrary to a previous report, pretreatment of normal men with carbidopa plus L-dopa (Sinemet 25/250) markedly inhibited the PRL response to TRH, a stimulus that acts directly on the pituitary. Carbidopa 63-72 prolactin Homo sapiens 125-128 3086358-0 1986 Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation. Carbidopa 0-9 prolactin Homo sapiens 48-57 3086358-0 1986 Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation. Carbidopa 0-9 prolactin Homo sapiens 59-62 3086358-0 1986 Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation. Levodopa 15-21 prolactin Homo sapiens 48-57 3086358-0 1986 Carbidopa plus L-dopa pretreatment inhibits the prolactin (PRL) response to thyrotropin-releasing hormone and thus cannot distinguish central from pituitary sites of prolactin stimulation. Levodopa 15-21 prolactin Homo sapiens 59-62 3086358-1 1986 Contrary to a previous report, pretreatment of normal men with carbidopa plus L-dopa (Sinemet 25/250) markedly inhibited the PRL response to TRH, a stimulus that acts directly on the pituitary. Levodopa 78-84 prolactin Homo sapiens 125-128 3086358-1 1986 Contrary to a previous report, pretreatment of normal men with carbidopa plus L-dopa (Sinemet 25/250) markedly inhibited the PRL response to TRH, a stimulus that acts directly on the pituitary. carbidopa, levodopa drug combination 86-93 prolactin Homo sapiens 125-128 3792121-7 1986 Dopamine Rx produced a statistically-significant increase in amplitude for PRL and T4 and an advance in acrophase for TSH, T3 and T4, but a delay for PRL. Dopamine 0-8 prolactin Homo sapiens 75-78 3792121-7 1986 Dopamine Rx produced a statistically-significant increase in amplitude for PRL and T4 and an advance in acrophase for TSH, T3 and T4, but a delay for PRL. Dopamine 0-8 prolactin Homo sapiens 150-153 3519644-12 1986 Serum PRL fell significantly in the bromocriptine group, and there was a significant fall in the serum LH response to GnRH in both groups. Bromocriptine 36-49 prolactin Homo sapiens 6-9 3519644-14 1986 The only significant effect of chronic bromocriptine therapy (5 mg/day) in patients with the polycystic ovary syndrome was to lower the serum PRL concentration. Bromocriptine 39-52 prolactin Homo sapiens 142-145 3755462-6 1986 Bromocriptine treatment in April (seasonal diapause) was followed by a significant reduction in prolactin concentrations and reduced growth rate of joeys belonging to treated females. Bromocriptine 0-13 prolactin Homo sapiens 96-105 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Domperidone 119-130 prolactin Homo sapiens 186-195 3711262-0 1986 Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine. Bromocriptine 125-138 prolactin Homo sapiens 28-37 3711262-1 1986 Since Corenblum reported in 1975 the first documented reduction of tumor size in two patients with macroprolactinoma, evidence has accumulated that bromocriptine causes shrinkage of PRL-secreting adenomas in most patients. Bromocriptine 148-161 prolactin Homo sapiens 182-185 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Domperidone 119-130 prolactin Homo sapiens 186-195 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 134-142 prolactin Homo sapiens 186-195 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 134-142 prolactin Homo sapiens 186-195 3711262-10 1986 In 7/8 patients with microprolactinomas plasma PRL levels decreased to within the normal range within 12 hours after the administration of bromocriptine LA. bromocriptine la 139-155 prolactin Homo sapiens 47-50 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 231-239 prolactin Homo sapiens 49-58 3711262-14 1986 Long-acting bromocriptine should be considered as the initial management for patients with PRL-secreting tumors. Bromocriptine 12-25 prolactin Homo sapiens 91-94 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 231-239 prolactin Homo sapiens 186-195 3755462-8 1986 In view of the effect of bromocriptine on plasma prolactin concentrations in late lactation and the demonstration that domperidone (a dopamine antagonist) significantly increases plasma prolactin concentrations, it would seem that dopamine can act as a prolactin inhibitory hormone in this as in other mammalian species. Dopamine 231-239 prolactin Homo sapiens 186-195 3725261-1 1986 The effect of a dopamine antagonist on prolactin concentrations was studied in maternal, fetal plasma, and amniotic fluid in term gestation. Dopamine 16-24 prolactin Homo sapiens 39-48 3725261-3 1986 The prolactin levels in maternal plasma increased significantly after metoclopramide. Metoclopramide 70-84 prolactin Homo sapiens 4-13 3725261-5 1986 Although the increased values of prolactin in maternal plasma were significantly correlated with metoclopramide concentrations after metoclopramide injection, there was no correlation between these two values in amniotic fluid. Metoclopramide 97-111 prolactin Homo sapiens 33-42 3725261-5 1986 Although the increased values of prolactin in maternal plasma were significantly correlated with metoclopramide concentrations after metoclopramide injection, there was no correlation between these two values in amniotic fluid. Metoclopramide 133-147 prolactin Homo sapiens 33-42 2424323-3 1986 Patients were given an overnight dexamethasone suppression test, and the effects of thyrotropin-releasing hormone and L-dopa on plasma growth hormone and prolactin were examined. Levodopa 118-124 prolactin Homo sapiens 154-163 3098457-11 1986 Radiotherapy, alone or in combination with surgery and bromocriptine, effectively decreases prolactin secretion and tumour size in patients with large prolactinomas at the expense of other anterior pituitary function. Bromocriptine 55-68 prolactin Homo sapiens 92-101 3717195-1 1986 Although several phenothiazines are known to stimulate prolactin (PRL) secretion, only chlorpromazine is in general use for this purpose in humans. Phenothiazines 17-31 prolactin Homo sapiens 55-64 3717195-1 1986 Although several phenothiazines are known to stimulate prolactin (PRL) secretion, only chlorpromazine is in general use for this purpose in humans. Phenothiazines 17-31 prolactin Homo sapiens 66-69 3717195-10 1986 For clinical testing, intramuscular perphenazine is preferred over oral perphenazine because of the shorter latency period and the higher PRL levels. Perphenazine 36-48 prolactin Homo sapiens 138-141 3717195-12 1986 This is the first report on the dynamic responses of PRL and blood pressure to intramuscular perphenazine in humans. Perphenazine 93-105 prolactin Homo sapiens 53-56 3090247-2 1986 The prolactin response to thyrotropin-releasing hormone (TRH) and metoclopramide was studied in 16 patients with Sheehan"s syndrome and 16 matched controls in the follicular phase. Metoclopramide 66-80 prolactin Homo sapiens 4-13 2880760-3 1986 When treatment with bromocriptine was reinstituted symptoms subsided within 24 h and serum prolactin concentrations fell from 54,000 mM/l to 2800 mU/l within 5 days and 500 mU/l 2 days after that. Bromocriptine 20-33 prolactin Homo sapiens 91-100 2880760-5 1986 One year after delivery, on treatment with bromocriptine, her serum prolactin concentration remains within the normal range and the CT scan shows persistence of a small prolactinoma, confined to the pituitary fossa. Bromocriptine 43-56 prolactin Homo sapiens 68-77 3090247-3 1986 Metoclopramide resulted in a greater prolactin response than TRH did in the controls. Metoclopramide 0-14 prolactin Homo sapiens 37-46 3090247-5 1986 Since metoclopramide is generally free of side effects and far cheaper than TRH, we recommend the prolactin response to metoclopramide as the preferred screening test in the diagnosis of Sheehan"s syndrome. Metoclopramide 120-134 prolactin Homo sapiens 98-107 3748874-0 1986 Ultrastructural morphometry of prolactin secreting adenomas treated with dopamine agonists. Dopamine 73-81 prolactin Homo sapiens 31-40 3748874-12 1986 The results display the influence of dopamine agonist on the hormone synthesis, release and degradation in PRL secreting adenoma cells. Dopamine 37-45 prolactin Homo sapiens 107-110 3092288-5 1986 The response of PA and PRL to metoclopramide showed blunted increases in CRF when compared to NV, in the absence of changes of PRA, cortisol and potassium. Metoclopramide 30-44 prolactin Homo sapiens 23-26 3092288-7 1986 Lisuride induced a decrease of both PA and PRL both in CRF and NV. Lisuride 0-8 prolactin Homo sapiens 43-46 3089848-10 1986 The pattern of serum prolactin levels in the patients with transient hyperprolactinemia was almost synchronized with that of serum estradiol levels. Estradiol 131-140 prolactin Homo sapiens 21-30 3084539-7 1986 The PRL responses to chlorpromazine- and insulin-induced hypoglycemia were blunted in patients with normal as well as elevated PRL levels. Chlorpromazine 21-35 prolactin Homo sapiens 4-7 3084539-7 1986 The PRL responses to chlorpromazine- and insulin-induced hypoglycemia were blunted in patients with normal as well as elevated PRL levels. Chlorpromazine 21-35 prolactin Homo sapiens 127-130 3089848-14 1986 After the administration of estradiol benzoate (100 micrograms/kg), serum estradiol levels increased markedly, serum prolactin levels increased with the similar change in serum estradiol levels, and serum prolactin levels in the patients with transient hyperprolactinemia were significantly higher compared to those of the controls (p less than 0.01 approximately 0.005). estradiol 3-benzoate 28-46 prolactin Homo sapiens 117-126 3089848-14 1986 After the administration of estradiol benzoate (100 micrograms/kg), serum estradiol levels increased markedly, serum prolactin levels increased with the similar change in serum estradiol levels, and serum prolactin levels in the patients with transient hyperprolactinemia were significantly higher compared to those of the controls (p less than 0.01 approximately 0.005). estradiol 3-benzoate 28-46 prolactin Homo sapiens 205-214 3089848-14 1986 After the administration of estradiol benzoate (100 micrograms/kg), serum estradiol levels increased markedly, serum prolactin levels increased with the similar change in serum estradiol levels, and serum prolactin levels in the patients with transient hyperprolactinemia were significantly higher compared to those of the controls (p less than 0.01 approximately 0.005). Estradiol 28-37 prolactin Homo sapiens 117-126 3089848-14 1986 After the administration of estradiol benzoate (100 micrograms/kg), serum estradiol levels increased markedly, serum prolactin levels increased with the similar change in serum estradiol levels, and serum prolactin levels in the patients with transient hyperprolactinemia were significantly higher compared to those of the controls (p less than 0.01 approximately 0.005). Estradiol 28-37 prolactin Homo sapiens 205-214 3708054-1 1986 Explants of human endometrium were cultured in serum-free nutrient medium and the effects of continuous and intermittent progesterone treatment on decidual prolactin (dPRL) production compared. Progesterone 121-133 prolactin Homo sapiens 147-165 3716756-0 1986 Human foetal prolactin but not thyrotropin secretion is decreased by bromocriptine. Bromocriptine 69-82 prolactin Homo sapiens 13-22 3716756-1 1986 In the adult, dopamine inhibits prolactin (Prl) secretion and less so thyrotropin (TSH) release. Dopamine 14-22 prolactin Homo sapiens 32-41 3716756-1 1986 In the adult, dopamine inhibits prolactin (Prl) secretion and less so thyrotropin (TSH) release. Dopamine 14-22 prolactin Homo sapiens 43-46 3716756-7 1986 Bromocriptine markedly inhibited maternal serum Prl concentrations compared to values in the placebo treated women (P less than 0.001) and this decrease was more marked as the time interval between bromocriptine administration and delivery increased (P less than 0.001, regression analysis). Bromocriptine 0-13 prolactin Homo sapiens 48-51 3716756-8 1986 Cord blood Prl was also significantly lower in newborns whose mothers received bromocriptine (P less than 0.001). Bromocriptine 79-92 prolactin Homo sapiens 11-14 3716756-11 1986 These findings suggest that bromocriptine crosses the term human placenta and suppresses foetal Prl secretion. Bromocriptine 28-41 prolactin Homo sapiens 96-99 3789642-6 1986 Dopamine-blocking activity was related more closely to dose of drug and to serum prolactin level than was serum chlorpromazine level measured by HPLC. Dopamine 0-8 prolactin Homo sapiens 81-90 3098454-0 1986 Interactions of oestradiol benzoate and promegestone upon basal and TRH-induced prolactin secretion in postmenopausal women. estradiol 3-benzoate 16-35 prolactin Homo sapiens 80-89 3098454-7 1986 In response to EB treatment serum PRL levels increased from 6.1 +/- 0.9 ng/ml to 22.9 +/- 3.4 ng/ml. ethylbenzene 15-17 prolactin Homo sapiens 34-37 3098454-9 1986 The PRL release induced by TRH was significantly greater with EB treatment than was the response with the combined treatment (P less than 0.05, Wilcoxon test to compare the areas under the curves). ethylbenzene 62-64 prolactin Homo sapiens 4-7 3098454-10 1986 These data suggest that in postmenopausal women oestrogens act as stimulators of PRL release and promegestone is able to partially counteract the stimulatory effect of oestradiol benzoate upon basal and TRH-stimulated PRL secretion. Promegestone 97-109 prolactin Homo sapiens 218-221 3516535-5 1986 On the contrary, plasma prolactin levels, previously suppressed during water immersion alone, were significantly stimulated during water immersion plus domperidone, thus indirectly suggesting a role of dopamine in mediating the blunted natriuresis seen during water immersion. Water 71-76 prolactin Homo sapiens 24-33 3516535-5 1986 On the contrary, plasma prolactin levels, previously suppressed during water immersion alone, were significantly stimulated during water immersion plus domperidone, thus indirectly suggesting a role of dopamine in mediating the blunted natriuresis seen during water immersion. Water 131-136 prolactin Homo sapiens 24-33 3516535-5 1986 On the contrary, plasma prolactin levels, previously suppressed during water immersion alone, were significantly stimulated during water immersion plus domperidone, thus indirectly suggesting a role of dopamine in mediating the blunted natriuresis seen during water immersion. Domperidone 152-163 prolactin Homo sapiens 24-33 3098454-10 1986 These data suggest that in postmenopausal women oestrogens act as stimulators of PRL release and promegestone is able to partially counteract the stimulatory effect of oestradiol benzoate upon basal and TRH-stimulated PRL secretion. estradiol 3-benzoate 168-187 prolactin Homo sapiens 218-221 3516535-5 1986 On the contrary, plasma prolactin levels, previously suppressed during water immersion alone, were significantly stimulated during water immersion plus domperidone, thus indirectly suggesting a role of dopamine in mediating the blunted natriuresis seen during water immersion. Dopamine 202-210 prolactin Homo sapiens 24-33 3516535-5 1986 On the contrary, plasma prolactin levels, previously suppressed during water immersion alone, were significantly stimulated during water immersion plus domperidone, thus indirectly suggesting a role of dopamine in mediating the blunted natriuresis seen during water immersion. Water 131-136 prolactin Homo sapiens 24-33 2938986-3 1986 One half of the women were given bromocriptine to control PRL levels during anesthesia. Bromocriptine 33-46 prolactin Homo sapiens 58-61 3958122-7 1986 These observations confirm the impairment of LH pulsatility in hyperprolactinemia and demonstrate that normalization of PRL levels by surgery can restore LH pulsatile secretion in certain women as early as the eighth day after operation in the absence of a significant change in serum E2 levels. Estradiol 285-287 prolactin Homo sapiens 120-123 3958126-1 1986 Afternoon-evening and nocturnal serum PRL levels and PRL responsiveness to metoclopramide (MCP) were determined in 34 women with normoprolactinemic anovulation (nPRL-Anov) and in the early follicular phase (EFP) in 6 normal women. Metoclopramide 75-89 prolactin Homo sapiens 53-56 3722953-0 1986 [Serum prolactin levels during sleep and in metoclopramide stimulation in normoprolactinemic anovulation and ovulation induction with bromocriptine]. Metoclopramide 44-58 prolactin Homo sapiens 7-16 3735922-0 1986 [Role of prolactin in disorders of water and salt metabolism in patients with hypertension]. Water 35-40 prolactin Homo sapiens 9-18 3735922-0 1986 [Role of prolactin in disorders of water and salt metabolism in patients with hypertension]. Salts 45-49 prolactin Homo sapiens 9-18 3735922-1 1986 The relationship between water-salt balance and blood prolactin (Prl) level was examined in 22 male patients with essential hypertension, stages IB-IIA. Water 25-30 prolactin Homo sapiens 54-63 3735922-5 1986 The rise in electrolyte excretion following lasix administration was accompanied with a fall in Prl in hyperprolactinemic patients. Furosemide 44-49 prolactin Homo sapiens 96-99 3735922-6 1986 Following the chronic furosemide test, all patients showed a tendency to Prl rise, while the hyperprolactinemic patients also exhibited sodium retention. Furosemide 22-32 prolactin Homo sapiens 73-76 3735922-7 1986 Therefore, blood Prl decrease leads to sodium retention in hyperprolactinemic hypertensive patients that may have an adverse pathogenetic significance. Sodium 39-45 prolactin Homo sapiens 17-20 3722953-0 1986 [Serum prolactin levels during sleep and in metoclopramide stimulation in normoprolactinemic anovulation and ovulation induction with bromocriptine]. Bromocriptine 134-147 prolactin Homo sapiens 7-16 3722953-2 1986 PRL responsiveness to metoclopramide (MCP) was assessed. Metoclopramide 22-36 prolactin Homo sapiens 0-3 3722953-2 1986 PRL responsiveness to metoclopramide (MCP) was assessed. Metoclopramide 38-41 prolactin Homo sapiens 0-3 3959754-3 1986 Further, bromocriptine which inhibits the release of PRL attenuated the effect of metoclopramide indicating that this drug could act by releasing PRL. Bromocriptine 9-22 prolactin Homo sapiens 53-56 3959754-3 1986 Further, bromocriptine which inhibits the release of PRL attenuated the effect of metoclopramide indicating that this drug could act by releasing PRL. Bromocriptine 9-22 prolactin Homo sapiens 146-149 3959754-3 1986 Further, bromocriptine which inhibits the release of PRL attenuated the effect of metoclopramide indicating that this drug could act by releasing PRL. Metoclopramide 82-96 prolactin Homo sapiens 53-56 3959754-3 1986 Further, bromocriptine which inhibits the release of PRL attenuated the effect of metoclopramide indicating that this drug could act by releasing PRL. Metoclopramide 82-96 prolactin Homo sapiens 146-149 3091297-4 1986 Similarly the reduced preoperative PRL responses to domperidone and TRH were significantly increased by successful surgery. Domperidone 52-63 prolactin Homo sapiens 35-38 3091297-6 1986 The PRL responses to domperidone and TRH were reduced or absent both in patients with prolactinomas and in those with stalk-compression hyperprolactinaemia. Domperidone 21-32 prolactin Homo sapiens 4-7 3091297-10 1986 In conclusion a reduced or absent PRL response to TRH or domperidone is not diagnostic of the presence of a prolactinoma since it occurs in hyperprolactinaemic patients with prolactinomas or stalk-compression. Domperidone 57-68 prolactin Homo sapiens 34-37 3742834-6 1986 At this stage treatment with a second dopamine agonist, pergolide, was effective in reducing the prolactin concentration to normal within four months. Dopamine 38-46 prolactin Homo sapiens 97-106 3742834-6 1986 At this stage treatment with a second dopamine agonist, pergolide, was effective in reducing the prolactin concentration to normal within four months. Pergolide 56-65 prolactin Homo sapiens 97-106 3742834-7 1986 Serial CT scans at 1, 6 and 12 months on dopamine agonist therapy showed a progressive decrease in tumour size, which seemed to be maintained even during the period of rising prolactin concentrations due to bromocriptine resistance. Dopamine 41-49 prolactin Homo sapiens 175-184 3742834-7 1986 Serial CT scans at 1, 6 and 12 months on dopamine agonist therapy showed a progressive decrease in tumour size, which seemed to be maintained even during the period of rising prolactin concentrations due to bromocriptine resistance. Bromocriptine 207-220 prolactin Homo sapiens 175-184 3742834-8 1986 This case illustrates that during dopamine agonist therapy a discrepancy may exist in the clinical response as judged by reduction in tumour size and decrease in the circulating prolactin level. Dopamine 34-42 prolactin Homo sapiens 178-187 3093202-2 1986 In 72 acromegalic patients, there was a tendency for patients with a plasma GH response to TRH or with an elevated basal plasma PRL level, but without a plasma GH response to LHRH, to have a plasma GH response to bromocriptine, though statistical analysis did not reveal a significant difference. Bromocriptine 213-226 prolactin Homo sapiens 128-131 3086201-6 1986 The response of prolactin and TSH to metoclopramide proved to be no greater than to domperidone. Metoclopramide 37-51 prolactin Homo sapiens 16-25 3086201-8 1986 The anti-dopaminergic activity of metoclopramide in the release of prolactin and TSH is likely for the greater part peripheral. Metoclopramide 34-48 prolactin Homo sapiens 67-76 3011885-5 1986 PRL levels decreased throughout the study period both in male and female subjects; however, when the PRL percentage decline was evaluated in the same group of subjects after saline and ACTH 1-17, the more obvious decrease of PRL levels after the peptide infusion was not statistically significant. Sodium Chloride 174-180 prolactin Homo sapiens 101-104 3011885-5 1986 PRL levels decreased throughout the study period both in male and female subjects; however, when the PRL percentage decline was evaluated in the same group of subjects after saline and ACTH 1-17, the more obvious decrease of PRL levels after the peptide infusion was not statistically significant. Sodium Chloride 174-180 prolactin Homo sapiens 101-104 3712366-4 1986 Treatment with bromocriptine or methergoline corrected the excessive prolactin production and associated symptoms. Bromocriptine 15-28 prolactin Homo sapiens 69-78 3712366-4 1986 Treatment with bromocriptine or methergoline corrected the excessive prolactin production and associated symptoms. Metergoline 32-44 prolactin Homo sapiens 69-78 3012190-5 1986 Pretreatment with terguride lowered the prolactin (PRL) increase (p less than 0.01) as well as the thyrotropin (TSH) peak (p less than 0.05) compared with the test without dopamine agonist pretreatment. dironyl 18-27 prolactin Homo sapiens 51-54 3084318-2 1986 Also the effect of including dopamine (DA) at 1 X 10(-7) mol/1 in these different in vitro systems on the release of LH, FSH and Prl was investigated. Dopamine 29-37 prolactin Homo sapiens 129-132 3084318-2 1986 Also the effect of including dopamine (DA) at 1 X 10(-7) mol/1 in these different in vitro systems on the release of LH, FSH and Prl was investigated. Dopamine 39-41 prolactin Homo sapiens 129-132 3084318-7 1986 Inclusion of 1 X 10(-7) M DA in the incubation medium stimulated the release of LH (80%) but inhibited the release of Prl (71%) by PHC. Dopamine 26-28 prolactin Homo sapiens 118-121 2423863-5 1986 For the remaining 96 patients with carcinomas other than por, the rate of positive prolactin increased according to the depth of invasion from 10/29 in m & sm to 3/4 in si & sei, the scope of lymph node metastasis from 20/40 in n0 to 4/4 in n3 & n4 and the clinical stages from 12/26 in stage 1 to 15/22 in stage 4. Adenosine Monophosphate 155-158 prolactin Homo sapiens 83-92 2423863-5 1986 For the remaining 96 patients with carcinomas other than por, the rate of positive prolactin increased according to the depth of invasion from 10/29 in m & sm to 3/4 in si & sei, the scope of lymph node metastasis from 20/40 in n0 to 4/4 in n3 & n4 and the clinical stages from 12/26 in stage 1 to 15/22 in stage 4. Adenosine Monophosphate 177-180 prolactin Homo sapiens 83-92 2423863-5 1986 For the remaining 96 patients with carcinomas other than por, the rate of positive prolactin increased according to the depth of invasion from 10/29 in m & sm to 3/4 in si & sei, the scope of lymph node metastasis from 20/40 in n0 to 4/4 in n3 & n4 and the clinical stages from 12/26 in stage 1 to 15/22 in stage 4. Adenosine Monophosphate 177-180 prolactin Homo sapiens 83-92 3701149-0 1986 [Nocturnal prolactin (PRL) levels and PRL release by metoclopramide in normoprolactinemic anovulation, and effects of bromocriptine in induction of ovulation]. Metoclopramide 53-67 prolactin Homo sapiens 38-41 3943108-7 1986 The secretory granules of bromocriptine-treated adenomas may contain a small amount of PRL, as suggested by a culture study reporting degradation of PRL by bromocriptine. Bromocriptine 26-39 prolactin Homo sapiens 149-152 3007174-1 1986 SKF 38393, a D-1 dopamine receptor agonist, produced dose-dependent elevations in plasma prolactin concentrations. 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine 0-9 prolactin Homo sapiens 89-98 2943108-9 1986 (Normal values of prolactin were on the average achieved on the 4th day after sulpiride discontinuation). Sulpiride 78-87 prolactin Homo sapiens 18-27 3943108-1 1986 To ascertain the mechanisms of bromocriptine in lowering serum prolactin (PRL) levels and reducing the cell size of human prolactinomas, stereological analysis at electron microscope level was performed on six adenomas treated with bromocriptine (10 mg/day for 2 weeks) and four untreated adenomas. Bromocriptine 31-44 prolactin Homo sapiens 63-72 3943108-1 1986 To ascertain the mechanisms of bromocriptine in lowering serum prolactin (PRL) levels and reducing the cell size of human prolactinomas, stereological analysis at electron microscope level was performed on six adenomas treated with bromocriptine (10 mg/day for 2 weeks) and four untreated adenomas. Bromocriptine 31-44 prolactin Homo sapiens 74-77 3943108-2 1986 The bromocriptine treatment significantly decreased all the major organelles involved in PRL synthesis when expressed in absolute volume per single tumor cell, although it decreased only Golgi apparatus when expressed in relative volume within the cells. Bromocriptine 4-17 prolactin Homo sapiens 89-92 3943108-7 1986 The secretory granules of bromocriptine-treated adenomas may contain a small amount of PRL, as suggested by a culture study reporting degradation of PRL by bromocriptine. Bromocriptine 156-169 prolactin Homo sapiens 87-90 3943108-7 1986 The secretory granules of bromocriptine-treated adenomas may contain a small amount of PRL, as suggested by a culture study reporting degradation of PRL by bromocriptine. Bromocriptine 156-169 prolactin Homo sapiens 149-152 3698093-1 1986 Prolactin (PRL) responses to dopamine (DA) blockers and to direct and indirect DA agonists have been studied in 23 healthy women, 17 women with catamenial migraine and 17 with non-catamenial migraine in both their follicular and luteal phases. Dopamine 29-37 prolactin Homo sapiens 0-9 3956453-0 1986 Prolactin secretion in epileptic subjects treated with phenobarbital: sex differences and circadian periodicity. Phenobarbital 55-68 prolactin Homo sapiens 0-9 3956453-3 1986 Circadian PRL secretion, studied in six male epileptic patients on PB monotherapy and in nine normal subjects, showed comparable 24-h PRL mean values and a preserved PRL surge during the night in both groups; however, a statistically significant additional peak was found in male epileptic subjects during the late afternoon. Phenobarbital 67-69 prolactin Homo sapiens 10-13 3956453-5 1986 These results indicate that central and/or peripheral mechanisms involved in PRL secretion control are more sensitive to PB alone or in combination with other antiepileptic drugs in male than in female subjects. Phenobarbital 121-123 prolactin Homo sapiens 77-80 2908279-4 1986 Thus, bromocriptine lowered the prolactin concentrations in both breast milk and plasma. Bromocriptine 6-19 prolactin Homo sapiens 32-41 3944233-2 1986 HA diphosphate infused iv for 120 min in a dose of 9, 18, 30, or 50 micrograms/kg BW.h to six normal men stimulated PRL secretion in a dose-dependent manner [absolute change in PRL (delta PRL) area = 52 X (HA dose) - 618; r = 0.9926; P less than 0.001]. Diphosphates 3-14 prolactin Homo sapiens 116-119 3944233-2 1986 HA diphosphate infused iv for 120 min in a dose of 9, 18, 30, or 50 micrograms/kg BW.h to six normal men stimulated PRL secretion in a dose-dependent manner [absolute change in PRL (delta PRL) area = 52 X (HA dose) - 618; r = 0.9926; P less than 0.001]. Diphosphates 3-14 prolactin Homo sapiens 177-180 3944233-2 1986 HA diphosphate infused iv for 120 min in a dose of 9, 18, 30, or 50 micrograms/kg BW.h to six normal men stimulated PRL secretion in a dose-dependent manner [absolute change in PRL (delta PRL) area = 52 X (HA dose) - 618; r = 0.9926; P less than 0.001]. Diphosphates 3-14 prolactin Homo sapiens 177-180 3944233-5 1986 The PRL-releasing effect of 11 micrograms HA dihydrochloride was not significantly different from that of an equimolar dose of HA diphosphate (18 micrograms). Histamine 42-60 prolactin Homo sapiens 4-7 3944233-6 1986 Selective activation of H2 receptors by combined infusion of HA and the H1 receptor antagonist mepyramine inhibited PRL secretion compared to the effect of NaCl [delta PRL, -55 +/- 23 (+/- SEM) vs. -20 +/- 17 microIU/ml; P less than 0.01; n = 6). Pyrilamine 95-105 prolactin Homo sapiens 116-119 3944233-8 1986 Selective activation of H1 receptors by combined infusion of HA and the H2 receptor antagonist cimetidine stimulated PRL secretion (delta PRL, 193 +/- 40 vs. -20 +/- 17 microIU/ml; P less than 0.0005; n = 6). Cimetidine 95-105 prolactin Homo sapiens 117-120 3944233-8 1986 Selective activation of H1 receptors by combined infusion of HA and the H2 receptor antagonist cimetidine stimulated PRL secretion (delta PRL, 193 +/- 40 vs. -20 +/- 17 microIU/ml; P less than 0.0005; n = 6). Cimetidine 95-105 prolactin Homo sapiens 138-141 3944233-9 1986 When infused alone, cimetidine had only a modest and late stimulatory effect (delta PRL, 35 +/- 22 vs. -27 +/- 15; P less than 0.025; n = 6). Cimetidine 20-30 prolactin Homo sapiens 84-87 3009803-4 1986 In the presence of intact HM and TC, significant elevations in the mean serum concentration of HCG, PRL, P and E2 were observed when compared to levels in GTD patients with normal-sized ovaries (P less than .01). Technetium 33-35 prolactin Homo sapiens 100-103 3943108-6 1986 This appears to be contradictory to the current view that a decrease in serum PRL levels with a concurrent increase in the intracellular PRL levels caused by bromocriptine treatment results from the inhibition of exocytosis of secretory granules. Bromocriptine 158-171 prolactin Homo sapiens 137-140 3943108-7 1986 The secretory granules of bromocriptine-treated adenomas may contain a small amount of PRL, as suggested by a culture study reporting degradation of PRL by bromocriptine. Bromocriptine 26-39 prolactin Homo sapiens 87-90 3009803-8 1986 These findings suggest that besides the markedly elevated HCG levels generally seen in TC patients, other hormones, such as P, PRL and E2 are elevated and may be involved in the formation and/or maintenance of TC. Technetium 210-212 prolactin Homo sapiens 127-130 3952483-12 1986 Dopaminergic drugs such as bromocriptine rapidly reduce serum prolactin levels in hyperprolactinemic women and men with micro- or macroadenoma. Bromocriptine 27-40 prolactin Homo sapiens 62-71 3743197-0 1986 [Galactorrhea and serum prolactin levels in women using compound norgestrol]. Norgestrel 65-75 prolactin Homo sapiens 24-33 3699687-1 1986 To examine the previous suggestion that the endogenous dopaminergic activity would be increased in patients with primary aldosteronism, dose-response curves of aldosterone and prolactin stimulation by the dopamine antagonist metoclopramide were established in a pilot study by injecting metoclopramide 1, 2.5, and 10 mg i.v. Dopamine 55-63 prolactin Homo sapiens 176-185 3081830-0 1986 Function of dopamine receptors in Parkinson"s disease: prolactin responses. Dopamine 12-20 prolactin Homo sapiens 55-64 3081830-2 1986 Bromocriptine (BCT) caused a significant suppression of PRL in all parkinsonian patients and controls. Bromocriptine 0-13 prolactin Homo sapiens 56-59 3081830-2 1986 Bromocriptine (BCT) caused a significant suppression of PRL in all parkinsonian patients and controls. Bromocriptine 15-18 prolactin Homo sapiens 56-59 3080893-5 1986 In control subjects, follicle-stimulating hormone, luteinizing hormone, and prolactin levels did not change significantly after naloxone in the follicular phase, but naloxone elicited a significant synchronous release of luteinizing hormone and prolactin during the luteal phase. Naloxone 166-174 prolactin Homo sapiens 245-254 3080893-6 1986 In contrast, oral contraceptive users showed increases in luteinizing hormone and prolactin after naloxone that were not significantly different from the basal plasma levels. Naloxone 98-106 prolactin Homo sapiens 82-91 3082094-9 1986 Longterm bromocriptine therapy (2.5 mg tid over 60-150 days) not only normalized serum Prl levels, but also reduced the TSH response to TRH in 7 hyperprolactinaemic women who had presented exaggerated TSH responses to the basal TRH test. Bromocriptine 9-22 prolactin Homo sapiens 87-90 3082100-1 1986 The responses of serum prolactin (Prl) to metoclopramide and LH and FSH to GnRH were studied simultaneously in 9 boys with hypogonadotrophic hypogonadism (HH), 7 boys with constitutional delay of puberty (D) and 15 controls. Metoclopramide 42-56 prolactin Homo sapiens 23-32 3082100-2 1986 Metoclopramide increased the Prl levels in all groups. Metoclopramide 0-14 prolactin Homo sapiens 29-32 3484903-0 1986 Influence of sequential doses of 5-hydroxytryptophan on prolactin release. 5-Hydroxytryptophan 33-52 prolactin Homo sapiens 56-65 3484903-1 1986 It is known that the administration of serotonin or its precursors induces the release of prolactin. Serotonin 39-48 prolactin Homo sapiens 90-99 3484903-2 1986 This study was performed (1) to determine the minimal dose of 5-hydroxytryptophan that would produce a consistent and significant prolactin increase and (2) to establish the frequency of 5-hydroxytryptophan administration necessary to induce a persistent prolactin increase. 5-Hydroxytryptophan 62-81 prolactin Homo sapiens 130-139 3484903-2 1986 This study was performed (1) to determine the minimal dose of 5-hydroxytryptophan that would produce a consistent and significant prolactin increase and (2) to establish the frequency of 5-hydroxytryptophan administration necessary to induce a persistent prolactin increase. 5-Hydroxytryptophan 62-81 prolactin Homo sapiens 255-264 3484903-2 1986 This study was performed (1) to determine the minimal dose of 5-hydroxytryptophan that would produce a consistent and significant prolactin increase and (2) to establish the frequency of 5-hydroxytryptophan administration necessary to induce a persistent prolactin increase. 5-Hydroxytryptophan 187-206 prolactin Homo sapiens 255-264 3484903-6 1986 5-Hydroxytryptophan at a dosage of 0.4 mg/kg/hr was the minimal amount to elicit a consistent and significant prolactin increase (p less than 0.01). 5-Hydroxytryptophan 0-19 prolactin Homo sapiens 110-119 3484903-7 1986 A positive correlation (r = 0.907, p less than 0.002) was also demonstrated between the maximal prolactin response and the 5-hydroxyindoleacetic acid/creatinine ratio. Hydroxyindoleacetic Acid 123-149 prolactin Homo sapiens 96-105 3484903-7 1986 A positive correlation (r = 0.907, p less than 0.002) was also demonstrated between the maximal prolactin response and the 5-hydroxyindoleacetic acid/creatinine ratio. Creatinine 150-160 prolactin Homo sapiens 96-105 3484903-9 1986 With exception of the 12-hour interval a significantly smaller plasma prolactin increase was seen following the third dose of 5-hydroxytryptophan (p less than 0.05). 5-Hydroxytryptophan 126-145 prolactin Homo sapiens 70-79 3484903-12 1986 In conclusion, this study has demonstrated a dose-related prolactin response to increasing doses of 5-hydroxytryptophan. 5-Hydroxytryptophan 100-119 prolactin Homo sapiens 58-67 3484903-13 1986 The maximum down regulation of prolactin release occurred when 5-hydroxytryptophan was administered at 4-hour intervals. 5-Hydroxytryptophan 63-82 prolactin Homo sapiens 31-40 3518389-2 1986 With this procedure, we compared the effect of various fixatives, with or without saponin permeabilization, on the immunoreactivity of a secretory product (prolactin) and membrane proteins in cultured prolactin cells. Saponins 82-89 prolactin Homo sapiens 156-165 3946520-1 1986 In vivo suppression of prolactin concentrations by bromocriptine near term, in a pregnant woman with a prolactinoma, was followed by augmentation of human chorionic gonadotropin levels. Bromocriptine 51-64 prolactin Homo sapiens 23-32 3699687-1 1986 To examine the previous suggestion that the endogenous dopaminergic activity would be increased in patients with primary aldosteronism, dose-response curves of aldosterone and prolactin stimulation by the dopamine antagonist metoclopramide were established in a pilot study by injecting metoclopramide 1, 2.5, and 10 mg i.v. Metoclopramide 225-239 prolactin Homo sapiens 176-185 3079774-6 1986 A positive correlation was found between the DIs of total and little PRL and creatinine clearance in group CRF. Creatinine 77-87 prolactin Homo sapiens 69-72 3085991-7 1986 There was a significant correlation between the maximum PRL response and the maximum LH response to GnRH in all the women studied (r = 0.7; P less than 0.01). Luteinizing Hormone 85-87 prolactin Homo sapiens 56-59 3002762-1 1986 The present paper describes a method of membrane preparation from ewe mammary gland using a sucrose cushion (1.3 M) to select smooth membranes; this results in a membrane preparation richer in PRL receptors than the microsomal preparation classically used. Sucrose 92-99 prolactin Homo sapiens 193-196 3002762-7 1986 The evolution of PRL and oPL receptors was determined during pregnancy and lactation and at different periods after an estradiol and progesterone treatment, which provokes growth of the mammary gland and milk secretion. Estradiol 119-128 prolactin Homo sapiens 17-20 3002762-7 1986 The evolution of PRL and oPL receptors was determined during pregnancy and lactation and at different periods after an estradiol and progesterone treatment, which provokes growth of the mammary gland and milk secretion. Progesterone 133-145 prolactin Homo sapiens 17-20 3002762-11 1986 Injections of large doses of estradiol and progesterone to nonpregnant ewes were able to reproduce effectively the pattern of PRL receptors observed during pregnancy, but had no effect on oPL receptor levels. Estradiol 29-38 prolactin Homo sapiens 126-129 3002762-11 1986 Injections of large doses of estradiol and progesterone to nonpregnant ewes were able to reproduce effectively the pattern of PRL receptors observed during pregnancy, but had no effect on oPL receptor levels. Progesterone 43-55 prolactin Homo sapiens 126-129 3950531-0 1986 Effects of various melatonin treatments on plasma prolactin concentrations in the ewe. Melatonin 19-28 prolactin Homo sapiens 50-59 3950531-5 1986 After treatment in June, prolactin levels were significantly suppressed after 7 days of oral and implant melatonin therapy, and after 28 days of a short artificial photoperiod. Melatonin 105-114 prolactin Homo sapiens 25-34 3950531-6 1986 Melatonin treatment appeared more efficient than an artificial photoperiod in reducing plasma prolactin concentrations. Melatonin 0-9 prolactin Homo sapiens 94-103 3945435-3 1986 Within four weeks, Metergoline treatment reduced these PRL concentrations to 39.5 ng/mL and 82.9 ng/mL, respectively. Metergoline 19-30 prolactin Homo sapiens 55-58 3012924-1 1986 In order to evaluate the influence of the GABAergic system in the regulation of PRL secretion in patients with IDDM, serum PRL levels were measured in 7 diabetics and in 7 normal men with sodium valproate (400 mg per os), a drug capable of increasing cerebral GABA concentrations. gamma-Aminobutyric Acid 42-46 prolactin Homo sapiens 80-83 3012924-2 1986 A significant decrease of serum PRL concentrations was observed between 30 and 120 min after sodium valproate administration in both control and diabetic subjects. Valproic Acid 93-109 prolactin Homo sapiens 32-35 3012924-4 1986 These data confirm the inhibitory control of the GABAergic system on PRL secretion in man as evidenced by the GABAergic drug sodium valproate. Valproic Acid 125-141 prolactin Homo sapiens 69-72 3080846-0 1986 Dynamic evaluation of prolactin secretion by successive TRH and metoclopramide stimulations. Metoclopramide 64-78 prolactin Homo sapiens 22-31 3472433-1 1986 An exaggerated, early prolactin response (p less than 0.01) was observed in ten patients with untreated essential hypertension (148 +/- 4/97 +/- 1 mmHg, means +/- SE) compared with ten healthy normotensive men of the same age (124 +/- 3/78 +/- 2 mmHg) after administration of metoclopramide, a competitive dopamine antagonist. Metoclopramide 276-290 prolactin Homo sapiens 22-31 3472433-1 1986 An exaggerated, early prolactin response (p less than 0.01) was observed in ten patients with untreated essential hypertension (148 +/- 4/97 +/- 1 mmHg, means +/- SE) compared with ten healthy normotensive men of the same age (124 +/- 3/78 +/- 2 mmHg) after administration of metoclopramide, a competitive dopamine antagonist. Dopamine 306-314 prolactin Homo sapiens 22-31 3588168-0 1986 Plasma cortisol, prolactin and thyroxine levels related to midazolam anaesthesia. Midazolam 59-68 prolactin Homo sapiens 17-26 3774415-3 1986 If the plasma prolactin level exceeded 5000 mU/l during pregnancy, bromocriptine was administered until delivery. Bromocriptine 67-80 prolactin Homo sapiens 14-23 3004215-1 1986 The permeability of human amnion to tritiated water is reduced in the presence of both human and ovine prolactin. Water 46-51 prolactin Homo sapiens 103-112 3004215-3 1986 The present study sought to confirm an epithelial site of action of prolactin on the permeability of amnionic membrane to tritiated water. Water 132-137 prolactin Homo sapiens 68-77 3004215-6 1986 However, when ovine prolactin was presented to the fetal surface of amnion, only intact membrane displayed decreased permeability to tritiated water. Water 143-148 prolactin Homo sapiens 20-29 3004215-7 1986 Although localization of iodine 125-labeled prolactin to the light cell population of amniotic epithelium was observed, positive evidence of a receptor-mediated mechanism could not be established. Iodine-125 25-35 prolactin Homo sapiens 44-53 3004215-8 1986 The results indicate that the permeability of human amnion to water is influenced principally by cells of the epithelium in response to prolactin. Water 62-67 prolactin Homo sapiens 136-145 3079953-0 1986 Cysteamine decreases prolactin responsiveness to thyrotropin-releasing hormone in normal men. Cysteamine 0-10 prolactin Homo sapiens 21-30 3079953-3 1986 The effect of cysteamine on prolactin secretion is reported in normal men. Cysteamine 14-24 prolactin Homo sapiens 28-37 3079953-8 1986 Peak serum prolactin levels following TRH, prolactin levels at the 10-min time point, and total area from 0 to 30 min under the prolactin secretory curve were significantly decreased by cysteamine administration. Cysteamine 186-196 prolactin Homo sapiens 11-20 3079953-8 1986 Peak serum prolactin levels following TRH, prolactin levels at the 10-min time point, and total area from 0 to 30 min under the prolactin secretory curve were significantly decreased by cysteamine administration. Cysteamine 186-196 prolactin Homo sapiens 43-52 3079953-8 1986 Peak serum prolactin levels following TRH, prolactin levels at the 10-min time point, and total area from 0 to 30 min under the prolactin secretory curve were significantly decreased by cysteamine administration. Cysteamine 186-196 prolactin Homo sapiens 43-52 3079953-11 1986 It was concluded that cysteamine reduced TRH-stimulated prolactin secretion. Cysteamine 22-32 prolactin Homo sapiens 56-65 3019282-1 1986 It has been established that natrium oxybutirate, prolactin, inderal and ionol affecting different links of pathogenetic chain of stress injury, efficiently prevent structural damage to cardiomyocytes and the accumulation of 99mTc-pyrophosphate in the myocardium. diphosphoric acid 230-244 prolactin Homo sapiens 50-59 3539083-0 1986 Improvement of prolactin immunolabelling in osmium-fixed acrylic-embedded pituitary gland. Osmium 44-50 prolactin Homo sapiens 15-24 3539083-1 1986 Immunolabelling of prolactin (PRL) with protein A-colloidal gold complex and tissue fine structure were enhanced after postfixation of pituitary gland with osmium tetroxide and embedment in acrylic momers (LR White). Osmium Tetroxide 156-172 prolactin Homo sapiens 19-28 3593120-0 1986 Prolactin response in Border-Leicester x merino ewes to administration of melatonin, melatonin analogues, a melatonin metabolite and 6-methoxybenzoxazolinone. Melatonin 74-83 prolactin Homo sapiens 0-9 3593120-0 1986 Prolactin response in Border-Leicester x merino ewes to administration of melatonin, melatonin analogues, a melatonin metabolite and 6-methoxybenzoxazolinone. Melatonin 85-94 prolactin Homo sapiens 0-9 3593120-0 1986 Prolactin response in Border-Leicester x merino ewes to administration of melatonin, melatonin analogues, a melatonin metabolite and 6-methoxybenzoxazolinone. Melatonin 85-94 prolactin Homo sapiens 0-9 3593120-0 1986 Prolactin response in Border-Leicester x merino ewes to administration of melatonin, melatonin analogues, a melatonin metabolite and 6-methoxybenzoxazolinone. 6-methoxybenzoxazolinone 133-157 prolactin Homo sapiens 0-9 3593120-3 1986 Melatonin, 6-chloromelatonin, 2,3-dihydromelatonin and 6-chloro-2,3-dihydromelatonin decreased plasma prolactin to 31, 45, 54 and 48% of control levels respectively when administered daily (100 micrograms at 1600 h) for 21 days. Melatonin 0-9 prolactin Homo sapiens 102-111 3593120-3 1986 Melatonin, 6-chloromelatonin, 2,3-dihydromelatonin and 6-chloro-2,3-dihydromelatonin decreased plasma prolactin to 31, 45, 54 and 48% of control levels respectively when administered daily (100 micrograms at 1600 h) for 21 days. 6-chloromelatonin 11-28 prolactin Homo sapiens 102-111 3593120-3 1986 Melatonin, 6-chloromelatonin, 2,3-dihydromelatonin and 6-chloro-2,3-dihydromelatonin decreased plasma prolactin to 31, 45, 54 and 48% of control levels respectively when administered daily (100 micrograms at 1600 h) for 21 days. 2,3-dihydromelatonin 30-50 prolactin Homo sapiens 102-111 3593120-3 1986 Melatonin, 6-chloromelatonin, 2,3-dihydromelatonin and 6-chloro-2,3-dihydromelatonin decreased plasma prolactin to 31, 45, 54 and 48% of control levels respectively when administered daily (100 micrograms at 1600 h) for 21 days. 6-chloro-2,3-dihydromelatonin 55-84 prolactin Homo sapiens 102-111 3768449-0 1986 Effect of metoclopramide treatment on thyrotropin and prolactin levels in sick neonates. Metoclopramide 10-24 prolactin Homo sapiens 54-63 3768449-4 1986 It has been demonstrated that in response to MTC administration PRL increased significantly from 4,010 +/- 383 to 5,478 +/- 441 mU/l (p less than 0.01), while TSH showed only a tendency to rise independent of the pretreatment hormone levels (from 2.85 +/- 0.44 to 3.06 +/- 0.38 mU/L. Metoclopramide 45-48 prolactin Homo sapiens 64-67 3768449-5 1986 In healthy control infants and in those infants with similar functional gastrointestinal disturbances who were treated without MTC, serum PRL levels fell significantly from days 3-4 to days 6-7, serum TSH, triiodothyronine and free thyroxine, however, remained unaltered. Metoclopramide 127-130 prolactin Homo sapiens 138-141 3768449-5 1986 In healthy control infants and in those infants with similar functional gastrointestinal disturbances who were treated without MTC, serum PRL levels fell significantly from days 3-4 to days 6-7, serum TSH, triiodothyronine and free thyroxine, however, remained unaltered. Thyroxine 232-241 prolactin Homo sapiens 138-141 3947689-0 1986 Plasma prolactin levels in full-term newborn infants with idiopathic edema: response to furosemide. Furosemide 88-98 prolactin Homo sapiens 7-16 3947689-3 1986 Plasma PRL proved to be significantly higher in the edematous group (11.0 +/- 1.9 vs. 4.2 +/- 3.1 U/l, p less than 0.01) but it remained unaltered by furosemide challenge (8.5 +/- 1.5 U/l) in spite of the marked elevation of urine flow and sodium excretion. Sodium 240-246 prolactin Homo sapiens 7-10 3956565-0 1986 Pharmacokinetics of a long-acting bromocriptine preparation (Parlodel LA) and its effect on release of prolactin and growth hormone. Bromocriptine 34-47 prolactin Homo sapiens 103-112 3956565-11 1986 Thus, the results show a prolonged inhibitory effect on PRL of this long-acting bromocriptine preparation in parallel with its slow plasma clearance. Bromocriptine 80-93 prolactin Homo sapiens 56-59 3956568-0 1986 Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine. Dopamine 57-65 prolactin Homo sapiens 14-23 3956568-0 1986 Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine. ibopamine 77-86 prolactin Homo sapiens 14-23 3956568-1 1986 In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol. ibopamine 73-82 prolactin Homo sapiens 151-160 3956568-1 1986 In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol. Dopamine 90-98 prolactin Homo sapiens 151-160 3956568-2 1986 The Metoclopramide-induced secretion of prolactin and aldosterone was blunted in 6 patients pretreated with 200 mg ibopamine. Metoclopramide 4-18 prolactin Homo sapiens 40-49 3956568-2 1986 The Metoclopramide-induced secretion of prolactin and aldosterone was blunted in 6 patients pretreated with 200 mg ibopamine. ibopamine 115-124 prolactin Homo sapiens 40-49 3709645-0 1986 Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women. dironyl 10-19 prolactin Homo sapiens 23-32 2458379-0 1986 Trophoblastic and decidual response to RU486: effects on human chorionic gonadotrophin, human placental lactogen, prolactin and pregnancy-associated plasma protein-A production in vitro. Mifepristone 39-44 prolactin Homo sapiens 114-123 2458379-6 1986 Decidual prolactin (Prl) or PAPP-A secretions were also inhibited by RU486. Mifepristone 69-74 prolactin Homo sapiens 9-18 2935474-1 1986 The intravenous administration of 250 micrograms D-Ala2-MePhe4-Met-enkephalin-O-ol (DAMME) caused a marked increase in circulating growth hormone (GH) and prolactin (PRL), and a fall in cortisol, in 14 normal subjects. d-ala2-mephe4-met-enkephalin-o-ol 49-82 prolactin Homo sapiens 155-164 2890594-3 1986 Both medications were found to reduce prolactin levels significantly from baseline, but an oscillatory pattern with significant fluctuation was seen in the mean prolactin levels in the patients taking bromocriptine. Bromocriptine 201-214 prolactin Homo sapiens 161-170 3079661-8 1986 Tamoxifen reduced both prolactin and inducible growth hormone (GH). Tamoxifen 0-9 prolactin Homo sapiens 23-32 3079661-9 1986 Trioxifene, although reducing prolactin, differed from tamoxifen in that an increase in inducible GH occurred. trioxifene 0-10 prolactin Homo sapiens 30-39 3818319-3 1986 Tritiated spiroperidol (3HSp) was selected for initial evaluation as a possible imaging agent based on: demonstrated localization in the pituitary and demonstrated binding to human PRL-secreting tumor tissue. tritiated spiroperidol 0-22 prolactin Homo sapiens 181-184 3818319-3 1986 Tritiated spiroperidol (3HSp) was selected for initial evaluation as a possible imaging agent based on: demonstrated localization in the pituitary and demonstrated binding to human PRL-secreting tumor tissue. 3hsp 24-28 prolactin Homo sapiens 181-184 2424860-0 1986 The effect of ergobromocriptine on serum testosterone and prolactin levels in patients with carcinoma of the prostate. ergobromocriptine 14-31 prolactin Homo sapiens 58-67 2424860-1 1986 The effect of Ergobromocriptine treatment on serum testosterone and prolactin levels in 15 patients with prostatic carcinoma and 15 patients with benign prostatic hyperplasia was examined. ergobromocriptine 14-31 prolactin Homo sapiens 68-77 2424860-2 1986 The prolactin levels which were elevated in patients with prostatic carcinoma showed a significant decrease after suppression with Ergobromocriptine. ergobromocriptine 131-148 prolactin Homo sapiens 4-13 2424860-3 1986 The selective effect of Ergobromocriptine on prolactin levels of patients with prostatic carcinoma may control the progression of the disease. ergobromocriptine 24-41 prolactin Homo sapiens 45-54 3462341-10 1986 In defined, serum-free medium, melatonin loses its antimitogenic capabilities unless cells are also simultaneously exposed to either estradiol or prolactin. Melatonin 31-40 prolactin Homo sapiens 146-155 3462341-11 1986 Therefore, the antiproliferative effect of melatonin may be dependent on the presence of serum and a complex interaction with hormones such as estradiol and/or prolactin. Melatonin 43-52 prolactin Homo sapiens 160-169 3944789-0 1986 Effect of naloxone on plasma concentrations of prolactin and LH in lactating sows. Naloxone 10-18 prolactin Homo sapiens 47-56 3944789-4 1986 Naloxone caused a marked suppression of plasma prolactin concentrations lasting 4-6 h. LH concentrations were also affected by naloxone: LH rose to reach maximum values 20-50 min after naloxone treatment. Naloxone 0-8 prolactin Homo sapiens 47-56 3093910-1 1986 The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH) before and after l-thyroxine replacement therapy. Metoclopramide 53-67 prolactin Homo sapiens 120-129 3093910-1 1986 The effects of the dopamine (DA) receptor antagonist metoclopramide on the plasma thyroid stimulating hormone (TSH) and prolactin (PRL) levels were studied in 8 patients with subclinical hypothyroidism (defined as absence of clinical signs of hypothyroidism with normal thyroid hormone levels, normal or slightly increased basal plasma TSH levels and increased and long-lasting TSH response to TRH) before and after l-thyroxine replacement therapy. Metoclopramide 53-67 prolactin Homo sapiens 131-134 3093910-5 1986 In analogy to the TSH behavior, plasma PRL secretion in response to metoclopramide and TRH administration was significantly (p less than 0.05) inhibited in the subclinical hypothyroid patients after l-thyroxine replacement therapy. Metoclopramide 68-82 prolactin Homo sapiens 39-42 3093910-5 1986 In analogy to the TSH behavior, plasma PRL secretion in response to metoclopramide and TRH administration was significantly (p less than 0.05) inhibited in the subclinical hypothyroid patients after l-thyroxine replacement therapy. Thyroxine 199-210 prolactin Homo sapiens 39-42 3587580-0 1986 Relation between plasma prolactin and plasma homovanillic acid in normal subjects. Homovanillic Acid 45-62 prolactin Homo sapiens 24-33 3587580-1 1986 The relation between fasting, a.m. plasma prolactin and plasma/homovanillic acid (HVA) was studied in 9 healthy males on one occasion and in 9 healthy females on two occasions (in the follicular and luteal phase of the menstrual cycle). Homovanillic Acid 63-80 prolactin Homo sapiens 42-51 3587580-1 1986 The relation between fasting, a.m. plasma prolactin and plasma/homovanillic acid (HVA) was studied in 9 healthy males on one occasion and in 9 healthy females on two occasions (in the follicular and luteal phase of the menstrual cycle). Homovanillic Acid 82-85 prolactin Homo sapiens 42-51 3785645-0 1986 Effect of sulpiride on plasma prolactin in healthy volunteers and depressed patients. Sulpiride 10-19 prolactin Homo sapiens 30-39 3510013-1 1986 The relationship between the deterioration of glucose tolerance and plasma prolactin (PRL) levels was investigated in 15 normal pregnant women and in 15 women with gestational diabetes mellitus. Glucose 46-53 prolactin Homo sapiens 75-84 3510013-1 1986 The relationship between the deterioration of glucose tolerance and plasma prolactin (PRL) levels was investigated in 15 normal pregnant women and in 15 women with gestational diabetes mellitus. Glucose 46-53 prolactin Homo sapiens 86-89 3940343-1 1986 A long-acting form of bromocriptine, a prolactin (PRL) secretion inhibitor, was administered to 122 postpartum women in single intramuscular injections of 20 (N = 24), 30 (N = 22), 40 (N = 46), and 50 mg (N = 30). Bromocriptine 22-35 prolactin Homo sapiens 50-53 3714202-10 1986 Addition of bromocriptine to the medium caused a rapid decline in PRL secretion while GH secretion remained the same. Bromocriptine 12-25 prolactin Homo sapiens 66-69 3081918-0 1986 Effect of a short-term oral administration of cimetidine and ranitidine on the basal and thyrotropin-releasing hormone-stimulated serum concentrations of prolactin, thyrotropin and thyroid hormones in healthy volunteers. Cimetidine 46-56 prolactin Homo sapiens 154-163 3081918-0 1986 Effect of a short-term oral administration of cimetidine and ranitidine on the basal and thyrotropin-releasing hormone-stimulated serum concentrations of prolactin, thyrotropin and thyroid hormones in healthy volunteers. Ranitidine 61-71 prolactin Homo sapiens 154-163 3081918-7 1986 Both cimetidine and ranitidine induced a significant increase in basal prolactin (PRL) values. Cimetidine 5-15 prolactin Homo sapiens 71-80 3081918-7 1986 Both cimetidine and ranitidine induced a significant increase in basal prolactin (PRL) values. Ranitidine 20-30 prolactin Homo sapiens 71-80 3031717-2 1986 In this report the effects of various receptor blockers on desimipramine (DMI)-induced prolactin (PRL) secretion in healthy male subjects are presented. Desipramine 59-72 prolactin Homo sapiens 87-96 3031717-2 1986 In this report the effects of various receptor blockers on desimipramine (DMI)-induced prolactin (PRL) secretion in healthy male subjects are presented. Desipramine 74-77 prolactin Homo sapiens 87-96 3016787-0 1986 Clomipramine enhances prolactin and growth hormone responses to L-tryptophan. Clomipramine 0-12 prolactin Homo sapiens 22-31 3016787-1 1986 The effects of the 5-hydroxytryptamine (5-HT) uptake inhibitor clomipramine on the prolactin (PRL) and growth hormone (GH) responses to L-tryptophan (LTP) were assessed in six normal subjects. Clomipramine 63-75 prolactin Homo sapiens 83-92 3016787-1 1986 The effects of the 5-hydroxytryptamine (5-HT) uptake inhibitor clomipramine on the prolactin (PRL) and growth hormone (GH) responses to L-tryptophan (LTP) were assessed in six normal subjects. Clomipramine 63-75 prolactin Homo sapiens 94-97 3016787-2 1986 Oral administration of 20 mg clomipramine 2 h prior to LTP infusion (50 mg/kg) significantly enhanced both endocrine responses, suggesting that the increases in plasma PRL and GH produced by LTP are mediated by 5-HT pathways. Clomipramine 29-41 prolactin Homo sapiens 168-171 3081931-2 1986 We investigated, therefore, whether a single dose of triazolam, a short-acting benzodiazepine, and flurazepam, a long-acting one, could influence the response of prolactin (PRL), growth hormone (GH) and cortisol to a mild hypoglycemic stress in young healthy volunteers. Triazolam 53-62 prolactin Homo sapiens 162-171 3081931-2 1986 We investigated, therefore, whether a single dose of triazolam, a short-acting benzodiazepine, and flurazepam, a long-acting one, could influence the response of prolactin (PRL), growth hormone (GH) and cortisol to a mild hypoglycemic stress in young healthy volunteers. Triazolam 53-62 prolactin Homo sapiens 173-176 3081931-2 1986 We investigated, therefore, whether a single dose of triazolam, a short-acting benzodiazepine, and flurazepam, a long-acting one, could influence the response of prolactin (PRL), growth hormone (GH) and cortisol to a mild hypoglycemic stress in young healthy volunteers. Flurazepam 99-109 prolactin Homo sapiens 162-171 3081931-2 1986 We investigated, therefore, whether a single dose of triazolam, a short-acting benzodiazepine, and flurazepam, a long-acting one, could influence the response of prolactin (PRL), growth hormone (GH) and cortisol to a mild hypoglycemic stress in young healthy volunteers. Flurazepam 99-109 prolactin Homo sapiens 173-176 3081933-2 1986 Significant increases were observed in plasma concentrations of growth hormone and prolactin after all three doses of L-tryptophan, but not after saline infusion. Tryptophan 118-130 prolactin Homo sapiens 83-92 3083453-0 1986 Effects of methysergide, bromocriptine and naloxone on prolactin, growth hormone and TSH release induced by D-Met2,Pro5-enkephalinamide in man. Naloxone 43-51 prolactin Homo sapiens 55-64 3083453-0 1986 Effects of methysergide, bromocriptine and naloxone on prolactin, growth hormone and TSH release induced by D-Met2,Pro5-enkephalinamide in man. d-met2 108-114 prolactin Homo sapiens 55-64 3083453-0 1986 Effects of methysergide, bromocriptine and naloxone on prolactin, growth hormone and TSH release induced by D-Met2,Pro5-enkephalinamide in man. pro5-enkephalinamide 115-135 prolactin Homo sapiens 55-64 3083453-1 1986 D-Met2,Pro5-enkephalinamide (EA) 10 mg, given SC, induced a dramatic rise in serum prolactin (PRL) and growth hormone (GH) levels in healthy male volunteers. d-met2 0-6 prolactin Homo sapiens 83-92 3083453-1 1986 D-Met2,Pro5-enkephalinamide (EA) 10 mg, given SC, induced a dramatic rise in serum prolactin (PRL) and growth hormone (GH) levels in healthy male volunteers. d-met2 0-6 prolactin Homo sapiens 94-97 3083453-1 1986 D-Met2,Pro5-enkephalinamide (EA) 10 mg, given SC, induced a dramatic rise in serum prolactin (PRL) and growth hormone (GH) levels in healthy male volunteers. pro5-enkephalinamide 7-27 prolactin Homo sapiens 83-92 3083453-1 1986 D-Met2,Pro5-enkephalinamide (EA) 10 mg, given SC, induced a dramatic rise in serum prolactin (PRL) and growth hormone (GH) levels in healthy male volunteers. pro5-enkephalinamide 7-27 prolactin Homo sapiens 94-97 3083453-4 1986 Bromocriptine 2.5 mg given per os also antagonized EA-induced PRL and TSH release but potentiated the GH surge. Bromocriptine 0-13 prolactin Homo sapiens 62-65 3083453-5 1986 Methysergide 2.0 mg administered orally partially reversed EA-elicited PRL release, further augmented GH liberation and did not modify TSH output. Methysergide 0-12 prolactin Homo sapiens 71-74 3765507-2 1986 Long-term treatment with tamoxifen was followed by a significant decrease in blood-estradiol, progesterone, testosterone and prolactin levels whereas FSH, LH and hydrocortisone concentrations remained virtually unchanged. Tamoxifen 25-34 prolactin Homo sapiens 125-134 3811672-1 1986 In 20 patients between the 6.-8. week of pregnancy serum prolactin concentration could be decreased successful by administration of a single dose bromocriptine. Bromocriptine 146-159 prolactin Homo sapiens 57-66 3811680-1 1986 In 23 patients between the 6.-8. week of pregnancy the serum prolactin concentration excessively increased by bolus injection of 10 mg metoclopramide. Metoclopramide 135-149 prolactin Homo sapiens 61-70 3911712-6 1985 After acute oral administration in 10 previously untreated patients, 0.5 mg of CU 32085 had a more prolonged suppressive effect on Prl levels than 2.5 mg of bromocriptine (approximately 18 vs 12 h). Copper 79-81 prolactin Homo sapiens 131-134 3935485-0 1985 Depressed follicle-stimulating hormone, luteinizing hormone, and prolactin responses to the luteinizing hormone-releasing hormone, thyrotropin-releasing hormone, and metoclopramide test in endurance runners in the hard-training season. Metoclopramide 166-180 prolactin Homo sapiens 65-74 3935485-7 1985 It is concluded that decreased ovarian activity explains, at least partly, the lowered responses of FSH and LH to LH-RH and the lowered response of PRL to MC in endurance runners. Metoclopramide 155-157 prolactin Homo sapiens 148-151 3911712-7 1985 According to this, 0.5 mg CU 32085 once a day was sufficient to maintain Prl levels within the normal range in 16 patients. Copper 26-28 prolactin Homo sapiens 73-76 2416632-2 1985 Sea turtle PRL is a protein of 22-24 kDa [sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis]. Sodium Dodecyl Sulfate 42-64 prolactin Homo sapiens 11-14 3938732-2 1985 Plasma PRL values showed clear decreases during the infusion of DA (5 micrograms/kg/min for 90 min) in both 6 normal and 7 PRL-oma subjects (%decrease: 43.8 +/- 3.9% vs. 53.9 +/- 5.6%; NS) and postinhibitory increases after the termination. Dopamine 64-66 prolactin Homo sapiens 7-10 3938732-5 1985 The maximal increments in plasma PRL in the combination test of DA plus domperidone were significantly larger in PRL-oma patients, but were almost the same in normal controls, compared to the single domperidone test. Dopamine 64-66 prolactin Homo sapiens 33-36 3938732-5 1985 The maximal increments in plasma PRL in the combination test of DA plus domperidone were significantly larger in PRL-oma patients, but were almost the same in normal controls, compared to the single domperidone test. Domperidone 72-83 prolactin Homo sapiens 33-36 3938732-5 1985 The maximal increments in plasma PRL in the combination test of DA plus domperidone were significantly larger in PRL-oma patients, but were almost the same in normal controls, compared to the single domperidone test. Domperidone 199-210 prolactin Homo sapiens 33-36 2416632-2 1985 Sea turtle PRL is a protein of 22-24 kDa [sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis]. Sodium Dodecyl Sulfate 66-69 prolactin Homo sapiens 11-14 2416632-2 1985 Sea turtle PRL is a protein of 22-24 kDa [sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis]. polyacrylamide gels 71-89 prolactin Homo sapiens 11-14 2416632-4 1985 The amino acid composition of sea turtle PRL is similar to ovine PRL and is characterized by a high content of aspartic acid (20 residues), glutamic acid (34 residues), serine (19 residues), and leucine (24 residues). Aspartic Acid 111-124 prolactin Homo sapiens 41-44 2416632-4 1985 The amino acid composition of sea turtle PRL is similar to ovine PRL and is characterized by a high content of aspartic acid (20 residues), glutamic acid (34 residues), serine (19 residues), and leucine (24 residues). Glutamic Acid 140-153 prolactin Homo sapiens 41-44 2416632-4 1985 The amino acid composition of sea turtle PRL is similar to ovine PRL and is characterized by a high content of aspartic acid (20 residues), glutamic acid (34 residues), serine (19 residues), and leucine (24 residues). Serine 169-175 prolactin Homo sapiens 41-44 4069417-0 1985 [Behavior of GH and prolactin during enflurane anesthesia and neuroleptoanesthesia in man]. Enflurane 37-46 prolactin Homo sapiens 20-29 4069417-1 1985 The present study was designed to investigate the effects of neuraleptanesthesia (NLA) and enflurane (Ethane) anesthesia on plasma levels of growth hormone (GH) and prolactin (PRL) in man. Enflurane 91-100 prolactin Homo sapiens 165-174 4069417-1 1985 The present study was designed to investigate the effects of neuraleptanesthesia (NLA) and enflurane (Ethane) anesthesia on plasma levels of growth hormone (GH) and prolactin (PRL) in man. Enflurane 91-100 prolactin Homo sapiens 176-179 4069417-1 1985 The present study was designed to investigate the effects of neuraleptanesthesia (NLA) and enflurane (Ethane) anesthesia on plasma levels of growth hormone (GH) and prolactin (PRL) in man. Ethane 102-108 prolactin Homo sapiens 165-174 4069417-1 1985 The present study was designed to investigate the effects of neuraleptanesthesia (NLA) and enflurane (Ethane) anesthesia on plasma levels of growth hormone (GH) and prolactin (PRL) in man. Ethane 102-108 prolactin Homo sapiens 176-179 4069417-12 1985 In conclusion NLA and enflurane induced a decrease of GH and PRL plasma levels; in both groups the anaesthetic agents, at the dosage used during anaesthesia, blocked the response of these hormones to the surgical stress likely due to a block of the hypothalamic-pituitary response. Enflurane 22-31 prolactin Homo sapiens 61-64 4053045-6 1985 In addition, cimetidine (10(-4) M) had a significant stimulatory effect on PRL secretion by 4-day-cultured HPA cells. Cimetidine 13-23 prolactin Homo sapiens 75-78 4042974-3 1985 Conditioned medium obtained from PRL-treated tumors, but not from control tumors, was found to exert a significant dose-dependent colony-stimulating effect when added to N-nitrosomethylurea-induced mammary tumors plated in soft agar under serum-free medium conditions. Methylnitrosourea 170-189 prolactin Homo sapiens 33-36 4042974-3 1985 Conditioned medium obtained from PRL-treated tumors, but not from control tumors, was found to exert a significant dose-dependent colony-stimulating effect when added to N-nitrosomethylurea-induced mammary tumors plated in soft agar under serum-free medium conditions. Agar 228-232 prolactin Homo sapiens 33-36 2995431-6 1985 When cells were preincubated with bromocriptine [6.6 +/- 4.8 (SD) X 10(-11) M], EKC (10(-11) to 10(-9) M) antagonized, in a dose-dependent manner, the dopaminergic inhibition of PRL release. Bromocriptine 34-47 prolactin Homo sapiens 178-181 2995431-10 1985 The binding of kappa-1 type opioid ligands modulates the inhibitory effect of dopamine upon PRL release. Dopamine 78-86 prolactin Homo sapiens 92-95 4067475-5 1985 Ovine prolactin stimulated both intestinal Ca absorption and placental Ca transfer; these effects were further increased by 1 alpha-OH-D3. alpha-oh-d3 126-137 prolactin Homo sapiens 6-15 4078422-7 1985 When bromocriptine was administered, serum prolactin levels of these patients dropped conspicuously, and the nocturnal surges of prolactin also suppressed. Bromocriptine 5-18 prolactin Homo sapiens 43-52 4078422-7 1985 When bromocriptine was administered, serum prolactin levels of these patients dropped conspicuously, and the nocturnal surges of prolactin also suppressed. Bromocriptine 5-18 prolactin Homo sapiens 129-138 3931086-0 1985 Prolactin stimulation of Nb 2 node lymphoma cell division is inhibited by polyamine biosynthesis inhibitors. Polyamines 74-83 prolactin Homo sapiens 0-9 3931086-1 1985 The mitogenic action of prolactin in Nb 2 node lymphoma cells was inhibited by two drugs which interfere with polyamine biosynthesis. Polyamines 110-119 prolactin Homo sapiens 24-33 3931086-2 1985 At concentrations of 0.5 mM and above alpha-difluoromethyl ornithine (DFMO), which inhibits ornithine decarboxylase and the conversion of ornithine to putrescine, significantly attenuated the mitogenic effect of prolactin. Eflornithine 38-68 prolactin Homo sapiens 212-221 3931086-2 1985 At concentrations of 0.5 mM and above alpha-difluoromethyl ornithine (DFMO), which inhibits ornithine decarboxylase and the conversion of ornithine to putrescine, significantly attenuated the mitogenic effect of prolactin. Eflornithine 70-74 prolactin Homo sapiens 212-221 3931086-2 1985 At concentrations of 0.5 mM and above alpha-difluoromethyl ornithine (DFMO), which inhibits ornithine decarboxylase and the conversion of ornithine to putrescine, significantly attenuated the mitogenic effect of prolactin. Ornithine 59-68 prolactin Homo sapiens 212-221 3931086-2 1985 At concentrations of 0.5 mM and above alpha-difluoromethyl ornithine (DFMO), which inhibits ornithine decarboxylase and the conversion of ornithine to putrescine, significantly attenuated the mitogenic effect of prolactin. Putrescine 151-161 prolactin Homo sapiens 212-221 3931086-4 1985 At concentrations of 1 microM and above methylglyoxal bis(guanylhydrazone) (MGBG), which inhibits S-adenosylmethionine decarboxylase and hence the conversion of putrescine to spermidine and spermine, abolished the mitogenic action of prolactin. Mitoguazone 40-74 prolactin Homo sapiens 234-243 3931086-4 1985 At concentrations of 1 microM and above methylglyoxal bis(guanylhydrazone) (MGBG), which inhibits S-adenosylmethionine decarboxylase and hence the conversion of putrescine to spermidine and spermine, abolished the mitogenic action of prolactin. Mitoguazone 76-80 prolactin Homo sapiens 234-243 3931086-6 1985 These studies show that ongoing polyamine biosynthesis is essential for prolactin to express its mitogenic effect in this lymphoma cell line. Polyamines 32-41 prolactin Homo sapiens 72-81 3904134-0 1985 Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate. Diethylstilbestrol 108-126 prolactin Homo sapiens 46-55 3904134-0 1985 Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate. Estramustine 130-152 prolactin Homo sapiens 46-55 2996932-0 1985 Involvement of lysine residues in the binding of ovine prolactin and human growth hormone to lactogenic receptors. Lysine 15-21 prolactin Homo sapiens 55-64 2416632-4 1985 The amino acid composition of sea turtle PRL is similar to ovine PRL and is characterized by a high content of aspartic acid (20 residues), glutamic acid (34 residues), serine (19 residues), and leucine (24 residues). Leucine 195-202 prolactin Homo sapiens 41-44 2416632-5 1985 It possess three disulfide bonds and 2 tryptophan residues which is also characteristic of many species of PRL. Disulfides 17-26 prolactin Homo sapiens 107-110 2416632-5 1985 It possess three disulfide bonds and 2 tryptophan residues which is also characteristic of many species of PRL. Tryptophan 39-49 prolactin Homo sapiens 107-110 4042883-4 1985 Of those patients in whom the operation was less successful, a normal prolactin level could be achieved in 77% by additional therapy with dopamine agonists. Dopamine 138-146 prolactin Homo sapiens 70-79 4042883-5 1985 Of 57 patients handled exclusively with drugs, the prolactin level was normalised by dopamine agonists in 78%. Dopamine 85-93 prolactin Homo sapiens 51-60 2998132-3 1985 The maximal Prl increase after 15 mg oral metoclopramide (MET) was also significantly larger in the normal (125 +/- 13 ng/ml) than in the thyrotoxic subjects (60 +/- 13 ng/ml, P less than 0.01). Metoclopramide 42-56 prolactin Homo sapiens 12-15 2998132-3 1985 The maximal Prl increase after 15 mg oral metoclopramide (MET) was also significantly larger in the normal (125 +/- 13 ng/ml) than in the thyrotoxic subjects (60 +/- 13 ng/ml, P less than 0.01). Metoclopramide 58-61 prolactin Homo sapiens 12-15 4050782-6 1985 In one patient the prolactin level fell from 2,210 to 100 ng/mL when methyldopa was discontinued. Methyldopa 69-79 prolactin Homo sapiens 19-28 4060968-1 1985 Controversy still exists regarding the role of serotonin in the regulation of prolactin (Prl) and growth hormone (GH) secretion in man. Serotonin 47-56 prolactin Homo sapiens 78-87 3904908-2 1985 Both drugs suppressed plasma testosterone and LH and increased plasma growth hormone and prolactin, though estramustine induced a greater rise in prolactin. Estramustine 107-119 prolactin Homo sapiens 146-155 3935458-11 1985 reversed the blunted response of PRL after sulpiride, 25 mg, in presence of naloxone. Sulpiride 43-52 prolactin Homo sapiens 33-36 3935458-11 1985 reversed the blunted response of PRL after sulpiride, 25 mg, in presence of naloxone. Naloxone 76-84 prolactin Homo sapiens 33-36 3935458-13 1985 inactive per se on basal PRL levels, is able to blunt significantly sulpiride-induced hyperprolactinaemia. Sulpiride 68-77 prolactin Homo sapiens 25-28 4029090-3 1985 Silver-stained gels of the extracts showed three major charge isoforms of 24,000 mol wt PRL (PRLs 1, 2, and 3, with PRL 3 being the most anodic) and what appeared to be an arc of products originating in the region of PRL 3. Silver 0-6 prolactin Homo sapiens 88-91 4029090-5 1985 When primary cell cultures were labeled with [35S] methionine, the three PRL isoforms and arc products were detectable by autoradiography. Sulfur-35 46-49 prolactin Homo sapiens 73-76 4029090-5 1985 When primary cell cultures were labeled with [35S] methionine, the three PRL isoforms and arc products were detectable by autoradiography. Methionine 51-61 prolactin Homo sapiens 73-76 4029090-7 1985 Treatment of the cell cultures with hydroxynorvaline (5 mM), which inhibits processing of pre-PRL to PRL, resulted in doublet spots in the arc. hydroxynorvaline 36-52 prolactin Homo sapiens 94-97 4029090-7 1985 Treatment of the cell cultures with hydroxynorvaline (5 mM), which inhibits processing of pre-PRL to PRL, resulted in doublet spots in the arc. hydroxynorvaline 36-52 prolactin Homo sapiens 101-104 4054318-3 1985 Ten milligrams of intravenous domperidone induced a rapid rise in PRL that was maximal at 30 to 45 minutes in normal, postpartum, and amenorrhea-galactorrhea patients who had no sign of tumor. Domperidone 30-41 prolactin Homo sapiens 66-69 4092671-0 1985 Effects of progesterone on prolactin secretion in hypogonadal women. Progesterone 11-23 prolactin Homo sapiens 27-36 4092671-2 1985 To test the hypothesis that progesterone is involved in the regulation of prolactin release, 50 mg of progesterone was administered intramuscularly at 0600 h to twelve hypogonadal women and blood samples were obtained at 15 min intervals between 1500 and 2000 h to determine the prolactin levels. Progesterone 28-40 prolactin Homo sapiens 74-83 4065553-1 1985 Thioridazine was found to increase the serum prolactin level as well as the tumor size of a prolactin--secreting pituitary chromophobe adenoma in a schizophrenic man. Thioridazine 0-12 prolactin Homo sapiens 45-54 4065553-1 1985 Thioridazine was found to increase the serum prolactin level as well as the tumor size of a prolactin--secreting pituitary chromophobe adenoma in a schizophrenic man. Thioridazine 0-12 prolactin Homo sapiens 92-101 2868996-3 1985 The peak responses of Prl after metoclopramide + LHRH and of testosterone after hCG correlated strongly in the patients as a whole (r = 0.87, P less than 0.001). Metoclopramide 32-46 prolactin Homo sapiens 22-25 2868996-5 1985 The findings also raise the possibility that Prl may play a role in the regulation of testosterone synthesis by the prepubertal testis. Testosterone 86-98 prolactin Homo sapiens 45-48 4044881-5 1985 Plasma prolactin levels 4 hours following administration of bromocriptine were negatively correlated with the dose of bromocriptine. Bromocriptine 60-73 prolactin Homo sapiens 7-16 4044881-5 1985 Plasma prolactin levels 4 hours following administration of bromocriptine were negatively correlated with the dose of bromocriptine. Bromocriptine 118-131 prolactin Homo sapiens 7-16 2939335-0 1985 [Relation between prolactin and dehydroepiandrosterone sulfate in women with polycystic ovary disease]. Dehydroepiandrosterone Sulfate 32-62 prolactin Homo sapiens 18-27 4087275-3 1985 Treatment with danazol was associated with a reduction in both the breast size and the prolactin level. Danazol 15-22 prolactin Homo sapiens 87-96 4069600-1 1985 Ten patients with prolactin-secreting pituitary adenomas (prolactinoma) and visual dysfunction were treated primarily with bromocriptine. Bromocriptine 123-136 prolactin Homo sapiens 18-27 4078410-3 1985 In the TIP-O (Transient Increase in serum PRL in the Ovulatory phase) group (7 cycles), the serum PRL was significantly increased in the ovulatory phase compared with the follicular phase. tip-o 7-12 prolactin Homo sapiens 42-45 4078410-3 1985 In the TIP-O (Transient Increase in serum PRL in the Ovulatory phase) group (7 cycles), the serum PRL was significantly increased in the ovulatory phase compared with the follicular phase. tip-o 7-12 prolactin Homo sapiens 98-101 2863272-14 1985 In addition, T-47D cells treated with hPRL plus hydrocortisone contained 10-fold more mRNA for PIPs than control cells, suggesting that the hormones" action is at the level of gene expression. piperidine 95-99 prolactin Homo sapiens 38-42 4037017-2 1985 In this study, tritiated leucine placed on the isolated maternal side of amniochorion with adherent decidua was incorporated into newly synthesized tritiated human decidual prolactin. Leucine 25-32 prolactin Homo sapiens 173-182 3929517-3 1985 In 10 patients with an intrasellar tumour (group I), Prl had a positive response to TRH, metoclopramide (MCP), and nomifensine (NOM), both pre- and postoperatively. Metoclopramide 89-103 prolactin Homo sapiens 53-56 3929517-3 1985 In 10 patients with an intrasellar tumour (group I), Prl had a positive response to TRH, metoclopramide (MCP), and nomifensine (NOM), both pre- and postoperatively. Nomifensine 115-126 prolactin Homo sapiens 53-56 4050429-7 1985 However, in both patients bromocriptine administration promptly suppressed PRL levels. Bromocriptine 26-39 prolactin Homo sapiens 75-78 4050429-10 1985 However, in these two boys bromocriptine has proved effective in controlling the PRL/GH oversecretion. Bromocriptine 27-40 prolactin Homo sapiens 81-84 4072731-7 1985 Patients on phenothiazines had higher PRL and lower TSH levels than those on other drugs or without medication, but there was no significant difference in the mean increment by ECT. Phenothiazines 12-26 prolactin Homo sapiens 38-41 4072731-8 1985 Dopamine depresses PRL and TSH secretion. Dopamine 0-8 prolactin Homo sapiens 19-22 3935346-1 1985 We have studied the effects of the TRH related dipeptide histidyl-proline diketopiperazine [cyclo (His-Pro)] on basal and stimulated TSH and PRL secretion in normal volunteers, in patients with microprolactinomas and in patients with primary hypothyroidism. dipeptide histidyl-proline diketopiperazine 47-90 prolactin Homo sapiens 141-144 3935346-1 1985 We have studied the effects of the TRH related dipeptide histidyl-proline diketopiperazine [cyclo (His-Pro)] on basal and stimulated TSH and PRL secretion in normal volunteers, in patients with microprolactinomas and in patients with primary hypothyroidism. emodepside 92-97 prolactin Homo sapiens 141-144 4075538-0 1985 Prolactin and growth hormone dynamics in epileptic patients receiving phenytoin. Phenytoin 70-79 prolactin Homo sapiens 0-9 4075538-2 1985 Mean resting levels of prolactin were higher in patients taking phenytoin (untreated patients 204 mU/l, phenytoin treated patients 302 mU/l), but dynamic responses to metoclopramide and bromocriptine were unaffected. Phenytoin 64-73 prolactin Homo sapiens 23-32 4075538-2 1985 Mean resting levels of prolactin were higher in patients taking phenytoin (untreated patients 204 mU/l, phenytoin treated patients 302 mU/l), but dynamic responses to metoclopramide and bromocriptine were unaffected. Phenytoin 104-113 prolactin Homo sapiens 23-32 4075538-2 1985 Mean resting levels of prolactin were higher in patients taking phenytoin (untreated patients 204 mU/l, phenytoin treated patients 302 mU/l), but dynamic responses to metoclopramide and bromocriptine were unaffected. Bromocriptine 186-199 prolactin Homo sapiens 23-32 2993040-2 1985 With steroid replacement therapy, PRL levels returned to normal, with resumption of normal ovulatory cycles; and the patient became pregnant. Steroids 5-12 prolactin Homo sapiens 34-37 4043929-0 1985 Effects of five days verapamil administration on serum GH and PRL levels. Verapamil 21-30 prolactin Homo sapiens 62-65 4033428-1 1985 We have recently shown that dermorphin (D), a new potent opioid peptide (H-Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) stimulates prolactin (PRL) and growth hormone (GH) secretion in humans. Dermorphin 73-108 prolactin Homo sapiens 121-130 2994332-0 1985 Cyproheptadine-mediated inhibition of growth hormone and prolactin release from pituitary adenoma cells of acromegaly and gigantism in culture. Cyproheptadine 0-14 prolactin Homo sapiens 57-66 3898690-7 1985 Bromocriptine treatment resulted in a sharp but reversible decline of serum prolactin levels followed by a significant reduction of milk production. Bromocriptine 0-13 prolactin Homo sapiens 76-85 3898690-11 1985 Short term prolactin suppression by bromocriptine can reduce milk yield, without complete ablactation. Bromocriptine 36-49 prolactin Homo sapiens 11-20 3929512-10 1985 Positive correlations were observed between FSH and LH (r = 0.41, P less than 0.01), and Prl and LH (r = 0.26, P less than 0.01), whereas Prl and testosterone (r = -0.17, P less than 0.01) were inversely correlated. Luteinizing Hormone 97-99 prolactin Homo sapiens 89-92 4040782-1 1985 It has been established that sodium hydroxybutyrate, prolactin, propranolol and ionol are capable of preventing the depression of the contractile function of the heart and of decreasing the glycogen level in the myocardium, provoked by emotional stress. Glycogen 190-198 prolactin Homo sapiens 53-62 2996735-5 1985 The response of bromocriptine was almost universal with lowering of serum prolactin and reversal of the clinical symptoms, as well as tumor shrinkage of most large adenomas with suprasellar extension. Bromocriptine 16-29 prolactin Homo sapiens 74-83 3931942-0 1985 Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinaemic women after dopamine synthesis blockade. Domperidone 36-47 prolactin Homo sapiens 0-9 3931942-0 1985 Prolactin and TSH responses to both domperidone and TRH in normal and hyperprolactinaemic women after dopamine synthesis blockade. Dopamine 102-110 prolactin Homo sapiens 0-9 3931943-0 1985 Effect of low-dose dopamine infusion on basal and stimulated TSH and prolactin concentrations in man. Dopamine 19-27 prolactin Homo sapiens 69-78 3931943-2 1985 The effect of low-dose DA infusion (0.1 microgram/kg/min) on TSH and prolactin (PRL) concentrations during stimulation with thyrotrophin releasing hormone (TRH) in normal male subjects is reported. Dopamine 23-25 prolactin Homo sapiens 69-78 4008606-4 1985 With reduction of disulfide bonds, there was a shift of the peak I PRL to smaller mol wt peptides. Disulfides 18-27 prolactin Homo sapiens 67-70 4008612-0 1985 Benserazide effects on growth hormone, prolactin, and thyrotropin in normal and acromegalic man. Benserazide 0-11 prolactin Homo sapiens 39-48 4067205-0 1985 Effects of melatonin on PRL secretion during different photoperiods of the day in prepubertal and pubertal healthy subjects. Melatonin 11-20 prolactin Homo sapiens 24-27 4067205-1 1985 The effect of melatonin on PRL secretion has not been established yet. Melatonin 14-23 prolactin Homo sapiens 27-30 4067205-2 1985 In an attempt to establish whether PRL response to melatonin changes in relation to the photoperiods of the day and pubertal maturation, we evaluated PRL plasma levels after melatonin administration in 19 prepubertal and pubertal healthy subjects of both sexes in two different periods of the day: in the morning, when the sensitivity to melatonin is low, and in the afternoon, when the responsiveness to melatonin is higher. Melatonin 51-60 prolactin Homo sapiens 35-38 4067205-3 1985 Melatonin was given im at a dose of 0.2 mg/kg BW PRL plasma levels were determined with double antibody RIA method. Melatonin 0-9 prolactin Homo sapiens 49-52 4067205-5 1985 On the contrary, when melatonin was given in the afternoon, a significant increase in PRL plasma levels was seen in all pubertal subjects; no significant changes were found in 6 prepubertal ones, while in the other 3 a marked decrease could be observed. Melatonin 22-31 prolactin Homo sapiens 86-89 4067205-6 1985 The results reveal that the response of PRL to melatonin depends upon the times of day of administration and on pubertal development. Melatonin 47-56 prolactin Homo sapiens 40-43 2995857-0 1985 Sex steroids modulate prolactin response to naloxone in postmenopausal women. Steroids 4-12 prolactin Homo sapiens 22-31 2995857-0 1985 Sex steroids modulate prolactin response to naloxone in postmenopausal women. Naloxone 44-52 prolactin Homo sapiens 22-31 2995857-4 1985 Naloxone induced a significant PRL increase after CE treatment alone (p less than 0.001) or in combination with MPA (p less than 0.001). Naloxone 0-8 prolactin Homo sapiens 31-34 2995857-6 1985 These data suggest that steroids modulate the stimulatory effect of naloxone on PRL secretion in postmenopausal women. Steroids 24-32 prolactin Homo sapiens 80-83 2995857-6 1985 These data suggest that steroids modulate the stimulatory effect of naloxone on PRL secretion in postmenopausal women. Naloxone 68-76 prolactin Homo sapiens 80-83 3905210-0 1985 Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients. Bromocriptine 10-23 prolactin Homo sapiens 37-46 3905210-1 1985 Bromocriptine (2.5 mg/day orally) produced a significant fall in supine mean arterial pressure in nine hypertensive haemodialysis patients with high serum prolactin levels, without causing significant changes in heart rate. Bromocriptine 0-13 prolactin Homo sapiens 155-164 3905210-2 1985 On bromocriptine, there was a significant decrease in the mean value of both serum prolactin and plasma noradrenaline, without significant changes in the mean value of plasma renin activity. Bromocriptine 3-16 prolactin Homo sapiens 83-92 3928413-3 1985 Within 1 h after oral administration of lisuride, PRL levels decreased significantly (P less than 0.05) and reached the lowest level at 4 h after ingestion and stayed low until 8 h in both normal women and hyperprolactinaemic patients. Lisuride 40-48 prolactin Homo sapiens 50-53 3928413-7 1985 These results suggest that lisuride acts as a long-acting prolactin suppressor and that it has little effects on the secretion of other pituitary hormones. Lisuride 27-35 prolactin Homo sapiens 58-67 4007192-0 1985 Return of menstruation and normalization of prolactin in hyperprolactinemic women with bromocriptine-induced pregnancy. Bromocriptine 87-100 prolactin Homo sapiens 44-53 3923032-3 1985 The increment of TSH levels in the obese group [mean maximum change (delta max), 19.3 +/- 3.0 (+/-SEM) mIU/liter] was significantly higher (P less than 0.025) than that in the control group (delta max, 11.3 +/- 1.3 mIU/liter), whereas PRL levels rose significantly less (P less than 0.025) in these obese women than in the control group (delta max, 738 +/- 132 and 1311 +/- 133 mIU/liter, respectively). Thyrotropin 17-20 prolactin Homo sapiens 235-238 3923032-4 1985 Since serotonin is known to stimulate PRL and inhibit TSH release, deficiency of serotonin has been hypothesized as the cause of this disparity between TSH and PRL levels in obesity. Serotonin 6-15 prolactin Homo sapiens 38-41 3923032-4 1985 Since serotonin is known to stimulate PRL and inhibit TSH release, deficiency of serotonin has been hypothesized as the cause of this disparity between TSH and PRL levels in obesity. Serotonin 81-90 prolactin Homo sapiens 160-163 3927279-4 1985 The basal serum PRL and its response to TRH and metoclopramide remained unchanged with 36 h starvation. Metoclopramide 48-62 prolactin Homo sapiens 16-19 4040632-3 1985 She responded to bromocriptine treatment with restoration of her menses, normalization of circulating prolactin and disappearance of galactorrhoea. Bromocriptine 17-30 prolactin Homo sapiens 102-111 3901563-1 1985 Because of the decreased dopamine concentration in the elderly brain an alteration of the dopaminergic suppression of aldosterone and prolactin incretion was postulated. Dopamine 25-33 prolactin Homo sapiens 134-143 2990210-5 1985 On the contrary, naloxone induced a remarkable increment in the secretion of prolactin via an increased frequency of pulsatile release which is synchronized with pulses of luteinizing hormone. Naloxone 17-25 prolactin Homo sapiens 77-86 3932105-4 1985 Serum prolactin levels decreased significantly (p less than 0.005) from two hours after the administration of bromocriptine and remained in a very low range until the end of the experiment. Bromocriptine 110-123 prolactin Homo sapiens 6-15 4023673-7 1985 Recent findings demonstrate that bromocriptine may cause irreversible tumor fibrosis, which decreases the chances of prolactin normalization by subsequent surgery. Bromocriptine 33-46 prolactin Homo sapiens 117-126 3930984-8 1985 Short-photoperiod exposure increased the ability of DA to suppress PRL secretion, and this effect could be reversed by the presence of an ectopic pituitary graft. Dopamine 52-54 prolactin Homo sapiens 67-70 4007798-5 1985 However, gonadal and reproductive tract tissue weights were markedly reduced and food and water consumption were significantly elevated in PRL-treated birds. Water 90-95 prolactin Homo sapiens 139-142 4018722-1 1985 The aim of this study was to ascertain whether there is a correlation between gonadal steroids and opioid control of prolactin (PRL) secretion. Steroids 86-94 prolactin Homo sapiens 117-126 2987289-0 1985 In vitro modulation of prolactin binding to human mammary carcinoma cells by steroid hormones and prolactin. Steroids 77-93 prolactin Homo sapiens 23-32 2987289-6 1985 Physiological concentrations of 17 beta-estradiol or dihydrotestosterone increased the cellular capacity of hPRL binding. Estradiol 32-49 prolactin Homo sapiens 108-112 2987289-6 1985 Physiological concentrations of 17 beta-estradiol or dihydrotestosterone increased the cellular capacity of hPRL binding. Dihydrotestosterone 53-72 prolactin Homo sapiens 108-112 2987289-7 1985 Pharmacological concentrations of dihydrotestosterone or physiological concentrations of progesterone reduced the binding of [125I]hPRL. Dihydrotestosterone 34-53 prolactin Homo sapiens 131-135 2987289-7 1985 Pharmacological concentrations of dihydrotestosterone or physiological concentrations of progesterone reduced the binding of [125I]hPRL. Progesterone 89-101 prolactin Homo sapiens 131-135 2987289-8 1985 The results provide evidence for complex regulatory mechanisms of PRL binding by human mammary carcinoma cells involving steroid hormones. Steroids 121-137 prolactin Homo sapiens 66-69 3161934-0 1985 Activation of PRL secretion by combined treatment with cyproterone acetate and ethinylestradiol. Cyproterone Acetate 55-74 prolactin Homo sapiens 14-17 3161934-0 1985 Activation of PRL secretion by combined treatment with cyproterone acetate and ethinylestradiol. Ethinyl Estradiol 79-95 prolactin Homo sapiens 14-17 4023466-5 1985 This macromolecular PRL was also bound specifically to Sepharose coupled with anti-PRL, indicating that this macromolecule contained a sequence of PRL in its structure. Sepharose 55-64 prolactin Homo sapiens 20-23 4023466-5 1985 This macromolecular PRL was also bound specifically to Sepharose coupled with anti-PRL, indicating that this macromolecule contained a sequence of PRL in its structure. Sepharose 55-64 prolactin Homo sapiens 83-86 4023466-5 1985 This macromolecular PRL was also bound specifically to Sepharose coupled with anti-PRL, indicating that this macromolecule contained a sequence of PRL in its structure. Sepharose 55-64 prolactin Homo sapiens 83-86 2989726-1 1985 The treatment of a slowly growing invasive prolactinoma with bromocriptine for 8 months resulted in a substantial decrease in plasma prolactin levels despite rapid suprasellar tumor expansion. Bromocriptine 61-74 prolactin Homo sapiens 43-52 3925361-5 1985 In the PRL stimulation tests, the mean +/- SE peak response was significantly greater (p less than 0.002) with domperidone (3,900 +/- 840 mIU/l) than with MIT (1,880 +/- 400 mIU/l) or TRH (2,094 +/- 450 mIU/l). Domperidone 111-122 prolactin Homo sapiens 7-10 3925361-6 1985 In the peripheral DA receptor blockade study the initial domperidone-induced PRL response was not sustained during the domperidone infusion. Domperidone 57-68 prolactin Homo sapiens 77-80 3839061-0 1985 Prolactin secretion during pregnancy and puerperium: response to metoclopramide and interactions with placental hormones. Metoclopramide 65-79 prolactin Homo sapiens 0-9 3839061-1 1985 Prolactin (PRL) response to an intravenous administration of metoclopramide (10 mg) was examined during normal pregnancy and puerperium. Metoclopramide 61-75 prolactin Homo sapiens 0-9 3839061-1 1985 Prolactin (PRL) response to an intravenous administration of metoclopramide (10 mg) was examined during normal pregnancy and puerperium. Metoclopramide 61-75 prolactin Homo sapiens 11-14 3839061-2 1985 Basal PRL and the metoclopramide-induced increase of PRL increased gradually during pregnancy. Metoclopramide 18-32 prolactin Homo sapiens 53-56 3839061-4 1985 A positive correlation between serum progesterone and metoclopramide-induced PRL concentrations was found at week 36 of pregnancy. Metoclopramide 54-68 prolactin Homo sapiens 77-80 3839061-5 1985 In lactating women, metoclopramide always induced higher increases of PRL than did suckling stimulation on the seventh day postpartum. Metoclopramide 20-34 prolactin Homo sapiens 70-73 4020203-3 1985 The plasma PRL levels rose significantly (p less than 0.001 approximately 0.05) after an intravenous bolus of 10mg metoclopramide (MCP). Metoclopramide 115-129 prolactin Homo sapiens 11-14 4020203-3 1985 The plasma PRL levels rose significantly (p less than 0.001 approximately 0.05) after an intravenous bolus of 10mg metoclopramide (MCP). Metoclopramide 131-134 prolactin Homo sapiens 11-14 4020203-6 1985 The plasma PRL levels dropped significantly (p less than 0.001 approximately 0.01) after an oral administration of 2.5mg bromocriptine (BRC), and the PRL release from the pituitary by MCP was suppressed significantly (p less than 0.001) by pretreatment with BRC in the puerperium. Bromocriptine 121-134 prolactin Homo sapiens 11-14 4020203-6 1985 The plasma PRL levels dropped significantly (p less than 0.001 approximately 0.01) after an oral administration of 2.5mg bromocriptine (BRC), and the PRL release from the pituitary by MCP was suppressed significantly (p less than 0.001) by pretreatment with BRC in the puerperium. Bromocriptine 121-134 prolactin Homo sapiens 150-153 4020206-6 1985 From the amniotic fluid, seven components of the PRL were eluted at NaCl concentrations from 0.065M to 0.13M in 0.02M Tris-HCl, pH 8.0. Sodium Chloride 68-72 prolactin Homo sapiens 49-52 4020206-6 1985 From the amniotic fluid, seven components of the PRL were eluted at NaCl concentrations from 0.065M to 0.13M in 0.02M Tris-HCl, pH 8.0. Tromethamine 118-122 prolactin Homo sapiens 49-52 4020206-6 1985 From the amniotic fluid, seven components of the PRL were eluted at NaCl concentrations from 0.065M to 0.13M in 0.02M Tris-HCl, pH 8.0. Hydrochloric Acid 123-126 prolactin Homo sapiens 49-52 4041291-0 1985 [A case of male prolactinoma presenting extremely high serum prolactin levels and biphasic response to CB-154 suppression test]. Bromocriptine 103-109 prolactin Homo sapiens 16-25 4041291-9 1985 A biphasic response was demonstrated in response to CB-154 suppression test to PRL secretion, that is, CB-154 stimulated PRL release initially (up to 90 min) and suppressed thereafter. Bromocriptine 52-58 prolactin Homo sapiens 79-82 4041291-9 1985 A biphasic response was demonstrated in response to CB-154 suppression test to PRL secretion, that is, CB-154 stimulated PRL release initially (up to 90 min) and suppressed thereafter. Bromocriptine 52-58 prolactin Homo sapiens 121-124 4041291-9 1985 A biphasic response was demonstrated in response to CB-154 suppression test to PRL secretion, that is, CB-154 stimulated PRL release initially (up to 90 min) and suppressed thereafter. Bromocriptine 103-109 prolactin Homo sapiens 79-82 4041291-9 1985 A biphasic response was demonstrated in response to CB-154 suppression test to PRL secretion, that is, CB-154 stimulated PRL release initially (up to 90 min) and suppressed thereafter. Bromocriptine 103-109 prolactin Homo sapiens 121-124 4041291-10 1985 Serum PRL levels (178, 400 ng/ml) reached to peak about 90 min after CB-154 administration. Bromocriptine 69-75 prolactin Homo sapiens 6-9 3923752-5 1985 Furthermore the 7 patients with prolactinomas studied both before and after bromocriptine-induced Prl normalization showed no difference in all the parameters of LH pulsatility in both conditions. Bromocriptine 76-89 prolactin Homo sapiens 98-101 4002999-3 1985 After iv injection of metoclopramide (MCP), a dopamine (DA) receptor blocker, the TSH and prolactin (Prl) increments in the critically ill patients were significantly lower than in the controls. Metoclopramide 22-36 prolactin Homo sapiens 101-104 4002999-3 1985 After iv injection of metoclopramide (MCP), a dopamine (DA) receptor blocker, the TSH and prolactin (Prl) increments in the critically ill patients were significantly lower than in the controls. Metoclopramide 38-41 prolactin Homo sapiens 101-104 3160473-6 1985 However, the enhancement of both PRL and LH release indicates that this calcium antagonist might interfere with the dopaminergic tonus. Calcium 72-79 prolactin Homo sapiens 33-36 4064503-2 1985 Five out of the six patients with high serum prolactin due to prolactinomas showed rapid and dramatic reduction in tumour size when treated with bromocriptine. Bromocriptine 145-158 prolactin Homo sapiens 45-54 2859194-7 1985 These drugs did, however, produce other biological responses at this time of year; pimozide increased serum PRL levels, and phenoxybenzamine decreased arterial blood pressure. Pimozide 83-91 prolactin Homo sapiens 108-111 3894101-1 1985 The clinical use of anti-dopaminergic drugs to stimulate plasma PRL levels, to induce lactogenesis and maintain an adequate lactation has been widely suggested, taking into consideration the main inhibitory role of hypothalamic dopamine on PRL secretion. Dopamine 25-33 prolactin Homo sapiens 64-67 3894101-1 1985 The clinical use of anti-dopaminergic drugs to stimulate plasma PRL levels, to induce lactogenesis and maintain an adequate lactation has been widely suggested, taking into consideration the main inhibitory role of hypothalamic dopamine on PRL secretion. Dopamine 25-33 prolactin Homo sapiens 240-243 3894101-5 1985 In both groups domperidone-treated subjects always showed baseline PRL levels and daily milk yield significantly higher than those of the placebo group (P less than 0.01). Domperidone 15-26 prolactin Homo sapiens 67-70 2413748-1 1985 Lisuride hydrogen maleate (LHM, SH-1072), a dopaminergic agonist and therefore an inhibitor of prolactin (PRL) secretion, were administered to 12 patients with mild to moderate BPH in order to evaluate the clinical effectiveness. Lisuride 0-25 prolactin Homo sapiens 106-109 2858494-6 1985 In 8 of 9 somatotroph adenomas that concomitantly secreted PRL, the addition of GHRH likewise increased PRL release. ghrh 80-84 prolactin Homo sapiens 104-107 2858494-7 1985 Omission of extracellular Ca2+ blocked the stimulatory effect of GHRH on GH and PRL secretion. ghrh 65-69 prolactin Homo sapiens 80-83 2858494-8 1985 When cells were coincubated with 0.1 nM somatostatin, GH and PRL secretion induced by 10 nM GHRH were completely blocked in most adenomas. ghrh 92-96 prolactin Homo sapiens 61-64 2858494-12 1985 In prolactinoma cells, somatostatin and dopamine unequivocally suppressed PRL secretion; however, other stimuli including GHRH, VIP, and CRF were ineffective. Dopamine 40-48 prolactin Homo sapiens 74-77 2984281-7 1985 CsA also did not alter the binding of a beta-receptor antagonist to MNC, again suggesting that CsA was specific in its antagonism of PRL binding. Cyclosporine 95-98 prolactin Homo sapiens 133-136 2984281-0 1985 Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. Cyclosporine 85-97 prolactin Homo sapiens 0-9 2984281-0 1985 Prolactin receptors on human T and B lymphocytes: antagonism of prolactin binding by cyclosporine. Cyclosporine 85-97 prolactin Homo sapiens 64-73 2984281-2 1985 Cyclosporine (CsA), an immunosuppressive cyclic endecapeptide utilized to prolong graft survival in human organ transplant patients, affects PRL binding to MNC. Cyclosporine 0-12 prolactin Homo sapiens 141-144 2984281-2 1985 Cyclosporine (CsA), an immunosuppressive cyclic endecapeptide utilized to prolong graft survival in human organ transplant patients, affects PRL binding to MNC. Cyclosporine 14-17 prolactin Homo sapiens 141-144 2984281-3 1985 At concentrations of CsA from 10(-10) through 10(-8) M, the amount of PRL bound to MNC markedly increased to ca. Cyclosporine 21-24 prolactin Homo sapiens 70-73 2984281-4 1985 400% of controls, whereas CsA concentrations of 10(-6) and 10(-5) M totally inhibited PRL binding to lymphocytes. Cyclosporine 26-29 prolactin Homo sapiens 86-89 2984281-5 1985 The ability of low concentrations of CsA to enhance PRL binding was temperature-dependent and did not occur when binding assays were conducted at 4 degrees C. PRL displaced [3H]CsA from lymphocytes with ca. Cyclosporine 37-40 prolactin Homo sapiens 52-55 2984281-10 1985 Finally, PRL receptors were identified on purified populations of T and B lymphocytes isolated from human spleens, and CsA again inhibited PRL binding at concentrations of 10(-7) and 10(-6) M. The presence of PRL receptors on T and B lymphocytes suggests that PRL may be involved in the regulation of humoral and cell-mediated immunity, and that one effect of CsA on immune function may be its ability to inhibit the effects of PRL action on these lymphocytes. Cyclosporine 119-122 prolactin Homo sapiens 139-142 2984281-10 1985 Finally, PRL receptors were identified on purified populations of T and B lymphocytes isolated from human spleens, and CsA again inhibited PRL binding at concentrations of 10(-7) and 10(-6) M. The presence of PRL receptors on T and B lymphocytes suggests that PRL may be involved in the regulation of humoral and cell-mediated immunity, and that one effect of CsA on immune function may be its ability to inhibit the effects of PRL action on these lymphocytes. Cyclosporine 119-122 prolactin Homo sapiens 139-142 2984281-10 1985 Finally, PRL receptors were identified on purified populations of T and B lymphocytes isolated from human spleens, and CsA again inhibited PRL binding at concentrations of 10(-7) and 10(-6) M. The presence of PRL receptors on T and B lymphocytes suggests that PRL may be involved in the regulation of humoral and cell-mediated immunity, and that one effect of CsA on immune function may be its ability to inhibit the effects of PRL action on these lymphocytes. Cyclosporine 119-122 prolactin Homo sapiens 139-142 2984281-10 1985 Finally, PRL receptors were identified on purified populations of T and B lymphocytes isolated from human spleens, and CsA again inhibited PRL binding at concentrations of 10(-7) and 10(-6) M. The presence of PRL receptors on T and B lymphocytes suggests that PRL may be involved in the regulation of humoral and cell-mediated immunity, and that one effect of CsA on immune function may be its ability to inhibit the effects of PRL action on these lymphocytes. Cyclosporine 119-122 prolactin Homo sapiens 139-142 2985726-9 1985 The prolactin-stimulating effects of TRH may be mediated by cyclic AMP. Cyclic AMP 60-70 prolactin Homo sapiens 4-13 2985726-2 1985 High K+ concentrations, hypothalamic extract, synthetic thyrotrophin-releasing hormone (TRH) and dibutyryl cyclic AMP (dbcAMP) all stimulated release of prolactin from control (non EGTA-treated) hemianterior pituitary glands. Cyclic AMP 107-117 prolactin Homo sapiens 153-162 2985726-2 1985 High K+ concentrations, hypothalamic extract, synthetic thyrotrophin-releasing hormone (TRH) and dibutyryl cyclic AMP (dbcAMP) all stimulated release of prolactin from control (non EGTA-treated) hemianterior pituitary glands. Bucladesine 119-125 prolactin Homo sapiens 153-162 2985726-2 1985 High K+ concentrations, hypothalamic extract, synthetic thyrotrophin-releasing hormone (TRH) and dibutyryl cyclic AMP (dbcAMP) all stimulated release of prolactin from control (non EGTA-treated) hemianterior pituitary glands. Egtazic Acid 181-185 prolactin Homo sapiens 153-162 2985726-4 1985 Reduction of Ca2+ availability with EGTA or verapamil reduced basal release of prolactin, prevented the prolactin-stimulating effects of high K+ concentrations and TRH, and markedly attenuated responses to hypothalamic extract and dbcAMP, EGTA being more effective than verapamil. Egtazic Acid 36-40 prolactin Homo sapiens 79-88 2985726-4 1985 Reduction of Ca2+ availability with EGTA or verapamil reduced basal release of prolactin, prevented the prolactin-stimulating effects of high K+ concentrations and TRH, and markedly attenuated responses to hypothalamic extract and dbcAMP, EGTA being more effective than verapamil. Egtazic Acid 36-40 prolactin Homo sapiens 104-113 2985726-4 1985 Reduction of Ca2+ availability with EGTA or verapamil reduced basal release of prolactin, prevented the prolactin-stimulating effects of high K+ concentrations and TRH, and markedly attenuated responses to hypothalamic extract and dbcAMP, EGTA being more effective than verapamil. Verapamil 44-53 prolactin Homo sapiens 79-88 2985726-4 1985 Reduction of Ca2+ availability with EGTA or verapamil reduced basal release of prolactin, prevented the prolactin-stimulating effects of high K+ concentrations and TRH, and markedly attenuated responses to hypothalamic extract and dbcAMP, EGTA being more effective than verapamil. Verapamil 44-53 prolactin Homo sapiens 104-113 2985726-6 1985 These results suggest that both Ca2+ and cyclic AMP may act as intracellular mediators in the release of prolactin. Cyclic AMP 41-51 prolactin Homo sapiens 105-114 2985726-8 1985 Although influx from the medium may be the major source of Ca2+, endogenous stores of Ca2+, perhaps mobilized by dbcAMP, may be able to maintain some release of prolactin. Bucladesine 113-119 prolactin Homo sapiens 161-170 3989426-2 1985 Doves given injections of prolactin twice a day starting on day 4 of incubation, during a 10-day period of isolation from their mates and nests, showed a higher persistence of incubation behaviour than doves injected with saline vehicle. Sodium Chloride 222-228 prolactin Homo sapiens 26-35 3159606-0 1985 Calcium mobilization potentiates prolactin release induced by protein kinase C activators. Calcium 0-7 prolactin Homo sapiens 33-42 3159606-1 1985 The in vitro effect of synthetic diacylglycerol (DG) and phorbol myristate acetate (PMA), potent stimulators of protein kinase C, was studied on prolactin release. Diglycerides 33-47 prolactin Homo sapiens 145-154 3159606-1 1985 The in vitro effect of synthetic diacylglycerol (DG) and phorbol myristate acetate (PMA), potent stimulators of protein kinase C, was studied on prolactin release. Tetradecanoylphorbol Acetate 57-82 prolactin Homo sapiens 145-154 3159606-1 1985 The in vitro effect of synthetic diacylglycerol (DG) and phorbol myristate acetate (PMA), potent stimulators of protein kinase C, was studied on prolactin release. Tetradecanoylphorbol Acetate 84-87 prolactin Homo sapiens 145-154 3159606-4 1985 The effect of Ca2+ mobilization on PMA-, synthetic DG- or phospholipase C-induced prolactin release was examined. Tetradecanoylphorbol Acetate 35-38 prolactin Homo sapiens 82-91 3159606-5 1985 A23187 at 400 nM or 2 ng/ml maitotoxin, a Ca2+ channel activator, did not affect prolactin release by themselves, but enhanced the release of prolactin induced by DG, PMA or phospholipase C. The stimulatory effects of DG, PMA and phospholipase C on prolactin release were reduced by co-incubation with dopamine. Calcimycin 0-6 prolactin Homo sapiens 142-151 3159606-5 1985 A23187 at 400 nM or 2 ng/ml maitotoxin, a Ca2+ channel activator, did not affect prolactin release by themselves, but enhanced the release of prolactin induced by DG, PMA or phospholipase C. The stimulatory effects of DG, PMA and phospholipase C on prolactin release were reduced by co-incubation with dopamine. Calcimycin 0-6 prolactin Homo sapiens 142-151 3159606-5 1985 A23187 at 400 nM or 2 ng/ml maitotoxin, a Ca2+ channel activator, did not affect prolactin release by themselves, but enhanced the release of prolactin induced by DG, PMA or phospholipase C. The stimulatory effects of DG, PMA and phospholipase C on prolactin release were reduced by co-incubation with dopamine. Dopamine 302-310 prolactin Homo sapiens 142-151 3159606-5 1985 A23187 at 400 nM or 2 ng/ml maitotoxin, a Ca2+ channel activator, did not affect prolactin release by themselves, but enhanced the release of prolactin induced by DG, PMA or phospholipase C. The stimulatory effects of DG, PMA and phospholipase C on prolactin release were reduced by co-incubation with dopamine. Dopamine 302-310 prolactin Homo sapiens 142-151 3159606-7 1985 Dopamine appears to inhibit prolactin release at a point distal to the DG-enhanced stimulation of the process. Dopamine 0-8 prolactin Homo sapiens 28-37 4022265-5 1985 Aluminum enhanced the permeability of the blood-brain barrier to labelled prolactin, thyroxine, cortisol, growth hormone, N-Tyr-DSIP and rat luteinizing hormone, but not to labelled TSH, iodide, or human luteinizing hormone, a substance with an octanol coefficient markedly different from that of luteinizing hormone from the rat. Aluminum 0-8 prolactin Homo sapiens 74-83 3998551-4 1985 In patients in group 2 who had successful pregnancies following incomplete resection of pituitary adenoma in combination with bromocriptine or bromocriptine therapy alone, high PRL levels were maintained from early in gestation until term. Bromocriptine 126-139 prolactin Homo sapiens 177-180 3998551-4 1985 In patients in group 2 who had successful pregnancies following incomplete resection of pituitary adenoma in combination with bromocriptine or bromocriptine therapy alone, high PRL levels were maintained from early in gestation until term. Bromocriptine 143-156 prolactin Homo sapiens 177-180 2994694-1 1985 2) Effects of a dopaminergic agonist, ibopamine, on the regulation of prolactin and gonadotropin secretion (LH, FSH)]. ibopamine 38-47 prolactin Homo sapiens 70-79 4014894-4 1985 HGH and bromocriptine therapy is initiated, resulting in and increase in height and a decrease of prolactin. Bromocriptine 8-21 prolactin Homo sapiens 98-107 2859725-3 1985 When ACTH-Prl adenoma cells were exposed to ovine corticotrophin-releasing factor (CRF), a dose-dependent increase in both ACTH and Prl secretion was observed, which was blocked by coincubation with hydrocortisone. Hydrocortisone 199-213 prolactin Homo sapiens 10-13 2984281-5 1985 The ability of low concentrations of CsA to enhance PRL binding was temperature-dependent and did not occur when binding assays were conducted at 4 degrees C. PRL displaced [3H]CsA from lymphocytes with ca. Cyclosporine 37-40 prolactin Homo sapiens 159-162 2984281-5 1985 The ability of low concentrations of CsA to enhance PRL binding was temperature-dependent and did not occur when binding assays were conducted at 4 degrees C. PRL displaced [3H]CsA from lymphocytes with ca. Tritium 174-176 prolactin Homo sapiens 159-162 2984281-5 1985 The ability of low concentrations of CsA to enhance PRL binding was temperature-dependent and did not occur when binding assays were conducted at 4 degrees C. PRL displaced [3H]CsA from lymphocytes with ca. Cyclosporine 177-180 prolactin Homo sapiens 159-162 2859725-3 1985 When ACTH-Prl adenoma cells were exposed to ovine corticotrophin-releasing factor (CRF), a dose-dependent increase in both ACTH and Prl secretion was observed, which was blocked by coincubation with hydrocortisone. Hydrocortisone 199-213 prolactin Homo sapiens 132-135 3927887-0 1985 Long-term bromocriptine therapy may restore the inhibitory control of prolactin release in some patients with pathological hyperprolactinemia. Bromocriptine 10-23 prolactin Homo sapiens 70-79 3927887-3 1985 The basal PRL level after withdrawal of bromocriptine therapy was significantly lower (p less than 0.001) than that before therapy. Bromocriptine 40-53 prolactin Homo sapiens 10-13 3927887-4 1985 All patients had blunted PRL stimulatory responses to TRH and metoclopramide (% delta 16.0 +/- 5.6%) before treatment. Metoclopramide 62-76 prolactin Homo sapiens 25-28 3927887-5 1985 After withdrawal of bromocriptine, PRL responses to stimulatory tests were significantly improved in seven patients (termed "responders", % delta 376 +/- 55%) but remained unchanged in eight patients (termed "non-responders", % delta 9.2 +/- 3.0%). Bromocriptine 20-33 prolactin Homo sapiens 35-38 3995129-1 1985 Concentrations of human prolactin (hPrl) greater than or equal to 600 ng/ml produced inhibition of progestin production in cultures of granulosa cells pooled from follicles of women stimulated with clomiphene citrate-human chorionic gonadotropin (hCG). Clomiphene 198-216 prolactin Homo sapiens 24-33 3995129-1 1985 Concentrations of human prolactin (hPrl) greater than or equal to 600 ng/ml produced inhibition of progestin production in cultures of granulosa cells pooled from follicles of women stimulated with clomiphene citrate-human chorionic gonadotropin (hCG). Clomiphene 198-216 prolactin Homo sapiens 35-39 3987071-0 1985 Naloxone reduces the fenfluramine-induced prolactin release in man. Naloxone 0-8 prolactin Homo sapiens 42-51 3987071-0 1985 Naloxone reduces the fenfluramine-induced prolactin release in man. Fenfluramine 21-33 prolactin Homo sapiens 42-51 3987071-1 1985 In order to ascertain whether there is a relation between opioids and the serotoninergic system in prolactin (PRL) secretion increase, we investigated in seven healthy men (21 to 26 years of age) the effect of naloxone, a specific opioid antagonist, on PRL secretion induced by fenfluramine, a drug that stimulates serotonin release and inhibits its re-uptake. Serotonin 74-83 prolactin Homo sapiens 99-108 3987071-2 1985 We observed that subjects receiving fenfluramine (60 mg orally) had a significantly (P less than 0.001) higher increase in PRL plasma levels than the controls receiving placebo. Fenfluramine 36-48 prolactin Homo sapiens 123-126 3987071-3 1985 In all subjects naloxone infusion at a dose of 15 mg caused a significant reduction (P less than 0.0005) in the PRL response to fenfluramine. Naloxone 16-24 prolactin Homo sapiens 112-115 3987071-3 1985 In all subjects naloxone infusion at a dose of 15 mg caused a significant reduction (P less than 0.0005) in the PRL response to fenfluramine. Fenfluramine 128-140 prolactin Homo sapiens 112-115 3987071-6 1985 It seems that in man, therefore, there is an interplay between opiates and the serotoninergic system in the facilitatory influence on PRL release. Opiate Alkaloids 63-70 prolactin Homo sapiens 134-137 4042986-0 1985 Disturbed prolactin responses to dopamine-related substances in patients with acromegaly and hyperprolactinemia. Dopamine 33-41 prolactin Homo sapiens 10-19 4042986-2 1985 In order to clarify the dopaminergic regulation of PRL secretion in patients with acromegaly and hyperprolactinemia, the effects of nomifensine, a central dopamine agonist, FK 33-824, a centrally antidopaminergically acting agent, and domperidone, a peripheral dopamine antagonist, on plasma PRL in these patients were studied. Dopamine 24-32 prolactin Homo sapiens 51-54 3987929-0 1985 Pergolide mesylate inhibits exercise-induced prolactin release in man. Pergolide 0-18 prolactin Homo sapiens 45-54 2986400-4 1985 A direct positive correlation was demonstrated between the plasma Prl level and the number of [3H]TRH binding sites (rho: 0.729 P less than 0.001). Tritium 95-97 prolactin Homo sapiens 66-69 3882737-1 1985 To assess the effectiveness of bromocriptine in reducing the size of PRL-secreting macroadenomas with extrasellar extension, we conducted a prospective multicenter trial in patients without prior radiotherapy, applying a standard protocol of treatment and tumor size evaluation. Bromocriptine 31-44 prolactin Homo sapiens 69-72 3882737-10 1985 Because of the excellent results found in most of the patients in this series, we suggest that therapy with bromocriptine should be considered as initial management for patients with PRL-secreting macroadenomas. Bromocriptine 108-121 prolactin Homo sapiens 183-186 3919052-11 1985 The mean peak values after domperidone were similar before and after BRC treatment, but the absolute increase over the basal value was much higher after BRC; PRL response to domperidone was present in 16% of 19 patients before BRC treatment and in 74% after BRC. Domperidone 174-185 prolactin Homo sapiens 158-161 3919052-13 1985 The variations in PRL responses to TRH and domperidone suggest profound modification of PRL secretion after BRC treatment. Domperidone 43-54 prolactin Homo sapiens 18-21 3919052-13 1985 The variations in PRL responses to TRH and domperidone suggest profound modification of PRL secretion after BRC treatment. Domperidone 43-54 prolactin Homo sapiens 88-91 3919054-1 1985 We investigated whether long term cysteamine therapy in cystinotic children altered their basal and stimulated serum PRL levels. Cysteamine 34-44 prolactin Homo sapiens 117-120 3919054-2 1985 Five subjects who had normal plasma PRL responses to TRH stimulation before cysteamine treatment each had a lower basal PRL level and a blunted PRL response during long term (19-59 months) cysteamine therapy. Cysteamine 76-86 prolactin Homo sapiens 120-123 3919054-2 1985 Five subjects who had normal plasma PRL responses to TRH stimulation before cysteamine treatment each had a lower basal PRL level and a blunted PRL response during long term (19-59 months) cysteamine therapy. Cysteamine 76-86 prolactin Homo sapiens 120-123 3919054-7 1985 These findings suggest that cysteamine alters PRL secretion in humans. Cysteamine 28-38 prolactin Homo sapiens 46-49 3972968-2 1985 The role of salsolinol, a minor constituent of beer, in beer-induced PRL secretion was investigated in humans and rats. salsolinol 12-22 prolactin Homo sapiens 69-72 4031381-0 1985 Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly. dironyl 35-44 prolactin Homo sapiens 55-58 4031381-3 1985 In PHP, PRL levels were significantly reduced up to 300 min after terguride with a nadir (45 +/- 4.0% SE) significantly lower (p less than 0.05) than the one observed in the 8 normal subjects (72 +/- 3.5%). dironyl 66-75 prolactin Homo sapiens 8-11 4031381-8 1985 Terguride and bromocriptine reduced PRL levels in acromegalics (p less than 0.01) without any significant difference between the two drug. dironyl 0-9 prolactin Homo sapiens 36-39 4031381-8 1985 Terguride and bromocriptine reduced PRL levels in acromegalics (p less than 0.01) without any significant difference between the two drug. Bromocriptine 14-27 prolactin Homo sapiens 36-39 4031381-9 1985 0.2 mg terguride bid given for 15 days to 7 healthy volunteers significantly reduced both basal and sulpiride (25 mg im)-stimulated PRL levels. dironyl 7-16 prolactin Homo sapiens 132-135 4031381-9 1985 0.2 mg terguride bid given for 15 days to 7 healthy volunteers significantly reduced both basal and sulpiride (25 mg im)-stimulated PRL levels. Sulpiride 100-109 prolactin Homo sapiens 132-135 3982277-1 1985 A group of 14 healthy subjects received 50 mg/kg body weight of 2 deoxy-D-glucose (2DG) IV in a 20-minute infusion to induce glucoprivation and stimulate the release of growth hormone (GH), prolactin (PRL), pancreatic polypeptide (hPP), and catecholamines. deoxy-d-glucose 66-81 prolactin Homo sapiens 190-199 3982277-1 1985 A group of 14 healthy subjects received 50 mg/kg body weight of 2 deoxy-D-glucose (2DG) IV in a 20-minute infusion to induce glucoprivation and stimulate the release of growth hormone (GH), prolactin (PRL), pancreatic polypeptide (hPP), and catecholamines. Deoxyglucose 83-86 prolactin Homo sapiens 190-199 3982277-7 1985 Clonidine administration significantly reduced total catecholamine, pancreatic polypeptide, and prolactin response to 2DG while opiate receptor blockade with naloxone (10 mg IV bolus followed by 2 mg/hr) did not affect catecholamine and pancreatic polypeptide response but did slightly attenuate the GH and PRL response to glucoprivation. Clonidine 0-9 prolactin Homo sapiens 96-105 3982277-7 1985 Clonidine administration significantly reduced total catecholamine, pancreatic polypeptide, and prolactin response to 2DG while opiate receptor blockade with naloxone (10 mg IV bolus followed by 2 mg/hr) did not affect catecholamine and pancreatic polypeptide response but did slightly attenuate the GH and PRL response to glucoprivation. Clonidine 0-9 prolactin Homo sapiens 307-310 3982277-7 1985 Clonidine administration significantly reduced total catecholamine, pancreatic polypeptide, and prolactin response to 2DG while opiate receptor blockade with naloxone (10 mg IV bolus followed by 2 mg/hr) did not affect catecholamine and pancreatic polypeptide response but did slightly attenuate the GH and PRL response to glucoprivation. Deoxyglucose 118-121 prolactin Homo sapiens 96-105 3921862-4 1985 Morphine administration induced a prompt, significant increase in serum TSH and PRL in all subjects. Morphine 0-8 prolactin Homo sapiens 80-83 3921862-5 1985 The degree of PRL release after morphine was similar in the two groups, while, as regards TSH, the increase was more evident in hypothyroid subjects. Morphine 32-40 prolactin Homo sapiens 14-17 3921862-9 1985 Moreover, in 5 other euthyroid volunteers, morphine significantly enhanced the response of TSH and PRL to TRH stimulation (200 micrograms i.v.). Morphine 43-51 prolactin Homo sapiens 99-102 3921862-10 1985 These data demonstrate that morphine exerts a stimulatory action on TSH and PRL secretion: the possible mode of action of this drug and the physiologic significance of these findings are discussed. Morphine 28-36 prolactin Homo sapiens 76-79 3976792-3 1985 In the present study the prolactin production by explants of normal, luteal phase defective, progesterone-corrected luteal phase defective, and clomiphene- or follicle-stimulating hormone/luteinizing hormone-corrected luteal phase defective late secretory endometrium was measured over 96 hours at 24-hour intervals. Progesterone 93-105 prolactin Homo sapiens 25-34 3976792-3 1985 In the present study the prolactin production by explants of normal, luteal phase defective, progesterone-corrected luteal phase defective, and clomiphene- or follicle-stimulating hormone/luteinizing hormone-corrected luteal phase defective late secretory endometrium was measured over 96 hours at 24-hour intervals. Clomiphene 144-154 prolactin Homo sapiens 25-34 3976792-5 1985 The prolactin production of normal late secretory endometrium rose over 96 hours under progesterone stimulation. Progesterone 87-99 prolactin Homo sapiens 4-13 3987929-1 1985 The effects of Pergolide, a potent dopamine agonist, on exercise-induced plasma prolactin (PRL) changes were studied in normal men. Pergolide 15-24 prolactin Homo sapiens 80-89 3987929-3 1985 In both circumstances, treatment with Pergolide, when compared with placebo or control values, resulted in a significant suppression of basal PRL (P less than 0.001) as well as of exercise-induced PRL increase (P less than 0.01). Pergolide 38-47 prolactin Homo sapiens 142-145 3987929-3 1985 In both circumstances, treatment with Pergolide, when compared with placebo or control values, resulted in a significant suppression of basal PRL (P less than 0.001) as well as of exercise-induced PRL increase (P less than 0.01). Pergolide 38-47 prolactin Homo sapiens 197-200 3157164-2 1985 Forty-two patients with prolactin-secreting pituitary adenoma (prolactinoma) demonstrated by a radiologically abnormal sella turcica and hyperprolactinaemia were treated with bromocriptine. Bromocriptine 175-188 prolactin Homo sapiens 24-33 3157164-3 1985 Baseline serum prolactin levels, which before treatment correlated with the size of the adenoma, returned to normal under bromocriptine in 30 out of 36 cases; in 6 female patients, however, they were lowered but remained moderately high. Bromocriptine 122-135 prolactin Homo sapiens 15-24 3974416-0 1985 Variations of prolactin content in human cerebrospinal fluid after metoclopramide and morphine. Metoclopramide 67-81 prolactin Homo sapiens 14-23 3974416-0 1985 Variations of prolactin content in human cerebrospinal fluid after metoclopramide and morphine. Morphine 86-94 prolactin Homo sapiens 14-23 3974416-4 1985 Serum and CSF PRL values after metoclopramide administration increased earlier and to a greater extent than after morphine. Metoclopramide 31-45 prolactin Homo sapiens 14-17 3974416-5 1985 Furthermore, the metoclopramide induced CSF PRL increase immediately followed the serum peak, whereas after morphine administration an evident delay in the CSF hormone peak with respect to the serum increase was found. Metoclopramide 17-31 prolactin Homo sapiens 44-47 3976764-4 1985 Dopamine infusion rates as low as 0.004 micrograms/kg/min, which were associated with physiologic serum dopamine levels, produced significant (p less than 0.01) suppression of prolactin in normal women and in normal males (p less than 0.05). Dopamine 0-8 prolactin Homo sapiens 176-185 3976764-4 1985 Dopamine infusion rates as low as 0.004 micrograms/kg/min, which were associated with physiologic serum dopamine levels, produced significant (p less than 0.01) suppression of prolactin in normal women and in normal males (p less than 0.05). Dopamine 104-112 prolactin Homo sapiens 176-185 3976764-5 1985 In contrast, a 10-fold increase in the dopamine infusion rate, 0.04 micrograms/kg/min, was required in the hyperprolactinemic subjects to produce prolactin suppression similar to that found in the control subjects. Dopamine 39-47 prolactin Homo sapiens 112-121 3976764-6 1985 Hence, prolactin secretion in both tumors and other hyperprolactinemic states is associated with a resistance to suppression by dopamine. Dopamine 128-136 prolactin Homo sapiens 7-16 3993881-5 1985 Those patients who received meptazinol showed elevated prolactin levels: this may be an indicator of agonist activity at the mu 1 opioid receptor. Meptazinol 28-38 prolactin Homo sapiens 55-64 3977547-0 1985 Evaluating prolactin response to dopamine agonists in schizophrenia. Dopamine 33-41 prolactin Homo sapiens 11-20 3977547-2 1985 Serum prolactin (PRL) level was assessed after challenges with apomorphine hydrochloride, saline, dopamine hydrochloride, or levodopa-carbidopa (Sinemet) in 19 control and 38 chronic schizophrenic subjects. Sodium Chloride 90-96 prolactin Homo sapiens 6-15 3977547-2 1985 Serum prolactin (PRL) level was assessed after challenges with apomorphine hydrochloride, saline, dopamine hydrochloride, or levodopa-carbidopa (Sinemet) in 19 control and 38 chronic schizophrenic subjects. Sodium Chloride 90-96 prolactin Homo sapiens 17-20 3977547-2 1985 Serum prolactin (PRL) level was assessed after challenges with apomorphine hydrochloride, saline, dopamine hydrochloride, or levodopa-carbidopa (Sinemet) in 19 control and 38 chronic schizophrenic subjects. Levodopa 125-133 prolactin Homo sapiens 6-15 3977547-2 1985 Serum prolactin (PRL) level was assessed after challenges with apomorphine hydrochloride, saline, dopamine hydrochloride, or levodopa-carbidopa (Sinemet) in 19 control and 38 chronic schizophrenic subjects. Carbidopa 134-143 prolactin Homo sapiens 6-15 3977547-4 1985 High correlations existed between baseline PRL level and any subsequent absolute measure of PRL after administration of a dopamine agonist or placebo. Dopamine 122-130 prolactin Homo sapiens 43-46 3977547-4 1985 High correlations existed between baseline PRL level and any subsequent absolute measure of PRL after administration of a dopamine agonist or placebo. Dopamine 122-130 prolactin Homo sapiens 92-95 3977547-7 1985 Percent PRL level decrease after apomorphine administration was significantly greater in normal subjects than in schizophrenics. Apomorphine 33-44 prolactin Homo sapiens 8-11 3977547-9 1985 Prolactin responses after dopamine or levodopa-carbidopa did not differ; however, placebo correction was not possible. Dopamine 26-34 prolactin Homo sapiens 0-9 3919915-7 1985 Weaker relationships were found between DHT and oestradiol, and between testosterone and PRL. Testosterone 72-84 prolactin Homo sapiens 89-92 3978163-0 1985 Prolactin response to morphine in depression. Morphine 22-30 prolactin Homo sapiens 0-9 3978163-3 1985 Morphine stimulated prolactin secretion. Morphine 0-8 prolactin Homo sapiens 20-29 4017937-2 1985 Prolactin levels temporary rise during the first day of clomipramine or amitriptyline treatment in 6 patients out of 11, with a lag in relation to the drug plasma peak. Clomipramine 56-68 prolactin Homo sapiens 0-9 4017937-2 1985 Prolactin levels temporary rise during the first day of clomipramine or amitriptyline treatment in 6 patients out of 11, with a lag in relation to the drug plasma peak. Amitriptyline 72-85 prolactin Homo sapiens 0-9 3979587-1 1985 We have shown that a smaller dose of bromocriptine is effective in lowering the PRL level to the normal range in some hyperprolactinemic women. Bromocriptine 37-50 prolactin Homo sapiens 80-83 4054664-0 1985 [Prolactin levels in women with polycystic ovary syndrome after treatment with clomiphene]. Clomiphene 79-89 prolactin Homo sapiens 1-10 3979587-2 1985 Based on these findings, we recommend that when treating hyperprolactinemic women who desire conception, the dose of bromocriptine should be titrated according to the response of circulating PRL levels. Bromocriptine 117-130 prolactin Homo sapiens 191-194 3157731-0 1985 A relationship between prolactin levels and dexamethasone suppression test results in major depressive disorder. Dexamethasone 44-57 prolactin Homo sapiens 23-32 2579087-6 1985 Theophylline and isobutylmethylxanthine, when added to the incubation medium, increased PRL secretion, and dopamine as well as somatostatin again inhibited PRL release induced by phosphodiesterase inhibitors. 1-Methyl-3-isobutylxanthine 17-39 prolactin Homo sapiens 156-159 2579087-0 1985 Mechanism of the inhibitory action of dopamine and somatostatin on prolactin secretion from human lactotrophs in culture. Dopamine 38-46 prolactin Homo sapiens 67-76 2579087-6 1985 Theophylline and isobutylmethylxanthine, when added to the incubation medium, increased PRL secretion, and dopamine as well as somatostatin again inhibited PRL release induced by phosphodiesterase inhibitors. Dopamine 107-115 prolactin Homo sapiens 156-159 2579087-2 1985 High K+ and the divalent cation ionophore A23187 both elevated PRL secretion, which was blocked by dopamine and somatostatin. Calcimycin 42-48 prolactin Homo sapiens 63-66 2579087-2 1985 High K+ and the divalent cation ionophore A23187 both elevated PRL secretion, which was blocked by dopamine and somatostatin. Dopamine 99-107 prolactin Homo sapiens 63-66 2579087-9 1985 Exposure of the cells to dopamine or somatostatin resulted in a parallel decrease in intracellular cAMP content and PRL secretion. Dopamine 25-33 prolactin Homo sapiens 116-119 2579087-3 1985 When the cells were incubated in low calcium medium, PRL secretion was significantly inhibited. Calcium 37-44 prolactin Homo sapiens 53-56 2579087-10 1985 The inhibitory effect of dopamine on PRL secretion and cAMP accumulation was blocked by coincubation of the cells with haloperidol. Dopamine 25-33 prolactin Homo sapiens 37-40 2579087-4 1985 The addition of dopamine or somatostatin to low calcium medium further decreased PRL release. Dopamine 16-24 prolactin Homo sapiens 81-84 2579087-10 1985 The inhibitory effect of dopamine on PRL secretion and cAMP accumulation was blocked by coincubation of the cells with haloperidol. Haloperidol 119-130 prolactin Homo sapiens 37-40 2579087-4 1985 The addition of dopamine or somatostatin to low calcium medium further decreased PRL release. calcium medium 48-62 prolactin Homo sapiens 81-84 2579087-5 1985 The stimulatory action of ionophore A23187 on PRL release was found even in the absence of extracellular calcium. Calcimycin 36-42 prolactin Homo sapiens 46-49 2579087-11 1985 These results suggest that an increase in cytosol calcium caused by either mobilization from intracellular calcium pools or influx from the extracellular compartment and intracellular cAMP accumulation may be involved in the mechanism of PRL secretion from human lactotrophs, and dopamine and somatostatin may influence these two messengers to suppress PRL secretion. Calcium 50-57 prolactin Homo sapiens 238-241 2579087-6 1985 Theophylline and isobutylmethylxanthine, when added to the incubation medium, increased PRL secretion, and dopamine as well as somatostatin again inhibited PRL release induced by phosphodiesterase inhibitors. Theophylline 0-12 prolactin Homo sapiens 88-91 2579087-6 1985 Theophylline and isobutylmethylxanthine, when added to the incubation medium, increased PRL secretion, and dopamine as well as somatostatin again inhibited PRL release induced by phosphodiesterase inhibitors. Theophylline 0-12 prolactin Homo sapiens 156-159 2579087-6 1985 Theophylline and isobutylmethylxanthine, when added to the incubation medium, increased PRL secretion, and dopamine as well as somatostatin again inhibited PRL release induced by phosphodiesterase inhibitors. 1-Methyl-3-isobutylxanthine 17-39 prolactin Homo sapiens 88-91 2579087-11 1985 These results suggest that an increase in cytosol calcium caused by either mobilization from intracellular calcium pools or influx from the extracellular compartment and intracellular cAMP accumulation may be involved in the mechanism of PRL secretion from human lactotrophs, and dopamine and somatostatin may influence these two messengers to suppress PRL secretion. Calcium 50-57 prolactin Homo sapiens 353-356 2579087-11 1985 These results suggest that an increase in cytosol calcium caused by either mobilization from intracellular calcium pools or influx from the extracellular compartment and intracellular cAMP accumulation may be involved in the mechanism of PRL secretion from human lactotrophs, and dopamine and somatostatin may influence these two messengers to suppress PRL secretion. Cyclic AMP 184-188 prolactin Homo sapiens 238-241 2579087-11 1985 These results suggest that an increase in cytosol calcium caused by either mobilization from intracellular calcium pools or influx from the extracellular compartment and intracellular cAMP accumulation may be involved in the mechanism of PRL secretion from human lactotrophs, and dopamine and somatostatin may influence these two messengers to suppress PRL secretion. Dopamine 280-288 prolactin Homo sapiens 238-241 2984068-1 1985 The disulfide bonds of two lactogenic hormones, ovine prolactin (oPRL) and human growth hormone (hGH), were reduced with dithiothreitol under denaturing conditions and alkylated with iodoacetic acid. Disulfides 4-13 prolactin Homo sapiens 54-63 2984068-1 1985 The disulfide bonds of two lactogenic hormones, ovine prolactin (oPRL) and human growth hormone (hGH), were reduced with dithiothreitol under denaturing conditions and alkylated with iodoacetic acid. Dithiothreitol 121-135 prolactin Homo sapiens 54-63 2984068-1 1985 The disulfide bonds of two lactogenic hormones, ovine prolactin (oPRL) and human growth hormone (hGH), were reduced with dithiothreitol under denaturing conditions and alkylated with iodoacetic acid. Iodoacetic Acid 183-198 prolactin Homo sapiens 54-63 2984068-3 1985 S-Carboxymethylated ovine prolactin (SCM-oPRL) with all six cysteine residues modified had a nearly 300-fold decrease in binding as compared to native oPRL in a competitive binding assay using [125I]ovine prolactin. Cysteine 60-68 prolactin Homo sapiens 26-35 2986023-0 1985 Cimetidine-induced prolactin release: possible involvement of the GABA-ergic system. Cimetidine 0-10 prolactin Homo sapiens 19-28 2986023-0 1985 Cimetidine-induced prolactin release: possible involvement of the GABA-ergic system. gamma-Aminobutyric Acid 66-70 prolactin Homo sapiens 19-28 2986023-1 1985 The mechanism of cimetidine-induced prolactin (PRL) release was studied. Cimetidine 17-27 prolactin Homo sapiens 36-45 4047435-0 1985 [Effect of subdural administration of morphine for analgesic purposes on serum cortisol, prolactin and urinary catecholamines during surgical stress]. Morphine 38-46 prolactin Homo sapiens 89-98 3888233-0 1985 Prolactin response to sulpiride in non insulin dependent diabetes mellitus. Sulpiride 22-31 prolactin Homo sapiens 0-9 3919045-3 1985 Patients given human menopausal gonadotropin and clomiphene citrate had significantly higher levels of plasma PRL compared to those given clomiphene only. Clomiphene 49-67 prolactin Homo sapiens 110-113 3919045-3 1985 Patients given human menopausal gonadotropin and clomiphene citrate had significantly higher levels of plasma PRL compared to those given clomiphene only. Clomiphene 49-59 prolactin Homo sapiens 110-113 3919048-4 1985 The PRL response to TRH was blunted in patients before lynestrenol therapy. Lynestrenol 55-66 prolactin Homo sapiens 4-7 3919048-8 1985 Therefore, lynestrenol, a potent 19-nortestosterone derivative, exhibits in vivo an anti-PRL effect that could be related to its antiestrogenic and/or androgenic activities. Lynestrenol 11-22 prolactin Homo sapiens 89-92 3922034-0 1985 [Effect of veralipride on LH, FSH, and PRL levels and on the climacteric syndrome]. veralipride 11-22 prolactin Homo sapiens 39-42 3888233-3 1985 Prolactin response to sulpiride was significantly higher in diabetics than in controls (at 20 min., p less than 0.01; at 30 and 60 min., p less than 0.005; at 90 min., p less than 0.01; at 120 min., p less than 0.05). Sulpiride 22-31 prolactin Homo sapiens 0-9 3888233-5 1985 Prolactin response to sulpiride was the same in diabetics with and in those without retinal changes. Sulpiride 22-31 prolactin Homo sapiens 0-9 3918401-1 1985 The effects of oestradiol and prolactin (Prl) on progesterone production by dispersed monkey luteal cells were examined. Progesterone 49-61 prolactin Homo sapiens 41-44 3157511-2 1985 We here report on PRL levels in 142 male-to-female transsexuals, treated with 100 mg cyproterone acetate and 100 micrograms ethinyloestradiol per day for 6-108 months (median 52). Cyproterone Acetate 85-104 prolactin Homo sapiens 18-21 2994621-3 1985 Several of the prolactinomas exhibited unusual features including excessively high prolactin secretion, a wide spectrum of sensitivity to bromocriptine, rapid expansion in pregnancy, association with the empty sella syndrome and even a secondary malignancy. Bromocriptine 138-151 prolactin Homo sapiens 15-24 3882143-0 1985 Domperidone: secretion in breast milk and effect on puerperal prolactin levels. Domperidone 0-11 prolactin Homo sapiens 62-71 3882143-3 1985 The mean serum level of prolactin 2 h after treatment with 20 mg of domperidone in the puerperium was 255 ng/ml compared with 150 ng/ml after a placebo. Domperidone 68-79 prolactin Homo sapiens 24-33 3157511-2 1985 We here report on PRL levels in 142 male-to-female transsexuals, treated with 100 mg cyproterone acetate and 100 micrograms ethinyloestradiol per day for 6-108 months (median 52). Ethinyl Estradiol 124-141 prolactin Homo sapiens 18-21 3157511-8 1985 Dopamine in doses of 0.1 microgram/kg/min and 1.0 microgram/kg/min was administered to six subjects with PRL levels greater than 1000 mU/l and six subjects with PRL levels less than 500 mU/l. Dopamine 0-8 prolactin Homo sapiens 105-108 3157511-8 1985 Dopamine in doses of 0.1 microgram/kg/min and 1.0 microgram/kg/min was administered to six subjects with PRL levels greater than 1000 mU/l and six subjects with PRL levels less than 500 mU/l. Dopamine 0-8 prolactin Homo sapiens 161-164 3965110-5 1985 This is the third reported case of prolactin cell carcinoma that metastasized despite high-dose dopamine agonist therapy. Dopamine 96-104 prolactin Homo sapiens 35-44 3157511-10 1985 However, administration of monoiodotyrosine, an inhibitor of central dopamine synthesis, to these two groups, induced a significantly smaller release of PRL (expressed as percentage change) in subjects with PRL greater than 1000 mU/l than in those with PRL less than 500 mU/1 possibly indicating a loss of control of central dopaminergic regulation. Monoiodotyrosine 27-43 prolactin Homo sapiens 153-156 3157511-10 1985 However, administration of monoiodotyrosine, an inhibitor of central dopamine synthesis, to these two groups, induced a significantly smaller release of PRL (expressed as percentage change) in subjects with PRL greater than 1000 mU/l than in those with PRL less than 500 mU/1 possibly indicating a loss of control of central dopaminergic regulation. Monoiodotyrosine 27-43 prolactin Homo sapiens 207-210 3157511-10 1985 However, administration of monoiodotyrosine, an inhibitor of central dopamine synthesis, to these two groups, induced a significantly smaller release of PRL (expressed as percentage change) in subjects with PRL greater than 1000 mU/l than in those with PRL less than 500 mU/1 possibly indicating a loss of control of central dopaminergic regulation. Monoiodotyrosine 27-43 prolactin Homo sapiens 207-210 4017978-0 1985 The negative correlation between prolactin and ionic calcium in cord blood of full term infants. Calcium 53-60 prolactin Homo sapiens 33-42 4017978-5 1985 These data suggest that there is an active system transporting calcium from mother to fetus through the placenta, and PRL is the only one of the three hormones which was correlated with ionic calcium values in the fetus. Calcium 192-199 prolactin Homo sapiens 118-121 3917455-2 1985 Normalization of serum PRL levels is generally associated with an increase in serum testosterone (T) to normal. Testosterone 84-96 prolactin Homo sapiens 23-26 3918955-0 1985 Prolactin and the hypothalamic-pituitary-testicular axis in cimetidine-treated men. Cimetidine 60-70 prolactin Homo sapiens 0-9 3921593-0 1985 Failure of nomifensine to reduce serum prolactin levels in patients with hepatic encephalopathy. Nomifensine 11-22 prolactin Homo sapiens 39-48 3921593-6 1985 The failure of nomifensine to depress PRL is an early finding in the course of encephalopathy and may be of diagnostic value. Nomifensine 15-26 prolactin Homo sapiens 38-41 3921593-2 1985 Inhibition of endogenous catecholamine reuptake by nomifensine was able to significantly reduce PRL levels in normal subjects and in patients with liver cirrhosis, whereas only one out of 8 patients with hepatic encephalopathy showed a reduction in PRL levels. Catecholamines 25-38 prolactin Homo sapiens 96-99 3921593-2 1985 Inhibition of endogenous catecholamine reuptake by nomifensine was able to significantly reduce PRL levels in normal subjects and in patients with liver cirrhosis, whereas only one out of 8 patients with hepatic encephalopathy showed a reduction in PRL levels. Catecholamines 25-38 prolactin Homo sapiens 249-252 3921593-2 1985 Inhibition of endogenous catecholamine reuptake by nomifensine was able to significantly reduce PRL levels in normal subjects and in patients with liver cirrhosis, whereas only one out of 8 patients with hepatic encephalopathy showed a reduction in PRL levels. Nomifensine 51-62 prolactin Homo sapiens 96-99 3921593-2 1985 Inhibition of endogenous catecholamine reuptake by nomifensine was able to significantly reduce PRL levels in normal subjects and in patients with liver cirrhosis, whereas only one out of 8 patients with hepatic encephalopathy showed a reduction in PRL levels. Nomifensine 51-62 prolactin Homo sapiens 249-252 3921597-0 1985 Effect of different doses of naloxone on serum levels of prolactin and gonadotropins in young male volunteers. Naloxone 29-37 prolactin Homo sapiens 57-66 3921593-3 1985 On the contrary, levodopa administration was able to reduce PRL secretion in all the subjects studied. Levodopa 17-25 prolactin Homo sapiens 60-63 3919123-4 1985 14 patients out of 16 cases (Group A) responded to bromocriptine, whose prolactin levels were more than 30 ng/ml during the night in the circadian studies. Bromocriptine 51-64 prolactin Homo sapiens 72-81 3973448-0 1985 [Effect of danazol on serum prolactin and cortisol levels]. Danazol 11-18 prolactin Homo sapiens 28-37 2983744-0 1985 [Prolactin after baclofen in healthy subjects and prolactinoma patients]. Baclofen 17-25 prolactin Homo sapiens 1-10 2983744-6 1985 On the contrary baclofen decreased PRL rise cimetidine induced. Baclofen 16-24 prolactin Homo sapiens 35-38 2983744-6 1985 On the contrary baclofen decreased PRL rise cimetidine induced. Cimetidine 44-54 prolactin Homo sapiens 35-38 3996685-8 1985 From these results, the mechanism of induction of ovulation by Bromocriptine in euprolactinemic anovulation exists on the suppression of the increased PRL secreting capacity, which may be related to the occulted hyperprolactinemia at night. Bromocriptine 63-76 prolactin Homo sapiens 151-154 3917709-0 1985 Long term suppression of prolactin concentrations after bromocriptine induced regression of pituitary prolactinomas. Bromocriptine 56-69 prolactin Homo sapiens 25-34 4040306-5 1985 The LH and FSH responses to LHRH were similar to those of XXY controls, and the variation of prolactin levels after sulpiride stimulus was in the normal range. Sulpiride 116-125 prolactin Homo sapiens 93-102 3919529-7 1985 Bromocriptine was equally beneficial in the two clinical subgroups, improving clinical symptoms and normalizing PRL levels in all but three patients. Bromocriptine 0-13 prolactin Homo sapiens 112-115 4034335-3 1985 Results showed that between the 28th-40th week there is an increase in the prolactin level of the umbilical arterial and venous blood with a parallel increase in the cortisol level of umbilical arterial blood and a fall in the progesterone level of umbilical arterial and venous blood which between the 36th and 40th week results in a rise of the oestradiol/progesterone quotient. Estradiol 347-357 prolactin Homo sapiens 75-84 4034335-3 1985 Results showed that between the 28th-40th week there is an increase in the prolactin level of the umbilical arterial and venous blood with a parallel increase in the cortisol level of umbilical arterial blood and a fall in the progesterone level of umbilical arterial and venous blood which between the 36th and 40th week results in a rise of the oestradiol/progesterone quotient. Progesterone 358-370 prolactin Homo sapiens 75-84 4013686-1 1985 The concentration of prolactin in amniotic fluid from 91 pregnant women (Group I: 51 specimens obtained at 15th-20th week of gestation; Group II: 40 specimens at term) has been correlated with the amniotic fluid concentrations of calcium, of the ions sodium, chloride, and potassium, and with the clinical data. Calcium 230-237 prolactin Homo sapiens 21-30 2981568-12 1985 The difference between the effect of chloroquine on 125I-labelled prolactin and 125I-labelled insulin uptake may reflect the greater stability of prolactin-receptor complexes in a low-pH environment. Chloroquine 37-48 prolactin Homo sapiens 66-75 4013686-1 1985 The concentration of prolactin in amniotic fluid from 91 pregnant women (Group I: 51 specimens obtained at 15th-20th week of gestation; Group II: 40 specimens at term) has been correlated with the amniotic fluid concentrations of calcium, of the ions sodium, chloride, and potassium, and with the clinical data. Sodium 251-257 prolactin Homo sapiens 21-30 4013686-1 1985 The concentration of prolactin in amniotic fluid from 91 pregnant women (Group I: 51 specimens obtained at 15th-20th week of gestation; Group II: 40 specimens at term) has been correlated with the amniotic fluid concentrations of calcium, of the ions sodium, chloride, and potassium, and with the clinical data. Chlorides 259-267 prolactin Homo sapiens 21-30 4013686-1 1985 The concentration of prolactin in amniotic fluid from 91 pregnant women (Group I: 51 specimens obtained at 15th-20th week of gestation; Group II: 40 specimens at term) has been correlated with the amniotic fluid concentrations of calcium, of the ions sodium, chloride, and potassium, and with the clinical data. Potassium 273-282 prolactin Homo sapiens 21-30 4013686-2 1985 When the week of gestation in multiple regression analyses was predetermined for inclusion in the first step, the amniotic prolactin concentration was found to be significantly correlated with sodium or chloride in both groups and the correlation coefficients in the two groups were alike. Sodium 193-199 prolactin Homo sapiens 123-132 4013686-2 1985 When the week of gestation in multiple regression analyses was predetermined for inclusion in the first step, the amniotic prolactin concentration was found to be significantly correlated with sodium or chloride in both groups and the correlation coefficients in the two groups were alike. Chlorides 203-211 prolactin Homo sapiens 123-132 4013686-4 1985 The results indicate that the amniotic sodium and chloride concentrations could be of importance for the regulation of the amniotic prolactin concentration. Sodium 39-45 prolactin Homo sapiens 132-141 4013686-4 1985 The results indicate that the amniotic sodium and chloride concentrations could be of importance for the regulation of the amniotic prolactin concentration. Chlorides 50-58 prolactin Homo sapiens 132-141 3881020-8 1985 If serum prolactin levels were above 100 ng/ml, bromocriptine was the most effective treatment. Bromocriptine 48-61 prolactin Homo sapiens 9-18 4083636-0 1985 [Results of bromocriptine treatment of giant or invasive prolactin adenomas. Bromocriptine 12-25 prolactin Homo sapiens 57-66 3966480-1 1985 This case report describes a 45-year-old man with a massive extrasellar prolactinoma, treated initially with surgery and radiotherapy, who experienced a dramatic reduction of the bulk of his tumor but persistence and subsequent progression of an extrasellar portion while receiving long-term bromocriptine therapy, despite stable, suppressed prolactin levels. Bromocriptine 292-305 prolactin Homo sapiens 72-81 4083636-8 1985 Five patients were referred secondarily for surgery for spontaneous rhinorrhea in 1 patient or because Bromocriptine was only partially effective in 4 patients; a postoperative visual improvement with reduced serum prolactin levels was observed in these 4 cases. Bromocriptine 103-116 prolactin Homo sapiens 215-224 3834948-2 1985 Results of research effected since then have shown that high levels of PRL could cause sterility either through its effects on ovulation at the hypothalamic, hypophyseal or gonadal level or through the inhibition of steroid synthesis in the ovaries which leads to amenorrhea. Steroids 216-223 prolactin Homo sapiens 71-74 3834948-3 1985 In parallel with these findings, bromocriptine, a dopamin agonist inhibiting PRL secretion has been used in the clinic for the treatment of hyperprolactinemic states and the positive results obtained confirmed the role of PRL in human reproduction. Bromocriptine 33-46 prolactin Homo sapiens 77-80 3834948-3 1985 In parallel with these findings, bromocriptine, a dopamin agonist inhibiting PRL secretion has been used in the clinic for the treatment of hyperprolactinemic states and the positive results obtained confirmed the role of PRL in human reproduction. Bromocriptine 33-46 prolactin Homo sapiens 222-225 3834948-3 1985 In parallel with these findings, bromocriptine, a dopamin agonist inhibiting PRL secretion has been used in the clinic for the treatment of hyperprolactinemic states and the positive results obtained confirmed the role of PRL in human reproduction. Dopamine 50-57 prolactin Homo sapiens 77-80 4027295-0 1985 Effect of low-dose dopamine infusion on prolactin and thyrotropin secretion in preterm infants with hyaline membrane disease. Dopamine 19-27 prolactin Homo sapiens 40-49 4027295-1 1985 The effect of low-dose (2-4 micrograms/kg/min) and long-term (greater than or equal to 46 h) dopamine infusion on serum prolactin and thyrotropin concentrations was investigated in 8 preterm infants with hyaline membrane disease. Dopamine 93-101 prolactin Homo sapiens 120-129 4027295-4 1985 Our data indicate that exogenous dopamine exerts an inhibitory effect on the secretion of prolactin and thyrotropin even in the sick preterm neonate. Dopamine 33-41 prolactin Homo sapiens 90-99 3890987-12 1985 Prolactin stimulates transcription of milk protein genes and this stimulation is modulated by glucocorticoids and progesterone. Progesterone 114-126 prolactin Homo sapiens 0-9 3978829-2 1985 Under basal conditions, after pituitary stimulation, and following treatment with bromocriptine which greatly decreased the serum PRL levels, the bioassay (BA) results closely paralleled fluctuations in the sum of radioimmunoassay (RIA) estimates of serum PRL and growth hormone concentrations. Bromocriptine 82-95 prolactin Homo sapiens 130-133 3938205-4 1985 Hormonal patterns of 5 of these subjects before, during, and after 3 months of treatment with Tamoxifen showed a progressive increase of gonadotropin (especially LH) and 17 beta E2 values; testosterone variations were minimal, and PRL showed a slight decrease. Tamoxifen 94-103 prolactin Homo sapiens 231-234 3978829-2 1985 Under basal conditions, after pituitary stimulation, and following treatment with bromocriptine which greatly decreased the serum PRL levels, the bioassay (BA) results closely paralleled fluctuations in the sum of radioimmunoassay (RIA) estimates of serum PRL and growth hormone concentrations. Bromocriptine 82-95 prolactin Homo sapiens 256-259 3978829-3 1985 The extreme sensitivity (10 pg/ml) of the BA facilitated measurement of PRL in fractions obtained after Sephadex G-100 chromatography of only 0.1 to 0.3 ml of sera from both untreated and bromocriptine-treated prolactinoma patients. sephadex 104-118 prolactin Homo sapiens 72-75 3978829-6 1985 Therapy with bromocriptine led to a reduction in the total serum PRL activity and, in particular, in the activity of the second peak. Bromocriptine 13-26 prolactin Homo sapiens 65-68 2578035-4 1985 By gel electrophoresis in sodium dodecyl sulfate, a mol wt of 25,000 was estimated for the glycosylated PRL. Sodium Dodecyl Sulfate 26-48 prolactin Homo sapiens 104-107 3924400-5 1985 This result could be explained by a serotoninergic activity of PRL changes produced by CBZ in these various conditions agrees with the absence of published reports of CBZ side effects associated with hyperprolactinemia. Carbamazepine 87-90 prolactin Homo sapiens 63-66 2578035-7 1985 Since there is only one Asn-X-Ser(Thr) sequence in hPRL, the asparagine at position 31 is the likely point of N-linked glycosylation. Threonine 34-37 prolactin Homo sapiens 51-55 2981065-2 1985 Arachidonate (100 microM) significantly (P less than 0.05) stimulated PRL release in the former system and stimulated PRL secretion in a dose-related manner in cultured cells. Arachidonic Acid 0-12 prolactin Homo sapiens 70-73 2981065-2 1985 Arachidonate (100 microM) significantly (P less than 0.05) stimulated PRL release in the former system and stimulated PRL secretion in a dose-related manner in cultured cells. Arachidonic Acid 0-12 prolactin Homo sapiens 118-121 2578035-7 1985 Since there is only one Asn-X-Ser(Thr) sequence in hPRL, the asparagine at position 31 is the likely point of N-linked glycosylation. Asparagine 61-71 prolactin Homo sapiens 51-55 3921384-0 1985 Effect of dihydroergokryptine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic and acromegalic subjects: evidence of potent and long-lasting pituitary dopamine receptor stimulation. Dihydroergocryptine 10-29 prolactin Homo sapiens 54-63 2981065-5 1985 BW755c also inhibited the stimulatory effect of TRH on PRL release in both experimental systems. 4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine 0-6 prolactin Homo sapiens 55-58 2981065-6 1985 Conversely, the stimulation of PRL release by phorbol myristate acetate (PMA), although significantly reduced, was not abolished by either nordihydroguaiaretic acid or BW755c. Tetradecanoylphorbol Acetate 46-71 prolactin Homo sapiens 31-34 2981065-6 1985 Conversely, the stimulation of PRL release by phorbol myristate acetate (PMA), although significantly reduced, was not abolished by either nordihydroguaiaretic acid or BW755c. Tetradecanoylphorbol Acetate 73-76 prolactin Homo sapiens 31-34 2981065-7 1985 Quinacrine, a phospholipase A2 inhibitor, also abolished the stimulatory effect of phospholipase A2 or TRH on PRL release. Quinacrine 0-10 prolactin Homo sapiens 110-113 2981065-8 1985 In cultured cells, quinacrine inhibits basal PRL release, but does not affect PRL release induced by arachidonate or (Bu)2 cAMP. Quinacrine 19-29 prolactin Homo sapiens 45-48 2981065-9 1985 These results more firmly establish a role for arachidonate as an intracellular mediator of PRL release and suggest the involvement of an arachidonate metabolic pathway(s) (lipoxygenase and epoxygenase) other than prostaglandin or thromboxane formation. Arachidonic Acid 47-59 prolactin Homo sapiens 92-95 2981065-10 1985 The effect of PMA on PRL release may be attributable only in part to an increase in the production of arachidonate metabolites, and most of PMA"s effect on PRL release may relate to its activation of protein kinase C. Arachidonic Acid 102-114 prolactin Homo sapiens 21-24 3921384-4 1985 The PRL- and GH- lowering activity of 6 mg dihydroergokryptine was significantly greater than that of 6 mg dihydroergocristine, and was similar to that of an oral dose of 500 mg 1-DOPA. Dihydroergocryptine 43-62 prolactin Homo sapiens 4-7 3932077-1 1985 The possible relationship between cortisol inhibition induced by deflazacort, a new glucocorticoid, and impairment of prolactin (PRL) and thyrotropin (TSH) secretion in healthy volunteers has been investigated. deflazacort 65-76 prolactin Homo sapiens 118-127 3932077-1 1985 The possible relationship between cortisol inhibition induced by deflazacort, a new glucocorticoid, and impairment of prolactin (PRL) and thyrotropin (TSH) secretion in healthy volunteers has been investigated. deflazacort 65-76 prolactin Homo sapiens 129-132 4042996-0 1985 Growth hormone and prolactin levels in the course of metoclopramide test in headache patients. Metoclopramide 53-67 prolactin Homo sapiens 19-28 3988149-0 1985 Effect of fenfluramine oral administration on serum prolactin levels in healthy and hyperprolactinemic women. Fenfluramine 10-22 prolactin Homo sapiens 52-61 3988149-1 1985 The effects of two different doses (40 and 80 mg orally) of fenfluramine on serum prolactin (PRL) levels have been evaluated in healthy and hyperprolactinemic women and compared with those of the potent dopamine antagonist sulpiride (100 mg i.m.). Fenfluramine 60-72 prolactin Homo sapiens 82-91 3988149-1 1985 The effects of two different doses (40 and 80 mg orally) of fenfluramine on serum prolactin (PRL) levels have been evaluated in healthy and hyperprolactinemic women and compared with those of the potent dopamine antagonist sulpiride (100 mg i.m.). Fenfluramine 60-72 prolactin Homo sapiens 93-96 3988149-2 1985 The lower fenfluramine dose resulted in a significant PRL rise in healthy women (n = 16) but not in hyperprolactinemics (n = 14). Fenfluramine 10-22 prolactin Homo sapiens 54-57 3988149-4 1985 Sulpiride resulted in a much greater PRL response. Sulpiride 0-9 prolactin Homo sapiens 37-40 3932177-2 1985 Particular emphasis was given to the role of changes in the turnover of specific membrane phospholipids, the polyphosphoinositides, in the stimulatory effect of TRH and neurotensin on prolactin release in vitro. Phospholipids 90-103 prolactin Homo sapiens 184-193 3917966-1 1985 Dopamine infusion 4 micrograms/kg/min over 4 h, administered to six subjects with diagnosis of polycystic ovarian disease laparoscopically confirmed, produced a significant decrease in serum LH, FSH and PRL, suggesting a reduced dopamine activity in these subjects. Dopamine 0-8 prolactin Homo sapiens 203-206 3932176-5 1985 When tumor cells were preincubated for 24 h with 5 X 10(-11) M bromocriptine, a 47 +/- 4% inhibition of PRL release was obtained. Bromocriptine 63-76 prolactin Homo sapiens 104-107 3932176-8 1985 When tumor cells were pretreated with various concentrations of triiodothyronine (T3), the PRL release was inhibited by 50% with 5 X 10(-11) M T3 and by 80% with 10(-9) M T3. Triiodothyronine 64-80 prolactin Homo sapiens 91-94 3932177-2 1985 Particular emphasis was given to the role of changes in the turnover of specific membrane phospholipids, the polyphosphoinositides, in the stimulatory effect of TRH and neurotensin on prolactin release in vitro. Phosphatidylinositol Phosphates 109-130 prolactin Homo sapiens 184-193 3932176-8 1985 When tumor cells were pretreated with various concentrations of triiodothyronine (T3), the PRL release was inhibited by 50% with 5 X 10(-11) M T3 and by 80% with 10(-9) M T3. Triiodothyronine 82-84 prolactin Homo sapiens 91-94 3932176-8 1985 When tumor cells were pretreated with various concentrations of triiodothyronine (T3), the PRL release was inhibited by 50% with 5 X 10(-11) M T3 and by 80% with 10(-9) M T3. Triiodothyronine 143-145 prolactin Homo sapiens 91-94 4029882-6 1985 Following therapy with bromocriptine (2.5 mg/day) plasma PRL levels dropped to normal (5-6.8 ng/ml) with an accompanying catch-up of pubertal development and linear growth and a marked increase in size of the uterus as documented by repeated ultrasonographic examinations. Bromocriptine 23-36 prolactin Homo sapiens 57-60 3932176-8 1985 When tumor cells were pretreated with various concentrations of triiodothyronine (T3), the PRL release was inhibited by 50% with 5 X 10(-11) M T3 and by 80% with 10(-9) M T3. Triiodothyronine 143-145 prolactin Homo sapiens 91-94 3932176-11 1985 In all cases tested (n = 4), preincubation of the tumor cells with estradiol (10(-8) M) modified the inhibition of PRL release induced by bromocriptine with a half-inhibitory concentration displaced from 3 X 10(-11) M (control) to 3 X 10(-10) M (estradiol). Estradiol 67-76 prolactin Homo sapiens 115-118 3932176-11 1985 In all cases tested (n = 4), preincubation of the tumor cells with estradiol (10(-8) M) modified the inhibition of PRL release induced by bromocriptine with a half-inhibitory concentration displaced from 3 X 10(-11) M (control) to 3 X 10(-10) M (estradiol). Bromocriptine 138-151 prolactin Homo sapiens 115-118 3932176-11 1985 In all cases tested (n = 4), preincubation of the tumor cells with estradiol (10(-8) M) modified the inhibition of PRL release induced by bromocriptine with a half-inhibitory concentration displaced from 3 X 10(-11) M (control) to 3 X 10(-10) M (estradiol). Estradiol 246-255 prolactin Homo sapiens 115-118 3972716-4 1985 Daily administration of bromocriptine caused a marked suppression of serum PRL (mean +/- SEM, 23.8 +/- 2.5 vs. 6.4 +/- 1.0 ng/ml) without concomitant changes in serum LH levels (mean +/- SEM, 8.3 +/- 1.6 vs. 8.9 +/- 2.1 ng/ml). Bromocriptine 24-37 prolactin Homo sapiens 75-78 4054837-0 1985 Interactions of steroids with prolactin secretion in vitro. Steroids 16-24 prolactin Homo sapiens 30-39 4054839-11 1985 Moreover, when serum PRL was lowered by bromocriptine, 6 patients recovered their potency before plasma testosterone clearly increased, and in 3 of those patients before it reached the normal range. Bromocriptine 40-53 prolactin Homo sapiens 21-24 4054839-11 1985 Moreover, when serum PRL was lowered by bromocriptine, 6 patients recovered their potency before plasma testosterone clearly increased, and in 3 of those patients before it reached the normal range. Testosterone 104-116 prolactin Homo sapiens 21-24 4054840-5 1985 Inhibition of PRL secretion with bromocriptine can normalize luteal function and restore the ability to conceive. Bromocriptine 33-46 prolactin Homo sapiens 14-17 3880562-6 1985 In contrast, when these subjects underwent the same infusion schedule using a structurally dissimilar calcium influx blocker, verapamil (5-mg bolus dose and 15 mg/h, continuous infusion), there was significant suppression of the delayed component of GnRH/TRH-stimulated LH release, with simultaneous enhancement of PRL secretion. Verapamil 126-135 prolactin Homo sapiens 315-318 3964791-0 1985 Naloxone-induced prolactin secretion in women: evidence against a direct prolactin stimulatory effect of endogenous opioids. Naloxone 0-8 prolactin Homo sapiens 17-26 3964791-4 1985 In the luteal phase women, the number of PRL pulses was significantly (P less than 0.001) greater during naloxone than during saline infusion (3.4 vs. 1.6 pulses/8 h), and a positive linear correlation was found between the integrated PRL response to naloxone and the levels of circulating estradiol (r = 0.62) and progesterone (r = 0.95). Progesterone 315-327 prolactin Homo sapiens 41-44 3964791-3 1985 In contrast, a prompt and sustained naloxone-induced release of PRL was found in the late follicular and midluteal phases of the cycle, with maximum increments (mean +/- SE) of 16.9 +/- 5.3 and 9.7 +/- 3.2 ng/ml, respectively. Naloxone 36-44 prolactin Homo sapiens 64-67 3964791-4 1985 In the luteal phase women, the number of PRL pulses was significantly (P less than 0.001) greater during naloxone than during saline infusion (3.4 vs. 1.6 pulses/8 h), and a positive linear correlation was found between the integrated PRL response to naloxone and the levels of circulating estradiol (r = 0.62) and progesterone (r = 0.95). Naloxone 105-113 prolactin Homo sapiens 41-44 3964791-4 1985 In the luteal phase women, the number of PRL pulses was significantly (P less than 0.001) greater during naloxone than during saline infusion (3.4 vs. 1.6 pulses/8 h), and a positive linear correlation was found between the integrated PRL response to naloxone and the levels of circulating estradiol (r = 0.62) and progesterone (r = 0.95). Sodium Chloride 126-132 prolactin Homo sapiens 41-44 3964791-4 1985 In the luteal phase women, the number of PRL pulses was significantly (P less than 0.001) greater during naloxone than during saline infusion (3.4 vs. 1.6 pulses/8 h), and a positive linear correlation was found between the integrated PRL response to naloxone and the levels of circulating estradiol (r = 0.62) and progesterone (r = 0.95). Naloxone 251-259 prolactin Homo sapiens 41-44 3964791-4 1985 In the luteal phase women, the number of PRL pulses was significantly (P less than 0.001) greater during naloxone than during saline infusion (3.4 vs. 1.6 pulses/8 h), and a positive linear correlation was found between the integrated PRL response to naloxone and the levels of circulating estradiol (r = 0.62) and progesterone (r = 0.95). Estradiol 290-299 prolactin Homo sapiens 41-44 3964791-5 1985 When serum LH concentrations were determined in the same samples, a significantly (P less than 0.001) greater synchrony of PRL with LH pulses during naloxone infusion (96%) compared to that during saline infusion (36%) was found in the luteal phase women. Luteinizing Hormone 11-13 prolactin Homo sapiens 123-126 3964791-5 1985 When serum LH concentrations were determined in the same samples, a significantly (P less than 0.001) greater synchrony of PRL with LH pulses during naloxone infusion (96%) compared to that during saline infusion (36%) was found in the luteal phase women. Luteinizing Hormone 132-134 prolactin Homo sapiens 123-126 3964791-5 1985 When serum LH concentrations were determined in the same samples, a significantly (P less than 0.001) greater synchrony of PRL with LH pulses during naloxone infusion (96%) compared to that during saline infusion (36%) was found in the luteal phase women. Naloxone 149-157 prolactin Homo sapiens 123-126 3964791-6 1985 Thus, naloxone infusion induced an increase in pulsatile PRL release which was synchronized with LH pulses. Naloxone 6-14 prolactin Homo sapiens 57-60 3964791-6 1985 Thus, naloxone infusion induced an increase in pulsatile PRL release which was synchronized with LH pulses. Luteinizing Hormone 97-99 prolactin Homo sapiens 57-60 4047382-1 1985 Therapeutic doses of phenothiazines increased serum levels of prolactin, resulting in a number of side effects. Phenothiazines 21-35 prolactin Homo sapiens 62-71 3926858-6 1985 So Gaba can be a neuro-modulator of the hypothalamo-pituitary axis, acting synergically with the dopaminergic tracts to decrease Prolactin secretion but opposing the dopaminergic tracts in the control over LH. gamma-Aminobutyric Acid 3-7 prolactin Homo sapiens 129-138 3906426-2 1985 Tiapride induced an increase of prolactin plasma levels, on the average, from 1,195 to 2,179 microIU/ml (p less than 0.01). Tiapride Hydrochloride 0-8 prolactin Homo sapiens 32-41 4047382-2 1985 Bromocriptine, a potent dopamine agonist, appears to effectively reduce the serum prolactin level. Bromocriptine 0-13 prolactin Homo sapiens 82-91 4047382-2 1985 Bromocriptine, a potent dopamine agonist, appears to effectively reduce the serum prolactin level. Dopamine 24-32 prolactin Homo sapiens 82-91 4047382-6 1985 The trend of decreased prolactin serum levels indicates that bromocriptine mesylate may prove a useful adjunct to reduce the side effects of hyperprolactinemia. Bromocriptine 61-83 prolactin Homo sapiens 23-32 3991396-6 1985 The correlation between serum prolactin level and fasting plasma glucose was weak though statistically significant (r = 0.26, P less than 0.05). Glucose 65-72 prolactin Homo sapiens 30-39 3991553-0 1985 Effects of naloxone infusion on gonadotrophin and prolactin concentrations in patients with chronic renal failure. Naloxone 11-19 prolactin Homo sapiens 50-59 2868493-0 1985 Remoxipride in schizophrenia: effects on plasma prolactin. Remoxipride 0-11 prolactin Homo sapiens 48-57 2866563-6 1985 apomorphine increased growth hormone in serum from 1.8 +/- 0.2 to 28.3 +/- 4.6 ng/ml and reduced prolactin by 57 +/- 7%. Apomorphine 0-11 prolactin Homo sapiens 97-106 2579369-4 1985 In the presence of testosterone (1 X 10(-7) M), prolactin at low concentrations (greater than 1 mIU/ml) but not at 10 mIU/ml, the concentration at which all other experiments were performed, produced a further stimulation in the proliferation. Testosterone 19-31 prolactin Homo sapiens 48-57 4001434-1 1985 The relationship between erectile dysfunction and sulpiride stimulatory effect on prolactin secretion was studied in 13 married male psychiatric outpatients. Sulpiride 50-59 prolactin Homo sapiens 82-91 4070643-1 1985 In 14 schizophrenic patients, prolactin levels are studied in relation to dosage of depot fluphenazine and gender of patient. Fluphenazine 90-102 prolactin Homo sapiens 30-39 2579369-5 1985 The increase in growth seen with cells cultured with 5 alpha-dihydrotestosterone (1 X 10(-7) M) was reduced with addition of prolactin at high concentrations (10-100 mIU). Dihydrotestosterone 53-80 prolactin Homo sapiens 125-134 4070643-3 1985 For males, the association between fluphenazine dosage and prolactin level was found to be significant (Spearman rho = .925, p less than .05). Fluphenazine 35-47 prolactin Homo sapiens 59-68 4089188-0 1985 Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine. Sulpiride 68-77 prolactin Homo sapiens 30-39 2579369-6 1985 When the fetal calf serum used in the cultures was stripped of endogenous steroids, prolactin still increased cell proliferation, although to a reduced extent. Steroids 74-82 prolactin Homo sapiens 84-93 4089188-0 1985 Effect of normal aging on the prolactin response to graded doses of sulpiride and to arginine. Arginine 85-93 prolactin Homo sapiens 30-39 2991963-0 1985 Responses of prolactin and growth hormone to L-tryptophan infusion: effects in normal subjects and schizophrenic patients receiving neuroleptics. Tryptophan 45-57 prolactin Homo sapiens 13-22 2991963-1 1985 Intravenous infusion of L-tryptophan (LTP) in 18 normal subjects produced a significant increase in plasma prolactin (PRL), growth hormone (GH), and self-ratings of drowsiness. Tryptophan 24-36 prolactin Homo sapiens 107-116 2991963-1 1985 Intravenous infusion of L-tryptophan (LTP) in 18 normal subjects produced a significant increase in plasma prolactin (PRL), growth hormone (GH), and self-ratings of drowsiness. Tryptophan 24-36 prolactin Homo sapiens 118-121 3003777-0 1985 Failure of the GABAergic drug, sodium valproate, to reduce basal plasma prolactin secretion in chronic schizophrenia. Valproic Acid 31-47 prolactin Homo sapiens 72-81 3889966-0 1985 Effect of benztropine on the diurnal prolactin responses to haloperidol. Benztropine 10-21 prolactin Homo sapiens 37-46 3003777-2 1985 Since a GABA disturbance has been recently proposed in the pathogenesis of certain schizophrenic symptoms, and since a tuberoinfundibular-GABA (TI-GABA) system has been shown to modulate PRL secretion in humans, we tested the activity of this system both in controls and in chronic schizophrenic women. gamma-Aminobutyric Acid 138-142 prolactin Homo sapiens 187-190 3003777-2 1985 Since a GABA disturbance has been recently proposed in the pathogenesis of certain schizophrenic symptoms, and since a tuberoinfundibular-GABA (TI-GABA) system has been shown to modulate PRL secretion in humans, we tested the activity of this system both in controls and in chronic schizophrenic women. ti-gaba 144-151 prolactin Homo sapiens 187-190 3003777-5 1985 Sodium valproate decreased PRL concentrations only in the healthy women. Valproic Acid 0-16 prolactin Homo sapiens 27-30 4001280-2 1985 In previous studies it was shown that the tricyclic antidepressant desimipramine (DMI) had different stimulatory effects on growth hormone (GH), prolactin (PRL), ACTH and cortisol secretion in healthy subjects, depending on the mode of administration. Desipramine 67-80 prolactin Homo sapiens 145-154 4001280-2 1985 In previous studies it was shown that the tricyclic antidepressant desimipramine (DMI) had different stimulatory effects on growth hormone (GH), prolactin (PRL), ACTH and cortisol secretion in healthy subjects, depending on the mode of administration. Desipramine 67-80 prolactin Homo sapiens 156-159 4001280-2 1985 In previous studies it was shown that the tricyclic antidepressant desimipramine (DMI) had different stimulatory effects on growth hormone (GH), prolactin (PRL), ACTH and cortisol secretion in healthy subjects, depending on the mode of administration. Desipramine 82-85 prolactin Homo sapiens 145-154 4001280-2 1985 In previous studies it was shown that the tricyclic antidepressant desimipramine (DMI) had different stimulatory effects on growth hormone (GH), prolactin (PRL), ACTH and cortisol secretion in healthy subjects, depending on the mode of administration. Desipramine 82-85 prolactin Homo sapiens 156-159 4001280-6 1985 Compared to placebo, significant increases occurred in GH (p less than 0.05) and in PRL (p less than 0.05) from a dose of DMI 25 mg on, and in cortisol (p less than 0.05) from 15 mg on. Desipramine 122-125 prolactin Homo sapiens 84-87 3889966-0 1985 Effect of benztropine on the diurnal prolactin responses to haloperidol. Haloperidol 60-71 prolactin Homo sapiens 37-46 4034850-0 1985 Differential responses in prolactin levels induced by naloxone in humans. Naloxone 54-62 prolactin Homo sapiens 26-35 3889966-1 1985 Prolactin (PRL) responses to haloperidol were investigated at 0900 and 1800 h in six young healthy men under basal conditions and after benztropine mesylate administration. Haloperidol 29-40 prolactin Homo sapiens 0-9 4034850-1 1985 The plasma prolactin (PRL) response to the opiate antagonist naloxone was tested in drug-free healthy volunteers (10 men, 18 regularly menstruating women who were in the late follicular phase of their ovarian cycles, and seven post-menopausal women). Opiate Alkaloids 43-49 prolactin Homo sapiens 11-20 4034850-1 1985 The plasma prolactin (PRL) response to the opiate antagonist naloxone was tested in drug-free healthy volunteers (10 men, 18 regularly menstruating women who were in the late follicular phase of their ovarian cycles, and seven post-menopausal women). Opiate Alkaloids 43-49 prolactin Homo sapiens 22-25 3889966-1 1985 Prolactin (PRL) responses to haloperidol were investigated at 0900 and 1800 h in six young healthy men under basal conditions and after benztropine mesylate administration. Haloperidol 29-40 prolactin Homo sapiens 11-14 4034850-1 1985 The plasma prolactin (PRL) response to the opiate antagonist naloxone was tested in drug-free healthy volunteers (10 men, 18 regularly menstruating women who were in the late follicular phase of their ovarian cycles, and seven post-menopausal women). Naloxone 61-69 prolactin Homo sapiens 11-20 3889966-2 1985 Haloperidol administration induced significantly higher PRL release during the evening compared to the morning. Haloperidol 0-11 prolactin Homo sapiens 56-59 4034850-1 1985 The plasma prolactin (PRL) response to the opiate antagonist naloxone was tested in drug-free healthy volunteers (10 men, 18 regularly menstruating women who were in the late follicular phase of their ovarian cycles, and seven post-menopausal women). Naloxone 61-69 prolactin Homo sapiens 22-25 4034850-4 1985 In the women of reproductive age, naloxone reduced plasma PRL concentrations, whereas in the post-menopausal women and the men, naloxone resulted in no significant change. Naloxone 34-42 prolactin Homo sapiens 58-61 3889966-3 1985 The anticholinergic drug, benztropine, potentiated the PRL responses to haloperidol both in the morning and in the evening. Benztropine 26-37 prolactin Homo sapiens 55-58 4034850-5 1985 However, in the post-menopausal women treated with estrogen (intramuscular 17-beta-estradiol), the opiate antagonist was able to lower plasma PRL concentrations. Estradiol 75-92 prolactin Homo sapiens 142-145 3889966-3 1985 The anticholinergic drug, benztropine, potentiated the PRL responses to haloperidol both in the morning and in the evening. Haloperidol 72-83 prolactin Homo sapiens 55-58 4034850-6 1985 Thus, it appears that opiate effects on PRL secretion are influenced by the gonadal steroid environment and that estrogens may play a modulating role. Steroids 84-91 prolactin Homo sapiens 40-43 3870537-5 1985 Although the estrogen receptor assay is a fundamental procedure to know hormone dependency in breast cancer, the changes produced in the serum prolactin level after administering L-dopa is a simple and reproducible method that can be used as alternative predictive test in some cases. Levodopa 179-185 prolactin Homo sapiens 143-152 4034885-0 1985 Cortisol and prolactin responses to dexamethasone in major depression, chronic pain, and chronic pain with major depression. Dexamethasone 36-49 prolactin Homo sapiens 13-22 2996093-0 1985 Thyrotropin-releasing hormone action: mechanism of calcium-mediated stimulation of prolactin secretion. Calcium 51-58 prolactin Homo sapiens 83-92 3870537-6 1985 This work shows that a 65 per 100 decrease or more in the L-dopa induced prolactin level prognosticates the existence of a hormone responsive tumor. Levodopa 58-64 prolactin Homo sapiens 73-82 4039514-0 1985 [Lactation inhibition with various dosages of lisuride--prolactin secretion and effectiveness]. Lisuride 46-54 prolactin Homo sapiens 56-65 4039514-1 1985 The influence of lisuride in three several dosages (600, 750, and 900 micrograms) was studied on prolactin secretion and inhibition of lactation in 30 normal postpartum patients. Lisuride 17-25 prolactin Homo sapiens 97-106 4039514-3 1985 A rebound effect of prolactin secretion was demonstrable following lisuride medication during 10 days. Lisuride 67-75 prolactin Homo sapiens 20-29 4039514-5 1985 600 micrograms of lisuride daily showed a good inhibition of lactation and suppression of prolactin secretion. Lisuride 18-26 prolactin Homo sapiens 90-99 6440388-1 1984 The results of this study offer further evidence that metergoline is a valuable alternative to bromocriptine in the suppression of excessive prolactin secretion. Metergoline 54-65 prolactin Homo sapiens 141-150 2420101-0 1985 [Effect of mestranol and chlormadinone acetate on basal and TRH-stimulated PRL secretion in Turner"s syndrome]. Mestranol 11-20 prolactin Homo sapiens 75-78 2420101-0 1985 [Effect of mestranol and chlormadinone acetate on basal and TRH-stimulated PRL secretion in Turner"s syndrome]. Chlormadinone Acetate 25-46 prolactin Homo sapiens 75-78 2420101-1 1985 In 19 patients aged from 12 to 24 years (average age 17.0 years) with Turner"s syndrome the influence of mestranol and chlormadinone acetate on both basal and TRH stimulated PRL secretion was investigated by means of sequential stimulation test (0.5 g arginine hydrochloride/kg body weight, 25 micrograms GnRH and 200 micrograms TRH). Mestranol 105-114 prolactin Homo sapiens 174-177 2420101-1 1985 In 19 patients aged from 12 to 24 years (average age 17.0 years) with Turner"s syndrome the influence of mestranol and chlormadinone acetate on both basal and TRH stimulated PRL secretion was investigated by means of sequential stimulation test (0.5 g arginine hydrochloride/kg body weight, 25 micrograms GnRH and 200 micrograms TRH). Chlormadinone Acetate 119-140 prolactin Homo sapiens 174-177 3937371-1 1985 In 13 healthy tall girls the influence of the hormonal treatment with depotestrogen ethinylestradiolsulfonate and norethisterone acetate was investigated on the basal and TRH stimulated PRL secretion. depotestrogen ethinylestradiolsulfonate 70-109 prolactin Homo sapiens 186-189 3937371-1 1985 In 13 healthy tall girls the influence of the hormonal treatment with depotestrogen ethinylestradiolsulfonate and norethisterone acetate was investigated on the basal and TRH stimulated PRL secretion. Norethindrone Acetate 114-136 prolactin Homo sapiens 186-189 6440388-1 1984 The results of this study offer further evidence that metergoline is a valuable alternative to bromocriptine in the suppression of excessive prolactin secretion. Bromocriptine 95-108 prolactin Homo sapiens 141-150 6440389-2 1984 An unexpectedly high proportion (36%) had a raised serum prolactin level before treatment which was reduced after 50 days of danazol (before treatment 783 +/- 333 mU/l; on danazol 243 +/- 113 mU/l, P less than 0.001). Danazol 125-132 prolactin Homo sapiens 57-66 6440389-5 1984 In one patient with hyperprolactinaemia danazol reduced both basal and stimulated prolactin levels, whereas in 5 women with normal prolactin levels we could detect no gross alteration in metoclopramide or TRH stimulated prolactin levels associated with danazol therapy. Danazol 40-47 prolactin Homo sapiens 25-34 6440389-5 1984 In one patient with hyperprolactinaemia danazol reduced both basal and stimulated prolactin levels, whereas in 5 women with normal prolactin levels we could detect no gross alteration in metoclopramide or TRH stimulated prolactin levels associated with danazol therapy. Danazol 40-47 prolactin Homo sapiens 82-91 6439551-6 1984 Anticonvulsant levels were unrelated to hormonal changes except for carbamazepine which was positively correlated with PRL levels. Carbamazepine 68-81 prolactin Homo sapiens 119-122 6440389-5 1984 In one patient with hyperprolactinaemia danazol reduced both basal and stimulated prolactin levels, whereas in 5 women with normal prolactin levels we could detect no gross alteration in metoclopramide or TRH stimulated prolactin levels associated with danazol therapy. Danazol 40-47 prolactin Homo sapiens 82-91 6441763-3 1984 The inhibitory effect of various doses of dopamine on serum PRL levels was assessed in both normal cycling women and patients with tumoral hyperprolactinemia before and after endogenous catecholamine synthesis inhibition by alpha-methyl-p-tyrosine, a strong and specific tyrosine-hydroxylase inhibitor. Dopamine 42-50 prolactin Homo sapiens 60-63 6441763-4 1984 Dopamine infusion induced a significant decrease in the serum PRL levels in both normal cycling and hyperprolactinemic subjects. Dopamine 0-8 prolactin Homo sapiens 62-65 6441763-5 1984 The mean percent inhibition of baseline PRL induced by the various dopamine infusion rates (0.1, 0.5, 1.0 and 2.0 micrograms/kg/min) was similar in regularly cycling women and in patients with tumoral hyperprolactinemia both before and after endogenous catecholamine synthesis inhibition by alpha-methyl-p-tyrosine. Dopamine 67-75 prolactin Homo sapiens 40-43 6441763-6 1984 Alpha-methyl-p-tyrosine pretreatment significantly increased serum PRL concentrations in normal women and enhanced their responsiveness to the exogenously administered dopamine. alpha-Methyltyrosine 0-23 prolactin Homo sapiens 67-70 6441763-8 1984 These data indicate that reduced dopamine delivery to the adenomatous lactotroph, either due to a primary hypothalamic abnormality or to a deranged vascular pituitary arrangement, rather than a reduced PRL sensitivity to dopamine inhibition, is the main event accounting for PRL hypersecretion in women with PRL-secreting pituitary tumors. Dopamine 33-41 prolactin Homo sapiens 275-278 6441763-8 1984 These data indicate that reduced dopamine delivery to the adenomatous lactotroph, either due to a primary hypothalamic abnormality or to a deranged vascular pituitary arrangement, rather than a reduced PRL sensitivity to dopamine inhibition, is the main event accounting for PRL hypersecretion in women with PRL-secreting pituitary tumors. Dopamine 33-41 prolactin Homo sapiens 275-278 6240524-2 1984 LH levels increase in the prelaying period, followed some days later by increased circulating levels of E, P, and PRL. Luteinizing Hormone 0-2 prolactin Homo sapiens 114-117 6240524-6 1984 Stimulatory effects of hypothalamic neurotransmitters, peptides, and ovarian steroids on PRL secretion have been shown. Steroids 77-85 prolactin Homo sapiens 89-92 6099509-0 1984 Dose-dependent influence of fentanyl on prolactin, growth hormone, and mood. Fentanyl 28-36 prolactin Homo sapiens 40-49 6099509-2 1984 FE caused a strong dose-dependent increase in prolactin (PRL) secretion in every subject. Fentanyl 0-2 prolactin Homo sapiens 46-55 6493000-0 1984 The effect of ethanol on prolactin secretion in vitro. Ethanol 14-21 prolactin Homo sapiens 25-34 6150065-0 1984 Somatostatin inhibits prolactin release from the lactotroph primed with oestrogen and cyproterone acetate in man. Cyproterone Acetate 86-105 prolactin Homo sapiens 22-31 6150065-3 1984 Release of prolactin was inhibited, however, when SRIF was administered to oestrogen-treated agonadal subjects (male-to-female trans-sexuals) and to an even greater degree when subjects had been pretreated with a combination of oestrogen and cyproterone acetate. Cyproterone Acetate 242-261 prolactin Homo sapiens 11-20 6528338-8 1984 Plasma PRL response to sulpiride also became exaggerated during the treatment. Sulpiride 23-32 prolactin Homo sapiens 7-10 6397077-0 1984 Cleaving of disulfide bridges and apparent molecular weight of human prolactin variants as revealed by immunoperoxidase electrophoresis. Disulfides 12-21 prolactin Homo sapiens 69-78 6096765-6 1984 In particular the variation of PRL synthesis and secretion due to dopamine deficiency during basal conditions and after pharmacological treatment is discussed. Dopamine 66-74 prolactin Homo sapiens 31-34 6493000-1 1984 In order to investigate the action of ethanol on the anterior pituitary gland, the effect of ethanol on prolactin secretion in vitro was studied. Ethanol 93-100 prolactin Homo sapiens 104-113 6493000-2 1984 Ethanol significantly increased the in vitro incorporation of 3H-leucine into both prolactin contained within the pituitary gland and that released into the medium. Ethanol 0-7 prolactin Homo sapiens 83-92 6493000-2 1984 Ethanol significantly increased the in vitro incorporation of 3H-leucine into both prolactin contained within the pituitary gland and that released into the medium. DL-Leucine 62-72 prolactin Homo sapiens 83-92 6493000-3 1984 The enhancement of 3H labelled-prolactin synthesis induced by ethanol was suppressed by cycloheximide. Tritium 19-21 prolactin Homo sapiens 31-40 6493000-3 1984 The enhancement of 3H labelled-prolactin synthesis induced by ethanol was suppressed by cycloheximide. Ethanol 62-69 prolactin Homo sapiens 31-40 6493000-3 1984 The enhancement of 3H labelled-prolactin synthesis induced by ethanol was suppressed by cycloheximide. Cycloheximide 88-101 prolactin Homo sapiens 31-40 6493000-4 1984 These results support the hypothesis that ethanol stimulates the in vitro synthesis and release of prolactin by the pituitary gland. Ethanol 42-49 prolactin Homo sapiens 99-108 6497565-2 1984 Growth hormone and prolactin (PRL) responses to 0.75 mg of apomorphine hydrochloride were measured in 19 newly admitted psychotic patients who had been untreated by neuroleptic or antidepressant drugs for at least nine months. Apomorphine 59-84 prolactin Homo sapiens 30-33 6525362-4 1984 It was found that the carbohydrate component of this prolactin form is attached to asparagine at position 31; no differences were revealed between the amino acid composition of the major and glycosylated forms of the hormone. Carbohydrates 22-34 prolactin Homo sapiens 53-62 6525362-4 1984 It was found that the carbohydrate component of this prolactin form is attached to asparagine at position 31; no differences were revealed between the amino acid composition of the major and glycosylated forms of the hormone. Asparagine 83-93 prolactin Homo sapiens 53-62 6525362-6 1984 A disulfide dimeric form of prolactin with Mr of about 50 000 was isolated and characterized. Disulfides 2-11 prolactin Homo sapiens 28-37 6514782-3 1984 Therefore, the hPRL excretion pattern after 60 mg fenfluramine orally was examined in eight euthymic manic-depressive patients under long-term lithium medication, and in nine healthy subjects. Fenfluramine 50-62 prolactin Homo sapiens 15-19 6480809-10 1984 Pharmacological studies of TSH, TSH-alpha, and PRL release using thyroid hormones (T3), dopamine agonist (bromocriptine), TRH, and cholera toxin yielded the following results: 1) T3 after 3 days of incubation produced a dose-dependent inhibition of TSH, TSH-alpha, and PRL release. Triiodothyronine 83-85 prolactin Homo sapiens 47-50 6480809-10 1984 Pharmacological studies of TSH, TSH-alpha, and PRL release using thyroid hormones (T3), dopamine agonist (bromocriptine), TRH, and cholera toxin yielded the following results: 1) T3 after 3 days of incubation produced a dose-dependent inhibition of TSH, TSH-alpha, and PRL release. Dopamine 88-96 prolactin Homo sapiens 47-50 6480809-10 1984 Pharmacological studies of TSH, TSH-alpha, and PRL release using thyroid hormones (T3), dopamine agonist (bromocriptine), TRH, and cholera toxin yielded the following results: 1) T3 after 3 days of incubation produced a dose-dependent inhibition of TSH, TSH-alpha, and PRL release. Bromocriptine 106-119 prolactin Homo sapiens 47-50 6512754-1 1984 Incubation with high concentrations of dopamine (greater than or equal to 10(-3) mol/l) depressed the ability of goat placental lactogen, human placental lactogen, ovine prolactin and human growth hormone to compete with labelled hormone in radioreceptor assays for lactogenic activity, with the greatest effects on placental lactogen. Dopamine 39-47 prolactin Homo sapiens 170-179 6098913-5 1984 DMI acutely increased plasma PRL, whereas ZIM had an effect only after chronic pretreatment. Desipramine 0-3 prolactin Homo sapiens 29-32 6514782-4 1984 A fenfluramine-induced stimulation of hPRL release was observed exhibiting marked sex differences. Fenfluramine 2-14 prolactin Homo sapiens 38-42 6098913-6 1984 Chronic DMI but not ZIM increased baseline PRL. Desipramine 8-11 prolactin Homo sapiens 43-46 28305103-4 1984 Prolactin and thyroxine, in combination, improved development of tail regenerates as compared with treatment with prolactin or thyroxine singly, supporting the results of earlier in vivo studies. Prolactin 114-123 prolactin Homo sapiens 0-9 6486269-0 1984 Ratio of serum prolactin to haloperidol and early clinical outcome in acute psychosis. Haloperidol 28-39 prolactin Homo sapiens 15-24 6486269-1 1984 The ratio of the increase in serum prolactin concentration to steady-state haloperidol concentration in acutely psychotic women correlated with early clinical improvement. Haloperidol 75-86 prolactin Homo sapiens 35-44 6496669-7 1984 Peak PRL release by cells from both old and mature rats occurred after exposure to E2 doses 1/100th of those required for peak LH release. Luteinizing Hormone 127-129 prolactin Homo sapiens 5-8 6440662-0 1984 Progesterone inhibits prolactin and growth hormone release from fowl pituitary glands in vitro. Progesterone 0-12 prolactin Homo sapiens 22-31 6440662-3 1984 Stimulation of the release of prolactin and growth hormone by both hypothalamic extract and TRH was reduced following incubation with progesterone, and the reduction of the prolactin response to TRH was related to progesterone concentration. Progesterone 134-146 prolactin Homo sapiens 30-39 6440662-3 1984 Stimulation of the release of prolactin and growth hormone by both hypothalamic extract and TRH was reduced following incubation with progesterone, and the reduction of the prolactin response to TRH was related to progesterone concentration. Progesterone 214-226 prolactin Homo sapiens 30-39 6440662-3 1984 Stimulation of the release of prolactin and growth hormone by both hypothalamic extract and TRH was reduced following incubation with progesterone, and the reduction of the prolactin response to TRH was related to progesterone concentration. Progesterone 214-226 prolactin Homo sapiens 173-182 6437954-1 1984 Metergoline, a prolactin (PRL)-lowering drug with an antiserotoninergic activity, is known to restore menstruations and fertility in hyper-PRL patients even when PRL levels are not normalized. Metergoline 0-11 prolactin Homo sapiens 15-24 6440785-3 1984 Mean (+/- SE) plasma levels of PRL on day 7 in the sulpiride treated cycle were significantly higher than those in the control cycle (118 +/- 24 ng/ml vs. 14 +/- 4 ng/ml, p less than 0.001). Sulpiride 51-60 prolactin Homo sapiens 31-34 6436062-0 1984 Dissociation of serum prolactin response to sequential thyrotropin-releasing hormone and chlorpromazine stimulation in patients with primary empty sella syndrome. Chlorpromazine 89-103 prolactin Homo sapiens 22-31 6436062-4 1984 The mean maximal increase of serum PRL following CPZ, however, was 16.1 +/- 18.5 ng/ml (standard deviation) in the PESS group, whereas the mean maximal PRL response was 68.6 +/- 40.9 ng/ml in subjects with IG and 67.7 +/- 48.1 ng/ml in the seven normal women. Chlorpromazine 49-52 prolactin Homo sapiens 35-38 6532954-0 1984 Cord blood prolactin in normal & abnormal deliveries. Adenosine Monophosphate 32-35 prolactin Homo sapiens 11-20 6437954-1 1984 Metergoline, a prolactin (PRL)-lowering drug with an antiserotoninergic activity, is known to restore menstruations and fertility in hyper-PRL patients even when PRL levels are not normalized. Metergoline 0-11 prolactin Homo sapiens 26-29 6437954-1 1984 Metergoline, a prolactin (PRL)-lowering drug with an antiserotoninergic activity, is known to restore menstruations and fertility in hyper-PRL patients even when PRL levels are not normalized. Metergoline 0-11 prolactin Homo sapiens 139-142 6437954-1 1984 Metergoline, a prolactin (PRL)-lowering drug with an antiserotoninergic activity, is known to restore menstruations and fertility in hyper-PRL patients even when PRL levels are not normalized. Metergoline 0-11 prolactin Homo sapiens 139-142 6151560-0 1984 Prolactin response to chlorpromazine in hypogonadism. Chlorpromazine 22-36 prolactin Homo sapiens 0-9 6437954-3 1984 In a double-blind cross-over study in 8 normal males, repeated administration of metergoline enhanced the LH response to LHRH and reduced the PRL response to TRH; for females, three different tests were performed on days 5, 8 and 21 of two different menstrual cycles, each test being preceded by metergoline or by placebo administration. Metergoline 81-92 prolactin Homo sapiens 142-145 6437954-4 1984 Metergoline always reduced the PRL response to TRH; on the 5th day, metergoline reduced the FSH response to LHRH and on the 21st day enhanced the LH response to LHRH. Metergoline 0-11 prolactin Homo sapiens 31-34 6090494-2 1984 In women with hyperprolactinemia whose pituitary-adrenal function was normal, there was significant correlation between serum PRL and dehydroepiandrosterone sulfate [(DHEA-S) gamma = 0.48, P less than 0.05, n = 34] and DHEA (gamma = 0.50, P less than 0.05, n = 34), but not with androstenedione. Dehydroepiandrosterone Sulfate 134-164 prolactin Homo sapiens 126-129 6090494-2 1984 In women with hyperprolactinemia whose pituitary-adrenal function was normal, there was significant correlation between serum PRL and dehydroepiandrosterone sulfate [(DHEA-S) gamma = 0.48, P less than 0.05, n = 34] and DHEA (gamma = 0.50, P less than 0.05, n = 34), but not with androstenedione. Dehydroepiandrosterone 167-173 prolactin Homo sapiens 126-129 6090494-2 1984 In women with hyperprolactinemia whose pituitary-adrenal function was normal, there was significant correlation between serum PRL and dehydroepiandrosterone sulfate [(DHEA-S) gamma = 0.48, P less than 0.05, n = 34] and DHEA (gamma = 0.50, P less than 0.05, n = 34), but not with androstenedione. Dehydroepiandrosterone 167-171 prolactin Homo sapiens 126-129 6434573-0 1984 Prolactin and thyrotropin responses to thyrotropin-releasing hormone and metoclopramide in men with chronic alcoholism. Metoclopramide 73-87 prolactin Homo sapiens 0-9 6434684-4 1984 Dopamine inhibited the release of prolactin stimulated by hypothalamic tissue or TRH, in a concentration-dependent fashion. Dopamine 0-8 prolactin Homo sapiens 34-43 6434684-6 1984 After pituitary glands were preincubated for 20 h in medium containing oestradiol-17 beta, the basal release of prolactin was enhanced as was the response to TRH. Estradiol 71-89 prolactin Homo sapiens 112-121 6434684-7 1984 Both basal and TRH-stimulated release of prolactin from the oestrogen-primed pituitary glands was inhibited by dopamine, an effect blocked by pimozide. Dopamine 111-119 prolactin Homo sapiens 41-50 6434684-7 1984 Both basal and TRH-stimulated release of prolactin from the oestrogen-primed pituitary glands was inhibited by dopamine, an effect blocked by pimozide. Pimozide 142-150 prolactin Homo sapiens 41-50 6434684-10 1984 Dopaminergic activity was also present in the hypothalami, since pimozide enhanced the prolactin-releasing activity of the medium. Pimozide 65-73 prolactin Homo sapiens 87-96 6434684-12 1984 These results suggest that dopamine inhibits release of prolactin directly from the pituitary gland only when prolactin secretion is high. Dopamine 27-35 prolactin Homo sapiens 56-65 6434684-12 1984 These results suggest that dopamine inhibits release of prolactin directly from the pituitary gland only when prolactin secretion is high. Dopamine 27-35 prolactin Homo sapiens 110-119 6434684-14 1984 Dopamine may also play an inhibitory role in the regulation of secretion of the prolactin-releasing factor. Dopamine 0-8 prolactin Homo sapiens 80-89 6480800-0 1984 Twenty four-hour prolactin profiles and prolactin responses to dopamine in long distance running women. Dopamine 63-71 prolactin Homo sapiens 40-49 6481291-3 1984 When prolactin was added along with hCG in four of six corpora lutea, however, progesterone production significantly increased and in three of six corpora lutea oestradiol production was increased above that induced by hCG alone. Progesterone 79-91 prolactin Homo sapiens 5-14 6481291-3 1984 When prolactin was added along with hCG in four of six corpora lutea, however, progesterone production significantly increased and in three of six corpora lutea oestradiol production was increased above that induced by hCG alone. Estradiol 161-171 prolactin Homo sapiens 5-14 6394371-5 1984 In normal volunteers, metoclopramide increased both PAC and PRL levels, and showed a maximum level at 30 minutes after injection. Metoclopramide 22-36 prolactin Homo sapiens 60-63 6394371-7 1984 Moreover another antagonist, sulpiride also increased PRL but contrary tended to decrease PAC. Sulpiride 29-38 prolactin Homo sapiens 54-57 6440815-5 1984 Serum prolactin levels decreased significantly (p less than 0.005) from two hours after the administration of bromocriptine and remained in a very low range in all phases of the cycles until the end of the experiments. Bromocriptine 110-123 prolactin Homo sapiens 6-15 6519314-2 1984 After gel filtration of serum sample on Sephadex G-100 (superfine) column, a few hPRL peaks were detected by RIA. sephadex 40-54 prolactin Homo sapiens 81-85 6519314-5 1984 Most of big-big, medium-big and big hPRL were converted to little hPRL after mercaptoethanol treatment. Mercaptoethanol 77-92 prolactin Homo sapiens 36-40 6519314-5 1984 Most of big-big, medium-big and big hPRL were converted to little hPRL after mercaptoethanol treatment. Mercaptoethanol 77-92 prolactin Homo sapiens 66-70 6496148-3 1984 While prolactin was decreased following dexamethasone in controls and nonendogenous depressed patients, in endogenous depressed patients prolactin was increased by 30%. Dexamethasone 40-53 prolactin Homo sapiens 6-15 6496148-4 1984 Due to this inverse prolactin response to dexamethasone, the sensitivity of this test should be considerably increased by using a higher dexamethasone dosage. Dexamethasone 42-55 prolactin Homo sapiens 20-29 6496148-4 1984 Due to this inverse prolactin response to dexamethasone, the sensitivity of this test should be considerably increased by using a higher dexamethasone dosage. Dexamethasone 137-150 prolactin Homo sapiens 20-29 6507109-3 1984 Bromocriptine lowered serum prolactin levels, thus confirming its absorption. Bromocriptine 0-13 prolactin Homo sapiens 28-37 6093618-6 1984 The plasma levels of prolactin showed a marked increase after the administration of fentanyl even in the presence of a high etomidate plasma level. Fentanyl 84-92 prolactin Homo sapiens 21-30 6093618-6 1984 The plasma levels of prolactin showed a marked increase after the administration of fentanyl even in the presence of a high etomidate plasma level. Etomidate 124-133 prolactin Homo sapiens 21-30 6149772-7 1984 PRL decreased from baseline following both d-amphetamine and placebo and there was no significant drug-placebo difference. Dextroamphetamine 43-56 prolactin Homo sapiens 0-3 6434210-4 1984 Bromocriptine reduced serum prolactin levels to normal; subsequently, serum testosterone levels increased and libido and potency improved markedly in each man. Bromocriptine 0-13 prolactin Homo sapiens 28-37 6430683-1 1984 Analogs of the aminothiol cysteamine (CySH) have been studied to clarify the structural features required for exertion of inhibitory effects on PRL. aminothiol cysteamine 15-36 prolactin Homo sapiens 144-147 6430683-4 1984 The aromatic compounds 2-aminothiophenol, 3-aminothiophenol, and 4-aminothiophenol shared with CySH the ability to inhibit PRL assayability and release, but were all more potent. 2-aminothiophenol 23-40 prolactin Homo sapiens 123-126 6430683-4 1984 The aromatic compounds 2-aminothiophenol, 3-aminothiophenol, and 4-aminothiophenol shared with CySH the ability to inhibit PRL assayability and release, but were all more potent. 3-Aminothiophenol 42-59 prolactin Homo sapiens 123-126 6430683-4 1984 The aromatic compounds 2-aminothiophenol, 3-aminothiophenol, and 4-aminothiophenol shared with CySH the ability to inhibit PRL assayability and release, but were all more potent. 4-aminothiophenol 65-82 prolactin Homo sapiens 123-126 6430683-6 1984 Thiols such as mercaptoethanol, cysteine, glutathione, and others without nearby amino groups were stimulators of PRL assayability and release. Sulfhydryl Compounds 0-6 prolactin Homo sapiens 114-117 6430683-6 1984 Thiols such as mercaptoethanol, cysteine, glutathione, and others without nearby amino groups were stimulators of PRL assayability and release. Mercaptoethanol 15-30 prolactin Homo sapiens 114-117 6430683-6 1984 Thiols such as mercaptoethanol, cysteine, glutathione, and others without nearby amino groups were stimulators of PRL assayability and release. Cysteine 32-40 prolactin Homo sapiens 114-117 6430683-6 1984 Thiols such as mercaptoethanol, cysteine, glutathione, and others without nearby amino groups were stimulators of PRL assayability and release. Glutathione 42-53 prolactin Homo sapiens 114-117 6430683-9 1984 Though CySH and 4-aminothiophenol induced changes in the electrophoretic migration of granule PRL, similar changes occurred in the migration of standard purified hormone despite the known absence of immunochemical effects. 4-aminothiophenol 16-33 prolactin Homo sapiens 94-97 6430683-11 1984 We conclude that the inhibitory aminothiol action on PRL requires the thiol rather than the sulfide form and involves a reversible interaction which diminishes the immunochemical recognition of granule PRL. Aminothiol 32-42 prolactin Homo sapiens 53-56 6430683-11 1984 We conclude that the inhibitory aminothiol action on PRL requires the thiol rather than the sulfide form and involves a reversible interaction which diminishes the immunochemical recognition of granule PRL. Aminothiol 32-42 prolactin Homo sapiens 202-205 6430683-11 1984 We conclude that the inhibitory aminothiol action on PRL requires the thiol rather than the sulfide form and involves a reversible interaction which diminishes the immunochemical recognition of granule PRL. Sulfhydryl Compounds 37-42 prolactin Homo sapiens 53-56 6430683-11 1984 We conclude that the inhibitory aminothiol action on PRL requires the thiol rather than the sulfide form and involves a reversible interaction which diminishes the immunochemical recognition of granule PRL. Sulfhydryl Compounds 37-42 prolactin Homo sapiens 202-205 6434315-2 1984 The study was oriented towards the endocrine effects of this combination since it was known from our previous studies that megestrol acetate induces suppression of serum gonadotropins and of the pituitary-adrenal axis, a decrease of peripheral concentration of SHBG and of estradiol, and an increase of basal and TRH-stimulated plasma prolactin concentration. Megestrol Acetate 123-140 prolactin Homo sapiens 335-344 6434315-3 1984 Tamoxifen, on the other hand, produces a decrease of prolactin and gonadotropins, whilst estradiol remains unaffected. Tamoxifen 0-9 prolactin Homo sapiens 53-62 6434315-5 1984 The results show that addition of tamoxifen to megestrol acetate treatment annihilated the hyper-response of prolactin to TRH stimulation, while basal prolactin levels remained unaffected. Tamoxifen 34-43 prolactin Homo sapiens 109-118 6434315-5 1984 The results show that addition of tamoxifen to megestrol acetate treatment annihilated the hyper-response of prolactin to TRH stimulation, while basal prolactin levels remained unaffected. Megestrol Acetate 47-64 prolactin Homo sapiens 109-118 6437958-1 1984 We have assessed the gonadotropin, TSH and PRL responses to the non aromatizable androgens, mesterolone and fluoxymestrone, in 27 patients with primary testicular failure. Fluoxymesterone 108-122 prolactin Homo sapiens 43-46 6746860-2 1984 In patient 1 with a large prolactinoma, a marked reduction in size and a remarkable decrease in elevated serum PRL levels occurred after bromocriptine treatment for 8 months. Bromocriptine 137-150 prolactin Homo sapiens 111-114 6746862-2 1984 Dopamine regulation of prolactin secretion. Dopamine 0-8 prolactin Homo sapiens 23-32 6746862-3 1984 Previous studies demonstrated that high doses of dopamine administered as a constant infusion were capable of suppressing PRL secretion in both normal and hyperprolactinemic individuals. Dopamine 49-57 prolactin Homo sapiens 122-125 6746862-4 1984 The present study was designed to examine the dose-response relationship of PRL suppression to low doses of dopamine (between 0.06 and 4 micrograms/kg X min) infused in a step-wise fashion. Dopamine 108-116 prolactin Homo sapiens 76-79 6095132-2 1984 The GH response was blunted following each antagonist used, PRL secretion was higher after yohimbine and diminished after phentolamine when compared to controls. Yohimbine 91-100 prolactin Homo sapiens 60-63 6095132-2 1984 The GH response was blunted following each antagonist used, PRL secretion was higher after yohimbine and diminished after phentolamine when compared to controls. Phentolamine 122-134 prolactin Homo sapiens 60-63 6209589-2 1984 Concentrations of plasma prolactin and growth hormone have been measured and correlated with hypothalamic serotonin and 5-hydroxyindole acetic acid (5HIAA) levels. Serotonin 106-115 prolactin Homo sapiens 25-34 6209589-2 1984 Concentrations of plasma prolactin and growth hormone have been measured and correlated with hypothalamic serotonin and 5-hydroxyindole acetic acid (5HIAA) levels. 5-hydroxyindole acetic acid 120-147 prolactin Homo sapiens 25-34 6209589-2 1984 Concentrations of plasma prolactin and growth hormone have been measured and correlated with hypothalamic serotonin and 5-hydroxyindole acetic acid (5HIAA) levels. Hydroxyindoleacetic Acid 149-154 prolactin Homo sapiens 25-34 6209589-4 1984 The administration of the MAO inhibitor, pargyline, produced dose- and time-related reductions in brain MAO type A and B activities, hypothalamic 5HIAA concentrations and plasma growth hormone levels, but increased the hypothalamic serotonin and plasma prolactin concentrations. Pargyline 41-50 prolactin Homo sapiens 253-262 6209589-5 1984 Clorgyline administration inhibited MAO type A (but not type B) activity and also increased hypothalamic serotonin and plasma prolactin levels, while reducing hypothalamic 5HIAA and circulating growth hormone concentrations. Clorgyline 0-10 prolactin Homo sapiens 126-135 6435653-2 1984 Fipexide induced significant decrease (P less than 0.05) in serum prolactin (PRL) values at 90 and 120 min after drug administration, without affecting serum growth hormone (GH), gonadotropin (LH and FSH), thyrotropin (TSH) and cortisol values. fipexide 0-8 prolactin Homo sapiens 66-75 6432375-3 1984 Comparison of bromocriptine with placebo in two double blind studies showed a modest increase in sexual interest when his prolactin levels fell to normal. Bromocriptine 14-27 prolactin Homo sapiens 122-131 6146654-0 1984 Effects of synthetic mammalian thyrotrophin releasing hormone, somatostatin and dopamine on the secretion of prolactin and growth hormone from amphibian and reptilian pituitary glands incubated in vitro. Dopamine 80-88 prolactin Homo sapiens 109-118 6146654-5 1984 Dopamine had little effect alone, but inhibited HE- and TRH-stimulated release of prolactin, but not GH, in both amphibia and reptiles. Dopamine 0-8 prolactin Homo sapiens 82-91 6146654-5 1984 Dopamine had little effect alone, but inhibited HE- and TRH-stimulated release of prolactin, but not GH, in both amphibia and reptiles. Helium 48-50 prolactin Homo sapiens 82-91 6330154-9 1984 Our results suggest that endogenous opiates have a prominent inhibitory effect on pituitary gonadotropin and PRL secretion only during the luteal phase of the menstrual cycle. Opiate Alkaloids 36-43 prolactin Homo sapiens 109-112 6540876-4 1984 Bromocriptine therapy resulted in a cessation of galactorrhoea and normalization of serum prolactin concentrations. Bromocriptine 0-13 prolactin Homo sapiens 90-99 6146751-4 1984 Treatment with either bromocriptine or pergolide relieved symptoms and suppressed prolactin secretion in most patients. Bromocriptine 22-35 prolactin Homo sapiens 82-91 6146751-4 1984 Treatment with either bromocriptine or pergolide relieved symptoms and suppressed prolactin secretion in most patients. Pergolide 39-48 prolactin Homo sapiens 82-91 6204691-0 1984 Polyamine requirement for prolactin action on macromolecular synthesis in the MCF-7 human mammary epithelial cell line. Polyamines 0-9 prolactin Homo sapiens 26-35 6204691-3 1984 Spermidine, in addition to insulin and hydrocortisone, was also essential for prolactin to manifest a stimulation of the rate of [3H]uridine incorporation; this effect of spermidine was optimal with spermidine concentrations between 1 and 5 mM. Spermidine 0-10 prolactin Homo sapiens 78-87 6204691-3 1984 Spermidine, in addition to insulin and hydrocortisone, was also essential for prolactin to manifest a stimulation of the rate of [3H]uridine incorporation; this effect of spermidine was optimal with spermidine concentrations between 1 and 5 mM. Tritium 130-133 prolactin Homo sapiens 78-87 6204691-3 1984 Spermidine, in addition to insulin and hydrocortisone, was also essential for prolactin to manifest a stimulation of the rate of [3H]uridine incorporation; this effect of spermidine was optimal with spermidine concentrations between 1 and 5 mM. Uridine 133-140 prolactin Homo sapiens 78-87 6204691-3 1984 Spermidine, in addition to insulin and hydrocortisone, was also essential for prolactin to manifest a stimulation of the rate of [3H]uridine incorporation; this effect of spermidine was optimal with spermidine concentrations between 1 and 5 mM. Spermidine 171-181 prolactin Homo sapiens 78-87 6204691-4 1984 Prolactin also stimulated the rate of [3H]leucine incorporation into total cellular protein and into an isoelectrically precipitable (pH 4.6) phosphoprotein fraction. Tritium 39-41 prolactin Homo sapiens 0-9 6204691-4 1984 Prolactin also stimulated the rate of [3H]leucine incorporation into total cellular protein and into an isoelectrically precipitable (pH 4.6) phosphoprotein fraction. Leucine 42-49 prolactin Homo sapiens 0-9 6204691-5 1984 The actions of prolactin on total protein and phosphoprotein synthesis were only expressed if spermidine, in addition to insulin and hydrocortisone, was contained in the culture medium. Spermidine 94-104 prolactin Homo sapiens 15-24 6204691-5 1984 The actions of prolactin on total protein and phosphoprotein synthesis were only expressed if spermidine, in addition to insulin and hydrocortisone, was contained in the culture medium. Hydrocortisone 133-147 prolactin Homo sapiens 15-24 6438614-0 1984 [Effect of dopamine on gonadotropin and prolactin secretion in patients with polycystic ovary syndrome]. Dopamine 11-19 prolactin Homo sapiens 40-49 6504724-0 1984 [Effect of metoclopramide on prolactin secretion in patients with primary hypothyroidism]. Metoclopramide 11-25 prolactin Homo sapiens 29-38 6429989-1 1984 In the first part of this study, we have demonstrated that, in 7 patients with untreated thyrotoxicosis, a 7 day regime of the long acting dopamine antagonist metoclopramide (10 mg orally 8 hourly) produces more adequate dopaminergic blockade at pituitary level than a single oral 10 mg dose of the compound as assessed by serum prolactin responses. Dopamine 139-147 prolactin Homo sapiens 329-338 6429989-1 1984 In the first part of this study, we have demonstrated that, in 7 patients with untreated thyrotoxicosis, a 7 day regime of the long acting dopamine antagonist metoclopramide (10 mg orally 8 hourly) produces more adequate dopaminergic blockade at pituitary level than a single oral 10 mg dose of the compound as assessed by serum prolactin responses. Metoclopramide 159-173 prolactin Homo sapiens 329-338 6429989-6 1984 Basal prolactin levels were similar in thyrotoxic and euthyroid individuals and the increase in prolactin, seen in both groups after metoclopramide, was smaller in the thyrotoxic group than in the euthyroid group. Metoclopramide 133-147 prolactin Homo sapiens 96-105 6429989-8 1984 After metoclopramide there was a significant decline in prolactin responsiveness in the euthyroid group, and a similar, though insignificant, trend in the thyrotoxic patients. Metoclopramide 6-20 prolactin Homo sapiens 56-65 6741402-3 1984 When the sodium chloride, potassium chloride, sucrose, and choline chloride media at 387 mmol/kg were compared in another 7 experiments, potassium chloride increased Prl secretion more effectively than the others (10%, P less than 0.05). Potassium Chloride 137-155 prolactin Homo sapiens 166-169 6741402-7 1984 These results indicate that the intracellular ionic concentrations, probably of potassium ion or of chloride ion, are of importance in the regulation of the synthesis and secretion of decidual Prl in vitro. Potassium 80-89 prolactin Homo sapiens 193-196 6741402-7 1984 These results indicate that the intracellular ionic concentrations, probably of potassium ion or of chloride ion, are of importance in the regulation of the synthesis and secretion of decidual Prl in vitro. Chlorides 100-108 prolactin Homo sapiens 193-196 6478270-0 1984 The stimulation of prolactin secretion by taurine: studies on the site of action. Taurine 42-49 prolactin Homo sapiens 19-28 6478270-1 1984 Taurine"s site of action within the central nervous system was localized by studying its effect on prolactin secretion following the microinfusion of 125 nmoles of this amino acid into discrete regions of the brain. Taurine 0-7 prolactin Homo sapiens 99-108 6478270-2 1984 Taurine was found to stimulate prolactin secretion only when microinfused into the arcuate nucleus of the hypothalamus. Taurine 0-7 prolactin Homo sapiens 31-40 6478270-5 1984 These studies extend previous observations on the prolactin-releasing action of centrally administered taurine and suggest further that the arcuate nucleus is one target site for this action. Taurine 103-110 prolactin Homo sapiens 50-59 6722826-0 1984 Effects of reserpine on prolactin levels and incidence of breast cancer in postmenopausal women. Reserpine 11-20 prolactin Homo sapiens 24-33 6090494-2 1984 In women with hyperprolactinemia whose pituitary-adrenal function was normal, there was significant correlation between serum PRL and dehydroepiandrosterone sulfate [(DHEA-S) gamma = 0.48, P less than 0.05, n = 34] and DHEA (gamma = 0.50, P less than 0.05, n = 34), but not with androstenedione. Androstenedione 279-294 prolactin Homo sapiens 126-129 6090494-3 1984 Long term administration of sulpiride to normal women increased both serum PRL and DHEA-S, whereas acute elevation of PRL after a single iv dose of domperidone had no influence on the serum DHEA-S levels. Sulpiride 28-37 prolactin Homo sapiens 75-78 6090494-3 1984 Long term administration of sulpiride to normal women increased both serum PRL and DHEA-S, whereas acute elevation of PRL after a single iv dose of domperidone had no influence on the serum DHEA-S levels. Domperidone 148-159 prolactin Homo sapiens 118-121 6090494-8 1984 PRL, when added in combination with ACTH, potentiated the effect of ACTH on DHEA-S and DHEA but not on androstenedione and cortisol secretion on the seventh day in culture. Dehydroepiandrosterone 76-82 prolactin Homo sapiens 0-3 6090494-8 1984 PRL, when added in combination with ACTH, potentiated the effect of ACTH on DHEA-S and DHEA but not on androstenedione and cortisol secretion on the seventh day in culture. Dehydroepiandrosterone 76-80 prolactin Homo sapiens 0-3 6090494-8 1984 PRL, when added in combination with ACTH, potentiated the effect of ACTH on DHEA-S and DHEA but not on androstenedione and cortisol secretion on the seventh day in culture. Androstenedione 103-118 prolactin Homo sapiens 0-3 6090494-10 1984 Increases in DHEA-S and DHEA but not androstenedione in vitro and correlation between serum PRL and DHEA-S and DHEA but not androstenedione in women with hyperprolactinemia suggest that the synergistic effect of PRL on adrenal androgen secretion may result from partial inhibition of adrenal 3 beta-hydroxysteroid dehydrogenase. Dehydroepiandrosterone 100-106 prolactin Homo sapiens 92-95 6722826-3 1984 We measured prolactin levels in 15 women who had been taking reserpine-containing drugs for at least 5 years and compared them to levels in 15 women taking non-reserpine-containing antihypertensives and 15 women taking no antihypertensive medicines. Reserpine 61-70 prolactin Homo sapiens 12-21 6432759-0 1984 Bromocriptine in the management of infertile men after surgery of prolactin secreting adenomas. Bromocriptine 0-13 prolactin Homo sapiens 66-75 6432759-1 1984 This study evaluated bromocriptine treatment in nine patients with prolactin secreting adenomas who continued to have elevated circulating levels of prolactin after surgery, and who were interested in improving their sperm counts. Bromocriptine 21-34 prolactin Homo sapiens 67-76 6432759-1 1984 This study evaluated bromocriptine treatment in nine patients with prolactin secreting adenomas who continued to have elevated circulating levels of prolactin after surgery, and who were interested in improving their sperm counts. Bromocriptine 21-34 prolactin Homo sapiens 149-158 6432759-8 1984 Bromocriptine therefore seems useful in the management of this type of patient because of the observed decline in prolactin levels and the increase in sperm counts. Bromocriptine 0-13 prolactin Homo sapiens 114-123 6427273-13 1984 These data suggest that men with serum PRL levels above 50 ng/ml maintain a normal diurnal pattern of serum testosterone at a lower set point, and demonstrate hypogonadism with reduced urinary LH excretion and NPT. Testosterone 108-120 prolactin Homo sapiens 39-42 6427273-13 1984 These data suggest that men with serum PRL levels above 50 ng/ml maintain a normal diurnal pattern of serum testosterone at a lower set point, and demonstrate hypogonadism with reduced urinary LH excretion and NPT. Luteinizing Hormone 193-195 prolactin Homo sapiens 39-42 6725527-2 1984 BC induced a significant decrease in plasma norepinephrine in the supine [167.7 +/- 16.8 (SEM) vs. 101.9 +/- 33.7 pg/ml, P less than 0.005] and upright positions [397.3 +/- 27.7 vs. 211.3 +/- 26.7 pg/ml, P less than 0.005], a decrease in systolic and diastolic BP and a decrease in plasma PRL (P less than 0.01). Bromocriptine 0-2 prolactin Homo sapiens 289-292 6736849-3 1984 Combined treatment with oestradiol and progesterone induced physiological development of the lobuloalveolar structure of the mammary gland in the presence of prolactin. Estradiol 24-34 prolactin Homo sapiens 158-167 6736849-3 1984 Combined treatment with oestradiol and progesterone induced physiological development of the lobuloalveolar structure of the mammary gland in the presence of prolactin. Progesterone 39-51 prolactin Homo sapiens 158-167 6736849-4 1984 Suppression of prolactin by bromocriptine prevented this effect. Bromocriptine 28-41 prolactin Homo sapiens 15-24 6736849-6 1984 The interaction of oestradiol-17 beta with prolactin appears to be a main trigger for mammary gland development. Estradiol 19-37 prolactin Homo sapiens 43-52 6736849-10 1984 Bromocriptine treatment suppressed prolactin concentrations in ewes to minimal values but did not affect ovine placental lactogen concentrations. Bromocriptine 0-13 prolactin Homo sapiens 35-44 6431039-6 1984 PRL release from the pituitary by MCP was suppressed significantly (p less than 0.01) by pretreatment with bromocriptine. Bromocriptine 107-120 prolactin Homo sapiens 0-3 6483849-6 1984 When bromocriptine, a prolactin lowering drug, was administered to hyperprolactinemic women in a double blind crossover study, there was a significant and progressive decrease of hostility, depression and anxiety while on bromocriptine, parallel with the decrease in prolactin and no change on placebo. Bromocriptine 5-18 prolactin Homo sapiens 22-31 6483849-6 1984 When bromocriptine, a prolactin lowering drug, was administered to hyperprolactinemic women in a double blind crossover study, there was a significant and progressive decrease of hostility, depression and anxiety while on bromocriptine, parallel with the decrease in prolactin and no change on placebo. Bromocriptine 5-18 prolactin Homo sapiens 72-81 6462509-1 1984 In a 32 year old woman harboring a macroprolactinoma with supra and laterosellar extension, bromocriptine was able to reduce the size of the tumor and the very high circulating levels of prolactin, restoring ovulatory menstrual cycles. Bromocriptine 92-105 prolactin Homo sapiens 40-49 6331435-0 1984 Prolactin receptors on human lymphocytes and their modulation by cyclosporine. Cyclosporine 65-77 prolactin Homo sapiens 0-9 6331435-3 1984 The specific binding of [125I]prolactin to these cells can be selectively enhanced at certain concentrations and blocked by higher concentrations of cyclosporine , a known immunosuppressive agent which inhibits the mitogenesis of T-cells. Cyclosporine 149-161 prolactin Homo sapiens 30-39 6547344-2 1984 In the anterior pituitary gland, dopamine controls the release of prolactin from the mammotrophs. Dopamine 33-41 prolactin Homo sapiens 66-75 6376278-2 1984 Several cells of the glandular lobules are erythrosin-positive and immunoreactive after incubation with a mammalian antibody to human prolactin. Erythrosine 43-53 prolactin Homo sapiens 134-143 6427260-11 1984 We conclude that 1) hyperprolactinemic women have a heterogeneous pattern of pulsatile gonadotropin secretion; 2) serum E2 correlates with LH pulse frequency but not pulse amplitude; 3) LH pulsations and PRL pulsations are asynchronous in hyperprolactinemic women before and during bromocriptine therapy; and 4) normal PRL secretory patterns are not required for ovulatory function in hyperprolactinemic women treated with bromocriptine. Luteinizing Hormone 186-188 prolactin Homo sapiens 204-207 6427260-11 1984 We conclude that 1) hyperprolactinemic women have a heterogeneous pattern of pulsatile gonadotropin secretion; 2) serum E2 correlates with LH pulse frequency but not pulse amplitude; 3) LH pulsations and PRL pulsations are asynchronous in hyperprolactinemic women before and during bromocriptine therapy; and 4) normal PRL secretory patterns are not required for ovulatory function in hyperprolactinemic women treated with bromocriptine. Luteinizing Hormone 186-188 prolactin Homo sapiens 319-322 6427264-7 1984 The basal levels of PRL in the first patient were elevated at both T4 doses; also, her PRL responses to TRH and metoclopramide were exaggerated and, compared to normal values, disproportionate to her TSH responses to these provocative agents. Metoclopramide 112-126 prolactin Homo sapiens 20-23 6427264-7 1984 The basal levels of PRL in the first patient were elevated at both T4 doses; also, her PRL responses to TRH and metoclopramide were exaggerated and, compared to normal values, disproportionate to her TSH responses to these provocative agents. Metoclopramide 112-126 prolactin Homo sapiens 87-90 6427264-7 1984 The basal levels of PRL in the first patient were elevated at both T4 doses; also, her PRL responses to TRH and metoclopramide were exaggerated and, compared to normal values, disproportionate to her TSH responses to these provocative agents. Thyrotropin 200-203 prolactin Homo sapiens 20-23 6427264-8 1984 In contrast, the other two patients had normal basal PRL concentrations and normal or near-normal PRL responses to TRH and metoclopramide. Metoclopramide 123-137 prolactin Homo sapiens 98-101 6726108-0 1984 An investigation of the involvement of calcium in the control of prolactin secretion: studies with low calcium, methoxyverapamil, cobalt and manganese. Calcium 39-46 prolactin Homo sapiens 65-74 6726108-1 1984 The possible role of calcium as a primary mediator in the control of prolactin secretion from normal pituitary cells was examined. Calcium 21-28 prolactin Homo sapiens 69-78 6726108-3 1984 The calcium channel antagonists, methoxyverapamil, cobalt and manganese, inhibited basal, TRH- and K+-stimulated prolactin secretion. Gallopamil 33-49 prolactin Homo sapiens 113-122 6726108-3 1984 The calcium channel antagonists, methoxyverapamil, cobalt and manganese, inhibited basal, TRH- and K+-stimulated prolactin secretion. Cobalt 51-57 prolactin Homo sapiens 113-122 6726108-3 1984 The calcium channel antagonists, methoxyverapamil, cobalt and manganese, inhibited basal, TRH- and K+-stimulated prolactin secretion. Manganese 62-71 prolactin Homo sapiens 113-122 6726108-4 1984 In addition, prolactin secretion stimulated by a phosphodiesterase inhibitor, isobutylmethylxanthine, which increases cellular cyclic AMP, was inhibited by these Ca2+ antagonists. 1-Methyl-3-isobutylxanthine 78-100 prolactin Homo sapiens 13-22 6726108-4 1984 In addition, prolactin secretion stimulated by a phosphodiesterase inhibitor, isobutylmethylxanthine, which increases cellular cyclic AMP, was inhibited by these Ca2+ antagonists. Cyclic AMP 127-137 prolactin Homo sapiens 13-22 6483092-7 1984 The basal serum prolactin (PRL) level was elevated at 790ng/ml, but other hormone basal plasma levels were within normal limits despite decrease in FSH, LH, The LH, FSH and PRL demonstrated a blunted response to LH-RH (100 micrograms). Luteinizing Hormone 161-163 prolactin Homo sapiens 27-30 6483092-7 1984 The basal serum prolactin (PRL) level was elevated at 790ng/ml, but other hormone basal plasma levels were within normal limits despite decrease in FSH, LH, The LH, FSH and PRL demonstrated a blunted response to LH-RH (100 micrograms). Luteinizing Hormone 161-163 prolactin Homo sapiens 173-176 6738811-1 1984 Results of previous studies have revealed that prolactin causes a delayed (12-16 h) increase in the rate of synthesis and turnover of dopamine (DA) in terminals of tuberoinfundibular (TI) neurons in the median eminence. Dopamine 134-142 prolactin Homo sapiens 47-56 6738811-1 1984 Results of previous studies have revealed that prolactin causes a delayed (12-16 h) increase in the rate of synthesis and turnover of dopamine (DA) in terminals of tuberoinfundibular (TI) neurons in the median eminence. Dopamine 144-146 prolactin Homo sapiens 47-56 6738811-6 1984 Hypophysectomy or treatment with bromocriptine (a DA agonist) reduce circulating levels of prolactin and reduce the rate of DA synthesis in the median eminence. Bromocriptine 33-46 prolactin Homo sapiens 91-100 6738811-6 1984 Hypophysectomy or treatment with bromocriptine (a DA agonist) reduce circulating levels of prolactin and reduce the rate of DA synthesis in the median eminence. Dopamine 50-52 prolactin Homo sapiens 91-100 6738811-8 1984 administration of prolactin to these animals increases the rate of DA synthesis in the median eminence within 4 h (rapid "tonic" component) and then causes a further increase after 12 h (delayed "induction" component); only the latter component is blocked by treatment with cycloheximide, indicating the involvement in protein synthesis. Cycloheximide 274-287 prolactin Homo sapiens 18-27 6747379-9 1984 On BBT, the resumption of ovulation tended to occur when the prolactin level, rather than the hCG level, returned to its normal range. bbt 3-6 prolactin Homo sapiens 61-70 6147051-10 1984 Three out of the six subjects tested showed an increase in serum prolactin levels in response to the highest dose of oxmetidine but this was not statistically significant. oxmetidine 117-127 prolactin Homo sapiens 65-74 6088162-0 1984 [Changes in serum prolactin during short-term treatment with cimetidine and ranitidine in males with ulcer]. Cimetidine 61-71 prolactin Homo sapiens 18-27 6088162-0 1984 [Changes in serum prolactin during short-term treatment with cimetidine and ranitidine in males with ulcer]. Ranitidine 76-86 prolactin Homo sapiens 18-27 6436078-4 1984 Pretreatment PRL levels, 180--420 ng/ml, were normalized by 7.5--12.5 mg/day of Bromocriptine treatment causing a rapid decrease in plasma PRL, reaching a plateau within several days. Bromocriptine 80-93 prolactin Homo sapiens 13-16 6436078-4 1984 Pretreatment PRL levels, 180--420 ng/ml, were normalized by 7.5--12.5 mg/day of Bromocriptine treatment causing a rapid decrease in plasma PRL, reaching a plateau within several days. Bromocriptine 80-93 prolactin Homo sapiens 139-142 6720732-0 1984 Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma. Thioridazine 21-33 prolactin Homo sapiens 72-81 6375368-2 1984 It was noted that tetrahydroaldosterone-3-glucuronide levels were highest in those cases which exhibited the highest prolactin levels. tetrahydroaldosterone 3 beta-glucosiduronic acid 18-53 prolactin Homo sapiens 117-126 6720732-0 1984 Interactions between thioridazine and bromocriptine in a patient with a prolactin-secreting pituitary adenoma. Bromocriptine 38-51 prolactin Homo sapiens 72-81 6720732-4 1984 His serum prolactin level fell to the 400 ng/ml range during bromocriptine therapy but rose whenever the antipsychotic thioridazine was added to his regimen. Bromocriptine 61-74 prolactin Homo sapiens 10-19 6720732-4 1984 His serum prolactin level fell to the 400 ng/ml range during bromocriptine therapy but rose whenever the antipsychotic thioridazine was added to his regimen. Thioridazine 119-131 prolactin Homo sapiens 10-19 6721674-0 1984 Growth hormone and prolactin response to apomorphine in schizophrenia and the major affective disorders. Apomorphine 41-52 prolactin Homo sapiens 19-28 6721674-2 1984 The responses of serum prolactin (PRL) and growth hormone (GH) to the dopamine agonist apomorphine hydrochloride (0.75 mg subcutaneously) were studied in a large group of unmedicated hospitalized patients with functional psychoses. Dopamine 70-78 prolactin Homo sapiens 23-32 6721674-2 1984 The responses of serum prolactin (PRL) and growth hormone (GH) to the dopamine agonist apomorphine hydrochloride (0.75 mg subcutaneously) were studied in a large group of unmedicated hospitalized patients with functional psychoses. Apomorphine 87-112 prolactin Homo sapiens 23-32 6721674-8 1984 The apomorphine-induced PRL suppression correlated significantly with various measures of depression across diagnostic groups. Apomorphine 4-15 prolactin Homo sapiens 24-27 6540702-1 1984 Prolactin (1, 5, 10 micrograms/ml) inhibited 5 alpha-dihydrotestosterone (DHT), testosterone (T) and estradiol-17 beta (E2) secretion by luteal cells isolated from porcine corpus luteum on the 13th day of the estrous cycle. alpha-dihydrotestosterone 47-72 prolactin Homo sapiens 0-9 6375368-4 1984 On administration of bromocryptine there was a reduction of tetrahydroaldosterone-3-glucuronide, prolactin and also a significant reduction of blood pressure. Bromocriptine 21-34 prolactin Homo sapiens 97-106 6540702-1 1984 Prolactin (1, 5, 10 micrograms/ml) inhibited 5 alpha-dihydrotestosterone (DHT), testosterone (T) and estradiol-17 beta (E2) secretion by luteal cells isolated from porcine corpus luteum on the 13th day of the estrous cycle. Dihydrotestosterone 74-77 prolactin Homo sapiens 0-9 6540702-1 1984 Prolactin (1, 5, 10 micrograms/ml) inhibited 5 alpha-dihydrotestosterone (DHT), testosterone (T) and estradiol-17 beta (E2) secretion by luteal cells isolated from porcine corpus luteum on the 13th day of the estrous cycle. Testosterone 60-72 prolactin Homo sapiens 0-9 6540702-3 1984 Inhibition of DHT, T and E2 secretion in luteal cells on the 5th day of the cycle occurred only after 6 hours of incubation, at prolactin doses of 5 and 10 micrograms/ml of the medium. Dihydrotestosterone 14-17 prolactin Homo sapiens 128-137 6540702-9 1984 The in vitro observations suggest the role of prolactin in inhibiting synthesis or release of DHT, T and E2 from luteal cells. Dihydrotestosterone 94-97 prolactin Homo sapiens 46-55 6146607-9 1984 The existence of multiple poly(A)-adjacent sequences was shown in the three species of human decidual PRL mRNA and in human pituitary PRL mRNA. Poly A 26-33 prolactin Homo sapiens 102-105 6146607-9 1984 The existence of multiple poly(A)-adjacent sequences was shown in the three species of human decidual PRL mRNA and in human pituitary PRL mRNA. Poly A 26-33 prolactin Homo sapiens 134-137 6707194-7 1984 Administration of bromocriptine for 4 months decreased serum TSH and PRL levels to normal with a concomitant fall in levels of serum T3 and T4. Bromocriptine 18-31 prolactin Homo sapiens 69-72 6144034-0 1984 Pentagastrin promotes prolactin release in patients with medullary carcinoma of the thyroid. Pentagastrin 0-12 prolactin Homo sapiens 22-31 6144034-2 1984 Following a pentagastrin infusion in several patients with medullary carcinoma of the thyroid, we noted a coincident increase in plasma calcitonin and prolactin (PRL) levels. Pentagastrin 12-24 prolactin Homo sapiens 151-160 6144034-2 1984 Following a pentagastrin infusion in several patients with medullary carcinoma of the thyroid, we noted a coincident increase in plasma calcitonin and prolactin (PRL) levels. Pentagastrin 12-24 prolactin Homo sapiens 162-165 6144034-4 1984 Plasma mean +/- SE PRL levels were significantly (P less than 0.01) increased in the active MTC patients from 7.6 +/- 0.5 to 12 +/- 1.4 ng/mL by 15 minutes post pentagastrin. Pentagastrin 161-173 prolactin Homo sapiens 19-22 6144034-6 1984 A significant (P less than 0.05) correlation was found between the percentage increase in plasma calcitonin concentrations and plasma PRL levels at five and ten minutes post pentagastrin stimulation in this group of active MTC patients. Pentagastrin 174-186 prolactin Homo sapiens 134-137 6203789-3 1984 Dopamine (DA) inhibited PRL release in a dose-dependent manner within a physiological range, and this inhibition was reversed by the stereospecific DA receptor antagonist (+)-butaclamol. Dopamine 0-8 prolactin Homo sapiens 24-27 6203789-3 1984 Dopamine (DA) inhibited PRL release in a dose-dependent manner within a physiological range, and this inhibition was reversed by the stereospecific DA receptor antagonist (+)-butaclamol. Dopamine 10-12 prolactin Homo sapiens 24-27 6203789-3 1984 Dopamine (DA) inhibited PRL release in a dose-dependent manner within a physiological range, and this inhibition was reversed by the stereospecific DA receptor antagonist (+)-butaclamol. Butaclamol 171-185 prolactin Homo sapiens 24-27 6203789-4 1984 In contrast, the inhibition of PRL secretion by norepinephrine (NE) required much higher doses and lacked specificity. Norepinephrine 48-62 prolactin Homo sapiens 31-34 6425749-6 1984 These findings suggest that the changes in serum triiodothyronine (T3) significantly influence the release of prolactin and thyroid-stimulating hormone in response to thyrotropin-releasing hormone during the periparturitional period. Triiodothyronine 49-65 prolactin Homo sapiens 110-119 6425749-6 1984 These findings suggest that the changes in serum triiodothyronine (T3) significantly influence the release of prolactin and thyroid-stimulating hormone in response to thyrotropin-releasing hormone during the periparturitional period. Triiodothyronine 67-69 prolactin Homo sapiens 110-119 6540373-17 1984 Postoperative serum prolactin level decreased to 150 ng/ml and finally returned to normal by administration of 2.5 mg of bromocriptine. Bromocriptine 121-134 prolactin Homo sapiens 20-29 6431636-7 1984 There was a significant positive correlation between cord prolactin and estradiol-17 beta levels in full-term infants. Estradiol 72-89 prolactin Homo sapiens 58-67 6234007-3 1984 The findings do not allow for definite conclusions: two patients have shown moderate increases in the PRL levels after cimetidine; all patients have shown optimum responses to the stimulation test. Cimetidine 119-129 prolactin Homo sapiens 102-105 6329591-0 1984 [Effects of the intravenous administration of cimetidine and ranitidine on the secretion of prolactin, FSH and LH in healthy males]. Cimetidine 46-56 prolactin Homo sapiens 92-101 6329591-0 1984 [Effects of the intravenous administration of cimetidine and ranitidine on the secretion of prolactin, FSH and LH in healthy males]. Ranitidine 61-71 prolactin Homo sapiens 92-101 6328142-0 1984 Plasma prolactin during the body fluid and electrolyte changes of dehydration and sodium depletion in steers. Sodium 82-88 prolactin Homo sapiens 7-16 6328142-11 1984 The means whereby both divergent physiological processes of dehydration and sodium depletion generate stimuli which inhibit prolactin secretion and the relevance of this response in fluid balance homeostasis requires further research. Sodium 76-82 prolactin Homo sapiens 124-133 6374346-0 1984 Stimulation of spontaneous and dopamine-inhibited prolactin release from anterior pituitary reaggregate cell cultures by angiotensin peptides. Dopamine 31-39 prolactin Homo sapiens 50-59 6374346-1 1984 In superfused anterior pituitary reaggregate cell cultures angiotensin II (AII) stimulated both spontaneous and dopamine-inhibited prolactin (PRL) release from subnanomolar concentrations. Dopamine 112-120 prolactin Homo sapiens 131-140 6727539-5 1984 In animals treated with clomiphene, the inhibition by SCT on PRL increase after injection stress was partially abolished. Clomiphene 24-34 prolactin Homo sapiens 61-64 6711639-1 1984 In vivo and in vitro endometrial stromal synthesis of prolactin occurs after progesterone-induced decidualization. Progesterone 77-89 prolactin Homo sapiens 54-63 6711639-11 1984 Tritium-labeled leucine incorporation into prolactin was confirmed by immunoprecipitation of Sephadex G-100 column fractions. Tritium 0-7 prolactin Homo sapiens 43-52 6711639-11 1984 Tritium-labeled leucine incorporation into prolactin was confirmed by immunoprecipitation of Sephadex G-100 column fractions. Leucine 16-23 prolactin Homo sapiens 43-52 6711639-11 1984 Tritium-labeled leucine incorporation into prolactin was confirmed by immunoprecipitation of Sephadex G-100 column fractions. sephadex 93-107 prolactin Homo sapiens 43-52 6539289-3 1984 Introduction of a dynamic function test of prolactin secretion into the endocrine work-up of such patients improves our diagnostic tools as can be seen by the fact that approximately two thirds of the patients with galactorrhea exhibited an exaggerated response of prolactin to metoclopramide despite normal baseline levels of prolactin. Metoclopramide 278-292 prolactin Homo sapiens 43-52 6539289-3 1984 Introduction of a dynamic function test of prolactin secretion into the endocrine work-up of such patients improves our diagnostic tools as can be seen by the fact that approximately two thirds of the patients with galactorrhea exhibited an exaggerated response of prolactin to metoclopramide despite normal baseline levels of prolactin. Metoclopramide 278-292 prolactin Homo sapiens 265-274 6539289-3 1984 Introduction of a dynamic function test of prolactin secretion into the endocrine work-up of such patients improves our diagnostic tools as can be seen by the fact that approximately two thirds of the patients with galactorrhea exhibited an exaggerated response of prolactin to metoclopramide despite normal baseline levels of prolactin. Metoclopramide 278-292 prolactin Homo sapiens 265-274 6144226-0 1984 Serotonin and acetylcholine affect the release of prolactin and growth hormone from pituitary glands of domestic fowl in vitro in the presence of hypothalamic tissue. Serotonin 0-9 prolactin Homo sapiens 50-59 6144226-0 1984 Serotonin and acetylcholine affect the release of prolactin and growth hormone from pituitary glands of domestic fowl in vitro in the presence of hypothalamic tissue. Acetylcholine 14-27 prolactin Homo sapiens 50-59 6144226-3 1984 Serotonin and its agonist quipazine stimulated the release of Prl and inhibited release of GH in a concentration-related manner. Serotonin 0-9 prolactin Homo sapiens 62-65 6144226-3 1984 Serotonin and its agonist quipazine stimulated the release of Prl and inhibited release of GH in a concentration-related manner. Quipazine 26-35 prolactin Homo sapiens 62-65 6144226-4 1984 The antagonist methysergide blocked the effects of serotonin and quipazine on Prl. Methysergide 15-27 prolactin Homo sapiens 78-81 6144226-4 1984 The antagonist methysergide blocked the effects of serotonin and quipazine on Prl. Serotonin 51-60 prolactin Homo sapiens 78-81 6144226-4 1984 The antagonist methysergide blocked the effects of serotonin and quipazine on Prl. Quipazine 65-74 prolactin Homo sapiens 78-81 6144226-5 1984 Acetylcholine and its agonist pilocarpine also stimulated release of Prl and inhibited release of GH in a concentration-related manner. Acetylcholine 0-13 prolactin Homo sapiens 69-72 6144226-5 1984 Acetylcholine and its agonist pilocarpine also stimulated release of Prl and inhibited release of GH in a concentration-related manner. Pilocarpine 30-41 prolactin Homo sapiens 69-72 6703855-3 1984 The ability of an intravenous infusion of the serotonin precursor tryptophan to raise serum prolactin (PRL) levels was determined in 13 depressed patients during placebo administration and after 28 to 35 days of treatment with either amitriptyline or desipramine. Serotonin 46-55 prolactin Homo sapiens 92-101 6703855-3 1984 The ability of an intravenous infusion of the serotonin precursor tryptophan to raise serum prolactin (PRL) levels was determined in 13 depressed patients during placebo administration and after 28 to 35 days of treatment with either amitriptyline or desipramine. Serotonin 46-55 prolactin Homo sapiens 103-106 6703855-3 1984 The ability of an intravenous infusion of the serotonin precursor tryptophan to raise serum prolactin (PRL) levels was determined in 13 depressed patients during placebo administration and after 28 to 35 days of treatment with either amitriptyline or desipramine. Tryptophan 66-76 prolactin Homo sapiens 92-101 6703855-3 1984 The ability of an intravenous infusion of the serotonin precursor tryptophan to raise serum prolactin (PRL) levels was determined in 13 depressed patients during placebo administration and after 28 to 35 days of treatment with either amitriptyline or desipramine. Tryptophan 66-76 prolactin Homo sapiens 103-106 6703855-4 1984 Both desipramine (N = 7) and amitriptyline (N = 6) significantly increased the PRL rise induced by tryptophan compared with a preceding placebo period. Desipramine 5-16 prolactin Homo sapiens 79-82 6703855-4 1984 Both desipramine (N = 7) and amitriptyline (N = 6) significantly increased the PRL rise induced by tryptophan compared with a preceding placebo period. Amitriptyline 29-42 prolactin Homo sapiens 79-82 6703855-4 1984 Both desipramine (N = 7) and amitriptyline (N = 6) significantly increased the PRL rise induced by tryptophan compared with a preceding placebo period. Tryptophan 99-109 prolactin Homo sapiens 79-82 6703855-5 1984 In contrast, following long-term amitriptyline and desipramine treatment, the ability of tryptophan to increase PRL was enhanced two weeks following abrupt cessation of amitriptyline therapy (N = 5), but not after discontinuation of desipramine therapy. Desipramine 51-62 prolactin Homo sapiens 112-115 6703855-5 1984 In contrast, following long-term amitriptyline and desipramine treatment, the ability of tryptophan to increase PRL was enhanced two weeks following abrupt cessation of amitriptyline therapy (N = 5), but not after discontinuation of desipramine therapy. Tryptophan 89-99 prolactin Homo sapiens 112-115 6703855-5 1984 In contrast, following long-term amitriptyline and desipramine treatment, the ability of tryptophan to increase PRL was enhanced two weeks following abrupt cessation of amitriptyline therapy (N = 5), but not after discontinuation of desipramine therapy. Amitriptyline 169-182 prolactin Homo sapiens 112-115 6703855-5 1984 In contrast, following long-term amitriptyline and desipramine treatment, the ability of tryptophan to increase PRL was enhanced two weeks following abrupt cessation of amitriptyline therapy (N = 5), but not after discontinuation of desipramine therapy. Desipramine 233-244 prolactin Homo sapiens 112-115 6703856-1 1984 Prolactin response to intravenous tryptophan in depressed patients and healthy subjects. Tryptophan 34-44 prolactin Homo sapiens 0-9 6703856-3 1984 Serotonin is an effective stimulant of prolactin release, and intravenous (IV) tryptophan (the amino acid precursor of serotonin), when administered to healthy subjects, produces a reliable and robust increase in serum prolactin level. Serotonin 0-9 prolactin Homo sapiens 39-48 6703856-3 1984 Serotonin is an effective stimulant of prolactin release, and intravenous (IV) tryptophan (the amino acid precursor of serotonin), when administered to healthy subjects, produces a reliable and robust increase in serum prolactin level. Serotonin 0-9 prolactin Homo sapiens 219-228 6703856-3 1984 Serotonin is an effective stimulant of prolactin release, and intravenous (IV) tryptophan (the amino acid precursor of serotonin), when administered to healthy subjects, produces a reliable and robust increase in serum prolactin level. Tryptophan 79-89 prolactin Homo sapiens 219-228 6703856-3 1984 Serotonin is an effective stimulant of prolactin release, and intravenous (IV) tryptophan (the amino acid precursor of serotonin), when administered to healthy subjects, produces a reliable and robust increase in serum prolactin level. Serotonin 119-128 prolactin Homo sapiens 219-228 6703856-5 1984 There was a marked blunting of the maximal prolactin response to the tryptophan in both the male and female patients. Tryptophan 69-79 prolactin Homo sapiens 43-52 6424977-0 1984 Changes in plasma levels of prolactin, in relation to those of FSH, oestradiol, androstenedione and progesterone around the preovulatory surge of LH in women. Estradiol 68-78 prolactin Homo sapiens 28-37 6424977-0 1984 Changes in plasma levels of prolactin, in relation to those of FSH, oestradiol, androstenedione and progesterone around the preovulatory surge of LH in women. Androstenedione 80-95 prolactin Homo sapiens 28-37 6424977-0 1984 Changes in plasma levels of prolactin, in relation to those of FSH, oestradiol, androstenedione and progesterone around the preovulatory surge of LH in women. Progesterone 100-112 prolactin Homo sapiens 28-37 6424977-0 1984 Changes in plasma levels of prolactin, in relation to those of FSH, oestradiol, androstenedione and progesterone around the preovulatory surge of LH in women. Luteinizing Hormone 146-148 prolactin Homo sapiens 28-37 6424977-5 1984 In 10 women oestradiol, androstenedione and prolactin were measured 8 hourly around the pre-ovulatory surge of LH beginning at 0800 h. Prolactin showed a sustained increase in levels beginning at the start of and lasting for the duration of the pre-ovulatory LH surge; oestradiol levels did not rise around this time, and declined by 24 h after the onset of the LH surge. Estradiol 12-22 prolactin Homo sapiens 135-144 6424977-5 1984 In 10 women oestradiol, androstenedione and prolactin were measured 8 hourly around the pre-ovulatory surge of LH beginning at 0800 h. Prolactin showed a sustained increase in levels beginning at the start of and lasting for the duration of the pre-ovulatory LH surge; oestradiol levels did not rise around this time, and declined by 24 h after the onset of the LH surge. Androstenedione 24-39 prolactin Homo sapiens 135-144 6424977-5 1984 In 10 women oestradiol, androstenedione and prolactin were measured 8 hourly around the pre-ovulatory surge of LH beginning at 0800 h. Prolactin showed a sustained increase in levels beginning at the start of and lasting for the duration of the pre-ovulatory LH surge; oestradiol levels did not rise around this time, and declined by 24 h after the onset of the LH surge. Estradiol 269-279 prolactin Homo sapiens 135-144 6424977-5 1984 In 10 women oestradiol, androstenedione and prolactin were measured 8 hourly around the pre-ovulatory surge of LH beginning at 0800 h. Prolactin showed a sustained increase in levels beginning at the start of and lasting for the duration of the pre-ovulatory LH surge; oestradiol levels did not rise around this time, and declined by 24 h after the onset of the LH surge. Luteinizing Hormone 111-113 prolactin Homo sapiens 135-144 6428747-0 1984 Dual effects of manganese on prolactin secretion. Manganese 16-25 prolactin Homo sapiens 29-38 6428747-1 1984 The effect of Mn2+ (a commonly used Ca2+ antagonist) on prolactin secretion from pituitary cells was investigated. Manganese(2+) 14-18 prolactin Homo sapiens 56-65 6428747-2 1984 In the presence of normal extracellular Ca2+ levels (2.5mM), Mn2+ inhibited basal, TRH- and K+- stimulated prolactin secretion. Manganese(2+) 61-65 prolactin Homo sapiens 107-116 6538517-0 1984 The value of prolactin dynamics as a predictor of ovulation with bromocriptine in patients with polycystic ovary syndrome. Bromocriptine 65-78 prolactin Homo sapiens 13-22 6725869-1 1984 The inhibitory effect of nomifensine ( Nom ; 200 mg orally) on prolactin (PRL) secretion was studied in 15 subjects with puerperal hyperprolactinemia and in 59 pathologic hyperprolactinemic women. Nomifensine 25-36 prolactin Homo sapiens 63-72 6725869-1 1984 The inhibitory effect of nomifensine ( Nom ; 200 mg orally) on prolactin (PRL) secretion was studied in 15 subjects with puerperal hyperprolactinemia and in 59 pathologic hyperprolactinemic women. Nomifensine 39-42 prolactin Homo sapiens 63-72 6700897-4 1984 Amniotic fluid prolactin levels correlate significantly with maternal plasma concentrations of estradiol and estrone. Estradiol 95-104 prolactin Homo sapiens 15-24 6707188-1 1984 Three immunoreactive forms of PRL, separated by Sephadex G-100 column chromatography, were identified in serum samples from 10 normal subjects and 7 patients with PRL-secreting pituitary tumors. sephadex 48-62 prolactin Homo sapiens 30-33 6374488-8 1984 Fenfluramine alone induced a slight nonsignificant decrease in GH values with a parallel and significant increase in prolactin (PRL) secretion in accordance with the proposed serotoninergic activity of the drug. Fenfluramine 0-12 prolactin Homo sapiens 117-126 6374488-8 1984 Fenfluramine alone induced a slight nonsignificant decrease in GH values with a parallel and significant increase in prolactin (PRL) secretion in accordance with the proposed serotoninergic activity of the drug. Fenfluramine 0-12 prolactin Homo sapiens 128-131 6425435-2 1984 It required thirteen weeks for the lactating group, four weeks for the non-lactating group and two days for the group receiving bromocriptine for serum PRL to be restored to pre-pregnancy levels. Bromocriptine 128-141 prolactin Homo sapiens 152-155 6330783-0 1984 Prolactin response to morphine in depression. Morphine 22-30 prolactin Homo sapiens 0-9 6330783-1 1984 The mean maximum prolactin response following administration of morphine sulfate, 5 mg, i.v., was significantly lower in 15 unmedicated inpatients with major depressive disorder than in 8 normal controls and 11 unmedicated inpatients with other psychiatric diagnoses. Morphine 64-80 prolactin Homo sapiens 17-26 6330783-4 1984 The diminished increase in serum prolactin after morphine in depressed patients may reflect anterior pituitary dysfunction or abnormalities in central endogenous opioid, dopamine, serotonin, or other neuroregulatory systems. Morphine 49-57 prolactin Homo sapiens 33-42 6330783-4 1984 The diminished increase in serum prolactin after morphine in depressed patients may reflect anterior pituitary dysfunction or abnormalities in central endogenous opioid, dopamine, serotonin, or other neuroregulatory systems. Dopamine 170-178 prolactin Homo sapiens 33-42 6330783-4 1984 The diminished increase in serum prolactin after morphine in depressed patients may reflect anterior pituitary dysfunction or abnormalities in central endogenous opioid, dopamine, serotonin, or other neuroregulatory systems. Serotonin 180-189 prolactin Homo sapiens 33-42 6712836-2 1984 Testosterone and androstenedione plasma levels were tested in males, oestradiol, progesterone and prolactin in both males and females. Testosterone 0-12 prolactin Homo sapiens 98-107 6712836-2 1984 Testosterone and androstenedione plasma levels were tested in males, oestradiol, progesterone and prolactin in both males and females. Androstenedione 17-32 prolactin Homo sapiens 98-107 6420042-2 1984 Two different tests of prolactin storage and control mechanisms, direct stimulation by thyrotropin-releasing hormone (TRH) and inhibition of dopaminergic control by domperidone, indicate a significant abnormality in patients with severe cyclical mastalgia and nodular breast disease (P less than 0.05 and P less than 0.002), but not in those with noncyclical mastalgia. Domperidone 165-176 prolactin Homo sapiens 23-32 6700367-0 1984 Plasma prolactin changes following fenfluramine in depressed patients compared to controls: an evaluation of central serotonergic responsivity in depression. Fenfluramine 35-47 prolactin Homo sapiens 7-16 6700367-3 1984 Fenfluramine produced a significant increase in prolactin in both patients and controls. Fenfluramine 0-12 prolactin Homo sapiens 48-57 6700367-4 1984 However, the prolactin response to fenfluramine whether measured as an absolute increase or percent increase from baseline was significantly less in depressed patients than controls. Fenfluramine 35-47 prolactin Homo sapiens 13-22 6475464-3 1984 This dopamine agonist is very effective in normalizing raised prolactin levels. Dopamine 5-13 prolactin Homo sapiens 62-71 6475464-15 1984 However, bromocriptine is extremely effective in normalizing hyperprolactinemia and undoubtedly the drug of choice for treatment of female infertility due to hypersecretion of prolactin. Bromocriptine 9-22 prolactin Homo sapiens 66-75 6231043-9 1984 Increasing the dose of thiopentone caused a further increase in PRL concentration which indicated a direct stimulatory action of thiopentone on PRL release. Thiopental 23-34 prolactin Homo sapiens 64-67 6231043-9 1984 Increasing the dose of thiopentone caused a further increase in PRL concentration which indicated a direct stimulatory action of thiopentone on PRL release. Thiopental 23-34 prolactin Homo sapiens 144-147 6231043-9 1984 Increasing the dose of thiopentone caused a further increase in PRL concentration which indicated a direct stimulatory action of thiopentone on PRL release. Thiopental 129-140 prolactin Homo sapiens 64-67 6231043-9 1984 Increasing the dose of thiopentone caused a further increase in PRL concentration which indicated a direct stimulatory action of thiopentone on PRL release. Thiopental 129-140 prolactin Homo sapiens 144-147 6704349-2 1984 Only five patients treated with bromocriptine and two treated with metergoline had PRL levels that remained normal or below 50% of pretreatment values. Bromocriptine 32-45 prolactin Homo sapiens 83-86 6704349-2 1984 Only five patients treated with bromocriptine and two treated with metergoline had PRL levels that remained normal or below 50% of pretreatment values. Metergoline 67-78 prolactin Homo sapiens 83-86 6426828-0 1984 Effects of the GABAergic drug, sodium valproate, on the prolactin release evoked by pharmacological stimuli in normal women. Valproic Acid 31-47 prolactin Homo sapiens 56-65 6426828-1 1984 Sodium valproate (DPA or Na-dipropylacetate), an anticonvulsant drug activating the endogenous GABAergic system, was administered orally at the dose of 400 mg to seventeen normal women 1 h before intravenous injections with three drugs which stimulate prolactin (PRL) release: TRH (200 micrograms bolus; six subjects); domperidone (5 mg bolus; six subjects); and sulpiride (5 mg bolus; five subjects). Valproic Acid 0-16 prolactin Homo sapiens 252-261 6723227-0 1984 Effect of amoxapine on serum prolactin concentrations in normal men. Amoxapine 10-19 prolactin Homo sapiens 29-38 6697960-4 1984 Treatment with 10(-6) M chloroquine resulted in 20-40% inhibition of PRL release (maximum inhibition at any dose), no change in the total amount of beta-glucuronidase activity, and a number of ultrastructural changes in the Golgi region consistent with an accumulation of chloroquine within the cisternae and immature granules. Chloroquine 24-35 prolactin Homo sapiens 69-72 6697960-6 1984 These results are consistent with an adverse effect of chloroquine on packaging of PRL into immature granules in the Golgi apparatus, without any effect on the release of mature secretory granules. Chloroquine 55-66 prolactin Homo sapiens 83-86 6425184-2 1984 Forty-three men with leprosy were studied by basal estimations of plasma LH, FSH, Prolactin, Testosterone, 17-beta estradiol, metoclopramide stimulated prolactin responses and hCG stimulated testosterone responses. Metoclopramide 126-140 prolactin Homo sapiens 152-161 6693543-3 1984 In 24 patients who had a PRL-secreting pituitary adenoma, diagnosed by pituitary dynamic function tests and CT scan, and confirmed at surgery, the TSH response to a dopamine (DA)-antagonist drug, metoclopramide (MCP), was studied pre- and postoperatively to elucidate whether altered DA tone was present and related to hyperprolactinemia. Thyrotropin 147-150 prolactin Homo sapiens 25-28 6693551-2 1984 A paradoxical increase in prolactin occurred with naloxone infusion during and 5-6 days after stopping the pills. Naloxone 50-58 prolactin Homo sapiens 26-35 6700897-4 1984 Amniotic fluid prolactin levels correlate significantly with maternal plasma concentrations of estradiol and estrone. Estrone 109-116 prolactin Homo sapiens 15-24 6233752-4 1984 The TRH-induced PRL release was more enhanced during treatment with cyproterone acetate (CA) than before CA therapy in four of five patients with idiopathic precocious puberty. Cyproterone Acetate 68-87 prolactin Homo sapiens 16-19 6319114-4 1984 In epileptic men, all individual AEDs (except valproate) and AED polytherapy increased both basal and stimulated plasma levels of PRL. Valproic Acid 46-55 prolactin Homo sapiens 130-133 6233421-6 1984 A statistically significant correlation was found between mean prolactin concentrations and the mean plasma dehydroepiandrosterone sulphate (DHEAS) concentration (r = 0.67, p less than 0.01). Dehydroepiandrosterone Sulfate 108-139 prolactin Homo sapiens 63-72 6233421-6 1984 A statistically significant correlation was found between mean prolactin concentrations and the mean plasma dehydroepiandrosterone sulphate (DHEAS) concentration (r = 0.67, p less than 0.01). Dehydroepiandrosterone Sulfate 141-146 prolactin Homo sapiens 63-72 6538707-3 1984 After 6-8 weeks of tamoxifen treatment, a significant decrease in FSH, LH and PRL basal levels was observed, whereas the concentrations of E1 and E2 were not significantly affected. Tamoxifen 19-28 prolactin Homo sapiens 78-81 6696004-0 1984 Sex steroid and human chorionic gonadotropin modulation of in vitro prolactin production by human term decidua. Steroids 4-11 prolactin Homo sapiens 68-77 6696004-1 1984 This study was undertaken to investigate the possible regulatory effects of the sex steroids estradiol and progesterone and the protein hormone human chorionic gonadotropin (hCG) on prolactin (PRL) production by human decidua in vitro. Steroids 84-92 prolactin Homo sapiens 182-191 6696005-7 1984 Six of the 18 patients who became pregnant after bromocriptine also showed a significant rise in serum prolactin levels above the treatment level. Bromocriptine 49-62 prolactin Homo sapiens 103-112 6696005-10 1984 Some patients who become pregnant after bromocriptine therapy may have further rises in prolactin greater than pretreatment levels. Bromocriptine 40-53 prolactin Homo sapiens 88-97 6366415-2 1984 This finding has been used to support the concept of a central dopamine mediated mechanism for LRF-induced PRL release. Dopamine 63-71 prolactin Homo sapiens 107-110 6320571-1 1984 A single oral dose of 400 mg ketoconazole, a broad-spectrum antifungal drug, administered orally to 5 young men induced a drop in serum and saliva testosterone into the range of hypogonadism, while LH, FSH and prolactin levels remained unchanged. Ketoconazole 29-41 prolactin Homo sapiens 210-219 6695548-2 1984 The increase in serum Prl was strictly related to testosterone aromatization to oestradiol, since anti-oestrogen compounds were effective in reducing (clomiphene) or abolishing (tamoxifen) the enhanced Prl secretion. Testosterone 50-62 prolactin Homo sapiens 22-25 6695548-2 1984 The increase in serum Prl was strictly related to testosterone aromatization to oestradiol, since anti-oestrogen compounds were effective in reducing (clomiphene) or abolishing (tamoxifen) the enhanced Prl secretion. Estradiol 80-90 prolactin Homo sapiens 22-25 6695548-2 1984 The increase in serum Prl was strictly related to testosterone aromatization to oestradiol, since anti-oestrogen compounds were effective in reducing (clomiphene) or abolishing (tamoxifen) the enhanced Prl secretion. Estradiol 80-90 prolactin Homo sapiens 202-205 6695548-2 1984 The increase in serum Prl was strictly related to testosterone aromatization to oestradiol, since anti-oestrogen compounds were effective in reducing (clomiphene) or abolishing (tamoxifen) the enhanced Prl secretion. Clomiphene 151-161 prolactin Homo sapiens 22-25 6695548-2 1984 The increase in serum Prl was strictly related to testosterone aromatization to oestradiol, since anti-oestrogen compounds were effective in reducing (clomiphene) or abolishing (tamoxifen) the enhanced Prl secretion. Tamoxifen 178-187 prolactin Homo sapiens 22-25 6695548-2 1984 The increase in serum Prl was strictly related to testosterone aromatization to oestradiol, since anti-oestrogen compounds were effective in reducing (clomiphene) or abolishing (tamoxifen) the enhanced Prl secretion. Tamoxifen 178-187 prolactin Homo sapiens 202-205 6695975-1 1984 As evidence continues to accumulate supporting a specific effect of prolactin on the permeability of reflected fetal membranes to tritiated water, no information on the role of decidual prolactin in this process is available. Water 140-145 prolactin Homo sapiens 68-77 6695975-7 1984 These in vitro results may suggest that the accumulation of decidual prolactin at the choriodecidual interface in vivo supports bulk water flow across fetal membrane from the amniotic to the maternal compartments. Water 133-138 prolactin Homo sapiens 69-78 6695993-0 1984 Effect of estriol on prolactin. Estriol 10-17 prolactin Homo sapiens 21-30 6698215-0 1984 Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Bromocriptine 34-47 prolactin Homo sapiens 5-14 6713309-3 1984 Their development has yielded valuable information on the pharmacology of dopamine receptors involved in the regulatory mechanisms of prolactin secretion and in striatal functions. Dopamine 74-82 prolactin Homo sapiens 134-143 6715064-2 1984 To assess this we have measured basal and TRH-stimulated prolactin levels in: Six eugonadal men before and after 2 weeks" administration of the aromatase inhibitor delta"-testolactone, which led to a fall in oestradiol levels with unchanged levels of testosterone. delta"-testolactone 164-183 prolactin Homo sapiens 57-66 6715064-7 1984 Again, it was found that dihydrotestosterone treatment decreased prolactin levels in patients from Group C. Six eugonadal subjects were also studied before and after 6 weeks" administration of the androgen receptor antagonist, spironolactone, and this treatment increased Prl secretion. Dihydrotestosterone 25-44 prolactin Homo sapiens 65-74 6363397-4 1984 A few amoxapine-treated patients developed adverse effects typical of neuroleptic drugs: some experienced extrapyramidal signs, one developed galactorrhea, and most showed elevated plasma prolactin concentrations. Amoxapine 6-15 prolactin Homo sapiens 188-197 6420434-6 1984 During the saline infusion, 11 of the 16 serum LH pulses (69%) were accompanied by an increase in serum PRL, and in 5 of the subjects, the first pulse of LH was synchronous with that of PRL (P = 0.0015). Luteinizing Hormone 47-49 prolactin Homo sapiens 104-107 6698215-1 1984 In patients with prolactin (PRL)-secreting tumors, plasma PRL concentrations after discontinuation of bromocriptine therapy have been used clinically as an index of tumor activity. Bromocriptine 102-115 prolactin Homo sapiens 58-61 6698215-3 1984 In these patients, peak PRL concentrations were achieved 28.1 days (mean; range, 14 to 49 days) after bromocriptine discontinuation. Bromocriptine 102-115 prolactin Homo sapiens 24-27 6199950-0 1984 Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Sulpiride 27-36 prolactin Homo sapiens 84-93 6420434-7 1984 Naloxone increased the number of LH pulses from 16 to 20 and the number of PRL pulses from 12 to 16, all of which were synchronous with LH pulses. Naloxone 0-8 prolactin Homo sapiens 75-78 6420434-8 1984 Administration of metoclopramide caused a substantial increase in PRL and a loss of further PRL pulsatility; however, LH pulsatility remained unaffected. Metoclopramide 18-32 prolactin Homo sapiens 66-69 6420434-8 1984 Administration of metoclopramide caused a substantial increase in PRL and a loss of further PRL pulsatility; however, LH pulsatility remained unaffected. Metoclopramide 18-32 prolactin Homo sapiens 92-95 6711067-1 1984 In 14 healthy persons, 31 patients with acute and 13 with chronic renal failure the influence of alpha-bromocriptine on the PTH and prolactin level in the blood serum was investigated. alpha-bromocriptine 97-116 prolactin Homo sapiens 132-141 6711067-2 1984 In all subjects examined alpha-bromocriptine caused a decrease of the prolactin level. alpha-bromocriptine 25-44 prolactin Homo sapiens 70-79 6141070-0 1984 Effects of growth hormone-releasing factor, somatostatin and dopamine on growth hormone and prolactin secretion from cultured ovine pituitary cells. Dopamine 61-69 prolactin Homo sapiens 92-101 6141070-5 1984 Dopamine (0.1 microM) inhibition of basal prolactin secretion was not affected by GRF (1 nM). Dopamine 0-8 prolactin Homo sapiens 42-51 6229966-0 1984 Prolactin secretion in polycystic ovary syndrome (PCO): correlation with the steroid pattern. Steroids 77-84 prolactin Homo sapiens 0-9 6421038-0 1984 Effects of 2-hydroxyoestradiol and 4-hydroxyoestradiol on gonadotrophin and prolactin secretion in women. 2-hydroxyoestradiol 11-30 prolactin Homo sapiens 76-85 6421038-0 1984 Effects of 2-hydroxyoestradiol and 4-hydroxyoestradiol on gonadotrophin and prolactin secretion in women. 4-hydroxyoestradiol 35-54 prolactin Homo sapiens 76-85 6421041-4 1984 On the other hand, PGE1 (10(-5) M) stimulated Prl secretion in 2 of the 4 adenomas examined. Alprostadil 19-23 prolactin Homo sapiens 46-49 6421041-5 1984 Addition of theophylline (5.5 mM) caused a marked increase of effluent Prl levels in all 8 prolactinomas regardless of the reactivity to TRH or PGE1. Theophylline 12-24 prolactin Homo sapiens 71-74 6421041-6 1984 Dopamine (5 X 10(-7) M) suppressed Prl secretion from adenoma tissue in 5 of 7 patients tested but had no effect in the remaining two adenomas. Dopamine 0-8 prolactin Homo sapiens 35-38 6421041-7 1984 When perifused simultaneously with dopamine, sulpiride (D2-selective dopamine receptor blocker, 5 X 10(-7) M) blocked the inhibitory effect of dopamine on Prl release in 3 of the 4 dopamine-sensitive prolactinomas. Sulpiride 45-54 prolactin Homo sapiens 155-158 6421041-8 1984 In one adenoma responsive to dopamine but resistant to sulpiride, YM-09151-2 (relatively specific D1-dopamine receptor blocker, 5 X 10(-7) M) antagonized the dopaminergic inhibition of Prl release. nemonapride 66-74 prolactin Homo sapiens 185-188 6199950-0 1984 Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Chlorpromazine 41-55 prolactin Homo sapiens 84-93 6199950-7 1984 There were significantly higher PRL levels in sulpiride- than in chlorpromazine-treated patients. Sulpiride 46-55 prolactin Homo sapiens 32-35 6199950-7 1984 There were significantly higher PRL levels in sulpiride- than in chlorpromazine-treated patients. Chlorpromazine 65-79 prolactin Homo sapiens 32-35 6199950-9 1984 The HVA/PRL ratio in CSF was significantly reduced in the sulpiride but not in the chlorpromazine group. Sulpiride 58-67 prolactin Homo sapiens 8-11 6199950-15 1984 The different effects of the drugs on PRL, 5-HIAA and MOPEG levels indicate that sulpiride has a more specific effect than chlorpromazine on dopaminergic mechanisms. Sulpiride 81-90 prolactin Homo sapiens 38-41 6197883-14 1984 The release of PAPP-A, hPL, and Prl is considered as a de novo production since concentration of these proteins are higher in media and tissues after incubation compared to concentrations initially present in the tissue before culture and since cycloheximide significantly inhibits the release of PAPP-A, Prl, and hPL from the cultured tissues. Cycloheximide 245-258 prolactin Homo sapiens 32-35 6197883-14 1984 The release of PAPP-A, hPL, and Prl is considered as a de novo production since concentration of these proteins are higher in media and tissues after incubation compared to concentrations initially present in the tissue before culture and since cycloheximide significantly inhibits the release of PAPP-A, Prl, and hPL from the cultured tissues. Cycloheximide 245-258 prolactin Homo sapiens 305-308 6229205-3 1984 Bromocriptine is extremely effective in suppressing prolactin secretion regardless of the cause, in restoring gonadal function and fertility, and in decreasing the size of prolactin-secreting pituitary tumors. Bromocriptine 0-13 prolactin Homo sapiens 52-61 6229205-3 1984 Bromocriptine is extremely effective in suppressing prolactin secretion regardless of the cause, in restoring gonadal function and fertility, and in decreasing the size of prolactin-secreting pituitary tumors. Bromocriptine 0-13 prolactin Homo sapiens 172-181 6548163-0 1984 Cord blood prolactin and thyroid hormone levels after antenatal administration of betamethasone or ambroxol for prevention of respiratory distress syndrome (RDS). Betamethasone 82-95 prolactin Homo sapiens 11-20 6730927-3 1984 Comparisons of these two groups showed that basal levels were similar but the PRL response to metoclopramide (MTC) and the day-to-day fluctuations were significantly lower in the group with altered ovulatory function. Metoclopramide 94-108 prolactin Homo sapiens 78-81 6730927-3 1984 Comparisons of these two groups showed that basal levels were similar but the PRL response to metoclopramide (MTC) and the day-to-day fluctuations were significantly lower in the group with altered ovulatory function. Metoclopramide 110-113 prolactin Homo sapiens 78-81 6730927-4 1984 In this group the PRL response to MTC was significantly greater than in control patients with hyperprolactinemic amenorrhea (n = 12), but lower than in normal women (n = 10). Metoclopramide 34-37 prolactin Homo sapiens 18-21 6730927-5 1984 The PRL response to MTC in hyperprolactinemic women with normal ovulatory function did not differ significantly from that of normal women, irrespective of whether hyperprolactinemia was sustained (n = 7) or intermittent (n = 5). Metoclopramide 20-23 prolactin Homo sapiens 4-7 6730927-6 1984 The study indicates that the degree of autonomy of PRL secretion reflected by both the fluctuations in basal levels and the response to a dopamine antagonist, may be used to evaluate whether or not slightly elevated PRL levels are of clinical significance in relation to fertility. Dopamine 138-146 prolactin Homo sapiens 51-54 6730939-3 1984 The lower PRL levels in cigarette-smoking pregnant women may be due either to a direct effect of nicotine or secondary to lower estrogen levels, and the finding may be of clinical importance in relation to lactation. Nicotine 97-105 prolactin Homo sapiens 10-13 6548163-0 1984 Cord blood prolactin and thyroid hormone levels after antenatal administration of betamethasone or ambroxol for prevention of respiratory distress syndrome (RDS). Ambroxol 99-107 prolactin Homo sapiens 11-20 6388911-4 1984 The serum PRL concentration showed a significant correlation with DA in the urine (gamma = 0.447, n = 24, p less than 0.05). Dopamine 66-68 prolactin Homo sapiens 10-13 6420095-6 1984 Dopamine infusion (0.5 microgram/kg/min) resulted in suppression of PRL (min 19 +/- 3% of basal) but not of LH or FSH. Dopamine 0-8 prolactin Homo sapiens 68-71 6420095-7 1984 A rebound of PRL (peak 188 +/- 68% of basal) but not LH or FSH occurred on cessation of dopamine. Dopamine 88-96 prolactin Homo sapiens 13-16 6420095-10 1984 The responses to MIT show that dopamine functions as an inhibitor of PRL but not of LH or FSH in normal subjects. Dopamine 31-39 prolactin Homo sapiens 69-72 6420095-14 1984 In PHP patients, PRL feedback results in increased hypothalamic dopamine activity which in turn inhibits LH release. Dopamine 64-72 prolactin Homo sapiens 17-20 6420095-14 1984 In PHP patients, PRL feedback results in increased hypothalamic dopamine activity which in turn inhibits LH release. Luteinizing Hormone 105-107 prolactin Homo sapiens 17-20 6420095-15 1984 We conclude that the inhibitory action of dopamine on PRL release restores LH secretion by removing central dopaminergic inhibition through hypothalamic feedback of PRL. Dopamine 42-50 prolactin Homo sapiens 54-57 6420095-15 1984 We conclude that the inhibitory action of dopamine on PRL release restores LH secretion by removing central dopaminergic inhibition through hypothalamic feedback of PRL. Dopamine 42-50 prolactin Homo sapiens 165-168 6420095-15 1984 We conclude that the inhibitory action of dopamine on PRL release restores LH secretion by removing central dopaminergic inhibition through hypothalamic feedback of PRL. Luteinizing Hormone 75-77 prolactin Homo sapiens 54-57 6420095-15 1984 We conclude that the inhibitory action of dopamine on PRL release restores LH secretion by removing central dopaminergic inhibition through hypothalamic feedback of PRL. Luteinizing Hormone 75-77 prolactin Homo sapiens 165-168 6705273-0 1984 Influence of naloxone on prolactin secretion in patients with acute and chronic renal failure. Naloxone 13-21 prolactin Homo sapiens 25-34 6705273-1 1984 The influence of the opiate antagonist naloxone on chlorpromazine induced prolactin secretion was examined in 12 patients with acute renal failure (ARF), 12 patients with chronic renal failure (CRF) and in 12 healthy subjects. Naloxone 39-47 prolactin Homo sapiens 74-83 6705273-1 1984 The influence of the opiate antagonist naloxone on chlorpromazine induced prolactin secretion was examined in 12 patients with acute renal failure (ARF), 12 patients with chronic renal failure (CRF) and in 12 healthy subjects. Chlorpromazine 51-65 prolactin Homo sapiens 74-83 6705273-2 1984 In all examined groups naloxone showed a suppressive effect on chlorpromazine induced prolactin secretion, which was more accentuated in normals and patients with ARF then with CRF. Naloxone 23-31 prolactin Homo sapiens 86-95 6705273-2 1984 In all examined groups naloxone showed a suppressive effect on chlorpromazine induced prolactin secretion, which was more accentuated in normals and patients with ARF then with CRF. Chlorpromazine 63-77 prolactin Homo sapiens 86-95 6499782-0 1984 Metoclopramide stimulation of prolactin secretion in women during puerperal lactation. Metoclopramide 0-14 prolactin Homo sapiens 30-39 6510364-0 1984 [Effect of bromocriptine on prolactin secretion after dopaminergic receptor blockade with metoclopramide in patients with prostatic cancer treated with estrogens]. Bromocriptine 11-24 prolactin Homo sapiens 28-37 6543333-0 1984 [Diurnal rhythm of prolactin secretion after excessive intake of alcohol]. Alcohols 65-72 prolactin Homo sapiens 19-28 6097456-4 1984 Plasma cortisol and prolactin levels were lower after ranitidine at the beginning of the test but their values were not significantly different after ambulation during ranitidine therapy. Ranitidine 54-64 prolactin Homo sapiens 20-29 6432552-2 1984 administration to 6 healthy adult male volunteers of 2 mg butorphanol, a potent synthetic opiate analgesic, resulted in a significant rise in serum PRL level, without affecting GH, LH, FSH, TSH or cortisol secretion. Butorphanol 58-69 prolactin Homo sapiens 148-151 6439566-0 1984 Possible mechanism of prolactin unresponsiveness to repeated sulpiride administration in man. Sulpiride 61-70 prolactin Homo sapiens 22-31 6538844-0 1984 Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man. cimoxatone 54-64 prolactin Homo sapiens 97-106 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Serotonin 43-52 prolactin Homo sapiens 0-9 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Serotonin 43-52 prolactin Homo sapiens 11-14 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Dopamine 77-85 prolactin Homo sapiens 0-9 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Dopamine 77-85 prolactin Homo sapiens 11-14 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Dopamine 87-89 prolactin Homo sapiens 0-9 6538844-1 1984 Prolactin (PRL) secretion is stimulated by serotonin (5-HT) and inhibited by dopamine (DA). Dopamine 87-89 prolactin Homo sapiens 11-14 6538844-3 1984 The effect of cimoxatone, a reversible, selective MAO-A inhibitor, on diurnal variation in plasma PRL level was investigated in healthy adults after a single 40 mg oral dose, as an indirect approach to investigating whether DA is preferentially a substrate for Type A or B MAO in man. cimoxatone 14-24 prolactin Homo sapiens 98-101 6538844-5 1984 There was a slight but significant reduction in circulating PRL in the six subjects, which persisted for at least 9 h after cimoxatone. cimoxatone 124-134 prolactin Homo sapiens 60-63 6420206-8 1984 The addition of dopamine, pergolide, or bromocriptine resulted in a depression of PRL during the treatment period. Dopamine 16-24 prolactin Homo sapiens 82-85 6420206-8 1984 The addition of dopamine, pergolide, or bromocriptine resulted in a depression of PRL during the treatment period. Pergolide 26-35 prolactin Homo sapiens 82-85 6420206-8 1984 The addition of dopamine, pergolide, or bromocriptine resulted in a depression of PRL during the treatment period. Bromocriptine 40-53 prolactin Homo sapiens 82-85 6537924-4 1984 LH pulses were associated with a concomitant P and PRL pulse in 100% to 80% of occasions, respectively. Luteinizing Hormone 0-2 prolactin Homo sapiens 51-54 6425187-4 1984 AMPT administration was followed by a prompt increase in serum PRL in regularly cycling women, but not in women with hyperprolactinemia either due to a PRL-secreting pituitary microadenoma or "idiopathic". alpha-Methyltyrosine 0-4 prolactin Homo sapiens 63-66 6425187-6 1984 DA infusion after endogenous catecholamine synthesis inhibition by AMPT, induced an appreciable decline in PRL levels in both normal and hyperprolactinemic subjects. Dopamine 0-2 prolactin Homo sapiens 107-110 6425187-6 1984 DA infusion after endogenous catecholamine synthesis inhibition by AMPT, induced an appreciable decline in PRL levels in both normal and hyperprolactinemic subjects. alpha-Methyltyrosine 67-71 prolactin Homo sapiens 107-110 6428199-0 1984 Indomethacin suppresses prolactin release in men. Indomethacin 0-12 prolactin Homo sapiens 24-33 6428199-1 1984 Indomethacin administered intrarectally at a dose of 100 mg elicited a statistically significant decrease of serum prolactin level in men. Indomethacin 0-12 prolactin Homo sapiens 115-124 6436160-2 1984 Restoration of the prolactin response to thyrotropin-releasing hormone by low-dose dopamine infusion in women with pathological hyperprolactinemia. Dopamine 83-91 prolactin Homo sapiens 19-28 6146579-0 1984 Prolactin response to sulpiride in ovulatory women (a clue for the screening of hyperprolactinemic states). Sulpiride 22-31 prolactin Homo sapiens 0-9 6146579-2 1984 The dynamics of prolactin secretion was investigated in 30 ovulatory females subjected to sulpiride stimulation. Sulpiride 90-99 prolactin Homo sapiens 16-25 6146579-5 1984 We conclude that basal prolactin levels and the 30-min value after sulpiride administration seem to be sufficient and valid representative estimations in the screening of abnormal prolactin secretion states. Sulpiride 67-76 prolactin Homo sapiens 180-189 6469437-0 1984 Changed plasma prolactin levels after etoperidone and placebo. etoperidone 38-49 prolactin Homo sapiens 15-24 6693678-0 1984 Prolactin, growth hormone and growth responses in boys with attention deficit disorder and hyperactivity treated with methylphenidate. Methylphenidate 118-133 prolactin Homo sapiens 0-9 6140273-2 1984 When dopamine (0.01-0.1 microM) or bromocriptine (0.01-0.1 microM) was added to the culture media, a significant inhibition of GH and PRL secretion from adenoma cells from acromegalic patients was observed. Dopamine 5-13 prolactin Homo sapiens 134-137 6140273-2 1984 When dopamine (0.01-0.1 microM) or bromocriptine (0.01-0.1 microM) was added to the culture media, a significant inhibition of GH and PRL secretion from adenoma cells from acromegalic patients was observed. Bromocriptine 35-48 prolactin Homo sapiens 134-137 6140273-4 1984 Similarly, dopamine suppressed GH and PRL release by nonadenomatous pituitary cells in a dose-dependent manner, which was again blocked by D2 receptor blockade. Dopamine 11-19 prolactin Homo sapiens 38-41 6140273-5 1984 The minimum effective concentration of dopamine required for a significant inhibition of PRL secretion (0.01 microM) was lower than that for GH release (0.1 microM). Dopamine 39-47 prolactin Homo sapiens 89-92 6140273-6 1984 Norepinephrine, likewise, caused a suppression of PRL secretion from adenomatous and nonadenomatous pituitary cells. Norepinephrine 0-14 prolactin Homo sapiens 50-53 6140273-9 1984 Coincubation of TRH and dopamine resulted in variable effects on GH and PRL secretion. Dopamine 24-32 prolactin Homo sapiens 72-75 6689678-6 1984 Upon cessation of DA infusion, there was a rapid rebound in PRL release, which was significantly greater (P less than 0.05) in patients (155 +/- 15%) than in normal subjects (118 +/- 13%). Dopamine 18-20 prolactin Homo sapiens 60-63 6387105-4 1984 Following pimozide plasma prolactin (PRL) levels correlated with clinical change, although the time courses of response of PRL and clinical response were dissimilar. Pimozide 10-18 prolactin Homo sapiens 26-35 6400338-12 1984 In conclusion, the effects of GnRH and PRL were synergistic in BL hamsters and additive in Mel-treated animals. Melatonin 91-94 prolactin Homo sapiens 39-42 6694156-8 1984 Although peak levels of prolactin at oestrus did not differ between treatments, they tended to occur before the LH peak in sows of Group C and after the LH peak in Group E.(ABSTRACT TRUNCATED AT 250 WORDS) Luteinizing Hormone 112-114 prolactin Homo sapiens 24-33 6151431-0 1984 Dopamine control of prolactin secretion in multiple endocrine neoplasia type I. Dopamine 0-8 prolactin Homo sapiens 20-29 6151431-3 1984 Dopamine (2 micrograms/kg/min) was less effective in reducing serum prolactin in the prolactinoma group than in the other three groups studied; serum prolactin also showed little rebound in prolactin comparable to controls. Dopamine 0-8 prolactin Homo sapiens 68-77 6151431-3 1984 Dopamine (2 micrograms/kg/min) was less effective in reducing serum prolactin in the prolactinoma group than in the other three groups studied; serum prolactin also showed little rebound in prolactin comparable to controls. Dopamine 0-8 prolactin Homo sapiens 85-94 6151431-3 1984 Dopamine (2 micrograms/kg/min) was less effective in reducing serum prolactin in the prolactinoma group than in the other three groups studied; serum prolactin also showed little rebound in prolactin comparable to controls. Dopamine 0-8 prolactin Homo sapiens 85-94 6694156-8 1984 Although peak levels of prolactin at oestrus did not differ between treatments, they tended to occur before the LH peak in sows of Group C and after the LH peak in Group E.(ABSTRACT TRUNCATED AT 250 WORDS) Luteinizing Hormone 153-155 prolactin Homo sapiens 24-33 6361642-4 1984 The concentration of prolactin in maternal serum was higher (P less than .001) during sulpiride than placebo treatment at one week (380 +/- 43 ng/ml vs 23 +/- 7 ng/ml, mean +/- SE) and two weeks of treatment (381 +/- 38 ng/ml vs 34 +/- 10 ng/ml). Sulpiride 86-95 prolactin Homo sapiens 21-30 6709609-6 1984 During compensation, the patients with insulin-depended diabetes manifested a reduction in the STH level and an increase in the prolactin/STH index. STH 138-141 prolactin Homo sapiens 128-137 6436857-0 1984 Effect of atropine on the diurnal PRL responses to TRH in normal subjects. Atropine 10-18 prolactin Homo sapiens 34-37 6699448-6 1984 The effects of the oral administration of two serotonin antagonist (cyproheptadine and metergoline) and the dopamine infusion on plasma PRL levels and the response to suckling were investigated during the 1st week postpartum. Dopamine 108-116 prolactin Homo sapiens 136-139 6699448-7 1984 Metergoline and dopamine suppressed basal PRL levels and abolished the response to suckling, whereas cyproheptadine suppressed the response less effectively without modifying the basal levels. Metergoline 0-11 prolactin Homo sapiens 42-45 6699448-7 1984 Metergoline and dopamine suppressed basal PRL levels and abolished the response to suckling, whereas cyproheptadine suppressed the response less effectively without modifying the basal levels. Dopamine 16-24 prolactin Homo sapiens 42-45 6420832-0 1984 Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism. Clomipramine 66-81 prolactin Homo sapiens 33-42 6420832-0 1984 Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism. Desipramine 86-99 prolactin Homo sapiens 33-42 6420832-0 1984 Comparison of growth hormone and prolactin stimulation induced by chlorimipramine and desimipramine in man in connection with chlorimipramine metabolism. Clomipramine 126-141 prolactin Homo sapiens 33-42 6425893-0 1984 Inhibition by phospholipid liposomes of the prolactin and cortisol response to insulin hypoglycemia in man. Phospholipids 14-26 prolactin Homo sapiens 44-53 6427833-0 1984 High dose diazepam treatment and its effect on prolactin secretion in adolescent schizophrenic patients. Diazepam 10-18 prolactin Homo sapiens 47-56 6427833-7 1984 The mild hyperprolactinemia achieved with the extremely high doses of diazepam (greater than 250 mg/day) is possibly due to activation of the GABA system which stimulates prolactin release directly or by inhibiting the dopaminergic neurons or alternatively to activation of the endorphinergic system. Diazepam 70-78 prolactin Homo sapiens 14-23 6427833-7 1984 The mild hyperprolactinemia achieved with the extremely high doses of diazepam (greater than 250 mg/day) is possibly due to activation of the GABA system which stimulates prolactin release directly or by inhibiting the dopaminergic neurons or alternatively to activation of the endorphinergic system. gamma-Aminobutyric Acid 142-146 prolactin Homo sapiens 14-23 6431476-4 1984 All subjects showed a release of PRL after FK 33-824, which was significantly diminished after pretreatment with methysergide. Methysergide 113-125 prolactin Homo sapiens 33-36 6440179-1 1984 Spontaneous prolactin patterns were determined at 15-min intervals over 5 h in 13 patients, who were suffering from melancholia, during illness and after treatment with amitriptyline. Amitriptyline 169-182 prolactin Homo sapiens 12-21 6543471-0 1984 [Plasma prolactin in the puerperium and its relation to the use of methylergonovine maleate]. Methylergonovine 67-91 prolactin Homo sapiens 8-17 6549590-1 1984 The authors study the correlation existing between prolactin and E-17-beta in breast cancer. e-17-beta 65-74 prolactin Homo sapiens 51-60 6523351-1 1984 The authors studied the basal and L-DOPA-stimulated levels of STH and basal level of prolactin in blood serum of 128 patients presenting with acromegaly. Levodopa 34-40 prolactin Homo sapiens 85-94 6514937-0 1984 Morphine inhibits cortisol and stimulates prolactin secretion in man. Morphine 0-8 prolactin Homo sapiens 42-51 6514937-3 1984 We report here the effects of intravenous morphine (5 mg) on plasma cortisol and prolactin. Morphine 42-50 prolactin Homo sapiens 81-90 6514937-7 1984 Morphine stimulated prolactin release. Morphine 0-8 prolactin Homo sapiens 20-29 6584932-0 1984 Prolactin response to single and multiple doses of haloperidol in schizophrenic patients. Haloperidol 51-62 prolactin Homo sapiens 0-9 6584932-3 1984 There were statistically significant relationships between steady-state plasma and red cell haloperidol levels (measured by radioreceptor or gas liquid chromatographic techniques) and serum prolactin response, but not between blood levels after the acute haloperidol dose and prolactin response. Haloperidol 92-103 prolactin Homo sapiens 190-199 6431658-3 1984 The levels of serum prolactin and oestradiol-17B were increased significantly (p less than 0.05, p less than 0.05, respectively) with a marked reduction in serum FSH, LH and testosterone (p less than 0.05, p less than 0.05, p less than 0.05, respectively). Luteinizing Hormone 167-169 prolactin Homo sapiens 20-29 6431658-3 1984 The levels of serum prolactin and oestradiol-17B were increased significantly (p less than 0.05, p less than 0.05, respectively) with a marked reduction in serum FSH, LH and testosterone (p less than 0.05, p less than 0.05, p less than 0.05, respectively). Testosterone 174-186 prolactin Homo sapiens 20-29 6657127-1 1983 The changes in prolactin release induced by acute doses of L-Dopa + benserazide (250 mg) were analysed in Parkinson disease patients undergoing various drug treatments. Levodopa 59-65 prolactin Homo sapiens 15-24 6657127-1 1983 The changes in prolactin release induced by acute doses of L-Dopa + benserazide (250 mg) were analysed in Parkinson disease patients undergoing various drug treatments. Benserazide 68-79 prolactin Homo sapiens 15-24 6662195-1 1983 The analgesic effect of prolactin (PRL) was tested by means of the acetic acid-induced writhing test and the hot plate method. Acetic Acid 67-78 prolactin Homo sapiens 24-33 6662195-1 1983 The analgesic effect of prolactin (PRL) was tested by means of the acetic acid-induced writhing test and the hot plate method. Acetic Acid 67-78 prolactin Homo sapiens 35-38 6662195-4 1983 Bromocriptine, which inhibits PRL secretion through dopaminergic activity, also antagonised PRL-induced analgesia implicating dopaminergic mechanisms in this action of PRL. Bromocriptine 0-13 prolactin Homo sapiens 30-33 6662195-4 1983 Bromocriptine, which inhibits PRL secretion through dopaminergic activity, also antagonised PRL-induced analgesia implicating dopaminergic mechanisms in this action of PRL. Bromocriptine 0-13 prolactin Homo sapiens 92-95 6662195-4 1983 Bromocriptine, which inhibits PRL secretion through dopaminergic activity, also antagonised PRL-induced analgesia implicating dopaminergic mechanisms in this action of PRL. Bromocriptine 0-13 prolactin Homo sapiens 92-95 6360431-0 1983 Effect of fenfluramine on prolactin secretion in obese patients: evidence for serotoninergic regulation of prolactin in man. Fenfluramine 10-22 prolactin Homo sapiens 26-35 6360431-5 1983 Since it has been reported that dopaminergic blockade raises PA concentration, the lack of change in PA in obese patients treated with fenfluramine suggests that the observed increase in PRL induced by fenfluramine is likely to be mediated by serotoninergic stimulation. Fenfluramine 202-214 prolactin Homo sapiens 187-190 6678600-3 1983 Following cessation of bromocriptine therapy one third of subjects whose initial serum prolactin (PRL) level was less than 4 times normal had a "spontaneous" resolution of their hyperprolactinaemia and resumed cyclical menstrual activity and fertility. Bromocriptine 23-36 prolactin Homo sapiens 87-96 6678600-3 1983 Following cessation of bromocriptine therapy one third of subjects whose initial serum prolactin (PRL) level was less than 4 times normal had a "spontaneous" resolution of their hyperprolactinaemia and resumed cyclical menstrual activity and fertility. Bromocriptine 23-36 prolactin Homo sapiens 98-101 6630409-9 1983 Ingestion of L-tyrosine and L-tryptophan induced remarkable increments in serum concentrations of both PRL and cortisol, suggesting that these essential amino acids may be active components of the high protein meal. Tyrosine 13-23 prolactin Homo sapiens 103-106 6630409-9 1983 Ingestion of L-tyrosine and L-tryptophan induced remarkable increments in serum concentrations of both PRL and cortisol, suggesting that these essential amino acids may be active components of the high protein meal. Tryptophan 28-40 prolactin Homo sapiens 103-106 6630409-9 1983 Ingestion of L-tyrosine and L-tryptophan induced remarkable increments in serum concentrations of both PRL and cortisol, suggesting that these essential amino acids may be active components of the high protein meal. Amino Acids, Essential 143-164 prolactin Homo sapiens 103-106 6630411-0 1983 Different rebound rise in plasma prolactin during the postdopamine infusion phase in puerperal women and patients with pathological hyperprolactinemia. postdopamine 54-66 prolactin Homo sapiens 33-42 6633994-1 1983 Prolactin response to an intravenous injection of 5 mg of metoclopramide was monitored in 1) normal subjects during the follicular and luteal phases of the menstrual cycle; 2) subjects with known prolactinomas, two of whom were breast-feeding; 3) subjects with suspected prolactinomas; 4) normal lactating women; and 5) normal postmenopausal women. Metoclopramide 58-72 prolactin Homo sapiens 0-9 6326414-5 1983 The possibility that prolactin, a proven osmoregulatory hormone in submammalian species but not in mammals and primates, may have an important role in this process is suggested by recent evidence that prolactin regulates tissue water in fetal and newborn animals. Water 228-233 prolactin Homo sapiens 21-30 6326414-5 1983 The possibility that prolactin, a proven osmoregulatory hormone in submammalian species but not in mammals and primates, may have an important role in this process is suggested by recent evidence that prolactin regulates tissue water in fetal and newborn animals. Water 228-233 prolactin Homo sapiens 201-210 6326414-6 1983 If this hormone assists in the regulation of water and electrolyte content of the brain during the perinatal period then prolactin receptors might be expected at blood-brain and blood-CSF barriers. Water 45-50 prolactin Homo sapiens 121-130 6667307-0 1983 [Preliminary evaluation of the effect of ibopamine on the secretion of prolactin]. ibopamine 41-50 prolactin Homo sapiens 71-80 6667307-2 1983 The prolactin-lowering activity of Ibopamine was studied in 8 subjects with normal prolactine levels given the drug in a single dose of 100 mg. Prolactin levels measured by radioimmuno assay were evaluated before and within 2, 4 and 8 h of administration. ibopamine 35-44 prolactin Homo sapiens 4-13 6667307-4 1983 Ibopamine was shown to decrease prolactin to a statistically significant extent at the 2nd h after administration. ibopamine 0-9 prolactin Homo sapiens 32-41 6638052-9 1983 In all patients treated with bromocriptine, symptoms improved irrespective of radiologic findings on the pituitary, and were abolished in 67 percent during treatment associated with a decrease in serum prolactin levels in all, and a return of levels to within normal limits in 80 percent of patients. Bromocriptine 29-42 prolactin Homo sapiens 202-211 6638052-16 1983 Long-term bromocriptine treatment for hyperprolactinemia is thus highly effective in alleviating symptoms and suppressing prolactin secretion, and induces persistent tumor regression on treatment without deterioration of other pituitary function in patients with macroadenomas. Bromocriptine 10-23 prolactin Homo sapiens 43-52 6638094-9 1983 The conclusion is that both patients with and those without radiologic evidence of a prolactin-secreting pituitary adenoma can be safely treated with bromocriptine. Bromocriptine 150-163 prolactin Homo sapiens 85-94 6229562-0 1983 Amoxapine elevates serum prolactin in depressed men. Amoxapine 0-9 prolactin Homo sapiens 25-34 6638109-3 1983 The de novo synthesis of myometrical prolactin is supported by no detectable prolactin in initial tissue homogenate, nondetectable prolactin production during the first 24 hours of culture, cycloheximide inhibition of prolactin production with recovery of production in control medium, and tritiated leucine incorporation into prolactin. Cycloheximide 190-203 prolactin Homo sapiens 37-46 6638109-3 1983 The de novo synthesis of myometrical prolactin is supported by no detectable prolactin in initial tissue homogenate, nondetectable prolactin production during the first 24 hours of culture, cycloheximide inhibition of prolactin production with recovery of production in control medium, and tritiated leucine incorporation into prolactin. Leucine 300-307 prolactin Homo sapiens 37-46 6639832-2 1983 Acute oral administration of various doses of fenfluramine, a 5-HT releaser, induced a dose-related increase of PRL secretion in nine healthy volunteers. Fenfluramine 46-58 prolactin Homo sapiens 112-115 6639832-3 1983 Fenfluramine reached the maximum effect on PRL secretion at 4 h after its administration. Fenfluramine 0-12 prolactin Homo sapiens 43-46 6639832-4 1983 This effect was already significant at 2 h and lasted till 8 h. Metergoline, a 5-HT receptor blocker, when administered alone, decreased serum PRL levels in six healthy subjects. Metergoline 64-75 prolactin Homo sapiens 143-146 6639832-5 1983 The pretreatment with this drug significantly antagonized the PRL-releasing action of fenfluramine (60 mg) suggesting that the effect of fenfluramine on PRL release may be mediated through a 5-HT mechanism in the brain. Fenfluramine 86-98 prolactin Homo sapiens 62-65 6639832-5 1983 The pretreatment with this drug significantly antagonized the PRL-releasing action of fenfluramine (60 mg) suggesting that the effect of fenfluramine on PRL release may be mediated through a 5-HT mechanism in the brain. Fenfluramine 86-98 prolactin Homo sapiens 153-156 6639832-5 1983 The pretreatment with this drug significantly antagonized the PRL-releasing action of fenfluramine (60 mg) suggesting that the effect of fenfluramine on PRL release may be mediated through a 5-HT mechanism in the brain. Fenfluramine 137-149 prolactin Homo sapiens 62-65 6639832-5 1983 The pretreatment with this drug significantly antagonized the PRL-releasing action of fenfluramine (60 mg) suggesting that the effect of fenfluramine on PRL release may be mediated through a 5-HT mechanism in the brain. Fenfluramine 137-149 prolactin Homo sapiens 153-156 6229562-2 1983 Clinically, an increase in serum prolactin occurs during neuroleptic treatment secondary to post-synaptic dopamine blockade. Dopamine 106-114 prolactin Homo sapiens 33-42 6229562-3 1983 Ten men who met DSM-III criteria for major depression exhibited a significant increase in their serum prolactin over drug-free baseline values during treatment with amoxapine. Amoxapine 165-174 prolactin Homo sapiens 102-111 6141186-0 1983 The prolactin response to flutroline hydrochloride in schizophrenic patients. 4-[8-fluoro-5-(4-fluorophenyl)-3,4-dihydro-1H-pyrido[4,3-b]indol-2-yl]-1-(4-fluorophenyl)butan-1-ol;hydrochloride 26-50 prolactin Homo sapiens 4-13 6619271-8 1983 The incremental PRL responses to domperidone were significantly less in hyperprolactinemic than in normal women and did not differ at each time of day. Domperidone 33-44 prolactin Homo sapiens 16-19 6197504-1 1983 The uptake of 125I-labelled human prolactin by subcellular fractions obtained from the human hyperplastic prostate was investigated and the specific binding sites were characterized. Iodine-125 14-18 prolactin Homo sapiens 34-43 6197504-6 1983 The addition of magnesium and copper ions to the incubation medium also markedly increased the specific binding, whereas calcium, manganese and EDTA inhibited the prolactin uptake. Calcium 121-128 prolactin Homo sapiens 163-172 6197504-6 1983 The addition of magnesium and copper ions to the incubation medium also markedly increased the specific binding, whereas calcium, manganese and EDTA inhibited the prolactin uptake. Manganese 130-139 prolactin Homo sapiens 163-172 6197504-6 1983 The addition of magnesium and copper ions to the incubation medium also markedly increased the specific binding, whereas calcium, manganese and EDTA inhibited the prolactin uptake. Edetic Acid 144-148 prolactin Homo sapiens 163-172 6580885-8 1983 Bromocriptine treatment was given to 38 patients, 13 with abnormal tomographic findings (mean serum PRL greater than 100ng/ml); 18 with suspected pituitary microadenoma (mean serum PRL 94 +/- 2.7 ng/ml) and 7 with idiopathic hyperprolactinaemia (mean serum PRL 65 +/- 4.7 ng/ml). Bromocriptine 0-13 prolactin Homo sapiens 100-103 6685061-0 1983 Effects of naloxone infusion on basal and breast-stimulation-induced prolactin secretion in puerperal women. Naloxone 11-19 prolactin Homo sapiens 69-78 6645503-0 1983 Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism. Dopamine 48-56 prolactin Homo sapiens 22-31 6645503-0 1983 Mineralocorticoid and prolactin response to the dopamine antagonist metoclopramide in patients with primary aldosteronism. Metoclopramide 68-82 prolactin Homo sapiens 22-31 6645503-2 1983 Significant increases of plasma aldosterone, 18-hydroxycorticosterone (18-OH-B), and prolactin levels were observed in all normal subjects and in patients with primary aldosteronism after metoclopramide, whereas plasma 18-corticosterone, corticosterone, and cortisol levels as well as plasma renin activity did not change. Metoclopramide 188-202 prolactin Homo sapiens 85-94 6645503-5 1983 Basal prolactin levels were within the normal range in all patients with primary aldosteronism, but the increase of prolactin observed 15 and 30 min after metoclopramide, was elevated in three patients with hyperplasia and in four patients with adenoma. Metoclopramide 155-169 prolactin Homo sapiens 116-125 6645503-8 1983 The positive correlation between the metoclopramide-induced increase of plasma aldosterone and prolactin may indicate a common inhibitory dopaminergic mechanism, working on the pituitary and adrenal level. Metoclopramide 37-51 prolactin Homo sapiens 95-104 6624968-3 1983 The elevation of serum prolactin during treatment in three patients suggests that postsynaptic dopamine blockade occurs with amoxapine treatment. Dopamine 95-103 prolactin Homo sapiens 23-32 6624968-3 1983 The elevation of serum prolactin during treatment in three patients suggests that postsynaptic dopamine blockade occurs with amoxapine treatment. Amoxapine 125-134 prolactin Homo sapiens 23-32 6138009-0 1983 The effect of buspirone on prolactin and growth hormone secretion in man. Buspirone 14-23 prolactin Homo sapiens 27-36 6138009-3 1983 In man, buspirone hydrochloride at doses of 30, 60, and 90 mg orally significantly elevated plasma prolactin (PRL) and growth hormone (GH) concentrations. Buspirone 8-31 prolactin Homo sapiens 99-108 6138009-3 1983 In man, buspirone hydrochloride at doses of 30, 60, and 90 mg orally significantly elevated plasma prolactin (PRL) and growth hormone (GH) concentrations. Buspirone 8-31 prolactin Homo sapiens 110-113 6138009-5 1983 The increase in PRL secretion could be due to a dopamine antagonist effect at the pituitary gland. Dopamine 48-56 prolactin Homo sapiens 16-19 6652155-0 1983 Ethanol-related prolactin responses and risk for alcoholism. Ethanol 0-7 prolactin Homo sapiens 16-25 6652155-1 1983 Serum prolactin (PRL) levels after drinking 0.75 ml/g of ethanol were observed in 44 nonalcoholic young men who had an alcoholic first-degree relative and 44 controls lacking a family history of alcoholism. Ethanol 57-64 prolactin Homo sapiens 6-15 6652155-1 1983 Serum prolactin (PRL) levels after drinking 0.75 ml/g of ethanol were observed in 44 nonalcoholic young men who had an alcoholic first-degree relative and 44 controls lacking a family history of alcoholism. Ethanol 57-64 prolactin Homo sapiens 17-20 6652155-4 1983 These results are consistent with an effect of a moderate dose of ethanol on PRL levels and further characterize differences in reactions to ethanol for men at higher and lower risk for the future development of alcoholism. Ethanol 66-73 prolactin Homo sapiens 77-80 6627697-0 1983 The participation of hypothalamic dopamine in morphine-induced prolactin release in man. Dopamine 34-42 prolactin Homo sapiens 63-72 6627697-0 1983 The participation of hypothalamic dopamine in morphine-induced prolactin release in man. Morphine 46-54 prolactin Homo sapiens 63-72 6627697-2 1983 Morphine (10 mg) stimulated prolactin release in all subjects; however, the effect was totally abolished when 10 mag metoclopramide or 200 mg benserazide were given before the opiate agonist. Morphine 0-8 prolactin Homo sapiens 28-37 6627697-3 1983 The prolactin releasing effect of a sub-maximal metoclopramide dose (1 mg) was potentiated by morphine. Metoclopramide 48-62 prolactin Homo sapiens 4-13 6627697-3 1983 The prolactin releasing effect of a sub-maximal metoclopramide dose (1 mg) was potentiated by morphine. Morphine 94-102 prolactin Homo sapiens 4-13 6642786-0 1983 The effect of acetylsalicylic acid and diclofenac on stimulated growth hormone and prolactin secretion in humans. Diclofenac 39-49 prolactin Homo sapiens 83-92 6643309-0 1983 Effects of ovarian secretions and dopamine on secretion of luteinizing hormone and prolactin in ewes. Dopamine 34-42 prolactin Homo sapiens 83-92 6643309-9 1983 Infusion of DA inhibited release of PRL, but there was no effect of method of progesterone withdrawal. Dopamine 12-14 prolactin Homo sapiens 36-39 6643309-10 1983 Lutectomized ewes, but not ovariectomized ewes with implants of estradiol-17 beta, had a surge of PRL associated with the surge of LH. Luteinizing Hormone 131-133 prolactin Homo sapiens 98-101 6689332-0 1983 Effect of 1,25-dihydroxyvitamin D3 on plasma prolactin in patients with renal failure on regular dialysis treatment. Calcitriol 10-34 prolactin Homo sapiens 45-54 6689332-4 1983 A direct effect of 1,25 (OH)2-D on PRL secretion may exist. Water 24-29 prolactin Homo sapiens 35-38 6674419-0 1983 Changes of CSF prolactin induced by metoclopramide in man. Metoclopramide 36-50 prolactin Homo sapiens 15-24 6674419-1 1983 A sharp increase in serum and CSF prolactin (PRL) values after acute metoclopramide (10 mg i.m.) Metoclopramide 69-83 prolactin Homo sapiens 34-43 6315507-9 1983 Phosphoethanolamine, which has been shown to be a growth factor for some rat and human mammary carcinoma cells, showed 2-fold growth stimulation when added with prolactin, insulin or hydrocortisone. phosphorylethanolamine 0-19 prolactin Homo sapiens 161-170 6139285-6 1983 Administration of the same dose of domperidone or sulpiride (5 mg/kg i.p., 21 days), compounds which penetrate poorly into brain, also elevated plasma prolactin levels, but failed to alter cerebral dopamine function. Domperidone 35-46 prolactin Homo sapiens 151-160 6139285-6 1983 Administration of the same dose of domperidone or sulpiride (5 mg/kg i.p., 21 days), compounds which penetrate poorly into brain, also elevated plasma prolactin levels, but failed to alter cerebral dopamine function. Sulpiride 50-59 prolactin Homo sapiens 151-160 6888442-1 1983 We gave pergolide mesylate, a new long-acting ergot derivative with dopaminergic properties, to 47 patients with hypersecretion of prolactin or growth hormone. Pergolide 8-26 prolactin Homo sapiens 131-140 6888442-3 1983 Among 41 patients (22 women and 19 men) with hyperprolactinemia who took pergolide for three months or more, prolactin levels fell to normal in 37 and remained slightly elevated in 2. Pergolide 73-82 prolactin Homo sapiens 50-59 6888442-8 1983 We conclude that pergolide reduces hypersecretion and shrinks most prolactin-secreting macroadenomas. Pergolide 17-26 prolactin Homo sapiens 67-76 6414205-0 1983 LRF and TRF test during long-term danazol treatment: increase of the LH and FSH responses but decrease of the prolactin and TSH responses. Danazol 34-41 prolactin Homo sapiens 110-119 6414205-8 1983 In the TRF-LRF test the responses of serum FSH and LH were significantly higher and those of serum Prl and TSH significantly lower during danazol treatment than before. Danazol 138-145 prolactin Homo sapiens 99-102 6614083-0 1983 Prolactin secretion by human chorion-decidua in vitro: influences of mode of delivery and agents that modify prostaglandin synthesis. Prostaglandins 109-122 prolactin Homo sapiens 0-9 6614083-5 1983 Indomethacin at 10(-4) M reduced only levels of stored prolactin but had no effect on stored or produced prolactin at lower concentrations (10(-7) M to 10(-5) M). Indomethacin 0-12 prolactin Homo sapiens 55-64 6614083-6 1983 Arachidonic acid (10(-4) M) suppressed both production and storage of prolactin (P less than 0.05). Arachidonic Acid 0-16 prolactin Homo sapiens 70-79 6414745-14 1983 In Group II females, PRL responsiveness to metoclopramide was associated with TSH non-responsiveness. Metoclopramide 43-57 prolactin Homo sapiens 21-24 6414745-14 1983 In Group II females, PRL responsiveness to metoclopramide was associated with TSH non-responsiveness. Thyrotropin 78-81 prolactin Homo sapiens 21-24 12265809-1 1983 This study was designed to report changes in circulating FSH, LH, and prolactin levels in women users of subdermal levonorgestrel implants. Levonorgestrel 115-129 prolactin Homo sapiens 70-79 6642414-0 1983 Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia. Amphetamine 29-40 prolactin Homo sapiens 0-9 6642414-1 1983 The effect on plasma prolactin (PRL) of d-amphetamine (Amph) was studied in normo- and hyperprolactinemic subjects. Dextroamphetamine 40-53 prolactin Homo sapiens 21-30 6642414-1 1983 The effect on plasma prolactin (PRL) of d-amphetamine (Amph) was studied in normo- and hyperprolactinemic subjects. Dextroamphetamine 40-53 prolactin Homo sapiens 32-35 6642414-1 1983 The effect on plasma prolactin (PRL) of d-amphetamine (Amph) was studied in normo- and hyperprolactinemic subjects. Dextroamphetamine 55-59 prolactin Homo sapiens 21-30 6642414-1 1983 The effect on plasma prolactin (PRL) of d-amphetamine (Amph) was studied in normo- and hyperprolactinemic subjects. Dextroamphetamine 55-59 prolactin Homo sapiens 32-35 6642414-2 1983 In normoprolactinemic women Amph failed to lower plasma PRL levels when infused intravenously over 1 h at the dose of 7.5 mg, but induced at the dose of 15.0 mg a modest inhibition of plasma PRL (maximum PRL inhibition 20 +/- 4.5% at 45 min). Dextroamphetamine 28-32 prolactin Homo sapiens 191-194 6642414-2 1983 In normoprolactinemic women Amph failed to lower plasma PRL levels when infused intravenously over 1 h at the dose of 7.5 mg, but induced at the dose of 15.0 mg a modest inhibition of plasma PRL (maximum PRL inhibition 20 +/- 4.5% at 45 min). Dextroamphetamine 28-32 prolactin Homo sapiens 191-194 6642414-5 1983 These results indicate that Amph is a poor PRL suppressor in either normo- or hyperprolactinemic subjects. Dextroamphetamine 28-32 prolactin Homo sapiens 43-46 6354944-10 1983 On the basis of the above findings it is suggested that indoprofen may be a safe alternative to opiates for relief of moderate to severe pain in women with breast tumors suspected of being prolactin-dependent. Indoprofen 56-66 prolactin Homo sapiens 189-198 6413878-2 1983 Agents that decrease its production by blocking phospholipase A2 activity, i.e., quinacrine and 4-bromophenacylbromide, significantly decreased prolactin secretion from anterior pituitary glands in vitro and from dispersed pituitary cells in a perifusion column. Quinacrine 81-91 prolactin Homo sapiens 144-153 6413878-2 1983 Agents that decrease its production by blocking phospholipase A2 activity, i.e., quinacrine and 4-bromophenacylbromide, significantly decreased prolactin secretion from anterior pituitary glands in vitro and from dispersed pituitary cells in a perifusion column. 4-bromophenacyl bromide 96-118 prolactin Homo sapiens 144-153 6413878-3 1983 Phospholipase A2 and phorbol myristate acetate, substances that increase intracellular concentrations of arachidonic acid, markedly stimulated prolactin release by dispersed pituitary cells and by anterior pituitary glands incubated in vitro. Tetradecanoylphorbol Acetate 21-46 prolactin Homo sapiens 143-152 6413878-3 1983 Phospholipase A2 and phorbol myristate acetate, substances that increase intracellular concentrations of arachidonic acid, markedly stimulated prolactin release by dispersed pituitary cells and by anterior pituitary glands incubated in vitro. Arachidonic Acid 105-121 prolactin Homo sapiens 143-152 6413878-4 1983 The involvement in prolactin secretion of arachidonic acid metabolic products produced via the lipoxygenase pathway was investigated indirectly using nordihydroguaiaretic acid (NDGA), a specific inhibitor of this enzyme. Arachidonic Acid 42-58 prolactin Homo sapiens 19-28 6413878-4 1983 The involvement in prolactin secretion of arachidonic acid metabolic products produced via the lipoxygenase pathway was investigated indirectly using nordihydroguaiaretic acid (NDGA), a specific inhibitor of this enzyme. Masoprocol 150-175 prolactin Homo sapiens 19-28 6413878-4 1983 The involvement in prolactin secretion of arachidonic acid metabolic products produced via the lipoxygenase pathway was investigated indirectly using nordihydroguaiaretic acid (NDGA), a specific inhibitor of this enzyme. Masoprocol 177-181 prolactin Homo sapiens 19-28 6413878-7 1983 The results suggest that arachidonic acid metabolism is involved in basal and TRH-stimulated prolactin secretion and that lipoxygenase pathway products are at least partially responsible for these effects. Arachidonic Acid 25-41 prolactin Homo sapiens 93-102 6619615-0 1983 [Effect of a histamine H2-receptor antagonist, cimetidine, on prolactin secretion in women]. Cimetidine 47-57 prolactin Homo sapiens 62-71 6619615-1 1983 The effect of acute intravenous injection of 400mg cimetidine, a histamine H2-receptor antagonist, on prolactin (PRL) secretion was investigated in women with normal menstrual cycles (n = 12) and normoprolactinemic secondary amenorrhea (n = 10). Cimetidine 51-61 prolactin Homo sapiens 102-111 6619615-1 1983 The effect of acute intravenous injection of 400mg cimetidine, a histamine H2-receptor antagonist, on prolactin (PRL) secretion was investigated in women with normal menstrual cycles (n = 12) and normoprolactinemic secondary amenorrhea (n = 10). Cimetidine 51-61 prolactin Homo sapiens 113-116 6619615-2 1983 In addition, the PRL response to cimetidine was also examined in women with puerperal (n = 10) and idiopathic (n = 10) hyperprolactinemia. Cimetidine 33-43 prolactin Homo sapiens 17-20 6619615-3 1983 The administration of cimetidine provoked a rapid rise in plasma PRL in both normal and amenorrheic women, with peak values occurring at 10-15 minutes, followed by a return toward the baseline by 2 hours. Cimetidine 22-32 prolactin Homo sapiens 65-68 6619615-6 1983 The cimetidine injection caused a remarkable increase in plasma PRL in women with puerperal hyperprolactinemia [110.8 +/- 31.1 vs. 288.8 +/- 39.6 ng/ml (p less than 0.001)], while the PRL response was diminished or absent in women with idiopathic hyperprolactinemia [103.3 +/- 19.3 vs. 122.9 +/- 14.6 ng/ml (p greater than 0.1)]. Cimetidine 4-14 prolactin Homo sapiens 64-67 6619615-6 1983 The cimetidine injection caused a remarkable increase in plasma PRL in women with puerperal hyperprolactinemia [110.8 +/- 31.1 vs. 288.8 +/- 39.6 ng/ml (p less than 0.001)], while the PRL response was diminished or absent in women with idiopathic hyperprolactinemia [103.3 +/- 19.3 vs. 122.9 +/- 14.6 ng/ml (p greater than 0.1)]. Cimetidine 4-14 prolactin Homo sapiens 184-187 6619615-8 1983 These results suggest that histamine may exert an inhibitory effect on PRL secretion through H2-receptors and that an altered central histaminergic tone may be involved in amenorrheic or pathological hyperprolactinemic state. Histamine 27-36 prolactin Homo sapiens 71-74 6140692-6 1983 The plasma prolactin (PRL) levels of the patients with high pretreatment levels decreased significantly during the administration of L-deprenyl. Selegiline 133-143 prolactin Homo sapiens 11-20 6146158-1 1983 Serum prolactin (PRL ng/ml) was measured in 7 male patients on cimetidine (CMT) and in 13 on ranitidine (RNT) before therapy and 5, 10, 15 and 30 days after; at the same intervals FSH (ng/ml), LH (ng/ml) and testosterone (ng/ml) were measured in 5 patients too, in order to ascertain hypothalamic, pituitary, gonadal dysfunction caused by H2 histamine blockers. Ranitidine 93-103 prolactin Homo sapiens 6-15 6410917-2 1983 The dosage of bromocriptine was modified to reduce the serum prolactin level to below 20 ng/ml. Bromocriptine 14-27 prolactin Homo sapiens 61-70 6411170-5 1983 This case of regrowth of a prolactinoma during bromocriptine treatment after an initial reduction in size indicates the need for close surveillance especially of patients whose serum prolactin concentration fails to fall into the normal range with bromocriptine treatment. Bromocriptine 47-60 prolactin Homo sapiens 27-36 6411170-5 1983 This case of regrowth of a prolactinoma during bromocriptine treatment after an initial reduction in size indicates the need for close surveillance especially of patients whose serum prolactin concentration fails to fall into the normal range with bromocriptine treatment. Bromocriptine 248-261 prolactin Homo sapiens 27-36 6310918-0 1983 The role of prolactin in the inhibitory action of bromocriptine on growth hormone secretion in acromegaly. Bromocriptine 50-63 prolactin Homo sapiens 12-21 6310918-8 1983 Plasma GH levels from 2 till 10 h after the administration of 2.5 mg bromocriptine measured before operation were significantly more suppressed in the patients with mixed GH/Prl-containing than in those with pure GH-containing pituitary adenomas, being 38 +/- 4% and 65 +/- 4% of basal values, respectively (P less than 0.01). Bromocriptine 69-82 prolactin Homo sapiens 174-177 6310918-13 1983 The simultaneous presence of Prl and GH in a GH-secreting pituitary tumour increases the sensitivity of GH secretion to bromocriptine. Bromocriptine 120-133 prolactin Homo sapiens 29-32 6310918-15 1983 The plasma Prl level is of value to predict which patients with acromegaly are likely to respond to bromocriptine with an inhibition of GH secretion. Bromocriptine 100-113 prolactin Homo sapiens 11-14 6580885-8 1983 Bromocriptine treatment was given to 38 patients, 13 with abnormal tomographic findings (mean serum PRL greater than 100ng/ml); 18 with suspected pituitary microadenoma (mean serum PRL 94 +/- 2.7 ng/ml) and 7 with idiopathic hyperprolactinaemia (mean serum PRL 65 +/- 4.7 ng/ml). Bromocriptine 0-13 prolactin Homo sapiens 181-184 6580885-8 1983 Bromocriptine treatment was given to 38 patients, 13 with abnormal tomographic findings (mean serum PRL greater than 100ng/ml); 18 with suspected pituitary microadenoma (mean serum PRL 94 +/- 2.7 ng/ml) and 7 with idiopathic hyperprolactinaemia (mean serum PRL 65 +/- 4.7 ng/ml). Bromocriptine 0-13 prolactin Homo sapiens 181-184 6411113-3 1983 The plasma concentration of prolactin, which decreased rapidly with bromocriptine, returned to the pretreatment level the day after drug treatment stopped, but with cyclofenil it remained low. Bromocriptine 68-81 prolactin Homo sapiens 28-37 6411113-3 1983 The plasma concentration of prolactin, which decreased rapidly with bromocriptine, returned to the pretreatment level the day after drug treatment stopped, but with cyclofenil it remained low. Cyclofenil 165-175 prolactin Homo sapiens 28-37 6411113-7 1983 The more sustained effect of cyclofenil on prolactin secretion with a reduced frequency of relapse, and the lower oestradiol level, which might indicate a reduced risk of thromboembolism, suggest that this drug has some advantage over bromocriptine in the inhibition of postpartum lactation. Cyclofenil 29-39 prolactin Homo sapiens 43-52 6411776-0 1983 Effect of subchronic lithium treatment on apomorphine-induced change in prolactin and growth hormone secretion. Lithium 21-28 prolactin Homo sapiens 72-81 6411776-0 1983 Effect of subchronic lithium treatment on apomorphine-induced change in prolactin and growth hormone secretion. Apomorphine 42-53 prolactin Homo sapiens 72-81 6863485-3 1983 These transitory elevations in hPRL to 27-70 ng/ml lasted only one to three days and coincided with the preovulatory estradiol peak. Estradiol 117-126 prolactin Homo sapiens 31-35 6881119-7 1983 Serum prolactin levels were rapidly suppressed during both bromocriptine periods. Bromocriptine 59-72 prolactin Homo sapiens 6-15 6138378-2 1983 Intravascular administration of agents to fetuses that significantly increased fetal prolactin concentrations (chlorpromazine 6.25 mg;thyrotrophin releasing hormone, 10 micrograms), significantly reduced fetal prolactin concentrations (bromocriptine, 0.033 mg/h), or significantly reduced fetal growth hormone (GH) concentrations (somatostatin, 2.5 micrograms/min), had no effect on maternal or fetal oPL concentrations. Chlorpromazine 111-125 prolactin Homo sapiens 85-94 6226542-1 1983 In order to investigate the relationship between the increment of plasma prolactin (PRL) levels and the change of plasma levels of PRL, DHEA-S, cortisol, aldosterone and 17 alpha OH delta 5-P were quantified by respective RIA in patients treated with TRH parenterally or with sulpiride orally. Dehydroepiandrosterone 136-142 prolactin Homo sapiens 73-82 6226542-1 1983 In order to investigate the relationship between the increment of plasma prolactin (PRL) levels and the change of plasma levels of PRL, DHEA-S, cortisol, aldosterone and 17 alpha OH delta 5-P were quantified by respective RIA in patients treated with TRH parenterally or with sulpiride orally. Dehydroepiandrosterone 136-142 prolactin Homo sapiens 84-87 6226542-1 1983 In order to investigate the relationship between the increment of plasma prolactin (PRL) levels and the change of plasma levels of PRL, DHEA-S, cortisol, aldosterone and 17 alpha OH delta 5-P were quantified by respective RIA in patients treated with TRH parenterally or with sulpiride orally. Hydrocortisone 144-152 prolactin Homo sapiens 73-82 6226542-1 1983 In order to investigate the relationship between the increment of plasma prolactin (PRL) levels and the change of plasma levels of PRL, DHEA-S, cortisol, aldosterone and 17 alpha OH delta 5-P were quantified by respective RIA in patients treated with TRH parenterally or with sulpiride orally. Hydrocortisone 144-152 prolactin Homo sapiens 84-87 6226542-1 1983 In order to investigate the relationship between the increment of plasma prolactin (PRL) levels and the change of plasma levels of PRL, DHEA-S, cortisol, aldosterone and 17 alpha OH delta 5-P were quantified by respective RIA in patients treated with TRH parenterally or with sulpiride orally. Aldosterone 154-165 prolactin Homo sapiens 73-82 6226542-1 1983 In order to investigate the relationship between the increment of plasma prolactin (PRL) levels and the change of plasma levels of PRL, DHEA-S, cortisol, aldosterone and 17 alpha OH delta 5-P were quantified by respective RIA in patients treated with TRH parenterally or with sulpiride orally. alpha oh delta 5-p 173-191 prolactin Homo sapiens 73-82 6226542-1 1983 In order to investigate the relationship between the increment of plasma prolactin (PRL) levels and the change of plasma levels of PRL, DHEA-S, cortisol, aldosterone and 17 alpha OH delta 5-P were quantified by respective RIA in patients treated with TRH parenterally or with sulpiride orally. Sulpiride 276-285 prolactin Homo sapiens 73-82 6226542-3 1983 Sulpiride given orally for 12 consecutive days in the luteal phase of the menstrual cycle caused a significant increase in the plasma PRL level. Sulpiride 0-9 prolactin Homo sapiens 134-137 6308934-0 1983 Lack of effect of chronic hypocalcaemia on serum prolactin response to chlorpromazine. Chlorpromazine 71-85 prolactin Homo sapiens 49-58 6308934-1 1983 The effects of chronic hypocalcaemia on serum basal and chlorpromazine-stimulated prolactin (Prl) levels were studied in 16 patients with idiopathic or secondary hypoparathyroidism. Chlorpromazine 56-70 prolactin Homo sapiens 82-91 6308934-1 1983 The effects of chronic hypocalcaemia on serum basal and chlorpromazine-stimulated prolactin (Prl) levels were studied in 16 patients with idiopathic or secondary hypoparathyroidism. Chlorpromazine 56-70 prolactin Homo sapiens 93-96 6880567-0 1983 Effects of a single oral dose of phenobarbital on prolactin, growth hormone and luteinizing hormone in normal women. Phenobarbital 33-46 prolactin Homo sapiens 50-59 6880567-1 1983 The effects of a single oral dose of phenobarbital (PB) on the 24 h secretion of prolactin, growth hormone and luteinizing hormone have been evaluated in normal women. Phenobarbital 37-50 prolactin Homo sapiens 81-90 6880567-1 1983 The effects of a single oral dose of phenobarbital (PB) on the 24 h secretion of prolactin, growth hormone and luteinizing hormone have been evaluated in normal women. Phenobarbital 52-54 prolactin Homo sapiens 81-90 6861440-1 1983 The effects of oral doses (100, 200, and 400 mg) of a dopamine derivative, ibopamine, on serum prolactin (PRL) and growth hormone (GH) levels were evaluated in hyperprolactinemic patients, some of whom also were acromegalic. Dopamine 54-62 prolactin Homo sapiens 95-104 6861440-1 1983 The effects of oral doses (100, 200, and 400 mg) of a dopamine derivative, ibopamine, on serum prolactin (PRL) and growth hormone (GH) levels were evaluated in hyperprolactinemic patients, some of whom also were acromegalic. ibopamine 75-84 prolactin Homo sapiens 95-104 6861440-1 1983 The effects of oral doses (100, 200, and 400 mg) of a dopamine derivative, ibopamine, on serum prolactin (PRL) and growth hormone (GH) levels were evaluated in hyperprolactinemic patients, some of whom also were acromegalic. ibopamine 75-84 prolactin Homo sapiens 106-109 6861440-3 1983 The highest dose was as effective as 500 mg L-dopa, although the duration of action was shorter, with a decrease to below 50% of basal PRL values in all patients. Levodopa 44-50 prolactin Homo sapiens 135-138 6635518-6 1983 Bromocriptine withdrawal was followed by a rapid increase of serum PRL into the pathological range, without a rapid reexpansion of the tumoral remnants: GT or surgical exploration of 4 cases, remitted until ESS showed a minimal evolution along 8 months after bromocriptine withdrawal. Bromocriptine 0-13 prolactin Homo sapiens 67-70 6684048-0 1983 The effect of tamoxifen on plasma growth hormone and prolactin in postmenopausal women with advanced breast cancer. Tamoxifen 14-23 prolactin Homo sapiens 53-62 6684048-1 1983 The effect of tamoxifen on serum levels of basal prolactin and basal and stimulated growth hormone was assessed in 10 women with advanced breast cancer prior to and after 1 and 8 weeks of treatment. Tamoxifen 14-23 prolactin Homo sapiens 49-58 6884978-0 1983 Effect of CCK-33 on prolactin and apomorphine-induced growth hormone secretion in man. Cholecystokinin 10-16 prolactin Homo sapiens 20-29 6884979-0 1983 Effect of cimetidine on prolactin secretion in postpartum women. Cimetidine 10-20 prolactin Homo sapiens 24-33 6310245-0 1983 Catechol estrogens and the control of gonadotropin and prolactin secretion in man. catechol 0-8 prolactin Homo sapiens 55-64 6310245-4 1983 There have been reports that the catechol estrogen 2-hydroxyestrone (2-OHE1) might act as a partial estrogen antagonist, stimulating gonadotropin secretion; and that it might have dopamine-like effects, suppressing the secretion of PRL. catechol 33-41 prolactin Homo sapiens 232-235 6310245-4 1983 There have been reports that the catechol estrogen 2-hydroxyestrone (2-OHE1) might act as a partial estrogen antagonist, stimulating gonadotropin secretion; and that it might have dopamine-like effects, suppressing the secretion of PRL. 2-hydroxyestrone 51-67 prolactin Homo sapiens 232-235 6310245-4 1983 There have been reports that the catechol estrogen 2-hydroxyestrone (2-OHE1) might act as a partial estrogen antagonist, stimulating gonadotropin secretion; and that it might have dopamine-like effects, suppressing the secretion of PRL. 2-hydroxyestrone 69-75 prolactin Homo sapiens 232-235 6310245-5 1983 In studies testing the chronic and acute effects of catechol estrogens on LH, FSH, and PRL in men and women, we found that they behaved as estrogens, suppressing gonadotropins when given in doses high enough to compensate for their rapid clearance and degradation. catechol 52-60 prolactin Homo sapiens 87-90 6411992-5 1983 This was, presumably, an estrogenic effect since non aromatizable androgens did not increase the PRL response; moreover, the antioestrogen, clomiphene, decreased the PRL response when given with HCG. Clomiphene 140-150 prolactin Homo sapiens 166-169 6683317-1 1983 The suppression of prolactin in anoestrous ewes by daily injections of bromocriptine reduced the average number of corpora lutea on Day 8 after induced oestrus from 2.8 to 1.6 (P less than 0.02). Bromocriptine 71-84 prolactin Homo sapiens 19-28 6875348-5 1983 In many of the patients whose prolactin levels were excessively lowered to 5 ng/ml or less, progesterone was decreased. Progesterone 92-104 prolactin Homo sapiens 30-39 6875348-6 1983 These results suggests that bromocriptine produces a favorable effect on hyperprolactinemic luteal insufficiency by secondarily stimulating progesterone secretion as a result of suppressing the follicular growth "inhibiting action of prolactin. Bromocriptine 28-41 prolactin Homo sapiens 78-87 6575400-0 1983 Inhibition by estradiol of the lactogenic effect of prolactin in primate mammary tissue: reversal by antiestrogens LY 156758 and tamoxifen. Tamoxifen 129-138 prolactin Homo sapiens 52-61 6575400-1 1983 Increasing concentrations of estradiol (E2) ranging from 0.01 to 10 nM were found to inhibit partially but significantly the lactogenic effect of ovine prolactin (oPRL) on alpha-lactalbumin production in primate mammary tissues maintained in organ culture for 9 days. Estradiol 29-38 prolactin Homo sapiens 152-161 6889295-0 1983 [Effect of acute levodopa load on blood prolactin concentration in patients with thyroid diseases]. Levodopa 17-25 prolactin Homo sapiens 40-49 6889295-1 1983 In 14 thyrotoxic patients and 5 persons with endemic euthyroid goiter the blood plasma prolactin content was studied under the action of an acute oral load of levodopa in a dose of 0.5 g. It was found that the basal prolactin level was significantly higher in the blood of patients of both sexes with thyrotoxicosis and endemic euthyroid goiter than that in the control group (10 healthy humans). Levodopa 159-167 prolactin Homo sapiens 87-96 6889295-1 1983 In 14 thyrotoxic patients and 5 persons with endemic euthyroid goiter the blood plasma prolactin content was studied under the action of an acute oral load of levodopa in a dose of 0.5 g. It was found that the basal prolactin level was significantly higher in the blood of patients of both sexes with thyrotoxicosis and endemic euthyroid goiter than that in the control group (10 healthy humans). Levodopa 159-167 prolactin Homo sapiens 216-225 6889295-2 1983 The blood plasma prolactin content markedly decreased in thyrotoxic patients under levodopa effect, regardless of the sex, whereas in patients with endemic euthyroid goiter the drug exhibited no considerable action on the prolactin level. Levodopa 83-91 prolactin Homo sapiens 17-26 6414103-0 1983 Persistence of impaired PRL responses to sulpiride in patients with PRL secreting pituitary adenomas after successful hypophysectomy. Sulpiride 41-50 prolactin Homo sapiens 24-27 6414103-0 1983 Persistence of impaired PRL responses to sulpiride in patients with PRL secreting pituitary adenomas after successful hypophysectomy. Sulpiride 41-50 prolactin Homo sapiens 68-71 6414103-5 1983 On the other hand, the PRL responses to sulpiride in both Groups I and II improved markedly after the hypophysectomy, but the absolute response in operated Group I patients was still lower than that in normal subjects. Sulpiride 40-49 prolactin Homo sapiens 23-26 6414103-7 1983 It is concluded 1) that even in hypophysectomized normoprolactinemic patients the circulating PRL may originate mainly from the residual tumor cells, and 2) that the sulpiride test is useful to detect the abnormalities of hypothalamo-pituitary axis in operated patients with PRL-secreting adenomas, whereas TRH, arginine, and L-dopa tests are less useful for such purposes. Sulpiride 166-175 prolactin Homo sapiens 94-97 6414103-7 1983 It is concluded 1) that even in hypophysectomized normoprolactinemic patients the circulating PRL may originate mainly from the residual tumor cells, and 2) that the sulpiride test is useful to detect the abnormalities of hypothalamo-pituitary axis in operated patients with PRL-secreting adenomas, whereas TRH, arginine, and L-dopa tests are less useful for such purposes. Sulpiride 166-175 prolactin Homo sapiens 275-278 6414103-7 1983 It is concluded 1) that even in hypophysectomized normoprolactinemic patients the circulating PRL may originate mainly from the residual tumor cells, and 2) that the sulpiride test is useful to detect the abnormalities of hypothalamo-pituitary axis in operated patients with PRL-secreting adenomas, whereas TRH, arginine, and L-dopa tests are less useful for such purposes. Arginine 312-320 prolactin Homo sapiens 94-97 6414103-7 1983 It is concluded 1) that even in hypophysectomized normoprolactinemic patients the circulating PRL may originate mainly from the residual tumor cells, and 2) that the sulpiride test is useful to detect the abnormalities of hypothalamo-pituitary axis in operated patients with PRL-secreting adenomas, whereas TRH, arginine, and L-dopa tests are less useful for such purposes. Levodopa 326-332 prolactin Homo sapiens 94-97 6636776-0 1983 [Clinical experiences with the prolactin-inhibiting serotonin antagonist metergoline]. Serotonin 52-61 prolactin Homo sapiens 31-40 6636776-0 1983 [Clinical experiences with the prolactin-inhibiting serotonin antagonist metergoline]. Metergoline 73-84 prolactin Homo sapiens 31-40 6636776-3 1983 Of 9 women with hyperprolactinaemic amenorrhoea treated with metergoline the raised prolactin level was lowered, followed by menstruation in 7 patients. Metergoline 61-72 prolactin Homo sapiens 21-30 6850519-6 1983 Intermittently elevated prolactin levels have been noted in some women who subsequently developed breast cancer, but epidemiologic studies of women who have received prolactin-releasing drugs such as reserpine and perphenazine have not disclosed increased risk. Reserpine 200-209 prolactin Homo sapiens 166-175 6580661-0 1983 Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. Chlorpromazine 28-42 prolactin Homo sapiens 6-15 6580661-0 1983 Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis. Dopamine 103-111 prolactin Homo sapiens 6-15 6580661-1 1983 The prolactin (PRL) response to 12.5 and 25 mg of chlorpromazine (CPZ) was studied in unmedicated schizophrenic patients and normal control subjects. Chlorpromazine 50-64 prolactin Homo sapiens 4-13 6580661-1 1983 The prolactin (PRL) response to 12.5 and 25 mg of chlorpromazine (CPZ) was studied in unmedicated schizophrenic patients and normal control subjects. Chlorpromazine 50-64 prolactin Homo sapiens 15-18 6580661-1 1983 The prolactin (PRL) response to 12.5 and 25 mg of chlorpromazine (CPZ) was studied in unmedicated schizophrenic patients and normal control subjects. Chlorpromazine 66-69 prolactin Homo sapiens 4-13 6580661-3 1983 The PRL response to the 12.5 mg dose only was significantly correlated with baseline PRL levels for both males and females, suggesting that endogenous dopamine release from tuberoinfundibular neurons has a much greater effect upon the PRL response to the 12.5 mg dose of CPZ than to the 25 mg dose. Dopamine 151-159 prolactin Homo sapiens 4-7 6580661-3 1983 The PRL response to the 12.5 mg dose only was significantly correlated with baseline PRL levels for both males and females, suggesting that endogenous dopamine release from tuberoinfundibular neurons has a much greater effect upon the PRL response to the 12.5 mg dose of CPZ than to the 25 mg dose. Dopamine 151-159 prolactin Homo sapiens 85-88 6580661-3 1983 The PRL response to the 12.5 mg dose only was significantly correlated with baseline PRL levels for both males and females, suggesting that endogenous dopamine release from tuberoinfundibular neurons has a much greater effect upon the PRL response to the 12.5 mg dose of CPZ than to the 25 mg dose. Dopamine 151-159 prolactin Homo sapiens 85-88 6580661-3 1983 The PRL response to the 12.5 mg dose only was significantly correlated with baseline PRL levels for both males and females, suggesting that endogenous dopamine release from tuberoinfundibular neurons has a much greater effect upon the PRL response to the 12.5 mg dose of CPZ than to the 25 mg dose. Chlorpromazine 271-274 prolactin Homo sapiens 4-7 6580661-4 1983 Both doses of CPZ tended to show lower PRL responses in the schizophrenic females. Chlorpromazine 14-17 prolactin Homo sapiens 39-42 6580661-6 1983 The PRL response to 25 mg correlated highly with the morning serum PRL levels following treatment with CPZ 100 mg and 200 mg orally b.i.d. Chlorpromazine 103-106 prolactin Homo sapiens 4-7 6580661-6 1983 The PRL response to 25 mg correlated highly with the morning serum PRL levels following treatment with CPZ 100 mg and 200 mg orally b.i.d. Chlorpromazine 103-106 prolactin Homo sapiens 67-70 6580661-9 1983 Serum PRL levels during treatment with CPZ 200 mg b.i.d. Chlorpromazine 39-42 prolactin Homo sapiens 6-9 6634885-0 1983 Cardiovascular and plasma prolactin responses to stereoisomers of phencyclidine. Phencyclidine 66-79 prolactin Homo sapiens 26-35 6307331-0 1983 The effect of enalapril on serum prolactin. Enalapril 14-23 prolactin Homo sapiens 33-42 6309505-1 1983 The effect of non-selective beta-blocker propranolol on the changes of plasma GH, prolactin and cortisol level during physical exercise in healthy untrained men has been evaluated. Propranolol 41-52 prolactin Homo sapiens 82-91 6343127-5 1983 Patients in both groups showed a decrease in prolactin levels, whether they were treated with Parlodel or Pergolide. Bromocriptine 94-102 prolactin Homo sapiens 45-54 6343127-5 1983 Patients in both groups showed a decrease in prolactin levels, whether they were treated with Parlodel or Pergolide. Pergolide 106-115 prolactin Homo sapiens 45-54 6411626-3 1983 Bromocriptine decreased the plasma levels of prolactin (Prl) and this decrease was unaffected by clomiphene. Bromocriptine 0-13 prolactin Homo sapiens 45-54 6411626-3 1983 Bromocriptine decreased the plasma levels of prolactin (Prl) and this decrease was unaffected by clomiphene. Bromocriptine 0-13 prolactin Homo sapiens 56-59 6411626-4 1983 The latter blunted the plasma LH response to LHRH whilst bromocriptine blunted the Prl response to TRH, but Clomiphene and bromocriptine together had no additive effects on gonadotrophin and Prl secretion. Bromocriptine 57-70 prolactin Homo sapiens 83-86 6404919-6 1983 Specific expression of the hPRL gene was demonstrated by the presence of electron microscopic secretory granules (650-800 nm), positive immunoperoxidase staining using anti-hPRL serum, and sustained secretion of immunoreactive hPRL, which comigrated with [125I] hPRL standard on Sephadex chromatography. sephadex 279-287 prolactin Homo sapiens 27-31 6404923-0 1983 Are fasting-induced effects on thyrotropin and prolactin secretion mediated by dopamine? Dopamine 79-87 prolactin Homo sapiens 47-56 6407250-0 1983 Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinaemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditions. Dihydroergocristine 10-29 prolactin Homo sapiens 54-63 6405619-0 1983 Variation of serum prolactin-releasing activity in women with the galactorrhea-amenorrhea syndrome after bromocriptine treatment. Bromocriptine 105-118 prolactin Homo sapiens 19-28 6405619-5 1983 Bromocriptine therapy suppressed serum PRL levels of five patients without tumors but increased the PRL-releasing activity in three out of five patients after treatment for 1 or 2 months. Bromocriptine 0-13 prolactin Homo sapiens 39-42 6405619-5 1983 Bromocriptine therapy suppressed serum PRL levels of five patients without tumors but increased the PRL-releasing activity in three out of five patients after treatment for 1 or 2 months. Bromocriptine 0-13 prolactin Homo sapiens 100-103 6405619-6 1983 Apparently hypothalamic regulation of PRL secretion was disrupted in these three patients after bromocriptine therapy. Bromocriptine 96-109 prolactin Homo sapiens 38-41 6872271-0 1983 Inhibition of prolactin secretion by low-dose dopamine infusion in patients with hyperprolactinaemia. Dopamine 46-54 prolactin Homo sapiens 14-23 6872271-1 1983 Dopamine inhibits the secretion of prolactin from the pituitary. Dopamine 0-8 prolactin Homo sapiens 35-44 6872271-2 1983 We have examined the relation between plasma dopamine and serum prolactin in 12 patients with hyperprolactinaemia during the infusion of dopamine at low doses (0.01, 0.1 and 1 microgram/kg/min). Dopamine 45-53 prolactin Homo sapiens 64-73 6872271-6 1983 Serum prolactin levels returned to values similar to or greater than basal on cessation of dopamine infusion. Dopamine 91-99 prolactin Homo sapiens 6-15 6872271-7 1983 Infusion of dopamine at doses much lower than previously used in man exposes the pituitary to a concentration of dopamine sufficient to suppress prolactin secretion. Dopamine 12-20 prolactin Homo sapiens 145-154 6872271-7 1983 Infusion of dopamine at doses much lower than previously used in man exposes the pituitary to a concentration of dopamine sufficient to suppress prolactin secretion. Dopamine 113-121 prolactin Homo sapiens 145-154 6403331-3 1983 The administration of a dopamine antagonist, haloperidol, to the ovine fetus in late gestation elevates plasma concentrations of PRL, suggesting tonic dopaminergic inhibition of fetal PRL secretion. Dopamine 24-32 prolactin Homo sapiens 129-132 6403331-3 1983 The administration of a dopamine antagonist, haloperidol, to the ovine fetus in late gestation elevates plasma concentrations of PRL, suggesting tonic dopaminergic inhibition of fetal PRL secretion. Dopamine 24-32 prolactin Homo sapiens 184-187 6403331-3 1983 The administration of a dopamine antagonist, haloperidol, to the ovine fetus in late gestation elevates plasma concentrations of PRL, suggesting tonic dopaminergic inhibition of fetal PRL secretion. Haloperidol 45-56 prolactin Homo sapiens 129-132 6403331-3 1983 The administration of a dopamine antagonist, haloperidol, to the ovine fetus in late gestation elevates plasma concentrations of PRL, suggesting tonic dopaminergic inhibition of fetal PRL secretion. Haloperidol 45-56 prolactin Homo sapiens 184-187 6403331-8 1983 The dopamine agonist apomorphine (100 micrograms/kg, iv) induced a similar suppression of fetal PRL concentrations in CON (n = 4) and SS (n = 2) fetuses. Dopamine 4-12 prolactin Homo sapiens 96-99 6403331-8 1983 The dopamine agonist apomorphine (100 micrograms/kg, iv) induced a similar suppression of fetal PRL concentrations in CON (n = 4) and SS (n = 2) fetuses. Apomorphine 21-32 prolactin Homo sapiens 96-99 6403331-9 1983 After the administration of haloperidol (1 mg, iv) to the CON fetuses (n = 7), the concentration of fetal PRL rose (P less than 0.01). Haloperidol 28-39 prolactin Homo sapiens 106-109 6403331-10 1983 In the SS fetus (n = 4), haloperidol induced a rise in PRL concentrations (P less than 0.01); however, the response to haloperidol was less (P less than 0.01) in SS than in CON fetuses. Haloperidol 25-36 prolactin Homo sapiens 55-58 6403331-11 1983 These data suggest that there is persistent dopaminergic inhibition of PRL secretion in the fetus after complete stalk section, and that the source of this dopamine is extrahypothalamic. Dopamine 44-52 prolactin Homo sapiens 71-74 6403566-1 1983 Gonadotropin responses to GnRH and PRL responses to TRH and metoclopramide (MTC) were investigated in nine consecutive women with amenorrhea and insulin-treated diabetes mellitus. Metoclopramide 60-74 prolactin Homo sapiens 35-38 6403566-8 1983 Amenorrheic diabetics had significantly lower PRL responses to MTC compared to other groups, and nondiabetics with amenorrhea had significantly lower PRL response than normal women. Metoclopramide 63-66 prolactin Homo sapiens 46-49 6403571-5 1983 Conversely, an iv bolus of sulpiride (25 mg), a dopaminergic antagonist, given to four subjects after 240 min, brought about a marked increase in serum PRL values above the plateau level. Sulpiride 27-36 prolactin Homo sapiens 152-155 6185329-3 1983 The migration position on agarose gels of prolactin-specific mRNA from human decidua-chorion is similar to that for mRNA from ovine pituitary, suggesting a similar sized mRNA coding for prolactin in these different tissues and species. Sepharose 26-33 prolactin Homo sapiens 42-51 6343157-3 1983 Elevated plasma prolactin levels, induced by pituitary transplants, resulted in increased in vitro biosynthesis of medial basal hypothalamic (MBH) dopamine (DA), but not norepinephrine (NE). Dopamine 147-155 prolactin Homo sapiens 16-25 6343157-8 1983 Gonadotroph responsiveness to LHRH was significantly increased, while the inhibition of prolactin by dopamine was not altered. Dopamine 101-109 prolactin Homo sapiens 88-97 6878514-0 1983 The relationship between prolactin levels and clinical ratings in manic patients treated with oral and intravenous test doses of haloperidol. Haloperidol 129-140 prolactin Homo sapiens 25-34 6878514-3 1983 After the first intravenous test doses of haloperidol, prolactin levels peaked at 1 hour; however, they fell to a low point at 24 hours, and no response to further test doses was seen for 3-5 days. Haloperidol 42-53 prolactin Homo sapiens 55-64 6882542-0 1983 Evidence for a dose-dependent effect in the sex-specific plasma prolactin response to naloxone in humans. Naloxone 86-94 prolactin Homo sapiens 64-73 6882542-1 1983 In attempt to ascertain if the sex specific plasma PRL response to naloxone, that we suggested in previous studies, was a dose dependent effect, 26 healthy volunteers were studied. Naloxone 67-75 prolactin Homo sapiens 51-54 6882542-5 1983 Naloxone, at dose of 2 mg, was able to decrease significantly plasma PRL levels in normally menstruating women (p less than 0.05 at 60 min. Naloxone 0-8 prolactin Homo sapiens 69-72 6882542-9 1983 These results suggest a dose-dependent effect in the sex specific PRL response to naloxone in humans. Naloxone 82-90 prolactin Homo sapiens 66-69 6838618-1 1983 The ability of 2-Hydroxyestradiol, a catecholestrogen, and 17 beta Estradiol to interact with the dopamine inhibition of prolactin and with dopamine receptors has been tested on dispersed human prolactin-secreting cells obtained from ten pituitary adenomas. 2-hydroxyestradiol 15-33 prolactin Homo sapiens 121-130 6838618-1 1983 The ability of 2-Hydroxyestradiol, a catecholestrogen, and 17 beta Estradiol to interact with the dopamine inhibition of prolactin and with dopamine receptors has been tested on dispersed human prolactin-secreting cells obtained from ten pituitary adenomas. Estradiol 59-76 prolactin Homo sapiens 121-130 6838618-1 1983 The ability of 2-Hydroxyestradiol, a catecholestrogen, and 17 beta Estradiol to interact with the dopamine inhibition of prolactin and with dopamine receptors has been tested on dispersed human prolactin-secreting cells obtained from ten pituitary adenomas. Dopamine 98-106 prolactin Homo sapiens 121-130 6838618-2 1983 There is a 80% inhibition of prolactin secretion obtained by addition of dopamine in a superfusion system. Dopamine 73-81 prolactin Homo sapiens 29-38 6405569-0 1983 Prolactin release in man: influence of cimetidine, thyrotrophin-releasing hormone and acute hypercalcaemia. Cimetidine 39-49 prolactin Homo sapiens 0-9 6405569-2 1983 Four-hundred mg Cim, injected iv, raised the serum prolactin level (Prl) from 14 +/- 2 to 58 +/- 9 ng/ml (P less than 0.001), but left the serum thyrotrophin level (TSH) unaffected. Cimetidine 16-19 prolactin Homo sapiens 51-60 6340535-6 1983 Two patients with prolactin-producing adenomas had been treated with bromocryptine before surgery. Bromocriptine 69-82 prolactin Homo sapiens 18-27 6680345-0 1983 [Effect of sulpiride on the secretion of prolactin and somatotropic hormone in premenopausal women affected by fibrocystic mastopathy]. Sulpiride 11-20 prolactin Homo sapiens 41-50 6133737-5 1983 Some of the above classes of drugs (e.g. the indirect-acting dopamine agonists, dopamine receptor antagonists, GABA-mimetic drugs, dopamine receptor blocking drugs, and H2-antagonists) may be useful for selecting among hyperprolactinaemic patients those with a prolactin-secreting tumour in an early stage of the disease. Dopamine 61-69 prolactin Homo sapiens 224-233 6416819-0 1983 The suppression of TSH in the presence of the normal PRL responses to TRH out of 26 patients with primary hyperparathyroidism. Thyrotropin 19-22 prolactin Homo sapiens 53-56 6833458-0 1983 Prolactin response to dopamine synthesis inhibition using monoiodotyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia. Dopamine 22-30 prolactin Homo sapiens 0-9 6833458-0 1983 Prolactin response to dopamine synthesis inhibition using monoiodotyrosine in subjects on oral contraceptives and patients with pathological hyperprolactinemia. Monoiodotyrosine 58-74 prolactin Homo sapiens 0-9 6863847-1 1983 To investigate the effect of metoclopramide (MET), a dopaminergic antagonist drug, on serum PRL concentration in maternal and cord blood (CB) serum, the drug was injected in 94 at term pregnant women whereas 28 mothers received saline. Metoclopramide 29-43 prolactin Homo sapiens 92-95 6863847-1 1983 To investigate the effect of metoclopramide (MET), a dopaminergic antagonist drug, on serum PRL concentration in maternal and cord blood (CB) serum, the drug was injected in 94 at term pregnant women whereas 28 mothers received saline. Metoclopramide 45-48 prolactin Homo sapiens 92-95 6835739-4 1983 Bromocriptine restored prolactin levels to normal in all three patients, two of whom had prior transsphenoidal surgery, and resulted in initiation of menses in one girl and pubertal development in both boys. Bromocriptine 0-13 prolactin Homo sapiens 23-32 6854094-2 1983 Pretreatment prolactin levels, 224 -496ng/ml, were normalized by 10-22.5mg/day of bromocriptine and the initial conceptions occurred. Bromocriptine 82-95 prolactin Homo sapiens 13-22 6576396-10 1983 A study of the PRL responses to haloperidol (hal) and hal + apomorphine (apo) challenges in normals revealed a strong correlation despite a highly significant 51% reduction in PRL response with the addition of apo. Haloperidol 32-43 prolactin Homo sapiens 15-18 6576396-10 1983 A study of the PRL responses to haloperidol (hal) and hal + apomorphine (apo) challenges in normals revealed a strong correlation despite a highly significant 51% reduction in PRL response with the addition of apo. Haloperidol 32-35 prolactin Homo sapiens 15-18 6576396-10 1983 A study of the PRL responses to haloperidol (hal) and hal + apomorphine (apo) challenges in normals revealed a strong correlation despite a highly significant 51% reduction in PRL response with the addition of apo. Haloperidol 45-48 prolactin Homo sapiens 15-18 6829654-3 1983 Further, the maintenance of decidualization and PRL production in specimens of late luteal phase in explant culture is dependent on the presence of progesterone (P). Progesterone 148-160 prolactin Homo sapiens 48-51 6829655-2 1983 The induction of decidualization and the initiation of PRL production in the proliferative endometrium is dependent on progesterone (P) in vitro. Progesterone 119-131 prolactin Homo sapiens 55-58 6829655-8 1983 In nonlabor decidua, a significant interaction between basal PRL production and response to progesterone was noted (p less than 0.01). Progesterone 92-104 prolactin Homo sapiens 61-64 6308959-3 1983 The stress induced reduction of DA turnover in MPZ may mediate the stress induced increase of prolactin secretion. Dopamine 32-34 prolactin Homo sapiens 94-103 6681939-4 1983 The plasma concentrations of beta-hCG correlated with those of prolactin (r = 0.93) and estradiol (r = 0.94), while the levels of the latter two hormones also correlated (r = 0.84). beta-hcg 29-37 prolactin Homo sapiens 63-72 6401764-7 1983 Five patients responded with significant reduction in the serum hPRL concentration after L-dopa, and in three patients, no change was observed. Levodopa 89-95 prolactin Homo sapiens 64-68 6833935-0 1983 Effects of prolactin on steroid production by human luteal cells in vitro. Steroids 24-31 prolactin Homo sapiens 11-20 6833935-3 1983 However, in two out of five corpora lutea, higher concentrations of prolactin (100 and 1000 ng/ml) significantly reduced the oestradiol-17 beta production induced by human chorionic gonadotrophin (hCG; 10 i.u./ml); lower doses of prolactin had little effect. Estradiol 125-143 prolactin Homo sapiens 68-77 6222183-3 1983 Following the administration of chlorpromazine, plasma prolactin concentrations increased four-fold above pretreatment concentrations, reaching a maximum at 120 minutes. Chlorpromazine 32-46 prolactin Homo sapiens 55-64 6222183-4 1983 Following L-dopa, plasma prolactin concentrations decreased by greater than 50%, with the nadir noted within 90 minutes. Levodopa 10-16 prolactin Homo sapiens 25-34 6834334-1 1983 The current experiment was designed to investigate whether changes in prolactin concentrations might be involved in the seasonal change in responsiveness of the hypothalamic-pituitary axis to the negative feedback effects of oestradiol in the ewe. Estradiol 225-235 prolactin Homo sapiens 70-79 6574535-0 1983 Bromocriptine therapy in chronic schizophrenia: effects on symptomatology, sleep patterns, and prolactin response to stimulation. Bromocriptine 0-13 prolactin Homo sapiens 95-104 6574535-3 1983 The prolactin (PRL) response to haloperidol stimulation (1 mg i.v.) Haloperidol 32-43 prolactin Homo sapiens 4-13 6574535-7 1983 The PRL response to haloperidol after therapy was markedly lower than that before therapy in the five patients treated with high doses, and markedly higher in the single patient tested who was treated only with low-dose therapy. Haloperidol 20-31 prolactin Homo sapiens 4-7 6825603-8 1983 This remained true even after additional bromocriptine treatment which normalised the level of prolactin. Bromocriptine 41-54 prolactin Homo sapiens 95-104 6401383-3 1983 Bromocriptine suppressed the secretion of growth hormone and prolactin, with a reduction in tumor size. Bromocriptine 0-13 prolactin Homo sapiens 61-70 6342861-0 1983 The effects of prolonged bromocriptine administration on PRL secretion GH and glycaemic control in stable insulin-dependent diabetes mellitus. Bromocriptine 25-38 prolactin Homo sapiens 57-60 6342861-2 1983 The pattern of PRL secretion was noted to be normal in stable diabetes (with a mean concentration of 205 mu/l +/- 23 SEM) and was effectively suppressed by bromocriptine (to a mean concentration of 51 mu/l +/- 2 SEM). Bromocriptine 156-169 prolactin Homo sapiens 15-18 6821925-0 1983 Use of immunoaffinity chromatography for purification of 125I-labeled human prolactin. Iodine-125 57-61 prolactin Homo sapiens 76-85 6821925-2 1983 125I-Labeled human prolactin purified by immunoaffinity chromatography is compared with that purified by gel filtration on Sephadex G-100. Iodine-125 0-4 prolactin Homo sapiens 19-28 6821925-4 1983 Prolactin was radiolabeled by the Chloramine T method, purified by each of the above procedures, and the binding and displacement characteristics were studied in radioimmunoassays in which either monoclonal antibodies or a rabbit anti-prolactin serum was the first antibody. chloramine-T 34-46 prolactin Homo sapiens 0-9 6821925-5 1983 A nonimmune fraction of 125I-labeled prolactin that co-eluted with the immunoreactive hormone from Sephadex G-100 was removed by affinity chromatography, which increased the antibody binding of 125I-labeled prolactin in the radioimmunoassay in the absence of unlabeled antigen (B/T0, in percent) twofold or more, increased the assay sensitivity, and increased the slope of antigen displacement measured by the 50% intercept. sephadex 99-113 prolactin Homo sapiens 37-46 6821925-5 1983 A nonimmune fraction of 125I-labeled prolactin that co-eluted with the immunoreactive hormone from Sephadex G-100 was removed by affinity chromatography, which increased the antibody binding of 125I-labeled prolactin in the radioimmunoassay in the absence of unlabeled antigen (B/T0, in percent) twofold or more, increased the assay sensitivity, and increased the slope of antigen displacement measured by the 50% intercept. sephadex 99-113 prolactin Homo sapiens 207-216 6851194-1 1983 The TSH and PRL responses to administration of the two dopamine (DA) receptor antagonists sulpiride and domperidone, were studied in fifteen normoprolactinaemic subjects, twenty-two post-partum women and sixteen subjects with presumptive evidence of (six subjects) or surgically confirmed (ten subjects) prolactinomas. Domperidone 104-115 prolactin Homo sapiens 12-15 6851194-5 1983 Conversely, sulpiride and domperidone strikingly stimulated PRL secretion in normoprolactinaemic and post-partum women, but only slightly enhanced base-line PRL levels in women with prolactinomas. Sulpiride 12-21 prolactin Homo sapiens 60-63 6851194-5 1983 Conversely, sulpiride and domperidone strikingly stimulated PRL secretion in normoprolactinaemic and post-partum women, but only slightly enhanced base-line PRL levels in women with prolactinomas. Domperidone 26-37 prolactin Homo sapiens 60-63 6851194-5 1983 Conversely, sulpiride and domperidone strikingly stimulated PRL secretion in normoprolactinaemic and post-partum women, but only slightly enhanced base-line PRL levels in women with prolactinomas. Domperidone 26-37 prolactin Homo sapiens 157-160 6851196-0 1983 Naloxone inhibits exercise-induced release of PRL and GH in athletes. Naloxone 0-8 prolactin Homo sapiens 46-49 6851196-4 1983 Infusion of naloxone (0.3 mg/min) antagonized these responses in mean serum GH (5.6 +/- 1.0 ng/ml to 8.6 +/- 1.1 ng/ml) and PRL levels (6.4 +/- 1.1 ng/ml-8.1 +/- 1.2 ng/ml), which were both significantly less than during the control infusions (P less than 0.01). Naloxone 12-20 prolactin Homo sapiens 124-127 6220047-2 1983 The relationship between improvement in symptomatology and changes in prolactin and serum cis-flupenthixol levels has been evaluated in 16 patients with a clinical diagnosis of depression, who were treated with 1 or 2 mg of flupenthixol in a once daily morning dose. Flupenthixol 90-106 prolactin Homo sapiens 70-79 6220047-2 1983 The relationship between improvement in symptomatology and changes in prolactin and serum cis-flupenthixol levels has been evaluated in 16 patients with a clinical diagnosis of depression, who were treated with 1 or 2 mg of flupenthixol in a once daily morning dose. Flupenthixol 94-106 prolactin Homo sapiens 70-79 6600459-1 1983 The increasing serum concentrations of various hormones (PTH, PRL, estrogens, and human placental lactogen) are hypothesized to regulate 1,25-dihydroxyvitamin D [1,25(OH)2D] and possibly 24,25-dihydroxyvitamin D [24,25(OH)2D] production during pregnancy. 1,25-dihydroxyvitamin D 137-160 prolactin Homo sapiens 62-65 6600459-1 1983 The increasing serum concentrations of various hormones (PTH, PRL, estrogens, and human placental lactogen) are hypothesized to regulate 1,25-dihydroxyvitamin D [1,25(OH)2D] and possibly 24,25-dihydroxyvitamin D [24,25(OH)2D] production during pregnancy. 24,25-dihydroxyvitamin D 187-211 prolactin Homo sapiens 62-65 6822635-0 1983 Differential effects of a low dose dopamine infusion on prolactin secretion in normal and hyperprolactinemic subjects. Dopamine 35-43 prolactin Homo sapiens 56-65 6841916-1 1983 We report two cases with macroprolactinoma who during medical treatment with bromocriptine showed a normalization of PRL levels and a reduction of tumor size as documented by computed tomography. Bromocriptine 77-90 prolactin Homo sapiens 117-120 6297956-0 1983 Modifications of membrane cholesterol content affects electrical properties and prolactin release of cultured pituitary cells. Cholesterol 26-37 prolactin Homo sapiens 80-89 6297956-1 1983 Treatment of cloned pituitary cells (GH3/B6) with cholesterol-enriched liposomes, which presumably increases membrane cholesterol content, affects the passive and active electrophysiological properties and stimulates the release of prolactin (PRL). Cholesterol 50-61 prolactin Homo sapiens 232-241 6675384-1 1983 The Authors describe their experience with a group of twelve volunteer healthy men in order to evaluate if the bromocriptine inhibition of serum prolactin concentration also modifies seminal plasma PRL values. Bromocriptine 111-124 prolactin Homo sapiens 198-201 6613612-6 1983 A positive correlation between haloperidol levels and clinical improvement and a significant increase in PRL levels in correspondence with haloperidol plasma peaks, but not with clinical improvement, were observed. Haloperidol 139-150 prolactin Homo sapiens 105-108 6421192-0 1983 Enhanced serum prolactin concentration after metoclopramide stimulation in idiopathic oligozoospermia and azoospermia. Metoclopramide 45-59 prolactin Homo sapiens 15-24 6421192-7 1983 The results indicate that men with idiopathic oligo- or azoospermia have significantly higher prolactin level in response to dopaminergic receptor blockade with metoclopramide and significantly lower serum testosterone and DHT concentrations. Metoclopramide 161-175 prolactin Homo sapiens 94-103 6683557-0 1983 [Effect of co-dergocrine mesylate on catecholamines and prolactin in elderly hypertensive patients]. Ergoloid Mesylates 11-33 prolactin Homo sapiens 56-65 6227379-1 1983 Previous studies in hyperprolactinaemic women have led to conflicting views about the influence of prolactin (PRL) on serum dehydroepiandrosterone sulphate (DS) levels. Dehydroepiandrosterone Sulfate 124-155 prolactin Homo sapiens 110-113 6227379-1 1983 Previous studies in hyperprolactinaemic women have led to conflicting views about the influence of prolactin (PRL) on serum dehydroepiandrosterone sulphate (DS) levels. Dehydroepiandrosterone Sulfate 157-159 prolactin Homo sapiens 110-113 6227379-2 1983 This study was designed to examine the effect of a reduction of normal levels of circulating prolactin on the serum DS concentration in twenty ovulating women treated with bromocriptine for 4 months in a double-blind crossover study. Dehydroepiandrosterone Sulfate 116-118 prolactin Homo sapiens 93-102 6227379-10 1983 Although the mechanism of this phenomenon is not clear, this study suggests that PRL may have a physiological role in modulating the tonic secretion or metabolism of DS. Dehydroepiandrosterone Sulfate 166-168 prolactin Homo sapiens 81-84 6362635-4 1983 In spite of the dramatic effect of ergocryptine on plasma prolactin all treated ewes secreted copious quantities of milk of normal composition. ergocryptine 35-47 prolactin Homo sapiens 58-67 6318847-0 1983 Cis-platinum complex with retained prolactin receptor specific binding. Cisplatin 0-12 prolactin Homo sapiens 35-44 6318847-3 1983 Prolactin could be used to increase the specificity of cis-platinum to cells with prolactin receptors. Cisplatin 55-67 prolactin Homo sapiens 0-9 6318847-3 1983 Prolactin could be used to increase the specificity of cis-platinum to cells with prolactin receptors. Cisplatin 55-67 prolactin Homo sapiens 82-91 6626630-0 1983 Postnatal development of plasma prolactin level in premature infants with and without NaCl supplementation. Sodium Chloride 86-90 prolactin Homo sapiens 32-41 6626630-1 1983 The role of prolactin in the adaptation of premature infants to the alterations of sodium balance was investigated by measuring plasma prolactin levels serially in 7 low birth weight, premature infants with (group I) and without (group II) NaCl supplementation. Sodium 83-89 prolactin Homo sapiens 12-21 6626630-5 1983 When supplemental sodium was given, the plasma prolactin level declined with age at a steady rate to the mean value of 3,516 +/- 502 mU/l by the end of 5th week. Sodium 18-24 prolactin Homo sapiens 47-56 6626630-7 1983 It is concluded that physiological sodium depletion may account for the prolonged hyperprolactinemia and prolactin might have some importance in the control of sodium homeostasis in low birth weight, premature infants. Sodium 35-41 prolactin Homo sapiens 87-96 6661508-3 1983 Prolactin rebound after the arrest of dopamine infusion and during domperidone are + 400% and + 2,300% in normal subjects. Dopamine 38-46 prolactin Homo sapiens 0-9 6420004-5 1983 In these women, PRL increases when VIP is administered at the 200th minute of DA infusion (1 microgram X kg/min.). Dopamine 78-80 prolactin Homo sapiens 16-19 6401176-1 1983 High plasma levels of PRL induced by transplants of two donor pituitaries under the kidney capsule of adult male rats resulted in a prolonged suppression of plasma levels of LH and FSH although testosterone levels were maintained within normal limits. Testosterone 194-206 prolactin Homo sapiens 22-25 6617716-0 1983 Effect of the orally absorbed dopamine analogue N-methyldopamine diisobutyric ester on plasma prolactin levels. Dopamine 30-38 prolactin Homo sapiens 94-103 6617716-0 1983 Effect of the orally absorbed dopamine analogue N-methyldopamine diisobutyric ester on plasma prolactin levels. n-methyldopamine diisobutyric ester 48-83 prolactin Homo sapiens 94-103 6617716-1 1983 The effect of the diisobutyric ester of N-methyldopamine (Ibopamine) on plasma prolactin levels was investigated in normoprolactinaemic subjects and in hyperprolactinaemic patients with prolactin-secreting tumours or idiopathic hyperprolactinaemia. diisobutyric ester 18-36 prolactin Homo sapiens 79-88 6617716-1 1983 The effect of the diisobutyric ester of N-methyldopamine (Ibopamine) on plasma prolactin levels was investigated in normoprolactinaemic subjects and in hyperprolactinaemic patients with prolactin-secreting tumours or idiopathic hyperprolactinaemia. Deoxyepinephrine 40-56 prolactin Homo sapiens 79-88 6617716-1 1983 The effect of the diisobutyric ester of N-methyldopamine (Ibopamine) on plasma prolactin levels was investigated in normoprolactinaemic subjects and in hyperprolactinaemic patients with prolactin-secreting tumours or idiopathic hyperprolactinaemia. ibopamine 58-67 prolactin Homo sapiens 79-88 6617716-2 1983 In hyperprolactinaemic states oral Ibopamine 50 mg induced a significant decrease in elevated plasma prolactin (PRL) levels, 30, 60 and 90 min after administration. ibopamine 35-44 prolactin Homo sapiens 8-17 6617716-2 1983 In hyperprolactinaemic states oral Ibopamine 50 mg induced a significant decrease in elevated plasma prolactin (PRL) levels, 30, 60 and 90 min after administration. ibopamine 35-44 prolactin Homo sapiens 112-115 6628512-1 1983 The prolactin (PRL) response to repeated injections of sulpiride, a dopamine antagonist, was evaluated in 18 healthy young men. Sulpiride 55-64 prolactin Homo sapiens 4-13 6628512-1 1983 The prolactin (PRL) response to repeated injections of sulpiride, a dopamine antagonist, was evaluated in 18 healthy young men. Sulpiride 55-64 prolactin Homo sapiens 15-18 6628512-4 1983 The second injection up to 24 h had no effect on serum PRL, but when two sulpiride injections were given at a 48 h-interval, both caused a sharp increase in PRL. Sulpiride 73-82 prolactin Homo sapiens 157-160 6628512-5 1983 To conclude, PRL cells in man, after a sulpiride injection, may therefore be unresponsive to a second sulpiride injection for more than 24 h. Sulpiride 39-48 prolactin Homo sapiens 13-16 6662181-7 1983 However, the plasma concentration of prolactin in 4 out of 7 neonates sampled taken during administration of metoclopramide to the mother were higher than the highest plasma prolactin level in children of same age of untreated mothers. Metoclopramide 109-123 prolactin Homo sapiens 37-46 6686115-0 1983 [Serum prolactin level in basal conditions and after metoclopramide stimulation in women with galactorrhea and in patients with pituitary tumors]. Metoclopramide 53-67 prolactin Homo sapiens 7-16 6413305-1 1983 The prolactin responses to an oral challenge of L-dopa (0.5 g) and bromocriptine (2.5 mg) were studied in 31 hyperprolactinemic females without radiological abnormalities of pituitary fossa, in 12 hyperprolactinemic patients with minor radiological evidence suggesting the presence of a pituitary adenoma and in 16 normal volunteers in the early puerperium with physiological hyperprolactinemia. Levodopa 48-54 prolactin Homo sapiens 4-13 6413305-2 1983 Administration of bromocriptine was followed by a similar suppression of prolactin secretion in the functional as well as the adenomatous hyperprolactinemic patients. Bromocriptine 18-31 prolactin Homo sapiens 73-82 6413305-4 1983 These results suggest that the L-dopa suppression test might serve as a reliable indicator to detect prolactin-secreting microadenomas in patients with persistent hyperprolactinemia and radiologically normal pituitary fossae. Levodopa 31-37 prolactin Homo sapiens 101-110 6642291-0 1983 Prolactin response to the dopamine antagonists sulpiride and domperidone. Dopamine 26-34 prolactin Homo sapiens 0-9 6642291-0 1983 Prolactin response to the dopamine antagonists sulpiride and domperidone. Sulpiride 47-56 prolactin Homo sapiens 0-9 6642291-0 1983 Prolactin response to the dopamine antagonists sulpiride and domperidone. Domperidone 61-72 prolactin Homo sapiens 0-9 6642291-7 1983 Since the PRL response to dopamine antagonists depends on the presence of an endogenous dopaminergic tone, it is suggested that these figures reflect the incidence of major dopamine deficiency at pituitary lactotrophs in different hyperprolactinemic states. Dopamine 26-34 prolactin Homo sapiens 10-13 6642291-7 1983 Since the PRL response to dopamine antagonists depends on the presence of an endogenous dopaminergic tone, it is suggested that these figures reflect the incidence of major dopamine deficiency at pituitary lactotrophs in different hyperprolactinemic states. Dopamine 88-96 prolactin Homo sapiens 10-13 6403444-7 1983 The rise in serum prolactin concentrations in response to arginine was unaffected by hyperglycaemia, whereas the TRH-induced release of prolactin was suppressed. Arginine 58-66 prolactin Homo sapiens 18-27 6403444-8 1983 Since arginine induces the release of growth hormone and prolactin via the hypothalamus, while TRH acts at the pituitary level, the glycaemic state appears to exert a modulatory effect on the secretion of growth hormone and prolactin in type II-diabetics at both locations. Arginine 6-14 prolactin Homo sapiens 57-66 6642422-13 1983 These data suggest that while plasma PRL levels are not sensitive to nonhypotensive changes in CBV, they do respond to hypotensive decreases in CBV and/or its associated nausea. CBV protocol 144-147 prolactin Homo sapiens 37-40 6642424-6 1983 On the other hand, the administration of L-dopa resulted in a significant decrease in growth hormone level from 74.25 +/- 22 ng/ml (mean +/- SEM) at zero time to a level of 52.8 +/- 21 and 58.77 +/- 22.7 ng/ml at the 60- and 90-min intervals, respectively (p less than 0.05), and a significant decrease in prolactin level from a baseline of 56.18 +/- 17 to 25.5 +/- 8.4 ng/ml (p less than 0.001) at the 60-min interval. Levodopa 41-47 prolactin Homo sapiens 306-315 6682397-1 1983 Bromocriptine suppressed lactation by depressing the serum prolactin (PRL) level in 10 of 12 cases with profuse galactorrhea. Bromocriptine 0-13 prolactin Homo sapiens 59-68 6682397-1 1983 Bromocriptine suppressed lactation by depressing the serum prolactin (PRL) level in 10 of 12 cases with profuse galactorrhea. Bromocriptine 0-13 prolactin Homo sapiens 70-73 6682397-4 1983 Although all the constituents decreased during treatment, the highly significant reduction in lipid and calcium levels shows the predominant effect of PRL on mammary synthesis and/or transport of these constituents. Calcium 104-111 prolactin Homo sapiens 151-154 6682397-5 1983 Fasting serum total lipids, total cholesterol and triglyceride levels were significantly higher in the galactorrhea group than in breast-feeding women with established lactation, suggesting that elevated serum PRL plays a role in lipid metabolism. Cholesterol 34-45 prolactin Homo sapiens 210-213 6682397-5 1983 Fasting serum total lipids, total cholesterol and triglyceride levels were significantly higher in the galactorrhea group than in breast-feeding women with established lactation, suggesting that elevated serum PRL plays a role in lipid metabolism. Triglycerides 50-62 prolactin Homo sapiens 210-213 6196473-1 1983 Lung and liver tissue slices from fetuses aborted at 20 weeks gestation were incubated for 8 hours in MEM Eagle"s medium containing PRL (85 ng/ml). mem eagle"s medium 102-120 prolactin Homo sapiens 132-135 6224137-4 1983 SV estradiol-17 beta and estriol levels were positively correlated with linoleic acid and protein intake, while NV prolactin levels were significantly correlated with intakes of oleic and linoleic acids and total fat. Linoleic Acids 188-202 prolactin Homo sapiens 115-124 6827165-6 1983 The mean plasma prolactin levels, studied in 10 subjects in group A at hourly intervals after the first metergoline dose, decreased significantly one hour later (p less than 0.05) and reached the nadir level, 19.9 +/- 2.6% of the mean basal value, 4 hours later. Metergoline 104-115 prolactin Homo sapiens 16-25 6203986-0 1983 [Increased secretion of prolactin after inhibition of dopaminergic receptors by metoclopramide in patients with cancer of the prostate]. Metoclopramide 80-94 prolactin Homo sapiens 24-33 6203986-1 1983 The authors begin by stressing the importance of the role of prolactin in the metabolism of testosterone in the cells of the prostate. Testosterone 92-104 prolactin Homo sapiens 61-70 6203986-3 1983 Inhibition of the dopaminergic receptors by metoclopramide only resulted in a significant increase in serum prolactin in the patients with prostatic cancer, while the serum prolactin level remained unchanged in the young men and in the patients with prostatic adenoma. Metoclopramide 44-58 prolactin Homo sapiens 108-117 6203986-4 1983 The authors believe that this increased secretion of prolactin in patients with prostatic cancer is related to a decrease in the testosterone: oestradiol ratio. Testosterone 129-141 prolactin Homo sapiens 53-62 6203986-4 1983 The authors believe that this increased secretion of prolactin in patients with prostatic cancer is related to a decrease in the testosterone: oestradiol ratio. Estradiol 143-153 prolactin Homo sapiens 53-62 6203986-5 1983 They suggest the use of bromocriptine in patients with prostatic cancer no longer responding to oestrogen therapy in the event of prolactin over-secretion. Bromocriptine 24-37 prolactin Homo sapiens 130-139 6823341-5 1983 The serum prolactin level was lowered and clinical symptoms improved with bromocriptine treatment. Bromocriptine 74-87 prolactin Homo sapiens 10-19 6133301-0 1983 Sedative effects and prolactin response to single oral doses of melperone. metylperon 64-73 prolactin Homo sapiens 21-30 6133301-3 1983 Melperone decreased arousal and increased prolactin secretion in a dose-dependent manner. metylperon 0-9 prolactin Homo sapiens 42-51 6133307-0 1983 Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment. Dopamine 0-8 prolactin Homo sapiens 106-115 6133307-0 1983 Dopamine, serotonin and alpha-adrenergic receptor blocking activities in serum and their relationships to prolactin level in schizophrenic patients receiving long-term chlorpromazine treatment. Chlorpromazine 168-182 prolactin Homo sapiens 106-115 6134298-2 1983 However, in a double-blind, random assignment, placebo controlled study of six young women in the first half of their menstrual cycle oral temazepam (20 mg) was found to significantly lower plasma cortisol and raise plasma prolactin. temazepam 139-148 prolactin Homo sapiens 223-232 6408670-0 1983 A preliminary study of sex-related differences in prolactin responses to dopamine blockade and insulin hypoglycemia and in penfluridol plasma levels in schizophrenic patients. Dopamine 73-81 prolactin Homo sapiens 50-59 6415730-4 1983 These doses of bromocriptine stimulated serum growth hormone and inhibited serum prolactin levels in some subjects. Bromocriptine 15-28 prolactin Homo sapiens 81-90 6623176-0 1983 [Blood prolactin level in primary hypothyroidism and its response to methyldopa and obzidan]. Methyldopa 69-79 prolactin Homo sapiens 7-16 6623176-0 1983 [Blood prolactin level in primary hypothyroidism and its response to methyldopa and obzidan]. Propranolol 84-91 prolactin Homo sapiens 7-16 6827165-7 1983 The daily plasma prolactin levels in 9 subjects were significantly lower than those of the control group during metergoline treatment (p less than 0.001). Metergoline 112-123 prolactin Homo sapiens 17-26 7169099-0 1982 [The effects of metoclopramide on maternal, umbilical and amniotic fluid prolactin at delivery]. Metoclopramide 16-30 prolactin Homo sapiens 73-82 7158225-0 1982 Potent 48 hours inhibition of prolactin secretion by pergolide in hyperprolactinaemic women. Pergolide 53-62 prolactin Homo sapiens 30-39 7158225-1 1982 The duration of the inhibition of Prl secretion by pergolide, a new dopaminergic ergoline, was investigated in 5 hyperprolactinaemic women after a single oral 50 micrograms dose. Pergolide 51-60 prolactin Homo sapiens 34-37 7158225-1 1982 The duration of the inhibition of Prl secretion by pergolide, a new dopaminergic ergoline, was investigated in 5 hyperprolactinaemic women after a single oral 50 micrograms dose. Ergolines 81-89 prolactin Homo sapiens 34-37 7158225-5 1982 This potent long-lasting inhibition of Prl secretion should enhance the efficacy and acceptability of the chronic treatment of hyperprolactinaemia with this new dopamine agonist and, for example, allow drug intake only once every other day. Dopamine 161-169 prolactin Homo sapiens 39-42 7155869-2 1982 Sexual deficiency, which for a long time is the only sign of the disease, is partly due to inhibition of testosterone secretion by high prolactin levels but also, probably, to reduced conversion of testosterone to dihydrotestosterone and, perhaps, to a direct effect of prolactin on the neurotransmitters involved in sexual activity. Testosterone 105-117 prolactin Homo sapiens 136-145 6404046-1 1983 Estradurin (a polymer of 17-beta-oestradiol) has an inhibitory effect on the synthesis/secretion of PRL. polyestradiol phosphate 0-10 prolactin Homo sapiens 100-103 6404046-1 1983 Estradurin (a polymer of 17-beta-oestradiol) has an inhibitory effect on the synthesis/secretion of PRL. Estradiol 25-43 prolactin Homo sapiens 100-103 6404046-3 1983 With increasing time of low doses of Estradurin (0.001 micrograms/ml) in vitro, the inhibitory effect on PRL secretion was overcome and the synthesis/secretion of PRL increased. polyestradiol phosphate 37-47 prolactin Homo sapiens 105-108 6404046-3 1983 With increasing time of low doses of Estradurin (0.001 micrograms/ml) in vitro, the inhibitory effect on PRL secretion was overcome and the synthesis/secretion of PRL increased. polyestradiol phosphate 37-47 prolactin Homo sapiens 163-166 6404046-5 1983 A stimulatory effect of 17-beta-oestradiol (0.01 micrograms/ml) on the synthesis/secretion of PRL was suggested by the tissue from one post-pregnancy pituitary. Estradiol 24-42 prolactin Homo sapiens 94-97 6404046-8 1983 Incubation with testosterone (0.001-1 microgram/ml) cause inhibition of PRL synthesis/secretion in two of three prolactinomas. Testosterone 16-28 prolactin Homo sapiens 72-75 7149902-3 1982 Methadone raised the prolactin level at 60 minutes to more than twice the mean baseline level for the full subject sample. Methadone 0-9 prolactin Homo sapiens 21-30 7149902-4 1982 Patients with depressive disorders had lower mean basal prolactin levels than did the other subjects, and also manifested attenuated prolactin responses to methadone. Methadone 156-165 prolactin Homo sapiens 133-142 6130077-0 1982 Effect of buspirone on prolactin and growth hormone secretion in laboratory rodents and man. Buspirone 10-19 prolactin Homo sapiens 23-32 6130077-4 1982 Buspirone also blocked the inhibitory effect of dopamine on PRL secretion in vitro, which is consistent with the action of a DA antagonist. Buspirone 0-9 prolactin Homo sapiens 60-63 6130077-4 1982 Buspirone also blocked the inhibitory effect of dopamine on PRL secretion in vitro, which is consistent with the action of a DA antagonist. Dopamine 48-56 prolactin Homo sapiens 60-63 6130077-5 1982 In a double-blind placebo-controlled study using eight normal male volunteers, buspirone (30, 60, and 90 mg) produced a dose-related increase in PRL levels 60-180 minutes later, and a significant increase in growth hormone in six of the eight volunteers, which could be evidence for a DA agonist effect in the human hypothalamus. Buspirone 79-88 prolactin Homo sapiens 145-148 6813347-5 1982 During saline infusion, a significant decrease in plasma PRL levels was observed in all subjects. Sodium Chloride 7-13 prolactin Homo sapiens 57-60 7130339-3 1982 Preoperatively, the PRL inhibitory responses to L-dopa cured, 4 .3 +/- 3.8%; uncured, 50.1 +/- 5.5% of baseline) was blunted by pretreatment with the decarboxylase inhibitor carbidopa (cured, 79.1 +/- 4.1%; uncured, 76.8 +/- 9.2%). Levodopa 48-54 prolactin Homo sapiens 20-23 7130339-3 1982 Preoperatively, the PRL inhibitory responses to L-dopa cured, 4 .3 +/- 3.8%; uncured, 50.1 +/- 5.5% of baseline) was blunted by pretreatment with the decarboxylase inhibitor carbidopa (cured, 79.1 +/- 4.1%; uncured, 76.8 +/- 9.2%). Carbidopa 174-183 prolactin Homo sapiens 20-23 7115837-5 1982 Measurement of prolactin levels should be routinely performed in all men presenting with the above sexual disorders and depressed testosterone levels. Testosterone 130-142 prolactin Homo sapiens 15-24 7145265-0 1982 Effect of metoclopramide on maternal and fetal prolactin secretion during labor. Metoclopramide 10-24 prolactin Homo sapiens 47-56 7145265-1 1982 The effect of acute and chronic maternal administration of metoclopramide on prolactin levels in serum of umbilical vein and artery was investigated in 30 women with normal term pregnancy during labor. Metoclopramide 59-73 prolactin Homo sapiens 77-86 7145265-2 1982 Serum maternal prolactin increased significantly when 20 mg metoclopramide was given intravenously 30 to 45 minutes before vaginal delivery. Metoclopramide 60-74 prolactin Homo sapiens 15-24 7145265-4 1982 Oral administration of metoclopramide in late pregnancy evoked a significant increase in maternal serum prolactin levels. Metoclopramide 23-37 prolactin Homo sapiens 104-113 7145265-5 1982 It is suggested that, in humans, therapeutic doses of metoclopramide administered to the mother in late pregnancy stimulate maternal, but not fetal, prolactin secretion. Metoclopramide 54-68 prolactin Homo sapiens 149-158 7172459-0 1982 Hydrotestolactone lowers serum oestradiol and PRL levels in normal men: evidence of a role of oestradiol in prl secretion. testololactone 0-17 prolactin Homo sapiens 46-49 7172459-0 1982 Hydrotestolactone lowers serum oestradiol and PRL levels in normal men: evidence of a role of oestradiol in prl secretion. Estradiol 94-104 prolactin Homo sapiens 108-111 7172459-1 1982 The effect on serum PRL levels of lowering serum oestradiol (E2) concentration by short-term administration of an aromatase activity inhibitor, hydrotestolactone (HT), was studied in six healthy male subjects. Estradiol 49-59 prolactin Homo sapiens 20-23 7172459-1 1982 The effect on serum PRL levels of lowering serum oestradiol (E2) concentration by short-term administration of an aromatase activity inhibitor, hydrotestolactone (HT), was studied in six healthy male subjects. Estradiol 61-63 prolactin Homo sapiens 20-23 7172459-1 1982 The effect on serum PRL levels of lowering serum oestradiol (E2) concentration by short-term administration of an aromatase activity inhibitor, hydrotestolactone (HT), was studied in six healthy male subjects. testololactone 144-161 prolactin Homo sapiens 20-23 6924910-0 1982 [Bromocriptine and tamoxifen--a new therapeutic approach in suppression-resistant prolactin-secreting adenomas]. Bromocriptine 1-14 prolactin Homo sapiens 82-91 6924910-0 1982 [Bromocriptine and tamoxifen--a new therapeutic approach in suppression-resistant prolactin-secreting adenomas]. Tamoxifen 19-28 prolactin Homo sapiens 82-91 6924910-1 1982 In the present study the combination of tamoxifen and bromocriptine was tried for the suppression of prolactin in prolactin secreting adenomas which were resistant to suppression with bromoergocriptine alone. Tamoxifen 40-49 prolactin Homo sapiens 101-110 6924910-1 1982 In the present study the combination of tamoxifen and bromocriptine was tried for the suppression of prolactin in prolactin secreting adenomas which were resistant to suppression with bromoergocriptine alone. Tamoxifen 40-49 prolactin Homo sapiens 114-123 6924910-1 1982 In the present study the combination of tamoxifen and bromocriptine was tried for the suppression of prolactin in prolactin secreting adenomas which were resistant to suppression with bromoergocriptine alone. Bromocriptine 54-67 prolactin Homo sapiens 101-110 6924910-1 1982 In the present study the combination of tamoxifen and bromocriptine was tried for the suppression of prolactin in prolactin secreting adenomas which were resistant to suppression with bromoergocriptine alone. Bromocriptine 54-67 prolactin Homo sapiens 114-123 6924910-1 1982 In the present study the combination of tamoxifen and bromocriptine was tried for the suppression of prolactin in prolactin secreting adenomas which were resistant to suppression with bromoergocriptine alone. Bromocriptine 184-201 prolactin Homo sapiens 114-123 6924910-13 1982 The results lead to the conclusion that tamoxifen is capable of improving the suppression of prolactin or render the adenomas suppressible in a large number of cases. Tamoxifen 40-49 prolactin Homo sapiens 93-102 7152474-0 1982 Propranolol induced changes in plasma catecholamine, corticosterone, T4, T3 and prolactin levels in the pigeon. Propranolol 0-11 prolactin Homo sapiens 80-89 6817001-0 1982 The effect of estrogen priming of hypogonadal women on the release of gonadotropins and prolactin in response to 2-hydroxyestradiol. 2-hydroxyestradiol 113-131 prolactin Homo sapiens 88-97 6817001-1 1982 We have previously shown that the administration of a 2-hydroxyestradiol (20H-E2) infusion (250 microgram/h x 4 h) to hypogonadal women resulted in a selective increase in the levels of circulating prolactin (PRL) without changes in LH or FSH. 2-hydroxyestradiol 54-72 prolactin Homo sapiens 198-207 6817001-1 1982 We have previously shown that the administration of a 2-hydroxyestradiol (20H-E2) infusion (250 microgram/h x 4 h) to hypogonadal women resulted in a selective increase in the levels of circulating prolactin (PRL) without changes in LH or FSH. 2-hydroxyestradiol 54-72 prolactin Homo sapiens 209-212 6817001-1 1982 We have previously shown that the administration of a 2-hydroxyestradiol (20H-E2) infusion (250 microgram/h x 4 h) to hypogonadal women resulted in a selective increase in the levels of circulating prolactin (PRL) without changes in LH or FSH. 20h-e2 74-80 prolactin Homo sapiens 198-207 6817001-1 1982 We have previously shown that the administration of a 2-hydroxyestradiol (20H-E2) infusion (250 microgram/h x 4 h) to hypogonadal women resulted in a selective increase in the levels of circulating prolactin (PRL) without changes in LH or FSH. 20h-e2 74-80 prolactin Homo sapiens 209-212 6817001-5 1982 In contrast, significant (P less than 0.05) increments in the release of PRL could clearly be detected after a lag period of 1.5 h reaching a peak (+91 +/- 11%) by 4 h. These and previous findings demonstrate that the inhibitory influence of 20H-E2 on gonadotropin secretion is conditional upon prior estrogen priming while the ability of 20H-E2 to stimulate the release of PRL is not. 20h-e2 242-248 prolactin Homo sapiens 73-76 6817001-5 1982 In contrast, significant (P less than 0.05) increments in the release of PRL could clearly be detected after a lag period of 1.5 h reaching a peak (+91 +/- 11%) by 4 h. These and previous findings demonstrate that the inhibitory influence of 20H-E2 on gonadotropin secretion is conditional upon prior estrogen priming while the ability of 20H-E2 to stimulate the release of PRL is not. 20h-e2 339-345 prolactin Homo sapiens 73-76 7132736-0 1982 Impaired prolactin responsiveness to dopamine antagonists in acromegaly. Dopamine 37-45 prolactin Homo sapiens 9-18 7132736-6 1982 bolus injection of DOM (4 mg) was barely effective to raise plasma PRL in the 11 normoprolactinemic and the 6 hyperprolactinemic patients. Domperidone 19-22 prolactin Homo sapiens 67-70 7145025-0 1982 Agreement of prolactin response to cimetidine and nomifensine in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. Cimetidine 35-45 prolactin Homo sapiens 13-22 7145025-0 1982 Agreement of prolactin response to cimetidine and nomifensine in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. Nomifensine 50-61 prolactin Homo sapiens 79-88 6217610-0 1982 Correlation between levels of dehydroepiandrosterone-sulphate and prolactin in human breast cyst fluid. Dehydroepiandrosterone Sulfate 30-61 prolactin Homo sapiens 66-75 7124858-2 1982 In response to AM ethinyl estradiol, mean circulating levels of serum prolactin during sleep and awake phases of the day rose 2.5-fold compared to untreated control values. Ethinyl Estradiol 18-35 prolactin Homo sapiens 70-79 7124858-4 1982 Altered time of administration, PM ethinyl estradiol or concomitant ethinyl estradiol and progestin treatment produced similar increases in mean prolactin levels, which were not different from the level observed during AM administration of ethinyl estradiol. Ethinyl Estradiol 35-52 prolactin Homo sapiens 145-154 7124858-4 1982 Altered time of administration, PM ethinyl estradiol or concomitant ethinyl estradiol and progestin treatment produced similar increases in mean prolactin levels, which were not different from the level observed during AM administration of ethinyl estradiol. Ethinyl Estradiol 68-85 prolactin Homo sapiens 145-154 7124858-4 1982 Altered time of administration, PM ethinyl estradiol or concomitant ethinyl estradiol and progestin treatment produced similar increases in mean prolactin levels, which were not different from the level observed during AM administration of ethinyl estradiol. Ethinyl Estradiol 68-85 prolactin Homo sapiens 145-154 7136447-0 1982 Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas. Benserazide 0-11 prolactin Homo sapiens 48-57 7136447-0 1982 Benserazide and nomifensine in the diagnosis of prolactin-secreting pituitary adenomas. Nomifensine 16-27 prolactin Homo sapiens 48-57 7136447-1 1982 Benserazide, an inhibitor of dopa-decarboxylase, stimulates prolactin (Prl) release in normal women and in puerperae; nomifensine, a dopaminergic drug able to release dopamine and to inhibit its re-uptake at the post-synaptic level, inhibits Prl release in the same subjects. Benserazide 0-11 prolactin Homo sapiens 60-69 6289664-2 1982 Particulate fractions from human chorion-decidua sedimenting between 1,500 and 45,000 x g display optimal binding of 215I-labeled ovine prolactin when incubated at a membrane protein concentration of 200 micrograms per assay tube for 2 hours at 22 degrees C. Specific binding was increased by pretreatment of the membrane particles with 5M magnesium chloride to remove endogenous prolactin. Magnesium Chloride 340-358 prolactin Homo sapiens 136-145 6814369-7 1982 There was good overall correlation of peak prolactin with peak, TSH concentrations. Thyrotropin 64-67 prolactin Homo sapiens 43-52 6814369-9 1982 All patients with low levels of serum thyroxine had abnormal prolactin or TSH levels, high in some, low in others. Thyroxine 38-47 prolactin Homo sapiens 61-70 6753959-0 1982 Effects of dopamine, norepinephrine and serotonin on plasma concentrations of luteinizing hormone and prolactin in ovariectomized and anestrous ewes. Serotonin 40-49 prolactin Homo sapiens 102-111 6814794-2 1982 Bromocriptine (2.5 mg as a single dose) caused, concurrently with a marked suppression of serum PRL, a significant increase of serum testosterone and a transient decrease of serum LH. Bromocriptine 0-13 prolactin Homo sapiens 96-99 6814794-9 1982 A significant increase in serum concentration of testosterone was also observed in a patient with PRL-producing pituitary tumour and four out of seven patients with acromegaly during bromocriptine treatment. Testosterone 49-61 prolactin Homo sapiens 98-101 6814794-10 1982 These results suggest an inhibitory effect of PRL on testosterone secretion at the gonadal level, or direct dopaminergic stimulatory control of testosterone secretion. Testosterone 53-65 prolactin Homo sapiens 46-49 6814795-1 1982 Endogenous opiates are involved in the control of pituitary gonadotrophin and PRL secretion, and possibly of food intake. Opiate Alkaloids 11-18 prolactin Homo sapiens 78-81 7151830-0 1982 Prolactin response to arginine in children with hyperthyroidism and primary hypothyroidism. Arginine 22-30 prolactin Homo sapiens 0-9 7151830-1 1982 Plasma prolactin (PRL) response to arginine was examined in 16 prepubertal and 18 pubertal children with constitutional short stature, 5 patients with hyperthyroidism and 4 patients with primary hypothyroidism. Arginine 35-43 prolactin Homo sapiens 7-16 7151830-1 1982 Plasma prolactin (PRL) response to arginine was examined in 16 prepubertal and 18 pubertal children with constitutional short stature, 5 patients with hyperthyroidism and 4 patients with primary hypothyroidism. Arginine 35-43 prolactin Homo sapiens 18-21 7151830-3 1982 Arginine infusion elicited significant (P less than 0.05) rises in plasma PRL in all groups. Arginine 0-8 prolactin Homo sapiens 74-77 7151830-4 1982 The maximal increment of plasma PRL above the baseline level after arginine stimulation was significantly larger (P less than 0.05) in pubertal than in prepubertal females and was significantly smaller (P less than 0.05) in patients with hyperthyroidism than in age- and sex-matched controls. Arginine 67-75 prolactin Homo sapiens 32-35 7151830-6 1982 These data suggest that arginine produces a significant increase in plasma PRL and the PRL response to arginine was greater in pubertal than in prepubertal children. Arginine 24-32 prolactin Homo sapiens 75-78 7151830-6 1982 These data suggest that arginine produces a significant increase in plasma PRL and the PRL response to arginine was greater in pubertal than in prepubertal children. Arginine 24-32 prolactin Homo sapiens 87-90 7151830-6 1982 These data suggest that arginine produces a significant increase in plasma PRL and the PRL response to arginine was greater in pubertal than in prepubertal children. Arginine 103-111 prolactin Homo sapiens 87-90 7151830-7 1982 Plasma PRL response to arginine is suppressed in children with hyperthyroidism and the basal plasma PRL is markedly elevated in primary hypothyroidism. Arginine 23-31 prolactin Homo sapiens 7-10 6819905-0 1982 [Effects of metergoline on serum levels of prolactin and gonadotropin in women]. Metergoline 12-23 prolactin Homo sapiens 43-52 7132728-0 1982 Cimetidine effect of dopaminergic modulation of prolactin release in healthy women. Cimetidine 0-10 prolactin Homo sapiens 48-57 7132728-1 1982 The aim of the present study was to test whether cimetidine (Cim) influences PIF (prolactin inhibitory factor), and thereby indirectly affects the release of prolactin (PRL) from the pituitary lactotrophs. Cimetidine 49-59 prolactin Homo sapiens 82-91 7132728-1 1982 The aim of the present study was to test whether cimetidine (Cim) influences PIF (prolactin inhibitory factor), and thereby indirectly affects the release of prolactin (PRL) from the pituitary lactotrophs. Cimetidine 49-59 prolactin Homo sapiens 169-172 7132728-1 1982 The aim of the present study was to test whether cimetidine (Cim) influences PIF (prolactin inhibitory factor), and thereby indirectly affects the release of prolactin (PRL) from the pituitary lactotrophs. Cimetidine 61-64 prolactin Homo sapiens 82-91 7132728-1 1982 The aim of the present study was to test whether cimetidine (Cim) influences PIF (prolactin inhibitory factor), and thereby indirectly affects the release of prolactin (PRL) from the pituitary lactotrophs. Cimetidine 61-64 prolactin Homo sapiens 169-172 7132728-6 1982 Placebo did not change the basal PRL level, but the subsequent Cim injection raised the PRL level from 14 +/- 4 to 66 +/- 9 ng/ml (p less than 0.01). Cimetidine 63-66 prolactin Homo sapiens 88-91 7132728-13 1982 The observation that Cim fails to elicit an increase in PRL after priming with Met thus indicates that Cim, under normal conditions, stimulates the PRL release via a reduced dopaminergic inhibition of the lactotrophs. Cimetidine 103-106 prolactin Homo sapiens 148-151 6294192-7 1982 We concluded that patterns of PRL and ACTH releases following epidural morphine were correspondent with the analgesic effect, and that appearance of amelioration of pain following epidural morphine may depend upon the dopaminergic mechanism. Morphine 71-79 prolactin Homo sapiens 30-33 6294192-0 1982 [Studies on changes of the plasma prolactin, growth hormone and ACTH levels following surgical stress and epidural micro-injections of morphine hydrochloride as a postoperative analgesic method]. Morphine hydrochloride 135-157 prolactin Homo sapiens 34-43 6294192-4 1982 Following epidural morphine, the plasma PRL levels significantly decreased in the effective cases, and significantly increased in the ineffective cases. Morphine 19-27 prolactin Homo sapiens 40-43 6760074-3 1982 But cimetidine, an H2 antagonist also induces PRL release in humans. Cimetidine 4-14 prolactin Homo sapiens 46-49 6760074-5 1982 Diphenhydramine and placebo injection resulted in a decrease of PRL from 0800 until 11.00 hours, suggesting a spontaneous diurnal variation. Diphenhydramine 0-15 prolactin Homo sapiens 64-67 6760074-6 1982 Cimetidine induced a short but significant rise of PRL before a similar diurnal secretory pattern. Cimetidine 0-10 prolactin Homo sapiens 51-54 7175275-5 1982 The PRL decreased significantly at 120 and 180 minutes after the administration of bromocriptine in any case. Bromocriptine 83-96 prolactin Homo sapiens 4-7 7173312-0 1982 Phencyclidine suppresses plasma prolactin levels. Phencyclidine 0-13 prolactin Homo sapiens 32-41 7133705-0 1982 [The effect of prenatal administration of vitamin B6 on the blood oxygen transport serum prolactin level in the mother and her newborn infant]. Vitamin B 6 42-52 prolactin Homo sapiens 89-98 6812343-4 1982 Serum Prl levels after sulpiride were higher in the patients than in the controls (P less than 0.01). Sulpiride 23-32 prolactin Homo sapiens 6-9 6812343-7 1982 The markedly enhanced Prl response to sulpiride in our patients with galactorrhoea could be due to a functional disorder of the hypothalamic-pituitary axis or to a lactotrope hyperplasia. Sulpiride 38-47 prolactin Homo sapiens 22-25 6816160-9 1982 The high PRL levels may be responsible for the impaired conversion of T to DHT, possibly by interference with the enzyme 5 alpha-reductase. Dihydrotestosterone 75-78 prolactin Homo sapiens 9-12 6816179-19 1982 The excellent chronological correlation between the change in blood pressure and prolactin level is compatible with the hypothesis of this type of dysfunction in essential hypertension, if the inhibition of prolactin is accepted as a central dopaminergic effect of bromocriptine. Bromocriptine 265-278 prolactin Homo sapiens 81-90 7149855-5 1982 Oral Zn seems to improve the conversion of A to T and also uncovered the possibility that plasma PRL levels greater than 100 ng/ml might cause a blockade in the 5 alfa-reductase. Zinc 5-7 prolactin Homo sapiens 97-100 7127180-1 1982 Plasma level of prolactin and its response to the injection of haloperidol were measured in nine women before and after elective gynecological surgery under neuroleptanalgesia using dextromoramidedroperidol combination. Haloperidol 63-74 prolactin Homo sapiens 16-25 6819898-4 1982 While the known PRL-stimulatory effect of metoclopramide and the PRL-lowering effect of lisuride could be confirmed, we were unable to demonstrate any substance-related effects on the other hypophyseal or gonadal hormones. Metoclopramide 42-56 prolactin Homo sapiens 16-19 6819898-4 1982 While the known PRL-stimulatory effect of metoclopramide and the PRL-lowering effect of lisuride could be confirmed, we were unable to demonstrate any substance-related effects on the other hypophyseal or gonadal hormones. Lisuride 88-96 prolactin Homo sapiens 65-68 7106054-8 1982 The bioactivity profiles of iodinated hGH and hPRL shifted anodally on polyacrylamide gel electrophoresis in comparison to the bioactivity distribution of the respective uniodinated hormones. polyacrylamide 71-85 prolactin Homo sapiens 46-50 6818270-7 1982 In response to metoclopramide, alcoholics had a brisk prolactin response, failed to demonstrate a TSH response, and had a decline in growth hormone when compared to controls. Metoclopramide 15-29 prolactin Homo sapiens 54-63 7096541-5 1982 In comparison to prior studies with PRL-secreting adenomas, several differences were apparent: 1) the maximum inhibition of GH release by DA is lower than that of PRL (50% vs. 80%), 2) the maximum number of binding sites is much lower (5-20 times) in GH-secreting adenomas than in PRL-secreting adenomas, and 3) [3H]domperidone does not show specific binding on GH-secreting adenomas but does on PRL-secreting adenomas. Dopamine 138-140 prolactin Homo sapiens 36-39 7140188-0 1982 [Effect of bromopride on prolactin secretion]. bromopride 11-21 prolactin Homo sapiens 25-34 7102764-3 1982 In puerperal hyperprolactinemic subjects, the basal PRL (116.8 +/- 16.4 ng/ml) was suppressed 77% +/- 2% after administration of L-dopa and 51% +/- 7% after L-dopa plus carbidopa, significantly different from that of L-dopa alone (p less than 0.005), but similar to that observed in normal subjects. Levodopa 129-135 prolactin Homo sapiens 52-55 7102764-3 1982 In puerperal hyperprolactinemic subjects, the basal PRL (116.8 +/- 16.4 ng/ml) was suppressed 77% +/- 2% after administration of L-dopa and 51% +/- 7% after L-dopa plus carbidopa, significantly different from that of L-dopa alone (p less than 0.005), but similar to that observed in normal subjects. Levodopa 157-163 prolactin Homo sapiens 52-55 7102764-3 1982 In puerperal hyperprolactinemic subjects, the basal PRL (116.8 +/- 16.4 ng/ml) was suppressed 77% +/- 2% after administration of L-dopa and 51% +/- 7% after L-dopa plus carbidopa, significantly different from that of L-dopa alone (p less than 0.005), but similar to that observed in normal subjects. Carbidopa 169-178 prolactin Homo sapiens 52-55 7102764-3 1982 In puerperal hyperprolactinemic subjects, the basal PRL (116.8 +/- 16.4 ng/ml) was suppressed 77% +/- 2% after administration of L-dopa and 51% +/- 7% after L-dopa plus carbidopa, significantly different from that of L-dopa alone (p less than 0.005), but similar to that observed in normal subjects. Levodopa 157-163 prolactin Homo sapiens 52-55 7102764-4 1982 In the patients with idiopathic hyperprolactinemia, the baseline PRL (131 +/- 38 ng/ml) decreased 56.3% after the administration of L-dopa. Levodopa 132-138 prolactin Homo sapiens 65-68 7102764-5 1982 In the presence of peripheral dopa decarboxylase inhibition, the administration of L-dopa decreased plasma PRL values 30%, a drop significantly different from that of L-dopa alone (p less than 0.02). Levodopa 83-89 prolactin Homo sapiens 107-110 7102764-8 1982 The increased pituitary sensitivity to L-dopa observed in puerperal women may be due to alterations in PRL receptors or vascularity. Levodopa 39-45 prolactin Homo sapiens 103-106 7102768-5 1982 Determinations of daily serum levels of prolactin in 20 primiparous women revealed significantly higher concentrations in the sulpiride group. Sulpiride 126-135 prolactin Homo sapiens 40-49 6812337-4 1982 Serum prolactin (Prl) increased significantly (P less than 0.001) after clebopride administration while these changes did not occur when placebo was used instead of clebopride at midnight. clebopride 72-82 prolactin Homo sapiens 17-20 6289583-8 1982 These results suggest that the hyperprolactinaemia in prolactinoma patients may cause an impaired positive feedback effect of oestrogen on LH release and that this derangement can be reversed by reduction of the Prl level by adenomectomy. Luteinizing Hormone 139-141 prolactin Homo sapiens 212-215 6812337-4 1982 Serum prolactin (Prl) increased significantly (P less than 0.001) after clebopride administration while these changes did not occur when placebo was used instead of clebopride at midnight. clebopride 72-82 prolactin Homo sapiens 6-15 6812337-5 1982 The Prl response to clebopride was qualitatively similar at 09.00 h and at 24.00 h. Clebopride given at midnight induced a significant increase (P less than 0.05) in serum TSH while this change did not occur when the drug was given at 09.00 h or when placebo was given at midnight. clebopride 20-30 prolactin Homo sapiens 4-7 6812337-5 1982 The Prl response to clebopride was qualitatively similar at 09.00 h and at 24.00 h. Clebopride given at midnight induced a significant increase (P less than 0.05) in serum TSH while this change did not occur when the drug was given at 09.00 h or when placebo was given at midnight. clebopride 84-94 prolactin Homo sapiens 4-7 6812337-7 1982 Thus, Prl responses to clebopride were similar in the morning and at midnight, TSH significantly increased after clebopride at midnight whereas this did not occur when the drug was given in the morning, and no significant changes were induced in LH, FSH or GH at the times studied. clebopride 23-33 prolactin Homo sapiens 6-9 6182128-0 1982 [Value of palliative treatment of metastasizing prostatic cancer with the prolactin inhibitor parlodel]. Bromocriptine 94-102 prolactin Homo sapiens 74-83 6286370-3 1982 Human PRL was isolated from amniotic fluid, and its intact monomeric iodinated isohormone B was prepared. isohormone b 79-91 prolactin Homo sapiens 6-9 6282921-16 1982 We postulate that PRL may exert multiple effects on steroid secretion and metabolism. Steroids 52-59 prolactin Homo sapiens 18-21 7085859-5 1982 PRL release was significantly lower in naloxone-pretreated subjects. Naloxone 39-47 prolactin Homo sapiens 0-3 7120089-0 1982 Serum prolactin level increase in normal subjects following administration of perphenazine oral dosage forms: possible application to bioavailability testing. Perphenazine 78-90 prolactin Homo sapiens 6-15 7120089-1 1982 Two pilot studies were performed to determine if oral phenothiazine products could generate a significant increase in serum levels of the hormone prolactin. phenothiazine 54-67 prolactin Homo sapiens 146-155 7089575-0 1982 Cysteamine: a potent and specific depletor of pituitary prolactin. Cysteamine 0-10 prolactin Homo sapiens 56-65 7089575-1 1982 Cysteamine rapidly reduces the concentration of prolactin in pituitary tissue in vivo and in vitro. Cysteamine 0-10 prolactin Homo sapiens 48-57 6123841-5 1982 In the macroadenoma group bromocriptine restored serum prolactin levels in 13 of the 16 and serum testosterone and potency in 5, whereas in the non-tumour group it restored serum prolactin levels in all 10 and serum testosterone and potency in 9. Bromocriptine 26-39 prolactin Homo sapiens 55-64 6807435-4 1982 In the sulpiride-treatment group the mean maternal serum prolactin concentration rose from 49.0 +/- SE 3.6 micrograms/l to a maximum of 402.1 +/0 43.2 micrograms/l at two weeks; in the placebo-treated group, however, the concentration fell during the trial (from 84.7 +/- 24.0 micrograms/l to 47.8 +/- 8.6 micrograms/l). Sulpiride 7-16 prolactin Homo sapiens 57-66 7201244-0 1982 Bromocriptine treatment of women with suspected pituitary prolactin-secreting microadenomas. Bromocriptine 0-13 prolactin Homo sapiens 58-67 7201244-1 1982 The present study was designed to investigate the efficacy of bromocriptine in reducing serum prolactin (PRL) levels and in decreasing the size of PRL-secreting microadenomas. Bromocriptine 62-75 prolactin Homo sapiens 94-103 7201244-1 1982 The present study was designed to investigate the efficacy of bromocriptine in reducing serum prolactin (PRL) levels and in decreasing the size of PRL-secreting microadenomas. Bromocriptine 62-75 prolactin Homo sapiens 105-108 7201244-1 1982 The present study was designed to investigate the efficacy of bromocriptine in reducing serum prolactin (PRL) levels and in decreasing the size of PRL-secreting microadenomas. Bromocriptine 62-75 prolactin Homo sapiens 147-150 7201244-8 1982 These data suggest that bromocriptine is an appropriate therapeutic modality for PRL-secreting pituitary microadenomas. Bromocriptine 24-37 prolactin Homo sapiens 81-84 7109850-3 1982 Moreover, BC-PL and nomifensine reduce plasma PRL levels in hyperprolactinaemic PCO syndromes but not in PRL secreting pituitary adenomas. Nomifensine 20-31 prolactin Homo sapiens 46-49 6805933-5 1982 The mean plasma prolactin levels after a bolus injection of thyrotropin-releasing hormone in the midluteal phase during cimetidine administration did not differ from the mean control levels, which indicates that cimetidine modulates the release of prolactin at the suprapituitary locus. Cimetidine 212-222 prolactin Homo sapiens 16-25 6805933-5 1982 The mean plasma prolactin levels after a bolus injection of thyrotropin-releasing hormone in the midluteal phase during cimetidine administration did not differ from the mean control levels, which indicates that cimetidine modulates the release of prolactin at the suprapituitary locus. Cimetidine 212-222 prolactin Homo sapiens 248-257 6282573-1 1982 l-Isoproterenol (l-ISO), a specific agonist of beta-adrenergic receptors, evoked a prompt rise of prolactin (PRL) release from superfused anterior pituitary cell aggregates established in culture for 5 days. LEVISOPRENALINE 0-15 prolactin Homo sapiens 98-107 6282573-1 1982 l-Isoproterenol (l-ISO), a specific agonist of beta-adrenergic receptors, evoked a prompt rise of prolactin (PRL) release from superfused anterior pituitary cell aggregates established in culture for 5 days. LEVISOPRENALINE 0-15 prolactin Homo sapiens 109-112 6282573-1 1982 l-Isoproterenol (l-ISO), a specific agonist of beta-adrenergic receptors, evoked a prompt rise of prolactin (PRL) release from superfused anterior pituitary cell aggregates established in culture for 5 days. l-iso 17-22 prolactin Homo sapiens 98-107 6282573-1 1982 l-Isoproterenol (l-ISO), a specific agonist of beta-adrenergic receptors, evoked a prompt rise of prolactin (PRL) release from superfused anterior pituitary cell aggregates established in culture for 5 days. l-iso 17-22 prolactin Homo sapiens 109-112 6282573-4 1982 When dopamine receptors were blocked with domperidone, PRL secretion was also stimulated by l-epinephrine (E) and l-norepinephrine (NE), the rank order of potency being l-ISO greater than E much greater than NE. Domperidone 42-53 prolactin Homo sapiens 55-58 6282573-4 1982 When dopamine receptors were blocked with domperidone, PRL secretion was also stimulated by l-epinephrine (E) and l-norepinephrine (NE), the rank order of potency being l-ISO greater than E much greater than NE. Epinephrine 92-105 prolactin Homo sapiens 55-58 6282573-4 1982 When dopamine receptors were blocked with domperidone, PRL secretion was also stimulated by l-epinephrine (E) and l-norepinephrine (NE), the rank order of potency being l-ISO greater than E much greater than NE. Norepinephrine 114-130 prolactin Homo sapiens 55-58 6282573-4 1982 When dopamine receptors were blocked with domperidone, PRL secretion was also stimulated by l-epinephrine (E) and l-norepinephrine (NE), the rank order of potency being l-ISO greater than E much greater than NE. l-iso 169-174 prolactin Homo sapiens 55-58 6282573-6 1982 Stimulation of PRL release by l-ISO and E was blocked by the beta-receptor antagonist, propranolol, but not by the alpha-receptor blocker, prazosin. l-iso 30-35 prolactin Homo sapiens 15-18 6282573-6 1982 Stimulation of PRL release by l-ISO and E was blocked by the beta-receptor antagonist, propranolol, but not by the alpha-receptor blocker, prazosin. Propranolol 87-98 prolactin Homo sapiens 15-18 7106550-0 1982 Increased loss of thyroxine from the blood streams of newts after injection with ovine prolactin. Thyroxine 18-27 prolactin Homo sapiens 87-96 7124282-0 1982 The effect of hyperosmotic and sodium chloride hyperosmotic environments on the secretion and synthesis of prolactin from human decidua in vitro. Sodium Chloride 31-46 prolactin Homo sapiens 107-116 6804481-3 1982 During saline infusion, serum PRL declined, as seen normally after sleep. Sodium Chloride 7-13 prolactin Homo sapiens 30-33 6804481-5 1982 This effect of HA on PRL secretion was inhibited during the combined infusion of HA and the H1-antagonist mepyramine (delta PRL, 28 +/- 20 vs. -77 +/- 13 microIU/ml; P less than 0.025). Pyrilamine 106-116 prolactin Homo sapiens 21-24 6804481-6 1982 The PRL-stimulating effect of HA was strongly enhanced during the combined infusion of HA and the H2-antagonist cimetidine (delta PRL, -28 +/- 20 vs. 132 +/- 57 microIU/ml; P less than 0.0125). Cimetidine 112-122 prolactin Homo sapiens 4-7 6804483-0 1982 Prolactin response to metoclopramide in hyperthyroidism. Metoclopramide 22-36 prolactin Homo sapiens 0-9 6804483-1 1982 The response of PRL to the oral administration of the dopamine receptor-blocking agent metoclopramide and the effect of metoclopramide on the TRH-induced release of PRL and TSH were measured in eight patients with hyperthyroidism and in eight age- and sex-matched euthyroid controls. Metoclopramide 87-101 prolactin Homo sapiens 16-19 6804483-1 1982 The response of PRL to the oral administration of the dopamine receptor-blocking agent metoclopramide and the effect of metoclopramide on the TRH-induced release of PRL and TSH were measured in eight patients with hyperthyroidism and in eight age- and sex-matched euthyroid controls. Metoclopramide 120-134 prolactin Homo sapiens 165-168 6804483-3 1982 PRL levels, on the other hand, rose significantly after the administration of metoclopramide in both the hyperthyroid and euthyroid subjects (P less than 0.0005 at 60 and 120 min). Metoclopramide 78-92 prolactin Homo sapiens 0-3 6804483-6 1982 We have previously suggested that thyroid hormones inhibit PRL secretion by stimulating the hypothalamic secretion of dopamine. Dopamine 118-126 prolactin Homo sapiens 59-62 7076803-1 1982 The presence of PRL in high concentration in human amniotic fluid has been related to changes in water transport across amnion but not chorion leave. Water 97-102 prolactin Homo sapiens 16-19 7076803-4 1982 Amniotic epithelium exposed to [125I]human PRL, [125I]human Gh, [125I]human beta-endorphin, [125I]bovine FSH, and sodium 125I alone was found to display a selectivity in its ability to localize [125I]human PRL only. sodium 125i 114-125 prolactin Homo sapiens 206-209 7122665-0 1982 Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes. fluphenazine depot 11-33 prolactin Homo sapiens 73-82 7122665-0 1982 Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes. phenothiazine 49-62 prolactin Homo sapiens 73-82 7122445-3 1982 It was found that the prolactin basal level in the blood of patients with Icenko-Cushing"s disease remained elevated at the early and late terms of the treatment with khloditan and low doses of peritol and the adenohypophyseal reactivity to stimulants did not return to normal. Cyproheptadine 194-201 prolactin Homo sapiens 22-31 7122445-4 1982 Khloditan and high dose peritol treatment did not induce clinical and hormonal remission of the disease but resulted in the blood prolactin basal level increase and even more pronounced decrease in the adenohypophyseal reactivity to stimulants in comparison with those of the active stage of the disease. Mitotane 0-9 prolactin Homo sapiens 130-139 7122445-4 1982 Khloditan and high dose peritol treatment did not induce clinical and hormonal remission of the disease but resulted in the blood prolactin basal level increase and even more pronounced decrease in the adenohypophyseal reactivity to stimulants in comparison with those of the active stage of the disease. Cyproheptadine 24-31 prolactin Homo sapiens 130-139 6805756-1 1982 Bromocriptine has an accepted place in the management of small pituitary tumours that secrete either prolactin or growth hormone. Bromocriptine 0-13 prolactin Homo sapiens 101-110 7186256-6 1982 In a small group of patients affected by hyperprolactinemia brain cortex phospholipids produced a more rapid and more marked reduction in blood prolactin (similar to that caused by bromocriptine) in functional conditions in comparison to the organic ones. Phospholipids 73-86 prolactin Homo sapiens 46-55 7081489-0 1982 Effect of dexamethasone on plasma prolactin and cortisol levels in psychiatric patients. Dexamethasone 10-23 prolactin Homo sapiens 34-43 7081489-1 1982 In addition to its ability to decrease plasma cortisol levels, dexamethasone can also significantly decrease plasma prolactin levels. Dexamethasone 63-76 prolactin Homo sapiens 116-125 7081489-2 1982 In 52 psychiatric patients, including 26 patients with primary major depression or schizoaffective depression, primarily affective type, there was a significant association between nonsuppression of plasma cortisol and prolactin after administration of dexamethasone. Dexamethasone 253-266 prolactin Homo sapiens 219-228 6807361-7 1982 injection of 1 mg, nor intracarotid injections of up to 1 mg, 5 alpha-DHT affected plasma LH, FSH or prolactin levels, despite dose-related increases in plasma 5 alpha-DHT levels. alpha-dht 64-73 prolactin Homo sapiens 101-110 7044409-0 1982 Inhibition of the renin--aldosterone axis and of prolactin secretion during pregnancy by L-dopa. Levodopa 89-95 prolactin Homo sapiens 49-58 6816577-1 1982 The effect of the decidualization induced by the administration of sex steroid hormones on the human endometrial PRL contents and the mechanism of synthesis and secretion of PRL in this decidualized endometrium of non-pregnant women were investigated. Steroids 71-87 prolactin Homo sapiens 113-116 7105430-0 1982 Menstrual function and serum prolactin levels after long-term bromocriptine treatment of hyperprolactinaemic amenorrhoea. Bromocriptine 62-75 prolactin Homo sapiens 29-38 6125462-0 1982 Effect of acute oral and intravenous administration of ranitidine on prolactin, thyrotropin and gonadotropin serum levels. Ranitidine 55-65 prolactin Homo sapiens 69-78 7076795-0 1982 Effects of nomifensine on growth hormone and prolactin secretion in normal subjects and in pathological hyperprolactinemia. Nomifensine 11-22 prolactin Homo sapiens 45-54 7076799-0 1982 Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary. Progesterone 82-94 prolactin Homo sapiens 0-9 7076799-0 1982 Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary. Estradiol 99-116 prolactin Homo sapiens 0-9 7076799-1 1982 An ovarian perifusion technique was used to determine if there is a direct suppressive effect of PRL on human gonadal steroid secretion. Steroids 118-125 prolactin Homo sapiens 97-100 7076799-3 1982 Ovine PRL (0.1-10 IU/ml) directly suppressed progesterone and 17 beta-estradiol secretion by human ovaries. Progesterone 45-57 prolactin Homo sapiens 6-9 7076799-3 1982 Ovine PRL (0.1-10 IU/ml) directly suppressed progesterone and 17 beta-estradiol secretion by human ovaries. Estradiol 62-79 prolactin Homo sapiens 6-9 7076799-7 1982 These results indicate that PRL inhibits both basal and gonadotropin-stimulated ovarian steroid secretion by human ovaries and that this may be one cause of the hypogonadism associated with hyperprolactinemia. Steroids 88-95 prolactin Homo sapiens 28-31 7097084-8 1982 Although bromocriptine suppressed the secretion of maternal serum PRL abruptly, the concentration of amniotic fluid PRL remained unchanged after the administration of bromocriptine at mid-gestation. Bromocriptine 9-22 prolactin Homo sapiens 66-69 7097084-10 1982 Analysis of molecular size of PRL by Sephadex G-100 column gel filtration revealed that the elution profiles of maternal serum PRL, fetal serum PRL, and amniotic fluid PRL differed from one another and furthermore, they were similar to those of adult pituitary PRL, fetal pituitary PRL, and decidual PRL, respectively. sephadex 37-51 prolactin Homo sapiens 30-33 7121729-10 1982 In conclusion, bromocriptine not only inhibits the release of prolactin, but also suppresses the synthesis of it at the initial phase. Bromocriptine 15-28 prolactin Homo sapiens 62-71 7105431-0 1982 Prolactin stimulation by intravenous labetalol is mediated inside the central nervous system. Labetalol 37-46 prolactin Homo sapiens 0-9 7121729-11 1982 With a long-term administration of bromocriptine, the cell organelles related to the hormone production, such as the Golgi apparatus and ER show gradual shrinkage under the prolonged tonic inhibition for prolactin release and synthesis. Bromocriptine 35-48 prolactin Homo sapiens 204-213 7105431-1 1982 We have previously reported that labetalol infusion increases prolactin (PRL) secretion in hypertensive patients. Labetalol 33-42 prolactin Homo sapiens 62-71 7105431-1 1982 We have previously reported that labetalol infusion increases prolactin (PRL) secretion in hypertensive patients. Labetalol 33-42 prolactin Homo sapiens 73-76 7105431-2 1982 In an attempt to investigate the site where labetalol stimulates PRL, the drug was infused intravenously (100 mg) into healthy subjects, both under basal conditions and after pretreatment with L-dopa plus carbidopa (250 mg and 25 mg respectively every 6 h for 1 day), since this regimen has been reported to blunt the PRL responses to centrally acting stimuli. Labetalol 44-53 prolactin Homo sapiens 65-68 7113733-7 1982 Patients on lithium medication had significantly more pronounced rises of PRL levels than patients treated with other psychotropic drugs and otherwise untreated patients. Lithium 12-19 prolactin Homo sapiens 74-77 6280965-1 1982 Electrophoretic analysis of soluble proteins from pituitary cells pulse labeled with [35S]methionine demonstrated that 10 nM T3 inhibited PRL synthesis, but did not affect the synthesis of most other pituitary proteins. Triiodothyronine 125-127 prolactin Homo sapiens 138-141 7095740-0 1982 Prolactin and growth hormone responses to the serotonin antagonist, metergoline, in liver cirrhosis: further evidence for serotoninergic dysfunction. Serotonin 46-55 prolactin Homo sapiens 0-9 7095740-0 1982 Prolactin and growth hormone responses to the serotonin antagonist, metergoline, in liver cirrhosis: further evidence for serotoninergic dysfunction. Metergoline 68-79 prolactin Homo sapiens 0-9 7086239-2 1982 Significant correlation between serum PRL and triglyceride (TG) levels was observed in the patients with hyperprolactinemia (r = 0.417, p less than 0.05). Triglycerides 46-58 prolactin Homo sapiens 38-41 7086239-2 1982 Significant correlation between serum PRL and triglyceride (TG) levels was observed in the patients with hyperprolactinemia (r = 0.417, p less than 0.05). Triglycerides 60-62 prolactin Homo sapiens 38-41 6807580-0 1982 The response of prolactin to chlorpromazine stimulation in men with hypogonadotrophic hypogonadism and early pubertal boys: relationship to sex steroid exposure. Chlorpromazine 29-43 prolactin Homo sapiens 16-25 6807580-1 1982 The effect of chlorpromazine (CPZ) on prolactin (PRL) secretion was studied in fourteen sexually immature males; nine with idiopathic hypogonadotrophic hypogonadism and five who proved to be normal early pubertal boys. Chlorpromazine 14-28 prolactin Homo sapiens 38-47 6807580-1 1982 The effect of chlorpromazine (CPZ) on prolactin (PRL) secretion was studied in fourteen sexually immature males; nine with idiopathic hypogonadotrophic hypogonadism and five who proved to be normal early pubertal boys. Chlorpromazine 30-33 prolactin Homo sapiens 38-47 6807580-5 1982 Treatment with human chorionic gonadotrophin (hCG) or testosterone enhanced the PRL response to CPZ in three of six hypogonadotrophic subjects. Testosterone 54-66 prolactin Homo sapiens 80-83 6807580-5 1982 Treatment with human chorionic gonadotrophin (hCG) or testosterone enhanced the PRL response to CPZ in three of six hypogonadotrophic subjects. Chlorpromazine 96-99 prolactin Homo sapiens 80-83 6807580-7 1982 These data indicate that lack of sex steroid exposure, rather than a more generalized hypothalamic disorder, explains the attenuated PRL response to CPZ found in untreated men with idiopathic hypogonadotrophic hypogonadism. Chlorpromazine 149-152 prolactin Homo sapiens 133-136 6807580-8 1982 Moreover, CPZ-stimulated PRL secretion may prove to be of practical value in distinguishing hypogonadotrophics from boys with delayed puberty. Chlorpromazine 10-13 prolactin Homo sapiens 25-28 6802681-0 1982 Exaggerated prolactin response of thyrotropin-releasing hormone in women with anovulatory cycles: possible role of endogenous estrogens and effect of bromocriptine. Bromocriptine 150-163 prolactin Homo sapiens 12-21 7060519-0 1982 Thiol regulation of protein, growth hormone, and prolactin release from isolated adenohypophysial secretory granules. Sulfhydryl Compounds 0-5 prolactin Homo sapiens 49-58 7128538-0 1982 Effect of cimetidine on prolactin secretion in normal controls and hyperthyroid patients. Cimetidine 10-20 prolactin Homo sapiens 24-33 7128538-2 1982 The intravenous administration of 200 mg cimetidine, an H2-receptor antagonist, was followed by a significant and marked rise in serum prolactin levels in all control subjects. Cimetidine 41-51 prolactin Homo sapiens 135-144 7128538-5 1982 There was a significant negative correlation between max delta PRL and serum T4 or T3 levels in hyperthyroid patients before and after treatment with MMI or PTU. Phenylthiourea 157-160 prolactin Homo sapiens 63-66 7128538-6 1982 It appears from our data that cimetidine induced PRL release was blunted in hyperthyroid patients. Cimetidine 30-40 prolactin Homo sapiens 49-52 6809519-6 1982 The results are shown below: 1) After one-shot intravenous administration of cimetidine 200 mg, serum-PRL significantly increased, the peak level, however, being within normal value range. Cimetidine 77-87 prolactin Homo sapiens 102-105 6809519-8 1982 2) During and after the repeated oral administration of 800 mg/day of cimetidine for the consecutive 28 days, serum PRL level did not significantly change. Cimetidine 70-80 prolactin Homo sapiens 116-119 7069345-0 1982 Effects of metoclopramide and bromocriptine on prolactin secretion in the pregnant ewe. Bromocriptine 30-43 prolactin Homo sapiens 47-56 7069345-5 1982 Treatment with metoclopramide alone provoked a progressively greater release of prolactin as pregnancy advanced whereas in bromocriptine-treated animals an associated release of prolactin in response to metoclopramide was seen only between days 120 and 140 of pregnancy. Metoclopramide 15-29 prolactin Homo sapiens 80-89 7069345-5 1982 Treatment with metoclopramide alone provoked a progressively greater release of prolactin as pregnancy advanced whereas in bromocriptine-treated animals an associated release of prolactin in response to metoclopramide was seen only between days 120 and 140 of pregnancy. Bromocriptine 123-136 prolactin Homo sapiens 178-187 7069345-5 1982 Treatment with metoclopramide alone provoked a progressively greater release of prolactin as pregnancy advanced whereas in bromocriptine-treated animals an associated release of prolactin in response to metoclopramide was seen only between days 120 and 140 of pregnancy. Metoclopramide 203-217 prolactin Homo sapiens 178-187 7069345-6 1982 These results are interpreted as evidence that the raised concentrations of prolactin characteristic of late pregnancy in the ewe are due to a reduced responsiveness of the pituitary gland to inhibitory stimuli, or to a decreased secretion of endogenous dopamine into the hypophysial portal blood system or to both. Dopamine 254-262 prolactin Homo sapiens 76-85 7097670-3 1982 The decrease of prolactin during the first 21 days of metergoline administration was compared with that in a group given bromoergocriptine (5 mg per day) and with that in a breast-binding control group. Metergoline 54-65 prolactin Homo sapiens 16-25 7141097-1 1982 To study the effect of 2-hydroxyestrone (2-OHE1) on circulating prolactin (PRL) in a hyperprolactinaemic state, seven anovulatory women with hyperprolactinaemia were given a 2-OHE1 infusion at a rate of 80 microgram/h for 3 h following a control infusion. 2-hydroxyestrone 41-47 prolactin Homo sapiens 64-73 6128096-0 1982 [Relationship between cimetidine and prolactin]. Cimetidine 22-32 prolactin Homo sapiens 37-46 7065035-0 1982 Regression of pituitary microadenoma during and following bromocriptine therapy: persistent defect in prolactin regulation before and throughout pregnancy. Bromocriptine 58-71 prolactin Homo sapiens 102-111 6283751-2 1982 The considerably increased prolactin level did not decrease postoperatively, but normalised only after a three months bromocriptine treatment. Bromocriptine 118-131 prolactin Homo sapiens 27-36 6280130-2 1982 Administered separately, naloxone was associated with a significant fall in PRL levels (p less than 0.01), a significant and unexpected rise in GH levels (p less than 0.02), and a suppression of the circadian decrease of ACTH and LPH levels. Naloxone 25-33 prolactin Homo sapiens 76-79 6807576-3 1982 The antibody-bound form of labeled prolactin was separated from the unbound form by a method based on the thiol-disulfide interchange reaction. Sulfhydryl Compounds 106-111 prolactin Homo sapiens 35-44 6807576-3 1982 The antibody-bound form of labeled prolactin was separated from the unbound form by a method based on the thiol-disulfide interchange reaction. Disulfides 112-121 prolactin Homo sapiens 35-44 6280130-3 1982 The association of naloxone with insulin-induced hypoglycemia significantly reduced the PRL peak (p less than 0.05), did not affect the rise of GH and lowered the ACTH peak, without altering the LPH peak. Naloxone 19-27 prolactin Homo sapiens 88-91 6280425-5 1982 After treatment with dexamethasone (2 mg/day for 3 days) however, prolactin concentrations were suppressed both in healthy women (-52 +/- 7%) and men (-25 +/- 11%) and in patients with adrenocortical insufficiency (-21 +/- 10%). Dexamethasone 21-34 prolactin Homo sapiens 66-75 6280425-6 1982 Thus the effect of ACTH on prolactin appeared to be mediated via enhanced cortisol secretion. Hydrocortisone 74-82 prolactin Homo sapiens 27-36 6803485-3 1982 In patients on Madopar therapy the TSH and Prl responses to TRH were greater than in unmedicated patients and comparable to those of controls, while in patients on Sinemet therapy the pituitary responses were undistinguishable from those of unmedicated subjects. benserazide, levodopa drug combination 15-22 prolactin Homo sapiens 43-46 6280425-7 1982 It is suggested that an acute increase in cortisol levels within the physiological range may modulate prolactin secretion. Hydrocortisone 42-50 prolactin Homo sapiens 102-111 7093595-0 1982 Plasma prolactin and growth hormone levels in manic patients treated with pimozide. Pimozide 74-82 prolactin Homo sapiens 7-16 6800644-16 1982 The concentration of prolactin in animals with diethylstilbestrol pellets increased with time and reached twice the value in the control animals without diethylstilbestrol pellets. Diethylstilbestrol 47-65 prolactin Homo sapiens 21-30 7093595-1 1982 During two weeks" treatment of 11 manic patients with pimozide there was close correspondence between the timecourse of improvement in clinical ratings and the rise in plasma prolactin between the second and fourteenth day. Pimozide 54-62 prolactin Homo sapiens 175-184 6800644-16 1982 The concentration of prolactin in animals with diethylstilbestrol pellets increased with time and reached twice the value in the control animals without diethylstilbestrol pellets. Diethylstilbestrol 153-171 prolactin Homo sapiens 21-30 7093595-3 1982 These findings are discussed in relation to the role of dopamine in the release of prolactin and growth hormone, and in the pathogenesis of mania. Dopamine 56-64 prolactin Homo sapiens 83-92 6800848-2 1982 A significant increase in serum prolactin as well as a significant decrease in LH were observed following the administration of morphine. Morphine 128-136 prolactin Homo sapiens 32-41 6804137-0 1982 Prolactin responsiveness to TRH and metoclopramide in thalassaemia. Metoclopramide 36-50 prolactin Homo sapiens 0-9 6800848-3 1982 It is suggested that morphine may affect a common neurotransmitter that controls both prolactin and LH secretion. Morphine 21-29 prolactin Homo sapiens 86-95 6800848-4 1982 It is also of interest that the increase in serum prolactin following morphine injection is of similar magnitude as observed in premenopausal patients. Morphine 70-78 prolactin Homo sapiens 50-59 6800849-6 1982 The low, single dose of bromocriptine per day supplied at night decreased PRL levels, but normalization of blood levels did not always occur. Bromocriptine 24-37 prolactin Homo sapiens 74-77 6978249-2 1982 To evaluate the possible involvement of prolactin in the regulation of testosterone secretion during exercise, the influence of prolactin inhibition by oral L-dopa (1 g) pretreatment was also studied. Levodopa 157-163 prolactin Homo sapiens 128-137 6978249-6 1982 Pharmacological blockade of prolactin release by L-dopa pretreatment failed to modify the response of testosterone to bicycle ergometer exercise. Levodopa 49-55 prolactin Homo sapiens 28-37 7035482-1 1982 This study examines the effect of bromocriptine therapy (2.5 mg three times daily for 4-5 days) on orthostatic increases in weight, PRA, plasma aldosterone, and PRL in patients with idiopathic edema and in normal female controls. Bromocriptine 34-47 prolactin Homo sapiens 161-164 6799535-0 1982 The effects of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects. Valproic Acid 35-51 prolactin Homo sapiens 56-65 6799535-1 1982 To find out whether the gamma-aminobutyric acid (GABA)ergic system affects PRL secretion in humans, sodium valproate (DPA or Na-dipropyl-acetate), a drug inducing increase of endogenous GABA, was administered to 20 normal and 15 hyperprolactinemic subjects. gamma-Aminobutyric Acid 49-53 prolactin Homo sapiens 75-78 6799535-2 1982 PRL circulating levels were measured by RIA in the samples obtained after acute oral treatment with 400 mg DPA. Valproic Acid 107-110 prolactin Homo sapiens 0-3 6799535-4 1982 DPA treatment also lowered blood PRL levels in hyperprolactinemic subjects (seven females) without evidence of pituitary tumor. Valproic Acid 0-3 prolactin Homo sapiens 33-36 7035482-5 1982 After metoclopramide administration, edema patients displayed normal PRA and aldosterone responses, but had exaggerated PRL responses. Metoclopramide 6-20 prolactin Homo sapiens 120-123 6799535-8 1982 They also suggest that GABA may exert an inhibitory control on PRL release in humans. gamma-Aminobutyric Acid 23-27 prolactin Homo sapiens 63-66 7035482-6 1982 After bromocriptine, the PRL, but not the PRA or aldosterone, response to metoclopramide was greatly reduced. Bromocriptine 6-19 prolactin Homo sapiens 25-28 7035482-6 1982 After bromocriptine, the PRL, but not the PRA or aldosterone, response to metoclopramide was greatly reduced. Metoclopramide 74-88 prolactin Homo sapiens 25-28 7035482-7 1982 The PRL responses to metoclopramide were similar in edema patients and controls after bromocriptine treatment. Metoclopramide 21-35 prolactin Homo sapiens 4-7 7035483-3 1982 Metoclopramide increased plasma aldosterone from 6.3 +/- 0.9 ng/dl to a maximum of 23.0 +/- 3.4 ng/dl, plasma 18-OHB from 11.4 +/- 1.1 ng/dl to a maximum level of 42.8 +/- 4.4 ng/dl, and PRL from 9.9 +/- 1.4 ng/ml to a maximum of 71.0 +/- 5.5 ng/ml. Metoclopramide 0-14 prolactin Homo sapiens 187-190 7035483-6 1982 min) begun 60 min before the administration of metoclopramide markedly decreased the 18-OHB as well as the aldosterone and PRL responses to the dopamine antagonist. Metoclopramide 47-61 prolactin Homo sapiens 123-126 7035483-6 1982 min) begun 60 min before the administration of metoclopramide markedly decreased the 18-OHB as well as the aldosterone and PRL responses to the dopamine antagonist. Dopamine 144-152 prolactin Homo sapiens 123-126 6804900-5 1982 Changes in hormonal parameters and liver function tests during bromocriptine treatment were minimal, whereas norethisterone decreased serum levels of luteinizing hormone (P less than .01), follicle-stimulating hormone (P less than .001), and progesterone (P less than .05), while increasing the serum level of prolactin (P less than .01) and gamma-glutamyltranspeptidase activity (P less than .05). Norethindrone 109-123 prolactin Homo sapiens 310-319 6806469-9 1982 In addition, bromocriptine treatment might be used to promote fertility in patients with prolactin-secreting microadenomas. Bromocriptine 13-26 prolactin Homo sapiens 89-98 7067928-2 1982 Extensive inhibition of DNA synthesis (61-78%) with hydroxyurea or cytosine arabinoside resulted in only 28-33% decrease in estrogen-induced prolactin synthesis. Hydroxyurea 52-63 prolactin Homo sapiens 141-150 7067928-2 1982 Extensive inhibition of DNA synthesis (61-78%) with hydroxyurea or cytosine arabinoside resulted in only 28-33% decrease in estrogen-induced prolactin synthesis. Cytarabine 67-87 prolactin Homo sapiens 141-150 7067928-5 1982 Estradiol treatment for corresponding periods resulted in prolactin synthesis representing 94 +/- 5, 144 +/- 11 and 270 +/- 22% of controls and prolactin mRNA levels representing 115 +/- 7, 160 +/- 7 and 322 +/- 22% of controls. Estradiol 0-9 prolactin Homo sapiens 58-67 7067928-5 1982 Estradiol treatment for corresponding periods resulted in prolactin synthesis representing 94 +/- 5, 144 +/- 11 and 270 +/- 22% of controls and prolactin mRNA levels representing 115 +/- 7, 160 +/- 7 and 322 +/- 22% of controls. Estradiol 0-9 prolactin Homo sapiens 144-153 7118395-3 1982 Insoluble trypsin has been shown to attack preferentially some peptide bonds of ovine prolactin, within the large disulfide loop. Disulfides 114-123 prolactin Homo sapiens 86-95 7066250-0 1982 Enlargement of a prolactin-secreting pituitary microadenoma during bromocriptine treatment. Bromocriptine 67-80 prolactin Homo sapiens 17-26 7066250-2 1982 A patient with prolactin-secreting pituitary microadenoma was treated with bromocriptine, 5 mg daily for 1 year. Bromocriptine 75-88 prolactin Homo sapiens 15-24 7054227-0 1982 Dynamic tests of prolactin secretion in hyperprolactinemic states: carbidopa-L-dopa and indirectly acting dopamine agonists. Dopamine 106-114 prolactin Homo sapiens 17-26 6798066-1 1982 The effects of tamoxifen and 17 beta-estradiol on the levels of FSH, PRL, and pregnancy zone protein were compared in two groups of postmenopausal women. Estradiol 29-46 prolactin Homo sapiens 69-72 6798066-6 1982 The decreases in PRL after 1 and 3 months of treatment with tamoxifen were 36% and 71%, and 19% and 31% after treatment with estradiol. Tamoxifen 60-69 prolactin Homo sapiens 17-20 6798066-6 1982 The decreases in PRL after 1 and 3 months of treatment with tamoxifen were 36% and 71%, and 19% and 31% after treatment with estradiol. Estradiol 125-134 prolactin Homo sapiens 17-20 7057390-5 1982 Effects of buprenorphine on LH and prolactin levels are more consistent with the actions of opiate agonists rather than opiate antagonists. Buprenorphine 11-24 prolactin Homo sapiens 35-44 7057390-0 1982 Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. Buprenorphine 0-13 prolactin Homo sapiens 56-65 6802684-5 1982 In addition to the dysfunction of gonadotropin secretion, the control of PRL secretion was disturbed in this disease since there was a poor PRL response to chlorpromazine in spite of normal responsiveness to TRH. Chlorpromazine 156-170 prolactin Homo sapiens 73-76 7057390-1 1982 Buprenorphine, a mixed opiate agonist-antagonist, suppressed plasma luteinizing hormone (LH) and increased prolactin levels after 12 consecutive days of ascending dose administration (0.5-8 mg/day s.c.) in comparison to drug-free control conditions. Buprenorphine 0-13 prolactin Homo sapiens 107-116 7057390-2 1982 During a subsequent 10-day period of buprenorphine maintenance at a dose of a 8 mg s.c., LH levels remained suppressed and prolactin levels continued to be elevated. Buprenorphine 37-50 prolactin Homo sapiens 123-132 7057390-3 1982 Tolerance to buprenorphine effects on LH and prolactin levels did not occur during chronic drug administration. Buprenorphine 13-26 prolactin Homo sapiens 45-54 7057390-4 1982 Buprenorphine-induced changes in plasma LH and prolactin after chronic administration to human males were smaller than those observed with less potent opiate agonist drugs. Buprenorphine 0-13 prolactin Homo sapiens 47-56 6802684-5 1982 In addition to the dysfunction of gonadotropin secretion, the control of PRL secretion was disturbed in this disease since there was a poor PRL response to chlorpromazine in spite of normal responsiveness to TRH. Chlorpromazine 156-170 prolactin Homo sapiens 140-143 7058674-0 1982 Increase in sleep related GH and Prl secretion after chronic arginine aspartate administration in man. arginine aspartate 61-79 prolactin Homo sapiens 33-36 6299050-0 1982 Plasma FSH, LH and prolactin levels in postmenopausal women undergoing cyclofenil treatment. Cyclofenil 71-81 prolactin Homo sapiens 19-28 6299050-6 1982 The results indicate that cyclofenil has two opposing actions on the hypothalamic-hypophyseal axis, one estrogen-like, in that it depresses serum FSH levels, and the other antiestrogen-like, in that it depresses serum PRL levels. Cyclofenil 26-36 prolactin Homo sapiens 218-221 7058674-5 1982 The nocturnal mean plasma Prl of each subject was higher after arginine aspartate than before. arginine aspartate 63-81 prolactin Homo sapiens 26-29 7058674-6 1982 The nocturnal rise of plasma Prl increased from a mean value of +21.5% during the placebo period to +95% at the end of the arginine aspartate treatment. arginine aspartate 123-141 prolactin Homo sapiens 29-32 6818826-7 1982 Furthermore, the low prolactin and LH levels despite a low estradiol-17 beta concentration may suggest an increased hypothalamic dopamine activity in patients with diabetes mellitus and secondary amenorrhea. Dopamine 129-137 prolactin Homo sapiens 21-30 6810655-1 1982 The effect of long-term cimetidine treatment for 6 months on basal and thyrotropin-releasing hormone (TRH)-stimulated prolactin (PRL) and thyroid-stimulating hormone (TSH) secretion was studied in eight male patients with duodenal ulcer. Cimetidine 24-34 prolactin Homo sapiens 118-127 6124090-7 1982 The occasional increase in serum PRL levels found in patients treated with lithium or the MAO inhibitor phenelzine are suggestive of important interindividual differences which may be revealed by neuroendocrine studies, differences which could be valuable in understanding the mechanism of action of these agents - e.g., does lithium decrease DA receptor sensitivity? Lithium 75-82 prolactin Homo sapiens 33-36 7158435-7 1982 During bromocriptine treatment, serum prolactin levels normalized in all but one patient. Bromocriptine 7-20 prolactin Homo sapiens 38-47 6124090-3 1982 At one end of the spectrum, the ability of nomifensine and buproprion to lower serum PRL levels, presumably due to their ability to block the reuptake of DA by tuberoinfundibular DA neurons, suggests that it may be necessary to reconsider the conclusion that these neurons lack a DA reuptake mechanism or that these two agents are antidepressant by virtue of their ability to block DA uptake. Nomifensine 43-54 prolactin Homo sapiens 85-88 6124090-7 1982 The occasional increase in serum PRL levels found in patients treated with lithium or the MAO inhibitor phenelzine are suggestive of important interindividual differences which may be revealed by neuroendocrine studies, differences which could be valuable in understanding the mechanism of action of these agents - e.g., does lithium decrease DA receptor sensitivity? Phenelzine 104-114 prolactin Homo sapiens 33-36 6124090-7 1982 The occasional increase in serum PRL levels found in patients treated with lithium or the MAO inhibitor phenelzine are suggestive of important interindividual differences which may be revealed by neuroendocrine studies, differences which could be valuable in understanding the mechanism of action of these agents - e.g., does lithium decrease DA receptor sensitivity? Lithium 326-333 prolactin Homo sapiens 33-36 6124090-3 1982 At one end of the spectrum, the ability of nomifensine and buproprion to lower serum PRL levels, presumably due to their ability to block the reuptake of DA by tuberoinfundibular DA neurons, suggests that it may be necessary to reconsider the conclusion that these neurons lack a DA reuptake mechanism or that these two agents are antidepressant by virtue of their ability to block DA uptake. buproprion 59-69 prolactin Homo sapiens 85-88 6124090-10 1982 It is likely that such studies will enrich our understanding of how these agents work, of the difference between agents which have been classed together on the basis of preclinical studies (e.g., DMI, which appears to increase PRL and GH, and NT which appears not to) and provided additional evidence to test current hypotheses about the biological basis of their antidepressant action. Desipramine 196-199 prolactin Homo sapiens 227-230 6959515-0 1982 Tics and serum prolactin response to pimozide in Tourette syndrome. Pimozide 37-45 prolactin Homo sapiens 15-24 7065590-6 1982 Bromocriptine can reduce the size of large prolactin-secreting adenomas, and is probably a better choice than surgery because of the high failure rate of trans-sphenoid operations in the case of macroadenomas, Long-term results of these two therapeutic procedures have still to be evaluated. Bromocriptine 0-13 prolactin Homo sapiens 43-52 7065592-0 1982 [Radiological control of prolactin adenomas treated with bromocriptine]. Bromocriptine 57-70 prolactin Homo sapiens 25-34 7171172-0 1982 Possible involvement of prolactin in sulpiride-induced changes in nigral and striatal GAD activity. Sulpiride 37-46 prolactin Homo sapiens 24-33 6797361-1 1982 A 25-year-old man with hypogonadotropic hypogonadism and elevated prolactin levels, presumably from a microadenoma of the pituitary gland, was treated with bromocriptine mesylate. Bromocriptine 156-178 prolactin Homo sapiens 66-75 6797361-5 1982 Within two weeks of re-treatment with bromocriptine, the prolactin level had fallen and both testosterone and gonadotropin levels rose. Bromocriptine 38-51 prolactin Homo sapiens 57-66 7184490-1 1982 In 44 patients with acute renal failure serum prolactin levels were estimated using chloropromazine as a stimulant and alfa-bromocriptine as an inhibitory agent. Chlorpromazine 84-99 prolactin Homo sapiens 46-55 6805485-2 1982 The effect of N-(2-diethylaminoethyl)-2-methoxy-5-(methylsulfonyl)-benzamide hydrochloride (tiapride, Tiapridex), a dopamine antagonist, on the serum levels of prolactin, luteinising hormone (LH) and follicle-stimulating hormone (FSH) was studied on 20 healthy individuals and 10 patients with dyskinesia resulting from extrapyramidal disorders. n-(2-diethylaminoethyl)-2-methoxy-5-(methylsulfonyl)-benzamide hydrochloride 14-90 prolactin Homo sapiens 160-169 7184490-1 1982 In 44 patients with acute renal failure serum prolactin levels were estimated using chloropromazine as a stimulant and alfa-bromocriptine as an inhibitory agent. alfa-bromocriptine 119-137 prolactin Homo sapiens 46-55 7184490-4 1982 administration of chloropromazine markedly increased serum prolactin concentrations. Chlorpromazine 18-33 prolactin Homo sapiens 59-68 7184490-5 1982 In patients with ARF the apparent half life of prolactin, calculated from the prolactin curve obtained after alfa-bromocriptine administration, was moderately longer than in normals. alfa-bromocriptine 109-127 prolactin Homo sapiens 47-56 7184490-5 1982 In patients with ARF the apparent half life of prolactin, calculated from the prolactin curve obtained after alfa-bromocriptine administration, was moderately longer than in normals. alfa-bromocriptine 109-127 prolactin Homo sapiens 78-87 7184490-9 1982 In patients with ARF prolactin secretion is hyperresponsive to intramuscularly administered chloropromazine. Chlorpromazine 92-107 prolactin Homo sapiens 21-30 6127069-7 1982 The use of 3-iodo-L-tyrosine to block brain DA synthesis in these studies has provided significant new data relating to prolactin control in hyperprolactinaemic states and indicates that this compound could be a useful clinical tool in the study of human hyperprolactinaemia. 3-iodotyrosine 11-28 prolactin Homo sapiens 120-129 6762263-8 1982 Plasma PRL levels resulted significantly higher in sulpiride treated groups than in placebo group. Sulpiride 51-60 prolactin Homo sapiens 7-10 7074974-0 1982 Histidyl-proline diketopiperazine suppresses prolactin secretion in human pituitary tumour cell cultures. histidyl-proline diketopiperazine 0-33 prolactin Homo sapiens 45-54 7168914-0 1982 Prolactin-secreting pituitary adenoma: occurrence following prenatal exposure to diethylstilbestrol. Diethylstilbestrol 81-99 prolactin Homo sapiens 0-9 6819897-5 1982 There was a statistically significative negative correlation between PRL and 17-beta-E2. 17-beta-e2 77-87 prolactin Homo sapiens 69-72 6809476-2 1982 Pretreatment with naloxone 0.8 mg increased TRH-induced TSH and PRL release in six healthy subjects. Naloxone 18-26 prolactin Homo sapiens 64-67 7053988-0 1982 Estradiol inhibits prolactin induced alpha-lactalbumin production in normal primate mammary tissue in vitro. Estradiol 0-9 prolactin Homo sapiens 19-28 7053988-1 1982 The effect of estradiol on prolactin induced alpha-lactalbumin production in normal primate mammary tissue was studied by maintaining tissues in organ culture with or without various combinations of oPRL and 17 beta-estradiol. Estradiol 14-23 prolactin Homo sapiens 27-36 7053988-4 1982 By 9 days in culture estradiol (10(-11) M) caused a mean 31% inhibition of prolactin-induced alpha-lactalbumin; with estradiol (10(-8) M) the inhibition was 40%. Estradiol 21-30 prolactin Homo sapiens 75-84 6809476-3 1982 The same pretreatment caused an enhancement of haloperidol-induced PRL secretion in further other group of six subjects. Haloperidol 47-58 prolactin Homo sapiens 67-70 6820778-0 1982 [Prolactin secretion in patients with diabetes mellitus - TRH or bromocriptine function tests]. Bromocriptine 65-78 prolactin Homo sapiens 1-10 7094872-3 1982 Very significant changes in GAD activity were only observed with sulpiride and nomifensine, two atypical antidepressants that selectively influence dopaminergic transmission and, in turn, prolactin secretion. Sulpiride 65-74 prolactin Homo sapiens 188-197 7118381-1 1982 The thermal denaturation of human choriomammotropin and ovine prolactin in 0.1 m tris-Cl buffer, pH 8.2, is a simple endothermic process which is at least partially reversible, and does not produce coagulation of the proteins. tris-cl 81-88 prolactin Homo sapiens 62-71 7094872-3 1982 Very significant changes in GAD activity were only observed with sulpiride and nomifensine, two atypical antidepressants that selectively influence dopaminergic transmission and, in turn, prolactin secretion. Nomifensine 79-90 prolactin Homo sapiens 188-197 7035305-7 1982 Metergoline normalized serum PRL levels (less than 20 ng/ml) in 46 cases and significantly reduced serum PRL levels in all but 3 of the remaining patients. Metergoline 0-11 prolactin Homo sapiens 29-32 7035305-7 1982 Metergoline normalized serum PRL levels (less than 20 ng/ml) in 46 cases and significantly reduced serum PRL levels in all but 3 of the remaining patients. Metergoline 0-11 prolactin Homo sapiens 105-108 6807859-4 1982 Although L-dopa suppresses prolactin normally, the ability of thyrotropin releasing hormone (TRH) to stimulate the release of prolactin and thyroid stimulating hormone (TSH) is blunted. Levodopa 9-15 prolactin Homo sapiens 27-36 6807859-6 1982 The response to chlorpromazine, a hypothalamic stimulus for prolactin secretion, is also blunted, and to a greater extent than the prolactin response to TRH. Chlorpromazine 16-30 prolactin Homo sapiens 60-69 7152714-0 1982 Effects of sulpiride treatment on plasma prolactin and steroid hormones in early human pregnancy. Sulpiride 11-20 prolactin Homo sapiens 41-50 7057118-3 1982 Explants incubated in calcium-deficient medium secreted 64 +/- 8% (P less than or equal to 0.001) less prolactin than controls (1.65 mmol Ca2+/1). Calcium 22-29 prolactin Homo sapiens 103-112 6889585-0 1982 The serum levels of testosterone and prolactin in patients with prostatic carcinoma treated with various doses of Fostrolin and bromocriptin. Bromocriptine 128-140 prolactin Homo sapiens 37-46 6889585-4 1982 Small doses of Fostrolin, however, caused a drop in T and PRL levels. fosfestrol 15-24 prolactin Homo sapiens 58-61 6889585-6 1982 Reduction of T concentration below castration level and attainment of trace PRL levels in response to small doses of Fostrolin and bromocriptin had a favourable effect on the clinical course of the malignant disease. fosfestrol 117-126 prolactin Homo sapiens 76-79 6889585-6 1982 Reduction of T concentration below castration level and attainment of trace PRL levels in response to small doses of Fostrolin and bromocriptin had a favourable effect on the clinical course of the malignant disease. Bromocriptine 131-143 prolactin Homo sapiens 76-79 7033264-0 1982 Influence of sodium homeostasis on dopaminergic modulation of aldosterone, renin, and prolactin secretion in man. Sodium 13-19 prolactin Homo sapiens 86-95 7057118-8 1982 Calcium, however, is essential for the basal secretion of decidual prolactin. Calcium 0-7 prolactin Homo sapiens 67-76 6808052-0 1982 Muscarinic receptor blockade by pirenzepine: effect on prolactin secretion in man. Pirenzepine 32-43 prolactin Homo sapiens 55-64 7108512-1 1982 Domperidone, a peripheral dopamine (DA) receptor blocker which poorly crosses the blood-brain barrier and which is inactive towards dopamine-sensitive adenylate cyclase, in a dose (100 micrograms/kg) sufficient to increase serum prolactin levels at least 5-fold, decreased the growth hormone (GH) response to the DA receptor agonist, apomorphine HCI (Apo) (0.5 gm s.c.) in each of six normal men examined. Domperidone 0-11 prolactin Homo sapiens 229-238 6808052-1 1982 The effect of pirenzepine, a muscarinic receptor blocker which does not cross the blood brain barrier, on basal and TRH-stimulated prolactin (PRL) secretion in normal subjects was studied. Pirenzepine 14-25 prolactin Homo sapiens 131-140 6808052-2 1982 Administration of 75 mg oral pirenzepine had no effects on prolactin levels in male subjects whereas it significantly reduced prolactin in females. Pirenzepine 29-40 prolactin Homo sapiens 126-135 6278076-6 1982 However, prolactin levels were significantly lower in the Parkinsonian patients treated with levodopa versus the untreated group. Levodopa 93-101 prolactin Homo sapiens 9-18 7043324-0 1982 [Cyclofenil inhibits the secretion and release of prolactin in the puerperium]. Cyclofenil 1-11 prolactin Homo sapiens 50-59 6804685-6 1982 A negative correlation was found between plasma prolactin and testosterone, and a positive one was found between prolactin and estradiol at the AOP of ARF. Testosterone 62-74 prolactin Homo sapiens 48-57 7078703-1 1982 Bromocriptine treatment of patients with invasive prolactin (PRL)-secreting pituitary adenomas does not invariably result in normalization of the plasma PRL levels. Bromocriptine 0-13 prolactin Homo sapiens 50-59 7078703-1 1982 Bromocriptine treatment of patients with invasive prolactin (PRL)-secreting pituitary adenomas does not invariably result in normalization of the plasma PRL levels. Bromocriptine 0-13 prolactin Homo sapiens 61-64 7078703-3 1982 In 8 patients with invasive PRL-secreting pituitary adenomas with extrasellar extension, the effect of the administration of tamoxifen was investigated on the plasma PRL concentration and on the bromocriptine-mediated inhibition of PRL release. Tamoxifen 125-134 prolactin Homo sapiens 166-169 7078703-3 1982 In 8 patients with invasive PRL-secreting pituitary adenomas with extrasellar extension, the effect of the administration of tamoxifen was investigated on the plasma PRL concentration and on the bromocriptine-mediated inhibition of PRL release. Tamoxifen 125-134 prolactin Homo sapiens 166-169 7078703-4 1982 Treatment for 5 days with tamoxifen (20 mg/day) suppressed plasma PRL levels as measured in 5 samples over the day significantly by 20 +/- 3% (means +/- SEM; p less than 0.01). Tamoxifen 26-35 prolactin Homo sapiens 66-69 7078703-5 1982 During tamoxifen administration the inhibition of PRL secretion by 2.5 mg bromocriptine was further suppressed by 36 +/- 7%, in comparison with the plasma PRL levels after bromocriptine alone (p less than 0.01). Tamoxifen 7-16 prolactin Homo sapiens 50-53 7078703-5 1982 During tamoxifen administration the inhibition of PRL secretion by 2.5 mg bromocriptine was further suppressed by 36 +/- 7%, in comparison with the plasma PRL levels after bromocriptine alone (p less than 0.01). Bromocriptine 74-87 prolactin Homo sapiens 50-53 7078703-5 1982 During tamoxifen administration the inhibition of PRL secretion by 2.5 mg bromocriptine was further suppressed by 36 +/- 7%, in comparison with the plasma PRL levels after bromocriptine alone (p less than 0.01). Bromocriptine 172-185 prolactin Homo sapiens 50-53 7078703-6 1982 Tamoxifen administration suppressed PRL release in patients with giant invasive PRL-secreting pituitary adenomas, and it had a slight but significant additive or potentiating effect on the bromocriptine-mediated inhibition of PRL secretion. Tamoxifen 0-9 prolactin Homo sapiens 36-39 7078703-6 1982 Tamoxifen administration suppressed PRL release in patients with giant invasive PRL-secreting pituitary adenomas, and it had a slight but significant additive or potentiating effect on the bromocriptine-mediated inhibition of PRL secretion. Tamoxifen 0-9 prolactin Homo sapiens 80-83 7078703-6 1982 Tamoxifen administration suppressed PRL release in patients with giant invasive PRL-secreting pituitary adenomas, and it had a slight but significant additive or potentiating effect on the bromocriptine-mediated inhibition of PRL secretion. Tamoxifen 0-9 prolactin Homo sapiens 80-83 7078703-7 1982 However, despite the simultaneous administration of bromocriptine and tamoxifen, normalization of the circulating PRL levels was not reached in this type of patient. Bromocriptine 52-65 prolactin Homo sapiens 114-117 7070643-0 1982 Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson"s disease. Levodopa 56-62 prolactin Homo sapiens 0-9 7070643-2 1982 PRL increase after benserazide was compared with PRL response after carbidopa at the same dosage in untreated parkinsonian patients. Benserazide 19-30 prolactin Homo sapiens 0-3 7133375-4 1982 Trazodone enhances the prolactin value, increasing chiefly the titres during sleep which were lower in respect to controls before treatment. Trazodone 0-9 prolactin Homo sapiens 23-32 6223322-2 1982 Evidence for autoreceptors on the tuberoinfundibular dopamine neurones which participate in the regulation of prolactin and growth hormone secretion is lacking. Dopamine 53-61 prolactin Homo sapiens 110-119 7201645-4 1982 Serum prolactin levels were within normal limits without treatment and were significantly reduced by bromocriptine. Bromocriptine 101-114 prolactin Homo sapiens 6-15 6805007-0 1982 Prolactin response following intravenous and oral sulpiride in healthy human subjects in relation to sulpiride concentrations. Sulpiride 50-59 prolactin Homo sapiens 0-9 6805007-0 1982 Prolactin response following intravenous and oral sulpiride in healthy human subjects in relation to sulpiride concentrations. Sulpiride 101-110 prolactin Homo sapiens 0-9 6805007-2 1982 Serum concentrations of sulpiride and prolactin were followed for 36 h. Both routes of drug administration resulted in a pronounced and sustained increase in serum prolactin concentration. Sulpiride 24-33 prolactin Homo sapiens 164-173 6805007-6 1982 The sustained prolactin elevation may be due to high affinity and strong binding of the compound to the regulating receptors or the formation of an active sulpiride metabolite. Sulpiride 155-164 prolactin Homo sapiens 14-23 6805007-7 1982 Prolactin and sulpiride concentrations were significantly correlated during the initial phase after intravenous sulpiride. Sulpiride 112-121 prolactin Homo sapiens 0-9 6805007-8 1982 Following intravenous and oral sulpiride the area under the concentration-time curve (AUC) for prolactin was similar despite a considerable difference in the sulpiride concentration. Sulpiride 31-40 prolactin Homo sapiens 95-104 6812112-2 1982 Apomorphine chloride (AP) (0.18-0.24 mg IV) induced stimulation of growth hormone (GH) and suppression of prolactin (PRL), as shown 2-3 days before and after ECT in mentally depressed patients (N = 12) and therapy-resistant parkinsonian patients with on-off phenomena (N = 9). Apomorphine 0-20 prolactin Homo sapiens 106-115 6812112-2 1982 Apomorphine chloride (AP) (0.18-0.24 mg IV) induced stimulation of growth hormone (GH) and suppression of prolactin (PRL), as shown 2-3 days before and after ECT in mentally depressed patients (N = 12) and therapy-resistant parkinsonian patients with on-off phenomena (N = 9). Apomorphine 0-20 prolactin Homo sapiens 117-120 6812143-0 1982 The effect of intravenous L-tryptophan on prolactin and growth hormone and mood in healthy subjects. Tryptophan 26-38 prolactin Homo sapiens 42-51 6812143-2 1982 The TRP infusion induced robust increases in PRL in all ten subjects. Tryptophan 4-7 prolactin Homo sapiens 45-48 6812143-5 1982 These findings indicate an important role for serotonin in PRL and GH secretion, as well as in mood regulation. Serotonin 46-55 prolactin Homo sapiens 59-62 6815695-2 1982 The TRP infusion induced robust increases in PRL in all ten subjects. Tryptophan 4-7 prolactin Homo sapiens 45-48 6815695-5 1982 These findings indicate an important role for serotonin in PRL and GH secretion, as well as in mood regulation. Serotonin 46-55 prolactin Homo sapiens 59-62 6818584-0 1982 Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients. Amoxapine 33-42 prolactin Homo sapiens 0-9 6818584-0 1982 Prolactin stimulating effects of amoxapine and loxapine in psychiatric patients. Loxapine 47-55 prolactin Homo sapiens 0-9 6818584-1 1982 The effects of acute and chronic administration of a new antidepressant, amoxapine, on serum prolactin levels were compared to the effects of loxapine, its parent compound, which is a widely used neuroleptic. Amoxapine 73-82 prolactin Homo sapiens 93-102 6818584-2 1982 Serum prolactin levels were significantly elevated after amoxapine. Amoxapine 57-66 prolactin Homo sapiens 6-15 6891082-3 1982 Behavioral excitation in response to amphetamine was highly correlated in monozygotic twins; it was predicted by the baseline variables of high plasma MHPG, low serum prolactin and low pulse; it correlated with a rise in cortisol; and it was not correlated with plasma amphetamine level. Amphetamine 37-48 prolactin Homo sapiens 167-176 6891082-4 1982 Pre-infusion baseline MHPG and growth hormone and prolactin responses to amphetamine also were concordant in twins. Amphetamine 73-84 prolactin Homo sapiens 50-59 7178369-6 1982 Prolactin secretion after administration of diazepam (10 mg i.v.) Diazepam 44-52 prolactin Homo sapiens 0-9 7329205-0 1981 Naltrexone partially inhibits the estrogen-induced increase in prolactin secretion and anterior pituitary weight. Naltrexone 0-10 prolactin Homo sapiens 63-72 6802092-2 1981 Oral administration of 20 mg domperidone was followed by marked increase in serum PRL in all subjects; the response, being significantly greater in women as compared to men, was maintained in patients with autonomous goiter. Domperidone 29-40 prolactin Homo sapiens 82-85 6802092-3 1981 The PRL response after oral domperidone was significantly greater than after 200 micrograms TRH intravenously. Domperidone 28-39 prolactin Homo sapiens 4-7 6802092-4 1981 The PRL response obtained with oral domperidone followed by 200 microgram TRH i.v. Domperidone 36-47 prolactin Homo sapiens 4-7 6802092-7 1981 The data of the present study suggest that dopamine blockade at pituitary (or median eminence) level is able to stimulate maximally the lactotrophs and emphasize the important role of the dopaminergic system in the interrelated regulation of TSH and PRL secretion at the pituitary level. Dopamine 43-51 prolactin Homo sapiens 250-253 7340823-6 1981 Prolactin could be adsorbed to phenyl-Sepharose at low ionic strengths (I<0.01); few other proteins were adsorbed under these conditions. phenyl-sepharose 31-47 prolactin Homo sapiens 0-9 7340823-8 1981 The amount of phenyl-Sepharose was limited to the minimum (35mg of protein/g of phenyl-Sepharose) necessary to adsorb human prolactin, further reducing the uptake of other pituitary protein. phenyl-sepharose 14-30 prolactin Homo sapiens 124-133 7340823-8 1981 The amount of phenyl-Sepharose was limited to the minimum (35mg of protein/g of phenyl-Sepharose) necessary to adsorb human prolactin, further reducing the uptake of other pituitary protein. phenyl-sepharose 80-96 prolactin Homo sapiens 124-133 7340823-9 1981 Desorption was achieved by using an acetonitrile gradient (0-30%, v/v), resulting in a purification of human prolactin of 85-fold and recovery of 78%. acetonitrile 36-48 prolactin Homo sapiens 109-118 7340823-10 1981 Acetonitrile (20%, v/v) was also included in all buffers for DEAE-cellulose chromatography, increasing the resolution and recovery of human prolactin, apparently by minimizing non-ionic interactions with the matrix. acetonitrile 0-12 prolactin Homo sapiens 140-149 7340823-10 1981 Acetonitrile (20%, v/v) was also included in all buffers for DEAE-cellulose chromatography, increasing the resolution and recovery of human prolactin, apparently by minimizing non-ionic interactions with the matrix. DEAE-Cellulose 61-75 prolactin Homo sapiens 140-149 6803821-0 1981 Effect of long-term treatment with sodium valproate on gonadotrophin and prolactin secretion in paediatric patients. Valproic Acid 35-51 prolactin Homo sapiens 73-82 6276054-3 1981 Ranitidine (100 and 200 mg) and cimetidine (300 mg) caused a significant increase in PRL secretion, whereas saline and ranitidine (50 mg) did not. Ranitidine 0-10 prolactin Homo sapiens 85-88 6276054-3 1981 Ranitidine (100 and 200 mg) and cimetidine (300 mg) caused a significant increase in PRL secretion, whereas saline and ranitidine (50 mg) did not. Cimetidine 32-42 prolactin Homo sapiens 85-88 6276054-5 1981 A dose-response relationship between ranitidine and PRL was established, and a dose of 65 mg ranitidine was found to be the minimal effective PRL-releasing dose. Ranitidine 37-47 prolactin Homo sapiens 52-55 6276054-5 1981 A dose-response relationship between ranitidine and PRL was established, and a dose of 65 mg ranitidine was found to be the minimal effective PRL-releasing dose. Ranitidine 93-103 prolactin Homo sapiens 142-145 6276054-8 1981 Histamine, therefore, may play a role in the regulation of PRL secretion. Histamine 0-9 prolactin Homo sapiens 59-62 6796443-0 1981 Changes of prolactin secretion following long-term danazol application. Danazol 51-58 prolactin Homo sapiens 11-20 6796443-5 1981 Basal and stimulated serum prolactin levels, measured during the luteal phase of the control cycle preceding danazol application, decreased continuously, reaching serum concentrations seen during the early follicular phase of the cycle. Danazol 109-116 prolactin Homo sapiens 27-36 7308513-5 1981 The release of prolactin to AS was blunted by higher-dose of opioid and by dopamine antagonists. Dopamine 75-83 prolactin Homo sapiens 15-24 7308514-1 1981 Eight consecutive patients with large prolactinomas, as assessed by elevated serum prolactin concentrations and suprasellar extension of the visualized pituitary adenoma on computerized tomographic (CT) scanning, were treated with bromocriptine. Bromocriptine 231-244 prolactin Homo sapiens 38-47 7033092-2 1981 The present study examines intravenous glucose tolerance in six subjects with prolactin secretion pituitary adenomas. Glucose 39-46 prolactin Homo sapiens 78-87 7033092-3 1981 Testing was performed in each individual both in the untreated high prolactin state and again after prolactin was reduced by bromocriptine treatment for three months. Bromocriptine 125-138 prolactin Homo sapiens 100-109 7319468-5 1981 A significant positive correlation between oestradiol and prolactin was found in patients and normals, but with larger prolactin levels in patients. Estradiol 43-53 prolactin Homo sapiens 58-67 7319468-5 1981 A significant positive correlation between oestradiol and prolactin was found in patients and normals, but with larger prolactin levels in patients. Estradiol 43-53 prolactin Homo sapiens 119-128 7319468-6 1981 The results point towards a prolactin secretory hypersensitivity for oestradiol in patients with cyclical mastalgia. Estradiol 69-79 prolactin Homo sapiens 28-37 7298805-1 1981 It has recently been proposed that nomifensine (Nom) administration discriminates those patients with PRL-secreting pituitary tumors from those who have hyperprolactinemia due to other causes. Nomifensine 35-46 prolactin Homo sapiens 102-105 6799603-7 1981 A positive correlation has been demonstrated in young men between melatonin and LH and between melatonin and prolactin, but no such correlation could be found in the elderly. Melatonin 95-104 prolactin Homo sapiens 109-118 7334406-0 1981 Growth hormone and prolactin stimulation by Madopar in Parkinson"s disease. benserazide, levodopa drug combination 44-51 prolactin Homo sapiens 19-28 7334406-3 1981 Madopar increased plasma prolactin (PRL) in controls, unmedicated patients and patients on Madopar therapy while in patients on Sinemet therapy the PRL-releasing effect of Madopar was strikingly reduced. benserazide, levodopa drug combination 0-7 prolactin Homo sapiens 25-34 7334406-3 1981 Madopar increased plasma prolactin (PRL) in controls, unmedicated patients and patients on Madopar therapy while in patients on Sinemet therapy the PRL-releasing effect of Madopar was strikingly reduced. benserazide, levodopa drug combination 0-7 prolactin Homo sapiens 36-39 7339271-0 1981 Interaction of prolactin, estrogen and progesterone in a human mammary carcinoma cell line, CAMA-1 - I Cell growth and thymidine uptake. Thymidine 119-128 prolactin Homo sapiens 15-24 7198792-0 1981 Suppression by naloxone of rise in plasma growth hormone and prolactin induced by sucking. Naloxone 15-23 prolactin Homo sapiens 61-70 7323251-0 1981 Growth hormone and prolactin secretion in adults and hyperactive children: relation to methylphenidate serum levels. Methylphenidate 87-102 prolactin Homo sapiens 19-28 6119229-0 1981 Phenothiazines inhibit prolactin secretion in vitro. Phenothiazines 0-14 prolactin Homo sapiens 23-32 7313648-10 1981 In contrast, bromocriptine therapy led, in the majority of patients, not only to improvement of hypogonadal symptoms but also to normalization of PRL levels. Bromocriptine 13-26 prolactin Homo sapiens 146-149 6270576-0 1981 Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. ergocryptine 52-64 prolactin Homo sapiens 34-43 6270576-0 1981 Transcriptional regulation of the prolactin gene by ergocryptine and cyclic AMP. Cyclic AMP 69-79 prolactin Homo sapiens 34-43 7033836-4 1981 PRL secretion was increased by D-sulpiride in a dose-dependent way, while insulin secretion was lowered and GH secretion slightly enhanced only in a restricted range of doses (6 mg and 12 mg i.v., respectively). d-sulpiride 31-42 prolactin Homo sapiens 0-3 6126066-2 1981 In both men and women there tended to be a significant correlation between the initial log plasma PRL level while on neuroleptic maintenance treatment and the dosage received converted to chlorpromazine equivalents. Chlorpromazine 188-202 prolactin Homo sapiens 98-101 6126066-4 1981 Switching to chlorpromazine 900 mg/day (16 cases) produced either increases or decreases in PRL plasma levels that were significantly correlated with the change in neuroleptic dosage converted to chlorpromazine equivalents. Chlorpromazine 13-27 prolactin Homo sapiens 92-95 6126066-4 1981 Switching to chlorpromazine 900 mg/day (16 cases) produced either increases or decreases in PRL plasma levels that were significantly correlated with the change in neuroleptic dosage converted to chlorpromazine equivalents. Chlorpromazine 196-210 prolactin Homo sapiens 92-95 7293665-0 1981 Effects of bromocriptine-induced pregnancy on prolactin-secreting pituitary tumours. Bromocriptine 11-24 prolactin Homo sapiens 46-55 7293666-0 1981 Inhibitory effect of calcium on serum prolactin. Calcium 21-28 prolactin Homo sapiens 38-47 7293666-4 1981 It is speculated that the inhibitory effect of Ca infusion or serum Prl may be due to dopamine release from nerve tracts in the hypothalamus. Dopamine 86-94 prolactin Homo sapiens 68-71 6120731-1 1981 Plasma prolactin response to haloperidol challenge. Haloperidol 29-40 prolactin Homo sapiens 7-16 6120731-2 1981 The plasma prolactin (PRL) response to haloperidol 2 or 4 mg i.m. Haloperidol 39-50 prolactin Homo sapiens 11-20 6120732-6 1981 Prolactin increment was higher following TRH than haloperidol challenge. Haloperidol 50-61 prolactin Homo sapiens 0-9 6120733-2 1981 Plasma growth hormone and prolactin responses to apomorphine. Apomorphine 49-60 prolactin Homo sapiens 26-35 6120733-9 1981 The absolute decline in plasma PRL following apomorphine correlated positively with the baseline PRL concentration and was unrelated to the daily doses of neuroleptics or to any other variable considered. Apomorphine 45-56 prolactin Homo sapiens 31-34 6120733-9 1981 The absolute decline in plasma PRL following apomorphine correlated positively with the baseline PRL concentration and was unrelated to the daily doses of neuroleptics or to any other variable considered. Apomorphine 45-56 prolactin Homo sapiens 97-100 6799231-0 1981 Effect of cimetidine on serum prolactin in normal women and patients with hyperprolactinaemia. Cimetidine 10-20 prolactin Homo sapiens 30-39 7078703-0 1982 Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Tamoxifen 10-19 prolactin Homo sapiens 38-47 7078703-0 1982 Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Tamoxifen 10-19 prolactin Homo sapiens 68-77 7197286-8 1981 The PRL response to metoclopramide in women with spontaneous disease was significantly smaller than that in controls (194 +/- 39% vs. 446 +/- 40%; P less than 0.001) and inversely correlated with basal PRL levels (r = -0.55; P less than 0.05). Metoclopramide 20-34 prolactin Homo sapiens 4-7 7197286-8 1981 The PRL response to metoclopramide in women with spontaneous disease was significantly smaller than that in controls (194 +/- 39% vs. 446 +/- 40%; P less than 0.001) and inversely correlated with basal PRL levels (r = -0.55; P less than 0.05). Metoclopramide 20-34 prolactin Homo sapiens 202-205 7287876-0 1981 Stimulatory effect of chlorpromazine on prolactin secretion in anencephalic infants. Chlorpromazine 22-36 prolactin Homo sapiens 40-49 7287876-1 1981 The effect of chlorpromazine on serum levels of PRL was studied in two anencephalic infants without identifiable hypothalamic tissue. Chlorpromazine 14-28 prolactin Homo sapiens 48-51 7287876-2 1981 After a single im injection of chlorpromazine, serum concentrations of PRL rose about 3-fold. Chlorpromazine 31-45 prolactin Homo sapiens 71-74 7287876-3 1981 This result indicates that chlorpromazine stimulates PRL release by directly acting on the pituitary gland in humans. Chlorpromazine 27-41 prolactin Homo sapiens 53-56 6795296-0 1981 Evidence for the involvement of hypothalamic dopamine and thyrotrophin-releasing hormone in suckling-induced release of prolactin. Dopamine 45-53 prolactin Homo sapiens 120-129 7301051-0 1981 Effect of two indirectly acting dopamine agonists on prolactin secretion in normo- and hyperprolactinemic subjects: comparison with the effect of nomifensine. Dopamine 32-40 prolactin Homo sapiens 53-62 6799231-1 1981 In normal women, intravenous injection of the H2-antihistamine, cimetidine, provoked a 3-4 fold rise in serum prolactin, without changes in serum growth hormone, thyrotrophin, or gonadotrophins. h2-antihistamine 46-62 prolactin Homo sapiens 110-119 6799231-1 1981 In normal women, intravenous injection of the H2-antihistamine, cimetidine, provoked a 3-4 fold rise in serum prolactin, without changes in serum growth hormone, thyrotrophin, or gonadotrophins. Cimetidine 64-74 prolactin Homo sapiens 110-119 6799231-3 1981 Post-partum women also demonstrated blunted percentage prolactin responses to cimetidine, although responses to TRH were, in most patients, normal. Cimetidine 78-88 prolactin Homo sapiens 55-64 6171291-0 1981 The use of a heptadeoxyribonucleotide as a specific primer for prolactin mRNA: a prediction of ambiguous RNA splicing. heptadeoxyribonucleotide 13-37 prolactin Homo sapiens 63-72 7197648-0 1981 Bromocriptine compared to long-acting estrogens in lactation prevention: clinical efficacy, prolactin secretion and coagulation parameters. Bromocriptine 0-13 prolactin Homo sapiens 92-101 6797817-1 1981 The effects of acute TRH and cimetidine administration on the plasma prolactin (PRL) response have been studied in cirrhotic patients with impaired glucose tolerance (IGT). Cimetidine 29-39 prolactin Homo sapiens 69-78 6797817-1 1981 The effects of acute TRH and cimetidine administration on the plasma prolactin (PRL) response have been studied in cirrhotic patients with impaired glucose tolerance (IGT). Cimetidine 29-39 prolactin Homo sapiens 80-83 7197648-6 1981 In the patients in whom the administration of bromocriptine was withdrawn after 15 days, a significant mean rebound elevation of hPRL levels above the normal range occurred on the 17th day. Bromocriptine 46-59 prolactin Homo sapiens 129-133 7278648-0 1981 Suppression of prolactin and growth hormone responses to 2-deoxy-D-glucose-induced glucoprivation by mazindol in humans. Deoxyglucose 57-74 prolactin Homo sapiens 15-24 6796631-7 1981 The basal levels of FSH and LH significantly increased but the basal levels of Prolactin decreased by Bromocriptine. Bromocriptine 102-115 prolactin Homo sapiens 79-88 7278648-0 1981 Suppression of prolactin and growth hormone responses to 2-deoxy-D-glucose-induced glucoprivation by mazindol in humans. Mazindol 101-109 prolactin Homo sapiens 15-24 6810204-3 1981 Levodopa elicited a normal suppression of prolactin concentrations in parkinsonian subjects; the major abnormality to emerge was attenuation of the response to thyrotropin-releasing hormone (TRH) in the parkinsonian patients following administration of Sinemet (levodopa plus carbidopa) or bromocriptine. Levodopa 0-8 prolactin Homo sapiens 42-51 7278648-1 1981 Glucoprivation induced by 2-deoxy-D-glucose (2DG) 20 min infusions (50 mg/kg) increases growth hormone (GH) and prolactin (PRL) levels in humans. Deoxyglucose 26-43 prolactin Homo sapiens 112-121 6810204-5 1981 Since the addition of carbidopa enhanced the suppression of prolactin induced by levodopa, exogenous levodopa probably acts predominantly through the formation of dopamine in the hypothalamus, but inside the blood-brain barrier, rather than as a direct effect of circulating dopamine on the anterior pituitary or areas of the hypothalamus outside the blood-brain barrier. Carbidopa 22-31 prolactin Homo sapiens 60-69 6810204-5 1981 Since the addition of carbidopa enhanced the suppression of prolactin induced by levodopa, exogenous levodopa probably acts predominantly through the formation of dopamine in the hypothalamus, but inside the blood-brain barrier, rather than as a direct effect of circulating dopamine on the anterior pituitary or areas of the hypothalamus outside the blood-brain barrier. Levodopa 81-89 prolactin Homo sapiens 60-69 7278648-1 1981 Glucoprivation induced by 2-deoxy-D-glucose (2DG) 20 min infusions (50 mg/kg) increases growth hormone (GH) and prolactin (PRL) levels in humans. Deoxyglucose 26-43 prolactin Homo sapiens 123-126 6810204-5 1981 Since the addition of carbidopa enhanced the suppression of prolactin induced by levodopa, exogenous levodopa probably acts predominantly through the formation of dopamine in the hypothalamus, but inside the blood-brain barrier, rather than as a direct effect of circulating dopamine on the anterior pituitary or areas of the hypothalamus outside the blood-brain barrier. Levodopa 101-109 prolactin Homo sapiens 60-69 7278648-1 1981 Glucoprivation induced by 2-deoxy-D-glucose (2DG) 20 min infusions (50 mg/kg) increases growth hormone (GH) and prolactin (PRL) levels in humans. Deoxyglucose 45-48 prolactin Homo sapiens 112-121 7278648-1 1981 Glucoprivation induced by 2-deoxy-D-glucose (2DG) 20 min infusions (50 mg/kg) increases growth hormone (GH) and prolactin (PRL) levels in humans. Deoxyglucose 45-48 prolactin Homo sapiens 123-126 7278648-2 1981 To determine if mazindol, a potent dopamine (DA) and norepinephrine (NE) reuptake blocking agent, might affect basal and stimulated GH and PRL levels in healthy male and female volunteers, mazindol (1 mg, TID,po) or placebo were administered for one week before 2DG infusions. Mazindol 16-24 prolactin Homo sapiens 139-142 7278648-6 1981 Mazindol therapy reduced 2DG-stimulated PRL responses (ng/ml) from 97.1 +/- 26.2 to 44.4 +/- 25.3 (p less than 0.0125) and from 21.4 +/- 5.3 to 13.6 +/- 3.4 (p less than 0.025) in females and males respectively, and GH responses (ng/ml) from 28.2 +/- 1.7 to 13.1 +/- 3.8 (p less than 0.05) and from 10.2 +/- 2.0 to 3.4 +/- 0.1 (p less than 0.05) in males and females respectively, but baseline PRL and GH levels were unaffected. Mazindol 0-8 prolactin Homo sapiens 40-43 7278648-6 1981 Mazindol therapy reduced 2DG-stimulated PRL responses (ng/ml) from 97.1 +/- 26.2 to 44.4 +/- 25.3 (p less than 0.0125) and from 21.4 +/- 5.3 to 13.6 +/- 3.4 (p less than 0.025) in females and males respectively, and GH responses (ng/ml) from 28.2 +/- 1.7 to 13.1 +/- 3.8 (p less than 0.05) and from 10.2 +/- 2.0 to 3.4 +/- 0.1 (p less than 0.05) in males and females respectively, but baseline PRL and GH levels were unaffected. Mazindol 0-8 prolactin Homo sapiens 394-397 7278648-6 1981 Mazindol therapy reduced 2DG-stimulated PRL responses (ng/ml) from 97.1 +/- 26.2 to 44.4 +/- 25.3 (p less than 0.0125) and from 21.4 +/- 5.3 to 13.6 +/- 3.4 (p less than 0.025) in females and males respectively, and GH responses (ng/ml) from 28.2 +/- 1.7 to 13.1 +/- 3.8 (p less than 0.05) and from 10.2 +/- 2.0 to 3.4 +/- 0.1 (p less than 0.05) in males and females respectively, but baseline PRL and GH levels were unaffected. Deoxyglucose 25-28 prolactin Homo sapiens 40-43 7278648-6 1981 Mazindol therapy reduced 2DG-stimulated PRL responses (ng/ml) from 97.1 +/- 26.2 to 44.4 +/- 25.3 (p less than 0.0125) and from 21.4 +/- 5.3 to 13.6 +/- 3.4 (p less than 0.025) in females and males respectively, and GH responses (ng/ml) from 28.2 +/- 1.7 to 13.1 +/- 3.8 (p less than 0.05) and from 10.2 +/- 2.0 to 3.4 +/- 0.1 (p less than 0.05) in males and females respectively, but baseline PRL and GH levels were unaffected. Deoxyglucose 25-28 prolactin Homo sapiens 394-397 6116045-2 1981 After a single 50 micrograms dose of pergolide mesylate, serum prolactin concentrations fell steadily to reach a mean minimum value at 6 h of 20% of baseline values; this degree of suppression was maintained throughout the 24 h study period. Pergolide 37-55 prolactin Homo sapiens 63-72 6116372-2 1981 Prolactin secretion was inhibited by bromocriptine in 3 out of 10 prolactin-secreting tumours and in explants from 2 normal pituitaries. Bromocriptine 37-50 prolactin Homo sapiens 0-9 6116372-2 1981 Prolactin secretion was inhibited by bromocriptine in 3 out of 10 prolactin-secreting tumours and in explants from 2 normal pituitaries. Bromocriptine 37-50 prolactin Homo sapiens 66-75 6116372-5 1981 Incubation of prolactin-secreting adenomas with oestradiol for as long as 24 days produced no change in hormone secretion. Estradiol 48-58 prolactin Homo sapiens 14-23 7348089-2 1981 The investigation was designed to study plasma drug concentration and prolactin response determined by two different doses of haloperidol, a standard one and four-fold higher the other, and to explore the relationships between clinical effects and pharmacokinetic and physiological variables in psychotic patients. Haloperidol 126-137 prolactin Homo sapiens 70-79 7348089-10 1981 Prolactin response was positive correlated with serum haloperidol concentration. Haloperidol 54-65 prolactin Homo sapiens 0-9 7023253-2 1981 Because the monoamines dopamine and serotonin are important in the control of its secretion, prolactin has been the subject of much psychoendocrine research in recent years. monoamines 12-22 prolactin Homo sapiens 93-102 7023253-2 1981 Because the monoamines dopamine and serotonin are important in the control of its secretion, prolactin has been the subject of much psychoendocrine research in recent years. Dopamine 23-31 prolactin Homo sapiens 93-102 7023253-2 1981 Because the monoamines dopamine and serotonin are important in the control of its secretion, prolactin has been the subject of much psychoendocrine research in recent years. Serotonin 36-45 prolactin Homo sapiens 93-102 7307108-0 1981 [Lisuride in the treatment of sterility and amenorrhoea induced by elevated prolactin levels (author"s transl)]. Lisuride 1-9 prolactin Homo sapiens 76-85 7307290-2 1981 A clearcut elevation in prolactin was produced by domperidone. Domperidone 50-61 prolactin Homo sapiens 24-33 6790560-4 1981 Calcium infusion blunted this PRL response by 33 +/- 8% (P less than 0.02), whereas verapamil, known for its calcium-antagonistic properties, left in unaffected. Calcium 0-7 prolactin Homo sapiens 30-33 6790560-5 1981 Five hundred milligrams of L-dopa increased the GH level from 2.2 +/- 0.7 to 16.7 +/- 2.2 ng/ml in 60 min (P less than 0.002) and reduced the PRL level from 11.6 +/- 2.9 to 3.1 +/- 0.4 ng/ml in 150 min (P less than 0.05). Levodopa 27-33 prolactin Homo sapiens 142-145 6974213-0 1981 Role of serotonin in the regulation of growth hormone and prolactin secretion in the domestic fowl. Serotonin 8-17 prolactin Homo sapiens 58-67 6974213-3 1981 The three serotonin receptor antagonists tested, methysergide, SQ-10631 and cyproheptadine, each resulted in a significant reduction in plasma prolactin while markedly increasing plasma GH levels. Methysergide 49-61 prolactin Homo sapiens 143-152 6974213-3 1981 The three serotonin receptor antagonists tested, methysergide, SQ-10631 and cyproheptadine, each resulted in a significant reduction in plasma prolactin while markedly increasing plasma GH levels. Cyproheptadine 76-90 prolactin Homo sapiens 143-152 6974213-4 1981 Administration of 5-hydroxytryptophan led to a rise in plasma prolactin and a drop in plasma GH levels in untreated birds or in animals pretreated with pCPA. 5-Hydroxytryptophan 18-37 prolactin Homo sapiens 62-71 6974213-5 1981 The serotonin receptor agonist, quipazine, resulted in a marked increase in plasma prolactin and a marked reduction in plasma GH concentrations in untreated birds. Quipazine 32-41 prolactin Homo sapiens 83-92 6974213-6 1981 In pCPA-pretreated animals quipazine was no longer effective in altering plasma prolactin levels but still caused a significant drop in circulating levels of GH. Quipazine 27-36 prolactin Homo sapiens 80-89 6974213-7 1981 These results suggest that in the young male domestic fowl serotonin has a stimulatory role in the regulation of prolactin and an inhibitory role in the regulation of GH secretion. Serotonin 59-68 prolactin Homo sapiens 113-122 7263848-2 1981 In previous experiments we observed that the inhibition of spontaneous uterine contractions produced by decidual RLX was masked or absent if the samples were contaminated with PRL. Relaxin 113-116 prolactin Homo sapiens 176-179 6272313-1 1981 Human growth hormone (hGH) and ovine prolactin (oPRL) are both lactogenic as defined by their ability to induce milk-protein synthesis in vitro in the presence of insulin and hydrocortisone. Hydrocortisone 175-189 prolactin Homo sapiens 37-46 6793282-0 1981 [Clinical and experimental studies of the mechanism of neuroendocrine action of cerebral phospholipids: the behavior of prolactin as a marker of such action]. Phospholipids 89-102 prolactin Homo sapiens 120-129 7270010-0 1981 Effect of short-term bromocriptine treatment on amniotic fluid prolactin concentration in the first half of pregnancy. Bromocriptine 21-34 prolactin Homo sapiens 63-72 7270010-1 1981 The effect of short-term bromocriptine treatment on amniotic fluid and maternal prolactin concentrations was studied in 9 pregnant women in the first half of pregnancy. Bromocriptine 25-38 prolactin Homo sapiens 80-89 7270010-2 1981 Bromocriptine suppressed the maternal serum prolactin level, but had no effect on the amniotic fluid level. Bromocriptine 0-13 prolactin Homo sapiens 44-53 7270010-3 1981 Since both foetal and maternal prolactin secretion are suppressed by bromocriptine our results suggest that amniotic fluid prolactin is produced by extrapituitary tissues, which do not contain dopamine receptors. Bromocriptine 69-82 prolactin Homo sapiens 123-132 7030443-4 1981 In the six patients who completed the whole study, plasma levels of chlorpromazine and chlorpromazine sulphoxide, total serum levels of neuroleptic and serum levels of prolactin were consistently and significantly elevated during treatment with chlorpromazine plus propranolol relative to levels during treatment with chlorpromazine alone. Propranolol 265-276 prolactin Homo sapiens 168-177 6796300-2 1981 In nursing, in non-nursing, non-medicated and in non-nursing, bromocriptine-treated women prolactin and 17 beta-oestradiol were measured during the early puerperium. Bromocriptine 62-75 prolactin Homo sapiens 90-99 6796300-5 1981 Nursing women had higher prolactin levels than the non-nursing groups, while bromocriptine decreased prolactin to very low levels. Bromocriptine 77-90 prolactin Homo sapiens 101-110 6796300-6 1981 Non-nursing non-medicated women had prolactin values between those of nursing and those of bromocriptine-treated mothers. Bromocriptine 91-104 prolactin Homo sapiens 36-45 6271518-7 1981 Treatment with cannabinoid compounds is also associated with lower testosterone levels in male and lower prolactin levels in female animals. Cannabinoids 15-26 prolactin Homo sapiens 105-114 6796300-8 1981 In non-nursing puerperal women treated with bromocriptine, exogenous oestradiol caused a significant rise in plasma prolactin. Bromocriptine 44-57 prolactin Homo sapiens 116-125 6796300-8 1981 In non-nursing puerperal women treated with bromocriptine, exogenous oestradiol caused a significant rise in plasma prolactin. Estradiol 69-79 prolactin Homo sapiens 116-125 6796300-10 1981 In the bromocriptine-treated group the basal concentration of prolactin and its response to TRH stimulation was similar to normal non-pregnant women. Bromocriptine 7-20 prolactin Homo sapiens 62-71 6796301-1 1981 Patients with prolactin-secreting pituitary tumours have a diminished prolactin (PRL) response after administration of a variety of stimulatory agents, including thyrotrophin-releasing hormone (TRH), chlorpromazine (CPZ) and insulin-induced hypoglycaemia. Chlorpromazine 200-214 prolactin Homo sapiens 14-23 6796300-11 1981 In nursing and in non-nursing women treated with bromocriptine prolactin responses to TRH were increased after oestradiol challenge. Estradiol 111-121 prolactin Homo sapiens 63-72 6796301-1 1981 Patients with prolactin-secreting pituitary tumours have a diminished prolactin (PRL) response after administration of a variety of stimulatory agents, including thyrotrophin-releasing hormone (TRH), chlorpromazine (CPZ) and insulin-induced hypoglycaemia. Chlorpromazine 216-219 prolactin Homo sapiens 14-23 7287491-3 1981 Suppression of prolactin levels by bromocriptine in those cases did not result in an increase of spermatogenetic activity. Bromocriptine 35-48 prolactin Homo sapiens 15-24 6796301-1 1981 Patients with prolactin-secreting pituitary tumours have a diminished prolactin (PRL) response after administration of a variety of stimulatory agents, including thyrotrophin-releasing hormone (TRH), chlorpromazine (CPZ) and insulin-induced hypoglycaemia. Chlorpromazine 216-219 prolactin Homo sapiens 81-84 6115806-4 1981 There was a dose-related increase in serum prolactin concentration within 15 min of injection of 200 and 400 mg of cimetidine, while injections of 20 and 40 mg of ranitidine failed to enhance prolactin secretion. Cimetidine 115-125 prolactin Homo sapiens 43-52 6115806-5 1981 It would appear that the stimulatory effect of cimetidine on serum prolactin concentration is not mediated through its histamine H2-receptor antagonist activity. Cimetidine 47-57 prolactin Homo sapiens 67-76 7327523-0 1981 Prolactin responsiveness to repeated decremental doses of sulpiride. Sulpiride 58-67 prolactin Homo sapiens 0-9 7327523-1 1981 The variation in the prolactin response to sulpiride was studied in six normal men by repeating the same dose of the drug (50 mg) after 24 hours and on three subsequent occasions, repeating this 2 day test at an interval of 6 days with progressively halved doses of sulpiride. Sulpiride 43-52 prolactin Homo sapiens 21-30 7327523-5 1981 The delta PRL increment on the second day was inversely proportional to the dose of sulpiride; the differences in delta PRL between periods 1 and 3 and periods 1 and 4 being highly significant (P less than 0.001). Sulpiride 84-93 prolactin Homo sapiens 10-13 7327523-5 1981 The delta PRL increment on the second day was inversely proportional to the dose of sulpiride; the differences in delta PRL between periods 1 and 3 and periods 1 and 4 being highly significant (P less than 0.001). Sulpiride 84-93 prolactin Homo sapiens 120-123 7327523-6 1981 This study suggests that a much lower dose of sulpiride than that normally used is adequate to stimulate PRL secretion and that care must be taken in the timing of repeat testing. Sulpiride 46-55 prolactin Homo sapiens 105-108 7019229-5 1981 Cortisol (0.2 micrograms/ml) plus PRL (2.5 micrograms/ml), when added to the medium from the beginning of the culture period, caused a 2- to 3-fold increase in the rate of choline incorporation into phosphatidylcholine, as measured on the second, fourth, sixth, and eighth days of incubation, as well as an increase in the phosphatidylcholine content of the explants. Choline 172-179 prolactin Homo sapiens 34-37 6788792-0 1981 Prolactin response to sulpiride in hypogonadotropic, normogonadotropic, and hypergonadotropic primary amenorrhea. Sulpiride 22-31 prolactin Homo sapiens 0-9 7019229-5 1981 Cortisol (0.2 micrograms/ml) plus PRL (2.5 micrograms/ml), when added to the medium from the beginning of the culture period, caused a 2- to 3-fold increase in the rate of choline incorporation into phosphatidylcholine, as measured on the second, fourth, sixth, and eighth days of incubation, as well as an increase in the phosphatidylcholine content of the explants. Phosphatidylcholines 199-218 prolactin Homo sapiens 34-37 7019229-5 1981 Cortisol (0.2 micrograms/ml) plus PRL (2.5 micrograms/ml), when added to the medium from the beginning of the culture period, caused a 2- to 3-fold increase in the rate of choline incorporation into phosphatidylcholine, as measured on the second, fourth, sixth, and eighth days of incubation, as well as an increase in the phosphatidylcholine content of the explants. Phosphatidylcholines 323-342 prolactin Homo sapiens 34-37 7019229-9 1981 Increases in phosphatidylcholine synthesis and lamellar body secretion also were observed in tissues incubated with insulin (2.5 micrograms/ml), cortisol, and PRL in combination or with insulin and cortisol in combination. Phosphatidylcholines 13-32 prolactin Homo sapiens 159-162 6789593-0 1981 Dynamic evaluation of prolactin secretion with sulpiride and thyrotrophin releasing hormone in amenorrhoeic and normally menstruating women. Sulpiride 47-56 prolactin Homo sapiens 22-31 6944708-0 1981 The prolactin-stimulating potency of reserpine in man. Reserpine 37-46 prolactin Homo sapiens 4-13 6944708-4 1981 The fact that reserpine was found to be a potent releaser of PRL--significantly greater than haloperidol--suggests a major role of storage pool dopamine in regulating PRL Secretion. Reserpine 14-23 prolactin Homo sapiens 61-64 6944708-4 1981 The fact that reserpine was found to be a potent releaser of PRL--significantly greater than haloperidol--suggests a major role of storage pool dopamine in regulating PRL Secretion. Reserpine 14-23 prolactin Homo sapiens 167-170 6944708-4 1981 The fact that reserpine was found to be a potent releaser of PRL--significantly greater than haloperidol--suggests a major role of storage pool dopamine in regulating PRL Secretion. Dopamine 144-152 prolactin Homo sapiens 167-170 6944708-5 1981 Since the PRL response to neuroleptics is highly correlated with clinical potency, reserpine could be a potent antipsychotic, and further clinical trials are indicated. Reserpine 83-92 prolactin Homo sapiens 10-13 6944710-0 1981 Effect of intramuscular chlorpromazine on serum prolactin levels in schizophrenic patients and normal controls. Chlorpromazine 24-38 prolactin Homo sapiens 48-57 6944710-9 1981 In six patients with mixed diagnoses, serum levels of CPZ and other active metabolites were determined by radioreceptor binding assay; peak serum drug levels were highly correlated with peak serum prolactin levels (4 = 0.92) during the first 2 hours following CPZ 50 mg i.m. Chlorpromazine 54-57 prolactin Homo sapiens 197-206 7196483-0 1981 Effect of 3-PPP, a putative dopamine autoreceptor agonist, on rat serum prolactin levels. preclamol 10-15 prolactin Homo sapiens 72-81 7246694-4 1981 These data indicate that the amount of prolactin produced by late secretory endometrium in explant culture can be used as an additional criterion for the diagnosis of luteal phase defects and may also provide a method for evaluating the response of the endometrium to progesterone. Progesterone 268-280 prolactin Homo sapiens 39-48 7018438-0 1981 The effect of amoxapine and imipramine on serum prolactin levels. Amoxapine 14-23 prolactin Homo sapiens 48-57 7018438-0 1981 The effect of amoxapine and imipramine on serum prolactin levels. Imipramine 28-38 prolactin Homo sapiens 48-57 7018438-3 1981 In contrast, amoxapine, a new antidepressant, produced significant elevations in serum prolactin levels in female and in male patients. Amoxapine 13-22 prolactin Homo sapiens 87-96 7018438-4 1981 Amoxapine may block dopamine receptors in central tuberoinfundibular pathways, which would account for its prolactin-elevating activity. Amoxapine 0-9 prolactin Homo sapiens 107-116 7196775-3 1981 In patients receiving oral CPZ, serum prolactin levels were elevated in the 8:00 AM samples; serum prolactin levels decreased between 8:00 AM and 10:00 AM and then increased sharply, reaching their peak from 11:00 AM to 2:00 PM. Chlorpromazine 27-30 prolactin Homo sapiens 38-47 7196775-3 1981 In patients receiving oral CPZ, serum prolactin levels were elevated in the 8:00 AM samples; serum prolactin levels decreased between 8:00 AM and 10:00 AM and then increased sharply, reaching their peak from 11:00 AM to 2:00 PM. Chlorpromazine 27-30 prolactin Homo sapiens 99-108 7196775-5 1981 The 8:00 AM serum prolactin levels were correlated with the peak serum prolactin levels during the day in female patients receiving oral CPZ, but not in male patients. Chlorpromazine 137-140 prolactin Homo sapiens 18-27 7196775-5 1981 The 8:00 AM serum prolactin levels were correlated with the peak serum prolactin levels during the day in female patients receiving oral CPZ, but not in male patients. Chlorpromazine 137-140 prolactin Homo sapiens 71-80 7274162-0 1981 Domperidone stimulated prolactin secretion in normal male and female volunteers. Domperidone 0-11 prolactin Homo sapiens 23-32 7291947-6 1981 In a case of sESS consecutive to the treatment with bromocriptine (for 6 months) of an invasive prolactinoma, TRH i. v. released PRL into the CSF but not into the blood, and the serum/ CSF ratio of PRL was very low, until a new cure with bromocriptine (for 3 months) mormalised it. Bromocriptine 52-65 prolactin Homo sapiens 129-132 7291947-6 1981 In a case of sESS consecutive to the treatment with bromocriptine (for 6 months) of an invasive prolactinoma, TRH i. v. released PRL into the CSF but not into the blood, and the serum/ CSF ratio of PRL was very low, until a new cure with bromocriptine (for 3 months) mormalised it. Bromocriptine 52-65 prolactin Homo sapiens 198-201 6263936-2 1981 During hypoglycemia, naloxone infusion reduced plasma PRL levels at 90 min, lowered the overall GH response, and enhanced that of ACTH. Naloxone 21-29 prolactin Homo sapiens 54-57 6787063-1 1981 TRH and metoclopramide tests were performed in 10 female patients with presumed phenothiazine-induced hyperprolactinemia to define the serum PRL response to these agents. phenothiazine 80-93 prolactin Homo sapiens 141-144 6787063-2 1981 Our results show that the serum PRL response to metoclopramide is blunted in most patients with phenothiazine-induced hyperprolactinemia, and the serum PRL response to TRH is exaggerated in most patients during and 3 weeks after stopping phenothiazines. Metoclopramide 48-62 prolactin Homo sapiens 32-35 6787063-2 1981 Our results show that the serum PRL response to metoclopramide is blunted in most patients with phenothiazine-induced hyperprolactinemia, and the serum PRL response to TRH is exaggerated in most patients during and 3 weeks after stopping phenothiazines. phenothiazine 96-109 prolactin Homo sapiens 32-35 6787063-2 1981 Our results show that the serum PRL response to metoclopramide is blunted in most patients with phenothiazine-induced hyperprolactinemia, and the serum PRL response to TRH is exaggerated in most patients during and 3 weeks after stopping phenothiazines. Phenothiazines 238-252 prolactin Homo sapiens 152-155 7028803-6 1981 A decreased prolactin response to morphine administration has been reported in depression, but is not direct evidence of opioid system dysfunction in depression since abnormal prolactin responses to other challenges in depression have previously been reported. Morphine 34-42 prolactin Homo sapiens 12-21 7320436-0 1981 Circadian rhythmicity of prolactin secretion in elderly subjects: changes during bromocriptine treatment. Bromocriptine 81-94 prolactin Homo sapiens 25-34 6788948-6 1981 Serum prolactin rose by about 50%, 48 h after the serum oestradiol peak, then declined during the mid-luteal phase before rising at the end of the cycle. Estradiol 56-66 prolactin Homo sapiens 6-15 7195940-3 1981 Bromocriptine decreased prolactin levels to less than 2.5 ng/ml (P less than 0.001) and increased the LH response to LH-RH (P less than 0.05). Bromocriptine 0-13 prolactin Homo sapiens 24-33 7291145-3 1981 In patients with thyrotoxicosis, a remarkable increase in prolactin level, which correlated with triiodothyronine content, was observed. Triiodothyronine 97-113 prolactin Homo sapiens 58-67 7302322-2 1981 Measurement of plasma prolactin levels in elderly subjects demonstrated the presence of a hyperprolactinemia with loss of normal circadian rhythm, regressing after bromocriptine treatment. Bromocriptine 164-177 prolactin Homo sapiens 22-31 6113354-0 1981 Heterogeneity of prolactin responses to oestradiol benzoate in women with prolactinomas. estradiol 3-benzoate 40-59 prolactin Homo sapiens 17-26 6113354-6 1981 This study demonstrated a heterogeneity of serum prolactin responses to acute oestradiol administration in women with prolactinomas. Estradiol 78-88 prolactin Homo sapiens 49-58 7241380-8 1981 The only significant difference in hormone levels was a small elevation in prolactin during the descending phase of the blood alcohol curve when nausea and vomiting coincident with alcohol-induced intoxication occurred. Alcohols 126-133 prolactin Homo sapiens 75-84 7241380-8 1981 The only significant difference in hormone levels was a small elevation in prolactin during the descending phase of the blood alcohol curve when nausea and vomiting coincident with alcohol-induced intoxication occurred. Alcohols 181-188 prolactin Homo sapiens 75-84 7246736-0 1981 Resumption of prolactin secretion after dopaminergic inhibition: differential effects of dopamine and its agonists. Dopamine 40-48 prolactin Homo sapiens 14-23 7246736-2 1981 PRL secretion over 4 h was inhibited comparably by 10(-6) M dopamine (DA), 10(-7) M apomorphine (APO), and 10(-10) M bromocriptine (45%, 42%, 51%, respectively) with reciprocal increases in intracellular hormone content. Dopamine 60-68 prolactin Homo sapiens 0-3 7246736-2 1981 PRL secretion over 4 h was inhibited comparably by 10(-6) M dopamine (DA), 10(-7) M apomorphine (APO), and 10(-10) M bromocriptine (45%, 42%, 51%, respectively) with reciprocal increases in intracellular hormone content. Dopamine 70-72 prolactin Homo sapiens 0-3 7246736-2 1981 PRL secretion over 4 h was inhibited comparably by 10(-6) M dopamine (DA), 10(-7) M apomorphine (APO), and 10(-10) M bromocriptine (45%, 42%, 51%, respectively) with reciprocal increases in intracellular hormone content. Apomorphine 84-95 prolactin Homo sapiens 0-3 7246736-2 1981 PRL secretion over 4 h was inhibited comparably by 10(-6) M dopamine (DA), 10(-7) M apomorphine (APO), and 10(-10) M bromocriptine (45%, 42%, 51%, respectively) with reciprocal increases in intracellular hormone content. Apomorphine 97-100 prolactin Homo sapiens 0-3 7246736-2 1981 PRL secretion over 4 h was inhibited comparably by 10(-6) M dopamine (DA), 10(-7) M apomorphine (APO), and 10(-10) M bromocriptine (45%, 42%, 51%, respectively) with reciprocal increases in intracellular hormone content. Bromocriptine 117-130 prolactin Homo sapiens 0-3 7246736-3 1981 After drug removal, the PRL secretion rate in the cultures that had been treated with DA was 208% of the control cultures by the 2nd h but returned to control values by 4 h, whereas the secretion rate after APO was 131-142% of control throughout the 4-h recovery period. Dopamine 86-88 prolactin Homo sapiens 24-27 7246736-4 1981 In contrast, PRL secretion remained significantly less than control 20 h after the removal of bromocriptine. Bromocriptine 94-107 prolactin Homo sapiens 13-16 7235822-4 1981 Saturation of antibody binding sites by incremental dosages of liothyronine (triiodothyronine) sodium (12.5 to 87.5 microgram/day) resulted in normalization of both the TSH and PRL levels. liothyronine (triiodothyronine) sodium 63-101 prolactin Homo sapiens 177-180 7247577-4 1981 Bromocriptine treatment, 2.5-7.5 mg daily for 8-16 weeks lowered prolactin to normal levels in all patients. Bromocriptine 0-13 prolactin Homo sapiens 65-74 7247630-0 1981 Motility, Parkinsonism, and prolactin with thiothixene and thioridazine. Thiothixene 43-54 prolactin Homo sapiens 28-37 7247630-0 1981 Motility, Parkinsonism, and prolactin with thiothixene and thioridazine. Thioridazine 59-71 prolactin Homo sapiens 28-37 6273142-0 1981 Effect of prolactin on the secretion of dehydroepiandrosterone (DHEA), its sulfate (DHEA-S), and cortisol by the human fetal adrenal in vitro. Dehydroepiandrosterone 40-62 prolactin Homo sapiens 10-19 6273142-0 1981 Effect of prolactin on the secretion of dehydroepiandrosterone (DHEA), its sulfate (DHEA-S), and cortisol by the human fetal adrenal in vitro. Dehydroepiandrosterone 64-68 prolactin Homo sapiens 10-19 6788664-5 1981 Similarly, a decrease of hPRL serum levels (p less than 0.001) was registered in the female subjects during treatment with 1 g cimetidine per day. Cimetidine 127-137 prolactin Homo sapiens 25-29 6273142-0 1981 Effect of prolactin on the secretion of dehydroepiandrosterone (DHEA), its sulfate (DHEA-S), and cortisol by the human fetal adrenal in vitro. Hydrocortisone 97-105 prolactin Homo sapiens 10-19 6273142-1 1981 The effect of prolactin on the secretions of dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) as well as that of cortisol were studied in vitro in order to investigate the possible regulatory role of prolactin on steroidogenesis of the human fetal adrenal at mid-gestational age. Dehydroepiandrosterone 45-67 prolactin Homo sapiens 14-23 6273142-1 1981 The effect of prolactin on the secretions of dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) as well as that of cortisol were studied in vitro in order to investigate the possible regulatory role of prolactin on steroidogenesis of the human fetal adrenal at mid-gestational age. Dehydroepiandrosterone 69-73 prolactin Homo sapiens 14-23 6273142-1 1981 The effect of prolactin on the secretions of dehydroepiandrosterone (DHEA) and its sulfate (DHEA-S) as well as that of cortisol were studied in vitro in order to investigate the possible regulatory role of prolactin on steroidogenesis of the human fetal adrenal at mid-gestational age. Sulfates 83-90 prolactin Homo sapiens 14-23 6273142-2 1981 The addition of 0.5 microgram/ml of human prolactin to the incubation medium produced a significant (P less than 0.05) increase in DHEA, DHEA-S, and cortisol secretion. Dehydroepiandrosterone 131-135 prolactin Homo sapiens 42-51 6273142-2 1981 The addition of 0.5 microgram/ml of human prolactin to the incubation medium produced a significant (P less than 0.05) increase in DHEA, DHEA-S, and cortisol secretion. Dehydroepiandrosterone 137-143 prolactin Homo sapiens 42-51 6273142-2 1981 The addition of 0.5 microgram/ml of human prolactin to the incubation medium produced a significant (P less than 0.05) increase in DHEA, DHEA-S, and cortisol secretion. Hydrocortisone 149-157 prolactin Homo sapiens 42-51 6785297-5 1981 Thus, the release of LH, FSH, TSH, and PRL in response to adequate acute stimuli at the pituitary level is not modulated by hyperglycemia in insulin-dependent diabetes, while arginine-induced GH release is suppressed. Arginine 175-183 prolactin Homo sapiens 39-42 7253823-0 1981 The prolactin response to intravenous dextroamphetamine in normal young men and postmenopausal women. Dextroamphetamine 38-55 prolactin Homo sapiens 4-13 7227210-1 1981 Conservative treatment with bromocriptine was performed in three patients with macroprolactinomas and increased prolactin levels. Bromocriptine 28-41 prolactin Homo sapiens 84-93 6784423-3 1981 Furthermore, the relationship between changes in prolactin and oestradiol-17 beta levels during the normal menstrual cycle and in the climacteric was studied. Estradiol 63-81 prolactin Homo sapiens 49-58 7223316-0 1981 Increased thyrotrophin and prolactin secretion induced by domperidone in hypothyroid subjects. Domperidone 58-69 prolactin Homo sapiens 27-36 7223316-1 1981 The thyrotrophin (TSH) and prolactin (Prl) releasing effects of domperidone, a recently developed antidopaminergic drug which does not cross the blood-brain barrier, were investigated in 8 women affected by primary hypothyroidism, and were compared to those elicited by another antidopaminergic drug, sulpiride. Domperidone 64-75 prolactin Homo sapiens 27-36 6113818-9 1981 Moreover, a significant reverse correlation was found between PRL and T basal in both group; this correlation disappeared during the bromocriptine treatment. Bromocriptine 133-146 prolactin Homo sapiens 62-65 7018950-2 1981 At the dosages selected, lisuride was as effective as bromocriptine for the inhibition of lactation but bromocriptine was more effective in lowering serum prolactin levels. Bromocriptine 104-117 prolactin Homo sapiens 155-164 7227576-0 1981 The effects on the ovulatory cycle of metoclopramide-induced increased prolactin levels during follicular development. Metoclopramide 38-52 prolactin Homo sapiens 71-80 7262825-1 1981 The serum prolactin response to acute hypercalcemia during calcium infusion was studied in 7 normal subjects. Calcium 59-66 prolactin Homo sapiens 10-19 6785431-0 1981 Serum prolactin concentrations in mangabey (Cercocebus atys lunulatus) and patas (Erythrocebus patas) monkeys in response to stress, ketamine, TRH, sulpiride and levodopa. Ketamine 133-141 prolactin Homo sapiens 6-15 6785431-0 1981 Serum prolactin concentrations in mangabey (Cercocebus atys lunulatus) and patas (Erythrocebus patas) monkeys in response to stress, ketamine, TRH, sulpiride and levodopa. Sulpiride 148-157 prolactin Homo sapiens 6-15 6785431-0 1981 Serum prolactin concentrations in mangabey (Cercocebus atys lunulatus) and patas (Erythrocebus patas) monkeys in response to stress, ketamine, TRH, sulpiride and levodopa. Levodopa 162-170 prolactin Homo sapiens 6-15 6785431-8 1981 Oral administration of levodopa was followed by a significant fall in serum prolactin. Levodopa 23-31 prolactin Homo sapiens 76-85 6785431-11 1981 The variations in serum prolactin levels observed in these monkeys under the influence of stress, TRH, sulpiride and levodopa are similar to those observed in man to the same stimuli, although the experimental conditions were quite different. Sulpiride 103-112 prolactin Homo sapiens 24-33 6785431-11 1981 The variations in serum prolactin levels observed in these monkeys under the influence of stress, TRH, sulpiride and levodopa are similar to those observed in man to the same stimuli, although the experimental conditions were quite different. Levodopa 117-125 prolactin Homo sapiens 24-33 6269192-0 1981 [Effects of tiapride infusion on plasma levels of beta-endorphin, prolactin and dopamine in patients with pain from cancer (author"s transl)]. Tiapride Hydrochloride 12-20 prolactin Homo sapiens 66-75 6269192-4 1981 The tiapride infusion produced a slight but significant increase in plasma beta-endorphin level, an early and significant increase in plasma prolactin, and a sudden and highly significant decrease in plasma dopamine. Tiapride Hydrochloride 4-12 prolactin Homo sapiens 141-150 6783964-2 1981 Bromocriptine can restore follicular growth and ovulation by inhibiting the release of prolactin from the pituitary. Bromocriptine 0-13 prolactin Homo sapiens 87-96 7304278-0 1981 Naloxone-induced decrease of plasma prolactin in healthy women. Naloxone 0-8 prolactin Homo sapiens 36-45 6790208-0 1981 Prolactin response to metoclopramide and chlorpromazine in primary testicular failure and isolated gonadotrophin deficiency. Metoclopramide 22-36 prolactin Homo sapiens 0-9 7238264-2 1981 Therefore, we measured plasma prolactin, a known sensitive indicator of functional dopamine activity in man, in an attempt to evaluate dopaminergic function in 21 patients with alcoholic liver disease and PSE and several control groups. Dopamine 83-91 prolactin Homo sapiens 30-39 7238264-5 1981 Although the degree of PSE was similar in both groups, those PSE patients with the higher prolactin values had significantly greater derangement of serum albumin, bilirubin, prothrombin time, and also had a higher mortality (100%). Bilirubin 163-172 prolactin Homo sapiens 90-99 7472275-0 1981 Sex steroids modulate prolactin action in spontaneously luteinizing porcine granulosa cells in vitro. Steroids 4-12 prolactin Homo sapiens 22-31 7472275-3 1981 Acute administration (within 36 h) of 17 beta-estradiol, but not 17 alpha-estradiol, suppressed both spontaneous and prolactin-stimulated progesterone production. Estradiol 38-55 prolactin Homo sapiens 117-126 7472275-3 1981 Acute administration (within 36 h) of 17 beta-estradiol, but not 17 alpha-estradiol, suppressed both spontaneous and prolactin-stimulated progesterone production. Progesterone 138-150 prolactin Homo sapiens 117-126 7472275-6 1981 The steroidogenic effect of prolactin was greater in the presence of 5 alpha-dihydrotestosterone, but did not elicit true synergism. Dihydrotestosterone 69-96 prolactin Homo sapiens 28-37 6782115-7 1981 The significance of these findings is discussed in relation to the milk let-down reflex and the relationship of TSH to PRL. Thyrotropin 112-115 prolactin Homo sapiens 119-122 6792262-1 1981 To investigate a possible hypothalamic alteration in obesity, we have studied the pattern of PRL secretion in response to insulin hypoglycemia, arginine infusion and TRH injection in 12 grossly obese patients and in 12 normal-weight controls. Arginine 144-152 prolactin Homo sapiens 93-96 6792262-2 1981 In the obese patients, PRL secretion was significantly lower than in normal subjects in response to insulin hypoglycemia and arginine infusion, while it was not significantly different from that in controls in response to TRH. Arginine 125-133 prolactin Homo sapiens 23-26 6792262-3 1981 The mean +/- SE values of the areas subtended by the PRL curves in the 3 above tests were 54.7 +/- 155.81 vs 3677.3 +/- 520.30 ng/2h, p less than 0,01, 210.3 +/- 148.93 vs 1034.8 +/- 203.15 ng/2h, p less than 0.05 and 1476.8 +/- 275.13 vs 2148.6 +/- 682.06 ng/2h, NS, respectively, in the obese and in controls. Deuterium 130-132 prolactin Homo sapiens 53-56 6792262-3 1981 The mean +/- SE values of the areas subtended by the PRL curves in the 3 above tests were 54.7 +/- 155.81 vs 3677.3 +/- 520.30 ng/2h, p less than 0,01, 210.3 +/- 148.93 vs 1034.8 +/- 203.15 ng/2h, p less than 0.05 and 1476.8 +/- 275.13 vs 2148.6 +/- 682.06 ng/2h, NS, respectively, in the obese and in controls. Deuterium 193-195 prolactin Homo sapiens 53-56 6792262-3 1981 The mean +/- SE values of the areas subtended by the PRL curves in the 3 above tests were 54.7 +/- 155.81 vs 3677.3 +/- 520.30 ng/2h, p less than 0,01, 210.3 +/- 148.93 vs 1034.8 +/- 203.15 ng/2h, p less than 0.05 and 1476.8 +/- 275.13 vs 2148.6 +/- 682.06 ng/2h, NS, respectively, in the obese and in controls. Deuterium 193-195 prolactin Homo sapiens 53-56 6792262-3 1981 The mean +/- SE values of the areas subtended by the PRL curves in the 3 above tests were 54.7 +/- 155.81 vs 3677.3 +/- 520.30 ng/2h, p less than 0,01, 210.3 +/- 148.93 vs 1034.8 +/- 203.15 ng/2h, p less than 0.05 and 1476.8 +/- 275.13 vs 2148.6 +/- 682.06 ng/2h, NS, respectively, in the obese and in controls. Nitrogen 264-266 prolactin Homo sapiens 53-56 6792265-5 1981 However, prolactin (PRL) response to both TRH and metoclopramide were blunted compared with normal male subjects. Metoclopramide 50-64 prolactin Homo sapiens 9-18 6792265-5 1981 However, prolactin (PRL) response to both TRH and metoclopramide were blunted compared with normal male subjects. Metoclopramide 50-64 prolactin Homo sapiens 20-23 7020720-0 1981 [Serum prolactin in obese subjects with and without glucose intolerance]. Glucose 52-59 prolactin Homo sapiens 7-16 7020721-0 1981 [Serum prolactin in obese subjects with glucose intolerance before and after treatment with phenformin]. Glucose 40-47 prolactin Homo sapiens 7-16 7020721-0 1981 [Serum prolactin in obese subjects with glucose intolerance before and after treatment with phenformin]. Phenformin 92-102 prolactin Homo sapiens 7-16 7460842-4 1981 The effect of PRL on the amounts of DA and NE released during exposure to a submaximal stimulus of 30 mM K+ was evaluated. Dopamine 36-38 prolactin Homo sapiens 14-17 7460842-5 1981 PRL in concentrations of 50-5000 ng/ml augmented the K+-induced release of DA and NE in a concentration-dependent manner. Dopamine 75-77 prolactin Homo sapiens 0-3 7460842-6 1981 The PRL augmentation of the release of both DA and NE was prevented by the addition of anti-PRL gamma-globulin to the superfusion medium. Dopamine 44-46 prolactin Homo sapiens 4-7 7460842-6 1981 The PRL augmentation of the release of both DA and NE was prevented by the addition of anti-PRL gamma-globulin to the superfusion medium. Dopamine 44-46 prolactin Homo sapiens 92-95 7460842-7 1981 In view of the inhibitory effect of DA on PRL secretion, these findings are consistent with the conclusion that PRL can influence its own secretion by stimulating the release of hypothalamic DA. Dopamine 36-38 prolactin Homo sapiens 42-45 7460842-7 1981 In view of the inhibitory effect of DA on PRL secretion, these findings are consistent with the conclusion that PRL can influence its own secretion by stimulating the release of hypothalamic DA. Dopamine 36-38 prolactin Homo sapiens 112-115 6780593-1 1981 To explore the effect of metoclopramide (MC) on the secretion of PRL, TSH, and thyroid hormones (T3 and T4) and on defective lactation, 17 mothers with poor lactation were treated with oral MC (10 mg. three times daily) for 3 weeks starting 18-141 days post partum. Metoclopramide 41-43 prolactin Homo sapiens 65-68 6780593-5 1981 Oral MC increased the mean (+/-SEM) plasma PRL level from 36.6 +/- 9.2 to 90.6 +/- 7.5 ng/ml (P less than 0.001) after 1 week, and the PRL level remained elevated for as long as MC was administered. Metoclopramide 5-7 prolactin Homo sapiens 43-46 6780593-5 1981 Oral MC increased the mean (+/-SEM) plasma PRL level from 36.6 +/- 9.2 to 90.6 +/- 7.5 ng/ml (P less than 0.001) after 1 week, and the PRL level remained elevated for as long as MC was administered. Metoclopramide 5-7 prolactin Homo sapiens 135-138 6780593-8 1981 The PRL level rose significantly after TRH and MC injections before and during oral treatments with MC, whereas the TSH concentrations were elevated only after TRH stimulation. Metoclopramide 47-49 prolactin Homo sapiens 4-7 6780593-8 1981 The PRL level rose significantly after TRH and MC injections before and during oral treatments with MC, whereas the TSH concentrations were elevated only after TRH stimulation. Metoclopramide 100-102 prolactin Homo sapiens 4-7 7341767-0 1981 [The effect of an intravenous calcium load on plasma prolactin in man (author"s transl)]. Calcium 30-37 prolactin Homo sapiens 53-62 7341767-9 1981 In the calcium treated-group, plasma PRL, PTH and urinary cyclic AMP decreased progressively. Calcium 7-14 prolactin Homo sapiens 37-40 6261178-7 1981 Dexamethasone (1.25--10 microM) inhibited the secretion of PRL. Dexamethasone 0-13 prolactin Homo sapiens 59-62 6261178-8 1981 However, in the presence of dexamethasone modulation of PRL release by TRH and dopamine remained unaltered. Dexamethasone 28-41 prolactin Homo sapiens 56-59 6261178-8 1981 However, in the presence of dexamethasone modulation of PRL release by TRH and dopamine remained unaltered. Dopamine 79-87 prolactin Homo sapiens 56-59 6261178-12 1981 It is concluded that TRH and dopamine regulate PRL release at sites which are not under corticosteroid regulation, while corticosteroids modulate PRL secretion in response to stress. Dopamine 29-37 prolactin Homo sapiens 47-50 6111843-4 1981 As a specific prolactin inhibitor, bromocriptine is the treatment of choice in many cases of hyperprolactinemia in female and male. Bromocriptine 35-48 prolactin Homo sapiens 14-23 6111843-5 1981 There is ample evidence that with bromocriptine a reduction of pituitary tumor size (particularly in prolactin-secreting tumors) can be achieved. Bromocriptine 34-47 prolactin Homo sapiens 101-110 6109991-0 1981 Effects of prosomatostatin on growth hormone and prolactin response to arginine in man. Arginine 71-79 prolactin Homo sapiens 49-58 6784423-8 1981 The levels of plasma prolactin during the ovulatory and the luteal phase in the cycle were significantly (P less than 0.02) higher than that of the follicular phase, and a positive correlation between changes in plasma concentration of oestradiol-17 beta and prolactin was found. Estradiol 236-254 prolactin Homo sapiens 21-30 6784423-8 1981 The levels of plasma prolactin during the ovulatory and the luteal phase in the cycle were significantly (P less than 0.02) higher than that of the follicular phase, and a positive correlation between changes in plasma concentration of oestradiol-17 beta and prolactin was found. Estradiol 236-254 prolactin Homo sapiens 259-268 6784423-9 1981 Also in post-menopausal women a relationship between plasma concentration of prolactin and oestradiol-17 beta was seen. Estradiol 91-109 prolactin Homo sapiens 77-86 6784680-0 1981 The fluorescein-mediated interaction of bovine serum albumin with fluorescent derivatives of prolactin and other polypeptides in polarization of fluorescence based assays. Fluorescein 4-15 prolactin Homo sapiens 93-102 6790201-8 1981 The presence of an exaggerated TSH response to DA antagonism in a euthyroid, radiologically normal (plain skull X-ray), hyperprolactinaemic patient is compatible with the presence of an autonomously-functioning, PRL secreting, pituitary microadenoma and the TSH changes seen in these patients after DA antagonist administration can be readily detected by sensitive TSH radioimmunoassay. Thyrotropin 31-34 prolactin Homo sapiens 212-215 7215159-1 1981 The prolactin response to oral metoclopramide (10 mg) was investigated in 53 chronic alcoholics (26 with alcoholic cirrhosis and 27 without evidence of liver disease) from two to seven days after alcohol suspension. Metoclopramide 31-45 prolactin Homo sapiens 4-13 7215159-3 1981 This finding may depend on the deactivation of the dopaminergic activities secondary to alcohol suspension; alternatively, ethanol could have a direct action on prolactin secretion. Ethanol 123-130 prolactin Homo sapiens 161-170 6972868-1 1981 Prolactin was purified from bullfrog adenohypophyses by extraction of acetone-dried powder with acid acetone and chromatography on DEAE-cellulose and Sephadex G100. Acetone 70-77 prolactin Homo sapiens 0-9 6972868-1 1981 Prolactin was purified from bullfrog adenohypophyses by extraction of acetone-dried powder with acid acetone and chromatography on DEAE-cellulose and Sephadex G100. acid acetone 96-108 prolactin Homo sapiens 0-9 6972868-1 1981 Prolactin was purified from bullfrog adenohypophyses by extraction of acetone-dried powder with acid acetone and chromatography on DEAE-cellulose and Sephadex G100. DEAE-Cellulose 131-145 prolactin Homo sapiens 0-9 6972868-1 1981 Prolactin was purified from bullfrog adenohypophyses by extraction of acetone-dried powder with acid acetone and chromatography on DEAE-cellulose and Sephadex G100. sephadex 150-163 prolactin Homo sapiens 0-9 6972868-2 1981 The bullfrog prolactin had a molecular weight of 23,000 as determined by SDS gel electrophoresis. Sodium Dodecyl Sulfate 73-76 prolactin Homo sapiens 13-22 7202740-0 1981 Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone. Nomifensine 76-87 prolactin Homo sapiens 9-18 7202740-4 1981 The administration of domperidone (4-mg bolus injected intravenously) showed in 36 of the 41 patients the existence of a homogeneity between PRL responsiveness to nomifensine and PRL responsiveness to domperidone. Domperidone 22-33 prolactin Homo sapiens 141-144 7202740-4 1981 The administration of domperidone (4-mg bolus injected intravenously) showed in 36 of the 41 patients the existence of a homogeneity between PRL responsiveness to nomifensine and PRL responsiveness to domperidone. Domperidone 22-33 prolactin Homo sapiens 179-182 7202740-4 1981 The administration of domperidone (4-mg bolus injected intravenously) showed in 36 of the 41 patients the existence of a homogeneity between PRL responsiveness to nomifensine and PRL responsiveness to domperidone. Nomifensine 163-174 prolactin Homo sapiens 141-144 7202740-5 1981 In only five patients was failure of nomifensine to lower plasma PRL levels associated with an increase in plasma PRL levels after domperidone administration (at least doubling of baseline PRL levels). Nomifensine 37-48 prolactin Homo sapiens 65-68 7202740-5 1981 In only five patients was failure of nomifensine to lower plasma PRL levels associated with an increase in plasma PRL levels after domperidone administration (at least doubling of baseline PRL levels). Nomifensine 37-48 prolactin Homo sapiens 114-117 7202740-5 1981 In only five patients was failure of nomifensine to lower plasma PRL levels associated with an increase in plasma PRL levels after domperidone administration (at least doubling of baseline PRL levels). Nomifensine 37-48 prolactin Homo sapiens 114-117 7203692-3 1981 Prolactin levels rose both in serum and in seminal plasma 1 week following the initiation of metoclopramide administration. Metoclopramide 93-107 prolactin Homo sapiens 0-9 6780584-0 1981 Prolactin-releasing activity in methanol extracts of human plasma: problems with the bioassay of this activity. Methanol 32-40 prolactin Homo sapiens 0-9 6783947-0 1981 Dopamine and serum prolactin in methadone withdrawal. Methadone 32-41 prolactin Homo sapiens 19-28 7266088-5 1981 CB154 reduced both GH and PRL serum levels, naloxone only GH serum levels. Bromocriptine 0-5 prolactin Homo sapiens 26-29 7266088-7 1981 Naloxone also interfered with the lowering effects of CB154 and GH and PRL serum levels, pointing to the existence of an interaction between dopaminergic and opiate control of GH and PRL secretion in acromegaly. Naloxone 0-8 prolactin Homo sapiens 71-74 6262702-0 1981 Effects of tiapride infusion on plasma levels of beta-endorphin, prolactin and dopamine in patients with pain from cancer. Tiapride Hydrochloride 11-19 prolactin Homo sapiens 65-74 6262702-4 1981 The tiapride infusion produced a slight but significant increase in plasma beta-endorphin level, an early and significant increase in plasma prolactin, and a sudden and highly significant decrease in plasma dopamine. Tiapride Hydrochloride 4-12 prolactin Homo sapiens 141-150 6109449-0 1981 Effect of cyproheptadine on chlorpromazine stimulation of prolactin in women. Cyproheptadine 10-24 prolactin Homo sapiens 58-67 6109449-0 1981 Effect of cyproheptadine on chlorpromazine stimulation of prolactin in women. Chlorpromazine 28-42 prolactin Homo sapiens 58-67 6109449-1 1981 In five normal women, the expected chlorpromazine-induced rise in serum prolactin was inhibited by pretreatment with a serotonin antagonist, cyproheptadine. Chlorpromazine 35-49 prolactin Homo sapiens 72-81 6109449-1 1981 In five normal women, the expected chlorpromazine-induced rise in serum prolactin was inhibited by pretreatment with a serotonin antagonist, cyproheptadine. Cyproheptadine 141-155 prolactin Homo sapiens 72-81 6109449-4 1981 In most cases, this chlorpromazine-induced reduction in the prolactin inhibitory factor could not further increase the secretion of prolactin, so that there was no rise to inhibit. Chlorpromazine 20-34 prolactin Homo sapiens 60-69 6454426-1 1981 On 22 male patients diagnosed as "functional hyperprolactinemia" (the Prolactin (PRL) basal value, was higher than the basal PRL means +/- 2 DS of a control group) we have measured the urinary excretion of Dehydroepiandrosterone (DHEA) mainly produced by adrenal cortex. Dehydroepiandrosterone 206-228 prolactin Homo sapiens 70-79 6894254-0 1981 Stimulation of 1,25-dihydroxycholecalciferol production by prolactin and related peptides in intact renal cell preparations in vitro. Calcitriol 15-44 prolactin Homo sapiens 59-68 6894254-1 1981 Ovine prolactin stimulated the 1 alpha-hydroxylase activity in isolated renal tubules and especially in primary kidney cell cultures, both prepared from vitamin D-deficient chicks. Vitamin D 153-162 prolactin Homo sapiens 6-15 6787839-5 1981 Low doses of bromocriptine (3.75-5 mg/day) normalized PRL. Bromocriptine 13-26 prolactin Homo sapiens 54-57 6787839-8 1981 The dose of bromocriptine required to normalize PRL ranged between 7.5 and 15 mg/day. Bromocriptine 12-25 prolactin Homo sapiens 48-51 6787839-9 1981 It is concluded that in subjects with sellar changes and intrasellar cisternal herniation ("empty sella"), and with moderate increases in PRL, the responses to TRH and L-dopa and to bromocriptine may help to differentiate between the empty sella syndrome and a coexisting pituitary tumour. Levodopa 168-174 prolactin Homo sapiens 138-141 6787839-9 1981 It is concluded that in subjects with sellar changes and intrasellar cisternal herniation ("empty sella"), and with moderate increases in PRL, the responses to TRH and L-dopa and to bromocriptine may help to differentiate between the empty sella syndrome and a coexisting pituitary tumour. Bromocriptine 182-195 prolactin Homo sapiens 138-141 7456982-0 1981 Effect of treatment with bromocriptine on the size and activity of prolactin producing pituitary tumours. Bromocriptine 25-38 prolactin Homo sapiens 67-76 7270091-0 1981 The acute effect of metoclopramide on plasma prolactin during pregnancy. Metoclopramide 20-34 prolactin Homo sapiens 45-54 7270091-1 1981 The effect of metoclopramide on plasma prolactin levels was studied in 10 women in the second half of pregnancy. Metoclopramide 14-28 prolactin Homo sapiens 39-48 7270091-2 1981 The IV injection of 10 mg metoclopramide produces a significant rise in prolactin in 15 minutes, a peak of up to 6.5-fold over basal levels at 30 minutes and a sustained significant elevation for at least 4 hours. Metoclopramide 26-40 prolactin Homo sapiens 72-81 7270091-4 1981 The elevated hyperprolactinemia induced by metoclopramide may be of help in investigating the role of prolactin in human pregnancy. Metoclopramide 43-57 prolactin Homo sapiens 18-27 6765010-1 1981 The increase in protein adsorption by charcoal as ionic strength increases (salting-out adsorption), was used to separate the bound and free fractions of glucagon, insulin, hGH, hLH and hPRL in the radioimmunoassay. Charcoal 38-46 prolactin Homo sapiens 186-190 6124186-0 1981 [Variations in blood prolactin in man during enflurane or Alfatesine anesthesias]. Enflurane 45-54 prolactin Homo sapiens 21-30 6124186-0 1981 [Variations in blood prolactin in man during enflurane or Alfatesine anesthesias]. Alfaxalone Alfadolone Mixture 58-68 prolactin Homo sapiens 21-30 6124186-2 1981 This finding led the authors to study variations in PRL during anaesthesia with Enflurane or Alfatesine. Enflurane 80-89 prolactin Homo sapiens 52-55 6124186-2 1981 This finding led the authors to study variations in PRL during anaesthesia with Enflurane or Alfatesine. Alfaxalone Alfadolone Mixture 93-103 prolactin Homo sapiens 52-55 6788010-2 1981 Her pregnancy was induced by pituitary gonadotrophins and the deficient prolactin pituitary reserve was shown by means of pituitary stimulation test with metoclopramide of pituitary stimulation test with metoclopramide and TRH. Metoclopramide 154-168 prolactin Homo sapiens 72-81 6788010-2 1981 Her pregnancy was induced by pituitary gonadotrophins and the deficient prolactin pituitary reserve was shown by means of pituitary stimulation test with metoclopramide of pituitary stimulation test with metoclopramide and TRH. Metoclopramide 204-218 prolactin Homo sapiens 72-81 7201788-0 1981 [Effect of oral administration of metoclopramide on blood levels of prolactin in the puerperium]. Metoclopramide 34-48 prolactin Homo sapiens 68-77 7337948-3 1981 On the contrary there was a statistically significant negative correlation between prolactin levels and palmitic acid/stearic acid ratio when this ratio was lower than 5 (incomplete fetal pulmonary maturation). Palmitic Acid 104-117 prolactin Homo sapiens 83-92 7337948-3 1981 On the contrary there was a statistically significant negative correlation between prolactin levels and palmitic acid/stearic acid ratio when this ratio was lower than 5 (incomplete fetal pulmonary maturation). stearic acid 118-130 prolactin Homo sapiens 83-92 7337949-1 1981 The authors examine the variations of PRL plasma levels after the administration of sodium thiopentale 500 mg i.v. sodium thiopentale 84-102 prolactin Homo sapiens 38-41 7337949-2 1981 to ten patients undergoing voluntary pregnancy interruption between the 8th and the 14th gestational week; PRL levels which were already elevated due to estrogen action, as is physiological in pregnancy, further increased after the anaesthetic drug injection confirming the ability of sodium thiopentale to increase prolactin levels even in estrogen-induced hyperprolactinemic conditions; the possible ways through which the drug may act are then discussed. sodium thiopentale 285-303 prolactin Homo sapiens 107-110 7015779-8 1981 In hyperprolactinemic anovulatory syndrome, a negative correlation between estradiol and PRL levels was found. Estradiol 75-84 prolactin Homo sapiens 89-92 7219880-0 1981 Effects of the interaction between methysergide and clonidine on growth hormone and prolactin secretion in normal man. Clonidine 52-61 prolactin Homo sapiens 84-93 7250073-0 1981 The effect of nomifensine on prolactin secretion in patients with suspected pituitary microadenoma. Nomifensine 14-25 prolactin Homo sapiens 29-38 7308272-0 1981 Radioimmunoassay of plasma lisuride in man following intravenous and oral administration of lisuride hydrogen maleate: effect on plasma prolactin level. Lisuride 27-35 prolactin Homo sapiens 136-145 6116608-0 1981 Prolactin secretion during reserpine and syrosingopine treatment. syrosingopine 41-54 prolactin Homo sapiens 0-9 6116608-1 1981 In 20 mild hypertensive women, reserpine induced a significant increase in mean plasma PRL, both under basal conditions (from 6.6 +/- 0.9 to 17.9 +/- 2.9 ng/ml), and on repeated determinations during the day. Reserpine 31-40 prolactin Homo sapiens 87-90 6800826-3 1981 Nalorphine produced a produced a prompt and sharp increase in serum PRL and a small, delayed rise in serum GH. Nalorphine 0-10 prolactin Homo sapiens 68-71 6896183-1 1981 In a placebo controlled double-blind study in six healthy male volunteers the effects of single oral doses of 100 mg and 200 mg of tolamolol on plasma concentrations of prolactin, growth hormone and luteinising hormone were investigated. tolamolol 131-140 prolactin Homo sapiens 169-178 6896183-3 1981 A dose dependent increase in plasma prolactin concentration was demonstrated after tolamolol. tolamolol 83-92 prolactin Homo sapiens 36-45 7337949-2 1981 to ten patients undergoing voluntary pregnancy interruption between the 8th and the 14th gestational week; PRL levels which were already elevated due to estrogen action, as is physiological in pregnancy, further increased after the anaesthetic drug injection confirming the ability of sodium thiopentale to increase prolactin levels even in estrogen-induced hyperprolactinemic conditions; the possible ways through which the drug may act are then discussed. sodium thiopentale 285-303 prolactin Homo sapiens 316-325 6894443-2 1981 Sprague-Dawley rats were treated with prolactin or with the prolactin-inhibitor ergocryptine. ergocryptine 80-92 prolactin Homo sapiens 60-69 6927819-2 1981 The nomifensine suppressive effect on prolactin serum levels was not significantly different between patients with or without enlargement of the sella turcica. Nomifensine 4-15 prolactin Homo sapiens 38-47 6927819-3 1981 A control group of 5 women with normal prolactin levels exhibited a nomifensine suppressive effect below 65% of the baseline prolactin level, which was significantly different from that in the hyperprolactinemic group. Nomifensine 68-79 prolactin Homo sapiens 39-48 6927819-3 1981 A control group of 5 women with normal prolactin levels exhibited a nomifensine suppressive effect below 65% of the baseline prolactin level, which was significantly different from that in the hyperprolactinemic group. Nomifensine 68-79 prolactin Homo sapiens 125-134 6120911-0 1981 Prolactin resistance to bromocryptine treatment: a case report. Bromocriptine 24-37 prolactin Homo sapiens 0-9 6120911-2 1981 After treatment with gradually increasing doses of bromocryptine, serum prolactin level (SPL) decreased slightly but became resistant and even elevated with increased doses. Bromocriptine 51-64 prolactin Homo sapiens 72-81 6120911-5 1981 The possibility that bromocryptine may have other effects on the process of ovulation than suppression of circulating prolactin is also to be considered. Bromocriptine 21-34 prolactin Homo sapiens 118-127 6117579-0 1981 The effect of amantadine on prolactin levels and galactorrhea on neuroleptic-treated patients. Amantadine 14-24 prolactin Homo sapiens 28-37 6278006-0 1981 Cyclic nucleotides and the control of epithelial cell proliferation: cyclic CMP may be a partial mediator of the response of the pigeon crop-sac to prolactin. Nucleotides, Cyclic 0-18 prolactin Homo sapiens 148-157 6787112-0 1981 Augmentation of prolactin response to TRH after cyproheptadine. Cyproheptadine 48-62 prolactin Homo sapiens 16-25 6455501-1 1981 Bromocriptine, a potent agonist at Dz receptors, was developed as a therapeutic agent for inhibiting prolactin (PRL) secretion in patients with hyperprolactinemia. Bromocriptine 0-13 prolactin Homo sapiens 101-110 6455501-1 1981 Bromocriptine, a potent agonist at Dz receptors, was developed as a therapeutic agent for inhibiting prolactin (PRL) secretion in patients with hyperprolactinemia. Bromocriptine 0-13 prolactin Homo sapiens 112-115 7264625-6 1981 During chronic L-Dopa + carbidopa therapy, the basal PRL levels, evaluated in 21 PP, showed a correlation with the severity of clinical features. Levodopa 15-21 prolactin Homo sapiens 53-56 7264625-6 1981 During chronic L-Dopa + carbidopa therapy, the basal PRL levels, evaluated in 21 PP, showed a correlation with the severity of clinical features. Carbidopa 24-33 prolactin Homo sapiens 53-56 7264625-7 1981 The effects of single doses of apomorphine, bromocriptine, lisuride and haloperidol, were studied on serum levels of PRL in 21 PP divided in two groups of "responders" and "non-responders". Apomorphine 31-42 prolactin Homo sapiens 117-120 7264625-7 1981 The effects of single doses of apomorphine, bromocriptine, lisuride and haloperidol, were studied on serum levels of PRL in 21 PP divided in two groups of "responders" and "non-responders". Haloperidol 72-83 prolactin Homo sapiens 117-120 7264625-8 1981 Haloperidol induced an enhancement of serum PRL; the dopaminergic drugs, apomorphine, bromocriptine and lisuride inhibited basal PRL secretion. Haloperidol 0-11 prolactin Homo sapiens 44-47 7264625-8 1981 Haloperidol induced an enhancement of serum PRL; the dopaminergic drugs, apomorphine, bromocriptine and lisuride inhibited basal PRL secretion. Haloperidol 0-11 prolactin Homo sapiens 129-132 7264625-8 1981 Haloperidol induced an enhancement of serum PRL; the dopaminergic drugs, apomorphine, bromocriptine and lisuride inhibited basal PRL secretion. Apomorphine 73-84 prolactin Homo sapiens 129-132 7264625-8 1981 Haloperidol induced an enhancement of serum PRL; the dopaminergic drugs, apomorphine, bromocriptine and lisuride inhibited basal PRL secretion. Bromocriptine 86-99 prolactin Homo sapiens 129-132 7264625-8 1981 Haloperidol induced an enhancement of serum PRL; the dopaminergic drugs, apomorphine, bromocriptine and lisuride inhibited basal PRL secretion. Lisuride 104-112 prolactin Homo sapiens 129-132 7288437-0 1981 Failure of naloxone to antagonize metoclopramide induced prolactin rise. Metoclopramide 34-48 prolactin Homo sapiens 57-66 6788910-0 1981 Prolactin response to thyrotropin-releasing hormone and cimetidine in patients with severe liver disease. Cimetidine 56-66 prolactin Homo sapiens 0-9 6796626-3 1981 In two patients taking medications (imipramine and dogmatil), prolactin levels were high. Imipramine 36-46 prolactin Homo sapiens 62-71 7202836-2 1981 Newly synthesized prolactin was identified by the amount of prolactin-associated tritium activity. Tritium 81-88 prolactin Homo sapiens 18-27 7202836-2 1981 Newly synthesized prolactin was identified by the amount of prolactin-associated tritium activity. Tritium 81-88 prolactin Homo sapiens 60-69 7202836-8 1981 During the 1-h incubation, estradiol (1.0 ng/ml) increased prolactin content in the medium, although no newly synthesized prolactin appeared in the medium or the cells. Estradiol 27-36 prolactin Homo sapiens 59-68 7202836-9 1981 During the 4-h incubation period significantly more labelled prolactin was released into the medium in the presence of estradiol (1.0 ng/ml) than in the control. Estradiol 119-128 prolactin Homo sapiens 61-70 7465018-0 1981 Effect of a psychoactive drug, trazodone, on prolactin secretion in man. Trazodone 31-40 prolactin Homo sapiens 45-54 7465018-1 1981 Administration of 50 mg trazodone, an antidepressant drug, in a single oral dose to 10 normal subjects of both sexes, aged 24--41, resulted in a significant (p less than 0.01) decrease of serum prolactin (PRL) values. Trazodone 24-33 prolactin Homo sapiens 194-203 7465018-1 1981 Administration of 50 mg trazodone, an antidepressant drug, in a single oral dose to 10 normal subjects of both sexes, aged 24--41, resulted in a significant (p less than 0.01) decrease of serum prolactin (PRL) values. Trazodone 24-33 prolactin Homo sapiens 205-208 7465018-2 1981 The mean serum PRL levels were 8.9 +/- 2.2 ng/ml in basal conditions and 4.5 +/- 1.7 ng/ml 180 min after trazodone. Trazodone 105-114 prolactin Homo sapiens 15-18 6170968-1 1981 Bromocriptine mesylate lowers the serum concentration of prolactin and TSH in patients with prostatic hypertrophy as a function of drug administration time. Bromocriptine 0-13 prolactin Homo sapiens 57-66 6170968-4 1981 Rigorous assessment of the effect of bromocriptine mesylate upon circulating TSH and prolactin requires consideration of the entire spectrum of rhythms, ultradian and infradian as well as circannual. Bromocriptine 37-50 prolactin Homo sapiens 85-94 6458025-5 1981 Plasma concentrations of FSH and LH were slightly diminished, whereas the prolactin level increased after CPA therapy. Cyproterone Acetate 106-109 prolactin Homo sapiens 74-83 6111824-1 1981 Plasma prolactin response to chlorpromazine challenge. Chlorpromazine 29-43 prolactin Homo sapiens 7-16 6111824-6 1981 It is concluded that the PRL rise following CPZ 50 mg IM identifies some patients whose PRL response to the current treatment was only submaximal but the absence of PRL increment after this test dose is not sufficient evidence that the baseline level was already maximal. Chlorpromazine 44-47 prolactin Homo sapiens 25-28 6111824-6 1981 It is concluded that the PRL rise following CPZ 50 mg IM identifies some patients whose PRL response to the current treatment was only submaximal but the absence of PRL increment after this test dose is not sufficient evidence that the baseline level was already maximal. Chlorpromazine 44-47 prolactin Homo sapiens 88-91 6111824-6 1981 It is concluded that the PRL rise following CPZ 50 mg IM identifies some patients whose PRL response to the current treatment was only submaximal but the absence of PRL increment after this test dose is not sufficient evidence that the baseline level was already maximal. Chlorpromazine 44-47 prolactin Homo sapiens 88-91 6267643-0 1981 Naloxone effects on beta-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers. Naloxone 0-8 prolactin Homo sapiens 46-55 6165128-1 1981 Three experiments were performed to determine whether human prolactin (hPr) affects prostatic uptake and metabolism of testosterone (T). Testosterone 119-131 prolactin Homo sapiens 60-69 6458145-0 1981 Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer. Cyproterone 10-21 prolactin Homo sapiens 49-58 6458145-0 1981 Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer. Acetates 22-29 prolactin Homo sapiens 49-58 6458145-0 1981 Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer. Cyproterone Acetate 31-37 prolactin Homo sapiens 49-58 6458145-1 1981 Plasma prolactin was measured in 10 patients with prostatic cancer during treatment with cyproterone acetate (300 mg/week i.m.) Cyproterone Acetate 89-108 prolactin Homo sapiens 7-16 6458145-5 1981 It is concluded from this study that cyproterone acetate interferes with prolactin secretion by the pituitary gland. Cyproterone Acetate 37-56 prolactin Homo sapiens 73-82 7202312-0 1981 [Gynaecological use of prolactin inhibitor bromocriptin (author"s transl)]. Bromocriptine 43-55 prolactin Homo sapiens 23-32 7202312-3 1981 Bromocriptin should be prescribed only at endocrinological institutions with facilities for follow-up control by serum prolactin assay. Bromocriptine 0-12 prolactin Homo sapiens 119-128 6258970-0 1980 Effect of prolactin on human red cell sodium transport. Sodium 38-44 prolactin Homo sapiens 10-19 6152844-0 1981 Effect of bromazepam on growth hormone and prolactin secretion in normal subjects. Bromazepam 10-20 prolactin Homo sapiens 43-52 6152844-1 1981 The growth hormone and prolactin response to oral bromazepam (3 mg) was assessed in 5 normal men and 5 normal women. Bromazepam 50-60 prolactin Homo sapiens 23-32 7437907-0 1980 Characterization of ergot and non-ergot serotonin antagonists by prolactin and growth hormone profiles during wakefulness and sleep. Serotonin 40-49 prolactin Homo sapiens 65-74 7437907-5 1980 Methysergide and bromocriptine, two ergot derivatives, significantly (P < 0.01 and P < 0.001 respectively) suppressed the basal secretion of PRL throughout the trial and increased plasma GH significantly (P < 0.01). Methysergide 0-12 prolactin Homo sapiens 147-150 7437907-5 1980 Methysergide and bromocriptine, two ergot derivatives, significantly (P < 0.01 and P < 0.001 respectively) suppressed the basal secretion of PRL throughout the trial and increased plasma GH significantly (P < 0.01). Bromocriptine 17-30 prolactin Homo sapiens 147-150 7437907-7 1980 Bromocriptine suppressed completely PRL secretion throughout the entire sleep period and significantly (P < 0.05) prolonged the secretory profile of GH. Bromocriptine 0-13 prolactin Homo sapiens 36-39 6779473-4 1980 The serum concentration of prolactin was unchanged in patients receiving 2 mg oestradiol-17 beta plus 1 mg oestriol but increased in patients receiving 4 mg oestradiol-17 beta plus 2 mg oestriol or 50 micrograms ethinyl-oestradiol, thus indicating dose-dependence for natural human oestrogens. Estradiol 78-96 prolactin Homo sapiens 27-36 6779473-4 1980 The serum concentration of prolactin was unchanged in patients receiving 2 mg oestradiol-17 beta plus 1 mg oestriol but increased in patients receiving 4 mg oestradiol-17 beta plus 2 mg oestriol or 50 micrograms ethinyl-oestradiol, thus indicating dose-dependence for natural human oestrogens. Estriol 107-115 prolactin Homo sapiens 27-36 6779473-4 1980 The serum concentration of prolactin was unchanged in patients receiving 2 mg oestradiol-17 beta plus 1 mg oestriol but increased in patients receiving 4 mg oestradiol-17 beta plus 2 mg oestriol or 50 micrograms ethinyl-oestradiol, thus indicating dose-dependence for natural human oestrogens. Estradiol 157-175 prolactin Homo sapiens 27-36 6779473-4 1980 The serum concentration of prolactin was unchanged in patients receiving 2 mg oestradiol-17 beta plus 1 mg oestriol but increased in patients receiving 4 mg oestradiol-17 beta plus 2 mg oestriol or 50 micrograms ethinyl-oestradiol, thus indicating dose-dependence for natural human oestrogens. Estriol 186-194 prolactin Homo sapiens 27-36 6779473-4 1980 The serum concentration of prolactin was unchanged in patients receiving 2 mg oestradiol-17 beta plus 1 mg oestriol but increased in patients receiving 4 mg oestradiol-17 beta plus 2 mg oestriol or 50 micrograms ethinyl-oestradiol, thus indicating dose-dependence for natural human oestrogens. Ethinyl Estradiol 212-230 prolactin Homo sapiens 27-36 7456974-2 1980 Benserazide induced in all subjects a quick and marked increment of serum prolactin (Prl) and TSH levels: at 180 min TSH and Prl levels were still significantly higher than the baseline values. Benserazide 0-11 prolactin Homo sapiens 74-83 6258970-1 1980 Incubation of red cells with higher concentrations of prolactin in vitro enhanced the cellular sodium level and produced a significant reduction in erythrocyte membrane adenosine triphosphatase activity. Sodium 95-101 prolactin Homo sapiens 54-63 7226569-0 1980 Effect of dopamine infusion on serum prolactin concentration in normal and hyperprolactinaemic subjects. Dopamine 10-18 prolactin Homo sapiens 37-46 7226569-1 1980 The serum prolactin response to intravenous dopamine infusion (5 micrograms . Dopamine 44-52 prolactin Homo sapiens 10-19 7226569-7 1980 Since intravenously infused dopamine is believed to inhibit prolactin secretion by acting at pituitary level, it is suggested that a normal functioning of pituitary dopamine receptors is maintained in most human prolactinomas. Dopamine 28-36 prolactin Homo sapiens 60-69 7226570-1 1980 It has been reported that administration of nomifensine (Nom) or of L-dopa + carbidopa (L-dopa + Carb) potentiates central dopaminergic tonus, resulting in decreased prolactin (PRL) secretion. Nomifensine 44-55 prolactin Homo sapiens 177-180 7226570-1 1980 It has been reported that administration of nomifensine (Nom) or of L-dopa + carbidopa (L-dopa + Carb) potentiates central dopaminergic tonus, resulting in decreased prolactin (PRL) secretion. Levodopa 68-74 prolactin Homo sapiens 177-180 7226570-1 1980 It has been reported that administration of nomifensine (Nom) or of L-dopa + carbidopa (L-dopa + Carb) potentiates central dopaminergic tonus, resulting in decreased prolactin (PRL) secretion. Carbidopa 77-86 prolactin Homo sapiens 177-180 7226570-1 1980 It has been reported that administration of nomifensine (Nom) or of L-dopa + carbidopa (L-dopa + Carb) potentiates central dopaminergic tonus, resulting in decreased prolactin (PRL) secretion. Levodopa 88-94 prolactin Homo sapiens 177-180 7226570-6 1980 PRL levels decreased in the normal controls below the basal values by 61.3% +/- 6.2 (SEM) after Nom and 77.6% +/- 4.2 after L-dopa + Carb. Levodopa 124-130 prolactin Homo sapiens 0-3 7226570-7 1980 Decreases in serum PRL of at least 50% (in three consecutive determinations) were found in group A in 20% of patients after Nom and in 25% after L-dopa + Carb; in group B in 15% and 40% of cases; in most of the hyperprolactinaemic women in group C; and some in group D. In conclusion, these two treatments did not discriminate between tumorous and non-tumorous cases of PRL hypersecretion. Levodopa 145-151 prolactin Homo sapiens 19-22 7226572-1 1980 The effects of two new ergolines, pergolide and CH29-717, on prolactin secretion in vitro and in vivo were compared with those of bromocriptine. Ergolines 23-32 prolactin Homo sapiens 61-70 7226572-1 1980 The effects of two new ergolines, pergolide and CH29-717, on prolactin secretion in vitro and in vivo were compared with those of bromocriptine. Pergolide 34-43 prolactin Homo sapiens 61-70 7226572-3 1980 However, in vivo both were longer acting than bromocriptine after a single dose of 100 micrograms, and effectively suppressed prolactin secretion for greater than 24 h. It would appear that the pharmacokinetics of these ergolines are different to those of bromocriptine, and this may have considerable therapeutic importance. Ergolines 220-229 prolactin Homo sapiens 126-135 6778717-0 1980 Exaggerated prolactin response to thyrotropin-releasing hormone and metoclopramide in primary testicular failure. Metoclopramide 68-82 prolactin Homo sapiens 12-21 7011468-4 1980 Average plasma prolactin levels were within the normal rage for untreated men in one quarter of non-relapsing patients on pimozide and three quarters on fluphenazine. Pimozide 122-130 prolactin Homo sapiens 15-24 7011468-4 1980 Average plasma prolactin levels were within the normal rage for untreated men in one quarter of non-relapsing patients on pimozide and three quarters on fluphenazine. Fluphenazine 153-165 prolactin Homo sapiens 15-24 7214106-2 1980 A correlation was found between extrapyramidal symptoms and prolactin levels and also between plasma haloperidol concentration and plasma prolactin levels. Haloperidol 101-112 prolactin Homo sapiens 138-147 7440704-0 1980 Central nervous system-mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. Cimetidine 70-80 prolactin Homo sapiens 47-56 7440704-0 1980 Central nervous system-mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. Cimetidine 70-80 prolactin Homo sapiens 159-168 7452120-0 1980 Decrease in human plasma prolactin levels by oral prostaglandin E2 in early puerperium. Dinoprostone 50-66 prolactin Homo sapiens 25-34 7452120-4 1980 It is suggested that a PGE2-induced decrease in prolactin could be mediated by hypothalamic dopaminergic neurones. Dinoprostone 23-27 prolactin Homo sapiens 48-57 6111101-0 1980 Increased serum prolactin levels during phenothiazine and butyrophenone treatment of six postpartum women. phenothiazine 40-53 prolactin Homo sapiens 16-25 6111101-0 1980 Increased serum prolactin levels during phenothiazine and butyrophenone treatment of six postpartum women. Butyrophenones 58-71 prolactin Homo sapiens 16-25 6110542-1 1980 Imidoline, 1-[2-(N,N-dimethylamino)ethyl]-3-m-chlorophenyl-2-imidazolidinone, has been found to be as potent as chlorpromazine in increasing striatal DOPA accumulation and prolactin secretion in vivo. imidoline 0-9 prolactin Homo sapiens 172-181 6110542-1 1980 Imidoline, 1-[2-(N,N-dimethylamino)ethyl]-3-m-chlorophenyl-2-imidazolidinone, has been found to be as potent as chlorpromazine in increasing striatal DOPA accumulation and prolactin secretion in vivo. 1-[2-(n,n-dimethylamino)ethyl]-3-m-chlorophenyl-2-imidazolidinone 11-76 prolactin Homo sapiens 172-181 6110542-1 1980 Imidoline, 1-[2-(N,N-dimethylamino)ethyl]-3-m-chlorophenyl-2-imidazolidinone, has been found to be as potent as chlorpromazine in increasing striatal DOPA accumulation and prolactin secretion in vivo. Chlorpromazine 112-126 prolactin Homo sapiens 172-181 6780195-0 1980 [Thyroid gland hormones and their effect on serum prolactin level after thyreoliberin-VUFB (author"s transl)]. thyreoliberin-vufb 72-90 prolactin Homo sapiens 50-59 6449151-0 1980 Prolactin modulation of dehydroepiandrosterone sulfate secretion. Dehydroepiandrosterone Sulfate 24-54 prolactin Homo sapiens 0-9 6449151-1 1980 To clarify the controversy about the effect of prolactin (PRL) on dehydroepiandrosterone sulfate (DHEA-S), this study was undertaken to investigate the effects of alterations in plasma PRL on plasma DHEA-S concentrations in hyperprolactinemic women, as well as in normal male subjects. Dehydroepiandrosterone Sulfate 66-96 prolactin Homo sapiens 58-61 7435530-5 1980 In an attempt to establish whether bromocriptine has a direct inhibitory effect on pituitary secretion of prolactin (PRL), variable doses of bromocriptine were added to duplicate plates. Bromocriptine 35-48 prolactin Homo sapiens 106-115 7435531-1 1980 Fetal calf serum (FCS) enhances the synthesis and secretion of prolactin (PRL) by explants of human decidua incubated in Gey"s balanced salt solution. gey"s balanced salt solution 121-149 prolactin Homo sapiens 63-72 6108034-1 1980 We have compared the effects of cimetidine and SK&F 92994, a new more potent histamine H2 receptor antagonist, on serum prolactin, and also assessed the effect of the H2 receptor agonist impromidine on the response to cimetidine. amicloral 47-53 prolactin Homo sapiens 124-133 6108034-2 1980 As previously reported, cimetidine 200 mg given as an iv bolus dose produced a marked rise in serum prolactin, but 50 mg and 200 mg of SK&F 92994 given by the same route had no effect. Cimetidine 24-34 prolactin Homo sapiens 100-109 6108034-4 1980 It is concluded that the rise in serum prolactin following iv administration of cimetidine may be due to a specific property of cimetidine. Cimetidine 80-90 prolactin Homo sapiens 39-48 6108034-4 1980 It is concluded that the rise in serum prolactin following iv administration of cimetidine may be due to a specific property of cimetidine. Cimetidine 128-138 prolactin Homo sapiens 39-48 6781229-0 1980 Prolactin, LH and FSH changes induced by cimetidine and bromocriptine. Cimetidine 41-51 prolactin Homo sapiens 0-9 6781229-0 1980 Prolactin, LH and FSH changes induced by cimetidine and bromocriptine. Bromocriptine 56-69 prolactin Homo sapiens 0-9 6781997-3 1980 When compared to normally ovulating women, 3 groups could be segregated: in group I basal (less 500 mU/l) as well as MTCL stimulated PRL (less 8000 mU/l) was normal; in group II-patients only basal PRL levels were elevated; in group III baseline levels of serum PRL were at the borderline, but PRL release after MTCL stimulation was exaggerated. Metoclopramide 117-121 prolactin Homo sapiens 133-136 6781997-5 1980 Suppression of PRL release by bromocriptin (2.5 mg bid) from the day following the MTCL test resulted in significantly reduced basal as well stimulated serum PRL on day 22 of the treatment cycle. Bromocriptine 30-42 prolactin Homo sapiens 15-18 6781997-5 1980 Suppression of PRL release by bromocriptin (2.5 mg bid) from the day following the MTCL test resulted in significantly reduced basal as well stimulated serum PRL on day 22 of the treatment cycle. Bromocriptine 30-42 prolactin Homo sapiens 158-161 6781997-9 1980 This is underlined by the fact that bromocriptin treatment resulted in normalization of luteal P output only, when PRL was elevated. Bromocriptine 36-48 prolactin Homo sapiens 115-118 7435124-0 1980 Bromocriptine treatment during early human pregnancy: effect on the levels of prolactin, sex steroids and placental lactogen. Bromocriptine 0-13 prolactin Homo sapiens 78-87 7435124-3 1980 Bromocriptine treatment induced a significant Prl depression at one week (7.3 +/- 4.3 ng/ml vs 23.7 +/- 11.4 ng/ml) and two weeks (5.3 +/- 2.5 ng/ml vs 31.9 +/- 16.4 ng/ml). Bromocriptine 0-13 prolactin Homo sapiens 46-49 6778717-8 1980 It is concluded that oligospermic and azoospermic subjects with the most severe testicular failure and the highest gonadotropin levels have the greatest PRL increases after TRH and metoclopramide, indicating that the PRL response is related to the degree of testicular failure. Metoclopramide 181-195 prolactin Homo sapiens 153-156 6778717-8 1980 It is concluded that oligospermic and azoospermic subjects with the most severe testicular failure and the highest gonadotropin levels have the greatest PRL increases after TRH and metoclopramide, indicating that the PRL response is related to the degree of testicular failure. Metoclopramide 181-195 prolactin Homo sapiens 217-220 6784976-3 1980 After 4 months treatment with bromocriptine a significant fall in plasma prolactin was observed (P less than 0.01), both under basal conditions and following thyroid stimulating hormone releasing hormone (TRH). Bromocriptine 30-43 prolactin Homo sapiens 73-82 6777202-0 1980 Stimulatory effect of clebopride on human prolactin secretion. clebopride 22-32 prolactin Homo sapiens 42-51 6775003-3 1980 Two to 6 months after successful tumor removal, serum PRL rose 2-fold (the usual criterion for a normal response) in 73% after TRH, in 100% after MCP, but in only 13% after CPZ and in only 14% on ITT. Metoclopramide 146-149 prolactin Homo sapiens 54-57 6775003-3 1980 Two to 6 months after successful tumor removal, serum PRL rose 2-fold (the usual criterion for a normal response) in 73% after TRH, in 100% after MCP, but in only 13% after CPZ and in only 14% on ITT. Chlorpromazine 173-176 prolactin Homo sapiens 54-57 6777462-1 1980 Levodopa with carbidopa suppressed prolactin release induced by thyrotrophin releasing hormone less effectively in patients with idiopathic Parkinson"s disease than in normal subjects. Levodopa 0-8 prolactin Homo sapiens 35-44 6777462-1 1980 Levodopa with carbidopa suppressed prolactin release induced by thyrotrophin releasing hormone less effectively in patients with idiopathic Parkinson"s disease than in normal subjects. Carbidopa 14-23 prolactin Homo sapiens 35-44 6111093-0 1980 [Effect of high single doses of bromocriptine in schizophrenic patients with elevated serum prolactin levels and extrapyramidal side effects associated with neuroleptic treatment (author"s transl)]. Bromocriptine 32-45 prolactin Homo sapiens 92-101 6111093-1 1980 The purpose of the present study was to investigate the effect of bromocriptine in single doses of 20 and 30 mg on the unwanted effects most frequently caused by neuroleptics: elevated prolactin levels and extrapyramidal disturbances. Bromocriptine 66-79 prolactin Homo sapiens 185-194 6111093-3 1980 It was found that a single dose of 30 mg bromocriptine brought about a statistically significant decrease in the prolactin levels of patients treated with haloperidol but produced no more than a downward tendency in patients receiving chlorpromazine (the initial prolactin levels of both groups of patients were equal.) Bromocriptine 41-54 prolactin Homo sapiens 113-122 6111093-3 1980 It was found that a single dose of 30 mg bromocriptine brought about a statistically significant decrease in the prolactin levels of patients treated with haloperidol but produced no more than a downward tendency in patients receiving chlorpromazine (the initial prolactin levels of both groups of patients were equal.) Bromocriptine 41-54 prolactin Homo sapiens 263-272 6111093-3 1980 It was found that a single dose of 30 mg bromocriptine brought about a statistically significant decrease in the prolactin levels of patients treated with haloperidol but produced no more than a downward tendency in patients receiving chlorpromazine (the initial prolactin levels of both groups of patients were equal.) Haloperidol 155-166 prolactin Homo sapiens 113-122 6776354-0 1980 [Response of prolactin to thyrotrophin-RH(TRH) and chlorpromazine stimulation in the syndrome of hypogonadism and anosmia (author"s transl)]. Chlorpromazine 51-65 prolactin Homo sapiens 13-22 7437461-1 1980 Three forms of human pituitary prolactin, separable at alkaline pH in a highly purified preparation, were isolated by means of column electrophoresis in agarose suspension. Sepharose 153-160 prolactin Homo sapiens 31-40 7414322-0 1980 Suppression of prolactin secretion in normal young women by 2-hydroxyestrone. 2-hydroxyestrone 60-76 prolactin Homo sapiens 15-24 7414322-1 1980 The nonuterotropic natural estrogen 2-hydroxyestrone administered to normal young women results in a prompt and profound suppression of serum prolactin in most of the subjects. 2-hydroxyestrone 36-52 prolactin Homo sapiens 142-151 7435113-0 1980 Effect of sulpiride on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia. Sulpiride 10-19 prolactin Homo sapiens 30-39 7435113-1 1980 The effect of 100 mg im sulpiride on plasma Prl levels was studied in 10 normal females, 21 patients with galactorrhoea and normal plasma Prl, 10 women with puerperal hyperprolactinaemia and 27 patients with amenorrhoea-galactorrhoea and high plasma Prl levels. Sulpiride 24-33 prolactin Homo sapiens 44-47 7435113-2 1980 The response to sulpiride in patients with galactorrhoea but normal PRL was slightly higher (P < 0.05) than that observed in normal women, but only if expressed in per cent. Sulpiride 16-25 prolactin Homo sapiens 68-71 7435113-6 1980 In the last 3 patients with pathological hyperprolactinaemia in whom a consistent Prl increase after sulpiride was observed, hyperprolactinaemia was probably not of tumourous origin. Sulpiride 101-110 prolactin Homo sapiens 82-85 7435113-7 1980 On the basis of these results, the sulpiride test appears promising for discriminating between organic and "functional" cases of enhanced Prl secretion. Sulpiride 35-44 prolactin Homo sapiens 138-141 6448002-0 1980 Stable prolactin level after enhanced estradiol production following dehydroepiandrosterone sulfate. Estradiol 38-47 prolactin Homo sapiens 7-16 6448002-0 1980 Stable prolactin level after enhanced estradiol production following dehydroepiandrosterone sulfate. Dehydroepiandrosterone Sulfate 69-99 prolactin Homo sapiens 7-16 6448002-1 1980 To evaluate whether intravenous injection of dehydroepiandrosterone sulfate (DHEAS), by enhancing estradiol (E2) production, would stimulate prolactin (PRL) secretion in late pregnancy, maternal serum PRL was determined before and 1 to 5 hours after administration of 100 mg of DHEAS in a total of 41 women with normal or complicated late pregnancies (twin pregnancy, pre-eclampsia, intrahepatic cholestasis of pregnancy, diabetes). Dehydroepiandrosterone Sulfate 45-75 prolactin Homo sapiens 141-150 6448002-1 1980 To evaluate whether intravenous injection of dehydroepiandrosterone sulfate (DHEAS), by enhancing estradiol (E2) production, would stimulate prolactin (PRL) secretion in late pregnancy, maternal serum PRL was determined before and 1 to 5 hours after administration of 100 mg of DHEAS in a total of 41 women with normal or complicated late pregnancies (twin pregnancy, pre-eclampsia, intrahepatic cholestasis of pregnancy, diabetes). Dehydroepiandrosterone Sulfate 45-75 prolactin Homo sapiens 152-155 6448002-1 1980 To evaluate whether intravenous injection of dehydroepiandrosterone sulfate (DHEAS), by enhancing estradiol (E2) production, would stimulate prolactin (PRL) secretion in late pregnancy, maternal serum PRL was determined before and 1 to 5 hours after administration of 100 mg of DHEAS in a total of 41 women with normal or complicated late pregnancies (twin pregnancy, pre-eclampsia, intrahepatic cholestasis of pregnancy, diabetes). Dehydroepiandrosterone Sulfate 45-75 prolactin Homo sapiens 201-204 7426491-3 1980 This increase was not seen in women treated with bromocriptine whose prolactin level of 8.6 +/- 1.4 ng/ml (mean +/- SE) before abortion was lower than that of 29.6 +/- 6.4 ng/ml found in normal women. Bromocriptine 49-62 prolactin Homo sapiens 69-78 6773746-5 1980 Thre rate of release of PRL (RIA) was stable throughout the experimental period. Threonine 0-4 prolactin Homo sapiens 24-27 6773746-6 1980 In unstimulated cells the ratio of 3H- to 14C-labeled PRL in the medium at the end of a 1-h incubation following the second chase was twice that in the cells at the beginning of this incubation, indicating that newly synthesized [3H]PRL was preferentially released. Carbon-14 42-45 prolactin Homo sapiens 54-57 6773746-7 1980 Stimulation with TRH resulted in increased release of older [14C]PRL. Carbon-14 61-64 prolactin Homo sapiens 65-68 6773746-8 1980 The earliest that radiolabeled (14C or 3H) PRL could be detected in the medium was 15--30 min after exposure of the cells to isotope. Carbon-14 32-35 prolactin Homo sapiens 43-46 6773746-8 1980 The earliest that radiolabeled (14C or 3H) PRL could be detected in the medium was 15--30 min after exposure of the cells to isotope. Tritium 39-41 prolactin Homo sapiens 43-46 6782152-0 1980 Effects of depot testosterone administration on serum levels of testosterone, FSH, LH and prolactin. Testosterone 17-29 prolactin Homo sapiens 90-99 7204884-0 1980 The effect of tamoxifen on GH and PRL secretion by human pituitary tumors. Tamoxifen 14-23 prolactin Homo sapiens 34-37 7204884-3 1980 In one patient with a presumably "mixed" GH-PRL secreting pituitary tumor tamoxifen had a suppressive action on hormone release. Tamoxifen 74-83 prolactin Homo sapiens 44-47 7430914-5 1980 While prolactin markedly proliferated and anti-prolactin serum significantly inhibited the mucosal weight, oestradiol, TRH and perphenazine dramatically depressed proliferation of the mucosa, suggesting that prolactin secretion was inhibited. Estradiol 107-117 prolactin Homo sapiens 47-56 7430914-5 1980 While prolactin markedly proliferated and anti-prolactin serum significantly inhibited the mucosal weight, oestradiol, TRH and perphenazine dramatically depressed proliferation of the mucosa, suggesting that prolactin secretion was inhibited. Estradiol 107-117 prolactin Homo sapiens 47-56 7430914-5 1980 While prolactin markedly proliferated and anti-prolactin serum significantly inhibited the mucosal weight, oestradiol, TRH and perphenazine dramatically depressed proliferation of the mucosa, suggesting that prolactin secretion was inhibited. Perphenazine 127-139 prolactin Homo sapiens 47-56 7430914-5 1980 While prolactin markedly proliferated and anti-prolactin serum significantly inhibited the mucosal weight, oestradiol, TRH and perphenazine dramatically depressed proliferation of the mucosa, suggesting that prolactin secretion was inhibited. Perphenazine 127-139 prolactin Homo sapiens 47-56 7430914-6 1980 Tamoxifen, anti-TRH serum and bromocriptine significantly increased the proliferation of the crop mucosa, indicating an increase in the endogenous release of prolactin. Tamoxifen 0-9 prolactin Homo sapiens 158-167 7430914-6 1980 Tamoxifen, anti-TRH serum and bromocriptine significantly increased the proliferation of the crop mucosa, indicating an increase in the endogenous release of prolactin. Bromocriptine 30-43 prolactin Homo sapiens 158-167 7005522-3 1980 Alterations in the metabolism of pancreatic alpha and beta cell hormones and of prolactin in chronic renal failure and their effect on the metabolism of lipids and carbohydrates and on reproductive function in this condition are discussed. Carbohydrates 164-177 prolactin Homo sapiens 80-89 7240824-4 1980 (2) There was a significant decrease of serum PRL following administration of CB-154, and the finding was the same in the group of women with successful ovulatory induction. Bromocriptine 78-84 prolactin Homo sapiens 46-49 7240824-8 1980 (5) The Little PRL content ratio decreased after administration of CB-154, and this data have suggested that not only the problem of immunologically measured serum PRL levels but the qualitative problems also bear relations to the effect of this hormone on the endocrinological environment. Bromocriptine 68-74 prolactin Homo sapiens 16-19 7240824-8 1980 (5) The Little PRL content ratio decreased after administration of CB-154, and this data have suggested that not only the problem of immunologically measured serum PRL levels but the qualitative problems also bear relations to the effect of this hormone on the endocrinological environment. Bromocriptine 68-74 prolactin Homo sapiens 165-168 7456470-0 1980 [The plasma prolactin level under fluphenazine treatment (author"s transl)]. Fluphenazine 34-46 prolactin Homo sapiens 12-21 7456470-7 1980 Infusions of 20 to 40 mg fluphenazine every three hours led to an average of fourfold increase of prolactin, which returned to the original level after 10 hours. Fluphenazine 25-37 prolactin Homo sapiens 98-107 7456470-8 1980 The plasma prolactin level reached a plateau on the 7th day of treatment with fluphenazine dihydrochloride. Fluphenazine 78-106 prolactin Homo sapiens 11-20 7456470-9 1980 Together with the stabilisation of the plasma prolactin level, which is reached more quickly with simultaneously administered fluphenazine decanoate, generally an improvement of the psychopathological condition takes place. fluphenazine depot 126-148 prolactin Homo sapiens 46-55 6893323-2 1980 Electrophoresis of cell extracts from cultures labeled with [35S]methionine demonstrated that treatment with the dopaminergic drug, ergocryptine, specifically inhibited prolactin synthesis. Sulfur-35 61-64 prolactin Homo sapiens 169-178 6893323-2 1980 Electrophoresis of cell extracts from cultures labeled with [35S]methionine demonstrated that treatment with the dopaminergic drug, ergocryptine, specifically inhibited prolactin synthesis. Methionine 65-75 prolactin Homo sapiens 169-178 6893323-2 1980 Electrophoresis of cell extracts from cultures labeled with [35S]methionine demonstrated that treatment with the dopaminergic drug, ergocryptine, specifically inhibited prolactin synthesis. ergocryptine 132-144 prolactin Homo sapiens 169-178 6893323-3 1980 Analysis of the time course of ergocryptine effects demonstrated that prolactin synthesis decreased sharply after 1 to 2 days of treatment and appeared to reach a new level of 26 to 28% of control values after 4 to 6 days of treatment. ergocryptine 31-43 prolactin Homo sapiens 70-79 6893323-4 1980 The concentration of ergocryptine which produced half-maximal inhibition of prolactin synthesis was about 0.3 nM. ergocryptine 21-33 prolactin Homo sapiens 76-85 6893323-5 1980 The inhibition of prolactin synthesis produced by ergoctryptine treatment was reversed by removal of the ergocryptine. ergoctryptine 50-63 prolactin Homo sapiens 18-27 6893323-5 1980 The inhibition of prolactin synthesis produced by ergoctryptine treatment was reversed by removal of the ergocryptine. ergocryptine 105-117 prolactin Homo sapiens 18-27 6893323-6 1980 Dopamine, ergocryptine, and bromoergocryptine (also a dopamine agonist) all inhibited prolactin synthesis while epinephrine and norepinephrine had little effect. Dopamine 0-8 prolactin Homo sapiens 86-95 6893323-6 1980 Dopamine, ergocryptine, and bromoergocryptine (also a dopamine agonist) all inhibited prolactin synthesis while epinephrine and norepinephrine had little effect. ergocryptine 10-22 prolactin Homo sapiens 86-95 6893323-6 1980 Dopamine, ergocryptine, and bromoergocryptine (also a dopamine agonist) all inhibited prolactin synthesis while epinephrine and norepinephrine had little effect. Bromocriptine 28-45 prolactin Homo sapiens 86-95 6893323-6 1980 Dopamine, ergocryptine, and bromoergocryptine (also a dopamine agonist) all inhibited prolactin synthesis while epinephrine and norepinephrine had little effect. Dopamine 54-62 prolactin Homo sapiens 86-95 6893323-8 1980 Analysis of cultures treated either for varying times or with varying doses of ergocryptine demonstrated that there was a close correspondence between the inhibition of prolactin synthesis and the inhibition of prolactin mRNA levels. ergocryptine 79-91 prolactin Homo sapiens 169-178 6893323-8 1980 Analysis of cultures treated either for varying times or with varying doses of ergocryptine demonstrated that there was a close correspondence between the inhibition of prolactin synthesis and the inhibition of prolactin mRNA levels. ergocryptine 79-91 prolactin Homo sapiens 211-220 6786002-0 1980 [Different effects of tricyclic (clomipramine and amitriptyline) and tetracyclic (maprotiline) antidepressors on the release of thyroid stimulating hormone, prolactin and growth hormone to thyrostimulating releasing hormone in patients with psychoaffective disorders (author"s transl)]. Clomipramine 33-45 prolactin Homo sapiens 157-166 6786002-0 1980 [Different effects of tricyclic (clomipramine and amitriptyline) and tetracyclic (maprotiline) antidepressors on the release of thyroid stimulating hormone, prolactin and growth hormone to thyrostimulating releasing hormone in patients with psychoaffective disorders (author"s transl)]. Amitriptyline 50-63 prolactin Homo sapiens 157-166 6786002-0 1980 [Different effects of tricyclic (clomipramine and amitriptyline) and tetracyclic (maprotiline) antidepressors on the release of thyroid stimulating hormone, prolactin and growth hormone to thyrostimulating releasing hormone in patients with psychoaffective disorders (author"s transl)]. Maprotiline 82-93 prolactin Homo sapiens 157-166 7234451-3 1980 Several unexpected findings related to neuroleptic-induced prolactin response and its suppression by dopamine infusion have been observed. Dopamine 101-109 prolactin Homo sapiens 59-68 7416906-6 1980 Haloperidol values determined by GC and RIA analyses correlated highly with prolactin concentrations in the same samples, suggesting that the usefulness of prolactin measurement as an "in vivo bioassay" for circulating levels of haloperidol should be further explored. Haloperidol 0-11 prolactin Homo sapiens 156-165 7011596-0 1980 Effects of cyproheptadine on insulin-induced hypoglycaemia secretion of PRL, GH and cortisol. Cyproheptadine 11-25 prolactin Homo sapiens 72-75 7011596-1 1980 The effect of cyproheptadine hydrochloride on release of prolactin (PRL), growth hormone (GH) and cortisol following insulin-induced hypoglycaemia was investigated in a group of eight adult female and male subjects. Cyproheptadine 14-42 prolactin Homo sapiens 57-66 6105975-0 1980 Dopamine, PIF, and other regulators of prolactin secretion. Dopamine 0-8 prolactin Homo sapiens 39-48 6105975-1 1980 Considerable evidence now exists that dopamine is a physiological prolactin inhibiting factor (PIF); however, it may not represent the only PIF. Dopamine 38-46 prolactin Homo sapiens 66-75 6105975-2 1980 Amphetamine, which releases newly synthesized dopamine and blocks prolactin release, caused an increased in dopamine levels in the pituitaryb gloand. Amphetamine 0-11 prolactin Homo sapiens 66-75 6105975-2 1980 Amphetamine, which releases newly synthesized dopamine and blocks prolactin release, caused an increased in dopamine levels in the pituitaryb gloand. Dopamine 108-116 prolactin Homo sapiens 66-75 6775949-0 1980 Prolactin response to exercise, metoclopramide and other provacative agents in children. Metoclopramide 32-46 prolactin Homo sapiens 0-9 7409210-5 1980 As assessed by the increased plasma prolactin levels following administration of a maximal dose of the DA antagonist thioproperazine, estrogens increase DA release from the hypothalamus. thioproperazine 117-132 prolactin Homo sapiens 36-45 7409210-7 1980 Under the same experimental conditions, dihydrotestosterone exerts inhibitory effects on spontaneous prolactin secretion and can reverse the stimulatory effects of estrogens. Dihydrotestosterone 40-59 prolactin Homo sapiens 101-110 7410539-0 1980 Prolactin responsiveness to nomifensine in patients with hyperprolactinemia of tumorous or uncertain etiology. Nomifensine 28-39 prolactin Homo sapiens 0-9 6773972-3 1980 However, medical therapy with bromocriptine, a dopamine agonist, not only suppresses PRL levels, but may also lead to a reduction in tumor size. Bromocriptine 30-43 prolactin Homo sapiens 85-88 6773972-3 1980 However, medical therapy with bromocriptine, a dopamine agonist, not only suppresses PRL levels, but may also lead to a reduction in tumor size. Dopamine 47-55 prolactin Homo sapiens 85-88 6773972-5 1980 We have now documented, for the first time, objective evidence of extremely rapid reduction in tumor size in two patients harboring large PRL-secreting pituitary tumors (mean pretreatment serum PRL levels, 2350 and 3900 ng/ml) who were prospectively treated with bromocriptine (7.5 mg/day) in preference to surgical intervention despite marked visual impairment in one of the patients. Bromocriptine 263-276 prolactin Homo sapiens 138-141 6773972-8 1980 Although the mechanism of bromocriptine"s antitumor activity is unclear, we believe that a large prospective trial to study the effects of bromocriptine therapy on the size of PRL-secreting macroadenomas is urgently needed to determine whether medical therapy should become the primary modality of treatment to reduce tumor size as well as restore endocrine function. Bromocriptine 139-152 prolactin Homo sapiens 176-179 6774202-4 1980 The remainder had decreased basal PRL levels with impaired PRL responses to TRH and the dopaminergic antagonist metoclopramide (MET). Metoclopramide 112-126 prolactin Homo sapiens 34-37 6998012-3 1980 Heterogeneous hypothalamic defects may be responsible for the variable PRL responses to chlorpromazine stimulation reported in the literature. Chlorpromazine 88-102 prolactin Homo sapiens 71-74 7434180-3 1980 Surgical treatment in patients with microadenomas is comparable to bromocriptine therapy for achieving normalization of prolactin levels and fertility. Bromocriptine 67-80 prolactin Homo sapiens 120-129 6259774-1 1980 Using feminizing adrenal neoplastic gland (FANG) cells we showed that hPRL stimulated cGMP biosynthesis. Cyclic GMP 86-90 prolactin Homo sapiens 70-74 6259774-3 1980 These findings indicate that a stimulatory effect of hPRL on estrogen biosynthesis by Fang-8 cells may act via increased cGMP concomitant with depressed cAMP. Cyclic GMP 121-125 prolactin Homo sapiens 53-57 6259774-3 1980 These findings indicate that a stimulatory effect of hPRL on estrogen biosynthesis by Fang-8 cells may act via increased cGMP concomitant with depressed cAMP. Cyclic AMP 153-157 prolactin Homo sapiens 53-57 7392156-1 1980 A 30-year-old acromegalic woman with amenorrhea and elevated growth hormone and prolactin levels was treated with bromocriptine. Bromocriptine 114-127 prolactin Homo sapiens 80-89 6776354-7 1980 Chlorpromazine administration caused an elevation of PRL to 43 and 30 ng/ml, respectively, in the two patients with a subnormal response to TRH, while the third case responded less than to TRH. Chlorpromazine 0-14 prolactin Homo sapiens 53-56 6776354-8 1980 In conclusion, the response to TRH of FSH and LH with lack of response to clomiphene supports the hypothalamic nature of the hypogonadism, while the response of PRL to both TRH and chlorpromazine, along with the normal levels of the remaining pituitary hormones (ACTH, TSH and STH) demonstrate the selectivity of the hypothalamic lesion whereby only gonadotrophin control is impaired. Chlorpromazine 181-195 prolactin Homo sapiens 161-164 7006374-7 1980 Since only some of the prolactin-producing adenomas stained with carmoisine--a dye that has been suggested as a marker for prolactin cells--immunocytochemistry is the method of choice for the identification of prolactin-secreting adenomas. azo rubin S 65-75 prolactin Homo sapiens 23-32 7002371-0 1980 The prolactin response to metoclopramide in growth hormone deficient adolescent males. Metoclopramide 26-40 prolactin Homo sapiens 4-13 6773818-2 1980 Baseline follicle-stimulating hormone, luteinizing hormone, and PRL levels were suppressed by bromocriptine, 2.5 mg daily (P < 0.05). Bromocriptine 94-107 prolactin Homo sapiens 64-67 7460861-0 1980 Effects of domperidone on serum prolactin levels in human beings. Domperidone 11-22 prolactin Homo sapiens 32-41 7460861-5 1980 These results indicate that domperidone may be an effective stimulator of serum prolactin secretion in human beings. Domperidone 28-39 prolactin Homo sapiens 80-89 6995475-6 1980 These results suggest that elevated plasma PRL concentrations may contribute to the development of hyperinsulinemia and accentuated glucagon suppression in response to glucose that is characteristic of late human pregnancy. Glucagon 132-140 prolactin Homo sapiens 43-46 6995475-6 1980 These results suggest that elevated plasma PRL concentrations may contribute to the development of hyperinsulinemia and accentuated glucagon suppression in response to glucose that is characteristic of late human pregnancy. Glucose 168-175 prolactin Homo sapiens 43-46 7190256-2 1980 Nine of 12 patients had a suppression of prolactin with oral L-dopa, and all of 4 patients undergoing dopamine infusion had suppression of prolactin. Dopamine 102-110 prolactin Homo sapiens 139-148 7378822-0 1980 Relationship of prolactin secretion to dopamine release into hypophysial portal blood and dopamine turnover in the median eminence. Dopamine 39-47 prolactin Homo sapiens 16-25 6792868-2 1980 PRL-response to 200 micrograms of TRH was assessed in 41 cases, and PRL-response to sulpiride in 38 cases. Sulpiride 84-93 prolactin Homo sapiens 68-71 6792868-10 1980 PRL-response to sulpiride doesn"t differ from that of normal males in the 3 categories of SD. Sulpiride 16-25 prolactin Homo sapiens 0-3 6792868-11 1980 Research of linear correlations between scores of anxiety and depression and PRL maximal increments after TRH and sulpiride in EP and ANEJ is negative. Sulpiride 114-123 prolactin Homo sapiens 77-80 6933738-0 1980 [Serum prolactin levels during therapy of prostatic cancer with oestradiol-17 beta-undecylate and cyproterone acetate (author"s transl)]. oestradiol-17 beta-undecylate 64-93 prolactin Homo sapiens 7-16 6933738-0 1980 [Serum prolactin levels during therapy of prostatic cancer with oestradiol-17 beta-undecylate and cyproterone acetate (author"s transl)]. Cyproterone Acetate 98-117 prolactin Homo sapiens 7-16 6933738-4 1980 Basal serum levels of prolactin were 7.76 +/- 4.84 ng/ml and 9.50 +/- 4.32 ng/ml in the two groups of patients before therapy with oestradiol-17 beta-undecylate or cyproterone acetate, respectively. oestradiol-17 beta-undecylate 131-160 prolactin Homo sapiens 22-31 6933738-4 1980 Basal serum levels of prolactin were 7.76 +/- 4.84 ng/ml and 9.50 +/- 4.32 ng/ml in the two groups of patients before therapy with oestradiol-17 beta-undecylate or cyproterone acetate, respectively. Cyproterone Acetate 164-183 prolactin Homo sapiens 22-31 6933738-7 1980 On the other hand, oestradiol-17 beta-undecylate raised serum prolactin levels significantly already after one month of treatment and the mean values were significantly higher than in the antiandrogen-treated group. oestradiol-17 beta-undecylate 19-48 prolactin Homo sapiens 62-71 7211478-0 1980 Sulpiride stimulation of prolactin secretion in adolescents with gynecomastia: relation to the circulating levels of estradiol. Sulpiride 0-9 prolactin Homo sapiens 25-34 7396309-6 1980 Although plasma prolactin was generally elevated, suppression of prolactin with bromocriptine resulted in resumption of ovulation in only one patient; the other 2 remained amenorrheic. Bromocriptine 80-93 prolactin Homo sapiens 65-74 7426514-2 1980 Elevated plasma prolactin concentration due to breast feeding or reduced plasma prolactin concentration due to treatment with bromocriptine was found not to be related to blood pressure changes in the puerperium in women with essential hypertension, pregnancy induced hypertension or in normotensive patients. Bromocriptine 126-139 prolactin Homo sapiens 80-89 6254696-1 1980 Sulpiride induces an increase in plasma prolactin and a simultaneous increase of aldosterone release in man. Sulpiride 0-9 prolactin Homo sapiens 40-49 6769937-3 1980 With 1000 micrograms pergolide daily and to 6.6% of control with 200 micrograms pergolide daily, PRL was unmeasurable in the great majority of samples over 24 h. In addition, the marked episodic fluctuation in PRL occurring in controls was not observed in treated animals. Pergolide 21-30 prolactin Homo sapiens 97-100 6769937-3 1980 With 1000 micrograms pergolide daily and to 6.6% of control with 200 micrograms pergolide daily, PRL was unmeasurable in the great majority of samples over 24 h. In addition, the marked episodic fluctuation in PRL occurring in controls was not observed in treated animals. Pergolide 80-89 prolactin Homo sapiens 97-100 6769937-4 1980 In three patients with Parkinson"s disease, treatment with pergolide also resulted in uniform 24-h suppression of PRL. Pergolide 59-68 prolactin Homo sapiens 114-117 6769937-5 1980 In one patient on pergolide (100 micrograms/day), the mean 24-h PRL level fell to 18% of control, and in two other patients on 200 and 600 micrograms pergolide, respectively, whose mean PRL levels were 4.1 and 7.4 ng/ml, respectively, before treatment, no PRL was detected in any of the blood samples obtained during the 24-h periods. Pergolide 18-27 prolactin Homo sapiens 64-67 7380989-0 1980 Sulpiride treatment during early human pregnancy: effect on the levels of prolactin, six steroids, and placental lactogen. Sulpiride 0-9 prolactin Homo sapiens 74-83 7380989-3 1980 Sulpiride treatment induced significant (P less than 0.001) elevations of plasma PRL at 1 week [84.1 +/- 4.9 vs. 23.7 +/- 2.8 ng/ml (mean +/- SE)] and 2 weeks (83.0 +/- 4.1 vs. 31.9 +/- 4.1 ng/ml). Sulpiride 0-9 prolactin Homo sapiens 81-84 7411481-2 1980 1 degree Histidyl-proline-diketopiperazine (DKP), a major degradation product of TRH in hypothalamus and pituitary, inhibited prolactin secretion from incubated hemipituitaries (Fig. histidyl-proline diketopiperazine 44-47 prolactin Homo sapiens 126-135 7411481-9 1980 3 degrees Morphinomimetic peptides had no effect on prolactin secretion in vitro, but blocked the dopamine inhibition of prolactin secretion. Dopamine 98-106 prolactin Homo sapiens 121-130 7443776-0 1980 [The influence of lithium salts and antidepressive medication on the serum prolactin level (author"s transl)]. lithium salts 18-31 prolactin Homo sapiens 75-84 7443776-5 1980 The mean hPRL level in patients with concomitant antidepressive medication was significantly higher as compared to the "only lithium" group, but never exceeded the normal range in both groups. Lithium 125-132 prolactin Homo sapiens 9-13 7443776-7 1980 However, with regard to recent communications suggesting that besides dopaminergic influences also serotonergic mechanisms play an important part in hPRL regulation, it is held that the prolactin response in lithium-treated patients warrants further investigations using serotonergic stimulation methods. Lithium 208-215 prolactin Homo sapiens 149-153 7443776-7 1980 However, with regard to recent communications suggesting that besides dopaminergic influences also serotonergic mechanisms play an important part in hPRL regulation, it is held that the prolactin response in lithium-treated patients warrants further investigations using serotonergic stimulation methods. Lithium 208-215 prolactin Homo sapiens 186-195 6108555-0 1980 Comparative effect of cimetidine and ranitidine on prolactin secretion. Cimetidine 22-32 prolactin Homo sapiens 51-60 6108555-0 1980 Comparative effect of cimetidine and ranitidine on prolactin secretion. Ranitidine 37-47 prolactin Homo sapiens 51-60 6108555-1 1980 Cimetidine has been shown to stimulate prolactin secretion after a intravenous administration. Cimetidine 0-10 prolactin Homo sapiens 39-48 6108555-5 1980 The prolactin stimulating effect of cimetidine was confirmed while ranitidine did not influence plasma prolactin levels. Cimetidine 36-46 prolactin Homo sapiens 4-13 7459063-3 1980 Both d- and l-sulpiride cause a remarkable rise in PL serum levels, the only difference between the two drugs being the lower decay rate of hormone levels after the l-isomer. d- and l-sulpiride 5-23 prolactin Homo sapiens 51-53 6247023-1 1980 The number of specific binding sites for 125I-labeled human prolactin (hPrl) in crude membrane fractions from rat liver is sexually differentiated. Iodine-125 41-45 prolactin Homo sapiens 71-75 6247023-4 1980 Treatment of male rats with estradiol valerate induced hepatic hPrl receptors, but only in the presence of an intact pituitary. Estradiol 28-37 prolactin Homo sapiens 63-67 7387339-10 1980 Melatonin and prolactin levels in serum decreased noticeably with propranolol treatment. Propranolol 66-77 prolactin Homo sapiens 14-23 7387339-11 1980 When phenothiazines were added, prolactin increased above drug-free levels. Phenothiazines 5-19 prolactin Homo sapiens 32-41 6932868-0 1980 The effect of thioridazine on prolactin levels in acutely schizophrenic patients: challenge-dose and steady-state levels. Thioridazine 14-26 prolactin Homo sapiens 30-39 6932868-1 1980 Prolactin (PRL) levels in unmedicated male patients with acute schizophrenia were within normal range at baseline, increased five fold after a challenge dose of thioridazine, did not significantly increase further after therapeutic dosages, and remained elevated for the duration of treatment. Thioridazine 161-173 prolactin Homo sapiens 0-9 6932868-1 1980 Prolactin (PRL) levels in unmedicated male patients with acute schizophrenia were within normal range at baseline, increased five fold after a challenge dose of thioridazine, did not significantly increase further after therapeutic dosages, and remained elevated for the duration of treatment. Thioridazine 161-173 prolactin Homo sapiens 11-14 6932868-2 1980 The rise in PRL levels was significantly correlated with the steady-state plasma levels of thioridazine and/or mesoridazine. Thioridazine 91-103 prolactin Homo sapiens 12-15 6932868-2 1980 The rise in PRL levels was significantly correlated with the steady-state plasma levels of thioridazine and/or mesoridazine. Mesoridazine 111-123 prolactin Homo sapiens 12-15 6994940-1 1980 The growth hormone (GH) and prolactin (PRL) responses to metoclopramide (MCP) were compared to those with arginine and insulin-induced hypoglycaemia in eight children. Metoclopramide 57-71 prolactin Homo sapiens 28-37 6247216-3 1980 Prolactin modulates renal formation of cyclic AMP and polyamines and it leads to demonstrable histological changes in the proximal tubules. Cyclic AMP 39-49 prolactin Homo sapiens 0-9 6247216-3 1980 Prolactin modulates renal formation of cyclic AMP and polyamines and it leads to demonstrable histological changes in the proximal tubules. Polyamines 54-64 prolactin Homo sapiens 0-9 6247216-5 1980 Prolactin seems able to cause a prolonged reduction in water, sodium, and potassium excretion, a pattern that is imitated by no other hormone with the possible exception of growth hormone. Water 55-60 prolactin Homo sapiens 0-9 6247216-5 1980 Prolactin seems able to cause a prolonged reduction in water, sodium, and potassium excretion, a pattern that is imitated by no other hormone with the possible exception of growth hormone. Sodium 62-68 prolactin Homo sapiens 0-9 6247216-5 1980 Prolactin seems able to cause a prolonged reduction in water, sodium, and potassium excretion, a pattern that is imitated by no other hormone with the possible exception of growth hormone. Potassium 74-83 prolactin Homo sapiens 0-9 6247216-8 1980 This is particularly so with the effects of prolactin on water movements across fetal skin, the amniotic membrane, and in the eye where prolactin and vasopressin have diametrically opposite effects. Water 57-62 prolactin Homo sapiens 44-53 6247216-8 1980 This is particularly so with the effects of prolactin on water movements across fetal skin, the amniotic membrane, and in the eye where prolactin and vasopressin have diametrically opposite effects. Water 57-62 prolactin Homo sapiens 136-145 6247218-5 1980 Subsequent actions of prolactin may involve the following: a) an increased intracellular concentration of potassium and a reduced level of sodium, b) an increased level of cGMP and a reduced level of cAMP, c) an enhanced rate of prostaglandin biosyntheesis mediated by a stimulation of phospholipase A2 activity, and d) a stimulation of polyamine synthesis. Potassium 106-115 prolactin Homo sapiens 22-31 6247218-5 1980 Subsequent actions of prolactin may involve the following: a) an increased intracellular concentration of potassium and a reduced level of sodium, b) an increased level of cGMP and a reduced level of cAMP, c) an enhanced rate of prostaglandin biosyntheesis mediated by a stimulation of phospholipase A2 activity, and d) a stimulation of polyamine synthesis. Sodium 139-145 prolactin Homo sapiens 22-31 6247218-5 1980 Subsequent actions of prolactin may involve the following: a) an increased intracellular concentration of potassium and a reduced level of sodium, b) an increased level of cGMP and a reduced level of cAMP, c) an enhanced rate of prostaglandin biosyntheesis mediated by a stimulation of phospholipase A2 activity, and d) a stimulation of polyamine synthesis. Cyclic GMP 172-176 prolactin Homo sapiens 22-31 6247218-5 1980 Subsequent actions of prolactin may involve the following: a) an increased intracellular concentration of potassium and a reduced level of sodium, b) an increased level of cGMP and a reduced level of cAMP, c) an enhanced rate of prostaglandin biosyntheesis mediated by a stimulation of phospholipase A2 activity, and d) a stimulation of polyamine synthesis. Cyclic AMP 200-204 prolactin Homo sapiens 22-31 6247218-5 1980 Subsequent actions of prolactin may involve the following: a) an increased intracellular concentration of potassium and a reduced level of sodium, b) an increased level of cGMP and a reduced level of cAMP, c) an enhanced rate of prostaglandin biosyntheesis mediated by a stimulation of phospholipase A2 activity, and d) a stimulation of polyamine synthesis. Prostaglandins 229-242 prolactin Homo sapiens 22-31 6247218-5 1980 Subsequent actions of prolactin may involve the following: a) an increased intracellular concentration of potassium and a reduced level of sodium, b) an increased level of cGMP and a reduced level of cAMP, c) an enhanced rate of prostaglandin biosyntheesis mediated by a stimulation of phospholipase A2 activity, and d) a stimulation of polyamine synthesis. Polyamines 337-346 prolactin Homo sapiens 22-31 6247218-6 1980 It has also been shown that the actions of prolactin require calcium ions in the extracellular environment. Calcium 61-68 prolactin Homo sapiens 43-52 6769714-2 1980 Dopamine may be a physiological prolactin inhibiting factor (PIF), while norepinephrine and possibly epinephrine regulate prolactin release at the level of the hypothalamus. Dopamine 0-8 prolactin Homo sapiens 32-41 6769714-2 1980 Dopamine may be a physiological prolactin inhibiting factor (PIF), while norepinephrine and possibly epinephrine regulate prolactin release at the level of the hypothalamus. Norepinephrine 73-87 prolactin Homo sapiens 122-131 6769714-2 1980 Dopamine may be a physiological prolactin inhibiting factor (PIF), while norepinephrine and possibly epinephrine regulate prolactin release at the level of the hypothalamus. Epinephrine 76-87 prolactin Homo sapiens 122-131 6769714-3 1980 Serotonin may participate in the regulation of prolactin secretion by stimulating the release of prolactin releasing factor (PRF). Serotonin 0-9 prolactin Homo sapiens 47-56 6769714-3 1980 Serotonin may participate in the regulation of prolactin secretion by stimulating the release of prolactin releasing factor (PRF). Serotonin 0-9 prolactin Homo sapiens 97-106 7190514-3 1980 PRL rapidly increases after bromocriptine withdrawal, reaching values higher than those in normal women in the same stage of pregnancy within a few weeks. Bromocriptine 28-41 prolactin Homo sapiens 0-3 7189523-0 1980 A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic admknistration of bromocriptine. Bromocriptine 45-58 prolactin Homo sapiens 20-29 7189523-0 1980 A broad spectrum of prolactin suppression by bromocriptine in hyperprolactinemic women: a study of serum prolactin and bromocriptine levels after acute and chronic admknistration of bromocriptine. Bromocriptine 45-58 prolactin Homo sapiens 67-76 7372794-0 1980 Functional studies of dopamine control of prolactin secretion in normal women and women with hyperprolactinemic pituitary microadenoma. Dopamine 22-30 prolactin Homo sapiens 42-51 6787150-6 1980 Of ten cases with visual disturbance, it was necessary to use Bromocriptine to reduce the serum PRL to the normal level after operation. Bromocriptine 62-75 prolactin Homo sapiens 96-99 6787150-10 1980 Our data indicate that neurosurgery, either selective or combined with Bromocriptine, can normalize PRL levels and induce regular menses in patients with hyperprolactinemia. Bromocriptine 71-84 prolactin Homo sapiens 100-103 7402998-8 1980 It is concluded that fattening of chicks induced by injections of corticosterone and prolactin is mainly due to the effect of corticosterone. Corticosterone 126-140 prolactin Homo sapiens 85-94 7374766-5 1980 have postulated a direct ovarian effect of prolactin, reporting that low prolactin levels were essential for progesterone production by preovulatory human granulosa cells cultured in vitro. Progesterone 109-121 prolactin Homo sapiens 43-52 7374766-5 1980 have postulated a direct ovarian effect of prolactin, reporting that low prolactin levels were essential for progesterone production by preovulatory human granulosa cells cultured in vitro. Progesterone 109-121 prolactin Homo sapiens 73-82 6246118-6 1980 The protease inhibitor N-alpha-p-tosyl-L-lysine chloromethyl ketone, lysosomotropic agents such as chloroquine and ammonium chloride, and metabolic inhibitors 2,4-dinitrophenol and sodium azide, all abolished prolactin degradation by the breast cancer cells. Tosyl-L-lysine chloromethyl ketone 23-67 prolactin Homo sapiens 209-218 7386120-0 1980 Potentiation of sulpiride-induced prolactin secretion by sodium deprivation in man. Sulpiride 16-25 prolactin Homo sapiens 34-43 7386120-0 1980 Potentiation of sulpiride-induced prolactin secretion by sodium deprivation in man. Sodium 57-63 prolactin Homo sapiens 34-43 6774657-0 1980 Lack of effect of oral pyridoxine on TRH and chlorpromazine induced prolactin secretion. Chlorpromazine 45-59 prolactin Homo sapiens 68-77 7189453-1 1980 After single doses (100 to 400 microgram orally), pergolide, a synthetic ergot, reduced basal plasma prolactin levels in normal subjects in a dose-related manner. Pergolide 50-59 prolactin Homo sapiens 101-110 10314517-2 1980 This notice requires that a precaution statement be included in physician labeling of neuroleptic drugs (except rauwolfia alkaloids) stating that these drugs elevate serum prolactin levels and may pose a potential risk to patients. Secologanin Tryptamine Alkaloids 112-131 prolactin Homo sapiens 172-181 7189453-3 1980 Multiple doses of pergolide (150 to 250 microgram daily for 7 days) resulted in a plasma prolactin decrease of more than 80%. Pergolide 18-27 prolactin Homo sapiens 89-98 7189453-4 1980 A single dose of pergolide (150 microgram orally) suppressed plasma prolactin and abolished the plasma prolactin diurnal rhythm, i.e., suppression of sleep-induced elevation in plasma prolactin during a 40-hr period. Pergolide 17-26 prolactin Homo sapiens 68-77 7189453-4 1980 A single dose of pergolide (150 microgram orally) suppressed plasma prolactin and abolished the plasma prolactin diurnal rhythm, i.e., suppression of sleep-induced elevation in plasma prolactin during a 40-hr period. Pergolide 17-26 prolactin Homo sapiens 103-112 7189453-4 1980 A single dose of pergolide (150 microgram orally) suppressed plasma prolactin and abolished the plasma prolactin diurnal rhythm, i.e., suppression of sleep-induced elevation in plasma prolactin during a 40-hr period. Pergolide 17-26 prolactin Homo sapiens 103-112 7189453-5 1980 Perphenazine (5 mg intramuscularly)-induced plasma prolactin elevation was inhibited by pergolide; the effect was dose dependent. Perphenazine 0-12 prolactin Homo sapiens 51-60 7428183-0 1980 Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: a cross-over study in healthy volunteers. Domperidone 74-85 prolactin Homo sapiens 7-16 7428183-0 1980 Plasma prolactin levels after acute and subchronic oral administration of domperidone and of metoclopramide: a cross-over study in healthy volunteers. Metoclopramide 93-107 prolactin Homo sapiens 7-16 7428183-2 1980 The aim of the present study was to find out whether peripheral dopaminergic blockage by domperidone causes prolactin release, and if so, whether this prolactin release persists during longer-term treatment. Domperidone 89-100 prolactin Homo sapiens 108-117 7428183-5 1980 After further treatment with metoclopramide the prolactin levels were further increased to 15-fold, but after prolonged administration of domperidone a decrease to a plasma level 6-fold higher than basal was observed. Metoclopramide 29-43 prolactin Homo sapiens 48-57 6248384-0 1980 [The inhibitory effect of tolbutamide on both secretions of cortisol in the adrenal cortex and of prolactin in the pituitary gland (author"s transl)]. Tolbutamide 26-37 prolactin Homo sapiens 98-107 6248384-2 1980 Although tolbutamide produces hypoglycemia through the increase of endogenous insulin secretion, in the present study tolbutamide was used instead of insulin, and the effect of tolbutamide on the secretion of PRL from the pituitary gland and also on the secretion of cortisol from the adrenal cortex as well as HGH was studied, using 44 healthy normal subjects (male 35 and female 9, from 15 approximately 75 years of age). Tolbutamide 9-20 prolactin Homo sapiens 209-212 6248384-2 1980 Although tolbutamide produces hypoglycemia through the increase of endogenous insulin secretion, in the present study tolbutamide was used instead of insulin, and the effect of tolbutamide on the secretion of PRL from the pituitary gland and also on the secretion of cortisol from the adrenal cortex as well as HGH was studied, using 44 healthy normal subjects (male 35 and female 9, from 15 approximately 75 years of age). Tolbutamide 118-129 prolactin Homo sapiens 209-212 6248384-2 1980 Although tolbutamide produces hypoglycemia through the increase of endogenous insulin secretion, in the present study tolbutamide was used instead of insulin, and the effect of tolbutamide on the secretion of PRL from the pituitary gland and also on the secretion of cortisol from the adrenal cortex as well as HGH was studied, using 44 healthy normal subjects (male 35 and female 9, from 15 approximately 75 years of age). Tolbutamide 118-129 prolactin Homo sapiens 209-212 6248384-3 1980 (1) PRL : One gram of tolbutamide injected into 5 normal subjects did not increase the serum concentration of PRL up to 120 minutes after the administration of the drug, while the concentration of PRL in the serum was increased clearly by the injection of insulin (0.1U/kg), with maximum PRL levels (approximately 50pg/ml) occurring at 60 minutes after the insulin administration. Tolbutamide 22-33 prolactin Homo sapiens 4-7 6248384-4 1980 These results indicated strongly that tolbutamide inhibited the secretion of PRL from the pituitary gland. Tolbutamide 38-49 prolactin Homo sapiens 77-80 6248384-8 1980 The data suggest that tolbutamide might have a direct inhibitory effect on the adrenal cortex as well as on pituitary PRL secretion. Tolbutamide 22-33 prolactin Homo sapiens 118-121 7393488-0 1980 [Bromocriptine (CB 154) in the treatment of amenorrheas with normal serum prolactin. Bromocriptine 1-14 prolactin Homo sapiens 74-83 7393488-0 1980 [Bromocriptine (CB 154) in the treatment of amenorrheas with normal serum prolactin. Bromocriptine 16-22 prolactin Homo sapiens 74-83 7393489-0 1980 [Possibilities of response to bromocriptine therapy in amenorrhea with normal serum prolactin. Bromocriptine 30-43 prolactin Homo sapiens 84-93 7190690-2 1980 Blood prolactin level fell after treatment with glucocorticosteroids. glucocorticosteroids 48-68 prolactin Homo sapiens 6-15 7190690-3 1980 Blood prolactin level was elevated, irrespective of normal or increased 24-hour 17-CS excretion in patients with congenital adrenal gland dysfunction treated with glucocorticosteroids and with persistent disturbances of ovarian function. glucocorticosteroids 163-183 prolactin Homo sapiens 6-15 6932063-3 1980 Serum PRL was significantly decreased during opiate withdrawal and after clonidine reversal of withdrawal symptoms when compared to serum PRL measured in the drug-free baseline samples. Clonidine 73-82 prolactin Homo sapiens 6-9 6778491-0 1980 [Inhibitory effects of atropine on serum prolactin levels after TRH stimulation]. Atropine 23-31 prolactin Homo sapiens 41-50 6245576-0 1980 Effect of prolactin on phospholipid biosynthesis by alveolar cell carcinoma (A549) in monolayer tissue culture. Phospholipids 23-35 prolactin Homo sapiens 10-19 6245576-1 1980 By means of an alveolar cell carcinoma (A549) model, the effect of prolactin on pulmonary surfactant phospholipid biosynthesis was investigated. Phospholipids 101-113 prolactin Homo sapiens 67-76 6245576-2 1980 Preliminary results suggest that phosphatidylcholine synthesis via the phosphatidic acid phosphohydrolase pathway in addition to phosphatidylglycerol may be stimulated by the presence of prolactin. Phosphatidylcholines 33-52 prolactin Homo sapiens 187-196 6245576-2 1980 Preliminary results suggest that phosphatidylcholine synthesis via the phosphatidic acid phosphohydrolase pathway in addition to phosphatidylglycerol may be stimulated by the presence of prolactin. Phosphatidylglycerols 129-149 prolactin Homo sapiens 187-196 7448058-0 1980 Effects of a single dose of barbiturate on prolactin secretion in woman. barbituric acid 28-39 prolactin Homo sapiens 43-52 7448058-1 1980 Barbiturate administration (100 mg% m2 body surface) decreases PRL levels in serum during night surge. barbituric acid 0-11 prolactin Homo sapiens 63-66 7386109-0 1980 Prolactin secretion in man following acute and long-term cimetidine administration. Cimetidine 57-67 prolactin Homo sapiens 0-9 7386109-2 1980 In addition, in 20 healthy volunteers we studied the effect of pre-treatment with bromocriptine, meterogline, nomifensine and cryroheptadine on cimetidine-induced prolactin release. Bromocriptine 82-95 prolactin Homo sapiens 163-172 7386109-2 1980 In addition, in 20 healthy volunteers we studied the effect of pre-treatment with bromocriptine, meterogline, nomifensine and cryroheptadine on cimetidine-induced prolactin release. meterogline 97-108 prolactin Homo sapiens 163-172 7386109-2 1980 In addition, in 20 healthy volunteers we studied the effect of pre-treatment with bromocriptine, meterogline, nomifensine and cryroheptadine on cimetidine-induced prolactin release. Nomifensine 110-121 prolactin Homo sapiens 163-172 7386109-2 1980 In addition, in 20 healthy volunteers we studied the effect of pre-treatment with bromocriptine, meterogline, nomifensine and cryroheptadine on cimetidine-induced prolactin release. cryroheptadine 126-140 prolactin Homo sapiens 163-172 7386109-2 1980 In addition, in 20 healthy volunteers we studied the effect of pre-treatment with bromocriptine, meterogline, nomifensine and cryroheptadine on cimetidine-induced prolactin release. Cimetidine 144-154 prolactin Homo sapiens 163-172 7386109-3 1980 Intravenous cimetidine stimulated prolactin secretion in patients and in normal subjects. Cimetidine 12-22 prolactin Homo sapiens 34-43 7386109-4 1980 In the latter, bromocroptine and metergoline pre-administration blunted the release of prolactin in response to iv cimetidine whereas nomifensine and cyproheptadine were ineffective. bromocroptine 15-28 prolactin Homo sapiens 87-96 7386109-4 1980 In the latter, bromocroptine and metergoline pre-administration blunted the release of prolactin in response to iv cimetidine whereas nomifensine and cyproheptadine were ineffective. Metergoline 33-44 prolactin Homo sapiens 87-96 7386109-4 1980 In the latter, bromocroptine and metergoline pre-administration blunted the release of prolactin in response to iv cimetidine whereas nomifensine and cyproheptadine were ineffective. Cimetidine 115-125 prolactin Homo sapiens 87-96 6250393-0 1980 Calcium and the secretory cycle of prolactin cells: a cytochemical and ultrastructural study of dopamine inhibition and monobutyryl cyclic AMP-stimulation of prolactin secretion. Calcium 0-7 prolactin Homo sapiens 158-167 6250393-0 1980 Calcium and the secretory cycle of prolactin cells: a cytochemical and ultrastructural study of dopamine inhibition and monobutyryl cyclic AMP-stimulation of prolactin secretion. Cyclic AMP 132-142 prolactin Homo sapiens 158-167 6250393-1 1980 To identify intracellular calcium pools that may be involved in the secretory process in prolactin (PRL) cells, hemi pituitaries were incubated in medium containing 10(-6) M dopamine, 5 mM cyclic cAMP (experimentals), or in medium alone (controls) and then processed for electron microscopy using potassium pyroantimonate to localize intracellular calcium. Calcium 26-33 prolactin Homo sapiens 89-98 6250393-1 1980 To identify intracellular calcium pools that may be involved in the secretory process in prolactin (PRL) cells, hemi pituitaries were incubated in medium containing 10(-6) M dopamine, 5 mM cyclic cAMP (experimentals), or in medium alone (controls) and then processed for electron microscopy using potassium pyroantimonate to localize intracellular calcium. Calcium 26-33 prolactin Homo sapiens 100-103 6250393-4 1980 Dopamine inhibition of PRL secretion (> 80% at 1, 2, 3 h) resulted in accumulation of secretory granules in all stages of maturation and dilation of Golgi saccules at 2 and 3 h, accompanied by increased mitochondria antimonate and increased Golgi-associated antimonate. Dopamine 0-8 prolactin Homo sapiens 23-26 6766668-6 1980 The increased synthesis of PRL with increasing gestation was thought to be due to the stimulatory effects of E2 and progesterone, resulting in hyperplasia of the lactotrophs. Progesterone 116-128 prolactin Homo sapiens 27-30 7189453-5 1980 Perphenazine (5 mg intramuscularly)-induced plasma prolactin elevation was inhibited by pergolide; the effect was dose dependent. Pergolide 88-97 prolactin Homo sapiens 51-60 6767630-3 1980 In one woman with a slightly increased serum prolactin level, the addition of bromocriptine necessitated halving the total hMG dosage. Bromocriptine 78-91 prolactin Homo sapiens 45-54 6767630-3 1980 In one woman with a slightly increased serum prolactin level, the addition of bromocriptine necessitated halving the total hMG dosage. Menotropins 123-126 prolactin Homo sapiens 45-54 6771199-0 1980 Dose-dependency and reproducibility of the prolactin response to metoclopramide. Metoclopramide 65-79 prolactin Homo sapiens 43-52 6771199-1 1980 Six normal volunteers were tested to ascertain the dose-dependency and reproducibility of the prolactin response to metoclopramide. Metoclopramide 116-130 prolactin Homo sapiens 94-103 6771199-4 1980 The oral administration of 5 mg metoclopramide produced a significant rise in prolactin at 60 min and a maximal elevation at 90 min. Metoclopramide 32-46 prolactin Homo sapiens 78-87 6771199-5 1980 The intravenous administration of 5 mg metoclopramide produced a significant increment at 15 min and a maximal prolactin level at 30 min. Metoclopramide 39-53 prolactin Homo sapiens 111-120 6771199-8 1980 Intravenous administration of 1 mg of metoclopramide produced a potential increment in plasma prolactin. Metoclopramide 38-52 prolactin Homo sapiens 94-103 6771199-12 1980 Reproducibilities of prolactin response were good in all doses and modes of administration of metoclopramide. Metoclopramide 94-108 prolactin Homo sapiens 21-30 6771199-13 1980 Pretreatment with 1-dopa inhibited the metoclopramide-induced prolactin response, but pretreatment with cyproheptadine did not influence the prolactin response to metoclopramide. 1-dopa 18-24 prolactin Homo sapiens 62-71 6771199-13 1980 Pretreatment with 1-dopa inhibited the metoclopramide-induced prolactin response, but pretreatment with cyproheptadine did not influence the prolactin response to metoclopramide. Metoclopramide 39-53 prolactin Homo sapiens 62-71 6771199-14 1980 Metoclopramide is a good and reproducible stimulator of prolactin secretion. Metoclopramide 0-14 prolactin Homo sapiens 56-65 7382102-0 1980 [Effects of halothane anesthesia and surgery on plasma prolactin levels in man (author"s transl)]. Halothane 12-21 prolactin Homo sapiens 55-64 7366897-3 1980 At 37 to 38 weeks" gestation the maternal plasma free estriol levels correlated positively with the prolactin levels in preeclampsia (r = .313; P less than .05; N = 64). Estriol 54-61 prolactin Homo sapiens 100-109 6768602-0 1980 [The effect of limbic system injections of prostaglandin E2 on blood and pituitary levels of gonadotropin and prolactin (author"s transl)]. Dinoprostone 43-59 prolactin Homo sapiens 110-119 7360258-3 1980 For example, in human clinical conditions of physiological or pathological prolactin excess, ovarian function is depressed, and in isolated, human granulosa cells in vitro, prolactin seems to inhibit progesterone production. Progesterone 200-212 prolactin Homo sapiens 173-182 7360258-6 1980 Prolactin suppresses steroid production by cultured granulosa cells isolated from small (1-2 mm), immature follicles, but stimulates progesterone secretion by granulosa cells collected from large (greater than 6 mm) mature follicles. Steroids 21-28 prolactin Homo sapiens 0-9 7360258-6 1980 Prolactin suppresses steroid production by cultured granulosa cells isolated from small (1-2 mm), immature follicles, but stimulates progesterone secretion by granulosa cells collected from large (greater than 6 mm) mature follicles. Progesterone 133-145 prolactin Homo sapiens 0-9 6246703-0 1980 Serum prolactin responses to metoclopramide in Cushing"s syndrome and Nelson"s syndrome. Metoclopramide 29-43 prolactin Homo sapiens 6-15 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Serotonin 86-95 prolactin Homo sapiens 0-9 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Serotonin 86-95 prolactin Homo sapiens 11-14 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Serotonin 97-100 prolactin Homo sapiens 0-9 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Serotonin 97-100 prolactin Homo sapiens 11-14 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Dopamine 119-127 prolactin Homo sapiens 0-9 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Dopamine 119-127 prolactin Homo sapiens 11-14 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Dopamine 129-131 prolactin Homo sapiens 0-9 7376792-1 1980 Prolactin (Prl) release, both in the experimental animal and in man, is stimulated by serotonin (5HT) and inhibited by dopamine (DA). Dopamine 129-131 prolactin Homo sapiens 11-14 7376792-7 1980 These data indicate that DA inhibits both LH and Prl release in normal women, and that 5HT stimulates Prl release but is not involved in the regulation of LH secretion. Dopamine 25-27 prolactin Homo sapiens 49-52 7376792-7 1980 These data indicate that DA inhibits both LH and Prl release in normal women, and that 5HT stimulates Prl release but is not involved in the regulation of LH secretion. Serotonin 87-90 prolactin Homo sapiens 102-105 6106414-5 1980 Basal serum prolactin levels of women correlate negative significant with serum sodium levels and positive significant with the sodium concentration of red blood cells and basal TSH values. Sodium 80-86 prolactin Homo sapiens 12-21 6106414-5 1980 Basal serum prolactin levels of women correlate negative significant with serum sodium levels and positive significant with the sodium concentration of red blood cells and basal TSH values. Sodium 128-134 prolactin Homo sapiens 12-21 6106414-6 1980 Relative prolactin out-put (prolactin-max--prolactin-basal) after TRH-application in women is found to correlate positiv significant with serum triglycerid levels. triglycerid 144-155 prolactin Homo sapiens 9-18 6106414-6 1980 Relative prolactin out-put (prolactin-max--prolactin-basal) after TRH-application in women is found to correlate positiv significant with serum triglycerid levels. triglycerid 144-155 prolactin Homo sapiens 28-37 6106414-6 1980 Relative prolactin out-put (prolactin-max--prolactin-basal) after TRH-application in women is found to correlate positiv significant with serum triglycerid levels. triglycerid 144-155 prolactin Homo sapiens 28-37 6996524-3 1980 Large MtTw15 tumors, which secrete growth hormone (GH) and prolactin (PRL), are composed of ovoid, elongated, and angular cells which demonstrated interdigitating processes and junctional complexes. mttw15 6-12 prolactin Homo sapiens 59-68 6102000-2 1980 Prazosin was followed by a rise in plasma glucose and serum free fatty acids (FFA) in both normal and diabetic subjects; there was a trend upward in serum albumin (IRI), but growth hormone (GH), prolactin (PRL), and gastrin did not change. Prazosin 0-8 prolactin Homo sapiens 206-209 6771065-0 1980 Inhibition of prolactin secretion by nomifensine in man. Nomifensine 37-48 prolactin Homo sapiens 14-23 6771065-3 1980 Inhibition of endogenous catecholamine reuptake by nomifensine significantly inhibited prolactin release whereas it had no effect on TSH and GH levels. Catecholamines 25-38 prolactin Homo sapiens 87-96 6771065-3 1980 Inhibition of endogenous catecholamine reuptake by nomifensine significantly inhibited prolactin release whereas it had no effect on TSH and GH levels. Nomifensine 51-62 prolactin Homo sapiens 87-96 7389157-0 1980 TSH and prolactin stimulation by the decarboxylase inhibitor benserazide in primary hypothyroidism. Benserazide 61-72 prolactin Homo sapiens 8-17 7389157-2 1980 Benserazide induced a significant increase in prolactin and TSH plasma concentration in all subjects. Benserazide 0-11 prolactin Homo sapiens 46-55 6766949-3 1980 Bromocriptine suppressed basal plasma PRL level to 3.6 +/- 0.8 ng/ml (P less than 0.001). Bromocriptine 0-13 prolactin Homo sapiens 38-41 6766949-5 1980 The absolute PRL response was significantly smaller (P less than 0.001) during bromocriptine intake than before, whereas the mean percent increments in PRL levels after TRH administration were similar in the presence and absence of bromocriptine. Bromocriptine 79-92 prolactin Homo sapiens 13-16 6445525-0 1980 [The effect of methergoline and of a synthetic estrogen on plasmatic prolactin levels and on postpartum lactation]. Metergoline 15-27 prolactin Homo sapiens 69-78 7356664-7 1980 The molecular weight of prolactin mRNA determined by electrophoresis on agarose gels containing 10 mM mercury hydroxide was 350,000. Sepharose 72-79 prolactin Homo sapiens 24-33 7356664-7 1980 The molecular weight of prolactin mRNA determined by electrophoresis on agarose gels containing 10 mM mercury hydroxide was 350,000. Mercury hydroxide 102-119 prolactin Homo sapiens 24-33 7357340-1 1980 Studies in animals and tissue culture have shown the importance of prolactin and growth hormone in regulating renal 1 alpha-hydroxylase activity and plasma concentrations of 1,25-dihydroxycholecalciferol (1,25(OH)2D3). Calcitriol 174-203 prolactin Homo sapiens 67-76 7357340-1 1980 Studies in animals and tissue culture have shown the importance of prolactin and growth hormone in regulating renal 1 alpha-hydroxylase activity and plasma concentrations of 1,25-dihydroxycholecalciferol (1,25(OH)2D3). )2d3 212-216 prolactin Homo sapiens 67-76 7357340-4 1980 These results suggest that prolactin and growth hormone are important regulators of renal vitamin D metabolism in the physiological conditions of pregnancy, lactation, and growth in man. Vitamin D 90-99 prolactin Homo sapiens 27-36 7376786-0 1980 Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man. gamma-Aminobutyric Acid 47-70 prolactin Homo sapiens 100-109 7376786-0 1980 Effect of acute and repeated administration of gamma aminobutyric acid (GABA) on growth hormone and prolactin secretion in man. gamma-Aminobutyric Acid 72-76 prolactin Homo sapiens 100-109 7376786-5 1980 Protracted GABA treatment significantly blunted the response of growth hormone and enhanced that of prolactin to insulin hypoglycaemia (P less than 0.01). gamma-Aminobutyric Acid 11-15 prolactin Homo sapiens 100-109 7376786-6 1980 These results indicate that pharmacological doses of GABA affect growth hormone and prolactin secretion in man. gamma-Aminobutyric Acid 53-57 prolactin Homo sapiens 84-93 6244494-1 1980 Receptor sites for lactogenic hormones such as prolactin (PRL), human growth hormone (HGH), and placental lactogens, are widely distributed in mammalian tissues, including mammary glands, steroid-secreting cells of the adrenal, testis, and ovary, and target cells of steroid hormone action such as liver, prostrate, and kidney. Steroids 188-195 prolactin Homo sapiens 47-56 6244494-1 1980 Receptor sites for lactogenic hormones such as prolactin (PRL), human growth hormone (HGH), and placental lactogens, are widely distributed in mammalian tissues, including mammary glands, steroid-secreting cells of the adrenal, testis, and ovary, and target cells of steroid hormone action such as liver, prostrate, and kidney. Steroids 267-282 prolactin Homo sapiens 47-56 6244494-2 1980 Although the biological functions of lactogen binding sites remain uncertain, a relationship between prolactin and lipoprotein metabolism is implied by the occurrence of prolactin receptors in steroidogenic cells of the gonads and adrenal, and by the ability of prolactin to increase esterified cholesterol in the testis. Cholesterol 295-306 prolactin Homo sapiens 101-110 6244494-6 1980 These findings indicate that increased turnover of lactogen receptors is an important component of the target-cell response, and suggest that prolactin receptors might be involved in the transport of lipoprotein precursors for steroid biosynthesis. Steroids 227-234 prolactin Homo sapiens 142-151 7357832-2 1980 In an attempt to test the hypothesis of a derangement in central catecholaminergic function in hypertensive patients, the serum growth hormone and prolactin responses to the alpha-adrenergic agonist clonidine (0.15 mg infused intravenously) and to L-dopa administration (500 mg orally) were evaluated in 15 hypertensive and 15 normotensive subjects matched for sex, age and body weight. Clonidine 199-208 prolactin Homo sapiens 147-156 7357832-6 1980 Prolactin levels were equally suppressed by L-dopa and did not change after clonidine in either group. Levodopa 44-50 prolactin Homo sapiens 0-9 7354124-0 1980 Suppression of prolactin and gonadotropin secretion in post-menopausal women by 2-hydroxyestrone. 2-hydroxyestrone 80-96 prolactin Homo sapiens 15-24 7354124-1 1980 An infusion of 2-hydroxyestrone given to estrogen primed post-menopausal women resulted in a rapid and total suppression of serum prolactin. 2-hydroxyestrone 15-31 prolactin Homo sapiens 130-139 7354512-3 1980 Elevation of serum prolactin levels was observed after treatment with cyproterone acetate but was to a lesser degree than that caused by estrogens. Cyproterone Acetate 70-89 prolactin Homo sapiens 19-28 6250983-1 1980 Studies were carried out of the effects of prolactin (0.5-1.0 mU) and 3"5" dibutyryl cyclic AMP -(dbcAMP) (100-500 ng) on oxygen uptake and (U-14C) glucose and (1-14C) acetate utilization by human spermatozoa. Oxygen 122-128 prolactin Homo sapiens 43-52 7375492-0 1980 Effect of acute ethanol ingestion on integrated plasma prolactin levels in normal men. Ethanol 16-23 prolactin Homo sapiens 55-64 7375492-3 1980 In 14 of the 15 men studied, plasma prolactin levels during the 2-hr period after alcohol administration were elevated an average of 31% above values for the preceding 2-hr period. Alcohols 82-89 prolactin Homo sapiens 36-45 7375492-4 1980 Data pooled for all subjects revealed a small but statistically significant increase in prolactin coinciding with ascending and peak concentrations of blood alcohol. Alcohols 157-164 prolactin Homo sapiens 88-97 7375492-5 1980 A significant increment in prolactin was associated with peak blood alcohol levels when values were compared between control and alcohol treatment days. Alcohols 68-75 prolactin Homo sapiens 27-36 7375492-5 1980 A significant increment in prolactin was associated with peak blood alcohol levels when values were compared between control and alcohol treatment days. Alcohols 129-136 prolactin Homo sapiens 27-36 7355667-2 1980 Serum prolactin levels increased in respect to baseline levels when 80, 125 or 250 mg of carbidopa and 10, 20, 30, 50, 80 or 125 mg of benserazide were given. Carbidopa 89-98 prolactin Homo sapiens 6-15 7355667-2 1980 Serum prolactin levels increased in respect to baseline levels when 80, 125 or 250 mg of carbidopa and 10, 20, 30, 50, 80 or 125 mg of benserazide were given. Benserazide 135-146 prolactin Homo sapiens 6-15 7355667-4 1980 Carbidopa induced the enhancement of serum prolactin at a later time and over a longer time span than benserazide. Carbidopa 0-9 prolactin Homo sapiens 43-52 7355667-7 1980 The observed prolactin increase fits with the hypothesis that a diminution of the inhibitory effect of dopamine at the pituitary and/or at the median eminence levels may occur in connection to the pharmacologically impaired monoamine synthesis. Dopamine 103-111 prolactin Homo sapiens 13-22 7355667-7 1980 The observed prolactin increase fits with the hypothesis that a diminution of the inhibitory effect of dopamine at the pituitary and/or at the median eminence levels may occur in connection to the pharmacologically impaired monoamine synthesis. monoamine 224-233 prolactin Homo sapiens 13-22 6785978-3 1980 After sulpiride loading, maximum changes in prolactin level were significantly smaller in acromegalic patients, irrespective of the basal prolactin concentration. Sulpiride 6-15 prolactin Homo sapiens 44-53 6785978-6 1980 Higher than normal basal prolactin levels in some of the acromegalic patients and abnormal prolactin responses following sulpiride and TRH loading in most of the patients with acromegaly are attributed to deranged hypothalamo-hypophyseal regulation. Sulpiride 121-130 prolactin Homo sapiens 91-100 6160719-3 1980 Thus the prostaglandin elicited increases in total estriol (p < 0.001) and decreases in prolactin (p < 0.01), TSH (p < 0.05) and HPL (p < 0.05) from the basal level to that immediately before parturition. Prostaglandins 9-22 prolactin Homo sapiens 91-100 6160719-7 1980 A similar time course was noted for the decrease of serum prolactin in PGE2 treated patients. Dinoprostone 71-75 prolactin Homo sapiens 58-67 6775490-9 1980 In all women from group B, in response to Parlodel (bromocriptine) therapy administered in 5-mg dose daily, the plasma concentration of prolactin decreased to a normal level, galactorrhea ceased within 15-62 days, and menstruation resumed within 38-75 days. Bromocriptine 42-50 prolactin Homo sapiens 136-145 6775490-9 1980 In all women from group B, in response to Parlodel (bromocriptine) therapy administered in 5-mg dose daily, the plasma concentration of prolactin decreased to a normal level, galactorrhea ceased within 15-62 days, and menstruation resumed within 38-75 days. Bromocriptine 52-65 prolactin Homo sapiens 136-145 7405671-0 1980 Effect of serotonin on prolactin secretion in vitro. Serotonin 10-19 prolactin Homo sapiens 23-32 7369248-5 1980 Although intrinsic pituitary dysfunction cannot be excluded, the dissociated response of prolactin to TRH and chlorpromazine suggests that the pituitary hormone deficiencies may be secondary to hypothalamic dysfunction. Chlorpromazine 110-124 prolactin Homo sapiens 89-98 7356016-0 1980 Prolactin in human milk: correlation with lactose, total protein, and alpha-lactalbumin levels. Lactose 42-49 prolactin Homo sapiens 0-9 7356016-6 1980 Milk PRL concentrations showed a significant negative correlation (P less than 0.001) with milk lactose (r = -0.59) and positive correlations (P less than 0.01) with total milk protein (r = 0.49) and alpha lactalbumin (r = 0.33) estimations. Lactose 96-103 prolactin Homo sapiens 5-8 7356016-7 1980 We conclude that i) PRL is a normal constituent of human milk, ii) high concentrations of PRL are present in human milk for the first 3 days postpartum but subsequently fall rapidly, and iii) milk PRL levels correlate significantly with milk lactose, total protein, and alpha-lactalbumin values. Lactose 242-249 prolactin Homo sapiens 90-93 7356016-7 1980 We conclude that i) PRL is a normal constituent of human milk, ii) high concentrations of PRL are present in human milk for the first 3 days postpartum but subsequently fall rapidly, and iii) milk PRL levels correlate significantly with milk lactose, total protein, and alpha-lactalbumin values. Lactose 242-249 prolactin Homo sapiens 90-93 7396395-0 1980 [Inhibition of prolactin release by methysergide and bromocriptine in hyperprolactinemic subjects: comparative dynamic studies (author"s transl)]. Methysergide 36-48 prolactin Homo sapiens 15-24 7396395-5 1980 However the serum prolactin levels were significantly lower 6 hours (n = 11 p = 0,01) and 12 hours (n = 10 p less than 0,01) after Bromocriptine than after methysergide. Bromocriptine 131-144 prolactin Homo sapiens 18-27 7396395-5 1980 However the serum prolactin levels were significantly lower 6 hours (n = 11 p = 0,01) and 12 hours (n = 10 p less than 0,01) after Bromocriptine than after methysergide. Methysergide 156-168 prolactin Homo sapiens 18-27 7396399-0 1980 [Effects of low, normal and high sodium diet on antidiuretic hormone and prolactin (author"s transl)]. Sodium 33-39 prolactin Homo sapiens 73-82 6774864-1 1980 Some investigators have reported that plasma prolactin levels are elevated in hypertensive men and that both their hyperprolactinemia and hypertension were controlled by bromocriptine, a dopamine agonist. Bromocriptine 170-183 prolactin Homo sapiens 45-54 6774864-1 1980 Some investigators have reported that plasma prolactin levels are elevated in hypertensive men and that both their hyperprolactinemia and hypertension were controlled by bromocriptine, a dopamine agonist. Dopamine 187-195 prolactin Homo sapiens 45-54 6774864-4 1980 TRH caused significant increase of both prolactin and TSH and metoclopramide caused significant increase of prolactin in both normals and hypertensives. Metoclopramide 62-76 prolactin Homo sapiens 108-117 6774864-5 1980 Bromocriptine suppressed prolactin and TSH significantly in both groups. Bromocriptine 0-13 prolactin Homo sapiens 25-34 7189698-3 1980 Prolactin levels remained constantly at the upper limit of normal (mean: 20.6 +/- 2.1 ng/ml, with a minimal increase after TRH, a slight decrease after somatostatin (54%) and a marked decrease after bromocriptine (88.5%). Bromocriptine 199-212 prolactin Homo sapiens 0-9 7249350-0 1980 Serum prolactin levels during inhibition of lactation by cyclofenil. Cyclofenil 57-67 prolactin Homo sapiens 6-15 7379313-0 1980 Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride. Dopamine 84-92 prolactin Homo sapiens 20-29 7379313-0 1980 Size reduction of a prolactin secreting adenoma during long-term treatment with the dopamine agonist lisuride. Lisuride 101-109 prolactin Homo sapiens 20-29 7379313-1 1980 A 38-year-old amenorrhoeic woman suffering from a prolactin (PRL) secreting adenoma, which had suprasellar extension as shown by caroe agonist (lisuride). Lisuride 144-152 prolactin Homo sapiens 50-59 7379313-1 1980 A 38-year-old amenorrhoeic woman suffering from a prolactin (PRL) secreting adenoma, which had suprasellar extension as shown by caroe agonist (lisuride). Lisuride 144-152 prolactin Homo sapiens 61-64 7226751-0 1980 Effect of propranolol treatment on serum prolactin level in schizophrenic patients. Propranolol 10-21 prolactin Homo sapiens 41-50 7398241-0 1980 Haloperidol stimulation of prolactin secretion: how many blood samples are needed to define the hormone response? Haloperidol 0-11 prolactin Homo sapiens 27-36 495675-6 1979 The addition of 100 micrograms/ml of cycloheximide to the medium prevented the net increase in PRL content during incubation. Cycloheximide 37-50 prolactin Homo sapiens 95-98 6986893-8 1980 In Phase 2 of the study the substitution of placebo for bromocriptine in a randomized double-blind trial significantly increased lying and standing blood pressures and plasma prolactin. Bromocriptine 56-69 prolactin Homo sapiens 175-184 6785158-2 1980 Her high serum prolactin levels (95 ng/ml) did not increase after thyrotropin-releasing hormone and sulpiride, but markedly decreased after acute bromocriptine and metergoline administration. Bromocriptine 146-159 prolactin Homo sapiens 15-24 6785158-2 1980 Her high serum prolactin levels (95 ng/ml) did not increase after thyrotropin-releasing hormone and sulpiride, but markedly decreased after acute bromocriptine and metergoline administration. Metergoline 164-175 prolactin Homo sapiens 15-24 6785158-5 1980 The patient was treated with metergoline, a prolactin-lowering drug which is believed to act as a serotonin antagonist, for 30 months. Metergoline 29-40 prolactin Homo sapiens 44-53 6244218-0 1980 Stimulatory effects of gamma-aminohydroxybutyric acid (GABOB) on growth hormone, prolactin and cortisol release in man. gamma-aminohydroxybutyric acid 23-53 prolactin Homo sapiens 81-90 6244218-0 1980 Stimulatory effects of gamma-aminohydroxybutyric acid (GABOB) on growth hormone, prolactin and cortisol release in man. 4-amino-3-hydroxybutyric acid 55-60 prolactin Homo sapiens 81-90 6262206-6 1980 Naloxone alone had no hormonal effect but abolished the increase in PRL and GH following injection of FK 33-824 without modifying the decrease in plasma cortisol or the increase in free water clearance following the same treatment. Naloxone 0-8 prolactin Homo sapiens 68-71 7203397-1 1980 The effect of hyperglycemia on growth hormone, thyroid-stimulating hormone, and prolactin response to oral diazepam (10 mg) was assessed in 7 normal subjects. Diazepam 107-115 prolactin Homo sapiens 80-89 6109649-5 1980 In one patient with primary hypothyroidism, regular menstrual cycles were restored and serum prolactin and thyroid-stimulating hormone levels normalized during thyroxine treatment. Thyroxine 160-169 prolactin Homo sapiens 93-102 6109654-4 1980 All patients received bromocriptine for three months, resulting in normal serum prolactin levels. Bromocriptine 22-35 prolactin Homo sapiens 80-89 6117525-6 1980 There was a significant and positive correlation between seminal prolactin concentration and fructose concentration. Fructose 93-101 prolactin Homo sapiens 65-74 7188934-3 1980 Pyridoxine induced lowering of growth hormone and prolactin levels in two acromegalic patients. Pyridoxine 0-10 prolactin Homo sapiens 50-59 7188934-6 1980 On bromocriptine therapy, all the patients reported signifcant clinical improvement paralleled by significant drops in plasma growth hormone and prolactin. Bromocriptine 3-16 prolactin Homo sapiens 145-154 7188612-8 1980 The demonstration or the efficacy of bromocriptine in lowering PRL levels documents the expected increase in dopaminergic tone; however, the lack of effect of bromocriptine in surpressing LH release suggests that either there is already maximal endogenous inhibition of GnRH in hyperprolactinemic women or, alternatively, that dopaminergic mechanisms are unimportant in the control of LH secretion. Bromocriptine 37-50 prolactin Homo sapiens 63-66 7188615-1 1980 It has recently been claimed that the PRL-lowering response to nomifensine administration (200 mg, orally) reliably discriminates patients with PRL-secreting tumors from those with so-called functional hyperprolactinemia. Nomifensine 63-74 prolactin Homo sapiens 38-41 7188615-1 1980 It has recently been claimed that the PRL-lowering response to nomifensine administration (200 mg, orally) reliably discriminates patients with PRL-secreting tumors from those with so-called functional hyperprolactinemia. Nomifensine 63-74 prolactin Homo sapiens 144-147 7188615-4 1980 The decrease of mean serum PRL concentration after nomifensine was only significant in the first and second groups. Nomifensine 51-62 prolactin Homo sapiens 27-30 7188615-5 1980 Analysis of variance showed a significant difference in the PRL inhibition by nomifensine between the tumor group and the two groups without evidence of pituitary adenoma. Nomifensine 78-89 prolactin Homo sapiens 60-63 7359073-1 1980 Human prolactin from amniotic fluid, consisting of isohormones B and C (major), was radio-iodinated after storage of the hormone for 3 years at -70 degrees C, and yielded a Ferguson plot in polyacrylamide gel electrophoresis that was indistinguishable from the original except that the zones of isohormone B and C were fused. polyacrylamide 190-204 prolactin Homo sapiens 6-15 6778909-5 1980 These results show that a rise in the reserves of prolactin in the pituitary is very common in anovulatory cycles and in progesterone deficiency. Progesterone 121-133 prolactin Homo sapiens 50-59 7421220-0 1980 Sex steroids interact with dopamine at the hypothalamic and pituitary levels to modulate prolactin secretion. Steroids 4-12 prolactin Homo sapiens 89-98 7421220-0 1980 Sex steroids interact with dopamine at the hypothalamic and pituitary levels to modulate prolactin secretion. Dopamine 27-35 prolactin Homo sapiens 89-98 6243383-0 1980 The effect of elevated prolactin levels on plasma 1,25-dihydroxyvitamin D and intestinal absorption of calcium. 1,25-dihydroxyvitamin D 50-73 prolactin Homo sapiens 23-32 6243383-1 1980 Because of evidence in experimental animals that prolactin stimulates production of 1,25-dihydroxyvitamin D, we evaluated several indices of calcium metabolism in patients who had hyperprolactinemia due to functioning pituitary adenomas and in normal age-matched controls. 1,25-dihydroxyvitamin D 84-107 prolactin Homo sapiens 49-58 7354887-0 1980 Prolactin-releasing effect of domperidone in normoprolactinemic and hyperprolactinemic subjects. Domperidone 30-41 prolactin Homo sapiens 0-9 7354887-1 1980 The prolactin (PRL)-releasing effect of domperidone (DOM), a novel antidopaminergic drug which does not cross the blood-brain barrier, was investigated in normoprolactinemic subjects, in subjects with physiologic puerperal hyperprolactinemia or pathological hyperprolactinemia. Domperidone 40-51 prolactin Homo sapiens 4-13 7354887-1 1980 The prolactin (PRL)-releasing effect of domperidone (DOM), a novel antidopaminergic drug which does not cross the blood-brain barrier, was investigated in normoprolactinemic subjects, in subjects with physiologic puerperal hyperprolactinemia or pathological hyperprolactinemia. Domperidone 53-56 prolactin Homo sapiens 4-13 7366815-0 1980 Plasma prolactin during treatment with nortriptyline. Nortriptyline 39-52 prolactin Homo sapiens 7-16 7366815-5 1980 The results indicate that nortriptyline does not belong to the group of psychotropics which produce considerable increases in the plasma concentration of prolactin. Nortriptyline 26-39 prolactin Homo sapiens 154-163 7413230-0 1980 Effect of domperidone on prolactin secretion in healthy subjects. Domperidone 10-21 prolactin Homo sapiens 25-34 7367458-0 1980 Effects of heroin and naltrexone on plasma prolactin levels in man. Heroin 11-17 prolactin Homo sapiens 43-52 7367458-0 1980 Effects of heroin and naltrexone on plasma prolactin levels in man. Naltrexone 22-32 prolactin Homo sapiens 43-52 7367458-1 1980 Plasma levels of prolactin were increased following intravenous self-administration of heroin by young men with a history of heroin addiction. Heroin 87-93 prolactin Homo sapiens 17-26 7367458-1 1980 Plasma levels of prolactin were increased following intravenous self-administration of heroin by young men with a history of heroin addiction. Heroin 125-131 prolactin Homo sapiens 17-26 7367458-2 1980 Following 10 days of controlled heroin usage, tolerance could be demonstrated to the acute prolactin-releasing effect of heroin. Heroin 32-38 prolactin Homo sapiens 91-100 7393830-5 1980 Clomipramine can, however, influence prolactin levels in man, and follicle-stimulating and luteinizing hormone levels in male rats. Clomipramine 0-12 prolactin Homo sapiens 37-46 7393831-0 1980 The effect of naloxone on psychotropic drug-induced prolactin, growth hormone and cortisol secretion--a preliminary report. Naloxone 14-22 prolactin Homo sapiens 52-61 6787583-9 1980 IN CONCLUSION: 1. neither normalisation of moderate hyperprolactinaemia in patients on HD, nor 2. suppression of serum Prl into the subnormal range affects serum gonadotrophin and testosterone levels. Testosterone 180-192 prolactin Homo sapiens 119-122 6777812-0 1980 Plasma fluphenazine and prolactin levels in schizophrenic patients during treatment with low and high doses of fluphenazine enanthate. Fluphenazine 111-123 prolactin Homo sapiens 24-33 6781007-0 1980 The effect of benztropine mesylate on the prolactin response to haloperidol. Benztropine 14-25 prolactin Homo sapiens 42-51 6781007-0 1980 The effect of benztropine mesylate on the prolactin response to haloperidol. Haloperidol 64-75 prolactin Homo sapiens 42-51 6781007-2 1980 The acute prolactin response (at 30, 45, and 60 min) to haloperidol plus benztropine was significantly delayed compared to the response to haloperidol alone, in the same subjects. Haloperidol 56-67 prolactin Homo sapiens 10-19 6781007-2 1980 The acute prolactin response (at 30, 45, and 60 min) to haloperidol plus benztropine was significantly delayed compared to the response to haloperidol alone, in the same subjects. Benztropine 73-84 prolactin Homo sapiens 10-19 6781007-2 1980 The acute prolactin response (at 30, 45, and 60 min) to haloperidol plus benztropine was significantly delayed compared to the response to haloperidol alone, in the same subjects. Haloperidol 139-150 prolactin Homo sapiens 10-19 6102775-8 1980 With classical neuroleptics, serum prolactin levels increase as the dose increases up to approximately the equivalent of chlorpromazine 600 mg/day and then remain fairly constant. Chlorpromazine 121-135 prolactin Homo sapiens 35-44 7368631-0 1980 [Determination of somatotropin and prolactin by dodecyl sulfate polyacrylamide gel electrophoresis]. dodecyl sulfate 48-63 prolactin Homo sapiens 35-44 7368631-0 1980 [Determination of somatotropin and prolactin by dodecyl sulfate polyacrylamide gel electrophoresis]. polyacrylamide 64-78 prolactin Homo sapiens 35-44 553575-0 1979 [Effect of pretreatment with metoclopramide on plasma prolactin response to methergoline]. Metoclopramide 29-43 prolactin Homo sapiens 54-63 553575-0 1979 [Effect of pretreatment with metoclopramide on plasma prolactin response to methergoline]. Metergoline 76-88 prolactin Homo sapiens 54-63 553575-4 1979 The Authors found a remarkable decline of prolactin serum levels after metergoline administration in all subjects. Metergoline 71-82 prolactin Homo sapiens 42-51 553575-5 1979 After metoclopramide administration prolactin serum levels increased meaningly. Metoclopramide 6-20 prolactin Homo sapiens 36-45 553575-6 1979 Metergoline administration gave again considerable fall of prolactin serum levels in the 14 subjects. Metergoline 0-11 prolactin Homo sapiens 59-68 553575-7 1979 From the data the Authors affirm that metergoline inhibits prolactin secretion with an antiserotonine action Metergoline 38-49 prolactin Homo sapiens 59-68 117385-0 1979 Dopamine inhibition of action potentials in a prolactin secreting cell line is modulated by oestrogen. Dopamine 0-8 prolactin Homo sapiens 46-55 117385-3 1979 Prolactin (PRL) secreting cells are, at least partially, under the stimulatory influence of thyrotropin releasing hromone (TRH) and of oestrogens. releasing hromone 104-121 prolactin Homo sapiens 0-9 119396-2 1979 L-Dopa, but not atropine pre-treatment, attenuated the prolactin (PRL) response to MET. Levodopa 0-6 prolactin Homo sapiens 55-64 394552-2 1979 Serum levels of prolactin (PRL) were elevated pre-operatively and decreased after administration of L-Dopa with no increase after TRH as is usually observed in PRL-secreting adenomas. Levodopa 100-106 prolactin Homo sapiens 16-25 507205-0 1979 Effect of clozapine on human serum prolactin levels. Clozapine 10-19 prolactin Homo sapiens 35-44 507205-1 1979 The authors determined serum prolactin levels in 13 patients receiving clozapine, an antipsychotic drug that does not produce extrapyramidal side effects. Clozapine 71-80 prolactin Homo sapiens 29-38 507205-3 1979 Serum prolactin levels were moderately increased between 90 minutes and 4 hours after administration of very high doses of oral clozapine in 4 patients but were smaller than those produced by chlorpromazine in other subjects. Clozapine 128-137 prolactin Homo sapiens 6-15 549431-0 1979 Serum prolactin response to acute and chronic cimetidine administration in man. Cimetidine 46-56 prolactin Homo sapiens 6-15 549431-1 1979 UNLABELLED: The effects of cimetidine administration on the serum prolactin (PRL) response has been studied in twenty healthy volunteers and 46 duodenal ulcer patients. Cimetidine 27-37 prolactin Homo sapiens 66-75 549431-1 1979 UNLABELLED: The effects of cimetidine administration on the serum prolactin (PRL) response has been studied in twenty healthy volunteers and 46 duodenal ulcer patients. Cimetidine 27-37 prolactin Homo sapiens 77-80 317700-3 1979 This study thus demonstrates that a quite specific and unexpected change occurs in the regulation of hypothalamic-median eminence dopamine when iproniazid is administered chronically and provides an explanation of previous observations in human subjects where raised serum prolactin levels are observed after chronic therapy with monoamine oxidase inhibitors. Dopamine 130-138 prolactin Homo sapiens 273-282 317700-3 1979 This study thus demonstrates that a quite specific and unexpected change occurs in the regulation of hypothalamic-median eminence dopamine when iproniazid is administered chronically and provides an explanation of previous observations in human subjects where raised serum prolactin levels are observed after chronic therapy with monoamine oxidase inhibitors. Iproniazid 144-154 prolactin Homo sapiens 273-282 43786-0 1979 Prolactin release by intravenous cimetidine in man: evidence for a suprapituitary locus on action. Cimetidine 33-43 prolactin Homo sapiens 0-9 43786-1 1979 In an attempt to identify the sites at which cimetidine stimulates prolactin release, the drug was administered intravenously (6 mg/kg body weight) to healthy subjects under basal conditions, during dopamine infusion (1 microgram/Kg-min for 120 min) and after pretreatment with L-dopa plus carbidopa (250 plus 25 mg every 6 for 1 day). Cimetidine 45-55 prolactin Homo sapiens 67-76 43786-2 1979 The serum prolactin response to cimetidine was abolished by dopamine infusion and almost completely suppressed by L-dopa plus carbidopa administration. Cimetidine 32-42 prolactin Homo sapiens 10-19 43786-2 1979 The serum prolactin response to cimetidine was abolished by dopamine infusion and almost completely suppressed by L-dopa plus carbidopa administration. Dopamine 60-68 prolactin Homo sapiens 10-19 43786-2 1979 The serum prolactin response to cimetidine was abolished by dopamine infusion and almost completely suppressed by L-dopa plus carbidopa administration. Levodopa 114-120 prolactin Homo sapiens 10-19 43786-2 1979 The serum prolactin response to cimetidine was abolished by dopamine infusion and almost completely suppressed by L-dopa plus carbidopa administration. Carbidopa 126-135 prolactin Homo sapiens 10-19 575318-3 1979 The mean prolactin level in the PMT group was lower in the follicular phase than in the luteal phase (P less than 0.01), but there was no difference between the PMT and control group in the luteal phase. pyridinium 3-methoxyestra-1,3,5(10)-trien-6-yl sulfate 32-35 prolactin Homo sapiens 9-18 575318-5 1979 Bromocriptine suppressed prolactin concentrations (P less than 0.01), but had no effect on the FSH, LH, 17-B-oestradiol or progesterone levels. Bromocriptine 0-13 prolactin Homo sapiens 25-34 44877-0 1979 Prolactin response and extrapyramidal side effects during propranolol and neuroleptic drugs treatment in chronic schizophrenic patients. Propranolol 58-69 prolactin Homo sapiens 0-9 583048-4 1979 In contrast with controls, PRL MCR was higher in hyperthyroidism (MCR = 52 +/- 8 ml/min per m2, P less than 0.05), was slightly lower in hypothyroidism (MCR = 38 +/- 10 ml/min per m2, P = NS), and was significantly correlated with serum thyroxine (r = 0.46, P less than 0.02). Thyroxine 237-246 prolactin Homo sapiens 27-30 583048-10 1979 Dopamine infusion decreased RPL PR from 270 to 66 micrograms/d per m2 indicating that its effect was on pituitary PRL secretion and not PRL metabolism. Dopamine 0-8 prolactin Homo sapiens 114-117 522987-2 1979 The Authors have treated 11 patients with benign breast diseases (fibroadenosis or fibrocystic disease) with two prolactin inhibitor drugs -- metergoline and bromocriptine -- at the dose of 8 mg/die and 7,5 mg/die respectively for sixty days with a 30 days interval from one to the other. Metergoline 142-153 prolactin Homo sapiens 113-122 522987-2 1979 The Authors have treated 11 patients with benign breast diseases (fibroadenosis or fibrocystic disease) with two prolactin inhibitor drugs -- metergoline and bromocriptine -- at the dose of 8 mg/die and 7,5 mg/die respectively for sixty days with a 30 days interval from one to the other. Bromocriptine 158-171 prolactin Homo sapiens 113-122 522987-5 1979 Coming from previous experience, the Authors conclude that the positive therapeutic effect of bromocriptine treatment is connected with the maintenance of prolactin reduction. Bromocriptine 94-107 prolactin Homo sapiens 155-164 316848-0 1979 Influence of bupropion HCl (Wellbatrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat. Bupropion 13-26 prolactin Homo sapiens 85-94 316848-0 1979 Influence of bupropion HCl (Wellbatrin), a novel antidepressant, on plasma levels of prolactin and growth hormone in man and rat. Bupropion 28-38 prolactin Homo sapiens 85-94 517046-2 1979 However, in cases of pituitary prolactin-producing adenomas, ovulation and pregnancy are readily induced medically with bromocriptine. Bromocriptine 120-133 prolactin Homo sapiens 31-40 574700-0 1979 Persisting suppression of prolactin secretion after long-term treatment with bromocriptine in patients with prolactinomas. Bromocriptine 77-90 prolactin Homo sapiens 26-35 574700-1 1979 The effect of bromocriptine withdrawal after long-term treatment on prolactin levels has been investigated in thirty-seven patients with prolactinomas. Bromocriptine 14-27 prolactin Homo sapiens 68-77 574700-2 1979 In ten patients with macroprolactinomas and post-operatively excessively high prolactin levels persisting suppression of prolactin secretion after bromocriptine withdrawal has been observed. Bromocriptine 147-160 prolactin Homo sapiens 26-35 574700-2 1979 In ten patients with macroprolactinomas and post-operatively excessively high prolactin levels persisting suppression of prolactin secretion after bromocriptine withdrawal has been observed. Bromocriptine 147-160 prolactin Homo sapiens 78-87 574700-7 1979 This anti-proliferative action of bromocriptine seems to be specific for the prolactin secreting cells in macroprolactinomas with high proliferation rate and high prolactin turn-over. Bromocriptine 34-47 prolactin Homo sapiens 77-86 574700-7 1979 This anti-proliferative action of bromocriptine seems to be specific for the prolactin secreting cells in macroprolactinomas with high proliferation rate and high prolactin turn-over. Bromocriptine 34-47 prolactin Homo sapiens 111-120 508675-0 1979 Effect of lisuride on inhibition of lactation and serum prolactin. Lisuride 10-18 prolactin Homo sapiens 56-65 508675-3 1979 Lisuride effectively inhibited lactation and also suppressed the serum prolactin levels; the latter effect was dose related. Lisuride 0-8 prolactin Homo sapiens 71-80 526541-1 1979 The effects of the oral administration of nomifensine, which inhibits endogenous cathecolamine re-uptake, on secretion of prolactin and cortisol were investigated in 12 normal subjects. Nomifensine 42-53 prolactin Homo sapiens 122-131 526541-2 1979 In all the volunteers, a significant decrease of prolactin levels was observed following nomifensine administration. Nomifensine 89-100 prolactin Homo sapiens 49-58 227585-2 1979 Optimal conditions for determining the binding of 125I-labeled human prolactin to these cells were established. Iodine-125 50-54 prolactin Homo sapiens 69-78 540209-1 1979 Apomorphine, a direct-acting dopamine agonist, stimulates release of growth hormone (hGH) and suppresses release of prolactin (PRL) from the anterior pituitary. Apomorphine 0-11 prolactin Homo sapiens 116-125 527340-0 1979 Serum prolactin concentrations related to copper or inert intrauterine devices (IUDs) in women. Copper 42-48 prolactin Homo sapiens 6-15 489713-4 1979 When pooling the results of the PRL-secreting adenomas, the mean levels of PRL with dopamine, L-dopa, and bromocriptine were, respectively, 49%, 55%, and 60% of the control levels. Dopamine 84-92 prolactin Homo sapiens 75-78 489713-4 1979 When pooling the results of the PRL-secreting adenomas, the mean levels of PRL with dopamine, L-dopa, and bromocriptine were, respectively, 49%, 55%, and 60% of the control levels. Levodopa 94-100 prolactin Homo sapiens 75-78 489713-4 1979 When pooling the results of the PRL-secreting adenomas, the mean levels of PRL with dopamine, L-dopa, and bromocriptine were, respectively, 49%, 55%, and 60% of the control levels. Bromocriptine 106-119 prolactin Homo sapiens 75-78 489713-10 1979 1) Dopamine acts directly on PRL and GH release from human pituitary adenomas; in vitro, L-dopa effects are similar (its action probably occurs after conversion to catecholamines). Dopamine 3-11 prolactin Homo sapiens 29-39 548046-0 1979 Changes in serum titres of prolactin, somatotropin and thyrotropin induced by fenfluramine in humans. Fenfluramine 78-90 prolactin Homo sapiens 27-36 548046-1 1979 An increase of serum titres of prolactin was observed upon acute and chronic administration of fenfluramine. Fenfluramine 95-107 prolactin Homo sapiens 31-40 540209-1 1979 Apomorphine, a direct-acting dopamine agonist, stimulates release of growth hormone (hGH) and suppresses release of prolactin (PRL) from the anterior pituitary. Apomorphine 0-11 prolactin Homo sapiens 127-130 115197-0 1979 Effect of cyproheptadine on thyrotrophin and prolactin secretion in normal man. Cyproheptadine 10-24 prolactin Homo sapiens 45-54 115197-1 1979 In order to investigate the effect of cyproheptadine, a compound with antiserotoninergic activity, on the secretion of thyrotrophin (TSH) and prolactin (PRL), the nocturnal secretory patterns of these hormones have been studied in 4 normal men in the basal state and after an oral treatment with the drug. Cyproheptadine 38-52 prolactin Homo sapiens 142-151 115197-1 1979 In order to investigate the effect of cyproheptadine, a compound with antiserotoninergic activity, on the secretion of thyrotrophin (TSH) and prolactin (PRL), the nocturnal secretory patterns of these hormones have been studied in 4 normal men in the basal state and after an oral treatment with the drug. Cyproheptadine 38-52 prolactin Homo sapiens 153-156 115197-5 1979 In contrast, the PRL secretion measured through the nocturnal investigation was significantly inhibited by cyproheptadine administration as were the PRL basal levels in the TRH test. Cyproheptadine 107-121 prolactin Homo sapiens 17-20 115197-5 1979 In contrast, the PRL secretion measured through the nocturnal investigation was significantly inhibited by cyproheptadine administration as were the PRL basal levels in the TRH test. Cyproheptadine 107-121 prolactin Homo sapiens 149-152 494989-3 1979 Tiapride, a benzamide derivative with dopaminergic blocking activity at the level of the lactotrophes, increased mean PRL secretion in each subject but a permanent hyperprolactinaemia above 700 uU/ml was attained only in one subject. Tiapride Hydrochloride 0-8 prolactin Homo sapiens 118-121 519119-0 1979 Clinical significance of plasma drug and prolactin levels during acute chlorpromazine treatment: a replication study. Chlorpromazine 71-85 prolactin Homo sapiens 41-50 519876-0 1979 Cimetidine induced prolactin (PRL) release in thyroid disease. Cimetidine 0-10 prolactin Homo sapiens 30-33 519876-1 1979 Effects of acute intravenous administration of cimetidine on serum levels or PRL, TSH, LH and FSH were investigated in six healthy euthyroid, five hypothyroid and five hyperthyroid patients. Cimetidine 47-57 prolactin Homo sapiens 77-80 519876-7 1979 We conclude that unlike the TRH-mediated PRL release, the cimetidine-induced PRL release is independent of the levels of thyroid hormone. Cimetidine 58-68 prolactin Homo sapiens 77-80 519877-6 1979 While bromocriptine effectively decreased the serum prolactin concentration, it had no significant effect over placebo on sperm volume, motility and morphology. Bromocriptine 6-19 prolactin Homo sapiens 52-61 488431-6 1979 Moreover, the high levels of intrafollicular prolactin were associated with a marked reduction in FSH accumulation and low levels of estradiol in antral fluid. Estradiol 133-142 prolactin Homo sapiens 45-54 521705-3 1979 Seasonal differences persisted throughout the experiment but became less obvious during tretment with oestradiol dipropionate and 19-hydroxytestosterone dipropionate, both of which raised prolactin concentrations. estradiol dipropionate 102-125 prolactin Homo sapiens 188-197 521705-3 1979 Seasonal differences persisted throughout the experiment but became less obvious during tretment with oestradiol dipropionate and 19-hydroxytestosterone dipropionate, both of which raised prolactin concentrations. 19-hydroxytestosterone dipropionate 130-165 prolactin Homo sapiens 188-197 396489-1 1979 Relationship between renin, aldosterone, catecholamines and prolactin]. Catecholamines 41-55 prolactin Homo sapiens 60-69 534183-5 1979 Bromocriptine given continuously at a dose of 10 to 20 mg/day for periods of 20 days to 6 months, results in suppression or a marked decrease in the 24-hour secretion of PRL. Bromocriptine 0-13 prolactin Homo sapiens 170-173 45130-0 1979 Serum prolactin levels following intramuscular chlorpromazine: two- and three-hour response as predictors of six-hour response. Chlorpromazine 47-61 prolactin Homo sapiens 6-15 120979-5 1979 From these results two important conclusions can be drawn: 1. the T3 and T4 levels interact with PRL secretion concomitantly with TSH only when they undergo a huge deviation from the normal range; 2. the goitrogenic action of PRL that has been reported in experimental animals cannot be excluded in man. Thyrotropin 130-133 prolactin Homo sapiens 97-100 120979-5 1979 From these results two important conclusions can be drawn: 1. the T3 and T4 levels interact with PRL secretion concomitantly with TSH only when they undergo a huge deviation from the normal range; 2. the goitrogenic action of PRL that has been reported in experimental animals cannot be excluded in man. Thyrotropin 130-133 prolactin Homo sapiens 226-229 382359-1 1979 Single-dose administration of pergolide mesylate (100 to 400 micrograms) results in a dose-related inhibition of prolactin secretion which persists for more than 24 hours. Pergolide 30-48 prolactin Homo sapiens 113-122 382359-2 1979 During multiple-dose administration of pergolide, plasma prolactin concentrations remain markedly reduced (greater than 80 percnet) and gradually return to control levels several days after drug administration is discontinued. Pergolide 39-48 prolactin Homo sapiens 57-66 158692-0 1979 Stimulation of prolactin secretion by morphine: role of the central serotonergic system. Morphine 38-46 prolactin Homo sapiens 15-24 386688-0 1979 Suppression of prolactin secretion by lisuride throughout the menstrual cycle and in hyperprolactinaemic menstrual disorders. Lisuride 38-46 prolactin Homo sapiens 15-24 386688-3 1979 Within 3 h after an oral dose of 200 micrograms lisuride, PRL levels decreased significantly in all subjects to a plateau which lasted up to 3 h. Thereafter a gradual increase of serum PRL was noted. Lisuride 48-56 prolactin Homo sapiens 58-61 386688-3 1979 Within 3 h after an oral dose of 200 micrograms lisuride, PRL levels decreased significantly in all subjects to a plateau which lasted up to 3 h. Thereafter a gradual increase of serum PRL was noted. Lisuride 48-56 prolactin Homo sapiens 185-188 386688-4 1979 In the normally menstruating volunteers lisuride treatment did not result in any significant change of gonadotrophin or of sex steroid secretion, while both, basal as well as metoclopramide (MTCL) stimulated PRL release were significantly diminished. Metoclopramide 175-189 prolactin Homo sapiens 208-211 386688-4 1979 In the normally menstruating volunteers lisuride treatment did not result in any significant change of gonadotrophin or of sex steroid secretion, while both, basal as well as metoclopramide (MTCL) stimulated PRL release were significantly diminished. Metoclopramide 191-195 prolactin Homo sapiens 208-211 386688-9 1979 The data presented demonstrate that lisuride is a potent inhibitor of PRL secretion and has proven its clinical usefulness for treatment of hyperprolactinaemic menstrual disorders. Lisuride 36-44 prolactin Homo sapiens 70-73 582843-6 1979 In all patients CB 154 therapy led to a quick decrease of the prolactin levels, to a regaining of typical LH- and FSH-episodes, as well as to a regeneration of ovarian function. Bromocriptine 16-22 prolactin Homo sapiens 62-71 467339-0 1979 Independent inhibition of prolactin secretion by dopamine and gamma-aminobutyric acid in vitro. Dopamine 49-57 prolactin Homo sapiens 26-35 467339-0 1979 Independent inhibition of prolactin secretion by dopamine and gamma-aminobutyric acid in vitro. gamma-Aminobutyric Acid 62-85 prolactin Homo sapiens 26-35 44254-0 1979 [The effect of propranolol, neuroleptics and their combination on serum prolactin levels of schizophrenic patients]. Propranolol 15-26 prolactin Homo sapiens 72-81 93568-2 1979 As an extension of this work, the same approach was used to test for and to localize prolactin binding sites in autopsy and biopsy specimens of formalin fixed, paraffin embedded human prostate. Formaldehyde 144-152 prolactin Homo sapiens 85-94 93568-2 1979 As an extension of this work, the same approach was used to test for and to localize prolactin binding sites in autopsy and biopsy specimens of formalin fixed, paraffin embedded human prostate. Paraffin 160-168 prolactin Homo sapiens 85-94 157360-0 1979 Intraamniotic or intravenous injection of dehydroepiandrosterone sulfate in midgestation: effect on prolactin level in maternal serum and amniotic fluid. Dehydroepiandrosterone Sulfate 42-72 prolactin Homo sapiens 100-109 157360-1 1979 The influence of dehydroepiandrosterone sulfate (DHEA-S) on PRL levels in maternal serum and amniotic fluid at midgestation was evaluated in a series of 32 women admitted for midtrimester abortion. Dehydroepiandrosterone Sulfate 17-47 prolactin Homo sapiens 60-63 295284-0 1979 The biphasic effect of gradually increased doses of diazepam on prolactin secretion in acute schizophrenic patients. Diazepam 52-60 prolactin Homo sapiens 64-73 313936-1 1979 Fluoxetine hydrochloride, a specific inhibitor of serotonin reuptake, was given orally to five adult males to study its effect on fasting and insulin-stimulated release of PRL. Fluoxetine 0-24 prolactin Homo sapiens 172-175 313936-3 1979 Fluoxetine significantly enhanced insulin-induced PRL release. Fluoxetine 0-10 prolactin Homo sapiens 50-53 116266-0 1979 Effects of zimelidine, a selective 5-HT uptake inhibitor, on serum prolactin levels in man. Zimeldine 11-21 prolactin Homo sapiens 67-76 116266-1 1979 The levels of serum prolactin were studied both after an acute intake of zimelidine and during a treatment period of 3--7 weeks. Zimeldine 73-83 prolactin Homo sapiens 20-29 116281-2 1979 Mescaline stimulated the secretion of PRL more than four-fold above base-line levels. Mescaline 0-9 prolactin Homo sapiens 38-41 116298-0 1979 Naloxone effects on serum growth hormone and prolactin in man. Naloxone 0-8 prolactin Homo sapiens 45-54 116298-2 1979 Naloxone, a relatively specific narcotic antagonist, decreases serum prolactin and growth hormone levels in animals. Naloxone 0-8 prolactin Homo sapiens 69-78 223069-0 1979 Endogenous opiates block dopamine inhibition of prolactin secretion in vitro. Dopamine 25-33 prolactin Homo sapiens 48-57 111552-0 1979 Effect of dexamethasone on prolactin secretion in late pregnancy. Dexamethasone 10-23 prolactin Homo sapiens 27-36 227202-3 1979 Bromocriptine treatment for 10 to 12 days significantly suppressed mean (+/- SE) serum prolactin (PRL) levels from 65.1 +/- 23.0 to 10.4 +/- 2.0 ng/ml, while LH (12.6 +/- 2.1 to 24.8 +/- 5.9 mIU/ml) and oestradiol (40.1 +/- 7.6 to 111.4 +/- 20.8 pg/ml) levels increased significantly. Bromocriptine 0-13 prolactin Homo sapiens 87-96 520386-0 1979 Effect of ergot alkaloids on serum prolactin in non-psychotic organic brain syndrome of the elderly. Ergot Alkaloids 10-25 prolactin Homo sapiens 35-44 520386-4 1979 It may be that a higher dose of Hydergine with an accompanying greater drop in prolactin would be required to observe this effect. Ergoloid Mesylates 32-41 prolactin Homo sapiens 79-88 111967-0 1979 Prolactin response to TRH after intravenous cimetidine. Cimetidine 44-54 prolactin Homo sapiens 0-9 111967-1 1979 Cimetidine administered intravenously to six healthy volunteers caused a significant increase in plasma prolactin response to TRH. Cimetidine 0-10 prolactin Homo sapiens 104-113 572372-1 1979 The suppressive action of dopamine (DA) on circulating gonadotropin and PRL levels is found to be positively correlated with their basal serum concentrations. Dopamine 26-34 prolactin Homo sapiens 72-75 572372-1 1979 The suppressive action of dopamine (DA) on circulating gonadotropin and PRL levels is found to be positively correlated with their basal serum concentrations. Dopamine 36-38 prolactin Homo sapiens 72-75 572372-5 1979 These findings indicate that castration and estrogen treatment significantly influence the inhibitory effect of DA on gonadotropin and PRL release. Dopamine 112-114 prolactin Homo sapiens 135-138 490081-3 1979 during each day in culture and incorporated 3H-labelled amino acids into immunoprecipitable prolactin. Tritium 44-46 prolactin Homo sapiens 92-101 288847-1 1979 The effects of haloperidol on the release of prolactin, growth hormone, and luteinizing hormone during sleep were studied in an adolescent male who had Gilles de la Tourette"s disease and delayed onset of puberty. Haloperidol 15-26 prolactin Homo sapiens 45-54 288847-2 1979 At doses of 5 and 2 mg, haloperidol led to an increase of prolactin secretion and a suppression of luteinizing hormone release. Haloperidol 24-35 prolactin Homo sapiens 58-67 485487-0 1979 [Influence of lisuridhydrogen maleate on prolactin secretion in puerperium]. lisuridhydrogen maleate 14-37 prolactin Homo sapiens 41-50 117916-1 1979 3H Domperidone binding on cellular membranes from human prolactin adenomas demonstrates the presence of two dopaminergic binding sites. 3h domperidone 0-14 prolactin Homo sapiens 56-65 112817-0 1979 The effect of metoclopramide, TRH and L-dopa on prolactin secretion in pituitary adenoma and in "functional" galactorrhoea syndrome. Levodopa 38-44 prolactin Homo sapiens 48-57 112817-2 1979 It was found that in patients with pituitary adenoma the basal prolactin (PRL) level often exceeded 150 micrograms/l and the response to stimulation with TRH and/or metoclopramide was markedly diminished or even nonexistent, while the response to L-DOPA was usually retained. Metoclopramide 165-179 prolactin Homo sapiens 63-72 112817-2 1979 It was found that in patients with pituitary adenoma the basal prolactin (PRL) level often exceeded 150 micrograms/l and the response to stimulation with TRH and/or metoclopramide was markedly diminished or even nonexistent, while the response to L-DOPA was usually retained. Metoclopramide 165-179 prolactin Homo sapiens 74-77 112817-2 1979 It was found that in patients with pituitary adenoma the basal prolactin (PRL) level often exceeded 150 micrograms/l and the response to stimulation with TRH and/or metoclopramide was markedly diminished or even nonexistent, while the response to L-DOPA was usually retained. Levodopa 247-253 prolactin Homo sapiens 63-72 112817-2 1979 It was found that in patients with pituitary adenoma the basal prolactin (PRL) level often exceeded 150 micrograms/l and the response to stimulation with TRH and/or metoclopramide was markedly diminished or even nonexistent, while the response to L-DOPA was usually retained. Levodopa 247-253 prolactin Homo sapiens 74-77 112818-4 1979 Methergoline (4 mg po) was shown to decrease serum PRL levels in 8 normal subjects, in 6 puerperal women, and 9 of 10 tumour patients. Metergoline 0-12 prolactin Homo sapiens 51-54 112818-5 1979 Bromoergocriptine (CB-154, 2.5 mg po) decreased serum PRL levels in 10 tumour patients. Bromocriptine 0-17 prolactin Homo sapiens 54-57 112818-5 1979 Bromoergocriptine (CB-154, 2.5 mg po) decreased serum PRL levels in 10 tumour patients. Bromocriptine 19-25 prolactin Homo sapiens 54-57 112818-11 1979 A positive PRL response to methergoline and bromocriptine was observed post-operatively in the patients tested regardless of their basal PRL level. Metergoline 27-39 prolactin Homo sapiens 11-14 112818-11 1979 A positive PRL response to methergoline and bromocriptine was observed post-operatively in the patients tested regardless of their basal PRL level. Bromocriptine 44-57 prolactin Homo sapiens 11-14 474034-0 1979 Study on the reproducibility of human prolactin response to sulpiride, benserazide, insulin hypoglycaemia and arginine infusion. Sulpiride 60-69 prolactin Homo sapiens 38-47 474034-0 1979 Study on the reproducibility of human prolactin response to sulpiride, benserazide, insulin hypoglycaemia and arginine infusion. Benserazide 71-82 prolactin Homo sapiens 38-47 474034-0 1979 Study on the reproducibility of human prolactin response to sulpiride, benserazide, insulin hypoglycaemia and arginine infusion. Arginine 110-118 prolactin Homo sapiens 38-47 474034-3 1979 In contrast to this, insulin hypoglycaemia yielded significantly lower PRL release, while the PRL response to the second sulpiride test was significantly higher than to the first one. Sulpiride 121-130 prolactin Homo sapiens 94-97 474034-4 1979 When an interval of 10 days was left between two consecutive sulpiride tests, an identical PRL release was observed. Sulpiride 61-70 prolactin Homo sapiens 91-94 474034-6 1979 Finally, sulpiride probably enhances both PRL release and synthesis thus making greater amounts of PRL available to a subsequent stimulus. Sulpiride 9-18 prolactin Homo sapiens 42-45 474034-6 1979 Finally, sulpiride probably enhances both PRL release and synthesis thus making greater amounts of PRL available to a subsequent stimulus. Sulpiride 9-18 prolactin Homo sapiens 99-102 115337-2 1979 Hyperprolactenemia induced by acute and chronic treatment with chlorpromazine showed significantly higher prolactin levels in seminal plasma on 8th and 16th day respectively, by which time the serum prolactin levels have already reached pretreatment levels. Chlorpromazine 63-77 prolactin Homo sapiens 106-115 115337-2 1979 Hyperprolactenemia induced by acute and chronic treatment with chlorpromazine showed significantly higher prolactin levels in seminal plasma on 8th and 16th day respectively, by which time the serum prolactin levels have already reached pretreatment levels. Chlorpromazine 63-77 prolactin Homo sapiens 199-208 496036-2 1979 There was only a weak negative correlation between hPRL and testosterone in oligozoospermic men. Testosterone 60-72 prolactin Homo sapiens 51-55 518021-0 1979 [The study of the influence of prolactin on gonadal steroids metabolism by the human chorionic gonadotropin test. Steroids 52-60 prolactin Homo sapiens 31-40 378199-3 1979 While the serum prolactin level decreased in response to bromocriptine, no difference was found between the effects of placebo and bromocriptine on the symptoms of spasmodic torticollis. Bromocriptine 57-70 prolactin Homo sapiens 16-25 117952-2 1979 Lisuride effectively inhibited basal PRL secretion as well as the PRL response to TRH given 3 h later. Lisuride 0-8 prolactin Homo sapiens 37-40 117952-2 1979 Lisuride effectively inhibited basal PRL secretion as well as the PRL response to TRH given 3 h later. Lisuride 0-8 prolactin Homo sapiens 66-69 43342-1 1979 The effects of acute and repeated administration of pyridoxine on serum prolactin levels were studied in 18 chronic schizophrenics, 10 women and 8 men, in whom hyperprolactinemia had been induced by long-term treatment with phenothiazines, haloperidol, sulpiride or clopentixol. Pyridoxine 52-62 prolactin Homo sapiens 72-81 393753-9 1979 Two of four women had elevated prolactin levels which increased defectuously after metoclopramide administration which could suggest an abnormal hypothalamic status. Metoclopramide 83-97 prolactin Homo sapiens 31-40 479727-3 1979 Because exposure to the young also promotes prolactin-induced crop sac growth, it appears probable that the squab-induced decrease in prolactin content of the pituitary gland reflects the release of prolactin into the circulation. squab 108-113 prolactin Homo sapiens 44-53 386688-5 1979 The inhibition of PRL secretion in patients with short luteal phases resulted in an increase of luteal progesterone output. luteal 55-61 prolactin Homo sapiens 18-21 386688-5 1979 The inhibition of PRL secretion in patients with short luteal phases resulted in an increase of luteal progesterone output. Progesterone 103-115 prolactin Homo sapiens 18-21 523856-0 1979 [Metoclopramide induced prolactin secretion in Sheehan"s syndrome (author"s transl)]. Metoclopramide 1-15 prolactin Homo sapiens 24-33 392771-7 1979 During gestation, greatly increased levels of endogenous sex steroids efficiently stimulate pituitary prolactin secretion; during lactation, the stimulus of suckling is responsible for hyperprolactinemia. Steroids 61-69 prolactin Homo sapiens 102-111 87748-0 1979 Naloxone lowers plasma-prolactin in man. Naloxone 0-8 prolactin Homo sapiens 23-32 86882-6 1979 Prolactin response to the acute oral administration of L-dopa and bromocriptine was of less diagnostic value. Levodopa 55-61 prolactin Homo sapiens 0-9 86882-10 1979 and metoclopramide stimulation have considerable value in identifying hyperprolactinaemic patients with prolactin-secreting adenomas, particularly those which are radiologically occult. Metoclopramide 4-18 prolactin Homo sapiens 75-84 479727-3 1979 Because exposure to the young also promotes prolactin-induced crop sac growth, it appears probable that the squab-induced decrease in prolactin content of the pituitary gland reflects the release of prolactin into the circulation. squab 108-113 prolactin Homo sapiens 134-143 479727-3 1979 Because exposure to the young also promotes prolactin-induced crop sac growth, it appears probable that the squab-induced decrease in prolactin content of the pituitary gland reflects the release of prolactin into the circulation. squab 108-113 prolactin Homo sapiens 134-143 528777-0 1979 Influence of bromocriptine on plasma levels of prolactin and steroid hormones in the 20th week of pregnancy. Bromocriptine 13-26 prolactin Homo sapiens 47-56 528777-1 1979 The influence of bromocriptine, a prolactin antagonist, on maternal plasma and amniotic fluid prolactin (PRL) was investigated in two pregnancies at the 20th week with medical indication for abortion. Bromocriptine 17-30 prolactin Homo sapiens 34-43 528777-1 1979 The influence of bromocriptine, a prolactin antagonist, on maternal plasma and amniotic fluid prolactin (PRL) was investigated in two pregnancies at the 20th week with medical indication for abortion. Bromocriptine 17-30 prolactin Homo sapiens 94-103 528777-1 1979 The influence of bromocriptine, a prolactin antagonist, on maternal plasma and amniotic fluid prolactin (PRL) was investigated in two pregnancies at the 20th week with medical indication for abortion. Bromocriptine 17-30 prolactin Homo sapiens 105-108 528777-3 1979 Blood sample determinations demonstrated that bromocriptine inhibits the secretion of PRL both in plasma and amniotic fluid. Bromocriptine 46-59 prolactin Homo sapiens 86-89 571691-2 1979 Fifteen women with a mean initial serum prolactin of 37 +/- 7 ng/mL received 16 to 24 mg of cyproheptadine daily; they had a significant decrease in prolactin concentration at 8 and at 16 weeks (P less than 0.01). Cyproheptadine 92-106 prolactin Homo sapiens 149-158 571691-6 1979 We conclude that long-term treatment of the galactorrhea-amenorrhea syndrome with cyproheptadine is effective in lowering serum prolactin in patients with mildly elevated or normal levels. Cyproheptadine 82-96 prolactin Homo sapiens 128-137 288387-6 1979 In contrast, serum prolactin (PRL) throughout the day suppressed significantly in all subjects after 5 mg/day bromocriptine. Bromocriptine 110-123 prolactin Homo sapiens 19-28 109323-1 1979 The course of pregnancy achieved after bromocriptine therapy is described in nine patients with radiologically evident prolactin-secreting pituitary tumors. Bromocriptine 39-52 prolactin Homo sapiens 119-128 463447-0 1979 Inhibition of prolactin and lactation by methylergometrine hydrogenmaleate. methylergometrine hydrogenmaleate 41-74 prolactin Homo sapiens 14-23 463447-1 1979 Reports on the effect of methylergometrine hydrogenmaleate (MEM) on prolactin (PRL) secretion and lactation are still controversial. methylergometrine hydrogenmaleate 25-58 prolactin Homo sapiens 68-77 463447-1 1979 Reports on the effect of methylergometrine hydrogenmaleate (MEM) on prolactin (PRL) secretion and lactation are still controversial. methylergometrine hydrogenmaleate 25-58 prolactin Homo sapiens 79-82 545976-0 1979 Effect of Lisuride on serum prolactin levels during puerperium. Lisuride 10-18 prolactin Homo sapiens 28-37 545976-4 1979 Lisuride lowered PRL levels, and the decrease was significantly more marked for the 600 microgram dose. Lisuride 0-8 prolactin Homo sapiens 17-20 221277-0 1979 Effect of prolactin on the calcium binding and/or transport of ejaculated and epididymal human spermatozoa. Calcium 27-34 prolactin Homo sapiens 10-19 467503-1 1979 Sulpiride, which differs from classical neuroleptics by not producing major extrapyramidal side effects, is a potent antiemetic agent and stimulates prolactin secretion in both laboratory animals and man. Sulpiride 0-9 prolactin Homo sapiens 149-158 468103-6 1979 Integrated perphenazine-induced PRL responses were likewise similar during the 2 study periods: 101 +/- 16 ng . Perphenazine 11-23 prolactin Homo sapiens 32-35 459701-0 1979 Effect of histamine and acetylcholine on hypophysial stalk plasma dopamine and peripheral plasma prolactin levels. Acetylcholine 24-37 prolactin Homo sapiens 97-106 110148-3 1979 Prolactin levels responded to thyrotropin releasing hormone and L-dopa administration, but not chlorpromazine. Levodopa 64-70 prolactin Homo sapiens 0-9 113144-6 1979 The basal level of PRL in the whole series was more closely related to the level of serum oestradiol (r = 0.778, P less than 0.001) than to that of serum progesterone (r = 0.442, P less than 0.05). Estradiol 90-100 prolactin Homo sapiens 19-22 113144-6 1979 The basal level of PRL in the whole series was more closely related to the level of serum oestradiol (r = 0.778, P less than 0.001) than to that of serum progesterone (r = 0.442, P less than 0.05). Progesterone 154-166 prolactin Homo sapiens 19-22 429533-0 1979 Circulating big human prolactin: conversion to small human prolactin by reduction of disulfide bonds. Disulfides 85-94 prolactin Homo sapiens 22-31 429533-0 1979 Circulating big human prolactin: conversion to small human prolactin by reduction of disulfide bonds. Disulfides 85-94 prolactin Homo sapiens 59-68 429533-1 1979 The heterogeneity of circulating human PRL (hPRL) in sera of patients with hyperprolactinemia was studied by exclusion chromatography on Sephadex G-100. sephadex 137-151 prolactin Homo sapiens 44-48 429533-2 1979 Big hPRL, which elutes between the void volume and the elution position of monomeric small hPRL, is stable upon rechromatography but is almost entirely converted into small hPRL after reduction with 0.5% mercaptoethanol. Mercaptoethanol 204-219 prolactin Homo sapiens 4-8 429533-3 1979 These results suggest that the existence of circulating big hPRL is dependent upon the formation of interpolypeptide disulfide bonds and does not represent a classical biosynthetic precursor of hPRL. Disulfides 117-126 prolactin Homo sapiens 60-64 433974-4 1979 Bromergocryptine and other ergot alkaloids have been shown to decrease the production of prolactin and to inhibit the rate of pituitary tumor growth in animal studies. Bromocriptine 0-16 prolactin Homo sapiens 89-98 433974-4 1979 Bromergocryptine and other ergot alkaloids have been shown to decrease the production of prolactin and to inhibit the rate of pituitary tumor growth in animal studies. Ergot Alkaloids 27-42 prolactin Homo sapiens 89-98 477223-2 1979 This study was done to examine the possibility that escape from the sodium retention produced by aldosterone may be associated with an inhibition of prolactin secretion. Sodium 68-74 prolactin Homo sapiens 149-158 225167-4 1979 Suppression of plasma prolactin (PRL) by levodopa (l-dopa) was impaired and elevation of basal plasma PRL was noted at the second admission. Levodopa 41-49 prolactin Homo sapiens 22-31 225167-4 1979 Suppression of plasma prolactin (PRL) by levodopa (l-dopa) was impaired and elevation of basal plasma PRL was noted at the second admission. Levodopa 51-57 prolactin Homo sapiens 22-31 554040-0 1979 Action of the serotoninergic and dopaminergic antagonist methiothepin maleate on serum prolactin and growth hormone levels in man. Methiothepin 57-77 prolactin Homo sapiens 87-96 398988-0 1979 The role of prostaglandins in the control of gonadotropin and prolactin secretion. Prostaglandins 12-26 prolactin Homo sapiens 62-71 483202-2 1979 Bromocriptine is a dopaminergic agonist that is used in acromegalic patients, as well as an inhibitor of prolactin in doses of 5 to 20 mg a day. Bromocriptine 0-13 prolactin Homo sapiens 105-114 121700-0 1979 [Role of 17-beta-estradiol in the synthesis and secretion of prolactin]. Estradiol 9-26 prolactin Homo sapiens 61-70 121700-3 1979 The data suggest that 17-beta-estradiol doesn"t increase the number of TRH receptors on pituitary cell surface, but stimulates prolactin synthesis. Estradiol 22-39 prolactin Homo sapiens 127-136 108715-0 1979 Variability of prolactin response to intravenous and intramuscular haloperidol in normal adult men. Haloperidol 67-78 prolactin Homo sapiens 15-24 108715-6 1979 Differences in serum heloperidol concentrations accounted for 88% of the variability in the magnitude of the PRL response to the 0.5 mg IM haloperidol dose, but only accounted for 60% of the PRL variability following the 0.5 mg IV dose. heloperidol 21-32 prolactin Homo sapiens 109-112 108715-6 1979 Differences in serum heloperidol concentrations accounted for 88% of the variability in the magnitude of the PRL response to the 0.5 mg IM haloperidol dose, but only accounted for 60% of the PRL variability following the 0.5 mg IV dose. Haloperidol 139-150 prolactin Homo sapiens 109-112 427008-0 1979 Plasma prolactin levels before and during propranolol treatment in chronic schizophrenia. Propranolol 42-53 prolactin Homo sapiens 7-16 447203-0 1979 Cimetidine effects on prolactin release and production. Cimetidine 0-10 prolactin Homo sapiens 22-31 447203-1 1979 The effect of cimetidine 1600 mg. daily for three months on prolactin and related hormones is reported. Cimetidine 14-24 prolactin Homo sapiens 60-69 447203-4 1979 Since intravenous cimetidine induces a transient hyperprolactinemia it appears that cimetidine may facilitate release of prolactin but has no effect on its synthesis. Cimetidine 18-28 prolactin Homo sapiens 54-63 447203-4 1979 Since intravenous cimetidine induces a transient hyperprolactinemia it appears that cimetidine may facilitate release of prolactin but has no effect on its synthesis. Cimetidine 84-94 prolactin Homo sapiens 54-63 447211-0 1979 Cimetidine and L-dopa in the control of prolactin secretion in man. Cimetidine 0-10 prolactin Homo sapiens 40-49 447211-0 1979 Cimetidine and L-dopa in the control of prolactin secretion in man. Levodopa 15-21 prolactin Homo sapiens 40-49 447381-0 1979 Serum prolactin levels in women before and after the use of copper IUD. Copper 60-66 prolactin Homo sapiens 6-15 429499-1 1979 The effect of oral administration of sulpiride on PRL secretion and initiation of puerperal lactation was studied in 130 randomly selected primiparous nursing mothers. Sulpiride 37-46 prolactin Homo sapiens 50-53 429499-5 1979 Every other day determinations of serum PRL levels revealed significantly higher concentrations in the sulpiride group than in the control group. Sulpiride 103-112 prolactin Homo sapiens 40-43 429499-6 1979 A single oral dose of 50 mg sulpiride raised serum PRL levels for 12 h, with a peak level at 2 h after dosing in 7 women on the second postpartum day. Sulpiride 28-37 prolactin Homo sapiens 51-54 429499-7 1979 These data suggest that sulpiride given orally promotes the initiation of lactation in puerperal women by stimulating PRL secretion. Sulpiride 24-33 prolactin Homo sapiens 118-121 424097-8 1979 It is concluded that prolactin may interfere with normal progesterone synthesis by the corpus luteum, as demonstrated by the prompt restoration of fertility by bromocriptine treatment in women with regular cycles and inadequate luteal function. Bromocriptine 160-173 prolactin Homo sapiens 21-30 313251-2 1979 As parachlorophenylalanine appears to reduce release of prolactin (PRL) and melanocyte-stimulating hormone (MSH) in the eel, a stimulating serotoninergic control of these adenohypophysial secretions was suspected. Fenclonine 3-26 prolactin Homo sapiens 56-65 313251-2 1979 As parachlorophenylalanine appears to reduce release of prolactin (PRL) and melanocyte-stimulating hormone (MSH) in the eel, a stimulating serotoninergic control of these adenohypophysial secretions was suspected. Fenclonine 3-26 prolactin Homo sapiens 67-70 552852-1 1979 Carbidopa, at the dose of 250 mg. and benserazide at the dose of 125 mg, given orally in a single dose to healthy women aged between 23 - 26 years enhance significantly serum prolactin. Carbidopa 0-9 prolactin Homo sapiens 175-184 552852-1 1979 Carbidopa, at the dose of 250 mg. and benserazide at the dose of 125 mg, given orally in a single dose to healthy women aged between 23 - 26 years enhance significantly serum prolactin. Benserazide 38-49 prolactin Homo sapiens 175-184 552853-0 1979 Dose and sex related effects of benserazide on prolactin secretion. Benserazide 32-43 prolactin Homo sapiens 47-56 552853-1 1979 Benserazide, given orally at various doses ranging from 10 to 125 mg. to healthy women aged 21 to 33 years induces a dose related increase of prolactin titres in serum. Benserazide 0-11 prolactin Homo sapiens 142-151 434010-1 1979 The addition of ovine prolactin (oPRL) to the fetal side of human term amnion in vitro is associated with a decrease in membrane permeability to tritiated water (THO). Water 155-160 prolactin Homo sapiens 22-31 419914-1 1979 In order to study the interaction between oestrogens and bromocriptine on PRL release, we evaluated the ability of bromocriptine (CB-154) to counteract the oestrogen-induced PRL release in four hyperprolactinaemic amenorrhoeic women. Bromocriptine 115-128 prolactin Homo sapiens 174-177 419914-1 1979 In order to study the interaction between oestrogens and bromocriptine on PRL release, we evaluated the ability of bromocriptine (CB-154) to counteract the oestrogen-induced PRL release in four hyperprolactinaemic amenorrhoeic women. Bromocriptine 130-136 prolactin Homo sapiens 174-177 419914-2 1979 Bromocriptine acutely administered induced a similar percentage of PRL decrease in the same patient before and after oestrogen administration. Bromocriptine 0-13 prolactin Homo sapiens 67-70 419914-4 1979 These results show that bromocriptine is able to block the release of PRL induced by oestrogens, suggesting an interaction between oestrogens and DA-mimetic compounds on PRL release. Bromocriptine 24-37 prolactin Homo sapiens 70-73 419914-4 1979 These results show that bromocriptine is able to block the release of PRL induced by oestrogens, suggesting an interaction between oestrogens and DA-mimetic compounds on PRL release. Bromocriptine 24-37 prolactin Homo sapiens 170-173 419914-4 1979 These results show that bromocriptine is able to block the release of PRL induced by oestrogens, suggesting an interaction between oestrogens and DA-mimetic compounds on PRL release. da-mimetic compounds 146-166 prolactin Homo sapiens 70-73 419914-4 1979 These results show that bromocriptine is able to block the release of PRL induced by oestrogens, suggesting an interaction between oestrogens and DA-mimetic compounds on PRL release. da-mimetic compounds 146-166 prolactin Homo sapiens 170-173 570900-0 1979 Bromocriptine treatment of seven women with primary amenorrhoea and prolactin-secreting pituitary tumours. Bromocriptine 0-13 prolactin Homo sapiens 68-77 570900-8 1979 Bromocriptine treatment normalized the raised serum prolactin levels (46-2900 microgram/l) in all but one woman, in whom the prolactin level decreased from 160 to 38 microgram/l. Bromocriptine 0-13 prolactin Homo sapiens 52-61 570900-8 1979 Bromocriptine treatment normalized the raised serum prolactin levels (46-2900 microgram/l) in all but one woman, in whom the prolactin level decreased from 160 to 38 microgram/l. Bromocriptine 0-13 prolactin Homo sapiens 125-134 429487-2 1979 A single oral dose of metergoline or methysergide induced a significant decrease of plasma PRL levels and abolished the PRL response to suckling. Metergoline 22-33 prolactin Homo sapiens 91-94 429487-2 1979 A single oral dose of metergoline or methysergide induced a significant decrease of plasma PRL levels and abolished the PRL response to suckling. Metergoline 22-33 prolactin Homo sapiens 120-123 429487-2 1979 A single oral dose of metergoline or methysergide induced a significant decrease of plasma PRL levels and abolished the PRL response to suckling. Methysergide 37-49 prolactin Homo sapiens 91-94 429487-2 1979 A single oral dose of metergoline or methysergide induced a significant decrease of plasma PRL levels and abolished the PRL response to suckling. Methysergide 37-49 prolactin Homo sapiens 120-123 439776-1 1979 Contamination of prolactin preparations with ADH and implications on renal and vascular prolactin research. adh 45-48 prolactin Homo sapiens 17-26 439776-4 1979 Antisera against ADH, oxytocin and prolactin are rather specific inactivators of the biologic activity of the respective hormone; the oxytocinasevasopressinase system of pregnancy plasma destroys ADH and oxytocin. adh 196-199 prolactin Homo sapiens 35-44 432553-5 1979 It is suggested that this patient"s erythrocytes may have been altered by placental lactogen and/or prolactin in such a way as to make them abnormally dependent on insulin for the uptake of glucose. Glucose 190-197 prolactin Homo sapiens 100-109 760259-0 1979 Effect of sex steroid hormones on the serum prolactin concentration. Steroids 14-30 prolactin Homo sapiens 44-53 760259-3 1979 The results obtained demonstrate that an inverse correlation of prolactin and gonadotropin secretions occurred during administration of the steroid sex hormones as seen in post partum period or patients with galactorrhea-amenorrhea. steroid sex hormones 140-160 prolactin Homo sapiens 64-73 428198-0 1979 [Influence of hematoporphyrin on the tonic or phasic secretion of prolactin]. Hematoporphyrins 14-29 prolactin Homo sapiens 66-75 581754-8 1979 The basal plasma PRL levels were inversely correlated with GH responsiveness (CB-154: r=-0.690, p less than 0.01. Bromocriptine 78-84 prolactin Homo sapiens 17-20 420411-0 1979 Prolactin in azoospermic men and its relation to testicular morphology, serum testosterone and gonadotrophin levels. Testosterone 78-90 prolactin Homo sapiens 0-9 288372-3 1979 Dopaminergic agonists (apomorphine, piribedil, d-amphetamine, L-DOPA, and the ergot derivatives bromocriptine and lisuride) all caused a decrease of serum prolactin levels. Apomorphine 23-34 prolactin Homo sapiens 155-164 288372-3 1979 Dopaminergic agonists (apomorphine, piribedil, d-amphetamine, L-DOPA, and the ergot derivatives bromocriptine and lisuride) all caused a decrease of serum prolactin levels. Piribedil 36-45 prolactin Homo sapiens 155-164 288372-3 1979 Dopaminergic agonists (apomorphine, piribedil, d-amphetamine, L-DOPA, and the ergot derivatives bromocriptine and lisuride) all caused a decrease of serum prolactin levels. Dextroamphetamine 47-60 prolactin Homo sapiens 155-164 288372-3 1979 Dopaminergic agonists (apomorphine, piribedil, d-amphetamine, L-DOPA, and the ergot derivatives bromocriptine and lisuride) all caused a decrease of serum prolactin levels. Levodopa 62-68 prolactin Homo sapiens 155-164 288372-3 1979 Dopaminergic agonists (apomorphine, piribedil, d-amphetamine, L-DOPA, and the ergot derivatives bromocriptine and lisuride) all caused a decrease of serum prolactin levels. Bromocriptine 96-109 prolactin Homo sapiens 155-164 288372-3 1979 Dopaminergic agonists (apomorphine, piribedil, d-amphetamine, L-DOPA, and the ergot derivatives bromocriptine and lisuride) all caused a decrease of serum prolactin levels. Lisuride 114-122 prolactin Homo sapiens 155-164 288372-6 1979 This was suggested by the inhibitory effect of pretreatment with the dopamine antagonist spiroperidol or with sulpiride on the prolactin-lowering effect of lisuride. Dopamine 69-77 prolactin Homo sapiens 127-136 288372-6 1979 This was suggested by the inhibitory effect of pretreatment with the dopamine antagonist spiroperidol or with sulpiride on the prolactin-lowering effect of lisuride. Spiperone 89-101 prolactin Homo sapiens 127-136 288372-6 1979 This was suggested by the inhibitory effect of pretreatment with the dopamine antagonist spiroperidol or with sulpiride on the prolactin-lowering effect of lisuride. Sulpiride 110-119 prolactin Homo sapiens 127-136 288372-6 1979 This was suggested by the inhibitory effect of pretreatment with the dopamine antagonist spiroperidol or with sulpiride on the prolactin-lowering effect of lisuride. Lisuride 156-164 prolactin Homo sapiens 127-136 760734-0 1979 Failure of cimetidine to antagonise dopamine-induced suppression of prolactin in vitro. Dopamine 36-44 prolactin Homo sapiens 68-77 760738-0 1979 Prolactin responses to cimetidine. Cimetidine 23-33 prolactin Homo sapiens 0-9 760738-1 1979 1 An intravenous injection of cimetidine 400 mg to four healthy male subjects resulted in high blood concentrations of cimetidine and a rapid three-fold increase in serum prolactin. Cimetidine 31-41 prolactin Homo sapiens 172-181 760769-1 1979 Clomiphene was administered to 16 patients with elevated serum prolactin levels in doses of 100, 200 and 300 mg/day for five days in succeeding months and total urinary oestrogens estimated on days 0, 5, 8, 12 and 15 following commencement of treatment. Clomiphene 0-10 prolactin Homo sapiens 63-72 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Chlorpromazine 86-100 prolactin Homo sapiens 65-68 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Chlorpromazine 86-100 prolactin Homo sapiens 145-148 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Chlorpromazine 86-100 prolactin Homo sapiens 145-148 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Chlorpromazine 86-100 prolactin Homo sapiens 145-148 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Levodopa 105-111 prolactin Homo sapiens 65-68 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Levodopa 105-111 prolactin Homo sapiens 145-148 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Levodopa 105-111 prolactin Homo sapiens 145-148 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Levodopa 105-111 prolactin Homo sapiens 145-148 114343-4 1979 On the other hand, in the hyperprolactinaemic group, an impaired PRL response to TRH, Chlorpromazine and L-Dopa was noted in patients with basal PRL levels higher than 30 ng/ml, whereas bromocriptine suppressed effectively PRL levels in all the hyperprolactinaemic patients tested irrespective of their basal PRL concentrations. Bromocriptine 186-199 prolactin Homo sapiens 65-68 114343-5 1979 The ratio between the fall in PRL concentrations (as percent of the baseline) after L-Dopa administration (delta%L) versus the PRL decrement after bromocriptine treatment (delta%B) was calculated. Levodopa 84-90 prolactin Homo sapiens 30-33 436308-2 1979 administration of cimetidine, an histamine receptor antagonist, produced a significant increase in serum prolactin (PRL) levels in fifteen normal men. Cimetidine 18-28 prolactin Homo sapiens 105-114 487614-3 1979 However, 400 mg cimetidine given intravenously as a bolus injection significantly stimulated PRL release in all subjects, without affecting any other measured hormone. Cimetidine 16-26 prolactin Homo sapiens 93-96 487614-4 1979 A dose-reponse relationship existed, and 200 mg cimetidine seems to be the minimum PRL-releasing dose when given as an intravenous bolus injection. Cimetidine 48-58 prolactin Homo sapiens 83-86 487614-5 1979 These results suggest that cimetidine releases PRL and that this effect is dose-related, but only when large intravenous injections are given. Cimetidine 27-37 prolactin Homo sapiens 47-50 428221-0 1979 Serum prolactin levels in short-term and long-term use of inert plastic and copper intrauterine devices. Copper 76-82 prolactin Homo sapiens 6-15 105938-1 1979 Serum prolactin levels were measured in 50 patients with oligospermia and in 20 control subjects under fasting conditions and following the administration of levodopa, pyridoxine, metoclopramide, and synthetic thyrotropin-releasing hormone. Pyridoxine 168-178 prolactin Homo sapiens 6-15 105938-5 1979 Metergoline administration promptly reduced the prolactin levels. Metergoline 0-11 prolactin Homo sapiens 48-57 535777-2 1979 Treatment with 600 or 900 micrograms lisuride over 14 days (each test group n = 25) caused an immediate drop of elevated prolactin (PRL) levels in all patients in comparison to values seen in normal, nonpregnant women (less than 30 ng/ml). Lisuride 37-45 prolactin Homo sapiens 121-130 535777-2 1979 Treatment with 600 or 900 micrograms lisuride over 14 days (each test group n = 25) caused an immediate drop of elevated prolactin (PRL) levels in all patients in comparison to values seen in normal, nonpregnant women (less than 30 ng/ml). Lisuride 37-45 prolactin Homo sapiens 132-135 535777-4 1979 The clinical efficacy in preventing or suppressing lactation was clear cut and comparable to the known PRL lowering effect of bromocryptine. Bromocriptine 126-139 prolactin Homo sapiens 103-106 535777-6 1979 The postsuckling PRL increase was abolished by a single oral dose of lisuride (100, 200, 300 micrograms), similar to that seen with bromocrytine (2.5 mg). Lisuride 69-77 prolactin Homo sapiens 17-20 118103-0 1979 Effect of triiodothyronine administration on the plasma TSH and prolactin responses to TRH in patients with hypothalamic-pituitary insufficiency. Triiodothyronine 10-26 prolactin Homo sapiens 64-73 118103-1 1979 A study was carried out in 10 patients with multiple pituitary hormone deficiencies to determine the response of thyroid-stimulating hormone (TSH) and prolactin (PRL) to thyrotropin-releasing hormone (TRH) and their suppressibility by treatment with triiodothyronine (T3) given at a dose of 60 microgram/day for 1 week. Triiodothyronine 250-266 prolactin Homo sapiens 151-160 118103-1 1979 A study was carried out in 10 patients with multiple pituitary hormone deficiencies to determine the response of thyroid-stimulating hormone (TSH) and prolactin (PRL) to thyrotropin-releasing hormone (TRH) and their suppressibility by treatment with triiodothyronine (T3) given at a dose of 60 microgram/day for 1 week. Triiodothyronine 250-266 prolactin Homo sapiens 162-165 118103-1 1979 A study was carried out in 10 patients with multiple pituitary hormone deficiencies to determine the response of thyroid-stimulating hormone (TSH) and prolactin (PRL) to thyrotropin-releasing hormone (TRH) and their suppressibility by treatment with triiodothyronine (T3) given at a dose of 60 microgram/day for 1 week. Triiodothyronine 268-270 prolactin Homo sapiens 151-160 118103-1 1979 A study was carried out in 10 patients with multiple pituitary hormone deficiencies to determine the response of thyroid-stimulating hormone (TSH) and prolactin (PRL) to thyrotropin-releasing hormone (TRH) and their suppressibility by treatment with triiodothyronine (T3) given at a dose of 60 microgram/day for 1 week. Triiodothyronine 268-270 prolactin Homo sapiens 162-165 220171-2 1979 After suppression of prolactin, statistically signific1nt circadian rhythms in PC and PA have been detected with a moderate decrease of PA concentration, while the PC level remained unalterated. Protactinium 86-88 prolactin Homo sapiens 21-30 478440-1 1979 The effect of repeated cimetidine ingestion on serum prolactin values was studied prospectively in 17 men with proven duodenal ulcers. Cimetidine 23-33 prolactin Homo sapiens 53-62 571836-2 1979 Following metoclopramide injection there was a prompt increase in serum PRL in normal subjects and in patients with moderate PRL elevations associated with galactorrhea-oligomenorrhea. Metoclopramide 10-24 prolactin Homo sapiens 72-75 571836-2 1979 Following metoclopramide injection there was a prompt increase in serum PRL in normal subjects and in patients with moderate PRL elevations associated with galactorrhea-oligomenorrhea. Metoclopramide 10-24 prolactin Homo sapiens 125-128 37181-7 1979 Our results show that bromocriptine may be effective even when no apparent indication for prolactin suppression can be demonstrated. Bromocriptine 22-35 prolactin Homo sapiens 90-99 536185-1 1979 Plasma prolactin levels during intravenous Trazodone infusion have been evaluated. Trazodone 43-52 prolactin Homo sapiens 7-16 422709-5 1979 Bromocriptine therapy had no discernible effect on the expected patterns of secretion of placental hormones, but inhibited completely the increase of PRL in the serum of the mother. Bromocriptine 0-13 prolactin Homo sapiens 150-153 489915-5 1979 In two patients, who had never received estrogen treatment prior to this study, estradiol induced a significant elevation of serum prolactin levels within 24 h and levels remained higher than basal values for the rest of the estrogen treatment period. Estradiol 80-89 prolactin Homo sapiens 131-140 489919-2 1979 In the infertile patients the prolactin concentrations were significantly higher (mean +/- SE 24.0 +/- 1.0 mug/l vs. 18.7 +/- mug/l) than in IUD users (p less than 0.001), and the progesterone concentrations were lower (22.9 +/- 1.7 vs. 37.4 +/- 2.3 mnol/l) (p less than 0.001). Progesterone 180-192 prolactin Homo sapiens 30-39 489921-1 1979 The PRL response to iv cimetidine was tested in 8 healthy males and 8 females at 4 different dose levels (0.75, 1.5, 3.0 and 6.0 mg/kg bw). Cimetidine 23-33 prolactin Homo sapiens 4-7 489921-2 1979 Serum PRL levels were significantly increased in comparison with a placebo study by the second cimetidine dose in both sexes. Cimetidine 95-105 prolactin Homo sapiens 6-9 489921-4 1979 A significant correlation between the cimetidine dose and the PRL response was observed. Cimetidine 38-48 prolactin Homo sapiens 62-65 489921-6 1979 Present findings demonstrate that the stimulation of PRL release by iv cimetidine is quite specific and dose-dependent. Cimetidine 71-81 prolactin Homo sapiens 53-56 489922-1 1979 23 women with benign breast disease (fibrocystic disease or fibroadenosis) were treated for three months consecutively with a prolactin inhibitor drug, bromocriptine, at the dose of 2.5 mg every eight hours. Bromocriptine 152-165 prolactin Homo sapiens 126-135 313977-0 1979 Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. Fluoxetine 68-78 prolactin Homo sapiens 48-57 221286-1 1979 Inhibition of plasma prolactin levels by 2-bromo-alpha-ergocryptine (CB-154) caused a 60% decrease and potentiated the inhibitory effects of [D-Ala6,des-Gly-NH2(10)]LHRH ethylamide on testicular LH receptor levels. Bromocriptine 41-67 prolactin Homo sapiens 21-30 221286-1 1979 Inhibition of plasma prolactin levels by 2-bromo-alpha-ergocryptine (CB-154) caused a 60% decrease and potentiated the inhibitory effects of [D-Ala6,des-Gly-NH2(10)]LHRH ethylamide on testicular LH receptor levels. Bromocriptine 69-75 prolactin Homo sapiens 21-30 221286-1 1979 Inhibition of plasma prolactin levels by 2-bromo-alpha-ergocryptine (CB-154) caused a 60% decrease and potentiated the inhibitory effects of [D-Ala6,des-Gly-NH2(10)]LHRH ethylamide on testicular LH receptor levels. [d-ala6, 141-149 prolactin Homo sapiens 21-30 221286-1 1979 Inhibition of plasma prolactin levels by 2-bromo-alpha-ergocryptine (CB-154) caused a 60% decrease and potentiated the inhibitory effects of [D-Ala6,des-Gly-NH2(10)]LHRH ethylamide on testicular LH receptor levels. des-gly-nh2 149-160 prolactin Homo sapiens 21-30 221286-1 1979 Inhibition of plasma prolactin levels by 2-bromo-alpha-ergocryptine (CB-154) caused a 60% decrease and potentiated the inhibitory effects of [D-Ala6,des-Gly-NH2(10)]LHRH ethylamide on testicular LH receptor levels. ]lhrh ethylamide 164-180 prolactin Homo sapiens 21-30 221286-4 1979 These data demonstrate that: (1) treatment with the LHRH agonist induces a blockage in the steroidogenic pathway at a step between progesterone and testosterone and (2) prolactin levels to an apparent accentuation of this blockage reflected by higher progesterone levels. Progesterone 251-263 prolactin Homo sapiens 169-178 431802-2 1979 Clozapine caused a slight (17%) but significant elevation in basal serum prolactin levels. Clozapine 0-9 prolactin Homo sapiens 73-82 503288-0 1979 Restoration of the prolactin response to sulpiride by metergoline administration in hyperprolactinemic patients. Sulpiride 41-50 prolactin Homo sapiens 19-28 503288-0 1979 Restoration of the prolactin response to sulpiride by metergoline administration in hyperprolactinemic patients. Metergoline 54-65 prolactin Homo sapiens 19-28 503305-1 1979 Benserazide induces an increase of serum prolactin in man, possibly as the result of an impairment of the dopamine effect on the pituitary and/or on the outer median eminence caused by the inhibition on L-dopa decarboxylase. Benserazide 0-11 prolactin Homo sapiens 41-50 503305-3 1979 Benserazide, given orally (125 mg) to 5 normal subjects, induced an increase of serum prolactin that did not change when 300 mg of phospholipid liposomes were given intravenously 60 min later. Benserazide 0-11 prolactin Homo sapiens 86-95 503307-0 1979 Effect of benztropine on haloperidol-induced prolactin secretion. Benztropine 10-21 prolactin Homo sapiens 45-54 503307-0 1979 Effect of benztropine on haloperidol-induced prolactin secretion. Haloperidol 25-36 prolactin Homo sapiens 45-54 503307-1 1979 The effect of benztropine on haloperidol-induced prolactin secretion was investigated in 10 normal male volunteers. Benztropine 14-25 prolactin Homo sapiens 49-58 503307-1 1979 The effect of benztropine on haloperidol-induced prolactin secretion was investigated in 10 normal male volunteers. Haloperidol 29-40 prolactin Homo sapiens 49-58 104214-4 1979 Prolactin was persistently elevated in one of them, who also demonstrated 2 abnormally high testosterone values among 6 determinations. Testosterone 92-104 prolactin Homo sapiens 0-9 43550-2 1979 This study evaluated with dopamine antagonists the possibility that such dopamine hypersensitivity extends to the tuberoinfundibular dopamine (TIDA) system, which regulates, by inhibition, pituitary prolactin secretion. Dopamine 26-34 prolactin Homo sapiens 199-208 43550-2 1979 This study evaluated with dopamine antagonists the possibility that such dopamine hypersensitivity extends to the tuberoinfundibular dopamine (TIDA) system, which regulates, by inhibition, pituitary prolactin secretion. Dopamine 73-81 prolactin Homo sapiens 199-208 43550-2 1979 This study evaluated with dopamine antagonists the possibility that such dopamine hypersensitivity extends to the tuberoinfundibular dopamine (TIDA) system, which regulates, by inhibition, pituitary prolactin secretion. Dopamine 73-81 prolactin Homo sapiens 199-208 43550-2 1979 This study evaluated with dopamine antagonists the possibility that such dopamine hypersensitivity extends to the tuberoinfundibular dopamine (TIDA) system, which regulates, by inhibition, pituitary prolactin secretion. tida 143-147 prolactin Homo sapiens 199-208 44374-0 1979 Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients. butaperazine 16-28 prolactin Homo sapiens 52-61 44374-1 1979 The relationship of plasma prolactin to plasma or red blood cell butaperazine levels was investigated in chronic schizophrenic patients treated with clinical doses of butaperazine, both after a single acute dose of the drug and during regular, twice daily butaperazine administration. butaperazine 65-77 prolactin Homo sapiens 27-36 44374-2 1979 Although there was a significant curvilinear relationship between peak plasma butaperazine levels after an acute single oral dose of butaperazine and the maximum prolactin response that we measured, steady-state levels of plasma or red cell butaperazine and plasma prolactin were not related. butaperazine 78-90 prolactin Homo sapiens 162-171 44374-2 1979 Although there was a significant curvilinear relationship between peak plasma butaperazine levels after an acute single oral dose of butaperazine and the maximum prolactin response that we measured, steady-state levels of plasma or red cell butaperazine and plasma prolactin were not related. butaperazine 133-145 prolactin Homo sapiens 162-171 44374-2 1979 Although there was a significant curvilinear relationship between peak plasma butaperazine levels after an acute single oral dose of butaperazine and the maximum prolactin response that we measured, steady-state levels of plasma or red cell butaperazine and plasma prolactin were not related. butaperazine 133-145 prolactin Homo sapiens 162-171 89747-3 1979 Bromocriptine resulted in a significant suppression of prolactin and testosterone as well and favored testosterone elimination from the plasma pool. Bromocriptine 0-13 prolactin Homo sapiens 55-64 82735-1 1978 An enkephalin analogue [D-Ala2, MePhe4, Met(o)-ol] enkephalin (DAMME), given intravenously to normal subjects raised serum prolactin and growth-hormone levels but lowered serum levels of luteinising hormone, follicle-stimulating hormone, cortisol, and corticotrophin. met(o)-ol] enkephalin 40-61 prolactin Homo sapiens 123-132 573041-3 1978 Treatment with bromocryptin for 20 weeks brought about a reduction to normal of both PRL and androgens. Bromocriptine 15-27 prolactin Homo sapiens 85-88 106990-2 1978 Acute administration of lisuride (100 microgram orally) significantly suppressed serum prolactin (PRL) levels in nine out of eleven subjects. Lisuride 24-32 prolactin Homo sapiens 87-96 106990-2 1978 Acute administration of lisuride (100 microgram orally) significantly suppressed serum prolactin (PRL) levels in nine out of eleven subjects. Lisuride 24-32 prolactin Homo sapiens 98-101 106990-3 1978 In these nine patients, prolonged treatment with lisuride (50--200 microgram daily) lowered PRL levels into the normal range, menstrual cycles were resumed and eight patients ovulated. Lisuride 49-57 prolactin Homo sapiens 92-95 106990-5 1978 These data demonstrate that lisuride may be used clinically to lower PRL levels and to restore cyclic gonadotrophin secretion and ovulation in amenorrhoeic patients with hyperprolactinaemia. Lisuride 28-36 prolactin Homo sapiens 69-72 729834-0 1978 Regression of a prolactin-secreting pituitary tumor during long-term treatment with bromocriptine. Bromocriptine 84-97 prolactin Homo sapiens 16-25 122426-0 1978 Effect of thyrotropin-releasing hormone and bromoergocriptine on growth hormone and prolactin secretion in perfused pituitary adenoma tissues of acromegaly. Bromocriptine 44-61 prolactin Homo sapiens 84-93 122427-0 1978 The relationship of changes in serum estradiol and progesterone during the menstrual cycle to the thyrotropin and prolactin responses to thyrotropin-releasing hormone. Estradiol 37-46 prolactin Homo sapiens 114-123 162520-0 1978 Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. Muscimol 57-65 prolactin Homo sapiens 15-24 162520-0 1978 Stimulation of prolactin and growth hormone secretion by muscimol, a gamma-aminobutyric acid agonist. gamma-Aminobutyric Acid 69-92 prolactin Homo sapiens 15-24 263356-2 1978 In 10 postpartum women and in 7 women with no evidence of PRL-secreting tumor, oral administration of nomifensine (100 or 200 mg, respectively) induced in the following 5 h a clear-cut inhibition of plasma PRL levels; in 10 patients with PRL-secreting tumors, the drug did not lower plasma PRL levels. Nomifensine 102-113 prolactin Homo sapiens 58-61 263356-2 1978 In 10 postpartum women and in 7 women with no evidence of PRL-secreting tumor, oral administration of nomifensine (100 or 200 mg, respectively) induced in the following 5 h a clear-cut inhibition of plasma PRL levels; in 10 patients with PRL-secreting tumors, the drug did not lower plasma PRL levels. Nomifensine 102-113 prolactin Homo sapiens 206-209 263356-2 1978 In 10 postpartum women and in 7 women with no evidence of PRL-secreting tumor, oral administration of nomifensine (100 or 200 mg, respectively) induced in the following 5 h a clear-cut inhibition of plasma PRL levels; in 10 patients with PRL-secreting tumors, the drug did not lower plasma PRL levels. Nomifensine 102-113 prolactin Homo sapiens 206-209 263356-2 1978 In 10 postpartum women and in 7 women with no evidence of PRL-secreting tumor, oral administration of nomifensine (100 or 200 mg, respectively) induced in the following 5 h a clear-cut inhibition of plasma PRL levels; in 10 patients with PRL-secreting tumors, the drug did not lower plasma PRL levels. Nomifensine 102-113 prolactin Homo sapiens 206-209 263659-5 1978 PRL levels fell with bromergocryptine therapy, galactorrhea ceased, and normal menses resumed. Bromocriptine 21-37 prolactin Homo sapiens 0-3 366483-6 1978 However, there was a statistically significant rise in PRL from mean basal levels of 139.9 ng/ml to a mean peak level of 159.0 ng/ml at 30 minutes after LHRH administration. LHRH 153-157 prolactin Homo sapiens 55-58 745694-0 1978 The effect of oral dextroamphetamine on prolactin secretion in man. Dextroamphetamine 19-36 prolactin Homo sapiens 40-49 720494-1 1978 The addition of dopamine to anterior pituitary incubations resulted in a marked decrease (88% for 3H prolactin and 69% for RIA prolactin) in prolactin release. Dopamine 16-24 prolactin Homo sapiens 101-110 720494-1 1978 The addition of dopamine to anterior pituitary incubations resulted in a marked decrease (88% for 3H prolactin and 69% for RIA prolactin) in prolactin release. Dopamine 16-24 prolactin Homo sapiens 127-136 720494-1 1978 The addition of dopamine to anterior pituitary incubations resulted in a marked decrease (88% for 3H prolactin and 69% for RIA prolactin) in prolactin release. Dopamine 16-24 prolactin Homo sapiens 127-136 709310-0 1978 Effect of chlormethiazole on serum prolactin. Chlormethiazole 10-25 prolactin Homo sapiens 35-44 745581-3 1978 There was no significant difference in plasma growth hormone levels before and after therapy with bromocriptine, but a significant fall in plasma prolactin levels was observed after the bromocriptine therapy was commenced. Bromocriptine 186-199 prolactin Homo sapiens 146-155 30426-2 1978 All available neuroleptics, including reserpine, raise serum prolactin levels. Reserpine 38-47 prolactin Homo sapiens 61-70 718334-1 1978 Chlorpromazine is frequently administered to patients with hyperprolactinemia to stimulate an increase in the serum levels of prolactin. Chlorpromazine 0-14 prolactin Homo sapiens 64-73 718334-2 1978 A patient with a prolactin secreting adenoma is described in whom pituitary apoplexy developed in association with a hypotensive episode following the administration of 25 mg of chlorpromazine. Chlorpromazine 178-192 prolactin Homo sapiens 17-26 698954-3 1978 Chronic CB-154 induced prolactin suppression was more effective than ovariectomy in the suppression of hyperplastic alveolar nodule development and comparable to ovariectomy in the suppression of mammary carcinoma development. Bromocriptine 8-14 prolactin Homo sapiens 23-32 570136-2 1978 In normal subjects during 24-hours saline infusion, plasma prolactin showed a number of small rises during day and night. Sodium Chloride 35-41 prolactin Homo sapiens 59-68 729195-4 1978 Within the ovary, sex steroid hormones mediate effects of gonadotrophins and prolactin on follicle maturation and participate in determining the fate of individual follicles. Steroids 22-29 prolactin Homo sapiens 77-86 744184-1 1978 When electroconvulsive therapy without anticonvulsive premedication was administered to male psychiatric patients, serum prolactin (PRL) increased regardless to the rather high initial values due to the chlorpromazine treatment. Chlorpromazine 203-217 prolactin Homo sapiens 121-130 744184-1 1978 When electroconvulsive therapy without anticonvulsive premedication was administered to male psychiatric patients, serum prolactin (PRL) increased regardless to the rather high initial values due to the chlorpromazine treatment. Chlorpromazine 203-217 prolactin Homo sapiens 132-135 748015-1 1978 Arginine has been demonstrated to be a potent stimulus to GH and PRL secretion. Arginine 0-8 prolactin Homo sapiens 65-68 703603-0 1978 Effect of apomorphine and piribedil on the secretion of thyrotropin and prolactin in patients with primary hypothyroidism. Apomorphine 10-21 prolactin Homo sapiens 72-81 703603-0 1978 Effect of apomorphine and piribedil on the secretion of thyrotropin and prolactin in patients with primary hypothyroidism. Piribedil 26-35 prolactin Homo sapiens 72-81 703603-1 1978 The administration of apomorphine and piribedil, two dopaminergic agents, significantly reduced thyrotropin (TSH) and prolactin levels in six female patients with primary hypothyroidism. Apomorphine 22-33 prolactin Homo sapiens 118-127 703603-1 1978 The administration of apomorphine and piribedil, two dopaminergic agents, significantly reduced thyrotropin (TSH) and prolactin levels in six female patients with primary hypothyroidism. Piribedil 38-47 prolactin Homo sapiens 118-127 103087-3 1978 L-DOPA and chlostylbegit were capable of reducing prolactin level in patients with the persisting lactorrhea-amenorrhea syndrome, this being accompanied by restoration of biphasic menstrual cycle in some of the patients. Levodopa 0-6 prolactin Homo sapiens 50-59 425782-2 1979 A rise in both, Prl and GH with a maximal increment of 15.9 +/- 6.7 (SE) ng/ml, and 12.4 +/- 4.9 ng/ml above basal levels, respectively, (P less than 0.05) was observed after iv arginine. Arginine 178-186 prolactin Homo sapiens 16-19 425782-3 1979 Following iv phenylalanine the mean peak level of Prl rose from 9.9 +/- 3.5 to 29.9 +/- 7.3 ng/ml (P less than 0.01), whereas GH concentration remained unchanged. Phenylalanine 13-26 prolactin Homo sapiens 50-53 364517-3 1978 Prolactin levels increased during treatment with the therapeutically active alpha-isomer of flupenthixol but were unchanged with the inactive beta-isomer and placebo. Flupenthixol 92-104 prolactin Homo sapiens 0-9 364517-4 1978 Although there was a significant relationship between prolactin level and antipsychotic effect in patients on alpha-flupenthixol, in the individual case prolactin level was not a strong predictor of therapeutic response; and in patients on inactive medication changes in prolactin level could not be related to sympton change. Flupenthixol 110-128 prolactin Homo sapiens 54-63 364517-5 1978 There was a time lag of at least 2 weeks between the increase in prolactin secretion in patients on alpha-flupenthixol and the therapeutic effect attributable to medication. Flupenthixol 100-118 prolactin Homo sapiens 65-74 211411-4 1978 In all 13 patients treated with bromocryptine major clinical improvement was associated with a decrease in serum prolactin levels and in nine with an increase in serum testosterone. Bromocriptine 32-45 prolactin Homo sapiens 113-122 570121-0 1978 Prolactin secretion inhibition by a new 8alpha-amino-ergoline, CH 29-171. 8alpha-amino-ergoline 40-61 prolactin Homo sapiens 0-9 707580-8 1978 However, patients given dexamethasone and promethazine together exhibited only a two- to threefold PRL increase, a significantly lesser response than that in any of the other groups. Dexamethasone 24-37 prolactin Homo sapiens 99-102 707580-8 1978 However, patients given dexamethasone and promethazine together exhibited only a two- to threefold PRL increase, a significantly lesser response than that in any of the other groups. Promethazine 42-54 prolactin Homo sapiens 99-102 362103-0 1978 d-Amphetamine raises serum prolactin in man: evaluations after chronic placebo, lithium and pimozide treatment. Dextroamphetamine 0-13 prolactin Homo sapiens 27-36 358720-1 1978 The effect of chronic administration of pyridoxine (vitamin B6) on HGH, basal and TRH stimulated PRL and TSH levels was studied in seven healthy female volunteers. Pyridoxine 40-50 prolactin Homo sapiens 97-100 358720-1 1978 The effect of chronic administration of pyridoxine (vitamin B6) on HGH, basal and TRH stimulated PRL and TSH levels was studied in seven healthy female volunteers. Vitamin B 6 52-62 prolactin Homo sapiens 97-100 358720-3 1978 Basal PRL and TRH stimulated PRL and TSH levels were slightly reduced without statistical significance (P greater than 0.05). Thyrotropin 37-40 prolactin Homo sapiens 6-9 696178-3 1978 Both after treatment with NOe or NOe plus CB-154, the number of PRL cells increased and displayed various ultrastructure signs of stimulation. Bromocriptine 42-48 prolactin Homo sapiens 64-67 29592-1 1978 It has been suggested that, if dopamine antagonism is a necessary condition for the antischizophrenic action of neuroleptics, the prolactin response, as an index of dopamine blockade, would correlate with clinical response. Dopamine 165-173 prolactin Homo sapiens 130-139 361149-0 1978 A double blind trial of the prolactin inhibitor bromocriptine in painful benign breast disease. Bromocriptine 48-61 prolactin Homo sapiens 28-37 361149-1 1978 A double blind crossover trial of the prolactin inhibitor bromocriptine in painful benign breast disease is reported. Bromocriptine 58-71 prolactin Homo sapiens 38-47 361149-4 1978 Bromocriptine produced a significant improvement in breast symptoms and a significant fall in prolactin levels in the cyclical pain group, but had no effect in the non-cyclical group. Bromocriptine 0-13 prolactin Homo sapiens 94-103 33802-0 1978 Changes in luteinizing hormone and prolactin control mechanisms produced by glutamate lesions of the arcuate nucleus. Glutamic Acid 76-85 prolactin Homo sapiens 35-44 710611-3 1978 Serum PRL levels were significantly higher at sampling times from 15 through 120 minutes when both PGF2alpha and urea were administered than after saline or urea alone. Dinoprost 99-108 prolactin Homo sapiens 6-9 710611-3 1978 Serum PRL levels were significantly higher at sampling times from 15 through 120 minutes when both PGF2alpha and urea were administered than after saline or urea alone. Urea 113-117 prolactin Homo sapiens 6-9 710611-3 1978 Serum PRL levels were significantly higher at sampling times from 15 through 120 minutes when both PGF2alpha and urea were administered than after saline or urea alone. Sodium Chloride 147-153 prolactin Homo sapiens 6-9 710611-3 1978 Serum PRL levels were significantly higher at sampling times from 15 through 120 minutes when both PGF2alpha and urea were administered than after saline or urea alone. Urea 157-161 prolactin Homo sapiens 6-9 710611-8 1978 These results suggest that PGF2alpha selectively causes pituitary release of PRL in women during midtrimester pregnancy. Dinoprost 27-36 prolactin Homo sapiens 77-80 45469-0 1978 Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson"s disease. Dopamine 10-18 prolactin Homo sapiens 90-99 45469-0 1978 Effect of dopamine agonist (Lergotrile mesylate) therapy on twenty-four hour secretion of prolactin in treated Parkinson"s disease. lergotrile mesylate 28-47 prolactin Homo sapiens 90-99 45469-4 1978 During chronic treatment with L-dopa-carbidopa (Sinemet), the 24-h PRL level was 12.8 +/- 4.9 ng/ml (mean +/- SD) and there was persistence of augmented PRL secretion during sleep. l-dopa-carbidopa 30-46 prolactin Homo sapiens 67-70 45469-4 1978 During chronic treatment with L-dopa-carbidopa (Sinemet), the 24-h PRL level was 12.8 +/- 4.9 ng/ml (mean +/- SD) and there was persistence of augmented PRL secretion during sleep. l-dopa-carbidopa 30-46 prolactin Homo sapiens 153-156 45469-4 1978 During chronic treatment with L-dopa-carbidopa (Sinemet), the 24-h PRL level was 12.8 +/- 4.9 ng/ml (mean +/- SD) and there was persistence of augmented PRL secretion during sleep. carbidopa, levodopa drug combination 48-55 prolactin Homo sapiens 67-70 45469-4 1978 During chronic treatment with L-dopa-carbidopa (Sinemet), the 24-h PRL level was 12.8 +/- 4.9 ng/ml (mean +/- SD) and there was persistence of augmented PRL secretion during sleep. carbidopa, levodopa drug combination 48-55 prolactin Homo sapiens 153-156 45469-6 1978 The addition of a dopamine agonist (Lergotrile mesylate) resulted in a significant (P less than 0.01) suppression of the 24-h mean PRL levels and abolition of the normal sleep augmentation after 2 weeks of therapy. Dopamine 18-26 prolactin Homo sapiens 131-134 45469-6 1978 The addition of a dopamine agonist (Lergotrile mesylate) resulted in a significant (P less than 0.01) suppression of the 24-h mean PRL levels and abolition of the normal sleep augmentation after 2 weeks of therapy. lergotrile mesylate 36-55 prolactin Homo sapiens 131-134 45469-9 1978 These results suggest a dichotomy between the PRL and GH responses to combined L-dopa-carbidopa and dopamine agonist therapy. Levodopa 79-85 prolactin Homo sapiens 46-49 45469-9 1978 These results suggest a dichotomy between the PRL and GH responses to combined L-dopa-carbidopa and dopamine agonist therapy. Carbidopa 86-95 prolactin Homo sapiens 46-49 45469-9 1978 These results suggest a dichotomy between the PRL and GH responses to combined L-dopa-carbidopa and dopamine agonist therapy. Dopamine 100-108 prolactin Homo sapiens 46-49 122417-0 1978 Progesterone induced acute release of prolactin in estrogen primed ovariectomized women. Progesterone 0-12 prolactin Homo sapiens 38-47 122417-1 1978 Progesterone (10 mg) administered intramuscularly induces a concurrent release of prolactin as well as gonadotropin in estrogen-primed women. Progesterone 0-12 prolactin Homo sapiens 82-91 263324-7 1978 Also, increasing amounts of radioactive substance similar to increasing amounts of radioactive substance similar to big PRL were formed by exposure of 125I-labeled small PRL to progressively larger concentrations of serum. Iodine-125 151-155 prolactin Homo sapiens 120-123 263324-7 1978 Also, increasing amounts of radioactive substance similar to increasing amounts of radioactive substance similar to big PRL were formed by exposure of 125I-labeled small PRL to progressively larger concentrations of serum. Iodine-125 151-155 prolactin Homo sapiens 170-173 117045-0 1978 Circulating prolactin and its response to TRH following administration of testosterone undecanoate in normal men. testosterone undecanoate 74-98 prolactin Homo sapiens 12-21 117045-1 1978 To investigate the effect of orally administered testosterone undercanoate (TU) on circulating prolactin (PRL) and PRL response to TRH stimulation, 8 eugonadal male volunteers, aged 19--30, presenting with normal plasma levels of FSH, LH, testosterone (T), estradiol (E2) and PRL, were given 120 mg/day of TU for 6 days. Thiouracil 76-78 prolactin Homo sapiens 95-104 117045-1 1978 To investigate the effect of orally administered testosterone undercanoate (TU) on circulating prolactin (PRL) and PRL response to TRH stimulation, 8 eugonadal male volunteers, aged 19--30, presenting with normal plasma levels of FSH, LH, testosterone (T), estradiol (E2) and PRL, were given 120 mg/day of TU for 6 days. Thiouracil 76-78 prolactin Homo sapiens 106-109 712316-0 1978 Effect of reserpine on plasma concentrations of growth hormone and prolactin in the domestic fowl. Reserpine 10-19 prolactin Homo sapiens 67-76 692379-0 1978 Inhibition of prolactin release by serotonin antagonists in hyperprolactinemic subjects. Serotonin 35-44 prolactin Homo sapiens 14-23 692379-2 1978 Mean serum prolactin concentration was significantly decreased between 120 and 240 min following the ingestion of all three drugs in comparison with a placebo; a consistent reduction to below 50% of basal values occurred in 10 of 14 patients after metergoline, in 5 of 10 after methysergide, and in 11 of 14 after bromocriptine administration. Metergoline 248-259 prolactin Homo sapiens 11-20 692379-2 1978 Mean serum prolactin concentration was significantly decreased between 120 and 240 min following the ingestion of all three drugs in comparison with a placebo; a consistent reduction to below 50% of basal values occurred in 10 of 14 patients after metergoline, in 5 of 10 after methysergide, and in 11 of 14 after bromocriptine administration. Methysergide 278-290 prolactin Homo sapiens 11-20 692379-2 1978 Mean serum prolactin concentration was significantly decreased between 120 and 240 min following the ingestion of all three drugs in comparison with a placebo; a consistent reduction to below 50% of basal values occurred in 10 of 14 patients after metergoline, in 5 of 10 after methysergide, and in 11 of 14 after bromocriptine administration. Bromocriptine 314-327 prolactin Homo sapiens 11-20 692379-3 1978 These data indicate that serotonin antagonists may acutely lower serum prolactin levels in hyperprolactinemic patients similarly to bromocriptine, though their mechanism of action is most likely different. Serotonin 25-34 prolactin Homo sapiens 71-80 753251-0 1978 [Bromocriptine treatment in 2 cases of oligospermia and asthenospermia with normal and excess blood prolactin]. Bromocriptine 1-14 prolactin Homo sapiens 100-109 698151-5 1978 Compared to controls, patients given bromocriptine had lower prolactin and higher FSH levels during the puerperium whereas the patients given quinestrol had increased prolactin levels and a late fall in FSH levels. Bromocriptine 37-50 prolactin Homo sapiens 61-70 698151-5 1978 Compared to controls, patients given bromocriptine had lower prolactin and higher FSH levels during the puerperium whereas the patients given quinestrol had increased prolactin levels and a late fall in FSH levels. Quinestrol 142-152 prolactin Homo sapiens 167-176 709890-5 1978 Sulpiride prevented the inhibitory effect on PRL levels of 500 mg levodopa, administered orally simultaneously; levodopa administered 2 hours prior to sulpiride failed to counteract the PRL-stimulatory effect of sulpiride. Sulpiride 0-9 prolactin Homo sapiens 45-48 709890-6 1978 Under chronic sulpiride-induced hyperprolactinaemia, levodopa exhibited however a very slight inhibitory effect on PRL concentrations. Levodopa 53-61 prolactin Homo sapiens 115-118 709894-4 1978 A significant correlation was observed between prolactin and creatinine concentrations in these patients (r = 0.45 P less than 0.005) and prolactin reverted towards normal after successful renal transplantation. Creatinine 61-71 prolactin Homo sapiens 47-56 709894-7 1978 The positive correlation between prolactin and creatinine reversion of prolactin towards normal after successful transplantation and arteriovenous hormone concentration differences across the normal kidney suggests that the kidney has a important role in prolactin metabolism. Creatinine 47-57 prolactin Homo sapiens 71-80 709894-7 1978 The positive correlation between prolactin and creatinine reversion of prolactin towards normal after successful transplantation and arteriovenous hormone concentration differences across the normal kidney suggests that the kidney has a important role in prolactin metabolism. Creatinine 47-57 prolactin Homo sapiens 71-80 680550-8 1978 During treatment with Pravidel all patients showed a significant increase of FSH and LH concentrations and a decrease of the prolactin concentrations. Bromocriptine 22-30 prolactin Homo sapiens 125-134 744120-0 1978 Steroid and gonadotropin responses to ergocryptine-suppressed prolactin secretion in hysterectomized, pseudopregnant hamsters. Steroids 0-7 prolactin Homo sapiens 62-71 744120-0 1978 Steroid and gonadotropin responses to ergocryptine-suppressed prolactin secretion in hysterectomized, pseudopregnant hamsters. ergocryptine 38-50 prolactin Homo sapiens 62-71 711134-0 1978 Dynamic evaluation of prolactin secretion with perphenazine in normal and hyperprolactinemic subjects. Perphenazine 47-59 prolactin Homo sapiens 22-31 45467-3 1978 The same treatment with quanfacine in six other normal subjects significantly reduced PRL secretion stimulated by insulin-induced hypoglycemia (P less than 0.05). quanfacine 24-34 prolactin Homo sapiens 86-89 122409-1 1978 The influence of endogenous estradiol (E2) levels on gonadotropin and PRL sensitivity to dopamine (DA) infusion (4 micrograms/kg/min) was assessed at different stages of the follicular phase of the menstrual cycle. Dopamine 89-97 prolactin Homo sapiens 70-73 122409-1 1978 The influence of endogenous estradiol (E2) levels on gonadotropin and PRL sensitivity to dopamine (DA) infusion (4 micrograms/kg/min) was assessed at different stages of the follicular phase of the menstrual cycle. Dopamine 99-101 prolactin Homo sapiens 70-73 122409-7 1978 The inhibition of PRL release by DA is correlated with endogenous E2 levels (r equal 0.685) as well as basal PRL levels (r = 0.878). Dopamine 33-35 prolactin Homo sapiens 18-21 122409-7 1978 The inhibition of PRL release by DA is correlated with endogenous E2 levels (r equal 0.685) as well as basal PRL levels (r = 0.878). Dopamine 33-35 prolactin Homo sapiens 109-112 712295-2 1978 A single dose of 5 mg bromocriptine during early pregnancy induced a profound fall in the serum level of prolactin with a substantial rise 20 h later. Bromocriptine 22-35 prolactin Homo sapiens 105-114 665840-0 1978 Suppression of prolactin by dopamine agonists in schizophrenics and controls. Dopamine 28-36 prolactin Homo sapiens 15-24 665840-1 1978 Prolactin levels were determined in plasma samples obtained before and after administration of apomorphine or L-dopa to otherwise unmedicated chronic schizophrenic patients or control subjects. Levodopa 110-116 prolactin Homo sapiens 0-9 665840-3 1978 Suppression of prolactin levels after each dopamine agonist was highly significant. Dopamine 43-51 prolactin Homo sapiens 15-24 680200-0 1978 Restoration of cyclic ovarian function by metergoline treatment in a patient with a prolactin-secreting pituitary microadenoma. Metergoline 42-53 prolactin Homo sapiens 84-93 680200-1 1978 A patient with amenorrhea due to a prolactin-secreting pituitary microadenoma was treated with the antiserotoninergic drug metergoline for 8 months. Metergoline 123-134 prolactin Homo sapiens 35-44 680200-6 1978 Metergoline might restore ovarian function in hyperprolactinemic amenorrhea either by prolactin suppression or perhaps by direct stimulation of gonadotropin release. Metergoline 0-11 prolactin Homo sapiens 51-60 122402-2 1978 T4 treatment also blunted the PRL response to chlorpromazine (P less than 0.05) in a separate group of euthyroid goitrous patients. Chlorpromazine 46-60 prolactin Homo sapiens 30-33 122406-1 1978 In an earlier study, normal adult men were shown to have increased plasma testosterone (T) levels over a several-hour period after haloperidol-induced increases in plasma PRL levels. Haloperidol 131-142 prolactin Homo sapiens 171-174 122406-4 1978 Only five of the eight subjects had prompt PRL responses to haloperidol equivalent to those of our earlier study. Haloperidol 60-71 prolactin Homo sapiens 43-46 122406-5 1978 As the purpose of this study was to examine the effect of increased PRL on plasma T levels, these five subjects were used for the determination of changes in plasma T. After haloperidol administration, their PRL levels rose an average of 19 ng/ml, to the high-normal range, and after the hLH infusions, their LH levels rose an average of 71 ng/ml. Haloperidol 174-185 prolactin Homo sapiens 68-71 704714-0 1978 The effect of fluphenazine on basal prolactin concentrations. Fluphenazine 14-26 prolactin Homo sapiens 36-45 704714-7 1978 The results demonstrate that fluphenazine elevates basal hPRL levels and the variation between levels of individual patients merits further investigation. Fluphenazine 29-41 prolactin Homo sapiens 57-61 209760-3 1978 There was a significant association of elevated prolactin levels with impaired LH-responses. Luteinizing Hormone 79-81 prolactin Homo sapiens 48-57 150951-0 1978 Effect of parachlorophenylalanine, a brain serotonin depletor, on the prolactin cells of the eel pituitary. Fenclonine 10-33 prolactin Homo sapiens 70-79 150951-5 1978 As injections of 5-hydroxytryptophan stimulate PRL cells, these findings suggest that a serotoninergic system may participate in the regulation of PRL cell activity. 5-Hydroxytryptophan 17-36 prolactin Homo sapiens 47-50 150951-5 1978 As injections of 5-hydroxytryptophan stimulate PRL cells, these findings suggest that a serotoninergic system may participate in the regulation of PRL cell activity. 5-Hydroxytryptophan 17-36 prolactin Homo sapiens 147-150 150951-6 1978 Brain serotonin depletion probably decreases granule release in PRL cells, a result comparable to the lowering action of pCPA on the plasma PRL level in some mammals. Serotonin 6-15 prolactin Homo sapiens 64-67 150951-6 1978 Brain serotonin depletion probably decreases granule release in PRL cells, a result comparable to the lowering action of pCPA on the plasma PRL level in some mammals. Fenclonine 121-125 prolactin Homo sapiens 140-143 101023-0 1978 Combined effect of pimozide and thyroliberin (TRH) on serum prolactin and thyroid stimulating hormone (TSH) in man. Pimozide 19-27 prolactin Homo sapiens 60-69 354298-1 1978 The histamine H2-receptor antagonist cimetidine, which has recently been introduced for the treatment of gastric and duodenal ulcers and haemorrhage, respectively, stimulates prolactin (PRL) secretion. Cimetidine 37-47 prolactin Homo sapiens 175-184 354298-1 1978 The histamine H2-receptor antagonist cimetidine, which has recently been introduced for the treatment of gastric and duodenal ulcers and haemorrhage, respectively, stimulates prolactin (PRL) secretion. Cimetidine 37-47 prolactin Homo sapiens 186-189 354298-4 1978 Treatment of male and female volunteers with cimetidine for 20 days (1 g/day orally) resulted in elevated serum PRL concentrations in both sexes. Cimetidine 45-55 prolactin Homo sapiens 112-115 354298-8 1978 The mechanism underlying the stimulatory effect of cimetidine on PRL secretion is not clear, but it does not seem that this ability is exerted via an inhibition of pituitary dopamine receptors. Cimetidine 51-61 prolactin Homo sapiens 65-68 581016-0 1978 Effects of two analgesic opiates (methadone and pentazocine) on the serum prolactin levels in breast cancer. Opiate Alkaloids 25-32 prolactin Homo sapiens 74-83 581016-0 1978 Effects of two analgesic opiates (methadone and pentazocine) on the serum prolactin levels in breast cancer. Methadone 34-43 prolactin Homo sapiens 74-83 581016-0 1978 Effects of two analgesic opiates (methadone and pentazocine) on the serum prolactin levels in breast cancer. Pentazocine 48-59 prolactin Homo sapiens 74-83 98247-3 1978 The patients with barbiturate coma presented normal basal TSH and PRL, elevated basal GH and normal PRL but blunted TSH responses to TRH; their GH concentrations varied widely without consistent relation to TRH administration. barbituric acid 18-29 prolactin Homo sapiens 66-69 98247-3 1978 The patients with barbiturate coma presented normal basal TSH and PRL, elevated basal GH and normal PRL but blunted TSH responses to TRH; their GH concentrations varied widely without consistent relation to TRH administration. barbituric acid 18-29 prolactin Homo sapiens 100-103 679504-3 1978 Ten patients with hyperprolactinaemia were treated with bromocriptine; prolactin was restored to normal values in eight patients but testosterone secretion remained deficient. Bromocriptine 56-69 prolactin Homo sapiens 23-32 680182-0 1978 Release of prolactin during pregnancy: effect of sulpiride. Sulpiride 49-58 prolactin Homo sapiens 11-20 680182-1 1978 The aim of this trial was to study the prolactin-releasing capacity of the pituitary during pregnancy by means of an acute stimulation with sulpiride. Sulpiride 140-149 prolactin Homo sapiens 39-48 680182-8 1978 The prolactin-releasing capacity of the pituitary, as judged by the response to sulpiride, seems to be maintained during pregnancy. Sulpiride 80-89 prolactin Homo sapiens 4-13 744072-0 1978 The biphasic regulation of prolactin secretion by dopamine agonist-antagonists. Dopamine 50-58 prolactin Homo sapiens 27-36 744072-1 1978 The in vitro secretion of PRL by the pituitary gland is inhibited by low concentrations of dopamine. Dopamine 91-99 prolactin Homo sapiens 26-29 744072-2 1978 Dopamine receptor-blocking agents, haloperidol and pimozide, in concentrations between 10-100 nM, neutralize virtually completely the dopamine-mediated inhibition of PRL secretion. Haloperidol 35-46 prolactin Homo sapiens 166-169 744072-2 1978 Dopamine receptor-blocking agents, haloperidol and pimozide, in concentrations between 10-100 nM, neutralize virtually completely the dopamine-mediated inhibition of PRL secretion. Pimozide 51-59 prolactin Homo sapiens 166-169 744072-2 1978 Dopamine receptor-blocking agents, haloperidol and pimozide, in concentrations between 10-100 nM, neutralize virtually completely the dopamine-mediated inhibition of PRL secretion. Dopamine 134-142 prolactin Homo sapiens 166-169 78873-5 1978 During one year of treatment with cyproterone acetate and ethinylestradiol there was a continuous rise of serum concentrations of prolactin. Cyproterone Acetate 34-53 prolactin Homo sapiens 130-139 78873-5 1978 During one year of treatment with cyproterone acetate and ethinylestradiol there was a continuous rise of serum concentrations of prolactin. Ethinyl Estradiol 58-74 prolactin Homo sapiens 130-139 681167-6 1978 Recent experience has shown that reduction of prolactin levels to normal by removal of prolactin-secreting tumors or by treatment with bromocriptine results in the restoration of normal menstrual cycles and fertility. Bromocriptine 135-148 prolactin Homo sapiens 46-55 80416-0 1978 Immunostaining of growth hormone and prolactin in paraffin-embedded and stored or previously stained materials. Paraffin 50-58 prolactin Homo sapiens 37-46 233660-2 1978 The stimulation of the release of endogenous parathyroid hormone by administration of disodium EDTA also resulted in a parallel increase of plasma PRL. Edetic Acid 86-99 prolactin Homo sapiens 147-150 233660-4 1978 The ingestion of L-dopa 2 h before parathyroid hormone infusion suppressed the PRL response, suggesting that dopamine and parathyroid hormone interact at a common site. Levodopa 17-23 prolactin Homo sapiens 79-82 233660-4 1978 The ingestion of L-dopa 2 h before parathyroid hormone infusion suppressed the PRL response, suggesting that dopamine and parathyroid hormone interact at a common site. Dopamine 109-117 prolactin Homo sapiens 79-82 233660-5 1978 As it has been recently shown that PRL stimulates the renal synthesis of 1,25-dihydroxycholecalciferol, the present data suggest that the effect of parathyroid hormone on this synthesis may be due to the increase in plasma PRL. Calcitriol 73-102 prolactin Homo sapiens 35-38 233660-5 1978 As it has been recently shown that PRL stimulates the renal synthesis of 1,25-dihydroxycholecalciferol, the present data suggest that the effect of parathyroid hormone on this synthesis may be due to the increase in plasma PRL. Calcitriol 73-102 prolactin Homo sapiens 223-226 263292-2 1978 Plasma PRL levels rose sharply in response to haloperidol, but plasma arginine vasopressin levels did not change significantly. Haloperidol 46-57 prolactin Homo sapiens 7-10 675856-2 1978 The prolactin inhibition by the Levodopa was verified, and the clinical and mammographic growth, the doubling time, and the labeling index of the tumor were determined. Levodopa 32-40 prolactin Homo sapiens 4-13 97718-2 1978 The effect of methylphenidate on serum prolactin was utilized as a method of evaluating methylphenidate"s central dopamimergic effects. Methylphenidate 14-29 prolactin Homo sapiens 39-48 97718-2 1978 The effect of methylphenidate on serum prolactin was utilized as a method of evaluating methylphenidate"s central dopamimergic effects. Methylphenidate 88-103 prolactin Homo sapiens 39-48 672445-0 1978 Prolactin in CSF selectively increases dopamine turnover in the median eminence. Dopamine 39-47 prolactin Homo sapiens 0-9 26606-2 1978 The locus of action of dopamine and dopaminergic agents such as the ergot alkaloids inhibiting prolactin secretion appears to be primarily at the pituitary level, though a hypothalamic action to increase secretion of prolactin inhibitory factor may also contribute. Dopamine 23-31 prolactin Homo sapiens 95-104 26606-2 1978 The locus of action of dopamine and dopaminergic agents such as the ergot alkaloids inhibiting prolactin secretion appears to be primarily at the pituitary level, though a hypothalamic action to increase secretion of prolactin inhibitory factor may also contribute. Dopamine 23-31 prolactin Homo sapiens 217-226 26606-2 1978 The locus of action of dopamine and dopaminergic agents such as the ergot alkaloids inhibiting prolactin secretion appears to be primarily at the pituitary level, though a hypothalamic action to increase secretion of prolactin inhibitory factor may also contribute. Ergot Alkaloids 68-83 prolactin Homo sapiens 95-104 26606-2 1978 The locus of action of dopamine and dopaminergic agents such as the ergot alkaloids inhibiting prolactin secretion appears to be primarily at the pituitary level, though a hypothalamic action to increase secretion of prolactin inhibitory factor may also contribute. Ergot Alkaloids 68-83 prolactin Homo sapiens 217-226 566222-4 1978 Within 2 months of bromocriptine therapy, the serum prolactin levels were normal (patient V. G., 12.21 ng/ml; patient S. R., 8.25 ng/ml) and the bilateral visual field defects were corrected. Bromocriptine 19-32 prolactin Homo sapiens 52-61 566222-5 1978 Bromocriptine has been shown to control prolactin secretion in patients with prolactin-secreting pituitary tumors. Bromocriptine 0-13 prolactin Homo sapiens 40-49 566222-5 1978 Bromocriptine has been shown to control prolactin secretion in patients with prolactin-secreting pituitary tumors. Bromocriptine 0-13 prolactin Homo sapiens 77-86 566222-6 1978 Normalization of restricted visual fields following bromocriptine therapy indicates the possibility of an anatomical regression of pituitary hyperplasia or an underlying prolactin-producing microadenoma. Bromocriptine 52-65 prolactin Homo sapiens 170-179 580536-0 1978 Histamine stimulates prolactin release in norman men. Histamine 0-9 prolactin Homo sapiens 21-30 580536-1 1978 Histamine stimulates prolactin (PRL) and growth hormone (GH) release in the experimental animal. Histamine 0-9 prolactin Homo sapiens 21-30 580536-1 1978 Histamine stimulates prolactin (PRL) and growth hormone (GH) release in the experimental animal. Histamine 0-9 prolactin Homo sapiens 32-35 580536-4 1978 Histamine induced a significant PRL release in 7 subjects, the maximum level reached being 36.2 +/- 12.09 ng/ml, while GH levels were not affected. Histamine 0-9 prolactin Homo sapiens 32-35 580536-7 1978 This fact suggests that, in man, histamine stimulates PRL release by acting directly on the pituitary. Histamine 33-42 prolactin Homo sapiens 54-57 656281-0 1978 The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours. Carbidopa 23-32 prolactin Homo sapiens 45-54 656281-0 1978 The effect of low dose carbidopa/levodopa on prolactin and growth hormone concentrations in patients with breast cancer and in benign breast tumours. Levodopa 33-41 prolactin Homo sapiens 45-54 656281-3 1978 3 Prolactin and growth hormone showed similar responses to carbidopa/levodopa irrespective of age or diagnosis. Carbidopa 59-68 prolactin Homo sapiens 2-11 656281-3 1978 3 Prolactin and growth hormone showed similar responses to carbidopa/levodopa irrespective of age or diagnosis. Levodopa 69-77 prolactin Homo sapiens 2-11 668928-6 1978 The estradiol benzoate injection also elicited a significant increase in serum prolactin levels- This enhanced prolactin release had no apparent effect on the gonadotropin surge. estradiol 3-benzoate 4-22 prolactin Homo sapiens 79-88 668928-6 1978 The estradiol benzoate injection also elicited a significant increase in serum prolactin levels- This enhanced prolactin release had no apparent effect on the gonadotropin surge. estradiol 3-benzoate 4-22 prolactin Homo sapiens 111-120 744042-0 1978 In vitro supersensitivity of the anterior pituitary to dopamine inhibition of prolactin secretion. Dopamine 55-63 prolactin Homo sapiens 78-87 681079-0 1978 Reaction of ovine prolactin with 2-(2-nitrophenylsulfenyl)-3-methyl-3"-bromoindolemine. 2-(2-nitrophenylsulfenyl)-3-methyl-3"-bromoindolemine 33-86 prolactin Homo sapiens 18-27 681079-1 1978 The two tryptophan bonds at positions 91 and 150 in ovine prolactin have been cleaved by the use of 2-(2-nitrophenylsulfenyl)-3-methyl-3"-bromoindolemine. Tryptophan 8-18 prolactin Homo sapiens 58-67 681079-1 1978 The two tryptophan bonds at positions 91 and 150 in ovine prolactin have been cleaved by the use of 2-(2-nitrophenylsulfenyl)-3-methyl-3"-bromoindolemine. 2-(2-nitrophenylsulfenyl)-3-methyl-3"-bromoindolemine 100-153 prolactin Homo sapiens 58-67 122292-0 1978 Influence of methyl-TRH-induced prolactin increase on serum testosterone levels in normal adult men. methyl-trh 13-23 prolactin Homo sapiens 32-41 122292-0 1978 Influence of methyl-TRH-induced prolactin increase on serum testosterone levels in normal adult men. Testosterone 60-72 prolactin Homo sapiens 32-41 122292-1 1978 Our previous studies suggest that increased serum PRL, secondary to haloperidol-induced dopamine blockade, augments serum testosterone (T) levels in normal men. Haloperidol 68-79 prolactin Homo sapiens 50-53 122292-1 1978 Our previous studies suggest that increased serum PRL, secondary to haloperidol-induced dopamine blockade, augments serum testosterone (T) levels in normal men. Dopamine 88-96 prolactin Homo sapiens 50-53 122292-1 1978 Our previous studies suggest that increased serum PRL, secondary to haloperidol-induced dopamine blockade, augments serum testosterone (T) levels in normal men. Testosterone 122-134 prolactin Homo sapiens 50-53 147932-4 1978 Serum prolactin concentrations in the patients with PA were not increased over those of the age-matched (less than 8 years) prepubertal girls. Protactinium 52-54 prolactin Homo sapiens 6-15 570200-3 1978 In the first group where bromocriptine was started in the first 24 hours with dosages of 2.5 mg every 12 hours for 14 days, clinical signs of breast engorgement and of milk secretion were insignificant and the level of prolactin had dropped to normal menstrual cycle levels from the third day after delivery. Bromocriptine 25-38 prolactin Homo sapiens 219-228 570200-4 1978 In the second group where the first dose of bromocriptine was given at least 48 hours after Caesarean section, the levels of prolactin dropped just as sharply from the third day after delivery, but on the other hand the clinical signs of breast engorgement and milk secretion were marked and completely comparable to those which are found in patients who are not going to breast feed but who have received no treatment to inhibit lactation. Bromocriptine 44-57 prolactin Homo sapiens 125-134 672408-0 1978 Prostaglandin the osmoregulatory role of prolactin in a teleost. Prostaglandins 0-13 prolactin Homo sapiens 41-50 96826-0 1978 Role of calcium in the thyrotropin-releasing hormone-stimulated release of prolactin from pituitary cells in culture. Calcium 8-15 prolactin Homo sapiens 75-84 565141-0 1978 Response of amenorrheic patients with normal serum prolactin to chlorpromazine during administration of human menopausal gonadotropin. Chlorpromazine 64-78 prolactin Homo sapiens 51-60 565141-1 1978 To study the effects of graded amounts of estrogens on prolactin (PRL) secretion, PRL response to chlorpromazine (CPZ) during administration of human menopausal gonadotropin (hMG) was determined. Chlorpromazine 98-112 prolactin Homo sapiens 82-85 565141-1 1978 To study the effects of graded amounts of estrogens on prolactin (PRL) secretion, PRL response to chlorpromazine (CPZ) during administration of human menopausal gonadotropin (hMG) was determined. Chlorpromazine 114-117 prolactin Homo sapiens 82-85 565141-7 1978 The maximal response of PRL to CPZ was significantly higher during hMG-induced high estrogenic state than during control testing (69.9 and 32.3 ng. Chlorpromazine 31-34 prolactin Homo sapiens 24-27 565141-7 1978 The maximal response of PRL to CPZ was significantly higher during hMG-induced high estrogenic state than during control testing (69.9 and 32.3 ng. Menotropins 67-70 prolactin Homo sapiens 24-27 637104-1 1978 Sequential administrations of progessively increasing amounts of estradiol benzoate (EB) for five days followed by 10 mg. of progesterone (P) elicited a prompt pituitary release of luteinizing hormone, follicle-stimulating hormone, and prolactin in normal women during the early follicular phase but not in women with normogonadotropic hypothalamic chronic anovulation with or without associated hyperprolactinemia. estradiol 3-benzoate 65-83 prolactin Homo sapiens 236-245 637104-1 1978 Sequential administrations of progessively increasing amounts of estradiol benzoate (EB) for five days followed by 10 mg. of progesterone (P) elicited a prompt pituitary release of luteinizing hormone, follicle-stimulating hormone, and prolactin in normal women during the early follicular phase but not in women with normogonadotropic hypothalamic chronic anovulation with or without associated hyperprolactinemia. estradiol 3-benzoate 85-87 prolactin Homo sapiens 236-245 637104-2 1978 Since hypothalamic dopamine functions as an inhibitor for the secretion of both prolactin and gonadotropin, we postulate that sequential EB-P stimulation for simultaneous release of gonadotropin and prolactin may be mediated by a reduction of hypothalamic dopamine in response to progesterone. Dopamine 19-27 prolactin Homo sapiens 80-89 637104-2 1978 Since hypothalamic dopamine functions as an inhibitor for the secretion of both prolactin and gonadotropin, we postulate that sequential EB-P stimulation for simultaneous release of gonadotropin and prolactin may be mediated by a reduction of hypothalamic dopamine in response to progesterone. Dopamine 19-27 prolactin Homo sapiens 199-208 637104-2 1978 Since hypothalamic dopamine functions as an inhibitor for the secretion of both prolactin and gonadotropin, we postulate that sequential EB-P stimulation for simultaneous release of gonadotropin and prolactin may be mediated by a reduction of hypothalamic dopamine in response to progesterone. estradiol benzoate, progesterone drug combination 137-141 prolactin Homo sapiens 80-89 637104-2 1978 Since hypothalamic dopamine functions as an inhibitor for the secretion of both prolactin and gonadotropin, we postulate that sequential EB-P stimulation for simultaneous release of gonadotropin and prolactin may be mediated by a reduction of hypothalamic dopamine in response to progesterone. estradiol benzoate, progesterone drug combination 137-141 prolactin Homo sapiens 199-208 638883-2 1978 Both dopamine and norepinephrine caused long lasting inhibition of prolactin release from either an isolated hemipituitary or a hemipituitary coincubated with a hypothalamus. Dopamine 5-13 prolactin Homo sapiens 67-76 638883-2 1978 Both dopamine and norepinephrine caused long lasting inhibition of prolactin release from either an isolated hemipituitary or a hemipituitary coincubated with a hypothalamus. Norepinephrine 18-32 prolactin Homo sapiens 67-76 638883-3 1978 Epinephrine also inhibited prolactin release. Epinephrine 0-11 prolactin Homo sapiens 27-36 638883-4 1978 L-Dihydroxyphenylalanine (L-dopa) inhibited prolactin release from pituitaries in the presence of a hypothalamus but not in isolated pituitaries. Levodopa 0-24 prolactin Homo sapiens 44-53 638883-4 1978 L-Dihydroxyphenylalanine (L-dopa) inhibited prolactin release from pituitaries in the presence of a hypothalamus but not in isolated pituitaries. Levodopa 26-32 prolactin Homo sapiens 44-53 638883-6 1978 Results confirm that dopamine and norepinephrine directly inhibit prolactin release from pituitary and suggest that the hypothalamic mechanism inhibiting prolactin involves dopamine but not norepinephrine. Dopamine 21-29 prolactin Homo sapiens 66-75 638883-6 1978 Results confirm that dopamine and norepinephrine directly inhibit prolactin release from pituitary and suggest that the hypothalamic mechanism inhibiting prolactin involves dopamine but not norepinephrine. Dopamine 21-29 prolactin Homo sapiens 154-163 638883-6 1978 Results confirm that dopamine and norepinephrine directly inhibit prolactin release from pituitary and suggest that the hypothalamic mechanism inhibiting prolactin involves dopamine but not norepinephrine. Norepinephrine 34-48 prolactin Homo sapiens 66-75 638883-6 1978 Results confirm that dopamine and norepinephrine directly inhibit prolactin release from pituitary and suggest that the hypothalamic mechanism inhibiting prolactin involves dopamine but not norepinephrine. Dopamine 173-181 prolactin Homo sapiens 154-163 217617-0 1978 Effect of piperoxane on serum prolactin: possible role of epinephrine-mediated synapses in the inhibition of prolactin secretion. Epinephrine 58-69 prolactin Homo sapiens 109-118 217617-1 1978 Intravenous administration of 2,5 mg/kg piperoxane produced a rapid and significant increase in serum PRL concentrations in four non-human primates. Piperoxan 40-50 prolactin Homo sapiens 102-105 217617-2 1978 This PRL increase was maximal 15 min after piperoxane infusion and significant, when compared with baseline levels, in the +15, +30, +45, +60, and +90-min samples. Piperoxan 43-53 prolactin Homo sapiens 5-8 217617-4 1978 The iv administration of 10 microgram/kg clonidine, but not saline, produced a rapid and significant reduction in serum PRL levels. Clonidine 41-50 prolactin Homo sapiens 120-123 217617-5 1978 PRL levels were significantly reduced +15, +30, and +60 min after the clonidine infusion. Clonidine 70-79 prolactin Homo sapiens 0-3 217617-6 1978 Pretreatment with a bolus of 10 microgram/kg clonidine at -15 min caused a significant attenuation of the piperoxane-induced elevation in serum PRL in two monkeys. Clonidine 45-54 prolactin Homo sapiens 144-147 217617-6 1978 Pretreatment with a bolus of 10 microgram/kg clonidine at -15 min caused a significant attenuation of the piperoxane-induced elevation in serum PRL in two monkeys. Piperoxan 106-116 prolactin Homo sapiens 144-147 148373-3 1978 Glucose utilization and production of 14C-lactate by the spermatozoa in the presence of 100 ng of ovine prolactin were greater than in the absence of the hormone. Glucose 0-7 prolactin Homo sapiens 104-113 148373-3 1978 Glucose utilization and production of 14C-lactate by the spermatozoa in the presence of 100 ng of ovine prolactin were greater than in the absence of the hormone. 14c-lactate 38-49 prolactin Homo sapiens 104-113 148373-4 1978 The production of pyruvate was 2.5 times less than the production of lactate wehn spermatozoa were incubated in the absence of prolactin and 1.6 times less in the presence of prolactin. Pyruvic Acid 18-26 prolactin Homo sapiens 175-184 148373-5 1978 These results indicate that, in spite of having an increased glycolytic metabolism, spermatozoa from oligospermic men are are able to show additional glucose utilization in the presence of prolactin. Glucose 150-157 prolactin Homo sapiens 189-198 206470-0 1978 Effect of prolactin on tetracycline binding to human spermatozoa. Tetracycline 23-35 prolactin Homo sapiens 10-19 206470-1 1978 The effect of different concentrations of prolactin (0 to 60 ng) on the release of tetracycline from human spermatozoa labeled with 7-3H-tetracycline hydrochloride was studied. Tetracycline 83-95 prolactin Homo sapiens 42-51 206470-2 1978 Prolactin significantly enhanced the release of bound tetracycline, indicating that prolactin may influence the processes associated with sperm capacitation. Tetracycline 54-66 prolactin Homo sapiens 0-9 206470-2 1978 Prolactin significantly enhanced the release of bound tetracycline, indicating that prolactin may influence the processes associated with sperm capacitation. Tetracycline 54-66 prolactin Homo sapiens 84-93 659585-1 1978 The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. Levodopa 22-28 prolactin Homo sapiens 40-49 659585-1 1978 The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. Levodopa 22-28 prolactin Homo sapiens 51-54 659585-1 1978 The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. Dihydroxyphenylalanine 24-28 prolactin Homo sapiens 40-49 659585-1 1978 The administration of l-dopa suppresses prolactin (PRL) secretion in normal subjects and in patients with hyperprolactinemia, although it is not known whether this effect, which requires the conversion of dopa to dopamine, is mediated peripherally or through the central nervous system. Dihydroxyphenylalanine 24-28 prolactin Homo sapiens 51-54 659585-3 1978 Similar degrees of PRL suppression were observed in normal subjects (basal plasma PRL 13+/-2 ng/ml) after l-dopa alone (48+/-4%) and after l-dopa plus carbidopa (58+/-6%). Levodopa 106-112 prolactin Homo sapiens 19-22 659585-3 1978 Similar degrees of PRL suppression were observed in normal subjects (basal plasma PRL 13+/-2 ng/ml) after l-dopa alone (48+/-4%) and after l-dopa plus carbidopa (58+/-6%). Levodopa 139-145 prolactin Homo sapiens 19-22 659585-4 1978 In patients with pituitary tumors and elevated plasma PRL (73+/-14 ng/ml), l-dopa alone led to PRL suppression comparable with that in normal subjects (47+/-6%). Levodopa 75-81 prolactin Homo sapiens 54-57 659585-4 1978 In patients with pituitary tumors and elevated plasma PRL (73+/-14 ng/ml), l-dopa alone led to PRL suppression comparable with that in normal subjects (47+/-6%). Levodopa 75-81 prolactin Homo sapiens 95-98 659585-5 1978 However, l-dopa plus carbidopa resulted in only minimal suppression of plasma PRL (19+/-4%) which was significantly less than after l-dopa alone (P < 0.001). Levodopa 9-15 prolactin Homo sapiens 78-81 659585-5 1978 However, l-dopa plus carbidopa resulted in only minimal suppression of plasma PRL (19+/-4%) which was significantly less than after l-dopa alone (P < 0.001). Carbidopa 21-30 prolactin Homo sapiens 78-81 659585-7 1978 Comparable suppression of PRL levels in response to a dopamine infusion (4 mug/kg per min for 3 h) was observed in controls and tumor patients. Dopamine 54-62 prolactin Homo sapiens 26-29 659585-8 1978 The results indicate that although peripheral conversion of exogenous dopa to dopamine can suppress PRL secretion, in normals, the central nervous system conversion of dopa to dopamine in the presence of peripheral dopa decarboxylase inhibition is sufficient to account for its PRL-suppressive effects. Dihydroxyphenylalanine 70-74 prolactin Homo sapiens 100-103 659585-8 1978 The results indicate that although peripheral conversion of exogenous dopa to dopamine can suppress PRL secretion, in normals, the central nervous system conversion of dopa to dopamine in the presence of peripheral dopa decarboxylase inhibition is sufficient to account for its PRL-suppressive effects. Dopamine 78-86 prolactin Homo sapiens 100-103 659585-8 1978 The results indicate that although peripheral conversion of exogenous dopa to dopamine can suppress PRL secretion, in normals, the central nervous system conversion of dopa to dopamine in the presence of peripheral dopa decarboxylase inhibition is sufficient to account for its PRL-suppressive effects. Dihydroxyphenylalanine 78-82 prolactin Homo sapiens 100-103 755053-0 1978 Effect of intravenous pyridoxine on plasma prolactin in hyperprolactinemic subjects. Pyridoxine 22-32 prolactin Homo sapiens 43-52 755053-1 1978 Intravenous pyridoxine has been reported to lower plasma PRL in normal subjects and in patients with the amenorrhea-galactorrhea syndrome. Pyridoxine 12-22 prolactin Homo sapiens 57-60 755053-2 1978 We tested the effect of pyridoxine (300-mg iv bolus) on plasma PRL in nine patients with hyperprolactinemia due to a variety of causes. Pyridoxine 24-34 prolactin Homo sapiens 63-66 418418-0 1978 Prolactin secretion from clonal pituitary cells following incubation with estradiol, progesterone, thyrotrophin releasing hormone and dopamine. Estradiol 74-83 prolactin Homo sapiens 0-9 418418-0 1978 Prolactin secretion from clonal pituitary cells following incubation with estradiol, progesterone, thyrotrophin releasing hormone and dopamine. Progesterone 85-97 prolactin Homo sapiens 0-9 418418-0 1978 Prolactin secretion from clonal pituitary cells following incubation with estradiol, progesterone, thyrotrophin releasing hormone and dopamine. Dopamine 134-142 prolactin Homo sapiens 0-9 704750-0 1978 Effect of dopamine and neuroleptics on plasma growth hormone and prolactin in normal men. Dopamine 10-18 prolactin Homo sapiens 65-74 27267-2 1978 This is followed by the presentation of the evidence that dopamine is the inhibitory hypothalamic transducer controlling hormone release by prolactin cells. Dopamine 58-66 prolactin Homo sapiens 140-149 27267-5 1978 Although the dopamine concept of an inhibitory control of prolactin secretion seems quite satisfactory, the possibility of another unrelated inhibitory control system is not excluded. Dopamine 13-21 prolactin Homo sapiens 58-67 627132-1 1978 Lergotrile, an ergot alkaloid, has been shown to be effective in treating disorders associated with elevated serum prolactin levels (e.g., galactorrhea-amenorrhea). lergotrile 0-10 prolactin Homo sapiens 115-124 639330-5 1978 After sulpiride a 800-4200% increment of prolactin over control values was noted in the females and 1200-3500% increment in the males. Sulpiride 6-15 prolactin Homo sapiens 41-50 639331-5 1978 After sulpiride a marked increase (3--10 times over control values) in PRL was noted in all normal and short children without pituitary disease. Sulpiride 6-15 prolactin Homo sapiens 71-74 346383-4 1978 Plasma prolactin levels after one single dose of 2.5 mg of bromocriptine were found to have no predictive value as to the dosage needed for treatment, whereas the plasma gonadotropin response after the administration of luteinizing hormone-releasing hormone appeared to be predictive with respect to the return of ovulation during bromocriptine therapy. Bromocriptine 59-72 prolactin Homo sapiens 7-16 566402-0 1978 [Changes induced with L-dopa in the serum levels of prolactin and somatotropin in the diagnosis of amenorrhea-galactorrhea]. Levodopa 22-28 prolactin Homo sapiens 52-61 25455-1 1978 Dibenzapine (720 mg, Noveril) was infused intravenously to 16 depressed patients during a period of 3 h. Serum prolactin levels were determined by radioimmunoassay and changes in clinical condition were evaluated according to the Hamilton Equation. dibenzapine 0-11 prolactin Homo sapiens 111-120 653534-1 1978 Pyridoxine has been reported as having an antilactogenic effect, presumably by suppressing prolactin secretion. Pyridoxine 0-10 prolactin Homo sapiens 91-100 653534-2 1978 We have measured serum prolactin levels during pyridoxine administration in two groups of hyperprolactinaemic subjects. Pyridoxine 47-57 prolactin Homo sapiens 23-32 415471-0 1978 Prolactin-lowering effect of low doses of lisuride in man. Lisuride 42-50 prolactin Homo sapiens 0-9 687436-0 1978 [Effects of benserazide administration on prolactin secretion]. Benserazide 12-23 prolactin Homo sapiens 42-51 415471-2 1978 Basal prolactin levels were suppressed after a single dose of 100 and 200 microgram lisuride. Lisuride 84-92 prolactin Homo sapiens 6-15 415471-4 1978 Two hundred microgram lisuride also decreased the high serum prolactin levels produced by im injection of 50 mg sulpiride, and conversely, sulpiride injection abolished the prolactin lowering effect of lisuride. Lisuride 22-30 prolactin Homo sapiens 61-70 415471-4 1978 Two hundred microgram lisuride also decreased the high serum prolactin levels produced by im injection of 50 mg sulpiride, and conversely, sulpiride injection abolished the prolactin lowering effect of lisuride. Sulpiride 112-121 prolactin Homo sapiens 61-70 415471-4 1978 Two hundred microgram lisuride also decreased the high serum prolactin levels produced by im injection of 50 mg sulpiride, and conversely, sulpiride injection abolished the prolactin lowering effect of lisuride. Sulpiride 139-148 prolactin Homo sapiens 173-182 415471-4 1978 Two hundred microgram lisuride also decreased the high serum prolactin levels produced by im injection of 50 mg sulpiride, and conversely, sulpiride injection abolished the prolactin lowering effect of lisuride. Lisuride 202-210 prolactin Homo sapiens 173-182 415471-5 1978 These results demonstrate that in man too lisuride is a very potent prolactin-lowering agent. Lisuride 42-50 prolactin Homo sapiens 68-77 639755-0 1978 Effect of cytidine diphosphate choline on growth hormone and prolactin secretion in man. Cytidine Diphosphate Choline 10-38 prolactin Homo sapiens 61-70 639755-1 1978 The effect of intravenous infusion of cytidine diphosphate choline (CDP-choline) on the serum levels of growth hormone (GH) and prolactin (PRL) was studied in six normal adult male subjects. Cytidine Diphosphate Choline 38-66 prolactin Homo sapiens 128-137 639755-1 1978 The effect of intravenous infusion of cytidine diphosphate choline (CDP-choline) on the serum levels of growth hormone (GH) and prolactin (PRL) was studied in six normal adult male subjects. Cytidine Diphosphate Choline 38-66 prolactin Homo sapiens 139-142 743973-1 1978 Bombesin and other related peptides isolated from the skin of anuran species and found in mammalian brain stimulate PRL and GH release in steroid-primed male rats. Steroids 138-145 prolactin Homo sapiens 116-119 632089-6 1978 The TRN stimulated prolactin levels are lowered when related to high testosterone levels. Testosterone 69-81 prolactin Homo sapiens 19-28 627685-0 1978 Bromocriptine: effect on serum prolactin and growth hormone in psychogeriatric hospital patients. Bromocriptine 0-13 prolactin Homo sapiens 31-40 24678-0 1978 Growth hormone and prolactin response to bromocriptine in patients with Huntington"s chorea. Bromocriptine 41-54 prolactin Homo sapiens 19-28 24678-1 1978 The growth hormone (hGH) and prolactin (hPRL) responses to oral bromocriptine were studied in two groups of patients with Huntington"s chorea and in seven healthy control subjects. Bromocriptine 64-77 prolactin Homo sapiens 29-38 24678-1 1978 The growth hormone (hGH) and prolactin (hPRL) responses to oral bromocriptine were studied in two groups of patients with Huntington"s chorea and in seven healthy control subjects. Bromocriptine 64-77 prolactin Homo sapiens 40-44 24678-7 1978 The basal concentrations of hPRL were also not different, apart from the findings of elevated hPRL concentrations in three patients previously treated with phenothiazines. Phenothiazines 156-170 prolactin Homo sapiens 94-98 24678-8 1978 The patients and control subjects showed a consistent fall in hPRL concentrations after taking bromocriptine. Bromocriptine 95-108 prolactin Homo sapiens 62-66 202988-9 1978 The concomitant increase in plasma PRL might synergize with ALDO in influencing the renal retention of sodium, but PRL alone has little apparent effect on human kidney function. Sodium 103-109 prolactin Homo sapiens 35-38 208171-0 1978 [From the determination of prolactin to use of its inhibitor: bromocriptine]. Bromocriptine 62-75 prolactin Homo sapiens 27-36 83873-0 1978 [Effect of methadone and pentazocine on blood levels of prolactin in the human]. Methadone 11-20 prolactin Homo sapiens 56-65 83873-0 1978 [Effect of methadone and pentazocine on blood levels of prolactin in the human]. Pentazocine 25-36 prolactin Homo sapiens 56-65 110024-1 1978 Intravenous administration of metaclopramide and cimetidine provokes an immediate rise in serum prolactin concentration. Metoclopramide 30-44 prolactin Homo sapiens 96-105 110024-1 1978 Intravenous administration of metaclopramide and cimetidine provokes an immediate rise in serum prolactin concentration. Cimetidine 49-59 prolactin Homo sapiens 96-105 110024-2 1978 The results are compared with the response of serum prolactin to arginine, insulin and TRH. Arginine 65-73 prolactin Homo sapiens 52-61 347858-4 1978 Bromocriptine therapy resulted in lowering of prolactin levels to normal in 85 of the 95 patients, and in the remainder prolactin levels were lowered in all but one patient. Bromocriptine 0-13 prolactin Homo sapiens 46-55 347862-0 1978 Bromocriptine therapy in patients with acromegaly: effects on growth hormone, somatomedin A and prolactin. Bromocriptine 0-13 prolactin Homo sapiens 96-105 347862-2 1978 These six patients had elevated or normal blood levels of prolactin, which could be stimulated by TRH and inhibited by bromocriptine. Bromocriptine 119-132 prolactin Homo sapiens 58-67 347862-6 1978 It is suggested that the presence of prolactin, per se or as an indication of a certain dopaminergic situation, is a prerequisite for successful bromocriptine treatment of patients with acromegaly. Bromocriptine 145-158 prolactin Homo sapiens 37-46 579527-0 1978 The effects of the dopamine agonist, lergotrile mesylate, on prolactin secretion in women. Dopamine 19-27 prolactin Homo sapiens 61-70 579527-0 1978 The effects of the dopamine agonist, lergotrile mesylate, on prolactin secretion in women. lergotrile mesylate 37-56 prolactin Homo sapiens 61-70 23087-1 1978 The prolactin response to neuroleptics can serve as an index of dopamine blockade in humans. Dopamine 64-72 prolactin Homo sapiens 4-13 23087-2 1978 Plasma prolactin increments to single doses of chlorpromazine, and prolactin decrements to single doses of levodopa, were similar in normal and schizophrenic subjects. Levodopa 107-115 prolactin Homo sapiens 67-76 23087-6 1978 Relative prolactin-stimulating potency in humans of chlorpromazine, thioridazine, trifluoperazine, butaperazine, and haloperidol correlated well with their relative clinical potencies. Chlorpromazine 52-66 prolactin Homo sapiens 9-18 23087-6 1978 Relative prolactin-stimulating potency in humans of chlorpromazine, thioridazine, trifluoperazine, butaperazine, and haloperidol correlated well with their relative clinical potencies. Thioridazine 68-80 prolactin Homo sapiens 9-18 23087-6 1978 Relative prolactin-stimulating potency in humans of chlorpromazine, thioridazine, trifluoperazine, butaperazine, and haloperidol correlated well with their relative clinical potencies. Trifluoperazine 82-97 prolactin Homo sapiens 9-18 23087-6 1978 Relative prolactin-stimulating potency in humans of chlorpromazine, thioridazine, trifluoperazine, butaperazine, and haloperidol correlated well with their relative clinical potencies. butaperazine 99-111 prolactin Homo sapiens 9-18 23087-6 1978 Relative prolactin-stimulating potency in humans of chlorpromazine, thioridazine, trifluoperazine, butaperazine, and haloperidol correlated well with their relative clinical potencies. Haloperidol 117-128 prolactin Homo sapiens 9-18 580204-0 1978 Serum prolactin levels after a single and subchronic oral administration of chlorpromazine and sulpiride. Chlorpromazine 76-90 prolactin Homo sapiens 6-15 580204-0 1978 Serum prolactin levels after a single and subchronic oral administration of chlorpromazine and sulpiride. Sulpiride 95-104 prolactin Homo sapiens 6-15 580204-2 1978 The effect of a single antianxiety dose of chlorpromazine (100 mg) and sulpiride (200 mg) on serum prolactin and gonadotrophins was studied in 6 healthy women in a cross-over study. Chlorpromazine 43-57 prolactin Homo sapiens 99-108 580204-2 1978 The effect of a single antianxiety dose of chlorpromazine (100 mg) and sulpiride (200 mg) on serum prolactin and gonadotrophins was studied in 6 healthy women in a cross-over study. Sulpiride 71-80 prolactin Homo sapiens 99-108 580204-7 1978 In acute study sulpiride caused a fivefold increase in serum prolactin at 1 h. Chlorpromazine induced a slower and smaller increase. Sulpiride 15-24 prolactin Homo sapiens 61-70 580204-8 1978 Prolactin concentrations remained raised for at least 6 h. The initial raised prolactin concentration induced by sulpiride was associated with antidiuresis. Sulpiride 113-122 prolactin Homo sapiens 0-9 580204-8 1978 Prolactin concentrations remained raised for at least 6 h. The initial raised prolactin concentration induced by sulpiride was associated with antidiuresis. Sulpiride 113-122 prolactin Homo sapiens 78-87 580204-11 1978 It is concluded that in doses useful in the treatment of neurotic patients sulpiride causes a greater increase in serum prolactin levels than does chlorpromazine. Sulpiride 75-84 prolactin Homo sapiens 120-129 3751462-0 1986 Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study. Bromocriptine 0-13 prolactin Homo sapiens 27-36 3751462-8 1986 It is concluded that in the medical treatment of macroprolactinomas 10-20 mg bromocriptine in four divided doses effectively reduces both plasma prolactin level and tumour size. Bromocriptine 77-90 prolactin Homo sapiens 54-63 103087-3 1978 L-DOPA and chlostylbegit were capable of reducing prolactin level in patients with the persisting lactorrhea-amenorrhea syndrome, this being accompanied by restoration of biphasic menstrual cycle in some of the patients. chlostylbegit 11-24 prolactin Homo sapiens 50-59 214777-2 1978 The labeled growth hormones (GH) and prolactin (Pl) secreted was assayed by the method of electrophoresis in polyacrylamide gel as modified by the authors. polyacrylamide 109-123 prolactin Homo sapiens 37-46 367717-4 1978 Moreover, in cases of ovarian dysfunction as well as of amenorrhoea where the prolactin levels were within the normal range, there was evidence to suggest that bromocriptine can be associated with a return of ovulation, although the mechanism by which it might do so still needs evaluation. Bromocriptine 160-173 prolactin Homo sapiens 78-87 627092-0 1978 Metergoline inhibition of thyrotrophin and prolactin secretions in primary hypothyroidism. Metergoline 0-11 prolactin Homo sapiens 43-52 627092-1 1978 The effect of acute oral administration of metergoline on serum thyrotrophin and prolactin levels in six patients with primary hypothyroidism was studied. Metergoline 43-54 prolactin Homo sapiens 81-90 627092-2 1978 Metergoline 4 mg by mouth caused a significant decrease in the concentration of serum thyrotrophin and prolactin in all subjects. Metergoline 0-11 prolactin Homo sapiens 103-112 627092-4 1978 These findings suggest that metergoline inhibits prolactin and thyrotrophin secretion by a direct action on the hypothalamus or pituitary gland. Metergoline 28-39 prolactin Homo sapiens 49-58 738536-1 1978 Serum prolactin levels were determined following stimulation by sulpiride in 20 patients with nonalcoholic liver cirrhosis and 10 normal controls. Sulpiride 64-73 prolactin Homo sapiens 6-15 627094-7 1978 We conclude that a single injection of fluphenazine (Modecate 12.5 mg) has a marked effect on hypothalamic-pituitary mechanisms controlling hGH and hPRL release. Fluphenazine 39-51 prolactin Homo sapiens 148-152 738536-3 1978 Only 5 cirrhotics, all with ascites, showed a lower prolactin response after sulpiride stimulation. Sulpiride 77-86 prolactin Homo sapiens 52-61 738536-6 1978 The higher prolactin levels found by others in alcoholic cirrhosis could be the result of a direct effect of alcohol on hypothalamic structures involved in prolactin secretion. Alcohols 47-54 prolactin Homo sapiens 11-20 738536-6 1978 The higher prolactin levels found by others in alcoholic cirrhosis could be the result of a direct effect of alcohol on hypothalamic structures involved in prolactin secretion. Alcohols 47-54 prolactin Homo sapiens 156-165 563808-0 1978 Serum levels of prolactin in basal conditions and after administration of 2-bromo-5alpha-ergocryptine in normal and galactorrheic subjects. 2-bromo-5alpha-ergocryptine 74-101 prolactin Homo sapiens 16-25 114566-2 1978 PRL secretion was studied in basal conditions and under dynamic tests: TRH and chlorpromazine. Chlorpromazine 79-93 prolactin Homo sapiens 0-3 414956-5 1978 However, when 25 mg chlorpromacine were administered intramuscularly, only one patient responded with an adequate rise of serum-hPRL. chlorpromacine 20-34 prolactin Homo sapiens 128-132 573767-0 1978 Inhibition of thyrotropin and prolactin secretion by dopamine in man. Dopamine 53-61 prolactin Homo sapiens 30-39 573767-1 1978 The effect of dopamine on thyrotropin (TSH) and prolactin (PRL) levels was studied in 5 normal subjects, 7 women with galactorrhea, 9 acromegalics and 4 patients with primary hypothyroidism. Dopamine 14-22 prolactin Homo sapiens 48-57 573767-2 1978 Dopamine infused at the rate of 280 micrograms/min produced significant decrease in plasma TSH and PRL levels in all four groups, though a lower fall in TSH was noted in acromegalics. Dopamine 0-8 prolactin Homo sapiens 99-102 573767-3 1978 A similar reduction in PRL was also noted after 28 micrograms/min dopamine. Dopamine 66-74 prolactin Homo sapiens 23-26 755842-10 1978 The males were also treated with bromocriptine leading to a significant fall of the PRL level accompanied by improvement of libido, sexual potency and headache. Bromocriptine 33-46 prolactin Homo sapiens 84-87 755842-12 1978 Since PRL levels remained low after withdrawal of bromocriptine for several months an antiproliferative effect of this drug is suggested. Bromocriptine 50-63 prolactin Homo sapiens 6-9 625190-0 1978 Naloxone inhibition of stress-induced increase in prolactin secretion. Naloxone 0-8 prolactin Homo sapiens 50-59 412411-5 1977 The percent content of the R-serine (C-I) apoprotein among the soluble apoproteins of very low density lipoproteins diminished markedly during the fast; 6) abnormal liver function immediately after fasting with increased abnormality after the 2 weeks of refeeding and return to normal by 6 weeks; 7) normal fat and xylose absorption, normal estradiol, estrone and prolactin levels, and renal function studies. r-serine 27-35 prolactin Homo sapiens 364-373 579030-0 1977 Perphenazine-induced prolactin secretion in acromegaly. Perphenazine 0-12 prolactin Homo sapiens 21-30 598012-4 1977 In this study serum oestradiol correlates with prolactin in the girls, but not in the boys. Estradiol 20-30 prolactin Homo sapiens 47-56 591612-1 1977 In 6 normal subjects, L-dopa (500 mg PO) and apomorphine (0.6 mg sc) increased circulating growth hormone and suppressed prolactin levels in a parallel and quantitatively similar fashion, but only L-dopa induced a rise in plasma glucagon, glucose, and insulin levels. Levodopa 22-28 prolactin Homo sapiens 121-130 591612-1 1977 In 6 normal subjects, L-dopa (500 mg PO) and apomorphine (0.6 mg sc) increased circulating growth hormone and suppressed prolactin levels in a parallel and quantitatively similar fashion, but only L-dopa induced a rise in plasma glucagon, glucose, and insulin levels. Apomorphine 45-56 prolactin Homo sapiens 121-130 923690-2 1977 Its transformation to the methanesulfonate led to the prolactin inhibitor bromocriptine-methanesulfonate, Parlodel. methanesulfonic acid 26-42 prolactin Homo sapiens 54-63 923690-2 1977 Its transformation to the methanesulfonate led to the prolactin inhibitor bromocriptine-methanesulfonate, Parlodel. Bromocriptine 74-104 prolactin Homo sapiens 54-63 923690-2 1977 Its transformation to the methanesulfonate led to the prolactin inhibitor bromocriptine-methanesulfonate, Parlodel. Bromocriptine 106-114 prolactin Homo sapiens 54-63 923833-0 1977 Chlorpromazine-induced changes in serum prolactin in women with oligomenorrhea, amenorrhea, and pituitary adenoma. Chlorpromazine 0-14 prolactin Homo sapiens 40-49 200633-4 1977 Since DHAS is virtually an exclusive product of the adrenal cortex, and since high PRL levels appear to inhibit ovarian steroid production, the findings suggest that hyperprolactinemia selectively stimulates adrenocortical androgen production. Steroids 120-127 prolactin Homo sapiens 83-86 562901-0 1977 Decrease of prolactin by methysergide in amenorrheic hyperprolactinemic women. Methysergide 25-37 prolactin Homo sapiens 12-21 925127-0 1977 Suppression of thyrotropin (TSH) and prolactin (PRL) release by pyridoxine in chronic primary hypothyroidism. Pyridoxine 64-74 prolactin Homo sapiens 37-46 925127-3 1977 The serum prolactin (PRL) levels were also suppressed by pyridoxine administration. Pyridoxine 57-67 prolactin Homo sapiens 10-19 563424-0 1977 Changes in catecholamine content of the median eminence precede the pro-oestrous surges of luteinizing hormone and prolactin. Catecholamines 11-24 prolactin Homo sapiens 115-124 19605035-0 1977 Modification by adrenergic blocking agents of arginine vasotocin-induced prolactin secretion in vitro. Vasotocin 46-64 prolactin Homo sapiens 73-82 910447-0 1977 [Serum prolactin levels during inhibition of lactation with 2-brom-alpha-ergocryptin (CB 154) (author"s transl)]. 2-Brom-alpha-ergocryptin 60-84 prolactin Homo sapiens 7-16 578618-0 1977 Stimulating action of sulpiride and pimozide on prolactin release. Sulpiride 22-31 prolactin Homo sapiens 48-57 578618-0 1977 Stimulating action of sulpiride and pimozide on prolactin release. Pimozide 36-44 prolactin Homo sapiens 48-57 578618-2 1977 In order to evaluate the mechanism of action of metergoline, an antiserotonin agent, the effect of pre-treatment with metergoline on prolactin (PRL) release induced by sulpiride was compared to that obtained after bromocriptine administration in normal subjects. Metergoline 118-129 prolactin Homo sapiens 133-142 578618-2 1977 In order to evaluate the mechanism of action of metergoline, an antiserotonin agent, the effect of pre-treatment with metergoline on prolactin (PRL) release induced by sulpiride was compared to that obtained after bromocriptine administration in normal subjects. Metergoline 118-129 prolactin Homo sapiens 144-147 578618-2 1977 In order to evaluate the mechanism of action of metergoline, an antiserotonin agent, the effect of pre-treatment with metergoline on prolactin (PRL) release induced by sulpiride was compared to that obtained after bromocriptine administration in normal subjects. Sulpiride 168-177 prolactin Homo sapiens 133-142 578618-2 1977 In order to evaluate the mechanism of action of metergoline, an antiserotonin agent, the effect of pre-treatment with metergoline on prolactin (PRL) release induced by sulpiride was compared to that obtained after bromocriptine administration in normal subjects. Sulpiride 168-177 prolactin Homo sapiens 144-147 578618-3 1977 In addition, the metergoline effect on PRL release induced by pimozide, specific dopamine receptor blocking agent, was compared to that obtained with L-dopa. Metergoline 17-28 prolactin Homo sapiens 39-42 578618-3 1977 In addition, the metergoline effect on PRL release induced by pimozide, specific dopamine receptor blocking agent, was compared to that obtained with L-dopa. Pimozide 62-70 prolactin Homo sapiens 39-42 578618-4 1977 Metergoline administration resulted in definite decrease in plasma PRL in all subjects; however, metergoline did not block, differently from bromocriptine, the PRL release induced by sulpiride. Metergoline 0-11 prolactin Homo sapiens 67-70 578618-5 1977 On the contrary, metergoline, like L-dopa, inhibited PRL release induced by pimozide pre-treatment. Metergoline 17-28 prolactin Homo sapiens 53-56 578618-5 1977 On the contrary, metergoline, like L-dopa, inhibited PRL release induced by pimozide pre-treatment. Levodopa 35-41 prolactin Homo sapiens 53-56 578618-5 1977 On the contrary, metergoline, like L-dopa, inhibited PRL release induced by pimozide pre-treatment. Pimozide 76-84 prolactin Homo sapiens 53-56 923106-1 1977 The acute administration of 2 mg of methysergide significantly reduced plasma prolactin levels in nine normal subjects and in seven hyperprolactinaemic patients. Methysergide 36-48 prolactin Homo sapiens 78-87 923106-2 1977 The prolactin lowering effect of this drug was abolished by sulpiride. Sulpiride 60-69 prolactin Homo sapiens 4-13 410826-0 1977 Failure of dopamine infusion to suppress the plasma prolactin response to sulpiride in normal and hyperprolactinemic subjects. Sulpiride 74-83 prolactin Homo sapiens 52-61 410826-1 1977 In eleven normal women dopamine infusion (5 microgram/Kg/min) significantly lowered plasma prolactin levels but failed to suppress the PRL response to sulpiride (10 or 100 mg i.v. Dopamine 23-31 prolactin Homo sapiens 91-100 410826-2 1977 ), while the same dose of dopamine was effective in abolishing the PRL response to TRH (200 microgram i.v.). Dopamine 26-34 prolactin Homo sapiens 67-70 410826-3 1977 In four hyperprolactinemic women showing an impaired PRL response to sulpiride, dopamine infusion was effective both in lowering PRL circulating levels and in restoring an evident response to sulpiride. Sulpiride 69-78 prolactin Homo sapiens 53-56 410826-3 1977 In four hyperprolactinemic women showing an impaired PRL response to sulpiride, dopamine infusion was effective both in lowering PRL circulating levels and in restoring an evident response to sulpiride. Dopamine 80-88 prolactin Homo sapiens 53-56 410826-3 1977 In four hyperprolactinemic women showing an impaired PRL response to sulpiride, dopamine infusion was effective both in lowering PRL circulating levels and in restoring an evident response to sulpiride. Dopamine 80-88 prolactin Homo sapiens 129-132 410827-0 1977 Effects of CNS dopamine augmentation on stimulated prolactin secretion. Dopamine 15-23 prolactin Homo sapiens 51-60 410827-2 1977 Consequently, the effect of central dopamine (DA) augmentation on stimulated PRL release was determined in 5 healthy men. Dopamine 36-44 prolactin Homo sapiens 77-80 410827-2 1977 Consequently, the effect of central dopamine (DA) augmentation on stimulated PRL release was determined in 5 healthy men. Dopamine 46-48 prolactin Homo sapiens 77-80 410827-6 1977 In contrast, during Sinemet therapy the hypoglycemia-mediated PRL release did not occur, and the PRL levels were significantly lower than after insulin alone from 40 through 180 minutes. carbidopa, levodopa drug combination 20-27 prolactin Homo sapiens 62-65 410827-6 1977 In contrast, during Sinemet therapy the hypoglycemia-mediated PRL release did not occur, and the PRL levels were significantly lower than after insulin alone from 40 through 180 minutes. carbidopa, levodopa drug combination 20-27 prolactin Homo sapiens 97-100 905911-0 1977 The effect of furosemide on serum prolactin levels in the postpartum period. Furosemide 14-24 prolactin Homo sapiens 34-43 578612-0 1977 Effect of piribedil on plasma prolactin levels in women with puerperal or pathological hyperprolactinaemia. Piribedil 10-19 prolactin Homo sapiens 30-39 578612-1 1977 In women with physiological puerperal hyperprolactinaemia, acute administration of Piribedil (100 mg po), a drug which stimulates dopamine receptor sites, was as effective as that of 2-Br-alpha-ergocryptine (CB 154, 5 mg po) in suppressing the elevated baseline plasma prolactin (PRL) levels. Piribedil 83-92 prolactin Homo sapiens 43-52 578612-1 1977 In women with physiological puerperal hyperprolactinaemia, acute administration of Piribedil (100 mg po), a drug which stimulates dopamine receptor sites, was as effective as that of 2-Br-alpha-ergocryptine (CB 154, 5 mg po) in suppressing the elevated baseline plasma prolactin (PRL) levels. Piribedil 83-92 prolactin Homo sapiens 280-283 578612-3 1977 These results indicate that Piribedil is an effective suppressor of plasma PRL levels in the human and suggest that its action is more evident in puerperal than in pathological hyperprolactinaemia. Piribedil 28-37 prolactin Homo sapiens 75-78 920042-4 1977 During the following 12 hours after PgF2alpha treatment the prolactin plasma levels showed an important and significant decrease in all cases. Dinoprost 36-45 prolactin Homo sapiens 60-69 409288-4 1977 After treatment with triiodothyronine (T3), the elevated TSH and PRL levels fell to within normal ranges, and the galactorrhea disappeared. Triiodothyronine 21-37 prolactin Homo sapiens 65-68 409288-4 1977 After treatment with triiodothyronine (T3), the elevated TSH and PRL levels fell to within normal ranges, and the galactorrhea disappeared. Triiodothyronine 39-41 prolactin Homo sapiens 65-68 582390-6 1978 The increase in PRL and TSH, which is induced by the thyrotrophin releasing hormone (TRH), is provable after acute as well as after chronic administration of DMI. Desipramine 158-161 prolactin Homo sapiens 16-19 662080-0 1978 Prolactin suppression by serotonin antagonists in man: further evidence for serotoninergic control of prolactin secretion. Serotonin 25-34 prolactin Homo sapiens 0-9 662080-2 1978 Highly significant falls (p less than 0.001) in serum Prl were observed at 120, 180, and 240 min following the oral administration of metergoline (Met) (4 mg; N = 34) and methysergide (Meth) (3 mg; N = 20) in comparison with placebo. Metergoline 134-145 prolactin Homo sapiens 54-57 662080-2 1978 Highly significant falls (p less than 0.001) in serum Prl were observed at 120, 180, and 240 min following the oral administration of metergoline (Met) (4 mg; N = 34) and methysergide (Meth) (3 mg; N = 20) in comparison with placebo. Metergoline 147-150 prolactin Homo sapiens 54-57 662080-2 1978 Highly significant falls (p less than 0.001) in serum Prl were observed at 120, 180, and 240 min following the oral administration of metergoline (Met) (4 mg; N = 34) and methysergide (Meth) (3 mg; N = 20) in comparison with placebo. Methysergide 171-183 prolactin Homo sapiens 54-57 662080-2 1978 Highly significant falls (p less than 0.001) in serum Prl were observed at 120, 180, and 240 min following the oral administration of metergoline (Met) (4 mg; N = 34) and methysergide (Meth) (3 mg; N = 20) in comparison with placebo. Methysergide 185-189 prolactin Homo sapiens 54-57 662080-4 1978 After Pim pretreatment (1 mg every 6 h for 7 days) the elevated serum Prl levels were reduced to 27.1% +/- 8.1 (SEM) of basal after Met and to 54.5% +/- 8.9 after Meth administration (N = 5 for each study). Methysergide 163-167 prolactin Homo sapiens 70-73 662080-5 1978 It is concluded that Met and Meth inhibit Prl secretion by mechanisms which are not or only partially related to dopaminergic receptors. Methysergide 29-33 prolactin Homo sapiens 42-45 662080-6 1978 These data are consistent with a stimulatory role for serotonin in human Prl release. Serotonin 54-63 prolactin Homo sapiens 73-76 619329-1 1978 Based on the known stimulatory effect of serotonin on prolactin secretion, a trial of suppression of puerperal lactation by a potent serotonin antagonist, metergoline, was carried out in 30 puerperal women who did not want to nurse. Serotonin 41-50 prolactin Homo sapiens 54-63 619329-5 1978 Metergoline administration was associated with a significant suppression of the plasma prolactin levels. Metergoline 0-11 prolactin Homo sapiens 87-96 643905-0 1978 Effect of ergot alkaloids on growth hormone and prolactin secretion in humans. Ergot Alkaloids 10-25 prolactin Homo sapiens 48-57 343747-0 1977 Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic women. metylperon 11-20 prolactin Homo sapiens 40-49 343747-0 1977 Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic women. Thiothixene 25-36 prolactin Homo sapiens 40-49 21571-0 1977 An evaluation of a unique new antipsychotic agent, sulpiride: effects on serum prolactin and growth hormone levels. Sulpiride 51-60 prolactin Homo sapiens 79-88 588500-2 1977 Prolactin levels were suppressed below normal whilst taking the bromocriptine, but rose significantly when this drug was stopped and by eight weeks of gestation reached values significantly higher than those observed in normal pregnancy. Bromocriptine 64-77 prolactin Homo sapiens 0-9 588500-6 1977 Because the effect is maintained until at least 14 weeks gestation, prolactin may also affect progesterone production by the placenta. Progesterone 94-106 prolactin Homo sapiens 68-77 591625-1 1977 The effect of oral L-tryptophan (90 mg/kg BW) on prolactin secretion in eight normal women studied either in the early or late follicular phase of the menstrual cycle was compared to the effect of a placebo alone. Tryptophan 19-31 prolactin Homo sapiens 49-58 591625-4 1977 Despite a 25-fold increase in plasma free L-tryptophan levels following the administration of this amino acid, the prolactin response to L-tryptophan was not significantly different from a placebo. Tryptophan 137-149 prolactin Homo sapiens 115-124 589073-0 1977 Prolactin concentrations in ovulatory but infertile women: treatment with bromocriptine. Bromocriptine 74-87 prolactin Homo sapiens 0-9 589073-5 1977 Treatment with various bromocriptine regimens effectively reduced prolactin concentrations to below normal in all cases, and 16 pregnancies followed-13 during bromocriptine treatment and three in the first post-treatment cycle. Bromocriptine 23-36 prolactin Homo sapiens 66-75 645325-0 1977 [The cimetidine induced stimulation of prolactin secretion in man (author"s transl)]. Cimetidine 5-15 prolactin Homo sapiens 39-48 562780-14 1977 Lowering prolactin secretion with bromocryptine allows resumption of normal gonadal function. Bromocriptine 34-47 prolactin Homo sapiens 9-18 412766-1 1977 The effect of TRH induced secretion of TSH and prolactin (hPrl) on plasma renin activity (PRA), water and electrolyte excretion, was studied in 7 normal males before and after an intravenous injection of 2 ml normal saline or 200 microgram TRH. Water 96-101 prolactin Homo sapiens 58-62 590923-0 1977 Effect of metoclopramide on prolactin secretion in man. Metoclopramide 10-24 prolactin Homo sapiens 28-37 590923-4 1977 The results obtained evidenced a considerable hPRL increase after Metoclopramide administration, similar to that observed with Sulpiride, completely abolished by 5-Br-2alpha-ergocryptine. Metoclopramide 66-80 prolactin Homo sapiens 46-50 590923-4 1977 The results obtained evidenced a considerable hPRL increase after Metoclopramide administration, similar to that observed with Sulpiride, completely abolished by 5-Br-2alpha-ergocryptine. 5-br-2alpha-ergocryptine 162-186 prolactin Homo sapiens 46-50 590923-5 1977 On the basis of these data it seems evident a strong and specific effect of Metoclopramide on hPRL secretion, probably more potent than Sulpiride. Metoclopramide 76-90 prolactin Homo sapiens 94-98 562901-1 1977 The effect of methysergide (MES), a serotoninergic antagonist on prolactin (PRL) blood levels was studied in five hyperprolactinemic amenorrheic women. Methysergide 14-26 prolactin Homo sapiens 65-74 562901-1 1977 The effect of methysergide (MES), a serotoninergic antagonist on prolactin (PRL) blood levels was studied in five hyperprolactinemic amenorrheic women. Methysergide 14-26 prolactin Homo sapiens 76-79 562901-1 1977 The effect of methysergide (MES), a serotoninergic antagonist on prolactin (PRL) blood levels was studied in five hyperprolactinemic amenorrheic women. Methysergide 28-31 prolactin Homo sapiens 65-74 562901-2 1977 The drug was administered for five days at a daily dosage of 11.2 mg. MES decreased significantly the PRL blood levels in all subjects (p less than 0.01). Methysergide 70-73 prolactin Homo sapiens 102-105 562901-3 1977 Since the MES has been shown to have antiserotoninergic effects and since serotonin has been thought to be involved in the control of PRL release, the effects of MES in lowering PRL might be due to a decrease of serotonin tone. Methysergide 162-165 prolactin Homo sapiens 134-137 562901-3 1977 Since the MES has been shown to have antiserotoninergic effects and since serotonin has been thought to be involved in the control of PRL release, the effects of MES in lowering PRL might be due to a decrease of serotonin tone. Methysergide 162-165 prolactin Homo sapiens 178-181 562901-3 1977 Since the MES has been shown to have antiserotoninergic effects and since serotonin has been thought to be involved in the control of PRL release, the effects of MES in lowering PRL might be due to a decrease of serotonin tone. Serotonin 74-83 prolactin Homo sapiens 134-137 562902-2 1977 Basal serum prolactin levels were raised, and were further elevated by the administration of L-dopa, chlorpromazine and TRH. Levodopa 93-99 prolactin Homo sapiens 12-21 562902-2 1977 Basal serum prolactin levels were raised, and were further elevated by the administration of L-dopa, chlorpromazine and TRH. Chlorpromazine 101-115 prolactin Homo sapiens 12-21 562902-3 1977 Intercostal nerve block and bromocryptine treatment reduced prolactin levels to normal, but did not noticably reduce milk secretion. Bromocriptine 28-41 prolactin Homo sapiens 60-69 335789-0 1977 Effect of chlorpromazine treatment on prolactin levels in cerebrospinal fluid and plasma of psychotic patients. Chlorpromazine 10-24 prolactin Homo sapiens 38-47 335789-1 1977 In psychotic patients, levels of prolactin in cerebrospinal fluid (CSF) and plasma were determined by radioimmunoassay before and after 2 and 4 weeks of treatment with chlorpromazine (CPZ). Chlorpromazine 168-182 prolactin Homo sapiens 33-42 335789-1 1977 In psychotic patients, levels of prolactin in cerebrospinal fluid (CSF) and plasma were determined by radioimmunoassay before and after 2 and 4 weeks of treatment with chlorpromazine (CPZ). Chlorpromazine 184-187 prolactin Homo sapiens 33-42 335789-6 1977 During CPZ treatment, the PRL levels in CSF as well as in plasma were significantly elevated in both sexes after 2 as well as 4 weeks. Chlorpromazine 7-10 prolactin Homo sapiens 26-29 335789-8 1977 There was a significantly positive relationship between the dose of CPZ and the PRL elevation in both body fluids in both men and women. Chlorpromazine 68-71 prolactin Homo sapiens 80-83 336077-0 1977 Effect of clomiphene on prolactin secretion and lactation in puerperal women. Clomiphene 10-20 prolactin Homo sapiens 24-33 594630-0 1977 Release of growth hormone, prolactin, LH, FSH and IRI in serum through orally administered 1-proline in high dosage. 1-proline 91-100 prolactin Homo sapiens 27-36 302840-0 1977 Effect of 1-5 hydroxytryptophan infusion on growth hormone and prolactin secretion in man. 1-5 hydroxytryptophan 10-31 prolactin Homo sapiens 63-72 908151-0 1977 Increased prolactin and thyrotrophin secretion following oral metoclopramide: dose-response relationships. Metoclopramide 62-76 prolactin Homo sapiens 10-19 908151-3 1977 Serum PRL levels peaked 60-90 min after ingestion of any dose of metoclopramide and values remained significantly elevated (P less than 0.05) for up to 8h after the tablet. Metoclopramide 65-79 prolactin Homo sapiens 6-9 908151-7 1977 It was concluded that metoclopramide elevated serum PRL and TSH. Metoclopramide 22-36 prolactin Homo sapiens 52-55 409726-9 1977 There was some suppression of prolactin levels after L-dopa. Levodopa 53-59 prolactin Homo sapiens 30-39 302840-1 1977 The effect of a new soluble ester of 1-5 hydroxytryptophan (1-5 HTP, Ro 3-5940, 200 mg infusion) on prolactin (PRL) and growth hormone (GH) release was tested in 11 young, healthy subjects (6 men, 5 women). 1-5 hydroxytryptophan 37-58 prolactin Homo sapiens 100-109 302840-1 1977 The effect of a new soluble ester of 1-5 hydroxytryptophan (1-5 HTP, Ro 3-5940, 200 mg infusion) on prolactin (PRL) and growth hormone (GH) release was tested in 11 young, healthy subjects (6 men, 5 women). 1-5 hydroxytryptophan 37-58 prolactin Homo sapiens 111-114 302840-1 1977 The effect of a new soluble ester of 1-5 hydroxytryptophan (1-5 HTP, Ro 3-5940, 200 mg infusion) on prolactin (PRL) and growth hormone (GH) release was tested in 11 young, healthy subjects (6 men, 5 women). Ro 11 69-78 prolactin Homo sapiens 100-109 903403-0 1977 Effects of a gamma aminobutyric acid (GABA) derivative, baclofen, on growth hormone and prolactin secretion in man. gamma-Aminobutyric Acid 13-36 prolactin Homo sapiens 88-97 302840-1 1977 The effect of a new soluble ester of 1-5 hydroxytryptophan (1-5 HTP, Ro 3-5940, 200 mg infusion) on prolactin (PRL) and growth hormone (GH) release was tested in 11 young, healthy subjects (6 men, 5 women). Ro 11 69-78 prolactin Homo sapiens 111-114 903403-0 1977 Effects of a gamma aminobutyric acid (GABA) derivative, baclofen, on growth hormone and prolactin secretion in man. gamma-Aminobutyric Acid 38-42 prolactin Homo sapiens 88-97 302840-3 1977 PRL increased significantly (P less than 0.01) after benserazide alone in all subjects. Benserazide 53-64 prolactin Homo sapiens 0-3 903403-0 1977 Effects of a gamma aminobutyric acid (GABA) derivative, baclofen, on growth hormone and prolactin secretion in man. Baclofen 56-64 prolactin Homo sapiens 88-97 302840-7 1977 It was postulated that benserazide penetrated at the level of the pituitary, decreasing the synthesis of dopamine and consequently reducing its known inhibitory effect on PRL release. Benserazide 23-34 prolactin Homo sapiens 171-174 578796-2 1977 They were treated for 50 days with 2-brom-alpha-ergocryptin (Pravidel, Sandoz AG, Nurnberg), which selectively inhibits prolactin release. 2-Brom-alpha-ergocryptin 35-59 prolactin Homo sapiens 120-129 925574-0 1977 Effect of clomiphene on release of prolactin induced by mechanical breast emptying in women post partum. Clomiphene 10-20 prolactin Homo sapiens 35-44 578796-2 1977 They were treated for 50 days with 2-brom-alpha-ergocryptin (Pravidel, Sandoz AG, Nurnberg), which selectively inhibits prolactin release. Bromocriptine 61-69 prolactin Homo sapiens 120-129 69827-3 1977 Oral administration of bromocriptine, a dopaminergic agonist, suppressed plasma-prolactin and lowered arterial pressure. Bromocriptine 23-36 prolactin Homo sapiens 80-89 70642-2 1977 Eight individuals with Huntington"s chorea had low basal and impaired human prolactin responses to both chlorpromazine and thyrotrophin-releasing hormone. Chlorpromazine 104-118 prolactin Homo sapiens 76-85 70642-4 1977 Two juvenile rigid patients with Huntington"s chorea had excessive prolactin responses to chlorpromazine. Chlorpromazine 90-104 prolactin Homo sapiens 67-76 70642-5 1977 Approximately half of the twenty-three potentially affected first-degree relatives of patients with Huntington"s chorea had normal prolactin responses to chlorpromazine. Chlorpromazine 154-168 prolactin Homo sapiens 131-140 578053-0 1977 The stimulation of prolactin secretion by sulpiride in "adolescent gynaecomastia". Sulpiride 42-51 prolactin Homo sapiens 19-28 327363-5 1977 Long-term treatment with bromocriptine in 11 women resulted in a decrease of serum prolactin, cessation of lactation in all, and pregnancy in 8. Bromocriptine 25-38 prolactin Homo sapiens 83-92 69827-4 1977 It is proposed that in the hypertensive patients the raised prolactin levels reflect a defect in central dopamine control which is normalised by bromocriptine. Dopamine 105-113 prolactin Homo sapiens 60-69 69827-4 1977 It is proposed that in the hypertensive patients the raised prolactin levels reflect a defect in central dopamine control which is normalised by bromocriptine. Bromocriptine 145-158 prolactin Homo sapiens 60-69 69814-0 1977 Bromocriptine inhibits prolactin and growth-hormone release by human pituitary tumours in culture. Bromocriptine 0-13 prolactin Homo sapiens 23-32 20170-4 1977 Since dopamine does not penetrate the blood-brain barrier, the enhanced PRL decrease observed during pyridoxine infusion might be explained only on the basis of a mechanism of action exerted by dopamine on extra blood-brain barrier sites. Dopamine 194-202 prolactin Homo sapiens 72-75 194447-1 1977 To investigate whether a direct influence exists between the prolactin suppressive effect of alpha-bromoergocriptine (CB 154) and the aldosterone response to a potassium stimulation, the present study was performed in 7 anephric patients and in 7 non-nephrectomized patients, all on regular haemodialysis. alpha-bromoergocriptine 93-116 prolactin Homo sapiens 61-70 194447-1 1977 To investigate whether a direct influence exists between the prolactin suppressive effect of alpha-bromoergocriptine (CB 154) and the aldosterone response to a potassium stimulation, the present study was performed in 7 anephric patients and in 7 non-nephrectomized patients, all on regular haemodialysis. Bromocriptine 118-124 prolactin Homo sapiens 61-70 20170-0 1977 Dissociation of growth hormone and prolactin response to levodopa during pyridoxine administration. Levodopa 57-65 prolactin Homo sapiens 35-44 20170-0 1977 Dissociation of growth hormone and prolactin response to levodopa during pyridoxine administration. Pyridoxine 73-83 prolactin Homo sapiens 35-44 562688-0 1977 Suppression of pimozide-induced prolactin secretion by piridoxine (vitamin B6). Pimozide 15-23 prolactin Homo sapiens 32-41 20170-1 1977 500 mg of levodopa was administered orally to 8 normal subjects and induced an increase of growth hormone (GH) and a decrease of prolactin (PRL) secretion. Levodopa 10-18 prolactin Homo sapiens 129-138 20170-1 1977 500 mg of levodopa was administered orally to 8 normal subjects and induced an increase of growth hormone (GH) and a decrease of prolactin (PRL) secretion. Levodopa 10-18 prolactin Homo sapiens 140-143 20170-2 1977 The levodopa-induced GH release was inhibited by an intravenous infusion of pyridoxine; on the contrary, the PRL response to levodopa was enhanced by pyridoxine infusion. Levodopa 125-133 prolactin Homo sapiens 109-112 20170-2 1977 The levodopa-induced GH release was inhibited by an intravenous infusion of pyridoxine; on the contrary, the PRL response to levodopa was enhanced by pyridoxine infusion. Pyridoxine 150-160 prolactin Homo sapiens 109-112 20170-3 1977 This dissociation of GH and PRL responses to levodopa during pyridoxine infusion appears to be mediated by peripheral acceleration of the conversion of levodopa to dopamine. Levodopa 45-53 prolactin Homo sapiens 28-31 562688-0 1977 Suppression of pimozide-induced prolactin secretion by piridoxine (vitamin B6). piridoxine 55-65 prolactin Homo sapiens 32-41 20170-3 1977 This dissociation of GH and PRL responses to levodopa during pyridoxine infusion appears to be mediated by peripheral acceleration of the conversion of levodopa to dopamine. Pyridoxine 61-71 prolactin Homo sapiens 28-31 20170-4 1977 Since dopamine does not penetrate the blood-brain barrier, the enhanced PRL decrease observed during pyridoxine infusion might be explained only on the basis of a mechanism of action exerted by dopamine on extra blood-brain barrier sites. Dopamine 6-14 prolactin Homo sapiens 72-75 562688-0 1977 Suppression of pimozide-induced prolactin secretion by piridoxine (vitamin B6). Vitamin B 6 67-77 prolactin Homo sapiens 32-41 20170-4 1977 Since dopamine does not penetrate the blood-brain barrier, the enhanced PRL decrease observed during pyridoxine infusion might be explained only on the basis of a mechanism of action exerted by dopamine on extra blood-brain barrier sites. Pyridoxine 101-111 prolactin Homo sapiens 72-75 562688-2 1977 administration of 300 mg. Pyridoxine caused an acute fall in prolactin (PRL) plasma levels in six normal subjects. Pyridoxine 26-36 prolactin Homo sapiens 61-70 562688-2 1977 administration of 300 mg. Pyridoxine caused an acute fall in prolactin (PRL) plasma levels in six normal subjects. Pyridoxine 26-36 prolactin Homo sapiens 72-75 562688-3 1977 Like levodopa, pyridoxine suppressed the increase in PRL secretion induced by treatment with pimozide, a specific dopamine receptor blocking agent. Levodopa 5-13 prolactin Homo sapiens 53-56 562688-3 1977 Like levodopa, pyridoxine suppressed the increase in PRL secretion induced by treatment with pimozide, a specific dopamine receptor blocking agent. Pyridoxine 15-25 prolactin Homo sapiens 53-56 562688-3 1977 Like levodopa, pyridoxine suppressed the increase in PRL secretion induced by treatment with pimozide, a specific dopamine receptor blocking agent. Pimozide 93-101 prolactin Homo sapiens 53-56 862554-0 1977 Effect of prolactin on sodium and potassium concentrations in mammary alveolar tissue. Sodium 23-29 prolactin Homo sapiens 10-19 17257-0 1977 Increased serum prolactin in diabetic ketoacidosis; correlation between serum sodium and serum prolacting concentration. Sodium 78-84 prolactin Homo sapiens 16-25 874063-1 1977 Pasma prolactin response to the acute injection of sulpiride (1.5 mg/k BW im) was measured at 0800-0900h in 4 girls with idiopathic precocious puberty before and after 6 to 11 months of continuous therapy with 50 mg daily of cyproterone acetate (CA) orally administered. Sulpiride 51-60 prolactin Homo sapiens 6-15 891746-0 1977 Influence of dopamine infusion on plasma prolactin released by kidney capsule transplanted anterior pituitaries. Dopamine 13-21 prolactin Homo sapiens 41-50 891746-1 1977 The infusion of dopamine into the renal artery resulted in decreased prolactin release from 3 anterior pituitary glands transplanted under the kidney capsule. Dopamine 16-24 prolactin Homo sapiens 69-78 891746-2 1977 Prolactin levels continually decreased over a 5 min period after DA infusion was terminated and thereafter approached preinfusion levels by the end of 10 min. amsonic acid 65-67 prolactin Homo sapiens 0-9 17257-6 1977 However, a significant negative correlation between log serum prolactin concentration and serum sodium concentration was demonstrated (r = -0.61, P less than 0.01). Sodium 96-102 prolactin Homo sapiens 62-71 17257-7 1977 It is suggested that serum prolactin may possible participate in sodium retention in man as has been demonstrated in studies on animals. Sodium 65-71 prolactin Homo sapiens 27-36 578115-7 1977 An increase in ovarian responsiveness to HPG during therapy with bromocriptine was recorded in the one patient with initially elevated prolactin values. Bromocriptine 65-78 prolactin Homo sapiens 135-144 328335-0 1977 [The effect of several sexual steroids, 2-bromo-ergokryptin and lisurid-hydrogenmaleate an the postpartum concentration of serum prolactin and lactation (author"s transl)]. Steroids 30-38 prolactin Homo sapiens 129-138 328335-0 1977 [The effect of several sexual steroids, 2-bromo-ergokryptin and lisurid-hydrogenmaleate an the postpartum concentration of serum prolactin and lactation (author"s transl)]. 2-bromo-ergokryptin 40-59 prolactin Homo sapiens 129-138 328335-0 1977 [The effect of several sexual steroids, 2-bromo-ergokryptin and lisurid-hydrogenmaleate an the postpartum concentration of serum prolactin and lactation (author"s transl)]. lisurid-hydrogenmaleate 64-87 prolactin Homo sapiens 129-138 328335-9 1977 The serum prolactin levels postpartum remained as high as a nursing mother"s or rose with the administration of steroids. Steroids 112-120 prolactin Homo sapiens 10-19 328335-10 1977 The administration of Cb 154 resulted in a drop of the serum prolactin to non-pregnant levels with in 2 days. Bromocriptine 22-28 prolactin Homo sapiens 61-70 343464-8 1977 On the contrary, after pretreatment with CB 154, we observed: 1) hPRL reduction; 2) GH increase, sometimes as early as 30 min after OGTT; 3) IRI was never present and blood glucose levels were lower than the values observed with glucose alone. Bromocriptine 41-47 prolactin Homo sapiens 65-69 141460-0 1977 Effect of prolactin on plasma DHEA (s) levels. Dehydroepiandrosterone 30-34 prolactin Homo sapiens 10-19 141460-1 1977 Plasma DHEA and DHEA-S levels were significantly higher (P less than 0.001) in women with elevated prolactin levels, due either to chronic treatment with psychotropic drugs or to a prolactinoma, than in untreated controls. Dehydroepiandrosterone 7-11 prolactin Homo sapiens 99-108 141460-1 1977 Plasma DHEA and DHEA-S levels were significantly higher (P less than 0.001) in women with elevated prolactin levels, due either to chronic treatment with psychotropic drugs or to a prolactinoma, than in untreated controls. Dehydroepiandrosterone 16-22 prolactin Homo sapiens 99-108 577621-5 1977 Brom-ergocryptine appears to be very effective in inhibiting prolactin secretion and thus reestablishing normal ovulatory menstrual cycles and fertility. Bromocriptine 0-17 prolactin Homo sapiens 61-70 406999-0 1977 [Bromocryptin effect on growth hormone and prolactin secretion after administration of thyrotropin-releasing hormone in patients with primary hypothyroidism and acromegaly (author"s transl)]. Bromocriptine 1-13 prolactin Homo sapiens 43-52 870513-0 1977 The effects of ovine prolactin on water and electrolyte excretion in man are attributable to vasopressin contamination. Water 34-39 prolactin Homo sapiens 21-30 849731-0 1977 Recovery of prolactin from acetone-dried human pituitary glands. Acetone 27-34 prolactin Homo sapiens 12-21 849731-1 1977 An improved method is described for the purification of prolactin from the same batch of acetone-dried pituitary glands which is used for the isolation of other anterior pituitary hormones. Acetone 89-96 prolactin Homo sapiens 56-65 849731-6 1977 A yield of 23 mg prolactin, 37 U/mg, was obtained per 1000 g pituitary acetone powder. Acetone 71-78 prolactin Homo sapiens 17-26 870513-10 1977 Aqueous vasopressin, 50 mU (containing in 25 mg of ovine prolactin), produced a decrease in CH2O not significantly different from prolactin in 6 water loaded subjects. Formaldehyde 92-96 prolactin Homo sapiens 57-66 140915-0 1977 Steroid sex hormones and prolactin in postmenopausal women with generalized mammary carcinoma during prolonged dexamethasone treatment. Dexamethasone 111-124 prolactin Homo sapiens 25-34 404308-8 1977 No significant suppression of serum PRL was seen in Group 2 patients given L-Dopa (500 mg orally),, which produced a significant response (P less than 0.05) in Group 1 subjects, while all patient showed marked reduction in serum PRL values following 2-bromo-alpha-ergocryptine (CB-154, 2.5 mg orally). Levodopa 75-81 prolactin Homo sapiens 229-232 140915-9 1977 The persistance of steroid sex hormones and the rise of plasma prolactin might explain the poor response to dexamethasone treatment in mammary carcinoma. Dexamethasone 108-121 prolactin Homo sapiens 63-72 558225-2 1977 There was a progressive and significant increase in serum prolactin during the late follicular phase, with a maximal value concomitant to the LH peak. Luteinizing Hormone 142-144 prolactin Homo sapiens 58-67 858775-0 1977 Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. 4-hydroxybutyric acid 23-48 prolactin Homo sapiens 71-80 558225-7 1977 The overall pattern of serum prolactin during the menstrual cycle resembles that reported for circulating 17beta-estradiol. Estradiol 106-122 prolactin Homo sapiens 29-38 858775-3 1977 The plasma prolactin level increased significantly at 45 and 60 min after GHB injection. 4-hydroxybutyric acid 74-77 prolactin Homo sapiens 11-20 858775-5 1977 It is conceivable that GHB could modify the release of serotonin from the nerve terminals and then stimulate the release of GH and prolactin. 4-hydroxybutyric acid 23-26 prolactin Homo sapiens 131-140 849673-0 1977 Prolactin and psychophysiologic measures after single doses of thioridazine. Thioridazine 63-75 prolactin Homo sapiens 0-9 406134-0 1977 Effect of sulpiride on serum growth hormone and prolactin concentrations following L-DOPA administration in man. Sulpiride 10-19 prolactin Homo sapiens 48-57 321260-9 1977 On discontinuation of bromoergocryptine therapy, serum prolactin levels rapidly returned to pretreatment values or higher in all of the patients studied. Bromocriptine 22-39 prolactin Homo sapiens 55-64 406134-1 1977 The effect of chronic administration of sulpiride on serum human growth hormone (hGH), prolactin and thyroid stimulating hormone (TSH) was examined in 6 normal subjects. Sulpiride 40-49 prolactin Homo sapiens 87-96 406134-4 1977 Sulpiride raised serum prolactin levels in all subjects examined. Sulpiride 0-9 prolactin Homo sapiens 23-32 406134-6 1977 Sulpiride treatment appeared to antagonize partially the inhibitory effect of L-dopa on prolactin release. Sulpiride 0-9 prolactin Homo sapiens 88-97 406134-6 1977 Sulpiride treatment appeared to antagonize partially the inhibitory effect of L-dopa on prolactin release. Levodopa 78-84 prolactin Homo sapiens 88-97 837884-1 1977 The addition of prolactin to the 150,000 x g sedimented fraction of mammary gland homogenates increased by about two-fold the rate of [3H]-arachidonic acid released from phosphatidyl choline. Tritium 135-137 prolactin Homo sapiens 16-25 406134-7 1977 Following thyrotropin-releasing hormone (TRH) injection, the percent increment in prolactin levels from the baseline in sulpiride-treated subjects was less than in controls without sulpiride. Sulpiride 120-129 prolactin Homo sapiens 82-91 837884-1 1977 The addition of prolactin to the 150,000 x g sedimented fraction of mammary gland homogenates increased by about two-fold the rate of [3H]-arachidonic acid released from phosphatidyl choline. Arachidonic Acid 139-155 prolactin Homo sapiens 16-25 837884-1 1977 The addition of prolactin to the 150,000 x g sedimented fraction of mammary gland homogenates increased by about two-fold the rate of [3H]-arachidonic acid released from phosphatidyl choline. Phosphatidylcholines 170-190 prolactin Homo sapiens 16-25 406134-9 1977 These observations suggest that sulpiride suppresses L-dopa-induced hGH release and stimulates prolactin release, presumably by acting against the dopaminergic mechanism either on the hypothalamus or on the pituitary. Sulpiride 32-41 prolactin Homo sapiens 95-104 837884-3 1977 The enhanced rate of arachidonic acid release from phosphatidyl choline suggests that prolactin stimulates phospholipase A activity and this may be the primary site of action of prolactin in the mammary gland. Arachidonic Acid 21-37 prolactin Homo sapiens 86-95 837884-3 1977 The enhanced rate of arachidonic acid release from phosphatidyl choline suggests that prolactin stimulates phospholipase A activity and this may be the primary site of action of prolactin in the mammary gland. Arachidonic Acid 21-37 prolactin Homo sapiens 178-187 406134-10 1977 The decreased prolactin response to TRH after sulpiride treatment may indicate a diminished reserve capacity in pituitary prolactin release. Sulpiride 46-55 prolactin Homo sapiens 14-23 837884-3 1977 The enhanced rate of arachidonic acid release from phosphatidyl choline suggests that prolactin stimulates phospholipase A activity and this may be the primary site of action of prolactin in the mammary gland. Phosphatidylcholines 51-71 prolactin Homo sapiens 86-95 837884-3 1977 The enhanced rate of arachidonic acid release from phosphatidyl choline suggests that prolactin stimulates phospholipase A activity and this may be the primary site of action of prolactin in the mammary gland. Phosphatidylcholines 51-71 prolactin Homo sapiens 178-187 406134-10 1977 The decreased prolactin response to TRH after sulpiride treatment may indicate a diminished reserve capacity in pituitary prolactin release. Sulpiride 46-55 prolactin Homo sapiens 122-131 576612-6 1977 Following the administration of CB-154 (2.5 mg. orally) to 6 women with hyperprolactinemic amenorrhea, there was also a significant fall in LH levels (P less than 0.00001) and in FSH levels (P less than 0.00001) from 5 h until the study ended at 10 h. The anticipated PRL suppression was also observed and persisted for the duration of the 10 h study. Bromocriptine 32-38 prolactin Homo sapiens 268-271 842694-0 1977 Prolactin and fetal osmoregulation: water transport across isolated human amnion. Water 36-41 prolactin Homo sapiens 0-9 849985-0 1977 Action of metergoline in suppressing prolactin release induced by mechanical breast emptying. Metergoline 10-21 prolactin Homo sapiens 37-46 66455-0 1977 Growth hormone and prolactin response to levodopa in affective illness. Levodopa 41-49 prolactin Homo sapiens 19-28 842694-7 1977 The results imply an active role for prolactin on water transport across human amnion. Water 50-55 prolactin Homo sapiens 37-46 903269-0 1977 Effect of metoclopramide on prolactin secretion in normal subjects. Metoclopramide 10-24 prolactin Homo sapiens 28-37 557353-0 1977 The release of prolactin by medroxy-progesterone acetate in human subjects. Medroxyprogesterone Acetate 28-56 prolactin Homo sapiens 15-24 557353-1 1977 Medroxyprogesterone acetate an injectable contraceptive when administered to four lactating women at a dose of 150 mg every three months significantly raised prolactin levels over those observed in four control women. Medroxyprogesterone Acetate 0-27 prolactin Homo sapiens 158-167 408065-6 1977 Neurotransmitter therapy, with dopamine agonists which act as functional analogues of PIF, restores prolactin levels to normal and leads to a return of normal gonadal function. Dopamine 31-39 prolactin Homo sapiens 100-109 560285-0 1977 Serum prolactin levels in women using copper IUDs. Copper 38-44 prolactin Homo sapiens 6-15 914330-0 1977 Luteinizing hormone & prolactin levels in blood serum & seminal plasma of cross-bred bulls. Adenosine Monophosphate 59-62 prolactin Homo sapiens 26-35 856708-3 1977 Sulpiride, a benzamide derivative with neuroleptic and thymoleptic properties, is known to act at the hypothalamic level and in particular, to inhibit releasing factors responsible for follicle-stimulating hormone and prolactin secretion. Sulpiride 0-9 prolactin Homo sapiens 218-227 192611-1 1977 Specific receptors for iodine-labelled human prolactin ([125I]hPrl) are present in membrane preparations of the rat ventral prostate. Iodine 23-29 prolactin Homo sapiens 62-66 192611-5 1977 Treatment of immature rats with varying doses of dihydrotestosterone propionate (10-5000 microng) causes a dose-dependent stimulation of Prl receptors calculated both as binding sites per mg of membrane protein and as binding sites per prostate. dihydrotestosterone propionate 49-79 prolactin Homo sapiens 137-140 192611-6 1977 Androgen stimulation of prostatic Prl receptors increases the tissue sensitivity for circulating Prl and may be one reason for the known increases in endogenous cAMP levels in prostatic tissue after androgen treatment in vivo. Cyclic AMP 161-165 prolactin Homo sapiens 34-37 197384-3 1977 We have also found that various hormones, including prolactin, vasopressin and angiotensin when present in physiological concentrations can be potent stimulators of prostaglandin synthesis. Prostaglandins 165-178 prolactin Homo sapiens 52-61 576342-5 1977 After pretreatment with dexamethasone the basal serum prolactin levels and the prolactin response to hypoglycaemia were significantly decreased compared with those in the ITT. Dexamethasone 24-37 prolactin Homo sapiens 54-63 556882-3 1977 Serum prolactin could be lowered with oral L-dopa. Levodopa 43-49 prolactin Homo sapiens 6-15 576342-0 1977 Prolactin levels in the insulin tolerance test with and without pre-treatment with dexamethasone. Dexamethasone 83-96 prolactin Homo sapiens 0-9 916803-0 1977 Enkephalin analogues and naloxone modulate the release of growth hormone and prolactin--evidence for regulation by an endogenous opioid peptide in brain. Naloxone 25-33 prolactin Homo sapiens 77-86 401733-4 1977 Kinetic studies showed apparent binding affinity constants for 125I-labeled human prolactin (hPRL) of the order of 10(9)M-1 and capacities of from 3 ng to over a microgram per organ in late pregnancy for all of these tissues except brain. Iodine-125 63-67 prolactin Homo sapiens 82-91 401733-4 1977 Kinetic studies showed apparent binding affinity constants for 125I-labeled human prolactin (hPRL) of the order of 10(9)M-1 and capacities of from 3 ng to over a microgram per organ in late pregnancy for all of these tissues except brain. Iodine-125 63-67 prolactin Homo sapiens 93-97 576342-5 1977 After pretreatment with dexamethasone the basal serum prolactin levels and the prolactin response to hypoglycaemia were significantly decreased compared with those in the ITT. Dexamethasone 24-37 prolactin Homo sapiens 79-88 576342-6 1977 The prolactin response both to insulin-induced hypoglycaemia and to dexamethasone showed such a large individual variation that this type of response seems unsuitable for evaluation of the hypothalamo-pituitary function. Dexamethasone 68-81 prolactin Homo sapiens 4-13 402375-1 1977 We studied the effects of administration of dexamethasone, 2 mg orally every 6 h, for 5 days on the thyrotropin-releasing hormone (TRH)-induced release of prolactin (PRL), thyrotropin (TSH), triiodothyronine (T3) and thyroxine (T4) in 9 normal men and on the metoclopramide-induced release of PRL in 7 normal men. Dexamethasone 44-57 prolactin Homo sapiens 155-164 401926-1 1977 The effects of acute changes in serum osmolality on basal serum PRL and TSH levels and on responses of prolactin (PRL) and thyrotropin (TSH) to the thyrotropin-releasing hormone (TRH) analogue, N3im-methyl-TRH, were studied in ten euthyroid subjects and in three patients with PRL-secreting pituitary tumors. n3im-methyl-trh 194-209 prolactin Homo sapiens 103-112 402375-2 1977 Dexamethasone suppressed the baseline serum levels of PRL, TSH and T3. Dexamethasone 0-13 prolactin Homo sapiens 54-57 402375-3 1977 The administration of dexamethasone blunted the PRL and TSH response to TRH; the blunted TSH response resulted in a decreased T3 and T4 response to TRH after dexamethasone. Dexamethasone 22-35 prolactin Homo sapiens 48-51 402375-4 1977 Following dexamethasone administration, the PRL response to metoclopramide, a dopamine antagonist which acts at the hypothalamicpituitary level to stimulate PRL secretion, was blunted in 7 normal men. Dexamethasone 10-23 prolactin Homo sapiens 44-47 402375-4 1977 Following dexamethasone administration, the PRL response to metoclopramide, a dopamine antagonist which acts at the hypothalamicpituitary level to stimulate PRL secretion, was blunted in 7 normal men. Dexamethasone 10-23 prolactin Homo sapiens 157-160 402375-4 1977 Following dexamethasone administration, the PRL response to metoclopramide, a dopamine antagonist which acts at the hypothalamicpituitary level to stimulate PRL secretion, was blunted in 7 normal men. Metoclopramide 60-74 prolactin Homo sapiens 44-47 402375-4 1977 Following dexamethasone administration, the PRL response to metoclopramide, a dopamine antagonist which acts at the hypothalamicpituitary level to stimulate PRL secretion, was blunted in 7 normal men. Metoclopramide 60-74 prolactin Homo sapiens 157-160 402375-4 1977 Following dexamethasone administration, the PRL response to metoclopramide, a dopamine antagonist which acts at the hypothalamicpituitary level to stimulate PRL secretion, was blunted in 7 normal men. Dopamine 78-86 prolactin Homo sapiens 44-47 402377-3 1977 Prolactin concentrations were increased by TRH and were suppressed by L-dopa. Levodopa 70-76 prolactin Homo sapiens 0-9 402381-0 1977 Apomorpine inhibits the prolactin but not the TSH response to thyrotropin releasing hormone. apomorpine 0-10 prolactin Homo sapiens 24-33 402381-1 1977 Pretreatment of normal subjects with apomorphine, a dopamine receptor agonist, resulted in significant impairment of the subsequent prolactin (PRL) response to thyrotropin releasing hormone (TRH). Apomorphine 37-48 prolactin Homo sapiens 133-142 401926-2 1977 An oral water load of 20 ml/kg had no effect on basal serum PRL or TSH levels but did result in an increased PRL response to methyl-TRH in the ten euthyroid patients. Water 8-13 prolactin Homo sapiens 109-112 401926-2 1977 An oral water load of 20 ml/kg had no effect on basal serum PRL or TSH levels but did result in an increased PRL response to methyl-TRH in the ten euthyroid patients. methyl-trh 125-135 prolactin Homo sapiens 109-112 401926-3 1977 Intravenous infusion of 5% sodium chloride in the ten euthyroid subjects significantly depressed basal serum PRL levels but had no effect on the PRL response to methyl-TRH. Sodium Chloride 27-42 prolactin Homo sapiens 109-112 319422-1 1977 In a group of 16 females and 2 males with hypogonadism and hyperprolactinemia, bromocriptine was found to suppress prolactin (PRL) high levels within one day without further significant lowering during a 3 weeks longitudinal survey. Bromocriptine 79-92 prolactin Homo sapiens 64-73 402671-1 1977 A previous report indicated that the tricyclic antidepressants imipramine and amitriptyline markedly increased plasma prolactin levels in man. Imipramine 63-73 prolactin Homo sapiens 118-127 402671-1 1977 A previous report indicated that the tricyclic antidepressants imipramine and amitriptyline markedly increased plasma prolactin levels in man. Amitriptyline 78-91 prolactin Homo sapiens 118-127 319422-1 1977 In a group of 16 females and 2 males with hypogonadism and hyperprolactinemia, bromocriptine was found to suppress prolactin (PRL) high levels within one day without further significant lowering during a 3 weeks longitudinal survey. Bromocriptine 79-92 prolactin Homo sapiens 126-129 401530-2 1977 Six of eight patients had impaired pituitary prolactin secretion after administration of thyrotropin-releasing hormone and chlorpromazine, with preservation of other anterior pituitary functions. Chlorpromazine 123-137 prolactin Homo sapiens 45-54 401530-3 1977 Peak serum prolactin levels after thyrotropin-releasing hormone and chlorpromazine in the prolactin-deficient patients were significantly lower than normal. Chlorpromazine 68-82 prolactin Homo sapiens 11-20 831500-3 1977 The release of decidual prolactin was affected by the presence or absence of oxygen and protein, and the amount of prolactin released far exceeded the decrease in tissue content during incubation. Oxygen 77-83 prolactin Homo sapiens 24-33 401530-3 1977 Peak serum prolactin levels after thyrotropin-releasing hormone and chlorpromazine in the prolactin-deficient patients were significantly lower than normal. Chlorpromazine 68-82 prolactin Homo sapiens 90-99 401530-4 1977 Administration of diethylstilbestrol for five days, which normally enhances prolactin responses to thyrotropin-releasing hormone, had no effect on prolactin secretion in these patients. Diethylstilbestrol 18-36 prolactin Homo sapiens 76-85 557719-6 1977 Serum PRL levels were of value in predicting the likely success in achieving ovulation with clomiphene citrate or CB-154; clomiphene citrate was less likely to be successful in the presence of hyperprolactinaemia, whereas the reverse applied for treatment with CB-154. Clomiphene 92-110 prolactin Homo sapiens 6-9 557719-6 1977 Serum PRL levels were of value in predicting the likely success in achieving ovulation with clomiphene citrate or CB-154; clomiphene citrate was less likely to be successful in the presence of hyperprolactinaemia, whereas the reverse applied for treatment with CB-154. Bromocriptine 114-120 prolactin Homo sapiens 6-9 557719-6 1977 Serum PRL levels were of value in predicting the likely success in achieving ovulation with clomiphene citrate or CB-154; clomiphene citrate was less likely to be successful in the presence of hyperprolactinaemia, whereas the reverse applied for treatment with CB-154. Bromocriptine 261-267 prolactin Homo sapiens 6-9 341635-3 1977 Bromocriptine significantly lowered plasma prolactin levels and suppressed breast milk, breast pain and engorgement quicker than placebo. Bromocriptine 0-13 prolactin Homo sapiens 43-52 19945-1 1977 At least three substances have been reported to be present in the hypothalamus that can inhibit prolactin release, namely a PIF, catecholamines and acetylcholine. Catecholamines 129-143 prolactin Homo sapiens 96-105 329643-0 1977 Regulation of prolactin secretion through dopamine, serotonin, and the cerebrospinal fluid. Dopamine 42-50 prolactin Homo sapiens 14-23 329643-0 1977 Regulation of prolactin secretion through dopamine, serotonin, and the cerebrospinal fluid. Serotonin 52-61 prolactin Homo sapiens 14-23 19945-1 1977 At least three substances have been reported to be present in the hypothalamus that can inhibit prolactin release, namely a PIF, catecholamines and acetylcholine. Acetylcholine 148-161 prolactin Homo sapiens 96-105 19945-2 1977 At least four substances have been reported to be present in the hypothalamus that can stimulate prolactin release, namely PRF, TRH, serotonin and prostaglandins. Serotonin 133-142 prolactin Homo sapiens 97-106 19945-2 1977 At least four substances have been reported to be present in the hypothalamus that can stimulate prolactin release, namely PRF, TRH, serotonin and prostaglandins. Prostaglandins 147-161 prolactin Homo sapiens 97-106 612263-3 1977 Mean prolactin level during oestriol administration, regardless of the dose, was statistically not significantly different from that observed during the control period. Estriol 28-36 prolactin Homo sapiens 5-14 911652-0 1977 Effects of nomifensine, an inhibitor of endogenous catecholamine re-uptake, in acromegaly, in hyperprolactinaemia, and against stimulated prolactin release in man. Nomifensine 11-22 prolactin Homo sapiens 99-108 911652-5 1977 It had no effect on thyrotrophin-releasing hormone (TRH)-induced thyrotrophin (TSH) or prolactin release in males, yet caused marked suppression of monoiodotyrosine (MIT)-induced prolactin release in males but not in females. Monoiodotyrosine 148-164 prolactin Homo sapiens 179-188 911652-5 1977 It had no effect on thyrotrophin-releasing hormone (TRH)-induced thyrotrophin (TSH) or prolactin release in males, yet caused marked suppression of monoiodotyrosine (MIT)-induced prolactin release in males but not in females. Monoiodotyrosine 166-169 prolactin Homo sapiens 179-188 911652-9 1977 It is proposed that the difference in male and female patterns of prolactin response to MIT after nomifensine, could be due to a "damping" effect of oestrogen on the hypothalamic dopaminergic system. Nomifensine 98-109 prolactin Homo sapiens 66-75 401825-0 1977 Effect of triiodothyronine treatment on prolactin secretion in patients with amenorrhea-galactorrhea. Triiodothyronine 10-26 prolactin Homo sapiens 40-49 833259-3 1977 The effects of water loading, hypertonic saline infusion and nicotine on serum PRL and on renal water metabolism were investigated in 6 normal subjects and in 8 patients with chronic hyperprolactinemia (four with and four without demonstrable pituitary tumors). Nicotine 61-69 prolactin Homo sapiens 79-82 327183-0 1977 Ergolines as potential prolactin and mammary tumor inhibitors. Ergolines 0-9 prolactin Homo sapiens 23-32 402375-0 1977 Effect of dexamethasone on prolactin and TSH responses to TRH and metoclopramide in man. Dexamethasone 10-23 prolactin Homo sapiens 27-36 576585-2 1977 Twenty of these patients, 16 of whom had galactorrhoea, had elevated basal serum prolactin values which were suppressed to normal or subnormal values during therapy with bromocriptine, the most commonly effective dose being 2.5 mg twice daily. Bromocriptine 170-183 prolactin Homo sapiens 81-90 216515-0 1977 Space occupying growth of a pituitary adenoma producing hGH and hPrl during bromocriptin therapy. Bromocriptine 76-88 prolactin Homo sapiens 64-68 862546-1 1977 Daily afternoon (at 7 p.m.) injections of melatonin (25 microng in oil) into adult male hamsters for 50 days led to atrophy of the testes and accessory sex organs (seminal vesicles and coagulating glands) and in a significant depression in pituitary LH and prolactin content and concentration. Melatonin 42-51 prolactin Homo sapiens 257-266 852930-1 1977 The C-terminal undecapeptide of ovine prolactin, H-Leu-Asn-Cys-Arg-Ile-Ile-Try-Asn-Asn-Asn-Cys-OH possesses several structural features common to protein proteinase inhibitors, yet has no inhibitor properties. h-leu-asn-cys 49-62 prolactin Homo sapiens 38-47 852930-1 1977 The C-terminal undecapeptide of ovine prolactin, H-Leu-Asn-Cys-Arg-Ile-Ile-Try-Asn-Asn-Asn-Cys-OH possesses several structural features common to protein proteinase inhibitors, yet has no inhibitor properties. Arginine 63-66 prolactin Homo sapiens 38-47 852930-1 1977 The C-terminal undecapeptide of ovine prolactin, H-Leu-Asn-Cys-Arg-Ile-Ile-Try-Asn-Asn-Asn-Cys-OH possesses several structural features common to protein proteinase inhibitors, yet has no inhibitor properties. asn-cys-oh 87-97 prolactin Homo sapiens 38-47 13217-0 1977 Ergoline congeners as potential inhibitors of prolactin release. Ergolines 0-8 prolactin Homo sapiens 46-55 13217-3 1977 In a continuation of our attempts to elucidate the prolactin release inhibiting pharmacophore within the ergoline structure, we have prepared several derivatives of 3-phenylpiperidine. Ergolines 105-113 prolactin Homo sapiens 51-60 13217-3 1977 In a continuation of our attempts to elucidate the prolactin release inhibiting pharmacophore within the ergoline structure, we have prepared several derivatives of 3-phenylpiperidine. 3-Phenylpiperidine 165-183 prolactin Homo sapiens 51-60 895996-0 1977 Plasma prolactin during lithium treatment. Lithium 24-31 prolactin Homo sapiens 7-16 1034579-3 1976 Treatment consists of inhibition of Prolactin by Bromocryptin following exclusion of other conditions of importance in the differential diagnosis. Bromocriptine 49-61 prolactin Homo sapiens 36-45 895996-1 1977 Plasma prolactin was determined in a longitudinal study, where -9 manic-depressive patients were examined before lithium treatment and at various times during the treatment with the aim of unravelling a possible association between initial changes in water and sodium balance during lithium treatment and changes in plasma prolactin level. Water 251-256 prolactin Homo sapiens 7-16 895996-1 1977 Plasma prolactin was determined in a longitudinal study, where -9 manic-depressive patients were examined before lithium treatment and at various times during the treatment with the aim of unravelling a possible association between initial changes in water and sodium balance during lithium treatment and changes in plasma prolactin level. Sodium 261-267 prolactin Homo sapiens 7-16 895996-1 1977 Plasma prolactin was determined in a longitudinal study, where -9 manic-depressive patients were examined before lithium treatment and at various times during the treatment with the aim of unravelling a possible association between initial changes in water and sodium balance during lithium treatment and changes in plasma prolactin level. Lithium 283-290 prolactin Homo sapiens 7-16 895996-3 1977 Some reports have indicated association between breast cancer and prolonged elevated plasma prolactin, such as is seen during treatment with phenothiazines and reserpine. Phenothiazines 141-155 prolactin Homo sapiens 92-101 895996-3 1977 Some reports have indicated association between breast cancer and prolonged elevated plasma prolactin, such as is seen during treatment with phenothiazines and reserpine. Reserpine 160-169 prolactin Homo sapiens 92-101 22216518-2 1976 Bromocriptine, like levodopa, causes improved mobility in patients with Parkinsonism, emesis, hallucinations, a fall in supine and erect blood pressure, increase of plasma growth hormone and suppression of prolactin concentration. Bromocriptine 0-13 prolactin Homo sapiens 206-215 1036743-2 1976 Treatment with bromocryptine in eight of these patients resulted in suppression of PRL in all, cessation of galactorrhea and ovulation in seven and conception in five. Bromocriptine 15-28 prolactin Homo sapiens 83-86 1002821-0 1976 Growth hormone and prolactin release in acromegalic patients following metergoline administration. Metergoline 71-82 prolactin Homo sapiens 19-28 1002821-1 1976 In six acromegalite patients oral administration of 4 mg of metergoline, an antiserotonin agent, produced a fall in plasma growth hormone (GH) and prolactin (PRL) concentrations. Metergoline 60-71 prolactin Homo sapiens 147-156 1036612-2 1976 On the basis of a reassessment of the aetiopathogenetic problem and the neuroendocrine implications, the therapeutic effectiveness of a prolactin inhibitor, 2-alpha-Br-ergocryptine (CB 154), in Parkinson"s disease is assessed. 2-alpha-br-ergocryptine 157-180 prolactin Homo sapiens 136-145 1036613-0 1976 Treatment of fibrocystic disease of the breast with a prolactin inhibitor: 2-Br-alpha-ergocryptine (CB-154). Bromocriptine 100-106 prolactin Homo sapiens 54-63 1036612-2 1976 On the basis of a reassessment of the aetiopathogenetic problem and the neuroendocrine implications, the therapeutic effectiveness of a prolactin inhibitor, 2-alpha-Br-ergocryptine (CB 154), in Parkinson"s disease is assessed. Bromocriptine 182-188 prolactin Homo sapiens 136-145 1026161-0 1976 [Ether and penthrane on LH and prolactin (author"s transl)]. Ether 1-6 prolactin Homo sapiens 31-40 1009676-5 1976 A direct relationship between oestradiol and prolactin levels was noted, although there was no correlation between prolactin on the one hand and FSH, LH and progesterone on the other. Estradiol 30-40 prolactin Homo sapiens 45-54 1026161-0 1976 [Ether and penthrane on LH and prolactin (author"s transl)]. Methoxyflurane 11-20 prolactin Homo sapiens 31-40 1026161-1 1976 The effects of long-term anesthesia with methoxyflurane on plasma LH and prolactin concentrations were compared to those induced by exposure to ether. Methoxyflurane 41-55 prolactin Homo sapiens 73-82 1026161-2 1976 Methoxyflurane significantly decreased prolactin levels and had a slight effect of LH, whereas ether produced an important release of prolactin without affecting LH. Methoxyflurane 0-14 prolactin Homo sapiens 39-48 1026161-2 1976 Methoxyflurane significantly decreased prolactin levels and had a slight effect of LH, whereas ether produced an important release of prolactin without affecting LH. Ether 95-100 prolactin Homo sapiens 134-143 1009679-0 1976 Effect of metroclopramide on serum prolactin levels in humans. metroclopramide 10-25 prolactin Homo sapiens 35-44 1009679-1 1976 The effect of acute and chronic administration of metoclopramide on serum prolactin levels in normal subjects was studied. Metoclopramide 50-64 prolactin Homo sapiens 74-83 1009679-5 1976 Prolactin levels were markedly elevated during a 5 day course of treatment with metoclopramide in six subjects. Metoclopramide 80-94 prolactin Homo sapiens 0-9 62213-0 1976 Dopamine-induced inhibition of prolactin secretion in amenorrhea-galactorrhea. Dopamine 0-8 prolactin Homo sapiens 31-40 1024568-0 1976 [Effects of the treatment with an antiestrogen(tamoxifen) and levodopa on the secretion of prolactin in patients affected by breast cancer]. Tamoxifen 47-56 prolactin Homo sapiens 91-100 1024568-0 1976 [Effects of the treatment with an antiestrogen(tamoxifen) and levodopa on the secretion of prolactin in patients affected by breast cancer]. Levodopa 62-70 prolactin Homo sapiens 91-100 971016-4 1976 The only other, but most striking abnormality, was an excessively high serum prolactin level, which was partially suppressed with levodopa. Levodopa 130-138 prolactin Homo sapiens 77-86 970353-3 1976 Likewise, the weekly treatment of dark-exposed hamsters with subcutaneous melatonin-beeswax pellets led to regeneration of the peripheral reproductive organs and an increase in pituitary LH and prolactin levels. Melatonin 74-83 prolactin Homo sapiens 194-203 992299-8 1976 The high levels of PRL in the maternal and the newborn serum may be caused by the high concentrations of estrogen or progesterone. Progesterone 117-129 prolactin Homo sapiens 19-22 977726-0 1976 Endogenous estrogen modulates phenothiazine stimulated prolactin secretion. phenothiazine 30-43 prolactin Homo sapiens 55-64 824297-2 1976 The mean PRL response to 100 mug of methyl-TRH was greater (P less than 0.025) than the PRL response to 500 mug of TRH at 10 min and at all sampling times from 30 to 240 min after administration of the releasing factors. methyl-trh 36-46 prolactin Homo sapiens 9-12 824297-3 1976 The mean peak PRL (at 10 min), maximum deltaPRL, and integrated PRL response area were greater (P less than 0.025) after administration of methyl-TRH than after TRH. methyl-trh 139-149 prolactin Homo sapiens 14-17 824297-3 1976 The mean peak PRL (at 10 min), maximum deltaPRL, and integrated PRL response area were greater (P less than 0.025) after administration of methyl-TRH than after TRH. methyl-trh 139-149 prolactin Homo sapiens 44-47 824297-4 1976 The PRL response to methyl-TRH was greater (P less than 0.005) for the 12 women than for the 20 men in this study. methyl-trh 20-30 prolactin Homo sapiens 4-7 824297-6 1976 Following administration of methyl-TRH, the peak PRL was correlated with the peak TSH (r=0.43, P less than 0.05), the maximum deltaPRL was correlated with the maximum deltaTSH (r=0.43, P less than 0.05), and integrated PRL response area was correlated with the integrated TSH response area (r=0.44, P less than 0.05). methyl-trh 28-38 prolactin Homo sapiens 49-52 824297-6 1976 Following administration of methyl-TRH, the peak PRL was correlated with the peak TSH (r=0.43, P less than 0.05), the maximum deltaPRL was correlated with the maximum deltaTSH (r=0.43, P less than 0.05), and integrated PRL response area was correlated with the integrated TSH response area (r=0.44, P less than 0.05). methyl-trh 28-38 prolactin Homo sapiens 131-134 961756-0 1976 The effect of L-dopa and chlorpromazine on prolactin and growth hormone secretion in normal women. Chlorpromazine 25-39 prolactin Homo sapiens 43-52 961756-1 1976 The time course of simultaneous changes in prolactin (PRL) and growth hormone secretion in response to a single dose of L-dopa and chlorpromazine was determined in normal women. Levodopa 120-126 prolactin Homo sapiens 43-52 961756-1 1976 The time course of simultaneous changes in prolactin (PRL) and growth hormone secretion in response to a single dose of L-dopa and chlorpromazine was determined in normal women. Levodopa 120-126 prolactin Homo sapiens 54-57 961756-1 1976 The time course of simultaneous changes in prolactin (PRL) and growth hormone secretion in response to a single dose of L-dopa and chlorpromazine was determined in normal women. Chlorpromazine 131-145 prolactin Homo sapiens 43-52 961756-1 1976 The time course of simultaneous changes in prolactin (PRL) and growth hormone secretion in response to a single dose of L-dopa and chlorpromazine was determined in normal women. Chlorpromazine 131-145 prolactin Homo sapiens 54-57 12259440-0 1976 Endogenous estrogen modulates phenothiazine stimulated prolactin secretion. phenothiazine 30-43 prolactin Homo sapiens 55-64 9662-0 1976 Growth hormone and prolactin response to methylphenidate. Methylphenidate 41-56 prolactin Homo sapiens 19-28 977726-2 1976 To evaluate the possible effect of endogenous fluctuations in serum estrogen on the regulation of prolactin secretion, the authors determined phenothiazine stimulated prolactin secretion in 12 women in the early follicular phase of the menstrual cycle when estrogen levels were low (mean +/- SE E1 + E2 = 82 +/- 7 pg/ml) and compared it to the response during the late follicular phase when estrogen levels were higher (mean E1 + E2 = 320 +/- 63 pg/ml). phenothiazine 142-155 prolactin Homo sapiens 167-176 961756-3 1976 The PRL peak following chlorpromazine occurred at the same time as the nadir of PRL after L-dopa (3.5 hours). Chlorpromazine 23-37 prolactin Homo sapiens 4-7 961756-3 1976 The PRL peak following chlorpromazine occurred at the same time as the nadir of PRL after L-dopa (3.5 hours). Levodopa 90-96 prolactin Homo sapiens 80-83 977726-4 1976 The integrated prolactin response following phenothiazine administration was significantly higher at mid-cycle (402 +/- 46 ng-hr/ml) than in the early follicular phase (317 +/0 46 ng-hr/ml, P less than .02). phenothiazine 44-57 prolactin Homo sapiens 15-24 961756-4 1976 The quantity of PRL release inhibited by L-dopa equaled the amount of PRL secretion during the period of rebound, suggesting L-dopa inhibits PRL release, but not synthesis, by the pituitary. Levodopa 41-47 prolactin Homo sapiens 16-19 977731-2 1976 A group of 6 normal men was treated for 4 consecutive days, on separate periods, with Sulpiride which is known to raise plasma prolactin (PRL) concentration. Sulpiride 86-95 prolactin Homo sapiens 127-136 961756-4 1976 The quantity of PRL release inhibited by L-dopa equaled the amount of PRL secretion during the period of rebound, suggesting L-dopa inhibits PRL release, but not synthesis, by the pituitary. Levodopa 125-131 prolactin Homo sapiens 16-19 977731-2 1976 A group of 6 normal men was treated for 4 consecutive days, on separate periods, with Sulpiride which is known to raise plasma prolactin (PRL) concentration. Sulpiride 86-95 prolactin Homo sapiens 138-141 977731-7 1976 These data demonstrate the interference of increased levels of PRL in the metabolism of testosterone into the active DHT form by 5alpha-reductase. Testosterone 88-100 prolactin Homo sapiens 63-66 977731-7 1976 These data demonstrate the interference of increased levels of PRL in the metabolism of testosterone into the active DHT form by 5alpha-reductase. Dihydrotestosterone 117-120 prolactin Homo sapiens 63-66 788774-6 1976 Bromocriptine effectively reduced serum prolactin and prevented lactation; stilboestrol increased serum prolactin and partially suppressed lactation; clomiphene citrate and testosterone propionate both lowered serum prolactin levels and partially suppressed lactation. Bromocriptine 0-13 prolactin Homo sapiens 40-49 788774-6 1976 Bromocriptine effectively reduced serum prolactin and prevented lactation; stilboestrol increased serum prolactin and partially suppressed lactation; clomiphene citrate and testosterone propionate both lowered serum prolactin levels and partially suppressed lactation. desacetyluvaricin 75-87 prolactin Homo sapiens 104-113 825329-14 1976 Treatment with bromocriptine lowers prolactin concentrations and rapidly repairs the reproductive defect. Bromocriptine 15-28 prolactin Homo sapiens 36-45 788774-6 1976 Bromocriptine effectively reduced serum prolactin and prevented lactation; stilboestrol increased serum prolactin and partially suppressed lactation; clomiphene citrate and testosterone propionate both lowered serum prolactin levels and partially suppressed lactation. desacetyluvaricin 75-87 prolactin Homo sapiens 104-113 991434-3 1976 Two subjects had elevated serum levels of prolactin, and in one of these prolactin suppression with bromoergocryptine failed to influence either somatomedin levels or urinary excretion of nitrogen, hydroxyproline and calcium. Bromocriptine 100-117 prolactin Homo sapiens 73-82 991435-0 1976 Effect of two serotonin antagonists on prolactin and thyrotrophin secretion in man. Serotonin 14-23 prolactin Homo sapiens 39-48 821964-1 1976 Prolactin is a salt-retaining hormone in fish, and a similar role is frequently postulated in man, althrough clincial observation does not generally support this. Salts 15-19 prolactin Homo sapiens 0-9 821964-2 1976 The effect of TRH induced acute elevation of endogenous serum prolactin on renal water, sodium, potassium and total solute excretion was investigated during metabolic balance conditions and during escape form mineralocorticoid excess in 8 normal volunteers (6 males, 2 females)... Water 81-86 prolactin Homo sapiens 62-71 956350-1 1976 Dopamine, infused at a rate of 4 mug/kg/min for 3-4 h unaccompanied by any significant changes in cardiovascular dynamics, induced a prompt and sustained suppression of circulating prolactin (PRL) levels in normal men and women as well as in patients with hyperprolactinemia. Dopamine 0-8 prolactin Homo sapiens 181-190 821964-2 1976 The effect of TRH induced acute elevation of endogenous serum prolactin on renal water, sodium, potassium and total solute excretion was investigated during metabolic balance conditions and during escape form mineralocorticoid excess in 8 normal volunteers (6 males, 2 females)... Sodium 88-94 prolactin Homo sapiens 62-71 821964-2 1976 The effect of TRH induced acute elevation of endogenous serum prolactin on renal water, sodium, potassium and total solute excretion was investigated during metabolic balance conditions and during escape form mineralocorticoid excess in 8 normal volunteers (6 males, 2 females)... Potassium 96-105 prolactin Homo sapiens 62-71 821965-2 1976 The peak response of serum PRL and the maximum increment of serum PRL (max deltaPRL) were greater (P less than 0.0005) after the administration of metoclopramide (deltaPRL 24.1 +/- 1.5 (SE) ng/ml) than after either TRH (14.9 +/- 1.5 ng/ml) or chlorpromazine (7.0 +/- 2.1 ng/ml). Metoclopramide 147-161 prolactin Homo sapiens 27-30 821965-2 1976 The peak response of serum PRL and the maximum increment of serum PRL (max deltaPRL) were greater (P less than 0.0005) after the administration of metoclopramide (deltaPRL 24.1 +/- 1.5 (SE) ng/ml) than after either TRH (14.9 +/- 1.5 ng/ml) or chlorpromazine (7.0 +/- 2.1 ng/ml). Metoclopramide 147-161 prolactin Homo sapiens 66-69 821965-2 1976 The peak response of serum PRL and the maximum increment of serum PRL (max deltaPRL) were greater (P less than 0.0005) after the administration of metoclopramide (deltaPRL 24.1 +/- 1.5 (SE) ng/ml) than after either TRH (14.9 +/- 1.5 ng/ml) or chlorpromazine (7.0 +/- 2.1 ng/ml). Chlorpromazine 243-257 prolactin Homo sapiens 66-69 821965-5 1976 Metoclopramide may be useful for dynamic testing of PRL release. Metoclopramide 0-14 prolactin Homo sapiens 52-55 967066-0 1976 Cortisol in physiological concentrations acts within minutes to modify effects of prolactin and growth hormone on prostaglandin secretion: importance of effect in modulating cellular responses to calcium and cyclic nucleotides. Prostaglandins 114-127 prolactin Homo sapiens 82-91 184342-15 1976 The experimental ergot derivative 2-Brom-alpha-ergocryptine is a potent suppressor of prolactin secretion from the anterior pituitary. 2-brom-alpha-ergocryptine 34-59 prolactin Homo sapiens 86-95 1021921-1 1976 Zones of somatotropin, prolactin and subunits of adenohypophysis glycoproteid hormones are identified in dodecyl sulphate-polyacrylamide gel after electrophoretic separation of these hormones in the tris-acetate system; The method is suitable for a quantitative determination of somatotropin and prolactin in adenohypophysis. dodecyl sulfate 105-121 prolactin Homo sapiens 23-32 1021921-1 1976 Zones of somatotropin, prolactin and subunits of adenohypophysis glycoproteid hormones are identified in dodecyl sulphate-polyacrylamide gel after electrophoretic separation of these hormones in the tris-acetate system; The method is suitable for a quantitative determination of somatotropin and prolactin in adenohypophysis. dodecyl sulfate 105-121 prolactin Homo sapiens 296-305 1021921-1 1976 Zones of somatotropin, prolactin and subunits of adenohypophysis glycoproteid hormones are identified in dodecyl sulphate-polyacrylamide gel after electrophoretic separation of these hormones in the tris-acetate system; The method is suitable for a quantitative determination of somatotropin and prolactin in adenohypophysis. polyacrylamide 122-136 prolactin Homo sapiens 23-32 1021921-1 1976 Zones of somatotropin, prolactin and subunits of adenohypophysis glycoproteid hormones are identified in dodecyl sulphate-polyacrylamide gel after electrophoretic separation of these hormones in the tris-acetate system; The method is suitable for a quantitative determination of somatotropin and prolactin in adenohypophysis. Tris acetate 199-211 prolactin Homo sapiens 23-32 954640-0 1976 Physiological cortisol levels block the inhibition of vascular reactivity produced by prolactin. Hydrocortisone 14-22 prolactin Homo sapiens 86-95 950367-0 1976 Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients. Ergolines 24-32 prolactin Homo sapiens 81-90 950367-0 1976 Inhibitory effect of an ergoline derivative, methergoline, on growth hormone and prolactin levels in acromegalic patients. Metergoline 45-57 prolactin Homo sapiens 81-90 965879-5 1976 After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide. Furosemide 24-33 prolactin Homo sapiens 62-71 965879-5 1976 After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide. Furosemide 24-33 prolactin Homo sapiens 194-203 965879-5 1976 After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide. Sodium 165-171 prolactin Homo sapiens 194-203 965879-5 1976 After the first dose of frusemide in study A, the mean plasma prolactin concentration correlated negatively with the urinary Na and K excretion over 5 h. After 38 h sodium depletion, the plasma prolactin concentration correlated positively with urinary Na excretion following the second dose of frusemide. Furosemide 295-304 prolactin Homo sapiens 194-203 965879-6 1976 In study B, after Na depletion for 14 h the plasma prolactin concentration of 08.00 h on Day 2 had a positive correlation with the 24 h urinary log10 Na:K ratio following placebo administration and had negative correlations with the true urinary log10 Na:K ratio following spironolactone and prorenoate potassium administration. Spironolactone 273-287 prolactin Homo sapiens 51-60 965879-6 1976 In study B, after Na depletion for 14 h the plasma prolactin concentration of 08.00 h on Day 2 had a positive correlation with the 24 h urinary log10 Na:K ratio following placebo administration and had negative correlations with the true urinary log10 Na:K ratio following spironolactone and prorenoate potassium administration. prorenoate potassium 292-312 prolactin Homo sapiens 51-60 952954-3 1976 Three methionine-modified derivatives of ovine prolactin have been prepared: two by oxidation of the methionines by H2O2 to sulfoxide (partial and complete), and the third by complete alkylation of the metionines with iodoacetic acid to the carboxymethyl sulfonium salts. Methionine 6-16 prolactin Homo sapiens 47-56 952954-3 1976 Three methionine-modified derivatives of ovine prolactin have been prepared: two by oxidation of the methionines by H2O2 to sulfoxide (partial and complete), and the third by complete alkylation of the metionines with iodoacetic acid to the carboxymethyl sulfonium salts. Methionine 101-112 prolactin Homo sapiens 47-56 952954-3 1976 Three methionine-modified derivatives of ovine prolactin have been prepared: two by oxidation of the methionines by H2O2 to sulfoxide (partial and complete), and the third by complete alkylation of the metionines with iodoacetic acid to the carboxymethyl sulfonium salts. Hydrogen Peroxide 116-120 prolactin Homo sapiens 47-56 952954-3 1976 Three methionine-modified derivatives of ovine prolactin have been prepared: two by oxidation of the methionines by H2O2 to sulfoxide (partial and complete), and the third by complete alkylation of the metionines with iodoacetic acid to the carboxymethyl sulfonium salts. sulfoxide 124-133 prolactin Homo sapiens 47-56 952954-3 1976 Three methionine-modified derivatives of ovine prolactin have been prepared: two by oxidation of the methionines by H2O2 to sulfoxide (partial and complete), and the third by complete alkylation of the metionines with iodoacetic acid to the carboxymethyl sulfonium salts. metionines 202-212 prolactin Homo sapiens 47-56 952954-3 1976 Three methionine-modified derivatives of ovine prolactin have been prepared: two by oxidation of the methionines by H2O2 to sulfoxide (partial and complete), and the third by complete alkylation of the metionines with iodoacetic acid to the carboxymethyl sulfonium salts. Iodoacetic Acid 218-233 prolactin Homo sapiens 47-56 990059-0 1976 The influence of the prolactin inhibitor bromocriptin (CB 154) on human luteal function in vivo. Bromocriptine 41-53 prolactin Homo sapiens 21-30 990059-0 1976 The influence of the prolactin inhibitor bromocriptin (CB 154) on human luteal function in vivo. Bromocriptine 55-61 prolactin Homo sapiens 21-30 949296-0 1976 Effect of ethyl alcohol on lonic calcium and prolactin in man. Ethanol 10-23 prolactin Homo sapiens 45-54 949296-5 1976 Even though two-fold elevations in plasma prolactin have been described in men with chronic alcoholism, no significant changes in plasma prolactin occurred during acute alcohol ingestion. Alcohols 92-99 prolactin Homo sapiens 42-51 7571-0 1976 Prolactin secretion by metoclopramide in man. Metoclopramide 23-37 prolactin Homo sapiens 0-9 7571-1 1976 Six men and nine women were given intravenous injections of 2.5 mg of metoclopramide to assess its potential as a stimulus to prolactin release. Metoclopramide 70-84 prolactin Homo sapiens 126-135 7571-2 1976 Following the administration of metoclopramide, there was prompt increase in serum prolactin to a peak response of 38.2 +/- 3.9 ng/ml in men and 103 +/- 10.2 ng/ml in women. Metoclopramide 32-46 prolactin Homo sapiens 83-92 7571-3 1976 The prolactin response to metoclopramide in men was compared with the response to 400 mug of TRH in 10 men. Metoclopramide 26-40 prolactin Homo sapiens 4-13 7571-5 1976 Pretreatment with 500 mg of L-dopa suppressed the prolactin response to metoclopramide in 6 men to a mean response of 16.3 +/- 4.3 ng/ml. Levodopa 28-34 prolactin Homo sapiens 50-59 7571-5 1976 Pretreatment with 500 mg of L-dopa suppressed the prolactin response to metoclopramide in 6 men to a mean response of 16.3 +/- 4.3 ng/ml. Metoclopramide 72-86 prolactin Homo sapiens 50-59 7571-6 1976 We have concluded that metoclopramide is a safe, reliable, and potent stimulus of prolactin secretion and exerts this effect by blocking dopamine receptors in the hypothalamus and decreasing prolactin inhibiting factor. Metoclopramide 23-37 prolactin Homo sapiens 82-91 7571-6 1976 We have concluded that metoclopramide is a safe, reliable, and potent stimulus of prolactin secretion and exerts this effect by blocking dopamine receptors in the hypothalamus and decreasing prolactin inhibiting factor. Metoclopramide 23-37 prolactin Homo sapiens 191-200 940657-0 1976 Effect of ergonovine on prolactin secretion and milk let-down. Ergonovine 10-20 prolactin Homo sapiens 24-33 940657-1 1976 The effect of ergonovine maleate on prolactin secretion and lactation was determined in 10 puerperal women. Ergonovine 14-32 prolactin Homo sapiens 36-45 940657-2 1976 Serum prolactin concentration measured by radioimmunoassay resulted in 537.2 +/- 45.9 ng/ml (M +/- SE) before the oral administration of 0.6 mg ergonovine maleate, and 89.7 +/- 25.6 ng/ml after 7 days of therapy. Selenium 99-101 prolactin Homo sapiens 6-15 940657-2 1976 Serum prolactin concentration measured by radioimmunoassay resulted in 537.2 +/- 45.9 ng/ml (M +/- SE) before the oral administration of 0.6 mg ergonovine maleate, and 89.7 +/- 25.6 ng/ml after 7 days of therapy. Ergonovine 144-162 prolactin Homo sapiens 6-15 940657-4 1976 In 2 additional patients it was also demonstrated that the simultaneous administration of ergonovine by oral and intravenous routes potentiates the suppressive effect on prolactin secretion. Ergonovine 90-100 prolactin Homo sapiens 170-179 940657-6 1976 This study shows that ergonovine maleate interferes with prolactin secretion, and may decrease milk production. Ergonovine 22-40 prolactin Homo sapiens 57-66 967066-4 1976 We propose that there is a basal level of PG synthesis unaffected by hormones but that above this level PG synthesis is regulated by the interplay between physiological levels of cortisol, prolactin, growth hormone and thyroid hormones. Prostaglandins 104-106 prolactin Homo sapiens 189-198 967066-5 1976 For the most part prolactin seems to stimulate PG synthesis and cortisol to inhibit it: cortisol has, however, no inhibitory effect on basal PG synthesis. Prostaglandins 47-49 prolactin Homo sapiens 18-27 967066-6 1976 In reducing prolactin-stimulated PG synthesis cortisol is 1000-2000 times more potent than indomethacin on a molar basis. Prostaglandins 33-35 prolactin Homo sapiens 12-21 967066-6 1976 In reducing prolactin-stimulated PG synthesis cortisol is 1000-2000 times more potent than indomethacin on a molar basis. Indomethacin 91-103 prolactin Homo sapiens 12-21 1000028-1 1976 The plasma PRL repsonse to synthetic TRH, L-dopa and metaclopramide was evaluated in patients with thyrotoxicosis. Metoclopramide 53-67 prolactin Homo sapiens 11-14 952954-3 1976 Three methionine-modified derivatives of ovine prolactin have been prepared: two by oxidation of the methionines by H2O2 to sulfoxide (partial and complete), and the third by complete alkylation of the metionines with iodoacetic acid to the carboxymethyl sulfonium salts. carboxymethyl sulfonium salts 241-270 prolactin Homo sapiens 47-56 952954-5 1976 Partially oxidized prolactin, having four of its seven methionines oxidized, was very similar to the native hormone. Methionine 55-66 prolactin Homo sapiens 19-28 952954-6 1976 The unmodified methionines in partially oxidized prolactin were found to be the residues at positions 36, 81 and 132. Methionine 15-26 prolactin Homo sapiens 49-58 952954-7 1976 The prolactin derivatives in which all the methionines had been oxidized, or alkylated, showed major changes in all parameters examined. Methionine 43-54 prolactin Homo sapiens 4-13 952954-8 1976 In addition, circular dichroism spectra indicated that complete modification of all the methionines in prolactin exposes the normally buried tryptophans. Methionine 88-99 prolactin Homo sapiens 103-112 952954-8 1976 In addition, circular dichroism spectra indicated that complete modification of all the methionines in prolactin exposes the normally buried tryptophans. Tryptophan 141-152 prolactin Homo sapiens 103-112 971488-7 1976 In addition, prolactin induced morphological changes in cells including the development of distended endoplasmic reticulum, large microvilli, and the deposition of glycogen granules. Glycogen 164-172 prolactin Homo sapiens 13-22 820705-0 1976 The effect of acetylsalicylic acid on TSH and PRL secretion after TRH stimulation in the human. Aspirin 14-34 prolactin Homo sapiens 46-49 947938-1 1976 The effect of prolactin suppression by bromocriptine. Bromocriptine 39-52 prolactin Homo sapiens 14-23 947938-5 1976 Although the PRL levels of the hyperprolactinemic patients were greatly suppressed by bromocriptine, the T-dT levels showed no systematic change. Bromocriptine 86-99 prolactin Homo sapiens 13-16 988468-4 1976 Reduction of serum prolactin levels to normal, by removal of a prolactin-secreting tumour or by treatment with bromoergocryptine, results in a restoration of normal menstrual cycles and fertility. Bromocriptine 111-128 prolactin Homo sapiens 19-28 180740-1 1976 The study describes the effects of ACTH, prolactin and other protein hormones on the synthesis and secretion of steroid hormones by tissue from a feminising adrenocortical carcinoma removed from a post-menopausal female. Steroids 112-128 prolactin Homo sapiens 41-50 1000028-0 1976 Plasma prolactin response to L-dopa TRH and metaclopramide in thyrotoxicosis. Levodopa 29-35 prolactin Homo sapiens 7-16 1000028-0 1976 Plasma prolactin response to L-dopa TRH and metaclopramide in thyrotoxicosis. Metoclopramide 44-58 prolactin Homo sapiens 7-16 986336-11 1976 Regardless of the cause of hyperprolactinemia in all patients hPRL-levels were lowered significantly by 2.5 mg CB 154 within 4 hours. Bromocriptine 111-117 prolactin Homo sapiens 62-66 986336-13 1976 Longtime suppression of hPRL by CB 154 normalized LH- and FSH- concentrations in serum and its response to LHRH. Bromocriptine 32-38 prolactin Homo sapiens 24-28 986336-13 1976 Longtime suppression of hPRL by CB 154 normalized LH- and FSH- concentrations in serum and its response to LHRH. Luteinizing Hormone 50-52 prolactin Homo sapiens 24-28 1000028-4 1976 This data suggests that, in thyrotoxicosis, PRl response to TRH only is impaired, but PRL can be suppressed by L-dopa or released by metaclopramide notwithstanding the elevated values of thyroid hormone levels. Levodopa 111-117 prolactin Homo sapiens 86-89 1000028-4 1976 This data suggests that, in thyrotoxicosis, PRl response to TRH only is impaired, but PRL can be suppressed by L-dopa or released by metaclopramide notwithstanding the elevated values of thyroid hormone levels. Metoclopramide 133-147 prolactin Homo sapiens 86-89 1027492-3 1976 Prolactin was extracted by acid aqueous acetone and was subsequently purified of extract by fractionation with acetone and NaCl and by isoelectric precipitation. Acetone 40-47 prolactin Homo sapiens 0-9 934580-9 1976 It is suggested that improvement of galactorrhea and resumption of menses in some patients with normal hPRL values are the result of increased serum E2 levels and may be due to a direct action of bromo-ergocryptine on the ovary. Bromocriptine 196-214 prolactin Homo sapiens 103-107 934580-10 1976 Bromo-ergocryptine may also be effective in treatment of amenorrhea, unassociated with galactorrhea or elevated hPRL levels. Bromocriptine 0-18 prolactin Homo sapiens 112-116 1027492-3 1976 Prolactin was extracted by acid aqueous acetone and was subsequently purified of extract by fractionation with acetone and NaCl and by isoelectric precipitation. Acetone 111-118 prolactin Homo sapiens 0-9 1027492-3 1976 Prolactin was extracted by acid aqueous acetone and was subsequently purified of extract by fractionation with acetone and NaCl and by isoelectric precipitation. Sodium Chloride 123-127 prolactin Homo sapiens 0-9 984083-2 1976 Circulating PRL levels in response to intravenous infusion of 17 beta-estradiol (E2), at a rate of 50 mug per hour for 4 hours, were studied in 10 subjects, and a chronic administration of ethinyl estradiol (EE) at a dose of 400 mug per day, for 1 week, was evaluated in five hypogonadal subjects. Estradiol 62-79 prolactin Homo sapiens 12-15 9604-6 1976 A brisk increase in plasma prolactin levels occurred in normal subjects during the administration of chlorpromazine and thyroid stimulating hormone releasing factor (TRH). Chlorpromazine 101-115 prolactin Homo sapiens 27-36 9604-8 1976 Basal plasma prolactin values were raised in most patients who were being treated with phenothiazines and were helpful diagnostically in patients with amenorrhoea, galactorrhoea, hypogonadism, cranio-pharyngioma, "non-functioning" pituitary tumours and acromegaly. Phenothiazines 87-101 prolactin Homo sapiens 13-22 9604-9 1976 In many of these disorders a significant reduction in the plasma prolactin concentration was observed following oral administration of bromocriptine. Bromocriptine 135-148 prolactin Homo sapiens 65-74 1016635-0 1976 [Effect of an anticholinergic drug, biperiden, on serum prolactin levels in humans]. Biperiden 36-45 prolactin Homo sapiens 56-65 777023-0 1976 Metoclopramide stimulates prolactin secretion in man. Metoclopramide 0-14 prolactin Homo sapiens 26-35 947942-4 1976 Since the tuberoinfundibular dopamine nerve terminals lie outside the blood brain barrier, this study suggests that these neurons are involved in prolactin but not in growth hormone or cortisol regulation. Dopamine 29-37 prolactin Homo sapiens 146-155 947942-5 1976 Findings are compatible with two alternate hypotheses--either that dopamine is a physiologic prolactin inhibiting factor (PIF) or that tuberoinfundibular dopamine neurons regulate the release of PIF. Dopamine 67-75 prolactin Homo sapiens 93-102 57506-7 1976 The relief of premenstrual symptoms by bromocriptine may be due to suppression of prolactin concentrations, which may be a major factor in premenstrual syndrome. Bromocriptine 39-52 prolactin Homo sapiens 82-91 131202-1 1976 Serum prolactin levels are significantly greater among hypertensive patients receiving reserpine as compared to levels six weeks after discontinuing the treatment (P less than .005). Reserpine 87-96 prolactin Homo sapiens 6-15 131202-2 1976 This association between regular, long-term reserpine use and greater prolactin levels may be clinically significant, since an increased incidence of breast cancer has been reported among hypertensive patients receiving reserpine. Reserpine 44-53 prolactin Homo sapiens 70-79 131202-2 1976 This association between regular, long-term reserpine use and greater prolactin levels may be clinically significant, since an increased incidence of breast cancer has been reported among hypertensive patients receiving reserpine. Reserpine 220-229 prolactin Homo sapiens 70-79 1268617-0 1976 Effects of methyldopa on prolactin and growth hormone. Methyldopa 11-21 prolactin Homo sapiens 25-34 1268617-1 1976 The effects of administration of methyldopa on serum prolactin and growth hormone (GH) concentrations in hypertensive patients were studied. Methyldopa 33-43 prolactin Homo sapiens 53-62 1268617-2 1976 Single doses of methyldopa (750 or 1000 mg) significantly increased serum prolactin levels, peak concentrations occurring four to six hours after drug administrations. Methyldopa 16-26 prolactin Homo sapiens 74-83 1268617-3 1976 Long-term methyldopa treatment was associated with threefold to fourfold increases in basal prolactin levels compared with those in normal subjects. Methyldopa 10-20 prolactin Homo sapiens 92-101 57445-0 1976 Breast and thyroid cancer and malignant melanoma promoted by alcohol-induced pituitary secretion of prolactin, T.S.H. Alcohols 61-68 prolactin Homo sapiens 100-109 57445-4 1976 A unifying hypothesis to explain these seemingly diverse associations suggests that alcohol stimulates anterior pituitary secretion of prolactin, thyroid-stimulating hormone (T.S.H. Alcohols 84-91 prolactin Homo sapiens 135-144 828474-2 1976 The following data were developed in this paper: --During the menstrual cycle, prolactin levels are more elevated during ovulatory and luteal phases than during follicular phase; --During pregnancy, prolactin levels progressively increase to reach their maximum at the end of gestation; --During lactation, prolactin levels increase for the two days following delivery, then progressively decrease; --Bromocryptine oral administration drastically reduces prolactin levels within the 24 hours as it inhibits the prolactin release normally induced by suckling. Bromocriptine 401-414 prolactin Homo sapiens 79-88 828474-2 1976 The following data were developed in this paper: --During the menstrual cycle, prolactin levels are more elevated during ovulatory and luteal phases than during follicular phase; --During pregnancy, prolactin levels progressively increase to reach their maximum at the end of gestation; --During lactation, prolactin levels increase for the two days following delivery, then progressively decrease; --Bromocryptine oral administration drastically reduces prolactin levels within the 24 hours as it inhibits the prolactin release normally induced by suckling. Bromocriptine 401-414 prolactin Homo sapiens 199-208 828474-2 1976 The following data were developed in this paper: --During the menstrual cycle, prolactin levels are more elevated during ovulatory and luteal phases than during follicular phase; --During pregnancy, prolactin levels progressively increase to reach their maximum at the end of gestation; --During lactation, prolactin levels increase for the two days following delivery, then progressively decrease; --Bromocryptine oral administration drastically reduces prolactin levels within the 24 hours as it inhibits the prolactin release normally induced by suckling. Bromocriptine 401-414 prolactin Homo sapiens 199-208 828474-2 1976 The following data were developed in this paper: --During the menstrual cycle, prolactin levels are more elevated during ovulatory and luteal phases than during follicular phase; --During pregnancy, prolactin levels progressively increase to reach their maximum at the end of gestation; --During lactation, prolactin levels increase for the two days following delivery, then progressively decrease; --Bromocryptine oral administration drastically reduces prolactin levels within the 24 hours as it inhibits the prolactin release normally induced by suckling. Bromocriptine 401-414 prolactin Homo sapiens 199-208 828474-2 1976 The following data were developed in this paper: --During the menstrual cycle, prolactin levels are more elevated during ovulatory and luteal phases than during follicular phase; --During pregnancy, prolactin levels progressively increase to reach their maximum at the end of gestation; --During lactation, prolactin levels increase for the two days following delivery, then progressively decrease; --Bromocryptine oral administration drastically reduces prolactin levels within the 24 hours as it inhibits the prolactin release normally induced by suckling. Bromocriptine 401-414 prolactin Homo sapiens 199-208 945033-6 1976 Treatment with bromergocryptine was associated with a lowering of serum prolactin, cessation of lactation in all, and return of ovulatory menses in 14 of 15 patients. Bromocriptine 15-31 prolactin Homo sapiens 72-81 1020916-5 1976 Administration of L-Dopa (500 mg orally) significantly suppressed the prolactin values in the 11 cases studied. Levodopa 18-24 prolactin Homo sapiens 70-79 1268149-0 1976 The influence of pyridoxine on prolactin secretion and milk production in women. Pyridoxine 17-27 prolactin Homo sapiens 31-40 56894-0 1976 Serum prolactin concentrations in women treated with chlormadinone acetate. Chlormadinone Acetate 53-74 prolactin Homo sapiens 6-15 1259521-4 1976 There was a lag between clinical response and dopamine blockade, as indicated by serum prolactin levels in most patients. Dopamine 46-54 prolactin Homo sapiens 87-96 1259521-6 1976 Serum prolactin levels tended to be higher with thioridazine than on equivalent doses of chlorpromazine or trifluoperazine hydrochloride. Thioridazine 48-60 prolactin Homo sapiens 6-15 1259521-6 1976 Serum prolactin levels tended to be higher with thioridazine than on equivalent doses of chlorpromazine or trifluoperazine hydrochloride. Chlorpromazine 89-103 prolactin Homo sapiens 6-15 1259521-6 1976 Serum prolactin levels tended to be higher with thioridazine than on equivalent doses of chlorpromazine or trifluoperazine hydrochloride. Trifluoperazine 107-136 prolactin Homo sapiens 6-15 1259521-8 1976 After cessation of phenothiazines, serum prolactin levels rapidly reverted to normal within 48 to 96 hours. Phenothiazines 19-33 prolactin Homo sapiens 41-50 2892-2 1976 We have studied the effect of chlorpromazine and PGF2alpha on the blood and amniotic fluid levels of prolactin over a 1-hour period of time in women who were in the 14th-20th week of gestation. Chlorpromazine 30-44 prolactin Homo sapiens 101-110 2892-2 1976 We have studied the effect of chlorpromazine and PGF2alpha on the blood and amniotic fluid levels of prolactin over a 1-hour period of time in women who were in the 14th-20th week of gestation. Dinoprost 49-58 prolactin Homo sapiens 101-110 2892-3 1976 Following intramuscular injection of chlorpromazine, maternal plasma prolactin rose 1.0- to 2.5-fold. Chlorpromazine 37-51 prolactin Homo sapiens 69-78 55749-0 1976 Letter: Dopamine-induced inhibition of prolactin and growth hormone secretion in acromegaly. Dopamine 8-16 prolactin Homo sapiens 39-48 55662-3 1976 There is evidence that catecholamines and indolamines directly affect prolactin release. indolamine 42-53 prolactin Homo sapiens 70-79 55662-3 1976 There is evidence that catecholamines and indolamines directly affect prolactin release. Catecholamines 23-37 prolactin Homo sapiens 70-79 943720-4 1976 3) Quantitative determination on PEG according to our own method showed that tumor size of these patients with abnormally high plasma prolactin level was larger than that of relatively lower plasma prolactin level. Polyethylene Glycols 33-36 prolactin Homo sapiens 134-143 943720-4 1976 3) Quantitative determination on PEG according to our own method showed that tumor size of these patients with abnormally high plasma prolactin level was larger than that of relatively lower plasma prolactin level. Polyethylene Glycols 33-36 prolactin Homo sapiens 198-207 945301-1 1976 Three women with the galactorrhea-amenorrhea syndrome and elevated prolactin concentrations experienced a return of regular ovulatory menses within 37-94 days after starting pyridoxine treatment (200-600 mg/day). Pyridoxine 174-184 prolactin Homo sapiens 67-76 945301-5 1976 In the three women effectively treated with pyridoxine, the galactorrhea returned, serum prolactin levels increased, and the menses ceased after discontinuing pyridoxine. Pyridoxine 44-54 prolactin Homo sapiens 89-98 945301-6 1976 These results imply that pyridoxine, by decreasing the excessive secretion of prolactin, may be useful in the long-term medical management of women with hyperprolactinemia and the galactorrhea-amenorrhea syndrome. Pyridoxine 25-35 prolactin Homo sapiens 78-87 777023-1 1976 Serum prolactin concentrations increased approximately 6-fold after oral or intravenous administration of 10 mg of metoclopramide to adult men. Metoclopramide 115-129 prolactin Homo sapiens 6-15 777023-2 1976 Prolactin remained significantly elevated up to 9 h after oral metoclopramide and for at least 2 h after iv metoclopramide. Metoclopramide 63-77 prolactin Homo sapiens 0-9 55535-1 1976 Prolactin interferes with the function of the corpus luteum, as was demonstrated by repeatedly finding a short luteal phase in the ovulatory cycles of two hyperprolactinaemic women after prolactin supression by bromocriptine had been discontinued. Bromocriptine 211-224 prolactin Homo sapiens 0-9 777023-2 1976 Prolactin remained significantly elevated up to 9 h after oral metoclopramide and for at least 2 h after iv metoclopramide. Metoclopramide 108-122 prolactin Homo sapiens 0-9 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Levodopa 26-32 prolactin Homo sapiens 76-85 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Levodopa 26-32 prolactin Homo sapiens 220-229 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Metoclopramide 53-67 prolactin Homo sapiens 76-85 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Metoclopramide 53-67 prolactin Homo sapiens 220-229 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Metoclopramide 142-156 prolactin Homo sapiens 76-85 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Metoclopramide 142-156 prolactin Homo sapiens 220-229 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Dopamine 176-184 prolactin Homo sapiens 76-85 777023-4 1976 Pre-treatment with 500 mg L-dopa inhibited the early metoclopramide-induced prolactin increase, which is consistent with the possibility that metoclopramide acts by inhibiting dopamine-mediated hypothalamic secretion of prolactin inhibitory factor. Dopamine 176-184 prolactin Homo sapiens 220-229 1247048-0 1976 Effect of clomiphene citrate on serum prolactin in infertile women with ovarian dysfunction. Clomiphene 10-28 prolactin Homo sapiens 38-47 1247048-8 1976 The serum PRL levels were normal during the control cycle in five of the patients who ovulated with Clomid and high in four patients who failed to ovulate. Clomiphene 100-106 prolactin Homo sapiens 10-13 1247048-9 1976 Although serum PRL levels were not significantly changed by Clomid in the patients who ovulated with the drug, they were markedly decreased during and immediately after Clomid treatment in patients who failed to ovulate with Clomid. Clomiphene 169-175 prolactin Homo sapiens 15-18 1247048-9 1976 Although serum PRL levels were not significantly changed by Clomid in the patients who ovulated with the drug, they were markedly decreased during and immediately after Clomid treatment in patients who failed to ovulate with Clomid. Clomiphene 169-175 prolactin Homo sapiens 15-18 777023-5 1976 As a potent stimulus of prolactin release, metoclopramide may be useful in clinical investigation of hypothalamic-pituitary function. Metoclopramide 43-57 prolactin Homo sapiens 24-33 819453-5 1976 During bromocriptine treatment, the raised PRL levels decreased in all cases, but levels over 30 mug/l remained in 3 patients, one of whom turned out to have a pituitary tumor. Bromocriptine 7-20 prolactin Homo sapiens 43-46 819453-6 1976 Prolactin responses to TRH were markedly inhibited in normoprolactinemic patients by the dose of bromocriptine used. Bromocriptine 97-110 prolactin Homo sapiens 0-9 174362-0 1976 Suppressive effect of L-dopa on human prolactin release during sleep. Levodopa 22-28 prolactin Homo sapiens 38-47 819453-7 1976 The mean maximal net increase of PRL was 2.0 +/- 0.9 mug/l in normoprolactinemic patients and 11.0 +/- 8.1 mug/l in hyperprolactinemic patients taking bromocriptine. Bromocriptine 151-164 prolactin Homo sapiens 33-36 819453-8 1976 After TRH stimulation during bromocriptine, the peak PRL levels in hyperprolactinemic patients were higher (32.7 +/- 10.5 mug/l) than in normoprolactinemic patients (7.2 +/- 1.5 mug/l). Bromocriptine 29-42 prolactin Homo sapiens 53-56 1249179-0 1976 Prolactin-related testosterone secretion in normal adult men. Testosterone 18-30 prolactin Homo sapiens 0-9 13627-0 1976 Control of prolactin secretion by the hypothalamic catecholamines. Catecholamines 51-65 prolactin Homo sapiens 11-20 13627-4 1976 Pharmacological agents such as apomorphine and many of the ergot alkaloids are very effective inhibitors of the secretion of prolactin. Apomorphine 31-42 prolactin Homo sapiens 125-134 13627-5 1976 Still other pharmacological agents such as DMPEA, alpha-methyldopa, reserpine, and certain of the phenothiazines are very effective in causing a stimulation of prolactin secretion. Dimethoxyphenylethylamine 43-48 prolactin Homo sapiens 160-169 13627-5 1976 Still other pharmacological agents such as DMPEA, alpha-methyldopa, reserpine, and certain of the phenothiazines are very effective in causing a stimulation of prolactin secretion. Methyldopa 50-66 prolactin Homo sapiens 160-169 13627-5 1976 Still other pharmacological agents such as DMPEA, alpha-methyldopa, reserpine, and certain of the phenothiazines are very effective in causing a stimulation of prolactin secretion. Reserpine 68-77 prolactin Homo sapiens 160-169 13627-5 1976 Still other pharmacological agents such as DMPEA, alpha-methyldopa, reserpine, and certain of the phenothiazines are very effective in causing a stimulation of prolactin secretion. Phenothiazines 98-112 prolactin Homo sapiens 160-169 828137-3 1976 This is at variance with the stimulatory action of intravenous tryptophan on human prolactin release. Tryptophan 63-73 prolactin Homo sapiens 83-92 1036731-1 1976 The possible role of endogenous prolactin (hPRL) in the regulation of renal water, Na and K excretion during sleep was tested in a group of 10 healthy female volunteers. Water 76-81 prolactin Homo sapiens 32-41 1036731-1 1976 The possible role of endogenous prolactin (hPRL) in the regulation of renal water, Na and K excretion during sleep was tested in a group of 10 healthy female volunteers. Water 76-81 prolactin Homo sapiens 43-47 183947-6 1976 Human GH and a single dose of 2mg PRL (but not lower doses) increased SB of PRL. Antimony 70-72 prolactin Homo sapiens 34-37 183947-6 1976 Human GH and a single dose of 2mg PRL (but not lower doses) increased SB of PRL. Antimony 70-72 prolactin Homo sapiens 76-79 1249179-1 1976 The sleep-related increase of plasma testosterone (T) in adult men appears to be related not only to plasma luteinizing hormone (LH) levels but to prolactin (PRL) levels as well, suggesting that PRL may have a stimulatory influence on Leydig cell function. Testosterone 37-49 prolactin Homo sapiens 147-156 1249179-1 1976 The sleep-related increase of plasma testosterone (T) in adult men appears to be related not only to plasma luteinizing hormone (LH) levels but to prolactin (PRL) levels as well, suggesting that PRL may have a stimulatory influence on Leydig cell function. Testosterone 37-49 prolactin Homo sapiens 158-161 1249179-1 1976 The sleep-related increase of plasma testosterone (T) in adult men appears to be related not only to plasma luteinizing hormone (LH) levels but to prolactin (PRL) levels as well, suggesting that PRL may have a stimulatory influence on Leydig cell function. Testosterone 37-49 prolactin Homo sapiens 195-198 1246056-0 1976 Ergoline congeners as potential inhibitors of prolactin release. Ergolines 0-8 prolactin Homo sapiens 46-55 1249179-6 1976 Mean PRL levels rose promptly and significantly in a dose-related manner in response to the haloperidol, which has strong dopamine blocking effects. Haloperidol 92-103 prolactin Homo sapiens 5-8 1246056-2 1976 In our attempts to elucidate the prolactin release inhibiting pharmacophore within the ergoline structure, we have prepared one indolealkylamine and several 2-aminotetralin derivatives. Ergolines 87-95 prolactin Homo sapiens 33-42 1249179-6 1976 Mean PRL levels rose promptly and significantly in a dose-related manner in response to the haloperidol, which has strong dopamine blocking effects. Dopamine 122-130 prolactin Homo sapiens 5-8 1246056-2 1976 In our attempts to elucidate the prolactin release inhibiting pharmacophore within the ergoline structure, we have prepared one indolealkylamine and several 2-aminotetralin derivatives. indolealkylamine 128-144 prolactin Homo sapiens 33-42 1249182-0 1976 Prolactin response to arginine in normal subjects and in patients with hyperthyroidism. Arginine 22-30 prolactin Homo sapiens 0-9 1246056-2 1976 In our attempts to elucidate the prolactin release inhibiting pharmacophore within the ergoline structure, we have prepared one indolealkylamine and several 2-aminotetralin derivatives. 2-aminotetralin 157-172 prolactin Homo sapiens 33-42 1249182-1 1976 The effect of arginine on serum prolactin concentrations was studied in 18 normal subjects and in 7 patients with hyperthyroidism in normal subjects, arginine infusion produced an increase of serum prolactin at least 6 ng/ml from the baseline, and the mean peak level (25.2 +/- 3.3 ng/ml, mean +/- SE) was significantly higher than the basal level (8.6 +/- 5.2 ng/ml, P less than 0.001). Arginine 14-22 prolactin Homo sapiens 32-41 1249182-1 1976 The effect of arginine on serum prolactin concentrations was studied in 18 normal subjects and in 7 patients with hyperthyroidism in normal subjects, arginine infusion produced an increase of serum prolactin at least 6 ng/ml from the baseline, and the mean peak level (25.2 +/- 3.3 ng/ml, mean +/- SE) was significantly higher than the basal level (8.6 +/- 5.2 ng/ml, P less than 0.001). Arginine 150-158 prolactin Homo sapiens 198-207 1249182-4 1976 In hyperthyroid patients, the increment of serum prolactin after arginine infusion at 30 min (3.9 +/- 1.5 ng/ml) was significantly lower than that of the normal controls which were matched by age and sex (17.1 +/- 4.4 ng/ml, P less than 0.05). Arginine 65-73 prolactin Homo sapiens 49-58 1246056-4 1976 One congener, 5,8-dihydroxy-2-dimethylaminotetralin, and the drug M-7 significantly inhibited prolactin secretion. 5,8-dihydroxy-2-dimethylaminotetralin 14-51 prolactin Homo sapiens 94-103 1249182-5 1976 After treatment when these patients were euthyroid, the increment of prolactin after arginine infusion at 30 min was significantly increased (16.3 +/- 4.3 ng/ml, P less than 0.05) and had reached the level of control subjects. Arginine 85-93 prolactin Homo sapiens 69-78 1249182-6 1976 These data indicate that the prolactin response to arginine in hyperthyroidism is diminished. Arginine 51-59 prolactin Homo sapiens 29-38 1249187-0 1976 Effect of sulpiride on serum prolactin levels in humans. Sulpiride 10-19 prolactin Homo sapiens 29-38 1249187-1 1976 The effect of acute and chronic administration of sulpiride sulphate on serum prolactin levels in humans was studied. sulpiride sulphate 50-68 prolactin Homo sapiens 78-87 1249187-6 1976 Sulpiride induced in all subjects a quick and marked increment of serum prolactin levels with peak values at 30 minutes. Sulpiride 0-9 prolactin Homo sapiens 72-81 1088302-1 1976 While the 5-HT precursors tryptophan and 1-5-HTP cause an increase in serum prolactin concentration, a combination of 1-5-HTP with a peripheral decarboxylase inhibitor was found to reduce the serum prolactin concentration. Tryptophan 26-36 prolactin Homo sapiens 76-85 959095-0 1976 The effect of clomipramine on prolactin levels--pilot studies. Clomipramine 14-26 prolactin Homo sapiens 30-39 959096-0 1976 Plasma prolactin concentrations in patients on clomipramine. Clomipramine 47-59 prolactin Homo sapiens 7-16 1088302-1 1976 While the 5-HT precursors tryptophan and 1-5-HTP cause an increase in serum prolactin concentration, a combination of 1-5-HTP with a peripheral decarboxylase inhibitor was found to reduce the serum prolactin concentration. 1-5-htp 41-48 prolactin Homo sapiens 76-85 1088302-1 1976 While the 5-HT precursors tryptophan and 1-5-HTP cause an increase in serum prolactin concentration, a combination of 1-5-HTP with a peripheral decarboxylase inhibitor was found to reduce the serum prolactin concentration. 1-5-htp 118-125 prolactin Homo sapiens 198-207 813152-0 1975 Spontaneous calcium action potentials in a clonal pituitary cell line and their relationship to prolactin secretion. Calcium 12-19 prolactin Homo sapiens 96-105 1030132-0 1976 [Effect of apomorphine on the secretion of prolactin in florid acromegaly]. Apomorphine 11-22 prolactin Homo sapiens 43-52 1243818-2 1975 Two days later (day 29), 15 ewes were injected subcutaneously with 18 mg ergocryptine, to inhibit specifically secretion of prolactin. ergocryptine 73-85 prolactin Homo sapiens 124-133 1190258-3 1975 Serum PRL was appropriately suppressed by the administration of L-dopa; however, chlorpromazine stimulation resulted in a blunted serum PRL response. Chlorpromazine 81-95 prolactin Homo sapiens 136-139 1243818-6 1975 Within 24 h of injecting ergocryptine, levels of prolactin in serum were reduced to negligible values (less than 2 ng/ml). ergocryptine 25-37 prolactin Homo sapiens 49-58 1243818-11 1975 However, oestradiol benzoate plus progesterone appeared to be lactogenic by virtue of the influence of oestrogen on the secretion of prolactin. estradiol 3-benzoate 9-28 prolactin Homo sapiens 133-142 819256-9 1975 The mode of LH-secretion in a group of functionally amenorrhoic patients was changed by a TRH-induced prolactin increase: the previously observed LH-spikes in these women could no longer be seen. Luteinizing Hormone 12-14 prolactin Homo sapiens 102-111 772521-2 1975 The labeling of human prolactin is carried out in the presence of a small quantity of chloramine T (10 mug). chloramine-T 86-98 prolactin Homo sapiens 22-31 772521-9 1975 Serum prolactin was determined in normal subjects and subjects treated with TRH and bromoergocryptine. Bromocriptine 84-101 prolactin Homo sapiens 6-15 1243732-0 1975 [Effect of sulpiride and 2Br-alfa ergocryptine on the neuroendocrine control of hPRL incretion (author"s transl)]. Sulpiride 11-20 prolactin Homo sapiens 80-84 1243732-0 1975 [Effect of sulpiride and 2Br-alfa ergocryptine on the neuroendocrine control of hPRL incretion (author"s transl)]. 2br-alfa ergocryptine 25-46 prolactin Homo sapiens 80-84 1243732-2 1975 The incretion of hPRL after infusion of SULPIRIDE (100 mg) by e.v. Sulpiride 40-49 prolactin Homo sapiens 17-21 1243732-5 1975 After CB-154 pretreatment the levels of hPRL were significantly lower. Bromocriptine 6-12 prolactin Homo sapiens 40-44 1243732-6 1975 Cb-154 is able to reduce incretion of hPRL, also after stimulation with Sulpiride by double mechanism. Bromocriptine 0-6 prolactin Homo sapiens 38-42 828709-5 1976 In pups pretreated with 6-OHDA, the GH-lowering effect of insulin hypoglycemia or cold exposure was markedly reduced, while the PRL responses were unmodified. Oxidopamine 24-30 prolactin Homo sapiens 128-131 828709-6 1976 Baseline plasma PRL levels were markedly increased following 6-OHDA administration. Oxidopamine 61-67 prolactin Homo sapiens 16-19 53377-3 1975 It is suggested that dopamine may modulate the normal secretion of aldosterone either directly, or indirectly, possible by inhibition of prolactin secretion. Dopamine 21-29 prolactin Homo sapiens 137-146 53377-3 1975 It is suggested that dopamine may modulate the normal secretion of aldosterone either directly, or indirectly, possible by inhibition of prolactin secretion. Aldosterone 67-78 prolactin Homo sapiens 137-146 812185-4 1975 Basal serum PRL levels and the responses to TRH were elevated in 2 of 5 patients, probably associated with phenothiazine administration. phenothiazine 107-120 prolactin Homo sapiens 12-15 1104218-11 1975 Treatment with bromocriptine in patients with normal gonadotrophins restores ovulation when the infertility is due to prolactin excess. Bromocriptine 15-28 prolactin Homo sapiens 118-127 819256-9 1975 The mode of LH-secretion in a group of functionally amenorrhoic patients was changed by a TRH-induced prolactin increase: the previously observed LH-spikes in these women could no longer be seen. Luteinizing Hormone 146-148 prolactin Homo sapiens 102-111 819256-11 1975 In patients with hyperprolactinemic anovulatory syndromes, prolactin suppressed LH-fluctuations reappeared after administration of 2-Bromo-alpha-ergocryptin. 2-bromo-alpha-ergocryptin 131-156 prolactin Homo sapiens 22-31 1206543-0 1975 Proceedings: The importance of intracerebral decarboxylation of L-DOPA in the suppression of prolactin secretion. Levodopa 64-70 prolactin Homo sapiens 93-102 1214038-3 1975 The authors demonstrate a human homologous radio-immune level estimating technique which uses a human anti-prolactin serum obtained from the rabbit human prolactin highly purified with iodine 125 using the lacto-peroxydase method. Iodine 185-191 prolactin Homo sapiens 107-116 1082005-0 1975 Proceedings: Effect of prolactin on sodium transport across frog skin in vitro. Sodium 36-42 prolactin Homo sapiens 23-32 53330-1 1975 2-bromo-alpha-ergocryptine (bromocriptine) in a dosage of 2-5 mg twice daily caused a rapid fall in plasma prolactin. Bromocriptine 0-26 prolactin Homo sapiens 107-116 53330-1 1975 2-bromo-alpha-ergocryptine (bromocriptine) in a dosage of 2-5 mg twice daily caused a rapid fall in plasma prolactin. Bromocriptine 28-41 prolactin Homo sapiens 107-116 1233923-0 1975 [Influence of prolactin on the appearance and development of experimental mammary tumors induced with 20-methylcholanthrene]. Methylcholanthrene 102-123 prolactin Homo sapiens 14-23 1101600-1 1975 A simple and rapid homologous radioimmunoassay of human prolactin (hPRL), by the use of 66% ethanol containing 6.6% ammonium acetate for the separation of free and bound hormones, has been established. Ethanol 92-99 prolactin Homo sapiens 56-65 1101600-1 1975 A simple and rapid homologous radioimmunoassay of human prolactin (hPRL), by the use of 66% ethanol containing 6.6% ammonium acetate for the separation of free and bound hormones, has been established. Ethanol 92-99 prolactin Homo sapiens 67-71 1101600-1 1975 A simple and rapid homologous radioimmunoassay of human prolactin (hPRL), by the use of 66% ethanol containing 6.6% ammonium acetate for the separation of free and bound hormones, has been established. ammonium acetate 116-132 prolactin Homo sapiens 56-65 1101600-1 1975 A simple and rapid homologous radioimmunoassay of human prolactin (hPRL), by the use of 66% ethanol containing 6.6% ammonium acetate for the separation of free and bound hormones, has been established. ammonium acetate 116-132 prolactin Homo sapiens 67-71 1101600-5 1975 Administration of oestradiol-17beta caused marked increase in plasma PRL levels during menstrual cycle. Estradiol 18-35 prolactin Homo sapiens 69-72 1176587-1 1975 Morphine administration in man results in a significant increase in serum prolactin without altering the levels of growth hormone, thyroid stimulating hormone and cortisol. Morphine 0-8 prolactin Homo sapiens 74-83 810369-0 1975 Stimulated plasma prolactin levels in women using medroxyprogesterone acetate or an intrauterine device for contraception. Medroxyprogesterone Acetate 50-77 prolactin Homo sapiens 18-27 813995-0 1975 Stimulation of human prolactin secretion by sulpiride. Sulpiride 44-53 prolactin Homo sapiens 21-30 813995-1 1975 Intramuscular injection of 100 mg of sulpiride significantly raised plasma human prolactin (hPRL) levels in all of 7 normal subjects examined. Sulpiride 37-46 prolactin Homo sapiens 81-90 813995-1 1975 Intramuscular injection of 100 mg of sulpiride significantly raised plasma human prolactin (hPRL) levels in all of 7 normal subjects examined. Sulpiride 37-46 prolactin Homo sapiens 92-96 813995-3 1975 Daily administration of sulpiride (50 mg tid po) raised plasma hPRL levels in all 7 patients with peptic ulcer, with peak values obtained within 2 weeks. Sulpiride 24-33 prolactin Homo sapiens 63-67 813995-5 1975 It is concluded that sulpiride stimulates hPRL secretion in man. Sulpiride 21-30 prolactin Homo sapiens 42-46 1176587-2 1975 Apomorphine prevented the morphine induced prolactin rise. Apomorphine 0-11 prolactin Homo sapiens 43-52 1176587-2 1975 Apomorphine prevented the morphine induced prolactin rise. Morphine 3-11 prolactin Homo sapiens 43-52 1174274-0 1975 Effect of methylergobasine maleate on serum gonadotrophin and prolactin in humans. Methylergonovine maleate 10-34 prolactin Homo sapiens 62-71 1101946-0 1975 Effect of bromocriptine and chlorotrianisene on inhibition of lactation and serum prolactin. Bromocriptine 10-23 prolactin Homo sapiens 82-91 1101946-0 1975 Effect of bromocriptine and chlorotrianisene on inhibition of lactation and serum prolactin. Chlorotrianisene 28-44 prolactin Homo sapiens 82-91 1101946-4 1975 Furthermore, bromocriptine significantly reduced serum prolactin levels to low normal values by the seventh day of treatment, whereas chlorotrianisene did not alter the normal progressive reduction in prolactin post-partum. Bromocriptine 13-26 prolactin Homo sapiens 55-64 808064-0 1975 Plasma prolactin levels after TRH and chlorpromazine in normal subjects and patients with impaired pituitary function. Chlorpromazine 38-52 prolactin Homo sapiens 7-16 808558-2 1975 Since catecholamines may be involved in the regulation of both thyrotropin (TSH) and prolactin (PRL) release from the pituitary, the effect of propranolol on the TSH and PRL responses to thyrotropin-releasing hormone (TRH) was also examined. Catecholamines 6-20 prolactin Homo sapiens 85-94 808558-2 1975 Since catecholamines may be involved in the regulation of both thyrotropin (TSH) and prolactin (PRL) release from the pituitary, the effect of propranolol on the TSH and PRL responses to thyrotropin-releasing hormone (TRH) was also examined. Catecholamines 6-20 prolactin Homo sapiens 96-99 808558-2 1975 Since catecholamines may be involved in the regulation of both thyrotropin (TSH) and prolactin (PRL) release from the pituitary, the effect of propranolol on the TSH and PRL responses to thyrotropin-releasing hormone (TRH) was also examined. Propranolol 143-154 prolactin Homo sapiens 170-173 1174274-1 1975 Intramuscular injection of 0.2 mg methylergobasine maleate3) (Methergin, Sandoz) in women on day 3 post-partum, in regularly menstruating women and in adult men, is followed within 30 to 75 min by a 50% decrease in serum prolactin concentration: the levels remain low until 180 min and increase between 180 and 240 min. methylergobasine maleate3 34-59 prolactin Homo sapiens 221-230 1159049-0 1975 The effect of chlorpromazine on the secretion of immunoreactive beta-MSH and prolactin in man. Chlorpromazine 14-28 prolactin Homo sapiens 77-86 1159050-0 1975 Failure of oral water loading and intravenous hypotonic saline to suppress plasma prolactin in man. Sodium Chloride 56-62 prolactin Homo sapiens 82-91 1159050-2 1975 In 10 normal men there was a small but statistically significant rise in mean prolactin, from 7.6 to 12.3 ng/ml, occurring within half an hour after the ingestion of a water load of 20 ml/kg. Water 168-173 prolactin Homo sapiens 78-87 1160505-0 1975 Clozapine increases rat serum prolactin levels. Clozapine 0-9 prolactin Homo sapiens 30-39 239662-0 1975 Thioridazine stimulates prolactin secretion in man. Thioridazine 0-12 prolactin Homo sapiens 24-33 239662-2 1975 We decided to test, indirectly, thioridazine"s effects on another brain dopaminergic system, the tuberoinfundibular tract, which regulates prolactin secretion by stimulating hypothalamic secretion of prolactin-inhibiting factor. Thioridazine 32-44 prolactin Homo sapiens 139-148 239662-2 1975 We decided to test, indirectly, thioridazine"s effects on another brain dopaminergic system, the tuberoinfundibular tract, which regulates prolactin secretion by stimulating hypothalamic secretion of prolactin-inhibiting factor. Thioridazine 32-44 prolactin Homo sapiens 200-209 239662-3 1975 Chlorpromazine and several other phenothiazines have been shown to stimulate prolactin secretion. Chlorpromazine 0-14 prolactin Homo sapiens 77-86 239662-3 1975 Chlorpromazine and several other phenothiazines have been shown to stimulate prolactin secretion. Phenothiazines 33-47 prolactin Homo sapiens 77-86 239662-6 1975 It is concluded that thioridazine is a potent dopamine antagonist in the tuberoinfundibular system, and it is suggested that this system"s regulation of prolactin secretion may provide a useful method for studying antipsychotic drug effects in man. Thioridazine 21-33 prolactin Homo sapiens 153-162 1165136-2 1975 2.5 and 3 mg doses of CB-154 induced a significant rise in growth hormone and free fatty acids, while prolactin decreased. Bromocriptine 22-28 prolactin Homo sapiens 102-111 1085462-0 1975 [Levels of growth hormone, prolactin and insulin in the course of acute administration of chlorpromazine (plegomazin) in psychiatric patients]. Chlorpromazine 90-104 prolactin Homo sapiens 27-36 807435-3 1975 The prolactin in serum detected by the radioimmunoassay behaved in a similar manner to purified human 125-I-labled prolactin on polyacrylamide gel electrophoresis. polyacrylamide 128-142 prolactin Homo sapiens 4-13 807435-3 1975 The prolactin in serum detected by the radioimmunoassay behaved in a similar manner to purified human 125-I-labled prolactin on polyacrylamide gel electrophoresis. polyacrylamide 128-142 prolactin Homo sapiens 115-124 1133152-0 1975 Nocturnal increase of plasma testosterone in men: relation to gonadotropins and prolactin. Testosterone 29-41 prolactin Homo sapiens 80-89 1164725-4 1975 Only a few prolactin cells stained with carmoisine. azo rubin S 40-50 prolactin Homo sapiens 11-20 1164725-10 1975 Staining of the prolactin cells with carmoisine was extensive. azo rubin S 37-47 prolactin Homo sapiens 16-25 1168997-4 1975 Serum prolactin levels become normal following initiation of Brom-ergocryptine. Bromocriptine 61-78 prolactin Homo sapiens 6-15 1168997-5 1975 Discontinuation of Brom-ergocryptine was found to result in a return of both inappropriate lactation and elevation of serum prolactin in this study. Bromocriptine 19-36 prolactin Homo sapiens 124-133 1122890-0 1975 Characteristics of the prolactin stimulation of uridine metabolism in mammary gland explants. Uridine 48-55 prolactin Homo sapiens 23-32 1122890-1 1975 Experiments were carried out to characterize the prolactin stimulation of labeled uridine uptake into mammary gland explants which were initially preincubated for 2 days in medium containing insulin plus hydrocortisone. Uridine 82-89 prolactin Homo sapiens 49-58 1122890-1 1975 Experiments were carried out to characterize the prolactin stimulation of labeled uridine uptake into mammary gland explants which were initially preincubated for 2 days in medium containing insulin plus hydrocortisone. Hydrocortisone 204-218 prolactin Homo sapiens 49-58 1122890-2 1975 Prolactin was found to enhance labeled uridine uptake after 4 h but not after 2 h when uridine concentrations ranging between 0.1 muM and 1 mM were tested. Uridine 39-46 prolactin Homo sapiens 0-9 1122890-3 1975 The effect of prolactin on labeled uridine uptake also appears to require ongoing RNA and protein synthesis since incubation with a variety of inhibitors of RNA and protein synthesis abolished the prolactin effect. Uridine 35-42 prolactin Homo sapiens 14-23 1122890-3 1975 The effect of prolactin on labeled uridine uptake also appears to require ongoing RNA and protein synthesis since incubation with a variety of inhibitors of RNA and protein synthesis abolished the prolactin effect. Uridine 35-42 prolactin Homo sapiens 197-206 1122890-4 1975 It was further discovered that prolactin stimulates the labeling of the cellular pools of the phosphorylated derivatives of uridine while the quantity of label present in the uridine and uracil pools was not affected. Uridine 125-132 prolactin Homo sapiens 31-40 1122890-5 1975 It is thus possible that the effect of prolactin on labeled uridine uptake may be caused by the enhanced phosphorylation of the uridine. Uridine 60-67 prolactin Homo sapiens 39-48 1122890-5 1975 It is thus possible that the effect of prolactin on labeled uridine uptake may be caused by the enhanced phosphorylation of the uridine. Uridine 128-135 prolactin Homo sapiens 39-48 1122890-6 1975 It was also found that the onset of the effect of prolactin on the phosphorylation of uridine to UTP was not different from the onset of the effect of this hormone on labeled uridine uptake and its incorporation into RNA. Uridine 87-94 prolactin Homo sapiens 50-59 1122890-6 1975 It was also found that the onset of the effect of prolactin on the phosphorylation of uridine to UTP was not different from the onset of the effect of this hormone on labeled uridine uptake and its incorporation into RNA. Uridine Triphosphate 98-101 prolactin Homo sapiens 50-59 1122890-8 1975 For this purpose the effect of prolactin on the uptake of radiolabeled phosphate and its incorporation into RNA was studied. Phosphates 71-80 prolactin Homo sapiens 31-40 1122890-9 1975 Prolactin stimulated the incorporation of phosphate into RNA after 4 h but the uptake of phosphate was not affected by the hormone at that time. Phosphates 42-51 prolactin Homo sapiens 0-9 1122890-10 1975 Further, the effect of prolactin on phosphate incorporation into RNA was temporally identical to the hormonal effect on the incorporation of 3H-uridine into RNA. Phosphates 36-45 prolactin Homo sapiens 23-32 240179-0 1975 Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients. Chlorpromazine 51-65 prolactin Homo sapiens 37-46 1172495-0 1975 Spontaneous diurnal variations of serum prolactin and prolactin response to L-dopa in man. Levodopa 76-82 prolactin Homo sapiens 54-63 1127080-0 1975 The stimulation of human prolactin secretion by 3-Iodo-L-tyrosine. 3-iodotyrosine 48-65 prolactin Homo sapiens 25-34 1168655-5 1975 L-Dopa suppression of serum PRL was not significantly influenced by T4 in these patients. Levodopa 0-6 prolactin Homo sapiens 28-31 808433-11 1975 There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects. Thyrotropin 145-148 prolactin Homo sapiens 71-74 808433-11 1975 There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects. Thyrotropin 145-148 prolactin Homo sapiens 113-116 808433-11 1975 There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects. Thyrotropin 153-156 prolactin Homo sapiens 71-74 808433-11 1975 There was a positive correlation between the maximum increase in serum PRL concentration above the base line (...PRL) and the increment in serum TSH (...TSH) after TRH administration in these subjects. Thyrotropin 153-156 prolactin Homo sapiens 113-116 1168856-6 1975 Chlorpromazine produced greater than two-fold increases in serum PRL concentrations in the controls and Group I patients; however, this response was absent in Group II. Chlorpromazine 0-14 prolactin Homo sapiens 65-68 1168856-7 1975 L-Dopa produced appropriate suppression of serum PRL concentrations in the normals and both patient groups. Levodopa 0-6 prolactin Homo sapiens 49-52 171136-1 1975 Specific prolactin (PRL) binding activity of lactoperoxidase catalyzed 125I-labeled ovine-PRL was determined in a membrane-rich particulate fraction of pigeon crop sacs. Iodine-125 71-75 prolactin Homo sapiens 9-18 171136-1 1975 Specific prolactin (PRL) binding activity of lactoperoxidase catalyzed 125I-labeled ovine-PRL was determined in a membrane-rich particulate fraction of pigeon crop sacs. Iodine-125 71-75 prolactin Homo sapiens 20-23 171136-1 1975 Specific prolactin (PRL) binding activity of lactoperoxidase catalyzed 125I-labeled ovine-PRL was determined in a membrane-rich particulate fraction of pigeon crop sacs. Iodine-125 71-75 prolactin Homo sapiens 90-93 803513-0 1975 Prolactin response to chlorpromazine and thyrotropin-releasing hormone in hyperthyroidism. Chlorpromazine 22-36 prolactin Homo sapiens 0-9 4377125-0 1974 [Comparative action of 3 thiobutyryl derivatives of cyclic AMP on the liberation and synthesis of pituitary prolactin]. thiobutyryl 25-36 prolactin Homo sapiens 108-117 4377125-0 1974 [Comparative action of 3 thiobutyryl derivatives of cyclic AMP on the liberation and synthesis of pituitary prolactin]. Cyclic AMP 52-62 prolactin Homo sapiens 108-117 4443693-0 1974 Influence of ovine prolactin on transport of fluid and sodium chloride by the mammalian intestine and gall bladder. Sodium Chloride 55-70 prolactin Homo sapiens 19-28 4416328-0 1974 The inhibitory effect of an ergoline derivative (lergotrile, compound 83636) on prolactin secretion in man. Ergolines 28-36 prolactin Homo sapiens 80-89 4416328-0 1974 The inhibitory effect of an ergoline derivative (lergotrile, compound 83636) on prolactin secretion in man. lergotrile 49-59 prolactin Homo sapiens 80-89 4366766-7 1974 The binding sites for ovine prolactin and human growth hormone were of high affinity in liver membranes from both female and estrone-treated male rats (K(a) = 0.6 to 1.4 x 10(9) M(-1)). Estrone 125-132 prolactin Homo sapiens 28-37 4600593-6 1974 Raised prolactin levels appear to block the actions of the gonadotrophins at a gonadal level rather than prevent their synthesis or release; lowering prolactin secretion with bromocriptine allows resumption of normal gonadal function. Bromocriptine 175-188 prolactin Homo sapiens 150-159 4821039-7 1974 Frusemide had no clear effect on the rate of beating of the controls, but it tended to reverse both the acceleration produced by 50 ng/ml prolactin and the slowing produced by the higher dose. Furosemide 0-9 prolactin Homo sapiens 138-147 4544920-0 1974 Effect of 5-hydroxytryptophan (5-HTP) on plasma prolactin levels in man. 5-Hydroxytryptophan 10-29 prolactin Homo sapiens 48-57 4544920-0 1974 Effect of 5-hydroxytryptophan (5-HTP) on plasma prolactin levels in man. 5-Hydroxytryptophan 31-36 prolactin Homo sapiens 48-57 4476414-0 1974 [Proceedings: Effect of estrogen or prolactin administration immediately after birth on blood estrogen level, mammary gland growth and occurrence of DMBA-induced mammary cancer]. 6,11-dimethylbenzo(b)naphtho(2,3-d)thiophene 149-153 prolactin Homo sapiens 36-45 4820963-0 1974 Proceedings: Chlorpromazine stimulation of prolactin secretion: a test of pituitary function. Chlorpromazine 13-27 prolactin Homo sapiens 43-52 4771991-0 1973 Prolactin and progesterone effect on specific estradiol binding in uterine and mammary tissues in vitro. Estradiol 46-55 prolactin Homo sapiens 0-9 4753435-0 1973 Estrogen potentiation of phenothiazine-induced prolactin secretion in man. phenothiazine 25-38 prolactin Homo sapiens 47-56 4364712-0 1973 [Effect of a new derivative of cyclic AMP on the liberation and synthesis of growth hormone and pituitary prolactin]. Cyclic AMP 31-41 prolactin Homo sapiens 106-115 4357307-0 1973 Prolactin secretion is specifically inhibited by nickel. Nickel 49-55 prolactin Homo sapiens 0-9 4199418-1 1973 The influence of serum triiodothyronine (T(3)) and thyroxine (T(4)) concentrations on the release of prolactin in man was studied by determining the prolactin response to synthetic thyrotropin-releasing hormone (TRH) in hypothyroid and hyperthyroid patients before and after correction of their serum thyroid hormone abnormalities. Triiodothyronine 23-39 prolactin Homo sapiens 101-110 4199418-1 1973 The influence of serum triiodothyronine (T(3)) and thyroxine (T(4)) concentrations on the release of prolactin in man was studied by determining the prolactin response to synthetic thyrotropin-releasing hormone (TRH) in hypothyroid and hyperthyroid patients before and after correction of their serum thyroid hormone abnormalities. Triiodothyronine 41-45 prolactin Homo sapiens 101-110 4199418-1 1973 The influence of serum triiodothyronine (T(3)) and thyroxine (T(4)) concentrations on the release of prolactin in man was studied by determining the prolactin response to synthetic thyrotropin-releasing hormone (TRH) in hypothyroid and hyperthyroid patients before and after correction of their serum thyroid hormone abnormalities. Thyroxine 51-60 prolactin Homo sapiens 101-110 4206490-0 1973 Childhood acromegaly: successful therapy with conventional radiation and effects of chlorpromazine on growth hormone and prolactin secretion. Chlorpromazine 84-98 prolactin Homo sapiens 121-130 4206493-0 1973 Growth hormone, thyrotropin, and prolactin responses to thyrotropin-releasing hormone following diethylstilbestrol pretreatment. Diethylstilbestrol 96-114 prolactin Homo sapiens 33-42 4541674-0 1973 Stimulation of human prolactin secretion by intravenous infusion of L-tryptophan. Tryptophan 68-80 prolactin Homo sapiens 21-30 4541674-1 1973 Previous studies have demonstrated that the secretion of human prolactin is regulated primarily by factors that influence catecholamines of the hypothalamus. Catecholamines 122-136 prolactin Homo sapiens 63-72 4541674-3 1973 Intravenous infusion of L-tryptophan, 5-10 g over a 20 min period, but not equivalent amounts of 17 other amino acids, induced marked increases in serum prolactin concentrations in eight normal human volunteers. Tryptophan 24-36 prolactin Homo sapiens 153-162 4541674-7 1973 Four subjects with juvenile diabetes demonstrated increases in serum prolactin values comparable with those observed in healthy individuals in response to infusions of L-tryptophan. Tryptophan 168-180 prolactin Homo sapiens 69-78 4541674-8 1973 Serum prolactin values in patients with surgically induced hypopituitarism were undetectable or deficient after infusion of 10 g of L-tryptophan. Tryptophan 132-144 prolactin Homo sapiens 6-15 4541674-10 1973 Further studies relating to the possible mechanism of action of L-tryptophan indicated that infusion of 5-hydroxytryptophan represents a much more potent stimulus for the secretion of prolactin and that premedication with the serotonin antagonist, methysergide maleate, serves to blunt the effect of L-tryptophan on prolactin secretion. Tryptophan 64-76 prolactin Homo sapiens 184-193 4541674-10 1973 Further studies relating to the possible mechanism of action of L-tryptophan indicated that infusion of 5-hydroxytryptophan represents a much more potent stimulus for the secretion of prolactin and that premedication with the serotonin antagonist, methysergide maleate, serves to blunt the effect of L-tryptophan on prolactin secretion. 5-Hydroxytryptophan 104-123 prolactin Homo sapiens 184-193 4541674-10 1973 Further studies relating to the possible mechanism of action of L-tryptophan indicated that infusion of 5-hydroxytryptophan represents a much more potent stimulus for the secretion of prolactin and that premedication with the serotonin antagonist, methysergide maleate, serves to blunt the effect of L-tryptophan on prolactin secretion. 5-Hydroxytryptophan 104-123 prolactin Homo sapiens 316-325 4541674-11 1973 These results support the concept that the effect of L-tryptophan on the secretion of human prolactin is mediated through its conversion to serotonin and are consistent with reported experimental observations that serotonin may participate in the reciprocal regulation of prolactin and gonadotropins. Tryptophan 53-65 prolactin Homo sapiens 92-101 4541674-11 1973 These results support the concept that the effect of L-tryptophan on the secretion of human prolactin is mediated through its conversion to serotonin and are consistent with reported experimental observations that serotonin may participate in the reciprocal regulation of prolactin and gonadotropins. Tryptophan 53-65 prolactin Homo sapiens 272-281 4541674-11 1973 These results support the concept that the effect of L-tryptophan on the secretion of human prolactin is mediated through its conversion to serotonin and are consistent with reported experimental observations that serotonin may participate in the reciprocal regulation of prolactin and gonadotropins. Serotonin 140-149 prolactin Homo sapiens 92-101 4541674-11 1973 These results support the concept that the effect of L-tryptophan on the secretion of human prolactin is mediated through its conversion to serotonin and are consistent with reported experimental observations that serotonin may participate in the reciprocal regulation of prolactin and gonadotropins. Serotonin 214-223 prolactin Homo sapiens 92-101 4541674-11 1973 These results support the concept that the effect of L-tryptophan on the secretion of human prolactin is mediated through its conversion to serotonin and are consistent with reported experimental observations that serotonin may participate in the reciprocal regulation of prolactin and gonadotropins. Serotonin 214-223 prolactin Homo sapiens 272-281 4735405-0 1973 Human prolactin in plasma, amniotic fluid and pituitary: identity and characterization by criteria of electrophoresis and isoelectric focusing in polyacrylamide gel. polyacrylamide 146-160 prolactin Homo sapiens 6-15 4695125-0 1973 Failure of reserpine to block ether-induced release of prolactin: physiological evidence that stress induced prolactin release is not caused by acute inhibition of PIF secretion. Ether 30-35 prolactin Homo sapiens 55-64 4196300-0 1973 [Effect of L-Dopa on the secretion of prolactin in eels]. Levodopa 11-17 prolactin Homo sapiens 38-47 4683266-0 1973 Effect of perphenazine on the secretion of prolactin in vivo and in vitro. Perphenazine 10-22 prolactin Homo sapiens 43-52 4672297-0 1972 The inhibition of prolactin secretion in man by CB-154 (2-Br-alpha-ergocryptine). Bromocriptine 48-54 prolactin Homo sapiens 18-27 4675488-0 1972 Galactorrhoea: successful treatment with reduction of plasma prolactin levels by brom-ergocryptine. Bromocriptine 81-98 prolactin Homo sapiens 61-70 4651582-0 1972 [Changes in N-acetylneuraminic acid content of the eel intestine after hypophysectomy and treatment with prolactin]. N-Acetylneuraminic Acid 12-35 prolactin Homo sapiens 105-114 5007980-1 1972 The secretion of prolactin as affected by milking, oestradiol administration and onset of parturition. Estradiol 51-61 prolactin Homo sapiens 17-26 5061810-0 1972 Effects of prolactin and ergot alkaloids on the tubero-infundibular dopamine (DA) neurons. Dopamine 68-76 prolactin Homo sapiens 11-20 5000704-0 1971 Prolactin and thyrotropin release in man by synthetic pyroglutamyl-histidyl-prolinamide. Thyrotropin-Releasing Hormone 54-87 prolactin Homo sapiens 0-9 5105218-3 1971 Plasma prolactin levels were examined in seven patients during oral glucose tolerance tests: no change occurred in the four patients with pituitary tumours, but the levels were suppressed in the three patients with normal pituitary fossae. Glucose 68-75 prolactin Homo sapiens 7-16 5540057-0 1971 Effect of ergocornine on prolactin secretion by hypophysial homografts. ergocornine 10-21 prolactin Homo sapiens 25-34 5483637-0 1970 Stimulation of RNA synthesis in isolated mammary cells by insulin and prolactin bound to sepharose. Sepharose 89-98 prolactin Homo sapiens 70-79 5482703-0 1970 Prolactin induction of enzymes controlling luteal cholesterol ester turnover. Cholesterol Esters 50-67 prolactin Homo sapiens 0-9 5818077-0 1969 Influence of norepinephrine and catecholamine-depleting agents on the synthesis and release of prolactin and growth hormone. Norepinephrine 13-27 prolactin Homo sapiens 95-104 5818077-0 1969 Influence of norepinephrine and catecholamine-depleting agents on the synthesis and release of prolactin and growth hormone. Catecholamines 32-45 prolactin Homo sapiens 95-104 5824080-0 1969 Estimation of prolactin and growth hormone levels by polyacrylamide disc electrophoresis. polyacrylamide 53-67 prolactin Homo sapiens 14-23 4980052-0 1969 [Sensitization of erythocytes to a protein antigen (ovine prolactin) by chromium chloride, CrCl3: constants relative to the coupling reaction studied by passive immunohemolysis]. chromous chloride 72-89 prolactin Homo sapiens 58-67 4980052-0 1969 [Sensitization of erythocytes to a protein antigen (ovine prolactin) by chromium chloride, CrCl3: constants relative to the coupling reaction studied by passive immunohemolysis]. chromic chloride 91-96 prolactin Homo sapiens 58-67 5407766-0 1969 Lactose synthesis as a function of prolactin dosage. Lactose 0-7 prolactin Homo sapiens 35-44 5748883-0 1968 Duration of prolactin-induced lactose synthesis. Lactose 30-37 prolactin Homo sapiens 12-21 14019835-0 1962 The onset of lactose synthesis after injection of prolactin. Lactose 13-20 prolactin Homo sapiens 50-59 13692309-0 1961 The effect of prolactin on some purine metabolizing activities. purine 32-38 prolactin Homo sapiens 14-23 13694571-0 1961 Ion exchange chromatography of prolactin in urea-containing buffers. Urea 44-48 prolactin Homo sapiens 31-40 13809132-0 1960 The effect of prolactin on the xanthine oxidizing activity of pigeon tissues. Xanthine 31-39 prolactin Homo sapiens 14-23 13464553-0 1957 [Endocrine picture in fibrocystic breast disease & modifications induced in the latter by chorionic gonadotropin alone & in combination with prolactin]. Adenosine Monophosphate 50-53 prolactin Homo sapiens 149-158 16746259-3 1936 The effect of prolactin on lactose synthesis by the mammary gland. Lactose 27-34 prolactin Homo sapiens 14-23 239963-5 1975 L-dopa significantly lowered basal plasma hPRL levels and also significantly blunted TRH-induced hPRL release. Levodopa 0-6 prolactin Homo sapiens 42-46 239963-5 1975 L-dopa significantly lowered basal plasma hPRL levels and also significantly blunted TRH-induced hPRL release. Levodopa 0-6 prolactin Homo sapiens 97-101 1080266-0 1975 Effect of methylergonovine on puerperal prolactin secretion. Methylergonovine 10-26 prolactin Homo sapiens 40-49 1080266-4 1975 The rise in serum prolactin concentration seen in the control women (266.4 ng/ml +/- 40.8 SE) was significantly greater than that seen in methylergonovine-treated patients (141.0 ng/ml +/- 29.0. Methylergonovine 138-154 prolactin Homo sapiens 18-27 1171026-1 1975 Previous observations by other workers indicating suppression of serum prolactin (hPRL) by water loading could not be confirmed. Water 91-96 prolactin Homo sapiens 71-80 1171026-1 1975 Previous observations by other workers indicating suppression of serum prolactin (hPRL) by water loading could not be confirmed. Water 91-96 prolactin Homo sapiens 82-86 1171026-3 1975 It was of interest that the acute ingestion of water resulted in a triphasic response in serum hPRL levels. Water 47-52 prolactin Homo sapiens 95-99 1095122-2 1975 L-Dopa lowers plasma prolactin levels, and there have been reports that patients with advanced breast cancer have been successfully treated with L-dopa. Levodopa 0-6 prolactin Homo sapiens 21-30 1236817-14 1975 Effect of arginine on the concentrations of serum hGH, hPRL and hCS during pregnancy. Arginine 10-18 prolactin Homo sapiens 55-59 1236817-18 1975 Effect of arginine on the concentrations of serum hGH and hPRL in puerperium. Arginine 10-18 prolactin Homo sapiens 58-62 1170984-0 1975 [Effects of metyrapone administration on LH, FSH, TSH, and prolactin secretion]. Metyrapone 12-22 prolactin Homo sapiens 59-68 1173307-7 1975 CB-154 suppressed PRL secretion and stimulated FSH and LH secretion in 3 cases where lactation was inhibited and ovulation was induced. Bromocriptine 0-6 prolactin Homo sapiens 18-21 811155-7 1975 After THR administration the PRL response is normal or exaggerated. Threonine 6-9 prolactin Homo sapiens 29-32 165221-1 1975 Lergotrile (Compound 83636), a specific inhibitor of prolactin release, was administered to 5 women with galactorrhea. lergotrile 0-10 prolactin Homo sapiens 53-62 805159-5 1975 These studies support a relationship between prolactin and sex steroids on the initiation and maintenance of human lactation. Steroids 63-71 prolactin Homo sapiens 45-54 1127094-1 1975 Ethinylestradiol (400 pg/day) does not only stimulate prolactin release in normal cycling women but also modifies the pattern of the circadian periodicity of circulating prolactin: the nocurnal rise is of reduced amplitude but covers a larger part of the nyctohemeral period as compared to the situation during a control period in the same subjects. Ethinyl Estradiol 0-16 prolactin Homo sapiens 54-63 1127094-1 1975 Ethinylestradiol (400 pg/day) does not only stimulate prolactin release in normal cycling women but also modifies the pattern of the circadian periodicity of circulating prolactin: the nocurnal rise is of reduced amplitude but covers a larger part of the nyctohemeral period as compared to the situation during a control period in the same subjects. Ethinyl Estradiol 0-16 prolactin Homo sapiens 170-179 1133566-5 1975 Prolactin-induced increases in transport of fluid, NaCl and organic nutrients by the mammalian jejunum may play an important role in nutritional and osmoregulatory adaptations. Sodium Chloride 51-55 prolactin Homo sapiens 0-9 1169337-0 1975 [Monoamine regulation of GH and prolactin secretion]. monoamine 1-10 prolactin Homo sapiens 32-41 163687-0 1975 Estrogen-prolactin dependency in 7,12-dimethylbenz(a)anthracene-induced tumors. 7,12-dimethylbenz 33-50 prolactin Homo sapiens 9-18 163687-0 1975 Estrogen-prolactin dependency in 7,12-dimethylbenz(a)anthracene-induced tumors. anthracene 53-63 prolactin Homo sapiens 9-18 163687-5 1975 On withdrawal of prolactin-nafoxidine, rapid regression of tumor occurred and readministration of prolactin failed to activate most of the tumors for as long as 28 days. Nafoxidine 27-37 prolactin Homo sapiens 17-26 805417-8 1975 Prolactin levels are raised, this no doubt explaining the negative response to TRH and chlorpromazine stimulation. Chlorpromazine 87-101 prolactin Homo sapiens 0-9 1120175-4 1975 We have found that thioridazine is as effective as chlorpromazine, trifluperazine, and prolixin enanthate in increasing serum prolactin levels in unmediated schizophrenic patients, indicating it is an effective dopamine-blocking agent. Thioridazine 19-31 prolactin Homo sapiens 126-135 1120175-4 1975 We have found that thioridazine is as effective as chlorpromazine, trifluperazine, and prolixin enanthate in increasing serum prolactin levels in unmediated schizophrenic patients, indicating it is an effective dopamine-blocking agent. Chlorpromazine 51-65 prolactin Homo sapiens 126-135 1120175-4 1975 We have found that thioridazine is as effective as chlorpromazine, trifluperazine, and prolixin enanthate in increasing serum prolactin levels in unmediated schizophrenic patients, indicating it is an effective dopamine-blocking agent. Trifluoperazine 67-81 prolactin Homo sapiens 126-135 1120175-4 1975 We have found that thioridazine is as effective as chlorpromazine, trifluperazine, and prolixin enanthate in increasing serum prolactin levels in unmediated schizophrenic patients, indicating it is an effective dopamine-blocking agent. fluphenazine enanthate 87-105 prolactin Homo sapiens 126-135 1122652-5 1975 Prolactin was very effectively suppressed by Bromergocryptine in all patients, as was lactation. Bromocriptine 45-61 prolactin Homo sapiens 0-9 1122652-16 1975 It is suggested that during the puerperium the ovaries are the more refractory part of the hypothalamicpituitaryovarian axis, due probably to an influence of prolactin on the ovarian steroid synthesis. Steroids 183-190 prolactin Homo sapiens 158-167 1237473-3 1975 The carboxyl terminal cyclic undecapeptide of the ovine prolactin molecule: Leu-Asn-Cys-Arg-Ile-Ile-Tyr-Asn-Asn-Asn-Cys has been synthesized by the solid-phase method. Leu-Asn-Cys 76-87 prolactin Homo sapiens 56-65 1237473-3 1975 The carboxyl terminal cyclic undecapeptide of the ovine prolactin molecule: Leu-Asn-Cys-Arg-Ile-Ile-Tyr-Asn-Asn-Asn-Cys has been synthesized by the solid-phase method. Asn-Cys 80-87 prolactin Homo sapiens 56-65 4215558-0 1974 The effect of dexamethasone on TSH and prolactin secretion after TRH stimulation. Dexamethasone 14-27 prolactin Homo sapiens 39-48 4419558-0 1974 The effect of perphenazine-induced serum prolactin response on estrogen-primed mammary tumor-host systems, 13762 and R-35 mammary adenocarcinomas. Perphenazine 14-26 prolactin Homo sapiens 41-50 4528642-1 1974 Effect of methadone on plasma testosterone, FSH, LH, and prolactin. Methadone 10-19 prolactin Homo sapiens 57-66 4478623-0 1974 [Proceedings: Arginine and synthesis and secretory functions of growth hormone and prolactin]. Arginine 14-22 prolactin Homo sapiens 83-92 4850268-0 1974 A possible role for prolactin in control of steroid secretion by the human Graafian follicle. Steroids 44-51 prolactin Homo sapiens 20-29 4369071-0 1974 Prolactin stimulation of estrogen receptor in vitro in 7,12 dimethylbenz(A)anthracene-induced mammary tumor. 7,12 dimethylbenz 55-72 prolactin Homo sapiens 0-9 4369071-0 1974 Prolactin stimulation of estrogen receptor in vitro in 7,12 dimethylbenz(A)anthracene-induced mammary tumor. anthracene 75-85 prolactin Homo sapiens 0-9 4857925-0 1974 Proceedings: The luteotrophic and lactogenic activities of prolactin, human chorionic somatomammotrophin and mouse placental extract on mice treated with an ergocornine derivative. ergocornine 157-168 prolactin Homo sapiens 59-68 4818768-0 1974 Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion. Dopamine 32-40 prolactin Homo sapiens 64-73 4818776-0 1974 Inhibition of prolactin secretion by ergolines. Ergolines 37-46 prolactin Homo sapiens 14-23 11344580-2 1974 Ethinyl estradiol at a dose of 1 microgram/kg per day induced a significant elevation of serum PRL levels within the 1st wk of treatment. Ethinyl Estradiol 0-17 prolactin Homo sapiens 95-98 4153459-0 1974 Rapid induction of prolactin secretion by 3-iodo-L-tyrosine. 3-iodotyrosine 42-59 prolactin Homo sapiens 19-28 4211473-0 1973 [Influence of estradiol-17 beta and progesterone during induction by prolactin and growth hormone of lobulo-alveolar differentiation of mammary tissue of the pregnant ewe: study in organotypic culture]. Estradiol 14-31 prolactin Homo sapiens 69-78 4211473-0 1973 [Influence of estradiol-17 beta and progesterone during induction by prolactin and growth hormone of lobulo-alveolar differentiation of mammary tissue of the pregnant ewe: study in organotypic culture]. Progesterone 36-48 prolactin Homo sapiens 69-78 4356808-0 1973 Growth hormone and prolactin in unipolar and bipolar depressed patients: responses to hypoglycemia and L-dopa. Levodopa 103-109 prolactin Homo sapiens 19-28 4201417-0 1973 Prolactin and growth hormone release in response to sequential stimulation by arginine and synthetic TRF. Arginine 78-86 prolactin Homo sapiens 0-9 4199493-0 1973 Effects of cations and colchicine on the release of prolactin and growth hormone by functional pituitary tumor cells in culture. Colchicine 23-33 prolactin Homo sapiens 52-61 4724931-2 1973 Mean serum prolactin fell to 10.5 percent of baseline after oral water loading and to 15 percent of baseline after intravenous hypotonic saline infusion. Water 65-70 prolactin Homo sapiens 11-20 4724931-2 1973 Mean serum prolactin fell to 10.5 percent of baseline after oral water loading and to 15 percent of baseline after intravenous hypotonic saline infusion. Sodium Chloride 137-143 prolactin Homo sapiens 11-20 4632690-1 1973 Prolactin secretion was assessed in 23 patients with hypothalamic-pituitary disorders using L-Dopa suppression, chlorpromazine (CPZ), and thyrotropin-releasing hormone (TRH) stimulation tests. Levodopa 92-98 prolactin Homo sapiens 0-9 4632690-1 1973 Prolactin secretion was assessed in 23 patients with hypothalamic-pituitary disorders using L-Dopa suppression, chlorpromazine (CPZ), and thyrotropin-releasing hormone (TRH) stimulation tests. Chlorpromazine 112-126 prolactin Homo sapiens 0-9 4632690-1 1973 Prolactin secretion was assessed in 23 patients with hypothalamic-pituitary disorders using L-Dopa suppression, chlorpromazine (CPZ), and thyrotropin-releasing hormone (TRH) stimulation tests. Chlorpromazine 128-131 prolactin Homo sapiens 0-9 4682868-0 1973 Effects of Ca ++ and Mg ++ on secretion and synthesis of growth hormone and prolactin by clonal strains of pituitary cell in culture. Magnesium 22-27 prolactin Homo sapiens 78-87 4630270-0 1973 Suppression of serum thyrotropin (TSH) by L-dopa in chronic hypothyroidism: interrelationships in the regulation of TSH and prolactin secretion. Levodopa 42-48 prolactin Homo sapiens 124-133 4560178-0 1972 Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Phenothiazines 60-74 prolactin Homo sapiens 0-9 4560178-0 1972 Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Reserpine 103-112 prolactin Homo sapiens 0-9 4560178-0 1972 Prolactin secretion in patients treated with various drugs: phenothiazines, tricyclic antidepressants, reserpine, and methyldopa. Methyldopa 118-128 prolactin Homo sapiens 0-9 4622109-3 1972 Chlorpromazine acts presumably at the hypothalamic level to increase prolactin secretion. Chlorpromazine 0-14 prolactin Homo sapiens 69-78 4622109-4 1972 L-Dopa (D,L-alpha-hydrazino-alpha-methyl-beta-[3,4-di-hydroxyphenyl]) has the opposite effect; it inhibits prolactin secretion and may be effective in suppressing galactorrhea. Levodopa 0-6 prolactin Homo sapiens 107-116 5061775-0 1972 Phenothiazine stimulation test for prolactin reserve: the syndrome of isolated prolactin deficiency. phenothiazine 0-13 prolactin Homo sapiens 35-44 4404153-0 1972 Studies on the feedback actions of gonadal steroids on gonadotropin and prolactin secretion: effects, sites and mechanism of action. Steroids 43-51 prolactin Homo sapiens 72-81 5107027-0 1971 Levodopa suppression of prolactin in nonpuerperal galactorrhea. Levodopa 0-8 prolactin Homo sapiens 24-33 5105903-2 1971 Investigation showed high levels of circulating prolactin which rose in response to insulin-induced hypoglycaemia and were suppressed by an oral glucose load. Glucose 145-152 prolactin Homo sapiens 48-57 5105903-3 1971 After treatment with thyroxine normal periods returned, the galactorrhoea improved, and the prolactin levels fell to undetectable levels. Thyroxine 21-30 prolactin Homo sapiens 92-101 18631571-0 1971 Prolactin-induced stimulation of H(3)-proline incorporation into the basement lamella of tadpole skin: light and electron microscope study. h(3)-proline 33-45 prolactin Homo sapiens 0-9 18631571-1 1971 Radioautographic studies revealed that prolactin markedly stimulates the incorporation of H(3)-proline into the basement lamella of the tail fin of frog tadpole. h(3)-proline 90-102 prolactin Homo sapiens 39-48 5468368-0 1970 Effect of oestrone-pellet implantation on plasma levels of prolactin. Estrone 10-18 prolactin Homo sapiens 59-68 5482108-0 1970 Prolactin and growth hormone production as influenced by catecholamines and agents that affect brain catecholamines. Catecholamines 57-71 prolactin Homo sapiens 0-9 5482108-0 1970 Prolactin and growth hormone production as influenced by catecholamines and agents that affect brain catecholamines. Catecholamines 101-115 prolactin Homo sapiens 0-9 5388414-0 1969 Effect of prolactin on thyroxine-induced metamorphosis. Thyroxine 23-32 prolactin Homo sapiens 10-19 5773110-2 1969 Prolactin induces the synthesis of both proteins in mammary gland explants treated with insulin and hydrocortisone, but the induction kinetics cannot account for the asynchronous synthesis of the two proteins that are observed in vivo. Hydrocortisone 100-114 prolactin Homo sapiens 0-9 5004688-0 1969 Location of prolactin activity in the polyacrylamide gel electrophoretograms prepared from the adenohypophyses of some species. polyacrylamide 38-52 prolactin Homo sapiens 12-21 5773783-0 1969 Effect of prolactin on the active transport of sodium by the isolated toad bladder. Sodium 47-53 prolactin Homo sapiens 10-19 4238188-0 1968 [Potentiation effect of endogenous prolactin on male sex effectors treated with testosterone]. Testosterone 80-92 prolactin Homo sapiens 35-44 33098548-8 2021 Lurasidone was associated with minimal changes in metabolic variables and prolactin levels, whereas risperidone was associated with clinically significant increases in prolactin and fasting glucose levels. Lurasidone Hydrochloride 0-10 prolactin Homo sapiens 74-83 33612017-9 2021 At day 14, 67.4% of women who received cabergoline had prolactin serum levels <25 mcg/L (threshold necessary for galactopoiesis). Cabergoline 39-50 prolactin Homo sapiens 55-64 33098548-8 2021 Lurasidone was associated with minimal changes in metabolic variables and prolactin levels, whereas risperidone was associated with clinically significant increases in prolactin and fasting glucose levels. Risperidone 100-111 prolactin Homo sapiens 168-177 33098548-10 2021 During OLE, patients switching from risperidone to lurasidone experienced a reduction in weight and prolactin levels; those continuing treatment with lurasidone experienced minimal changes in metabolic variables and prolactin. Risperidone 36-47 prolactin Homo sapiens 100-109 33098548-10 2021 During OLE, patients switching from risperidone to lurasidone experienced a reduction in weight and prolactin levels; those continuing treatment with lurasidone experienced minimal changes in metabolic variables and prolactin. Lurasidone Hydrochloride 51-61 prolactin Homo sapiens 100-109 33098548-15 2021 Patients switching from risperidone experienced improvements in metabolic parameters and prolactin levels. Risperidone 24-35 prolactin Homo sapiens 89-98 34058017-3 2021 Dietary calcium is transported across the mucosal epithelia via saturable transcellular and nonsaturable paracellular pathways, both of which are under the regulation of 1,25-dihydroxyvitamin D3 and several other endocrine and paracrine factors, such as parathyroid hormone, prolactin, 17beta-estradiol, calcitonin, and fibroblast growth factor-23. Calcium 8-15 prolactin Homo sapiens 275-284 33109441-8 2021 While prolactin has important roles in milk production including calcium and bone homeostasis, in the disease state it can also affect bone homeostasis. Calcium 65-72 prolactin Homo sapiens 6-15 34053993-10 2021 These findings support the validity of the algorithm and demonstrate that the prolactin-adjusted IPS-to-peripheral ACTH ratio can improve the differentiation between CD and EAS. IPS 97-100 prolactin Homo sapiens 78-87 34053993-10 2021 These findings support the validity of the algorithm and demonstrate that the prolactin-adjusted IPS-to-peripheral ACTH ratio can improve the differentiation between CD and EAS. CHEMBL4167713 173-176 prolactin Homo sapiens 78-87 34054112-6 2021 Mean change from baseline in metabolic parameters and prolactin were similar to or reduced in lumateperone 42 mg relative to placebo-treated patients and were smaller than risperidone. ITI-722 94-106 prolactin Homo sapiens 54-63 34035313-6 2021 However, aripiprazole was more favorable than pooled D2R antagonists for depressive symptoms, prolactin levels, and triglyceride levels. Aripiprazole 9-21 prolactin Homo sapiens 94-103 33914699-1 2021 CONTEXT: Prolactinomas frequently cause amenorrhoea, galactorrhoea and infertility and require dopamine agonist (DA) treatment to normalize prolactin levels and hence restore ovulation. Dopamine 95-103 prolactin Homo sapiens 140-149 33986418-6 2021 Two of these broad-spectrum PRL inhibitors, Salirasib and Candesartan, blocked PRL-3-induced migration in human embryonic kidney cells with no impact on cell viability. farnesylthiosalicylic acid 44-53 prolactin Homo sapiens 28-31 33979866-2 2021 The increase in plasma prolactin at 15 min following administration of 12.5 microg TRH i. v. ( prol) was introduced in Pharmacopsychiatry as an inverse estimate of tuberoinfundibular dopamine (TIDA) activity 1. tida 193-197 prolactin Homo sapiens 23-32 33485193-5 2021 RESULTS: Multiple linear regression models showed that detectable levels of TCPy were associated with an increase in DHEAS and decreases in E2, FSH, and AMH; detectable IMPy with increases in E2, DHEAS, FSH, AMH, and prolactin and decreases in SHBG and LH; and detectable DETP with marginally-significant increases in TT and TT3 and decreases in FSH, AMH, and prolactin. 3,5,6-trichloro-2-pyridinol 76-80 prolactin Homo sapiens 217-226 33485193-5 2021 RESULTS: Multiple linear regression models showed that detectable levels of TCPy were associated with an increase in DHEAS and decreases in E2, FSH, and AMH; detectable IMPy with increases in E2, DHEAS, FSH, AMH, and prolactin and decreases in SHBG and LH; and detectable DETP with marginally-significant increases in TT and TT3 and decreases in FSH, AMH, and prolactin. 3,5,6-trichloro-2-pyridinol 76-80 prolactin Homo sapiens 360-369 33986418-6 2021 Two of these broad-spectrum PRL inhibitors, Salirasib and Candesartan, blocked PRL-3-induced migration in human embryonic kidney cells with no impact on cell viability. candesartan 58-69 prolactin Homo sapiens 28-31 33961352-0 2021 Factors associated with the level of prolactin in patients under remission from Alcohol Use Disorder: A gender perspective. Alcohols 80-87 prolactin Homo sapiens 37-46 33757729-0 2021 Idiopathic granulomatous mastitis with normal prolactin level caused by risperidone. Risperidone 72-83 prolactin Homo sapiens 46-55 33961352-1 2021 BACKGROUND: Prolactin mirrors the dopaminergic activity in the brain which is key to understanding alcohol use disorders (AUD). Alcohols 99-106 prolactin Homo sapiens 12-21 32767245-9 2021 Total testosterone was positively correlated with some amino acids, while prolactin was negatively correlated with glycine (P 0.05 for all). Glycine 115-122 prolactin Homo sapiens 74-83 33961352-2 2021 Still, patients with AUD are a heterogenous group and there seem to be gender differences in the relationship between alcohol use and the level of prolactin. Alcohols 118-125 prolactin Homo sapiens 147-156 33961352-3 2021 In this study, we examined gender-wise relationship of alcohol use trait- and state-related factors with the level of prolactin among AUD inpatients in remission. Alcohols 55-62 prolactin Homo sapiens 118-127 33961352-7 2021 Among females, younger age, early alcohol debut, and absence of parental drinking problem predicted higher level of prolactin. Alcohols 34-41 prolactin Homo sapiens 116-125 33961352-10 2021 Especially in the female AUD patients under remission, alcohol use trait-related factors were better predictors of the level of prolactin than the alcohol use state-related factors, indicating that individuals might characteristically have varying degree of dopamine reactivity. Alcohols 55-62 prolactin Homo sapiens 128-137 33961352-10 2021 Especially in the female AUD patients under remission, alcohol use trait-related factors were better predictors of the level of prolactin than the alcohol use state-related factors, indicating that individuals might characteristically have varying degree of dopamine reactivity. Dopamine 258-266 prolactin Homo sapiens 128-137 33880739-3 2021 Reports have suggested that aripiprazole may decrease elevated prolactin. Aripiprazole 28-40 prolactin Homo sapiens 63-72 33933067-8 2021 Administration of cabergoline together with somatostatin resulted in sharp decreases in his GH, PRL, and serum and urinary calcium concentrations. Cabergoline 18-29 prolactin Homo sapiens 96-99 33880739-9 2021 Reductions in prolactin from baseline, before the introduction of aripiprazole, were significantly greater for adjunct aripiprazole than for adjunct placebo in all the studies (p = 0.04 to p < 0.0001). Aripiprazole 119-131 prolactin Homo sapiens 14-23 33880739-10 2021 Normalisation of serum prolactin levels was significantly more likely with adjunct aripiprazole than adjunct placebo (p = 0.028 to p < 0.001, data from three studies). Aripiprazole 83-95 prolactin Homo sapiens 23-32 33880739-13 2021 Adjunct aripiprazole was statistically significantly effective in treating elevated serum prolactin levels in six RCTs. Aripiprazole 8-20 prolactin Homo sapiens 90-99 33902531-11 2021 CONCLUSIONS: Reasons for the association between prolactin and metabolic parameters include direct effects of prolactin on adipose tissue, hyperprolactinaemia-triggered hypogonadism and dopamine-agonist therapy per se. Dopamine 186-194 prolactin Homo sapiens 49-58 33647379-11 2021 Particularly, strategies mediated by prolactin, a somatotropin family-related hormone that displays a significant neuroprotective effect against both Glu and kainic acid-induced excitotoxicity in the hippocampus, are described. Glutamic Acid 150-153 prolactin Homo sapiens 37-46 33647379-11 2021 Particularly, strategies mediated by prolactin, a somatotropin family-related hormone that displays a significant neuroprotective effect against both Glu and kainic acid-induced excitotoxicity in the hippocampus, are described. Kainic Acid 158-169 prolactin Homo sapiens 37-46 33905023-8 2021 The prolactin antagonist was characterized by SDS-PAGE, Western blotting, reversed-phase high-performance liquid chromatography (RP-HPLC) and MALDI-TOF-MS. Sodium Dodecyl Sulfate 46-49 prolactin Homo sapiens 4-13 33398769-7 2021 Novel aspects of our case series include the first report of a prolactinoma in a transwoman associated with spironolactone and the alternate progestin medroxyprogesterone acetate and documentation of the transient changes in prolactin from baseline (prior to feminizing hormones) in two transwomen which demonstrate that marked hyperprolactinemia develops early in the course of GAHT. Spironolactone 108-122 prolactin Homo sapiens 63-72 33398769-10 2021 Screening of prolactin levels in transwomen receiving GAHT could potentially prevent morbidity related to hyperprolactinemia and allow for early detection of prolactin secreting pituitary adenomas. gaht 54-58 prolactin Homo sapiens 13-22 33398769-10 2021 Screening of prolactin levels in transwomen receiving GAHT could potentially prevent morbidity related to hyperprolactinemia and allow for early detection of prolactin secreting pituitary adenomas. gaht 54-58 prolactin Homo sapiens 111-120 32860210-9 2021 Placental iodine had strong, very strong, and weak negative correlations with TSH, hCG, and PRL, respectively (rTSH = - 0.763, p < 0.001;rHCG = - 0.919, p < 0.001; rPRL = - 0.312, p = 0.044). Iodine 10-16 prolactin Homo sapiens 92-95 32860210-10 2021 CONCLUSION: This study showed that the placental iodine level was inversely correlated with neonatal TSH, hCG, and PRL. Iodine 49-55 prolactin Homo sapiens 115-118 34025189-7 2021 In prolactin-producing pituitary adenomas, distinct hypointense areas in early phase on T2WI, possibly owning to diffuse hemorrhage, indicate pronounced regressions of invasive macroprolactinomas during cabergoline therapy. Cabergoline 203-214 prolactin Homo sapiens 3-12 33421066-10 2021 The prolactin-adjusted IPS:P ACTH ratio can improve differentiation between CD and EAS when there is a lack of proper IPS venous efflux. Ethacrynic Acid 83-86 prolactin Homo sapiens 4-13 33883897-6 2021 Results: Switching to brexpiprazole significantly decreased the Drug-Induced Extrapyramidal Symptoms Scale total score (p=0.008), prolactin levels (p<0.001), body weight (p=0.046), and body-mass index (p=0.034), and increased HDL cholesterol (p=0.008). brexpiprazole 22-35 prolactin Homo sapiens 130-139 33883897-8 2021 Conclusion: Switching to brexpiprazole significantly improved EPS, high prolactin levels, and metabolic side effects without elevating plasma HVA levels. brexpiprazole 25-38 prolactin Homo sapiens 72-81 32706496-4 2021 Bromocriptine, a dopamine D2 receptor agonist, was administered to reduce her serum prolactin level. Bromocriptine 0-13 prolactin Homo sapiens 84-93 33898438-4 2021 We found that prednisolone treatment reduced hESF cytokine expression (IL6, IL11, IL18, LIF, and LIFR) but had no effect on hESF expression or secretion of the classic markers of decidualization [prolactin (PRL) and IGFBP1]. Prednisolone 14-26 prolactin Homo sapiens 196-205 33898438-4 2021 We found that prednisolone treatment reduced hESF cytokine expression (IL6, IL11, IL18, LIF, and LIFR) but had no effect on hESF expression or secretion of the classic markers of decidualization [prolactin (PRL) and IGFBP1]. Prednisolone 14-26 prolactin Homo sapiens 207-210 33898216-6 2021 However, she was administered oral cabergoline (0.25 mg per week) when her PRL levels were elevated to 250 ng/mL 38 months after therapeutic intervention with sirolimus. Cabergoline 35-46 prolactin Homo sapiens 75-78 33884915-7 2021 Total testosterone and prolactin levels tended to be lower in the control group than in the LPE group. LPC-ETHER 92-95 prolactin Homo sapiens 23-32 32948308-8 2021 Hyperprolactinemia (i.e. prolactin levels above the reference range) was observed in 26% of CHR-P and 45% of FEP patients. chr-p 92-97 prolactin Homo sapiens 5-14 33485686-6 2021 Serum prolactin (PRL) concentration during the ISO period was greater in heifers exposed to LDP than in those exposed to SDP. sdp 121-124 prolactin Homo sapiens 6-15 33485686-6 2021 Serum prolactin (PRL) concentration during the ISO period was greater in heifers exposed to LDP than in those exposed to SDP. sdp 121-124 prolactin Homo sapiens 17-20 33268090-1 2021 Styrene increases serum prolactin (PRL) concentration. Styrene 0-7 prolactin Homo sapiens 24-33 33706313-2 2022 The preferred first-line therapy is a medical treatment with dopamine agonists (DA), mainly cabergoline, to reduce serum prolactin levels, tumor volume, and mass effect. Dopamine 61-69 prolactin Homo sapiens 121-130 33706313-2 2022 The preferred first-line therapy is a medical treatment with dopamine agonists (DA), mainly cabergoline, to reduce serum prolactin levels, tumor volume, and mass effect. Cabergoline 92-103 prolactin Homo sapiens 121-130 33578589-7 2021 The increased PRL may be a putative mechanism that underlies the onset in female patients with a moderate inverse relationship between TSH and PRL. Thyrotropin 135-138 prolactin Homo sapiens 14-17 33578589-7 2021 The increased PRL may be a putative mechanism that underlies the onset in female patients with a moderate inverse relationship between TSH and PRL. Thyrotropin 135-138 prolactin Homo sapiens 143-146 33560411-8 2021 RESULTS: Despite some statistical differences, findings were consistent across the two alcohol administration paradigms: IV ghrelin, compared to placebo, increased blood concentrations of GLP-1, PP, cortisol, and prolactin, both acutely and during the whole session. Ghrelin 124-131 prolactin Homo sapiens 213-222 33734638-6 2021 Prolactin level was measured by the immunoenzyme method with manual PEG precipitation and TRACE. Polyethylene Glycols 68-71 prolactin Homo sapiens 0-9 33734638-12 2021 Measurements of prolactin levels by the TRACE method is useful for correct diagnosis in patients with equivocal results received by traditional method with PEG precipitation. Polyethylene Glycols 156-159 prolactin Homo sapiens 16-25 33682941-7 2021 The inhibitory effects of OCT on GH- and PRL-secretion and proliferation were improved in the presence of TGF-beta1, as well as by SSTR2 overexpression. Octreotide 26-29 prolactin Homo sapiens 41-44 33202169-2 2021 Domperidone stimulates the release of prolactin, thereby increasing breast milk production. Domperidone 0-11 prolactin Homo sapiens 38-47 33202169-4 2021 The secondary outcomes included the effect of domperidone on prolactin levels, adverse effects of domperidone, and outcome on breastfeeding rates at discharge. Domperidone 46-57 prolactin Homo sapiens 61-70 33202169-11 2021 The prolactin levels in the DG and PG increased from 72.85 (22.2-167.15) and 42.33 (14.02-93.54) ng/mL, respectively, to 223.4 (49.79-280.2) ng/mL (p = 0.005) in the DG and 60.08 (14.31-132.14) ng/mL (p = 0.232) in the PG on the 7th day of treatment. pg 35-37 prolactin Homo sapiens 4-13 33202169-11 2021 The prolactin levels in the DG and PG increased from 72.85 (22.2-167.15) and 42.33 (14.02-93.54) ng/mL, respectively, to 223.4 (49.79-280.2) ng/mL (p = 0.005) in the DG and 60.08 (14.31-132.14) ng/mL (p = 0.232) in the PG on the 7th day of treatment. pg 219-221 prolactin Homo sapiens 4-13 33080146-0 2021 Prolactin-to-Testosterone Ratio Predicts Pituitary Abnormalities in Mildly Hyperprolactinemic Men with Symptoms of Hypogonadism. Testosterone 13-25 prolactin Homo sapiens 0-9 33080146-10 2021 The partition incorporating a prolactin-to-testosterone ratio cutoff of 0.10 and prolactin cutoff of 25 ng/mL achieved 90% sensitivity, 48% specificity, and reduced diagnostic expenses by 28%. Testosterone 43-55 prolactin Homo sapiens 30-39 33380894-1 2021 Introduction: High prolactin (PRL) concentrations are found in laboratory test results of patients on majority of antipsychotic drugs. Prolactin 30-33 prolactin Homo sapiens 19-28 33538741-3 2021 The ns-PRL in a reductive atmosphere simulated the electron/proton donors of amino acid residues in Lyso upon photoexcitation and revealed the reduction mechanism of TZs, as that first followed one-electron-transfer and then probably proton-coupled electron transfer. Tetrazolium Salts 166-169 prolactin Homo sapiens 7-10 33278020-3 2021 The aim of the study was to evaluate if aripiprazole and olanzapine alter prolactin levels, lipid and glucose metabolism and hepatic, haematological, thyroid and renal function. Aripiprazole 40-52 prolactin Homo sapiens 74-83 33278020-3 2021 The aim of the study was to evaluate if aripiprazole and olanzapine alter prolactin levels, lipid and glucose metabolism and hepatic, haematological, thyroid and renal function. Olanzapine 57-67 prolactin Homo sapiens 74-83 33268090-1 2021 Styrene increases serum prolactin (PRL) concentration. Styrene 0-7 prolactin Homo sapiens 35-38 33605905-8 2021 Prolactin correlated positively with E2 (r = 0.296, P = 0.037), and TAC (r = 0.336, P = 0.011) in women with BCa. Estradiol 37-39 prolactin Homo sapiens 0-9 33549979-0 2021 Factors influencing the effect of aripiprazole on prolactin levels in patients treated with risperidone or paliperidone. Aripiprazole 34-46 prolactin Homo sapiens 50-59 33549979-0 2021 Factors influencing the effect of aripiprazole on prolactin levels in patients treated with risperidone or paliperidone. Risperidone 92-103 prolactin Homo sapiens 50-59 33549979-0 2021 Factors influencing the effect of aripiprazole on prolactin levels in patients treated with risperidone or paliperidone. Paliperidone Palmitate 107-119 prolactin Homo sapiens 50-59 33496984-7 2021 Mean prolactin levels increased slightly in the aripiprazole group, but decreased in the non-aripiprazole group. Aripiprazole 48-60 prolactin Homo sapiens 5-14 33496984-7 2021 Mean prolactin levels increased slightly in the aripiprazole group, but decreased in the non-aripiprazole group. Aripiprazole 93-105 prolactin Homo sapiens 5-14 33637446-8 2021 Despite comparable anthropometric parameters, the overweight/obese patients with a higher PRL tertile had decreased levels of triglycerides, nonesterified fatty acids, homeostasis model assessment of insulin resistance, and adipo-IR compared with the patients in the moderate and lower PRL tertiles. Triglycerides 126-139 prolactin Homo sapiens 90-93 33477154-0 2022 PROLACTIN RESPONSE TO METFORMIN IN CABERGOLINE-RESISTANT PROLACTINOMAS: A PILOT STUDY. Metformin 22-31 prolactin Homo sapiens 0-9 33477154-0 2022 PROLACTIN RESPONSE TO METFORMIN IN CABERGOLINE-RESISTANT PROLACTINOMAS: A PILOT STUDY. Cabergoline 35-46 prolactin Homo sapiens 0-9 33477154-3 2022 Metformin, a biguanide widely used in the treatment of diabetes mellitus, has been shown to reduce prolactin secretion in various pituitary tumor cell lineages both in vitro and in vivo and in human pituitary adenomas in vitro. Metformin 0-9 prolactin Homo sapiens 99-108 33477154-3 2022 Metformin, a biguanide widely used in the treatment of diabetes mellitus, has been shown to reduce prolactin secretion in various pituitary tumor cell lineages both in vitro and in vivo and in human pituitary adenomas in vitro. Biguanides 13-22 prolactin Homo sapiens 99-108 33477154-4 2022 The aim of this study is to test the effects of metformin addition to cabergoline treatment on prolactin levels in patients with resistant prolactinomas. Metformin 48-57 prolactin Homo sapiens 95-104 33477154-4 2022 The aim of this study is to test the effects of metformin addition to cabergoline treatment on prolactin levels in patients with resistant prolactinomas. Cabergoline 70-81 prolactin Homo sapiens 95-104 33477154-12 2022 Two patients were considered partial responders for exhibiting prolactin decreases >=50% at a single time point during metformin. Metformin 119-128 prolactin Homo sapiens 63-72 33477154-13 2022 CONCLUSION: Metformin addition to ongoing high dose cabergoline treatment in patients with cabergoline-resistant prolactinomas failed to show a consistent inhibitory effect in serum prolactin levels. Metformin 12-21 prolactin Homo sapiens 113-122 33477154-13 2022 CONCLUSION: Metformin addition to ongoing high dose cabergoline treatment in patients with cabergoline-resistant prolactinomas failed to show a consistent inhibitory effect in serum prolactin levels. Cabergoline 91-102 prolactin Homo sapiens 113-122 33637446-8 2021 Despite comparable anthropometric parameters, the overweight/obese patients with a higher PRL tertile had decreased levels of triglycerides, nonesterified fatty acids, homeostasis model assessment of insulin resistance, and adipo-IR compared with the patients in the moderate and lower PRL tertiles. Fatty Acids, Nonesterified 141-166 prolactin Homo sapiens 90-93 33488290-7 2021 CSE concentrations at 0.01% and 0.025% increased the prolactin expression levels after treatment with E2 and MPA, whereas 0.1% and 0.25% CSE concentrations suppressed prolactin. Estradiol 102-104 prolactin Homo sapiens 53-62 33488290-7 2021 CSE concentrations at 0.01% and 0.025% increased the prolactin expression levels after treatment with E2 and MPA, whereas 0.1% and 0.25% CSE concentrations suppressed prolactin. Medroxyprogesterone Acetate 109-112 prolactin Homo sapiens 53-62 31234219-0 2021 The Impact of Ethinyl Estradiol on Metformin Action on Prolactin Levels in Women with Hyperprolactinemia. Ethinyl Estradiol 14-31 prolactin Homo sapiens 55-64 31234219-0 2021 The Impact of Ethinyl Estradiol on Metformin Action on Prolactin Levels in Women with Hyperprolactinemia. Metformin 35-44 prolactin Homo sapiens 55-64 31234219-1 2021 BACKGROUND: Metformin reduced prolactin levels only in women with hyperprolactinemia. Metformin 12-21 prolactin Homo sapiens 30-39 31234219-9 2021 Although metformin treatment decreased plasma prolactin levels in both study groups, this effect was stronger in women taking oral contraceptive pills. Metformin 9-18 prolactin Homo sapiens 46-55 31234219-11 2021 The changes in plasma prolactin correlated with their baseline insulin sensitivity and the effect of metformin on insulin sensitivity. Metformin 101-110 prolactin Homo sapiens 22-31 33155660-1 2021 As hyperprolactinemia is observed in patients with bromocriptine-resistant prolactinoma, prolactin (PRL) has been implicated in the development of bromocriptine resistance. Bromocriptine 51-64 prolactin Homo sapiens 8-17 33497040-7 2021 Results: The rhFSH treated group showed a significant increase in the level of FSH, luteinizing hormone (LH), testosterone (T) and prolactin (PRL), as well as significant improvements in sperm parameters compared to the control group. rhfsh 13-18 prolactin Homo sapiens 131-140 33497040-7 2021 Results: The rhFSH treated group showed a significant increase in the level of FSH, luteinizing hormone (LH), testosterone (T) and prolactin (PRL), as well as significant improvements in sperm parameters compared to the control group. rhfsh 13-18 prolactin Homo sapiens 142-145 33347020-0 2021 Prolactin and Estrogen Levels in Postmenopausal Women Receiving Aripiprazole Augmentation Treatment for Depression. Aripiprazole 64-76 prolactin Homo sapiens 0-9 33347020-4 2021 Aripiprazole is known to be a prolactin-sparing antipsychotic; however, data regarding its effects on prolactin and estrogens in postmenopausal women are lacking. Aripiprazole 0-12 prolactin Homo sapiens 30-39 33347020-4 2021 Aripiprazole is known to be a prolactin-sparing antipsychotic; however, data regarding its effects on prolactin and estrogens in postmenopausal women are lacking. Aripiprazole 0-12 prolactin Homo sapiens 102-111 32649802-3 2020 This study was aimed at investigating whether prolactin excess determines the effect of vitamin D/selenomethionine combination therapy on thyroid autoimmunity. Vitamin D 88-97 prolactin Homo sapiens 46-55 33112804-4 2021 There was a significant correlation between cells displaying spontaneous calcium spikes and cells showing spontaneous bursts in prolactin expression. Calcium 73-80 prolactin Homo sapiens 128-137 33112804-9 2021 We suggest that maintenance of a heterogeneous bimodal population is a fundamental characteristic of this cell type and that calcium activation and histone acetylation at least in part, drive prolactin transcriptional competence. Calcium 125-132 prolactin Homo sapiens 192-201 33132356-0 2020 Changes in luteinizing hormone pulse frequency and prolactin levels in bitches in response to estrus induction by cabergoline-its cases where it is delayed to induce estrus. Cabergoline 114-125 prolactin Homo sapiens 51-60 33132356-8 2020 A positive correlation was found between the LH levels two weeks after cabergoline administration and PRL reduction. Cabergoline 71-82 prolactin Homo sapiens 102-105 33358454-10 2021 Erectile dysfunction caused by pituitary neoplasms is a multifactorial disease and elevated prolactin has consequences on testosterone, LH, FSH, and dopamine precursor levels. Testosterone 122-134 prolactin Homo sapiens 92-101 33358454-10 2021 Erectile dysfunction caused by pituitary neoplasms is a multifactorial disease and elevated prolactin has consequences on testosterone, LH, FSH, and dopamine precursor levels. Dopamine 149-157 prolactin Homo sapiens 92-101 33426414-9 2020 Prior to the treatment, significant negative correlation between PRL and E2 (r = -0.386, p = 0.007), PRL and progesterone (r = -0.420, p = 0.003) was detected. Estradiol 73-75 prolactin Homo sapiens 65-68 33064050-8 2020 Uniquely, aripiprazole treatment is associated with reduced serum prolactin levels and QTc interval. Aripiprazole 10-22 prolactin Homo sapiens 66-75 32822526-11 2020 In levothyroxine-treated patients, metformin slightly reduced prolactin levels. Thyroxine 3-16 prolactin Homo sapiens 62-71 32822526-11 2020 In levothyroxine-treated patients, metformin slightly reduced prolactin levels. Metformin 35-44 prolactin Homo sapiens 62-71 33038380-11 2020 SIGNIFICANCE: Prolactin can be used peripherally and centrally, and exerts its neuro regenerative effects against further damage post-TBI and NTBI. ntbi 142-146 prolactin Homo sapiens 14-23 33055297-14 2020 CPA+E worsened the metabolic profile with a slight increase in PRL levels. Cyproterone Acetate 0-3 prolactin Homo sapiens 63-66 32822526-13 2020 The thyrotrophin-lowering effect of metformin correlated with the improvement in insulin sensitivity and in levothyroxine-treated women with the changes in prolactin levels. Thyroxine 108-121 prolactin Homo sapiens 156-165 32649802-3 2020 This study was aimed at investigating whether prolactin excess determines the effect of vitamin D/selenomethionine combination therapy on thyroid autoimmunity. Selenomethionine 98-114 prolactin Homo sapiens 46-55 32649802-10 2020 The decrease in antibody titres, as well as the improvement in vitamin D status, was more pronounced in subjects with prolactin levels within the reference range than in subjects with hyperprolactinaemia and was inversely correlated with prolactin levels. Vitamin D 63-72 prolactin Homo sapiens 118-127 32649802-10 2020 The decrease in antibody titres, as well as the improvement in vitamin D status, was more pronounced in subjects with prolactin levels within the reference range than in subjects with hyperprolactinaemia and was inversely correlated with prolactin levels. Vitamin D 63-72 prolactin Homo sapiens 189-198 32748152-2 2020 Evening primrose oil (EPO) may restore the saturated/unsaturated fatty acid balance and decrease sensitivity to steroidal hormones or prolactin. evening primrose oil 8-20 prolactin Homo sapiens 134-143 33041043-14 2020 Cabergoline dramatically inhibited PRL secretion and decreased milk yield and udder volume of lactating dairy ewes. Cabergoline 0-11 prolactin Homo sapiens 35-38 33228575-0 2020 Abnormally low prolactin levels in schizophrenia patients after switching to aripiprazole in a randomized trial: a biomarker for rebound in psychotic symptoms? Aripiprazole 77-89 prolactin Homo sapiens 15-24 33228575-1 2020 BACKGROUND: Switching to aripiprazole from other antipsychotics can avoid antipsychotic-induced hyperprolactinemia but may result in an abnormally low prolactin level. Aripiprazole 25-37 prolactin Homo sapiens 101-110 33228575-2 2020 This study aimed to assess whether the aripiprazole-induced abnormally low prolactin level was a biomarker for subsequent rebound of positive symptoms in schizophrenia patients. Aripiprazole 39-51 prolactin Homo sapiens 75-84 33228575-9 2020 CONCLUSIONS: An abnormally low prolactin level after switching to aripiprazole in schizophrenia patients was a potential warning sign of a psychotic rebound. Aripiprazole 66-78 prolactin Homo sapiens 31-40 33228575-10 2020 Hence, monitoring of prolactin levels after switching to aripiprazole may help avoid such rebound in schizophrenia. Aripiprazole 57-69 prolactin Homo sapiens 21-30 33168897-7 2020 Pathway enrichment analysis revealed specific alterations of these clusters: calcium signaling pathway in CNFPA; renin-angiotensin system for ACTH-adenomas and fatty acid metabolism for the TSH-, PRL-, GH-cluster. Calcium 77-84 prolactin Homo sapiens 196-199 33168897-7 2020 Pathway enrichment analysis revealed specific alterations of these clusters: calcium signaling pathway in CNFPA; renin-angiotensin system for ACTH-adenomas and fatty acid metabolism for the TSH-, PRL-, GH-cluster. Fatty Acids 160-170 prolactin Homo sapiens 196-199 32857272-3 2020 We present the rare case of a patient who had prolactin elevation typical of a prolactin-secreting pituitary macroadenoma,with a normal cranial MRI, and in whom the prolactin rose further with dopamine agonist treatment. Dopamine 193-201 prolactin Homo sapiens 79-88 32857272-3 2020 We present the rare case of a patient who had prolactin elevation typical of a prolactin-secreting pituitary macroadenoma,with a normal cranial MRI, and in whom the prolactin rose further with dopamine agonist treatment. Dopamine 193-201 prolactin Homo sapiens 79-88 32781144-4 2020 She was initially treated with dopamine agonists with normalization of prolactin levels but no changes on the size of the lesion. Dopamine 31-39 prolactin Homo sapiens 71-80 33047125-0 2020 Impact of arginine supplementation on serum prolactin and mRNA abundance of amino acid transporter genes in mammary tissue of lactating sows. Arginine 10-18 prolactin Homo sapiens 44-53 32827513-1 2020 In fishes, Prl signaling underlies the homeostatic regulation of hydromineral balance by controlling essential solute and water transporting functions performed by the gill, gastrointestinal tract, kidney, urinary bladder, and integument. Water 122-127 prolactin Homo sapiens 11-14 32827513-2 2020 Comparative studies spanning over 60 years have firmly established that Prl promotes physiological activities that enable euryhaline and stenohaline teleosts to reside in freshwater environments; nonetheless, the specific molecular and cellular targets of Prl in ion- and water-transporting tissues are still being resolved. euryhaline 122-132 prolactin Homo sapiens 72-75 32827513-2 2020 Comparative studies spanning over 60 years have firmly established that Prl promotes physiological activities that enable euryhaline and stenohaline teleosts to reside in freshwater environments; nonetheless, the specific molecular and cellular targets of Prl in ion- and water-transporting tissues are still being resolved. stenohaline 137-148 prolactin Homo sapiens 72-75 32827513-2 2020 Comparative studies spanning over 60 years have firmly established that Prl promotes physiological activities that enable euryhaline and stenohaline teleosts to reside in freshwater environments; nonetheless, the specific molecular and cellular targets of Prl in ion- and water-transporting tissues are still being resolved. Water 176-181 prolactin Homo sapiens 72-75 32748473-8 2020 There was significantly higher serum concentration of PRL on day 7 of lactation in sows consuming silymarin than sows from the CGP group. Silymarin 98-107 prolactin Homo sapiens 54-57 32748473-10 2020 In summary, our results indicate that silymarin supplementation during transition and lactation can increase circulating concentrations of PRL transiently, reduce oxidative stress, increase feed intake and enhance protein metabolism, thereby significantly increasing milk yield of sows and subsequently improving growth performance of their offsprings. Silymarin 38-47 prolactin Homo sapiens 139-142 33047125-1 2020 This study was conducted to test the hypothesis that supplemental dietary Arg to late-pregnant and lactating sows increases serum prolactin concentrations and mRNA abundance of SLC7A1, SLC7A2 and SLC6A14 in mammary parenchymal tissue. Arginine 74-77 prolactin Homo sapiens 130-139 33047125-12 2020 Compared to controls, serum prolactin concentrations tended to be greater (P = 0.08) in ARG sows on d 4 of lactation, and did not differ on d 18. Arginine 88-91 prolactin Homo sapiens 28-37 33047125-14 2020 Dietary Arg supplementation at a rate of 0.10 g/kg BW during late pregnancy and lactation tended to increase serum prolactin concentrations with no increase in mammary transcript abundance of SLC7A1, SLC7A2 and SLC6A14 in early lactation. Arginine 8-11 prolactin Homo sapiens 115-124 32484287-9 2020 In women with normal prolactin levels, levothyroxine reduced also thyroglobulin antibody titers and increased 25-hydroxyvitamin D levels. Thyroxine 39-52 prolactin Homo sapiens 21-30 32597541-3 2020 METHODS: From January to July in 2018, totally 317 patients with elevated PRL were subjected to the polyethylene glycol (PEG) precipitation assay. Polyethylene Glycols 100-119 prolactin Homo sapiens 74-77 33241169-1 2020 Estrogen (17beta-estradiol or E2) is a crucial regulator of the synthesis and secretion of pituitary reproductive hormones luteinizing hormone, follicle-stimulating hormone, and prolactin. Estradiol 10-26 prolactin Homo sapiens 178-187 33136923-0 2020 Effect of Brexpiprazole on Prolactin and Sexual Functioning: An Analysis of Short- and Long-Term Study Data in Major Depressive Disorder. brexpiprazole 10-23 prolactin Homo sapiens 27-36 33136923-3 2020 We evaluated the effect of brexpiprazole on prolactin and sexual functioning in patients with MDD. brexpiprazole 27-40 prolactin Homo sapiens 44-53 33136923-8 2020 FINDINGS/RESULTS: Median changes in prolactin levels from baseline to week 6 in short-term studies were as follows: brexpiprazole, 5.99 ng/mL (females) and 1.61 ng/mL (males); placebo, -0.15 ng/mL (females) and -0.08 ng/mL (males).Median changes from baseline to week 52 in the OLE were as follows: 0.27 ng/mL (females) and 0.27 ng/mL (males). brexpiprazole 116-129 prolactin Homo sapiens 36-45 33136923-9 2020 Prolactin levels in patients with baseline prolactin greater than 1x upper limit of normal values tended to decrease over time.The proportion of brexpiprazole-treated patients with greater than 3x upper limit of normal postbaseline prolactin values in short-term studies for both sexes was low (0%-0.3%) and did not differ from placebo: OLE, 0.5% (females) and 0.8% (males).In short-term studies, the incidence of prolactin-related TEAEs was 3.1% for brexpiprazole and 0.7% for placebo (OLE, 3.1%). brexpiprazole 145-158 prolactin Homo sapiens 0-9 33136923-9 2020 Prolactin levels in patients with baseline prolactin greater than 1x upper limit of normal values tended to decrease over time.The proportion of brexpiprazole-treated patients with greater than 3x upper limit of normal postbaseline prolactin values in short-term studies for both sexes was low (0%-0.3%) and did not differ from placebo: OLE, 0.5% (females) and 0.8% (males).In short-term studies, the incidence of prolactin-related TEAEs was 3.1% for brexpiprazole and 0.7% for placebo (OLE, 3.1%). brexpiprazole 145-158 prolactin Homo sapiens 43-52 33136923-9 2020 Prolactin levels in patients with baseline prolactin greater than 1x upper limit of normal values tended to decrease over time.The proportion of brexpiprazole-treated patients with greater than 3x upper limit of normal postbaseline prolactin values in short-term studies for both sexes was low (0%-0.3%) and did not differ from placebo: OLE, 0.5% (females) and 0.8% (males).In short-term studies, the incidence of prolactin-related TEAEs was 3.1% for brexpiprazole and 0.7% for placebo (OLE, 3.1%). brexpiprazole 145-158 prolactin Homo sapiens 232-241 33136923-9 2020 Prolactin levels in patients with baseline prolactin greater than 1x upper limit of normal values tended to decrease over time.The proportion of brexpiprazole-treated patients with greater than 3x upper limit of normal postbaseline prolactin values in short-term studies for both sexes was low (0%-0.3%) and did not differ from placebo: OLE, 0.5% (females) and 0.8% (males).In short-term studies, the incidence of prolactin-related TEAEs was 3.1% for brexpiprazole and 0.7% for placebo (OLE, 3.1%). brexpiprazole 145-158 prolactin Homo sapiens 232-241 33254515-3 2020 It has been reported that by controlled enhancement of blood PRL level (within the physiological limit and in some cases a little elevated above the normal to induce mild hyperprolactinemia) using dopamine antagonists such immune-stimulatory advantage can led to survival of the patients in many critical conditions. Dopamine 197-205 prolactin Homo sapiens 61-64 33254515-4 2020 Here it is hypothesized that through controlled augmentation of blood PRL level using dopamine antagonists like domperidone/metoclopramide, which are commonly used drugs for the treatment of nausea and vomiting, both innate and adaptive immunity can be boosted to evade or tone down COVID-19. Dopamine 86-94 prolactin Homo sapiens 70-73 33254515-4 2020 Here it is hypothesized that through controlled augmentation of blood PRL level using dopamine antagonists like domperidone/metoclopramide, which are commonly used drugs for the treatment of nausea and vomiting, both innate and adaptive immunity can be boosted to evade or tone down COVID-19. Domperidone 112-123 prolactin Homo sapiens 70-73 33254515-4 2020 Here it is hypothesized that through controlled augmentation of blood PRL level using dopamine antagonists like domperidone/metoclopramide, which are commonly used drugs for the treatment of nausea and vomiting, both innate and adaptive immunity can be boosted to evade or tone down COVID-19. Metoclopramide 124-138 prolactin Homo sapiens 70-73 33051752-4 2020 In our study we evaluated the effect of pregabalin, at concentrations 150 and 300 mg/kg/day for 90 days, on hormones; FSH, LH, testosterone and prolactin secretion. Pregabalin 40-50 prolactin Homo sapiens 144-153 33241169-1 2020 Estrogen (17beta-estradiol or E2) is a crucial regulator of the synthesis and secretion of pituitary reproductive hormones luteinizing hormone, follicle-stimulating hormone, and prolactin. Estradiol 30-32 prolactin Homo sapiens 178-187 33081268-9 2020 In conclusion, elevated secretion of COR and PRL in infertile women impairs the menstrual cycle by decreasing the pre-ovulatory LH peak and E2 and postovulatory E2 levels that affect the endometrial growth, and consequently reduce the chances to conceive. Estradiol 140-142 prolactin Homo sapiens 45-48 33123590-8 2020 Conclusions: Our study results provide mechanistic insight to the effect of BPDE on trophoblast dysfunction through enhanced cell apoptosis and inhibited migration, providing further experimental evidence to the causative links between BaP exposure and PRL. 7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide 76-80 prolactin Homo sapiens 253-256 33123590-8 2020 Conclusions: Our study results provide mechanistic insight to the effect of BPDE on trophoblast dysfunction through enhanced cell apoptosis and inhibited migration, providing further experimental evidence to the causative links between BaP exposure and PRL. Benzo(a)pyrene 236-239 prolactin Homo sapiens 253-256 33081268-9 2020 In conclusion, elevated secretion of COR and PRL in infertile women impairs the menstrual cycle by decreasing the pre-ovulatory LH peak and E2 and postovulatory E2 levels that affect the endometrial growth, and consequently reduce the chances to conceive. Estradiol 161-163 prolactin Homo sapiens 45-48 32707429-10 2020 Concentrations of PRL were greater (P < 0.05) in IXP compared with DXP and CON, regardless of treatment day. dxp 67-70 prolactin Homo sapiens 18-21 33162942-2 2020 Studies in animals and humans have documented that PRL receptors (PRL-Rs) are widely expressed on uterine cells and that PRL is directly synthesized by the endometrium under the stimulatory action of progesterone. Progesterone 200-212 prolactin Homo sapiens 51-54 33031334-8 2020 Preoperative PRL level (adjusted OR = 1.741, P = .03) was the exclusive predictor for PRL normalization after adjusting for tumor volume, preoperative serum FT4 concentration, and postoperative residual. CHEMBL179036 157-160 prolactin Homo sapiens 13-16 33031334-8 2020 Preoperative PRL level (adjusted OR = 1.741, P = .03) was the exclusive predictor for PRL normalization after adjusting for tumor volume, preoperative serum FT4 concentration, and postoperative residual. CHEMBL179036 157-160 prolactin Homo sapiens 86-89 32654174-4 2020 PATIENTS AND MEASUREMENTS: The study population consisted of three age-matched groups of young women with normal, regular menstrual cycles: 15 subjects with cabergoline-induced hypoprolactinemia (group A), 25 cabergoline-treated individuals with prolactin levels within the reference range (group B) and 30 dopamine agonist-naive women with normoprolactinemia. Cabergoline 157-168 prolactin Homo sapiens 181-190 32654174-5 2020 Because of low prolactin levels, the dose of cabergoline in group A (but not in group B) was then reduced. Cabergoline 45-56 prolactin Homo sapiens 15-24 32654174-10 2020 Cabergoline dose reduction normalized the FSFI score, desire, arousal, the BDI-II score, as well as normalized prolactin, total testosterone and the free androgen index. Cabergoline 0-11 prolactin Homo sapiens 111-120 32654174-11 2020 CONCLUSIONS: The obtained results suggest that dopamine agonist-induced hypoprolactinemia impairs sexual functioning and well-being in young women, as well as that these disturbances are secondary to low prolactin levels, not to specific properties of cabergoline. Dopamine 47-55 prolactin Homo sapiens 76-85 32654174-11 2020 CONCLUSIONS: The obtained results suggest that dopamine agonist-induced hypoprolactinemia impairs sexual functioning and well-being in young women, as well as that these disturbances are secondary to low prolactin levels, not to specific properties of cabergoline. Cabergoline 252-263 prolactin Homo sapiens 76-85 32508315-2 2020 Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. Dopamine 32-40 prolactin Homo sapiens 92-95 32599424-0 2020 Efficacy of cabergoline and triptans for cluster-like headache caused by prolactin-secreting pituitary adenoma: A literature review and case report. Cabergoline 12-23 prolactin Homo sapiens 73-82 32599424-0 2020 Efficacy of cabergoline and triptans for cluster-like headache caused by prolactin-secreting pituitary adenoma: A literature review and case report. Tryptamines 28-36 prolactin Homo sapiens 73-82 32508315-2 2020 Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. Dopamine 0-8 prolactin Homo sapiens 81-90 32700179-6 2020 (2) PRL was negatively associated with neck circumference, waist-to-hip ratio, systolic blood pressure, heart rate, basal metabolism rate (BMR), ALP, TCH, and LDL in all subjects. thiocarbohydrazide 150-153 prolactin Homo sapiens 4-7 32700179-7 2020 PRL levels were positively associated with weight, HC, and BMR in males but were negatively associated with ALT, AST, ALP, BG 30 min, BG 60 min, FFA, and TCH in females (all P < 0.05). Blood Glucose 123-125 prolactin Homo sapiens 0-3 32700179-7 2020 PRL levels were positively associated with weight, HC, and BMR in males but were negatively associated with ALT, AST, ALP, BG 30 min, BG 60 min, FFA, and TCH in females (all P < 0.05). Blood Glucose 134-136 prolactin Homo sapiens 0-3 32700179-7 2020 PRL levels were positively associated with weight, HC, and BMR in males but were negatively associated with ALT, AST, ALP, BG 30 min, BG 60 min, FFA, and TCH in females (all P < 0.05). thiocarbohydrazide 154-157 prolactin Homo sapiens 0-3 32700179-11 2020 Increased PRL was associated with a change in TCH in the NP group (P < 0.05). thiocarbohydrazide 46-49 prolactin Homo sapiens 10-13 32860866-7 2020 Male employees occupationally exposed to Pb exhibited significantly higher blood Pb, lower sperm-count, poor sperm motility and higher serum prolactin levels as compared to the Pb unexposed males. Lead 41-43 prolactin Homo sapiens 141-150 32860866-12 2020 Thus, Pb exposure at workplaces is detrimental to male reproductive function, with lower sperm-count and higher prolactin levels. Lead 6-8 prolactin Homo sapiens 112-121 32737582-2 2020 In addition to its role in the regulation of HPT axis, TRH is a potent regulator of prolactin (PRL) secretion by stimulating PRL secretion either directly from lactotrophs or indirectly via its action on the tuberoinfundibular dopamine (TIDA) neurons. Dopamine 227-235 prolactin Homo sapiens 84-93 32737582-2 2020 In addition to its role in the regulation of HPT axis, TRH is a potent regulator of prolactin (PRL) secretion by stimulating PRL secretion either directly from lactotrophs or indirectly via its action on the tuberoinfundibular dopamine (TIDA) neurons. Dopamine 227-235 prolactin Homo sapiens 95-98 32737582-2 2020 In addition to its role in the regulation of HPT axis, TRH is a potent regulator of prolactin (PRL) secretion by stimulating PRL secretion either directly from lactotrophs or indirectly via its action on the tuberoinfundibular dopamine (TIDA) neurons. tida 237-241 prolactin Homo sapiens 84-93 32737582-2 2020 In addition to its role in the regulation of HPT axis, TRH is a potent regulator of prolactin (PRL) secretion by stimulating PRL secretion either directly from lactotrophs or indirectly via its action on the tuberoinfundibular dopamine (TIDA) neurons. tida 237-241 prolactin Homo sapiens 95-98 32741482-1 2020 Dopamine agonist therapy is the primary therapy for prolactin-secreting adenomas and usually results in normoprolactinemia, eugonadism, and tumor reduction. Dopamine 0-8 prolactin Homo sapiens 52-61 32741482-3 2020 Withdrawal of cabergoline can be attempted in patients with normal prolactin levels on low doses of medication and evidence of radiographic tumor involution. Cabergoline 14-25 prolactin Homo sapiens 67-76 32508315-2 2020 Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. Dopamine 32-40 prolactin Homo sapiens 81-90 32570208-2 2020 We aimed to investigate associations between prolactin and glucose status in pregnant women with and without gestational diabetes mellitus (GDM) or polycystic ovary syndrome (PCOS). Glucose 59-66 prolactin Homo sapiens 45-54 32909148-15 2020 Finally, by blocking the lncRNA-UCA1-promoted glycolysis of pituitary cancer cells by glycolysis inhibitor, 2-DG, we obtained recovery of cell growth rate and PRL secretion from an in vitro model. Deoxyglucose 108-112 prolactin Homo sapiens 159-162 32508315-2 2020 Dopamine agonists stimulate the dopamine D2 receptor, resulting in a decrease in prolactin (PRL) levels and in prolactinoma size but action on dopamine receptors in the meso-limbic system may rarely cause psychosis and more commonly cause impulse control disorders. Dopamine 0-8 prolactin Homo sapiens 92-95 32508315-5 2020 In those who require dopamine agonists for PRL and tumor size control, the introduction of antipsychotics may blunt this effect, so that higher doses of the dopamine agonists may be needed. Dopamine 21-29 prolactin Homo sapiens 43-46 33072650-3 2020 Conversely, dopamine antagonist drugs increase prolactin in patients with simultaneous schizophrenia. Dopamine 12-20 prolactin Homo sapiens 47-56 32784639-3 2020 The solution was modified by the addition of Se (1 microg/L), prolactin (0.1 microg/L) and Se with prolactin (1 microg/L Se + 0.1 microg/L PRL). Selenium 91-93 prolactin Homo sapiens 99-108 32999655-1 2020 We present a young male patient with breast cancer having several risk factors likely acting in consort: irradiation of the breast for gynecomastia in adolescence and a life-long administration of phenothiazine for schizophrenia from the age of 16 years, with elevated serum prolactin level resulting in breast cancer development 24 years after irradiation. phenothiazine 197-210 prolactin Homo sapiens 275-284 32879783-0 2020 Levosulpiride Increases the Levels of Prolactin and Antiangiogenic Vasoinhibin in the Vitreous of Patients with Proliferative Diabetic Retinopathy. levosulpiride 0-13 prolactin Homo sapiens 38-47 32879783-3 2020 Here, we tested whether levosulpiride-induced hyperprolactinemia elevates PRL and vasoinhibin in the vitreous of volunteer patients with proliferative DR (PDR) undergoing elective pars plana vitrectomy. levosulpiride 24-37 prolactin Homo sapiens 74-77 32879783-6 2020 Results: Levosulpiride elevated the systemic (101 +- 13 [SEM] vs. 9.2 +- 1.3 ng/mL, P < 0.0001) and vitreous (3.2 +- 0.4 vs. 1.5 +- 0.2 ng/mL, P < 0.0001) levels of PRL, and both levels were directly correlated (r = 0.58, P < 0.0002). levosulpiride 9-22 prolactin Homo sapiens 165-168 32879783-10 2020 Conclusions: Levosulpiride increases the levels of PRL in the vitreous of PDR patients and promotes its MMP-mediated conversion to vasoinhibin, which can inhibit angiogenesis in DR. Translational Relevance: These findings support the potential therapeutic benefit of levosulpiride against vision loss in diabetes. levosulpiride 13-26 prolactin Homo sapiens 51-54 32781018-4 2020 Tryptophan significantly stimulates the expression of prolactin and insulin growth factor binding protein 1, reliable markers for human decidualization. Tryptophan 0-10 prolactin Homo sapiens 54-63 32784639-8 2020 We proposed the mechanism of prolactin action in the metabolic reduction of selenite (SO32-) during ischemia/reperfusion. Selenious Acid 76-84 prolactin Homo sapiens 29-38 32784639-8 2020 We proposed the mechanism of prolactin action in the metabolic reduction of selenite (SO32-) during ischemia/reperfusion. so32- 86-91 prolactin Homo sapiens 29-38 33471679-6 2020 Among those who were treatment-naive, the increase in serum prolactin levels over baseline was greater at 3 months following CPA initiation (mean change 397 +- 335 mIU/L) than following spironolactone (20.1 +- 87 mIU/L) or GA initiation (64.6 +- 268 mIU/L; P = .0002). Cyproterone Acetate 125-128 prolactin Homo sapiens 60-69 33471679-6 2020 Among those who were treatment-naive, the increase in serum prolactin levels over baseline was greater at 3 months following CPA initiation (mean change 397 +- 335 mIU/L) than following spironolactone (20.1 +- 87 mIU/L) or GA initiation (64.6 +- 268 mIU/L; P = .0002). Gallium 223-225 prolactin Homo sapiens 60-69 33471679-7 2020 Prolactin levels remained higher in the CPA-treated group throughout follow-up, irrespective of estradiol levels, which were similar between the groups. Cyproterone Acetate 40-43 prolactin Homo sapiens 0-9 32609140-3 2020 The bridged skeleton of PrL was changed to diamines 1-methyl-ethylenediamine, trimethylenediamine and 2,2"-dimethyl-trimethylenediamine, and the corresponding ligands were designated as Lme, Lpr and Ldmpr, for each Pr in these complexes upon UV-excitation. Diamines 43-51 prolactin Homo sapiens 24-27 32609140-3 2020 The bridged skeleton of PrL was changed to diamines 1-methyl-ethylenediamine, trimethylenediamine and 2,2"-dimethyl-trimethylenediamine, and the corresponding ligands were designated as Lme, Lpr and Ldmpr, for each Pr in these complexes upon UV-excitation. 1-methyl-ethylenediamine 52-76 prolactin Homo sapiens 24-27 32609140-3 2020 The bridged skeleton of PrL was changed to diamines 1-methyl-ethylenediamine, trimethylenediamine and 2,2"-dimethyl-trimethylenediamine, and the corresponding ligands were designated as Lme, Lpr and Ldmpr, for each Pr in these complexes upon UV-excitation. trimethylenediamine 78-97 prolactin Homo sapiens 24-27 32609140-3 2020 The bridged skeleton of PrL was changed to diamines 1-methyl-ethylenediamine, trimethylenediamine and 2,2"-dimethyl-trimethylenediamine, and the corresponding ligands were designated as Lme, Lpr and Ldmpr, for each Pr in these complexes upon UV-excitation. 2,2"-dimethyl-trimethylenediamine 102-135 prolactin Homo sapiens 24-27 32507371-12 2020 Five RCTs testing the addition of aripiprazole yielded a significant reduction in prolactin concentration compared to placebo (N = 3) or maintaining antipsychotic treatment (N = 2): Hedges" g was -1.35 (CI 95%: -1.93 to -0.76, p < 0.001). Aripiprazole 34-46 prolactin Homo sapiens 82-91 32430710-10 2020 Furthermore, DHT suppressed the expression of GLUT1 and GLUT12 as well as decidualization markers, IGFBP1 and prolactin, during in vitro decidualization. Dihydrotestosterone 13-16 prolactin Homo sapiens 110-119 32507371-14 2020 Our study suggests that, in terms of levels of evidence, adding aripiprazole is the first option to be considered for lowering prolactin concentrations in patients with schizophrenia and hyperprolactinaemia. Aripiprazole 64-76 prolactin Homo sapiens 127-136 32715655-7 2021 There was no advantage of aripiprazole compared to paliperidone with regards to weight change, although aripiprazole was associated with lower triglycerides and prolactin levels. Aripiprazole 104-116 prolactin Homo sapiens 161-170 32657631-7 2021 When patients were subdivided into those who were treated with risperidone, haloperidol, paliperidone, amisulpride, and a group that was not treated with these antipsychotics, aggressive patients in both groups had significantly higher PRL concentrations than non-aggressive patients. Risperidone 63-74 prolactin Homo sapiens 236-239 32657631-7 2021 When patients were subdivided into those who were treated with risperidone, haloperidol, paliperidone, amisulpride, and a group that was not treated with these antipsychotics, aggressive patients in both groups had significantly higher PRL concentrations than non-aggressive patients. Haloperidol 76-87 prolactin Homo sapiens 236-239 32657631-7 2021 When patients were subdivided into those who were treated with risperidone, haloperidol, paliperidone, amisulpride, and a group that was not treated with these antipsychotics, aggressive patients in both groups had significantly higher PRL concentrations than non-aggressive patients. Paliperidone Palmitate 89-101 prolactin Homo sapiens 236-239 32657631-7 2021 When patients were subdivided into those who were treated with risperidone, haloperidol, paliperidone, amisulpride, and a group that was not treated with these antipsychotics, aggressive patients in both groups had significantly higher PRL concentrations than non-aggressive patients. Amisulpride 103-114 prolactin Homo sapiens 236-239 32243999-4 2020 Almost all antipsychotics lead to hyperprolactinemia by blocking dopamine D2 receptors in the anterior pituitary gland, which counteracts dopamine"s inhibitory action on prolactin secretion. Dopamine 65-73 prolactin Homo sapiens 39-48 32760348-4 2020 Despite the continuation of dopamine agonist after surgery, serum prolactin level progressively increased to above 8,000 ng/ml in 5 years. Dopamine 28-36 prolactin Homo sapiens 66-75 32760348-14 2020 This case suggests that highly sustained serum prolactin levels during the dopamine agonist may indicate prolactin-producing pituitary carcinomas with hidden metastases. Dopamine 75-83 prolactin Homo sapiens 47-56 32760348-14 2020 This case suggests that highly sustained serum prolactin levels during the dopamine agonist may indicate prolactin-producing pituitary carcinomas with hidden metastases. Dopamine 75-83 prolactin Homo sapiens 105-114 32720617-9 2020 The bromocriptine treatment was associated with a significant decrease in prolactin level (62 %). Bromocriptine 4-17 prolactin Homo sapiens 74-83 32642517-5 2020 Meta-analysis of randomized clinical trials (RCTs) considering aripiprazole addition for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia were conducted with two softwares: 1) R and the metaphor package (for the meta-analysis of the primary outcome [prolactin reduction]); 2) MedCalc version 18.11 (for the meta-analysis of the secondary outcome [withdrawal rates]). Aripiprazole 63-75 prolactin Homo sapiens 98-107 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Risperidone 89-100 prolactin Homo sapiens 63-72 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Risperidone 89-100 prolactin Homo sapiens 74-77 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Risperidone 102-105 prolactin Homo sapiens 63-72 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Risperidone 102-105 prolactin Homo sapiens 74-77 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Olanzapine 111-121 prolactin Homo sapiens 63-72 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Olanzapine 111-121 prolactin Homo sapiens 74-77 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Olanzapine 123-126 prolactin Homo sapiens 63-72 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Olanzapine 123-126 prolactin Homo sapiens 74-77 32695960-2 2020 Aims: This study aimed to explore the risk factors of elevated prolactin (PRL) caused by risperidone (RIS) and olanzapine (OLZ) and the relationship between PRL and fasting plasma glucose and lipids. Glucose 180-187 prolactin Homo sapiens 157-160 32695960-9 2020 In patients taking RIS, the elevated PRL subgroup took the drug for a longer period (U=-2.76, p=0.006) and had lower triglyceride levels (U=2.76, p=0.006). Triglycerides 117-129 prolactin Homo sapiens 37-40 32695960-10 2020 In patients taking OLZ, the elevated PRL subgroup had lower fasting plasma glucose levels (U=2.29, p=0.022). Olanzapine 19-22 prolactin Homo sapiens 37-40 32695960-10 2020 In patients taking OLZ, the elevated PRL subgroup had lower fasting plasma glucose levels (U=2.29, p=0.022). Glucose 75-82 prolactin Homo sapiens 37-40 32695960-11 2020 Logistic regression analysis showed that gender, dose and fasting glucose levels were significantly associated with elevated PRL levels (RIS: p=0.001, OLZ: p<0.001; RIS: p<0.001; OLZ: p=0.003; RIS: p=0.020, OLZ: p=0.001, respectively). Glucose 66-73 prolactin Homo sapiens 125-128 32695960-13 2020 Moreover, the plasma glucose level of the group with elevated PRL was lower than that of the group with normal PRL. Glucose 21-28 prolactin Homo sapiens 62-65 32695960-13 2020 Moreover, the plasma glucose level of the group with elevated PRL was lower than that of the group with normal PRL. Glucose 21-28 prolactin Homo sapiens 111-114 32695960-14 2020 The results also showed that high serum PRL may be associated with a favourable glucose metabolic profile in patients with schizophrenia taking RIS or OLZ. Glucose 80-87 prolactin Homo sapiens 40-43 32695960-14 2020 The results also showed that high serum PRL may be associated with a favourable glucose metabolic profile in patients with schizophrenia taking RIS or OLZ. Olanzapine 151-154 prolactin Homo sapiens 40-43 32413670-9 2020 RESULTS: Methyldopa alterate neurotrophic factors levels, impairs cerebral blood flow, and through dopamine level reduction it impairs reward system and increase prolactin release. Methyldopa 9-19 prolactin Homo sapiens 162-171 32413670-9 2020 RESULTS: Methyldopa alterate neurotrophic factors levels, impairs cerebral blood flow, and through dopamine level reduction it impairs reward system and increase prolactin release. Dopamine 99-107 prolactin Homo sapiens 162-171 32639294-3 2020 The objective of this study was to compare tramadol abuse patients and healthy controls regarding free testosterone and prolactin levels and semen analysis. Tramadol 43-51 prolactin Homo sapiens 120-129 32361395-9 2020 Cyclic AMP-mediated decidualization significantly upregulates ID1 mRNA expression in DSCs and siRNA-mediated knockdown of ID1 significantly interferes with decidualization as shown by a reduction in PRL and FOXO1 expression, and morphologic criteria. Cyclic AMP 0-10 prolactin Homo sapiens 199-202 32642517-5 2020 Meta-analysis of randomized clinical trials (RCTs) considering aripiprazole addition for lowering prolactin in people with a psychotic disorder and hyperprolactinaemia were conducted with two softwares: 1) R and the metaphor package (for the meta-analysis of the primary outcome [prolactin reduction]); 2) MedCalc version 18.11 (for the meta-analysis of the secondary outcome [withdrawal rates]). Aripiprazole 63-75 prolactin Homo sapiens 153-162 32612510-13 2020 The different types of pituitary prolactin in fish play particularly important roles in the adaptation of eutherian species to fresh water environments. Water 133-138 prolactin Homo sapiens 33-42 32612510-15 2020 In turn, the released prolactin acts on branchial epithelia, especially ionocytes of the gill to retain salt and excrete water. Salts 104-108 prolactin Homo sapiens 22-31 32612510-15 2020 In turn, the released prolactin acts on branchial epithelia, especially ionocytes of the gill to retain salt and excrete water. Water 121-126 prolactin Homo sapiens 22-31 31823444-10 2020 The incidence of adverse events was lower for lurasidone vs. risperidone for extrapyramidal symptoms (17.0% vs. 38.2%), akathisia (7.2% vs. 13.6%), prolactin increase (3.1% vs. 14.1%), and weight increase (0.5% vs. 5.2%). lurasidone 46-56 prolactin Homo sapiens 148-157 32793702-2 2020 Dopamine receptor agonists (DAs) are effective in reducing prolactin levels and tumor mass, but some prolactinoma patients are resistant to DAs. Dopamine 0-8 prolactin Homo sapiens 59-68 32087250-4 2020 The expression of HOXA10, PRL and IGFBP-1 was down-regulated upon BPA treatment. bisphenol A 66-69 prolactin Homo sapiens 26-29 32429916-8 2020 We identified four significant predictors of dopamine agonist resistance: male gender, a large tumour volume, prolonged time to prolactin normalization and presence of a cystic, hemorrhagic and/or necrotic component. Dopamine 45-53 prolactin Homo sapiens 128-137 32565790-6 2020 Moreover, ghrelin makes the skeletal muscle more excitable and stimulates its regeneration following injury; delays puberty; promotes fetal lung development; decreases thyroid hormone and testosterone; stimulates release of growth hormone, prolactin, glucagon, adrenocorticotropic hormone, cortisol, vasopressin, and oxytocin; inhibits insulin release; and promotes wound healing. Ghrelin 10-17 prolactin Homo sapiens 240-249 32370778-12 2020 CONCLUSIONS: In this 6-month extension study, lurasidone treatment was generally well-tolerated and associated with minimal effects on weight, metabolic parameters, and prolactin levels. Lurasidone Hydrochloride 46-56 prolactin Homo sapiens 169-178 32477263-5 2020 In the PCOS patients, serum PRL was significantly and positively correlated with FPG, serum TSH and serum FT4, and significantly and negatively correlated with LH, LH/FSH, TC, TG, LDL-C, AST, ALT, gamma-GGT, FT3, and FT3/FT4 (p < 0.05 or 0.01). Technetium 172-174 prolactin Homo sapiens 28-31 32477263-5 2020 In the PCOS patients, serum PRL was significantly and positively correlated with FPG, serum TSH and serum FT4, and significantly and negatively correlated with LH, LH/FSH, TC, TG, LDL-C, AST, ALT, gamma-GGT, FT3, and FT3/FT4 (p < 0.05 or 0.01). Thioguanine 176-178 prolactin Homo sapiens 28-31 32550971-4 2020 Recovery of less than 40% of serum prolactin after polyethylene glycol (PEG) precipitation was indicative of macroprolactinemia. Polyethylene Glycols 51-70 prolactin Homo sapiens 35-44 32550971-4 2020 Recovery of less than 40% of serum prolactin after polyethylene glycol (PEG) precipitation was indicative of macroprolactinemia. Polyethylene Glycols 72-75 prolactin Homo sapiens 35-44 32370778-13 2020 Patients who switched from risperidone to lurasidone experienced reductions in weight, metabolic parameters and prolactin levels commensurate with increases in these safety parameters experienced during the previous 12 months of treatment with risperidone. Risperidone 27-38 prolactin Homo sapiens 112-121 32370778-13 2020 Patients who switched from risperidone to lurasidone experienced reductions in weight, metabolic parameters and prolactin levels commensurate with increases in these safety parameters experienced during the previous 12 months of treatment with risperidone. Lurasidone Hydrochloride 42-52 prolactin Homo sapiens 112-121 32509382-8 2020 In TNBC/HER2+ cell lines, CPD and EDD protein expression were upregulated by PRL or synthetic androgen methyltrienolone (R1881) at 3-6 h. PRL/R1881-induced CPD in TNBC and HER2+ cells increased intracellular NO production, which was abolished by PRLR antagonist 1-9-G129R-hPRL and AR antagonist flutamide. Metribolone 103-119 prolactin Homo sapiens 138-141 32509382-8 2020 In TNBC/HER2+ cell lines, CPD and EDD protein expression were upregulated by PRL or synthetic androgen methyltrienolone (R1881) at 3-6 h. PRL/R1881-induced CPD in TNBC and HER2+ cells increased intracellular NO production, which was abolished by PRLR antagonist 1-9-G129R-hPRL and AR antagonist flutamide. Metribolone 103-119 prolactin Homo sapiens 273-277 32509382-8 2020 In TNBC/HER2+ cell lines, CPD and EDD protein expression were upregulated by PRL or synthetic androgen methyltrienolone (R1881) at 3-6 h. PRL/R1881-induced CPD in TNBC and HER2+ cells increased intracellular NO production, which was abolished by PRLR antagonist 1-9-G129R-hPRL and AR antagonist flutamide. Flutamide 296-305 prolactin Homo sapiens 77-80 32509382-8 2020 In TNBC/HER2+ cell lines, CPD and EDD protein expression were upregulated by PRL or synthetic androgen methyltrienolone (R1881) at 3-6 h. PRL/R1881-induced CPD in TNBC and HER2+ cells increased intracellular NO production, which was abolished by PRLR antagonist 1-9-G129R-hPRL and AR antagonist flutamide. Flutamide 296-305 prolactin Homo sapiens 138-141 32286456-8 2020 Thus, we uncover an axis whereby CD34+PRLR+ GMPs inhibit CD56+ lineage development through TGF-beta1 production and PRL stimulation leads to SMAD7 activation, repression of TGF-beta1, resulting in CD56+ cell development. Guanosine 5'-monophosphorothioate 44-48 prolactin Homo sapiens 38-41 32390374-7 2020 Prolactin and cleaved prolactin products were investigated by SDS-PAGE and western blotting. Sodium Dodecyl Sulfate 62-65 prolactin Homo sapiens 22-31 32350130-9 2020 During lactation, prolactin induced serotonin production in beta cells. Serotonin 36-45 prolactin Homo sapiens 18-27 32373171-0 2020 Assessment of Changes in Concentration of Total Antioxidant Status, Acute-Phase Protein, and Prolactin in Patients with Osteoarthritis Subjected to a Complex Spa Treatment with Radon Water: Preliminary Results. Water 183-188 prolactin Homo sapiens 93-102 32373171-3 2020 The main purpose of our study was the assessment of the effect of spa treatment on changes in concentration of TAS, CRP, and PRL in patients with osteoarthritis. spa 66-69 prolactin Homo sapiens 125-128 31990677-8 2020 Our results show that resveratrol supplementation increased, in a dose-dependent manner, the expression levels of prolactin and IGFBP1 (RT-PCR and ELISA) indicating an enhanced in vitro decidualization of human ESC. resveratrol 22-33 prolactin Homo sapiens 114-123 31853893-5 2020 She was successfully managed with cabergoline, a dopamine agonist, with a reduction in the size of the tumor and normalization of serum prolactin levels. cabergoline 34-45 prolactin Homo sapiens 136-145 31853893-5 2020 She was successfully managed with cabergoline, a dopamine agonist, with a reduction in the size of the tumor and normalization of serum prolactin levels. Dopamine 49-57 prolactin Homo sapiens 136-145 31972188-4 2020 Data from in vitro and in vivo rodent studies demonstrated that prucalopride-related stimulation of prolactin secretion (via dopamine receptor D2 antagonism at high doses) is a rodent-specific, non-genotoxic mechanism for inducing hyperplasia and neoplasia in prolactin receptor-expressing endocrine tissues. prucalopride 64-76 prolactin Homo sapiens 100-109 32265749-11 2020 The mean prolactin concentration value significantly increased over time only in the risperidone group (P = 0.04). Risperidone 85-96 prolactin Homo sapiens 9-18 32265749-15 2020 However, in findings such as statistically significant increments of BMI and heart rate mean values, the variations over time in prolactin levels observed with risperidone and the differences between the two drugs remark the necessity of systematic monitoring. Risperidone 160-171 prolactin Homo sapiens 129-138 31420971-0 2020 Endogenous testosterone determines metformin action on prolactin levels in hyperprolactinaemic men: A pilot study. Testosterone 11-23 prolactin Homo sapiens 55-64 32296740-5 2020 This case illustrates the need to consider an ectopic source of prolactin in a patient who has hyperprolactinemia that is not associated with a large sellar mass and is completely resistant to cabergoline. Cabergoline 193-204 prolactin Homo sapiens 64-73 31520576-0 2020 Effects of aripiprazole on circadian prolactin secretion related to pharmacogenetics in healthy volunteers. Aripiprazole 11-23 prolactin Homo sapiens 37-46 31520576-1 2020 Aripiprazole treatment in schizophrenic patients was previously associated with lower or normalized prolactin levels. Aripiprazole 0-12 prolactin Homo sapiens 100-109 31520576-3 2020 Our aim was to evaluate whether aripiprazole affects prolactin secretion and its relationship with pharmacogenetics. Aripiprazole 32-44 prolactin Homo sapiens 53-62 31520576-6 2020 Prolactin concentrations of the 31 volunteers taking aripiprazole and 12 volunteers receiving ibuprofen were determined by ELISA. Aripiprazole 53-65 prolactin Homo sapiens 0-9 31520576-8 2020 Prolactin concentrations were slightly higher in the aripiprazole group compared to the ibuprofen group. Aripiprazole 53-65 prolactin Homo sapiens 0-9 31520576-8 2020 Prolactin concentrations were slightly higher in the aripiprazole group compared to the ibuprofen group. Ibuprofen 88-97 prolactin Homo sapiens 0-9 31520576-11 2020 The DRD3 rs6280 polymorphism affected prolactin levels: volunteers carrying Ser/Ser genotype had significantly lower prolactin levels than volunteers carrying the Gly allele. Serine 76-79 prolactin Homo sapiens 38-47 31520576-11 2020 The DRD3 rs6280 polymorphism affected prolactin levels: volunteers carrying Ser/Ser genotype had significantly lower prolactin levels than volunteers carrying the Gly allele. Serine 76-79 prolactin Homo sapiens 117-126 31520576-11 2020 The DRD3 rs6280 polymorphism affected prolactin levels: volunteers carrying Ser/Ser genotype had significantly lower prolactin levels than volunteers carrying the Gly allele. Serine 80-83 prolactin Homo sapiens 38-47 31520576-11 2020 The DRD3 rs6280 polymorphism affected prolactin levels: volunteers carrying Ser/Ser genotype had significantly lower prolactin levels than volunteers carrying the Gly allele. Serine 80-83 prolactin Homo sapiens 117-126 31520576-13 2020 Nevertheless, aripiprazole did increase prolactin levels compared to ibuprofen. Aripiprazole 14-26 prolactin Homo sapiens 40-49 31201099-4 2020 CAB resistance was defined as the failure to normalize PRL (biochemical resistance, BR) or reduce tumor size by at least 50% (morphological resistance, MR) with a CAB dose up to 2mg/week (or 3mg/week in cases where lower doses were not tested) for at least 3 months. Cabergoline 0-3 prolactin Homo sapiens 55-58 29792513-3 2020 This analysis sought to investigate the role of early percutaneous mechanical circulatory support with micro-axial flow-pumps and/or veno-arterial extracorporeal membrane oxygenation in combination with the prolactin inhibitor bromocriptine in refractory cardiogenic shock complicating peripartum cardiomyopathy. Bromocriptine 227-240 prolactin Homo sapiens 207-216 32318637-5 2020 Results: Olanzapine increased plasma prolactin, an effect that was reversed by co-administration of the D2 receptor agonist bromocriptine (P = .0002). Olanzapine 9-19 prolactin Homo sapiens 37-46 32318637-5 2020 Results: Olanzapine increased plasma prolactin, an effect that was reversed by co-administration of the D2 receptor agonist bromocriptine (P = .0002). Bromocriptine 124-137 prolactin Homo sapiens 37-46 32268424-6 2020 The hyperprolactinemic group had significantly higher levels of Th2 associated CCL22 (p=0.022), Th17 associated CXCL1 (p=0.001), B cell attracting CXCL13 (p=0.003), and C-reactive protein (p<0.001) compared to controls, and these proteins were also positively correlated with prolactin levels. th2 64-67 prolactin Homo sapiens 9-18 31420971-0 2020 Endogenous testosterone determines metformin action on prolactin levels in hyperprolactinaemic men: A pilot study. Metformin 35-44 prolactin Homo sapiens 55-64 31420971-1 2020 Metformin was found to reduce elevated prolactin levels in women but not in men. Metformin 0-9 prolactin Homo sapiens 39-48 31420971-7 2020 Only in patients with abnormally low testosterone levels, the drug decreased prolactin levels. Testosterone 37-49 prolactin Homo sapiens 77-86 31770105-0 2020 Prolactin <=1 ng/mL predicts macroprolactinoma reduction after cabergoline therapy. Cabergoline 63-74 prolactin Homo sapiens 0-9 31919769-1 2020 PURPOSE: Low prolactin (PRL) serum levels are associated with glucose intolerance and type 2 diabetes in adults, and with metabolic syndrome and obesity in children. Glucose 62-69 prolactin Homo sapiens 13-22 31919769-1 2020 PURPOSE: Low prolactin (PRL) serum levels are associated with glucose intolerance and type 2 diabetes in adults, and with metabolic syndrome and obesity in children. Glucose 62-69 prolactin Homo sapiens 24-27 31770105-10 2020 Conclusions: A prolactin level <=1 ng/mL at 3 months after cabergoline treatment was correlated with a significant tumor size reduction in patients with macroprolactinoma. Cabergoline 59-70 prolactin Homo sapiens 15-24 31686376-6 2020 Although most prolactin secreting adenomas diagnosed during menopause are large, they respond well to dopamine agonist treatment. Dopamine 102-110 prolactin Homo sapiens 14-23 31389032-10 2020 In men with neither low or normal testosterone levels, metformin affected free thyroid hormones, prolactin, testosterone, gonadotropins, and SPINA-GD. Metformin 55-64 prolactin Homo sapiens 97-106 31444987-6 2020 RESULTS AND DISCUSSION: Men with elevated levels of big-big prolactin were characterized by higher levels of hsCRP and fibrinogen and lower levels of 25-hydroxyvitamin D as well as decreased insulin sensitivity than subjects with prolactin levels within the reference range. 25-hydroxyvitamin D 150-169 prolactin Homo sapiens 60-69 31444987-9 2020 With the exception of homocysteine, cardiometabolic effects of fenofibrate were stronger in subjects without than in subjects with elevated levels of big-big prolactin. Fenofibrate 63-74 prolactin Homo sapiens 158-167 31999895-4 2020 Results: In general, the addition of aripiprazole to the treatment regimen of each of the patients corresponded to a decline in their serum prolactin levels. aripiprazole 37-49 prolactin Homo sapiens 140-149 31802331-2 2020 Prolactin levels are high, associated with low testosterone, anemia, metabolic syndrome and if long-standing also osteoporosis. Testosterone 47-59 prolactin Homo sapiens 0-9 31802331-3 2020 RESULTS: Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients. Dopamine 36-44 prolactin Homo sapiens 118-127 31802331-3 2020 RESULTS: Medical treatment with the dopamine agonist, cabergoline, became the preferred first-line treatment for male prolactinomas as well as for giant tumors, leading to prolactin normalization in ~ 80% of treated men, and tumor shrinkage, improved visual fields and recovery of hypogonadism in most patients. Cabergoline 54-65 prolactin Homo sapiens 118-127 31545521-1 2020 OBJECTIVE: Antipsychotics may increase serum prolactin, which has particularly been observed with risperidone. Risperidone 98-109 prolactin Homo sapiens 45-54 32597492-11 2020 Dopamine receptors were positively immunostained in all the investigated PRL-immunopositive and all PRL-immunonegative adenomas. Dopamine 0-8 prolactin Homo sapiens 73-76 31837240-5 2020 (c) The effect of blonanserin on prolactin (PRL) elevation was less. blonanserin 18-29 prolactin Homo sapiens 33-42 31837240-5 2020 (c) The effect of blonanserin on prolactin (PRL) elevation was less. blonanserin 18-29 prolactin Homo sapiens 44-47 31837240-6 2020 The model was used to predict that prolactin elevations in patients administered risperidone were 2.41-fold of those in patients administered blonanserin. Risperidone 81-92 prolactin Homo sapiens 35-44 31837240-6 2020 The model was used to predict that prolactin elevations in patients administered risperidone were 2.41-fold of those in patients administered blonanserin. blonanserin 142-153 prolactin Homo sapiens 35-44 31837240-9 2020 The model demonstrated Blonanserin has similar antischizophrenic efficacy and less serum prolactin rising compared to risperidone in Chinese patients. blonanserin 23-34 prolactin Homo sapiens 89-98 31612424-11 2020 Thyroid hormones and prolactin-lowering drugs (e.g. cabergoline, aripiprazole) are candidate drugs to be tested in repurposing clinical trials aiming to improve the cognitive abilities of patients with major mood disorder and schizophrenia. cabergoline 52-63 prolactin Homo sapiens 21-30 31612424-11 2020 Thyroid hormones and prolactin-lowering drugs (e.g. cabergoline, aripiprazole) are candidate drugs to be tested in repurposing clinical trials aiming to improve the cognitive abilities of patients with major mood disorder and schizophrenia. aripiprazole 65-77 prolactin Homo sapiens 21-30 32392109-0 2020 Melatonin modulates lactation by regulating prolactin secretion via tuberoinfundibular dopaminergic neurons in Hypothalamus-Pituitary system. Melatonin 0-9 prolactin Homo sapiens 44-53 32392109-4 2020 The hypothalamus-pituitary system, the most important endocrine system in the body, regulates prolactin secretion mainly through dopamine released from tuberoinfundibular dopaminergic neurons. Dopamine 129-137 prolactin Homo sapiens 94-103 32392109-5 2020 This review provides a reference for further study and describes regulation of lactation and prolactin secretion by melatonin, primarily via the protection and stimulation of tuberoinfundibular dopaminergic neurons. Melatonin 116-125 prolactin Homo sapiens 93-102 32736755-3 2020 From a neurologic perspective, the key hormone changes are those of the sex steroids, estradiol and progesterone, secreted first from the ovary and then from the placenta, the adrenal glucocorticoid cortisol, as well as the anterior pituitary peptide hormone prolactin and its pregnancy-specific homolog placental lactogen. Estradiol 86-95 prolactin Homo sapiens 259-268 32736755-3 2020 From a neurologic perspective, the key hormone changes are those of the sex steroids, estradiol and progesterone, secreted first from the ovary and then from the placenta, the adrenal glucocorticoid cortisol, as well as the anterior pituitary peptide hormone prolactin and its pregnancy-specific homolog placental lactogen. Progesterone 100-112 prolactin Homo sapiens 259-268 33305662-9 2020 CONCLUSIONS: PRL involvement in GE pathogenesis and more intense therapeutic impact on pain syndrome in case of combined administration of dopamine and standard hormone therapy prove cabergoline application in clinical practice. Dopamine 139-147 prolactin Homo sapiens 13-16 33305662-9 2020 CONCLUSIONS: PRL involvement in GE pathogenesis and more intense therapeutic impact on pain syndrome in case of combined administration of dopamine and standard hormone therapy prove cabergoline application in clinical practice. Cabergoline 183-194 prolactin Homo sapiens 13-16 32597492-11 2020 Dopamine receptors were positively immunostained in all the investigated PRL-immunopositive and all PRL-immunonegative adenomas. Dopamine 0-8 prolactin Homo sapiens 100-103 33454942-7 2020 After a month of drug-free period and cabergoline treatment, the prolactin levels returned to normal. Cabergoline 38-49 prolactin Homo sapiens 65-74 33179012-0 2020 S179D Prolactin Sensitizes Human PC3 Prostate Cancer Xenografts to Anti-tumor Effects of Well-Tolerated Doses of Calcitriol. Calcitriol 113-123 prolactin Homo sapiens 6-15 33179012-3 2020 In previous work, we had observed that the selective prolactin receptor modulator, S179D PRL, sensitized prostate cancer cells in vitro to physiological concentrations of calcitriol through an ability to increase expression of the vitamin D receptor. Calcitriol 171-181 prolactin Homo sapiens 89-92 32083234-9 2020 The increased proliferation induced by estradiol was enhanced after adding prolactin in both cell lines. Estradiol 39-48 prolactin Homo sapiens 75-84 32083234-10 2020 All changes caused by prolactin were inhibited in Ishikawa cells pretreated with U0126. U 0126 81-86 prolactin Homo sapiens 22-31 32083234-11 2020 Long-term effects of serum prolactin on persistent proliferative endometrium in the presence of estradiol may induce abnormal proliferation of EG in hyperprolactinemic women. Estradiol 96-105 prolactin Homo sapiens 27-36 32461718-11 2019 Additionally, significant decrease in serum testosterone level and increase in serum prolactin level as tramadol daily dose and duration increased was found. Tramadol 104-112 prolactin Homo sapiens 85-94 31504637-13 2019 Assessing relationships between serum PRL levels and TRH-stimulated TSH levels would contribute to predict the etiologies of congenital i-TSHD. Thyrotropin 68-71 prolactin Homo sapiens 38-41 31422510-2 2019 We examined the prolactin levels of previously minimally treated patients with first episode schizophrenia over their first year of treatment with flupenthixol decanoate and the relationship between prolactin levels, gender and clinical features of schizophrenia. flupenthixol decanoate 147-169 prolactin Homo sapiens 16-25 31319705-1 2019 Prolactin (PRL) levels can usually be controlled by PRL-inhibiting psychiatric drugs that include anti-dopamine agents. Dopamine 103-111 prolactin Homo sapiens 0-9 31834097-0 2020 Lower Prolactin Levels in Patients Treated With Aripiprazole Regardless of Antipsychotic Monopharmacy or Polypharmacy. Aripiprazole 48-60 prolactin Homo sapiens 6-15 31834097-2 2020 Aripiprazole (ARP), which is one of second-generation antipsychotics, has been reported to lower serum prolactin (PRL) levels. Aripiprazole 0-12 prolactin Homo sapiens 103-112 31834097-2 2020 Aripiprazole (ARP), which is one of second-generation antipsychotics, has been reported to lower serum prolactin (PRL) levels. Aripiprazole 0-12 prolactin Homo sapiens 114-117 31834097-2 2020 Aripiprazole (ARP), which is one of second-generation antipsychotics, has been reported to lower serum prolactin (PRL) levels. Aripiprazole 14-17 prolactin Homo sapiens 103-112 31834097-2 2020 Aripiprazole (ARP), which is one of second-generation antipsychotics, has been reported to lower serum prolactin (PRL) levels. Aripiprazole 14-17 prolactin Homo sapiens 114-117 31834097-6 2020 Serum PRL levels in ARP combination group were lower than non-ARP combination group, regardless of antipsychotic monopharmacy or polypharmacy. Aripiprazole 20-23 prolactin Homo sapiens 6-9 31834097-6 2020 Serum PRL levels in ARP combination group were lower than non-ARP combination group, regardless of antipsychotic monopharmacy or polypharmacy. Aripiprazole 62-65 prolactin Homo sapiens 6-9 32200584-0 2019 Basal and metoclopramide induced prolactin secretion in lean PCOS women. Metoclopramide 10-24 prolactin Homo sapiens 33-42 32200584-2 2019 In retrospective study the prolactin levels during the oral metoclopramide test among lean PCOS woman according to four phenotypes and free androgen index (FAI) were compared. Metoclopramide 60-74 prolactin Homo sapiens 27-36 32200584-7 2019 The ratio of prolactin value in 120th minute in the metoclopramide test to the basal prolactin value was higher in group D than in groups A and B. Metoclopramide 52-66 prolactin Homo sapiens 13-22 32200584-9 2019 The ratio of prolactin in 60th minute (12.3 vs 16.7; p=0.006) and in the 120th minute (10.9 versus 13.3; p<0.001) of the metoclopramide test to the basal prolactin were lower in patients with FAI>=5. Metoclopramide 121-135 prolactin Homo sapiens 13-22 31470351-4 2019 Especially, GHA1 (the ratio of g-C3N4 and aerogel component was 1:1) exhibited a good synergy in photodegradation and adsorption, with a Rhodamine B (Rh B) removal up to 97.99% in 90 min. rhodamine B 137-148 prolactin Homo sapiens 12-16 31470351-4 2019 Especially, GHA1 (the ratio of g-C3N4 and aerogel component was 1:1) exhibited a good synergy in photodegradation and adsorption, with a Rhodamine B (Rh B) removal up to 97.99% in 90 min. rhodamine B 150-154 prolactin Homo sapiens 12-16 31319705-1 2019 Prolactin (PRL) levels can usually be controlled by PRL-inhibiting psychiatric drugs that include anti-dopamine agents. Dopamine 103-111 prolactin Homo sapiens 11-14 31319705-1 2019 Prolactin (PRL) levels can usually be controlled by PRL-inhibiting psychiatric drugs that include anti-dopamine agents. Dopamine 103-111 prolactin Homo sapiens 52-55 31660059-11 2019 We further found that GRP78 was located in the cytoplasm of BMECs, and that stimulating methionine, leucine, estrogen and prolactin expression led to a significant increase in the protein expression of GRP78 in BMECs. Methionine 88-98 prolactin Homo sapiens 122-131 32082942-1 2019 The inverse relationship between prolactin and dopamine is important in the context of treatment with antipsychotic medications in men and nonpregnant women with thought disorders. Dopamine 47-55 prolactin Homo sapiens 33-42 32082942-4 2019 Our previously published paper, "Placental Barrier and Autism Spectrum Disorders: The Role of Prolactin and Dopamine on the Developing Fetal Brain," summarized evidence for dysregulated dopamine and prolactin levels in the etiology of ASDs and suggested a possible method for assessing whether such aberrations increase the risk of ASDs. Dopamine 108-116 prolactin Homo sapiens 199-208 32082942-4 2019 Our previously published paper, "Placental Barrier and Autism Spectrum Disorders: The Role of Prolactin and Dopamine on the Developing Fetal Brain," summarized evidence for dysregulated dopamine and prolactin levels in the etiology of ASDs and suggested a possible method for assessing whether such aberrations increase the risk of ASDs. Dopamine 186-194 prolactin Homo sapiens 94-103 31570595-3 2019 While exploring how the pathogenic Eomes+ Th cells are generated during the course of EAE, we unexpectedly found that B cells and MHC class II+ myeloid cells isolated from the late EAE lesions strikingly up-regulated the expression of prolactin (PRL). Thorium 42-44 prolactin Homo sapiens 235-244 31570595-4 2019 We demonstrate that such PRL-producing cells have a unique potential to induce Eomes+ Th cells from naive T cells ex vivo, and that anti-MHC class II antibody could block this process. Thorium 86-88 prolactin Homo sapiens 25-28 31570595-5 2019 Furthermore, PRL levels in the cerebrospinal fluid were significantly increased in the late phase of EAE, and blocking the production of PRL by bromocriptine or Zbtb20-specific siRNA significantly reduced the numbers of Eomes+ Th cells in the central nervous system (CNS) and ameliorated clinical signs in the later phase of EAE. Bromocriptine 144-157 prolactin Homo sapiens 137-140 31570595-5 2019 Furthermore, PRL levels in the cerebrospinal fluid were significantly increased in the late phase of EAE, and blocking the production of PRL by bromocriptine or Zbtb20-specific siRNA significantly reduced the numbers of Eomes+ Th cells in the central nervous system (CNS) and ameliorated clinical signs in the later phase of EAE. Thorium 227-229 prolactin Homo sapiens 13-16 31570595-5 2019 Furthermore, PRL levels in the cerebrospinal fluid were significantly increased in the late phase of EAE, and blocking the production of PRL by bromocriptine or Zbtb20-specific siRNA significantly reduced the numbers of Eomes+ Th cells in the central nervous system (CNS) and ameliorated clinical signs in the later phase of EAE. Thorium 227-229 prolactin Homo sapiens 137-140 31570595-6 2019 The PRL dependency of Eomes+ Th cells was confirmed in a series of in vitro and ex vivo experiments. Thorium 0-2 prolactin Homo sapiens 4-7 31570595-7 2019 Collectively, these results indicate that extrapituitary PRL plays a crucial role in the CNS inflammation mediated by pathogenic Eomes+ Th cells. Thorium 136-138 prolactin Homo sapiens 57-60 31025313-6 2019 In this pilot study, we aim to evaluate the effect of bromocriptine, a prolactin inhibitor, on menstrual bleeding and pain in women with adenomyosis. Bromocriptine 54-67 prolactin Homo sapiens 71-80 32377250-9 2019 Carbergoline treatment for 12 months decreased prolactin levels to 27 ng/mL. carbergoline 0-12 prolactin Homo sapiens 47-56 31742116-5 2019 Prolactin serum levels were higher in glyburide-treated patients compared with metformin-treated patients (P < 0.01). Glyburide 38-47 prolactin Homo sapiens 0-9 31742116-5 2019 Prolactin serum levels were higher in glyburide-treated patients compared with metformin-treated patients (P < 0.01). Metformin 79-88 prolactin Homo sapiens 0-9 31742116-7 2019 Metformin but not glyburide reduced prolactin levels due to the improvement of insulin resistance. Metformin 0-9 prolactin Homo sapiens 36-45 31323004-7 2019 Treatment with cabergoline resulted in a marked reduction in prolactin concentration in all nine patients. Cabergoline 15-26 prolactin Homo sapiens 61-70 31352040-10 2019 However, DELAQ, but not TCDD, attenuated quinpirole-inhibited prolactin gene expression by 51% in primary pituitary cells. delaq 9-14 prolactin Homo sapiens 62-71 31352040-10 2019 However, DELAQ, but not TCDD, attenuated quinpirole-inhibited prolactin gene expression by 51% in primary pituitary cells. Quinpirole 41-51 prolactin Homo sapiens 62-71 31323004-13 2019 Conclusions Cabergoline effectively lowers prolactin levels and may reduce tumour mass in paediatric and adolescent patients with prolactinomas. Cabergoline 12-23 prolactin Homo sapiens 43-52 31967975-3 2019 The treatment decreased the tumour size after 3 months (MRI scans of the brain) and brought back to normal the level of the PRL (345 mIU/L) after 6 months of CAB treatment. cabergoline 158-161 prolactin Homo sapiens 124-127 31174092-0 2019 Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis. Domperidone 0-11 prolactin Homo sapiens 39-48 31174092-2 2019 We analyzed serum prolactin and cytokine, chemokine and growth factor levels in sera from MS patients enrolled in two clinical trials who were treated with domperidone, a generic drug that increases systemic prolactin levels. Domperidone 156-167 prolactin Homo sapiens 208-217 31967975-16 2019 CAB therapy was effective in normalization of the PRL level, tumour shrinkage, menarche and pregnancy-induction which led to the birth of healthy children in a woman with primary amenorrhoea and a giant prolactinoma invading the skull base bones. cabergoline 0-3 prolactin Homo sapiens 50-53 31967975-18 2019 Cabergoline therapy can be effective in the normalization of the PRL level, tumour shrinkage, menarche induction in a woman with primary amenorrhoea, and giant prolactinoma. cabergoline 0-11 prolactin Homo sapiens 65-68 32082947-0 2019 Brexpiprazole as a New Serotonin-Dopamine Receptor Modulator: Considering the Clinical Relevance for Metabolic Parameters and Prolactin Levels. brexpiprazole 0-13 prolactin Homo sapiens 126-135 31673677-8 2019 The aripiprazole group had a significantly lower endpoint serum prolactin level in all patients (five RCTs, n=385; WMD: -50.43 ng/mL (95% CI: -75.05 to -25.81), p<0.00001; I2=99%), female patients (two RCTs, n=186; WMD: -22.58 ng/mL (95% CI: -25.67 to -19.49), p<0.00001; I2=0%) and male patients (two RCTs, n=127; WMD: -68.80 ng/mL (95% CI: -100.11 to -37.49), p<0.0001). aripiprazole 4-16 prolactin Homo sapiens 64-73 31673677-12 2019 Conclusions: Adjunctive aripiprazole appears to be associated with reduced AP-induced hyperprolactinaemia and improved prolactin-related symptoms in first-episode schizophrenia. aripiprazole 24-36 prolactin Homo sapiens 91-100 30848967-8 2019 CONCLUSIONS: Our study confirmed the effects of LAI paliperidone and risperidone on PRL levels. Paliperidone Palmitate 52-64 prolactin Homo sapiens 84-87 30848967-8 2019 CONCLUSIONS: Our study confirmed the effects of LAI paliperidone and risperidone on PRL levels. Risperidone 69-80 prolactin Homo sapiens 84-87 31051246-3 2019 In an attempt to increase the yield of recombinant vasoinhibin and avoid incorrect intra- and inter-disulfide bond formation, the cDNA sequence comprising the first 123 amino acids of human PRL, in which cysteine 58 was or not mutated to serine, was codon-optimized. Cysteine 204-212 prolactin Homo sapiens 190-193 31041855-10 2019 Extrapyramidal adverse events, sedation, hypotension, and prolactin increase were rarer with blonanserin than with haloperidol. blonanserin 93-104 prolactin Homo sapiens 58-67 30948205-0 2019 [Aripiprazole in the treatment of patients with intellectual disability and elevated prolactin levels]. Aripiprazole 1-13 prolactin Homo sapiens 85-94 31468229-4 2019 N-Glycoprofiling analysis of G-hPRL provided: (i) identification of each N-glycan structure and relative intensity; (ii) average N-glycan mass; (iii) molecular mass of the whole glycoprotein and relative carbohydrate mass fraction; (iv) mass fraction of each monosaccharide. n-glycan 73-81 prolactin Homo sapiens 31-35 31468229-4 2019 N-Glycoprofiling analysis of G-hPRL provided: (i) identification of each N-glycan structure and relative intensity; (ii) average N-glycan mass; (iii) molecular mass of the whole glycoprotein and relative carbohydrate mass fraction; (iv) mass fraction of each monosaccharide. n-glycan 129-137 prolactin Homo sapiens 31-35 31468229-4 2019 N-Glycoprofiling analysis of G-hPRL provided: (i) identification of each N-glycan structure and relative intensity; (ii) average N-glycan mass; (iii) molecular mass of the whole glycoprotein and relative carbohydrate mass fraction; (iv) mass fraction of each monosaccharide. Carbohydrates 204-216 prolactin Homo sapiens 31-35 31468229-4 2019 N-Glycoprofiling analysis of G-hPRL provided: (i) identification of each N-glycan structure and relative intensity; (ii) average N-glycan mass; (iii) molecular mass of the whole glycoprotein and relative carbohydrate mass fraction; (iv) mass fraction of each monosaccharide. Monosaccharides 259-273 prolactin Homo sapiens 31-35 31468229-8 2019 The "in vitro" bioactivity of HEK-G-hPRL was ~ fourfold lower than that of native G-hPRL, with which it had in common also the number of N-glycan structures. n-glycan 137-145 prolactin Homo sapiens 36-40 31523679-6 2019 Dopamine and prolactin were significantly higher in the caffeine ingestion group than in the control group at the Post time point (P<0.001). Caffeine 56-64 prolactin Homo sapiens 13-22 31523679-8 2019 Prolactin responses during passive heat loading were also significantly related to caffeine ingestion in this study. Caffeine 83-91 prolactin Homo sapiens 0-9 31523679-9 2019 However, the inhibitory effects of dopamine on prolactin by caffeine remain to be elucidated. Dopamine 35-43 prolactin Homo sapiens 47-56 31523679-9 2019 However, the inhibitory effects of dopamine on prolactin by caffeine remain to be elucidated. Caffeine 60-68 prolactin Homo sapiens 47-56 31167164-0 2019 Confirmation of a new therapeutic option for aggressive or dopamine agonist-resistant prolactin pituitary neuroendocrine tumors. Dopamine 59-67 prolactin Homo sapiens 86-95 30865525-0 2019 THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA. Raloxifene Hydrochloride 14-24 prolactin Homo sapiens 34-43 31056781-0 2019 Association of dopamine D2 receptor gene polymorphisms with prolactin levels related to risperidone treatment: A systematic review and meta-analysis. Risperidone 88-99 prolactin Homo sapiens 60-69 31056781-1 2019 WHAT IS KNOWN AND OBJECTIVE: Dopamine D2 receptor (DRD2) polymorphisms are inconsistently associated with elevated prolactin levels related to risperidone treatment. Risperidone 143-154 prolactin Homo sapiens 115-124 31056781-2 2019 The aim of this systematic review and meta-analysis was to investigate whether DRD2 polymorphisms could modulate prolactin levels in patients treated with risperidone. Risperidone 155-166 prolactin Homo sapiens 113-122 31056781-3 2019 METHODS: Three electronic databases (PubMed, EMBASE and the Cochrane Library) were searched for studies investigating the effect of DRD2 polymorphisms on prolactin levels in patients treated with risperidone until May 2018. Risperidone 196-207 prolactin Homo sapiens 154-163 31056781-11 2019 Based on univariable meta-regression analyses, the effects of publication year, study design, ethnicity, comparison groups and study quality could bias the identified association of DRD2 Taq1A with risperidone-related prolactin levels. Risperidone 198-209 prolactin Homo sapiens 218-227 31056781-13 2019 As there were few A1 homozygotes, large prospective studies with robust designs are still needed to investigate whether A1A1 could affect risperidone-related prolactin levels in the Asian population. Risperidone 138-149 prolactin Homo sapiens 158-167 30865525-1 2019 Objective: To evaluate the effect of raloxifene on prolactin (PRL) levels in addition to dopamine agonist (DA) therapy in patients with prolactinoma. Raloxifene Hydrochloride 37-47 prolactin Homo sapiens 51-60 30865525-1 2019 Objective: To evaluate the effect of raloxifene on prolactin (PRL) levels in addition to dopamine agonist (DA) therapy in patients with prolactinoma. Raloxifene Hydrochloride 37-47 prolactin Homo sapiens 62-65 30865525-4 2019 PRL level was measured at 1 to 6 months after starting raloxifene and at 1 to 3 months following its discontinuation. Raloxifene Hydrochloride 55-65 prolactin Homo sapiens 0-3 30865525-5 2019 Raloxifene was stopped in 8 out of 14 patients after 2 (1 to 6) months of treatment as the absolute change in PRL level was felt to be small. Raloxifene Hydrochloride 0-10 prolactin Homo sapiens 110-113 30865525-8 2019 Ten patients had an absolute and percentage decrease in PRL of 8.3 ng/mL (1.5 to 54.2 ng/mL) and 25.9% (8 to 55%) from baseline, respectively, after 1 to 6 months on raloxifene treatment. Raloxifene Hydrochloride 166-176 prolactin Homo sapiens 56-59 30865525-11 2019 Conclusion: Raloxifene was associated with a 25.9% (8 to 55%) decrease in PRL level in 10/14 (71%) patients with prolactinoma who were on stable doses of DA including 2 patients (14%) who achieved normoprolactinemia. Raloxifene Hydrochloride 12-22 prolactin Homo sapiens 74-77 31620350-1 2019 Background: Prolactin (PRL) is involved in the regulation of glucose metabolism since high PRL serum levels are associated with low incidence of type 2 diabetes mellitus (T2DM). Glucose 61-68 prolactin Homo sapiens 12-21 31075759-1 2019 Objective: Acyl ghrelin, which is the endogenous ligand for the growth hormone secretagogue receptor, potently stimulates pituitary growth hormone release, and to some degree adrenocorticotropic hormone and prolactin. acyl ghrelin 11-23 prolactin Homo sapiens 207-216 31620350-1 2019 Background: Prolactin (PRL) is involved in the regulation of glucose metabolism since high PRL serum levels are associated with low incidence of type 2 diabetes mellitus (T2DM). Glucose 61-68 prolactin Homo sapiens 23-26 31620350-1 2019 Background: Prolactin (PRL) is involved in the regulation of glucose metabolism since high PRL serum levels are associated with low incidence of type 2 diabetes mellitus (T2DM). Glucose 61-68 prolactin Homo sapiens 91-94 31620350-2 2019 Therefore, the aim of the present study was to assess the metabolic effects of PRL on glucose homeostasis in men with T2DM. Glucose 86-93 prolactin Homo sapiens 79-82 31620350-10 2019 PRL serum level was high in glyburide-treated patients as compared with metformin-treated patients (P = 0.002). Glyburide 28-37 prolactin Homo sapiens 0-3 31620350-10 2019 PRL serum level was high in glyburide-treated patients as compared with metformin-treated patients (P = 0.002). Metformin 72-81 prolactin Homo sapiens 0-3 31620350-12 2019 Diabetic pharmacotherapy mainly metformin reduced PRL serum level in patients with T2DM through amelioration of IR. Metformin 32-41 prolactin Homo sapiens 50-53 31312753-2 2019 One hypothesis is that an increase in the 16-kDa form of prolactin is pathogenic and suggests that breastfeeding may worsen peripartum cardiomyopathy by increasing prolactin, while bromocriptine, which blocks prolactin release, may be therapeutic. Bromocriptine 181-194 prolactin Homo sapiens 57-66 31062140-6 2019 The PCACP with mixed calcification had the highest PRL level in all kinds of PCACP with calcification. pcacp 4-9 prolactin Homo sapiens 51-54 31062140-6 2019 The PCACP with mixed calcification had the highest PRL level in all kinds of PCACP with calcification. pcacp 77-82 prolactin Homo sapiens 51-54 31368267-0 2019 [Efficacy of Ropivacaine injection at acupoints for labor analgesia and its effect on breastfeeding and serum prolactin]. Ropivacaine 13-24 prolactin Homo sapiens 110-119 30986806-1 2019 Dopamine agonists (DAs, especially cabergoline) are recommended as first-line treatment in patients with prolactin-secreting pituitary adenomas, to reduce hormone secretion and tumor size. Cabergoline 35-46 prolactin Homo sapiens 105-114 31368267-1 2019 OBJECTIVE: To investigate the efficacy of acupoint injection of Ropivacaine for labor analgesia and its effect on breastfeeding and prolactin secretion. Ropivacaine 64-75 prolactin Homo sapiens 132-141 31368267-12 2019 CONCLUSION: Injection of Ropivacaine at LI4 and SP6 is effective for labor analgesia and raising prolactin level, and favorable to breastfeeding in the early postpartum period. Ropivacaine 25-36 prolactin Homo sapiens 97-106 31099581-5 2019 On the basis of the simulated data, an activation mechanism of PRL with the importance of two symmetrical tryptophan residues was proposed in detail to determine the conformational change of its receptor, which is essential for signal transduction. Tryptophan 106-116 prolactin Homo sapiens 63-66 32641968-7 2019 Results revealed that within the cabergoline group the reduction in the mean prolactin level was significantly greater than that of the chamomile group (p <0.0001). Cabergoline 33-44 prolactin Homo sapiens 77-86 30986806-0 2019 Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. Temozolomide 0-12 prolactin Homo sapiens 70-79 30986806-0 2019 Temozolomide cytoreductive treatment in a giant cabergoline-resistant prolactin-secreting pituitary neuroendocrine tumor. Cabergoline 48-59 prolactin Homo sapiens 70-79 30986806-5 2019 Cabergoline treatment (at first 1.5 mg/week, and then increased to 3.5 mg/week after 3 months) achieved prolactin suppression; however, magnetic resonance revealed a stable mass. Cabergoline 0-11 prolactin Homo sapiens 104-113 30986806-1 2019 Dopamine agonists (DAs, especially cabergoline) are recommended as first-line treatment in patients with prolactin-secreting pituitary adenomas, to reduce hormone secretion and tumor size. Dopamine 0-8 prolactin Homo sapiens 105-114 31112855-8 2019 These results were maintained after controlling prolactin levels for sex, age, THC consumption, baseline TSH, and PSS. Dronabinol 79-82 prolactin Homo sapiens 48-57 31112855-9 2019 A significant correlation between prolactin and PSS was not observed. pss 48-51 prolactin Homo sapiens 34-43 30999628-11 2019 CONCLUSIONS: Inhibiting the effect of prolactin (by the level of reactive oxygen species) on the activity of GPx3 could be a starting point for the increase in antioxidative stress and the development of the inflammatory state associated with PCOS pathophysiology. Reactive Oxygen Species 65-88 prolactin Homo sapiens 38-47 31106995-7 2019 Results: Risperidone, paliperidone, and amisulpride are associated with higher prolactin levels than would be anticipated from striatal dopamine receptor occupancy studies. Risperidone 9-20 prolactin Homo sapiens 79-88 31106995-7 2019 Results: Risperidone, paliperidone, and amisulpride are associated with higher prolactin levels than would be anticipated from striatal dopamine receptor occupancy studies. Paliperidone Palmitate 22-34 prolactin Homo sapiens 79-88 31106995-7 2019 Results: Risperidone, paliperidone, and amisulpride are associated with higher prolactin levels than would be anticipated from striatal dopamine receptor occupancy studies. Amisulpride 40-51 prolactin Homo sapiens 79-88 31106995-7 2019 Results: Risperidone, paliperidone, and amisulpride are associated with higher prolactin levels than would be anticipated from striatal dopamine receptor occupancy studies. Dopamine 136-144 prolactin Homo sapiens 79-88 31106995-10 2019 Conclusions: The anatomy of the portal circulation, the presence of P-gp, and the high affinity of this protein to risperidone, paliperidone, and amisulpride all conspire to concentrate the antipsychotic concentration in the anterior pituitary to levels higher than in other parts of the brain, with consequent increase of prolactin above expectations. Risperidone 115-126 prolactin Homo sapiens 323-332 31106995-10 2019 Conclusions: The anatomy of the portal circulation, the presence of P-gp, and the high affinity of this protein to risperidone, paliperidone, and amisulpride all conspire to concentrate the antipsychotic concentration in the anterior pituitary to levels higher than in other parts of the brain, with consequent increase of prolactin above expectations. Paliperidone Palmitate 128-140 prolactin Homo sapiens 323-332 31106995-10 2019 Conclusions: The anatomy of the portal circulation, the presence of P-gp, and the high affinity of this protein to risperidone, paliperidone, and amisulpride all conspire to concentrate the antipsychotic concentration in the anterior pituitary to levels higher than in other parts of the brain, with consequent increase of prolactin above expectations. Amisulpride 146-157 prolactin Homo sapiens 323-332 29940665-5 2019 Dopamine agonist represented an efficient method to control PRL concentrations (98.8%) and reduce tumor burdens (81.2 %). Dopamine 0-8 prolactin Homo sapiens 60-63 29940665-6 2019 PRL normalization was detected in 13 out of the 27 patients initially treated with bromocriptine (BRC) whereas none of the 14 patients with first-line operation gained a normalization of PRL concentration after surgery. Bromocriptine 83-96 prolactin Homo sapiens 0-3 29940665-7 2019 Although there was no reliable predictor of tumor response, First PRL reduction was a predictive criterion for the nadir PRL level during the long-time period of follow-up for first-line bromocriptine treatment. nadir 115-120 prolactin Homo sapiens 66-69 29940665-7 2019 Although there was no reliable predictor of tumor response, First PRL reduction was a predictive criterion for the nadir PRL level during the long-time period of follow-up for first-line bromocriptine treatment. nadir 115-120 prolactin Homo sapiens 121-124 29940665-7 2019 Although there was no reliable predictor of tumor response, First PRL reduction was a predictive criterion for the nadir PRL level during the long-time period of follow-up for first-line bromocriptine treatment. Bromocriptine 187-200 prolactin Homo sapiens 66-69 29940665-7 2019 Although there was no reliable predictor of tumor response, First PRL reduction was a predictive criterion for the nadir PRL level during the long-time period of follow-up for first-line bromocriptine treatment. Bromocriptine 187-200 prolactin Homo sapiens 121-124 30875676-2 2019 However, the effectiveness of aripiprazole to treat high prolactin levels induced by antidepressant drugs with serotoninergic activity, such as duloxetine, remains unknown. Aripiprazole 30-42 prolactin Homo sapiens 57-66 30609152-12 2019 Discontinuation of risperidone may have beneficial effects on weight, waist circumference, prolactin levels and testosterone levels. Risperidone 19-30 prolactin Homo sapiens 91-100 30817321-2 2019 The inductions of prolactin (PRL) and IGF-binding protein-1 (IGFBP1), specific markers of decidualization, were inhibited by incubating ESCs under low glucose concentrations. Glucose 151-158 prolactin Homo sapiens 18-27 30817321-2 2019 The inductions of prolactin (PRL) and IGF-binding protein-1 (IGFBP1), specific markers of decidualization, were inhibited by incubating ESCs under low glucose concentrations. Glucose 151-158 prolactin Homo sapiens 29-32 30817321-12 2019 Thus, our results show that glucose is indispensable for decidualization by activating the histone modification status of the promoters of PRL, IGFBP1 and FOXO1. Glucose 28-35 prolactin Homo sapiens 139-142 30967134-4 2019 Moreover, the activity of prolactin-producing lactotrophs also depends on other hormones which are regulated by the extra-pituitary activity of dopamine receptors, dopamine transporters, enzymes of neurotransmitter metabolism and other factors. Dopamine 144-152 prolactin Homo sapiens 26-35 30967134-4 2019 Moreover, the activity of prolactin-producing lactotrophs also depends on other hormones which are regulated by the extra-pituitary activity of dopamine receptors, dopamine transporters, enzymes of neurotransmitter metabolism and other factors. Dopamine 164-172 prolactin Homo sapiens 26-35 29806538-2 2019 The objective was to investigate safety, tolerability, pharmacokinetic characteristics, and effects of BAY 1158061 on serum PRL level. bay 1158061 103-114 prolactin Homo sapiens 124-127 31215873-0 2019 [EFFECT OF MANGANESE AND NICKEL ON PROLACTIN LEVELS IN WOMEN WITH POLYCYSTIC OVARY SYNDROME]. Nickel 25-31 prolactin Homo sapiens 35-44 31215873-1 2019 To study the relationship between the level of exposure to manganese and nickel and prolactin levels in the serum in women with rolycystic ovary syndrome (PCOS). Manganese 59-68 prolactin Homo sapiens 84-93 31215873-8 2019 In the group of women with PCOS, elevated serum manganese concentrations correlated with an increase in prolactin levels (P=0.0134). Manganese 48-57 prolactin Homo sapiens 104-113 31215873-11 2019 These results confirm the existing view that exposure to manganese may be the cause of increased levels of prolactin. Manganese 57-66 prolactin Homo sapiens 107-116 31215873-13 2019 Women with PCOS show an increase in prolactin levels, that depends on the level of exposure to manganese. Manganese 95-104 prolactin Homo sapiens 36-45 30590797-11 2019 Furthermore, PRL induced the lipid synthesis of organ-cultured pigeon crops in a dose- and time-dependent manner, which was related to the increased expression of genes involved in fatty acid transportation and lipogenesis. Fatty Acids 181-191 prolactin Homo sapiens 13-16 29806538-11 2019 Based on the data obtained, BAY 1158061 is considered a good candidate for further development in endometriosis or other PRL-mediated disease conditions. bay 1158061 28-39 prolactin Homo sapiens 121-124 31073929-10 2019 The increase in PRL likely reflects a stress response after physical exercise, amplified by hyperbaric oxygen. Oxygen 103-109 prolactin Homo sapiens 16-19 30519818-0 2019 Effect of metoclopramide administration to mothers on neonatal bilirubin and maternal prolactin: a randomized, controlled, clinical trial. Metoclopramide 10-24 prolactin Homo sapiens 86-95 30519818-2 2019 This study was conducted to determine the effect of metoclopramide on neonatal bilirubin and maternal prolactin (primary outcomes) and milk volume (secondary outcome). Metoclopramide 52-66 prolactin Homo sapiens 102-111 30519818-9 2019 RESULTS: After the intervention, the two groups did not differ significantly in terms of the mean neonatal indirect bilirubin (P = 0.565) and milk volume (P = 0.261), but the mean serum prolactin was significantly higher in the metoclopramide group compared to the placebo group (adjusted mean difference 37; 95% confidence interval 58.1-16.5; P = 0.001). Metoclopramide 228-242 prolactin Homo sapiens 186-195 30519818-10 2019 CONCLUSIONS: Metoclopramide increased maternal serum prolactin but had no effects on neonatal jaundice. Metoclopramide 13-27 prolactin Homo sapiens 53-62 30894514-4 2019 Using primary human endometrial stromal cell (HESC) cultures, we demonstrate that resveratrol has anti-deciduogenic properties, repressing not only the induction of the decidual marker genes PRL and IGFBP1 but also abrogating decidual senescence. Resveratrol 82-93 prolactin Homo sapiens 191-194 30734859-3 2019 Novel praseodymium metal-organic framework nanofibers (Pr-MOF-NFs) were synthesized by a facile and simple method for the determination of human prolactin in serum samples. Metals 19-24 prolactin Homo sapiens 145-154 30718434-4 2019 Mutations or CRISPR-Cas9 targeting of the conserved upstream ORF present in the mRNA leader derepress PRL protein synthesis and attenuate the translational response to magnesium levels. Magnesium 168-177 prolactin Homo sapiens 102-105 30718434-5 2019 Mechanistically, magnesium depletion reduces intracellular ATP but up-regulates PRL protein expression via activation of the AMPK/mTORC2 pathway, which controls cellular energy status. Magnesium 17-26 prolactin Homo sapiens 80-83 30718434-7 2019 These findings uncover a magnesium-sensitive mechanism controlling PRL expression, which plays a role in cellular bioenergetics. Magnesium 25-34 prolactin Homo sapiens 67-70 30362146-8 2019 Ropinirole concentrations peaked at 4.4 +- 2.7 h and exhibited a half-life of 5.8 +- 1.7 h. A dose-dependent prolactin nadir occurred 4.4 +- 1.2 h after drug intake and prolactin concentrations transiently normalized in two of five subjects. ropinirole 0-10 prolactin Homo sapiens 109-118 30362146-8 2019 Ropinirole concentrations peaked at 4.4 +- 2.7 h and exhibited a half-life of 5.8 +- 1.7 h. A dose-dependent prolactin nadir occurred 4.4 +- 1.2 h after drug intake and prolactin concentrations transiently normalized in two of five subjects. ropinirole 0-10 prolactin Homo sapiens 169-178 30660191-5 2019 On the basis of the patient"s serum concentration of prolactin, we diagnosed a prolactinoma and started dopamine agonist therapy with cabergoline. Dopamine 104-112 prolactin Homo sapiens 53-62 30660191-5 2019 On the basis of the patient"s serum concentration of prolactin, we diagnosed a prolactinoma and started dopamine agonist therapy with cabergoline. Cabergoline 134-145 prolactin Homo sapiens 53-62 30718434-0 2019 Magnesium-sensitive upstream ORF controls PRL phosphatase expression to mediate energy metabolism. Magnesium 0-9 prolactin Homo sapiens 42-45 30506237-10 2019 Prolactin elevation is highest with paliperidone, risperidone, and amisulpride. Paliperidone Palmitate 36-48 prolactin Homo sapiens 0-9 30506237-10 2019 Prolactin elevation is highest with paliperidone, risperidone, and amisulpride. Risperidone 50-61 prolactin Homo sapiens 0-9 30506237-10 2019 Prolactin elevation is highest with paliperidone, risperidone, and amisulpride. Amisulpride 67-78 prolactin Homo sapiens 0-9 30465960-7 2019 Her serum prolactin level at hospitalization was 11,300 mug/L; therefore, we initiated cabergoline therapy. Cabergoline 87-98 prolactin Homo sapiens 10-19 30899469-1 2019 Long-acting pasireotide and bromocriptine provided biochemical control of growth hormone and prolactin in a patient with plurihormonal pituitary macroadenoma, allowing near-complete tumor excision while restoring pituitary function and avoiding adjunctive radiotherapy. Bromocriptine 28-41 prolactin Homo sapiens 93-102 30740089-1 2018 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. Dopamine 0-8 prolactin Homo sapiens 96-105 30740089-1 2018 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. Bromocriptine 26-39 prolactin Homo sapiens 96-105 30740089-1 2018 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size. Cabergoline 44-55 prolactin Homo sapiens 96-105 32145165-6 2019 A slight decrease in total protein in the blood and a tendency to a decrease in the level of PRL with increasing age against the background of a negative correlations between the low degree of PRL and age (r=-0,20; p=0,01), total protein and age (r=-0,35; p=0,01) confirm the participation of PRL in protein metabolism, and also indirectly indicate changes in the regulatory effect of dopamine on prolactin synthesis and secretion. Dopamine 385-393 prolactin Homo sapiens 93-96 32145165-6 2019 A slight decrease in total protein in the blood and a tendency to a decrease in the level of PRL with increasing age against the background of a negative correlations between the low degree of PRL and age (r=-0,20; p=0,01), total protein and age (r=-0,35; p=0,01) confirm the participation of PRL in protein metabolism, and also indirectly indicate changes in the regulatory effect of dopamine on prolactin synthesis and secretion. Dopamine 385-393 prolactin Homo sapiens 193-196 32145165-6 2019 A slight decrease in total protein in the blood and a tendency to a decrease in the level of PRL with increasing age against the background of a negative correlations between the low degree of PRL and age (r=-0,20; p=0,01), total protein and age (r=-0,35; p=0,01) confirm the participation of PRL in protein metabolism, and also indirectly indicate changes in the regulatory effect of dopamine on prolactin synthesis and secretion. Dopamine 385-393 prolactin Homo sapiens 193-196 30453151-4 2019 Also ours is the first study that evaluated the correlation between psychopathology & prolactin levels after considering the confounding agents. Adenosine Monophosphate 85-88 prolactin Homo sapiens 90-99 30030156-2 2019 Therefore, PRL level changes in type II diabetes and it can be concluded that PRL can play an important role in metabolic disorders of glucose. Glucose 135-142 prolactin Homo sapiens 11-14 30030156-2 2019 Therefore, PRL level changes in type II diabetes and it can be concluded that PRL can play an important role in metabolic disorders of glucose. Glucose 135-142 prolactin Homo sapiens 78-81 30462197-11 2019 Because G129R-hPrl treatment also improved the insulin sensitivity of ob/ob mice, pharmacological compounds that inhibit Prl signaling may represent a promising therapeutic approach to control blood glucose levels in individuals with insulin resistance. Glucose 199-206 prolactin Homo sapiens 14-18 30129670-9 2019 The results of the study suggest that cardiometabolic effects of atorvastatin depend on the prolactin status of patients. Atorvastatin 65-77 prolactin Homo sapiens 92-101 30566415-0 2019 Effect of Brexpiprazole on Prolactin: An Analysis of Short- and Long-Term Studies in Schizophrenia. brexpiprazole 10-23 prolactin Homo sapiens 27-36 30566415-2 2019 We assessed the effect of the D2-receptor partial agonist brexpiprazole on prolactin, based on pooled data from three 6-week, randomized, placebo-controlled studies and two open-label extension studies in patients with schizophrenia. brexpiprazole 58-71 prolactin Homo sapiens 75-84 30566415-7 2019 Prolactin levels in patients with baseline values greater than 1x upper limit of normal tended to decrease over time regardless of previous treatment.The proportions of brexpiprazole-treated patients with greater than 3x upper limit of normal postbaseline prolactin values in short-term studies were as follows: 1.5% (females), 1.6% (males); placebo: 3.6% (females), 3.4% (males). brexpiprazole 169-182 prolactin Homo sapiens 0-9 30566415-7 2019 Prolactin levels in patients with baseline values greater than 1x upper limit of normal tended to decrease over time regardless of previous treatment.The proportions of brexpiprazole-treated patients with greater than 3x upper limit of normal postbaseline prolactin values in short-term studies were as follows: 1.5% (females), 1.6% (males); placebo: 3.6% (females), 3.4% (males). brexpiprazole 169-182 prolactin Homo sapiens 256-265 30566415-8 2019 Corresponding figures in long-term studies were 5.3% (females) and 2.0% (males).In short-term studies, the incidence of prolactin-related TEAEs was 1.8% for brexpiprazole and 0.6% for placebo. brexpiprazole 157-170 prolactin Homo sapiens 120-129 30566415-10 2019 CONCLUSIONS: Small changes in prolactin levels, low proportions of patients with postbaseline elevated prolactin values, and low incidence of prolactin-related TEAEs were observed after treatment with brexpiprazole. brexpiprazole 201-214 prolactin Homo sapiens 30-39 30566415-10 2019 CONCLUSIONS: Small changes in prolactin levels, low proportions of patients with postbaseline elevated prolactin values, and low incidence of prolactin-related TEAEs were observed after treatment with brexpiprazole. brexpiprazole 201-214 prolactin Homo sapiens 103-112 30566415-10 2019 CONCLUSIONS: Small changes in prolactin levels, low proportions of patients with postbaseline elevated prolactin values, and low incidence of prolactin-related TEAEs were observed after treatment with brexpiprazole. brexpiprazole 201-214 prolactin Homo sapiens 103-112 30828702-0 2019 A Proposed Efficacious Treatment with Clioquinol (Zinc Ionophore) and Cabergoline (Prolactin Dopamine Agonist) for the Treatment of Terminal Androgen-independent Prostate Cancer. Cabergoline 70-81 prolactin Homo sapiens 83-92 30828702-11 2019 Cabergoline (dopamine agonist) is employed to decrease prolactin production and its role in the progression of androgen-independent malignancy. Cabergoline 0-11 prolactin Homo sapiens 55-64 30828702-11 2019 Cabergoline (dopamine agonist) is employed to decrease prolactin production and its role in the progression of androgen-independent malignancy. Dopamine 13-21 prolactin Homo sapiens 55-64 30911516-14 2019 Hypothyroidism was a common endocrinal abnormality and prolactin was inversely correlated to TSH levels in PCOS patients. Thyrotropin 93-96 prolactin Homo sapiens 55-64 31211288-8 2019 He was treated with cabergoline (dopamine agonist) treatment, which decreased the plasma prolactin 88%; by inhibiting the pituitary production of prolactin. Cabergoline 20-31 prolactin Homo sapiens 89-98 31211288-8 2019 He was treated with cabergoline (dopamine agonist) treatment, which decreased the plasma prolactin 88%; by inhibiting the pituitary production of prolactin. Cabergoline 20-31 prolactin Homo sapiens 146-155 31211288-8 2019 He was treated with cabergoline (dopamine agonist) treatment, which decreased the plasma prolactin 88%; by inhibiting the pituitary production of prolactin. Dopamine 33-41 prolactin Homo sapiens 89-98 31211288-8 2019 He was treated with cabergoline (dopamine agonist) treatment, which decreased the plasma prolactin 88%; by inhibiting the pituitary production of prolactin. Dopamine 33-41 prolactin Homo sapiens 146-155 31211288-12 2019 When testosterone availability diminishes; prolactin regulation is manifested. Testosterone 5-17 prolactin Homo sapiens 43-52 31208951-4 2019 Prolactin level is affected by (and reflects) brain dopamine availability. Dopamine 52-60 prolactin Homo sapiens 0-9 31208951-10 2019 We also found a significant correlation between prolactin (18.2 +- 9.6 ng/ml) and Phe levels (852 +- 472 mumol/l) on the day of assessment (rs = 0.470; p < .001). Phenylalanine 82-85 prolactin Homo sapiens 48-57 30347396-6 2019 They respond to medical treatment with dopamine agonists in terms of prolactin normalization, tumor shrinkage, and improvement in pituitary function. Dopamine 39-47 prolactin Homo sapiens 69-78 30852578-2 2019 Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists. Dopamine 50-58 prolactin Homo sapiens 99-102 30852578-2 2019 Herein we provide an overview of the evolution of dopamine agonists and their use in patients with PRL-secreting pituitary tumors, starting from the 1970s up to today, highlighting that normalization of PRL levels, restoration of eugonadism, and reduction of tumor mass can be achieved in the majority of patients by treatment with dopamine agonists. Dopamine 50-58 prolactin Homo sapiens 203-206 30347396-8 2019 Reducing doses of cabergoline to the lowest that keeps prolactin levels normal prior to withdrawal is proposed to patients with macroprolactinomas who normalize prolactin after > 5 years of treatment and who do not have cavernous sinus invasion. Cabergoline 18-29 prolactin Homo sapiens 55-64 30347396-8 2019 Reducing doses of cabergoline to the lowest that keeps prolactin levels normal prior to withdrawal is proposed to patients with macroprolactinomas who normalize prolactin after > 5 years of treatment and who do not have cavernous sinus invasion. Cabergoline 18-29 prolactin Homo sapiens 133-142 31328184-6 2019 This has been achieved with cabergoline (dopamine agonist; Dostinex) treatment of a patient that resulted in 88% decreased plasma prolactin, and terminated the malignancy. Cabergoline 28-39 prolactin Homo sapiens 130-139 31328184-6 2019 This has been achieved with cabergoline (dopamine agonist; Dostinex) treatment of a patient that resulted in 88% decreased plasma prolactin, and terminated the malignancy. Dopamine 41-49 prolactin Homo sapiens 130-139 31328184-6 2019 This has been achieved with cabergoline (dopamine agonist; Dostinex) treatment of a patient that resulted in 88% decreased plasma prolactin, and terminated the malignancy. Cabergoline 59-67 prolactin Homo sapiens 130-139 31050980-2 2019 The aim of this study was to find out the relationship of prolactin concentration with parameters of arterial stiffness in hypertensive men with low testosterone. Testosterone 149-161 prolactin Homo sapiens 58-67 31050980-6 2019 Prolactin levels appeared to be significantly higher in hypertensive men with lower testosterone, they had more unfavorable parameters of arterial stiffness and the difference between 1 and 2 group in terms of central aoSBP and aoPWV became statistically significant. Testosterone 84-96 prolactin Homo sapiens 0-9 31050980-6 2019 Prolactin levels appeared to be significantly higher in hypertensive men with lower testosterone, they had more unfavorable parameters of arterial stiffness and the difference between 1 and 2 group in terms of central aoSBP and aoPWV became statistically significant. aopwv 228-233 prolactin Homo sapiens 0-9 30587989-0 2018 Influence of olanzapine on serum prolactin levels and BMI in female patients with schizophrenia. Olanzapine 13-23 prolactin Homo sapiens 33-42 30587989-2 2018 The existing evidences show that serum PRL is elevated in schizophrenic patients treated with olanzapine. Olanzapine 94-104 prolactin Homo sapiens 39-42 30587989-9 2018 Results: The olanzapine treatment for 12 weeks significantly increased serum PRL (P<0.01) level and BMI (P<0.01). Olanzapine 13-23 prolactin Homo sapiens 77-80 30587989-11 2018 Conclusion: Our findings suggest that PRL might conceivably modulate weight gain in female patients with schizophrenia receiving olanzapine treatment; however, the exact mechanism remains unclear. Olanzapine 129-139 prolactin Homo sapiens 38-41 30188234-11 2018 AAs associated with no/low prolactin elevation reduce the risk of hyperprolactinemia by 4-5-times compared to AAs associated with moderate/high prolactin elevation. aas 0-3 prolactin Homo sapiens 27-36 29694255-6 2018 PATIENTS AND METHODS: The serum PRL level of 40 female patients with CU was measured using the electrochemiluminescence immunoassay. Copper 69-71 prolactin Homo sapiens 32-35 30188234-11 2018 AAs associated with no/low prolactin elevation reduce the risk of hyperprolactinemia by 4-5-times compared to AAs associated with moderate/high prolactin elevation. aas 0-3 prolactin Homo sapiens 71-80 31149301-3 2018 Objective: The purpose of our study was to observe long-term (one year) prolactin level change in first episode schizophrenia patients treated with one of the four AAs: olanzapine, quetiapine, amisulpride, ziprasidone. aas 164-167 prolactin Homo sapiens 72-81 30272319-9 2018 Furthermore, E2 alone or in combination with 60 kDa PRL increased the sensitivity of SiHa cells to cisplatin and increased the percentage of apoptosis; in HaCaT cells, these treatment strategies had the opposite effect on cisplatin sensitivity. Cisplatin 99-108 prolactin Homo sapiens 52-55 30272319-9 2018 Furthermore, E2 alone or in combination with 60 kDa PRL increased the sensitivity of SiHa cells to cisplatin and increased the percentage of apoptosis; in HaCaT cells, these treatment strategies had the opposite effect on cisplatin sensitivity. Cisplatin 222-231 prolactin Homo sapiens 52-55 31149301-3 2018 Objective: The purpose of our study was to observe long-term (one year) prolactin level change in first episode schizophrenia patients treated with one of the four AAs: olanzapine, quetiapine, amisulpride, ziprasidone. Quetiapine Fumarate 181-191 prolactin Homo sapiens 72-81 31149301-3 2018 Objective: The purpose of our study was to observe long-term (one year) prolactin level change in first episode schizophrenia patients treated with one of the four AAs: olanzapine, quetiapine, amisulpride, ziprasidone. ziprasidone 206-217 prolactin Homo sapiens 72-81 31149301-9 2018 In case of the female patients, treatment with olanzapine (p=.021) and ziprasidone (p=.005) has been associated with a decrease of prolactin level in one year compared with baseline. Olanzapine 47-57 prolactin Homo sapiens 131-140 31149301-9 2018 In case of the female patients, treatment with olanzapine (p=.021) and ziprasidone (p=.005) has been associated with a decrease of prolactin level in one year compared with baseline. ziprasidone 71-82 prolactin Homo sapiens 131-140 31149301-10 2018 Conclusions: In both men and women, the administration of these four AAs is not associated with the increase of prolactin levels, moreover, in women"s case, there is a reduction of prolactin values at administration of Olanzapine and Ziprasidone. Olanzapine 219-229 prolactin Homo sapiens 181-190 30334324-0 2018 Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts. Metformin 0-9 prolactin Homo sapiens 30-39 29955115-0 2018 UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder. Risperidone 59-70 prolactin Homo sapiens 37-46 29955115-1 2018 The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients. ethyl 3,4-dioxobutyrate-di-(4,4-dimethylthiosemicarbazone) 102-106 prolactin Homo sapiens 151-160 29955115-1 2018 The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients. ethyl 3,4-dioxobutyrate-di-(4,4-dimethylthiosemicarbazone) 102-106 prolactin Homo sapiens 216-225 29955115-1 2018 The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients. Risperidone 131-142 prolactin Homo sapiens 151-160 29955115-1 2018 The aim of this study was to investigate the association of drug-metabolizing enzyme and transporter (DMET) polymorphisms with the risperidone-induced prolactin response using an overlapping gene model between serum prolactin level and hyperprolactinemia in autism spectrum disorder (ASD) patients. Risperidone 131-142 prolactin Homo sapiens 216-225 29955115-6 2018 An overlapping allelic association analysis of both analyses discovered five DMET SNPs with a suggestive association (P < 0.05) with risperidone-induced prolactin response. Risperidone 136-147 prolactin Homo sapiens 156-165 29955115-8 2018 In this DMET microarray platform, we found three UGT1A1 variants with suggestive evidences of association with the risperidone-induced prolactin response both measured by hyperprolactinemia and by prolactin level. Risperidone 115-126 prolactin Homo sapiens 135-144 29955115-8 2018 In this DMET microarray platform, we found three UGT1A1 variants with suggestive evidences of association with the risperidone-induced prolactin response both measured by hyperprolactinemia and by prolactin level. Risperidone 115-126 prolactin Homo sapiens 176-185 30542321-18 2018 Conclusion: This study confirms that tumors resistant to dopamine agonists are more aggressive, since we did not have any microadenoma; treatment with high dose of cabergoline may reduce the size of the tumor without its disappearance, and that normalization of prolactin concentration rarely occurs. Dopamine 57-65 prolactin Homo sapiens 262-271 30542321-18 2018 Conclusion: This study confirms that tumors resistant to dopamine agonists are more aggressive, since we did not have any microadenoma; treatment with high dose of cabergoline may reduce the size of the tumor without its disappearance, and that normalization of prolactin concentration rarely occurs. Cabergoline 164-175 prolactin Homo sapiens 262-271 30238326-6 2018 RESULTS: Cabergoline was effective for the treatment of the patients with bromocriptine -resistant IGPs as represented by normalization of the prolactin level in 12/15 patients; improvement or normalization of the pituitary function in 4/5 patients with hypopituitarism; significant reduction in tumor size in 14/15 patients; and relief of the clinical symptoms in 11/15 patients. Cabergoline 9-20 prolactin Homo sapiens 143-152 30238326-6 2018 RESULTS: Cabergoline was effective for the treatment of the patients with bromocriptine -resistant IGPs as represented by normalization of the prolactin level in 12/15 patients; improvement or normalization of the pituitary function in 4/5 patients with hypopituitarism; significant reduction in tumor size in 14/15 patients; and relief of the clinical symptoms in 11/15 patients. Bromocriptine 74-87 prolactin Homo sapiens 143-152 30120801-2 2018 This study aimed to determine the relationship between PRL and psoriasis through clinical case-control studies, and explore the function of PRL in the pathogenesis of imiquimod (IMQ)-induced psoriasis-like mouse model. Imiquimod 167-176 prolactin Homo sapiens 140-143 30120801-2 2018 This study aimed to determine the relationship between PRL and psoriasis through clinical case-control studies, and explore the function of PRL in the pathogenesis of imiquimod (IMQ)-induced psoriasis-like mouse model. Imiquimod 178-181 prolactin Homo sapiens 140-143 30613511-2 2018 Prolactin (PRL) secretion is stimulated by dopamine antagonism and thyroid-releasing hormone. Dopamine 43-51 prolactin Homo sapiens 0-9 30613511-2 2018 Prolactin (PRL) secretion is stimulated by dopamine antagonism and thyroid-releasing hormone. Dopamine 43-51 prolactin Homo sapiens 11-14 31149301-3 2018 Objective: The purpose of our study was to observe long-term (one year) prolactin level change in first episode schizophrenia patients treated with one of the four AAs: olanzapine, quetiapine, amisulpride, ziprasidone. Olanzapine 169-179 prolactin Homo sapiens 72-81 30267533-6 2018 RESULTS Serum prolactin concentrations were significantly higher in elderly people ($65 vs. >65) and in men (70.65+-58.02 vs. 150.82+-114.05 mIU/L), as well as in patients with lower renal function (156.70+-127.23 vs. 72.53+-37.25 mIU/L, the bottom vs. top quartile of creatinine clearance), higher serum homocysteine and TSH concentrations, and in those who used NSAID and statins. N-{(1S)-1-{[4-(3-AMINOPROPYL)PIPERAZIN-1-YL]CARBONYL}-4-[(DIAMINOMETHYLENE)AMINO]BUTYL}-3-(TRIFLUOROMETHYL)BENZENESULFONAMIDE 144-147 prolactin Homo sapiens 14-23 30267533-6 2018 RESULTS Serum prolactin concentrations were significantly higher in elderly people ($65 vs. >65) and in men (70.65+-58.02 vs. 150.82+-114.05 mIU/L), as well as in patients with lower renal function (156.70+-127.23 vs. 72.53+-37.25 mIU/L, the bottom vs. top quartile of creatinine clearance), higher serum homocysteine and TSH concentrations, and in those who used NSAID and statins. Creatinine 272-282 prolactin Homo sapiens 14-23 30267533-6 2018 RESULTS Serum prolactin concentrations were significantly higher in elderly people ($65 vs. >65) and in men (70.65+-58.02 vs. 150.82+-114.05 mIU/L), as well as in patients with lower renal function (156.70+-127.23 vs. 72.53+-37.25 mIU/L, the bottom vs. top quartile of creatinine clearance), higher serum homocysteine and TSH concentrations, and in those who used NSAID and statins. Homocysteine 308-320 prolactin Homo sapiens 14-23 30267533-6 2018 RESULTS Serum prolactin concentrations were significantly higher in elderly people ($65 vs. >65) and in men (70.65+-58.02 vs. 150.82+-114.05 mIU/L), as well as in patients with lower renal function (156.70+-127.23 vs. 72.53+-37.25 mIU/L, the bottom vs. top quartile of creatinine clearance), higher serum homocysteine and TSH concentrations, and in those who used NSAID and statins. Thyrotropin 325-328 prolactin Homo sapiens 14-23 30267533-7 2018 Parameters indicating chronic inflammation (CRP) and renal function decline (creatinine clearance) were significantly and independently correlated with increased serum prolactin concentrations in multiple regression analysis. Creatinine 77-87 prolactin Homo sapiens 168-177 30256543-0 2018 Symptomatic Extreme Elevation of Prolactin Related to Risperidone Use. Risperidone 54-65 prolactin Homo sapiens 33-42 30214207-0 2018 Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level. Aripiprazole 0-12 prolactin Homo sapiens 74-83 29735004-0 2018 Exchange protein directly activated by cAMP (EPAC) promotes transcriptional activation of the decidual prolactin gene via CCAAT/enhancer-binding protein in human endometrial stromal cells. Cyclic AMP 39-43 prolactin Homo sapiens 94-112 29620428-3 2018 As prolactin release is negatively regulated by dopamine, peripheral prolactin levels confirmed the efficacy of our manipulation. Dopamine 48-56 prolactin Homo sapiens 3-12 30214207-0 2018 Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level. Paliperidone Palmitate 41-53 prolactin Homo sapiens 74-83 30214207-3 2018 Herein, we followed up a patient with elevated prolactin caused by paliperidone and found that the prolactin level was decreased after the administration of a combination with a low-dose aripiprazole. Paliperidone Palmitate 67-79 prolactin Homo sapiens 47-56 30214207-3 2018 Herein, we followed up a patient with elevated prolactin caused by paliperidone and found that the prolactin level was decreased after the administration of a combination with a low-dose aripiprazole. Paliperidone Palmitate 67-79 prolactin Homo sapiens 99-108 30214207-3 2018 Herein, we followed up a patient with elevated prolactin caused by paliperidone and found that the prolactin level was decreased after the administration of a combination with a low-dose aripiprazole. Aripiprazole 187-199 prolactin Homo sapiens 47-56 30214207-3 2018 Herein, we followed up a patient with elevated prolactin caused by paliperidone and found that the prolactin level was decreased after the administration of a combination with a low-dose aripiprazole. Aripiprazole 187-199 prolactin Homo sapiens 99-108 29752978-5 2018 We predicted that increasing prolactin would increase brooding and feeding behaviors towards foster chicks compared to the saline control group. Sodium Chloride 123-129 prolactin Homo sapiens 29-38 29788161-4 2018 The CD spectra of non-PEGylated and PEGylated chPRL were almost identical and similar to that of hPRL, indicating proper refolding. Cadmium 4-6 prolactin Homo sapiens 47-51 30250766-5 2018 While cabergoline treatment resulted in normalization of prolactin levels and androgen excess, no significant biochemical or clinical improvement occurred with metformin treatment. Cabergoline 6-17 prolactin Homo sapiens 57-66 29490377-5 2018 However, in comparison, risperidone was associated with higher weight gain and prolactin levels. Risperidone 24-35 prolactin Homo sapiens 79-88 29912799-0 2018 Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial. Aripiprazole 8-20 prolactin Homo sapiens 29-38 29912799-0 2018 Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial. Aripiprazole 8-20 prolactin Homo sapiens 43-52 29912799-9 2018 Aripiprazole (mean dose, 11.7 +- 2.4 mg/d) was effective for lowering prolactin relative to placebo (P = 0.04). Aripiprazole 0-12 prolactin Homo sapiens 70-79 29912799-10 2018 In addition, 45% (9/20) of the aripiprazole group had a normalized prolactin (<24 mg/mL) compared with 12% (2/17) of the placebo group (P = 0.028). Aripiprazole 31-43 prolactin Homo sapiens 67-76 29912799-15 2018 IMPLICATIONS/CONCLUSIONS: Building upon prior studies, this rigorous evaluation confirms the utility of adjunctive aripiprazole as a strategy for improving prolactin and managing prolactin-related adverse effects in premenopausal women with psychosis. Aripiprazole 115-127 prolactin Homo sapiens 156-165 29912799-15 2018 IMPLICATIONS/CONCLUSIONS: Building upon prior studies, this rigorous evaluation confirms the utility of adjunctive aripiprazole as a strategy for improving prolactin and managing prolactin-related adverse effects in premenopausal women with psychosis. Aripiprazole 115-127 prolactin Homo sapiens 179-188 30093983-1 2018 A new concept: Testosterone-independent malignancy is the development of prolactin-dependent malignancy! Testosterone 15-27 prolactin Homo sapiens 73-82 30093983-6 2018 Citrate production, along with growth and proliferation by these cells, is regulated by co-existing testosterone and prolactin signaling pathways; and by the oncogenic down-regulation of ZIP1 transporter/zinc/citrate in the development of malignancy. Citric Acid 0-7 prolactin Homo sapiens 117-126 30093983-9 2018 The oncogenic factor along with testosterone-dependent and prolactin-dependent relationships leads to the plausible concept that androgen ablation for the treatment of testosteronedependent malignancy results in the development of prolactindependent malignancy; which is testosterone-independent malignancy. Testosterone 168-180 prolactin Homo sapiens 59-68 29482256-0 2018 Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. Risperidone 11-22 prolactin Homo sapiens 59-68 29482256-0 2018 Effects of Risperidone and Aripiprazole on Serum Levels of Prolactin, Testosterone and Estradiol in Female Patients with Schizophrenia. Aripiprazole 27-39 prolactin Homo sapiens 59-68 29482256-1 2018 OBJECTIVE: To evaluate the effects of treatment with risperidone and aripiprazole on serum prolactin, testosterone and estradiol levels in female patients with schizophrenia in China. Risperidone 53-64 prolactin Homo sapiens 91-100 29482256-1 2018 OBJECTIVE: To evaluate the effects of treatment with risperidone and aripiprazole on serum prolactin, testosterone and estradiol levels in female patients with schizophrenia in China. Aripiprazole 69-81 prolactin Homo sapiens 91-100 29482256-5 2018 RESULTS: Serum prolactin, testosterone and estradiol levels in both studies were significantly decreased after risperidone treatment compared with baseline (P<0.05), and prolactin levels remained at a high level. Risperidone 111-122 prolactin Homo sapiens 15-24 29482256-5 2018 RESULTS: Serum prolactin, testosterone and estradiol levels in both studies were significantly decreased after risperidone treatment compared with baseline (P<0.05), and prolactin levels remained at a high level. Risperidone 111-122 prolactin Homo sapiens 173-182 29482256-6 2018 Serum prolactin levels in the adjunctive aripiprazole group were significantly decreased after treatment compared with baseline in the prospective study (P<0.05). Aripiprazole 41-53 prolactin Homo sapiens 6-15 29708436-0 2018 PROLACTIN LEVELS DO NOT RISE AMONG TRANSGENDER WOMEN TREATED WITH ESTRADIOL AND SPIRONOLACTONE. Estradiol 66-75 prolactin Homo sapiens 0-9 29708436-0 2018 PROLACTIN LEVELS DO NOT RISE AMONG TRANSGENDER WOMEN TREATED WITH ESTRADIOL AND SPIRONOLACTONE. Spironolactone 80-94 prolactin Homo sapiens 0-9 29708436-1 2018 OBJECTIVE: Existing transgender treatment guidelines suggest that there is a need to monitor prolactin levels in patients receiving transfeminine hormone treatment. transfeminine hormone 132-153 prolactin Homo sapiens 93-102 29708436-2 2018 Also, recent studies suggest that use of cyproterone acetate as an adjunctive anti-androgen during transgender hormone treatment may elevate serum prolactin. Cyproterone Acetate 41-60 prolactin Homo sapiens 147-156 29914302-0 2018 Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants. Risperidone 52-63 prolactin Homo sapiens 0-9 29914302-0 2018 Prolactin levels: sex differences in the effects of risperidone, 9-hydroxyrisperidone levels, CYP2D6 and ABCB1 variants. Paliperidone Palmitate 65-85 prolactin Homo sapiens 0-9 29914302-1 2018 AIM: The role of sex on the association of plasma prolactin levels with risperidone (R) and 9-hydroxyrisperidone (9-OHR) concentrations is investigated. Risperidone 72-83 prolactin Homo sapiens 50-59 29914302-1 2018 AIM: The role of sex on the association of plasma prolactin levels with risperidone (R) and 9-hydroxyrisperidone (9-OHR) concentrations is investigated. Paliperidone Palmitate 92-112 prolactin Homo sapiens 50-59 29914302-1 2018 AIM: The role of sex on the association of plasma prolactin levels with risperidone (R) and 9-hydroxyrisperidone (9-OHR) concentrations is investigated. 9-ohr 114-119 prolactin Homo sapiens 50-59 29914302-7 2018 CONCLUSION: Genes had sex-specific effects on risperidone-associated prolactin elevations. Risperidone 46-57 prolactin Homo sapiens 69-78 29530699-5 2018 Surprisingly, combining the patient"s treatment with metformin decreased prolactin (PRL) levels to 12 ng/mL and significantly decreased the size of the tumor after 1 year of combination therapy. Metformin 53-62 prolactin Homo sapiens 84-87 29530699-9 2018 After 14 months of using bromocriptine alone, her PRL level increased to 208 ng/mL and the tumor reappeared (7 mm x 8 mm x 9 mm). Bromocriptine 25-38 prolactin Homo sapiens 50-53 29530699-10 2018 Interestingly, the patient"s PRL level decreased from 208 ng/mL to 150 ng/mL 2 months after using combination treatment with bromocriptine and metformin. Bromocriptine 125-138 prolactin Homo sapiens 29-32 29530699-10 2018 Interestingly, the patient"s PRL level decreased from 208 ng/mL to 150 ng/mL 2 months after using combination treatment with bromocriptine and metformin. Metformin 143-152 prolactin Homo sapiens 29-32 29530699-12 2018 After 3 months of combined treatment with bromocriptine and metformin, the patient"s PRL level decreased to 2.08 ng/mL, testosterone levels increased significantly, and the tumor size decreased. Bromocriptine 42-55 prolactin Homo sapiens 85-88 29530699-12 2018 After 3 months of combined treatment with bromocriptine and metformin, the patient"s PRL level decreased to 2.08 ng/mL, testosterone levels increased significantly, and the tumor size decreased. Metformin 60-69 prolactin Homo sapiens 85-88 29169197-0 2018 Sex-Dependent Effect of Metformin on Serum Prolactin Levels In Hyperprolactinemic Patients With Type 2 Diabetes: A Pilot Study. Metformin 24-33 prolactin Homo sapiens 43-52 29802039-12 2018 Risperidone, haloperidol, paliperidone and olanzapine were associated with prolactin increase. Risperidone 0-11 prolactin Homo sapiens 75-84 29802039-12 2018 Risperidone, haloperidol, paliperidone and olanzapine were associated with prolactin increase. Haloperidol 13-24 prolactin Homo sapiens 75-84 29802039-12 2018 Risperidone, haloperidol, paliperidone and olanzapine were associated with prolactin increase. Paliperidone Palmitate 26-38 prolactin Homo sapiens 75-84 29169197-9 2018 However, only in women metformin decreased elevated prolactin levels and this effect correlated with an improvement insulin sensitivity, as well as with the impact on SPINA-GT. Metformin 23-32 prolactin Homo sapiens 52-61 29802039-12 2018 Risperidone, haloperidol, paliperidone and olanzapine were associated with prolactin increase. Olanzapine 43-53 prolactin Homo sapiens 75-84 29169197-10 2018 CONCLUSIONS: The results of the study suggest that the effect of metformin on serum prolactin levels is sex-dependent. Metformin 65-74 prolactin Homo sapiens 84-93 29615476-4 2018 Actions of neuronostatin differs from somatostatin which in this study reduced GH/PRL/ACTH/LH/TSH secretion and GH/PRL/POMC/LH gene expression. neuronostatin 11-24 prolactin Homo sapiens 82-85 29615476-4 2018 Actions of neuronostatin differs from somatostatin which in this study reduced GH/PRL/ACTH/LH/TSH secretion and GH/PRL/POMC/LH gene expression. neuronostatin 11-24 prolactin Homo sapiens 115-118 29397924-11 2018 Addition of DHEA to decidualized hESF increased expression of the decidualization markers IGFBP1 and PRL and the endometrial receptivity marker SPP1. Dehydroepiandrosterone 12-16 prolactin Homo sapiens 101-104 29452209-1 2018 BACKGROUND & AIMS: Prolactin (PRL) is a multifunctional polypeptide with effects on metabolism, however, little is known about its effect on hepatic steatosis and lipid metabolism. Adenosine Monophosphate 12-15 prolactin Homo sapiens 23-32 29452209-1 2018 BACKGROUND & AIMS: Prolactin (PRL) is a multifunctional polypeptide with effects on metabolism, however, little is known about its effect on hepatic steatosis and lipid metabolism. Adenosine Monophosphate 12-15 prolactin Homo sapiens 34-37 29452209-9 2018 In FFA-induced HepG2 cells, PRL treatment or PRLR overexpression significantly reduced the expression of CD36 and lipid content, effects that were abrogated after silencing of PRLR. Fatty Acids, Nonesterified 3-6 prolactin Homo sapiens 28-31 29452209-13 2018 Using cell experiments, we found that PRL ameliorates hepatic steatosis via the hepatic PRLR and fatty acid translocase (FAT)/CD36, a key transporter of free fatty acid uptake in liver. Fatty Acids 97-107 prolactin Homo sapiens 38-41 29452209-13 2018 Using cell experiments, we found that PRL ameliorates hepatic steatosis via the hepatic PRLR and fatty acid translocase (FAT)/CD36, a key transporter of free fatty acid uptake in liver. Fatty Acids, Nonesterified 153-168 prolactin Homo sapiens 38-41 29546691-13 2018 This quantitative and systematic review provides preliminary evidence in favor of CAB as a medical therapy for treating giant prolactinomas in male patients, especially those with extremely high PRL levels. Cabergoline 82-85 prolactin Homo sapiens 195-198 29896154-11 2018 Discussion: This trial will provide important knowledge on the potential benefits and safety of elevating circulating and intraocular PRL levels with levosulpiride in patients with DR and DME. levosulpiride 150-163 prolactin Homo sapiens 134-137 29896154-11 2018 Discussion: This trial will provide important knowledge on the potential benefits and safety of elevating circulating and intraocular PRL levels with levosulpiride in patients with DR and DME. dme 188-191 prolactin Homo sapiens 134-137 29427634-3 2018 L-dopa is a natural inhibitor of prolactin (PRL) hormone which is required to maintain lactation in women but it"s over production (hyperprolactinemia) plays critical role in advancement of breast cancer. Levodopa 0-6 prolactin Homo sapiens 33-42 29427634-3 2018 L-dopa is a natural inhibitor of prolactin (PRL) hormone which is required to maintain lactation in women but it"s over production (hyperprolactinemia) plays critical role in advancement of breast cancer. Levodopa 0-6 prolactin Homo sapiens 44-47 29427634-10 2018 The effect of MP extract on PRL-mediated signaling was validated using dopaminergic agonist bromocriptine. Bromocriptine 92-105 prolactin Homo sapiens 28-31 29427634-14 2018 Cancer-related hyperprolactinemia confers cisplatin resistance, we observed that MP via PRL inhibition, enhances cisplatin efficacy after their combinatorial treatment in breast cancer cells. Cisplatin 113-122 prolactin Homo sapiens 88-91 30079289-6 2018 Similar to the reported cases in the literature, our patient"s thyroid stimulating hormone (TSH) and prolactin levels returned to normal with levothyroxine therapy. Thyroxine 142-155 prolactin Homo sapiens 101-110 29896154-3 2018 Here, we describe the protocol of an ongoing clinical trial investigating a new therapy for DR and DME based on elevating the circulating levels of PRL with the prokinetic, dopamine D2 receptor blocker, levosulpiride. dme 99-102 prolactin Homo sapiens 148-151 29896154-3 2018 Here, we describe the protocol of an ongoing clinical trial investigating a new therapy for DR and DME based on elevating the circulating levels of PRL with the prokinetic, dopamine D2 receptor blocker, levosulpiride. levosulpiride 203-216 prolactin Homo sapiens 148-151 29731635-7 2018 Subjects experiencing the most pronounced side effects under haloperidol, which compelled them to drop out, showed significantly higher prolactin concentration increases than those who tolerated haloperidol well. Haloperidol 61-72 prolactin Homo sapiens 136-145 29524401-4 2018 Here, we found that the estrogen-responsive pituitary hormone prolactin (PRL), through specific PRL receptor (PRLR), down-regulates hepatic triglyceride (TG) accumulation. Triglycerides 140-152 prolactin Homo sapiens 73-76 29524401-7 2018 PRL could decrease the expression of stearoyl-coenzyme A desaturase 1 (SCD1), the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids, in animal models and multiple hepatic cell lines. Fatty Acids, Monounsaturated 126-153 prolactin Homo sapiens 0-3 29397924-12 2018 DHEA enhanced secretion of IGFBP1, PRL, and SPP1 proteins maximally by day 8 of the decidualization time course concomitant with peak androgen concentrations. Dehydroepiandrosterone 0-4 prolactin Homo sapiens 35-38 29805808-4 2018 Results: Five RCTs, including 989 patients combined, have evaluated the changes in prolactin for pediatric patients after 6 weeks of treatment with risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone. Risperidone 148-159 prolactin Homo sapiens 83-92 29912235-7 2018 The recent demonstration of the cardiotoxic effect of aberrant PRL has led to successful testing of the therapeutic effects of bromocriptine, a 2D dopamine agonist that blocks PRL. Bromocriptine 127-140 prolactin Homo sapiens 176-179 29327380-8 2018 Deficient or ST threonine intake may induce a delay in changes in progesterone and prolactin concentrations during the prepartum period impeding the transition from pregnancy to lactation. Threonine 16-25 prolactin Homo sapiens 83-92 29805808-4 2018 Results: Five RCTs, including 989 patients combined, have evaluated the changes in prolactin for pediatric patients after 6 weeks of treatment with risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone. Quetiapine Fumarate 161-171 prolactin Homo sapiens 83-92 29805808-4 2018 Results: Five RCTs, including 989 patients combined, have evaluated the changes in prolactin for pediatric patients after 6 weeks of treatment with risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone. Aripiprazole 173-185 prolactin Homo sapiens 83-92 29805808-4 2018 Results: Five RCTs, including 989 patients combined, have evaluated the changes in prolactin for pediatric patients after 6 weeks of treatment with risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone. Olanzapine 187-197 prolactin Homo sapiens 83-92 29805808-5 2018 In the overall study population, treatment with risperidone was associated with the highest increase in mean prolactin levels compared to other SGAs. Risperidone 48-59 prolactin Homo sapiens 109-118 29805808-6 2018 Patients treated with risperidone 4-6 mg/day were found to experience the greatest increases (55.06 ng/ml [95% CrI: 40.53-69.58]) in prolactin levels, followed by risperidone 1-3 mg/day, paliperidone 3-6 mg/day, and paliperidone 6-12 mg/day. Risperidone 22-33 prolactin Homo sapiens 133-142 30785690-4 2018 A greater imbalance in the content of dopamine in Aborigines compared with the European population was combined with a higher levels of prolactin, sex hormone binding globulin, antisperm antibodies and with lower concentrations of lutropine, progesterone, total and free testosterone. Dopamine 38-46 prolactin Homo sapiens 136-145 29314615-0 2018 Serum prolactin levels might become a useful marker for switching strategy to paliperidone palmitate in male schizophrenia patient. Paliperidone Palmitate 78-100 prolactin Homo sapiens 6-15 28925774-5 2018 A bromocriptine loading test revealed an increased serum prolactin concentration after loading. Bromocriptine 2-15 prolactin Homo sapiens 57-66 28925774-8 2018 A prolactin-producing uterine leiomyoma should be considered as a possible cause of hyperprolactinemia resistant to dopamine agonists. Dopamine 116-124 prolactin Homo sapiens 2-11 29035904-0 2018 Improvement in cognitive abilities following cabergoline treatment in patients with a prolactin-secreting pituitary adenoma. Cabergoline 45-56 prolactin Homo sapiens 86-95 29035904-3 2018 We aimed to study whether the reduction in prolactin levels by cabergoline in patients with hyperprolactinaemia is followed by an improvement in cognitive tasks. Cabergoline 63-74 prolactin Homo sapiens 43-52 29035904-9 2018 In summary, a reduction in prolactin levels by cabergoline in patients with hyperprolactinaemia is followed by an improvement in cognitive abilities. Cabergoline 47-58 prolactin Homo sapiens 27-36 29369118-7 2018 The mean serum prolactin levels showed a significant decrease after the administration of cabergoline in the cabergoline group (25.2 [24.0] vs 5.2 [4.2] ng/mL, P = 0.003), and this decreased level was also significantly lower than that in the noncabergoline group (5.2 [4.2] vs 12.0 [5.0] ng/mL, P < 0.001). Cabergoline 90-101 prolactin Homo sapiens 15-24 29369118-7 2018 The mean serum prolactin levels showed a significant decrease after the administration of cabergoline in the cabergoline group (25.2 [24.0] vs 5.2 [4.2] ng/mL, P = 0.003), and this decreased level was also significantly lower than that in the noncabergoline group (5.2 [4.2] vs 12.0 [5.0] ng/mL, P < 0.001). Cabergoline 109-120 prolactin Homo sapiens 15-24 29483903-9 2018 Dopamine is an effective inhibitor of PRL secretion due to either a direct influence on the hypophysis or stimulation of postsynaptic dopamine receptors in the hypothalamus, arousing the release of the PRL inhibitory factor. Dopamine 0-8 prolactin Homo sapiens 38-41 29483903-9 2018 Dopamine is an effective inhibitor of PRL secretion due to either a direct influence on the hypophysis or stimulation of postsynaptic dopamine receptors in the hypothalamus, arousing the release of the PRL inhibitory factor. Dopamine 0-8 prolactin Homo sapiens 202-205 28972407-7 2018 Similar results, among groups, were obtained, when PRL expression was stimulated by PGE2 or 8-Br-cAMP. Dinoprostone 84-88 prolactin Homo sapiens 51-54 28972407-7 2018 Similar results, among groups, were obtained, when PRL expression was stimulated by PGE2 or 8-Br-cAMP. 8-Bromo Cyclic Adenosine Monophosphate 92-101 prolactin Homo sapiens 51-54 29386559-5 2018 Here we show that the adrenergic hormones epinephrine and norepinephrine induce PRL expression in the human monocytic cell line THP-1 at physiological concentrations. Epinephrine 42-53 prolactin Homo sapiens 80-83 29386559-5 2018 Here we show that the adrenergic hormones epinephrine and norepinephrine induce PRL expression in the human monocytic cell line THP-1 at physiological concentrations. Norepinephrine 58-72 prolactin Homo sapiens 80-83 28954263-7 2018 At the last assessment, his prolactin level was 21.5 ng/mL, recorded after 21 years of treatment with the dopamine agonist cabergoline at a dose as high as 4.5 mg per week. Dopamine 106-114 prolactin Homo sapiens 28-37 28954263-7 2018 At the last assessment, his prolactin level was 21.5 ng/mL, recorded after 21 years of treatment with the dopamine agonist cabergoline at a dose as high as 4.5 mg per week. Cabergoline 123-134 prolactin Homo sapiens 28-37 28817397-7 2018 The mean maximum prolactin levels were significantly higher with PP1M than with haloperidol decanoate; however, neither drug differs in the frequency of prolactin-related adverse events. haloperidol decanoate 80-101 prolactin Homo sapiens 17-26 30072818-10 2018 Measurement of prolactin post polyethylene glycol precipitation (PEG) when prolactin levels are above the reference interval is routinely used to identify macroprolactin, however harmonisation of PEG precipitation process and reporting may improve clinical care. Polyethylene Glycols 30-49 prolactin Homo sapiens 15-24 30072818-10 2018 Measurement of prolactin post polyethylene glycol precipitation (PEG) when prolactin levels are above the reference interval is routinely used to identify macroprolactin, however harmonisation of PEG precipitation process and reporting may improve clinical care. Polyethylene Glycols 30-49 prolactin Homo sapiens 75-84 30072818-10 2018 Measurement of prolactin post polyethylene glycol precipitation (PEG) when prolactin levels are above the reference interval is routinely used to identify macroprolactin, however harmonisation of PEG precipitation process and reporting may improve clinical care. Polyethylene Glycols 65-68 prolactin Homo sapiens 15-24 30072818-10 2018 Measurement of prolactin post polyethylene glycol precipitation (PEG) when prolactin levels are above the reference interval is routinely used to identify macroprolactin, however harmonisation of PEG precipitation process and reporting may improve clinical care. Polyethylene Glycols 65-68 prolactin Homo sapiens 75-84 29186352-4 2018 We observed that PRL increased viability of breast cancer cells treated with doxorubicin or etoposide. Doxorubicin 77-88 prolactin Homo sapiens 17-20 29186352-4 2018 We observed that PRL increased viability of breast cancer cells treated with doxorubicin or etoposide. Etoposide 92-101 prolactin Homo sapiens 17-20 29186352-6 2018 Two different HSP90 inhibitors, 17-allylamino-17-demethoxygeldanamycin and BIIB021, reduced the PRL-mediated increase in cell viability of doxorubicin-treated cells and led to a decrease in JAK2, ATM, and phosphorylated ATM protein levels. tanespimycin 32-70 prolactin Homo sapiens 96-99 29186352-6 2018 Two different HSP90 inhibitors, 17-allylamino-17-demethoxygeldanamycin and BIIB021, reduced the PRL-mediated increase in cell viability of doxorubicin-treated cells and led to a decrease in JAK2, ATM, and phosphorylated ATM protein levels. Doxorubicin 139-150 prolactin Homo sapiens 96-99 29186352-7 2018 Inhibitors of JAK2 (G6) and ATM (KU55933) abolished the PRL-mediated increase in cell viability of DNA-damaged cells, supporting the involvement of each, as well as the crosstalk of ATM with the PRL pathway in the context of DNA damage. 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one 33-40 prolactin Homo sapiens 56-59 29186352-7 2018 Inhibitors of JAK2 (G6) and ATM (KU55933) abolished the PRL-mediated increase in cell viability of DNA-damaged cells, supporting the involvement of each, as well as the crosstalk of ATM with the PRL pathway in the context of DNA damage. 2-morpholin-4-yl-6-thianthren-1-yl-pyran-4-one 33-40 prolactin Homo sapiens 195-198 29186352-9 2018 Short interfering RNA directed against ATM prevented the PRL-mediated increase in cell survival in two-dimensional cell culture, three-dimensional collagen gel cultures, and clonogenic cell survival, after doxorubicin treatment. Doxorubicin 206-217 prolactin Homo sapiens 57-60 29434564-9 2017 Moreover, in the patients, we found a negative relationship between serum prolactin levels and the GMV of the left hippocampus and right IFC, whereas a positive relationship was found between the GMV of the left hippocampus and serum levels of estradiol and luteinizing hormone. Guanosine-5'-Phosphovanadate 99-102 prolactin Homo sapiens 74-83 29168011-5 2018 Dopamine agonist treatment (n = 22) was safe and effective, leading to reductions in tumor size (p < 0.01) and prolactin levels (p < 0.01). Dopamine 0-8 prolactin Homo sapiens 114-123 29403128-3 2018 However, data on prolactin changes with add-on aripiprazole in a real-world naturalistic clinical setting from India are sparse. Aripiprazole 47-59 prolactin Homo sapiens 17-26 29403128-9 2018 Patients had a significant reduction in prolactin level (35.6 +- 29.1 ng/ml) following treatment with aripiprazole (P = 0.004). Aripiprazole 102-114 prolactin Homo sapiens 40-49 29277270-8 2018 RESULTS: Under the effect of progesterone and cAMP, these lines decidualized in vitro: the cells became rounder and secreted prolactin, a marker of physiological DSC differentiation (decidualization). Cyclic AMP 46-50 prolactin Homo sapiens 125-134 29333150-2 2017 Poly ethylene glycol (PEG) pretreatment is the preventive process but such process includes the probability of loss of a fraction of bioactive prolactin. Polyethylene Glycols 0-20 prolactin Homo sapiens 143-152 29333150-2 2017 Poly ethylene glycol (PEG) pretreatment is the preventive process but such process includes the probability of loss of a fraction of bioactive prolactin. Polyethylene Glycols 22-25 prolactin Homo sapiens 143-152 29285144-9 2017 The PRL expression and upregulated IGFBP-1 mRNA and protein levels in the E2+P4+cAMP treatment group indicated successful decidualization of the in vitro model. Cyclic AMP 80-84 prolactin Homo sapiens 4-7 29731797-0 2018 The Association between ocular problems and Serum Testosterone, Prolactin and Thyroglobulin concentrations in Delayed phase of Sulfur Mustard exposure. Mustard Gas 127-141 prolactin Homo sapiens 64-73 29731797-11 2018 In the chronic phase of SM toxicity, some ocular surface problems are associated with alterations in the serum concentrations of testosterone, prolactin, and Tg. Mustard Gas 24-26 prolactin Homo sapiens 143-152 29285144-10 2017 However, the addition of Icaritin inhibited the expression of PRL and IGFBP-1 mRNA, as well as IGFBP-1 protein in the induced ESCs compared with groups without Icaritin. icaritin 25-33 prolactin Homo sapiens 62-65 29039523-3 2017 The patient"s serum prolactin (PRL) levels were successfully controlled via bromocriptine therapy, and the serum levels of calcium and intact parathyroid hormone (PTH) reduced one day following parathyroidectomy. Bromocriptine 76-89 prolactin Homo sapiens 20-29 29039523-3 2017 The patient"s serum prolactin (PRL) levels were successfully controlled via bromocriptine therapy, and the serum levels of calcium and intact parathyroid hormone (PTH) reduced one day following parathyroidectomy. Bromocriptine 76-89 prolactin Homo sapiens 31-34 29209406-8 2017 In patients treated with antipsychotic monotherapy, the serum prolactin levels were significantly lower in patients treated with APZ than with other antipsychotics. Aripiprazole 129-132 prolactin Homo sapiens 62-71 28828544-4 2017 In two affected patients at our institutions, we performed RT-PCR and ELISA of prolactin secretagogues that are produced by vascular tissue and/or upregulated in pregnancy: AGT (encoding angiotensinogen), TAC1 (encoding substance P), HDC (encoding the enzyme responsible for conversion of histidine to histamine), and prolactin-releasing hormone (PRLH). Histidine 289-298 prolactin Homo sapiens 79-88 28828544-4 2017 In two affected patients at our institutions, we performed RT-PCR and ELISA of prolactin secretagogues that are produced by vascular tissue and/or upregulated in pregnancy: AGT (encoding angiotensinogen), TAC1 (encoding substance P), HDC (encoding the enzyme responsible for conversion of histidine to histamine), and prolactin-releasing hormone (PRLH). Histamine 302-311 prolactin Homo sapiens 79-88 28828544-8 2017 In both men, dopamine agonist therapy markedly reduced serum prolactin. Dopamine 13-21 prolactin Homo sapiens 61-70 29209406-9 2017 In patients receiving 2 or more antipsychotics, the serum prolactin levels were significantly lower in patients treated with APZ-containing regimens than in patients treated with APZ-free regimens. Aripiprazole 125-128 prolactin Homo sapiens 58-67 29209406-9 2017 In patients receiving 2 or more antipsychotics, the serum prolactin levels were significantly lower in patients treated with APZ-containing regimens than in patients treated with APZ-free regimens. Aripiprazole 179-182 prolactin Homo sapiens 58-67 28690611-7 2017 Previously, a small number of open-label clinical trials using bromocriptine, which indirectly decreases PRL levels, were performed in RA patients and showed clinical benefit, although others found the opposite effect. Bromocriptine 63-76 prolactin Homo sapiens 105-108 29226628-4 2017 Using interspecies scaling approaches, human D2 receptor occupancy and plasma prolactin concentrations were predicted for a range of clinical paliperidone and remoxipride doses. Paliperidone Palmitate 142-154 prolactin Homo sapiens 78-87 29226628-4 2017 Using interspecies scaling approaches, human D2 receptor occupancy and plasma prolactin concentrations were predicted for a range of clinical paliperidone and remoxipride doses. Remoxipride 159-170 prolactin Homo sapiens 78-87 29226628-6 2017 The pool model could predict D2 receptor occupancy and prolactin response in humans following single doses of paliperidone and remoxipride. Paliperidone Palmitate 110-122 prolactin Homo sapiens 55-64 29226628-6 2017 The pool model could predict D2 receptor occupancy and prolactin response in humans following single doses of paliperidone and remoxipride. Remoxipride 127-138 prolactin Homo sapiens 55-64 28223031-0 2017 Effects of aripiprazole, quetiapine and ziprasidone on plasma prolactin levels in individuals with first episode nonaffective psychosis: Analysis of a randomized open-label 1year study. ziprasidone 40-51 prolactin Homo sapiens 62-71 28223031-4 2017 OBJECTIVES: To explore the differential effect of three widely used prolactin-sparing antipsychotics, aripiprazole, quetiapine and ziprasidone, on prolactin plasma levels in first episode non-affective psychosis during a 1year of treatment. Aripiprazole 102-114 prolactin Homo sapiens 147-156 28223031-4 2017 OBJECTIVES: To explore the differential effect of three widely used prolactin-sparing antipsychotics, aripiprazole, quetiapine and ziprasidone, on prolactin plasma levels in first episode non-affective psychosis during a 1year of treatment. Quetiapine Fumarate 116-126 prolactin Homo sapiens 147-156 28223031-4 2017 OBJECTIVES: To explore the differential effect of three widely used prolactin-sparing antipsychotics, aripiprazole, quetiapine and ziprasidone, on prolactin plasma levels in first episode non-affective psychosis during a 1year of treatment. ziprasidone 131-142 prolactin Homo sapiens 147-156 28223031-9 2017 RESULTS: Male patients on aripiprazole had a lower risk of suffering an increase on prolactin plasma levels (N=71; F=12.645; p<0.001). Aripiprazole 26-38 prolactin Homo sapiens 84-93 28223031-13 2017 The percentages of mild prolactin excess were: 14.3% on aripiprazole, 36.1% on quetiapine and 18.4% on ziprasidone (chi2=6.611 p=0.037). Aripiprazole 56-68 prolactin Homo sapiens 24-33 28223031-13 2017 The percentages of mild prolactin excess were: 14.3% on aripiprazole, 36.1% on quetiapine and 18.4% on ziprasidone (chi2=6.611 p=0.037). Quetiapine Fumarate 79-89 prolactin Homo sapiens 24-33 28223031-13 2017 The percentages of mild prolactin excess were: 14.3% on aripiprazole, 36.1% on quetiapine and 18.4% on ziprasidone (chi2=6.611 p=0.037). ziprasidone 103-114 prolactin Homo sapiens 24-33 28919264-0 2017 Prolactin Alters the Mammary Epithelial Hierarchy, Increasing Progenitors and Facilitating Ovarian Steroid Action. Steroids 99-106 prolactin Homo sapiens 0-9 28919264-6 2017 However, despite facilitating some steroid actions, PRL opposed steroid-driven luminal maturation and increased CD61+ luminal cells. Steroids 64-71 prolactin Homo sapiens 52-55 28919264-7 2017 Our findings demonstrate that PRL can powerfully influence the epithelial hierarchy alone and temper the actions of ovarian steroids, which may underlie its role in the development of breast cancer. Steroids 124-132 prolactin Homo sapiens 30-33 28880825-0 2017 Transient Elevated Serum Prolactin in Trans Women Is Caused by Cyproterone Acetate Treatment. Cyproterone Acetate 63-82 prolactin Homo sapiens 25-34 28880825-3 2017 This analysis evaluates whether CPA contributes to the elevation of prolactin in trans women receiving gender affirming hormones. Cyproterone Acetate 32-35 prolactin Homo sapiens 68-77 28880825-13 2017 CONCLUSIONS: CPA is likely to cause a temporary increase in serum prolactin, with prolactin levels returning to normal after orchiectomy and CPA discontinuation. Cyproterone Acetate 13-16 prolactin Homo sapiens 66-75 28880825-13 2017 CONCLUSIONS: CPA is likely to cause a temporary increase in serum prolactin, with prolactin levels returning to normal after orchiectomy and CPA discontinuation. Cyproterone Acetate 13-16 prolactin Homo sapiens 82-91 28660406-0 2017 Evaluation of Potentially Prolactin-Related Adverse Events and Sexual Maturation in Adolescents with Schizophrenia Treated with Paliperidone Extended-Release (ER) for 2 Years: A Post Hoc Analysis of an Open-Label Multicenter Study. Paliperidone Palmitate 128-140 prolactin Homo sapiens 26-35 28660406-3 2017 OBJECTIVE: This study assessed potentially prolactin-related treatment-emergent adverse events (PPRL-TEAEs) and sexual maturation during long-term treatment of adolescents with paliperidone extended-release (ER). Paliperidone Palmitate 177-189 prolactin Homo sapiens 43-52 28129477-2 2017 We hypothesized that higher prolactin levels are associated with reduced glucose tolerance, as determined by higher 2-h glucose level from an oral glucose tolerance test in pregnancy. Glucose 73-80 prolactin Homo sapiens 28-37 28129477-2 2017 We hypothesized that higher prolactin levels are associated with reduced glucose tolerance, as determined by higher 2-h glucose level from an oral glucose tolerance test in pregnancy. Glucose 120-127 prolactin Homo sapiens 28-37 28129477-4 2017 A multiple regression analysis was used to determine the relationship between serum prolactin and 2-h glucose levels. Glucose 102-109 prolactin Homo sapiens 84-93 28129477-5 2017 Multivariable regression analysis showed an independent and significant relationship between third trimester prolactin and 2-h glucose levels post oral glucose tolerance test. Glucose 127-134 prolactin Homo sapiens 109-118 28129477-5 2017 Multivariable regression analysis showed an independent and significant relationship between third trimester prolactin and 2-h glucose levels post oral glucose tolerance test. Glucose 152-159 prolactin Homo sapiens 109-118 28129477-6 2017 Higher prolactin levels were associated with higher glucose levels independent of age, body mass index, gravidity and parity. Glucose 52-59 prolactin Homo sapiens 7-16 28364216-0 2017 Prolactin/androgen-inducible carboxypeptidase-D increases with nitrotyrosine and Ki67 for breast cancer progression in vivo, and upregulates progression markers VEGF-C and Runx2 in vitro. 3-nitrotyrosine 63-76 prolactin Homo sapiens 0-9 28397357-0 2017 Submaximal doses of ghrelin do not inhibit gonadotrophin levels but stimulate prolactin secretion in postmenopausal women. Ghrelin 20-27 prolactin Homo sapiens 78-87 28397357-2 2017 The aim of this study was to examine the effect of ghrelin on gonadotrophin and prolactin (PRL) secretion in oestrogen-deprived postmenopausal women. Ghrelin 51-58 prolactin Homo sapiens 80-89 28397357-2 2017 The aim of this study was to examine the effect of ghrelin on gonadotrophin and prolactin (PRL) secretion in oestrogen-deprived postmenopausal women. Ghrelin 51-58 prolactin Homo sapiens 91-94 28397357-9 2017 Ghrelin administration did not affect serum levels of follicle-stimulating hormone (FSH) and luteinizing hormone (LH), whereas it increased significantly those of growth hormone (GH) and PRL. Ghrelin 0-7 prolactin Homo sapiens 187-190 28397357-10 2017 In Exp 15A, serum PRL increment in response to ghrelin (area under the curve, net increment) was significantly greater than in Exp 1A (P<.05). Ghrelin 47-54 prolactin Homo sapiens 18-21 28397357-11 2017 CONCLUSIONS: This study demonstrates for the first time that in oestrogen-deprived postmenopausal women, ghrelin administration affects neither FSH nor LH levels but stimulates PRL secretion, that is amplified by exogenous oestrogen administration. Ghrelin 105-112 prolactin Homo sapiens 177-180 28892958-5 2017 Patients having conditions/medications known to elevate prolactin levels such as cranial surgery/irradiation, pituitary disease, chronic renal failure, drugs such as neuroleptics, metoclopramide, aldosterone antagonists, etc., were excluded. Aldosterone 196-207 prolactin Homo sapiens 56-65 28412548-8 2017 MG7 exhibited effective antagonistic activity, which not only inhibited PRL binding to PRLR in a dose-dependent manner but also inhibited PRLR-mediated intracellular signalling. 7-methylguanosine 0-3 prolactin Homo sapiens 72-75 28412548-9 2017 Furthermore, MG7 also blocked Nb2 cell proliferation induced by PRL. 7-methylguanosine 13-16 prolactin Homo sapiens 64-67 28412548-10 2017 The current study suggests that MG7 has the potential application in the PRL/PRLR-related studies in future. 7-methylguanosine 32-35 prolactin Homo sapiens 73-76 28744986-3 2017 We show for the first time that mechanical circulatory support combined with high-dose bromocriptine therapy to suppress systemic prolactin levels may serve as an effective therapeutic option in patients with fulminant PPCM and cardiogenic shock. Bromocriptine 87-100 prolactin Homo sapiens 130-139 29264460-4 2017 Patients: Two women (32 and 36 years old) with chronic hPRL-HA (prolactin: between 94 and 102 and 98 and 112 ng/mL, respectively) caused by cabergoline-resistant microprolactinomas. Cabergoline 140-151 prolactin Homo sapiens 55-59 28674764-2 2017 Cabergoline is a potent dopamine receptor agonist of D2 receptors and has a direct inhibitory effect on pituitary PRL secretion. Cabergoline 0-11 prolactin Homo sapiens 114-117 29028670-9 2017 After adjustment, BPA level was negatively associated with prolactin (PRL) (beta = -0.38). bisphenol A 18-21 prolactin Homo sapiens 59-68 29048190-9 2017 Paliperidone was associated with a greater use of anticholinergic medications (p = .002), increased body weight (p < .001), and higher serum prolactin level (p < .001) compared with a placebo. Paliperidone Palmitate 0-12 prolactin Homo sapiens 144-153 29066495-6 2017 Prolactin was significantly affected even at low levels (Biotin 1.5 ng/mL). Biotin 57-63 prolactin Homo sapiens 0-9 28456446-3 2017 Our lab recently reported that the hormone of lactation, prolactin, helps the retinal pigment epithelium to survive via antioxidant actions that result in the inhibition of sirtuin2-dependent cell death (EbioMedicine issue of May). ebiomedicine 204-216 prolactin Homo sapiens 57-66 28456446-5 2017 The main purposes of my commentary are to discuss mechanisms that could explain this effect in the context of previously identified defense mechanisms against oxidative stress and focus particularly on the potential regulation of reduced glutathione levels by prolactin. Glutathione 238-249 prolactin Homo sapiens 260-269 28593164-5 2017 RESULTS: Obtained PRL mean and range in Autobio and Liason systems were X = 414.8 +- 230.0; Range: 25.7-980.9 mulU/mL & X = 391.7 +- 225.6; Range: 26.0-991.4 mulU/mL respectively. Adenosine Monophosphate 119-122 prolactin Homo sapiens 18-21 28302567-5 2017 In both T47D and MCF-7 cell lines, the incubation with the alpha2-adrenergic agonist dexmedetomidine significantly increased Prl release into the culture medium (measured by the Nb2 bioassay), this effect being reversed by the alpha2-adrenergic antagonist rauwolscine. Dexmedetomidine 85-100 prolactin Homo sapiens 125-128 28302567-7 2017 In IBH-6 cells a decrease in Prl secretion was observed at the lower dexmedetomidine concentration. ibh 3-6 prolactin Homo sapiens 29-32 28302567-7 2017 In IBH-6 cells a decrease in Prl secretion was observed at the lower dexmedetomidine concentration. Dexmedetomidine 69-84 prolactin Homo sapiens 29-32 28073129-2 2017 Objective: The aim of this study was to compare metabolic- and prolactin-lowering effects of low-dose bromocriptine/metformin combination therapy and cabergoline in patients with elevated prolactin levels. Bromocriptine 102-115 prolactin Homo sapiens 188-197 28085502-2 2017 Metabolic alterations in the urea cycle, with changes in collagen fibril stability, oxidative stress, thyroid hormones and prolactin with regulatory effect on biosynthesis and biomechanical stability of corneal stroma, may all play a role in keratoconus etiology. Urea 29-33 prolactin Homo sapiens 123-132 28204229-8 2017 As CD24 is hPRL-regulated and has been implicated in drug resistance in EC, we further showed that CD24 is a critical mediator of hPRL-stimulated reduced sensitivity to doxorubicin and paclitaxel in EC cells. Paclitaxel 185-195 prolactin Homo sapiens 130-134 28073129-8 2017 Cabergoline reduced prolactin levels, while no effect on plasma prolactin was found in group B. Cabergoline 0-11 prolactin Homo sapiens 20-29 28579786-0 2017 Topiramate add-on treatment associated with normalization of prolactin levels in a patient with schizophrenia. Topiramate 0-10 prolactin Homo sapiens 61-70 28579786-4 2017 However, the remarkable finding of this case is the concomitant decrease in the level of prolactin when topiramate (50 mg/day) was started and the rebound after discontinuation of topiramate. Topiramate 104-114 prolactin Homo sapiens 89-98 28277129-8 2017 The multivariate regression analysis revealed that the daytime changes of prolactin level are proportional to TSH concentration and coexistence of PCOS as well as inversely relative to BMI. Thyrotropin 110-113 prolactin Homo sapiens 74-83 28372526-6 2017 The metformin group had significantly lower serum prolactin level at endpoint (four randomized controlled trials, n=501; weighted mean difference: -6.87 ug/L (95% confidence interval: -13.24 to -0.51), p=0.03; I2=80%) with "moderate quality" based on the grading of recommendations assessment, development, and evaluation system. Metformin 4-13 prolactin Homo sapiens 50-59 28372526-9 2017 Adjunctive metformin appears to be effective and safe for reducing antipsychotic-induced hyperprolactinemia and prolactin-related symptoms in schizophrenia patients. Metformin 11-20 prolactin Homo sapiens 94-103 28204229-6 2017 In addition, forced expression of hPRL decreased sensitivity of EC cells to chemotherapeutic drugs (i.e., doxorubicin and paclitaxel), both in vitro and in vivo. Doxorubicin 106-117 prolactin Homo sapiens 34-38 28204229-6 2017 In addition, forced expression of hPRL decreased sensitivity of EC cells to chemotherapeutic drugs (i.e., doxorubicin and paclitaxel), both in vitro and in vivo. Paclitaxel 122-132 prolactin Homo sapiens 34-38 28204229-8 2017 As CD24 is hPRL-regulated and has been implicated in drug resistance in EC, we further showed that CD24 is a critical mediator of hPRL-stimulated reduced sensitivity to doxorubicin and paclitaxel in EC cells. Doxorubicin 169-180 prolactin Homo sapiens 130-134 28539956-2 2017 The purpose of this study was to identify the relationship between the prolactin level and the administration of SSRIs such as escitalopram and sertraline. Citalopram 127-139 prolactin Homo sapiens 71-80 28539956-2 2017 The purpose of this study was to identify the relationship between the prolactin level and the administration of SSRIs such as escitalopram and sertraline. Sertraline 144-154 prolactin Homo sapiens 71-80 28539956-3 2017 An additional purpose was to determine whether the elevation of prolactin differs between escitalopram and sertraline treatment. Sertraline 107-117 prolactin Homo sapiens 64-73 28539956-8 2017 CONCLUSION: Clinicians should be aware that hyperprolactinemia can appear in patients receiving escitalopram or sertraline, even though they do not need routine monitoring for prolactin levels. Citalopram 96-108 prolactin Homo sapiens 49-58 28539956-8 2017 CONCLUSION: Clinicians should be aware that hyperprolactinemia can appear in patients receiving escitalopram or sertraline, even though they do not need routine monitoring for prolactin levels. Sertraline 112-122 prolactin Homo sapiens 49-58 28418929-10 2017 RESULTS: We found that the same cells of the normal adenohypophysis can co-express prolactin with ACTH, TSH, FSH, LH; GH with ACTH, TSH, FSH, LH, and TSH with ACTH, FSH, LH. Luteinizing Hormone 114-116 prolactin Homo sapiens 83-92 28418929-10 2017 RESULTS: We found that the same cells of the normal adenohypophysis can co-express prolactin with ACTH, TSH, FSH, LH; GH with ACTH, TSH, FSH, LH, and TSH with ACTH, FSH, LH. acth 98-102 prolactin Homo sapiens 83-92 27750350-1 2017 Background: Metformin decreases serum levels of monomeric prolactin. Metformin 12-21 prolactin Homo sapiens 58-67 28459037-4 2017 Dopamine is the main endogenous inhibitor of prolactin synthesis and secretion in the anterior pituitary. Dopamine 0-8 prolactin Homo sapiens 45-54 28130617-10 2017 Bromocriptine, a dopamine analog that suppresses PRL secretion, was associated with decreased lupus activity, prolonged lifespan, and restoration of immune competence in experimental model. Bromocriptine 0-13 prolactin Homo sapiens 49-52 28130617-10 2017 Bromocriptine, a dopamine analog that suppresses PRL secretion, was associated with decreased lupus activity, prolonged lifespan, and restoration of immune competence in experimental model. Dopamine 17-25 prolactin Homo sapiens 49-52 28271677-8 2017 Therefore, the aim of this study is to investigate the correlation of serum progesterone, estradiol, and prolactin results measured with Architect i2000sr and Cobas e601. Progesterone 76-88 prolactin Homo sapiens 105-114 28462541-17 2017 Prolactin, on quartile based analysis, associated with better HbA1c and fasting plasma glucose. Glucose 87-94 prolactin Homo sapiens 0-9 28459037-5 2017 Levosulpiride causes significant elevation of serum prolactin levels in significant number of patients. levosulpiride 0-13 prolactin Homo sapiens 52-61 28459037-7 2017 A significant number of patients who use levosulpiride develop serum prolactin levels of > 200 ng/mL that goes against the classical textbook teaching where pituitary tumor is supposed to be the mostly likely cause. levosulpiride 41-54 prolactin Homo sapiens 69-78 29264479-11 2017 Conclusion: In patients with macroprolactinomas, the CAB dosage required to maintain a normal PRL level long term is lower than the initial dosage necessary to normalize the PRL level. Cabergoline 53-56 prolactin Homo sapiens 94-97 29264479-11 2017 Conclusion: In patients with macroprolactinomas, the CAB dosage required to maintain a normal PRL level long term is lower than the initial dosage necessary to normalize the PRL level. Cabergoline 53-56 prolactin Homo sapiens 174-177 28127934-10 2017 Few adverse effect differences emerged: D2 antagonist augmentation was associated with less insomnia (p=0.028), but more prolactin elevation (p=0.015), while aripiprazole augmentation was associated with reduced prolactin levels (p<0.001) and body weight (p=0.030). Aripiprazole 158-170 prolactin Homo sapiens 212-221 27651307-12 2017 The absence of cavernous sinus invasion, serum PRL level lower than 132 7 ng/ml before cabergoline therapy or nadir serum PRL below 1 9 ng/ml were related to more frequent remission after withdrawal of cabergoline in patients receiving this medication for 5 years. Cabergoline 202-213 prolactin Homo sapiens 47-50 27651307-12 2017 The absence of cavernous sinus invasion, serum PRL level lower than 132 7 ng/ml before cabergoline therapy or nadir serum PRL below 1 9 ng/ml were related to more frequent remission after withdrawal of cabergoline in patients receiving this medication for 5 years. Cabergoline 202-213 prolactin Homo sapiens 122-125 27841032-5 2017 RESULTS: The response profile of total and monomeric prolactin following the administration of metoclopramide was similar in women with monomeric hyperprolactinemia and normoprolactinemia but different in women with macroprolactinemia. Metoclopramide 95-109 prolactin Homo sapiens 53-62 27836773-5 2017 MECs cultured with PRL, EGF and dexamethasone (DEX: glucocorticoid analog) developed the beta-casein secretion pathway. Dextromethorphan 47-50 prolactin Homo sapiens 19-22 28262171-0 2017 Partial regimen replacement with aripiprazole reduces serum prolactin in patients with a long history of schizophrenia: A case series. Aripiprazole 33-45 prolactin Homo sapiens 60-69 29256128-8 2017 The exception is the tricyclic antidepressant clomipramine, which profoundly increases PRL levels and may depress semen quality. Clomipramine 46-58 prolactin Homo sapiens 87-90 29256128-14 2017 Lithium increases PRL and LH levels and decreases testosterone although this is informed by few studies. Lithium 0-7 prolactin Homo sapiens 18-21 28791188-4 2017 After cabergoline treatment was started, prolactin levels normalized and galactorrhea disappeared. Cabergoline 6-17 prolactin Homo sapiens 41-50 28595559-0 2017 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma. 25-hydroxyvitamin D 0-19 prolactin Homo sapiens 37-46 28595559-0 2017 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma. 25-hydroxyvitamin D 0-19 prolactin Homo sapiens 111-120 28595559-1 2017 OBJECTIVE: The present research explored the relationship of vitamin D status with prolactin levels and adenoma size in female patients with newly diagnosed prolactinoma and determination of hypovitaminosis D prevalence among female patients with prolactinoma. Vitamin D 61-70 prolactin Homo sapiens 83-92 28595559-8 2017 Furthermore, we found prolactinoma patients with 25-hydroxyvitamin D &gt;20.00 ng/ml showing significant differences in the prolactin levels and adenoma size when compared with those who had 25- hydroxyvitamin D <20.00 ng/ml. 25-hydroxyvitamin d & 49-73 prolactin Homo sapiens 22-31 28595559-8 2017 Furthermore, we found prolactinoma patients with 25-hydroxyvitamin D &gt;20.00 ng/ml showing significant differences in the prolactin levels and adenoma size when compared with those who had 25- hydroxyvitamin D <20.00 ng/ml. 25- hydroxyvitamin d < 195-219 prolactin Homo sapiens 22-31 28595559-11 2017 Also vitamin D deficiency in prolactinoma patients associated with larger adenoma size and higher prolactin level. Vitamin D 5-14 prolactin Homo sapiens 29-38 28595559-12 2017 Finally, 25-hydroxyvitamin D level was a statistically significant predictor of prolactinoma size but not prolactin levels. 25-hydroxyvitamin D 9-28 prolactin Homo sapiens 80-89 28245452-5 2017 Very recently, dopamine agonists have been demonstrated to be efficacious in the treatment of some autoimmune disorders, placing PRL-mediated interactions as potential therapeutic targets for treating autoimmunity. Dopamine 15-23 prolactin Homo sapiens 129-132 28273980-7 2017 In this case, raised prolactin was possibly an important factor which was secondary to risperidone therapy. Risperidone 87-98 prolactin Homo sapiens 21-30 28065354-0 2017 Concerning the Article by Fung et al, Titled "Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women". Cyproterone Acetate 70-89 prolactin Homo sapiens 146-155 28065354-0 2017 Concerning the Article by Fung et al, Titled "Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women". Spironolactone 93-107 prolactin Homo sapiens 146-155 27825323-11 2016 In evidence gathered from randomized controlled trials, risperidone, olanzapine, and two doses of paliperidone (3-5 mg/day and 6-12 mg/day) were associated with increased prolactin levels compared to baseline. Risperidone 56-67 prolactin Homo sapiens 171-180 27815961-0 2016 Successful treatment of a child with a prolactin secreting macroadenoma with temozolomide. Temozolomide 77-89 prolactin Homo sapiens 39-48 27815961-2 2016 We report a child with a prolactin secreting macroadenoma which was refractory to initial treatment with a dopamine antagonist. Dopamine 107-115 prolactin Homo sapiens 25-34 27815961-4 2016 Temozolomide (200 mg/m2x5 days each month) was administered with a dramatic and prolonged response in tumor size, prolactin level, and symptoms, with no side effects from treatment. Temozolomide 0-12 prolactin Homo sapiens 114-123 28966250-11 2017 Based on these results, we concluded that patients with menstrual disorders presented increased serum PRL, and that most of them underwent treatment with risperidone. Risperidone 154-165 prolactin Homo sapiens 102-105 27825323-11 2016 In evidence gathered from randomized controlled trials, risperidone, olanzapine, and two doses of paliperidone (3-5 mg/day and 6-12 mg/day) were associated with increased prolactin levels compared to baseline. Olanzapine 69-79 prolactin Homo sapiens 171-180 27825323-11 2016 In evidence gathered from randomized controlled trials, risperidone, olanzapine, and two doses of paliperidone (3-5 mg/day and 6-12 mg/day) were associated with increased prolactin levels compared to baseline. Paliperidone Palmitate 98-110 prolactin Homo sapiens 171-180 27438182-5 2016 Aripiprazole was administered to patients with mild hyperprolactinemia (serum prolactin level < 50 ng/mL). Aripiprazole 0-12 prolactin Homo sapiens 57-66 27489110-5 2016 In this report, a novel PRL-inducible regulatory phosphorylation site within the activation segment of NEK3, threonine 165 (Thr-165), was identified. Threonine 109-118 prolactin Homo sapiens 24-27 27696687-4 2016 We confirmed that PA induced decidualization of hESCs by observing morphological changes and measuring increased levels of decidualization markers such as IGFBP1 and prolactin transcripts (P < 0.05). Phosphatidic Acids 18-20 prolactin Homo sapiens 166-175 27696687-5 2016 Treatment with PA reduced phosphorylation of Akt and consequently that of FoxO1, which led to the increased IGFBP1 and prolactin mRNA levels (P < 0.05). Phosphatidic Acids 15-17 prolactin Homo sapiens 119-128 27207910-5 2016 Risperidone-long-acting injectable was associated with higher incidence of prolactin-related adverse events (risk ratio=4.82, P=.001) and weight gain (risk ratio=3.80, P<.0001) than placebo. Risperidone 0-11 prolactin Homo sapiens 75-84 27207910-10 2016 Risperidone-long-acting injectable was also associated with higher incidence of prolactin-related adverse events than oral medications (RR=2.66, P=.03). Risperidone 0-11 prolactin Homo sapiens 80-89 27693265-2 2016 Previous studies have suggested that these two agents might have opposite effects on high-density lipoprotein (HDL) level when used in this context, and limited data have suggested CPA increases prolactin more than spironolactone. Cyproterone Acetate 181-184 prolactin Homo sapiens 195-204 27693265-3 2016 AIM: To compare the effects of spironolactone and CPA on HDL and prolactin serum concentrations in transgender women. Spironolactone 31-45 prolactin Homo sapiens 65-74 27693265-3 2016 AIM: To compare the effects of spironolactone and CPA on HDL and prolactin serum concentrations in transgender women. Cyproterone Acetate 50-53 prolactin Homo sapiens 65-74 27693265-11 2016 The change in prolactin was +3.10 mug/L (SD = 5.70) in the spironolactone group and +11.8 mug/L (SD = 8.63) in the CPA group (P < 0.001). Spironolactone 59-73 prolactin Homo sapiens 14-23 27693265-14 2016 CPA also is associated with a larger increase in prolactin. Cyproterone Acetate 0-3 prolactin Homo sapiens 49-58 27521731-10 2016 Sellar lesions with only moderate elevations in serum prolactin, particularly those that are refractory to medical management with a dopamine agonist, should prompt further investigation to confirm the diagnosis. Dopamine 133-141 prolactin Homo sapiens 54-63 27535625-5 2016 Because of the increased levels of serum prolactin (PRL), we treated the patient with cabergoline, which decreased the tumor size and improved the hydrocephalus. Cabergoline 86-97 prolactin Homo sapiens 41-50 27535625-5 2016 Because of the increased levels of serum prolactin (PRL), we treated the patient with cabergoline, which decreased the tumor size and improved the hydrocephalus. Cabergoline 86-97 prolactin Homo sapiens 52-55 27535625-6 2016 Six months after the treatment, the tumor began to increase in size, despite the normalization of the PRL level with cabergoline treatment. Cabergoline 117-128 prolactin Homo sapiens 102-105 27489110-5 2016 In this report, a novel PRL-inducible regulatory phosphorylation site within the activation segment of NEK3, threonine 165 (Thr-165), was identified. Threonine 124-127 prolactin Homo sapiens 24-27 26879343-1 2016 Although our previous study revealed an association between prolactin level and risperidone dosage, data regarding the plasma concentration of risperidone are lacking. Risperidone 80-91 prolactin Homo sapiens 60-69 26879343-2 2016 Therefore, this study aimed to investigate the association between plasma drug concentrations of risperidone, 9-hydroxyrisperidone and serum prolactin level in Thai children and adolescents with autism spectrum disorder (ASD). Risperidone 97-108 prolactin Homo sapiens 141-150 26879343-2 2016 Therefore, this study aimed to investigate the association between plasma drug concentrations of risperidone, 9-hydroxyrisperidone and serum prolactin level in Thai children and adolescents with autism spectrum disorder (ASD). Paliperidone Palmitate 110-130 prolactin Homo sapiens 141-150 26879343-7 2016 Serum prolactin level was significantly positively correlated with plasma 9-hydroxyrisperidone level (rs = 0.355, p < 0.001). Paliperidone Palmitate 74-94 prolactin Homo sapiens 6-15 26879343-9 2016 By multivariate analysis, high prolactin level was correlated to high 9-hydroxyrisperidone level (p = 0.010). Paliperidone Palmitate 70-90 prolactin Homo sapiens 31-40 26879343-10 2016 The results of this study showed that serum prolactin levels, especially in autistic individuals with hyperprolactinaemia during risperidone treatment, were significantly correlated with the level of 9-hydroxyrisperidone. Risperidone 129-140 prolactin Homo sapiens 44-53 26879343-10 2016 The results of this study showed that serum prolactin levels, especially in autistic individuals with hyperprolactinaemia during risperidone treatment, were significantly correlated with the level of 9-hydroxyrisperidone. Paliperidone Palmitate 200-220 prolactin Homo sapiens 44-53 27278054-12 2016 Prolactin levels were decreased in the aripiprazole group. Aripiprazole 39-51 prolactin Homo sapiens 0-9 27542844-0 2016 Prolactin-induced PAK1 tyrosyl phosphorylation promotes FAK dephosphorylation, breast cancer cell motility, invasion and metastasis. cyclo(tyrosyl-tyrosyl) 23-30 prolactin Homo sapiens 0-9 27542844-3 2016 Our lab has previously demonstrated that PRL-activated tyrosine kinase JAK2 phosphorylates PAK1 on tyrosines 153, 201, and 285, and that tyrosyl phosphorylated PAK1 (pTyr-PAK1) augments migration and invasion of breast cancer cells. Tyrosine 99-108 prolactin Homo sapiens 41-44 27542844-3 2016 Our lab has previously demonstrated that PRL-activated tyrosine kinase JAK2 phosphorylates PAK1 on tyrosines 153, 201, and 285, and that tyrosyl phosphorylated PAK1 (pTyr-PAK1) augments migration and invasion of breast cancer cells. cyclo(tyrosyl-tyrosyl) 137-144 prolactin Homo sapiens 41-44 27542844-5 2016 We demonstrate a distinct reduction in PRL-induced FAK auto-phosphorylation in T47D and TMX2-28 breast cancer cells overexpressing wild-type PAK1 (PAK1 WT) when compared to cells overexpressing either GFP or phospho-tyrosine-deficient mutant PAK1 (PAK1 Y3F). Tyrosine 216-224 prolactin Homo sapiens 39-42 27520906-3 2016 Cabergoline is generally a safe and effective method of reducing prolactin levels and it may be associated with psychiatric side effects, including psychotic features. Cabergoline 0-11 prolactin Homo sapiens 65-74 27334805-7 2016 Multiple regression analysis revealed that the difference in serum prolactin values was independent of thyroid function (TSH, FT4, T3) and serum cortisol levels. Hydrocortisone 145-153 prolactin Homo sapiens 67-76 27466075-1 2016 Prolactin plays an important role in maintaining a normal glucose homeostasis during pregnancy and beyond. Glucose 58-65 prolactin Homo sapiens 0-9 27130369-7 2016 Reduction of prolactin, insulin-like growth factor binding protein-3, and matrix metalloproteinase-9 correlated with edema reduction after injection of a VEGF-neutralizing protein as well as dexamethasone implant, suggesting their modulation is likely secondary to changes in edema rather than causative. Dexamethasone 191-204 prolactin Homo sapiens 13-22 26932202-6 2016 Prolactin was significantly increased at month 12 in the CPA+E group only. Cyproterone Acetate 57-60 prolactin Homo sapiens 0-9 27281387-2 2016 Aripiprazole (ARI) is beneficial for antipsychotic-associated hyperprolactinemia but has been reported to decrease PRL secretion. Aripiprazole 0-12 prolactin Homo sapiens 115-118 27281387-2 2016 Aripiprazole (ARI) is beneficial for antipsychotic-associated hyperprolactinemia but has been reported to decrease PRL secretion. Aripiprazole 14-17 prolactin Homo sapiens 115-118 27281387-7 2016 The PRL value of patients who took ARI alone was significantly lower than those who were also taking other antipsychotics (5.45 +- 3.93 vs 10.85 +- 5.53, P = 0.02; mean +- SD). Aripiprazole 35-38 prolactin Homo sapiens 4-7 27281387-10 2016 CONCLUSIONS: Monitoring of PRL levels in patients treated with ARI may be useful in minimizing hypoprolactinemia, which has the potential to negatively impact patients. Aripiprazole 63-66 prolactin Homo sapiens 27-30 27617238-5 2016 Recent in-vivo studies have highlighted the ability of 8-prenylnaringenin to reduce serum-luteinizing hormone (LH) and follicle-stimulating hormone (FSH), to increase serum prolactin levels and uterine weight, and to induce vaginal hyperplastic epithelium. 8-prenylnaringenin 55-73 prolactin Homo sapiens 173-182 27111215-0 2016 Relation between serum prolactin levels and antipsychotic response to risperidone in patients with schizophrenia. Risperidone 70-81 prolactin Homo sapiens 23-32 27455388-4 2016 A dopamine agonist is a compound with high efficacy in lowering prolactin levels and restoring gonadal function. Dopamine 2-10 prolactin Homo sapiens 64-73 27305175-0 2016 A Complex Dance: The Importance of Glycosaminoglycans and Zinc in the Aggregation of Human Prolactin. Glycosaminoglycans 35-53 prolactin Homo sapiens 91-100 27305175-3 2016 Here we, for the first time, study the impact of GAGs in combination with Zn(2+) on the reversible hPRL aggregation across the pH range of 7.4-5.5. Glycosaminoglycans 49-53 prolactin Homo sapiens 99-103 27305175-3 2016 Here we, for the first time, study the impact of GAGs in combination with Zn(2+) on the reversible hPRL aggregation across the pH range of 7.4-5.5. Zinc 74-76 prolactin Homo sapiens 99-103 27305175-4 2016 Zn(2+) alone causes hPRL aggregation at pH 7.4, while aggregation between pH 7.4 and 5.5 requires both Zn(2+) and GAGs. Zinc 0-2 prolactin Homo sapiens 20-24 27305175-5 2016 GAGs alone cause hPRL aggregation below pH 5.5. Glycosaminoglycans 0-4 prolactin Homo sapiens 17-21 27305175-6 2016 Comprehensive thermal stability investigations show that hPRL is particularly destabilized toward thermal denaturation at pH 5.5 and that GAGs increasingly destabilize hPRL at decreasing pH values. Glycosaminoglycans 138-142 prolactin Homo sapiens 168-172 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 16-18 prolactin Homo sapiens 30-34 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 16-18 prolactin Homo sapiens 92-96 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 16-18 prolactin Homo sapiens 92-96 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 68-70 prolactin Homo sapiens 30-34 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 68-70 prolactin Homo sapiens 92-96 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 68-70 prolactin Homo sapiens 92-96 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Glycosaminoglycans 102-106 prolactin Homo sapiens 30-34 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Glycosaminoglycans 102-106 prolactin Homo sapiens 92-96 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Glycosaminoglycans 102-106 prolactin Homo sapiens 92-96 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 68-70 prolactin Homo sapiens 30-34 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 68-70 prolactin Homo sapiens 92-96 27305175-7 2016 We propose that Zn(2+) causes hPRL aggregation through low-affinity Zn(2+) binding sites on hPRL with GAGs facilitating Zn(2+) binding by neutralizing repulsive positive charges of hPRL in the acidic environments of the TGN and mature secretory granules. Zinc 68-70 prolactin Homo sapiens 92-96 26828146-4 2016 Bromocriptine treatment gradually reduced the prolactin level. Bromocriptine 0-13 prolactin Homo sapiens 46-55 27800283-0 2016 Prolactin Levels After Switching to Paliperidone Palmitate in Patients with Schizophrenia. Paliperidone Palmitate 36-58 prolactin Homo sapiens 0-9 27800283-1 2016 Objective: The aim of this study was to investigate the tolerability and efficacy of paliperidone palmitate and its effect on the levels of prolactin in patients with schizophrenia. Paliperidone Palmitate 85-107 prolactin Homo sapiens 140-149 27800283-4 2016 Results: There were significant reductions in prolactin levels at one, three, and six months relative to baseline in the male subjects switched from risperidone long-acting injectable, while prolactin levels in male subjects switched from paliperidone-extended release and the female subjects switched from risperidone long-acting injectable or paliperidone-extended release were largely unchanged. Risperidone 149-160 prolactin Homo sapiens 46-55 27800283-7 2016 As measurement of paliperidone concentrations is limited in routine practice, a fluctuation range of prolactin levels may be a useful marker for confirmation of safety maintenance treatment with long-acting injectables in clinical settings. Paliperidone Palmitate 18-30 prolactin Homo sapiens 101-110 25429611-0 2016 Involvement of prolactin in the meloxicam-dependent inflammatory response of the gonadotropic axis to prolonged lipopolysaccharide treatment in anoestrous ewes. Meloxicam 32-41 prolactin Homo sapiens 15-24 27267119-7 2016 A dose-dependent inhibition of PRL secretion occurred in three mixed GH/PRL adenomas under PEG with a maximum of 52.8+-11.5% at 10mug/mL (P<0.0001 vs control). pegvisomant 91-94 prolactin Homo sapiens 31-34 27267119-9 2016 We conclude that PEG inhibits the secretion of GH and PRL in primary cultures of human GH(/PRL)-secreting pituitary adenomas without effect on cell viability or cell proliferation. pegvisomant 17-20 prolactin Homo sapiens 54-57 27267119-9 2016 We conclude that PEG inhibits the secretion of GH and PRL in primary cultures of human GH(/PRL)-secreting pituitary adenomas without effect on cell viability or cell proliferation. pegvisomant 17-20 prolactin Homo sapiens 91-94 26561015-9 2016 Cabergoline treatment resulted in the normalization of PRL levels in 68 % and in the reduction of >50 % in tumor volume in 87 % of the gPRLoma patients. Cabergoline 0-11 prolactin Homo sapiens 55-58 27052498-21 2016 Human ESCs cultured in the presence of PA had markedly decreased mRNA expression of the decidualization markers, decidual prolactin (PRL) (P< 0.0001) and insulin-like growth factor binding protein 1 (IGFBP1) (P< 0.0001). Palmitic Acid 39-41 prolactin Homo sapiens 133-136 25429611-9 2016 The effect of meloxicam depended on the circulating level of prolactin: meloxicam abolished inflammatory-dependent suppression of GnRH and LH secretion when plasma prolactin levels were similar to those in untreated animals, but was ineffective in those with elevated levels of prolactin. Meloxicam 14-23 prolactin Homo sapiens 61-70 25429611-9 2016 The effect of meloxicam depended on the circulating level of prolactin: meloxicam abolished inflammatory-dependent suppression of GnRH and LH secretion when plasma prolactin levels were similar to those in untreated animals, but was ineffective in those with elevated levels of prolactin. Meloxicam 72-81 prolactin Homo sapiens 61-70 25429611-9 2016 The effect of meloxicam depended on the circulating level of prolactin: meloxicam abolished inflammatory-dependent suppression of GnRH and LH secretion when plasma prolactin levels were similar to those in untreated animals, but was ineffective in those with elevated levels of prolactin. Meloxicam 72-81 prolactin Homo sapiens 164-173 25429611-9 2016 The effect of meloxicam depended on the circulating level of prolactin: meloxicam abolished inflammatory-dependent suppression of GnRH and LH secretion when plasma prolactin levels were similar to those in untreated animals, but was ineffective in those with elevated levels of prolactin. Meloxicam 72-81 prolactin Homo sapiens 164-173 27399926-4 2016 The pharmacological suppression of prolactin production by D2 dopamine receptor agonists bromocriptine and cabergoline has demonstrated satisfactory results in the therapeutic response to the treatment. Bromocriptine 89-102 prolactin Homo sapiens 35-44 27399926-4 2016 The pharmacological suppression of prolactin production by D2 dopamine receptor agonists bromocriptine and cabergoline has demonstrated satisfactory results in the therapeutic response to the treatment. Cabergoline 107-118 prolactin Homo sapiens 35-44 27169416-0 2016 Serum prolactin as a biomarker for the study of intracerebral dopamine effect in adult patients with phenylketonuria: a cross-sectional monocentric study. Dopamine 62-70 prolactin Homo sapiens 6-15 27169416-1 2016 BACKGROUND: It has been previously postulated that high phenylalanine (Phe) might disturb intracerebral dopamine production, which is the main regulator of prolactin secretion in the pituitary gland. Phenylalanine 56-69 prolactin Homo sapiens 156-165 27169416-1 2016 BACKGROUND: It has been previously postulated that high phenylalanine (Phe) might disturb intracerebral dopamine production, which is the main regulator of prolactin secretion in the pituitary gland. Phenylalanine 71-74 prolactin Homo sapiens 156-165 27169416-1 2016 BACKGROUND: It has been previously postulated that high phenylalanine (Phe) might disturb intracerebral dopamine production, which is the main regulator of prolactin secretion in the pituitary gland. Dopamine 104-112 prolactin Homo sapiens 156-165 27169416-3 2016 The aim of the present study was to clarify whether any relation between serum phenylalanine and prolactin levels can be found in adult PKU patients. Phenylalanine 79-92 prolactin Homo sapiens 97-106 27111215-12 2016 CONCLUSION: Patients were showing more than 20% increase in prolactin levels had a better chance of responding to risperidone therapy. Risperidone 114-125 prolactin Homo sapiens 60-69 26858210-0 2016 The effect of metformin on prolactin levels in patients with drug-induced hyperprolactinemia. Metformin 14-23 prolactin Homo sapiens 27-36 27212171-0 2016 A new criteria for screening macroprolactinemia using polyethylene glycol treatment combined with different assays for prolactin. Polyethylene Glycols 54-73 prolactin Homo sapiens 34-43 27212171-15 2016 CONCLUSIONS: Establishment of different criteria for screening MP by using PEG-method is helpful for the accuracy of PRL determination and its comparability. Polyethylene Glycols 75-78 prolactin Homo sapiens 117-120 26944939-0 2016 Synergistic Activation of ERalpha by Estrogen and Prolactin in Breast Cancer Cells Requires Tyrosyl Phosphorylation of PAK1. cyclo(tyrosyl-tyrosyl) 92-99 prolactin Homo sapiens 50-59 27322457-4 2016 PRL promotes the antioxidant capacity of ARPE-19 cells by reducing glutathione. Glutathione 67-78 prolactin Homo sapiens 0-3 27335526-3 2016 Adjunctive treatment with aripiprazole has been shown to normalize prolactin levels without affecting already achieved improvements in psychotic symptoms. Aripiprazole 26-38 prolactin Homo sapiens 67-76 27335526-5 2016 Dopamine acts as a tonic inhibitor of prolactin secretion through the tubero-infundibular dopaminergic system. Dopamine 0-8 prolactin Homo sapiens 38-47 27335526-7 2016 Hence, in the absence of a competing D2 antagonist and the presence of dopamine (the natural agonist), aripiprazole could act as a functional antagonist and thus elevate prolactin levels. Aripiprazole 103-115 prolactin Homo sapiens 170-179 27168837-0 2016 Effects of preoperative bromocriptine treatment on prolactin-secreting pituitary adenoma surgery. Bromocriptine 24-37 prolactin Homo sapiens 51-60 26858210-1 2016 BACKGROUND: In bromocriptine-treated hyperprolactinemic patients with impaired glucose tolerance, metformin was found to reduce plasma levels of prolactin. Metformin 98-107 prolactin Homo sapiens 42-51 27168837-2 2016 The aim of the present study was to analyze the effects of preoperative treatment with bromocriptine on the surgical treatment and postoperative complications of prolactin-secreting pituitary adenomas (prolactinomas). Bromocriptine 87-100 prolactin Homo sapiens 162-171 26858210-6 2016 RESULTS: Despite reducing plasma glucose, HOMA1-IR, and glycated hemoglobin in all treatment groups, metformin decreased prolactin levels only if given at high doses to patients with elevated prolactin levels. Metformin 101-110 prolactin Homo sapiens 121-130 26858210-6 2016 RESULTS: Despite reducing plasma glucose, HOMA1-IR, and glycated hemoglobin in all treatment groups, metformin decreased prolactin levels only if given at high doses to patients with elevated prolactin levels. Metformin 101-110 prolactin Homo sapiens 192-201 26858210-8 2016 CONCLUSIONS: The obtained results suggest that the effect of metformin on plasma prolactin depends on its dose and is observed only in patients with elevated levels of this hormone. Metformin 61-70 prolactin Homo sapiens 81-90 27244767-6 2016 In the representation of meta-analysis with a single study comparing testolactone versus placebo, related to the hormone concentrations, there was a statistically significance difference favoring the use of testolactone for Luteinizing Hormone (LH); Estrogen (E2); free Testosterone (free T); free Estrogen (free E2); 17-Hydroxyprogesterone (17OHP); prolactin (PRL). Testolactone 207-219 prolactin Homo sapiens 350-359 27244767-6 2016 In the representation of meta-analysis with a single study comparing testolactone versus placebo, related to the hormone concentrations, there was a statistically significance difference favoring the use of testolactone for Luteinizing Hormone (LH); Estrogen (E2); free Testosterone (free T); free Estrogen (free E2); 17-Hydroxyprogesterone (17OHP); prolactin (PRL). Testolactone 207-219 prolactin Homo sapiens 361-364 27003261-5 2016 Tyrosyl phosphorylation of PAK1 is essential for this nuclear translocation because phospho-tyrosyl-deficient PAK1 Y3F mutant is retained in the cytoplasm in response to PRL. cyclo(tyrosyl-tyrosyl) 0-7 prolactin Homo sapiens 170-173 27119847-2 2016 (2016) report that oscillating hypothalamic TIDA neurons, previously thought to be simple neurosecretory neurons controlling pituitary prolactin secretion, control dopamine output via autoregulatory mechanisms and thus could potentially regulate other physiologically important hypothalamic neuronal circuits. Dopamine 164-172 prolactin Homo sapiens 135-144 27003261-5 2016 Tyrosyl phosphorylation of PAK1 is essential for this nuclear translocation because phospho-tyrosyl-deficient PAK1 Y3F mutant is retained in the cytoplasm in response to PRL. cyclo(tyrosyl-tyrosyl) 92-99 prolactin Homo sapiens 170-173 27078222-23 2016 However more people receiving depot risperidone experienced prolactin-related adverse events compared to those receiving oral aripiprazole (2 RCTs, n=729, RR 9.91 95% CI 2.78 to 35.29, very low quality of evidence). Risperidone 36-47 prolactin Homo sapiens 60-69 27093067-4 2016 It is well-known that dopamine constitutively inhibits prolactin (PRL) secretion via the dopamine receptor 2 (DR2D). Dopamine 22-30 prolactin Homo sapiens 66-69 27093067-5 2016 If dopamine is increased or if dopamine receptors hyperfunction, PRL may be reduced. Dopamine 3-11 prolactin Homo sapiens 65-68 27093067-10 2016 In this dopamine-PRL pathway-focused-hypothesis-driven review on the association of SCZ with T2D, we report a specific revision of what it is known about PRL and dopamine in relation to what we theorize is one of the missing links between the two disorders. Dopamine 8-16 prolactin Homo sapiens 17-20 26921057-6 2016 The estradiol level correlated negatively with serum prolactin level both in the treatment group and the control group at the end of the 8th week and the 4th week respectively. Estradiol 4-13 prolactin Homo sapiens 53-62 27144151-11 2016 Mean serum prolactin showed a significant increase in risperidone group (P = 0.00). Risperidone 54-65 prolactin Homo sapiens 11-20 26872113-0 2016 Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders. Risperidone 78-89 prolactin Homo sapiens 56-65 27284122-3 2016 There are a few reports in literature on paroxetine use and related prolactin level changes. Paroxetine 41-51 prolactin Homo sapiens 68-77 26822064-5 2016 Metformin patients had a significant decrease in serum prolactin level with a mean of 54.6mug/l in the three trials. Metformin 0-9 prolactin Homo sapiens 55-64 26822064-9 2016 Our systematic review indicated that adjunctive metformin significantly lowered prolactin level and relieved prolactin-related symptoms in patients with antipsychotic-induced hyperprolactinemia. Metformin 48-57 prolactin Homo sapiens 80-89 26822064-9 2016 Our systematic review indicated that adjunctive metformin significantly lowered prolactin level and relieved prolactin-related symptoms in patients with antipsychotic-induced hyperprolactinemia. Metformin 48-57 prolactin Homo sapiens 109-118 26971354-9 2016 CONCLUSIONS: Treatments with dopamine agonists represent a beneficial strategy for patients with prolactinoma accompanied with bone loss, in addition to their established efficacy in shrinkage of the size of pituitary tumors, normalization of PRL levels, and improvement of metabolic disorders. Dopamine 29-37 prolactin Homo sapiens 243-246 26757742-2 2016 Our patient was a 19-year-old male adolescent who had been treated since the age of 9 years with GH and thyroxine for an idiopathic combined GH, thyroid-stimulating hormone (TSH), and prolactin (PRL) deficiency. Thyroxine 104-113 prolactin Homo sapiens 184-193 31156828-4 2016 He asked if carbamazepine and/or lercanidipine might be the cause of his raised prolactin level; his urologist had denied this. Carbamazepine 12-25 prolactin Homo sapiens 80-89 31156828-4 2016 He asked if carbamazepine and/or lercanidipine might be the cause of his raised prolactin level; his urologist had denied this. lercanidipine 33-46 prolactin Homo sapiens 80-89 27042412-12 2016 Normalization of PRL with cabergoline corrects all the metabolic abnormalities. Cabergoline 26-37 prolactin Homo sapiens 17-20 26744030-8 2016 The effects of human epidermal growth factor (hEGF) and dopamine (DA) on the expression and secretion of PRL in BAPDL at passage 4 were also investigated. Dopamine 56-64 prolactin Homo sapiens 105-108 26724569-0 2016 Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Amisulpride 150-161 prolactin Homo sapiens 117-126 26724569-2 2016 The aim of this study was to examine the relationship between COMT variants, plasma prolactin level, and the therapeutic effectiveness of amisulpride treatment in patients with schizophrenia. Amisulpride 138-149 prolactin Homo sapiens 84-93 26724569-11 2016 Our results suggest that variation of the COMT gene is associated with treatment response regarding negative symptoms and prolactin changes after amisulpride treatment in patients with schizophrenia. Amisulpride 146-157 prolactin Homo sapiens 122-131 26944776-2 2016 Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction. Cabergoline 0-11 prolactin Homo sapiens 73-82 26944776-2 2016 Cabergoline is a dopamine agonist that acts centrally to normalize serum prolactin that could improve orgasmic dysfunction. Dopamine 17-25 prolactin Homo sapiens 73-82 26691151-3 2016 We found that GH3 cell lines stably expressing Luc under control of the ERE-mutated hPRL promoter (ERE-Mut) displayed a dramatically reduced transcriptional response to 17beta-estradiol (E2) treatment compared with cells expressing Luc from the wild-type (WT) ERE hPRL-Luc promoter (ERE-WT). Estradiol 169-185 prolactin Homo sapiens 84-88 26930529-0 2016 Prolactin Levels During Long-Term Risperidone Treatment in Children and Adolescents: a reanalysis of data. Risperidone 34-45 prolactin Homo sapiens 0-9 26817618-8 2016 Addition of flutamide significantly reduced secretion of IGFBP1 and prolactin and altered the expression of endometrial receptivity markers. Flutamide 12-21 prolactin Homo sapiens 68-77 29193914-3 2016 Less than 10% of patientswith prolactinomas exhibit resistance to the action of dopamine agonists, asdefined by the lack of normalization of the serum prolactin levels despite long-term treatment at high doses of these drugs. Dopamine 80-88 prolactin Homo sapiens 30-39 29193914-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. Dopamine 31-39 prolactin Homo sapiens 237-246 29193914-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. bromocriptinebut 163-179 prolactin Homo sapiens 237-246 29193914-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. Dopamine 194-202 prolactin Homo sapiens 237-246 29193928-3 2016 Less than 10% of patientswith prolactinomas exhibit resistance to the action of dopamine agonists, asdefined by the lack of normalization of the serum prolactin levels despite long-term treatment at high doses of these drugs. Dopamine 80-88 prolactin Homo sapiens 30-39 29193928-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. Dopamine 31-39 prolactin Homo sapiens 237-246 29193928-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. bromocriptinebut 163-179 prolactin Homo sapiens 237-246 29193928-4 2016 However secondary resistanceto dopamine agonists therapy has also been described in patients who wereinitially responsive to treatment, either with Cabergoline or Bromocriptinebut later develop dopamine agonist resistance, with elevated prolactin levelsand sometimes an enlarging tumor volume several years afterwards. Dopamine 194-202 prolactin Homo sapiens 237-246 26067083-8 2016 Circulating prolactin was also negatively correlated with fasting glycemia (only in patients with normal glucose metabolism, p = 0.037) and was inversely correlated with the presence of metabolic syndrome (p < 0.001), but this association was not maintained after adjustment for possible confounders. Glucose 105-112 prolactin Homo sapiens 12-21 27855233-4 2016 We present the case of a 62-year-old man with an apparently indolent prolactin-secreting macroadenoma managed with partial resection and initially showing a biochemical response to cabergoline. Cabergoline 181-192 prolactin Homo sapiens 69-78 27855233-6 2016 The patient then underwent two further transsphenoidal operations and continued on high-dose cabergoline; despite these interventions, the tumour continued enlarging and prolactin increased to 107 269 U/L. Cabergoline 93-104 prolactin Homo sapiens 170-179 26904472-10 2016 In metformin-treated group, there was a lowest prolactin serum level. Metformin 3-12 prolactin Homo sapiens 47-56 26958514-11 2016 Additionally, a statistically significant association was observed between serum prolactin levels with serum bilirubin (rho =0.67, P = 0.04) and aspartate aminotransferase (rho =0.72, P = 0.05). Bilirubin 109-118 prolactin Homo sapiens 81-90 26515614-0 2016 Target Prolactin Range in Treatment of Tetrahydrobiopterin Deficiency. sapropterin 39-58 prolactin Homo sapiens 7-16 26515614-1 2016 The introduction of dopamine agonists for treating tetrahydrobiopterin deficiency imposes the evaluation of peripheral prolactin as the sole reliable biochemical marker of dopaminergic homeostasis. Dopamine 20-28 prolactin Homo sapiens 119-128 26515614-2 2016 Here we provide the clinical interpretation of the previously described short prolactin profile, based on the longitudinal monitoring of 8 patients with tetrahydrobiopterin deficiency. sapropterin 153-172 prolactin Homo sapiens 78-87 27703744-2 2015 AIMS: This double-blind, placebo-controlled study aimed at examining the effect of adjunctive treatment with 10 mg aripiprazole on prolactin levels and sexual side-effects in patients with schizophrenia symptomatically maintained on risperidone. Aripiprazole 115-127 prolactin Homo sapiens 131-140 27703744-7 2015 RESULTS: Prolactin levels decreased by 58% in the aripiprazole group compared with an increase by 22% in the placebo group. Aripiprazole 50-62 prolactin Homo sapiens 9-18 27703744-8 2015 Prolactin levels normalised in 46% of patients in the aripiprazole group (number needed to treat, NNT=2). Aripiprazole 54-66 prolactin Homo sapiens 0-9 27703744-11 2015 CONCLUSIONS: Adjunctive aripiprazole reduced prolactin levels in those treated with risperidone, with no effect on psychopathology and extrapyramidal symptoms. Aripiprazole 24-36 prolactin Homo sapiens 45-54 27703744-11 2015 CONCLUSIONS: Adjunctive aripiprazole reduced prolactin levels in those treated with risperidone, with no effect on psychopathology and extrapyramidal symptoms. Risperidone 84-95 prolactin Homo sapiens 45-54 26546756-4 2015 RESULTS: Median PRL levels were unchanged after 4 weeks, but significantly decreased 8 and 12 weeks after the first leuporeline administration (p1=0.085, p2=0.020, p3=0.001). leuporeline 116-127 prolactin Homo sapiens 16-19 26788160-12 2015 Similarly, expression level of MMP9 in the PRL/PRF/5 cells treated with 1.0 microm niclosamide deceased to 18.7+-10.7% (P<0.05) compared with those in the untreated control PRL/PRF/5 cells. Niclosamide 83-94 prolactin Homo sapiens 43-46 26788160-12 2015 Similarly, expression level of MMP9 in the PRL/PRF/5 cells treated with 1.0 microm niclosamide deceased to 18.7+-10.7% (P<0.05) compared with those in the untreated control PRL/PRF/5 cells. Niclosamide 83-94 prolactin Homo sapiens 176-179 26834965-7 2015 Lurasidone was associated with minimal changes in weight, metabolic parameters, and prolactin levels. Lurasidone Hydrochloride 0-10 prolactin Homo sapiens 84-93 26590188-8 2015 After 10 years of treatment with dopamine agonists, the prolactin levels decreased by 96.8%, there was an effective reduction in tumour size, and the neurological signs and symptoms resolved. Dopamine 33-41 prolactin Homo sapiens 56-65 26583049-2 2015 Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. Dopamine 38-46 prolactin Homo sapiens 17-26 26583049-2 2015 Normalization of prolactin (PRL) with dopamine agonists has been found to reverse these abnormalities. Dopamine 38-46 prolactin Homo sapiens 28-31 26583049-12 2015 Normalization of PRL with cabergoline corrects all the metabolic abnormalities. Cabergoline 26-37 prolactin Homo sapiens 17-20 26275984-7 2015 Patients with hyperprolactinaemia had higher urinary excretion of lactose than normoprolactinemic controls and urinary lactose correlated positively to prolactin levels (r = 0.51, p < 0.05). Lactose 66-73 prolactin Homo sapiens 19-28 26275984-7 2015 Patients with hyperprolactinaemia had higher urinary excretion of lactose than normoprolactinemic controls and urinary lactose correlated positively to prolactin levels (r = 0.51, p < 0.05). Lactose 119-126 prolactin Homo sapiens 19-28 26275984-9 2015 The acidic oligosaccharide 3-sialyl lactose was found in high amount in urine from two patients with prolactin of >10,000 mU/l. Oligosaccharides 11-26 prolactin Homo sapiens 101-110 26275984-9 2015 The acidic oligosaccharide 3-sialyl lactose was found in high amount in urine from two patients with prolactin of >10,000 mU/l. Lactose 36-43 prolactin Homo sapiens 101-110 26872113-1 2016 OBJECTIVE: The aim of the study was to identify the impact of pharmacogenetic markers associated with prolactin concentration in risperidone-treated children and adolescents with autism spectrum disorders. Risperidone 129-140 prolactin Homo sapiens 102-111 25711510-2 2016 Compared to other atypical antipsychotics, aripiprazole has less metabolic side effects and is less likely to increase prolactin. Aripiprazole 43-55 prolactin Homo sapiens 119-128 25711510-4 2016 While aripiprazole has been associated with subnormal prolactin levels in children, no documented cases of hypoprolactinemia in adults exist thus far. Aripiprazole 6-18 prolactin Homo sapiens 54-63 25711510-5 2016 Here we report a case of aripiprazole-induced hypoprolactinemia in an adult male with first-episode psychosis, and the possible effects of abnormally low prolactin are discussed. Aripiprazole 25-37 prolactin Homo sapiens 50-59 27284453-4 2016 LEARNING POINTS: Prolactinoma coinciding with psychosis can represent a therapeutic challenge.In contrast to many other antipsychotic drugs, aripiprazole is associated with a decrease in prolactin levels.Aripiprazole can be a valuable pharmaceutical tool to treat both prolactinoma and psychosis. Aripiprazole 141-153 prolactin Homo sapiens 187-196 27284453-4 2016 LEARNING POINTS: Prolactinoma coinciding with psychosis can represent a therapeutic challenge.In contrast to many other antipsychotic drugs, aripiprazole is associated with a decrease in prolactin levels.Aripiprazole can be a valuable pharmaceutical tool to treat both prolactinoma and psychosis. Aripiprazole 204-216 prolactin Homo sapiens 187-196 26336917-1 2016 BACKGROUND: Loss-of-function mutations in immunoglobulin superfamily member 1 (IGSF1) cause an X-linked syndrome of central hypothyroidism, macroorchidism, delayed pubertal testosterone rise, variable prolactin deficiency and variable partial GH deficiency in childhood. Testosterone 173-185 prolactin Homo sapiens 201-210 26788160-7 2015 Compared with the control treatment, treatment with 10 microm niclosamide suppressed the proliferation of the HLF and PRL/PRF/5 cells to 49.9+-3.7 and 17.9+-11.5% (P<0.05), respectively. Niclosamide 62-73 prolactin Homo sapiens 118-121 26788160-8 2015 Furthermore, compared with the control treatment, treatment with 1.0 microM niclosamide downregulated the expression of cyclin D1 to 52.4+-4.4 and 23.9+-5.4% (P<0.05) in the HLF and PRL/PRF/5 cells, respectively. Niclosamide 76-87 prolactin Homo sapiens 185-188 26788160-10 2015 Similarly, treatment of the PRL/PRF/5 cells with niclosamide (1.0 microm) also decreased the distance of the scratched line from the growing edge to 3.0+-0.8 mm compared with the 5.5+-0.9 mm observed with the control treatment (P<0.05). Niclosamide 49-60 prolactin Homo sapiens 28-31 26817308-3 2015 High levels of prolactin can induce erectile dysfunction and results in secondary male infertility, which are mainly associated with the inhibition of dopaminergic activity, reduction of the testosterone level, and contraction of the cavernous smooth muscle. Testosterone 191-203 prolactin Homo sapiens 15-24 26338693-6 2015 Body mass index change did not differ between treatments but advantages were found for aripiprazole treatment for total and low-density lipoprotein cholesterol, fasting glucose, and prolactin levels. Aripiprazole 87-99 prolactin Homo sapiens 182-191 26202060-0 2015 Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer. 3-nitrotyrosine 81-95 prolactin Homo sapiens 0-9 26202060-0 2015 Prolactin- and testosterone-induced carboxypeptidase-D correlates with increased nitrotyrosines and Ki67 in prostate cancer. ki67 100-104 prolactin Homo sapiens 0-9 26514951-5 2015 RESULTS: Decrease of prolactin levels and the tumor shrinkage after cabergoline treatment were 93.9+-5.9% and 58.3+-33.1% in microadenomas and 96.1+-6.1% and 51.7+-29.3 in macroadenomas (P=0.02 and P>0.05, respectively). Cabergoline 68-79 prolactin Homo sapiens 21-30 26886772-12 2015 The existence of a dynamic prolactin-induced sorting machinery for GLUT1 could be important for transport of free glucose into the Golgi for lactose synthesis during lactation. Glucose 114-121 prolactin Homo sapiens 27-36 26886772-12 2015 The existence of a dynamic prolactin-induced sorting machinery for GLUT1 could be important for transport of free glucose into the Golgi for lactose synthesis during lactation. Lactose 141-148 prolactin Homo sapiens 27-36 26256063-8 2015 Dopamine agonist therapy remains the first line of treatment for prolactinomas, as it is effective in normalizing serum prolactin levels and reducing tumor size. Dopamine 0-8 prolactin Homo sapiens 65-74 26816428-0 2015 Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Olanzapine 82-92 prolactin Homo sapiens 50-59 26816428-0 2015 Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Risperidone 94-105 prolactin Homo sapiens 50-59 26816428-0 2015 Comparative study of sexual dysfunction and serum prolactin level associated with olanzapine, risperidone, and clozapine in patients with remitted schizophrenia. Clozapine 111-120 prolactin Homo sapiens 50-59 26816428-13 2015 Prolactin level elevation was statistically significant in risperidone group followed by clozapine and olanzapine groups, respectively. Risperidone 59-70 prolactin Homo sapiens 0-9 26816428-13 2015 Prolactin level elevation was statistically significant in risperidone group followed by clozapine and olanzapine groups, respectively. Clozapine 89-98 prolactin Homo sapiens 0-9 26816428-13 2015 Prolactin level elevation was statistically significant in risperidone group followed by clozapine and olanzapine groups, respectively. Olanzapine 103-113 prolactin Homo sapiens 0-9 26243714-5 2015 Dopamine agonist therapy is the first line of treatment for prolactinomas because of its effectiveness in normalizing serum prolactin levels and shrinking tumor size. Dopamine 0-8 prolactin Homo sapiens 60-69 26270200-6 2015 In addition, an obvious increase in PRL level and a reduction of sex hormone secretion after amisulpride treatment were found. Amisulpride 93-104 prolactin Homo sapiens 36-39 26270200-9 2015 CONCLUSIONS: The PRL-raising antipsychotic drug amisulpride influenced bone turnover balance very early in the course of treatment, which may require long-term monitoring of bone metabolism. Amisulpride 48-59 prolactin Homo sapiens 17-20 26664488-9 2015 Our study found decreased estradiol levels in men with schizophrenia treated with clozapine and risperidone, while prolactin levels were increased only in the risperidone treated group. Risperidone 159-170 prolactin Homo sapiens 115-124 26508971-1 2015 In our previous study, a prolactin elevation was more frequently in risperidone than in blonanserin; however, it was more often in blonanserin than in olanzapine. blonanserin 131-142 prolactin Homo sapiens 25-34 26398376-5 2015 RESULTS: Oral contraceptive pills administered for 16 weeks slightly increased pre-polyethylene glycol serum prolactin levels and macroprolactin levels and the effect of this treatment correlated with their baseline values. Polyethylene Glycols 83-102 prolactin Homo sapiens 109-118 26508971-0 2015 One-Year Follow-Up of Serum Prolactin Level in Schizophrenia Patients Treated with Blonanserin: A Case Series. blonanserin 83-94 prolactin Homo sapiens 28-37 26508971-1 2015 In our previous study, a prolactin elevation was more frequently in risperidone than in blonanserin; however, it was more often in blonanserin than in olanzapine. Olanzapine 151-161 prolactin Homo sapiens 25-34 26508971-1 2015 In our previous study, a prolactin elevation was more frequently in risperidone than in blonanserin; however, it was more often in blonanserin than in olanzapine. Risperidone 68-79 prolactin Homo sapiens 25-34 26508971-1 2015 In our previous study, a prolactin elevation was more frequently in risperidone than in blonanserin; however, it was more often in blonanserin than in olanzapine. blonanserin 88-99 prolactin Homo sapiens 25-34 26508971-4 2015 As a result, blonanserin dose was clearly associated with serum prolactin level. blonanserin 13-24 prolactin Homo sapiens 64-73 26508971-5 2015 The average prolactin level was almost normal when the mean blonanserin dosage was 8.0 mg/day. blonanserin 60-71 prolactin Homo sapiens 12-21 26634176-7 2015 This review article explores a possible link between in-utero exposure to a high maternal prolactin/dopamine ratio and subsequent development of autism spectrum disorders. Dopamine 100-108 prolactin Homo sapiens 90-99 25059808-8 2015 Both cases responded well to treatment with cabergoline treatment whereupon serum prolactin normalised. Cabergoline 44-55 prolactin Homo sapiens 82-91 26542707-10 2015 Hyperactivity of the dopaminergic system can explain only a few of the aforementioned findings, whereas a hypo-serotonergic tone fits well with the clinical features associated with low PRL, and there is significant evidence supporting the hypothesis that PRL could be a mirror of serotonin in the brain. Serotonin 281-290 prolactin Homo sapiens 256-259 26043691-0 2015 Src tyrosyl phosphorylates cortactin in response to prolactin. cyclo(tyrosyl-tyrosyl) 4-11 prolactin Homo sapiens 52-61 26043691-6 2015 We determine that cortactin is tyrosyl phosphorylated in response to PRL in a time and dose-dependent manner in TMX2-28 cells, but not in T47D cells. cyclo(tyrosyl-tyrosyl) 31-38 prolactin Homo sapiens 69-72 26043691-7 2015 Furthermore, we show that PRL mediates cortactin tyrosyl phosphorylation via Src, but not JAK2. cyclo(tyrosyl-tyrosyl) 49-56 prolactin Homo sapiens 26-29 26043691-9 2015 Thus PRL may induce cell invasion via two pathways: through a JAK2/PAK1 mediated pathway that we have previously demonstrated, and Src-dependent activation and tyrosyl phosphorylation of cortactin. cyclo(tyrosyl-tyrosyl) 160-167 prolactin Homo sapiens 5-8 26101377-1 2015 The hypothalamic control of prolactin secretion is different from other anterior pituitary hormones, in that it is predominantly inhibitory, by means of dopamine from the tuberoinfundibular dopamine neurons. Dopamine 153-161 prolactin Homo sapiens 28-37 26016707-7 2015 Dexmedetomidine also decreased prolactin levels with a mean difference of -19.42 (-39.37, 0.52) mug/L (P = 0.06). Dexmedetomidine 0-15 prolactin Homo sapiens 31-40 26108095-3 2015 It has been suggested that serum prolactin could represent a biomarker of heavy metal exposure. Metals 80-85 prolactin Homo sapiens 33-42 26108095-7 2015 Interestingly, inhibition of nitric oxide synthase by N-nitro-L-arginine completely prevented the decrease in prolactin release without acute neurotoxic effects of methylmercury. nitric 29-35 prolactin Homo sapiens 110-119 26108095-7 2015 Interestingly, inhibition of nitric oxide synthase by N-nitro-L-arginine completely prevented the decrease in prolactin release without acute neurotoxic effects of methylmercury. Nitroarginine 54-72 prolactin Homo sapiens 110-119 25993525-4 2015 We therefore investigated the contribution of central PRL/PRLR signaling to the control of estradiol-induced surges of LH and PRL and pulsatile LH secretion under basal and hyperprolactinemic conditions. Estradiol 91-100 prolactin Homo sapiens 54-57 25993525-4 2015 We therefore investigated the contribution of central PRL/PRLR signaling to the control of estradiol-induced surges of LH and PRL and pulsatile LH secretion under basal and hyperprolactinemic conditions. Luteinizing Hormone 119-121 prolactin Homo sapiens 54-57 25993525-7 2015 Next, we revealed that sustained blockade of hypothalamic PRLR using Delta1-9-G129R-hPRL augmented the magnitude of LH surges induced by estradiol benzoate and progesterone treatment and suppressed the concomitant surges of PRL. estradiol 3-benzoate 137-155 prolactin Homo sapiens 84-88 25993525-7 2015 Next, we revealed that sustained blockade of hypothalamic PRLR using Delta1-9-G129R-hPRL augmented the magnitude of LH surges induced by estradiol benzoate and progesterone treatment and suppressed the concomitant surges of PRL. Progesterone 160-172 prolactin Homo sapiens 84-88 26101377-1 2015 The hypothalamic control of prolactin secretion is different from other anterior pituitary hormones, in that it is predominantly inhibitory, by means of dopamine from the tuberoinfundibular dopamine neurons. Dopamine 190-198 prolactin Homo sapiens 28-37 26101377-3 2015 Instead, it is regulated by short loop feedback, whereby prolactin itself acts in the brain to stimulate production of dopamine and thereby inhibit its own secretion. Dopamine 119-127 prolactin Homo sapiens 57-66 26000778-0 2015 Prolactin serum concentrations after electroconvulsive therapy in a depressed patient with cabergoline-treated prolactinoma: implications for treatment. Cabergoline 91-102 prolactin Homo sapiens 0-9 25399742-7 2015 The level of sex hormones was positively correlated with better mood and quality of life in patients affected with Parkinson"s disease; prolactin levels correlated negatively with sex steroid concentrations. Steroids 184-191 prolactin Homo sapiens 136-145 25797370-7 2015 PRL of 60kDa released by monocytes exhibited bioactivity in Nb2 cells, and both synthesized PRL and synthesized PRLr were related with nitrite and proinflammatory cytokine levels proapoptotic activity in CFP-M. bovis-induced monocytes. Nitrites 135-142 prolactin Homo sapiens 92-95 25062894-1 2015 BACKGROUND: The management of giant prolactinomas remains a major challenge, despite dopamine agonists being the first line of treatment, owing to its efficacy to normalize prolactin levels and reduce tumor volume. Dopamine 85-93 prolactin Homo sapiens 36-45 26074878-3 2015 A dopamine agonist (DA) (bromocriptine or cabergoline) is the treatment of choice that can normalize prolactin levels, reduce tumor size, and restore ovulation and fertility. Dopamine 2-10 prolactin Homo sapiens 101-110 26074878-3 2015 A dopamine agonist (DA) (bromocriptine or cabergoline) is the treatment of choice that can normalize prolactin levels, reduce tumor size, and restore ovulation and fertility. Bromocriptine 25-38 prolactin Homo sapiens 101-110 26074878-3 2015 A dopamine agonist (DA) (bromocriptine or cabergoline) is the treatment of choice that can normalize prolactin levels, reduce tumor size, and restore ovulation and fertility. Cabergoline 42-53 prolactin Homo sapiens 101-110 25499076-6 2015 The main objective of this study was to determine the N-glycan structures present in native, pituitary G-hPRL and compare them with those present in the recombinant hormone. n-glycan 54-62 prolactin Homo sapiens 105-109 25499076-7 2015 To obtain recombinant G-hPRL, genetically modified Chinese hamster ovary cells (CHO), adapted to growth in suspension, were treated with cycloheximide, thus increasing the glycosylation site occupancy from 5.5% to 38.3%, thereby facilitating G-hPRL purification. Cycloheximide 137-150 prolactin Homo sapiens 24-28 25499076-7 2015 To obtain recombinant G-hPRL, genetically modified Chinese hamster ovary cells (CHO), adapted to growth in suspension, were treated with cycloheximide, thus increasing the glycosylation site occupancy from 5.5% to 38.3%, thereby facilitating G-hPRL purification. Cycloheximide 137-150 prolactin Homo sapiens 244-248 25499076-11 2015 N-Glycan profiling proved to be a useful and accurate methodology also for MM and carbohydrate content determination for the two G-hPRL preparations, in good agreement with the values obtained directly via MALDI-TOF-MS. n-glycan 0-8 prolactin Homo sapiens 131-135 25499076-11 2015 N-Glycan profiling proved to be a useful and accurate methodology also for MM and carbohydrate content determination for the two G-hPRL preparations, in good agreement with the values obtained directly via MALDI-TOF-MS. Carbohydrates 82-94 prolactin Homo sapiens 131-135 25701231-5 2015 Consumption of a high-protein/low carbohydrate diet increased prolactin concentration, with a concomitant increase in SNAT2 expression not only in the MG during lactation, but also in the liver and adipose tissue. Carbohydrates 34-46 prolactin Homo sapiens 62-71 25701231-6 2015 There was a correlation between SNAT2 expression and serum prolactin levels depending on the amount of dietary protein/carbohydrate ratio consumed. Carbohydrates 119-131 prolactin Homo sapiens 59-68 25239203-0 2015 The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Metformin 25-34 prolactin Homo sapiens 55-64 25239203-0 2015 The effect of short-term metformin treatment on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance: a pilot study. Bromocriptine 75-88 prolactin Homo sapiens 55-64 25239203-2 2015 This study was aimed at investigating whether metformin treatment has an impact on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance. Metformin 46-55 prolactin Homo sapiens 90-99 25239203-2 2015 This study was aimed at investigating whether metformin treatment has an impact on plasma prolactin levels in bromocriptine-treated patients with hyperprolactinaemia and impaired glucose tolerance. Bromocriptine 110-123 prolactin Homo sapiens 90-99 25239203-7 2015 In patients with hyperprolactinaemia, but not in the other groups of patients, metformin slightly reduced plasma levels of prolactin, and this effect correlated weakly with the metabolic effects of this drug. Metformin 79-88 prolactin Homo sapiens 22-31 25239203-8 2015 Our study shows that metformin decreases plasma prolactin levels only in patients with elevated levels of this hormone. Metformin 21-30 prolactin Homo sapiens 48-57 25856298-0 2015 Effects of tibolone and its metabolites on prolactin and insulin-like growth factor binding protein-1 expression in human endometrial stromal cells. tibolone 11-19 prolactin Homo sapiens 43-52 25856298-3 2015 Over 21 days, specific ELISAs observed linear increases in secreted IGFBP-1 and prolactin levels elicited by tibolone and its metabolites. tibolone 109-117 prolactin Homo sapiens 80-89 25856298-4 2015 Cultured HESCs were refractory to E2 and dexamethasone, whereas tibolone and each metabolite exceeded medroxyprogesterone acetate in significantly elevating IGFBP-1 and prolactin output. tibolone 64-72 prolactin Homo sapiens 169-178 25659646-5 2015 Moreover, prolactin-reducing drug bromocriptine mesylate resulted in elevated expression of the hepcidin in hyperprolactinemia patients. Bromocriptine 34-47 prolactin Homo sapiens 10-19 25659646-9 2015 In this paper, the authors described a further modification of their previously described nanopore silica film-based enrichment approach for quantification of hepcidin and found correlation between hepcidin and prolactin. Silicon Dioxide 99-105 prolactin Homo sapiens 211-220 25917731-6 2015 Furthermore, PRL levels were higher in SCO syndrome patients compared with subjects showing normal spermatogenesis and the levels positively correlated with NAG, FSH, and LH amounts. Luteinizing Hormone 171-173 prolactin Homo sapiens 13-16 25587116-3 2015 Basolateral application of several different concentrations of PRL dramatically stimulated the transepithelial current in A6 cells, increasing both amiloride-sensitive (ENaC) and amiloride-insensitive currents. Amiloride 148-157 prolactin Homo sapiens 63-66 25587116-3 2015 Basolateral application of several different concentrations of PRL dramatically stimulated the transepithelial current in A6 cells, increasing both amiloride-sensitive (ENaC) and amiloride-insensitive currents. enac 169-173 prolactin Homo sapiens 63-66 25587116-3 2015 Basolateral application of several different concentrations of PRL dramatically stimulated the transepithelial current in A6 cells, increasing both amiloride-sensitive (ENaC) and amiloride-insensitive currents. Amiloride 179-188 prolactin Homo sapiens 63-66 25587116-5 2015 Inhibition of PKA with H-89 abolished the effect of PRL on amiloride-sensitive and insensitive transepithelial currents and eliminated the increase in ENaC NPo with PRL exposure. N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide 23-27 prolactin Homo sapiens 52-55 25587116-5 2015 Inhibition of PKA with H-89 abolished the effect of PRL on amiloride-sensitive and insensitive transepithelial currents and eliminated the increase in ENaC NPo with PRL exposure. N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide 23-27 prolactin Homo sapiens 165-168 25587116-5 2015 Inhibition of PKA with H-89 abolished the effect of PRL on amiloride-sensitive and insensitive transepithelial currents and eliminated the increase in ENaC NPo with PRL exposure. Amiloride 59-68 prolactin Homo sapiens 52-55 25587116-6 2015 PRL also increased cAMP in A6 cells, consistent with signaling through the cAMP-dependent PKA pathway. Cyclic AMP 19-23 prolactin Homo sapiens 0-3 25715833-5 2015 Likewise, AP expression and circulating levels of PRL are reduced in streptozotocin-induced diabetic rats and are associated with higher AP expression and protein levels of TGF-beta and TNF-alpha. Streptozocin 69-83 prolactin Homo sapiens 50-53 25707872-5 2015 According to the finding that dopamine is the natural inhibitor of prolactin (PRL) incretion, we introduced the use of peripheral PRL measurement as an index of dopaminergic homeostasis, so avoiding the need of repeated lumbar punctures in patients with BH4 deficiency. Dopamine 30-38 prolactin Homo sapiens 67-76 25856298-5 2015 Anti-progestins eliminated IGFBP-1 and prolactin induction by tibolone and its metabolites. tibolone 62-70 prolactin Homo sapiens 39-48 25014320-0 2015 Effect of dopamine infusion on thyroid hormone tests and prolactin levels in very low birth weight infants. Dopamine 10-18 prolactin Homo sapiens 57-66 25014320-1 2015 OBJECTIVE: To evaluate the effect of dopamine on thyroid hormone tests and prolactin (PRL) and to assess requirement for L-thyroxin (LT4). Dopamine 37-45 prolactin Homo sapiens 75-84 25659520-6 2015 RESULTS: Morphine increased tolerance to muscle pain, together with significant reductions in pupil diameter and increase in prolactin concentration (all P < 0.001). Morphine 9-17 prolactin Homo sapiens 125-134 25659520-10 2015 DISCUSSION: Prolactin concentration and pupil diameter showed similar temporal development, had good dynamic ranges and were sensitive to morphine. Morphine 138-146 prolactin Homo sapiens 12-21 26285330-4 2015 RESULTS: The application of the sulfide-containing siltypeloids was shown to have positive clinical effect on the adrenal and ovarian function and to exert the modulating action on the levels of the pituitary and sex hormones in women with bacterial vaginosis and normal prolactin levels. Sulfides 32-39 prolactin Homo sapiens 271-280 25062894-6 2015 Baseline mean serum prolactin level were extremely high for both sexes which eventually decreased by as much as 97% after cabergoline treatment. Cabergoline 122-133 prolactin Homo sapiens 20-29 25376133-1 2015 OBJECTIVE: Cabergoline is the treatment of choice for prolactin (PRL)-producing pituitary adenomas, because of its efficacy in normalizing PRL levels, and inducing tumor shrinkage. Cabergoline 11-22 prolactin Homo sapiens 54-63 25123447-0 2015 Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Cabergoline 21-32 prolactin Homo sapiens 122-131 25784810-2 2015 Prolactin levels usually increase in patients treated with risperidone. Risperidone 59-70 prolactin Homo sapiens 0-9 25784810-8 2015 Baseline prolactin levels were measured in all patients who were candidates for treatment with risperidone. Risperidone 95-106 prolactin Homo sapiens 9-18 25784810-9 2015 In subjects with elevated serum prolactin, aripiprazole was added to their treatment. Aripiprazole 43-55 prolactin Homo sapiens 32-41 25123447-0 2015 Different effects of cabergoline and bromocriptine on metabolic and cardiovascular risk factors in patients with elevated prolactin levels. Bromocriptine 37-50 prolactin Homo sapiens 122-131 25123447-11 2015 These findings seem to support previous observations that cabergoline may be a better treatment for patients with elevated prolactin levels than bromocriptine. Cabergoline 58-69 prolactin Homo sapiens 123-132 25732643-3 2015 Dopamine agonists are efficacious in about 80% to 90% of patients with prolactinoma, leading to reduction of serum prolactin levels and tumor dimensions. Dopamine 0-8 prolactin Homo sapiens 71-80 25954648-11 2015 It was only in the control group that prolactin correlated positively and significantly with TSH. Thyrotropin 93-96 prolactin Homo sapiens 38-47 25466889-2 2015 We have previously shown that the prolactin (PRL)-activated tyrosine kinase JAK2 phosphorylates PAK1 in vivo and in vitro and identified tyrosines 153, 201, and 285 in PAK1 as sites of JAK2 tyrosyl phosphorylation. Tyrosine 137-146 prolactin Homo sapiens 45-48 25466889-2 2015 We have previously shown that the prolactin (PRL)-activated tyrosine kinase JAK2 phosphorylates PAK1 in vivo and in vitro and identified tyrosines 153, 201, and 285 in PAK1 as sites of JAK2 tyrosyl phosphorylation. cyclo(tyrosyl-tyrosyl) 190-197 prolactin Homo sapiens 45-48 25466889-5 2015 We demonstrate that PRL/JAK2-dependent phosphorylation of these tyrosines promotes a motile phenotype in the cells upon adhesion, participates in regulation of cell adhesion on collagen IV, and is required for maximal PAK1 kinase activity. Tyrosine 64-73 prolactin Homo sapiens 20-23 25466889-8 2015 Using phosphospecific antibodies (Abs) directed to single phosphorylated tyrosines on PAK1, we identified Tyr285 as a site of PRL-dependent phosphorylation of PAK1 by JAK2. Tyrosine 73-82 prolactin Homo sapiens 126-129 25514607-0 2015 Prolactin variations during risperidone therapy in a sample of drug-naive children and adolescents. Risperidone 28-39 prolactin Homo sapiens 0-9 25514607-1 2015 The aim of this prospective observational study was to investigate the variations of serum prolactin hormone (PRL) in a sample of 34 drug-naive patients (mean age 13 years) who started risperidone therapy assuming that several factors may favor the increase in serum PRL. Risperidone 185-196 prolactin Homo sapiens 91-100 25514607-1 2015 The aim of this prospective observational study was to investigate the variations of serum prolactin hormone (PRL) in a sample of 34 drug-naive patients (mean age 13 years) who started risperidone therapy assuming that several factors may favor the increase in serum PRL. Risperidone 185-196 prolactin Homo sapiens 110-113 25514607-1 2015 The aim of this prospective observational study was to investigate the variations of serum prolactin hormone (PRL) in a sample of 34 drug-naive patients (mean age 13 years) who started risperidone therapy assuming that several factors may favor the increase in serum PRL. Risperidone 185-196 prolactin Homo sapiens 267-270 25514607-5 2015 The mean serum PRL was higher in females in the pubertal/postpubertal stage and for risperidone dosage up 1 mg/day. Risperidone 84-95 prolactin Homo sapiens 15-18 25514607-9 2015 This study suggests that the increase in serum PRL in patients treated with risperidone may be linked not only to the drug and its dosage but also to several risk factors such as sex, pubertal stage, psychiatric disease, and autoimmune disorders. Risperidone 76-87 prolactin Homo sapiens 47-50 25362934-4 2015 BC patients have higher levels of circulating thyroid-stimulating hormone (TSH) and prolactin (PRL), both regulated by the thyrotropin-releasing hormone (TRH), a hypothalamic tripeptide. tripeptide K-26 175-185 prolactin Homo sapiens 84-93 25717285-13 2015 Depletion of endogenous NR4A receptors with shRNA reduced basal and PGE2-induced PRL levels by 95%. Dinoprostone 68-72 prolactin Homo sapiens 81-84 25162753-4 2015 After stabilizing surgery, the patient responded to dopamine agonist therapy with normalization of serum prolactin levels and pronounced reduction in tumor volume. Dopamine 52-60 prolactin Homo sapiens 105-114 25352525-0 2015 Associations of acrylamide intake with circulating levels of sex hormones and prolactin in premenopausal Japanese women. Acrylamide 16-26 prolactin Homo sapiens 78-87 26587235-5 2015 The aripiprazole suppressed her prolactin levels for over 18 months of follow-up, even after the dose was lowered to 2 mg/day. Aripiprazole 4-16 prolactin Homo sapiens 32-41 26587235-7 2015 LEARNING POINTS: Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline. Dopamine 17-25 prolactin Homo sapiens 96-105 26587235-7 2015 LEARNING POINTS: Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline. Dopamine 17-25 prolactin Homo sapiens 332-341 26587235-7 2015 LEARNING POINTS: Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline. Cabergoline 43-54 prolactin Homo sapiens 96-105 26587235-7 2015 LEARNING POINTS: Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline. Cabergoline 43-54 prolactin Homo sapiens 332-341 26587235-7 2015 LEARNING POINTS: Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline. Aripiprazole 188-200 prolactin Homo sapiens 96-105 26587235-7 2015 LEARNING POINTS: Dopamine agonists such as cabergoline, which are a standard treatment for microprolactinomas, can have serious adverse effects such as psychosis or valvular heart disease.Aripiprazole is a well-tolerated atypical antipsychotic that, unlike other antipsychotics, is a partial dopamine agonist capable of suppressing prolactin levels.Adjunctive, low-dose aripiprazole has been utilized to reverse risperidone-induced hyperprolactinemia.This case report demonstrates how aripiprazole monotherapy, in doses ranging from 2 to 10 mg/day, was effective in suppressing prolactin in a woman with a microprolactinoma who developed psychiatric side effects from cabergoline. Aripiprazole 188-200 prolactin Homo sapiens 332-341 25222841-5 2015 All hyperprolactinemic patients were studied prior to and following the suppression of circulating PRL levels by cabergoline. Cabergoline 113-124 prolactin Homo sapiens 99-102 25222841-11 2015 In conclusion, this is a pilot study which shows for the first time that PRL increases the uterine, endometrial, and intraovarian vascular resistance and cabergoline reverses this effect. Cabergoline 154-165 prolactin Homo sapiens 73-76 26583155-5 2015 Furthermore, a small subset of women who were on DHEA therapy and had a TT genotype showed a significant decrease in prolactin gene expression and lower disease activity scores (SLEDAI). Dehydroepiandrosterone 49-53 prolactin Homo sapiens 117-126 25670946-1 2015 OBJECTIVE: The present cross-sectional study was designed to assess the risk of elevated prolactin levels and other hormonal or metabolic changes in children and adolescents taking risperidone. Risperidone 181-192 prolactin Homo sapiens 89-98 25670946-6 2015 The dosage of risperidone was positively correlated with serum prolactin level (r=0.767, p<0.001). Risperidone 14-25 prolactin Homo sapiens 63-72 25670946-8 2015 CONCLUSION: In young patients taking risperidone, a high serum prolactin level may influence lipid metabolism, even when cholesterol levels are within the normal range. Risperidone 37-48 prolactin Homo sapiens 63-72 25670946-8 2015 CONCLUSION: In young patients taking risperidone, a high serum prolactin level may influence lipid metabolism, even when cholesterol levels are within the normal range. Cholesterol 121-132 prolactin Homo sapiens 63-72 25670946-10 2015 Serum prolactin assessment is recommended for children and adolescents taking risperidone. Risperidone 78-89 prolactin Homo sapiens 6-15 25587116-6 2015 PRL also increased cAMP in A6 cells, consistent with signaling through the cAMP-dependent PKA pathway. Cyclic AMP 75-79 prolactin Homo sapiens 0-3 25587116-9 2015 Here, we show for the first time that PRL activates sodium and chloride transport in renal epithelial cells via ENaC and ClC4. Sodium 52-58 prolactin Homo sapiens 38-41 25587116-9 2015 Here, we show for the first time that PRL activates sodium and chloride transport in renal epithelial cells via ENaC and ClC4. Chlorides 63-71 prolactin Homo sapiens 38-41 25653528-2 2015 The main aim of this study was to investigate important clinical factors influencing the prolactin response in risperidone-treated Thai ASD. Risperidone 111-122 prolactin Homo sapiens 89-98 25653528-7 2015 Median prolactin level at the high doses (24.00, interquartile range [IQR] 14.30-29.20) of risperidone was significantly found to be higher than at the recommended (16.20, IQR 10.65-22.30) and low (11.70, IQR 7.51-16.50) doses of risperidone. Risperidone 91-102 prolactin Homo sapiens 7-16 25653528-7 2015 Median prolactin level at the high doses (24.00, interquartile range [IQR] 14.30-29.20) of risperidone was significantly found to be higher than at the recommended (16.20, IQR 10.65-22.30) and low (11.70, IQR 7.51-16.50) doses of risperidone. Risperidone 230-241 prolactin Homo sapiens 7-16 25653528-10 2015 This study suggests that risperidone treatment causes prolactin elevations and the effects of risperidone on prolactin are probably dose-related in pediatric patients. Risperidone 25-36 prolactin Homo sapiens 54-63 25653528-10 2015 This study suggests that risperidone treatment causes prolactin elevations and the effects of risperidone on prolactin are probably dose-related in pediatric patients. Risperidone 94-105 prolactin Homo sapiens 109-118 25472532-2 2015 PRL affects metabolic homeostasis by regulating key enzymes and transporters associated with glucose and lipid metabolism in several target organs. Glucose 93-100 prolactin Homo sapiens 0-3 25472532-3 2015 In the lactating mammary gland, PRL increases the production of milk proteins, lactose, and lipids. Lactose 79-86 prolactin Homo sapiens 32-35 25472536-0 2015 Tyrosyl phosphorylated serine-threonine kinase PAK1 is a novel regulator of prolactin-dependent breast cancer cell motility and invasion. cyclo(tyrosyl-tyrosyl) 0-7 prolactin Homo sapiens 76-85 25472536-4 2015 Tyrosyl phosphorylated PAK1 facilitates PRL-dependent motility via at least two mechanisms: formation of paxillin/GIT1/betaPIX/pTyr-PAK1 complexes resulting in increased adhesion turnover and phosphorylation of actin-binding protein filamin A. cyclo(tyrosyl-tyrosyl) 0-7 prolactin Homo sapiens 40-43 25472536-6 2015 Tyrosyl phosphorylated PAK1 also stimulates invasion of breast cancer cells in response to PRL and three-dimensional (3D) collagen IV via transcription and secretion of MMP-1 and MMP-3 in a MAPK-dependent manner. cyclo(tyrosyl-tyrosyl) 0-7 prolactin Homo sapiens 91-94 25074991-8 2015 Mean (SD) post-PEG percentage recovery of the IS 84/500 prolactin standard was 80 (2.3)%. Polyethylene Glycols 15-18 prolactin Homo sapiens 56-65 26753478-4 2015 RESULTS: They found a correlation between serum PRL concentration and result of M. Hamilton depression scale (R = 0.21; p = 0.005) and a between serum PRL concentration and serum 17beta-estradiol concentration (R = 0.21; p = 0.003). Estradiol 179-195 prolactin Homo sapiens 151-154 26299069-8 2015 Higher urine PRL levels were associated with lower glomerular filtration rates, higher serum creatinine, and higher urinary albumin-to-creatinine ratios (UACR). Creatinine 93-103 prolactin Homo sapiens 13-16 26299069-8 2015 Higher urine PRL levels were associated with lower glomerular filtration rates, higher serum creatinine, and higher urinary albumin-to-creatinine ratios (UACR). Creatinine 135-145 prolactin Homo sapiens 13-16 26299069-8 2015 Higher urine PRL levels were associated with lower glomerular filtration rates, higher serum creatinine, and higher urinary albumin-to-creatinine ratios (UACR). uacr 154-158 prolactin Homo sapiens 13-16 26406562-1 2015 The European Commission lists styrene (S) as an endocrine disruptor based primarily on reports of increased prolactin (PRL) levels in S-exposed workers. Styrene 30-37 prolactin Homo sapiens 119-122 25973434-2 2015 76 pregnant SLE patients were enrolled in this study to evaluate the efficacy of bromocriptine (an inhibitor of prolactin secretion) on preventing the postpartum disease relapse. Bromocriptine 81-94 prolactin Homo sapiens 112-121 25973434-8 2015 RESULTS: (1) Serum levels of prolactin and estradiol decreased significantly in bromocriptine treatment group at the second week (P < 0.001) and second month (P < 0.05) after delivery compared to control group. Bromocriptine 80-93 prolactin Homo sapiens 29-38 27344867-15 2015 The administration of cabergoline to patients with macroprolactinoma is effective in reaching PRL level normalisation as well as in tumour size reduction. Cabergoline 22-33 prolactin Homo sapiens 94-97 24711223-12 2014 Cabergoline normalized/near-normalized PRL in eleven women; one woman was dopamine agonist-resistant. Cabergoline 0-11 prolactin Homo sapiens 39-42 25461348-1 2014 Macroprolactin is an antigen-antibody complex of higher molecular mass than prolactin (>150kDa), consisting of monomeric prolactin and immunoglobulin G. The term "macroprolactinemia" is used when the concentration of macroprolactin exceeds 60% of the total serum prolactin concentration determined by polyethylene glycol precipitation. Polyethylene Glycols 304-323 prolactin Homo sapiens 5-14 25230324-0 2014 Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Cabergoline 30-41 prolactin Homo sapiens 6-15 25230324-0 2014 Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Cabergoline 30-41 prolactin Homo sapiens 89-98 25230324-1 2014 Dopamine agonists are considered as the first line therapy in prolactin (PRL) secreting pituitary adenomas inducing a normalization of serum PRL and reduction of tumor size. Dopamine 0-8 prolactin Homo sapiens 62-71 25230324-1 2014 Dopamine agonists are considered as the first line therapy in prolactin (PRL) secreting pituitary adenomas inducing a normalization of serum PRL and reduction of tumor size. Dopamine 0-8 prolactin Homo sapiens 73-76 25230324-1 2014 Dopamine agonists are considered as the first line therapy in prolactin (PRL) secreting pituitary adenomas inducing a normalization of serum PRL and reduction of tumor size. Dopamine 0-8 prolactin Homo sapiens 141-144 25230324-10 2014 Cabergoline therapy with the goal of achieving PRL levels below the lower limit of normal range can increase the chance to obtain tumor shrinkage of PRL-secreting pituitary adenomas. Cabergoline 0-11 prolactin Homo sapiens 47-50 25230324-10 2014 Cabergoline therapy with the goal of achieving PRL levels below the lower limit of normal range can increase the chance to obtain tumor shrinkage of PRL-secreting pituitary adenomas. Cabergoline 0-11 prolactin Homo sapiens 149-152 24337778-0 2014 Prolactin levels in manganese-exposed male welders. Manganese 20-29 prolactin Homo sapiens 0-9 25279148-9 2014 SU11274 (30 muM) decreased the expression levels of cyclin D1 in HLF and PLC/PRL/5 cells to 45.1+-11.6 and 30.1+-10.3%, respectively. ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) 0-7 prolactin Homo sapiens 77-80 25279148-10 2014 SU11274, at a concentration of 30 muM damaged the morphology of the co-cultures of HLF or PLC/PRL/5 cells with HUVECs and all the cells died. ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) 0-7 prolactin Homo sapiens 94-97 25279148-13 2014 SU11274 (30 muM) damages the co-cultures of HLF or PLC/PRL/5 cells with HUVECs. ((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) 0-7 prolactin Homo sapiens 55-58 25253414-6 2014 After oral administration of 2.5 mg of bromocriptine, serum GH levels were unexpectedly increased from 30.7 ng/mL to 189 ng/mL, despite the fact that the levels of prolactin (PRL) were decreased from 4.2 ng/mL to 0.6 ng/mL. Bromocriptine 39-52 prolactin Homo sapiens 164-173 25397403-8 2014 In contrast, treatment of HDSC with a chemical Notch/gamma-secretase inhibitor decreased cAMP/E2P4-stimulated Notch luciferase activity, HES1 transcript levels and mRNA expression of the decidual marker genes prolactin (PRL) and insulin-like growth factor binding protein 1 (IGFBP1). Cyclic AMP 89-93 prolactin Homo sapiens 209-218 25397403-8 2014 In contrast, treatment of HDSC with a chemical Notch/gamma-secretase inhibitor decreased cAMP/E2P4-stimulated Notch luciferase activity, HES1 transcript levels and mRNA expression of the decidual marker genes prolactin (PRL) and insulin-like growth factor binding protein 1 (IGFBP1). Cyclic AMP 89-93 prolactin Homo sapiens 220-223 24337778-2 2014 Dopamine serves as a tonic inhibitor of prolactin release in the anterior hypophysis. Dopamine 0-8 prolactin Homo sapiens 40-49 24337778-3 2014 Our aim was to determine the relation between serum prolactin levels and manganese-exposure. Manganese 73-82 prolactin Homo sapiens 52-61 24337778-10 2014 There was a significantly positive correlation between whole blood manganese levels and serum prolactin (r = 0.860, p < 0.001). Manganese 67-76 prolactin Homo sapiens 94-103 24337778-12 2014 CONCLUSIONS: Serum prolactin level is a diagnostic marker for determining the effect of manganese-exposure. Manganese 88-97 prolactin Homo sapiens 19-28 24718588-11 2014 CONCLUSIONS: there was a positive association between prolactin levels and the SDI (overall and its renal and cardiac/peripheral vascular domains), independently of other well-known risk factors. sdi 79-82 prolactin Homo sapiens 54-63 25063756-4 2014 Recipient mice expressing Del1-9-G129R-hPRL exhibited a decrease in plasma cholesterol levels (-29%; P<0.05) upon feeding a Western-type diet (WTD), which could be attributed to a marked decrease (-47%; P<0.01) in the amount of cholesterol esters associated with pro-atherogenic lipoproteins VLDL/LDL. Cholesterol 75-86 prolactin Homo sapiens 39-43 25063756-4 2014 Recipient mice expressing Del1-9-G129R-hPRL exhibited a decrease in plasma cholesterol levels (-29%; P<0.05) upon feeding a Western-type diet (WTD), which could be attributed to a marked decrease (-47%; P<0.01) in the amount of cholesterol esters associated with pro-atherogenic lipoproteins VLDL/LDL. Cholesterol Esters 234-252 prolactin Homo sapiens 39-43 25247425-5 2014 Several studies have demonstrated that prolactin (PRL) may be differently affected by inorganic and organic mercury based on interference with various neurotransmitters involved in the regulation of PRL secretion. Mercury 108-115 prolactin Homo sapiens 39-48 25247425-5 2014 Several studies have demonstrated that prolactin (PRL) may be differently affected by inorganic and organic mercury based on interference with various neurotransmitters involved in the regulation of PRL secretion. Mercury 108-115 prolactin Homo sapiens 50-53 25247425-5 2014 Several studies have demonstrated that prolactin (PRL) may be differently affected by inorganic and organic mercury based on interference with various neurotransmitters involved in the regulation of PRL secretion. Mercury 108-115 prolactin Homo sapiens 199-202 25187719-2 2014 Earlier studies have indicated that terguride, which is a partial dopamine agonist, reduces the prolactin levels that are induced by prolactinemia. dironyl 36-45 prolactin Homo sapiens 96-105 24952131-0 2014 Suppression of prolactin signaling by pyrrolidine dithiocarbamate is alleviated by N-acetylcysteine in mammary epithelial cells. pyrrolidine dithiocarbamic acid 38-65 prolactin Homo sapiens 15-24 24952131-0 2014 Suppression of prolactin signaling by pyrrolidine dithiocarbamate is alleviated by N-acetylcysteine in mammary epithelial cells. Acetylcysteine 83-99 prolactin Homo sapiens 15-24 24952131-3 2014 Here we examined the effect of pyrrolidine dithiocarbamate (PDTC) on prolactin signaling. pyrrolidine dithiocarbamic acid 31-58 prolactin Homo sapiens 69-78 24952131-3 2014 Here we examined the effect of pyrrolidine dithiocarbamate (PDTC) on prolactin signaling. pyrrolidine dithiocarbamic acid 60-64 prolactin Homo sapiens 69-78 24952131-4 2014 Our results show that PDTC downregulates prolactin receptor levels, and inhibits prolactin-induced Stat5 tyrosine phosphorylation and beta-casein expression. Tyrosine 105-113 prolactin Homo sapiens 81-90 24952131-6 2014 Instead, the pro-oxidant activity of PDTC is involved as inclusion of the antioxidant N-acetylcysteine restores prolactin signaling. Acetylcysteine 86-102 prolactin Homo sapiens 112-121 25187719-2 2014 Earlier studies have indicated that terguride, which is a partial dopamine agonist, reduces the prolactin levels that are induced by prolactinemia. Dopamine 66-74 prolactin Homo sapiens 96-105 25187719-3 2014 Thus, we examined the dose effects of adjunctive treatment with terguride on the plasma concentrations of prolactin in patients with elevated prolactin levels resulting from antipsychotic treatment. dironyl 64-73 prolactin Homo sapiens 106-115 25187719-3 2014 Thus, we examined the dose effects of adjunctive treatment with terguride on the plasma concentrations of prolactin in patients with elevated prolactin levels resulting from antipsychotic treatment. dironyl 64-73 prolactin Homo sapiens 142-151 25187719-8 2014 The average (+- standard deviation) plasma prolactin concentration during terguride coadministration was significantly lower than the baseline concentration in females (82.3+-37.1 ng/mL versus 56.5+-28.5 ng/mL, P<0.01) but not in males (28.8+-18.0 ng/mL versus 26.2+-13.1 ng/mL, not significant). dironyl 74-83 prolactin Homo sapiens 43-52 25187719-11 2014 This study suggests that additional treatment with terguride decreases the prolactin concentrations in females experiencing high prolactin levels as a result of antipsychotic treatment. dironyl 51-60 prolactin Homo sapiens 75-84 25187719-11 2014 This study suggests that additional treatment with terguride decreases the prolactin concentrations in females experiencing high prolactin levels as a result of antipsychotic treatment. dironyl 51-60 prolactin Homo sapiens 129-138 24903198-9 2014 Macroprolactinemia was excluded by the precipitation of serum with polyethylene glycol in patients with increased prolactin levels. Polyethylene Glycols 67-86 prolactin Homo sapiens 5-14 24903198-13 2014 In the patient population prolactin levels were inversely associated with age, smoking status, waist circumference, total cholesterol, triglyceride and low-density lipoprotein (LDL) and positively associated with high-density lipoprotein, estradiol, total testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone and cortisol levels. Cholesterol 122-133 prolactin Homo sapiens 26-35 24903198-13 2014 In the patient population prolactin levels were inversely associated with age, smoking status, waist circumference, total cholesterol, triglyceride and low-density lipoprotein (LDL) and positively associated with high-density lipoprotein, estradiol, total testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone and cortisol levels. Triglycerides 135-147 prolactin Homo sapiens 26-35 24903198-13 2014 In the patient population prolactin levels were inversely associated with age, smoking status, waist circumference, total cholesterol, triglyceride and low-density lipoprotein (LDL) and positively associated with high-density lipoprotein, estradiol, total testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone and cortisol levels. Estradiol 239-248 prolactin Homo sapiens 26-35 24903198-13 2014 In the patient population prolactin levels were inversely associated with age, smoking status, waist circumference, total cholesterol, triglyceride and low-density lipoprotein (LDL) and positively associated with high-density lipoprotein, estradiol, total testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone and cortisol levels. Testosterone 256-268 prolactin Homo sapiens 26-35 24903198-13 2014 In the patient population prolactin levels were inversely associated with age, smoking status, waist circumference, total cholesterol, triglyceride and low-density lipoprotein (LDL) and positively associated with high-density lipoprotein, estradiol, total testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone and cortisol levels. Dehydroepiandrosterone Sulfate 270-300 prolactin Homo sapiens 26-35 24903198-13 2014 In the patient population prolactin levels were inversely associated with age, smoking status, waist circumference, total cholesterol, triglyceride and low-density lipoprotein (LDL) and positively associated with high-density lipoprotein, estradiol, total testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone and cortisol levels. 17-alpha-Hydroxyprogesterone 302-324 prolactin Homo sapiens 26-35 24903198-13 2014 In the patient population prolactin levels were inversely associated with age, smoking status, waist circumference, total cholesterol, triglyceride and low-density lipoprotein (LDL) and positively associated with high-density lipoprotein, estradiol, total testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone and cortisol levels. Hydrocortisone 329-337 prolactin Homo sapiens 26-35 24903198-14 2014 In multiple regression analyses, prolactin was inversely associated with LDL and positively associated with estradiol, 17-hydroxyprogesterone and cortisol after correcting for age, BMI and smoking status in patients with PCOS. Estradiol 108-117 prolactin Homo sapiens 33-42 24903198-14 2014 In multiple regression analyses, prolactin was inversely associated with LDL and positively associated with estradiol, 17-hydroxyprogesterone and cortisol after correcting for age, BMI and smoking status in patients with PCOS. 17-alpha-Hydroxyprogesterone 119-141 prolactin Homo sapiens 33-42 24903198-14 2014 In multiple regression analyses, prolactin was inversely associated with LDL and positively associated with estradiol, 17-hydroxyprogesterone and cortisol after correcting for age, BMI and smoking status in patients with PCOS. Hydrocortisone 146-154 prolactin Homo sapiens 33-42 24911440-0 2014 Prolactin deficiency by aripiprazole. Aripiprazole 24-36 prolactin Homo sapiens 0-9 25083394-6 2014 One month after administration of cabergoline, the diplopia was improved to some extent and serum prolactin was decreased to 290 ng/ml. Cabergoline 34-45 prolactin Homo sapiens 98-107 24888527-6 2014 Moreover, prolactin was negatively correlated with estradiol and testosterone in the group of all male subjects and the male patients. Estradiol 51-60 prolactin Homo sapiens 10-19 24888527-6 2014 Moreover, prolactin was negatively correlated with estradiol and testosterone in the group of all male subjects and the male patients. Testosterone 65-77 prolactin Homo sapiens 10-19 25092954-0 2014 Randomized controlled trial comparing changes in serum prolactin and weight among female patients with first-episode schizophrenia over 12 months of treatment with risperidone or quetiapine. Quetiapine Fumarate 179-189 prolactin Homo sapiens 55-64 24094029-2 2014 Increased serum prolactin level is frequently associated with dopamine blocking antipsychotics. Dopamine 62-70 prolactin Homo sapiens 16-25 24094029-5 2014 AIMS: We purpose to investigate serum baseline prolactin levels in drug-naive first-episode patients with schizophrenia (FES) and to explore the differences in serum prolactin levels between FES, drug-free schizophrenic patients (DFS) and healthy controls (HC). fes 121-124 prolactin Homo sapiens 47-56 24094029-13 2014 The mean value of prolactin was higher in the FES group (34.1 +- 19.9 ng/dl) compared with DFS (17.9 +- 6.5 ng/dl) and HC (9.7 +- 2.3 ng/dl) (F = 35.5, P < 0.001). fes 46-49 prolactin Homo sapiens 18-27 25016269-8 2014 Additionally, the postoperative PRL normalization rate was lower in patients with LI>3% compared with patients with LI<3% (p=0.028). li> 82-87 prolactin Homo sapiens 32-35 25016269-8 2014 Additionally, the postoperative PRL normalization rate was lower in patients with LI>3% compared with patients with LI<3% (p=0.028). li< 119-124 prolactin Homo sapiens 32-35 24913037-13 2014 In T47D cells, PRL down-regulated LKB1 transcriptional activity, an effect that was reversed upon culture in phenol red-free media. Phenolsulfonphthalein 109-119 prolactin Homo sapiens 15-18 23756783-10 2014 Serum prolactin was positively correlated with triglycerides, apoB/apoA-I ratio, hypogonadal, hsCRP and fibrinogen (P < 0.05), but inversely associated with apoA-I and HDL-C (P <= 0.001). Triglycerides 47-60 prolactin Homo sapiens 6-15 24677189-8 2014 Although the highest rates of HPRL are consistently reported in association with amisulpride, risperidone and paliperidone, while aripiprazole and quetiapine have the most favorable profile with respect to this outcome, all SGAs can induce PRL elevations, especially at the beginning of treatment, and have the potential to cause new-onset HPRL. Amisulpride 81-92 prolactin Homo sapiens 31-34 24677189-8 2014 Although the highest rates of HPRL are consistently reported in association with amisulpride, risperidone and paliperidone, while aripiprazole and quetiapine have the most favorable profile with respect to this outcome, all SGAs can induce PRL elevations, especially at the beginning of treatment, and have the potential to cause new-onset HPRL. Risperidone 94-105 prolactin Homo sapiens 31-34 24677189-8 2014 Although the highest rates of HPRL are consistently reported in association with amisulpride, risperidone and paliperidone, while aripiprazole and quetiapine have the most favorable profile with respect to this outcome, all SGAs can induce PRL elevations, especially at the beginning of treatment, and have the potential to cause new-onset HPRL. Paliperidone Palmitate 110-122 prolactin Homo sapiens 31-34 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Amisulpride 67-78 prolactin Homo sapiens 52-55 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Amisulpride 67-78 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Amisulpride 67-78 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Amisulpride 67-78 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Risperidone 80-91 prolactin Homo sapiens 52-55 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Risperidone 80-91 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Risperidone 80-91 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Risperidone 80-91 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Paliperidone Palmitate 96-108 prolactin Homo sapiens 52-55 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Paliperidone Palmitate 96-108 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Paliperidone Palmitate 96-108 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Paliperidone Palmitate 96-108 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Quetiapine Fumarate 287-297 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Quetiapine Fumarate 287-297 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Quetiapine Fumarate 287-297 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Aripiprazole 310-322 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Aripiprazole 310-322 prolactin Homo sapiens 140-143 24677189-11 2014 However, antipsychotics having a high potential for PRL elevation (amisulpride, risperidone and paliperidone) can have a profound impact on PRL levels even at relatively low doses, while PRL levels with antipsychotics having a minimal effect on PRL, in most cases, can remain unchanged (quetiapine) or reduce (aripiprazole) over all dosages. Aripiprazole 310-322 prolactin Homo sapiens 140-143 24697217-2 2014 AREAS COVERED: The aim of this review is to describe the PRL propensity of the different second-generation and newly approved APs. Adenosine Phosphosulfate 126-129 prolactin Homo sapiens 57-60 24697217-4 2014 Furthermore, we address the lingering question regarding the association between SDs and PRL. Sodium Dodecyl Sulfate 81-84 prolactin Homo sapiens 89-92 24697217-8 2014 This makes it difficult to assess the degree to which these side effects are associated with "PRL-raising" APs, and what part of this fraction is directly reducible to serum PRL levels. Adenosine Phosphosulfate 107-110 prolactin Homo sapiens 94-97 24697217-10 2014 Therefore, longer-term randomized controlled trials, using reliable and valid structured interviews or questionnaires, are necessary to establish the precise relationship between APs, PRL levels and SDs rates and develop valuable treatment options. Sodium Dodecyl Sulfate 199-202 prolactin Homo sapiens 184-187 25223176-8 2014 Only the PRL level was higher in the GYDS group than in the non-GYDS group (P < 0.01). gyds 37-41 prolactin Homo sapiens 9-12 25223176-8 2014 Only the PRL level was higher in the GYDS group than in the non-GYDS group (P < 0.01). gyds 64-68 prolactin Homo sapiens 9-12 24094029-14 2014 Additionally, the mean value of serum prolactin is higher in the DFS group compared with HC (P < 0.001). dfs 65-68 prolactin Homo sapiens 38-47 24677189-3 2014 Moreover, at this moment, no review has been published about the effect of the newly approved antipsychotics asenapine, iloperidone and lurasidone on PRL levels. asenapine 109-118 prolactin Homo sapiens 150-153 24677189-3 2014 Moreover, at this moment, no review has been published about the effect of the newly approved antipsychotics asenapine, iloperidone and lurasidone on PRL levels. iloperidone 120-131 prolactin Homo sapiens 150-153 24677189-3 2014 Moreover, at this moment, no review has been published about the effect of the newly approved antipsychotics asenapine, iloperidone and lurasidone on PRL levels. Lurasidone Hydrochloride 136-146 prolactin Homo sapiens 150-153 24533748-6 2014 In case of coexistence of macroprolactinaemia and raised free PRL after PEG precipitation of macroprolactin, the chance of finding of either a micro- or a macroadenoma was 36% (13 cases out of 36). Polyethylene Glycols 72-75 prolactin Homo sapiens 62-65 24533748-8 2014 Furthermore, if free PRL is raised after PEG precipitation of macroprolactin, then the chance of finding either a pituitary micro- or macroadenoma in women with oligo-/amenorrhoea is over 30%. Polyethylene Glycols 41-44 prolactin Homo sapiens 21-24 24615730-10 2014 T and PRL acted synergistically to increase NO production, which was abolished only when receptor antagonists flutamide and Delta1-9-G129R-hPRL were used together. Flutamide 110-119 prolactin Homo sapiens 6-9 24615730-13 2014 Our study implicates a critical role for the T/PRL-stimulated CPD-Arg-NO pathway in pCa progression, and suggests that AR+PRLR inhibition is a more effective treatment for pCa. Arginine 66-69 prolactin Homo sapiens 47-50 24776630-6 2014 Treatment with cabergoline was initiated resulting in improvement in visual fields, tumor shrinkage and prolactin level decrease. Cabergoline 15-26 prolactin Homo sapiens 104-113 25092954-2 2014 AIM: Compare the effects of risperidone and quetiapine on serum prolactin and weight over 12 months of treatment among female patients with first-episode schizophrenia. Risperidone 28-39 prolactin Homo sapiens 64-73 25092954-2 2014 AIM: Compare the effects of risperidone and quetiapine on serum prolactin and weight over 12 months of treatment among female patients with first-episode schizophrenia. Quetiapine Fumarate 44-54 prolactin Homo sapiens 64-73 25092954-8 2014 In the quetiapine group serum prolactin remained stable throughout the 12 months but in the risperidone group the serum prolactin level increased 3.5- to 5.2-fold over the one-year follow-up. Risperidone 92-103 prolactin Homo sapiens 120-129 25092954-11 2014 The correlation between changes in weight and changes in prolactin levels were weakly positive: rs=0.17(p=0.104) in the risperidone group and r=0.07 (p=0.862) in the quetiapine group. Risperidone 120-131 prolactin Homo sapiens 57-66 25092954-11 2014 The correlation between changes in weight and changes in prolactin levels were weakly positive: rs=0.17(p=0.104) in the risperidone group and r=0.07 (p=0.862) in the quetiapine group. Quetiapine Fumarate 166-176 prolactin Homo sapiens 57-66 24264376-6 2014 Prolactin, which stimulates the transcription of casein genes, also induces the production of arachidonic acid, leading to accelerated casein transport and/or secretion. Arachidonic Acid 94-110 prolactin Homo sapiens 0-9 24264376-8 2014 As SNAREs can bind arachidonic acid, they could be the effectors of the secretagogue effect of prolactin in MESCs. Arachidonic Acid 19-35 prolactin Homo sapiens 95-104 24405794-9 2014 However, aripiprazole improved serum prolactin level in some participants and overall did not show any adverse effect on QTc interval. Aripiprazole 9-21 prolactin Homo sapiens 37-46 24782376-1 2014 OBJECTIVE: To establish a polyethylene glycol (PEG6000) precipitation method for screening macroprolactinemia in patients with high serum prolactin (PRL). Polyethylene Glycols 26-45 prolactin Homo sapiens 96-105 24361460-7 2014 CONCLUSIONS: In this study, we show that rodent and human macrophages synthesize prolactin in response to inflammation and high glucose concentrations. Glucose 128-135 prolactin Homo sapiens 81-90 24782376-1 2014 OBJECTIVE: To establish a polyethylene glycol (PEG6000) precipitation method for screening macroprolactinemia in patients with high serum prolactin (PRL). Polyethylene Glycol 6000 47-54 prolactin Homo sapiens 96-105 24169561-8 2014 Knock-down of CRT expression in cultured ESCs significantly inhibited PKA-selective cAMP analog- or PKA-selective cAMP analog plus EPAC-selective cAMP analog-induced PRL and IGFBP1 expression. epac 131-135 prolactin Homo sapiens 166-169 24586772-10 2014 A mediation analysis showed that both prolactin and benzodiazepine treatment act as mediators of the relationship between risperidone/paliperidone treatment and speed of processing. Risperidone 122-133 prolactin Homo sapiens 38-47 24586772-10 2014 A mediation analysis showed that both prolactin and benzodiazepine treatment act as mediators of the relationship between risperidone/paliperidone treatment and speed of processing. Paliperidone Palmitate 134-146 prolactin Homo sapiens 38-47 23836327-2 2014 Bromocriptine inhibits prolactin secretion, and patients with hyperprolactinaemia display impaired insulin sensitivity. Bromocriptine 0-13 prolactin Homo sapiens 23-32 23836327-9 2014 Glycated haemoglobin (HbA1c) and AUC(0-120)Glucose correlated negatively with prolactin, and an interaction with age was found as well. Glucose 43-50 prolactin Homo sapiens 78-87 23836327-10 2014 Higher prolactin levels are associated with improved insulin sensitivity and lower glucose in individuals without diabetes. Glucose 83-90 prolactin Homo sapiens 7-16 23928066-6 2014 Antipsychotic-drugs block these receptors and thus remove the inhibitory effect of dopamine on prolactin secretion. Dopamine 83-91 prolactin Homo sapiens 95-104 24248464-0 2014 Importance of C/EBPbeta binding and histone acetylation status in the promoter regions for induction of IGFBP-1, PRL, and Mn-SOD by cAMP in human endometrial stromal cells. Cyclic AMP 132-136 prolactin Homo sapiens 113-116 24169561-9 2014 Furthermore, CRT knock-down suppressed the ovarian steroid-stimulated PRL and IGFBP1 expression and morphological differentiation, and silencing of EPAC2 or CRT significantly increased senescence-associated beta-galactosidase activity with enhanced p21 expression and decreased p53 expression. Steroids 51-58 prolactin Homo sapiens 70-73 24248464-4 2014 This study investigated the molecular and epigenetic mechanisms by which cAMP up-regulates the expression of IGF-binding protein-1 (IGFBP-1), prolactin (PRL), and manganese superoxide dismutase (Mn-SOD) in ESC. Cyclic AMP 73-77 prolactin Homo sapiens 142-151 24035672-0 2014 Prolactin response to buspirone is not impaired in drug-naive first episode patients with major depressive disorder. Buspirone 22-31 prolactin Homo sapiens 0-9 24248464-4 2014 This study investigated the molecular and epigenetic mechanisms by which cAMP up-regulates the expression of IGF-binding protein-1 (IGFBP-1), prolactin (PRL), and manganese superoxide dismutase (Mn-SOD) in ESC. Cyclic AMP 73-77 prolactin Homo sapiens 153-156 24248464-9 2014 cAMP induced mRNA expressions of IGFBP-1 and PRL accompanied by the increases in both C/EBPbeta binding activities and H3K27ac levels in the promoters. Cyclic AMP 0-4 prolactin Homo sapiens 45-48 25248588-4 2014 In general, cabergoline is the preferred treatment for micro- and macroprolactinomas, because it is more effective with respect to normalization of prolactin levels and reduction of prolactinoma size and because it has fewer side-effects compared to bromocriptine. Cabergoline 12-23 prolactin Homo sapiens 71-80 25248588-5 2014 Recently, it has been suggested that a standardized, individualized, stepwise, dose-escalating regimen of cabergoline may normalize prolactin levels and reduce prolactinoma size in patients who were otherwise considered to be dopamine agonist resistant. Cabergoline 106-117 prolactin Homo sapiens 132-141 24035672-4 2014 METHODS: This cross-sectional case-control pharmacologic challenge study was designed to investigate the prolactin (PRL) response to buspirone in 21 non-late-life adult, treatment-naive MDD patients with the first affective episode and in 20 age- and sex-matched healthy controls. Buspirone 133-142 prolactin Homo sapiens 105-114 24035672-4 2014 METHODS: This cross-sectional case-control pharmacologic challenge study was designed to investigate the prolactin (PRL) response to buspirone in 21 non-late-life adult, treatment-naive MDD patients with the first affective episode and in 20 age- and sex-matched healthy controls. Buspirone 133-142 prolactin Homo sapiens 116-119 24035672-8 2014 The significantly higher PRL response to buspirone was observed in melancholic patients as compared to non-melancholic subjects. Buspirone 41-50 prolactin Homo sapiens 25-28 23945126-3 2014 Cabergoline leads to significant reduction in serum prolactin levels and tumor size in patients with prolactinoma. Cabergoline 0-11 prolactin Homo sapiens 52-61 23506485-0 2013 Higher doses of cabergoline further improve metabolic parameters in patients with prolactinoma regardless of the degree of reduction in prolactin levels. Cabergoline 16-27 prolactin Homo sapiens 82-91 24625910-9 2014 At week 8, the mean serum prolactin level was markedly higher in risperidone patients. Risperidone 65-76 prolactin Homo sapiens 26-35 23397510-5 2013 The purposes of this work were to assess prolactin levels in broader age adults homozygous and heterozygous (MUT/N) for the mutation and in normal controls (N/N), and to correlate them to sex steroids levels. Steroids 192-200 prolactin Homo sapiens 41-50 23973924-3 2013 In addition, the role of 17beta-estradiol as a possible modulator of LPS-induced PRL cell proliferation was further investigated. Estradiol 25-41 prolactin Homo sapiens 81-84 23973924-10 2013 The TLR4/PRL and PRL/NF-kappaB co-localization was also corroborated by immunofluorescence and the involvement of PI3K/Akt signaling in lactotroph proliferation and IL-6 release was revealed through the PI3K inhibitor Ly-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 218-227 prolactin Homo sapiens 9-12 23973924-10 2013 The TLR4/PRL and PRL/NF-kappaB co-localization was also corroborated by immunofluorescence and the involvement of PI3K/Akt signaling in lactotroph proliferation and IL-6 release was revealed through the PI3K inhibitor Ly-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 218-227 prolactin Homo sapiens 17-20 23933342-9 2013 PRL positively correlated with sperm concentration (p = 0.019), TMC (p < 0.001), TNC (p = 0.003), and TMNC (p < 0.001). tmc 64-67 prolactin Homo sapiens 0-3 23938015-3 2013 The bioactive testosterone/luteinizing hormone ratio and the prolactin level were significantly elevated in the VPA treatment group. Valproic Acid 112-115 prolactin Homo sapiens 61-70 24148306-5 2013 Treatment with PRL (200 ng/ml) increased cell proliferation in HeLa cells determined by the MTT assay at day 3 and after 1 day a protective effect against etoposide induced apoptosis in HeLa, SiHa and C-33A cervical cancer cell lines analyzed by the TUNEL assay. monooxyethylene trimethylolpropane tristearate 92-95 prolactin Homo sapiens 15-18 24148306-5 2013 Treatment with PRL (200 ng/ml) increased cell proliferation in HeLa cells determined by the MTT assay at day 3 and after 1 day a protective effect against etoposide induced apoptosis in HeLa, SiHa and C-33A cervical cancer cell lines analyzed by the TUNEL assay. Etoposide 155-164 prolactin Homo sapiens 15-18 24052061-3 2013 This is the first report to measure serum prolactin levels in an olanzapine-overdosed toddler and the second to calculate olanzapine"s elimination half-life. Olanzapine 65-75 prolactin Homo sapiens 42-51 23325368-0 2013 The 5-HT1D/1B receptor agonist sumatriptan enhances fear of simulated speaking and reduces plasma levels of prolactin. Sumatriptan 31-42 prolactin Homo sapiens 108-117 23325368-6 2013 Sumatriptan decreased plasma levels of prolactin. Sumatriptan 0-11 prolactin Homo sapiens 39-48 23590895-9 2013 As enhanced prolactin can increase dopamine release through a feedback mechanism, this could contribute to explaining how stress can trigger the outbreak of psychosis. Dopamine 35-43 prolactin Homo sapiens 12-21 24088550-13 2014 Eighteen patients were treated with cabergoline; standard doses (<2.0 mg/week) were able to normalise prolactin in only 4/18 patients, and 7/18 patients were resistant to weekly doses ranging from 3.0 to 7.0 mg. Cabergoline 36-47 prolactin Homo sapiens 105-114 24236210-0 2013 Cadmium mimics estrogen-driven cell proliferation and prolactin secretion from anterior pituitary cells. Cadmium 0-7 prolactin Homo sapiens 54-63 24236210-4 2013 The aim of this work was to examine whether Cd at nanomolar concentrations can induce cell proliferation and prolactin release in anterior pituitary cells in culture and whether these effects are mediated through ERs. Cadmium 44-46 prolactin Homo sapiens 109-118 24236210-8 2013 Cd enhanced prolactin synthesis and secretion. Cadmium 0-2 prolactin Homo sapiens 12-21 24236210-12 2013 This study shows for the first time that Cd at nanomolar concentration displays xenoestrogenic activities by inducing cell growth and stimulating prolactin secretion from anterior pituitary cells in an ERs-dependent manner. Cadmium 41-43 prolactin Homo sapiens 146-155 24201238-10 2013 CONCLUSIONS: Switching to blonanserin can reverse medication-induced prolactin elevations found in female patients- and blonanserin is a suitable antipsychotic for schizophrenic patients. blonanserin 26-37 prolactin Homo sapiens 69-78 24109443-10 2013 Prolactin levels increased in the naltrexone group, but did not differ between haloperidol and placebo, implying that naltrexone but not haloperidol may have been functionally active at these doses. Naltrexone 34-44 prolactin Homo sapiens 0-9 24109443-10 2013 Prolactin levels increased in the naltrexone group, but did not differ between haloperidol and placebo, implying that naltrexone but not haloperidol may have been functionally active at these doses. Naltrexone 118-128 prolactin Homo sapiens 0-9 24251133-6 2013 Revaluation at 10 months of cabergoline therapy revealed normal serum prolactin (14 ng/ml), normal pituitary function, with 91% decrease in adenoma size (11.5 x 13.6 x 12.7 mm). Cabergoline 28-39 prolactin Homo sapiens 70-79 24251133-7 2013 Evaluation at 36 months of cabergoline therapy for growth arrest and weight gain for past 6 months revealed low serum prolactin, growth hormone deficiency, and secondary hypothyroidism with empty sella. Cabergoline 27-38 prolactin Homo sapiens 118-127 23868656-2 2013 The objective of this analysis was to report the results of a population pharmacokinetic analysis and to describe the relationship between risperidone and 9-hydroxyrisperidone levels with dopamine (DA) D2-receptor occupancy, prolactin levels, and adverse events using data collected in 45 clinically stable schizophrenic patients receiving RBP-7000 in single ascending doses (risperidone) of 60, 90, and 120 mg. Risperidone 139-150 prolactin Homo sapiens 225-234 23868656-2 2013 The objective of this analysis was to report the results of a population pharmacokinetic analysis and to describe the relationship between risperidone and 9-hydroxyrisperidone levels with dopamine (DA) D2-receptor occupancy, prolactin levels, and adverse events using data collected in 45 clinically stable schizophrenic patients receiving RBP-7000 in single ascending doses (risperidone) of 60, 90, and 120 mg. Dopamine 188-196 prolactin Homo sapiens 225-234 24218952-6 2013 The serum prolactin levels were significantly decreased in the trial and control groups ([152.00 +/- 22.32] and [160.45 +/- 26.65] mIU/L), as compared with premedication ([482.25 +/- 65.32] and [477.32 +/- 60.25] mIU/L) (P<0.01), while the serum testosterone levels were remarkably higher ([16.35 +/- 5.52] and [11.15 +/- 4.65] nmol/L) than before treatment ([3.75 +/- 1.10] and [4.05 +/- 1.30] nmol/L) (P<0.01). Testosterone 249-261 prolactin Homo sapiens 10-19 24086495-11 2013 Treatment with the ERK1/2 inhibitor, U0126, significantly decreased the expression of the known decidualization marker genes, IGFBP1 and PRL as well as inhibited the induction of known ERK1/2 target genes; FOS, MSK1, STAT1, and STAT3. U 0126 37-42 prolactin Homo sapiens 137-140 23851570-5 2013 RESULTS: Prolactin levels were associated positively and significantly with risperidone levels (P=0.05), 9-hydroxyrisperidone levels (P<=0.0001), and with the oral risperidone dose in milligrams per kilogram (P<=0.0001). Risperidone 76-87 prolactin Homo sapiens 9-18 23851570-5 2013 RESULTS: Prolactin levels were associated positively and significantly with risperidone levels (P=0.05), 9-hydroxyrisperidone levels (P<=0.0001), and with the oral risperidone dose in milligrams per kilogram (P<=0.0001). Paliperidone Palmitate 105-125 prolactin Homo sapiens 9-18 23851570-5 2013 RESULTS: Prolactin levels were associated positively and significantly with risperidone levels (P=0.05), 9-hydroxyrisperidone levels (P<=0.0001), and with the oral risperidone dose in milligrams per kilogram (P<=0.0001). Risperidone 114-125 prolactin Homo sapiens 9-18 23968123-0 2013 Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). daamsel 97-104 prolactin Homo sapiens 26-35 23968123-0 2013 Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). Dopamine 121-129 prolactin Homo sapiens 26-35 23968123-0 2013 Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). Aripiprazole 147-159 prolactin Homo sapiens 26-35 24023549-9 2013 Compared with placebo, aripiprazole significantly reduced mean baseline serum prolactin levels within 1 week (p=0.015). Aripiprazole 23-35 prolactin Homo sapiens 78-87 24023549-10 2013 CONCLUSION: Adjunctive treatment with and switching to aripiprazole were not associated with improved cognitive function in patients with schizophrenia receiving risperidone; however, aripiprazole treatment decreased negative symptoms and risperidone-induced motor side effects and lowered serum prolactin levels. Aripiprazole 184-196 prolactin Homo sapiens 296-305 23397510-12 2013 In all 74 individuals, prolactin correlated inversely with age (p < 0.0001) and directly with serum estradiol (p = 0.018). Estradiol 103-112 prolactin Homo sapiens 23-32 23397510-13 2013 Prolactin levels in subjects with IGHD due to a homozygous GHRHR mutation are similar to heterozygous and normal homozygous, but total testosterone and SHBG are higher in male MUT/MUT, with no difference in free testosterone. Testosterone 212-224 prolactin Homo sapiens 0-9 24021518-12 2013 While aripiprazole decreased serum prolactin concentration (P<.0001), it increased mean body weight, body mass index, and waist circumference significantly (P=.0055, P=.0142, and P=.0270, respectively). Aripiprazole 6-18 prolactin Homo sapiens 35-44 23340889-2 2013 Most studies of the role of prolactin on glucose metabolism have been conducted in humans and animals during pregnancy. Glucose 41-48 prolactin Homo sapiens 28-37 23936389-7 2013 Adjunctive aripiprazole was associated with a 79.11% (125/158) prolactin level normalization rate. Aripiprazole 11-23 prolactin Homo sapiens 63-72 23936389-10 2013 Meta-analysis of the prolactin level normalization indicated adjunctive aripiprazole was superior to placebo (risk difference (Mantel-Haenszel, random) 0.76 (95% confidence interval 0.67 to 0.85); I(2) =43%, P<0.00001). Aripiprazole 72-84 prolactin Homo sapiens 21-30 23936389-11 2013 The subgroup analysis confirmed that the subjects who received adjunctive aripiprazole 5 mg/day showed a degree of prolactin normalization similar to that of all participants. Aripiprazole 74-86 prolactin Homo sapiens 115-124 23340889-8 2013 RESULTS: Prolactin levels decreased from normal glucose regulation to IGR to diabetes. Glucose 48-55 prolactin Homo sapiens 9-18 23998115-8 2013 The mean serum prolactin levels of the patients of adenomyosis in comparison to those of the controls and of the patients who were treated with fluoxetine (before and after the fluoxetine administration), were significantly high (p=0.001 in both the cases). Fluoxetine 144-154 prolactin Homo sapiens 15-24 23998115-8 2013 The mean serum prolactin levels of the patients of adenomyosis in comparison to those of the controls and of the patients who were treated with fluoxetine (before and after the fluoxetine administration), were significantly high (p=0.001 in both the cases). Fluoxetine 177-187 prolactin Homo sapiens 15-24 24062725-5 2013 Elevated cAMP also modulates prolactin release downstream of Ca(2+) influx by changing the kinetic of secretory pores: stimulate at low and inhibit at high concentrations. Cyclic AMP 9-13 prolactin Homo sapiens 29-38 24062725-6 2013 Induction of prolactin gene and lactotroph proliferation is also stimulated by elevated cAMP through protein kinase A. Cyclic AMP 88-92 prolactin Homo sapiens 13-22 23385474-11 2013 CONCLUSIONS: Our data support recent evidence that the serum PRL concentration is rarely >1000 mIU/l in males, or >2000 mIU/l in females, with non-functioning macroadenomas and that, once other contributing factors to the hyperprolactinemia have been excluded, a trial of dopamine agonist therapy for such lesions is indicated. Dopamine 278-286 prolactin Homo sapiens 61-64 23340889-3 2013 However, little is known concerning the association between circulating prolactin and glucose metabolism outside pregnancy in epidemiological studies. Glucose 86-93 prolactin Homo sapiens 72-81 23392818-2 2013 Prolactin elevation is the result of a direct antagonistic D(2) effect blocking the tonic inhibition of prolactin release by dopamine. Dopamine 125-133 prolactin Homo sapiens 0-9 23744893-2 2013 We have shown previously that PAK1 is tyrosyl phosphorylated by prolactin (PRL)-activated Janus tyrosine kinase (JAK2). cyclo(tyrosyl-tyrosyl) 38-45 prolactin Homo sapiens 64-73 23744893-2 2013 We have shown previously that PAK1 is tyrosyl phosphorylated by prolactin (PRL)-activated Janus tyrosine kinase (JAK2). cyclo(tyrosyl-tyrosyl) 38-45 prolactin Homo sapiens 75-78 23744893-5 2013 Three-dimensional (3D) collagen IV stimulates the secretion of the matrix proteases, metalloproteinase (MMP)-1 and -3 that is further enhanced by the PRL-dependent tyrosyl phosphorylation of PAK1. cyclo(tyrosyl-tyrosyl) 164-171 prolactin Homo sapiens 150-153 23744893-11 2013 Together, these data illustrate the complex interaction between the substratum and PRL/PAK1 signaling in human breast cancer cells and suggest a pivotal role for PRL-dependent PAK1 tyrosyl phosphorylation in MMP secretion. cyclo(tyrosyl-tyrosyl) 181-188 prolactin Homo sapiens 162-165 23817395-13 2013 CONCLUSION: Macroprolactin is a significant cause of misdiagnosis, unnecessary investigation, and inappropriate treatment and hence it is useful to screen all patients with high PRL levels with PEG precipitation and to apply GFC to samples with recoveries <50%. Polyethylene Glycols 194-197 prolactin Homo sapiens 178-181 23384117-5 2013 Central serotonergic neurotransmission was assessed by a neuroendocrine method, that is, the prolactin (PRL) response to the selective 5-HT reuptake inhibitor citalopram. Citalopram 159-169 prolactin Homo sapiens 93-102 23384117-5 2013 Central serotonergic neurotransmission was assessed by a neuroendocrine method, that is, the prolactin (PRL) response to the selective 5-HT reuptake inhibitor citalopram. Citalopram 159-169 prolactin Homo sapiens 104-107 23384117-7 2013 RESULTS: Alcohol-dependent individuals with childhood experience of emotional abuse had significantly lower PRL response compared with those without such abuse (3 +- 5 and 64 +- 24 mU/l, respectively; t = 6.51, p < 0.001). Alcohols 9-16 prolactin Homo sapiens 108-111 23421963-9 2013 Modest increases in prolactin (median increase, 0.7 ng/mL) and extrapyramidal symptoms were observed following treatment with lurasidone compared with placebo. Lurasidone Hydrochloride 126-136 prolactin Homo sapiens 20-29 23898534-3 2013 RESULTS: The main clinical symptoms of male patients with prolactinomas were sexual dysfunction, headache and hypopsia, which were released significantly at 6 months after Bromocriptine therapy, with the decrease of serum prolactin (PRL) level (P < 0.05) and the improvement of basal testosterone (T) level (P < 0.05). Bromocriptine 172-185 prolactin Homo sapiens 58-67 23898534-3 2013 RESULTS: The main clinical symptoms of male patients with prolactinomas were sexual dysfunction, headache and hypopsia, which were released significantly at 6 months after Bromocriptine therapy, with the decrease of serum prolactin (PRL) level (P < 0.05) and the improvement of basal testosterone (T) level (P < 0.05). Testosterone 287-299 prolactin Homo sapiens 58-67 23758962-11 2013 The protein encoded by one of the PRL-regulated transcripts, PTHrP, was examined in a panel of 92 human breast cancers and found by in situ quantitative immunofluorescence analysis to be highly positively correlated with nuclear localized and tyrosine phosphorylated Stat5. Tyrosine 243-251 prolactin Homo sapiens 34-37 25610268-4 2013 We report a case of a 43-year-old woman with an extremely high prolactin level in medication-induced hyperprolactinemia caused by a combination of an antipsychotic (sulpirid) and an antidepressant (paroxetine). Sulpiride 165-173 prolactin Homo sapiens 63-72 25610268-4 2013 We report a case of a 43-year-old woman with an extremely high prolactin level in medication-induced hyperprolactinemia caused by a combination of an antipsychotic (sulpirid) and an antidepressant (paroxetine). Paroxetine 198-208 prolactin Homo sapiens 63-72 23270686-6 2013 The PR-L contains a proline not existing in the epitope that is postulated to induce kinks in the backbones of all peptides and create a spatial element mimicking the N-terminal conformationally variable binding site. Proline 20-27 prolactin Homo sapiens 4-8 23329574-6 2013 Cabergoline therapy has been reported to achieve normalization of prolactin levels and gonadal function and reduction of tumor volume in >50% of patients with macroprolactinoma. Cabergoline 0-11 prolactin Homo sapiens 66-75 23530035-8 2013 In stiff matrices, prolactin increased SRC family kinase-dependent phosphorylation of focal adhesion kinase (FAK) at tyrosine 925, FAK association with the mitogen-activated protein kinase mediator GRB2, and pERK1/2. Tyrosine 117-125 prolactin Homo sapiens 19-28 23647135-0 2013 Prolactin serum concentrations during aripiprazole treatment in youth. Aripiprazole 38-50 prolactin Homo sapiens 0-9 23647135-1 2013 OBJECTIVE: This study aimed to: document the extent of the reduction of serum prolactin (PRL) levels induced by aripiprazole (ARI) treatment in children and adolescents, compare this effect by age group, and shed light on this phenomenon. Aripiprazole 112-124 prolactin Homo sapiens 78-87 23647135-1 2013 OBJECTIVE: This study aimed to: document the extent of the reduction of serum prolactin (PRL) levels induced by aripiprazole (ARI) treatment in children and adolescents, compare this effect by age group, and shed light on this phenomenon. Aripiprazole 112-124 prolactin Homo sapiens 89-92 23647135-1 2013 OBJECTIVE: This study aimed to: document the extent of the reduction of serum prolactin (PRL) levels induced by aripiprazole (ARI) treatment in children and adolescents, compare this effect by age group, and shed light on this phenomenon. Aripiprazole 126-129 prolactin Homo sapiens 78-87 23647135-1 2013 OBJECTIVE: This study aimed to: document the extent of the reduction of serum prolactin (PRL) levels induced by aripiprazole (ARI) treatment in children and adolescents, compare this effect by age group, and shed light on this phenomenon. Aripiprazole 126-129 prolactin Homo sapiens 89-92 23647135-4 2013 RESULTS: Sixty percent of those treated with aripiprazole exhibited subnormal PRL serum levels versus 8% of unmedicated subjects. Aripiprazole 45-57 prolactin Homo sapiens 78-81 23647135-5 2013 The rate of PRL subnormality in response to aripiprazole was half as frequent in adolescents and was minimal in adults. Aripiprazole 44-56 prolactin Homo sapiens 12-15 23647135-6 2013 The drug-induced reduction of PRL serum levels became more prominent with increasing doses of aripiprazole and with an increased treatment duration. Aripiprazole 94-106 prolactin Homo sapiens 30-33 23392818-2 2013 Prolactin elevation is the result of a direct antagonistic D(2) effect blocking the tonic inhibition of prolactin release by dopamine. Dopamine 125-133 prolactin Homo sapiens 104-113 24096218-3 2013 Newer antipsychotic aripiprazole, partial dopamine agonist, with neutral effect on prolactin level or even decreasing it, is associated with avoidance of sexual dysfunction. Aripiprazole 20-32 prolactin Homo sapiens 83-92 23325364-3 2013 Treatment with cabergoline was started with normalization of prolactin levels; the following MRI, performed in 2005 and 2008, showed shrinkage of the pituitary lesion. Cabergoline 15-26 prolactin Homo sapiens 61-70 23336594-9 2013 RESULTS: After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Inositol 27-30 prolactin Homo sapiens 57-60 24096218-3 2013 Newer antipsychotic aripiprazole, partial dopamine agonist, with neutral effect on prolactin level or even decreasing it, is associated with avoidance of sexual dysfunction. Dopamine 42-50 prolactin Homo sapiens 83-92 23570413-9 2013 For all samples, inverse significant correlations between P-selectin expression and prolactin concentration were found for both 5 muM ADP (r = - 0.61, p < 0.01), 10 muM ADP (r = - 0.62, p < 0.001) and PAR4-AP (r = - 0.69, p < 0.001). Adenosine Diphosphate 134-137 prolactin Homo sapiens 84-93 23570413-9 2013 For all samples, inverse significant correlations between P-selectin expression and prolactin concentration were found for both 5 muM ADP (r = - 0.61, p < 0.01), 10 muM ADP (r = - 0.62, p < 0.001) and PAR4-AP (r = - 0.69, p < 0.001). Adenosine Diphosphate 172-175 prolactin Homo sapiens 84-93 23053124-0 2013 The impact of increased blood lactate on serum S100B and prolactin concentrations in male adult athletes. Lactic Acid 30-37 prolactin Homo sapiens 57-66 23375624-2 2013 We examined the differences in plasma PRL levels among 268 patients treated for schizophrenia with olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), quetiapine (QTP), or perospirone (PER). Olanzapine 99-109 prolactin Homo sapiens 38-41 23375624-2 2013 We examined the differences in plasma PRL levels among 268 patients treated for schizophrenia with olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), quetiapine (QTP), or perospirone (PER). Olanzapine 111-114 prolactin Homo sapiens 38-41 23375624-2 2013 We examined the differences in plasma PRL levels among 268 patients treated for schizophrenia with olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), quetiapine (QTP), or perospirone (PER). Risperidone 117-128 prolactin Homo sapiens 38-41 23375624-2 2013 We examined the differences in plasma PRL levels among 268 patients treated for schizophrenia with olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), quetiapine (QTP), or perospirone (PER). Risperidone 130-133 prolactin Homo sapiens 38-41 23375624-2 2013 We examined the differences in plasma PRL levels among 268 patients treated for schizophrenia with olanzapine (OLZ), risperidone (RIS), aripiprazole (ARP), quetiapine (QTP), or perospirone (PER). Aripiprazole 136-148 prolactin Homo sapiens 38-41 23375624-5 2013 A stepwise multiple regression analysis showed that ARP treatment was found to contribute to lower plasma PRL level, while female sex, RIS, OLZ and chlorpromazine equivalent dose were found to contribute to a higher plasma PRL level. Chlorpromazine 148-162 prolactin Homo sapiens 223-226 23404929-0 2013 Establishment of paediatric age-related reference intervals for serum prolactin to aid in the diagnosis of neurometabolic conditions affecting dopamine metabolism. Dopamine 143-151 prolactin Homo sapiens 70-79 23404929-1 2013 BACKGROUND: There are a number of inborn errors of dopamine biosynthesis for which prolactin measurement may be a useful screening tool. Dopamine 51-59 prolactin Homo sapiens 83-92 23340249-0 2013 Tyrosyl phosphorylated PAK1 regulates breast cancer cell motility in response to prolactin through filamin A. cyclo(tyrosyl-tyrosyl) 0-7 prolactin Homo sapiens 81-90 23352189-6 2013 However, CPT potentiated IGFBP-1 and PRL expression stimulated by the PKA-selective cAMP analog N(6)-Phe-cAMP (Phe) and activated Rap1, a downstream regulator of Epac signaling. Cyclic AMP 84-88 prolactin Homo sapiens 37-40 23352189-6 2013 However, CPT potentiated IGFBP-1 and PRL expression stimulated by the PKA-selective cAMP analog N(6)-Phe-cAMP (Phe) and activated Rap1, a downstream regulator of Epac signaling. n(6)-phe-camp 96-109 prolactin Homo sapiens 37-40 23352189-6 2013 However, CPT potentiated IGFBP-1 and PRL expression stimulated by the PKA-selective cAMP analog N(6)-Phe-cAMP (Phe) and activated Rap1, a downstream regulator of Epac signaling. Phenylalanine 101-104 prolactin Homo sapiens 37-40 23352189-7 2013 Knock-down of Epac1, Epac2, or Rap1 significantly inhibited the Phe- or Phe/CPT-induced increase in IGFBP-1 and PRL expression, as well as Rap1 activation. Phenylalanine 64-67 prolactin Homo sapiens 112-115 23441455-8 2013 One case was treated with oral bromocriptine, which restored the prolactin level to normal at 12 months (IIEF-5 > 21). Bromocriptine 31-44 prolactin Homo sapiens 65-74 24991131-8 2013 RESULTS: We found a dramatic 4-fold increase in prolactin levels in women of childbearing age treated with risperidone, but the pretreatment and posttreatment levels of prolactin were not different between patients who did and did not develop amenorrhea with treatment. Risperidone 107-118 prolactin Homo sapiens 48-57 23497585-2 2013 Here we report a patient with a giant prolactinoma presented with central hypogonadism, suppressed adrenal and thyroid function, supra sellar extension, visual field impairment and high prolactin level.The patient was treated with cabergoline, levothyroxin and prednisolone. Cabergoline 231-242 prolactin Homo sapiens 38-47 23497585-2 2013 Here we report a patient with a giant prolactinoma presented with central hypogonadism, suppressed adrenal and thyroid function, supra sellar extension, visual field impairment and high prolactin level.The patient was treated with cabergoline, levothyroxin and prednisolone. Thyroxine 244-256 prolactin Homo sapiens 38-47 23497585-2 2013 Here we report a patient with a giant prolactinoma presented with central hypogonadism, suppressed adrenal and thyroid function, supra sellar extension, visual field impairment and high prolactin level.The patient was treated with cabergoline, levothyroxin and prednisolone. Prednisolone 261-273 prolactin Homo sapiens 38-47 23352189-7 2013 Knock-down of Epac1, Epac2, or Rap1 significantly inhibited the Phe- or Phe/CPT-induced increase in IGFBP-1 and PRL expression, as well as Rap1 activation. Phenylalanine 72-75 prolactin Homo sapiens 112-115 23159947-11 2013 TMA analysis revealed a marked increase in nuclear, but not cytoplasmic, PRLr TAD phosphorylation as a function of neoplastic progression. 4,4-dimethylcholesta-8,14-dien-3-ol 0-3 prolactin Homo sapiens 73-81 23762662-3 2013 Cabergoline is a potent and long-acting inhibitor of prolactin secretion, which exhibits high specificity and affinity for dopamine D2 receptor. Cabergoline 0-11 prolactin Homo sapiens 53-62 23647190-8 2013 Daidzein affected serum P4 and GH concentrations and T4 rhythm, up-regulated GnRH mRNA and PRLR mRNA levels in the hypothalamus, down-regulated PRLR mRNA in the hypothalamus, PRL mRNA in the pituitary, and ESR2 mRNA levels in the ovary, respectively. daidzein 0-8 prolactin Homo sapiens 91-94 23762662-6 2013 Cabergoline seems to be safe and effective in the treatment of prolactin and growth hormone cosecreting pituitary adenomas as well as prolactinomas. Cabergoline 0-11 prolactin Homo sapiens 63-72 23011923-6 2012 cAMP induced the expressions of both genes in ESCs but induced the expression of only PRL in HDFs. Cyclic AMP 0-4 prolactin Homo sapiens 86-89 24683423-4 2013 Structural analysis carried in conjunction with calculated pH-dependence of the binding revealed that the main reason for pH-dependence of the binding of hPRL-hPRLr-ECD is a number of salt- bridges across the interface of the complex, while no salt-bridges are formed in the hGH-hPRlr-ECD. Salts 184-188 prolactin Homo sapiens 154-158 23232756-0 2013 Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Risperidone 120-131 prolactin Homo sapiens 11-20 23232756-0 2013 Changes in prolactin levels and sexual function in young psychotic patients after switching from long-acting injectable risperidone to paliperidone palmitate. Paliperidone Palmitate 135-157 prolactin Homo sapiens 11-20 23232756-2 2013 The aim of our study was to assess the effect of switching from long-acting injectable (LAI) risperidone to paliperidone palmitate (PP) on sexual function and prolactin levels in patients with psychosis. Risperidone 93-104 prolactin Homo sapiens 159-168 23232756-8 2013 Our study suggests that prolactin levels seem to decrease after switching from risperidone-LAI to PP in patients with a psychotic disorder. Risperidone 79-90 prolactin Homo sapiens 24-33 23853622-7 2013 A linear regression model was used to evaluate the relationship between prolactin levels with intellectual disability level, bromocriptine use, demographics, and antipsychotic. Bromocriptine 125-138 prolactin Homo sapiens 72-81 23853622-12 2013 Two variables, gender and bromocriptine use, were found to be significant predictors of prolactin levels. Bromocriptine 26-39 prolactin Homo sapiens 88-97 23853622-18 2013 Use of bromocriptine was associated with higher prolactin levels. Bromocriptine 7-20 prolactin Homo sapiens 48-57 23678840-4 2013 The aim of this study was to explore the effects of heroin and methadone maintenance treatment on the plasma prolactin levels and sexual function. Heroin 52-58 prolactin Homo sapiens 109-118 23678840-4 2013 The aim of this study was to explore the effects of heroin and methadone maintenance treatment on the plasma prolactin levels and sexual function. Methadone 63-72 prolactin Homo sapiens 109-118 22748186-6 2012 Both prolactin and thyroid hormones may be involved in a complex compensatory mechanism to correct reduced central serotonin activity. Serotonin 115-124 prolactin Homo sapiens 5-14 23227451-2 2012 Laboratory and epidemiologic evidence suggests that a prolactin-mediated mechanism secondary to increased serotonin levels at neuronal synapses could lead to a potentially carcinogenic effect of SSRIs. Serotonin 106-115 prolactin Homo sapiens 54-63 23565404-3 2012 We hypothesize that rapid escalation of CAB doses, may help in both the earlier normalization of PRL and also significant shrinkage of tumor mass. Cabergoline 40-43 prolactin Homo sapiens 97-100 23565404-11 2012 The duration of CAB treatment to normalize PRL was 10.2 +- 9.2 week(2-36) in group A and 7.2 +- 6.2 weeks(1-24) in group B (P = 0.28). Cabergoline 16-19 prolactin Homo sapiens 43-46 23131886-0 2012 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. Haloperidol 20-31 prolactin Homo sapiens 71-80 23131886-0 2012 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. Olanzapine 33-43 prolactin Homo sapiens 71-80 23131886-0 2012 Long-term effect of haloperidol, olanzapine, and risperidone on plasma prolactin levels in patients with first-episode psychosis. Risperidone 49-60 prolactin Homo sapiens 71-80 23131886-1 2012 OBJECTIVE: The main goal of this study was to assess the long-term effect of haloperidol, olanzapine, and risperidone on serum prolactin levels in a naturalistically treated first-episode psychosis population. Haloperidol 77-88 prolactin Homo sapiens 127-136 23131886-1 2012 OBJECTIVE: The main goal of this study was to assess the long-term effect of haloperidol, olanzapine, and risperidone on serum prolactin levels in a naturalistically treated first-episode psychosis population. Olanzapine 90-100 prolactin Homo sapiens 127-136 23131886-1 2012 OBJECTIVE: The main goal of this study was to assess the long-term effect of haloperidol, olanzapine, and risperidone on serum prolactin levels in a naturalistically treated first-episode psychosis population. Risperidone 106-117 prolactin Homo sapiens 127-136 23131886-5 2012 At 1-year follow-up, most patients in the haloperidol and olanzapine arms had prolactin values that fell within the reference range. Haloperidol 42-53 prolactin Homo sapiens 78-87 23131886-5 2012 At 1-year follow-up, most patients in the haloperidol and olanzapine arms had prolactin values that fell within the reference range. Olanzapine 58-68 prolactin Homo sapiens 78-87 23131886-6 2012 Patients treated with risperidone experienced a significant increase at 3 months resulting in prolactin levels above the reference range in 90% of men and 87% of women. Risperidone 22-33 prolactin Homo sapiens 94-103 23131886-10 2012 After 1 year, elevated prolactin levels persist in most patients treated with risperidone. Risperidone 78-89 prolactin Homo sapiens 23-32 21660520-3 2012 She was treated with dopamine agonists for 10 years and after cessation of therapy her prolactin levels remain normal. Dopamine 21-29 prolactin Homo sapiens 87-96 21660520-6 2012 With decline of pituitary size, after starting dopamine agonists, the traction probably reduced resulting in a normal prolactin level. Dopamine 47-55 prolactin Homo sapiens 118-127 23110951-0 2012 Stimulatory effect of PGF2alpha on PRL based on experimental inhibition of each hormone in mares. Dinoprost 22-31 prolactin Homo sapiens 35-38 23110951-7 2012 Compared to the controls, concentrations of PRL in June were lower (P < 0.05) in the FM group at Hours 4 to 8 and in the bromocriptine group at Hours 4 to 10. Bromocriptine 124-137 prolactin Homo sapiens 44-47 23110951-9 2012 Results supported the hypothesis that the positive association between PGFM and PRL concentrations in mares represents an effect of PGF2alpha on PRL rather than an effect of PRL on PGF2alpha. Dhk-pgf2alpha 71-75 prolactin Homo sapiens 80-83 23110951-9 2012 Results supported the hypothesis that the positive association between PGFM and PRL concentrations in mares represents an effect of PGF2alpha on PRL rather than an effect of PRL on PGF2alpha. Dhk-pgf2alpha 71-75 prolactin Homo sapiens 145-148 23110951-9 2012 Results supported the hypothesis that the positive association between PGFM and PRL concentrations in mares represents an effect of PGF2alpha on PRL rather than an effect of PRL on PGF2alpha. Dhk-pgf2alpha 71-75 prolactin Homo sapiens 145-148 23110951-9 2012 Results supported the hypothesis that the positive association between PGFM and PRL concentrations in mares represents an effect of PGF2alpha on PRL rather than an effect of PRL on PGF2alpha. Dinoprost 132-141 prolactin Homo sapiens 80-83 23110951-9 2012 Results supported the hypothesis that the positive association between PGFM and PRL concentrations in mares represents an effect of PGF2alpha on PRL rather than an effect of PRL on PGF2alpha. Dinoprost 132-141 prolactin Homo sapiens 145-148 23110951-9 2012 Results supported the hypothesis that the positive association between PGFM and PRL concentrations in mares represents an effect of PGF2alpha on PRL rather than an effect of PRL on PGF2alpha. Dinoprost 132-141 prolactin Homo sapiens 145-148 23110952-7 2012 Average concentration of PRL was lower (P < 0.05) and number of PRL pulses was less (P < 0.05) in the Bc group than in the Ct group. Bromocriptine 108-110 prolactin Homo sapiens 25-28 23110952-7 2012 Average concentration of PRL was lower (P < 0.05) and number of PRL pulses was less (P < 0.05) in the Bc group than in the Ct group. Bromocriptine 108-110 prolactin Homo sapiens 67-70 23110952-8 2012 Acyline inhibited LH in the Ac and BcAc groups as indicated by a decrease (P < 0.05) in concentration between Hours 0 and 2 and a decrease (P < 0.001) in number of pulses/heifer during the 8 h. A decrease in PRL but not an increase in P4 and LH occurred in the BcAc group. acyline 0-7 prolactin Homo sapiens 214-217 23110952-8 2012 Acyline inhibited LH in the Ac and BcAc groups as indicated by a decrease (P < 0.05) in concentration between Hours 0 and 2 and a decrease (P < 0.001) in number of pulses/heifer during the 8 h. A decrease in PRL but not an increase in P4 and LH occurred in the BcAc group. bcac 35-39 prolactin Homo sapiens 214-217 23110952-9 2012 Results supported the hypothesis that the P4 increase associated with PRL suppression by bromocriptine treatment is attributable to an increase in LH. Bromocriptine 89-102 prolactin Homo sapiens 70-73 23110952-9 2012 Results supported the hypothesis that the P4 increase associated with PRL suppression by bromocriptine treatment is attributable to an increase in LH. Luteinizing Hormone 147-149 prolactin Homo sapiens 70-73 23647190-9 2013 The mRNA rhythms of PRLR in the hypothalamus, PRL, PRLR and FSHbeta in the pituitary, FSHR, ESR1 and ESR2 in the ovary were significantly changed in the Da2 group. da2 153-156 prolactin Homo sapiens 20-23 24194758-13 2013 Serum PRL precipitated with PEG is a convenient and simple procedure to screen for the presence of macroprolactinemia. Polyethylene Glycols 28-31 prolactin Homo sapiens 6-9 23581407-5 2013 It was found that in the presence of estradiol, prolactin inhibits prolidase activity and its down-stream signaling proteins: HIF-1alpha, mTOR, AKT and MAPK p-38, while in the absence of estradiol, an opposite effect was observed. Estradiol 37-46 prolactin Homo sapiens 48-57 23581407-5 2013 It was found that in the presence of estradiol, prolactin inhibits prolidase activity and its down-stream signaling proteins: HIF-1alpha, mTOR, AKT and MAPK p-38, while in the absence of estradiol, an opposite effect was observed. Estradiol 187-196 prolactin Homo sapiens 48-57 23244563-8 2012 Raised Prl concentrations were found in 10 women with thyroid disease (5.5%), and of those a significant macroprolactinaemia (i.e., reduction of Prl concentrations of more than 60% after PEG precipitation) was found in 9 subjects (4.94%). Polyethylene Glycols 187-190 prolactin Homo sapiens 7-10 22947594-0 2012 An analysis of potentially prolactin-related adverse events and abnormal prolactin values in randomized clinical trials with paliperidone palmitate. Paliperidone Palmitate 125-147 prolactin Homo sapiens 27-36 22947594-1 2012 BACKGROUND: Paliperidone palmitate has been associated with serum prolactin elevations in some patients. Paliperidone Palmitate 12-34 prolactin Homo sapiens 66-75 22105468-6 2012 Given that prolactin is under negative control by dopamine and positive control by serotonin, typical antipsychotics induce elevations in prolactin, while atypical antipsychotics do not. Dopamine 50-58 prolactin Homo sapiens 11-20 23074699-1 2012 Antipsychotic drug therapy, e.g., risperidone, can be associated with endocrine abnormalities, including an increase in serum prolactin level (sPrl) due to a drug-induced benign pituitary tumor (prolactinoma). Risperidone 34-45 prolactin Homo sapiens 126-135 23723555-2 2012 Iloperidone is usually considered as a prolactin sparing atypical antipsychotic thereby offering treatment advantage. iloperidone 0-11 prolactin Homo sapiens 39-48 23723555-6 2012 Iloperidone was stopped and aripiprazole was initiated with which galactorrhea subsided and prolactin level returned to normal. Aripiprazole 28-40 prolactin Homo sapiens 92-101 23211297-8 2012 PRL synthesis and secretion is mainly regulated by the inhibitory influence of dopamine but other hormones are also involved in these mechanisms. Dopamine 79-87 prolactin Homo sapiens 0-3 21878805-7 2012 Change in prolactin concentration following citalopram challenge was used as an index of central serotonergic response. Citalopram 44-54 prolactin Homo sapiens 10-19 22729360-3 2012 This notion is supported by the observation that inhibition of PRL secretion by bromocriptine, a dopamine D2-receptor agonist, prevented the onset of disease in an animal model of PPCM and by first clinical experiences where bromocriptine seem to exert positive effects with respect to prevention or treatment of PPCM patients. Bromocriptine 80-93 prolactin Homo sapiens 63-66 22729360-3 2012 This notion is supported by the observation that inhibition of PRL secretion by bromocriptine, a dopamine D2-receptor agonist, prevented the onset of disease in an animal model of PPCM and by first clinical experiences where bromocriptine seem to exert positive effects with respect to prevention or treatment of PPCM patients. Bromocriptine 225-238 prolactin Homo sapiens 63-66 22935052-4 2012 Domperidone is a potent dopamine D2 receptor antagonist which stimulates the release of prolactin. Domperidone 0-11 prolactin Homo sapiens 88-97 22288612-7 2012 RESULTS: Dopamine agonists normalized prolactin levels in 73 3% and 65 2% of patients with micro- and macroprolactinomas, respectively. Dopamine 9-17 prolactin Homo sapiens 38-47 22639180-14 2012 Treatment with cabergoline had significantly reduced the prolactin levels and had also improved the patient"s headaches. Cabergoline 15-26 prolactin Homo sapiens 57-66 22700773-8 2012 We demonstrated that a 2-wk treatment with ABT-510 and ABT-898 counteracted the increase in pituitary size and serum prolactin levels as well as the pituitary proliferation rate induced by DES. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 43-46 prolactin Homo sapiens 117-126 22700773-8 2012 We demonstrated that a 2-wk treatment with ABT-510 and ABT-898 counteracted the increase in pituitary size and serum prolactin levels as well as the pituitary proliferation rate induced by DES. 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid 55-58 prolactin Homo sapiens 117-126 22105468-6 2012 Given that prolactin is under negative control by dopamine and positive control by serotonin, typical antipsychotics induce elevations in prolactin, while atypical antipsychotics do not. Serotonin 83-92 prolactin Homo sapiens 11-20 22105468-6 2012 Given that prolactin is under negative control by dopamine and positive control by serotonin, typical antipsychotics induce elevations in prolactin, while atypical antipsychotics do not. Serotonin 83-92 prolactin Homo sapiens 138-147 22626779-0 2012 Direct effect of PGF2alpha pulses on PRL pulses, based on inhibition of PRL or PGF2alpha secretion in heifers. Dinoprost 17-26 prolactin Homo sapiens 37-40 22626779-0 2012 Direct effect of PGF2alpha pulses on PRL pulses, based on inhibition of PRL or PGF2alpha secretion in heifers. Dinoprost 17-26 prolactin Homo sapiens 72-75 22626779-0 2012 Direct effect of PGF2alpha pulses on PRL pulses, based on inhibition of PRL or PGF2alpha secretion in heifers. Dinoprost 79-88 prolactin Homo sapiens 37-40 22626779-2 2012 Heifers were treated with a dopamine-receptor agonist (bromocriptine; Bc) and a Cox-1 and -2 inhibitor (flunixin meglumine [FM]) to inhibit PRL and PGF(2alpha), respectively. flunixin meglumine 104-122 prolactin Homo sapiens 140-143 22626779-7 2012 During the greatest decrease in PRL (Hours 2-6), LH concentrations were increased. Luteinizing Hormone 49-51 prolactin Homo sapiens 32-35 22626779-12 2012 The hypothesis that PRL has a role in luteolysis was supported but was confounded by the known positive effect of LH on progesterone. Luteinizing Hormone 114-116 prolactin Homo sapiens 20-23 22626779-12 2012 The hypothesis that PRL has a role in luteolysis was supported but was confounded by the known positive effect of LH on progesterone. Progesterone 120-132 prolactin Homo sapiens 20-23 22626779-13 2012 The hypothesis was supported that the synchrony of PGFM and PRL pulses represents a positive effect of PGF(2alpha) on PRL, rather than an effect of PRL on PGF(2alpha). 15-keto-13,14-dihydroprostaglandin F2alpha 51-55 prolactin Homo sapiens 118-121 22626779-13 2012 The hypothesis was supported that the synchrony of PGFM and PRL pulses represents a positive effect of PGF(2alpha) on PRL, rather than an effect of PRL on PGF(2alpha). 15-keto-13,14-dihydroprostaglandin F2alpha 51-55 prolactin Homo sapiens 118-121 22626779-13 2012 The hypothesis was supported that the synchrony of PGFM and PRL pulses represents a positive effect of PGF(2alpha) on PRL, rather than an effect of PRL on PGF(2alpha). Prostaglandins F 51-54 prolactin Homo sapiens 118-121 22626779-13 2012 The hypothesis was supported that the synchrony of PGFM and PRL pulses represents a positive effect of PGF(2alpha) on PRL, rather than an effect of PRL on PGF(2alpha). Prostaglandins F 51-54 prolactin Homo sapiens 118-121 22626779-13 2012 The hypothesis was supported that the synchrony of PGFM and PRL pulses represents a positive effect of PGF(2alpha) on PRL, rather than an effect of PRL on PGF(2alpha). Prostaglandins F 103-106 prolactin Homo sapiens 60-63 22626779-13 2012 The hypothesis was supported that the synchrony of PGFM and PRL pulses represents a positive effect of PGF(2alpha) on PRL, rather than an effect of PRL on PGF(2alpha). Prostaglandins F 103-106 prolactin Homo sapiens 118-121 22626779-13 2012 The hypothesis was supported that the synchrony of PGFM and PRL pulses represents a positive effect of PGF(2alpha) on PRL, rather than an effect of PRL on PGF(2alpha). Prostaglandins F 103-106 prolactin Homo sapiens 118-121 22828169-8 2012 Compared to no treatment, dopamine agonists significantly reduced prolactin level (weighted mean difference, -45; 95% confidence interval, -77 to -11) and the likelihood of persistent hyperprolactinemia (relative risk, 0.90; 95% confidence interval, 0.81 to 0.99). Dopamine 26-34 prolactin Homo sapiens 66-75 22702896-7 2012 Prolactin enhances the calcium mobilization process even at sufficient calcium intakes. Calcium 23-30 prolactin Homo sapiens 0-9 22702896-7 2012 Prolactin enhances the calcium mobilization process even at sufficient calcium intakes. Calcium 71-78 prolactin Homo sapiens 0-9 22702896-8 2012 It is suggested that prolactin takes part in regulation of calcium homeostasis in the organism. Calcium 59-66 prolactin Homo sapiens 21-30 22828169-12 2012 CONCLUSION: Our results provide evidence to support the use of dopamine agonists in reducing prolactin levels and persistent hyperprolactinemia, with cabergoline proving more efficacious than bromocriptine. Dopamine 63-71 prolactin Homo sapiens 93-102 23983962-0 2012 Risperidone-associated prolactin elevation and markers of bone turnover during acute treatment. Risperidone 0-11 prolactin Homo sapiens 23-32 22732335-10 2012 Serum creatinine levels correleted positively with both prolactin (r = 0.51, p < 0.001) and macroprolactin levels (r = 0.43, p < 0.001). Creatinine 6-16 prolactin Homo sapiens 56-65 19288176-10 2012 Measurement of serum prolactin can expedite a diagnosis and prevent delay of treatment with dopamine agonists. Dopamine 92-100 prolactin Homo sapiens 21-30 22619354-0 2012 Reporting of post-polyethylene glycol prolactin: precipitation by polyethylene glycol 6000 or polyethylene glycol 8000 will change reference intervals for monomeric prolactin. Polyethylene Glycol 6000 66-90 prolactin Homo sapiens 38-47 22619354-0 2012 Reporting of post-polyethylene glycol prolactin: precipitation by polyethylene glycol 6000 or polyethylene glycol 8000 will change reference intervals for monomeric prolactin. Polyethylene Glycol 6000 66-90 prolactin Homo sapiens 165-174 22619354-0 2012 Reporting of post-polyethylene glycol prolactin: precipitation by polyethylene glycol 6000 or polyethylene glycol 8000 will change reference intervals for monomeric prolactin. polyethylene glycol 8000 94-118 prolactin Homo sapiens 38-47 22619354-0 2012 Reporting of post-polyethylene glycol prolactin: precipitation by polyethylene glycol 6000 or polyethylene glycol 8000 will change reference intervals for monomeric prolactin. polyethylene glycol 8000 94-118 prolactin Homo sapiens 165-174 22619354-1 2012 BACKGROUND: When screening for macroprolactin, many laboratories use precipitation by polyethylene glycol (PEG) with molecular weight 6000 (PEG6000) or 8000 (PEG8000), and report the percentage prolactin recovery. Polyethylene Glycols 86-105 prolactin Homo sapiens 36-45 22619354-1 2012 BACKGROUND: When screening for macroprolactin, many laboratories use precipitation by polyethylene glycol (PEG) with molecular weight 6000 (PEG6000) or 8000 (PEG8000), and report the percentage prolactin recovery. Polyethylene Glycols 107-110 prolactin Homo sapiens 36-45 22407277-6 2012 The serum prolactin level decreased significantly after switching to aripiprazole (chi(2) = 11.14 and P = 0.004), but the changes in the total testosterone level were not significant (chi(2) = 4.75 and P = 0.93). Aripiprazole 69-81 prolactin Homo sapiens 10-19 22520146-0 2012 Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment. Temozolomide 74-86 prolactin Homo sapiens 28-37 22520146-1 2012 We report here a rare case of a young male patient presenting with a Multiple Endocrine Neoplasia Type 1 - prolactin-secreting pituitary carcinoma, controlled long-term after temozolomide withdrawal. Temozolomide 175-187 prolactin Homo sapiens 107-116 22520146-3 2012 Dopamine agonists and radiotherapy allowed control of prolactin secretion and pituitary remnant. Dopamine 0-8 prolactin Homo sapiens 54-63 22520146-6 2012 The patient is still currently followed in our department, 3 years after temozolomide withdrawal: prolactin level and pituitary tumor volume remain controlled without any chemotherapy. Temozolomide 73-85 prolactin Homo sapiens 98-107 22520146-7 2012 To our knowledge, this is the first case of MEN1 prolactin secreting pituitary carcinoma controlled long-term after temozolomide discontinuation. Temozolomide 116-128 prolactin Homo sapiens 49-58 22415638-6 2012 Some basic and clinical evidence for the addition of aripiprazole to lower prolactin levels was identified. Aripiprazole 53-65 prolactin Homo sapiens 75-84 22153972-2 2012 Pramipexole was generally well-tolerated (82% trial-completion), and yielded greater decreases in PANSS-total scores (drug/placebo=2.1; p=0.04), with similar decreases in PANSS positive and negative scores and 6.7-fold greater reduction of serum prolactin concentrations compared to placebo. Pramipexole 0-11 prolactin Homo sapiens 246-255 23983962-2 2012 Our objective was to study the acute effects of prolactin elevation on serum markers of bone formation and resorption in patients treated with risperidone. Risperidone 143-154 prolactin Homo sapiens 48-57 23983962-11 2012 CONCLUSIONS: These findings suggest that prolactin elevation is associated with changes in bone physiology very early in the course of treatment with risperidone. Risperidone 150-161 prolactin Homo sapiens 41-50 22399233-0 2012 Associations of intakes of fat, dietary fiber, soy isoflavones, and alcohol with levels of sex hormones and prolactin in premenopausal Japanese women. Alcohols 68-75 prolactin Homo sapiens 108-117 22447799-0 2012 Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version). ziprasidone 93-104 prolactin Homo sapiens 6-15 22074059-2 2012 The aim of this pilot study was to determine the efficacy of cabergoline, a dopamine receptor agonist, on body weight and glucose tolerance in obese non-diabetic persons with normal plasma prolactin levels. Cabergoline 61-72 prolactin Homo sapiens 189-198 22074059-7 2012 RESULTS: As expected, prolactin levels decreased after cabergoline (p < 0.001). Cabergoline 55-66 prolactin Homo sapiens 22-31 22357343-5 2012 Three types of self-association have been characterized: dimers of human GH that form with Zn(2+), low-affinity self-association of human prolactin caused by acidic pH and Zn(2+) with macromolecular crowding, and amyloid fibers of prolactin. Zinc 172-174 prolactin Homo sapiens 138-147 22247016-8 2012 The ratios of PEG-precipitable PRL and IgG-bound PRL did not significantly change, but (125)I-PRL binding ratios significantly increased. Polyethylene Glycols 14-17 prolactin Homo sapiens 31-34 22138220-9 2012 Prolactin, an adenohypophyseal hormone, regulates 7alpha-hydroxypregnenolone synthesis in the brain, and also induces seasonal locomotor changes. 7-hydroxypregnenolone 50-76 prolactin Homo sapiens 0-9 22472310-2 2012 Higher levels of prolactin result from longer exposure to higher doses, especially with older antipsychotics or with risperidone, sulpiride or amisulpride. Risperidone 117-128 prolactin Homo sapiens 17-26 22472310-2 2012 Higher levels of prolactin result from longer exposure to higher doses, especially with older antipsychotics or with risperidone, sulpiride or amisulpride. Sulpiride 130-139 prolactin Homo sapiens 17-26 22472310-2 2012 Higher levels of prolactin result from longer exposure to higher doses, especially with older antipsychotics or with risperidone, sulpiride or amisulpride. Amisulpride 143-154 prolactin Homo sapiens 17-26 22392353-11 2012 Importantly, the proliferative effects induced by prolactin could be effectively attenuated by adding AG490, a JAK2 inhibitor. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 102-107 prolactin Homo sapiens 50-59 22447799-0 2012 Serum prolactin levels and the acute-phase efficacy in drug-naive schizophrenia treated with ziprasidone and olanzapine (translated version). Olanzapine 109-119 prolactin Homo sapiens 6-15 22447799-2 2012 To study the efficacy and associated serum prolactin levels of ziprasidone and olanzapine treatment in drug-naive schizophrenia patients. ziprasidone 63-74 prolactin Homo sapiens 43-52 22447799-2 2012 To study the efficacy and associated serum prolactin levels of ziprasidone and olanzapine treatment in drug-naive schizophrenia patients. Olanzapine 79-89 prolactin Homo sapiens 43-52 22447799-11 2012 The increase of serum prolactin in the ziprasidone female group (47 +- 51 microg/L) was significantly higher than that in the ziprasidone male group (17 +- 11 microg/L), the olanzapine male group (5 +- 16 microg/L), and the olanzapine female group (21 +- 34 microg/L) [p < 0.05]. ziprasidone 39-50 prolactin Homo sapiens 22-31 22447799-11 2012 The increase of serum prolactin in the ziprasidone female group (47 +- 51 microg/L) was significantly higher than that in the ziprasidone male group (17 +- 11 microg/L), the olanzapine male group (5 +- 16 microg/L), and the olanzapine female group (21 +- 34 microg/L) [p < 0.05]. Olanzapine 174-184 prolactin Homo sapiens 22-31 22447799-11 2012 The increase of serum prolactin in the ziprasidone female group (47 +- 51 microg/L) was significantly higher than that in the ziprasidone male group (17 +- 11 microg/L), the olanzapine male group (5 +- 16 microg/L), and the olanzapine female group (21 +- 34 microg/L) [p < 0.05]. Olanzapine 224-234 prolactin Homo sapiens 22-31 22447799-14 2012 In women, ziprasidone was associated with greater changes in prolactin level than olanzapine. ziprasidone 10-21 prolactin Homo sapiens 61-70 22127489-1 2012 OBJECTIVE: Dopamine agonists normalize prolactin (PRL) levels and reduce tumour size in responsive prolactinoma. Dopamine 11-19 prolactin Homo sapiens 50-53 22664046-1 2012 Fasting serum prolactin (PRL) levels in response to metoclopramide (MCP) and lymphocyte cytokine profiles was studied in patients given allografts and their donors. Metoclopramide 52-66 prolactin Homo sapiens 14-23 22351885-11 2012 Olanzapine caused more dyslipidemia and weight gain, but fewer prolactin-related events, than risperidone. Olanzapine 0-10 prolactin Homo sapiens 63-72 22411694-0 2012 Relationship between prolactin levels and subjective endocrine-related adverse effects in patients with schizophrenia receiving long-term treatment with amisulpride. Amisulpride 153-164 prolactin Homo sapiens 21-30 21688280-0 2012 Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells. Nitric Oxide 59-71 prolactin Homo sapiens 17-26 22333523-5 2012 Since dopamine is a prolactin-inhibiting factor and dopamine imbalance has been implicated in the pathophysiology of psychotic disorders, we investigated the probable relationship between hyperprolactinemia and the development of psychotic symptoms. Dopamine 6-14 prolactin Homo sapiens 20-29 22333523-4 2012 OBJECTIVE: Since dopamine is a prolactin-inhibiting factor and dopamine imbalanced has been implicated in the pathophysiology of psychotic disorders, we investigated the probable relationship between hyperprolactinemia and the development of psychotic symptoms, in a patient with hypogonadism due to hyperprolactnemia and subsequent first episode of psychosis. Dopamine 17-25 prolactin Homo sapiens 31-40 22205628-7 2012 However, hPRL complexation was antagonized by cyclosporine A and anti-cyclophilins. Cyclosporine 46-60 prolactin Homo sapiens 9-13 21780951-4 2012 An examination of the patient revealed that PRL level was still high so the dose of cabergoline was further increased and subsequently, bromocriptine was added to the treatment. Cabergoline 84-95 prolactin Homo sapiens 44-47 21780951-4 2012 An examination of the patient revealed that PRL level was still high so the dose of cabergoline was further increased and subsequently, bromocriptine was added to the treatment. Bromocriptine 136-149 prolactin Homo sapiens 44-47 22333523-7 2012 RESULTS: Psychotic symptoms resolved soon after treatment with aripiprazole in conjunction with cabergoline, with a concomitant decrease in serum prolactin level. Aripiprazole 63-75 prolactin Homo sapiens 146-155 22078782-8 2012 RESULT(S): Prolactin production was induced in HESCs in response to 8-br-cAMP and P. 8-Bromo Cyclic Adenosine Monophosphate 68-77 prolactin Homo sapiens 11-20 22250612-3 2012 The aim of this study was to examine whether low dosages of amisulpride can increase serum levels of prolactin or not clinically in Korean patients. Amisulpride 60-71 prolactin Homo sapiens 101-110 22250612-4 2012 METHOD: Serum prolactin levels were measured in 20 Korean patients (12 men and eight women) with various diagnoses who were treated with less than 300 mg of amisulpride per day. Amisulpride 157-168 prolactin Homo sapiens 14-23 22250612-7 2012 CONCLUSIONS: The low dosages of amisulpride elevate serum prolactin level in the majority of patients. Amisulpride 32-43 prolactin Homo sapiens 58-67 22250612-9 2012 Clinicians should monitor serum prolactin level even when low dosages of amisulpride are administered. Amisulpride 73-84 prolactin Homo sapiens 32-41 22493925-8 2012 CONCLUSION: Postpartum Tuina on breasts could increase the quantity of lactation and delay the decreasing of the levels of prolactin, which contributes primiparas to lactate more and sooner. Lactic Acid 166-173 prolactin Homo sapiens 123-132 22654846-3 2011 Here we describe a patient initially diagnosed with a pure prolactin-secreting microadenoma, who experienced the progressive apparition of symptomatic autonomous GH secretion while on intermittent long term dopamine agonist therapy. Dopamine 207-215 prolactin Homo sapiens 59-68 23035290-10 2012 Suicide attempters also exhibit a blunted release of prolactin in response to administration of fenfluramine, a measure of 5-HT activity (Dulchin et al. Fenfluramine 96-108 prolactin Homo sapiens 53-62 22614073-3 2012 Absence or lower abundance of calcium-binding proteins and higher abundance of prolactin-induced proteins were found in biofilm formed in the presence of sucrose or its monosaccharide constituents compared with water, the negative control group. Sucrose 154-161 prolactin Homo sapiens 79-88 22614073-3 2012 Absence or lower abundance of calcium-binding proteins and higher abundance of prolactin-induced proteins were found in biofilm formed in the presence of sucrose or its monosaccharide constituents compared with water, the negative control group. Monosaccharides 169-183 prolactin Homo sapiens 79-88 22614073-3 2012 Absence or lower abundance of calcium-binding proteins and higher abundance of prolactin-induced proteins were found in biofilm formed in the presence of sucrose or its monosaccharide constituents compared with water, the negative control group. Water 211-216 prolactin Homo sapiens 79-88 22870355-9 2012 No female patient had clinical signs of androgenization and the determined androgens testosterone, androstendione and dihydroepiandrostendione were in the normal range.According to these results, moderate elevated prolactin levels in association with diffuse or androgenetic hair loss can be neglected as causative for the hair loss, because there is no evidence that they have an influence to the pattern, the extent or the duration of the hair loss. Testosterone 85-97 prolactin Homo sapiens 214-223 22870355-9 2012 No female patient had clinical signs of androgenization and the determined androgens testosterone, androstendione and dihydroepiandrostendione were in the normal range.According to these results, moderate elevated prolactin levels in association with diffuse or androgenetic hair loss can be neglected as causative for the hair loss, because there is no evidence that they have an influence to the pattern, the extent or the duration of the hair loss. Androstenedione 99-113 prolactin Homo sapiens 214-223 22870355-9 2012 No female patient had clinical signs of androgenization and the determined androgens testosterone, androstendione and dihydroepiandrostendione were in the normal range.According to these results, moderate elevated prolactin levels in association with diffuse or androgenetic hair loss can be neglected as causative for the hair loss, because there is no evidence that they have an influence to the pattern, the extent or the duration of the hair loss. dihydroepiandrostendione 118-142 prolactin Homo sapiens 214-223 22635088-5 2012 A normalization of plasma prolactin levels by quinagolide and replacement of risperidone with aripiprazole improved her clinical condition. quinagolide 46-57 prolactin Homo sapiens 26-35 22405602-8 2012 Quetiapine and ziprasidone display a better tolerability profile than risperidone and olanzapine in terms of weight gain, glucose metabolism, increases in prolactin levels, and EPS, while aripiprazole seems to be the most weight-neutral. Quetiapine Fumarate 0-10 prolactin Homo sapiens 155-164 22405602-8 2012 Quetiapine and ziprasidone display a better tolerability profile than risperidone and olanzapine in terms of weight gain, glucose metabolism, increases in prolactin levels, and EPS, while aripiprazole seems to be the most weight-neutral. ziprasidone 15-26 prolactin Homo sapiens 155-164 22405602-8 2012 Quetiapine and ziprasidone display a better tolerability profile than risperidone and olanzapine in terms of weight gain, glucose metabolism, increases in prolactin levels, and EPS, while aripiprazole seems to be the most weight-neutral. Olanzapine 86-96 prolactin Homo sapiens 155-164 22333523-3 2012 Dopamine is the most important prolactin-inhibiting factor, and dopaminergic hyperactivity has been implicated in the pathophysiology of psychosis. Dopamine 0-8 prolactin Homo sapiens 31-40 22378062-14 2012 The observed increases in neopterin and phenylalanine/tyrosine ratio are indicative of changes in tetrahydrobiopterin, which is involved in the metabolism of serotonin, noradrenaline and dopamine, and possibly mediating the increase in prolactin. sapropterin 98-117 prolactin Homo sapiens 236-245 22412226-7 2012 Prolactin and 16-kDa PRL correlated inversely with the 6-minute-walk distance (P <0.01) and with peak oxygen uptake during exercise (P <0.005).Serum levels of prolactin and 16-kDa PRL were significantly higher in patients with precapillary pulmonary hypertension and were inversely correlated with 6-minute-walk distance and peak oxygen uptake.These results indicate that prolactin and 16-kDa PRL might play a role in the pathophysiology of precapillary pulmonary hypertension. 16-kda 14-20 prolactin Homo sapiens 165-174 23090266-7 2012 Prolactin levels were higher in the patients treated with olanzapine compared with in those treated with clozapine at study start, but there were no differences in the other parameters between the treatment groups at study start. Olanzapine 58-68 prolactin Homo sapiens 0-9 23090266-7 2012 Prolactin levels were higher in the patients treated with olanzapine compared with in those treated with clozapine at study start, but there were no differences in the other parameters between the treatment groups at study start. Clozapine 105-114 prolactin Homo sapiens 0-9 22943024-0 2012 Quetiapine-induced galactorrhea with normal prolactin level in an adult female patient. Quetiapine Fumarate 0-10 prolactin Homo sapiens 44-53 22629484-3 2012 CASE DESCRIPTION: We described a case of a 31-year-old male with a serum prolactin (PRL) value of 240 ng/ml Magnetic resonance imaging (MRI) showed a space-occupying mass within the sphenoid sinus (SS) which partially enhanced by gadolinium. Gadolinium 230-240 prolactin Homo sapiens 73-82 22412226-7 2012 Prolactin and 16-kDa PRL correlated inversely with the 6-minute-walk distance (P <0.01) and with peak oxygen uptake during exercise (P <0.005).Serum levels of prolactin and 16-kDa PRL were significantly higher in patients with precapillary pulmonary hypertension and were inversely correlated with 6-minute-walk distance and peak oxygen uptake.These results indicate that prolactin and 16-kDa PRL might play a role in the pathophysiology of precapillary pulmonary hypertension. Oxygen 105-111 prolactin Homo sapiens 0-9 22412226-7 2012 Prolactin and 16-kDa PRL correlated inversely with the 6-minute-walk distance (P <0.01) and with peak oxygen uptake during exercise (P <0.005).Serum levels of prolactin and 16-kDa PRL were significantly higher in patients with precapillary pulmonary hypertension and were inversely correlated with 6-minute-walk distance and peak oxygen uptake.These results indicate that prolactin and 16-kDa PRL might play a role in the pathophysiology of precapillary pulmonary hypertension. 16-kda 179-185 prolactin Homo sapiens 165-174 22412226-7 2012 Prolactin and 16-kDa PRL correlated inversely with the 6-minute-walk distance (P <0.01) and with peak oxygen uptake during exercise (P <0.005).Serum levels of prolactin and 16-kDa PRL were significantly higher in patients with precapillary pulmonary hypertension and were inversely correlated with 6-minute-walk distance and peak oxygen uptake.These results indicate that prolactin and 16-kDa PRL might play a role in the pathophysiology of precapillary pulmonary hypertension. Oxygen 336-342 prolactin Homo sapiens 165-174 21404115-0 2011 Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study. Clomipramine 0-12 prolactin Homo sapiens 27-36 22863502-5 2011 Polyetilenoglycol (PEG) is the most used method that removes PRL from serum. polyetilenoglycol 0-17 prolactin Homo sapiens 61-64 22863502-5 2011 Polyetilenoglycol (PEG) is the most used method that removes PRL from serum. Polyethylene Glycols 19-22 prolactin Homo sapiens 61-64 21872321-0 2012 Temporal relationships of a pulse of prolactin (PRL) to a pulse of a metabolite of PGF2alpha in mares. Dinoprost 83-92 prolactin Homo sapiens 48-51 21872321-2 2012 The autocorrelation function of the R program was used to detect pulse rhythmicity, and the intra-assay CV was used to locate and characterize pulses of prolactin (PRL) and a metabolite of prostaglandin F2alpha (PGFM). Prolactin 153-162 prolactin Homo sapiens 164-167 21872321-6 2012 Concentrations of PRL during hours of a PGFM pulse were different (P<0.003) within the luteolytic period and postluteolytic period and were greatest at the PGFM peak; PRL concentrations during a PGFM pulse were not different during the preluteolytic period. 15-keto-13,14-dihydroprostaglandin F2alpha 40-44 prolactin Homo sapiens 18-21 21872321-6 2012 Concentrations of PRL during hours of a PGFM pulse were different (P<0.003) within the luteolytic period and postluteolytic period and were greatest at the PGFM peak; PRL concentrations during a PGFM pulse were not different during the preluteolytic period. 15-keto-13,14-dihydroprostaglandin F2alpha 40-44 prolactin Homo sapiens 170-173 22151839-15 2011 Supplementation of cAMP induced mRNA and protein expression of PRL and IGFBP-1 in both cell types at day 3, 6, 9, and 12 of treatment. Cyclic AMP 19-23 prolactin Homo sapiens 63-66 22151839-19 2011 In both cell types combined treatments with cAMP and E2P4 provoked higher expression levels of PRL and IGFBP1 mRNA and protein as compared to cAMP stimulation alone. Cyclic AMP 44-48 prolactin Homo sapiens 95-98 22151839-19 2011 In both cell types combined treatments with cAMP and E2P4 provoked higher expression levels of PRL and IGFBP1 mRNA and protein as compared to cAMP stimulation alone. Cyclic AMP 142-146 prolactin Homo sapiens 95-98 21404115-0 2011 Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study. Serotonin 53-62 prolactin Homo sapiens 27-36 21404115-0 2011 Clomipramine-induced serum prolactin as a marker for serotonin and dopamine turnover: results of an open label study. Dopamine 67-75 prolactin Homo sapiens 27-36 21404115-3 2011 The prolactin response to clomipramine has been widely used to assess CNS functioning. Clomipramine 26-38 prolactin Homo sapiens 4-13 21404115-4 2011 This open label study investigates the prolactin response induced by clomipramine in the plasma of healthy volunteers and whether it is related to changes in monoamine metabolites. Clomipramine 69-81 prolactin Homo sapiens 39-48 21404115-5 2011 The effects of clomipramine challenge on prolactin, 5-HIAA, HVA and MHPG were measured in 12 healthy volunteers. Clomipramine 15-27 prolactin Homo sapiens 41-50 21404115-9 2011 Changes in HVA and 5-HIAA correlated statistically significantly and positively with the amount of prolactin release in the whole sample. Homovanillic Acid 11-14 prolactin Homo sapiens 99-108 21404115-9 2011 Changes in HVA and 5-HIAA correlated statistically significantly and positively with the amount of prolactin release in the whole sample. Hydroxyindoleacetic Acid 19-25 prolactin Homo sapiens 99-108 21404115-12 2011 Correlations between intra-individual changes in HVA, 5-HIAA and serum prolactin might indicate a central nervous effect of clomipramine on monoamine turnover. Clomipramine 124-136 prolactin Homo sapiens 71-80 21404115-12 2011 Correlations between intra-individual changes in HVA, 5-HIAA and serum prolactin might indicate a central nervous effect of clomipramine on monoamine turnover. monoamine 140-149 prolactin Homo sapiens 71-80 21404115-13 2011 We conclude that monoamine changes in relation to prolactin response after clomipramine challenge may be suitable for characterizing the relationship between central serotonergic and dopaminergic function. monoamine 17-26 prolactin Homo sapiens 50-59 21404115-13 2011 We conclude that monoamine changes in relation to prolactin response after clomipramine challenge may be suitable for characterizing the relationship between central serotonergic and dopaminergic function. Clomipramine 75-87 prolactin Homo sapiens 50-59 22031511-11 2011 One patient with cyclic EAS had a false-positive IPSS when eucortisolemic (baseline prolactin IPS/P = 1.7; normalized ratio = 5.6). cyclic eas 17-27 prolactin Homo sapiens 84-93 19104942-3 2011 Treatment with dopamine agonist alleviated all symptoms, with concomitant suppression of plasma prolactin levels and a significant reduction in tumor mass. Dopamine 15-23 prolactin Homo sapiens 96-105 22713195-3 2011 Conventional antipsychotics and some of the atypical antipsychotics, such as risperidone, paliperidone, amisulpride and zotepine, are frequently associated with the raise in prolactin plasma levels. Risperidone 77-88 prolactin Homo sapiens 174-183 23983946-10 2011 CONCLUSIONS: The clinical data from the present study supports the fact that amisulpride is an effective and safe antipsychotic drug, but elevates prolactin levels in both sexes. Amisulpride 77-88 prolactin Homo sapiens 147-156 22713195-3 2011 Conventional antipsychotics and some of the atypical antipsychotics, such as risperidone, paliperidone, amisulpride and zotepine, are frequently associated with the raise in prolactin plasma levels. Paliperidone Palmitate 90-102 prolactin Homo sapiens 174-183 22713195-3 2011 Conventional antipsychotics and some of the atypical antipsychotics, such as risperidone, paliperidone, amisulpride and zotepine, are frequently associated with the raise in prolactin plasma levels. Amisulpride 104-115 prolactin Homo sapiens 174-183 22713195-3 2011 Conventional antipsychotics and some of the atypical antipsychotics, such as risperidone, paliperidone, amisulpride and zotepine, are frequently associated with the raise in prolactin plasma levels. zotepine 120-128 prolactin Homo sapiens 174-183 22713195-12 2011 The management of a patient with antipsychotic-induced hyperprolactinemia must be adapted to each patient and it may include a reduction in the dosage of the offending antipsychotic, switching to a prolactin-sparing antipsychotic or the use of a dopamine receptor agonist, such as bromocriptine, cabergoline and amantadine. Bromocriptine 281-294 prolactin Homo sapiens 60-69 22713195-12 2011 The management of a patient with antipsychotic-induced hyperprolactinemia must be adapted to each patient and it may include a reduction in the dosage of the offending antipsychotic, switching to a prolactin-sparing antipsychotic or the use of a dopamine receptor agonist, such as bromocriptine, cabergoline and amantadine. Cabergoline 296-307 prolactin Homo sapiens 60-69 22713195-12 2011 The management of a patient with antipsychotic-induced hyperprolactinemia must be adapted to each patient and it may include a reduction in the dosage of the offending antipsychotic, switching to a prolactin-sparing antipsychotic or the use of a dopamine receptor agonist, such as bromocriptine, cabergoline and amantadine. Amantadine 312-322 prolactin Homo sapiens 60-69 21479550-9 2011 These results remained consistent after considering specific atypical antipsychotics known to significantly increase prolactin levels such as risperidone (RR: 0.86, 95% CI: 0.60, 1.25). Risperidone 142-153 prolactin Homo sapiens 117-126 22036815-9 2011 Normalization rate in serum level of prolactin and cure rate were 91% and 63% in the Cabergoline group. Cabergoline 85-96 prolactin Homo sapiens 37-46 22036815-14 2011 The factors that cabergoline and / or TSS can cure prolactinoma are non-invasive tumor and prolactin level under 200 ng/mL at pretreatment. Cabergoline 17-28 prolactin Homo sapiens 51-60 21820424-0 2011 Clinical efficacy of propylthiouracil and its influence on prolactin in psoriatic patients. Propylthiouracil 21-37 prolactin Homo sapiens 59-68 21820424-3 2011 Hence, the objective is to find the effect of PTU on PRL level in psoriatic patients. Propylthiouracil 46-49 prolactin Homo sapiens 53-56 21820424-10 2011 CONCLUSION: Since PRL is a growth hormone involved in hyperproliferation of keratinocytes, this study reveals the antiproliferative effect of PTU. Propylthiouracil 142-145 prolactin Homo sapiens 18-21 21531845-14 2011 The greater concentration of lactose in colostrum from IF sows could be attributed to this transient increase in prolactin and cortisol. Lactose 29-36 prolactin Homo sapiens 113-122 21869700-5 2011 Multiple regression analyses revealed that prolactin increases in maximum concentration and in area under the curve depended on drug (quetiapine < olanzapine < risperidone; P < 0.001), sex (women > men; P < 0.001), and Taq1A polymorphism (A1+ > A2/A2; P < 0.05). Quetiapine Fumarate 134-144 prolactin Homo sapiens 43-52 21869700-5 2011 Multiple regression analyses revealed that prolactin increases in maximum concentration and in area under the curve depended on drug (quetiapine < olanzapine < risperidone; P < 0.001), sex (women > men; P < 0.001), and Taq1A polymorphism (A1+ > A2/A2; P < 0.05). Olanzapine 150-160 prolactin Homo sapiens 43-52 21869700-5 2011 Multiple regression analyses revealed that prolactin increases in maximum concentration and in area under the curve depended on drug (quetiapine < olanzapine < risperidone; P < 0.001), sex (women > men; P < 0.001), and Taq1A polymorphism (A1+ > A2/A2; P < 0.05). Risperidone 166-177 prolactin Homo sapiens 43-52 21869700-6 2011 Analysis of the individual drugs revealed that prolactin secretion was modulated by sex and Taq1A polymorphism in olanzapine and risperidone (P < 0.05); however, these factors were not linked to prolactin secretion in quetiapine. Olanzapine 114-124 prolactin Homo sapiens 47-56 21869700-6 2011 Analysis of the individual drugs revealed that prolactin secretion was modulated by sex and Taq1A polymorphism in olanzapine and risperidone (P < 0.05); however, these factors were not linked to prolactin secretion in quetiapine. Risperidone 129-140 prolactin Homo sapiens 47-56 21869700-6 2011 Analysis of the individual drugs revealed that prolactin secretion was modulated by sex and Taq1A polymorphism in olanzapine and risperidone (P < 0.05); however, these factors were not linked to prolactin secretion in quetiapine. Quetiapine Fumarate 221-231 prolactin Homo sapiens 47-56 22001219-0 2011 Serum prolactin rises in Mexican school children exposed to airborne manganese. Manganese 69-78 prolactin Homo sapiens 6-15 22001219-2 2011 Dopamine serves as a tonic inhibitor of prolactin release in the anterior hypophysis, thus the serum prolactin levels in occupationally Mn exposed workers has been found increased. Dopamine 0-8 prolactin Homo sapiens 40-49 22001219-2 2011 Dopamine serves as a tonic inhibitor of prolactin release in the anterior hypophysis, thus the serum prolactin levels in occupationally Mn exposed workers has been found increased. Dopamine 0-8 prolactin Homo sapiens 101-110 21658381-5 2011 Based on these nine top sequences in the combination group excluding four overlapping pathways (MAPK-ERK, Kitlg, Icam1-Ap1, and prolactin), the jasminoidin group had four (PRLR-STAT1, AcvR2-AcvR1B, ACVR1/2A-SMAD1, GHR-NF-kappaB) contributing pathways, and the ursodeoxycholic acid group had one (IL-6) contributing pathway. geniposide 144-155 prolactin Homo sapiens 128-137 21324816-0 2011 Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Bromocriptine 31-44 prolactin Homo sapiens 9-18 21777304-8 2011 Applied at a ratio of 1 : 1 (PRL:Delta1-9-G129R-hPRL; 40 nm each), this antagonist was able to nearly ( 80%) reverse PRL-induced sensitization of capsaicin responses in rat sensory neurons. Capsaicin 147-156 prolactin Homo sapiens 48-52 21871373-9 2011 Subjects taking risperidone had increased prolactin levels (week 7; p = .001). Risperidone 16-27 prolactin Homo sapiens 42-51 21719533-6 2011 We show that mutation of PAK1 Tyr 153, 201, and 285 (sites of JAK2 phosphorylation; PAK1 Y3F) decreases both PAK1 nuclear translocation in response to PRL and PRL-induced cyclin D1 promoter activity by 55%. Tyrosine 30-33 prolactin Homo sapiens 151-154 21719533-6 2011 We show that mutation of PAK1 Tyr 153, 201, and 285 (sites of JAK2 phosphorylation; PAK1 Y3F) decreases both PAK1 nuclear translocation in response to PRL and PRL-induced cyclin D1 promoter activity by 55%. Tyrosine 30-33 prolactin Homo sapiens 159-162 21719533-11 2011 We propose two PAK1-dependent mechanisms to activate cyclin D1 promoter activity in response to PRL: via nuclear translocation of tyrosyl-phosphorylated PAK1 and via formation of a Nck-PAK1 complex that sequesters PAK1 in the cytoplasm. cyclo(tyrosyl-tyrosyl) 130-137 prolactin Homo sapiens 96-99 22679041-4 2011 Following 18 months of treatment with cabergoline, the prolactin level reduced to 914 mU/l. Cabergoline 38-49 prolactin Homo sapiens 55-64 21823053-7 2011 This review discusses the role of lactogens on glucose homeostasis during pregnancy and proposes a mechanism by which the hormonal control of lactation, led by prolactin, may regulate adipocyte biology, glucose and lipid metabolism, and guard postpartum women against type 2 diabetes. Glucose 203-210 prolactin Homo sapiens 160-169 21823168-0 2011 Dose-dependent effects of olanzapine on QT intervals and plasma prolactin levels in Japanese patients with stable schizophrenia. Olanzapine 26-36 prolactin Homo sapiens 64-73 21566085-7 2011 We also show that phosphorylation of the three tyrosines of PAK1 by JAK2, as well as the presence of FLNa, play a role in PRL-dependent cell ruffling. Tyrosine 47-56 prolactin Homo sapiens 122-125 21566085-8 2011 Finally, we show that the actin- and FLNa-binding-deficient mutant of SH2B1beta (SH2B1beta 3Delta) abolished PRL-dependent ruffling and PRL-dependent cell migration when expressed along with PAK1 Y3F (JAK2 tyrosyl-phosphorylation-deficient mutant). cyclo(tyrosyl-tyrosyl) 206-213 prolactin Homo sapiens 109-112 21095016-0 2011 Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women. Olanzapine 71-81 prolactin Homo sapiens 49-58 21095016-2 2011 Single nucleotide polymorphisms (SNPs), rs2734842(C), rs6275(T), and rs6279(C) located within DRD2, have been shown to be associated with prolactin increase in olanzapine/fluoxetine combination (OFC)-treated women. Olanzapine 160-170 prolactin Homo sapiens 138-147 21095016-2 2011 Single nucleotide polymorphisms (SNPs), rs2734842(C), rs6275(T), and rs6279(C) located within DRD2, have been shown to be associated with prolactin increase in olanzapine/fluoxetine combination (OFC)-treated women. Fluoxetine 171-181 prolactin Homo sapiens 138-147 21095016-4 2011 An ANCOVA was used to test whether change from baseline in the natural log of prolactin concentration (ln[prolactin]) was associated with SNPs in the pooled olanzapine studies. Olanzapine 157-167 prolactin Homo sapiens 78-87 21095016-6 2011 Negative strand alleles rs2734842(C), rs6275(T), and rs6279(C) were significantly associated with increased prolactin in olanzapine-treated women, replicating previous results. Olanzapine 121-131 prolactin Homo sapiens 108-117 21095016-7 2011 These SNPs also showed moderate association with increased prolactin in olanzapine-treated and OFC-treated women in the meta-analysis, as did rs4938016, rs2734848, rs2734841, rs1124493, and rs1076562. Olanzapine 72-82 prolactin Homo sapiens 59-68 21592821-0 2011 Calcitriol stimulates prolactin expression in non-activated human peripheral blood mononuclear cells: breaking paradigms. Calcitriol 0-10 prolactin Homo sapiens 22-31 21592821-1 2011 Calcitriol, the hormonal form of vitamin D(3), exerts immunomodulatory effects through the vitamin D(3) receptor (VDR) and increases prolactin (PRL) expression in the pituitary and decidua. Calcitriol 0-10 prolactin Homo sapiens 133-142 21592821-1 2011 Calcitriol, the hormonal form of vitamin D(3), exerts immunomodulatory effects through the vitamin D(3) receptor (VDR) and increases prolactin (PRL) expression in the pituitary and decidua. Calcitriol 0-10 prolactin Homo sapiens 144-147 21592821-1 2011 Calcitriol, the hormonal form of vitamin D(3), exerts immunomodulatory effects through the vitamin D(3) receptor (VDR) and increases prolactin (PRL) expression in the pituitary and decidua. Vitamin D 33-42 prolactin Homo sapiens 133-142 21592821-1 2011 Calcitriol, the hormonal form of vitamin D(3), exerts immunomodulatory effects through the vitamin D(3) receptor (VDR) and increases prolactin (PRL) expression in the pituitary and decidua. Vitamin D 33-42 prolactin Homo sapiens 144-147 21592821-3 2011 Therefore, we investigated calcitriol effects upon PRL in resting and phytohemagglutinin-activated human peripheral blood mononuclear cells (PBMNC) and Jurkat T lymphoma cells. Calcitriol 27-37 prolactin Homo sapiens 51-54 21592821-5 2011 Only in resting PBMNC calcitriol significantly stimulated PRL expression in a dose-dependent manner. pbmnc 16-21 prolactin Homo sapiens 58-61 21592821-5 2011 Only in resting PBMNC calcitriol significantly stimulated PRL expression in a dose-dependent manner. Calcitriol 22-32 prolactin Homo sapiens 58-61 21592821-7 2011 Calcitriol upregulation of PRL and CYP24A1 was significantly inhibited by the VDR antagonist TEI-9647. Calcitriol 0-10 prolactin Homo sapiens 27-30 21592821-7 2011 Calcitriol upregulation of PRL and CYP24A1 was significantly inhibited by the VDR antagonist TEI-9647. TEI 9647 93-101 prolactin Homo sapiens 27-30 21592821-10 2011 In summary, calcitriol stimulated PRL and CYP24A1 gene expression in quiescent lymphocytes through a VDR-mediated mechanism. Calcitriol 12-22 prolactin Homo sapiens 34-37 21910340-12 2011 Higher PRL levels were obtained in the GDT group than in the PDT group and the SDT group (P<0.01). 3,4-Dihydroxy-9,10-secoandrosta-1,3,5(10)-triene-9,17-dione 79-82 prolactin Homo sapiens 7-10 21385106-5 2011 EXPERT OPINION: Typical antipsychotics, in addition to the atypical antipsychotics risperidone and amisulpride, have been shown to increase serum prolactin levels in in vivo human studies. Risperidone 83-94 prolactin Homo sapiens 146-155 21385106-5 2011 EXPERT OPINION: Typical antipsychotics, in addition to the atypical antipsychotics risperidone and amisulpride, have been shown to increase serum prolactin levels in in vivo human studies. Amisulpride 99-110 prolactin Homo sapiens 146-155 30200042-4 2011 We report a case of a 30 year old non-pregnant, non-puerperal, opioid-dependent, HIV positive woman on long-term methadone maintenance programme, who presented with bilateral, milky nipple discharge, associated with painful breast lumps, but with serum prolactin levels below the normal range. Methadone 113-122 prolactin Homo sapiens 253-262 21527503-7 2011 In addition, progestin prevented dissociation of the corepressors Yin and Yang 1 and histone deacetylase 3 from the promoter, and demethylation of lysine 9 of histone 3 induced by PRL and glucocorticoids. Lysine 147-153 prolactin Homo sapiens 180-183 23983929-0 2011 Aripiprazole use combined with depot antipsychotic medication: two cases demonstrating its ability to reduce prolactin levels in an adolescent forensic hospital. Aripiprazole 0-12 prolactin Homo sapiens 109-118 23983929-2 2011 The addition of aripiprazole can reduce prolactin levels and restore sexual function in these patients. Aripiprazole 16-28 prolactin Homo sapiens 40-49 21324816-0 2011 Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Cabergoline 64-75 prolactin Homo sapiens 9-18 21324816-1 2011 OBJECTIVE: To describe a positive prolactin response to bromocriptine treatment in 2 patients with cabergoline-resistant prolactinomas. Bromocriptine 56-69 prolactin Homo sapiens 34-43 21324816-1 2011 OBJECTIVE: To describe a positive prolactin response to bromocriptine treatment in 2 patients with cabergoline-resistant prolactinomas. Cabergoline 99-110 prolactin Homo sapiens 34-43 21324816-7 2011 Her prolactin concentration decreased to 13 ng/mL after her regimen was switched to bromocriptine, 5 mg daily. Bromocriptine 84-97 prolactin Homo sapiens 4-13 21324816-9 2011 Oral cabergoline was started at 0.5 mg twice weekly and increased to 1 mg 3 times weekly when prolactin levels continued to rise to 340 ng/mL over 18 months. Cabergoline 5-16 prolactin Homo sapiens 94-103 21324816-14 2011 After 4.5 months of bromocriptine therapy, her serum prolactin concentration decreased to 133 ng/mL. Bromocriptine 20-33 prolactin Homo sapiens 53-62 21695901-5 2011 RESULT: The PRL level in the BPA exposure group was significantly higher to that in the control group (t = 2.127, P = 0.047). bisphenol A 29-32 prolactin Homo sapiens 12-15 21501721-4 2011 The resulting bio-conjugate was trapped on the surface of the screen-printed electrode with a small magnet and prolactin quantification was accomplished by differential pulse voltammetry of 1-naphtol formed in the enzyme reaction using 1-naphtyl phosphate as alkaline phosphatase substrate. 1-naphthol 190-199 prolactin Homo sapiens 111-120 21501721-4 2011 The resulting bio-conjugate was trapped on the surface of the screen-printed electrode with a small magnet and prolactin quantification was accomplished by differential pulse voltammetry of 1-naphtol formed in the enzyme reaction using 1-naphtyl phosphate as alkaline phosphatase substrate. 1-naphtyl phosphate 236-255 prolactin Homo sapiens 111-120 21695901-12 2011 The multivariate analysis found that BPA exposure was the independent risk factor to effect serum PRL (OR = 2.623, P = 0.030) of occupational women. bisphenol A 37-40 prolactin Homo sapiens 98-101 21695901-14 2011 CONCLUSION: BPA occupational exposure of women maked PRL level set up and effected progesterone level. bisphenol A 12-15 prolactin Homo sapiens 53-56 21695901-15 2011 After adjusting for age, exposure age and other potential confounding factors, BPA exposure is an independent risk factor to arise the level of serum PRL in occupational women. bisphenol A 79-82 prolactin Homo sapiens 150-153 21308737-2 2011 We have reported that L-arginine, released from extracellular substrates by prolactin (PRL)- and 17beta-estradiol (E2)-induced carboxypeptidase-D in the cell membrane, promotes nitric oxide (NO) production for MCF-7 cell survival. Arginine 22-32 prolactin Homo sapiens 87-90 21308737-2 2011 We have reported that L-arginine, released from extracellular substrates by prolactin (PRL)- and 17beta-estradiol (E2)-induced carboxypeptidase-D in the cell membrane, promotes nitric oxide (NO) production for MCF-7 cell survival. Nitric Oxide 177-189 prolactin Homo sapiens 87-90 21346608-7 2011 After haloperidol and reserpine, increases in prolactin were significantly more pronounced in women than in men. Haloperidol 6-17 prolactin Homo sapiens 46-55 21346608-7 2011 After haloperidol and reserpine, increases in prolactin were significantly more pronounced in women than in men. Reserpine 22-31 prolactin Homo sapiens 46-55 21346608-12 2011 The partial agonistic effect of aripiprazole was sufficient to maintain prolactin on physiologic levels. Aripiprazole 32-44 prolactin Homo sapiens 72-81 20530986-0 2011 Effect of ghrelin and metoclopramide on prolactin secretion in normal women. Ghrelin 10-17 prolactin Homo sapiens 40-49 20530986-0 2011 Effect of ghrelin and metoclopramide on prolactin secretion in normal women. Metoclopramide 22-36 prolactin Homo sapiens 40-49 20530986-1 2011 BACKGROUND: Administration of ghrelin to women stimulates the secretion of PRL but the mechanism is not known. Ghrelin 30-37 prolactin Homo sapiens 75-78 20530986-2 2011 AIM: The aim of the study was to investigate the effect of the dopamine receptor blocker, metoclopramide, on ghrelin-induced PRL release. Metoclopramide 90-104 prolactin Homo sapiens 125-128 20530986-2 2011 AIM: The aim of the study was to investigate the effect of the dopamine receptor blocker, metoclopramide, on ghrelin-induced PRL release. Ghrelin 109-116 prolactin Homo sapiens 125-128 20530986-7 2011 RESULTS: Following ghrelin administration (cycles 2 and 4), plasma ghrelin and serum PRL and GH levels increased rapidly, peaking at 30 min (p<0.001). Ghrelin 19-26 prolactin Homo sapiens 85-88 20530986-8 2011 PRL was also increased after the injection of metoclopramide (p<0.001, cycle 3), but the increase was much greater than after the administration of ghrelin. Metoclopramide 46-60 prolactin Homo sapiens 0-3 20530986-8 2011 PRL was also increased after the injection of metoclopramide (p<0.001, cycle 3), but the increase was much greater than after the administration of ghrelin. Ghrelin 151-158 prolactin Homo sapiens 0-3 20530986-9 2011 The combination of ghrelin and metoclopramide stimulated PRL secretion to the same extent with metoclopramide alone. Ghrelin 19-26 prolactin Homo sapiens 57-60 20530986-9 2011 The combination of ghrelin and metoclopramide stimulated PRL secretion to the same extent with metoclopramide alone. Metoclopramide 31-45 prolactin Homo sapiens 57-60 20530986-11 2011 CONCLUSIONS: These results demonstrate that the stimulating effect of ghrelin on PRL secretion is not additive with that of metoclopramide, although a dose range study might provide further information. Ghrelin 70-77 prolactin Homo sapiens 81-84 21168464-9 2011 There was no significant difference in the Drug-Induced Extrapyramidal Symptom Scale score or serum prolactin increase between the treatment groups, but RIS-OS appeared to induce less serum prolactin increase than RIS-ST in drug-naive female patients. ris-os 153-159 prolactin Homo sapiens 190-199 21216266-0 2011 The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Risperidone 90-101 prolactin Homo sapiens 60-69 21216266-9 2011 These findings suggest that smoking status has an impact on prolactin concentration during risperidone treatment. Risperidone 91-102 prolactin Homo sapiens 60-69 21159852-4 2011 Time-course analysis demonstrated that cAMP enhances endogenous reactive oxygen species production, apparent after 12 h of stimulation, which coincides with a dramatic increase in decidual PRL and IGFBP1 expression. Cyclic AMP 39-43 prolactin Homo sapiens 189-192 21226500-9 2011 Finally, we identified a third group of residues that are outside site 1 (>5 A) and extend to site 2 and whose mutation to alanine significantly weakened receptor binding at site 1 of prolactin. Alanine 126-133 prolactin Homo sapiens 187-196 21148631-0 2011 Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls. Sodium Oxybate 0-14 prolactin Homo sapiens 25-34 21294903-0 2011 Establishing a relationship between prolactin and altered fatty acid beta-oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. altered 50-57 prolactin Homo sapiens 36-45 21294903-0 2011 Establishing a relationship between prolactin and altered fatty acid beta-oxidation via carnitine palmitoyl transferase 1 in breast cancer cells. Fatty Acids 58-68 prolactin Homo sapiens 36-45 21294903-3 2011 The current study examined breast cancer as a metabolic disease in the context of altered fatty acid catabolism by examining the effect of PRL on carnitine palmitoyl transferase 1 (CPT1), an enzyme that shuttles long-chain fatty acids into the mitochondrial matrix for beta-oxidation. long-chain fatty acids 212-234 prolactin Homo sapiens 139-142 21294903-13 2011 CONCLUSIONS: PRL enhances fatty acid beta-oxidation by stimulating CPT1 expression and/or activity in MCF-7 and MDA-MB-231 breast cancer cells. Fatty Acids 26-36 prolactin Homo sapiens 13-16 21121933-0 2011 Prolactin serum levels during alcohol withdrawal are associated with the severity of alcohol dependence and withdrawal symptoms. Alcohols 30-37 prolactin Homo sapiens 0-9 21121933-1 2011 BACKGROUND: Prolactin serum levels have been described to be elevated during alcohol withdrawal in alcohol-dependent patients and normalize during abstinence. Alcohols 77-84 prolactin Homo sapiens 12-21 21121933-1 2011 BACKGROUND: Prolactin serum levels have been described to be elevated during alcohol withdrawal in alcohol-dependent patients and normalize during abstinence. Alcohols 99-106 prolactin Homo sapiens 12-21 21121933-2 2011 Alterations in prolactin levels may reflect disturbances of dopaminergic neurotransmission which is of crucial importance for alcohol-seeking behavior. Alcohols 126-133 prolactin Homo sapiens 15-24 21121933-3 2011 METHODS: In this longitudinal observational study, we investigated prolactin serum levels in 99 male patients during the first 14 days of alcohol withdrawal and early abstinence and in 43 healthy controls. Alcohols 138-145 prolactin Homo sapiens 67-76 21121933-5 2011 RESULTS: Prolactin serum levels were elevated during the whole study period in alcohol-dependent patients compared to the healthy control group. Alcohols 79-86 prolactin Homo sapiens 9-18 21121933-6 2011 Prolactin levels at admission (first day of alcohol withdrawal) were associated with the severity of alcohol withdrawal (CIWA-Ar) and of alcohol dependence (SESA) but not with the other assessed psychologic parameters. Alcohols 44-51 prolactin Homo sapiens 0-9 21121933-6 2011 Prolactin levels at admission (first day of alcohol withdrawal) were associated with the severity of alcohol withdrawal (CIWA-Ar) and of alcohol dependence (SESA) but not with the other assessed psychologic parameters. Alcohols 101-108 prolactin Homo sapiens 0-9 21121933-7 2011 CONCLUSIONS: The presented findings confirm that prolactin is significantly elevated in alcohol-dependent patients during alcohol withdrawal and early abstinence, not showing a rapid decline after cessation of drinking. Alcohols 88-95 prolactin Homo sapiens 49-58 21121933-7 2011 CONCLUSIONS: The presented findings confirm that prolactin is significantly elevated in alcohol-dependent patients during alcohol withdrawal and early abstinence, not showing a rapid decline after cessation of drinking. Alcohols 122-129 prolactin Homo sapiens 49-58 21159852-4 2011 Time-course analysis demonstrated that cAMP enhances endogenous reactive oxygen species production, apparent after 12 h of stimulation, which coincides with a dramatic increase in decidual PRL and IGFBP1 expression. Reactive Oxygen Species 64-87 prolactin Homo sapiens 189-192 20345874-2 2011 Sex steroids, thyroid and pituitary hormones (oxytocin and prolactin) have been proposed to control the ejaculatory process at various levels; however, only a few reports are currently available. Steroids 4-12 prolactin Homo sapiens 59-68 21262884-7 2011 Milk calcium levels increased in subjects treated with r-hPRL twice daily (2.8 +- 0.6 to 5.0 +- 0.9 mmol/L; P = .03). Calcium 5-12 prolactin Homo sapiens 57-61 21262884-10 2011 r-hPRL also increased antimicrobially active oligosaccharide concentrations. Oligosaccharides 45-60 prolactin Homo sapiens 2-6 21265942-0 2011 Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Aripiprazole 70-82 prolactin Homo sapiens 21-30 21265942-0 2011 Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series. Risperidone 88-99 prolactin Homo sapiens 21-30 21265942-4 2011 After treatment with aripiprazole, all patients showed reduced serum prolactin (26.54 +- 17.03 ng/mL to 3.71 +- 1.87 ng/mL, P=0.008) and five reported improved sexual function. Aripiprazole 21-33 prolactin Homo sapiens 69-78 21619835-10 2011 There was negative correlation between blood (RBC) Mn and urinary Mn (r = -0.310, P < 0.05), also there was negative correlation between serum PRL and serum TST (r = -0.409, P < 0.01), the positive correlation between serum LH and serum FSH was observed (r = 0.361, P < 0.05). Luteinizing Hormone 230-232 prolactin Homo sapiens 146-149 21146499-6 2011 Furthermore, knockdown of Nur77 in hESCs significantly decreased decidual PRL promoter activation and substantially attenuated PRL mRNA expression and PRL secretion (P < 0.01) induced by 8-Br-cAMP and MPA. 8-Bromo Cyclic Adenosine Monophosphate 190-199 prolactin Homo sapiens 127-130 21146499-6 2011 Furthermore, knockdown of Nur77 in hESCs significantly decreased decidual PRL promoter activation and substantially attenuated PRL mRNA expression and PRL secretion (P < 0.01) induced by 8-Br-cAMP and MPA. 8-Bromo Cyclic Adenosine Monophosphate 190-199 prolactin Homo sapiens 127-130 20713347-10 2011 In our series, all false-negative IPS:P ACTH ratios had a corresponding IPS:P prolactin ratio less than 1.3. IPS 34-37 prolactin Homo sapiens 78-87 21309169-3 2011 The efficacy of cabergoline in the normalization of prolactin level and in the tumoral volume reduction is well documented. Cabergoline 16-27 prolactin Homo sapiens 52-61 21309169-4 2011 Following more than two years of cabergoline treatment, in case the level of prolactin is normalized and the MRI shows no tumor residue, the medication can be withdrawn with chance of remission. Cabergoline 33-44 prolactin Homo sapiens 77-86 21440837-0 2011 An association of elevated serum prolactin with phthalate exposure in adult men. phthalic acid 48-57 prolactin Homo sapiens 33-42 21440837-5 2011 In linear regression models adjusted for potential confounders and excluding subjects with undetectable phthalates, a 10-fold increase in semen DEHP was associated with a 23% increase in serum PRL, as well as a 26% increase in serum DBP and a 20% increase in serum DEHP. Diethylhexyl Phthalate 144-148 prolactin Homo sapiens 193-196 21440837-6 2011 In logistic regression models all subjects demonstrated a dose-response relationship between above reference value PRL and semen DEHP (odds ratio per tertile adjusted for potential confounders = 1.0, 1.70, 3.50; P for trend = 0.01), and serum DBP (1.0, 1.10, 2.62; P for trend = 0.04), and serum DEHP (1.0, 1.46, 4.69; P for trend < 0.01). Dibutyl Phthalate 243-246 prolactin Homo sapiens 115-118 21440837-6 2011 In logistic regression models all subjects demonstrated a dose-response relationship between above reference value PRL and semen DEHP (odds ratio per tertile adjusted for potential confounders = 1.0, 1.70, 3.50; P for trend = 0.01), and serum DBP (1.0, 1.10, 2.62; P for trend = 0.04), and serum DEHP (1.0, 1.46, 4.69; P for trend < 0.01). Diethylhexyl Phthalate 129-133 prolactin Homo sapiens 115-118 21142706-0 2011 Elevated plasma prolactin in abstinent methamphetamine-dependent subjects. Methamphetamine 39-54 prolactin Homo sapiens 16-25 22144220-4 2011 The most commonly used technique to separate the isoforms of PRL is precipitation with polyethylene glycol (PEG). Polyethylene Glycols 87-106 prolactin Homo sapiens 61-64 22144220-4 2011 The most commonly used technique to separate the isoforms of PRL is precipitation with polyethylene glycol (PEG). Polyethylene Glycols 108-111 prolactin Homo sapiens 61-64 20713347-10 2011 In our series, all false-negative IPS:P ACTH ratios had a corresponding IPS:P prolactin ratio less than 1.3. IPS 72-75 prolactin Homo sapiens 78-87 21750634-7 2011 Bromocriptine and cabergoline were equally effective in lowering serum prolactin levels. Bromocriptine 0-13 prolactin Homo sapiens 71-80 21750634-7 2011 Bromocriptine and cabergoline were equally effective in lowering serum prolactin levels. Cabergoline 18-29 prolactin Homo sapiens 71-80 21876517-4 2011 RESULTS: Elevated PRL levels were found in about 45% of the patients and occurred more often in patients receiving risperidone or haloperidol, compared to patients receiving clozapine or olanzapine. Risperidone 115-126 prolactin Homo sapiens 18-21 21106881-5 2011 Lapatinib, a dual tyrosine kinase inhibitor (TKI) of both epidermal growth factor receptor (EGFR)/ErbB1 and HER2, blocked receptor signaling, and suppressed PRL expression more than gefitinib, a TKI of EGFR/ErbB1. Lapatinib 0-9 prolactin Homo sapiens 157-160 21106881-8 2011 In cultured human cells derived from resected prolactinoma tissue, lapatinib suppressed both PRL mRNA expression and secretion. Lapatinib 67-76 prolactin Homo sapiens 93-96 21876517-4 2011 RESULTS: Elevated PRL levels were found in about 45% of the patients and occurred more often in patients receiving risperidone or haloperidol, compared to patients receiving clozapine or olanzapine. Haloperidol 130-141 prolactin Homo sapiens 18-21 22167148-3 2011 With Somatostatin and/or its analogues, the DBM has an antiproliferative effect, negatively regulating the most powerful mitogenic molecule (GH), receptorially co-expressed and interactive with Prolactin, inhibited by Cabergoline and/or Bromocriptin. dbm 44-47 prolactin Homo sapiens 194-203 22167128-9 2011 Prolactin levels returned to normal within 15 days of sibutramine cessation and remained normal within 90 days of follow-up, with resolution of the amenogalactorrhea syndrome. sibutramine 54-65 prolactin Homo sapiens 0-9 22167148-3 2011 With Somatostatin and/or its analogues, the DBM has an antiproliferative effect, negatively regulating the most powerful mitogenic molecule (GH), receptorially co-expressed and interactive with Prolactin, inhibited by Cabergoline and/or Bromocriptin. Cabergoline 218-229 prolactin Homo sapiens 194-203 21876517-4 2011 RESULTS: Elevated PRL levels were found in about 45% of the patients and occurred more often in patients receiving risperidone or haloperidol, compared to patients receiving clozapine or olanzapine. Clozapine 174-183 prolactin Homo sapiens 18-21 22167148-3 2011 With Somatostatin and/or its analogues, the DBM has an antiproliferative effect, negatively regulating the most powerful mitogenic molecule (GH), receptorially co-expressed and interactive with Prolactin, inhibited by Cabergoline and/or Bromocriptin. Bromocriptine 237-249 prolactin Homo sapiens 194-203 21876517-8 2011 Additionally, the PRL (median 24 h) levels correlated positively to the 2 h glucose level at OGTT (rs=0.42, p=0.04). Glucose 76-83 prolactin Homo sapiens 18-21 21876517-9 2011 CONCLUSIONS: Our findings point to that hyperprolactinemia due to 1st and 2nd generation antipsychotics may decrease insulin sensitivity, whereas other mechanisms probably underlie insulin resistance induced by PRL-sparing antipsychotics such as clozapine and olanzapine. Clozapine 246-255 prolactin Homo sapiens 211-214 22506441-3 2011 We report a case of gynecomastia and galactorrhea in an adolescent male while on a combination of risperidone and fluvoxamine, although the serum prolactin was within normal range. Risperidone 98-109 prolactin Homo sapiens 146-155 22506441-3 2011 We report a case of gynecomastia and galactorrhea in an adolescent male while on a combination of risperidone and fluvoxamine, although the serum prolactin was within normal range. Fluvoxamine 114-125 prolactin Homo sapiens 146-155 20720166-4 2010 Using a gonadotroph cell monoculture, the first series of experiments showed that PRL is, paradoxically, a potent stimulator of LH release, with a three- to fourfold increase in LH values at hyperprolactinemic concentrations of PRL. Luteinizing Hormone 128-130 prolactin Homo sapiens 82-85 22379847-4 2011 The paper demonstrates that according to dynamics of visual function, neurological and hypopituitary symptoms, and probability of prolactin level normalization, treatment with cabergoline has significant advantages in comparison to surgery. Cabergoline 176-187 prolactin Homo sapiens 130-139 20889499-0 2010 Two independent histidines, one in human prolactin and one in its receptor, are critical for pH-dependent receptor recognition and activation. Histidine 16-26 prolactin Homo sapiens 41-50 20720166-4 2010 Using a gonadotroph cell monoculture, the first series of experiments showed that PRL is, paradoxically, a potent stimulator of LH release, with a three- to fourfold increase in LH values at hyperprolactinemic concentrations of PRL. Luteinizing Hormone 178-180 prolactin Homo sapiens 82-85 20720166-5 2010 Conversely, PRL dose-dependently modulated the LH secretory response to GnRH in a biphasic manner, with classical suppression of LH output only detected under a narrow dose range. Luteinizing Hormone 47-49 prolactin Homo sapiens 12-15 20720166-5 2010 Conversely, PRL dose-dependently modulated the LH secretory response to GnRH in a biphasic manner, with classical suppression of LH output only detected under a narrow dose range. Luteinizing Hormone 129-131 prolactin Homo sapiens 12-15 20720166-8 2010 Moreover, the experiments showed that these actions of PRL within gonadotroph cells are controlled by dopamine, the main hypothalamic inhibitory regulator of PRL release in vivo. Dopamine 102-110 prolactin Homo sapiens 55-58 20720166-8 2010 Moreover, the experiments showed that these actions of PRL within gonadotroph cells are controlled by dopamine, the main hypothalamic inhibitory regulator of PRL release in vivo. Dopamine 102-110 prolactin Homo sapiens 158-161 20874771-3 2010 We also investigated whether we could predict the composition of macroprolactin based on the ratio of polyethylene glycol (PEG)-precipitable PRL. Polyethylene Glycols 123-126 prolactin Homo sapiens 141-144 21175437-0 2010 Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin. Remoxipride 92-103 prolactin Homo sapiens 107-116 21175437-1 2010 AIMS: The tolerance to the prolactin response following administration of antipsychotic drugs has been modelled as a depletion of a prolactin pool (pool model) and a model where the tolerance is explained by a feedback loop including the dopamine interaction of prolactin release (agonist-antagonist interaction model, (AAI model)). Dopamine 238-246 prolactin Homo sapiens 27-36 21175437-9 2010 CONCLUSIONS: According to the analysis performed here, a previous analysis of several clinical studies and literature reports on prolactin concentrations, it appears that the dopamine feedback mechanism included in the AAI model is better than the storage depletion mechanism in the pool model to estimate the bio-rhythm of prolactin time-course and the tolerance development across different populations, drugs, treatment schedules and time. Dopamine 175-183 prolactin Homo sapiens 129-138 21175437-9 2010 CONCLUSIONS: According to the analysis performed here, a previous analysis of several clinical studies and literature reports on prolactin concentrations, it appears that the dopamine feedback mechanism included in the AAI model is better than the storage depletion mechanism in the pool model to estimate the bio-rhythm of prolactin time-course and the tolerance development across different populations, drugs, treatment schedules and time. Dopamine 175-183 prolactin Homo sapiens 324-333 20874771-6 2010 Macroprolactinaemia was defined by PEG-precipitable PRL ratio greater than 60%. Polyethylene Glycols 35-38 prolactin Homo sapiens 52-55 20874771-10 2010 A non-IgG-bound form of macroprolactin was found mainly in sera with marginally elevated PEG-precipitable PRL. Polyethylene Glycols 89-92 prolactin Homo sapiens 106-109 20874771-11 2010 The higher the PEG-precipitable PRL ratio, the greater the likelihood that autoantibodies were involved in the composition of macroprolactin. Polyethylene Glycols 15-18 prolactin Homo sapiens 32-35 20874771-13 2010 Long-term follow-up (2-17 years) revealed that the ratios of PEG-precipitable PRL, IgG-bound PRL and anti-PRL autoantibody-bound PRL were relatively stable. Polyethylene Glycols 61-64 prolactin Homo sapiens 78-81 20874771-14 2010 CONCLUSIONS: This study showed that higher PEG-precipitable PRL ratio in macroprolactinaemic sera might preferentially indicate the presence of anti-PRL autoantibodies and that macroprolactinaemia might be a long-lasting condition. Polyethylene Glycols 43-46 prolactin Homo sapiens 60-63 20874771-14 2010 CONCLUSIONS: This study showed that higher PEG-precipitable PRL ratio in macroprolactinaemic sera might preferentially indicate the presence of anti-PRL autoantibodies and that macroprolactinaemia might be a long-lasting condition. Polyethylene Glycols 43-46 prolactin Homo sapiens 149-152 20962042-4 2010 Treatment of cells with PRL inhibited pyruvate kinase activity and increased the lactate content in human cells in a manner that was dependent on the abundance of PRLr, activation of Janus kinase 2, and tyrosine phosphorylation of the intracellular domain of PRLr. Lactic Acid 81-88 prolactin Homo sapiens 24-27 21186967-9 2010 In both drug phases, risperidone prolactin was higher than the other groups, which did not differ. Risperidone 21-32 prolactin Homo sapiens 33-42 21186967-10 2010 The higher prolactin of the risperidone group may partially explain the bone density effect. Risperidone 28-39 prolactin Homo sapiens 11-20 20823101-9 2010 This reduction was blocked by bromocriptine, an inhibitor of pituitary PRL secretion, which lowers the levels of circulating PRL and retinal vasoinhibins. Bromocriptine 30-43 prolactin Homo sapiens 71-74 20823101-9 2010 This reduction was blocked by bromocriptine, an inhibitor of pituitary PRL secretion, which lowers the levels of circulating PRL and retinal vasoinhibins. Bromocriptine 30-43 prolactin Homo sapiens 125-128 20962042-4 2010 Treatment of cells with PRL inhibited pyruvate kinase activity and increased the lactate content in human cells in a manner that was dependent on the abundance of PRLr, activation of Janus kinase 2, and tyrosine phosphorylation of the intracellular domain of PRLr. Tyrosine 203-211 prolactin Homo sapiens 24-27 20978293-8 2010 Routine determination of prolactin is not clear and it seems it should be determined when testosterone levels are diminished. Testosterone 90-102 prolactin Homo sapiens 25-34 20732372-8 2010 For those who took risperidone before the study started, 14 of 15 (93.3%) patients had normalized prolactin levels, while only 1 of 10 (10%) taking benzamide antipsychotics had normalized prolactin levels. Risperidone 19-30 prolactin Homo sapiens 98-107 20732372-8 2010 For those who took risperidone before the study started, 14 of 15 (93.3%) patients had normalized prolactin levels, while only 1 of 10 (10%) taking benzamide antipsychotics had normalized prolactin levels. Risperidone 19-30 prolactin Homo sapiens 188-197 20571820-2 2010 STUDY DESIGN: Cabergoline was administered orally at a dose of 0.5 mg twice per week to 164 de novo hyperprolactinemic patients until serum prolactin level normalized. Cabergoline 14-25 prolactin Homo sapiens 105-114 20823114-6 2010 Expression of both prolactin and insulin-like growth factor binding protein-1, the two established decidualization marker genes, were minimally up-regulated by AZA after 10 days of treatment. Decitabine 160-163 prolactin Homo sapiens 19-28 20660056-6 2010 RESULTS: Three of the eight patients (two ACTH adenomas and one PRL carcinoma) responded to temozolomide as demonstrated by significant tumor shrinkage and reduced hormone secretion. Temozolomide 92-104 prolactin Homo sapiens 64-67 19747187-2 2010 This study was designed to test the hypothesis that salsolinol, acting from the CNS level, is able to stimulate pituitary prolactin release as well as prolactin mRNA expression in the anterior pituitary cells (AP) and in the mediobasal hypothalamus (MBH) in lactating ewes. salsolinol 52-62 prolactin Homo sapiens 122-131 20814315-11 2010 The findings suggest that risperidone monotherapy may yield higher prolactin levels than a combination of low-dose risperidone plus low-dose haloperidol. Risperidone 26-37 prolactin Homo sapiens 67-76 20547007-1 2010 BACKGROUND: Oxytocin (OXT) and prolactin (PRL) are neuropeptide hormones that interact with the serotonin system and are involved in the stress response and social affiliation. Serotonin 96-105 prolactin Homo sapiens 31-40 20547007-1 2010 BACKGROUND: Oxytocin (OXT) and prolactin (PRL) are neuropeptide hormones that interact with the serotonin system and are involved in the stress response and social affiliation. Serotonin 96-105 prolactin Homo sapiens 42-45 20814333-2 2010 Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Aripiprazole 35-47 prolactin Homo sapiens 89-98 20814333-2 2010 Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Dopamine 59-67 prolactin Homo sapiens 89-98 20814333-3 2010 Thus, we examined the dose effects of adjunctive treatment with aripiprazole on the plasma concentration of prolactin in patients who had elevated prolactin levels because of risperidone treatment. Aripiprazole 64-76 prolactin Homo sapiens 108-117 20814333-3 2010 Thus, we examined the dose effects of adjunctive treatment with aripiprazole on the plasma concentration of prolactin in patients who had elevated prolactin levels because of risperidone treatment. Risperidone 175-186 prolactin Homo sapiens 108-117 20814333-8 2010 The plasma concentration of prolactin during aripiprazole administration (3, 6, 9, or 12 mg/d) was significantly lower than that at baseline. Aripiprazole 45-57 prolactin Homo sapiens 28-37 20814333-12 2010 The present study suggests that adjunctive treatment with aripiprazole reduces the prolactin concentration that had been increased because of risperidone treatment. Aripiprazole 58-70 prolactin Homo sapiens 83-92 20814333-12 2010 The present study suggests that adjunctive treatment with aripiprazole reduces the prolactin concentration that had been increased because of risperidone treatment. Risperidone 142-153 prolactin Homo sapiens 83-92 20621147-0 2010 Gender differences in the relationship between the risperidone metabolism and the plasma prolactin levels in psychiatric patients. Risperidone 51-62 prolactin Homo sapiens 89-98 20621147-1 2010 BACKGROUND: Risperidone (RIS) has the highest propensity to elevate plasma prolactin (PRL) levels. Risperidone 12-23 prolactin Homo sapiens 75-84 20621147-1 2010 BACKGROUND: Risperidone (RIS) has the highest propensity to elevate plasma prolactin (PRL) levels. Risperidone 12-23 prolactin Homo sapiens 86-89 20621147-1 2010 BACKGROUND: Risperidone (RIS) has the highest propensity to elevate plasma prolactin (PRL) levels. Risperidone 25-28 prolactin Homo sapiens 75-84 20621147-1 2010 BACKGROUND: Risperidone (RIS) has the highest propensity to elevate plasma prolactin (PRL) levels. Risperidone 25-28 prolactin Homo sapiens 86-89 20621147-3 2010 The present study evaluated the gender differences in the relationship between plasma levels of RIS or 9-OH-RIS and PRL. Paliperidone Palmitate 103-111 prolactin Homo sapiens 116-119 20621147-8 2010 In the female patients, there was a significant positive correlation between the plasma 9-OH-RIS levels and PRL levels (rs=0.456, p=0.049). Paliperidone Palmitate 88-96 prolactin Homo sapiens 108-111 20621147-11 2010 CONCLUSION: 9-OH-RIS is considered to play a more important role in PRL elevation than RIS, and a gender difference exists in the effect of 9-OH-RIS on PRL level. Paliperidone Palmitate 12-20 prolactin Homo sapiens 68-71 20621147-11 2010 CONCLUSION: 9-OH-RIS is considered to play a more important role in PRL elevation than RIS, and a gender difference exists in the effect of 9-OH-RIS on PRL level. Paliperidone Palmitate 140-148 prolactin Homo sapiens 152-155 19747187-2 2010 This study was designed to test the hypothesis that salsolinol, acting from the CNS level, is able to stimulate pituitary prolactin release as well as prolactin mRNA expression in the anterior pituitary cells (AP) and in the mediobasal hypothalamus (MBH) in lactating ewes. salsolinol 52-62 prolactin Homo sapiens 151-160 19747187-5 2010 The obtained results showed that salsolinol infused at the higher dose significantly (p < 0.001) increased plasma prolactin concentration in lactating ewes, when compared with the concentration noted before the infusion and with that in lactating controls. salsolinol 33-43 prolactin Homo sapiens 117-126 19747187-8 2010 We conclude that in ewes, salsolinol may be involved, at least, in the process of stimulation of prolactin release during lactation and that hypothalamic prolactin plays an important role in the central mechanisms of adaptation to lactation. salsolinol 26-36 prolactin Homo sapiens 97-106 20363276-0 2010 The wide variability of perospirone metabolism and the effect of perospirone on prolactin in psychiatric patients. perospirone 65-76 prolactin Homo sapiens 80-89 23446038-5 2010 Comparisons between SGAs have shown that treatment with olanzapine was associated with greater weight gain and increased cholesterol levels, and that treatment with risperidone was associated with a greater increase in prolactin levels. Risperidone 165-176 prolactin Homo sapiens 219-228 19782352-0 2010 Blockage of ghrelin-induced prolactin secretion in women by bromocriptine. Ghrelin 12-19 prolactin Homo sapiens 28-37 19782352-0 2010 Blockage of ghrelin-induced prolactin secretion in women by bromocriptine. Bromocriptine 60-73 prolactin Homo sapiens 28-37 19782352-1 2010 OBJECTIVE: To investigate the effect of bromocriptine on ghrelin-induced PRL secretion in women. Bromocriptine 40-53 prolactin Homo sapiens 73-76 19782352-1 2010 OBJECTIVE: To investigate the effect of bromocriptine on ghrelin-induced PRL secretion in women. Ghrelin 57-64 prolactin Homo sapiens 73-76 19782352-8 2010 RESULT(S): Bromocriptine suppressed basal PRL levels significantly. Bromocriptine 11-24 prolactin Homo sapiens 42-45 19782352-9 2010 The injection of ghrelin stimulated a significant increase in serum PRL levels in cycle 2 but not in cycle 3, in which PRL levels remained stable. Ghrelin 17-24 prolactin Homo sapiens 68-71 19782352-9 2010 The injection of ghrelin stimulated a significant increase in serum PRL levels in cycle 2 but not in cycle 3, in which PRL levels remained stable. Ghrelin 17-24 prolactin Homo sapiens 119-122 19782352-11 2010 CONCLUSION(S): The present study demonstrates for the first time that bromocriptine blocked the stimulating effect of ghrelin on PRL release and attenuated the GH response to the same stimulus. Bromocriptine 70-83 prolactin Homo sapiens 129-132 19782352-11 2010 CONCLUSION(S): The present study demonstrates for the first time that bromocriptine blocked the stimulating effect of ghrelin on PRL release and attenuated the GH response to the same stimulus. Ghrelin 118-125 prolactin Homo sapiens 129-132 20657009-4 2010 Consistent with these idea, blockade of prolactin by bromocriptine, a dopamine D2 receptor agonist, prevented the onset of disease in an experimental model of PPCM and appeared successful in small pilot trials with respect to prevention or treatment of PPCM in patients. Bromocriptine 53-66 prolactin Homo sapiens 40-49 20601496-4 2010 Several recent studies indicated that PRL action in vivo may be influenced by the hormonal milieu, e.g. other growth factors such as 17beta-oestradiol (E(2)). Estradiol 133-150 prolactin Homo sapiens 38-41 20363276-6 2010 The 10 male patients showed a positive correlation between the plasma perospirone levels and plasma prolactin levels (r=0.688, p=0.028) and between the plasma ID15036 levels and prolactin levels (r=0.775, p=0.009). perospirone 70-81 prolactin Homo sapiens 100-109 20439242-4 2010 Testosterone replacement or hCG therapy in this patient resulted in an increase in serum prolactin levels, which declined after discontinuation of this therapy. Testosterone 0-12 prolactin Homo sapiens 89-98 20818143-6 2010 Prolactin secretion can be reduced with bromocriptine which had beneficial effects in a small study. Bromocriptine 40-53 prolactin Homo sapiens 0-9 20527996-7 2010 The mechanism by which antidepressants may cause hyperprolactinaemia is not fully understood, though several theories have been postulated, such as serotonin stimulation of GABAergic neurons and indirect modulation of prolactin release by serotonin. Serotonin 148-157 prolactin Homo sapiens 54-63 20527996-7 2010 The mechanism by which antidepressants may cause hyperprolactinaemia is not fully understood, though several theories have been postulated, such as serotonin stimulation of GABAergic neurons and indirect modulation of prolactin release by serotonin. Serotonin 239-248 prolactin Homo sapiens 54-63 20439242-5 2010 The combination of high doses of bromocriptine, hCG, and an aromatase inhibitor facilitated near-normalization of serum prolactin levels, shrinkage of the macroprolactinoma, recovery of serum testosterone levels, sexual function, and sperm count, and achievement of fertility. Bromocriptine 33-46 prolactin Homo sapiens 120-129 20304671-4 2010 Plasma prolactin (PRL) levels are elevated during pregnancy and, in view of the presence of PRL receptors in gut, bone and mammary glands, as well as recent evidence of the stimulatory effects of PRL on intestinal calcium transport, bone resorption and mammary calcium secretion, we postulate that PRL is the cardinal calciotropic hormone during pregnancy and lactation. Calcium 214-221 prolactin Homo sapiens 7-16 20371569-1 2010 Human prolactin (PRL) is currently viewed as a hormone of pituitary origin, whose production (i.e. serum levels) is controlled by dopamine, whose biological actions relate exclusively to lactation and reproductive functions, for which any genetic disorder is yet to be identified, and whose unique associated pathology is hyperprolactinemia. Dopamine 130-138 prolactin Homo sapiens 6-15 20371569-1 2010 Human prolactin (PRL) is currently viewed as a hormone of pituitary origin, whose production (i.e. serum levels) is controlled by dopamine, whose biological actions relate exclusively to lactation and reproductive functions, for which any genetic disorder is yet to be identified, and whose unique associated pathology is hyperprolactinemia. Dopamine 130-138 prolactin Homo sapiens 17-20 19825908-0 2010 A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. Paliperidone Palmitate 71-83 prolactin Homo sapiens 22-31 19825908-0 2010 A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. Risperidone 105-116 prolactin Homo sapiens 22-31 19825908-1 2010 Increases in serum prolactin concentrations after administration of risperidone have been attributed, by some, to the availability of paliperidone in plasma. Risperidone 68-79 prolactin Homo sapiens 19-28 19825908-1 2010 Increases in serum prolactin concentrations after administration of risperidone have been attributed, by some, to the availability of paliperidone in plasma. Paliperidone Palmitate 134-146 prolactin Homo sapiens 19-28 19825908-2 2010 This double-blind, randomized, parallel-group study in patients with schizophrenia compared serum prolactin concentrations following the administration of paliperidone extended-release and risperidone immediate-release tablets. Paliperidone Palmitate 155-167 prolactin Homo sapiens 98-107 19825908-5 2010 Mean serum prolactin concentrations increased on day 1 (C(max): 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively). Paliperidone Palmitate 129-141 prolactin Homo sapiens 11-20 19825908-5 2010 Mean serum prolactin concentrations increased on day 1 (C(max): 71.8 ng/ml and 89.7 ng/ml reached at 6.5 hours and 2.6 hours for paliperidone extended-release and risperidone immediate-release, respectively). Risperidone 163-174 prolactin Homo sapiens 11-20 19825908-7 2010 These results indicate that paliperidone extended-release 12 mg and risperidone immediate-release 4 mg, administered over a period of 6 days, lead to similar elevations in serum prolactin concentrations. Paliperidone Palmitate 28-40 prolactin Homo sapiens 178-187 19825908-7 2010 These results indicate that paliperidone extended-release 12 mg and risperidone immediate-release 4 mg, administered over a period of 6 days, lead to similar elevations in serum prolactin concentrations. Risperidone 68-79 prolactin Homo sapiens 178-187 20304671-4 2010 Plasma prolactin (PRL) levels are elevated during pregnancy and, in view of the presence of PRL receptors in gut, bone and mammary glands, as well as recent evidence of the stimulatory effects of PRL on intestinal calcium transport, bone resorption and mammary calcium secretion, we postulate that PRL is the cardinal calciotropic hormone during pregnancy and lactation. Calcium 214-221 prolactin Homo sapiens 18-21 20304671-4 2010 Plasma prolactin (PRL) levels are elevated during pregnancy and, in view of the presence of PRL receptors in gut, bone and mammary glands, as well as recent evidence of the stimulatory effects of PRL on intestinal calcium transport, bone resorption and mammary calcium secretion, we postulate that PRL is the cardinal calciotropic hormone during pregnancy and lactation. Calcium 261-268 prolactin Homo sapiens 7-16 20304671-4 2010 Plasma prolactin (PRL) levels are elevated during pregnancy and, in view of the presence of PRL receptors in gut, bone and mammary glands, as well as recent evidence of the stimulatory effects of PRL on intestinal calcium transport, bone resorption and mammary calcium secretion, we postulate that PRL is the cardinal calciotropic hormone during pregnancy and lactation. Calcium 261-268 prolactin Homo sapiens 18-21 20156584-4 2010 Experiments have been conducted using the ceramide analogue (+/-)-treo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol hydrochloride ([D]-PDMP), which inhibits ceramide glucosyltransferase resulting in the endogenous ganglioside depletion, and the lactogenic hormone mix DIP (dexamethasone, insulin, prolactin), which induces cell differentiation and beta-casein mRNA synthesis. (+/-)-treo-1-phenyl-2-decanoylamino 60-95 prolactin Homo sapiens 301-310 20929122-7 2010 Besides, the level of PRL was positively correlated with LH and E2 levels in patients. Luteinizing Hormone 57-59 prolactin Homo sapiens 22-25 20929122-7 2010 Besides, the level of PRL was positively correlated with LH and E2 levels in patients. Estradiol 64-66 prolactin Homo sapiens 22-25 20347273-2 2010 At doses lower than those needed to stimulate prolactin release directly, TRH almost completely antagonizes the inhibitory effect of dopamine on prolactin release. Dopamine 133-141 prolactin Homo sapiens 145-154 20478621-5 2010 The results demonstrated that the expression of IGFBP1, Prolactin (PRL), HOXA10, IL11, and IL15 are co-regulated during steroid hormone-mediated decidualization of human endometrial stromal cells in vitro. Steroids 120-135 prolactin Homo sapiens 56-65 20478621-5 2010 The results demonstrated that the expression of IGFBP1, Prolactin (PRL), HOXA10, IL11, and IL15 are co-regulated during steroid hormone-mediated decidualization of human endometrial stromal cells in vitro. Steroids 120-135 prolactin Homo sapiens 67-70 20595935-0 2010 Verapamil stimulation test in hyperprolactinemia: loss of prolactin response in anatomic or functional stalk effect. Verapamil 0-9 prolactin Homo sapiens 35-44 20595935-4 2010 Prolactin responses to verapamil in 65 female patients (age: 29.9 +/- 8.1 years) with hyperprolactinemia were tested in a descriptive, matched case-control study. Verapamil 23-32 prolactin Homo sapiens 0-9 20595935-7 2010 Verapamil responsiveness was determined by peak percent change in basal prolactin levels (PRL). Verapamil 0-9 prolactin Homo sapiens 72-81 20595935-7 2010 Verapamil responsiveness was determined by peak percent change in basal prolactin levels (PRL). Verapamil 0-9 prolactin Homo sapiens 90-93 20595935-9 2010 ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL <7%, discriminated anatomical or functional stalk effect (sensitivity: 74%, specificity: 73%, AUC: 0.855+/-0.04, P <0.001, CI: 0.768-0.942) associated with pseudoprolactinoma or risperidone-induced hyperprolactinemia, respectively. Verapamil 53-62 prolactin Homo sapiens 74-77 18846427-5 2010 Dopamine agonist therapy was initiated with significant decline in PRL levels; however, nausea, fatigue, and anorexia developed. Dopamine 0-8 prolactin Homo sapiens 67-70 20058099-3 2010 We present herein a giant prolactin-secreting pituitary adenoma in a middle-aged man that had responded partially to dopamine agonist therapy. Dopamine 117-125 prolactin Homo sapiens 26-35 19962139-9 2010 RESULT(S): Heparin dose- and time-dependently delayed the production of IGFBP-1 and amplified the levels of PRL and IGF-I in ESCs during decidualization in vitro. Heparin 11-18 prolactin Homo sapiens 108-111 20403941-2 2010 Because having a family history of alcoholism is associated with blunted prolactin responses to an alcohol challenge in nonlactating individuals, this study aimed to identify associations in family history of alcoholism, prolactin, and breastfeeding behaviors in lactating women. Alcohols 35-42 prolactin Homo sapiens 73-82 19251828-6 2010 The test itself did not significantly change cortisol and prolactin levels but under the higher dose of escitalopram, cortisol and prolactin increased immediately after SPS. Citalopram 104-116 prolactin Homo sapiens 131-140 20384451-0 2010 Sex differences in plasma prolactin response to tryptophan in chronic fatigue syndrome patients with and without comorbid fibromyalgia. Tryptophan 48-58 prolactin Homo sapiens 26-35 20403941-2 2010 Because having a family history of alcoholism is associated with blunted prolactin responses to an alcohol challenge in nonlactating individuals, this study aimed to identify associations in family history of alcoholism, prolactin, and breastfeeding behaviors in lactating women. Alcohols 35-42 prolactin Homo sapiens 221-230 20403941-9 2010 CONCLUSIONS: This is the first evidence that family history of alcoholism is associated with a blunted magnitude, rapidity, and duration of the prolactin response to breast stimulation and an alcohol challenge in lactating women. Alcohols 63-70 prolactin Homo sapiens 144-153 20424304-12 2010 Symptoms improved in majority (93%) of patients after four weeks of cabergoline therapy with a dramatic fall in serum prolactin by 99 per cent from 6249.3 +/- 3259.2 to 46.9 +/- 14.9 microg/l and it was normalized in 93 per cent of the patients by 8.2 wk. Cabergoline 68-79 prolactin Homo sapiens 118-127 20568397-10 2010 Prolactin biological activity was estimated by using polyethylene glycol (PEG) method. Polyethylene Glycols 53-72 prolactin Homo sapiens 0-9 20568397-10 2010 Prolactin biological activity was estimated by using polyethylene glycol (PEG) method. Polyethylene Glycols 74-77 prolactin Homo sapiens 0-9 20568397-11 2010 RESULTS: Patients with hyperprolactinemia and regular menstrual cycle presented low biological activity of prolactin and normal serum FSH, LH and estradiol levels. Luteinizing Hormone 139-141 prolactin Homo sapiens 28-37 20568397-11 2010 RESULTS: Patients with hyperprolactinemia and regular menstrual cycle presented low biological activity of prolactin and normal serum FSH, LH and estradiol levels. Estradiol 146-155 prolactin Homo sapiens 28-37 20170699-0 2010 Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Risperidone 68-79 prolactin Homo sapiens 16-25 20170699-0 2010 Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Olanzapine 84-94 prolactin Homo sapiens 16-25 20170699-1 2010 Hyperprolactinemia is a frequent consequence of treatment with antipsychotic agents, partially because the prolactin response to antipsychotics is related to dopamine blockade. Dopamine 158-166 prolactin Homo sapiens 5-14 20170699-2 2010 Recent studies have suggested that the prolactin response to olanzapine is weaker than that to risperidone. Olanzapine 61-71 prolactin Homo sapiens 39-48 20170699-7 2010 Treatment with either risperidone or olanzapine boosted plasma prolactin levels above baseline in both males and females. Risperidone 22-33 prolactin Homo sapiens 63-72 20170699-7 2010 Treatment with either risperidone or olanzapine boosted plasma prolactin levels above baseline in both males and females. Olanzapine 37-47 prolactin Homo sapiens 63-72 20170699-9 2010 Risperidone increased prolactin significantly more than did olanzapine in both males and females. Risperidone 0-11 prolactin Homo sapiens 22-31 20170699-10 2010 Delta prolactin (prolactin level at four weeks minus the baseline prolactin level) during olanzapine treatment significantly correlated with olanzapine concentration at 4th week (r=-0.518, p<0.01) only in males. Olanzapine 90-100 prolactin Homo sapiens 6-15 20170699-10 2010 Delta prolactin (prolactin level at four weeks minus the baseline prolactin level) during olanzapine treatment significantly correlated with olanzapine concentration at 4th week (r=-0.518, p<0.01) only in males. Olanzapine 90-100 prolactin Homo sapiens 17-26 20170699-10 2010 Delta prolactin (prolactin level at four weeks minus the baseline prolactin level) during olanzapine treatment significantly correlated with olanzapine concentration at 4th week (r=-0.518, p<0.01) only in males. Olanzapine 90-100 prolactin Homo sapiens 17-26 20170699-10 2010 Delta prolactin (prolactin level at four weeks minus the baseline prolactin level) during olanzapine treatment significantly correlated with olanzapine concentration at 4th week (r=-0.518, p<0.01) only in males. Olanzapine 141-151 prolactin Homo sapiens 6-15 20170699-10 2010 Delta prolactin (prolactin level at four weeks minus the baseline prolactin level) during olanzapine treatment significantly correlated with olanzapine concentration at 4th week (r=-0.518, p<0.01) only in males. Olanzapine 141-151 prolactin Homo sapiens 17-26 20170699-10 2010 Delta prolactin (prolactin level at four weeks minus the baseline prolactin level) during olanzapine treatment significantly correlated with olanzapine concentration at 4th week (r=-0.518, p<0.01) only in males. Olanzapine 141-151 prolactin Homo sapiens 17-26 20170699-11 2010 Multiple regression analyses showed that delta prolactin during risperidone was significantly correlated with gender (p<0.001) and age (p<0.05) and that delta prolactin during olanzapine significantly correlated with gender (p<0.001) and drug concentration (p<0.01). Risperidone 64-75 prolactin Homo sapiens 47-56 20170699-11 2010 Multiple regression analyses showed that delta prolactin during risperidone was significantly correlated with gender (p<0.001) and age (p<0.05) and that delta prolactin during olanzapine significantly correlated with gender (p<0.001) and drug concentration (p<0.01). Olanzapine 182-192 prolactin Homo sapiens 165-174 20373475-3 2010 We evaluated prolactin levels in schizophrenic patients receiving risperidone (3 mg twice daily), olanzapine (10 mg twice daily), or perospirone (16 mg twice daily) for at least 4 weeks. Risperidone 66-77 prolactin Homo sapiens 13-22 20373475-3 2010 We evaluated prolactin levels in schizophrenic patients receiving risperidone (3 mg twice daily), olanzapine (10 mg twice daily), or perospirone (16 mg twice daily) for at least 4 weeks. Olanzapine 98-108 prolactin Homo sapiens 13-22 20373475-3 2010 We evaluated prolactin levels in schizophrenic patients receiving risperidone (3 mg twice daily), olanzapine (10 mg twice daily), or perospirone (16 mg twice daily) for at least 4 weeks. perospirone 133-144 prolactin Homo sapiens 13-22 20373475-6 2010 Prolactin concentrations before dosing during risperidone treatment were significantly higher than during treatment with olanzapine and perospirone in females. Risperidone 46-57 prolactin Homo sapiens 0-9 20373475-7 2010 The daily fluctuation of prolactin concentration after perospirone treatment was larger than that observed after risperidone and olanzapine treatments. perospirone 55-66 prolactin Homo sapiens 25-34 20373475-9 2010 These findings suggest that daily fluctuations in prolactin concentration after perospirone treatment are larger than following treatment with risperidone and olanzapine. perospirone 80-91 prolactin Homo sapiens 50-59 20373475-10 2010 The plasma concentration of prolactin during perospirone treatment therefore depends on the time of sampling. perospirone 45-56 prolactin Homo sapiens 28-37 20578590-10 2010 PRL levels elevation in these diseases might result from several factors: an increased release of prolactin from the anterior pituitary due to inflammatory cytokines or reduced production of suppressive dopamine, or, alternatively, an increased production of prolactin in immune system cells. Dopamine 203-211 prolactin Homo sapiens 0-3 20578590-10 2010 PRL levels elevation in these diseases might result from several factors: an increased release of prolactin from the anterior pituitary due to inflammatory cytokines or reduced production of suppressive dopamine, or, alternatively, an increased production of prolactin in immune system cells. Dopamine 203-211 prolactin Homo sapiens 98-107 20051257-9 2010 The differences on the FSH, PRL, and E2 levels of patients were significant before and after the treatment with WJJ. (2R)-3-(4-bromophenyl)-2-methylpropanamide 112-115 prolactin Homo sapiens 28-31 19377875-0 2010 Prolactin and estradiol utilize distinct mechanisms to increase serine-118 phosphorylation and decrease levels of estrogen receptor alpha in T47D breast cancer cells. Serine 64-70 prolactin Homo sapiens 0-9 20424304-17 2010 INTERPRETATION & CONCLUSIONS: Our preliminary findings show that rapid build-up of cabergoline doses increases its efficacy as well as rapidity of response in terms clinical improvement, normalization of serum prolactin and gonadal functions and reduction in tumour size, without compromising its safety in men with macroprolactinomas. Cabergoline 87-98 prolactin Homo sapiens 214-223 20152122-1 2010 Hypothalamic dopamine neurons inhibit pituitary prolactin secretion. Dopamine 13-21 prolactin Homo sapiens 48-57 19844859-0 2010 Effect of ghrelin and thyrotropin-releasing hormone on prolactin secretion in normal women. Ghrelin 10-17 prolactin Homo sapiens 55-64 19844859-1 2010 It is known that ghrelin stimulates the secretion of prolactin in women. Ghrelin 17-24 prolactin Homo sapiens 53-62 19844859-2 2010 The aim of this study was to examine the effect of exogenous thyrotropin-releasing hormone (TRH) on ghrelin-induced prolactin release. Ghrelin 100-107 prolactin Homo sapiens 116-125 19844859-7 2010 After ghrelin administration (cycles 2 and 4), plasma ghrelin, serum prolactin, and growth hormone levels increased rapidly, peaking at 15-30 min (p<0.001). Ghrelin 6-13 prolactin Homo sapiens 69-78 19844859-9 2010 Ghrelin induced a smaller prolactin increase than thyrotropin-releasing hormone (p<0.05). Ghrelin 0-7 prolactin Homo sapiens 26-35 19844859-12 2010 These results demonstrate that the stimulating effect of ghrelin on prolactin secretion is not additive with that of thyrotropin-releasing hormone. Ghrelin 57-64 prolactin Homo sapiens 68-77 20177667-7 2010 The PRL effects were inhibited by TRAM-34 and clotrimazole, the most used hIKCa1 blockers. Clotrimazole 46-58 prolactin Homo sapiens 4-7 19969014-2 2010 This study was developed to examine how nicotine dependence alters endogenous opioid regulation of prolactin response, a peripheral marker of dopaminergic activity. Nicotine 40-48 prolactin Homo sapiens 99-108 20305606-7 2010 Hormonal blood tests were performed and high prolactin values were registered (2567.0 mIJ/L),due to which a gradual risperidone retractement was indicated. Risperidone 116-127 prolactin Homo sapiens 45-54 20305606-9 2010 A gradual risperidone retractement lead to a lowered and normal prolactin level within a month. Risperidone 10-21 prolactin Homo sapiens 64-73 20067810-0 2010 Synthesis, purification and characterization of recombinant glycosylated human prolactin (G-hPRL) secreted by cycloheximide-treated CHO cells. Cycloheximide 110-123 prolactin Homo sapiens 79-88 20067810-0 2010 Synthesis, purification and characterization of recombinant glycosylated human prolactin (G-hPRL) secreted by cycloheximide-treated CHO cells. Cycloheximide 110-123 prolactin Homo sapiens 92-96 20067810-5 2010 Addition of cycloheximide increased the absolute concentration of G-hPRL approximately 4-fold and the glycosylated versus non-glycosylated hPRL concentration ratio by approximately 7-fold. Cycloheximide 12-25 prolactin Homo sapiens 68-72 20032052-4 2010 A combination of Western blot analyses and immunocytochemistry demonstrated that PRL inhibited sperm capacitation in a dose-dependent manner, suppressing SRC kinase activation and phosphotyrosine expression, two hallmarks of this process. Phosphotyrosine 180-195 prolactin Homo sapiens 81-84 20032052-6 2010 Western blot analyses indicated that the prosurvival effect of PRL on human spermatozoa involved the stimulation of Akt phosphorylation, whereas inhibitors of phosphatidylinositol-3-OH kinase and Akt negated this effect, as did the direct induction of sperm capacitation with cAMP analogues. Cyclic AMP 276-280 prolactin Homo sapiens 63-66 19943807-4 2010 The goal of this study was to determine the need to continue PEG precipitation when prolactin measurements with the Wallac AutoDELFIA were replaced by the Beckman DxI 800. Polyethylene Glycols 61-64 prolactin Homo sapiens 84-93 19896213-0 2010 Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Olanzapine 46-56 prolactin Homo sapiens 24-33 19896213-0 2010 Genetic associations of prolactin increase in olanzapine/fluoxetine combination-treated patients. Fluoxetine 57-67 prolactin Homo sapiens 24-33 19896213-1 2010 In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. Olanzapine 183-193 prolactin Homo sapiens 137-146 19896213-1 2010 In patients from two clinical trials, we investigated the associations of single nucleotide polymorphisms (SNPs) in candidate genes with prolactin level changes during treatment with olanzapine/fluoxetine combination. Fluoxetine 194-204 prolactin Homo sapiens 137-146 20616493-8 2010 A coordinated suppression of D2 receptor- and TbetaRII receptor-mediated signaling as well as enhancement of bFGF activity might be critical for ethanol action on PRL production and cell proliferation in lactotropes. Ethanol 145-152 prolactin Homo sapiens 163-166 20938100-11 2010 PRL levels decreased to normal in all patients after thyroid functions normalized with L-thyroxine treatment. Thyroxine 87-98 prolactin Homo sapiens 0-3 20938100-12 2010 In the hypothyroid patients (overt and subclinical) a positive correlation was found between TSH and PRL levels (r=0.208, p=0.003). Thyrotropin 93-96 prolactin Homo sapiens 101-104 20938100-13 2010 PRL regulation is altered in overt and subclinical hypothyroidism, and PRL levels normalize with appropriate L-thyroxine treatment. Thyroxine 109-120 prolactin Homo sapiens 71-74 20616493-4 2010 In animal studies, it was found that chronic ethanol administration not only elevates plasma levels of PRL but also increases proliferation of pituitary lactotropes. Ethanol 45-52 prolactin Homo sapiens 103-106 19809337-9 2010 Risperidone was significantly more likely to be associated with elevation in serum prolactin levels in this population. Risperidone 0-11 prolactin Homo sapiens 83-92 19887646-0 2010 A Pit-1 threonine 220 phosphomimic reduces binding to monomeric DNA sites to inhibit Ras and estrogen stimulation of the prolactin gene promoter. Threonine 8-17 prolactin Homo sapiens 121-130 28621165-0 2010 Prolactin levels in risperidone treatment of first-episode schizophrenia. Risperidone 20-31 prolactin Homo sapiens 0-9 28621165-1 2010 OBJECTS: To evaluate the risperidone effect on prolactin (PRL) levels and to analyse the relation between PRL change and treatment response in first-episode schizophrenia patients. Risperidone 25-36 prolactin Homo sapiens 47-56 28621165-1 2010 OBJECTS: To evaluate the risperidone effect on prolactin (PRL) levels and to analyse the relation between PRL change and treatment response in first-episode schizophrenia patients. Risperidone 25-36 prolactin Homo sapiens 58-61 28621165-12 2010 Risperidone-induced changes of PRL levels may not be associated with treatment response. Risperidone 0-11 prolactin Homo sapiens 31-34 20625486-0 2010 Enhancement of human prolactin synthesis by sodium butyrate addition to serum-free CHO cell culture. Butyric Acid 44-59 prolactin Homo sapiens 21-30 20625486-0 2010 Enhancement of human prolactin synthesis by sodium butyrate addition to serum-free CHO cell culture. cho 83-86 prolactin Homo sapiens 21-30 20625486-2 2010 Thus, the influence of NaBu on the production of recombinant human prolactin (hPRL) from CHO cells was investigated for the first time. sethoxydim 23-27 prolactin Homo sapiens 67-76 20625486-2 2010 Thus, the influence of NaBu on the production of recombinant human prolactin (hPRL) from CHO cells was investigated for the first time. sethoxydim 23-27 prolactin Homo sapiens 78-82 20625486-4 2010 Quantitative and qualitative analyses by reverse-phase high-performance liquid chromatography (RP-HPLC) and Western blot or SDS-PAGE, carried out directly on CHO-conditioned medium, showed that the highest hPRL expression was obtained with 1 mM NaBu. Sodium Dodecyl Sulfate 124-127 prolactin Homo sapiens 206-210 20625486-4 2010 Quantitative and qualitative analyses by reverse-phase high-performance liquid chromatography (RP-HPLC) and Western blot or SDS-PAGE, carried out directly on CHO-conditioned medium, showed that the highest hPRL expression was obtained with 1 mM NaBu. sethoxydim 245-249 prolactin Homo sapiens 206-210 20625486-7 2010 Our results show that NaBu increased the synthesis of recombinant hPRL in CHO cells, apparently without compromising either its structure or function. sethoxydim 22-26 prolactin Homo sapiens 66-70 19857203-6 2009 Reversible conjugation by a disulfide bond of a carrier peptide bearing a penetration accelerating sequence to PRL, facilitated the cellular uptake of this peptide and significantly inhibited phosphorylation of tau by PKN1 at the PKN1-specific phosphorylation site in vivo. Disulfides 28-37 prolactin Homo sapiens 111-114 20008425-8 2010 Serum prolactin increased by 97% in the domperidone group and by 17% in the placebo group (P = .07). Domperidone 40-51 prolactin Homo sapiens 6-15 19755483-1 2010 Our objective was to test the hypothesis that prolactin (PRL) acts at both the pituitary and testis levels to regulate testosterone secretion in the adult ram. Testosterone 119-131 prolactin Homo sapiens 57-60 19755483-5 2010 Suppression of PRL tended (P<0.10) to increase the amplitude of natural LH pulses (transition stages) or reduce the number of LH receptors in the testis (regressed stage), although neither change disturbed testosterone levels in peripheral blood. Luteinizing Hormone 75-77 prolactin Homo sapiens 15-18 19706318-0 2009 Short- and long-term effects on prolactin of risperidone and olanzapine treatments in children and adolescents. Risperidone 45-56 prolactin Homo sapiens 32-41 31569887-6 2009 All the patients included in the study were examined for the measurement of monomeric prolactin (PRL) by separation of individual fractions in the precipitation reaction with 25% polyethyleneglycol. polyethyleneglycol palmitate 179-197 prolactin Homo sapiens 97-100 31569891-0 2009 [Interactions of estrogens, progesterone, and dopamine in regulation of prolactin secretion]. Estrogens 17-26 prolactin Homo sapiens 72-81 31569891-0 2009 [Interactions of estrogens, progesterone, and dopamine in regulation of prolactin secretion]. Progesterone 28-40 prolactin Homo sapiens 72-81 31569891-0 2009 [Interactions of estrogens, progesterone, and dopamine in regulation of prolactin secretion]. Dopamine 46-54 prolactin Homo sapiens 72-81 19467668-4 2009 Nineteen drug-free inpatients with unipolar major depression underwent a neuroendocrine challenge test by measuring cortisol and prolactin in response to intravenously administered clomipramine (12.5mg). Clomipramine 181-193 prolactin Homo sapiens 129-138 21183909-6 2010 The increase of psychopathologic symptoms leads to lowering of prolactin level regardless of sex that confirms the dopamine theory of schizophrenia. Dopamine 115-123 prolactin Homo sapiens 63-72 31569891-2 2009 The author analyses results of experimental and clinical investigations published in the literature with special reference to the role of estrogens, progesterone, and dopamine in control of prolactin secretion and its regulation under normal and pathological conditions. Estrogens 138-147 prolactin Homo sapiens 190-199 31569891-2 2009 The author analyses results of experimental and clinical investigations published in the literature with special reference to the role of estrogens, progesterone, and dopamine in control of prolactin secretion and its regulation under normal and pathological conditions. Progesterone 149-161 prolactin Homo sapiens 190-199 31569891-2 2009 The author analyses results of experimental and clinical investigations published in the literature with special reference to the role of estrogens, progesterone, and dopamine in control of prolactin secretion and its regulation under normal and pathological conditions. Dopamine 167-175 prolactin Homo sapiens 190-199 19706318-1 2009 This study investigated prolactin levels in two groups of children and adolescents receiving risperidone (N=29) or olanzapine (N=13). Risperidone 93-104 prolactin Homo sapiens 24-33 19706318-1 2009 This study investigated prolactin levels in two groups of children and adolescents receiving risperidone (N=29) or olanzapine (N=13). Olanzapine 115-125 prolactin Homo sapiens 24-33 19706318-4 2009 After adjusting for gender, treatment duration and individual effects, mean prolactin levels on risperidone were 4.9 ng/mL higher than on olanzapine (10.3 times higher after controlling for dosing potency). Risperidone 96-107 prolactin Homo sapiens 76-85 19706318-5 2009 On risperidone treatment, the adjusted mean prolactin level at the 3rd month of treatment was significantly higher than at the 1st month; at the 12th month it was significantly lower than at the 1st month; the 1st and 6th months were not significantly different. Risperidone 3-14 prolactin Homo sapiens 44-53 19706318-6 2009 On olanzapine treatment, adjusted mean prolactin levels at the 3rd and 6th months of treatment were significantly higher than at the 1st month; at the 12th month it was lower than at the 1st month, but the difference was not significant. Olanzapine 3-13 prolactin Homo sapiens 39-48 19551610-0 2009 Prolactin suppresses malonyl-CoA concentration in human adipose tissue. Malonyl Coenzyme A 21-32 prolactin Homo sapiens 0-9 19662384-1 2009 PURPOSE: Citalopram, a selective serotonin reuptake inhibitor, is used as a neuroendocrine probe in human subjects to assess serotonin function as reflected in prolactin and plasma cortisol release. Citalopram 9-19 prolactin Homo sapiens 160-169 19662384-6 2009 METHODS: Plasma cortisol and prolactin levels following a single oral dose of citalopram (40 mg) or escitalopram (20 mg) were compared in samples taken every 15-30 min over a period of 240 min. Citalopram 78-88 prolactin Homo sapiens 29-38 19662384-6 2009 METHODS: Plasma cortisol and prolactin levels following a single oral dose of citalopram (40 mg) or escitalopram (20 mg) were compared in samples taken every 15-30 min over a period of 240 min. Citalopram 100-112 prolactin Homo sapiens 29-38 19662384-8 2009 RESULTS: Escitalopram and citalopram caused equivalent increases in plasma cortisol and prolactin. Citalopram 9-21 prolactin Homo sapiens 88-97 19662384-8 2009 RESULTS: Escitalopram and citalopram caused equivalent increases in plasma cortisol and prolactin. Citalopram 11-21 prolactin Homo sapiens 88-97 19595304-2 2009 The present study assessed the relationship between metal concentrations in blood and serum prolactin (PRL) and thyrotropin (TSH) levels, markers of dopaminergic, and thyroid function, respectively, among men participating in a study of environmental influences on male reproductive health. Metals 52-57 prolactin Homo sapiens 92-101 19595304-2 2009 The present study assessed the relationship between metal concentrations in blood and serum prolactin (PRL) and thyrotropin (TSH) levels, markers of dopaminergic, and thyroid function, respectively, among men participating in a study of environmental influences on male reproductive health. Metals 52-57 prolactin Homo sapiens 103-106 19595304-4 2009 In multiple linear regression models adjusted for age, BMI and smoking, PRL was inversely associated with arsenic, cadmium, copper, lead, manganese, molybdenum, and zinc, but positively associated with chromium. Arsenic 106-113 prolactin Homo sapiens 72-75 19595304-4 2009 In multiple linear regression models adjusted for age, BMI and smoking, PRL was inversely associated with arsenic, cadmium, copper, lead, manganese, molybdenum, and zinc, but positively associated with chromium. Cadmium 115-122 prolactin Homo sapiens 72-75 19595304-4 2009 In multiple linear regression models adjusted for age, BMI and smoking, PRL was inversely associated with arsenic, cadmium, copper, lead, manganese, molybdenum, and zinc, but positively associated with chromium. Copper 124-130 prolactin Homo sapiens 72-75 19595304-4 2009 In multiple linear regression models adjusted for age, BMI and smoking, PRL was inversely associated with arsenic, cadmium, copper, lead, manganese, molybdenum, and zinc, but positively associated with chromium. Manganese 138-147 prolactin Homo sapiens 72-75 19595304-4 2009 In multiple linear regression models adjusted for age, BMI and smoking, PRL was inversely associated with arsenic, cadmium, copper, lead, manganese, molybdenum, and zinc, but positively associated with chromium. Molybdenum 149-159 prolactin Homo sapiens 72-75 19595304-4 2009 In multiple linear regression models adjusted for age, BMI and smoking, PRL was inversely associated with arsenic, cadmium, copper, lead, manganese, molybdenum, and zinc, but positively associated with chromium. Chromium 202-210 prolactin Homo sapiens 72-75 19664636-7 2009 Hormonal sampling indicated that testosterone levels showed an inverse relationship to prolactin levels during a normal peripartum period and prolactin treatment reduced this relationship. Testosterone 33-45 prolactin Homo sapiens 87-96 19664636-8 2009 Prepartum estradiol levels were significantly elevated during the lowered prolactin treatment and estradiol was significantly lowered postpartum with the elevated prolactin treatment. Estradiol 10-19 prolactin Homo sapiens 74-83 19551610-6 2009 In addition, prolactin was found to decrease glucose transporter 4 ( GLUT4) mRNA expression, which may cause decreased glucose uptake. Glucose 45-52 prolactin Homo sapiens 13-22 19758960-4 2009 The first-line therapy of prolactinomas are the dopamine agonists, and the aims of the treatment are to normalize the prolactin level, restore fertility in child-bearing age, decrease tumor mass, save or improve the residual pituitary function and inhibit the relapse of the disease. Dopamine 48-56 prolactin Homo sapiens 26-35 19794986-4 2009 Three months after initiation of cabergoline treatment, serum prolactin concentrations decreased more than 97% in 9 patients; at last follow-up (mean treatment duration, 19 months), the mean decrease in serum prolactin concentrations was 98%, with 5 patients having normal serum prolactin levels. Cabergoline 33-44 prolactin Homo sapiens 62-71 19794986-4 2009 Three months after initiation of cabergoline treatment, serum prolactin concentrations decreased more than 97% in 9 patients; at last follow-up (mean treatment duration, 19 months), the mean decrease in serum prolactin concentrations was 98%, with 5 patients having normal serum prolactin levels. Cabergoline 33-44 prolactin Homo sapiens 209-218 19794986-4 2009 Three months after initiation of cabergoline treatment, serum prolactin concentrations decreased more than 97% in 9 patients; at last follow-up (mean treatment duration, 19 months), the mean decrease in serum prolactin concentrations was 98%, with 5 patients having normal serum prolactin levels. Cabergoline 33-44 prolactin Homo sapiens 209-218 19794986-7 2009 These findings indicate that cabergoline treatment led to a significant and rapid reduction in serum prolactin concentrations and tumor size in patients with giant prolactinoma. Cabergoline 29-40 prolactin Homo sapiens 101-110 19494234-6 2009 To delineate the responsible mechanisms, we first determined that prolactin-mediated ZnT2 induction was inhibited by pretreatment with the Jak2 inhibitor AG490 but not by the MAPK inhibitor PD-98059. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 154-159 prolactin Homo sapiens 66-75 19094072-0 2009 Growth hormone and prolactin response to ghrelin during the normal menstrual cycle. Ghrelin 41-48 prolactin Homo sapiens 19-28 19094072-3 2009 The aim of this study was to test the hypothesis that physiological changes in ovarian steroids during the normal menstrual cycle modulate GH and prolactin (PRL) response to ghrelin. Steroids 87-95 prolactin Homo sapiens 146-155 19094072-3 2009 The aim of this study was to test the hypothesis that physiological changes in ovarian steroids during the normal menstrual cycle modulate GH and prolactin (PRL) response to ghrelin. Steroids 87-95 prolactin Homo sapiens 157-160 19094072-3 2009 The aim of this study was to test the hypothesis that physiological changes in ovarian steroids during the normal menstrual cycle modulate GH and prolactin (PRL) response to ghrelin. Ghrelin 174-181 prolactin Homo sapiens 146-155 19094072-3 2009 The aim of this study was to test the hypothesis that physiological changes in ovarian steroids during the normal menstrual cycle modulate GH and prolactin (PRL) response to ghrelin. Ghrelin 174-181 prolactin Homo sapiens 157-160 19094072-11 2009 After ghrelin administration, in the three phases of the cycle, plasma ghrelin and serum GH and PRL levels increased rapidly, peaking at 30 min and declining gradually thereafter (P < 0.001). Ghrelin 6-13 prolactin Homo sapiens 96-99 19094072-14 2009 CONCLUSIONS: These results demonstrate that GH and PRL responses to ghrelin do not change across the menstrual cycle. Ghrelin 68-75 prolactin Homo sapiens 51-54 19415692-3 2009 The CHIT-1 induction PRL-mediated was reduced by wortmannin and LY-294002, inhibitors of phosphatidylinositol 3-kinase (PI3-K) and by genistein an inhibitor of protein tyrosine kinase (PTK). Wortmannin 49-59 prolactin Homo sapiens 21-24 19443905-0 2009 Prolactin confers resistance against cisplatin in breast cancer cells by activating glutathione-S-transferase. Cisplatin 37-46 prolactin Homo sapiens 0-9 19443905-3 2009 Treatment of breast cancer cells with PRL caused variable resistance to taxol, vinblastine, doxorubicin and cisplatin. Paclitaxel 72-77 prolactin Homo sapiens 38-41 19443905-3 2009 Treatment of breast cancer cells with PRL caused variable resistance to taxol, vinblastine, doxorubicin and cisplatin. Vinblastine 79-90 prolactin Homo sapiens 38-41 19443905-3 2009 Treatment of breast cancer cells with PRL caused variable resistance to taxol, vinblastine, doxorubicin and cisplatin. Doxorubicin 92-103 prolactin Homo sapiens 38-41 19443905-3 2009 Treatment of breast cancer cells with PRL caused variable resistance to taxol, vinblastine, doxorubicin and cisplatin. Cisplatin 108-117 prolactin Homo sapiens 38-41 19443905-4 2009 PRL prevented cisplatin-induced G(2)/M cell cycle arrest and apoptosis. Cisplatin 14-23 prolactin Homo sapiens 0-3 19443905-5 2009 In the presence of PRL, significantly less cisplatin was bound to DNA, as determined by mass spectroscopy, and little DNA damage was seen by gamma-H2AX staining. Cisplatin 43-52 prolactin Homo sapiens 19-22 19443905-5 2009 In the presence of PRL, significantly less cisplatin was bound to DNA, as determined by mass spectroscopy, and little DNA damage was seen by gamma-H2AX staining. gamma-h2ax 141-151 prolactin Homo sapiens 19-22 19443905-6 2009 PRL dramatically increased the activity of glutathione-S-transferase (GST), which sequesters cisplatin in the cytoplasm; this increase was abrogated by Jak and mitogen-activated protein kinase inhibitors. Cisplatin 93-102 prolactin Homo sapiens 0-3 19443905-7 2009 PRL upregulated the expression of the GSTmu, but not the pi, isozyme. gstmu 38-43 prolactin Homo sapiens 0-3 19443905-8 2009 A GST inhibitor abrogated antagonism of cisplatin cytotoxicity by PRL. Cisplatin 40-49 prolactin Homo sapiens 66-69 19443905-9 2009 In conclusion, PRL confers resistance against cisplatin by activating a detoxification enzyme, thereby reducing drug entry into the nucleus. Cisplatin 46-55 prolactin Homo sapiens 15-18 19415692-6 2009 In addition, PRL induced a phosphorylation of AKT that was prevented both by the two MAPK inhibitors SB203580 and U0126 and by the PI3-K inhibitors wortmannin and LY-294002. SB 203580 101-109 prolactin Homo sapiens 13-16 19415692-6 2009 In addition, PRL induced a phosphorylation of AKT that was prevented both by the two MAPK inhibitors SB203580 and U0126 and by the PI3-K inhibitors wortmannin and LY-294002. U 0126 114-119 prolactin Homo sapiens 13-16 19415692-6 2009 In addition, PRL induced a phosphorylation of AKT that was prevented both by the two MAPK inhibitors SB203580 and U0126 and by the PI3-K inhibitors wortmannin and LY-294002. Wortmannin 148-158 prolactin Homo sapiens 13-16 19415692-6 2009 In addition, PRL induced a phosphorylation of AKT that was prevented both by the two MAPK inhibitors SB203580 and U0126 and by the PI3-K inhibitors wortmannin and LY-294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 163-172 prolactin Homo sapiens 13-16 19415692-3 2009 The CHIT-1 induction PRL-mediated was reduced by wortmannin and LY-294002, inhibitors of phosphatidylinositol 3-kinase (PI3-K) and by genistein an inhibitor of protein tyrosine kinase (PTK). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 64-73 prolactin Homo sapiens 21-24 19415692-3 2009 The CHIT-1 induction PRL-mediated was reduced by wortmannin and LY-294002, inhibitors of phosphatidylinositol 3-kinase (PI3-K) and by genistein an inhibitor of protein tyrosine kinase (PTK). Genistein 134-143 prolactin Homo sapiens 21-24 19415692-4 2009 Pre-treatment of macrophages with SB203580, a specific inhibitor of the mitogen-activated kinases (MAPK) p38, or with U0126, an inhibitor of MAPK p44/42, prevented both basal and exogenous PRL-mediated CHIT-1 expression. SB 203580 34-42 prolactin Homo sapiens 189-192 19415692-4 2009 Pre-treatment of macrophages with SB203580, a specific inhibitor of the mitogen-activated kinases (MAPK) p38, or with U0126, an inhibitor of MAPK p44/42, prevented both basal and exogenous PRL-mediated CHIT-1 expression. U 0126 118-123 prolactin Homo sapiens 189-192 19243891-0 2009 Ethanol administration dampens the prolactin response to psychosocial stress exposure in sons of alcohol-dependent fathers. Ethanol 0-7 prolactin Homo sapiens 35-44 19702492-2 2009 METHOD: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. Haloperidol 52-63 prolactin Homo sapiens 16-25 19702492-2 2009 METHOD: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. Pimozide 65-73 prolactin Homo sapiens 16-25 19702492-2 2009 METHOD: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. Risperidone 75-86 prolactin Homo sapiens 16-25 19702492-2 2009 METHOD: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. Olanzapine 88-98 prolactin Homo sapiens 16-25 19702492-2 2009 METHOD: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. Clozapine 100-109 prolactin Homo sapiens 16-25 19702492-2 2009 METHOD: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. ziprasidone 111-122 prolactin Homo sapiens 16-25 19702492-2 2009 METHOD: Data on prolactin levels were available for haloperidol, pimozide, risperidone, olanzapine, clozapine, ziprasidone, and quetiapine. Quetiapine Fumarate 128-138 prolactin Homo sapiens 16-25 19702492-4 2009 RESULTS: All antipsychotics, except clozapine, ziprasidone, and quetiapine, increase the mean prolactin level from baseline values of 8.0 ng/mL to 25-28 ng/mL after 4 weeks of treatment (reference range 0-15 ng/mL). Clozapine 36-45 prolactin Homo sapiens 94-103 19702492-4 2009 RESULTS: All antipsychotics, except clozapine, ziprasidone, and quetiapine, increase the mean prolactin level from baseline values of 8.0 ng/mL to 25-28 ng/mL after 4 weeks of treatment (reference range 0-15 ng/mL). ziprasidone 47-58 prolactin Homo sapiens 94-103 19702492-4 2009 RESULTS: All antipsychotics, except clozapine, ziprasidone, and quetiapine, increase the mean prolactin level from baseline values of 8.0 ng/mL to 25-28 ng/mL after 4 weeks of treatment (reference range 0-15 ng/mL). Quetiapine Fumarate 64-74 prolactin Homo sapiens 94-103 19702492-6 2009 Five risperidone studies (n = 577) show an increase of prolactin level from 7.8 ng/mL to 17.7 ng/mL after 1 year of treatment, and two risperidone studies (n = 60) show an increase from 7.4 ng/mL to 24.9 ng/mL after 2 years of treatment. Risperidone 5-16 prolactin Homo sapiens 55-64 19702492-10 2009 CONCLUSION: Persistent elevation of prolactin for periods up to 2 years has been documented in maintenance treatment with risperidone. Risperidone 122-133 prolactin Homo sapiens 36-45 19243891-0 2009 Ethanol administration dampens the prolactin response to psychosocial stress exposure in sons of alcohol-dependent fathers. Alcohols 97-104 prolactin Homo sapiens 35-44 19243891-3 2009 We tested whether such an interaction is also revealed by prolactin secretion, which is predominantly controlled by hypothalamic dopamine. Dopamine 129-137 prolactin Homo sapiens 58-67 19243891-8 2009 Alcohol administration significantly increased prolactin before stress and during startle in both groups, did not alter stress-induced prolactin stimulation in FHN, but significantly attenuated the prolactin stress response in PHA subjects. Alcohols 0-7 prolactin Homo sapiens 47-56 19243891-9 2009 The alcohol effects on prolactin, cortisol, and adrenocorticotropin stress response were positively interrelated with each other. Alcohols 4-11 prolactin Homo sapiens 23-32 19524180-15 2009 CONCLUSION: Dopamine agonists are effective in normalizing prolactin values, and inducing tumor shrinkage. Dopamine 12-20 prolactin Homo sapiens 59-68 19551763-4 2009 RESULTS: For males, post-treatment PRL levels were significantly higher in the typical neuroleptic group compared with the melperone (p = 0.0001) and clozapine (p = 0.0001) groups, with no significant difference between clozapine and melperone. Clozapine 220-229 prolactin Homo sapiens 35-38 19533481-0 2009 Metformin administration was associated with a modification of LH, prolactin and insulin secretion dynamics in women with polycystic ovarian syndrome. Metformin 0-9 prolactin Homo sapiens 67-76 19551763-0 2009 Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. metylperon 0-9 prolactin Homo sapiens 79-88 19551763-0 2009 Melperone, an aytpical antipsychotic drug with clozapine-like effect on plasma prolactin: contrast with typical neuroleptics. Clozapine 47-56 prolactin Homo sapiens 79-88 19551763-1 2009 OBJECTIVE: To evaluate the effect of melperone, a butyrophenone with atypical antipsychotic properties, on plasma prolactin (PRL) concentrations compared with clozapine and typical neuroleptics. metylperon 37-46 prolactin Homo sapiens 114-123 19551763-1 2009 OBJECTIVE: To evaluate the effect of melperone, a butyrophenone with atypical antipsychotic properties, on plasma prolactin (PRL) concentrations compared with clozapine and typical neuroleptics. metylperon 37-46 prolactin Homo sapiens 125-128 19551763-4 2009 RESULTS: For males, post-treatment PRL levels were significantly higher in the typical neuroleptic group compared with the melperone (p = 0.0001) and clozapine (p = 0.0001) groups, with no significant difference between clozapine and melperone. metylperon 123-132 prolactin Homo sapiens 35-38 19551763-4 2009 RESULTS: For males, post-treatment PRL levels were significantly higher in the typical neuroleptic group compared with the melperone (p = 0.0001) and clozapine (p = 0.0001) groups, with no significant difference between clozapine and melperone. metylperon 234-243 prolactin Homo sapiens 35-38 19551763-5 2009 For females, post-treatment PRL levels were significantly higher in the melperone group as compared to the clozapine group (p = 0.004). metylperon 72-81 prolactin Homo sapiens 28-31 19551763-7 2009 However, the cross-sectional analysis of PRL data confirmed the results for melperone- and clozapine-treated females, and showed higher PRL levels in typical neuroleptic-treated females as compared with those who received melperone and clozapine. Clozapine 91-100 prolactin Homo sapiens 41-44 19551763-7 2009 However, the cross-sectional analysis of PRL data confirmed the results for melperone- and clozapine-treated females, and showed higher PRL levels in typical neuroleptic-treated females as compared with those who received melperone and clozapine. metylperon 76-85 prolactin Homo sapiens 41-44 19365811-5 2009 Concentration of PRL mimicked a lactating period (100 ng/ml) was used to incubate SV-HFO for 21 days in osteogenic medium. sv-hfo 82-88 prolactin Homo sapiens 17-20 19365811-9 2009 Calcium measurement and Alizarin red staining showed a reduction of mineralization by PRL while having neither an effect on osteoblast activity nor RANKL/OPG mRNA ratio. alizarin 24-36 prolactin Homo sapiens 86-89 19754555-10 2009 A single dose of injectable cabergoline caused a significant reduction in serum PRL concentration and a significant reduction in milk flow. Cabergoline 28-39 prolactin Homo sapiens 80-83 19339512-4 2009 The PRL-stimulated transcellular calcium transport was completely inhibited by the L-type calcium channel blockers (nifedipine and verapamil) and plasma membrane Ca(2+)-ATPase (PMCA) inhibitor (trifluoperazine) as well as small interfering RNA targeting voltage-dependent L-type calcium channel Ca(v)1.3, but not TRPV6 or calbindin-D(9k). Nifedipine 116-126 prolactin Homo sapiens 4-7 19754555-0 2009 Effect of an injectable cabergoline formulation on serum prolactin (PRL) and milk secretion in early postpartum Beagle bitches. Cabergoline 24-35 prolactin Homo sapiens 57-66 19754555-0 2009 Effect of an injectable cabergoline formulation on serum prolactin (PRL) and milk secretion in early postpartum Beagle bitches. Cabergoline 24-35 prolactin Homo sapiens 68-71 19754555-7 2009 The day after cabergoline injection, an 80% decrease of PRL serum concentration was observed (p < 0.05). Cabergoline 14-25 prolactin Homo sapiens 56-59 19754555-8 2009 The circadian oscillatory pattern of PRL secretion disappeared after administration of cabergoline, and PRL values remained significantly lower than in the previous days for the first 60 h following treatment (p < 0.001). Cabergoline 87-98 prolactin Homo sapiens 37-40 19339512-0 2009 Enhancement of calcium transport in Caco-2 monolayer through PKCzeta-dependent Cav1.3-mediated transcellular and rectifying paracellular pathways by prolactin. Calcium 15-22 prolactin Homo sapiens 149-158 19339512-1 2009 Previous investigations suggested that prolactin (PRL) stimulated the intestinal calcium absorption through phosphoinositide 3-kinase (PI3K), protein kinase C (PKC), and RhoA-associated coiled-coil forming kinase (ROCK) signaling pathways. Calcium 81-88 prolactin Homo sapiens 39-48 19339512-4 2009 The PRL-stimulated transcellular calcium transport was completely inhibited by the L-type calcium channel blockers (nifedipine and verapamil) and plasma membrane Ca(2+)-ATPase (PMCA) inhibitor (trifluoperazine) as well as small interfering RNA targeting voltage-dependent L-type calcium channel Ca(v)1.3, but not TRPV6 or calbindin-D(9k). Verapamil 131-140 prolactin Homo sapiens 4-7 19339512-1 2009 Previous investigations suggested that prolactin (PRL) stimulated the intestinal calcium absorption through phosphoinositide 3-kinase (PI3K), protein kinase C (PKC), and RhoA-associated coiled-coil forming kinase (ROCK) signaling pathways. Calcium 81-88 prolactin Homo sapiens 50-53 19339512-3 2009 By using Ussing chamber technique, we found that the PRL-induced increase in the transcellular calcium flux and decrease in transepithelial resistance of intestinal-like Caco-2 monolayer were not abolished by inhibitors of gene transcription and protein biosynthesis. Calcium 95-102 prolactin Homo sapiens 53-56 19339512-4 2009 The PRL-stimulated transcellular calcium transport was completely inhibited by the L-type calcium channel blockers (nifedipine and verapamil) and plasma membrane Ca(2+)-ATPase (PMCA) inhibitor (trifluoperazine) as well as small interfering RNA targeting voltage-dependent L-type calcium channel Ca(v)1.3, but not TRPV6 or calbindin-D(9k). Trifluoperazine 194-209 prolactin Homo sapiens 4-7 19339512-4 2009 The PRL-stimulated transcellular calcium transport was completely inhibited by the L-type calcium channel blockers (nifedipine and verapamil) and plasma membrane Ca(2+)-ATPase (PMCA) inhibitor (trifluoperazine) as well as small interfering RNA targeting voltage-dependent L-type calcium channel Ca(v)1.3, but not TRPV6 or calbindin-D(9k). Calcium 33-40 prolactin Homo sapiens 4-7 19339512-5 2009 As demonstrated by (45)Ca uptake study, PI3K and PKC, but not ROCK, were essential for the PRL-enhanced apical calcium entry. Calcium 111-118 prolactin Homo sapiens 91-94 19339512-7 2009 Such PRL effects on paracellular transport were completely abolished by inhibitors of PI3K (LY-294002) and ROCK (Y-27632). Lysine 92-94 prolactin Homo sapiens 5-8 19339512-8 2009 It could be concluded that the PRL-stimulated transcellular calcium transport in Caco-2 monolayer was mediated by Ca(v)1.3 and PMCA, presumably through PI3K and PKC(zeta) pathways, while the enhanced voltage-dependent calcium transport occurred through PI3K and ROCK pathways. Calcium 60-67 prolactin Homo sapiens 31-34 19339512-8 2009 It could be concluded that the PRL-stimulated transcellular calcium transport in Caco-2 monolayer was mediated by Ca(v)1.3 and PMCA, presumably through PI3K and PKC(zeta) pathways, while the enhanced voltage-dependent calcium transport occurred through PI3K and ROCK pathways. Calcium 218-225 prolactin Homo sapiens 31-34 19272447-2 2009 Nvarepsilon-(propanoyl)lysine (propionyllysine, or PRL) is formed from the reaction of the oxidized products of n-3 PUFAs and lysine. nvarepsilon-(propanoyl)lysine 0-29 prolactin Homo sapiens 51-54 19272447-2 2009 Nvarepsilon-(propanoyl)lysine (propionyllysine, or PRL) is formed from the reaction of the oxidized products of n-3 PUFAs and lysine. propionyllysine 31-46 prolactin Homo sapiens 51-54 19272447-2 2009 Nvarepsilon-(propanoyl)lysine (propionyllysine, or PRL) is formed from the reaction of the oxidized products of n-3 PUFAs and lysine. Fatty Acids, Omega-3 112-121 prolactin Homo sapiens 51-54 19272447-2 2009 Nvarepsilon-(propanoyl)lysine (propionyllysine, or PRL) is formed from the reaction of the oxidized products of n-3 PUFAs and lysine. Lysine 23-29 prolactin Homo sapiens 51-54 19272447-7 2009 The level of urinary PRL (21.6+/-10.6 micromol/mol of creatinine) significantly correlated with the other oxidative stress markers, 8-oxo-deoxyguanosine, dityrosine, and isoprostanes. Creatinine 54-64 prolactin Homo sapiens 21-24 19272447-7 2009 The level of urinary PRL (21.6+/-10.6 micromol/mol of creatinine) significantly correlated with the other oxidative stress markers, 8-oxo-deoxyguanosine, dityrosine, and isoprostanes. 8-ohdg 132-152 prolactin Homo sapiens 21-24 19272447-7 2009 The level of urinary PRL (21.6+/-10.6 micromol/mol of creatinine) significantly correlated with the other oxidative stress markers, 8-oxo-deoxyguanosine, dityrosine, and isoprostanes. dityrosine 154-164 prolactin Homo sapiens 21-24 19121641-7 2009 But estrogen, alone and especially in synergy with progesterone, is a potent stimulator of prolactin release. Progesterone 51-63 prolactin Homo sapiens 91-100 19272447-7 2009 The level of urinary PRL (21.6+/-10.6 micromol/mol of creatinine) significantly correlated with the other oxidative stress markers, 8-oxo-deoxyguanosine, dityrosine, and isoprostanes. Isoprostanes 170-182 prolactin Homo sapiens 21-24 19121641-8 2009 Prolactin affects calcium metabolism and hyperprolactinemia associated with pregnancy, lactation, antipsychotic drug treatment, or aging is reflected in decreased bone mineral density. Calcium 18-25 prolactin Homo sapiens 0-9 19440083-0 2009 Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. Olanzapine 0-10 prolactin Homo sapiens 166-175 19440083-8 2009 Prolactin concentration was correlated with olanzapine concentration (r = 0.46, P < 0.001). Olanzapine 44-54 prolactin Homo sapiens 0-9 19131173-0 2009 Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men. Olanzapine 0-10 prolactin Homo sapiens 81-90 19131173-0 2009 Olanzapine shifts the temporal relationship between the daily acrophase of serum prolactin and cortisol concentrations rhythm in healthy men. Hydrocortisone 95-103 prolactin Homo sapiens 81-90 19131173-3 2009 This study evaluated the effects of short-term treatment with olanzapine on 12h plasma prolactin and cortisol concentrations in healthy men. Olanzapine 62-72 prolactin Homo sapiens 87-96 19131173-12 2009 In conclusion olanzapine OST and ODT equally elevated the prolactin concentration and significantly shifted its acrophase, thus dissociating PRL and cortisol, while both formulations induced similar insulin resistance as evidenced by the elevated HOMA-IR. Olanzapine 14-24 prolactin Homo sapiens 58-67 19223454-0 2009 Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Cabergoline 68-79 prolactin Homo sapiens 38-47 20043526-0 2009 Imipramine induced elevation of prolactin levels in patients with HIV/AIDS improved their immune status. Imipramine 0-10 prolactin Homo sapiens 32-41 20043526-2 2009 Imipramine, a monoamine oxidase inhibitor stimulates prolactin production because it decreases dopamine which inhibits secretion of prolactin. Imipramine 0-10 prolactin Homo sapiens 53-62 20043526-2 2009 Imipramine, a monoamine oxidase inhibitor stimulates prolactin production because it decreases dopamine which inhibits secretion of prolactin. Imipramine 0-10 prolactin Homo sapiens 132-141 20043526-2 2009 Imipramine, a monoamine oxidase inhibitor stimulates prolactin production because it decreases dopamine which inhibits secretion of prolactin. Dopamine 95-103 prolactin Homo sapiens 53-62 20043526-2 2009 Imipramine, a monoamine oxidase inhibitor stimulates prolactin production because it decreases dopamine which inhibits secretion of prolactin. Dopamine 95-103 prolactin Homo sapiens 132-141 20043526-11 2009 Results showed a trend of prolactin levels decreasing after washout (p = 0.015) and increasing by the end of the trial period once imipramine dispensation had recommenced (p = 0.006). Imipramine 131-141 prolactin Homo sapiens 26-35 19401448-7 2009 Gefitinib, the tyrosine kinase inhibitor, suppressed heregulin-mediated p185(c-neu)/ErbB3 signaling to PRL. Gefitinib 0-9 prolactin Homo sapiens 103-106 19398999-3 2009 Cessation of therapy with metoclopramide (0.2 mg kg(-1) per dose q 6 h) resulted in the resolution of galactorrhea with a decrease in serum prolactin level (20.1 ng ml(-1)). Metoclopramide 26-40 prolactin Homo sapiens 140-149 19412154-5 2009 However, dopamine has potentially detrimental effects on the release of pituitary hormones and especially prolactin, although the clinical relevance of these effects is unclear. Dopamine 9-17 prolactin Homo sapiens 106-115 19273609-0 2009 Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation. Tyrosine 0-8 prolactin Homo sapiens 42-51 19273609-5 2009 We identify tyrosine phosphorylation of the growth factor receptor-bound protein 2 (Grb2) as a critical mechanism by which PRL antagonizes EGF-induced cell proliferation by attenuating the activation of the Ras/mitogen-activated protein kinase (MAPK) pathway. Tyrosine 12-20 prolactin Homo sapiens 123-126 19273609-6 2009 Together, our results define a novel negative cross-regulation between PRL and EGF involving the Jak2/Stat5a and Ras/MAPK pathways through tyrosine phosphorylation of Grb2. Tyrosine 139-147 prolactin Homo sapiens 71-74 19115200-8 2009 Finally, we show that PRL-induced SOCS3 expression can be potentiated by co-treatment with PGE(2). Prostaglandins E 91-94 prolactin Homo sapiens 22-25 19384991-0 2009 Contribution of individual histidines to the global stability of human prolactin. Histidine 27-37 prolactin Homo sapiens 71-80 19384991-4 2009 hPRL contains nine histidines, compared with hGH"s three, and they are likely responsible for hPRL"s pH-dependent behavior. Histidine 19-29 prolactin Homo sapiens 0-4 19384991-5 2009 We have systematically mutated each of hPRL"s histidines to alanine and measured the effect on pH-dependent global stability. Histidine 46-56 prolactin Homo sapiens 39-43 19384991-5 2009 We have systematically mutated each of hPRL"s histidines to alanine and measured the effect on pH-dependent global stability. Alanine 60-67 prolactin Homo sapiens 39-43 19384991-7 2009 Changes in the overall pH dependence to hPRL global stability can be rationalized according to the predominant structural interactions of individual histidines in the hPRL tertiary structure. Histidine 149-159 prolactin Homo sapiens 40-44 19384991-7 2009 Changes in the overall pH dependence to hPRL global stability can be rationalized according to the predominant structural interactions of individual histidines in the hPRL tertiary structure. Histidine 149-159 prolactin Homo sapiens 167-171 19384991-9 2009 Finally, by comparing the structural locations of hPRL"s nine histidines with their homologous residues in hGH, we speculate on the evolutionary role of replacing structurally stabilizing residues with histidine to introduce pH dependence to cytokine function. Histidine 62-72 prolactin Homo sapiens 50-54 19384991-9 2009 Finally, by comparing the structural locations of hPRL"s nine histidines with their homologous residues in hGH, we speculate on the evolutionary role of replacing structurally stabilizing residues with histidine to introduce pH dependence to cytokine function. Histidine 62-71 prolactin Homo sapiens 50-54 19339912-7 2009 Age, stage of sexual development, and the dose of risperidone independently predicted a higher prolactin concentration, whereas the dose of psychostimulants was negatively correlated with it. Risperidone 50-61 prolactin Homo sapiens 95-104 19339912-12 2009 CONCLUSION: Prolactin concentration is closely related to central DRD2 blockade, as reflected by risperidone serum concentration. Risperidone 97-108 prolactin Homo sapiens 12-21 19095742-9 2009 Interestingly, also human islets subjected to prolactin treatment before experimental transplantation demonstrated improved revascularization, blood perfusion, and oxygen tension when evaluated 1 month after transplantation. Oxygen 164-170 prolactin Homo sapiens 46-55 19350575-6 2009 CCL20 production by PRL was suppressed by antisense oligonucleotides against the AP-1 components c-Fos and c-Jun, whereas that by IL-17 was suppressed by antisense NF-kappaB p50 and p65. Oligonucleotides 52-68 prolactin Homo sapiens 20-23 19172414-2 2009 Patient was initially responsive to cabergoline with reduction of prolactin levels and shrinkage of tumor burden for at least 36 months. Cabergoline 36-47 prolactin Homo sapiens 66-75 22478877-0 2009 Monitoring of serum prolactin in pediatric patients with cystic fibrosis who are receiving domperidone. Domperidone 91-102 prolactin Homo sapiens 20-29 19200963-2 2009 Cd significantly increased PRL concentrations in the culture media and significantly up-regulated PRL messenger RNA expression of the endometrial stromal cells, suggesting that Cd stimulates decidualization of the endometrium and may disrupt endometrial environment, causing early decidualization. Cadmium 0-2 prolactin Homo sapiens 27-30 19200963-2 2009 Cd significantly increased PRL concentrations in the culture media and significantly up-regulated PRL messenger RNA expression of the endometrial stromal cells, suggesting that Cd stimulates decidualization of the endometrium and may disrupt endometrial environment, causing early decidualization. Cadmium 0-2 prolactin Homo sapiens 98-101 19200963-2 2009 Cd significantly increased PRL concentrations in the culture media and significantly up-regulated PRL messenger RNA expression of the endometrial stromal cells, suggesting that Cd stimulates decidualization of the endometrium and may disrupt endometrial environment, causing early decidualization. Cadmium 177-179 prolactin Homo sapiens 27-30 19200963-2 2009 Cd significantly increased PRL concentrations in the culture media and significantly up-regulated PRL messenger RNA expression of the endometrial stromal cells, suggesting that Cd stimulates decidualization of the endometrium and may disrupt endometrial environment, causing early decidualization. Cadmium 177-179 prolactin Homo sapiens 98-101 19523391-0 2009 Differential regulation of gene expression and release of FSH and prolactin by long day and sulfamethazine in chicks. Sulfamethazine 92-106 prolactin Homo sapiens 66-75 19523391-6 2009 Results demonstrate a differential role of long day exposure and SMZ intake on the regulation of FSH and PRL synthesis and secretion and suggest that some effects of SMZ on gonadal development may be mediated by the pituitary. Sulfamethazine 65-68 prolactin Homo sapiens 105-108 19169277-5 2009 Moreover, PRL leads to phosphorylation of ERalpha in serine-118 (P-ERalpha), a modification related to the potentiation of ligand-independent transcriptional activation. Serine 53-59 prolactin Homo sapiens 10-13 22478877-3 2009 OBJECTIVES: To characterize how prolactin levels were being used in monitoring patients with cystic fibrosis who were receiving domperidone therapy at this institution, to evaluate the need for this practice, and to formulate recommendations accordingly. Domperidone 128-139 prolactin Homo sapiens 32-41 22478877-10 2009 In particular, more information is needed about prolactin levels in pediatric patients and the relationship of prolactin level to domperidone dose. Domperidone 130-141 prolactin Homo sapiens 111-120 18930473-5 2009 Serotoninergic function was assessed by measuring cortisol and prolactin in response to intravenously administered clomipramine (12.5mg) before and after the treatment period. Clomipramine 115-127 prolactin Homo sapiens 63-72 22478877-1 2009 BACKGROUND: Since 2003, it has been routine practice at Children"s and Women"s Health Centre of British Columbia to monitor serum levels of prolactin in pediatric patients with cystic fibrosis who are receiving domperidone. Domperidone 211-222 prolactin Homo sapiens 140-149 22478877-2 2009 Although a pharmacologic relationship between domperidone and prolactin has been documented in the literature, there is no information about routine monitoring of prolactin, and guidance on interpretation of prolactin values is lacking. Domperidone 46-57 prolactin Homo sapiens 62-71 19059524-15 2009 Basal PRL concentration and PRL level after metoclopramide stimulation test significantly increased after 3 and 12 months of treatment in the group receiving orally given HST. Metoclopramide 44-58 prolactin Homo sapiens 28-31 19354088-13 2009 The administration of atropine before 90 minutes of low-intensity exercise significantly increased cortisol, prolactin, and norepinephrine, decreased growth hormone, and significantly increased cardiovascular stress. Atropine 22-30 prolactin Homo sapiens 109-118 19168522-3 2009 Prolactin secretion can be reduced with bromocriptine which had beneficial effects in a small study. Bromocriptine 40-53 prolactin Homo sapiens 0-9 19168522-4 2009 We present a case of a patient with PPCM who received cabergoline, a strong and long lasting antagonist of prolactin secretion. Cabergoline 54-65 prolactin Homo sapiens 107-116 20579476-6 2009 The start of bromocriptin treatment was followed by a fall in the prolactin level to less then 200 ng/ml in 1 month. Bromocriptine 13-25 prolactin Homo sapiens 66-75 19038534-0 2009 Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Aripiprazole 11-23 prolactin Homo sapiens 27-36 19038534-8 2009 Following aripiprazole initiation, mean prolactin levels decreased significantly (p<0.001) at week-1 and were maintained to week-8 in all groups irrespective of prior treatment. Aripiprazole 10-22 prolactin Homo sapiens 40-49 19038534-9 2009 Previously elevated prolactin levels in the risperidone groups were reduced to within normal range within 1 week, irrespective of switching strategy. Risperidone 44-55 prolactin Homo sapiens 20-29 19038534-11 2009 Overall, rapid decreases of prolactin levels were achieved safely with all three aripiprazole switching strategies. Aripiprazole 81-93 prolactin Homo sapiens 28-37 19038534-12 2009 Reversal of hyperprolactinemia during the crossover period indicates the safety and potential utility of aripiprazole addition in patients with elevated prolactin. Aripiprazole 105-117 prolactin Homo sapiens 17-26 19128569-2 2009 A brief review of the literature is provided with emphasis on recent data indicating that an antiangiogenic cleavage product of prolactin contributes to the molecular mechanisms underlying peripartum cardiomyopathy, and that blocking the release of prolactin with bromocriptine can ameliorate the condition. Bromocriptine 264-277 prolactin Homo sapiens 249-258 18815356-7 2009 Lower expression of IGFBP1 and prolactin mRNA and protein was observed in hESF from women with vs. those without endometriosis in response to 8-Br-cAMP, but not P4, suggesting a blunted response of these decidual biomarkers to activation of the PKA pathway in eutopic endometrium in women with disease. 8-Bromo Cyclic Adenosine Monophosphate 142-151 prolactin Homo sapiens 31-40 21686651-6 2009 Treatment with Cabergolin resulted in a normalisation of prolactin levels and a decrease in tumour size. cabergolin 15-25 prolactin Homo sapiens 57-66 18978497-10 2009 From our laboratory findings of an increase in prolactin and estradiol levels and no change in testosterone level and normal hepatic, renal, and thyroid function during venlafaxine therapy, the gynecomastia seen in the case may have been due to an impaired balance in the serum estrogen-serum androgen ratio, whatever the mechanism, or a rise in prolactin level. Venlafaxine Hydrochloride 169-180 prolactin Homo sapiens 346-355 19074549-2 2009 1,25(OH)(2) vitamin D(3) [1alpha,25(OH)(2)D(3)] has antiproliferative effects on osteosarcoma cells, and a complex interregulatory situation exists between PRL and 1alpha,25(OH)(2)D(3). Vitamin D 12-21 prolactin Homo sapiens 156-159 19154213-9 2009 Aripiprazole was associated with significant decrease of serum prolactin level. Aripiprazole 0-12 prolactin Homo sapiens 63-72 22140413-3 2009 The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Metoclopramide 128-142 prolactin Homo sapiens 11-20 22140413-3 2009 The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Metoclopramide 128-142 prolactin Homo sapiens 227-236 22140413-3 2009 The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Dopamine 155-163 prolactin Homo sapiens 11-20 22140413-3 2009 The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Dopamine 179-187 prolactin Homo sapiens 11-20 22140413-3 2009 The raised prolactin level had led to oligomenorrhoea prompting her general practitioner (GP) to check pituitary hormone levels.Metoclopramide is a potent dopamine antagonist and dopamine acts as the physiological inhibitor of prolactin synthesis. Dopamine 179-187 prolactin Homo sapiens 227-236 22140413-4 2009 Thus, the dopamine antagonism led to elevated prolactin level and the symptom of oligomenorrhoea.Following curtailment of the metoclopramide, the prolactin level normalised very quickly and the patient was reassured.Consideration should be given to non-pathological causes of hyperprolactinaemia, including physiological states such as pregnancy and concurrent medication. Dopamine 10-18 prolactin Homo sapiens 46-55 22140413-4 2009 Thus, the dopamine antagonism led to elevated prolactin level and the symptom of oligomenorrhoea.Following curtailment of the metoclopramide, the prolactin level normalised very quickly and the patient was reassured.Consideration should be given to non-pathological causes of hyperprolactinaemia, including physiological states such as pregnancy and concurrent medication. Dopamine 10-18 prolactin Homo sapiens 146-155 22140413-4 2009 Thus, the dopamine antagonism led to elevated prolactin level and the symptom of oligomenorrhoea.Following curtailment of the metoclopramide, the prolactin level normalised very quickly and the patient was reassured.Consideration should be given to non-pathological causes of hyperprolactinaemia, including physiological states such as pregnancy and concurrent medication. Metoclopramide 126-140 prolactin Homo sapiens 146-155 19367058-10 2009 After six months of bromocriptine treatment her prolactin level was normal and no adenoma was detected in pituitary MRI. Bromocriptine 20-33 prolactin Homo sapiens 48-57 19358813-8 2009 Noteworthy, the neurotoxin-induced increase of prolactin secretion returns with time to a normal level due to the stimulation of DA synthesis by the tuberoinfundibular most probably monoenzymatic neurons. Dopamine 129-131 prolactin Homo sapiens 47-56 19784597-4 2009 We recently identified propanoyl-lysine (propionyl-lysine, PRL) from the reaction of an n-3 FA and a lysine residue. propanoyllysine 23-39 prolactin Homo sapiens 59-62 19557099-7 2009 In males, lower testosterone was associated with higher prolactin (p < 0.001) and with orgasmic (p = 0.004) and ejaculatory dysfunction (p = 0.028). Testosterone 16-28 prolactin Homo sapiens 56-65 19784597-4 2009 We recently identified propanoyl-lysine (propionyl-lysine, PRL) from the reaction of an n-3 FA and a lysine residue. Fatty Acids, Omega-3 88-94 prolactin Homo sapiens 59-62 19784597-4 2009 We recently identified propanoyl-lysine (propionyl-lysine, PRL) from the reaction of an n-3 FA and a lysine residue. Lysine 33-39 prolactin Homo sapiens 59-62 19784597-7 2009 Moreover, both amide-type adducts, HEL and PRL, can be simultaneously measured using liquid chromatography mass spectrometry (LC/MS/MS) with isotope dilution methods. Amides 15-20 prolactin Homo sapiens 43-46 18791324-1 2009 BACKGROUND/AIMS: Prolactin (PRL) secretion and its gene expression are inhibited by dopamine. Dopamine 84-92 prolactin Homo sapiens 17-26 18651225-7 2009 Our data showed that that patients treated with dopamine agonists prior to surgery experienced greater reductions in prolactin levels, had lower prolactin levels, were more likely to have normal prolactin levels at long term follow-up, and were less likely to require additional therapy to control their prolactin levels. Dopamine 48-56 prolactin Homo sapiens 117-126 19326843-0 2009 [Effect of estradiol on Ca2+ release from intracellular stores in porcine oocytes stimulated by prolactin, theophylline, or guanosine triphosphate]. Estradiol 11-20 prolactin Homo sapiens 96-105 19326843-1 2009 The interaction between prolactin and theophylline as well as between prolactin and guanosine triphosphate during Ca2+ release from intracellular stores of estradiol-treated porcine oocytes isolated from the ovary at the stage of follicular growth were studied using fluorescent Ca(2+)-sensitive probe chlortetracycline. Estradiol 156-165 prolactin Homo sapiens 70-79 19326843-3 2009 Conversely, Ca2+ release from intracellular stores increased only after the combined exposure to prolactin and theophylline in the the presence of estradiol. Estradiol 147-156 prolactin Homo sapiens 97-106 19326843-4 2009 In the absence of estradiol, guanosine triphosphate induced calcium release alone and together with prolactin. Guanosine Triphosphate 29-51 prolactin Homo sapiens 100-109 19326843-5 2009 Protein kinase C regulated Ca2+ release from intracellular stores after the combined exposure to prolactin and theophylline only in the presence of estradiol; while the activation of protein kinase C required no estradiol during the combined exposure to prolactin and guanosine triphosphate. Estradiol 148-157 prolactin Homo sapiens 97-106 19326843-6 2009 The data obtained indicate the effect of estradiol on Ca2+ release from intracellular stores after the combined exposure to prolactin and theophylline, while no such effect was observed after the combined exposure to prolactin and guanosine triphosphate. Estradiol 41-50 prolactin Homo sapiens 124-133 18651225-7 2009 Our data showed that that patients treated with dopamine agonists prior to surgery experienced greater reductions in prolactin levels, had lower prolactin levels, were more likely to have normal prolactin levels at long term follow-up, and were less likely to require additional therapy to control their prolactin levels. Dopamine 48-56 prolactin Homo sapiens 145-154 18651225-7 2009 Our data showed that that patients treated with dopamine agonists prior to surgery experienced greater reductions in prolactin levels, had lower prolactin levels, were more likely to have normal prolactin levels at long term follow-up, and were less likely to require additional therapy to control their prolactin levels. Dopamine 48-56 prolactin Homo sapiens 145-154 18651225-7 2009 Our data showed that that patients treated with dopamine agonists prior to surgery experienced greater reductions in prolactin levels, had lower prolactin levels, were more likely to have normal prolactin levels at long term follow-up, and were less likely to require additional therapy to control their prolactin levels. Dopamine 48-56 prolactin Homo sapiens 145-154 18651225-9 2009 In fact, pretreatment with dopamine agonist drugs, possibly by inducing tumor regression, seemed to improve the surgeon"s ability to resect a greater percentage of the tumor and led to better control of the prolactin level. Dopamine 27-35 prolactin Homo sapiens 207-216 19333405-0 2009 Prolactin levels in olanzapine treatment correlate with positive symptoms of schizophrenia: results from an open-label, flexible-dose study. Olanzapine 20-30 prolactin Homo sapiens 0-9 19333405-1 2009 OBJECTIVE: This study was designed to investigate the relationship between the treatment effect of olanzapine and the serum prolactin level in schizophrenia and to investigate the factors that may act as predictors of response for olanzapine treatment. Olanzapine 99-109 prolactin Homo sapiens 124-133 19333405-8 2009 RESULTS: In general, the serum prolactin level was decreased in schizophrenia patients with olanzapine treatment, although the difference is not statistically significant (p = .974, p = .246, and p = .363 for the first, second, and third months, respectively). Olanzapine 92-102 prolactin Homo sapiens 31-40 19333405-9 2009 There was a close relationship between the improvement in positive symptoms and the change in serum prolactin levels before and after olanzapine treatment (p = .002). Olanzapine 134-144 prolactin Homo sapiens 100-109 19082309-5 2008 During the investigation, computed tomography and magnetic resonance imaging (MRI) showed a sellar mass associated with high prolactin level (1.403 microg/L) that initially was considered a macroprolactinoma, and treated with bromocriptine. Bromocriptine 226-239 prolactin Homo sapiens 125-134 19011427-10 2008 Prolactin increased in the olanzapine group and decreased in the aripiprazole group with a significant between-group difference (P < 0.001). Olanzapine 27-37 prolactin Homo sapiens 0-9 19011427-10 2008 Prolactin increased in the olanzapine group and decreased in the aripiprazole group with a significant between-group difference (P < 0.001). Aripiprazole 65-77 prolactin Homo sapiens 0-9 19032898-3 2008 She was given Bromocriptine, which normalized her menstruation as well as the prolactin level followed by conception during treatment. Bromocriptine 14-27 prolactin Homo sapiens 78-87 19032898-9 2008 Later, treatment with Bromocriptine (15 mg/day) failed to keep prolactin level normal and Lisuride hydrogen (0.8 mg/day) reduced the prolactin levels. lisuride hydrogen 90-107 prolactin Homo sapiens 133-142 18765484-11 2008 Mean changes in prolactin were -8.45, -11.93, and -15.14 ng/ml for placebo and 10 mg and 30 mg of aripirazole, respectively. aripirazole 98-109 prolactin Homo sapiens 16-25 18633321-3 2008 Among the 40 patients with PRL-producing pituitary adenoma, 16 had been preoperatively treated with the dopamine agonist bromocriptine. Dopamine 104-112 prolactin Homo sapiens 27-30 18633321-3 2008 Among the 40 patients with PRL-producing pituitary adenoma, 16 had been preoperatively treated with the dopamine agonist bromocriptine. Bromocriptine 121-134 prolactin Homo sapiens 27-30 18633321-15 2008 It is conceivable that SNAP-25 plays an important role in PRL release and is involved in the bromocriptine-induced suppression of PRL secretion from PRL-producing adenoma cells. Bromocriptine 93-106 prolactin Homo sapiens 130-133 18633321-15 2008 It is conceivable that SNAP-25 plays an important role in PRL release and is involved in the bromocriptine-induced suppression of PRL secretion from PRL-producing adenoma cells. Bromocriptine 93-106 prolactin Homo sapiens 130-133 19113797-3 2009 First-generation antipsychotics pose the greatest risk of causing this adverse effect; however, second-generation antipsychotics, particularly risperidone and paliperidone, also often increase prolactin secretion. Risperidone 143-154 prolactin Homo sapiens 193-202 19113797-3 2009 First-generation antipsychotics pose the greatest risk of causing this adverse effect; however, second-generation antipsychotics, particularly risperidone and paliperidone, also often increase prolactin secretion. Paliperidone Palmitate 159-171 prolactin Homo sapiens 193-202 19102734-1 2008 BACKGROUND: The aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (SOC), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (The Schizophrenia Trial of Aripiprazole [STAR] study [NCT00237913]). Aripiprazole 201-213 prolactin Homo sapiens 163-172 18848860-2 2008 All first generation antipsychotics and the second generation antipsychotics amisulpride and risperidone have been shown to cause marked elevation in serum prolactin levels, whereas most other second generation antipsychotics and aripiprazole appear to have little or no effect on serum prolactin levels. Amisulpride 77-88 prolactin Homo sapiens 156-165 18848860-2 2008 All first generation antipsychotics and the second generation antipsychotics amisulpride and risperidone have been shown to cause marked elevation in serum prolactin levels, whereas most other second generation antipsychotics and aripiprazole appear to have little or no effect on serum prolactin levels. Amisulpride 77-88 prolactin Homo sapiens 287-296 18848860-2 2008 All first generation antipsychotics and the second generation antipsychotics amisulpride and risperidone have been shown to cause marked elevation in serum prolactin levels, whereas most other second generation antipsychotics and aripiprazole appear to have little or no effect on serum prolactin levels. Risperidone 93-104 prolactin Homo sapiens 156-165 18848860-2 2008 All first generation antipsychotics and the second generation antipsychotics amisulpride and risperidone have been shown to cause marked elevation in serum prolactin levels, whereas most other second generation antipsychotics and aripiprazole appear to have little or no effect on serum prolactin levels. Risperidone 93-104 prolactin Homo sapiens 287-296 18848860-8 2008 Switching antipsychotic drugs to aripiprazole was effective in reducing serum prolactin levels and restoring menstruation in schizophrenic patients who received prolactin-raising antipsychotics. Aripiprazole 33-45 prolactin Homo sapiens 78-87 18848860-8 2008 Switching antipsychotic drugs to aripiprazole was effective in reducing serum prolactin levels and restoring menstruation in schizophrenic patients who received prolactin-raising antipsychotics. Aripiprazole 33-45 prolactin Homo sapiens 161-170 18848860-12 2008 The prolactin-normalizing effects of aripiprazole are likely caused by the unique characteristics of the dopamine partial agonist with its high affinity for dopamine D2 receptors. Aripiprazole 37-49 prolactin Homo sapiens 4-13 18848860-12 2008 The prolactin-normalizing effects of aripiprazole are likely caused by the unique characteristics of the dopamine partial agonist with its high affinity for dopamine D2 receptors. Dopamine 105-113 prolactin Homo sapiens 4-13 18466271-3 2008 AIM: The primary objective of the present study was to examine the relationship between sexual dysfunction, subjective well-being and prolactin levels in patients with schizophrenia treated either with risperidone or quetiapine. Risperidone 202-213 prolactin Homo sapiens 134-143 18466271-3 2008 AIM: The primary objective of the present study was to examine the relationship between sexual dysfunction, subjective well-being and prolactin levels in patients with schizophrenia treated either with risperidone or quetiapine. Quetiapine Fumarate 217-227 prolactin Homo sapiens 134-143 18466271-13 2008 Risperidone was significantly associated with elevated prolactin levels. Risperidone 0-11 prolactin Homo sapiens 55-64 18715274-5 2008 RESULTS: Alcohol consumption increased basal PRL levels (p < 0.0001) and modified the PRL response to pumping (p < 0.0001) but the directionality of the response depended on when pumping occurred along the BAC curve. Alcohols 9-16 prolactin Homo sapiens 45-48 18715274-5 2008 RESULTS: Alcohol consumption increased basal PRL levels (p < 0.0001) and modified the PRL response to pumping (p < 0.0001) but the directionality of the response depended on when pumping occurred along the BAC curve. Alcohols 9-16 prolactin Homo sapiens 89-92 18715274-7 2008 The slower the alcohol was metabolized, the greater the relative PRL response to breast pumping (p < 0.05). Alcohols 15-22 prolactin Homo sapiens 65-68 18715274-9 2008 If women pumped within the hour after drinking alcohol, the PRL response during the next pumping some 1.5 hours later, was delayed by a few minutes. Alcohols 47-54 prolactin Homo sapiens 60-63 18715274-11 2008 CONCLUSIONS: Effects of alcohol on suckling-induced PRL were biphasic in nature, but could not explain the deficits in lactational performance. Alcohols 24-31 prolactin Homo sapiens 52-55 18797434-10 2008 MANAGEMENT: Steroid replacement, careful control of fluid and electrolyte balance and conservative nonsurgical management with the dopamine agonist cabergoline resulted in resolution of the patient"s headache, improvement of the third nerve palsy and subsequent normalization of the prolactin level, with reduction in size of the prolactinoma on MRI scan. Dopamine 131-139 prolactin Homo sapiens 283-292 18797434-10 2008 MANAGEMENT: Steroid replacement, careful control of fluid and electrolyte balance and conservative nonsurgical management with the dopamine agonist cabergoline resulted in resolution of the patient"s headache, improvement of the third nerve palsy and subsequent normalization of the prolactin level, with reduction in size of the prolactinoma on MRI scan. Cabergoline 148-159 prolactin Homo sapiens 283-292 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Glutamic Acid 41-50 prolactin Homo sapiens 120-129 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Glutamic Acid 41-50 prolactin Homo sapiens 235-244 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Phencyclidine 73-86 prolactin Homo sapiens 120-129 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Phencyclidine 73-86 prolactin Homo sapiens 235-244 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Phencyclidine 186-199 prolactin Homo sapiens 120-129 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Phencyclidine 186-199 prolactin Homo sapiens 235-244 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Dopamine 206-214 prolactin Homo sapiens 120-129 18720422-1 2008 It has previously been reported that the glutamate ionotropic antagonist phencyclidine directly inhibits the release of prolactin in anterior pituitary cells in culture, suggesting that phencyclidine has a dopamine (DA)-like action on prolactin-releasing cells. Dopamine 216-218 prolactin Homo sapiens 120-129 19082309-7 2008 On low bromocriptine dose (1.25 mg/day), there was a prompt normalization of prolactin levels with a great increase (> 600 microg/L) after withdrawal, which was confirmed several times, suggesting HPD. Bromocriptine 7-20 prolactin Homo sapiens 77-86 19623273-7 2008 Recent research findings suggest a possible new approach to the treatment of PPCM with bromocriptine, which inhibits the release of prolactin, a lactation-promoting hormone. Bromocriptine 87-100 prolactin Homo sapiens 132-141 18574709-6 2008 DISCUSSION: Enhancement of plasma prolactin levels is linked to the mechanism of action of risperidone. Risperidone 91-102 prolactin Homo sapiens 34-43 18574709-7 2008 Mammoplasia and increased plasma prolactin can occur during SSRI (Selective Serotonin Reuptake Inhibitors) or trazodone administration. Trazodone 110-119 prolactin Homo sapiens 33-42 18535109-0 2008 Prolactin and estrogen up-regulate carboxypeptidase-d to promote nitric oxide production and survival of mcf-7 breast cancer cells. Nitric Oxide 65-77 prolactin Homo sapiens 0-9 18535109-8 2008 In the presence of Fa-Ala-Arg, NO production was enhanced by PRL and/or E2 but inhibited by CPD/CPM-specific inhibitor, 2-mercaptomethyl-3-guanidinoethylthio-propanoic acid (MGTA). Furylacryloylalanylarginine 19-29 prolactin Homo sapiens 61-64 18535109-15 2008 In summary, PRL/E2-induced cell-surface CPD released Arg from extracellular substrates, increased intracellular NO, promoted survival and inhibited apoptosis of MCF-7 cells. Arginine 53-56 prolactin Homo sapiens 12-15 18647802-9 2008 The cAMP elevating compound forskolin increased PRL release in both cell types. Cyclic AMP 4-8 prolactin Homo sapiens 48-51 18647802-9 2008 The cAMP elevating compound forskolin increased PRL release in both cell types. Colforsin 28-37 prolactin Homo sapiens 48-51 18321529-0 2008 Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. 1-(3-chlorophenyl)piperazine 69-96 prolactin Homo sapiens 47-56 18321529-0 2008 Relationship of the serotonin transporter with prolactin response to meta-chlorophenylpiperazine in cocaine dependence. Cocaine 100-107 prolactin Homo sapiens 47-56 18321529-3 2008 OBJECTIVE: We examined the relationship between platelet 5-HTT, a presynaptic 5-HT measure, and prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP), a postsynaptic 5-HT receptor agonist in cocaine dependent individuals. 1-(3-chlorophenyl)piperazine 124-151 prolactin Homo sapiens 96-105 18321529-3 2008 OBJECTIVE: We examined the relationship between platelet 5-HTT, a presynaptic 5-HT measure, and prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP), a postsynaptic 5-HT receptor agonist in cocaine dependent individuals. 1-(3-chlorophenyl)piperazine 153-158 prolactin Homo sapiens 96-105 18332900-0 2008 Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Cabergoline 56-67 prolactin Homo sapiens 93-102 18332900-1 2008 Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). Dopamine 0-8 prolactin Homo sapiens 42-51 18332900-1 2008 Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). Dopamine 0-8 prolactin Homo sapiens 107-116 18332900-1 2008 Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). Cabergoline 17-28 prolactin Homo sapiens 42-51 18332900-1 2008 Dopamine-agonist cabergoline (CB) reduces prolactin (PRL) secretion and tumor size in 80% of patients with prolactin-secreting adenomas (PRL-omas) by binding type 2 dopamine receptor (DRD2). Cabergoline 17-28 prolactin Homo sapiens 107-116 18597078-8 2008 Compared to placebo, treatment with bifeprunox led to small but statistically significant decreases in weight and prolactin levels. bifeprunox 36-46 prolactin Homo sapiens 114-123 31507951-0 2008 Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin. Risperidone 14-25 prolactin Homo sapiens 102-111 18279498-0 2008 Prolactin response to fenfluramine in abstinent, alcohol-dependent patients. Fenfluramine 22-34 prolactin Homo sapiens 0-9 18279498-0 2008 Prolactin response to fenfluramine in abstinent, alcohol-dependent patients. Alcohols 49-56 prolactin Homo sapiens 0-9 18279498-2 2008 The prolactin response to fenfluramine (PRF) is generally believed to reflect the activity of the 5HT system and has been previously used to investigate 5HT activity in a variety of conditions, including alcoholism. Fenfluramine 26-38 prolactin Homo sapiens 4-13 18279498-2 2008 The prolactin response to fenfluramine (PRF) is generally believed to reflect the activity of the 5HT system and has been previously used to investigate 5HT activity in a variety of conditions, including alcoholism. Serotonin 98-101 prolactin Homo sapiens 4-13 18279498-2 2008 The prolactin response to fenfluramine (PRF) is generally believed to reflect the activity of the 5HT system and has been previously used to investigate 5HT activity in a variety of conditions, including alcoholism. Serotonin 153-156 prolactin Homo sapiens 4-13 18716488-6 2008 Low testosterone was significantly associated with less time since injury, lower hemoglobin, and higher prolactin in the univariate analyses at P < 0.05. Testosterone 4-16 prolactin Homo sapiens 104-113 18716488-8 2008 Testosterone levels were also related to time since injury and hemoglobin and prolactin levels. Testosterone 0-12 prolactin Homo sapiens 78-87 18556224-5 2008 However, the alkaline phosphatase activity was decreased in a dose-response manner within 24 h. The effect of PRL on alkaline phosphatase was abolished by LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 155-163 prolactin Homo sapiens 110-113 18779591-5 2008 This sole substitution was sufficient to confer constitutive activity to the receptor variant (PrlR(I146L)), as assessed in three reconstituted cell models (Ba/F3, HEK293 and MCF-7 cells) by Prl-independent (i) PrlR tyrosine phosphorylation, (ii) activation of signal transducer and activator of transcription 5 (STAT5) signaling, (iii) transcriptional activity toward a Prl-responsive reporter gene, and (iv) cell proliferation and protection from cell death. Tyrosine 216-224 prolactin Homo sapiens 95-98 18714140-1 2008 Radon risk maps have been produced in many countries using non-geologically based techniques utilising the lognormal and gamma distributions to display point estimates of the probability, P(RL), that indoor radon levels will exceed a reference level. Radon 207-212 prolactin Homo sapiens 188-193 18652486-0 2008 Analysis of site-specific histidine protonation in human prolactin. Histidine 26-35 prolactin Homo sapiens 57-66 18652486-4 2008 hPRL has a surprising number of nine histidines, nearly all of which are present on the protein surface. Histidine 37-47 prolactin Homo sapiens 0-4 18579277-0 2008 Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Dopamine 20-28 prolactin Homo sapiens 80-89 18579277-0 2008 Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Risperidone 97-108 prolactin Homo sapiens 80-89 18579277-1 2008 Hyperprolactinemia is an inevitable consequence of treatment with antipsychotic agents to some extent because prolactin response to antipsychotics is related to dopamine blockade. Dopamine 161-169 prolactin Homo sapiens 5-14 18579277-3 2008 Thus, we studied the effects of major polymorphisms of dopamine-related genes on plasma concentration of prolactin. Dopamine 55-63 prolactin Homo sapiens 105-114 18467331-3 2008 The binding of PRL variants to the PRLR extracellular domain was furthermore characterized by the solution state techniques, hydrogen exchange mass spectrometry, and NMR spectroscopy. Hydrogen 125-133 prolactin Homo sapiens 15-18 31507951-0 2008 Comparison of risperidone, olanzapine and quetiapine: effects on body weight, serum blood glucose and prolactin. Quetiapine Fumarate 42-52 prolactin Homo sapiens 102-111 18455849-5 2008 After establishing cabergoline therapy, we achieved a remarkable decrease in both serum PRL levels and tumor mass, and surprisingly, proteinuria disappeared. Cabergoline 19-30 prolactin Homo sapiens 88-91 18651348-0 2008 Aripiprazole reduces serum prolactin in a woman with prolactinoma and acute psychosis. Aripiprazole 0-12 prolactin Homo sapiens 27-36 18480682-3 2008 This study was designed to compare the herbal preparation called Peony-Glycyrrhiza Decoction (PGD) with bromocriptine (BMT), a dopamine agonist widely used for PRL-secreting disorders, in the treatment of risperidone-induced hyperprolactinemia. Bromocriptine 104-117 prolactin Homo sapiens 160-163 18194152-2 2008 The aims of this study were to determine if buspirone stimulates prolactin release through the 5-hydroxytryptamine (5HT)1a receptor and whether this response is altered in patients with IBS and in the rat maternal separation model. Buspirone 44-53 prolactin Homo sapiens 65-74 18492821-4 2008 The PRL-stimulated Isc was significantly reduced by pretreatment with an apical addition of 5-nitro-2-(3-phenylpropylamino) benzoic acid (200 microM), diphenylamine-2-carboxylic acid (1 mM) or 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid (200 microM), Cl(-) channel blockers, but not by amiloride (10 microM), a Na(+) channel blocker. 5-nitro-2-(3-phenylpropylamino)benzoic acid 92-136 prolactin Homo sapiens 4-7 18492821-4 2008 The PRL-stimulated Isc was significantly reduced by pretreatment with an apical addition of 5-nitro-2-(3-phenylpropylamino) benzoic acid (200 microM), diphenylamine-2-carboxylic acid (1 mM) or 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid (200 microM), Cl(-) channel blockers, but not by amiloride (10 microM), a Na(+) channel blocker. fenamic acid 151-182 prolactin Homo sapiens 4-7 18492821-4 2008 The PRL-stimulated Isc was significantly reduced by pretreatment with an apical addition of 5-nitro-2-(3-phenylpropylamino) benzoic acid (200 microM), diphenylamine-2-carboxylic acid (1 mM) or 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid (200 microM), Cl(-) channel blockers, but not by amiloride (10 microM), a Na(+) channel blocker. 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid 193-243 prolactin Homo sapiens 4-7 18492821-4 2008 The PRL-stimulated Isc was significantly reduced by pretreatment with an apical addition of 5-nitro-2-(3-phenylpropylamino) benzoic acid (200 microM), diphenylamine-2-carboxylic acid (1 mM) or 4,4"-diisothiocyanatostilbene-2,2"-disulfonic acid (200 microM), Cl(-) channel blockers, but not by amiloride (10 microM), a Na(+) channel blocker. Amiloride 293-302 prolactin Homo sapiens 4-7 18492821-5 2008 In addition, pretreatment with bumetanide (200 microM), a Na(+)-K(+)-2Cl(-) cotransporter inhibitor, in the basolateral solution significantly reduced the PRL-stimulated Isc. Bumetanide 31-41 prolactin Homo sapiens 155-158 18492821-7 2008 Pretreatment of the monolayer with AG490 (50 microM), an inhibitor of JAK2 activity significantly inhibited the PRL-induced increase in Isc. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 35-40 prolactin Homo sapiens 112-115 18194152-3 2008 Buspirone (30 mg) was used to stimulate prolactin release in 40 patients with IBS and in 40 healthy controls. Buspirone 0-9 prolactin Homo sapiens 40-49 18194152-5 2008 In study 2, 30 patients with IBS and 30 healthy controls had prolactin release stimulated by buspirone. Buspirone 93-102 prolactin Homo sapiens 61-70 18194152-8 2008 Pindolol produced a dose-dependent decrease in the buspirone prolactin response. Pindolol 0-8 prolactin Homo sapiens 61-70 18417268-2 2008 Plasma prolactin responses to a tryptophan enhancement challenge are used as a measure of central nervous system serotonergic activity. Tryptophan 32-42 prolactin Homo sapiens 7-16 18482912-2 2008 We report two cases of hyperprolactinaemia in which a low recovery of serum prolactin (PRL) after PEG precipitation indicated the presence of macroprolactin, but no macroprolactin was detected by gel filtration chromatography (GFC). Polyethylene Glycols 98-101 prolactin Homo sapiens 87-90 18482912-4 2008 METHODS: The effect of increasing concentrations of gamma globulin on the precipitation of PRL by PEG was studied by adding purified human gamma globulin to serum. Polyethylene Glycols 98-101 prolactin Homo sapiens 91-94 18482912-6 2008 RESULTS: Addition of gamma globulin decreased the recovery of PRL following precipitation with PEG and gamma globulin concentrations correlated inversely with PRL concentrations (r = 0.9429, P < 0.0167) and percentage recovery of PRL (r = -1.000, P < 0.005). Polyethylene Glycols 95-98 prolactin Homo sapiens 62-65 18482912-7 2008 Only one out of 10 samples from HIV-infected patients with PRL recoveries of <60% following PEG precipitation showed a substantial macroprolactin component on GFC. Polyethylene Glycols 95-98 prolactin Homo sapiens 59-62 18482912-8 2008 CONCLUSIONS: Monomeric PRL is co-precipitated with serum globulins by PEG. Polyethylene Glycols 70-73 prolactin Homo sapiens 23-26 18482912-9 2008 Increased serum globulin concentrations can increase the amount of monomeric PRL precipitated by PEG giving a false estimate of the monomeric PRL and the erroneous impression that macroprolactin is present. Polyethylene Glycols 97-100 prolactin Homo sapiens 77-80 18346598-3 2008 Accumulating evidence shows consistent "prolactin-raising" effects of conventional antipsychotics and risperidone compared with other current atypical antipsychotics, which are more likely to have "prolactin-sparing" properties. Risperidone 102-113 prolactin Homo sapiens 40-49 18346598-4 2008 Prolactin-sparing antipsychotics (for example, aripiprazole and quetiapine) tend to show lower frequencies of hyperprolactinaemia-associated side effects. Aripiprazole 47-59 prolactin Homo sapiens 0-9 18346598-4 2008 Prolactin-sparing antipsychotics (for example, aripiprazole and quetiapine) tend to show lower frequencies of hyperprolactinaemia-associated side effects. Quetiapine Fumarate 64-74 prolactin Homo sapiens 0-9 18346598-5 2008 In recent studies, aripiprazole-treated patients have demonstrated lower prolactin levels compared with patients receiving other prolactin-sparing antipsychotics. Aripiprazole 19-31 prolactin Homo sapiens 73-82 18346598-5 2008 In recent studies, aripiprazole-treated patients have demonstrated lower prolactin levels compared with patients receiving other prolactin-sparing antipsychotics. Aripiprazole 19-31 prolactin Homo sapiens 129-138 18615392-9 2008 The mixed (GH/PRL) adenomas showed a tendency to a higher expression of rsst2A + + rsst2B and a greater response to octreotide administration. Octreotide 116-126 prolactin Homo sapiens 14-17 18426817-10 2008 The SSTR5 compound, BIM-23206, produced a dose-dependent inhibition of PRL release similar to that of cabergoline in three DA-sensitive prolactinomas. bim 20-23 prolactin Homo sapiens 71-74 18426817-13 2008 Cabergoline and BIM-23A760 produced a partial inhibition of PRL secretion (19+/-6 and 21+/-3% respectively). Cabergoline 0-11 prolactin Homo sapiens 60-63 18426817-13 2008 Cabergoline and BIM-23A760 produced a partial inhibition of PRL secretion (19+/-6 and 21+/-3% respectively). bim 16-19 prolactin Homo sapiens 60-63 18417268-3 2008 We examined prolactin responses to a tryptophan challenge as they relate to the personality domains of neuroticism, extraversion, openness, agreeableness, and conscientiousness. Tryptophan 37-47 prolactin Homo sapiens 12-21 18096663-0 2008 Dopamine inhibits basal prolactin release in pituitary lactotrophs through pertussis toxin-sensitive and -insensitive signaling pathways. Dopamine 0-8 prolactin Homo sapiens 24-33 18375569-3 2008 In addition, paliperidone is associated with substantial increases in serum prolactin that may be associated with sexual dysfunction, although sexual functioning outcomes were not reported. Paliperidone Palmitate 13-25 prolactin Homo sapiens 76-85 18096663-4 2008 Here we show that the dopamine agonist-induced inhibition of spontaneous Ca(2+) influx and release of prestored PRL was preserved when cAMP levels were elevated by forskolin treatment. Dopamine 22-30 prolactin Homo sapiens 112-115 18096663-4 2008 Here we show that the dopamine agonist-induced inhibition of spontaneous Ca(2+) influx and release of prestored PRL was preserved when cAMP levels were elevated by forskolin treatment. Cyclic AMP 135-139 prolactin Homo sapiens 112-115 18096663-4 2008 Here we show that the dopamine agonist-induced inhibition of spontaneous Ca(2+) influx and release of prestored PRL was preserved when cAMP levels were elevated by forskolin treatment. Colforsin 164-173 prolactin Homo sapiens 112-115 18096663-8 2008 The PTX-insensitive step in agonist-induced inhibition of PRL release was not affected by the addition of wortmannin, an inhibitor of phosphatidylinositol 3-kinase, and lithium, an inhibitor of glycogen synthase kinase-3, but was attenuated in the presence of phorbol 12-myristate 13-acetate, which inhibits G(z) signaling pathway in a protein kinase C-dependent manner. Tetradecanoylphorbol Acetate 260-291 prolactin Homo sapiens 58-61 18096663-9 2008 Thus, dopamine inhibits basal PRL release by blocking voltage-gated Ca(2+) influx through the PTX-sensitive signaling pathway and by desensitizing Ca(2+) secretion coupling through the PTX-insensitive and protein kinase C-sensitive signaling pathway. Dopamine 6-14 prolactin Homo sapiens 30-33 18484195-9 2008 PRL may form a novel regulatory system for steroid hormone secretion and cell proliferation in the adrenal cortex. Steroids 43-58 prolactin Homo sapiens 0-3 23105749-4 2008 A positive correlation among serum prolactin and nitrite suggested that hyperprolactinemia could contribute to infertility by inducing oxidative damage. Nitrites 49-56 prolactin Homo sapiens 35-44 18335328-9 2008 RESULTS: After 12 weeks of MYO administration plasma LH, PRL, T, insulin levels and LH/FSH resulted significantly reduced. Inositol 27-30 prolactin Homo sapiens 57-60 18843962-4 2008 Group I was composed of 48 cases who received bromocriptine administration before induction of ovulation cycles, and the dose of bromocriptine was modulated depending on the level of serum prolactin. Bromocriptine 129-142 prolactin Homo sapiens 189-198 18843963-5 2008 CONCLUSIONS: During controlled ovarian stimulation, prolactin secretion is not affected by Gn but may be stimulated by estradiol. Estradiol 119-128 prolactin Homo sapiens 52-61 18053626-0 2008 The impact of MDR1 polymorphisms on prolactin concentrations in patients treated with risperidone. Risperidone 86-97 prolactin Homo sapiens 36-45 18393218-2 2008 We hypothesized that women with chronic anovulation should show exacerbated secretion of prolactin (PRL) after thyrotropin-releasing hormone (TRH) stimulation test, having more chances for dopamine inhibitory dysfunction due to alterations in the structure of DRD3. Dopamine 189-197 prolactin Homo sapiens 89-98 18089703-1 2008 BACKGROUND: Estradiol (E(2)) stimulates GH and prolactin secretion and suppresses FSH secretion in postmenopausal women. Estradiol 12-21 prolactin Homo sapiens 47-56 18089703-1 2008 BACKGROUND: Estradiol (E(2)) stimulates GH and prolactin secretion and suppresses FSH secretion in postmenopausal women. Estradiol 23-27 prolactin Homo sapiens 47-56 18477617-2 2008 Dopamine (DA) holds a predominant role in the regulation of prolactin (PRL) secretion. Dopamine 0-8 prolactin Homo sapiens 60-69 18477617-2 2008 Dopamine (DA) holds a predominant role in the regulation of prolactin (PRL) secretion. Dopamine 10-12 prolactin Homo sapiens 60-69 18477617-6 2008 A variety of other modulators of prolactin secretion act at the hypothalamic level by either disinhibition of the dopaminergic tone (e.g. serotonin, GABA, oestrogens and opioids) or by reinforcing it (e.g. substance P). Serotonin 138-147 prolactin Homo sapiens 33-42 18477617-6 2008 A variety of other modulators of prolactin secretion act at the hypothalamic level by either disinhibition of the dopaminergic tone (e.g. serotonin, GABA, oestrogens and opioids) or by reinforcing it (e.g. substance P). gamma-Aminobutyric Acid 149-153 prolactin Homo sapiens 33-42 18477617-8 2008 Of those atypicals that are associated with prolactin elevation, the main causative factor appears to be a higher peripheral-to-central dopamine receptor potency of either the parent drug or its active metabolite (e.g. risperidone, 9-hydroxy-risperidone and amisulpride). Risperidone 219-230 prolactin Homo sapiens 44-53 18477617-8 2008 Of those atypicals that are associated with prolactin elevation, the main causative factor appears to be a higher peripheral-to-central dopamine receptor potency of either the parent drug or its active metabolite (e.g. risperidone, 9-hydroxy-risperidone and amisulpride). Paliperidone Palmitate 232-253 prolactin Homo sapiens 44-53 18477617-8 2008 Of those atypicals that are associated with prolactin elevation, the main causative factor appears to be a higher peripheral-to-central dopamine receptor potency of either the parent drug or its active metabolite (e.g. risperidone, 9-hydroxy-risperidone and amisulpride). Amisulpride 258-269 prolactin Homo sapiens 44-53 18477618-3 2008 Prolactin is secreted from the anterior pituitary gland under the influence of dopamine, which exerts a tonic inhibitory effect on prolactin secretion. Dopamine 79-87 prolactin Homo sapiens 0-9 18477618-3 2008 Prolactin is secreted from the anterior pituitary gland under the influence of dopamine, which exerts a tonic inhibitory effect on prolactin secretion. Dopamine 79-87 prolactin Homo sapiens 131-140 18080171-9 2008 There was a greater increase of prolactin in the risperidone group, while alanine amino transferase (ALT) had further increased in the haloperidol group. Risperidone 49-60 prolactin Homo sapiens 32-41 18053652-1 2008 BACKGROUND: Treatment with the atypical antipsychotic risperidone can result in elevated prolactin levels. Risperidone 54-65 prolactin Homo sapiens 89-98 18006630-1 2008 Estrogens have been implicated in the regulation of prolactin gene expression in man, although previous studies have not defined the molecular mechanism whereby estradiol activates the human prolactin gene promoter (hPrl). Estradiol 161-170 prolactin Homo sapiens 216-220 18006630-2 2008 We found that estradiol induced a reproducible 1.8-fold activation of the hPrl gene promoter, using pituitary GH3 cells stably transfected with a 5000-bp hPrl promoter fragment linked to luciferase reporter gene. Estradiol 14-23 prolactin Homo sapiens 74-78 17846080-2 2008 Cytokines such as growth hormone, prolactin, erythropoietin, and interleukin-2 stimulate the activation of STAT5a by tyrosine phosphorylation. Tyrosine 117-125 prolactin Homo sapiens 34-43 18252950-7 2008 We therefore tested whether ERK1/2 might be involved in the leptin PRL response and found that the ERK inhibitor, PD98059, hindered leptin-induced PRL release. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 114-121 prolactin Homo sapiens 67-70 18252950-7 2008 We therefore tested whether ERK1/2 might be involved in the leptin PRL response and found that the ERK inhibitor, PD98059, hindered leptin-induced PRL release. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 114-121 prolactin Homo sapiens 147-150 18006630-2 2008 We found that estradiol induced a reproducible 1.8-fold activation of the hPrl gene promoter, using pituitary GH3 cells stably transfected with a 5000-bp hPrl promoter fragment linked to luciferase reporter gene. Estradiol 14-23 prolactin Homo sapiens 154-158 18006630-8 2008 When cells were treated with both estradiol and TNFalpha, we observed synergistic activation of the hPrl promoter, which was mediated by the -1189-bp ERE. Estradiol 34-43 prolactin Homo sapiens 100-104 18053652-5 2008 RESULTS: Compared with pretreatment values, prolactin levels at endpoint were significantly increased (p<0.00001) and correlated with risperidone doses (r=0.58, N=16, p<0.02), and plasma levels of risperidone (r=0.60, N=16, p<0.02) and 9-hydroxyrisperidone (r=0.54, N=16, p=0.03). Risperidone 137-148 prolactin Homo sapiens 44-53 18053652-5 2008 RESULTS: Compared with pretreatment values, prolactin levels at endpoint were significantly increased (p<0.00001) and correlated with risperidone doses (r=0.58, N=16, p<0.02), and plasma levels of risperidone (r=0.60, N=16, p<0.02) and 9-hydroxyrisperidone (r=0.54, N=16, p=0.03). Risperidone 203-214 prolactin Homo sapiens 44-53 18053652-5 2008 RESULTS: Compared with pretreatment values, prolactin levels at endpoint were significantly increased (p<0.00001) and correlated with risperidone doses (r=0.58, N=16, p<0.02), and plasma levels of risperidone (r=0.60, N=16, p<0.02) and 9-hydroxyrisperidone (r=0.54, N=16, p=0.03). Paliperidone Palmitate 245-265 prolactin Homo sapiens 44-53 18053652-6 2008 CONCLUSIONS: These data suggest that risperidone"s effect on prolactin release is dose-dependent in adolescents and is linked to both plasma risperidone and 9-hydroxyrisperidone concentrations. Risperidone 37-48 prolactin Homo sapiens 61-70 18000814-6 2008 Memantine, between 200 and 2000 nM, directly acted on D2(High) to inhibit the release of prolactin from isolated anterior pituitary cells in culture. Memantine 0-9 prolactin Homo sapiens 89-98 18053652-6 2008 CONCLUSIONS: These data suggest that risperidone"s effect on prolactin release is dose-dependent in adolescents and is linked to both plasma risperidone and 9-hydroxyrisperidone concentrations. Risperidone 141-152 prolactin Homo sapiens 61-70 18053652-6 2008 CONCLUSIONS: These data suggest that risperidone"s effect on prolactin release is dose-dependent in adolescents and is linked to both plasma risperidone and 9-hydroxyrisperidone concentrations. Paliperidone Palmitate 157-177 prolactin Homo sapiens 61-70 17590551-0 2008 A case of 6-pyruvoyl-tetrahydropterin synthase deficiency demonstrates a more significant correlation of L-Dopa dosage with serum prolactin levels than CSF homovanillic acid levels. Levodopa 105-111 prolactin Homo sapiens 130-139 18056831-6 2008 Antipsychotic agents have been reported to lower the seizure threshold, and elevated prolactin levels have been associated with risperidone use. Risperidone 128-139 prolactin Homo sapiens 85-94 17590551-5 2008 Combined treatment of BH4, L-Dopa/carbidopa, and 5HTP was started as the CSF neopterin/biopterin ratio (N/B ratio 7.54, control 0.46-1.59) and serum prolactin level (36.79 ng/ml, control <15) were elevated. 5-Hydroxytryptophan 49-53 prolactin Homo sapiens 149-158 17590551-3 2008 It has been reported that serum prolactin levels are elevated in patients with PTPS deficiency indicating that inhibition of prolactin secretion by dopamine is insufficient and is negatively correlated with the CSF level of HVA. Dopamine 148-156 prolactin Homo sapiens 125-134 17590551-8 2008 On the other hand, even in this relatively small dosing range, the serum prolactin level showed significant negative correlation with the dosage of L-Dopa/carbidopa (R=0.645, p=0.023). Levodopa 148-154 prolactin Homo sapiens 73-82 17590551-8 2008 On the other hand, even in this relatively small dosing range, the serum prolactin level showed significant negative correlation with the dosage of L-Dopa/carbidopa (R=0.645, p=0.023). Carbidopa 155-164 prolactin Homo sapiens 73-82 17590551-10 2008 From these results, we suggest that the serum prolactin level may be a more sensitive marker than the CSF HVA level to guide the dose adjustment of L-Dopa/carbidopa in the management of patients with PTPS deficiency. Levodopa 148-154 prolactin Homo sapiens 46-55 17590551-10 2008 From these results, we suggest that the serum prolactin level may be a more sensitive marker than the CSF HVA level to guide the dose adjustment of L-Dopa/carbidopa in the management of patients with PTPS deficiency. Carbidopa 155-164 prolactin Homo sapiens 46-55 17590551-4 2008 Here, we present a case of PTPS deficiency which showed a more significant correlation of dosage of L-Dopa/carbidopa with serum prolactin levels than with CSF HVA levels. Levodopa 100-106 prolactin Homo sapiens 128-137 17590551-4 2008 Here, we present a case of PTPS deficiency which showed a more significant correlation of dosage of L-Dopa/carbidopa with serum prolactin levels than with CSF HVA levels. Carbidopa 107-116 prolactin Homo sapiens 128-137 18681966-7 2008 Doxorubicin accordingly induced expression of prolactin mRNA and protein in all five breast cancer cell lines tested. Doxorubicin 0-11 prolactin Homo sapiens 46-55 19014541-9 2008 Both prolactin and its downstream protein effector, HSP90alpha, promote survival, as shown by apoptosis assays and by the addition of the HSP90 inhibitor, 17-allylamino-17-demethoxygeldanamycin (17-AAG), in both untransformed HC11 mammary epithelial cells and SKBR3 breast cancer cells. tanespimycin 155-193 prolactin Homo sapiens 5-14 18567406-4 2008 All of the typical antipsychotics and risperidone can cause substantial PRL elevation. Risperidone 38-49 prolactin Homo sapiens 72-75 17658223-2 2008 PRL in lactation initially aroused relatively little interest, but it rose when with ovarian steroids and chemical carcinogens, it was implicated in rodent mammary carcinoma. Steroids 93-101 prolactin Homo sapiens 0-3 18080914-1 2008 A standard protocol for isolation of buffalo prolactin (buPRL) was modified at the alcohol precipitation step. Alcohols 83-90 prolactin Homo sapiens 45-54 18080914-3 2008 Reloading the prolactin onto a Sephacryl S-200 gel purified the buPRL monomer. buprl 64-69 prolactin Homo sapiens 14-23 18063941-8 2007 Olanzapine led to a transient mild prolactin elevation. Olanzapine 0-10 prolactin Homo sapiens 35-44 17967478-1 2008 BACKGROUND: Cabergoline (CAB) has been proposed as the first-line treatment in the management of prolactin (PRL)-secreting tumors (prolactinoma [PRLoma]), including those resistant to standard dopamine agonist (DAA) therapy. Cabergoline 12-23 prolactin Homo sapiens 97-106 17967478-1 2008 BACKGROUND: Cabergoline (CAB) has been proposed as the first-line treatment in the management of prolactin (PRL)-secreting tumors (prolactinoma [PRLoma]), including those resistant to standard dopamine agonist (DAA) therapy. Cabergoline 12-23 prolactin Homo sapiens 108-111 17967478-1 2008 BACKGROUND: Cabergoline (CAB) has been proposed as the first-line treatment in the management of prolactin (PRL)-secreting tumors (prolactinoma [PRLoma]), including those resistant to standard dopamine agonist (DAA) therapy. Cabergoline 25-28 prolactin Homo sapiens 97-106 17967478-1 2008 BACKGROUND: Cabergoline (CAB) has been proposed as the first-line treatment in the management of prolactin (PRL)-secreting tumors (prolactinoma [PRLoma]), including those resistant to standard dopamine agonist (DAA) therapy. Cabergoline 25-28 prolactin Homo sapiens 108-111 17967478-6 2008 Cabergoline normalized serum PRL level, shrank the tumor mass remarkably, and caused marked improvement of visual acuity. Cabergoline 0-11 prolactin Homo sapiens 29-32 18004132-5 2007 The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. Risperidone 84-95 prolactin Homo sapiens 196-205 18004132-5 2007 The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. Risperidone 84-95 prolactin Homo sapiens 307-316 18004132-5 2007 The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. Risperidone 84-95 prolactin Homo sapiens 307-316 18004132-5 2007 The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. Paliperidone Palmitate 122-134 prolactin Homo sapiens 196-205 18004132-5 2007 The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. Paliperidone Palmitate 122-134 prolactin Homo sapiens 307-316 18004132-5 2007 The first-generation antipsychotics, as well as the second-generation antipsychotic risperidone and its active metabolite paliperidone, have been shown to cause marked and sustained elevations in prolactin levels, whereas others of the second-generation antipsychotics appear to have little or no effect on prolactin levels or may decrease prolactin. Paliperidone Palmitate 122-134 prolactin Homo sapiens 307-316 18357860-1 2007 Prolactin is a one of the stress hormones, like the growth hormone, ACTH, cortisol and catecholamins. catecholamins 87-100 prolactin Homo sapiens 0-9 18063941-12 2007 CONCLUSION: Amisulpride and risperidone had marked and early prolactin elevating effects, requiring, therefore, more frequent monitoring of prolactinaemia and associated undesirable effects and risks than olanzapine, quetiapine and zotepine. Amisulpride 12-23 prolactin Homo sapiens 61-70 18063941-12 2007 CONCLUSION: Amisulpride and risperidone had marked and early prolactin elevating effects, requiring, therefore, more frequent monitoring of prolactinaemia and associated undesirable effects and risks than olanzapine, quetiapine and zotepine. Risperidone 28-39 prolactin Homo sapiens 61-70 18063946-10 2007 The rhythm of Prl secretion was disturbed in: 72.7% of children with GHD-PSIS, 23.5% - with GHD-HP, 10.5% with GHD-NORM and 7.3% with ISS, only. ghd-hp 92-98 prolactin Homo sapiens 14-17 18063946-10 2007 The rhythm of Prl secretion was disturbed in: 72.7% of children with GHD-PSIS, 23.5% - with GHD-HP, 10.5% with GHD-NORM and 7.3% with ISS, only. ISS 134-137 prolactin Homo sapiens 14-17 17785459-6 2007 On the contrary, residual agonism of the hPRL variants was found to be inversely correlated to their thermodynamic stability, which was altered by all the Gly(129) mutations but not by those involving the N terminus. Glycine 155-158 prolactin Homo sapiens 41-45 17578485-9 2007 Concentrations of prolactin and TSH were increased by domperidone. Domperidone 54-65 prolactin Homo sapiens 18-27 17578485-10 2007 Pramipexole reduced prolactin and increased GH concentrations. Pramipexole 0-11 prolactin Homo sapiens 20-29 17260098-5 2007 RESULTS: In linear regression models adjusted for age, body mass index, race, smoking, alcohol use, parity and physical activity, among the 400 women who were not recent users of HT, prolactin was positively and statistically significantly associated with mammographic density (Beta log base 2 prolactin 0.0369 [95% CI: 0.0094-0.0645]. Alcohols 87-94 prolactin Homo sapiens 183-192 17715206-1 2007 The object of this study is to assess 1) the relationship between plasma antipsychotic drug concentration, serum prolactin levels and the clinical efficacy of risperidone, 2) the relationship between the CYP2D6 polymorphisms and metabolizing of risperidone and 3) the role of 9-hydroxyrisperidone in elevating prolactin levels. Risperidone 159-170 prolactin Homo sapiens 113-122 17715206-1 2007 The object of this study is to assess 1) the relationship between plasma antipsychotic drug concentration, serum prolactin levels and the clinical efficacy of risperidone, 2) the relationship between the CYP2D6 polymorphisms and metabolizing of risperidone and 3) the role of 9-hydroxyrisperidone in elevating prolactin levels. Risperidone 159-170 prolactin Homo sapiens 310-319 17715206-1 2007 The object of this study is to assess 1) the relationship between plasma antipsychotic drug concentration, serum prolactin levels and the clinical efficacy of risperidone, 2) the relationship between the CYP2D6 polymorphisms and metabolizing of risperidone and 3) the role of 9-hydroxyrisperidone in elevating prolactin levels. Risperidone 245-256 prolactin Homo sapiens 113-122 17715206-1 2007 The object of this study is to assess 1) the relationship between plasma antipsychotic drug concentration, serum prolactin levels and the clinical efficacy of risperidone, 2) the relationship between the CYP2D6 polymorphisms and metabolizing of risperidone and 3) the role of 9-hydroxyrisperidone in elevating prolactin levels. Risperidone 245-256 prolactin Homo sapiens 310-319 17715206-6 2007 Risperidone treatment significantly increased serum prolactin levels. Risperidone 0-11 prolactin Homo sapiens 52-61 18173145-3 2007 RESULTS: It was shown that T level in SYiD, serum LH and LH/FSH ratio in SYaD, PRL in GSH and INS in PYD patients were higher as compared with those in patients of other three types (P < 0.05 or P < 0.01), except for the above-mentioned, the differences in all the paired comparisons of all the indexes between TCM types were insignificant. Glutathione 86-89 prolactin Homo sapiens 79-82 18075468-0 2007 CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Perphenazine 113-125 prolactin Homo sapiens 91-100 18075468-1 2007 OBJECTIVES: We observed that CYP2D6 contributes to pharmacodynamic tissue sensitivity to perphenazine as measured by the areas under the curve (AUCs) expressed as a ratio (prolactin-AUC0-6/perphenazine-AUC0-6) in Chinese Canadians [Pharmacogenetics and Genomics 2007; 17:339-347]. Perphenazine 89-101 prolactin Homo sapiens 172-181 18075468-6 2007 A1/A1 genotype displayed a higher prolactin elevation 2 h after perphenazine administration (P=0.02). Perphenazine 64-76 prolactin Homo sapiens 34-43 18059975-0 2007 Genistein-induced pituitary prolactin gene expression and prolactin release in ovariectomized ewes following a series of intracerebroventricular infusions. Genistein 0-9 prolactin Homo sapiens 28-37 18059975-0 2007 Genistein-induced pituitary prolactin gene expression and prolactin release in ovariectomized ewes following a series of intracerebroventricular infusions. Genistein 0-9 prolactin Homo sapiens 58-67 18059975-1 2007 The aim of the study was to evaluate whether genistein, a phytoestrogen commonly present in feed plants, affects prolactin release and its gene expression in the pituitary gland. Genistein 45-54 prolactin Homo sapiens 113-122 18059975-2 2007 In the experimental model, genistein was infused into the third ventricle (IIIv) of the brain in ewes during the short-daylight period (November-December), when the physiological plasma level of prolactin is low. Genistein 27-36 prolactin Homo sapiens 195-204 18059975-6 2007 Northern blot analysis revealed that pituitary prolactin mRNA content increased significantly in response to genistein, compared to the vehicle-infused ewes (p<0.05). Genistein 109-118 prolactin Homo sapiens 47-56 18059975-7 2007 Prolactin concentration in plasma rose significantly during the periods of genistein infusion, as compared to the values found before infusion (p<0.05-p<0.01) as well as to the values of the concomitant periods in vehicle-infused ewes (p<0.001). Genistein 75-84 prolactin Homo sapiens 0-9 18473017-4 2007 Risperidone is one of the atypical neuroleptics most likely to induce hyperprolactinemia, while other atypical drugs are unfrequenlty and only transiently associated with increase of prolactin levels. Risperidone 0-11 prolactin Homo sapiens 75-84 17898346-10 2007 Patients treated with olanzapine, however, had significantly greater weight gain and increases in the levels of hepatic enzymes, prolactin, fasting glucose, fasting total cholesterol, and uric acid. Olanzapine 22-32 prolactin Homo sapiens 129-138 17873693-0 2007 Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone. Risperidone 121-132 prolactin Homo sapiens 26-35 17676064-3 2007 Prolactin is cleaved to yield vasoinhibins, a family of peptides that inhibit angiogenesis and nitric oxide-dependent vasodilation. Nitric Oxide 95-107 prolactin Homo sapiens 0-9 17680631-0 2007 S179D prolactin sensitizes human prostate cancer cells such that physiological concentrations of 1, 25 dihydroxy vitamin D3 result in growth inhibition and cell death. Calcitriol 97-123 prolactin Homo sapiens 6-15 17329276-8 2007 Suppression of TSH, T(4) and PRL was observed in dopamine-treated newborns from 12 h of treatment onwards, whereas levels of growth hormone reduced significantly only at 12 h and 36 h of treatment (p<0.01). Dopamine 49-57 prolactin Homo sapiens 29-32 17438530-3 2007 We have shown that PRL stimulates activating protein-1 (AP-1) activity in breast cancer cells, and can cooperate with estradiol in this pathway. Estradiol 118-127 prolactin Homo sapiens 19-22 17329276-9 2007 TSH, T(4) and PRL rebound was observed from the first day onwards after stopping dopamine. Dopamine 81-89 prolactin Homo sapiens 14-17 17329276-12 2007 Dopamine reduces serum levels of TSH, T(4) and PRL in VLBW infants but such suppression is quickly reversed after treatment is stopped. Dopamine 0-8 prolactin Homo sapiens 47-50 16787735-7 2007 It was found that plasma PRL concentration was lower (p<0.01) in bromocriptine treated birds with high concentrations of LH, its 3h LH surges, E(2)beta and P(4) in plasma. Bromocriptine 68-81 prolactin Homo sapiens 25-28 17550976-2 2007 We now report marked PRL-induced tyrosine phosphorylation of Jak1, in addition to Jak2, in a series of human breast cancer cell lines, including T47D, MCF7, and SKBR3. Tyrosine 33-41 prolactin Homo sapiens 21-24 17550976-7 2007 Instead, PRL activated Jak1 through a Jak2-dependent mechanism, based on disruption of PRL activation of Jak1 after Jak2 suppression by 1) lentiviral delivery of Jak2 short hairpin RNA, 2) adenoviral delivery of dominant-negative Jak2, and 3) AG490 pharmacological inhibition. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 243-248 prolactin Homo sapiens 9-12 17550976-7 2007 Instead, PRL activated Jak1 through a Jak2-dependent mechanism, based on disruption of PRL activation of Jak1 after Jak2 suppression by 1) lentiviral delivery of Jak2 short hairpin RNA, 2) adenoviral delivery of dominant-negative Jak2, and 3) AG490 pharmacological inhibition. alpha-cyano-(3,4-dihydroxy)-N-benzylcinnamide 243-248 prolactin Homo sapiens 87-90 17550976-8 2007 Finally, suppression of Jak1 by lentiviral delivery of Jak1 short hairpin RNA blocked PRL activation of ERK and signal transducer and activator of transcription (Stat)3 and suppressed PRL activation of Jak2, Stat5a, Stat5b, and Akt, as well as tyrosine phosphorylation of PRLR. Tyrosine 244-252 prolactin Homo sapiens 86-89 17559997-0 2007 Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Risperidone 120-131 prolactin Homo sapiens 103-112 17415019-11 2007 Opiate use was significantly associated with lower inhibin B and E2 and increased prolactin. Opiate Alkaloids 0-6 prolactin Homo sapiens 82-91 16787735-7 2007 It was found that plasma PRL concentration was lower (p<0.01) in bromocriptine treated birds with high concentrations of LH, its 3h LH surges, E(2)beta and P(4) in plasma. Luteinizing Hormone 124-126 prolactin Homo sapiens 25-28 16787735-9 2007 In conclusion, bromocriptine administration decreased (p<0.01) PRL concentration increased (p<0.01) steroid hormones and LH surges, for egg formation and oviposition and enabled the birds to lay more eggs even later in the productive period with the available resources under normal husbandry practices. Bromocriptine 15-28 prolactin Homo sapiens 66-69 16787735-9 2007 In conclusion, bromocriptine administration decreased (p<0.01) PRL concentration increased (p<0.01) steroid hormones and LH surges, for egg formation and oviposition and enabled the birds to lay more eggs even later in the productive period with the available resources under normal husbandry practices. Steroids 106-122 prolactin Homo sapiens 66-69 17587388-5 2007 PRL expression and release increases during early pre-adipocyte differentiation and is stimulated by cyclic AMP activators, including beta adrenergic receptor agonists. Cyclic AMP 101-111 prolactin Homo sapiens 0-3 17660130-8 2007 Similarly, patients of the PCEA group exhibited diminished postoperative elevation of serum prolactin level (20.7, 15.7 ng/mL) compared with PCA (24.9, 17.1) group. pcea 27-31 prolactin Homo sapiens 92-101 17854246-9 2007 There were no significant differences in Positive and Negative Syndrome Scale (PANSS) scores between the 2 groups, but the risperidone long-acting injection group showed reduced UKU Side Effect Rating Scale total scores (p = .048), Simpson-Angus Scale scores (p = .028), prolactin levels (p = .046), and serum concentrations of risperidone metabolites (p = .028). Risperidone 123-134 prolactin Homo sapiens 271-280 17626900-6 2007 RESULTS: In linear regression models including age, gender, race, and citalopram concentration, a 1 SD lower prolactin response was associated with greater maximum intima-media thickness (+0.016 mm; P=0.006) and with greater mean intima-media thickness (+0.009 mm; P=0.03). Citalopram 70-80 prolactin Homo sapiens 109-118 17626900-7 2007 The odds ratio for carotid artery plaque corresponding to a 1 SD decrease in prolactin response, adjusted for age, race, sex, and citalopram concentration, was 1.47 (95% CI, 0.98 to 2.19; P=0.06). Citalopram 130-140 prolactin Homo sapiens 77-86 17626900-9 2007 CONCLUSIONS: In this young and relatively healthy sample, blunted prolactin response to citalopram was associated with carotid artery thickening, suggesting that individual differences in central serotonergic responsivity are inversely related to preclinical vascular disease. Citalopram 88-98 prolactin Homo sapiens 66-75 17297458-6 2007 In addition, PRL stimulation induced an interaction between Nek3 and paxillin and significantly increased paxillin serine phosphorylation, whereas Nek3 siRNA-transfected cells showed a marked reduction in paxillin phosphorylation. paxillin serine 106-121 prolactin Homo sapiens 13-16 17636605-2 2007 As a result, a variety of empirical, non-specific treatments have been used in an attempt to improve semen characteristics and fertility.Whilst bromocriptine treatment for reducing prolactin levels in hyperprolactinaemic males (as in females), and, in the treatment of hypogonadotropic hypogonadism with hyperprolactinaemia, is beneficial, it has also been used for oligospermic men in the absence of any endocrinopathy. Bromocriptine 144-157 prolactin Homo sapiens 181-190 17636605-5 2007 It has been proposed that the administration of bromocriptine under these circumstances might counteract a prolactin-induced block on the action of gonadotrophins on the testicles and, subsequently, that the reduction in prolactin levels might lead to an improvement in semen parameters and fertility. Bromocriptine 48-61 prolactin Homo sapiens 107-116 17636605-5 2007 It has been proposed that the administration of bromocriptine under these circumstances might counteract a prolactin-induced block on the action of gonadotrophins on the testicles and, subsequently, that the reduction in prolactin levels might lead to an improvement in semen parameters and fertility. Bromocriptine 48-61 prolactin Homo sapiens 221-230 17636605-6 2007 Although it is not licensed for use in male infertility, bromocriptine has been used for normogonadotrophic individuals with oligospermia and normal or slightly elevated prolactin levels. Bromocriptine 57-70 prolactin Homo sapiens 170-179 17636605-14 2007 Compared with placebo, bromocriptine was associated with a significant reduction in serum prolactin levels (weighted mean difference -195.3 micro international units per litre, 95% confidence interval -276.5 to -114). Bromocriptine 23-36 prolactin Homo sapiens 90-99 17636605-17 2007 AUTHORS" CONCLUSIONS: Bromocriptine appears to reduce prolactin levels in subfertile men with normal gonadotrophic function. Bromocriptine 22-35 prolactin Homo sapiens 54-63 17045431-0 2007 Effect of small doses of naloxone on the pulsatile secretion of prolactin in the crossbreed ewe during the non-breeding season. Naloxone 25-33 prolactin Homo sapiens 64-73 17045431-1 2007 The objective of this work was to study the effect of small doses of naloxone (Nx) on the pulsatile secretion of prolactin (Pr). Naloxone 69-77 prolactin Homo sapiens 113-122 17045431-1 2007 The objective of this work was to study the effect of small doses of naloxone (Nx) on the pulsatile secretion of prolactin (Pr). Naloxone 79-81 prolactin Homo sapiens 113-122 17599334-0 2007 Limitations in discerning the effects of risperidone and its 9-hydroxy metabolite on prolactin levels in a small study of patients with schizophrenia. Risperidone 41-52 prolactin Homo sapiens 85-94 17669717-7 2007 CONCLUSION: Our findings demonstrate that cabergoline should be considered for medical treatment of adenomas cosecreting growth hormone and prolactin, even in the presence of large tumors with appreciable suprasellar extension, because substantial tumor shrinkage is possible with this therapy. Cabergoline 42-53 prolactin Homo sapiens 140-149 17519641-0 2007 Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone. Risperidone 95-106 prolactin Homo sapiens 0-9 17519641-2 2007 Various reports have linked the use of risperidone, an atypical antipsychotic drug, with the significant rise of prolactin levels. Risperidone 39-50 prolactin Homo sapiens 113-122 17519641-6 2007 These results suggest that the blockade of higher dopamine activity in the paranoid schizophrenia corresponds to the prolactin increase, more than in the schizoaffective and disorganized subtypes. Dopamine 50-58 prolactin Homo sapiens 117-126 17521855-4 2007 Dopamine has numerous potential deleterious effects on local circulations (pulmonary, cerebral, coronary and cutaneous), respiratory function, gastroduodenal motility, endocrine function (further depression of the hypothalamic-pituitary axis induced by stress) and immunity (partially due to decreased production of prolactin). Dopamine 0-8 prolactin Homo sapiens 316-325 17272923-4 2007 When treated with the decidual stimulus dibutyryl-cAMP (db-cAMP) or forskolin, the fibroblastic cell-shaped EtsT cells transformed into large- and round-shaped cells and secreted large amounts of the decidual markers prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1). Bucladesine 40-54 prolactin Homo sapiens 228-231 17272923-4 2007 When treated with the decidual stimulus dibutyryl-cAMP (db-cAMP) or forskolin, the fibroblastic cell-shaped EtsT cells transformed into large- and round-shaped cells and secreted large amounts of the decidual markers prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1). Bucladesine 56-63 prolactin Homo sapiens 228-231 17272923-4 2007 When treated with the decidual stimulus dibutyryl-cAMP (db-cAMP) or forskolin, the fibroblastic cell-shaped EtsT cells transformed into large- and round-shaped cells and secreted large amounts of the decidual markers prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1). Colforsin 68-77 prolactin Homo sapiens 228-231 17272923-7 2007 It also abolished db-cAMP-induced PRL and IGFBP-1 mRNA expression and protein secretion. Bucladesine 18-25 prolactin Homo sapiens 34-37 17187171-0 2007 Analysis on the promoter region of human decidual prolactin gene in the progesterone-induced decidualization and cAMP-induced decidualization of human endometrial stromal cells. Progesterone 72-84 prolactin Homo sapiens 41-59 17187171-0 2007 Analysis on the promoter region of human decidual prolactin gene in the progesterone-induced decidualization and cAMP-induced decidualization of human endometrial stromal cells. Cyclic AMP 113-117 prolactin Homo sapiens 41-59 17309739-0 2007 Serum prolactin concentration and its relationship with dehydroepiandrosterone sulfate concentration in chronic urticaria patients with positive and negative response to autologous serum skin test. Dehydroepiandrosterone Sulfate 56-86 prolactin Homo sapiens 6-15 17557033-8 2007 Normalization of PRL levels during therapy with dopamine agonists was significantly more frequent in patients with monomeric hyperprolactinemia than in subjects with macroprolactinemia (78.6% vs 32%, P=0.0006). Dopamine 48-56 prolactin Homo sapiens 17-20 17255201-10 2007 Prolactin modestly or IFN-gamma greatly induced serine phosphorylation of STAT1, which was suppressed by MEK or p38 MAPK inhibitor, respectively. Serine 48-54 prolactin Homo sapiens 0-9 17364141-5 2007 Gamma-aminobutyric acid and several peptide factors, including cytokines, growth hormone-releasing hormone and prolactin, are related to sleep promotion. gamma-Aminobutyric Acid 0-23 prolactin Homo sapiens 111-120 17454518-0 2007 The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. Risperidone 176-187 prolactin Homo sapiens 31-40 17255201-9 2007 Prolactin modestly or IFN-gamma greatly induced tyrosine phosphorylation of STAT1, and both were suppressed by JAK inhibitor. Tyrosine 48-56 prolactin Homo sapiens 0-9 17642293-1 2007 To evaluate chronic effect of polychlorinated biphenyls (PCB) and polychlorinated dibenzofurans (PCDF) on sex hormones and prolactin, serum levels of estradiol, progesterone and prolactin were studied in 71 female patients with Yusho and 23 controls in 2006. Dibenzofurans, Polychlorinated 97-101 prolactin Homo sapiens 123-132 17454518-1 2007 Examine the relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder who were treated with risperidone or quetiapine. Risperidone 170-181 prolactin Homo sapiens 39-48 17454518-1 2007 Examine the relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder who were treated with risperidone or quetiapine. Quetiapine Fumarate 185-195 prolactin Homo sapiens 39-48 17454518-9 2007 In this 6-week randomized double-blind trial, higher serum prolactin level was related to greater impairment of sexual functioning in male outpatients who were treated with risperidone, but not with quetiapine. Risperidone 173-184 prolactin Homo sapiens 59-68 17058022-0 2007 Low dose of dopamine may stimulate prolactin secretion by increasing fast potassium currents. Dopamine 12-20 prolactin Homo sapiens 35-44 17355517-0 2007 Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Risperidone 34-45 prolactin Homo sapiens 0-9 17355517-1 2007 OBJECTIVE: To investigate prolactin levels and related side effects in 128 men and 90 women initially treated with risperidone. Risperidone 115-126 prolactin Homo sapiens 26-35 17355517-7 2007 For patients on continuous monotherapy risperidone treatment, there was a marked linear reduction of prolactin level over all 5 years. Risperidone 39-50 prolactin Homo sapiens 101-110 17355517-8 2007 CONCLUSION: Risperidone induces a higher prolactin elevation than other atypical antipsychotics, but the effect adapts over time. Risperidone 12-23 prolactin Homo sapiens 41-50 17479443-8 2007 We observed significant positive correlation between prolactin and TSH in insulin sensitive and normoglycemic subjects (r=0.273, p=0.039 and r=0.253, p=0.023, respectively) but this correlation was lost in insulin resistant subjects and subjects who had fasting glucose levels >or=100 mg/dl (r=0.057, p=0.609 and r=0.090, p=0.404, respectively). Glucose 262-269 prolactin Homo sapiens 53-62 17058022-0 2007 Low dose of dopamine may stimulate prolactin secretion by increasing fast potassium currents. Potassium 74-83 prolactin Homo sapiens 35-44 17058022-3 2007 Surprisingly, at concentrations approximately 1000 lower, DA can stimulate prolactin secretion. Dopamine 58-60 prolactin Homo sapiens 75-84 17391744-6 2007 Prolactin (PRL) increased significantly within 17 min (P=.04) and reached peak levels of 22.1+/-7.1 ng/ml and 54.1+/-11.3 at 60 min after low and high dose nalbuphine administration, respectively. Nalbuphine 156-166 prolactin Homo sapiens 0-9 17110010-8 2007 Finally, a significant and positive correlation was found between the prolactin and estradiol levels in the paranoid subgroup alone. Estradiol 84-93 prolactin Homo sapiens 70-79 17465868-4 2007 METHODS AND RESULTS: In both patients, elevated serum prolactin levels (123 ng/mL in patient 1 and 48 ng/mL in patient 2) were documented at the time when radioiodine uptake in the breast was observed. Iodine-131 155-166 prolactin Homo sapiens 54-63 17465868-7 2007 CONCLUSION: These cases provide the first documented correlation between serum levels of endogenous prolactin and radioiodine uptake by involuted breast tissue in humans. Iodine-131 114-125 prolactin Homo sapiens 100-109 17110010-9 2007 Thus, it appears that low estradiol levels are associated with low prolactin levels, alleged hyperdopaminergic tone and psychotic breakdown in paranoid schizophrenia. Estradiol 26-35 prolactin Homo sapiens 67-76 17126974-6 2007 The marked and moderate increase in plasma PRL levels were found in patients treated with fluphenazine and olanzapine, respectively. Fluphenazine 90-102 prolactin Homo sapiens 43-46 17126974-6 2007 The marked and moderate increase in plasma PRL levels were found in patients treated with fluphenazine and olanzapine, respectively. Olanzapine 107-117 prolactin Homo sapiens 43-46 16730335-0 2007 Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Risperidone 32-43 prolactin Homo sapiens 57-66 17566512-4 2007 RESULTS: After cabergoline treatment, the mean decrease in plasma prolactin levels was statistically significant (p < 0.05) for the global sample of youths with schizophrenia. Cabergoline 15-26 prolactin Homo sapiens 66-75 17436584-0 2007 Effects of sulfhydryl compounds on cancer cell lines: I: N-(2-mercaptopropionyl)-glycine exerts antiproliferating effects and antagonizes the stimulating effect of prolactin on MCF-7 human breast cancer cells. Tiopronin 57-88 prolactin Homo sapiens 164-173 16950514-1 2007 To evaluate the effect of occupational exposure to manganese (Mn) on serum prolactin (PRL) and the interrelationship among other hypophyseal-pituitary hormones, a cross-sectional study was conducted on 251 welders and 100 age-matched, office workers. Manganese 51-60 prolactin Homo sapiens 86-89 17240357-0 2007 Prolactin expression is induced in Jurkat T-cells by beta-catenin LEF-1, AP-1 and cAMP. Cyclic AMP 82-86 prolactin Homo sapiens 0-9 17240357-3 2007 We have previously reported that cAMP regulates PRL transcription in Jurkat lymphocytes in part through a cAMP responsive element. Cyclic AMP 33-37 prolactin Homo sapiens 48-51 17240357-3 2007 We have previously reported that cAMP regulates PRL transcription in Jurkat lymphocytes in part through a cAMP responsive element. Cyclic AMP 106-110 prolactin Homo sapiens 48-51 16730335-1 2007 BACKGROUND: The effects of short- and long-term risperidone treatment on serum prolactin were assessed in children and adolescents with autism. Risperidone 48-59 prolactin Homo sapiens 79-88 16730335-6 2007 After 8 weeks of risperidone, prolactin increased to 39.0 +/- 19.2 ng/ml, compared with 10.1 +/- 8.8 ng/ml for placebo (p < .0001). Risperidone 17-28 prolactin Homo sapiens 30-39 16730335-9 2007 CONCLUSIONS: Risperidone treatment was associated with two- to four-fold mean increases in serum prolactin in children with autism. Risperidone 13-24 prolactin Homo sapiens 97-106 16983572-6 2007 Bromocriptine treatment was started resulting in lowered prolactin levels, improved vision and tumour shrinkage on imaging. Bromocriptine 0-13 prolactin Homo sapiens 57-66 17065600-2 2007 When treated with 0.5 mM 8-Br-cAMP for 12 days, ES cells were transformed into a decidualized morphology and produced significant amounts of prolactin (PRL) and insulin-like growth factor-binding protein 1 (IGFBP1). 8-Bromo Cyclic Adenosine Monophosphate 25-34 prolactin Homo sapiens 152-155 17065600-2 2007 When treated with 0.5 mM 8-Br-cAMP for 12 days, ES cells were transformed into a decidualized morphology and produced significant amounts of prolactin (PRL) and insulin-like growth factor-binding protein 1 (IGFBP1). Einsteinium 48-50 prolactin Homo sapiens 152-155 17065600-6 2007 Moreover, knockdown of PLD1 by siRNA and blockage of PLD by treatment with 0.3% 1-butanol decreased PRL/IGFBP1 mRNA expression, whereas PLD1 overexpression increased PRL/IGFBP1 mRNA expression. 1-Butanol 80-89 prolactin Homo sapiens 100-103 17065600-7 2007 Treatment of ES cells with phosphatidic acid (PA) for 3 days induced PRL mRNA expression and morphological changes, which implies that PA is an end-product of PLD activation-induced decidualization. Einsteinium 13-15 prolactin Homo sapiens 69-72 17065600-7 2007 Treatment of ES cells with phosphatidic acid (PA) for 3 days induced PRL mRNA expression and morphological changes, which implies that PA is an end-product of PLD activation-induced decidualization. Phosphatidic Acids 27-44 prolactin Homo sapiens 69-72 17065600-7 2007 Treatment of ES cells with phosphatidic acid (PA) for 3 days induced PRL mRNA expression and morphological changes, which implies that PA is an end-product of PLD activation-induced decidualization. Phosphatidic Acids 46-48 prolactin Homo sapiens 69-72 17065600-7 2007 Treatment of ES cells with phosphatidic acid (PA) for 3 days induced PRL mRNA expression and morphological changes, which implies that PA is an end-product of PLD activation-induced decidualization. Phosphatidic Acids 135-137 prolactin Homo sapiens 69-72 17065600-8 2007 In addition, pretreatment of ES cells with mepacrine decreased PRL/IGFBP1 expression and inhibited morphological change, whereas pretreatment with propranolol caused no changes, as compared to cAMP-treated cells, which suggests that PA induces decidualization through phospholipase A2 (PLA2G1B). Einsteinium 29-31 prolactin Homo sapiens 63-66 17065600-8 2007 In addition, pretreatment of ES cells with mepacrine decreased PRL/IGFBP1 expression and inhibited morphological change, whereas pretreatment with propranolol caused no changes, as compared to cAMP-treated cells, which suggests that PA induces decidualization through phospholipase A2 (PLA2G1B). Quinacrine 43-52 prolactin Homo sapiens 63-66 17027953-9 2007 In contrast, recovery of prolactin in samples without macroprolactin showed a considerable disagreement between ultrafiltration and PEG precipitation (r(s)=0.48). Polyethylene Glycols 132-135 prolactin Homo sapiens 25-34 17319502-0 2007 [Pharmacokinetics of perospirone hydrochloride at an excessive dose and changes in the serum prolactin level]. perospirone 21-46 prolactin Homo sapiens 93-102 16938372-1 2007 BACKGROUND: Although amisulpride is considered to be a prolactin-raising atypical antipsychotic drug, a limited number of studies have documented the extent of its prolactin-elevating properties. Amisulpride 21-32 prolactin Homo sapiens 55-64 16938372-2 2007 In the present study the effect of amisulpride on plasma levels of prolactin and the reversibility of this untoward side effect were investigated. Amisulpride 35-46 prolactin Homo sapiens 67-76 16938372-7 2007 Following amisulpride discontinuation prolactin levels were significantly (p<000) reduced (mean+/-S.D. Amisulpride 10-21 prolactin Homo sapiens 38-47 16938372-10 2007 CONCLUSION: Amisulpride has a pronounced prolactin-elevating effect which appears to be independent of dosage and duration of administration. Amisulpride 12-23 prolactin Homo sapiens 41-50 16965263-3 2007 However, few studies have focused on the regulation of calcium homoeostasis by prolactin. Calcium 55-62 prolactin Homo sapiens 79-88 17224713-0 2007 Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. Risperidone 43-54 prolactin Homo sapiens 0-9 17224713-1 2007 OBJECTIVE: Little is known about the role of CYP2D6 polymorphism in risperidone-induced prolactin release in children. Risperidone 68-79 prolactin Homo sapiens 88-97 17224713-9 2007 CONCLUSIONS: Low-to-intermediate doses of risperidone induced a 4-fold prolactin increase in children without a clear development of tolerance up to 6 months. Risperidone 42-53 prolactin Homo sapiens 71-80 17224713-10 2007 CYP2D6 ultrarapid metabolism may be a risk factor for more pronounced prolactin elevation. ultrarapid 7-17 prolactin Homo sapiens 70-79 17174995-4 2007 Both estradiol (E(2)) and compounds representing various classes of xenoestrogens (diethylstilbestrol, coumestrol, bisphenol A, DDE, nonylphenol, endosulfan, and dieldrin) act via a membrane version of the estrogen receptor-alpha on pituitary cells, and can provoke Ca(2+) influx via L-type channels, leading to prolactin (PRL) secretion. Diethylstilbestrol 83-101 prolactin Homo sapiens 312-321 17174995-4 2007 Both estradiol (E(2)) and compounds representing various classes of xenoestrogens (diethylstilbestrol, coumestrol, bisphenol A, DDE, nonylphenol, endosulfan, and dieldrin) act via a membrane version of the estrogen receptor-alpha on pituitary cells, and can provoke Ca(2+) influx via L-type channels, leading to prolactin (PRL) secretion. Diethylstilbestrol 83-101 prolactin Homo sapiens 323-326 17112509-3 2007 Elevated prolactin secretion can be an indicator of increased serotonergic function and prolactin is increased by combined estrogen and progesterone treatment. Progesterone 136-148 prolactin Homo sapiens 88-97 17112509-4 2007 We examined extracellular serotonin by microdialysis in a well-characterized macaque model of steroid-induced prolactin secretion. Serotonin 26-35 prolactin Homo sapiens 110-119 17112509-4 2007 We examined extracellular serotonin by microdialysis in a well-characterized macaque model of steroid-induced prolactin secretion. Steroids 94-101 prolactin Homo sapiens 110-119 17129574-2 2007 Direct addition of PRL did not affect cytoplasmic Ca2+ concentration ([Ca2+]i); however, treatment with PRL for 24h significantly decreased the peak level and duration time of [Ca2+]i elevation evoked by ATP or thapsigargin (TG). Adenosine Triphosphate 204-207 prolactin Homo sapiens 19-22 17129574-2 2007 Direct addition of PRL did not affect cytoplasmic Ca2+ concentration ([Ca2+]i); however, treatment with PRL for 24h significantly decreased the peak level and duration time of [Ca2+]i elevation evoked by ATP or thapsigargin (TG). Adenosine Triphosphate 204-207 prolactin Homo sapiens 104-107 17129574-2 2007 Direct addition of PRL did not affect cytoplasmic Ca2+ concentration ([Ca2+]i); however, treatment with PRL for 24h significantly decreased the peak level and duration time of [Ca2+]i elevation evoked by ATP or thapsigargin (TG). Thapsigargin 211-223 prolactin Homo sapiens 104-107 17129574-2 2007 Direct addition of PRL did not affect cytoplasmic Ca2+ concentration ([Ca2+]i); however, treatment with PRL for 24h significantly decreased the peak level and duration time of [Ca2+]i elevation evoked by ATP or thapsigargin (TG). Thapsigargin 225-227 prolactin Homo sapiens 104-107 17156261-6 2007 High values of FSH, LH and FSH-to-LH ratio were common with carbamazepine while that of T and PRL were common in untreated patients and with valproate. Valproic Acid 141-150 prolactin Homo sapiens 94-97 17690509-10 2007 The patient was treated with bromocriptine mesilate, in addition to adjuvant chemotherapy for breast cancer, and the plasma prolactin level has since normalized. Bromocriptine 29-51 prolactin Homo sapiens 124-133 16874502-4 2007 Hyperprolactinaemia is mainly induced by treatment with risperidone and amisulpride, and there is evidence for more pronounced prolactin levels in females. Risperidone 56-67 prolactin Homo sapiens 5-14 17284127-11 2007 Aripiprazole showed significantly less EPS liability as assessed by the Simpson-Angus Scale (p < .005) and less serum prolactin level elevation (p < .001) than risperidone. Aripiprazole 0-12 prolactin Homo sapiens 121-130 17166669-11 2007 Finally, cysteamine treatment was found to decrease weight gain, cataleptic behavior, and serum prolactin levels, which are the major beneficial properties of contemporary atypical antipsychotics. Cysteamine 9-19 prolactin Homo sapiens 96-105 24790350-8 2007 PRL response to TRH was normal and levodopa suppressed the increased basal PRL level. Levodopa 35-43 prolactin Homo sapiens 75-78 17056093-0 2007 Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. Temozolomide 0-12 prolactin Homo sapiens 49-58 17056093-1 2007 Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin (PRL)-secreting pituitary neoplasm resulted in improvement of the clinical condition and significant decrease of blood PRL levels. Temozolomide 18-30 prolactin Homo sapiens 80-89 17056093-1 2007 Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin (PRL)-secreting pituitary neoplasm resulted in improvement of the clinical condition and significant decrease of blood PRL levels. Temozolomide 18-30 prolactin Homo sapiens 91-94 17056093-1 2007 Administration of temozolomide to a 46-year-old man with an invasive aggressive prolactin (PRL)-secreting pituitary neoplasm resulted in improvement of the clinical condition and significant decrease of blood PRL levels. Temozolomide 18-30 prolactin Homo sapiens 209-212 16728967-3 2007 In the cabergoline-treated group, significant interactions between prolactin and testosterone serum concentrations were observed. Cabergoline 7-18 prolactin Homo sapiens 67-76 16874502-4 2007 Hyperprolactinaemia is mainly induced by treatment with risperidone and amisulpride, and there is evidence for more pronounced prolactin levels in females. Amisulpride 72-83 prolactin Homo sapiens 5-14 17641533-1 2007 BACKGROUND: Plasma prolactin levels are sensitive to dopamine and serotonin function, and fatigue. Dopamine 53-61 prolactin Homo sapiens 19-28 17641533-1 2007 BACKGROUND: Plasma prolactin levels are sensitive to dopamine and serotonin function, and fatigue. Serotonin 66-75 prolactin Homo sapiens 19-28 17641533-7 2007 The high prolactin burnout subjects tended to show cortisol-induced decreased prolactin and fatigue, and increased vigor. Hydrocortisone 51-59 prolactin Homo sapiens 9-18 17641533-7 2007 The high prolactin burnout subjects tended to show cortisol-induced decreased prolactin and fatigue, and increased vigor. Hydrocortisone 51-59 prolactin Homo sapiens 78-87 16785991-9 2006 PRL-induced PTP101-reactive phosphorylation was prevented by pretreatment with PD98059, an ERK pathway inhibitor. 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 79-86 prolactin Homo sapiens 0-3 17141818-6 2007 We showed that Cr VI accumulates in the pituitary and hypothalamus, and decreases serum prolactin levels in vivo but observed no effects on LH levels. Chromium 15-17 prolactin Homo sapiens 88-97 16824658-0 2006 Gender differences in prolactin elevation induced by olanzapine in Japanese drug-naive schizophrenic patients. Olanzapine 53-63 prolactin Homo sapiens 22-31 16824658-5 2006 Two-way ANOVA showed a significant difference in olanzapine-induced prolactin changes between male and female patients (P = 0.037). Olanzapine 49-59 prolactin Homo sapiens 68-77 16824658-8 2006 Our results indicate the possibility of gender differences in prolactin elevation induced by olanzapine in Japanese drug-naive schizophrenic patients. Olanzapine 93-103 prolactin Homo sapiens 62-71 16785991-8 2006 Notably, PRL also caused phosphorylation of the EGFR and ErbB-2 at sites detected by PTP101, an antibody that recognizes threonine phosphorylation at consensus motifs for ERK-induced phosphorylation. Threonine 121-130 prolactin Homo sapiens 9-12 16785991-13 2006 Our data suggest that PRL synergistically augments EGF signaling in T47D breast cancer cells at least in part by lessening EGF-induced EGFR downregulation and that this effect requires PRL-induced ERK activity and threonine phosphorylation of EGFR. Threonine 214-223 prolactin Homo sapiens 22-25 16785991-13 2006 Our data suggest that PRL synergistically augments EGF signaling in T47D breast cancer cells at least in part by lessening EGF-induced EGFR downregulation and that this effect requires PRL-induced ERK activity and threonine phosphorylation of EGFR. Threonine 214-223 prolactin Homo sapiens 185-188 16843010-1 2006 PURPOSE: The histamine-2 (H(2)) blocker cimetidine may alter androgen, zinc, and prolactin levels, which could alter prostate cancer risk. Cimetidine 40-50 prolactin Homo sapiens 81-90 17187006-3 2006 METHODS: Prolactin levels were measured in 4 men (mean age 49.5+/-19.1 years) and 8 women (mean age 31.3+/-8.2 years) inpatients with depressive and anxiety disorders who were treated with risperidone (median doses per day 1.25 mg) for median 15.5 days as an augmentation treatment to antidepressants (n=8), anxiolytics (n=6) and mood stabilizers (n=2). Risperidone 189-200 prolactin Homo sapiens 9-18 17094165-0 2006 Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Risperidone 41-52 prolactin Homo sapiens 0-9 17094165-2 2006 The aim of this study was to evaluate the role of the main compound risperidone and its active 9-hydroxy metabolite on elevating prolactin levels. Risperidone 68-79 prolactin Homo sapiens 129-138 17094165-5 2006 Morning serum samples for prolactin were analyzed and investigated in relation to the serum concentrations of risperidone and 9-hydroxyrisperidone. Paliperidone Palmitate 126-146 prolactin Homo sapiens 26-35 17094165-7 2006 Levels of prolactin were positively correlated to the 9-hydroxyrisperidone serum concentration (r(s) = 0.48, p = 0.03) and to the daily dose of risperidone (r(s) = 0.51, p = 0.03), but did not correlate to the risperidone serum concentration. Paliperidone Palmitate 54-74 prolactin Homo sapiens 10-19 17094165-7 2006 Levels of prolactin were positively correlated to the 9-hydroxyrisperidone serum concentration (r(s) = 0.48, p = 0.03) and to the daily dose of risperidone (r(s) = 0.51, p = 0.03), but did not correlate to the risperidone serum concentration. Risperidone 63-74 prolactin Homo sapiens 10-19 17094165-7 2006 Levels of prolactin were positively correlated to the 9-hydroxyrisperidone serum concentration (r(s) = 0.48, p = 0.03) and to the daily dose of risperidone (r(s) = 0.51, p = 0.03), but did not correlate to the risperidone serum concentration. Risperidone 144-155 prolactin Homo sapiens 10-19 17094165-8 2006 CONCLUSION: The present results suggest that 9-hydroxyrisperidone and not risperidone is the main contributor to the increased serum levels of prolactin observed in many risperidone-treated patients. Paliperidone Palmitate 45-65 prolactin Homo sapiens 143-152 17094165-8 2006 CONCLUSION: The present results suggest that 9-hydroxyrisperidone and not risperidone is the main contributor to the increased serum levels of prolactin observed in many risperidone-treated patients. Risperidone 54-65 prolactin Homo sapiens 143-152 17110820-8 2006 This could be because prolactin does not have a major effect on glucose homeostasis or that the effects of prolactin reduction are countered by clozapine. Clozapine 144-153 prolactin Homo sapiens 107-116 17308959-2 2007 During therapy with a dopamine agonist, prolactin levels usually normalize and the tumors shrink substantially. Dopamine 22-30 prolactin Homo sapiens 40-49 17308959-12 2007 We conclude that in patients with massive prolactin hypersecretion, therapy with a dopamine agonist will lead to tumor shrinkage and improvement of mass effects, but usually does not normalize prolactin or testosterone. Dopamine 83-91 prolactin Homo sapiens 42-51 17110820-3 2006 The effect of reducing prolactin levels by switching patients" antipsychotic treatment to clozapine was ascertained by performing the measures before and after the switch to clozapine. Clozapine 90-99 prolactin Homo sapiens 23-32 17110820-3 2006 The effect of reducing prolactin levels by switching patients" antipsychotic treatment to clozapine was ascertained by performing the measures before and after the switch to clozapine. Clozapine 174-183 prolactin Homo sapiens 23-32 17110820-5 2006 There was a large reduction in prolactin (593 mIU/L) after switching to clozapine, but this was not associated with changes in glucose-insulin measures. Clozapine 72-81 prolactin Homo sapiens 31-40 17187006-6 2006 Significant correlation between risperidone daily dose and plasma prolactin level (Spearman"s R=0.655, p=0.02) was detected. Risperidone 32-43 prolactin Homo sapiens 66-75 17000009-0 2006 Polymorphism in the serotonin transporter gene and moderators of prolactin response to meta-chlorophenylpiperazine in African-American cocaine abusers and controls. 1-(3-chlorophenyl)piperazine 87-114 prolactin Homo sapiens 65-74 17010299-0 2006 Characterization of the metal-binding site of human prolactin by site-specific metal-catalyzed oxidation. Metals 24-29 prolactin Homo sapiens 52-61 17010299-0 2006 Characterization of the metal-binding site of human prolactin by site-specific metal-catalyzed oxidation. Metals 79-84 prolactin Homo sapiens 52-61 17010299-1 2006 Site-specific metal-catalyzed oxidation (MCO) was applied to characterize the metal-binding site (MBS) of recombinant human prolactin (hPRL), which belongs to the hematopoietic cytokine family. Metals 14-19 prolactin Homo sapiens 124-133 17010299-1 2006 Site-specific metal-catalyzed oxidation (MCO) was applied to characterize the metal-binding site (MBS) of recombinant human prolactin (hPRL), which belongs to the hematopoietic cytokine family. Metals 14-19 prolactin Homo sapiens 135-139 17010299-1 2006 Site-specific metal-catalyzed oxidation (MCO) was applied to characterize the metal-binding site (MBS) of recombinant human prolactin (hPRL), which belongs to the hematopoietic cytokine family. Metals 78-83 prolactin Homo sapiens 124-133 17010299-1 2006 Site-specific metal-catalyzed oxidation (MCO) was applied to characterize the metal-binding site (MBS) of recombinant human prolactin (hPRL), which belongs to the hematopoietic cytokine family. Metals 78-83 prolactin Homo sapiens 135-139 17010299-2 2006 Copper and ascorbate of various concentrations were used to initiate the oxidation of hPRL, and the oxidation-sensitive motifs were characterized and quantitated by mass spectrometry. Copper 0-6 prolactin Homo sapiens 86-90 17010299-2 2006 Copper and ascorbate of various concentrations were used to initiate the oxidation of hPRL, and the oxidation-sensitive motifs were characterized and quantitated by mass spectrometry. Ascorbic Acid 11-20 prolactin Homo sapiens 86-90 17010299-3 2006 Based on the results obtained with 10 microM Cu(2+) and 0.3-2.0mM ascorbate, we propose that the MBS in hPRL is composed of His27, His30, and His173. Copper 45-47 prolactin Homo sapiens 104-108 17010299-3 2006 Based on the results obtained with 10 microM Cu(2+) and 0.3-2.0mM ascorbate, we propose that the MBS in hPRL is composed of His27, His30, and His173. Ascorbic Acid 66-75 prolactin Homo sapiens 104-108 17000009-3 2006 We investigated the relationship of a polymorphism in the 5" promoter region of the serotonin transporter gene (5-HTTLPR) with prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP) in a sample of 68 African-American individuals, 35 CD subjects and 33 controls. 1-(3-chlorophenyl)piperazine 155-182 prolactin Homo sapiens 127-136 17000009-3 2006 We investigated the relationship of a polymorphism in the 5" promoter region of the serotonin transporter gene (5-HTTLPR) with prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP) in a sample of 68 African-American individuals, 35 CD subjects and 33 controls. 1-(3-chlorophenyl)piperazine 155-182 prolactin Homo sapiens 138-141 17000009-3 2006 We investigated the relationship of a polymorphism in the 5" promoter region of the serotonin transporter gene (5-HTTLPR) with prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP) in a sample of 68 African-American individuals, 35 CD subjects and 33 controls. 1-(3-chlorophenyl)piperazine 184-189 prolactin Homo sapiens 127-136 17000009-3 2006 We investigated the relationship of a polymorphism in the 5" promoter region of the serotonin transporter gene (5-HTTLPR) with prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP) in a sample of 68 African-American individuals, 35 CD subjects and 33 controls. 1-(3-chlorophenyl)piperazine 184-189 prolactin Homo sapiens 138-141 17000009-8 2006 Cocaine abuse was the most significant moderator of DeltaPRL (peak PRL-baseline PRL), and the interaction of genetic, behavioral and psychopathological measures helped predict most of the observed DeltaPRL (62.5%). Cocaine 0-7 prolactin Homo sapiens 57-60 17000009-8 2006 Cocaine abuse was the most significant moderator of DeltaPRL (peak PRL-baseline PRL), and the interaction of genetic, behavioral and psychopathological measures helped predict most of the observed DeltaPRL (62.5%). Cocaine 0-7 prolactin Homo sapiens 67-70 17054466-12 2006 CONCLUSIONS: Our study demonstrates for the first time that raloxifene and clomiphene affect the secretion of PRL in postmenopausal women in a similar manner. Raloxifene Hydrochloride 60-70 prolactin Homo sapiens 110-113 17054466-12 2006 CONCLUSIONS: Our study demonstrates for the first time that raloxifene and clomiphene affect the secretion of PRL in postmenopausal women in a similar manner. Clomiphene 75-85 prolactin Homo sapiens 110-113 17054466-13 2006 It is suggested that oestradiol stimulates the secretion of PRL in women by acting through oestrogen receptors. Estradiol 21-31 prolactin Homo sapiens 60-63 17111306-0 2006 Increased prolactin in acute coronary syndromes as putative Co-activator of ADP-stimulated P-selectin expression. Adenosine Diphosphate 76-79 prolactin Homo sapiens 10-19 17111306-1 2006 Prolactin and leptin are newly recognized platelet co-stimulators due to enhancement of ADP-induced platelet aggregation. Adenosine Diphosphate 88-91 prolactin Homo sapiens 0-9 17357577-11 2006 Prolactin levels showed a decrease in the group treated with alpha dihidroergocriptine with an important difference between both groups at the end of the 6 months study period. alpha dihidroergocriptine 61-86 prolactin Homo sapiens 0-9 17111306-6 2006 In the myocardial infarction subgroup prolactin values showed a significant correlation to ADP stimulated P-selectin expression on platelets (r (2)=0.41; p=0.025), whereas leptin was not correlated. Adenosine Diphosphate 91-94 prolactin Homo sapiens 38-47 16401653-8 2006 Pramipexole reduced alertness, caused pupil dilatation, increased heart rate, reduced prolactin and thyroid stimulating hormone, and increased growth hormone level. Pramipexole 0-11 prolactin Homo sapiens 86-95 16401653-9 2006 Modafinil caused small increases in blood pressure and core temperature, and reduced prolactin levels. Modafinil 0-9 prolactin Homo sapiens 85-94 16880478-6 2006 Compared with placebo, aripiprazole treatment was associated with a significant decrease in relapse rates, increased compliance with the study protocol, and a decrease in prolactin levels below the expected values. Aripiprazole 23-35 prolactin Homo sapiens 171-180 16966351-4 2006 The objective of this study was to determine the effect of infant iron status on serum prolactin levels after a stressor in early adolescence. Iron 66-70 prolactin Homo sapiens 87-96 17195425-4 2006 She was treated for over 2 years with dopamine agonists, with which her prolactin level normalized, but she remained infertile. Dopamine 38-46 prolactin Homo sapiens 72-81 16919253-3 2006 Macro-PRL was assessed from (1) percent PRL recovery, using cut-off values derived by gel filtration chromatography (GFC) and (2) significant (p<0.05) normalisation of PRL following PEG. Polyethylene Glycols 185-188 prolactin Homo sapiens 6-9 16919253-6 2006 The total PRL normalised following PEG in 7.4%. Polyethylene Glycols 35-38 prolactin Homo sapiens 10-13 16919253-9 2006 Regression analysis suggested that PEG precipitated both macro-PRL and big-PRL. Polyethylene Glycols 35-38 prolactin Homo sapiens 63-66 16919253-9 2006 Regression analysis suggested that PEG precipitated both macro-PRL and big-PRL. Polyethylene Glycols 35-38 prolactin Homo sapiens 75-78 16919253-11 2006 Screening using PEG is applicable to assays with low macro-PRL reactivity provided specific reference values are derived. Polyethylene Glycols 16-19 prolactin Homo sapiens 59-62 17024154-1 2006 Resistance to dopamine agonists occurs in a subset of patients with prolactin-secreting pituitary tumors. Dopamine 14-22 prolactin Homo sapiens 68-77 17024156-3 2006 Currently, therapeutic management of hyperprolactinemia relies on dopamine agonists, since dopamine is the primary physiological suppressor of pituitary prolactin production. Dopamine 66-74 prolactin Homo sapiens 42-51 17024156-3 2006 Currently, therapeutic management of hyperprolactinemia relies on dopamine agonists, since dopamine is the primary physiological suppressor of pituitary prolactin production. Dopamine 91-99 prolactin Homo sapiens 42-51 17024156-7 2006 These findings have renewed the interest in finding alternative strategies to suppress prolactin actions when dopamine agonists are ineffective. Dopamine 110-118 prolactin Homo sapiens 87-96 16740972-8 2006 Treatment of cytochalasin-D-treated cells with hormones and dbcAMP resulted in an increase in the secretion of IGF-binding protein-1 (IGFBP-1) and prolactin. Cytochalasin D 13-27 prolactin Homo sapiens 147-156 16740972-8 2006 Treatment of cytochalasin-D-treated cells with hormones and dbcAMP resulted in an increase in the secretion of IGF-binding protein-1 (IGFBP-1) and prolactin. Bucladesine 60-66 prolactin Homo sapiens 147-156 16740972-9 2006 Treatment of cytochalasin-D-treated cells with recombinant IGFBP-1 and prolactin also inhibited apoptosis. Cytochalasin D 13-27 prolactin Homo sapiens 71-80 16780797-1 2006 Pituitary lactotrophs fire action potentials spontaneously and the associated voltage-gated calcium influx is sufficient to maintain high prolactin release. Calcium 92-99 prolactin Homo sapiens 138-147 16780797-8 2006 Agonist and Bay K 8644-stimulated prolactin release was also inhibited by ZD7288, indicating that this compound attenuates the exocytotic pathway downstream of calcium influx. 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester 12-22 prolactin Homo sapiens 34-43 16780797-8 2006 Agonist and Bay K 8644-stimulated prolactin release was also inhibited by ZD7288, indicating that this compound attenuates the exocytotic pathway downstream of calcium influx. ICI D2788 74-80 prolactin Homo sapiens 34-43 16780797-8 2006 Agonist and Bay K 8644-stimulated prolactin release was also inhibited by ZD7288, indicating that this compound attenuates the exocytotic pathway downstream of calcium influx. Calcium 160-167 prolactin Homo sapiens 34-43 16690806-3 2006 Treatment of human endometrial stromal cells with hormones (estradiol and medroxyprogesterone acetate) plus dibutyryl cAMP (H+dbcAMP) for 48 h increased expression of IGFBP1, PRL, TIMP3, CNR1, and DCN but not LAMB1, as measured by real-time PCR. Estradiol 60-69 prolactin Homo sapiens 175-178 16690806-3 2006 Treatment of human endometrial stromal cells with hormones (estradiol and medroxyprogesterone acetate) plus dibutyryl cAMP (H+dbcAMP) for 48 h increased expression of IGFBP1, PRL, TIMP3, CNR1, and DCN but not LAMB1, as measured by real-time PCR. Medroxyprogesterone Acetate 74-101 prolactin Homo sapiens 175-178 16690806-3 2006 Treatment of human endometrial stromal cells with hormones (estradiol and medroxyprogesterone acetate) plus dibutyryl cAMP (H+dbcAMP) for 48 h increased expression of IGFBP1, PRL, TIMP3, CNR1, and DCN but not LAMB1, as measured by real-time PCR. Cyclic AMP 118-122 prolactin Homo sapiens 175-178 16966351-8 2006 Controlling for these factors, the serum prolactin response pattern differed significantly by infant iron status. Iron 101-105 prolactin Homo sapiens 41-50 17076438-2 2006 The parental roles of prolactin and glucorticoids (corticosterone or cortisol) have many similarities in birds and in mammals. Corticosterone 51-65 prolactin Homo sapiens 22-31 17076438-2 2006 The parental roles of prolactin and glucorticoids (corticosterone or cortisol) have many similarities in birds and in mammals. Hydrocortisone 69-77 prolactin Homo sapiens 22-31 16879162-5 2006 Synergistic activation of the prolactin promoter by Pitx factors and Pit-1 is involved not only in basal condition, but also in responsiveness to forskolin, thyrotrophin-releasing-hormone and epidermal growth factor. Colforsin 146-155 prolactin Homo sapiens 30-39 16690806-3 2006 Treatment of human endometrial stromal cells with hormones (estradiol and medroxyprogesterone acetate) plus dibutyryl cAMP (H+dbcAMP) for 48 h increased expression of IGFBP1, PRL, TIMP3, CNR1, and DCN but not LAMB1, as measured by real-time PCR. Bucladesine 126-132 prolactin Homo sapiens 175-178 16690806-7 2006 Addition of H+dbcAMP caused an increased expression of IGFBP1, PRL, and DCN beyond that of FOXO1A alone. h+dbcamp 12-20 prolactin Homo sapiens 63-66 16690806-12 2006 Addition of H+dbcAMP resulted in a significant increase in PRL promoter activity and a significant decrease in TIMP3 promoter activity. h+dbcamp 12-20 prolactin Homo sapiens 59-62 16882508-0 2006 Manganese as a potential confounder of serum prolactin. Manganese 0-9 prolactin Homo sapiens 45-54 16880478-7 2006 Compared with risperidone, aripiprazole caused less elevation of prolactin levels and less prolongation of the average QTc interval. Aripiprazole 27-39 prolactin Homo sapiens 65-74 16915581-0 2006 Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. 1-(3-chlorophenyl)piperazine 38-65 prolactin Homo sapiens 16-25 16915581-0 2006 Relationship of prolactin response to meta-chlorophenylpiperazine with severity of drug use in cocaine dependence. Cocaine 95-102 prolactin Homo sapiens 16-25 16915581-3 2006 OBJECTIVES: We investigated whether prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP), a mixed 5-HT agonist/antagonist were associated with severity of cocaine use. 1-(3-chlorophenyl)piperazine 64-91 prolactin Homo sapiens 36-45 16915581-3 2006 OBJECTIVES: We investigated whether prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP), a mixed 5-HT agonist/antagonist were associated with severity of cocaine use. 1-(3-chlorophenyl)piperazine 64-91 prolactin Homo sapiens 47-50 16915581-3 2006 OBJECTIVES: We investigated whether prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP), a mixed 5-HT agonist/antagonist were associated with severity of cocaine use. 1-(3-chlorophenyl)piperazine 93-98 prolactin Homo sapiens 36-45 16915581-7 2006 DeltaPRL (peak PRL-baseline PRL) was negatively correlated with ASI-drug (r = -0.45, p < 0.01), ASI-alcohol (r = -0.32, p < 0.05), and ASI-psychological (r = -0.41, p < 0.01) composite scores, and with the quantity, frequency and duration of drug use (r ranged from - 0.41 to - 0.32, p ranged from < 0.01 to 0.05). asi-alcohol 99-110 prolactin Homo sapiens 5-8 16915581-7 2006 DeltaPRL (peak PRL-baseline PRL) was negatively correlated with ASI-drug (r = -0.45, p < 0.01), ASI-alcohol (r = -0.32, p < 0.05), and ASI-psychological (r = -0.41, p < 0.01) composite scores, and with the quantity, frequency and duration of drug use (r ranged from - 0.41 to - 0.32, p ranged from < 0.01 to 0.05). asi-alcohol 99-110 prolactin Homo sapiens 15-18 16598425-8 2006 He was started on Cabergoline with normalization of his prolactin level and more than 50% decrease in residual tumor size over 9 months periods. Cabergoline 18-29 prolactin Homo sapiens 56-65 16899564-6 2006 PRL activation of mTOR was inhibited by rapamycin (mTOR inhibitor), LY249002, and wortmannin (P13K inhibitors), but not by AG490 (Jak2 inhibitor), indicating that it was mediated by the P13K/Akt, but not Jak2, pathway. Sirolimus 40-49 prolactin Homo sapiens 0-3 16899564-6 2006 PRL activation of mTOR was inhibited by rapamycin (mTOR inhibitor), LY249002, and wortmannin (P13K inhibitors), but not by AG490 (Jak2 inhibitor), indicating that it was mediated by the P13K/Akt, but not Jak2, pathway. ly249002 68-76 prolactin Homo sapiens 0-3 16899564-6 2006 PRL activation of mTOR was inhibited by rapamycin (mTOR inhibitor), LY249002, and wortmannin (P13K inhibitors), but not by AG490 (Jak2 inhibitor), indicating that it was mediated by the P13K/Akt, but not Jak2, pathway. Wortmannin 82-92 prolactin Homo sapiens 0-3 16899564-8 2006 PRL-induced phosphorylation of p70S6K and 4E-BP1 was inhibited by rapamycin, but not by okadaic acid (inhibitor of protein phosphatase, PP2A). Sirolimus 66-75 prolactin Homo sapiens 0-3 16807649-1 2006 Prolactin and leptin are newly recognised platelet co-stimulators due to potentiation of ADP-induced platelet aggregation. Adenosine Diphosphate 89-92 prolactin Homo sapiens 0-9 16482082-2 2006 We tested the hypothesis that, independent of the antipsychotic-induced rise in prolactin, the incidence of TD would be associated with the incidence of prolactin-related sexual disturbances (PRSD), which would be suggestive of a common pathology involving multiple dopamine tracts. Dopamine 266-274 prolactin Homo sapiens 153-162 16889455-1 2006 OBJECTIVE: To study the effect of risperidone on prolactin levels in 3 adolescent patients. Risperidone 34-45 prolactin Homo sapiens 49-58 16807649-4 2006 We determined plasma prolactin and leptin levels as well as platelet P-selectin expression in 36 patients with ischemic stroke or transient ischemic attack and detected a significant correlation between increased prolactin values and enhanced ADP stimulated P-selectin expression on platelets. Adenosine Diphosphate 243-246 prolactin Homo sapiens 21-30 16807649-4 2006 We determined plasma prolactin and leptin levels as well as platelet P-selectin expression in 36 patients with ischemic stroke or transient ischemic attack and detected a significant correlation between increased prolactin values and enhanced ADP stimulated P-selectin expression on platelets. Adenosine Diphosphate 243-246 prolactin Homo sapiens 213-222 16371109-10 2006 Serum melatonin correlated positively with serum PRL (r = 0.611, p = 0.01). Melatonin 6-15 prolactin Homo sapiens 49-52 16775175-0 2006 Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Raloxifene Hydrochloride 11-21 prolactin Homo sapiens 37-46 16775175-2 2006 Estrogen is a significant positive regulator of prolactin synthesis; therefore, raloxifene, a selective estrogen receptor modulator under study as a breast cancer prevention agent, may modulate both estradiol and prolactin levels by inhibiting estradiol from binding to its receptor. Raloxifene Hydrochloride 80-90 prolactin Homo sapiens 48-57 16775175-2 2006 Estrogen is a significant positive regulator of prolactin synthesis; therefore, raloxifene, a selective estrogen receptor modulator under study as a breast cancer prevention agent, may modulate both estradiol and prolactin levels by inhibiting estradiol from binding to its receptor. Raloxifene Hydrochloride 80-90 prolactin Homo sapiens 213-222 16775175-8 2006 CONCLUSIONS: This report is the first to examine the long-term effects of raloxifene on prolactin, estradiol, and SHBG levels in premenopausal women who are also at increased risk for developing invasive breast cancer. Raloxifene Hydrochloride 74-84 prolactin Homo sapiens 88-97 16466670-0 2006 The relationship between prolactin response and clinical efficacy of risperidone in acute psychotic inpatients. Risperidone 69-80 prolactin Homo sapiens 25-34 17073213-5 2006 The aim of our study was to evaluate the results of the switch to quetiapine in the cases of elevated prolactin with galactorrhea. Quetiapine Fumarate 66-76 prolactin Homo sapiens 102-111 17073213-9 2006 RESULTS: The galactorrhoea disappeared and prolactin levels normalized after the switching to quetiapine. Quetiapine Fumarate 94-104 prolactin Homo sapiens 43-52 17073213-14 2006 After the switch to quetiapine the galactorrhea and breast tenderness stopped, the level of prolactin normalized and the psychiatric condition of the patients showed remission. Quetiapine Fumarate 20-30 prolactin Homo sapiens 92-101 17073213-15 2006 Our data support the benefit of the switch to another new generation drug, first of all to quetiapine, in the cases of galactorrhea and/or elevated prolactin level related to the antipsychotic pharmacotherapy. Quetiapine Fumarate 91-101 prolactin Homo sapiens 148-157 16768639-8 2006 The mean prolactin level among all patients on risperidone was significantly greater than controls, as well as for those on quetiapine or olanzapine. Risperidone 47-58 prolactin Homo sapiens 9-18 16768639-8 2006 The mean prolactin level among all patients on risperidone was significantly greater than controls, as well as for those on quetiapine or olanzapine. Quetiapine Fumarate 124-134 prolactin Homo sapiens 9-18 16768639-8 2006 The mean prolactin level among all patients on risperidone was significantly greater than controls, as well as for those on quetiapine or olanzapine. Olanzapine 138-148 prolactin Homo sapiens 9-18 16768639-10 2006 Overt side effects were infrequent in the overall sample, but serum prolactin assessment is recommended for youths taking risperidone chronically. Risperidone 122-133 prolactin Homo sapiens 68-77 16848655-0 2006 Serum prolactin levels among outpatients with major depressive disorder during the acute phase of treatment with fluoxetine. Fluoxetine 113-123 prolactin Homo sapiens 6-15 16848655-1 2006 OBJECTIVE: To determine changes in serum prolactin levels in outpatients with DSM-IV-diagnosed major depressive disorder (MDD) following a 12-week open-label trial of fluoxetine. Fluoxetine 167-177 prolactin Homo sapiens 41-50 16848655-7 2006 Specifically, 2 (4.5%) of 44 men and 8 (22.2%) of 36 women with normal prolactin levels at baseline developed hyperprolactinemia following treatment with fluoxetine (p = .0174 for between-gender difference). Fluoxetine 154-164 prolactin Homo sapiens 71-80 16848655-8 2006 In addition, there was a significant increase in mean +/- SD serum prolactin levels following treatment with fluoxetine in all patients with normal baseline prolactin levels (6.4 +/- 3.4 to 10.0 +/- 7.0 ng/mL, p = .002). Fluoxetine 109-119 prolactin Homo sapiens 67-76 16848655-8 2006 In addition, there was a significant increase in mean +/- SD serum prolactin levels following treatment with fluoxetine in all patients with normal baseline prolactin levels (6.4 +/- 3.4 to 10.0 +/- 7.0 ng/mL, p = .002). Fluoxetine 109-119 prolactin Homo sapiens 157-166 16724376-3 2006 We investigated the prevalence of prolactin (PRL)-secreting pituitary adenoma and evaluated production of PRL by dynamic testing with MTC in SSc. Metoclopramide 134-137 prolactin Homo sapiens 106-109 16466670-2 2006 The author investigated the relationship between changes in prolactin (PRL) and clinical efficacy of risperidone. Risperidone 101-112 prolactin Homo sapiens 60-69 16466670-2 2006 The author investigated the relationship between changes in prolactin (PRL) and clinical efficacy of risperidone. Risperidone 101-112 prolactin Homo sapiens 71-74 16466670-5 2006 Risperidone treatment significantly elevated serum PRL level (range: 26.9 ng/ml-320.0 ng/ml). Risperidone 0-11 prolactin Homo sapiens 51-54 16466670-8 2006 PRL-related symptoms such as irregular menstruation, galactorrhea, or erectile dysfunction occurred in nine subjects (7 females and 2 males) whose serum PRL levels increase very highly after 2 weeks of risperidone. Risperidone 202-213 prolactin Homo sapiens 0-3 16466670-8 2006 PRL-related symptoms such as irregular menstruation, galactorrhea, or erectile dysfunction occurred in nine subjects (7 females and 2 males) whose serum PRL levels increase very highly after 2 weeks of risperidone. Risperidone 202-213 prolactin Homo sapiens 153-156 16719908-0 2006 Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. Methylprednisolone 20-38 prolactin Homo sapiens 143-152 16630538-0 2006 Induction of prolactin expression and release in human preadipocytes by cAMP activating ligands. Cyclic AMP 72-76 prolactin Homo sapiens 13-22 16630538-5 2006 Both isoproterenol, a beta-adrenergic receptor agonist, and PACAP, pituitary adenylate cyclase activating peptide, increased PRL expression, and release from preadipocytes. Isoproterenol 5-18 prolactin Homo sapiens 125-128 16630538-8 2006 These data establish the transcriptional regulation of adipocyte PRL by the superdistal PRL promoter, its transient expression during adipogenesis, and the stimulatory effect of catecholamines and PACAP. Catecholamines 178-192 prolactin Homo sapiens 65-68 16488084-4 2006 Baseline prolactin levels in female patients randomized to receive olanzapine (n=14) were 66.3+/-38.7 ng/ml and were 82.0+/-37.6 (p=.32) in those remaining on their pre-study antipsychotic medication (n=14). Olanzapine 67-77 prolactin Homo sapiens 9-18 16488084-6 2006 At study end, patients switched to olanzapine experienced significant reductions in mean serum prolactin levels of 19.8+/-18.1 ng/ml in males (p=.02), and 32.3+/-47.5 ng/ml in females (p=.01), but prolactin continued to be elevated in patients who remained on pre-study antipsychotic treatment. Olanzapine 35-45 prolactin Homo sapiens 95-104 16488084-6 2006 At study end, patients switched to olanzapine experienced significant reductions in mean serum prolactin levels of 19.8+/-18.1 ng/ml in males (p=.02), and 32.3+/-47.5 ng/ml in females (p=.01), but prolactin continued to be elevated in patients who remained on pre-study antipsychotic treatment. Olanzapine 35-45 prolactin Homo sapiens 197-206 16488084-11 2006 Olanzapine treatment may offer sustained reduction in serum prolactin and improvement in sexual and reproductive comorbid symptoms in patients with schizophrenia who have treatment-emergent hyperprolactinemia. Olanzapine 0-10 prolactin Homo sapiens 60-69 16719919-1 2006 BACKGROUND: Domperidone, a drug that enhances upper gastric motility, is an anti-dopaminergic medication that also elevates prolactin levels. Domperidone 12-23 prolactin Homo sapiens 124-133 16484327-8 2006 Previous parity resulted in modest, yet significant, reductions in E(2) and PRL levels on proestrus, a limited increase in pituitary estrogen receptor alpha expression, and a significant shift in estrogen sensitivity, as measured by EB-induced PRL secretion. estradiol 3-benzoate 233-235 prolactin Homo sapiens 244-247 19338911-4 2006 Serum prolactin levels were high, and she was treated with carbegoline, a dopamine agonist, which suppressed the prolactin secretion and led to rapid cessation of lactation. carbegoline 59-70 prolactin Homo sapiens 6-15 19338911-4 2006 Serum prolactin levels were high, and she was treated with carbegoline, a dopamine agonist, which suppressed the prolactin secretion and led to rapid cessation of lactation. carbegoline 59-70 prolactin Homo sapiens 113-122 19338911-4 2006 Serum prolactin levels were high, and she was treated with carbegoline, a dopamine agonist, which suppressed the prolactin secretion and led to rapid cessation of lactation. Dopamine 74-82 prolactin Homo sapiens 113-122 16480723-4 2006 Circulating prolactin levels were suppressed using cabergoline (Dostinex: Pfizer), a long acting dopamine (D2) agonist with minimal behavioural side-effects. Cabergoline 51-62 prolactin Homo sapiens 12-21 16675366-4 2006 Older antipsychotic medicines such as haloperidol and chlorpromazine have a high likelihood of elevating prolactin. Haloperidol 38-49 prolactin Homo sapiens 105-114 16772199-10 2006 Approximately 40% of patients in the macroprolactin group were treated with a dopamine agonist, 28% of whom had normalization of the total prolactin level. Dopamine 78-86 prolactin Homo sapiens 42-51 16785144-4 2006 Current methadone use was associated with lower levels of total testosterone (p = 0.03) and higher levels of prolactin (p = 0.002); mean estradiol levels were 43% lower in women who used intravenous drugs (p < 0.001). Methadone 8-17 prolactin Homo sapiens 109-118 16675366-4 2006 Older antipsychotic medicines such as haloperidol and chlorpromazine have a high likelihood of elevating prolactin. Chlorpromazine 54-68 prolactin Homo sapiens 105-114 16480723-4 2006 Circulating prolactin levels were suppressed using cabergoline (Dostinex: Pfizer), a long acting dopamine (D2) agonist with minimal behavioural side-effects. Cabergoline 64-72 prolactin Homo sapiens 12-21 16675366-8 2006 Aripiprazole is the antipsychotic medicine least likely to increase prolactin (and may actually decrease prolactin); risperidone, the most likely to increase prolactin. Aripiprazole 0-12 prolactin Homo sapiens 68-77 16480723-4 2006 Circulating prolactin levels were suppressed using cabergoline (Dostinex: Pfizer), a long acting dopamine (D2) agonist with minimal behavioural side-effects. Dopamine 97-105 prolactin Homo sapiens 12-21 16675366-8 2006 Aripiprazole is the antipsychotic medicine least likely to increase prolactin (and may actually decrease prolactin); risperidone, the most likely to increase prolactin. Aripiprazole 0-12 prolactin Homo sapiens 105-114 16480723-6 2006 Cabergoline reduced prolactin to negligible levels in all fathers without effecting testosterone, DHT and cortisol and without adverse side-effects. Cabergoline 0-11 prolactin Homo sapiens 20-29 16675366-8 2006 Aripiprazole is the antipsychotic medicine least likely to increase prolactin (and may actually decrease prolactin); risperidone, the most likely to increase prolactin. Aripiprazole 0-12 prolactin Homo sapiens 105-114 16675366-9 2006 Olanzapine, quetiapine and ziprazadone are antipsychotic medicines with a lower likelihood of elevating prolactin. Olanzapine 0-10 prolactin Homo sapiens 104-113 16449333-3 2006 Although exogenous ghrelin stimulates appetite, GH, prolactin, and cortisol release in humans, its effects have not been studied, during infusions, in AN patients. Ghrelin 19-26 prolactin Homo sapiens 52-61 16675366-9 2006 Olanzapine, quetiapine and ziprazadone are antipsychotic medicines with a lower likelihood of elevating prolactin. Quetiapine Fumarate 12-22 prolactin Homo sapiens 104-113 16675366-9 2006 Olanzapine, quetiapine and ziprazadone are antipsychotic medicines with a lower likelihood of elevating prolactin. ziprazadone 27-38 prolactin Homo sapiens 104-113 16675366-10 2006 Older ("neuroleptic") antipsychotics, such as chlorpromazine, droperidol and haloperidol, perphenazine and many others, are likely to elevate serum prolactin. Chlorpromazine 46-60 prolactin Homo sapiens 148-157 16675366-10 2006 Older ("neuroleptic") antipsychotics, such as chlorpromazine, droperidol and haloperidol, perphenazine and many others, are likely to elevate serum prolactin. Droperidol 62-72 prolactin Homo sapiens 148-157 16675366-10 2006 Older ("neuroleptic") antipsychotics, such as chlorpromazine, droperidol and haloperidol, perphenazine and many others, are likely to elevate serum prolactin. Haloperidol 77-88 prolactin Homo sapiens 148-157 16675366-10 2006 Older ("neuroleptic") antipsychotics, such as chlorpromazine, droperidol and haloperidol, perphenazine and many others, are likely to elevate serum prolactin. Perphenazine 90-102 prolactin Homo sapiens 148-157 16675366-11 2006 Among antidepressants, most serotonin reuptake inhibitors, with the exception of sertraline, can slightly elevate prolactin. Sertraline 81-91 prolactin Homo sapiens 114-123 16675366-12 2006 The atypical (i.e., alone in their class) antidepressants bupropion and mirtazapine are prolactin neutral. Bupropion 58-67 prolactin Homo sapiens 88-97 16675366-12 2006 The atypical (i.e., alone in their class) antidepressants bupropion and mirtazapine are prolactin neutral. Mirtazapine 72-83 prolactin Homo sapiens 88-97 16675366-14 2006 The dopamine agonists used to treat Parkinson"s disease--bromocriptine, pergolide, pramipexole, ropinerole--usually reverse antipsychotic-induced prolactin increases without compromising psychiatric effectiveness. Dopamine 4-12 prolactin Homo sapiens 146-155 16675366-14 2006 The dopamine agonists used to treat Parkinson"s disease--bromocriptine, pergolide, pramipexole, ropinerole--usually reverse antipsychotic-induced prolactin increases without compromising psychiatric effectiveness. Pergolide 72-81 prolactin Homo sapiens 146-155 16675366-14 2006 The dopamine agonists used to treat Parkinson"s disease--bromocriptine, pergolide, pramipexole, ropinerole--usually reverse antipsychotic-induced prolactin increases without compromising psychiatric effectiveness. Pramipexole 83-94 prolactin Homo sapiens 146-155 16675366-14 2006 The dopamine agonists used to treat Parkinson"s disease--bromocriptine, pergolide, pramipexole, ropinerole--usually reverse antipsychotic-induced prolactin increases without compromising psychiatric effectiveness. ropinerole 96-106 prolactin Homo sapiens 146-155 16584506-9 2006 Cabergoline therapy significantly reduced serum PRL, insulin, hsCRP and sELAM-1 levels. Cabergoline 0-11 prolactin Homo sapiens 48-51 16288952-4 2006 These pituitary tumours may produce an excessive amount of prolactin or disrupt the normal delivery of dopamine from the hypothalamus to the pituitary; prolactin secretion from the pituitary is inhibited by dopamine released from neurones in the hypothalamus. Dopamine 207-215 prolactin Homo sapiens 152-161 16288952-8 2006 Pharmacological intervention should be considered the first line therapy and involves the use of dopamine agonists to reduce tumour size and prolactin levels. Dopamine 97-105 prolactin Homo sapiens 141-150 16288952-15 2006 Surgery should be considered only in certain circumstances, and for the majority of patients, dopamine agonists will be sufficient to alleviate symptoms and restore normal prolactin levels. Dopamine 94-102 prolactin Homo sapiens 172-181 16633146-1 2006 Studies performed in adult patients unambiguously demonstrate a marked effect of risperidone on prolactin blood levels, with possible clinical effects related to hyperprolactinemia, such as gynecomastia and galactorrhea. Risperidone 81-92 prolactin Homo sapiens 96-105 16633146-2 2006 However, the largest study performed in children and adolescents showed a weak effect of risperidone on prolactin concentrations during short-term treatment and a negligible effect during long-term treatment, which was probably because of the relatively low dosages of risperidone used [approximately 0.04 mg/(kg x d)]. Risperidone 89-100 prolactin Homo sapiens 104-113 16633146-5 2006 Thus, risperidone administered to adolescents at doses commonly used for the treatment of psychotic symptoms can strongly increase prolactin levels, with clinical consequences such as gynecomastia and/or galactorrhea. Risperidone 6-17 prolactin Homo sapiens 131-140 16517173-2 2006 PRL affects metabolic homeostasis by regulating key enzymes and transporters that are associated with glucose and lipid metabolism in several target organs. Glucose 102-109 prolactin Homo sapiens 0-3 16711341-1 2006 A large proportion of prolactin secreting tumours of the pituitary gland are treatable by dopamine agonist drugs. Dopamine 90-98 prolactin Homo sapiens 22-31 16679982-0 2006 Bicarbonate reduces serum prolactin increase induced by exercise to exhaustion. Bicarbonates 0-11 prolactin Homo sapiens 26-35 16517173-3 2006 In the lactating mammary gland, PRL increases the production of milk proteins, lactose and lipids. Lactose 79-86 prolactin Homo sapiens 32-35 16517173-5 2006 PRL supports the growth of pancreatic islets, stimulates insulin secretion and increases citrate production in the prostate. Citric Acid 89-96 prolactin Homo sapiens 0-3 16848115-8 2006 It was noteworthy that bromocriptine (BRC) therapy started in three patients caused an abrupt decrease in PRL levels. Bromocriptine 23-36 prolactin Homo sapiens 106-109 16452531-4 2006 Bromocriptine has a long history of use; however, a range of 5-18% of patients are reported to show bromocriptine resistance, with only partial lowering of plasma prolactin levels and an absence of tumour shrinkage. Bromocriptine 0-13 prolactin Homo sapiens 163-172 16490177-9 2006 All 23 subjects experienced high prolactin levels when treated with risperidone. Risperidone 68-79 prolactin Homo sapiens 33-42 16490177-12 2006 Administration of risperidone resulted in high serum prolactin levels. Risperidone 18-29 prolactin Homo sapiens 53-62 16690466-9 2006 Treatment with cabergoline normalized the patient"s serum prolactin level and considerably decreased the size of her pituitary adenoma. Cabergoline 15-26 prolactin Homo sapiens 58-67 16418827-0 2006 Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients. 1-(3-chlorophenyl)piperazine 78-105 prolactin Homo sapiens 56-65 16418827-0 2006 Relationship of disinhibition and aggression to blunted prolactin response to meta-chlorophenylpiperazine in cocaine-dependent patients. Cocaine 109-116 prolactin Homo sapiens 56-65 16418827-2 2006 OBJECTIVE: We investigated whether prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP), a mixed 5-HT agonist/antagonist, differed between abstinent cocaine-dependent patients and controls and whether m-CPP challenge responses were related to measures of disinhibition and aggression. 1-(3-chlorophenyl)piperazine 63-90 prolactin Homo sapiens 35-44 16418827-2 2006 OBJECTIVE: We investigated whether prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP), a mixed 5-HT agonist/antagonist, differed between abstinent cocaine-dependent patients and controls and whether m-CPP challenge responses were related to measures of disinhibition and aggression. 1-(3-chlorophenyl)piperazine 63-90 prolactin Homo sapiens 46-49 16418827-2 2006 OBJECTIVE: We investigated whether prolactin (PRL) response to meta-chlorophenylpiperazine (m-CPP), a mixed 5-HT agonist/antagonist, differed between abstinent cocaine-dependent patients and controls and whether m-CPP challenge responses were related to measures of disinhibition and aggression. 1-(3-chlorophenyl)piperazine 92-97 prolactin Homo sapiens 35-44 16213031-8 2006 The high levels of GH and PRL in the pre-weaning period may be due to the fact that they have to counteract the cortisol-mediated negative effect on lymphocyte production and development. Hydrocortisone 112-120 prolactin Homo sapiens 26-29 16507890-5 2006 Treatment of organ-cultured human scalp HFs with high-dose PRL (400 ng/ml) results in a significant inhibition of hair shaft elongation and premature catagen development, along with reduced proliferation and increased apoptosis of hair bulb keratinocytes (Ki-67/terminal dUTP nick-end labeling immunohistomorphometry). deoxyuridine triphosphate 271-275 prolactin Homo sapiens 59-62 16051446-0 2006 Bromocriptine treatment for cocaine addiction: association with plasma prolactin levels. Bromocriptine 0-13 prolactin Homo sapiens 71-80 16051446-8 2006 Bromocriptine significantly suppressed prolactin concentrations (4.4 ng/ml decrease), while placebo did not (0.1 ng/ml decrease). Bromocriptine 0-13 prolactin Homo sapiens 39-48 16328513-0 2006 Morphologic changes of prolactin-producing pituitary adenomas after short treatment with dopamine agonists. Dopamine 89-97 prolactin Homo sapiens 23-32 16328513-1 2006 Treatment of patients with prolactin (PRL)-producing pituitary adenomas with dopamine agonists has proved successful for most cases. Dopamine 77-85 prolactin Homo sapiens 27-36 16328513-1 2006 Treatment of patients with prolactin (PRL)-producing pituitary adenomas with dopamine agonists has proved successful for most cases. Dopamine 77-85 prolactin Homo sapiens 38-41 16328513-2 2006 Dopamine agonists inhibit PRL secretion, suppress cell proliferation, and may induce apoptosis to adenoma cells. Dopamine 0-8 prolactin Homo sapiens 26-29 16328513-3 2006 Dopamine agonists induce striking morphologic changes in the majority of treated PRL-producing adenomas. Dopamine 0-8 prolactin Homo sapiens 81-84 16328513-6 2006 The purpose of this report is to describe the morphologic changes seen in PRL-producing adenomas after short-term dopamine agonist treatment. Dopamine 114-122 prolactin Homo sapiens 74-77 16328513-7 2006 We present two cases of PRL-producing macroadenomas, both from male patients who received treatment with dopamine agonists, the first for 5 and the second for 8 days. Dopamine 105-113 prolactin Homo sapiens 24-27 16601364-2 2006 OBJECTIVES: The study was performed to analyze the association between prolactin serum levels and alcohol craving during withdrawal differentiating alcohol-dependent patients using Lesch"s typology. Alcohols 98-105 prolactin Homo sapiens 71-80 16508259-1 2006 BACKGROUND: Previous studies demonstrated that dopamine infusion reduces plasma concentration of thyroxine (T4), thyroid stimulating hormone (TSH), prolactin (PRL), and growth hormone (GH) in adults, children, and infants. Dopamine 47-55 prolactin Homo sapiens 148-157 16508259-1 2006 BACKGROUND: Previous studies demonstrated that dopamine infusion reduces plasma concentration of thyroxine (T4), thyroid stimulating hormone (TSH), prolactin (PRL), and growth hormone (GH) in adults, children, and infants. Dopamine 47-55 prolactin Homo sapiens 159-162 16508259-2 2006 OBJECTIVES: The purpose of this prospective observational study was to evaluate the relationship between dopamine infusion and the dynamics of T4, TSH, PRL, and GH in preterm newborns weighing less than 1,500 g (very low birth weight infants, VLBW) admitted in a neonatal intensive care unit of a university hospital over a one year period. Dopamine 105-113 prolactin Homo sapiens 152-155 16508259-6 2006 RESULTS: Among the VLBW newborns who were given dopamine, the four pituitary hormones had different dynamics: a reduction of T4, TSH, and PRL levels was noticed since the first day of treatment, and a rebound of their levels was evident since the first day after its interruption. Dopamine 48-56 prolactin Homo sapiens 138-141 16508259-9 2006 CONCLUSIONS: The results suggest that dopamine infusion reduces T4, TSH, and PRL plasma levels in preterm VLBW infants and have no effect on postprandial GH rate. Dopamine 38-46 prolactin Homo sapiens 77-80 16518066-11 2006 We report the second case of a patient given long-term phenothiazine therapy, which is known to increase serum prolactin levels. phenothiazine 55-68 prolactin Homo sapiens 111-120 16887755-9 2006 The plasma prolactin profile did not display a physiological nocturnal increase in the basal condition; however, it did during melatonin treatment, with the rise coinciding with the nocturnal peak of melatonin concentration. Melatonin 127-136 prolactin Homo sapiens 11-20 16887755-9 2006 The plasma prolactin profile did not display a physiological nocturnal increase in the basal condition; however, it did during melatonin treatment, with the rise coinciding with the nocturnal peak of melatonin concentration. Melatonin 200-209 prolactin Homo sapiens 11-20 16357488-1 2006 BACKGROUND/AIMS: In animal models, prolactin increases tuberoinfundibular dopamine turnover, which has been demonstrated to suppress both hypothalamic GnRH and pituitary TSH secretion. Dopamine 74-82 prolactin Homo sapiens 35-44 16357488-2 2006 To test the hypothesis that prolactin suppresses GnRH and TSH secretion in women, as preliminary evidence that a short-feedback dopamine loop also operates in the human, the effect of hyperprolactinemia on GnRH and TSH secretion was examined. Thyrotropin 58-61 prolactin Homo sapiens 28-37 16357488-6 2006 LH pulse frequency decreased (8.7+/-1.0 to 6.0+/-1.0 pulses/12 h; p<0.05) with r-hPRL administration, but there were no changes in LH pulse amplitude or mean LH levels. Luteinizing Hormone 0-2 prolactin Homo sapiens 84-88 16378242-0 2006 Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells. Cyclic AMP 9-13 prolactin Homo sapiens 50-59 16378242-2 2006 Here we report that cAMP is an important stimulator of PRL transcription in primary human T lymphocytes. Cyclic AMP 20-24 prolactin Homo sapiens 55-58 16378242-3 2006 Inhibition of both protein kinase A (PKA) and p38 MAPK partially abrogated cAMP-induced PRL expression. Cyclic AMP 75-79 prolactin Homo sapiens 88-91 16378242-5 2006 Our findings suggest that cAMP induces PRL expression in T lymphocytes via cooperation of at least two different signaling pathways: a PKA-dependent pathway leading to the phosphorylation of cAMP response element-binding protein, and a PKA-independent pathway leading to p38 phosphorylation. Cyclic AMP 26-30 prolactin Homo sapiens 39-42 16378242-5 2006 Our findings suggest that cAMP induces PRL expression in T lymphocytes via cooperation of at least two different signaling pathways: a PKA-dependent pathway leading to the phosphorylation of cAMP response element-binding protein, and a PKA-independent pathway leading to p38 phosphorylation. Cyclic AMP 191-195 prolactin Homo sapiens 39-42 16509147-14 2006 CONCLUSIONS: Dopamine agonist medications are effective as a first-line therapy for invasive giant prolactinomas, because they can significantly shrink tumor volume and control the PRL level. Dopamine 13-21 prolactin Homo sapiens 181-184 16601364-2 2006 OBJECTIVES: The study was performed to analyze the association between prolactin serum levels and alcohol craving during withdrawal differentiating alcohol-dependent patients using Lesch"s typology. Alcohols 148-155 prolactin Homo sapiens 71-80 16601364-7 2006 CONCLUSIONS: In patients of Lesch"s type 2, who are characterized to suffer from anxiety and to use alcohol because of its anxiolytic effects, prolactin is associated with craving during early alcohol withdrawal. Alcohols 100-107 prolactin Homo sapiens 143-152 16112673-2 2005 Carassius RFamide (C-RFa) is an orthologous PRL secretagogue in fishes and a gene encoding a 20-amino acid peptide of identical sequence is present in the chicken. carassius rfamide 0-17 prolactin Homo sapiens 44-47 16123156-6 2005 This response was inhibited by the prolactin receptor antagonist Delta1-9-G129R-human prolactin and the JAK inhibitor AG490, but was unaffected by selected serine/threonine kinase inhibitors (H89, KN-93, bisindolymaleimide, or PD98059). bisindolymaleimide 204-222 prolactin Homo sapiens 86-95 16123156-6 2005 This response was inhibited by the prolactin receptor antagonist Delta1-9-G129R-human prolactin and the JAK inhibitor AG490, but was unaffected by selected serine/threonine kinase inhibitors (H89, KN-93, bisindolymaleimide, or PD98059). 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one 227-234 prolactin Homo sapiens 86-95 16318956-5 2005 Our results showed that 86.96% of the opium-dependent and 41.67 % of the nicotine-dependent group displayed high prolactin values (p<0.002). Nicotine 73-81 prolactin Homo sapiens 113-122 16112673-2 2005 Carassius RFamide (C-RFa) is an orthologous PRL secretagogue in fishes and a gene encoding a 20-amino acid peptide of identical sequence is present in the chicken. C-RFa 19-24 prolactin Homo sapiens 44-47 16379508-0 2005 Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. Risperidone 0-11 prolactin Homo sapiens 20-29 16379508-2 2005 Risperidone elevates prolactin more than other atypical antipsychotic medications. Risperidone 0-11 prolactin Homo sapiens 21-30 16379509-0 2005 Elevated prolactin levels in male youths treated with risperidone and quetiapine. Risperidone 54-65 prolactin Homo sapiens 9-18 16379509-0 2005 Elevated prolactin levels in male youths treated with risperidone and quetiapine. Quetiapine Fumarate 70-80 prolactin Homo sapiens 9-18 16379509-1 2005 The aim of this study was to report on the serum prolactin levels in 70 male youths at a residential treatment center who were treated with either risperidone or quetiapine. Risperidone 147-158 prolactin Homo sapiens 49-58 16379509-1 2005 The aim of this study was to report on the serum prolactin levels in 70 male youths at a residential treatment center who were treated with either risperidone or quetiapine. Quetiapine Fumarate 162-172 prolactin Homo sapiens 49-58 16379509-4 2005 Prolactin was above the upper limit of normal for 68% of the patients on risperidone and 20% of the patients on quetiapine (chi2 analysis: R>Q; p<0.001). Risperidone 73-84 prolactin Homo sapiens 0-9 16379509-4 2005 Prolactin was above the upper limit of normal for 68% of the patients on risperidone and 20% of the patients on quetiapine (chi2 analysis: R>Q; p<0.001). Quetiapine Fumarate 112-122 prolactin Homo sapiens 0-9 16379509-5 2005 Both risperidone and quetiapine produced dose-related increases in serum prolactin levels (R, r=0.34, p=0.017; Q, r=0.45, p=0.05). Risperidone 5-16 prolactin Homo sapiens 73-82 16379509-5 2005 Both risperidone and quetiapine produced dose-related increases in serum prolactin levels (R, r=0.34, p=0.017; Q, r=0.45, p=0.05). Quetiapine Fumarate 21-31 prolactin Homo sapiens 73-82 16268803-13 2005 A moderate correlation was found between PRL and creatinine levels (r = 0.609, P < 0.001). Creatinine 49-59 prolactin Homo sapiens 41-44 16483172-6 2005 Moreover, acitretin treatment induced a significant reduction of PRL levels after 3 months (from 182 +/- 70 to 150 +/- 56 mU/l, p < 0.05). Acitretin 10-19 prolactin Homo sapiens 65-68 16483172-8 2005 In conclusion, we demonstrated that treatment with low dose of acitretin induced a series of hormonal modifications that, in addition to a mild and transient reduction of TSH levels, included a persistent reduction of FT3, probably due to changes in thyroid hormone metabolism, and a decrease in PRL levels. Acitretin 63-72 prolactin Homo sapiens 296-299 15956984-10 2005 Amoxapine was associated with less EPS and less prolactin elevation than risperidone. Amoxapine 0-9 prolactin Homo sapiens 48-57 15988468-0 2005 Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? nalmefene 0-9 prolactin Homo sapiens 37-46 15988468-1 2005 In humans, mu- and kappa-opioid receptor agonists lower tuberoinfundibular dopamine, which tonically inhibits prolactin release. Dopamine 75-83 prolactin Homo sapiens 110-119 15988468-2 2005 Serum prolactin is, therefore, a useful biomarker for tuberoinfundibular dopamine. Dopamine 73-81 prolactin Homo sapiens 6-15 15988468-3 2005 The current study evaluated the unexpected finding that the relative mu- and kappa-opioid receptor selective antagonist nalmefene increases serum prolactin, indicating possible kappa-opioid receptor agonist activity. nalmefene 120-129 prolactin Homo sapiens 146-155 15988468-8 2005 Compared to placebo, both doses of nalmefene caused significant elevations in serum prolactin (p<0.002 for nalmefene 3 mg and p<0.0005 for nalmefene 10 mg). nalmefene 35-44 prolactin Homo sapiens 84-93 15988468-12 2005 Elevations in serum prolactin following nalmefene are consistent with this partial agonist effect at kappa-opioid receptors. nalmefene 40-49 prolactin Homo sapiens 20-29 16566383-7 2005 In the identification of hyperprolactinemia not only simple measurements of the prolactin serum level are used, the dynamic tests with the use of dopamine antagonists have a special role as well. Dopamine 146-154 prolactin Homo sapiens 30-39 16526181-0 2005 [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine]. Risperidone 104-115 prolactin Homo sapiens 1-10 16526181-0 2005 [Prolactin secretion disturbances in schizophrenic patients treated with 2nd generation antipsychotics--risperidone and olanzapine]. Olanzapine 120-130 prolactin Homo sapiens 1-10 16264405-12 2005 Serum prolactin normalized (25.4ng/ml) after bromocriptine was increased to 7.5mg/d. Bromocriptine 45-58 prolactin Homo sapiens 6-15 16444347-2 2005 Bromocriptine (BRC) resistance, defined as failure to normalize prolactin (PRL) and/or to shrink the tumor is reported in 5 to 18% of the patients treated with this drug, the first DA widely used. Bromocriptine 0-13 prolactin Homo sapiens 75-78 16444347-3 2005 Cabergoline (CBG) can bring PRL to normalization and reduce tumor size in up to 86% and 92% of the patients, respectively. Cabergoline 0-11 prolactin Homo sapiens 28-31 16444347-3 2005 Cabergoline (CBG) can bring PRL to normalization and reduce tumor size in up to 86% and 92% of the patients, respectively. Cabergoline 13-16 prolactin Homo sapiens 28-31 16311416-3 2005 It is well known that dopamine agonists, such as bromocriptine, pergolide, quinagolide, cabergoline, and lisuride, can inhibit PRL secretion by binding to the D(2) dopamine receptors located on normal as well as tumorous pituitary cells. Dopamine 22-30 prolactin Homo sapiens 127-130 16311416-3 2005 It is well known that dopamine agonists, such as bromocriptine, pergolide, quinagolide, cabergoline, and lisuride, can inhibit PRL secretion by binding to the D(2) dopamine receptors located on normal as well as tumorous pituitary cells. Bromocriptine 49-62 prolactin Homo sapiens 127-130 16311416-3 2005 It is well known that dopamine agonists, such as bromocriptine, pergolide, quinagolide, cabergoline, and lisuride, can inhibit PRL secretion by binding to the D(2) dopamine receptors located on normal as well as tumorous pituitary cells. Pergolide 64-73 prolactin Homo sapiens 127-130 16311416-3 2005 It is well known that dopamine agonists, such as bromocriptine, pergolide, quinagolide, cabergoline, and lisuride, can inhibit PRL secretion by binding to the D(2) dopamine receptors located on normal as well as tumorous pituitary cells. quinagolide 75-86 prolactin Homo sapiens 127-130 16311416-3 2005 It is well known that dopamine agonists, such as bromocriptine, pergolide, quinagolide, cabergoline, and lisuride, can inhibit PRL secretion by binding to the D(2) dopamine receptors located on normal as well as tumorous pituitary cells. Cabergoline 88-99 prolactin Homo sapiens 127-130 16311416-3 2005 It is well known that dopamine agonists, such as bromocriptine, pergolide, quinagolide, cabergoline, and lisuride, can inhibit PRL secretion by binding to the D(2) dopamine receptors located on normal as well as tumorous pituitary cells. Lisuride 105-113 prolactin Homo sapiens 127-130 16216913-8 2005 BIM-23244 reduced PRL secretion only in adenomas expressing sst2, sst5 and DR2. bim 0-3 prolactin Homo sapiens 18-21 16264405-11 2005 RESULTS: The patient was initially placed on 2.5mg/d bromocriptine but after three months only a nominal reduction of serum prolactin was achieved. Bromocriptine 53-66 prolactin Homo sapiens 124-133 16264405-16 2005 For males with elevated serum prolactin even when associated with focal encephalomalacia and seizure disorder, bromocriptine therapy can offer safe benefits including improved semen parameters and normal serum testosterone levels. Bromocriptine 111-124 prolactin Homo sapiens 30-39 16101186-0 2005 A phase II study of tamoxifen in hormone-resistant metastatic prostate cancer: possible relation with prolactin secretion. Tamoxifen 20-29 prolactin Homo sapiens 102-111 15922343-4 2005 Our previous studies have shown that cortisol rapidly inhibits prolactin (PRL) release from the tilapia pituitary by suppressing intracellular Ca(2+) ([Ca(2+)]i) and cAMP. Hydrocortisone 37-45 prolactin Homo sapiens 63-72 15922343-4 2005 Our previous studies have shown that cortisol rapidly inhibits prolactin (PRL) release from the tilapia pituitary by suppressing intracellular Ca(2+) ([Ca(2+)]i) and cAMP. Hydrocortisone 37-45 prolactin Homo sapiens 74-77 15922343-4 2005 Our previous studies have shown that cortisol rapidly inhibits prolactin (PRL) release from the tilapia pituitary by suppressing intracellular Ca(2+) ([Ca(2+)]i) and cAMP. Cyclic AMP 166-170 prolactin Homo sapiens 63-72 15922343-4 2005 Our previous studies have shown that cortisol rapidly inhibits prolactin (PRL) release from the tilapia pituitary by suppressing intracellular Ca(2+) ([Ca(2+)]i) and cAMP. Cyclic AMP 166-170 prolactin Homo sapiens 74-77 15922343-7 2005 Significant dose-related increases in PRL release were observed at higher doses of ouabain (100-1000 nM), whereas significant inhibition was seen in GH release at 1000 nM during 2-24h of incubation. Ouabain 83-90 prolactin Homo sapiens 38-41 15922343-10 2005 Ouabain also attenuated stimulation of PRL release by the Ca(2+) ionophore, A23187, and by a combination of dibutyryl cAMP and a phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthin. Ouabain 0-7 prolactin Homo sapiens 39-42 15922343-10 2005 Ouabain also attenuated stimulation of PRL release by the Ca(2+) ionophore, A23187, and by a combination of dibutyryl cAMP and a phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthin. Calcimycin 76-82 prolactin Homo sapiens 39-42 15922343-10 2005 Ouabain also attenuated stimulation of PRL release by the Ca(2+) ionophore, A23187, and by a combination of dibutyryl cAMP and a phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthin. Cyclic AMP 118-122 prolactin Homo sapiens 39-42 15922343-10 2005 Ouabain also attenuated stimulation of PRL release by the Ca(2+) ionophore, A23187, and by a combination of dibutyryl cAMP and a phosphodiesterase inhibitor, 3-isobutyl-1-methylxanthin. 3-isobutyl-1-methylxanthin 158-184 prolactin Homo sapiens 39-42 15922343-11 2005 Intracellular Ca(2+) concentrations were monitored in the dispersed PRL cells with the Ca(2+)-sensitive dye, fura-2. Fura-2 109-115 prolactin Homo sapiens 68-71 15922343-13 2005 A rapid reduction in [Ca(2+)]i was also observed when PRL cells were exposed to 1 microM cortisol, whereas there was no consistent effect at 1 nM. Hydrocortisone 89-97 prolactin Homo sapiens 54-57 15922343-14 2005 These results suggest that ouabain at physiological concentrations rapidly inhibits PRL release from the tilapia pituitary by suppressing intracellular Ca(2+) and cAMP metabolism. Ouabain 27-34 prolactin Homo sapiens 84-87 15922343-14 2005 These results suggest that ouabain at physiological concentrations rapidly inhibits PRL release from the tilapia pituitary by suppressing intracellular Ca(2+) and cAMP metabolism. Cyclic AMP 163-167 prolactin Homo sapiens 84-87 16279400-8 2005 Despite the finding of in vitro biological activity in all macroprolactinemic sera tested, our results suggest a variable in vivo bioactivity of bb-PRL, probably related to a reduced capacity to cross vascular endothelium. boeravinone B 145-147 prolactin Homo sapiens 148-151 16279400-9 2005 In this study, we demonstrated that in 12 out of 13 samples (85%), bb-PRL consisted of PRL-IgG complexes. boeravinone B 67-69 prolactin Homo sapiens 70-73 16279400-9 2005 In this study, we demonstrated that in 12 out of 13 samples (85%), bb-PRL consisted of PRL-IgG complexes. boeravinone B 67-69 prolactin Homo sapiens 87-90 16101186-11 2005 Finally, a significant decline in mean PRL levels upon tamoxifen therapy occurred only in the responder patients. Tamoxifen 55-64 prolactin Homo sapiens 39-42 16817144-3 2005 MATERIAL AND METHODS: We identified 58 patients with hyperprolactinaemia, in whom BB-PRL consisted>or=60% of the total PRL concentration. boeravinone B 82-84 prolactin Homo sapiens 85-88 16817144-9 2005 In hyperprolactinaemic patients with predominance of BB-PRL, there was no direct correlation between the presence of clinical features and the concentration of residual "free" PRL. boeravinone B 53-55 prolactin Homo sapiens 56-59 16817144-13 2005 During the short time of metoclopramide stimulation test, there was a marked rise mainly of the total and "free" PRL concentrations, and, in some tested subjects, the predominance of BB-PRL was lost temporally for 1 to 2 hours. Metoclopramide 25-39 prolactin Homo sapiens 113-116 16817144-13 2005 During the short time of metoclopramide stimulation test, there was a marked rise mainly of the total and "free" PRL concentrations, and, in some tested subjects, the predominance of BB-PRL was lost temporally for 1 to 2 hours. boeravinone B 183-185 prolactin Homo sapiens 186-189 16279371-9 2005 Treatment with the non-selective dopamine agonist pergolide caused a significant reduction of serum PRL concentration with a remarkable decrease of body weight. Dopamine 33-41 prolactin Homo sapiens 100-103 16279371-9 2005 Treatment with the non-selective dopamine agonist pergolide caused a significant reduction of serum PRL concentration with a remarkable decrease of body weight. Pergolide 50-59 prolactin Homo sapiens 100-103 16279371-11 2005 The reduction of the daily dose of pergolide was associated with an increase of serum PRL with significant weight gain. Pergolide 35-44 prolactin Homo sapiens 86-89 15763432-0 2005 Multiple, PKA-dependent and PKA-independent, signals are involved in cAMP-induced PRL expression in the eosinophilic cell line Eol-1. Cyclic AMP 69-73 prolactin Homo sapiens 82-85 16012288-0 2005 Comments on "Prolactin levels and erectile function in patients treated with risperidone" (J Clin Psychopharmacol 2004;24:161-166). Risperidone 77-88 prolactin Homo sapiens 13-22 15763432-7 2005 We postulate that cAMP induces PRL expression via two different signalling pathways: a PKA-dependent pathway leading to the phosphorylation of CREB, and a PKA-independent pathway leading to the phosphorylation of p38. Cyclic AMP 18-22 prolactin Homo sapiens 31-34 16085789-6 2005 Abnormally high prolactin levels occurred in 78.0% of risperidone patients, compared with 16.7% for olanzapine and 5.0% for placebo. Risperidone 54-65 prolactin Homo sapiens 16-25 16002311-4 2005 Cortisol and prolactin concentrations both increased with the period of pregnancy (P = 0.01 and P < 0.01, respectively), suggesting that a sustained increase in cortisol level underlies the increased susceptibility of pregnant women, particularly primigravidae women, to malaria. Hydrocortisone 164-172 prolactin Homo sapiens 13-22 15763432-3 2005 In leukocytes, cAMP is an important regulator of PRL expression. Cyclic AMP 15-19 prolactin Homo sapiens 49-52 15763432-4 2005 We report that in the human eosinophilic cell line Eol-1, cAMP-induced PRL expression is partially abrogated by two protein kinase A (PKA) inhibitors (H89, PKI) and by the p38 inhibitor SB203580. Cyclic AMP 58-62 prolactin Homo sapiens 71-74 16544004-6 2005 After treatment with carbidopa/L-dopa, basal TSH (1.6 microU/mL) and Prl (34 ng/mL) decreased and the response to TRH was partially blocked (10.3 microU/mL and 61 ng/mL, respectively). Carbidopa 21-30 prolactin Homo sapiens 69-72 15763432-4 2005 We report that in the human eosinophilic cell line Eol-1, cAMP-induced PRL expression is partially abrogated by two protein kinase A (PKA) inhibitors (H89, PKI) and by the p38 inhibitor SB203580. SB 203580 186-194 prolactin Homo sapiens 71-74 15994755-11 2005 CONCLUSIONS: Novel dopamine-somatostatin chimeric molecules with differing, enhanced activity at sstr2, sstr5 and DAD2, consistently produced significatly greater suppression of GH and PRL than either octreotide or single-receptor-interacting ligands in tumors from patients classified as only partially responsive to octreotide therapy. Dopamine 19-27 prolactin Homo sapiens 185-188 15700312-0 2005 Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Cisplatin 87-96 prolactin Homo sapiens 0-9 15700312-7 2005 Interestingly, the cisplatin-induced cell death of the prolactin receptor-positive cells was significantly inhibited by pretreatment with prolactin. Cisplatin 19-28 prolactin Homo sapiens 55-64 15968232-7 2005 Metoclopramide was well tolerated with no significant laboratory or cardiac changes noted other than an increase in serum prolactin. Metoclopramide 0-14 prolactin Homo sapiens 122-131 15811931-5 2005 Application of an absolute prolactin threshold after polyethylene glycol treatment of sera, rather than the traditional method, i.e. less than 40% recovery, minimizes the opportunity for misclassification of patients in whom macroprolactin accounted for more than 60% of prolactin and the residual bioactive prolactin was present in excess. Polyethylene Glycols 53-72 prolactin Homo sapiens 27-36 16026128-5 2005 First-line treatment of prolactin adenomas is based on the use of dopaminergic agonists, especially cabergoline, because of their excellent efficacy and the risk of relapse following surgery. Cabergoline 100-111 prolactin Homo sapiens 24-33 16544004-6 2005 After treatment with carbidopa/L-dopa, basal TSH (1.6 microU/mL) and Prl (34 ng/mL) decreased and the response to TRH was partially blocked (10.3 microU/mL and 61 ng/mL, respectively). Levodopa 31-37 prolactin Homo sapiens 69-72 16019380-3 2005 The patient responded well to bromocriptine (7.5 mg/day) with improvement of clinical symptoms and normalization of plasma prolactin within a few weeks. Bromocriptine 30-43 prolactin Homo sapiens 123-132 16019380-5 2005 During continued treatment at the same dose of bromocriptine the plasma prolactin level remained normal, but after 8 months of treatment the patient suddenly complained of worsening of her visual fields, and magnetic resonance imaging indicated re-enlargement of the tumor. Bromocriptine 47-60 prolactin Homo sapiens 72-81 16019380-8 2005 Postoperative treatment with quinagolide (0.15 mg/day) resulted in disappearance of all clinical symptoms, normalization of prolactin level and a reduction in size of the residual tumor. quinagolide 29-40 prolactin Homo sapiens 124-133 15960571-1 2005 OBJECTIVE: The aim of this cross-sectional study was to investigate the degree and frequency of prolactin (PRL) elevation and related symptoms in patients treated with 3 different atypical antipsychotics: clozapine, olanzapine, and risperidone. Olanzapine 216-226 prolactin Homo sapiens 96-105 15960571-1 2005 OBJECTIVE: The aim of this cross-sectional study was to investigate the degree and frequency of prolactin (PRL) elevation and related symptoms in patients treated with 3 different atypical antipsychotics: clozapine, olanzapine, and risperidone. Risperidone 232-243 prolactin Homo sapiens 96-105 15960571-5 2005 RESULTS: Elevated PRL levels were found in 16 (89%) of the patients receiving risperidone and in 7 (24%) of the patients receiving olanzapine, but in none of the patients receiving clozapine. Risperidone 78-89 prolactin Homo sapiens 18-21 15960571-5 2005 RESULTS: Elevated PRL levels were found in 16 (89%) of the patients receiving risperidone and in 7 (24%) of the patients receiving olanzapine, but in none of the patients receiving clozapine. Olanzapine 131-141 prolactin Homo sapiens 18-21 15960571-6 2005 In addition, there was a significant difference in median PRL level among the treatment groups (p < .0001), in that the PRL level was higher both in the patients treated with risperidone and in the patients treated with olanzapine, compared to those treated with clozapine. Risperidone 178-189 prolactin Homo sapiens 58-61 15960571-6 2005 In addition, there was a significant difference in median PRL level among the treatment groups (p < .0001), in that the PRL level was higher both in the patients treated with risperidone and in the patients treated with olanzapine, compared to those treated with clozapine. Risperidone 178-189 prolactin Homo sapiens 123-126 15960571-6 2005 In addition, there was a significant difference in median PRL level among the treatment groups (p < .0001), in that the PRL level was higher both in the patients treated with risperidone and in the patients treated with olanzapine, compared to those treated with clozapine. Olanzapine 223-233 prolactin Homo sapiens 58-61 15960571-6 2005 In addition, there was a significant difference in median PRL level among the treatment groups (p < .0001), in that the PRL level was higher both in the patients treated with risperidone and in the patients treated with olanzapine, compared to those treated with clozapine. Olanzapine 223-233 prolactin Homo sapiens 123-126 15960571-6 2005 In addition, there was a significant difference in median PRL level among the treatment groups (p < .0001), in that the PRL level was higher both in the patients treated with risperidone and in the patients treated with olanzapine, compared to those treated with clozapine. Clozapine 266-275 prolactin Homo sapiens 58-61 15960571-6 2005 In addition, there was a significant difference in median PRL level among the treatment groups (p < .0001), in that the PRL level was higher both in the patients treated with risperidone and in the patients treated with olanzapine, compared to those treated with clozapine. Clozapine 266-275 prolactin Homo sapiens 123-126 15960571-8 2005 CONCLUSION: Treatment with risperidone was frequently associated with hyperprolactinemia and related symptoms, whereas the occurrence of PRL elevation and related symptoms was modest in patients receiving olanzapine and nonexistent in those receiving clozapine. Olanzapine 205-215 prolactin Homo sapiens 137-140 15960571-8 2005 CONCLUSION: Treatment with risperidone was frequently associated with hyperprolactinemia and related symptoms, whereas the occurrence of PRL elevation and related symptoms was modest in patients receiving olanzapine and nonexistent in those receiving clozapine. Clozapine 251-260 prolactin Homo sapiens 137-140 15956887-6 2005 After failing to respond to bromocriptine and standard-dose cabergoline, he responded well to very high daily doses of cabergoline (1.5 mg daily), with a current prolactin level of 726 ng/mL and notable reduction in tumor size. Cabergoline 119-130 prolactin Homo sapiens 162-171 15939519-0 2005 Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment. Nicotine 121-129 prolactin Homo sapiens 77-86 15939519-0 2005 Changes of smoking behavior and serum adrenocorticotropic hormone, cortisol, prolactin, and endogenous opioids levels in nicotine dependence after naltrexone treatment. Naltrexone 147-157 prolactin Homo sapiens 77-86 15814850-6 2005 Such compounds are thus candidates to counteract the undesired actions of PRL, not only in tumors, but also in dopamine-resistant prolactinomas. Dopamine 111-119 prolactin Homo sapiens 74-77 15833589-0 2005 Effects of cortisol and cocaine on plasma prolactin and growth hormone levels in cocaine-dependent volunteers. Hydrocortisone 11-19 prolactin Homo sapiens 42-51 15833589-0 2005 Effects of cortisol and cocaine on plasma prolactin and growth hormone levels in cocaine-dependent volunteers. Cocaine 24-31 prolactin Homo sapiens 42-51 15856525-3 2005 Firstly, there had been long experience of use of dopamine antagonists (that increase prolactin) in human medicine and no evidence of an increase in breast cancer incidence or risk had been reported. Dopamine 50-58 prolactin Homo sapiens 86-95 15856525-4 2005 Secondly, dopamine agonists (that lower prolactin) had been shown to have no effect in human breast cancer treatment. Dopamine 10-18 prolactin Homo sapiens 40-49 15687336-4 2005 Western blot and mass spectrometric analyses revealed that human pituitary PRL was phosphorylated at serine 194 and serine 163, whereas serine 163 in serum PRL was dephosphorylated. Serine 101-107 prolactin Homo sapiens 75-78 15687336-4 2005 Western blot and mass spectrometric analyses revealed that human pituitary PRL was phosphorylated at serine 194 and serine 163, whereas serine 163 in serum PRL was dephosphorylated. Serine 116-122 prolactin Homo sapiens 75-78 15687336-4 2005 Western blot and mass spectrometric analyses revealed that human pituitary PRL was phosphorylated at serine 194 and serine 163, whereas serine 163 in serum PRL was dephosphorylated. Serine 116-122 prolactin Homo sapiens 75-78 15687336-6 2005 Our data first demonstrate that human pituitary PRL is serine phosphorylated and partially dephosphorylated in serum, and suggest that the acidic isoforms may give rise to chronic antigen stimulation in patients with anti-PRL autoantibodies. Serine 55-61 prolactin Homo sapiens 48-51 15966512-5 2005 Bromocriptine therapy resulted in normalization of PRL levels and menstrual cycle, while a repeat MRI showed no change. Bromocriptine 0-13 prolactin Homo sapiens 51-54 15820828-2 2005 The formula containing bromocriptine and a releasing agent (Pluronic F127) showed an increased dissolution rate, 39-fold greater than that of the pure drug alone, and subsequently was effective in lowering serum prolactin. Bromocriptine 23-36 prolactin Homo sapiens 212-221 15939210-2 2005 We hypothesized that environmental Pb exposure can interact with prolactin (PRL) secretion, regulated by calcium and dopamine, during pregnancy and in fetus. Lead 35-37 prolactin Homo sapiens 65-74 15939210-2 2005 We hypothesized that environmental Pb exposure can interact with prolactin (PRL) secretion, regulated by calcium and dopamine, during pregnancy and in fetus. Lead 35-37 prolactin Homo sapiens 76-79 15939210-2 2005 We hypothesized that environmental Pb exposure can interact with prolactin (PRL) secretion, regulated by calcium and dopamine, during pregnancy and in fetus. Calcium 105-112 prolactin Homo sapiens 65-74 15939210-2 2005 We hypothesized that environmental Pb exposure can interact with prolactin (PRL) secretion, regulated by calcium and dopamine, during pregnancy and in fetus. Calcium 105-112 prolactin Homo sapiens 76-79 15939210-2 2005 We hypothesized that environmental Pb exposure can interact with prolactin (PRL) secretion, regulated by calcium and dopamine, during pregnancy and in fetus. Dopamine 117-125 prolactin Homo sapiens 65-74 15939210-2 2005 We hypothesized that environmental Pb exposure can interact with prolactin (PRL) secretion, regulated by calcium and dopamine, during pregnancy and in fetus. Dopamine 117-125 prolactin Homo sapiens 76-79 15939210-3 2005 The objective of this longitudinal study was to determine the relationships between blood Pb concentration and serum PRL levels in 101 pregnant women recruited during pregnancy and their fetuses exposed to low environmental levels of Pb. Lead 90-92 prolactin Homo sapiens 117-120 15939210-3 2005 The objective of this longitudinal study was to determine the relationships between blood Pb concentration and serum PRL levels in 101 pregnant women recruited during pregnancy and their fetuses exposed to low environmental levels of Pb. Lead 234-236 prolactin Homo sapiens 117-120 15939210-4 2005 We observed a significant negative relationship between maternal blood Pb concentrations and maternal serum PRL levels. Lead 71-73 prolactin Homo sapiens 108-111 15939210-5 2005 Cord blood PRL was weakly correlated with blood Pb levels. Lead 48-50 prolactin Homo sapiens 11-14 15795909-4 2005 Treatment with metoclopramide induces the release of prolactin from the pituitary and stimulates erythropoiesis. Metoclopramide 15-29 prolactin Homo sapiens 53-62 15623810-4 2005 Oxytocin levels significantly decreased, whereas prolactin levels and measures of sedation, dysphoria, and drunkenness significantly increased, during the immediate hours after alcohol consumption. Alcohols 177-184 prolactin Homo sapiens 49-58 15726024-7 2005 Two weeks after the ziprasidone withdrawal, galactorrhea disappeared and the prolactin level decreased down to 18 ng/ml. ziprasidone 20-31 prolactin Homo sapiens 77-86 15722441-8 2005 RLX increased the PRL promoter activity mediated through the region containing multiple CCAAT/enhancer-binding proteins (C/EBP) binding sites that have been shown to mediate the PRL gene activation by cAMP analogue (Pohnke et al., 1999). Cyclic AMP 201-205 prolactin Homo sapiens 18-21 15722441-8 2005 RLX increased the PRL promoter activity mediated through the region containing multiple CCAAT/enhancer-binding proteins (C/EBP) binding sites that have been shown to mediate the PRL gene activation by cAMP analogue (Pohnke et al., 1999). Cyclic AMP 201-205 prolactin Homo sapiens 178-181 15722441-10 2005 PRL promoter activity was inhibited by both H-89 and U0126 indicating multiple signalling pathways are activated by RLX in endometrial cells for different target gene activation. U 0126 53-58 prolactin Homo sapiens 0-3 15829128-1 2005 Half of all men with prolactin (PRL)-producing macroadenomas present with hypogonadism, decreased libido and impotence, and therefore require testosterone replacement. Testosterone 142-154 prolactin Homo sapiens 21-30 15829128-1 2005 Half of all men with prolactin (PRL)-producing macroadenomas present with hypogonadism, decreased libido and impotence, and therefore require testosterone replacement. Testosterone 142-154 prolactin Homo sapiens 32-35 15829128-4 2005 On separate occasions, we documented a rise in PRL when testosterone replacement was started and a fall in PRL when testosterone replacement was stopped (r = 0.6090, P = 0.0095). Testosterone 116-128 prolactin Homo sapiens 107-110 15829128-6 2005 We hypothesize that the exogenous testosterone was aromatized to oestradiol, which stimulated the release of PRL by the anterior pituitary. Testosterone 34-46 prolactin Homo sapiens 109-112 15829128-6 2005 We hypothesize that the exogenous testosterone was aromatized to oestradiol, which stimulated the release of PRL by the anterior pituitary. Estradiol 65-75 prolactin Homo sapiens 109-112 15939977-0 2005 Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. Buspirone 50-59 prolactin Homo sapiens 28-37 15939977-1 2005 Prolactin response to buspirone was evaluated in patients with schizophrenia, with and without tardive dyskinesia (TD). Buspirone 22-31 prolactin Homo sapiens 0-9 15939977-3 2005 Furthermore, prolactin levels after administration of buspirone were not significantly increased from baseline. Buspirone 54-63 prolactin Homo sapiens 13-22 15907146-9 2005 Clozapine and olanzapine are most likely to cause weight gain and metabolic effects, while risperidone is more likely to cause EPS and prolactin elevations. Risperidone 91-102 prolactin Homo sapiens 135-144 16209236-2 2005 Occasionally, verapamil-treated patients experience a slight asymptomatic increase in serum prolactin level. Verapamil 14-23 prolactin Homo sapiens 92-101 16209236-4 2005 A marked increase in prolactin levels and the preserved reactivity of this hormone in dynamic tests suggested that the patient exhibited "hypersensitivity" to verapamil. Verapamil 159-168 prolactin Homo sapiens 21-30 15289996-0 2005 Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Risperidone 61-72 prolactin Homo sapiens 0-9 15289996-0 2005 Prolactin levels in male schizophrenic patients treated with risperidone and haloperidol: a double-blind and randomized study. Haloperidol 77-88 prolactin Homo sapiens 0-9 15289996-2 2005 OBJECTIVES: The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia. Risperidone 64-75 prolactin Homo sapiens 101-104 15289996-2 2005 OBJECTIVES: The goal of this study was to compare the effect of risperidone and haloperidol on serum PRL and investigate the relationship between serum PRL levels and clinical response in patients with schizophrenia. Haloperidol 80-91 prolactin Homo sapiens 101-104 15289996-6 2005 RESULTS: Both risperidone and haloperidol treatment significantly increased serum PRL levels in drug-free chronic schizophrenia patients (both P<0.001). Risperidone 14-25 prolactin Homo sapiens 82-85 15289996-6 2005 RESULTS: Both risperidone and haloperidol treatment significantly increased serum PRL levels in drug-free chronic schizophrenia patients (both P<0.001). Haloperidol 30-41 prolactin Homo sapiens 82-85 15289996-8 2005 Considering dose-adjusted serum PRL levels, risperidone treatment induced a significant elevation of PRL levels compared with haloperidol treatment at the haloperidol equivalent (P<0.001). Risperidone 44-55 prolactin Homo sapiens 32-35 15289996-8 2005 Considering dose-adjusted serum PRL levels, risperidone treatment induced a significant elevation of PRL levels compared with haloperidol treatment at the haloperidol equivalent (P<0.001). Risperidone 44-55 prolactin Homo sapiens 101-104 15289996-9 2005 Change in PRL levels at pre-treatment and post-treatment were related to positive symptom improvement seen in the risperidone group (r=0.51, P=0.016), but not in the haloperidol group (P>0.05). Risperidone 114-125 prolactin Homo sapiens 10-13 15289996-11 2005 CONCLUSIONS: Risperidone is associated with a robust effect on prolactin secretion in contrast to the conventional antipsychotic haloperidol. Risperidone 13-24 prolactin Homo sapiens 63-72 15289996-12 2005 Prolactin monitoring during risperidone treatment should be performed. Risperidone 28-39 prolactin Homo sapiens 0-9 15388649-5 2005 Prolactin stimulated a time- and concentration-dependent increase in catecholamine synthesis, which was maximal after 60-120 min (1 microg/ml prolactin) and inhibited by the prolactin antagonist Delta1-9-G129R-hPRL. Catecholamines 69-82 prolactin Homo sapiens 210-214 15780482-0 2005 Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion. N-Methyl-3,4-methylenedioxyamphetamine 0-7 prolactin Homo sapiens 137-146 15652901-8 2005 RESULT(S): Prolactin release in response to fenfluramine was significantly greater in the HSR group compared with the MSR or SS groups. Fenfluramine 44-56 prolactin Homo sapiens 11-20 24945334-12 2005 Conclusion Stopping risperidone (without starting any other antipsychotic) or switching to a prolactin-sparing antipsychotic is an effective strategy for resolution of amenorrhoea on risperidone, but that dose reduction is rarely effective either because amenorrhoea continues despite lower dose or because relapse of psychosis appears. Risperidone 183-194 prolactin Homo sapiens 93-102 15671135-0 2005 Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma. Olanzapine 63-73 prolactin Homo sapiens 109-118 15671135-0 2005 Successful treatment of refractory schizophrenia with combined olanzapine and quetiapine in a patient with a prolactin secreting pituitary microadenoma. Quetiapine Fumarate 78-88 prolactin Homo sapiens 109-118 15671135-4 2005 We present a patient with treatment resistant schizophrenia and a prolactin-secreting microadenoma of the pituitary who was intolerant of clozapine therapy. Clozapine 138-147 prolactin Homo sapiens 66-75 15822682-7 2005 RESULTS: The serum levels of PRL before treatment, as well as the frequencies of its increase, were significantly higher in BCP in comparison to controls (p<0.01, 0.02). bcp 124-127 prolactin Homo sapiens 29-32 15780482-0 2005 Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion. N-Methyl-3,4-methylenedioxyamphetamine 9-13 prolactin Homo sapiens 137-146 15780482-0 2005 Ecstasy (MDMA) mimics the post-orgasmic state: impairment of sexual drive and function during acute MDMA-effects may be due to increased prolactin secretion. N-Methyl-3,4-methylenedioxyamphetamine 100-104 prolactin Homo sapiens 137-146 15780482-6 2005 In addition, MDMA also induces a prominent increase of prolactin plasma levels with a similar time kinetic compared to the post-orgasmic prolactin increase. N-Methyl-3,4-methylenedioxyamphetamine 13-17 prolactin Homo sapiens 55-64 16379032-11 2005 These data suggest that, in male macro- and giant prolactinomas, dopamine agonists represent the first-line therapy effective in reducing PRL, restoration of libido and potency, improvement of VFD and determining tumor shrinkage. Dopamine 65-73 prolactin Homo sapiens 138-141 16411067-6 2005 Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma. Cabergoline 0-11 prolactin Homo sapiens 58-61 16411067-6 2005 Cabergoline treatments is able to induce normalization of PRL levels and a reduction of tumor mass in the majority of patients and consequently restoring the normal semen quality and ameliorating the quality of life of men with pituitary PRL-secreting adenoma. Cabergoline 0-11 prolactin Homo sapiens 238-241 15588247-0 2004 Novel ghrelin analogs with improved affinity for the GH secretagogue receptor stimulate GH and prolactin release from human pituitary cells. Ghrelin 6-13 prolactin Homo sapiens 95-104 15677431-2 2004 Our findings indicate that sexual function improved with euprolactinemia in patients switched from treatment with prolactin-elevating antipsychotics to olanzapine. Olanzapine 152-162 prolactin Homo sapiens 59-68 15665801-1 2004 OBJECTIVES: Relationship between melatonin and prolactin has been suggested on the basis of both experimental and clinical studies. Melatonin 33-42 prolactin Homo sapiens 47-56 15665801-9 2004 CONCLUSION: The results of the present study confirm suggestions of the presence of the relationship between melatonin and prolactin secretion. Melatonin 109-118 prolactin Homo sapiens 123-132 15550345-4 2004 Oxytocin, serotonin, opioids, histamine, substance P, and arginine-leucine modulate prolactin release by means of an autocrine/paracrine mechanism, whereas estrogen and progesterone hormones can act at the hypothalamic and adenohypophysial levels. Serotonin 10-19 prolactin Homo sapiens 84-93 15665803-3 2004 METHODOLOGY: Plasma prolactin levels were measured in 5 males and 5 females with depressive symptoms who were treated with 50 mg of amisulpride per day as an augmentation to antidepressants (n=5), benzodiazepine anxiolytics (n=8) or in monotherapy (n=1). Amisulpride 132-143 prolactin Homo sapiens 20-29 15550345-4 2004 Oxytocin, serotonin, opioids, histamine, substance P, and arginine-leucine modulate prolactin release by means of an autocrine/paracrine mechanism, whereas estrogen and progesterone hormones can act at the hypothalamic and adenohypophysial levels. Histamine 30-39 prolactin Homo sapiens 84-93 15665807-5 2004 After the naloxone administration the mean plasma prolactin level decreased significantly (p=0.01) in Klinefelter subjects. Naloxone 10-18 prolactin Homo sapiens 50-59 15665807-8 2004 CONCLUSIONS: The naloxone administration in Klinefelter syndrome caused the decrease in plasma prolactin levels but did not affect the plasma level of another hypophyseal and gonadal hormones. Naloxone 17-25 prolactin Homo sapiens 95-104 15529390-5 2004 Neurosurgical resection and medical therapy with bromocriptine mesylate were independently associated with decreased prolactin levels, loss of arthritis, and reduced levels of inflammatory mediators. Bromocriptine 49-71 prolactin Homo sapiens 117-126 15528329-0 2004 Mechanism of prostaglandin (PG)E2-induced prolactin expression in human T cells: cooperation of two PGE2 receptor subtypes, E-prostanoid (EP) 3 and EP4, via calcium- and cyclic adenosine 5"-monophosphate-mediated signaling pathways. Dinoprostone 13-33 prolactin Homo sapiens 42-51 15528329-0 2004 Mechanism of prostaglandin (PG)E2-induced prolactin expression in human T cells: cooperation of two PGE2 receptor subtypes, E-prostanoid (EP) 3 and EP4, via calcium- and cyclic adenosine 5"-monophosphate-mediated signaling pathways. Calcium 157-164 prolactin Homo sapiens 42-51 15528329-0 2004 Mechanism of prostaglandin (PG)E2-induced prolactin expression in human T cells: cooperation of two PGE2 receptor subtypes, E-prostanoid (EP) 3 and EP4, via calcium- and cyclic adenosine 5"-monophosphate-mediated signaling pathways. cyclic adenosine 5"-monophosphate 170-203 prolactin Homo sapiens 42-51 15528329-1 2004 We previously reported that prolactin gene expression in the T-leukemic cell line Jurkat is stimulated by PGE(2) and that cAMP acts synergistically with Ca(2+) or protein kinase C on the activation of the upstream prolactin promoter. Prostaglandins E 106-109 prolactin Homo sapiens 28-37 15528329-1 2004 We previously reported that prolactin gene expression in the T-leukemic cell line Jurkat is stimulated by PGE(2) and that cAMP acts synergistically with Ca(2+) or protein kinase C on the activation of the upstream prolactin promoter. Cyclic AMP 122-126 prolactin Homo sapiens 28-37 15528329-1 2004 We previously reported that prolactin gene expression in the T-leukemic cell line Jurkat is stimulated by PGE(2) and that cAMP acts synergistically with Ca(2+) or protein kinase C on the activation of the upstream prolactin promoter. Cyclic AMP 122-126 prolactin Homo sapiens 214-223 15528329-2 2004 Using the transcription inhibitor actinomycin D, we now show that PGE(2)-induced prolactin expression requires de novo prolactin mRNA synthesis and that PGE(2) does not influence prolactin mRNA stability. Dactinomycin 34-47 prolactin Homo sapiens 81-90 15528329-2 2004 Using the transcription inhibitor actinomycin D, we now show that PGE(2)-induced prolactin expression requires de novo prolactin mRNA synthesis and that PGE(2) does not influence prolactin mRNA stability. Dinoprostone 66-72 prolactin Homo sapiens 81-90 15528329-2 2004 Using the transcription inhibitor actinomycin D, we now show that PGE(2)-induced prolactin expression requires de novo prolactin mRNA synthesis and that PGE(2) does not influence prolactin mRNA stability. Dinoprostone 66-72 prolactin Homo sapiens 119-128 15528329-2 2004 Using the transcription inhibitor actinomycin D, we now show that PGE(2)-induced prolactin expression requires de novo prolactin mRNA synthesis and that PGE(2) does not influence prolactin mRNA stability. Dinoprostone 66-72 prolactin Homo sapiens 119-128 15528329-2 2004 Using the transcription inhibitor actinomycin D, we now show that PGE(2)-induced prolactin expression requires de novo prolactin mRNA synthesis and that PGE(2) does not influence prolactin mRNA stability. Prostaglandins E 66-69 prolactin Homo sapiens 81-90 15528329-2 2004 Using the transcription inhibitor actinomycin D, we now show that PGE(2)-induced prolactin expression requires de novo prolactin mRNA synthesis and that PGE(2) does not influence prolactin mRNA stability. Prostaglandins E 66-69 prolactin Homo sapiens 119-128 15528329-2 2004 Using the transcription inhibitor actinomycin D, we now show that PGE(2)-induced prolactin expression requires de novo prolactin mRNA synthesis and that PGE(2) does not influence prolactin mRNA stability. Prostaglandins E 66-69 prolactin Homo sapiens 119-128 15528329-3 2004 Furthermore, PGE(2)-induced prolactin expression was inhibited by protein kinase inhibitor fragment 14-22 and BAPTA-AM, which respectively, inhibit protein kinase A- and Ca(2+)-mediated signaling cascades. Dinoprostone 13-19 prolactin Homo sapiens 28-37 15528329-3 2004 Furthermore, PGE(2)-induced prolactin expression was inhibited by protein kinase inhibitor fragment 14-22 and BAPTA-AM, which respectively, inhibit protein kinase A- and Ca(2+)-mediated signaling cascades. 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester 110-118 prolactin Homo sapiens 28-37 15528329-4 2004 Using specific PGE(2) receptor agonists and antagonists, we show that PGE(2) induces prolactin expression through engagement of E-prostanoid (EP) 3 and EP4 receptors. Prostaglandins E 15-18 prolactin Homo sapiens 85-94 15528329-4 2004 Using specific PGE(2) receptor agonists and antagonists, we show that PGE(2) induces prolactin expression through engagement of E-prostanoid (EP) 3 and EP4 receptors. Dinoprostone 15-21 prolactin Homo sapiens 85-94 15528329-6 2004 In transient transfections, 3000 bp flanking the leukocyte prolactin promoter conferred a weak induction of the luciferase reporter gene by PGE(2) and cAMP, whereas cAMP in synergy with ionomycin strongly activated the promoter. Prostaglandins E 140-143 prolactin Homo sapiens 59-68 15528329-6 2004 In transient transfections, 3000 bp flanking the leukocyte prolactin promoter conferred a weak induction of the luciferase reporter gene by PGE(2) and cAMP, whereas cAMP in synergy with ionomycin strongly activated the promoter. Cyclic AMP 151-155 prolactin Homo sapiens 59-68 15528329-6 2004 In transient transfections, 3000 bp flanking the leukocyte prolactin promoter conferred a weak induction of the luciferase reporter gene by PGE(2) and cAMP, whereas cAMP in synergy with ionomycin strongly activated the promoter. Ionomycin 186-195 prolactin Homo sapiens 59-68 15528329-7 2004 Mutation of a C/EBP responsive element at -214 partially abolished the response of the leukocyte prolactin promoter to PGE(2), cAMP, and ionomycin plus cAMP. Prostaglandins E 119-122 prolactin Homo sapiens 97-106 15528329-7 2004 Mutation of a C/EBP responsive element at -214 partially abolished the response of the leukocyte prolactin promoter to PGE(2), cAMP, and ionomycin plus cAMP. Cyclic AMP 127-131 prolactin Homo sapiens 97-106 15528329-7 2004 Mutation of a C/EBP responsive element at -214 partially abolished the response of the leukocyte prolactin promoter to PGE(2), cAMP, and ionomycin plus cAMP. Ionomycin 137-146 prolactin Homo sapiens 97-106 15528329-7 2004 Mutation of a C/EBP responsive element at -214 partially abolished the response of the leukocyte prolactin promoter to PGE(2), cAMP, and ionomycin plus cAMP. Cyclic AMP 152-156 prolactin Homo sapiens 97-106 15572180-5 2004 A neuropharmacological challenge was administered to index central serotonergic function, i.e., the maximal prolactin (PRL) response to fenfluramine, a serotonin releasing agent. Fenfluramine 136-148 prolactin Homo sapiens 119-122 15572180-6 2004 Hierarchical linear regression analyses indicated that the peak PRL response to fenfluramine was positively associated with positive mood, averaged over 7 days, after controlling for known predictors of the PRL response. Fenfluramine 80-92 prolactin Homo sapiens 64-67 15572180-6 2004 Hierarchical linear regression analyses indicated that the peak PRL response to fenfluramine was positively associated with positive mood, averaged over 7 days, after controlling for known predictors of the PRL response. Fenfluramine 80-92 prolactin Homo sapiens 207-210 15572180-8 2004 In contrast, the PRL response to fenfluramine was not associated with average negative mood, although it was inversely correlated with trait negative affectivity (i.e., Neuroticism). Fenfluramine 33-45 prolactin Homo sapiens 17-20 15736476-3 2004 The negative influence of high blood levels of PRL on the efficacy of chemotherapy in metastatic breast cancer has been confirmed by previous preliminary studies, showing that the concomitant administration of the anti-prolactinemic dopaminergic agent bromocriptine may enhance the therapeutic effect of chemotherapy. Bromocriptine 252-265 prolactin Homo sapiens 47-50 15736476-5 2004 Therefore, new anti-prolactinemic drugs, characterized by less toxicity and a longer duration of activity, such as Cabergoline (CBG), could be more appropriated to control PRL secretion in breast cancer. Cabergoline 115-126 prolactin Homo sapiens 172-175 15736476-5 2004 Therefore, new anti-prolactinemic drugs, characterized by less toxicity and a longer duration of activity, such as Cabergoline (CBG), could be more appropriated to control PRL secretion in breast cancer. Cabergoline 128-131 prolactin Homo sapiens 172-175 15736476-11 2004 Abnormally high pre-treatment levels of PRL were seen in 24/70 (34%) patients, 11 of whom were treated with TXT plus CBG, whereas the other 13 received TXT alone. Cabergoline 117-120 prolactin Homo sapiens 40-43 15736476-12 2004 CBG induced a complete normalization of the PRL levels in all patients within the first two weeks of therapy, whereas no normalization of PRL occurred spontaneously in patients treated with chemotherapy alone. Cabergoline 0-3 prolactin Homo sapiens 44-47 15736476-13 2004 The objective tumor regression rate was significantly higher in patients concomitantly treated with CBG than in those who received chemotherapy alone (31/34 vs 13/36, p < 0.05), and this difference was particularly evident in patients with high PRL levels prior to therapy (6/11 vs 2/13). Cabergoline 100-103 prolactin Homo sapiens 248-251 15465537-3 2004 These studies examined the possibility that prolactin"s orexigenic effects are mediated through the increased secretion of corticosterone. Corticosterone 123-137 prolactin Homo sapiens 44-53 15672465-7 2004 Monolayers exposed to 10 nM prolactin for 24 hr revealed an inhibition of 40% in ouabain-sensitive 86Rb+ uptake, a sensitive measure of pump-mediated transport. Ouabain 81-88 prolactin Homo sapiens 28-37 15672465-7 2004 Monolayers exposed to 10 nM prolactin for 24 hr revealed an inhibition of 40% in ouabain-sensitive 86Rb+ uptake, a sensitive measure of pump-mediated transport. Rubidium-86 99-104 prolactin Homo sapiens 28-37 15465537-4 2004 Twice-daily intracerebroventricular (icv) injection of prolactin increased plasma corticosterone concentration in non-breeding doves of both sexes, with males exhibiting more pronounced effects than females. Corticosterone 82-96 prolactin Homo sapiens 55-64 15465537-7 2004 These findings suggest that elevated corticosterone titers in blood may contribute to the hyperphagia observed in response to prolactin, but corticosterone signaling through a mammalian-type glucocorticoid receptor is not essential. Corticosterone 37-51 prolactin Homo sapiens 126-135 15554761-10 2004 For the study sample, a highly significant correlation was observed between neuroleptic dose (chlorpromazine equivalent) and serum prolactin level; however, this relationship was not determined on a medication-by-medication basis. Chlorpromazine 94-108 prolactin Homo sapiens 131-140 21191524-4 2004 Upon discontinuation of risperidone, the prolactin level dropped to 17.2ng/mL within one week. Risperidone 24-35 prolactin Homo sapiens 41-50 15531715-1 2004 The prolactin pulse down-regulates mammary type I deiodinase responsiveness to norepinephrine. Norepinephrine 79-93 prolactin Homo sapiens 4-13 15160263-8 2004 RESULTS: Perospirone 4 mg increased prolactin levels significantly higher than placebo, whereas paroxetine 20 mg plus perospirone 4 mg significantly attenuated cortisol responses induced by paroxetine 20 mg. perospirone 9-20 prolactin Homo sapiens 36-45 21191524-6 2004 Repeated prolactin levels continued to be normal during treatment with quetiapine. Quetiapine Fumarate 71-81 prolactin Homo sapiens 9-18 15465997-0 2004 Prolactin elevation with ziprasidone. ziprasidone 25-36 prolactin Homo sapiens 0-9 15365707-5 2004 The within-subject correlation of prolactin levels was 0.32 with clozapine levels and 0.75 with haloperidol levels. Clozapine 65-74 prolactin Homo sapiens 34-43 15365707-5 2004 The within-subject correlation of prolactin levels was 0.32 with clozapine levels and 0.75 with haloperidol levels. Haloperidol 96-107 prolactin Homo sapiens 34-43 15365707-0 2004 Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. Clozapine 105-114 prolactin Homo sapiens 76-85 15365707-6 2004 An increment of 100 ng/ml in clozapine level yielded an average increment of 0.45 ng/ml of prolactin levels in females and of 0.15 ng/ml in males. Clozapine 29-38 prolactin Homo sapiens 91-100 15365707-1 2004 In vitro, animal studies and acute short-term clinical studies suggest clozapine releases prolactin but the effect is much smaller than that of typical antipsychotics. Clozapine 71-80 prolactin Homo sapiens 90-99 15365707-7 2004 An increment of 1 ng/ml in haloperidol level yielded an average increment of 2.6 ng/ml of prolactin levels in females and of 1.5 ng/ml in males. Haloperidol 27-38 prolactin Homo sapiens 90-99 15365707-8 2004 At least one fourth of patients demonstrated a significant and strong (r > 0.6) correlation between clozapine and prolactin levels. Clozapine 103-112 prolactin Homo sapiens 117-126 15365707-9 2004 This study suggests that clozapine has effects on prolactin levels but effects are small and may be more evident in some individuals, particularly females. Clozapine 25-34 prolactin Homo sapiens 50-59 15377706-3 2004 Bromocriptine (5 mg/day) was given for 15 years, but the plasma prolactin levels remained elevated. Bromocriptine 0-13 prolactin Homo sapiens 64-73 15650492-2 2004 In our study, we present preliminary data of an ongoing study, which compares changes in prolactin levels in children and adolescents after treatment to risperidone versus olanzapine versus quetiapine. Risperidone 153-164 prolactin Homo sapiens 89-98 15650492-3 2004 We hypothesized: (1) risperidone would be associated with hyperprolactinemia most frequently, and (2) postpubertal females may be at higher risk of prolactin elevation and associated adverse effects. Risperidone 21-32 prolactin Homo sapiens 63-72 15650492-6 2004 RESULTS: End-point prolactin levels were significantly higher with risperidone, compared to olanzapine (p = 0.027) or quetiapine (p = 0.008). Risperidone 67-78 prolactin Homo sapiens 19-28 15650492-6 2004 RESULTS: End-point prolactin levels were significantly higher with risperidone, compared to olanzapine (p = 0.027) or quetiapine (p = 0.008). Olanzapine 92-102 prolactin Homo sapiens 19-28 15650492-9 2004 CONCLUSION: Risperidone significantly increased prolactin levels in children and adolescents. Risperidone 12-23 prolactin Homo sapiens 48-57 15377706-8 2004 On administration of high dose cabergoline, 0.5 mg twice a day orally, the plasma prolactin levels decreased within one month and then normalised within 26 months. Cabergoline 31-42 prolactin Homo sapiens 82-91 15672600-2 2004 Secondary objectives were to compare the antipsychotic and prolactin-related effects of quetiapine versus prestudy antipsychotic treatment. Quetiapine Fumarate 88-98 prolactin Homo sapiens 59-68 15672600-6 2004 Plasma prolactin levels tended to decrease after the transition to quetiapine (p = 0.09). Quetiapine Fumarate 67-77 prolactin Homo sapiens 7-16 15192082-7 2004 The antiangiogenic activity of N-terminal hPRL fragments was assessed by the inhibition of growth factor-induced thymidine uptake and MAPK activation in bovine umbilical endothelial cells. Thymidine 113-122 prolactin Homo sapiens 42-46 15064918-8 2004 At baseline, PRL was positively correlated with ASI-drug (r=0.38, P<0.01), ASI-alcohol (r=0.19, P<0.05), and ASI-psychological (r=0.25, P<0.01) composite scores, and with the quantity of cocaine use (r=0.18, P<0.05). asi-alcohol 78-89 prolactin Homo sapiens 13-16 15064918-1 2004 RATIONALE: Alteration in serum prolactin (PRL) levels may reflect changes in central dopamine activity, which modulates the behavioral effects of cocaine. Dopamine 85-93 prolactin Homo sapiens 31-40 15064918-1 2004 RATIONALE: Alteration in serum prolactin (PRL) levels may reflect changes in central dopamine activity, which modulates the behavioral effects of cocaine. Dopamine 85-93 prolactin Homo sapiens 42-45 15064918-1 2004 RATIONALE: Alteration in serum prolactin (PRL) levels may reflect changes in central dopamine activity, which modulates the behavioral effects of cocaine. Cocaine 146-153 prolactin Homo sapiens 31-40 15064918-1 2004 RATIONALE: Alteration in serum prolactin (PRL) levels may reflect changes in central dopamine activity, which modulates the behavioral effects of cocaine. Cocaine 146-153 prolactin Homo sapiens 42-45 15064918-8 2004 At baseline, PRL was positively correlated with ASI-drug (r=0.38, P<0.01), ASI-alcohol (r=0.19, P<0.05), and ASI-psychological (r=0.25, P<0.01) composite scores, and with the quantity of cocaine use (r=0.18, P<0.05). Cocaine 196-203 prolactin Homo sapiens 13-16 15225684-7 2004 This report shows that the short-term use of amisulpride treatment was linked to an elevation in the PRL level with a possible induction of a pituitary adenoma. Amisulpride 45-56 prolactin Homo sapiens 101-104 15462250-11 2004 Individuals with schizophrenia who previously received oral risperidone therapy have shown a reduction in prolactin levels after a switch to the long-acting formulation. Risperidone 60-71 prolactin Homo sapiens 106-115 15352176-9 2004 Furthermore, to determine whether PRL-induced HO-1 activity was required for VEGF production by macrophages, the effect of PRL on the induction of VEGF was studied in the presence of an inducer stannic chloride (SnCl(2)) and of an inhibitor stannic mesoporphyrin (SnMP) of HO activity. Holmium 46-48 prolactin Homo sapiens 34-37 15727399-9 2004 ACTH, cortisol, PRL, FT3, FT4, FSH, and PRG levels are affected by acute organophosphate poisoning. Organophosphates 73-88 prolactin Homo sapiens 16-19 15356045-2 2004 The release of PRL by the pituitary is tonically inhibited by dopamine through activation of the dopamine D2 receptor (D2R) of lactotroph cells, and obese humans appear to have reduced D2R-binding sites in their brain. Dopamine 62-70 prolactin Homo sapiens 15-18 15523934-5 2004 The estimation of PRL release in a test of stimulation with metoclopramide can be a sensitive (though not specific) test of dopaminergic activity in tuberous--infundibulum pathway and may be used to control the treatment. Metoclopramide 60-74 prolactin Homo sapiens 18-21 14997280-2 2004 It has not been clarified why some atypical antipsychotic drugs, such as amisulpride, induce prolactin plasma concentration (PRL) elevation, but little EPS. Amisulpride 73-84 prolactin Homo sapiens 125-128 15380861-9 2004 We hypothesize that acute exercise may have a stronger effect on serotonin (5-HT) release in depressed patients, which is reflected in increased plasma prolactin concentration. Serotonin 65-74 prolactin Homo sapiens 152-161 15359398-0 2004 Effects of ropivacaine infiltration on cortisol and prolactin responses to postoperative pain after inguinal hernioraphy in children. Ropivacaine 11-22 prolactin Homo sapiens 52-61 15359398-3 2004 The aim of this study was to compare the effects of pre- and postincisional infiltration of the surgical area with ropivacaine on cortisol (C) and prolactin (PRL) release and postoperative pain in children undergoing inguinal hernia repair. Ropivacaine 115-126 prolactin Homo sapiens 147-156 15359398-3 2004 The aim of this study was to compare the effects of pre- and postincisional infiltration of the surgical area with ropivacaine on cortisol (C) and prolactin (PRL) release and postoperative pain in children undergoing inguinal hernia repair. Ropivacaine 115-126 prolactin Homo sapiens 158-161 14997280-4 2004 OBJECTIVE: We have evaluated the relationship between PRL and central (striatum, temporal cortex and thalamus) D2/D3 receptor occupancy in amisulpride treated schizophrenic patients. Amisulpride 139-150 prolactin Homo sapiens 54-57 14997280-12 2004 Higher D2/D3 receptor occupancy at the pituitary gland than at central regions is a possible explanation for amisulpride PRL elevation with low EPS. Amisulpride 109-120 prolactin Homo sapiens 121-124 15286066-5 2004 RESULTS: Prolactin levels increased across medication groups reflecting increasingly tight D(2) receptor binding (clozapine, olanzapine, typical antipsychotics and risperidone). Clozapine 114-123 prolactin Homo sapiens 9-18 15185102-11 2004 Our study suggests that cosecretion of GH and/or PRL from TSH-secreting adenoma has no correlation with response of tumor cells to medical treatment. Thyrotropin 58-61 prolactin Homo sapiens 49-52 15286066-5 2004 RESULTS: Prolactin levels increased across medication groups reflecting increasingly tight D(2) receptor binding (clozapine, olanzapine, typical antipsychotics and risperidone). Olanzapine 125-135 prolactin Homo sapiens 9-18 15286066-5 2004 RESULTS: Prolactin levels increased across medication groups reflecting increasingly tight D(2) receptor binding (clozapine, olanzapine, typical antipsychotics and risperidone). Risperidone 164-175 prolactin Homo sapiens 9-18 15286066-7 2004 In patients treated with clozapine (the loosest D(2) receptor binding agent), patients with the DRD2(*)A1allele had prolactin levels twice those of patients without this allele. Clozapine 25-34 prolactin Homo sapiens 116-125 14997271-2 2004 Although neuroendocrine [e.g. plasma prolactin (PRL)] responses to the serotonin agonist, fenfluramine, have been used widely to index CNS serotonergic responsivity, safety concerns constrain continued use of fenfluramine. Serotonin 71-80 prolactin Homo sapiens 37-46 15296821-1 2004 Serotonin (5-hydroxytryptamine, 5-HT) is involved in the regulation of hypothalamic-pituitary-adrenal axis (HPA) activity and prolactin (PRL) secretion. Serotonin 0-9 prolactin Homo sapiens 126-135 15296821-1 2004 Serotonin (5-hydroxytryptamine, 5-HT) is involved in the regulation of hypothalamic-pituitary-adrenal axis (HPA) activity and prolactin (PRL) secretion. Serotonin 0-9 prolactin Homo sapiens 137-140 15296821-1 2004 Serotonin (5-hydroxytryptamine, 5-HT) is involved in the regulation of hypothalamic-pituitary-adrenal axis (HPA) activity and prolactin (PRL) secretion. Serotonin 11-30 prolactin Homo sapiens 126-135 15296821-1 2004 Serotonin (5-hydroxytryptamine, 5-HT) is involved in the regulation of hypothalamic-pituitary-adrenal axis (HPA) activity and prolactin (PRL) secretion. Serotonin 11-30 prolactin Homo sapiens 137-140 15223825-0 2004 Molecular targeting of antiangiogenic factor 16K hPRL inhibits oxygen-induced retinopathy in mice. Oxygen 63-69 prolactin Homo sapiens 49-53 15223825-4 2004 16K hPRL inhibited retinal neovascularization in a mouse model of oxygen-induced retinopathy. Oxygen 66-72 prolactin Homo sapiens 4-8 15223825-9 2004 CONCLUSIONS: Intravitreal administration of 16K hPRL inhibited neovascularization in the mouse model of oxygen-induced retinopathy. Oxygen 104-110 prolactin Homo sapiens 48-52 15786695-3 2004 Moreover, since hyperprolactinemia negatively influences the efficacy of anticancer therapies in breast cancer, it could be fundamental to achieve a normalization of PRL levels by long-acting dopaminergic agents, such as cabergoline. Cabergoline 221-232 prolactin Homo sapiens 166-169 15786695-4 2004 On this basis, a study was planned to evaluate the effect of cabergoline on PRL levels in hyperprolactinemic metastatic breast cancer subjects. Cabergoline 61-72 prolactin Homo sapiens 76-79 15024549-8 2004 Also, relative to placebo, haloperidol influenced several variables irrespective of group status, including serum prolactin secretion, times to complete attention and working memory tasks, and accuracy of working memory performance. Haloperidol 27-38 prolactin Homo sapiens 114-123 15305227-7 2004 Previously, we detected a significant correlation between prolactin values and ADP-stimulated P-selectin expression on platelets in pregnant women, patients with pituitary tumours, and patients on anti-psychotic therapy. Adenosine Diphosphate 79-82 prolactin Homo sapiens 58-67 15305227-11 2004 Moreover, our data suggest that the stronger effect of prolactin on ADP-stimulated platelet aggregation, compared to leptin, depends on higher stimulation of CD62p expression by prolactin. Adenosine Diphosphate 68-71 prolactin Homo sapiens 55-64 15305227-11 2004 Moreover, our data suggest that the stronger effect of prolactin on ADP-stimulated platelet aggregation, compared to leptin, depends on higher stimulation of CD62p expression by prolactin. Adenosine Diphosphate 68-71 prolactin Homo sapiens 178-187 14997271-2 2004 Although neuroendocrine [e.g. plasma prolactin (PRL)] responses to the serotonin agonist, fenfluramine, have been used widely to index CNS serotonergic responsivity, safety concerns constrain continued use of fenfluramine. Serotonin 71-80 prolactin Homo sapiens 48-51 14997271-2 2004 Although neuroendocrine [e.g. plasma prolactin (PRL)] responses to the serotonin agonist, fenfluramine, have been used widely to index CNS serotonergic responsivity, safety concerns constrain continued use of fenfluramine. Fenfluramine 90-102 prolactin Homo sapiens 37-46 14997271-2 2004 Although neuroendocrine [e.g. plasma prolactin (PRL)] responses to the serotonin agonist, fenfluramine, have been used widely to index CNS serotonergic responsivity, safety concerns constrain continued use of fenfluramine. Fenfluramine 90-102 prolactin Homo sapiens 48-51 14997271-2 2004 Although neuroendocrine [e.g. plasma prolactin (PRL)] responses to the serotonin agonist, fenfluramine, have been used widely to index CNS serotonergic responsivity, safety concerns constrain continued use of fenfluramine. Fenfluramine 209-221 prolactin Homo sapiens 37-46 15240360-3 2004 We have recently observed that salsolinol, which is produced by the neuro-intermediate lobe of the pituitary gland and by the hypothalamus, can selectively release PRL. salsolinol 31-41 prolactin Homo sapiens 164-167 15234536-8 2004 PRL-treated monocyte-derived macrophages showed also an enhanced release of superoxide anion (O2-) release. Superoxides 76-92 prolactin Homo sapiens 0-3 15234536-8 2004 PRL-treated monocyte-derived macrophages showed also an enhanced release of superoxide anion (O2-) release. Superoxides 94-96 prolactin Homo sapiens 0-3 15240360-4 2004 Salsolinol is therefore considered to be a putative endogenous PRL-releasing factor. salsolinol 0-10 prolactin Homo sapiens 63-66 15240360-7 2004 Thus, the present study shows for the first time that salsolinol is not only a PRL-releasing factor but is also a potent inhibitor of stress-induced release of epinephrine and norepinephrine. salsolinol 54-64 prolactin Homo sapiens 79-82 15003147-5 2004 The low dose of haloperidol was better tolerated, with fewer extrapyramidal side-effects, less frequent use of anticholinergic medication and smaller elevations in prolactin levels. Haloperidol 16-27 prolactin Homo sapiens 164-173 15181094-8 2004 In contrast, octreotide inhibited GH, PRL, and alpha-subunit from the respective adenoma by 18 +/- 12 (P = 0.39), 22 +/- 4 (P = 0.04), and 20 +/- 10% (P = 0.34). Octreotide 13-23 prolactin Homo sapiens 38-41 15138671-0 2004 Effects of dopexamine, dobutamine or dopamine on prolactin and thyreotropin serum concentrations in high-risk surgical patients. Dopamine 37-45 prolactin Homo sapiens 49-58 15138671-2 2004 The objective was to compare endocrine effects of equipotent inotropic doses of dopexamine, dobutamine and dopamine on prolactin and thyreotropin release perioperatively. dopexamine 80-90 prolactin Homo sapiens 119-128 15138671-2 2004 The objective was to compare endocrine effects of equipotent inotropic doses of dopexamine, dobutamine and dopamine on prolactin and thyreotropin release perioperatively. Dobutamine 92-102 prolactin Homo sapiens 119-128 15138671-2 2004 The objective was to compare endocrine effects of equipotent inotropic doses of dopexamine, dobutamine and dopamine on prolactin and thyreotropin release perioperatively. Dopamine 107-115 prolactin Homo sapiens 119-128 15138671-12 2004 In contrast, dopamine suppressed prolactin and thyreotropin secretion with a maximal effect after 4 h. After dopamine withdrawal, a rebound release of prolactin and thyreotropin was observed. Dopamine 13-21 prolactin Homo sapiens 33-42 15138671-12 2004 In contrast, dopamine suppressed prolactin and thyreotropin secretion with a maximal effect after 4 h. After dopamine withdrawal, a rebound release of prolactin and thyreotropin was observed. Dopamine 13-21 prolactin Homo sapiens 151-160 15138671-12 2004 In contrast, dopamine suppressed prolactin and thyreotropin secretion with a maximal effect after 4 h. After dopamine withdrawal, a rebound release of prolactin and thyreotropin was observed. Dopamine 109-117 prolactin Homo sapiens 151-160 15138671-13 2004 CONCLUSIONS: In high-risk surgical patients dopexamine or dobutamine produced fewer effects on prolactin and thyreotropin serum concentrations in comparison with DA when used in equivalent dosages. dopexamine 44-54 prolactin Homo sapiens 95-104 15138671-13 2004 CONCLUSIONS: In high-risk surgical patients dopexamine or dobutamine produced fewer effects on prolactin and thyreotropin serum concentrations in comparison with DA when used in equivalent dosages. Dobutamine 58-68 prolactin Homo sapiens 95-104 15163258-12 2004 Serum prolactin levels decreased with quetiapine but increased with haloperidol, differing significantly between the groups at endpoint (p =.005). Quetiapine Fumarate 38-48 prolactin Homo sapiens 6-15 15260904-11 2004 Haloperidol, but not quetiapine, elevated serum prolactin level. Haloperidol 0-11 prolactin Homo sapiens 48-57 15003426-0 2004 Low prolactin response to fenfluramine in impulsive aggression. Fenfluramine 26-38 prolactin Homo sapiens 4-13 15003426-1 2004 To examine the prolactin (prl) response to d,l-fenfluramine in a large sample of personality disorder patients with impulsive aggression. d,l-fenfluramine 43-59 prolactin Homo sapiens 15-24 15003426-4 2004 The peak change in prolactin(deltapkprl) was calculated by subtracting baseline prolactin from peak response following fenfluramine administration (3 h). Fenfluramine 119-131 prolactin Homo sapiens 19-28 15173390-1 2004 There is an inverse relation between zinc (Zn) intake and plasma prolactin in men and nonpregnant women. Zinc 43-45 prolactin Homo sapiens 65-74 14990868-8 2004 There was no difference between genotypes of either sex in the prolactin response to fenfluramine. Fenfluramine 85-97 prolactin Homo sapiens 63-72 15163258-12 2004 Serum prolactin levels decreased with quetiapine but increased with haloperidol, differing significantly between the groups at endpoint (p =.005). Haloperidol 68-79 prolactin Homo sapiens 6-15 15142390-14 2004 In all children, serum prolactin levels increased significantly (p < 0.001) from 166 +/- 88 UI/mL at baseline to 504 +/- 207 UI/mL at week 12 of risperidone treatment. Risperidone 148-159 prolactin Homo sapiens 23-32 15070934-0 2004 Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. Cabergoline 11-22 prolactin Homo sapiens 45-54 15070934-1 2004 The outcome of 24 months of cabergoline treatment on prolactin (PRL) normalization, tumor shrinkage, restoration of pituitary function, and semen alterations was prospectively investigated in 41 men with macro- (age 17-70 yr) and 10 with microprolactinoma (age 18-53 yr). Cabergoline 28-39 prolactin Homo sapiens 53-62 15093954-4 2004 Since the release of cortisol and prolactin is under serotonergic control, we hypothesized that pindolol augmentation of synaptic 5-HT concentrations produced by an SSRI in humans should lead to enhanced SSRI-induced cortisol and prolactin responses. Pindolol 96-104 prolactin Homo sapiens 34-43 15093954-4 2004 Since the release of cortisol and prolactin is under serotonergic control, we hypothesized that pindolol augmentation of synaptic 5-HT concentrations produced by an SSRI in humans should lead to enhanced SSRI-induced cortisol and prolactin responses. Pindolol 96-104 prolactin Homo sapiens 230-239 15146102-0 2004 Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Raloxifene Hydrochloride 11-21 prolactin Homo sapiens 102-111 15134429-5 2004 DP and NC had comparable levels of reproductive hormones, with the exception of elevated prolactin levels, which increased, as did thyroid-stimulating hormone levels, in response to estradiol treatment. Estradiol 182-191 prolactin Homo sapiens 89-98 15031390-8 2004 For women, the change in blood styrene between sessions 1 and 2 was a significant predictor of the change in serum PRL between sessions. Styrene 31-38 prolactin Homo sapiens 115-118 15031390-9 2004 CONCLUSIONS: Results confirm that styrene exposure enhances serum PRL concentrations and support an acute effect of styrene on PRL secretion. Styrene 34-41 prolactin Homo sapiens 66-69 15031390-9 2004 CONCLUSIONS: Results confirm that styrene exposure enhances serum PRL concentrations and support an acute effect of styrene on PRL secretion. Styrene 116-123 prolactin Homo sapiens 127-130 15206663-0 2004 Prolactin levels and erectile function in patients treated with risperidone. Risperidone 64-75 prolactin Homo sapiens 0-9 15206663-1 2004 Treatment with risperidone is associated with prolactin (PRL) elevation, and PRL elevations are associated with erectile dysfunction (ED). Risperidone 15-26 prolactin Homo sapiens 46-55 15206663-1 2004 Treatment with risperidone is associated with prolactin (PRL) elevation, and PRL elevations are associated with erectile dysfunction (ED). Risperidone 15-26 prolactin Homo sapiens 57-60 15206663-2 2004 We evaluated whether the PRL elevations caused by risperidone treatment of subjects with schizophrenia are associated with objective measures of erectile function. Risperidone 50-61 prolactin Homo sapiens 25-28 15206663-6 2004 Consistent with previous reports, the correlation between total risperidone level and PRL was very high (r = 0.92, df = 12, P < 0.0001), but risperidone did not appear to affect either testosterone (r = 0.29, df = 5, P = 0.51) or free and weakly bound testosterone (r = -0.11, df = 10, P = 0.72). Risperidone 64-75 prolactin Homo sapiens 86-89 15031390-0 2004 Temporal association between serum prolactin concentration and exposure to styrene. Styrene 75-82 prolactin Homo sapiens 35-44 15031390-1 2004 BACKGROUND: Previous studies have suggested that occupational exposure to styrene is associated with increased serum levels of the anterior pituitary hormone prolactin (PRL). Styrene 74-81 prolactin Homo sapiens 158-167 15031390-1 2004 BACKGROUND: Previous studies have suggested that occupational exposure to styrene is associated with increased serum levels of the anterior pituitary hormone prolactin (PRL). Styrene 74-81 prolactin Homo sapiens 169-172 15031390-2 2004 AIMS: To test the hypotheses that: (1) the effect of styrene exposure on PRL secretion is an acute effect, not a subchronic or chronic effect; (2) blood styrene, as a measure of absorbed dose, is a stronger predictor of serum PRL level than personal breathing zone air styrene concentration. Styrene 53-60 prolactin Homo sapiens 73-76 15031390-6 2004 RESULTS: Acute blood styrene concentration was the strongest predictor of serum PRL concentration, with the model predicting a 2.06-fold increase in PRL (95% CI 1.11 to 3.84) for every 10-fold increase in blood styrene. Styrene 21-28 prolactin Homo sapiens 80-83 15031390-6 2004 RESULTS: Acute blood styrene concentration was the strongest predictor of serum PRL concentration, with the model predicting a 2.06-fold increase in PRL (95% CI 1.11 to 3.84) for every 10-fold increase in blood styrene. Styrene 21-28 prolactin Homo sapiens 149-152 15031390-6 2004 RESULTS: Acute blood styrene concentration was the strongest predictor of serum PRL concentration, with the model predicting a 2.06-fold increase in PRL (95% CI 1.11 to 3.84) for every 10-fold increase in blood styrene. Styrene 211-218 prolactin Homo sapiens 149-152 15031390-7 2004 Serum PRL tended to increase with increasing styrene exposure in both men and women; however, women tended to have higher PRL levels. Styrene 45-52 prolactin Homo sapiens 6-9 15146102-6 2004 The prolactin level decreased in the raloxifene group but not in the CCEP group (-17.0%; p < 0.001 vs +13.3%, p = no significance; NS). Raloxifene Hydrochloride 37-47 prolactin Homo sapiens 4-13 15146102-7 2004 Consequently, long-term administration of raloxifene up to 1 yr decreases serum prolactin level significantly and may be a therapeutic alternative for postmenopausal osteoporotic women with hyperprolactinemia. Raloxifene Hydrochloride 42-52 prolactin Homo sapiens 80-89 15001366-6 2004 RESULTS: Microbiological evaluation of amniotic fluid PPROM revealed aerobic, anaerobic or mixed aerobic anaerobic infections PPROM was associated with significant elevation of both fetal serum and amniotic fluid prolactin concentrations, increased amniotic fluid osmolality, sodium, chlorides and calcium. Sodium 276-282 prolactin Homo sapiens 213-222 15013031-7 2004 RESULTS: Pindolol significantly antagonized ACTH, PRL, GH and temperature responses to flesinoxan and ritanserin exhibited similar activity on PRL and ACTH responses. Pindolol 9-17 prolactin Homo sapiens 50-53 15013031-8 2004 CONCLUSIONS: These results show the role of 5-HT1A mechanisms in the PRL, ACTH, GH, and temperature responses to flesinoxan, and the role of 5-HT2 mechanisms in PRL and ACTH responses. flesinoxan 113-123 prolactin Homo sapiens 69-72 15013031-2 2004 In a recent study, in normal volunteers, flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature. flesinoxan 41-51 prolactin Homo sapiens 151-160 15013031-2 2004 In a recent study, in normal volunteers, flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature. flesinoxan 41-51 prolactin Homo sapiens 162-165 15001366-6 2004 RESULTS: Microbiological evaluation of amniotic fluid PPROM revealed aerobic, anaerobic or mixed aerobic anaerobic infections PPROM was associated with significant elevation of both fetal serum and amniotic fluid prolactin concentrations, increased amniotic fluid osmolality, sodium, chlorides and calcium. Chlorides 284-293 prolactin Homo sapiens 213-222 15001366-6 2004 RESULTS: Microbiological evaluation of amniotic fluid PPROM revealed aerobic, anaerobic or mixed aerobic anaerobic infections PPROM was associated with significant elevation of both fetal serum and amniotic fluid prolactin concentrations, increased amniotic fluid osmolality, sodium, chlorides and calcium. Calcium 298-305 prolactin Homo sapiens 213-222 14586031-5 2004 This current depended on PRL-induced Ca(2+) mobilization, through a JAK2-dependent pathway from a thapsigargin- and 2-APB-sensitive Ca(2+) pool. Thapsigargin 98-110 prolactin Homo sapiens 25-28 15012589-2 2004 Photoperiodic regulation of prolactin secretion is believed to occur via melatonin-mediated changes in the secretion of a putative prolactin secretagogue, tuberalin, from the pituitary pars tuberalis. Melatonin 73-82 prolactin Homo sapiens 28-37 15012589-2 2004 Photoperiodic regulation of prolactin secretion is believed to occur via melatonin-mediated changes in the secretion of a putative prolactin secretagogue, tuberalin, from the pituitary pars tuberalis. Melatonin 73-82 prolactin Homo sapiens 131-140 14586031-5 2004 This current depended on PRL-induced Ca(2+) mobilization, through a JAK2-dependent pathway from a thapsigargin- and 2-APB-sensitive Ca(2+) pool. 2-aminoethoxydiphenyl borate 116-121 prolactin Homo sapiens 25-28 14586031-6 2004 Second, PRL also activated an inwardly directed current, mainly due to the stimulation of calcium influx via nickel- and 2-APB-sensitive calcium channels. Calcium 90-97 prolactin Homo sapiens 8-11 14586031-6 2004 Second, PRL also activated an inwardly directed current, mainly due to the stimulation of calcium influx via nickel- and 2-APB-sensitive calcium channels. Nickel 109-115 prolactin Homo sapiens 8-11 14586031-10 2004 Finally, PRL also activated a DIDS-sensitive Cl(-) current, which may participate in the PRL-induced hyperpolarization. 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid 30-34 prolactin Homo sapiens 9-12 14586031-10 2004 Finally, PRL also activated a DIDS-sensitive Cl(-) current, which may participate in the PRL-induced hyperpolarization. 4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid 30-34 prolactin Homo sapiens 89-92 14764772-6 2004 After 6 months of cabergoline treatment, prolactin levels normalized in 74.5% of patients: 73.2% of macroprolactinomas and 80% of microprolactinomas. Cabergoline 18-29 prolactin Homo sapiens 41-50 15230214-8 2004 After bromocriptine therapy, when PRL levels diminished until 189, 78.3 and 110 ng/ml, the erectile dysfunction disappeared. Bromocriptine 6-19 prolactin Homo sapiens 34-37 15107193-6 2004 Sulpiride caused an increase in prolactin (643 U/ml) [confidence interval (CI) 549-737). Sulpiride 0-9 prolactin Homo sapiens 32-41 14565846-7 2004 This single-channel activity increase was reduced by the tyrosine kinase inhibitors genistein, herbimycin A and lavandustine A, thereby indicating that tyrosine kinase phosphorylation is required in PRL-induced K(+) channel stimulation. Genistein 84-93 prolactin Homo sapiens 199-202 14565846-7 2004 This single-channel activity increase was reduced by the tyrosine kinase inhibitors genistein, herbimycin A and lavandustine A, thereby indicating that tyrosine kinase phosphorylation is required in PRL-induced K(+) channel stimulation. herbimycin 95-107 prolactin Homo sapiens 199-202 14565846-7 2004 This single-channel activity increase was reduced by the tyrosine kinase inhibitors genistein, herbimycin A and lavandustine A, thereby indicating that tyrosine kinase phosphorylation is required in PRL-induced K(+) channel stimulation. lavandustine a 112-126 prolactin Homo sapiens 199-202 14565846-10 2004 Furthermore, the PRL-stimulated proliferation is inhibited by the K(+) channel inhibitors alpha-dendrotoxin and tetraethylammonium. Tetraethylammonium 112-130 prolactin Homo sapiens 17-20 14960274-3 2004 Here we show that mammary glands stimulated by prolactin (PRL) express genes essential for serotonin biosynthesis (tryptophan hydroxylase [TPH] and aromatic amine decarboxylase). Serotonin 91-100 prolactin Homo sapiens 58-61 15003071-7 2004 RESULTS: After cabergoline treatment, the mean decrease in plasma prolactin levels was statistically significant (p <.05) for the total sample, and 11 patients showed remission of clinical signs with prolactin values within the normal range. Cabergoline 15-26 prolactin Homo sapiens 66-75 15003071-7 2004 RESULTS: After cabergoline treatment, the mean decrease in plasma prolactin levels was statistically significant (p <.05) for the total sample, and 11 patients showed remission of clinical signs with prolactin values within the normal range. Cabergoline 15-26 prolactin Homo sapiens 203-212 15004429-0 2004 Genistein, a phytoestrogen, effectively modulates luteinizing hormone and prolactin secretion in ovariectomized ewes during seasonal anestrus. Genistein 0-9 prolactin Homo sapiens 74-83 15004429-3 2004 The hypothesis studied was that genistein, infused for several hours into the third ventricle, could immediately affect LH and PRL secretion in ovariectomized (OVX) ewes during seasonal anestrus. Genistein 32-41 prolactin Homo sapiens 127-130 15004429-13 2004 Because the changes in PRL secretion were more dynamic in response to genistein infusion, the statistical analysis included 2-hour periods. Genistein 70-79 prolactin Homo sapiens 23-26 15004429-17 2004 In contrast, significant (p < 0.01 to p < 0.001) increases in PRL concentration were noted regularly during and shortly after the genistein infusion in either low-dose or high-dose genistein-infused ewes, compared with the concentrations noted before genistein treatment. Genistein 136-145 prolactin Homo sapiens 68-71 15004429-17 2004 In contrast, significant (p < 0.01 to p < 0.001) increases in PRL concentration were noted regularly during and shortly after the genistein infusion in either low-dose or high-dose genistein-infused ewes, compared with the concentrations noted before genistein treatment. Genistein 187-196 prolactin Homo sapiens 68-71 15004429-17 2004 In contrast, significant (p < 0.01 to p < 0.001) increases in PRL concentration were noted regularly during and shortly after the genistein infusion in either low-dose or high-dose genistein-infused ewes, compared with the concentrations noted before genistein treatment. Genistein 187-196 prolactin Homo sapiens 68-71 15004429-18 2004 Plasma PRL concentrations during and after genistein infusion in both experimental groups were also significantly higher than the control (p < 0.01 to p < 0.001). Genistein 43-52 prolactin Homo sapiens 7-10 15004429-19 2004 The presented data demonstrate that genistein, a phytoestrogen, may effectively modulate LH and PRL secretion in OVX ewes by acting within the CNS. Genistein 36-45 prolactin Homo sapiens 96-99 14715860-5 2004 Central serotonergic responsivity was indexed as the prolactin (PRL) response evoked by the serotonin-releasing agent, fenfluramine. Fenfluramine 119-131 prolactin Homo sapiens 53-62 14604600-0 2004 Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects. Reboxetine 0-10 prolactin Homo sapiens 65-74 14604600-1 2004 In this single-blind study the effects of acute oral administration of the selective noradrenaline reuptake inhibitor reboxetine on the cortisol (COR), ACTH, growth hormone (GH) and prolactin (PRL) secretion were examined in 12 healthy male volunteers. Reboxetine 118-128 prolactin Homo sapiens 182-191 14604600-1 2004 In this single-blind study the effects of acute oral administration of the selective noradrenaline reuptake inhibitor reboxetine on the cortisol (COR), ACTH, growth hormone (GH) and prolactin (PRL) secretion were examined in 12 healthy male volunteers. Reboxetine 118-128 prolactin Homo sapiens 193-196 15554747-11 2004 Other atypical antipsychotics, namely olanzapine and ziprasidone, have been reported to be prolactin sparing in adults, but may not be completely devoid of hyperprolactinaemic effects in children and adolescents. Olanzapine 38-48 prolactin Homo sapiens 91-100 15554747-11 2004 Other atypical antipsychotics, namely olanzapine and ziprasidone, have been reported to be prolactin sparing in adults, but may not be completely devoid of hyperprolactinaemic effects in children and adolescents. ziprasidone 53-64 prolactin Homo sapiens 91-100 14648180-0 2004 A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptin in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Bromocriptine 78-90 prolactin Homo sapiens 166-175 14648180-4 2004 PATIENTS: One hundred polycystic ovary patients and normal prolactin (PRL) who were clomiphene citrate resistant. Clomiphene 84-102 prolactin Homo sapiens 59-68 14648180-10 2004 After 3 and 6 months of treatment with bromocriptin, there was a significant decrease in serum level of prolactin ( P=0.000001). Bromocriptine 39-51 prolactin Homo sapiens 104-113 14648180-12 2004 CONCLUSIONS: The only significant effect of long-term bromocriptin therapy in clomiphene citrate resistant polycystic ovary women was to lower the serum prolactin concentration. Bromocriptine 54-66 prolactin Homo sapiens 153-162 14648180-12 2004 CONCLUSIONS: The only significant effect of long-term bromocriptin therapy in clomiphene citrate resistant polycystic ovary women was to lower the serum prolactin concentration. Clomiphene 78-96 prolactin Homo sapiens 153-162 15006013-2 2004 Prolactin secretion is promoted by various physiological stimuli and pathological processes and is inhibited by the action of dopamine on the lactotroph cells of the hypothalamus. Dopamine 126-134 prolactin Homo sapiens 0-9 15239558-12 2004 Pharmacologic treatment with bromocriptine (2.5 - 7.5 mg) prevailed and showed a major impact upon symptoms improvement and significant decrease of serum prolactin levels (p < 0.05). Bromocriptine 29-42 prolactin Homo sapiens 154-163 15239558-18 2004 Treatment with dopaminergic agonists (bromocriptine) was highly effective to decrease prolactin circulating levels. Bromocriptine 38-51 prolactin Homo sapiens 86-95 14744169-0 2004 Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Clozapine 85-94 prolactin Homo sapiens 0-9 14744169-0 2004 Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Olanzapine 96-106 prolactin Homo sapiens 0-9 14744169-0 2004 Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Risperidone 108-119 prolactin Homo sapiens 0-9 14744169-0 2004 Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. Haloperidol 124-135 prolactin Homo sapiens 0-9 14744169-10 2004 Clozapine and olanzapine were associated with decreases of prolactin, whereas haloperidol led to a minor, nonsignificant increase. Olanzapine 14-24 prolactin Homo sapiens 59-68 14744169-13 2004 CONCLUSION: Antipsychotics show major differences in their effects on prolactin, and risperidone has clearly the most robust effect. Risperidone 85-96 prolactin Homo sapiens 70-79 14870917-1 2004 Prolactin (PRL) secretion by the pituitary is under the control of dopamine. Dopamine 67-75 prolactin Homo sapiens 0-9 15104523-6 2004 All conventional and some atypical antipsychotics (e.g., risperidone) increase serum prolactin levels. Risperidone 57-68 prolactin Homo sapiens 85-94 14744169-9 2004 RESULTS: Risperidone caused significant elevation of prolactin levels (p <.05) that appeared to be dose-dependent. Risperidone 9-20 prolactin Homo sapiens 53-62 14744169-10 2004 Clozapine and olanzapine were associated with decreases of prolactin, whereas haloperidol led to a minor, nonsignificant increase. Clozapine 0-9 prolactin Homo sapiens 59-68 14870917-1 2004 Prolactin (PRL) secretion by the pituitary is under the control of dopamine. Dopamine 67-75 prolactin Homo sapiens 11-14 14870917-7 2004 The serum BIO-PRL response after metoclopramide was higher than RIA-PRL in SLE, and this increment was also greater than in control subjects. Metoclopramide 33-47 prolactin Homo sapiens 14-17 14870917-9 2004 After metoclopramide, secretion and production of PRL increased only in PBMNC from control women and not in those from SLE patients. Metoclopramide 6-20 prolactin Homo sapiens 50-53 15067204-7 2004 Domperidone administration resulted in a significant increase in prolactin (PRL) concentrations. Domperidone 0-11 prolactin Homo sapiens 65-74 14755134-0 2004 Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Mirtazapine 0-11 prolactin Homo sapiens 93-102 14575729-1 2004 OBJECTIVE: To investigate the relationship between sex hormones (estradiol, testosterone, androstendione, DHEA-S) and prolactin on one hand and musculo-skeletal pain and psychological distress on the other during the menopausal transition. Estradiol 65-74 prolactin Homo sapiens 118-127 14755134-0 2004 Mirtazapine decreases stimulatory effects of reboxetine on cortisol, adrenocorticotropin and prolactin secretion in healthy male subjects. Reboxetine 45-55 prolactin Homo sapiens 93-102 14755134-10 2004 When reboxetine was given in combination with mirtazapine, a significant reduction of the COR, ACTH, and PRL stimulation was observed whereas GH secretion patterns remained unchanged, compared to single administration of reboxetine. Reboxetine 5-15 prolactin Homo sapiens 105-108 14755134-10 2004 When reboxetine was given in combination with mirtazapine, a significant reduction of the COR, ACTH, and PRL stimulation was observed whereas GH secretion patterns remained unchanged, compared to single administration of reboxetine. Mirtazapine 46-57 prolactin Homo sapiens 105-108 14575729-1 2004 OBJECTIVE: To investigate the relationship between sex hormones (estradiol, testosterone, androstendione, DHEA-S) and prolactin on one hand and musculo-skeletal pain and psychological distress on the other during the menopausal transition. Testosterone 76-88 prolactin Homo sapiens 118-127 14575729-1 2004 OBJECTIVE: To investigate the relationship between sex hormones (estradiol, testosterone, androstendione, DHEA-S) and prolactin on one hand and musculo-skeletal pain and psychological distress on the other during the menopausal transition. Androstenedione 90-104 prolactin Homo sapiens 118-127 14645190-0 2003 Prolactin acts as a potent survival factor against C2-ceramide-induced apoptosis in human granulosa cells. N-acetylsphingosine 51-62 prolactin Homo sapiens 0-9 14750048-3 2004 The withdrawal of risperidone resulted in disappearance of prolactinoma though her prolactin level remained elevated along with persistent galactorrhea. Risperidone 18-29 prolactin Homo sapiens 59-68 14750048-5 2004 Ultimately, only adding of bromocriptine resulted in disappearance of symptoms of prolactinemia and normal serum prolactin level was achieved and galactorrhea stopped. Bromocriptine 27-40 prolactin Homo sapiens 82-91 14645190-8 2003 On co- incubation, prolactin alone had no effect on cell death, whereas C2-ceramide induced an approximately 62.6% increase in apoptosis, which was inhibited in the presence of prolactin. N-acetylsphingosine 72-83 prolactin Homo sapiens 177-186 14676445-6 2003 Multiple regression analysis showed that VAS anxiety, preoperative baseline prolactin level, and cortisol level had statistically significant effects on the propofol induction dose for target controlled conscious sedation. Propofol 157-165 prolactin Homo sapiens 76-85 14624190-6 2003 Prolactin levels decreased among those switched from risperidone (P < 0.0001) or conventionals (P = 0.05), but not for patients switched from olanzapine. Risperidone 53-64 prolactin Homo sapiens 0-9 14624190-8 2003 Thus, in these studies, switching to ziprasidone in patients with continuing symptoms or side effects on their current medication was often associated with improved health status indices, lowered prolactin levels, or less EPS, with the magnitude benefit consistent with the known side-effect profile of the preswitch antipsychotic. ziprasidone 37-48 prolactin Homo sapiens 196-205 14676445-7 2003 We concluded that the induction dose and time requirements for propofol in anesthesiologist-controlled conscious sedation be modified based on the preoperative anxiety level and the baseline blood concentration of stress hormone, cortisol and prolactin. Propofol 63-71 prolactin Homo sapiens 243-252 14627787-9 2003 CONCLUSIONS: Cabergoline can be safely withdrawn in patients with normalized prolactin levels and no evidence of tumor. Cabergoline 13-24 prolactin Homo sapiens 77-86 14656205-9 2003 Administration of cabergoline decreased prolactin levels and significantly enhanced all parameters of sexual drive (P<0.05), function (P<0.01) and positive perception of the refractory period (P<0.01). Cabergoline 18-29 prolactin Homo sapiens 40-49 14616880-0 2003 The TSH response to domperidone reflects the biological activity of prolactin in macroprolactinaemia and hyperprolactinaemia. Domperidone 20-31 prolactin Homo sapiens 68-77 14616880-2 2003 DESIGN: Comparison of the TSH and PRL responses to dopamine antagonism with domperidone (10 mg i.v.) Dopamine 51-59 prolactin Homo sapiens 34-37 14616880-2 2003 DESIGN: Comparison of the TSH and PRL responses to dopamine antagonism with domperidone (10 mg i.v.) Domperidone 76-87 prolactin Homo sapiens 34-37 14616880-6 2003 RESULTS: Patients with macroprolactinaemia showed normal TSH and PRL responses to dopamine antagonism whereas patients with microprolactinomas showed exaggerated TSH responses and reduced PRL responses. Dopamine 82-90 prolactin Homo sapiens 65-68 14511790-3 2003 In contrast, mean plasma prolactin concentration decreased significantly after the start of bromocriptine treatment in the 20- and 50-groups. Bromocriptine 92-105 prolactin Homo sapiens 25-34 14602793-7 2003 In NW, ghrelin increased (P < 0.05) GH, prolactin (PRL), ACTH, cortisol, and glucose levels but did not modify insulin. Ghrelin 7-14 prolactin Homo sapiens 43-52 14658952-0 2003 Prolactin levels during long-term risperidone treatment in children and adolescents. Risperidone 34-45 prolactin Homo sapiens 0-9 14658952-1 2003 BACKGROUND: This analysis was designed to investigate prolactin levels in children and adolescents on long-term risperidone treatment and explore any relationship with side effects hypothetically attributable to prolactin (SHAP). Risperidone 112-123 prolactin Homo sapiens 54-63 14658952-10 2003 CONCLUSION: With long-term risperidone treatment in children and adolescents, serum prolactin levels tended to rise and peak within the first 1 to 2 months and then steadily decline to values within or very close to the normal range by 3 to 5 months. Risperidone 27-38 prolactin Homo sapiens 84-93 12907754-6 2003 Expression of Fak mutant Y397F abrogated PRL-dependent activation of Fak, Erk1/2, and thymidine incorporation, but had no effect on p70S6K and Akt kinases. Thymidine 86-95 prolactin Homo sapiens 41-44 12907754-7 2003 MAPK kinase 1/2 (Mek1/2) inhibitor PD184352 blocked PRL-induced stimulation of Erk1/2 and cell proliferation; however, p70S6K and Akt activation were unaffected. 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide 35-43 prolactin Homo sapiens 52-55 14658967-1 2003 BACKGROUND: This study evaluates whether high-dose olanzapine is associated with elevation of serum prolactin levels. Olanzapine 51-61 prolactin Homo sapiens 100-109 14533141-0 2003 Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects. Pindolol 10-18 prolactin Homo sapiens 76-85 14533141-0 2003 Effect of pindolol and milnacipran versus milnacipran and placebo on plasma prolactin and adrenocorticotrophic hormone in depressed subjects. Milnacipran 23-34 prolactin Homo sapiens 76-85 14533141-2 2003 The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo. Milnacipran 120-131 prolactin Homo sapiens 59-68 14533141-2 2003 The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo. Milnacipran 120-131 prolactin Homo sapiens 70-73 14533141-2 2003 The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo. Pindolol 136-144 prolactin Homo sapiens 59-68 14533141-2 2003 The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo. Pindolol 136-144 prolactin Homo sapiens 70-73 14533141-2 2003 The present study analyses the relationship between plasma prolactin (PRL) and ACTH levels and changes in relation to a milnacipran and pindolol combination versus milnacipran plus placebo. Milnacipran 164-175 prolactin Homo sapiens 59-68 12885788-2 2003 FEN-evoked increases in PRL levels inversely correlate with arterial blood pressure (ABP) in humans (Muldoon et al. Fenfluramine 0-3 prolactin Homo sapiens 24-27 14562140-2 2003 It is generally believed that the mechanism of the prolactin (PRL)-induced sexual dysfunctions is a decrease in testosterone secretion. Testosterone 112-124 prolactin Homo sapiens 51-60 14562140-2 2003 It is generally believed that the mechanism of the prolactin (PRL)-induced sexual dysfunctions is a decrease in testosterone secretion. Testosterone 112-124 prolactin Homo sapiens 62-65 14562140-9 2003 Dopamine-agonist therapy is the first choice treatment for the PRL-induced sexual dysfunctions. Dopamine 0-8 prolactin Homo sapiens 63-66 14658967-2 2003 METHOD: Twenty-four patients taking daily doses of olanzapine of 20, 25, 30, and 40 mg for DSM-IV schizophrenia or schizoaffective disorder had serum prolactin levels measured. Olanzapine 51-61 prolactin Homo sapiens 150-159 14658967-10 2003 Thus, preliminary evidence suggests that using higher doses of olanzapine is generally safe with regard to prolactin levels. Olanzapine 63-73 prolactin Homo sapiens 107-116 12950692-1 2003 The aim of this study was to compare the effects of treatment with repeated injections of sulpiride (a dopamine D2 antagonist) on prolactin secretion and induced lactation in ovariectomized and intact adult mares and to verify if this induction was possible at the beginning and at the end of the birth season. Sulpiride 90-99 prolactin Homo sapiens 130-139 12902212-6 2003 In this observational study, risperidone enhanced serum prolactin in 65% of patients. Risperidone 29-40 prolactin Homo sapiens 56-65 12893845-13 2003 After high nicotine cigarette smoking, prolactin increased to hyperpro-lactinemic levels within 6 min and remained significantly above baseline levels for 42 min (P < 0.05-0.03). Nicotine 11-19 prolactin Homo sapiens 39-48 14598712-5 2003 The retinal conditions of the PRL were classified using color fundus photographs and fluorescein angiography. Fluorescein 85-96 prolactin Homo sapiens 30-33 12950692-10 2003 Prolactin increase after sulpiride treatment was not so great in the ovariectomized-treated mares as in the intact-treated mares. Sulpiride 25-34 prolactin Homo sapiens 0-9 12928232-8 2003 For macroprolactinemic samples, PEG treatment decreased mean (SD) prolactin from 1524 (202) mIU/L to 202 (27) mIU/L but decreased it only from 2096 (233) mIU/L to 1705 (190) mIU/L in true hyperprolactinemic patients (P <0.01 between groups). Polyethylene Glycols 32-35 prolactin Homo sapiens 9-18 14611708-1 2003 This study investigated the effect of levothyroxine treatment on serum prolactin (PRL) levels in women with subclinical hypothyroidism. Thyroxine 38-51 prolactin Homo sapiens 71-80 14611708-1 2003 This study investigated the effect of levothyroxine treatment on serum prolactin (PRL) levels in women with subclinical hypothyroidism. Thyroxine 38-51 prolactin Homo sapiens 82-85 14611708-8 2003 In the levothyroxine group (n = 31) basal and peak PRL levels were significantly reduced after 24 and 48 weeks (p = 0.03 and p = 0.001). Thyroxine 7-20 prolactin Homo sapiens 51-54 14611708-11 2003 Based on this double-blinded, placebo-controlled study we demonstrate that in subclinical hypothyroidism PRL regulation is altered with elevated basal and stimulated PRL levels, and that physiologic levothyroxine treatment restores PRL concentrations. Thyroxine 199-212 prolactin Homo sapiens 166-169 14611708-11 2003 Based on this double-blinded, placebo-controlled study we demonstrate that in subclinical hypothyroidism PRL regulation is altered with elevated basal and stimulated PRL levels, and that physiologic levothyroxine treatment restores PRL concentrations. Thyroxine 199-212 prolactin Homo sapiens 166-169 12928232-13 2003 The use of an appropriate reference interval for the PEG immunoprecipitation procedure may be of particular importance in those patients who have an excess of both macroprolactin and monomeric prolactin. Polyethylene Glycols 53-56 prolactin Homo sapiens 169-178 15985953-2 2003 The novel antipsychotic, risperidone, has also been shown to elevate prolactin levels. Risperidone 25-36 prolactin Homo sapiens 69-78 12915764-1 2003 The aim of this study was to investigate whether prolactin, melatonin and cortisol are altered in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated monkeys and if so, whether MPTP may alter the availability of these hormones in chronic experimental parkinsonism. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 144-148 prolactin Homo sapiens 49-58 14567882-5 2003 Prolonged exposure to progesterone induces a rounded cell characterized by release of prolactin and insulin-like growth factor binding protein-1 (IGFBP-1), and expression of tissue factor. Progesterone 22-34 prolactin Homo sapiens 86-95 14659314-2 2003 Women undergoing chemotherapy for breast cancer are often administered dopamine antagonist adjuvant medications that may increase levels of prolactin potentially increasing the risk of cancer. Dopamine 71-79 prolactin Homo sapiens 140-149 12874491-10 2003 CONCLUSIONS: Ziprasidone acutely blocks dopamine transmission, as indicated by increased prolactin levels, and, in a delayed fashion, appears to stimulate dopaminergic transmission, as indicated by the increase in spontaneous eye blinks. ziprasidone 13-24 prolactin Homo sapiens 89-98 12943941-0 2003 Growth hormone and prolactin response to apomorphine in bipolar and unipolar depression. Apomorphine 41-52 prolactin Homo sapiens 19-28 12943941-2 2003 This was investigated by measuring growth hormone (GH) or prolactin (PRL) response to apomorphine (APO), a dopamine receptor agonist, in patients with bipolar depression, unipolar depression and control subjects. Apomorphine 86-97 prolactin Homo sapiens 58-67 12943959-0 2003 Blunted prolactin response to D-fenfluramine in post-stroke major depression. Dexfenfluramine 30-44 prolactin Homo sapiens 8-17 12943959-7 2003 CONCLUSIONS: Patients suffering from major depression in the post-stroke period have a blunted prolactin response to D-fenfluramine. Dexfenfluramine 117-131 prolactin Homo sapiens 95-104 12915764-8 2003 Both MPTP-treated monkeys and the control group displayed a similar secretion pattern for the three hormones, except at several specific times when prolactin and melatonin showed significant differences. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 5-9 prolactin Homo sapiens 148-157 12728300-0 2003 Elevated prolactin responses to L-tryptophan infusion in medication-free depressed patients. Tryptophan 32-44 prolactin Homo sapiens 9-18 12728300-7 2003 The prolactin response to l-tryptophan was significantly greater in MDD patients than in healthy controls (P=0.008). Tryptophan 26-38 prolactin Homo sapiens 4-13 12728300-11 2003 The greater prolactin response to l-tryptophan infusion in depressed subjects may be the result of an increase in dopamine receptor sensitivity, secondary to reduced dopamine levels. Tryptophan 34-46 prolactin Homo sapiens 12-21 12728300-11 2003 The greater prolactin response to l-tryptophan infusion in depressed subjects may be the result of an increase in dopamine receptor sensitivity, secondary to reduced dopamine levels. Dopamine 114-122 prolactin Homo sapiens 12-21 12914892-4 2003 Central 5-HT function was assessed by measuring the prolactin response to a 1 mg/kg oral dose of d,l-fenfluramine. d,l-fenfluramine 97-113 prolactin Homo sapiens 52-61 12810546-0 2003 Nitric oxide inhibits prolactin secretion in pituitary cells downstream of voltage-gated calcium influx. Nitric Oxide 0-12 prolactin Homo sapiens 22-31 12914892-5 2003 Aggressive children with low-prolactin responses to fenfluramine had a significantly greater incidence of first- and second-degree relatives with aggressive and antisocial characteristics compared to both non-aggressive children and aggressive children with high-prolactin responses. Fenfluramine 52-64 prolactin Homo sapiens 29-38 17003021-8 2003 Upon bromocriptine discontinuation, PRL levels increased to 13.8 nmol/l. Bromocriptine 5-18 prolactin Homo sapiens 36-39 12831762-6 2003 Tilapia ghrelin stimulated growth hormone (GH) and prolactin (PRL) release from the organ-cultured tilapia pituitary at a dose of 10 nM. Ghrelin 8-15 prolactin Homo sapiens 62-65 12831762-8 2003 Stimulation of PRL release by homologous ghrelin has been reported in human, bullfrog and eel, and suggests the presence of growth hormone secretagogue receptor not only on somatotrophs but also on PRL cells of the tilapia pituitary. Ghrelin 41-48 prolactin Homo sapiens 15-18 12810546-0 2003 Nitric oxide inhibits prolactin secretion in pituitary cells downstream of voltage-gated calcium influx. Calcium 89-96 prolactin Homo sapiens 22-31 12810546-1 2003 The coupling between nitric oxide (NO)-cGMP signaling pathway and prolactin (PRL) release in pituitary lactotrophs has been established previously. Nitric Oxide 21-33 prolactin Homo sapiens 66-75 12810546-1 2003 The coupling between nitric oxide (NO)-cGMP signaling pathway and prolactin (PRL) release in pituitary lactotrophs has been established previously. Nitric Oxide 21-33 prolactin Homo sapiens 77-80 12810546-1 2003 The coupling between nitric oxide (NO)-cGMP signaling pathway and prolactin (PRL) release in pituitary lactotrophs has been established previously. Cyclic GMP 39-43 prolactin Homo sapiens 66-75 12810546-1 2003 The coupling between nitric oxide (NO)-cGMP signaling pathway and prolactin (PRL) release in pituitary lactotrophs has been established previously. Cyclic GMP 39-43 prolactin Homo sapiens 77-80 12810546-3 2003 In cultured pituitary cells, basal PRL release was controlled by spontaneous voltage-gated calcium influx and was further enhanced by depolarization of cells and stimulation with TRH. Calcium 91-98 prolactin Homo sapiens 35-38 12810546-10 2003 These experiments indicate that NO inhibits calcium-dependent PRL secretion in a cGMP-independent manner and downstream of voltage-gated calcium influx. Calcium 44-51 prolactin Homo sapiens 62-65 12810546-10 2003 These experiments indicate that NO inhibits calcium-dependent PRL secretion in a cGMP-independent manner and downstream of voltage-gated calcium influx. Cyclic GMP 81-85 prolactin Homo sapiens 62-65 12810546-10 2003 These experiments indicate that NO inhibits calcium-dependent PRL secretion in a cGMP-independent manner and downstream of voltage-gated calcium influx. Calcium 137-144 prolactin Homo sapiens 62-65 12934975-7 2003 RESULTS: Serum prolactin levels were higher in the risperidone-treated group as compared with the olanzapine subjects (123 +/- 144 and 25.9 +/- 25.7, p <.05). Risperidone 51-62 prolactin Homo sapiens 15-24 12781656-6 2003 The result was that prolactin levels decreased significantly in WS with respect to CS when compared with pre-test levels (WS: -22.7%; P<0.05). H-TRP-SER-OH 64-66 prolactin Homo sapiens 20-29 12854820-2 2003 The goal of the present study was to determine the effect of inhibiting prolactin with bromocriptine during specific time windows during the second half of gestation on mammary gland development in gilts. Bromocriptine 87-100 prolactin Homo sapiens 72-81 12854820-8 2003 Concentrations of prolactin were decreased markedly (P < 0.001) at the end of each bromocriptine treatment period compared with controls, but there was no overall treatment effect (P > 0.1) on estradiol concentrations. Bromocriptine 86-99 prolactin Homo sapiens 18-27 12781656-6 2003 The result was that prolactin levels decreased significantly in WS with respect to CS when compared with pre-test levels (WS: -22.7%; P<0.05). Cesium 83-85 prolactin Homo sapiens 20-29 12824819-0 2003 Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland. Ethanol 0-7 prolactin Homo sapiens 144-153 12782310-0 2003 Cytokine induction of prolactin receptors mediates prolactin inhibition of nitric oxide synthesis in pulmonary fibroblasts. Nitric Oxide 75-87 prolactin Homo sapiens 22-31 12782310-0 2003 Cytokine induction of prolactin receptors mediates prolactin inhibition of nitric oxide synthesis in pulmonary fibroblasts. Nitric Oxide 75-87 prolactin Homo sapiens 51-60 12824819-0 2003 Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland. Estradiol 12-21 prolactin Homo sapiens 144-153 12824819-0 2003 Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland. Bromocriptine 127-140 prolactin Homo sapiens 144-153 12824819-2 2003 Previously we have shown that ethanol increases PRL release both in vivo and in vitro. Ethanol 30-37 prolactin Homo sapiens 48-51 12824819-3 2003 How ethanol increases PRL release is not well understood. Ethanol 4-11 prolactin Homo sapiens 22-25 12824819-6 2003 RESULTS: Estradiol and ethanol alone increased PRL mRNA expression in the pituitary gland. Ethanol 23-30 prolactin Homo sapiens 47-50 12824819-7 2003 Ethanol also potentiated estradiol action on PRL mRNA expression in the pituitary. Ethanol 0-7 prolactin Homo sapiens 45-48 12824819-11 2003 Evaluation of bromocriptine"s inhibition of PRL release in primary cultures of pituitary cells indicated that ethanol reduced the ability of this D2 receptor agonist to inhibit PRL release. Bromocriptine 14-27 prolactin Homo sapiens 44-47 12763633-1 2003 Physiologic control of prolactin (PRL) secretion is largely dependent upon levels of dopamine accessing the adenohypophysis via the hypophysial portal vessels. Dopamine 85-93 prolactin Homo sapiens 23-32 12763633-1 2003 Physiologic control of prolactin (PRL) secretion is largely dependent upon levels of dopamine accessing the adenohypophysis via the hypophysial portal vessels. Dopamine 85-93 prolactin Homo sapiens 34-37 12824819-11 2003 Evaluation of bromocriptine"s inhibition of PRL release in primary cultures of pituitary cells indicated that ethanol reduced the ability of this D2 receptor agonist to inhibit PRL release. Bromocriptine 14-27 prolactin Homo sapiens 177-180 12824819-11 2003 Evaluation of bromocriptine"s inhibition of PRL release in primary cultures of pituitary cells indicated that ethanol reduced the ability of this D2 receptor agonist to inhibit PRL release. Ethanol 110-117 prolactin Homo sapiens 44-47 12824819-11 2003 Evaluation of bromocriptine"s inhibition of PRL release in primary cultures of pituitary cells indicated that ethanol reduced the ability of this D2 receptor agonist to inhibit PRL release. Ethanol 110-117 prolactin Homo sapiens 177-180 12824819-12 2003 CONCLUSIONS: These results confirm estradiol"s inhibition of D2 function and provide novel evidence that ethanol, like estradiol, reduces dopamine"s ability to inhibit PRL release by modifying alternative splicing of the dopamine D2 receptor in the pituitary. Ethanol 105-112 prolactin Homo sapiens 168-171 12824819-12 2003 CONCLUSIONS: These results confirm estradiol"s inhibition of D2 function and provide novel evidence that ethanol, like estradiol, reduces dopamine"s ability to inhibit PRL release by modifying alternative splicing of the dopamine D2 receptor in the pituitary. Dopamine 138-146 prolactin Homo sapiens 168-171 12890303-5 2003 Risperidone was the antipsychotic employed and elevation of prolactin concentrations were noted each time. Risperidone 0-11 prolactin Homo sapiens 60-69 12890303-7 2003 Rechallenge with risperidone resulted in re-elevation of prolactin levels along with recurrent delusions. Risperidone 17-28 prolactin Homo sapiens 57-66 12890303-8 2003 Substituting risperidone with another antipsychotic (either olanzapine or quetiapine) also led to abatement of the delusions and lowering of prolactin. Risperidone 13-24 prolactin Homo sapiens 141-150 12890303-8 2003 Substituting risperidone with another antipsychotic (either olanzapine or quetiapine) also led to abatement of the delusions and lowering of prolactin. Olanzapine 60-70 prolactin Homo sapiens 141-150 12890303-8 2003 Substituting risperidone with another antipsychotic (either olanzapine or quetiapine) also led to abatement of the delusions and lowering of prolactin. Quetiapine Fumarate 74-84 prolactin Homo sapiens 141-150 12729864-9 2003 Serum prolactin increased with haloperidol, but not aripiprazole. Haloperidol 31-42 prolactin Homo sapiens 6-15 12832945-3 2003 Available data comparing quetiapine with other atypical antipsychotics, while limited, suggest it is as efficacious as other atypical agents and has a favorable tolerability profile; in particular, the incidence of motor adverse effects and prolactin elevation is comparable to that of placebo across its entire dose range. Quetiapine Fumarate 25-35 prolactin Homo sapiens 241-250 12729864-10 2003 In conclusion, aripiprazole shows a favorable safety and tolerability profile with low potential for EPS, weight gain, prolactin elevation, QT(c) prolongation, and sedation. Aripiprazole 15-27 prolactin Homo sapiens 119-128 12729745-10 2003 The backbone dynamics of prolactin were investigated by analysis of 15N NMR relaxation phenomena and demonstrated a rigid four-helical bundle with relatively mobile interconnecting loops. 15n 68-71 prolactin Homo sapiens 25-34 12809367-9 2003 The search for the chemical identity of the dopaminergic compounds resulted in isolation of a number of diterpenes of which some clerodadienols were most important for the prolactin-suppressive effects. Diterpenes 104-114 prolactin Homo sapiens 172-181 12684699-1 2003 Normal human endometrial stromal cells (ESCs) stimulated with 8-Br-cAMP secrete significantly large amounts of PRL and granulocyte colony-stimulating factor (G-CSF), whereas unstimulated stromal cells secreted little. 8-Bromo Cyclic Adenosine Monophosphate 62-71 prolactin Homo sapiens 111-114 12684699-3 2003 Recently we found that macrophage colony-stimulating factor (M-CSF) inhibits 8-Br-cAMP-induced decidualization, differentiation to prolactin (PRL)-secreting cells, by suppressing viable decidualizing cells. 8-Bromo Cyclic Adenosine Monophosphate 77-86 prolactin Homo sapiens 142-145 12684699-6 2003 A high concentration of M-CSF strongly suppressed the viable cell numbers and PRL secretion of stromal cells co-stimulated with 8-Br-cAMP and M-CSF, although G-CSF release from the co-stimulated stromal cells was not affected by M-CSF. 8-Bromo Cyclic Adenosine Monophosphate 128-137 prolactin Homo sapiens 78-81 12966789-5 2003 The application of a dopamine agonist lead to a reduction of serum prolactin level to 0.5% of the initial value and a considerable tumor regression within three months. Dopamine 21-29 prolactin Homo sapiens 67-76 12828393-6 2003 Serum prolactin was associated with current exposure to "soluble inhalable manganese", duration of exposure, and smoking habits. Manganese 75-84 prolactin Homo sapiens 6-15 12828393-7 2003 The subjects with the longest duration of exposure to manganese or the highest current exposure to "soluble inhalable manganese" had a statistically significantly higher serum prolactin concentration than the referents. Manganese 54-63 prolactin Homo sapiens 176-185 12828393-7 2003 The subjects with the longest duration of exposure to manganese or the highest current exposure to "soluble inhalable manganese" had a statistically significantly higher serum prolactin concentration than the referents. Manganese 118-127 prolactin Homo sapiens 176-185 12828393-10 2003 CONCLUSIONS: The study indicates that manganese exposure can increase the serum prolactin concentration. Manganese 38-47 prolactin Homo sapiens 80-89 12621061-5 2003 These conformational differences may in part be due to differential effects of Prl and Src on Stat5b tyrosine phosphorylation, since Src induced several additional sites of tyrosine phosphorylation of Stat5b at residues other than Tyr-699, including Tyr-724 and Tyr-679. Tyrosine 101-109 prolactin Homo sapiens 79-82 12713511-0 2003 Growth hormone and prolactin responses during partial and whole body warm-water immersions. Water 74-79 prolactin Homo sapiens 19-28 12699451-2 2003 Cabergoline (CAB), a long-lasting dopamine agonist (DA), safe and well tolerated, is effective in normalizing PRL levels and inducing tumour shrinkage in micro- and macroprolactinomas. Cabergoline 0-11 prolactin Homo sapiens 110-113 12699451-2 2003 Cabergoline (CAB), a long-lasting dopamine agonist (DA), safe and well tolerated, is effective in normalizing PRL levels and inducing tumour shrinkage in micro- and macroprolactinomas. Cabergoline 13-16 prolactin Homo sapiens 110-113 12699451-11 2003 RESULTS: In every patient, a significant PRL decrease (P = 0.0086) of at least 96% of the pretreatment values occurred (from 5794 +/- 1996 to 77 +/- 38, mean +/- SEM); a persistent normalization of PRL levels was achieved in five out of 10 patients (50%) beginning from the first 3-6 months of CAB treatment (only one patient needed 12 months of therapy). Cabergoline 294-297 prolactin Homo sapiens 41-44 12689612-0 2003 Prolactin response to fenfluramine administration in patients with unipolar and bipolar depression and healthy controls. Fenfluramine 22-34 prolactin Homo sapiens 0-9 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Amisulpride 78-89 prolactin Homo sapiens 1-10 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Amisulpride 78-89 prolactin Homo sapiens 39-48 12809367-9 2003 The search for the chemical identity of the dopaminergic compounds resulted in isolation of a number of diterpenes of which some clerodadienols were most important for the prolactin-suppressive effects. clerodadienols 129-143 prolactin Homo sapiens 172-181 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Risperidone 91-102 prolactin Homo sapiens 1-10 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Risperidone 91-102 prolactin Homo sapiens 39-48 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Olanzapine 104-114 prolactin Homo sapiens 1-10 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Quetiapine Fumarate 119-129 prolactin Homo sapiens 1-10 13130349-0 2003 [Prolactin Levels and Symptoms of Hyperprolactinemia in Patients Treated with Amisulpride, Risperidone, Olanzapine and Quetiapine] Elevations in prolactin plasma concentration occur with antipsychotics due to their dopamine D2 receptor antagonism. Quetiapine Fumarate 119-129 prolactin Homo sapiens 39-48 12778366-1 2003 Prolactin is a newly recognized platelet coactivator that functions through potentiation of ADP-induced platelet activation. Adenosine Diphosphate 92-95 prolactin Homo sapiens 0-9 13130349-4 2003 Our findings confirm that amisulpride frequently leads to a remarkable elevation of prolactin plasma concentration, same - in minor degree - for risperidone. Amisulpride 26-37 prolactin Homo sapiens 84-93 13130349-5 2003 Under treatment with quetiapine and olanzapine just temporary elevated prolactin levels were registered. Quetiapine Fumarate 21-31 prolactin Homo sapiens 71-80 13130349-5 2003 Under treatment with quetiapine and olanzapine just temporary elevated prolactin levels were registered. Olanzapine 36-46 prolactin Homo sapiens 71-80 14509051-5 2003 Our findings confirm that amisulpride frequently leads to a remarkable elevation of prolactin plasma concentration, same--in minor degree--for risperidone. Amisulpride 26-37 prolactin Homo sapiens 84-93 14509051-6 2003 Under treatment with quetiapine and olanzapine just temporary elevated prolactin levels were registered. Quetiapine Fumarate 21-31 prolactin Homo sapiens 71-80 14509051-6 2003 Under treatment with quetiapine and olanzapine just temporary elevated prolactin levels were registered. Olanzapine 36-46 prolactin Homo sapiens 71-80 12668823-5 2003 Repeat prolactin measurement after polyethylene glycol precipitation showed that the majority of circulating prolactin was macroprolactin. Polyethylene Glycols 35-54 prolactin Homo sapiens 109-118 12660899-9 2003 In the meantime, because of persistent galactorrhea and elevated prolactin levels, treatment with cabergolin 0.5 mg/week was started. cabergolin 98-108 prolactin Homo sapiens 65-74 12668823-7 2003 Polyethylene glycol study showed that macroprolactinaemia exists simultaneously with genuine hyperprolactinaemia leading to falsely high serum prolactin levels. Polyethylene Glycols 0-19 prolactin Homo sapiens 43-52 12841542-1 2003 It has been shown that prolactin (PRL) induces glucose intolerance, hyperinsulinemia and insulin resistance in several animal species. Glucose 47-54 prolactin Homo sapiens 23-32 12660266-0 2003 An investigation of the effectiveness of testosterone implants in combination with the prolactin inhibitor quinagolide in the suppression of spermatogenesis in men. quinagolide 107-118 prolactin Homo sapiens 87-96 12660266-3 2003 This study investigated whether concomitant suppression of prolactin (PRL) with the non-ergot, dopamine receptor agonist quinagolide (Q), would enhance the efficacy of testosterone in its inhibition of spermatogenesis in healthy eugonadal men. Testosterone 168-180 prolactin Homo sapiens 59-68 12660266-3 2003 This study investigated whether concomitant suppression of prolactin (PRL) with the non-ergot, dopamine receptor agonist quinagolide (Q), would enhance the efficacy of testosterone in its inhibition of spermatogenesis in healthy eugonadal men. Testosterone 168-180 prolactin Homo sapiens 70-73 12660266-8 2003 However, Q did not totally block PRL secretion in the subjects, possibly because testosterone replacement itself stimulated PRL by a direct action on the lactotroph, thus the effectiveness of dual inhibition of gonadotrophin and PRL could not be fully investigated. Testosterone 81-93 prolactin Homo sapiens 124-127 12660266-8 2003 However, Q did not totally block PRL secretion in the subjects, possibly because testosterone replacement itself stimulated PRL by a direct action on the lactotroph, thus the effectiveness of dual inhibition of gonadotrophin and PRL could not be fully investigated. Testosterone 81-93 prolactin Homo sapiens 124-127 12650682-6 2003 RESULTS: Factors that influenced the risk of hyperprolactinemia included gender, with females appearing to be more sensitive than males, and drug treatment, with risperidone and conventional antipsychotic agents increasing prolactin more than olanzapine. Risperidone 162-173 prolactin Homo sapiens 50-59 12650682-6 2003 RESULTS: Factors that influenced the risk of hyperprolactinemia included gender, with females appearing to be more sensitive than males, and drug treatment, with risperidone and conventional antipsychotic agents increasing prolactin more than olanzapine. Olanzapine 243-253 prolactin Homo sapiens 50-59 12660899-14 2003 We therefore suggest a drug treatment trial with dopamine agonists in all macroadenoms with hyperprolactinemia, particularly in those with prolactin levels above 2000 mU/l (100 ng/ml). Dopamine 49-57 prolactin Homo sapiens 97-106 12686750-0 2003 Prolactin levels in schizophrenic patients receiving perospirone in comparison to risperidone. perospirone 53-64 prolactin Homo sapiens 0-9 12600435-4 2003 The effect of PRL on TRAIL-, staurosporine- and flavopiridol-induced apoptosis was assessed by Timelapse microscopy and Annexin V binding. Staurosporine 29-42 prolactin Homo sapiens 14-17 12600435-4 2003 The effect of PRL on TRAIL-, staurosporine- and flavopiridol-induced apoptosis was assessed by Timelapse microscopy and Annexin V binding. alvocidib 48-60 prolactin Homo sapiens 14-17 12680745-0 2003 The prolactin response to fenfluramine in depression: effects of melancholia and baseline cortisol. Fenfluramine 26-38 prolactin Homo sapiens 4-13 12680745-2 2003 The prolactin response to fenfluramine, an indicator of serotonergic activity, has been reported to be blunted in depressed patients compared to controls. Fenfluramine 26-38 prolactin Homo sapiens 4-13 12680745-7 2003 Amongst all the depressed patients, body mass index showed a significant association with prolactin response to fenfluramine. Fenfluramine 112-124 prolactin Homo sapiens 90-99 12680745-8 2003 There was an interaction between baseline cortisol and DSM-III-R melancholic subtype of depression whereby non-melancholic patients appeared more likely to increase prolactin response to fenfluramine in response to higher cortisol levels. Hydrocortisone 42-50 prolactin Homo sapiens 165-174 12699689-8 2003 Sixteen kilodalton PRL was posttranslationally modified with apparent molecular weights of 16 and 18 kDa on SDS-PAGE. Sodium Dodecyl Sulfate 108-111 prolactin Homo sapiens 19-22 12686750-1 2003 Serum prolactin levels were investigated in 41 patients with schizophrenia who were receiving clinically effective doses of perospirone or risperidone for more than 4 weeks. perospirone 124-135 prolactin Homo sapiens 6-15 12686750-1 2003 Serum prolactin levels were investigated in 41 patients with schizophrenia who were receiving clinically effective doses of perospirone or risperidone for more than 4 weeks. Risperidone 139-150 prolactin Homo sapiens 6-15 12644299-1 2003 In the mammal, melatonin regulates the seasonal and/or circadian rhythm of PRL levels. Melatonin 15-24 prolactin Homo sapiens 75-78 12680745-8 2003 There was an interaction between baseline cortisol and DSM-III-R melancholic subtype of depression whereby non-melancholic patients appeared more likely to increase prolactin response to fenfluramine in response to higher cortisol levels. Fenfluramine 187-199 prolactin Homo sapiens 165-174 12680745-9 2003 Prolactin response to fenfluramine was not blunted in major depression and there was no difference between melancholic and non-melancholic depression. Fenfluramine 22-34 prolactin Homo sapiens 0-9 12680745-10 2003 However, the relationship between prolactin response to fenfluramine and baseline cortisol levels appeared to differ between these two subtypes of depression. Fenfluramine 56-68 prolactin Homo sapiens 34-43 12680745-10 2003 However, the relationship between prolactin response to fenfluramine and baseline cortisol levels appeared to differ between these two subtypes of depression. Hydrocortisone 82-90 prolactin Homo sapiens 34-43 12520313-8 2003 The rate of decrease in PRL level after pergolide administration was greater in adolescents with alcohol abuse as compared to the control group ( t=-3.05, P=0.0028, 95% CI -0.01923, -0.00409). Pergolide 40-49 prolactin Homo sapiens 24-27 12574200-10 2003 Progesterone suppressed PRL release from glandular explants without affecting adipose explants. Progesterone 0-12 prolactin Homo sapiens 24-27 12568792-4 2003 We carried out a biological validation of the prolactin assay by administering three different doses each of sulpiride and cabergoline to adult male meerkats. Sulpiride 109-118 prolactin Homo sapiens 46-55 12568792-4 2003 We carried out a biological validation of the prolactin assay by administering three different doses each of sulpiride and cabergoline to adult male meerkats. Cabergoline 123-134 prolactin Homo sapiens 46-55 12568792-5 2003 Increasing doses of sulpiride and cabergoline caused substantial increases and decreases, respectively, in the plasma prolactin of the study animals as expected. Sulpiride 20-29 prolactin Homo sapiens 118-127 12568792-5 2003 Increasing doses of sulpiride and cabergoline caused substantial increases and decreases, respectively, in the plasma prolactin of the study animals as expected. Cabergoline 34-45 prolactin Homo sapiens 118-127 12568792-6 2003 Activation of the stress response in meerkats by capture and ketamine hydrochloride anesthesia caused short-term but significant increases in prolactin levels in individuals bled repeatedly. Ketamine 61-83 prolactin Homo sapiens 142-151 12574225-6 2003 LIF (5 nM) treatment reduced PRL secretion in primary human prolactinoma cultures by up to 42% (P < 0.0005), an effect that was surprisingly blocked by sulpiride, a D2-like dopamine receptor antagonist. Sulpiride 155-164 prolactin Homo sapiens 29-32 12788307-5 2003 In addition, 15ng/ml of prolactin reversed hydrocortisone suppressive effect on IFN-gamma, IL-12 p70, and IL-10 production in PHA+LPS-stimulated whole blood. Hydrocortisone 43-57 prolactin Homo sapiens 24-33 12708352-4 2003 The experimental studies have demonstrated that the prolactin and lactogen placental have direct effect on the islands of Langerhans, where diminish the transport of glucose, other results indicate that the plasm contains some factors able to decrease the metabolism of glucose in muscle. Glucose 166-173 prolactin Homo sapiens 52-61 12708352-4 2003 The experimental studies have demonstrated that the prolactin and lactogen placental have direct effect on the islands of Langerhans, where diminish the transport of glucose, other results indicate that the plasm contains some factors able to decrease the metabolism of glucose in muscle. Glucose 270-277 prolactin Homo sapiens 52-61 12713252-9 2003 CONCLUSIONS: PRL response to domperidone allowed us to characterize hyperprolactinemias, although the presence of a blunted response should be confirmed in a larger number of patients with tumors with "low" PRL levels (dependence on etiology or basal PRL level? Domperidone 29-40 prolactin Homo sapiens 13-16 12713252-9 2003 CONCLUSIONS: PRL response to domperidone allowed us to characterize hyperprolactinemias, although the presence of a blunted response should be confirmed in a larger number of patients with tumors with "low" PRL levels (dependence on etiology or basal PRL level? Domperidone 29-40 prolactin Homo sapiens 207-210 12576230-3 2003 In freshly isolated peripheral blood mononuclear cells (PBMC), PRL expression could only be stimulated by cptcAMP. cptcamp 106-113 prolactin Homo sapiens 63-66 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Cyclic AMP 32-36 prolactin Homo sapiens 58-61 12713252-9 2003 CONCLUSIONS: PRL response to domperidone allowed us to characterize hyperprolactinemias, although the presence of a blunted response should be confirmed in a larger number of patients with tumors with "low" PRL levels (dependence on etiology or basal PRL level? Domperidone 29-40 prolactin Homo sapiens 207-210 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Cyclic AMP 32-36 prolactin Homo sapiens 129-132 12535582-0 2003 Effect of prolactin infused into the third ventricle on LH secretion in follicular-phase and ovariectomized ewes. Luteinizing Hormone 56-58 prolactin Homo sapiens 10-19 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Prostaglandins E 159-174 prolactin Homo sapiens 58-61 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Prostaglandins E 159-174 prolactin Homo sapiens 129-132 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Terbutaline 213-224 prolactin Homo sapiens 58-61 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Terbutaline 213-224 prolactin Homo sapiens 129-132 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Cyclic AMP 252-256 prolactin Homo sapiens 58-61 12576230-4 2003 The physiological importance of cAMP in the regulation of PRL expression in leukocytes is suggested by the finding that in PBMC, PRL expression is enhanced by prostaglandin-E(2) and the beta(2)-adrenergic agonist terbutaline, which both signal through cAMP. Cyclic AMP 252-256 prolactin Homo sapiens 129-132 12535582-1 2003 This study tested a hypothesis that an acute enhancement of prolactin concentration within the central nervous system (CNS) would affect the LH secretion in ewes, depending on the level of endogenous estrogens in the organism. Luteinizing Hormone 141-143 prolactin Homo sapiens 60-69 12535582-6 2003 From the two doses of prolactin used in OVX ewes (25 and 50 microg/100 microl/h) only the lower dose suppressed significantly the mean plasma LH concentration after the infusion, compared to those noted before (P < 0.01) and during (P < 0.001) prolactin treatment. Luteinizing Hormone 142-144 prolactin Homo sapiens 22-31 12583871-4 2003 Prolactin (PRL) responses to the 5HT1A receptor agonist drug buspirone were compared in 30 female subjects with migraine (ten migraine with aura, MA; ten migraine without aura, MO and ten chronic/transformed migraine, CM), and ten healthy controls matched for age, gender and menstrual status. Buspirone 61-70 prolactin Homo sapiens 0-9 12543792-9 2003 Thus, the apparent effect of 23-kDa PRL on the growth of DU145 and PC-3 cells in vivo may result from the combined effects of 23-kDa PRL and 16-kDa PRL. 23-kda 29-35 prolactin Homo sapiens 133-136 12543792-9 2003 Thus, the apparent effect of 23-kDa PRL on the growth of DU145 and PC-3 cells in vivo may result from the combined effects of 23-kDa PRL and 16-kDa PRL. 23-kda 29-35 prolactin Homo sapiens 133-136 14516163-11 2003 In the OVX+EB II group, PHEN alone, but ISOP with PROP, potentiated PRL secretion by the cells. Phenylephrine 24-28 prolactin Homo sapiens 68-71 12543792-9 2003 Thus, the apparent effect of 23-kDa PRL on the growth of DU145 and PC-3 cells in vivo may result from the combined effects of 23-kDa PRL and 16-kDa PRL. 23-kda 126-132 prolactin Homo sapiens 36-39 12543792-9 2003 Thus, the apparent effect of 23-kDa PRL on the growth of DU145 and PC-3 cells in vivo may result from the combined effects of 23-kDa PRL and 16-kDa PRL. 16-kda 141-147 prolactin Homo sapiens 36-39 15206800-7 2003 A major release of prolactin in serum on days 1 and 3 post-partum there was in women with normal delivery, revealing a correlation between Trp and prolactin in the first few days after birth, in relation to different conditions of delivery. Tryptophan 139-142 prolactin Homo sapiens 19-28 14498762-11 2003 In solution, the aggregation of human prolactin at mildly acidic pH and physiological concentrations of Zn(2+) resembles that which occurs in cells if the reaction is performed with macromolecular crowding, which will mimic the conditions in cells. Zinc 104-106 prolactin Homo sapiens 38-47 14516163-12 2003 In OVX+P4 animals, PHEN alone or in combination with PHENT and also ISOP alone or with PROP enhanced PRL output from the cells. Phenylephrine 19-23 prolactin Homo sapiens 101-104 14516163-12 2003 In OVX+P4 animals, PHEN alone or in combination with PHENT and also ISOP alone or with PROP enhanced PRL output from the cells. Propranolol 87-91 prolactin Homo sapiens 101-104 14516163-15 2003 In turn, in the OVX+EB I group, effect of PHENT and PROP on PRL secretion by pituitary cells was inhibitory. Propranolol 52-56 prolactin Homo sapiens 60-63 12439628-2 2003 The prolactin response to fenfluramine (PRF) is an indicator of 5HT activity. Fenfluramine 26-38 prolactin Homo sapiens 4-13 12439628-2 2003 The prolactin response to fenfluramine (PRF) is an indicator of 5HT activity. Serotonin 64-67 prolactin Homo sapiens 4-13 12504073-7 2003 For example, dose-related increases in prolactin concentrations occur with risperidone whereas olanzapine is associated with mild and transient increases in long-term treatment. Risperidone 75-86 prolactin Homo sapiens 39-48 12439628-9 2003 Post-hoc analysis revealed that at low TRP/LNAA values, outcome improved as prolactin levels increased while at high TRP/LNAA values the opposite was the case. Tryptophan 39-42 prolactin Homo sapiens 76-85 12729501-2 2003 Theca cells were incubated with PRL for 24 h to stimulate progesterone (P4) production. Progesterone 58-70 prolactin Homo sapiens 32-35 12729501-11 2003 Prolactin significantly increased 3H-PDBu-specific binding in theca cells. Tritium 34-36 prolactin Homo sapiens 0-9 12470131-1 2002 BACKGROUND: Although animal studies have raised the possibility that prolactin-elevating dopamine antagonists used to treat psychotic disorders may initiate and promote breast cancers, epidemiologic studies in humans have been limited and inconsistent. Dopamine 89-97 prolactin Homo sapiens 69-78 29662350-9 2002 Bromocriptine treatment completely inhibited the PRL increase, but further increased serum E2 concentration on the late follicular day. Bromocriptine 0-13 prolactin Homo sapiens 49-52 29662350-11 2002 The clomiphene treatment increased serum E2 but decreased PRL concentrations. Clomiphene 4-14 prolactin Homo sapiens 58-61 12527854-1 2002 To assess the effectiveness of bromocriptine (BRC) as primary therapy in reducing the size of PRL-secreting macroadenomas with extra-sellar extension, we conducted a multicenter study in 29 patients without prior radiotherapy. Bromocriptine 31-44 prolactin Homo sapiens 94-97 12467944-3 2002 We examined central 5-HT(2) responses by measuring the serum prolactin (PRL) over 5 h in response to 30 mg of D-fenfluramine (DFEN) in two groups of male schizophrenic patients. Dexfenfluramine 110-124 prolactin Homo sapiens 61-70 12467944-3 2002 We examined central 5-HT(2) responses by measuring the serum prolactin (PRL) over 5 h in response to 30 mg of D-fenfluramine (DFEN) in two groups of male schizophrenic patients. Dexfenfluramine 110-124 prolactin Homo sapiens 72-75 12467944-3 2002 We examined central 5-HT(2) responses by measuring the serum prolactin (PRL) over 5 h in response to 30 mg of D-fenfluramine (DFEN) in two groups of male schizophrenic patients. Dexfenfluramine 126-130 prolactin Homo sapiens 61-70 12467944-3 2002 We examined central 5-HT(2) responses by measuring the serum prolactin (PRL) over 5 h in response to 30 mg of D-fenfluramine (DFEN) in two groups of male schizophrenic patients. Dexfenfluramine 126-130 prolactin Homo sapiens 72-75 12467944-4 2002 Blunted PRL responses to DFEN indicate functional 5-HT(2) receptor antagonism. Dexfenfluramine 25-29 prolactin Homo sapiens 8-11 12467944-8 2002 The olanzapine-treated patients showed a significantly lower maximal DFEN-evoked PRL response and a significantly lower group x time overall PRL release compared with the untreated patient group. Olanzapine 4-14 prolactin Homo sapiens 81-84 12467944-8 2002 The olanzapine-treated patients showed a significantly lower maximal DFEN-evoked PRL response and a significantly lower group x time overall PRL release compared with the untreated patient group. Olanzapine 4-14 prolactin Homo sapiens 141-144 12467944-8 2002 The olanzapine-treated patients showed a significantly lower maximal DFEN-evoked PRL response and a significantly lower group x time overall PRL release compared with the untreated patient group. Dexfenfluramine 69-73 prolactin Homo sapiens 81-84 12470131-7 2002 The increased risk was also seen in women who used prolactin-elevating antiemetic dopamine antagonists despite having different breast cancer risk profiles than antipsychotic dopamine antagonist users. Dopamine 82-90 prolactin Homo sapiens 51-60 12588043-10 2002 In HIV-infected men with anti-PRL autoantibodies, gel filtration showed that big big PRL isoform was present as the predominant circulating form of PRL throughout each measurement after iv metoclopramide. Metoclopramide 189-203 prolactin Homo sapiens 85-88 12505103-11 2002 While there was no significant difference in PRL level between groups at the beginning of the study, control prolactin (PRL) levels were significantly lower in quetiapine compared to haloperidol group. Quetiapine Fumarate 160-170 prolactin Homo sapiens 120-123 12466351-0 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. Dopamine 61-69 prolactin Homo sapiens 126-135 12466351-0 2002 Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. bim 80-83 prolactin Homo sapiens 126-135 12527023-2 2002 Fenfluramine-induced, peak PRL rises were smaller in subjects whose "aggression" scores fell above the sample median, compared to their less aggressive counterparts (P<.002). Fenfluramine 0-12 prolactin Homo sapiens 27-30 12527023-6 2002 Men in the 2/3 allele group had significantly higher aggression scores (P<.05) and smaller peak PRL responses to fenfluramine (P<.009) than men in the 1/4 allele group. Fenfluramine 116-128 prolactin Homo sapiens 99-102 12505103-4 2002 The aim of the present study was to compare effects of haloperidol, the most commonly used antipsychotic, and quetiapine, a novel antipsychotic agent used in Turkey, on serum prolactin (PRL) levels. Haloperidol 55-66 prolactin Homo sapiens 175-184 12505103-4 2002 The aim of the present study was to compare effects of haloperidol, the most commonly used antipsychotic, and quetiapine, a novel antipsychotic agent used in Turkey, on serum prolactin (PRL) levels. Quetiapine Fumarate 110-120 prolactin Homo sapiens 175-184 12505103-4 2002 The aim of the present study was to compare effects of haloperidol, the most commonly used antipsychotic, and quetiapine, a novel antipsychotic agent used in Turkey, on serum prolactin (PRL) levels. Quetiapine Fumarate 110-120 prolactin Homo sapiens 186-189 12505103-11 2002 While there was no significant difference in PRL level between groups at the beginning of the study, control prolactin (PRL) levels were significantly lower in quetiapine compared to haloperidol group. Quetiapine Fumarate 160-170 prolactin Homo sapiens 109-118 12588043-10 2002 In HIV-infected men with anti-PRL autoantibodies, gel filtration showed that big big PRL isoform was present as the predominant circulating form of PRL throughout each measurement after iv metoclopramide. Metoclopramide 189-203 prolactin Homo sapiens 85-88 12588043-12 2002 On the other hand, high serum total PRL levels were observed at each measurement throughout the metoclopramide test in HIV-infected men with anti-PRL autoantibodies; however, the serum free PRL levels were similar to those found in subjects without anti-PRL autoantibodies. Metoclopramide 96-110 prolactin Homo sapiens 36-39 12570169-0 2002 A prospective, double-blind, randomized, placebo-controlled clinical trial of bromocriptine in clomiphene-resistant patients with polycystic ovary syndrome and normal prolactin level. Bromocriptine 78-91 prolactin Homo sapiens 167-176 12722409-5 2002 RESULTS: Normal prolactin levels were found in 96.7% of cases, but in 8 women with recurrent breast cysts after repeated FNA-biopsies prolactin secretion stimulated by metoclopramide was significantly increased. Metoclopramide 168-182 prolactin Homo sapiens 134-143 12570169-10 2002 After 3 and 6 months of treatment with bromocriptine, there was a significant decrease in serum level of prolactin (p = 0.000001). Bromocriptine 39-52 prolactin Homo sapiens 105-114 12570169-12 2002 CONCLUSIONS: The only significant effect of long-term bromocriptine therapy in CC-resistant women with PCOS was to lower the serum PRL concentration. Bromocriptine 54-67 prolactin Homo sapiens 131-134 12387684-4 2002 Short-term acute studies done after single parenteral or oral doses of phenothiazines found rapid two- to tenfold increases in hPrl. Phenothiazines 71-85 prolactin Homo sapiens 127-131 12397212-0 2002 The effect of mifepristone on the expression of insulin-like growth factor binding protein-1, prolactin and progesterone receptor mRNA and protein during the implantation phase in human endometrium. Mifepristone 14-26 prolactin Homo sapiens 94-103 12397212-2 2002 The purpose of the study was to investigate the effect of mifepristone on the expression of IGFBP-1, prolactin and progesterone receptors (PR) during the implantation phase in human endometrium. Mifepristone 58-70 prolactin Homo sapiens 101-110 12351372-2 2002 Because the serum prolactin level is elevated at these times, we later treated her with metoclopramide (10 mg orally 3 times daily), a medication known to induce prolactin release. Metoclopramide 88-102 prolactin Homo sapiens 18-27 12351372-2 2002 Because the serum prolactin level is elevated at these times, we later treated her with metoclopramide (10 mg orally 3 times daily), a medication known to induce prolactin release. Metoclopramide 88-102 prolactin Homo sapiens 162-171 12420085-6 2002 Baseline PRL values were significantly lower for patients with IPD than for those with MSA, both for levodopa-treated and naive patients ( p < 0.004, estimated decrease 55.1 %, 95 % CI from 29.4 % to 71.52 %). Levodopa 101-109 prolactin Homo sapiens 9-12 12370106-0 2002 Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Raloxifene Hydrochloride 24-34 prolactin Homo sapiens 54-63 12370106-1 2002 OBJECTIVE: To evaluate the effects of a 6 month administration of raloxifene hydrochloride, a selective estrogen receptor modulator which was recently approved for the prevention of osteoporosis, on serum gonadotropin and prolactin (PRL) levels and on TRH-stimulated PRL responsiveness in postmenopausal women who have not undergone estrogen replacement therapy. Raloxifene Hydrochloride 66-90 prolactin Homo sapiens 222-231 12370106-1 2002 OBJECTIVE: To evaluate the effects of a 6 month administration of raloxifene hydrochloride, a selective estrogen receptor modulator which was recently approved for the prevention of osteoporosis, on serum gonadotropin and prolactin (PRL) levels and on TRH-stimulated PRL responsiveness in postmenopausal women who have not undergone estrogen replacement therapy. Raloxifene Hydrochloride 66-90 prolactin Homo sapiens 233-236 12370106-14 2002 CONCLUSIONS: The decrease of PRL values induced by long-term raloxifene administration in postmenopausal women could be explained by a direct antiestrogenic effect of raloxifene on lactotrope cells or by the recently suggested increase of opiatergic tone on the hypothalamic-pituitary region. Raloxifene Hydrochloride 61-71 prolactin Homo sapiens 29-32 12370106-14 2002 CONCLUSIONS: The decrease of PRL values induced by long-term raloxifene administration in postmenopausal women could be explained by a direct antiestrogenic effect of raloxifene on lactotrope cells or by the recently suggested increase of opiatergic tone on the hypothalamic-pituitary region. Raloxifene Hydrochloride 167-177 prolactin Homo sapiens 29-32 12387684-16 2002 Olanzapine, quetiapine and ziprasidone have all been found to have little effect or produce decreases in hPrl. ziprasidone 27-38 prolactin Homo sapiens 105-109 12387684-17 2002 Most recently, aripiprazole, in early studies, appears to produce significant reductions in hPrl while maintaining therapeutic efficacy for psychosis. Aripiprazole 15-27 prolactin Homo sapiens 92-96 12387684-10 2002 However, prolactin is secreted by the anterior pituitary and is under inhibitory control of dopamine released from the tuberoinfundibular neurones. Dopamine 92-100 prolactin Homo sapiens 9-18 12387684-11 2002 Thus, increases in prolactin are due to antipsychotic impact on tuberoinfundibular tract, one of four dopamine-related tracts. Dopamine 102-110 prolactin Homo sapiens 19-28 12387684-12 2002 With the application of clozapine and other atypical antipsychotics, it was found that medications can successfully treat psychosis without increasing hPrl. Clozapine 24-33 prolactin Homo sapiens 151-155 12387684-13 2002 In fact, early single-dose trails found clozapine to reduce hPrl by 16%. Clozapine 40-49 prolactin Homo sapiens 60-64 12387684-15 2002 Risperidone, however, has been found to persistently elevate hPrl in studies, despite its impact on other receptor sites. Risperidone 0-11 prolactin Homo sapiens 61-65 12352286-0 2002 Re: Prolactin levels and adverse events in patients treated with risperidone. Risperidone 65-76 prolactin Homo sapiens 4-13 12364416-5 2002 Eleven months of dopamine agonist therapy at standard doses lowered PRL levels to 299 micro g/liter. Dopamine 17-25 prolactin Homo sapiens 68-71 12364416-6 2002 Subsequent stepwise increases in cabergoline (3 mg daily) further lowered PRL levels to 71 micro g/liter, but hypogonadism persisted. Cabergoline 33-44 prolactin Homo sapiens 74-77 12364416-7 2002 Initiation of testosterone replacement resulted in a rise and discontinuation in a fall of PRL levels. Testosterone 14-26 prolactin Homo sapiens 91-94 12364416-8 2002 Aromatization of exogenous testosterone to estradiol and subsequent estrogen-stimulated PRL release was suspected. Testosterone 27-39 prolactin Homo sapiens 88-91 12364416-9 2002 Concomitant use of cabergoline with the aromatase inhibitor anastrozole after resuming testosterone replacement resulted in the maintenance of testosterone levels and restoration of normal sexual function, without increasing PRL. Cabergoline 19-30 prolactin Homo sapiens 225-228 12364416-9 2002 Concomitant use of cabergoline with the aromatase inhibitor anastrozole after resuming testosterone replacement resulted in the maintenance of testosterone levels and restoration of normal sexual function, without increasing PRL. Anastrozole 60-71 prolactin Homo sapiens 225-228 12364416-10 2002 Ultimately, further reduction in PRL on this therapy permitted endogenous testosterone production. Testosterone 74-86 prolactin Homo sapiens 33-36 12452534-0 2002 Involvement of nitric oxide on prolactin release induced by immobilization stress in rats. Nitric Oxide 15-27 prolactin Homo sapiens 31-40 12377401-4 2002 The prolactin (PRL) response to d,l-fenfluramine (60 mg p.o.) d,l-fenfluramine 32-48 prolactin Homo sapiens 4-13 12377401-6 2002 The NPI aggression score, NPI irritability score, and Behavioral Pathology in AD aggression score were positively correlated to prolactin concentrations following fenfluramine challenge (r(S) =.61, p =.003; r(S) =.53, p =.012; and r(S) =.47, p =.029 respectively). Fenfluramine 163-175 prolactin Homo sapiens 128-137 12373416-5 2002 RESULTS: Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature. flesinoxan 9-19 prolactin Homo sapiens 119-128 12373416-5 2002 RESULTS: Flesinoxan induced a significant and dose-dependent increase in adrenocorticotropic hormone (ACTH), cortisol, prolactin (PRL), growth hormone (GH) and a decrease in body temperature. flesinoxan 9-19 prolactin Homo sapiens 130-133 12373416-7 2002 CONCLUSIONS: These results showed the role of 5-HT(1A) mechanisms in the PRL, ACTH, cortisol, GH, and temperature responses to flesinoxan. flesinoxan 127-137 prolactin Homo sapiens 73-76 12239590-6 2002 Similarly, addition of stannic mesoporphyrin, the inhibitor of HO activity, prevented PRL-mediated increase in endothelial cell proliferation. mesoporphyrin IX 31-44 prolactin Homo sapiens 86-89 12239590-6 2002 Similarly, addition of stannic mesoporphyrin, the inhibitor of HO activity, prevented PRL-mediated increase in endothelial cell proliferation. Holmium 63-65 prolactin Homo sapiens 86-89 12452534-2 2002 The authors investigated the effect of NO donor, isosorbide dinitrate (ISDN), on prolactin (PRL) release induced by immobilization stress (IS) in male rats. Isosorbide Dinitrate 49-69 prolactin Homo sapiens 81-90 12452534-2 2002 The authors investigated the effect of NO donor, isosorbide dinitrate (ISDN), on prolactin (PRL) release induced by immobilization stress (IS) in male rats. Isosorbide Dinitrate 71-75 prolactin Homo sapiens 81-90 12390633-3 2002 Sumatriptan, a 5-HT1B/1D receptor agonist, stimulates the release of growth hormone (GH) and inhibits the release of ACTH, cortisol, and prolactin. Sumatriptan 0-11 prolactin Homo sapiens 137-146 12202292-0 2002 Prolactin elevation with quetiapine. Quetiapine Fumarate 25-35 prolactin Homo sapiens 0-9 12193569-0 2002 Calcium dynamics and resting transcriptional activity regulates prolactin gene expression. Calcium 0-7 prolactin Homo sapiens 64-73 12585566-4 2002 Risperidone at higher doses has been shown to produce increases in prolactin similar to conventional antipsychotics. Risperidone 0-11 prolactin Homo sapiens 67-76 12585566-5 2002 At the other end of the spectrum, clozapine and quetiapine produce minimal sustained increases in prolactin that are no different from placebo. Clozapine 34-43 prolactin Homo sapiens 98-107 12585566-5 2002 At the other end of the spectrum, clozapine and quetiapine produce minimal sustained increases in prolactin that are no different from placebo. Quetiapine Fumarate 48-58 prolactin Homo sapiens 98-107 12585566-7 2002 This paper reviews the published literature regarding prolactin levels in treated and untreated patients with schizophrenia and the relationship of prolactin and dopamine. Dopamine 162-170 prolactin Homo sapiens 148-157 12392686-6 2002 In winter-acclimatized male carp, where the pituitary PRL level is low, 17beta-estradiol treatment increased PRL but not GK immunoreactivity. Estradiol 72-88 prolactin Homo sapiens 54-57 12392686-6 2002 In winter-acclimatized male carp, where the pituitary PRL level is low, 17beta-estradiol treatment increased PRL but not GK immunoreactivity. Estradiol 72-88 prolactin Homo sapiens 109-112 12390633-7 2002 GH and PRL secretion after sumatriptan administration was significantly (P<0.01 and <0.05) altered in CTTH patients in comparison with controls. Sumatriptan 27-38 prolactin Homo sapiens 7-10 12242577-6 2002 The PRL responses to CMI of the patients were blunted compared to healthy controls, while the PRL responses to HAL were not significantly different from controls. Haloperidol 111-114 prolactin Homo sapiens 94-97 12200196-0 2002 Physiological role of salsolinol: its hypophysiotrophic function in the regulation of pituitary prolactin secretion. salsolinol 22-32 prolactin Homo sapiens 96-105 12200196-1 2002 We have recently observed that 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) produced by hypothalamic neurons can selectively release prolactin from the anterior lobe (AL) of the pituitary gland. salsolinol 31-84 prolactin Homo sapiens 155-164 12200196-1 2002 We have recently observed that 1-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (salsolinol) produced by hypothalamic neurons can selectively release prolactin from the anterior lobe (AL) of the pituitary gland. salsolinol 86-96 prolactin Homo sapiens 155-164 12376268-7 2002 The basal PRL levels in patients with exclusive phenytion (PHT) or valproate (VPA), and in those with combined ministration of carbamazpine (CBZ+VPA+PHT), were significantly lower than the control levels (P<0.05). pht 59-62 prolactin Homo sapiens 10-13 12376268-7 2002 The basal PRL levels in patients with exclusive phenytion (PHT) or valproate (VPA), and in those with combined ministration of carbamazpine (CBZ+VPA+PHT), were significantly lower than the control levels (P<0.05). Valproic Acid 67-76 prolactin Homo sapiens 10-13 12376268-7 2002 The basal PRL levels in patients with exclusive phenytion (PHT) or valproate (VPA), and in those with combined ministration of carbamazpine (CBZ+VPA+PHT), were significantly lower than the control levels (P<0.05). Valproic Acid 78-81 prolactin Homo sapiens 10-13 12376268-7 2002 The basal PRL levels in patients with exclusive phenytion (PHT) or valproate (VPA), and in those with combined ministration of carbamazpine (CBZ+VPA+PHT), were significantly lower than the control levels (P<0.05). carbamazpine 127-139 prolactin Homo sapiens 10-13 12366878-3 2002 The effects of a single dose of 7.0 g Trp on mood, cortisol and prolactin (Prl) in FH subjects were compared with healthy matched controls (n = 15) in a placebo-controlled, double blind cross-over design. Tryptophan 38-41 prolactin Homo sapiens 64-73 12450312-0 2002 Dexamethasone and adrenocorticotropin suppress prolactin secretion in humans. Dexamethasone 0-13 prolactin Homo sapiens 47-56 12450312-5 2002 In hyperprolactinemic patients, the DEX-induced increase in PRL (APRL, expressed in percentage of baseline) was significantly larger compared with normoprolactinemic subjects in all groups except those who received high-dose DEX) or adrenocorticotropin. Dexamethasone 36-39 prolactin Homo sapiens 60-63 12450312-5 2002 In hyperprolactinemic patients, the DEX-induced increase in PRL (APRL, expressed in percentage of baseline) was significantly larger compared with normoprolactinemic subjects in all groups except those who received high-dose DEX) or adrenocorticotropin. Dexamethasone 225-228 prolactin Homo sapiens 60-63 12242577-4 2002 Before the ECT course, we assessed the central serotonergic and dopaminergic responsivities, by measuring the PRL responses to the administration of the serotonin uptake inhibitor clomipramine (CMI) intravenously, and, two days later, the PRL responses dopamine receptor blocker haloperidol (HAL), administered intramuscularly. Clomipramine 180-192 prolactin Homo sapiens 110-113 12242577-4 2002 Before the ECT course, we assessed the central serotonergic and dopaminergic responsivities, by measuring the PRL responses to the administration of the serotonin uptake inhibitor clomipramine (CMI) intravenously, and, two days later, the PRL responses dopamine receptor blocker haloperidol (HAL), administered intramuscularly. Clomipramine 194-197 prolactin Homo sapiens 110-113 12242577-7 2002 Searching for correlations among the maximal PRL responses to the three stimuli in the patient"s group, we found that the PRL responses to ECT were significantly correlated to the PRL responses to i. m. HAL (r = 0.8205, N = 15, p < 0.001) and not to the PRL responses to i. v. CMI (r = 0.1713, n. s.). Haloperidol 203-206 prolactin Homo sapiens 45-48 12242577-7 2002 Searching for correlations among the maximal PRL responses to the three stimuli in the patient"s group, we found that the PRL responses to ECT were significantly correlated to the PRL responses to i. m. HAL (r = 0.8205, N = 15, p < 0.001) and not to the PRL responses to i. v. CMI (r = 0.1713, n. s.). Haloperidol 203-206 prolactin Homo sapiens 122-125 12242577-7 2002 Searching for correlations among the maximal PRL responses to the three stimuli in the patient"s group, we found that the PRL responses to ECT were significantly correlated to the PRL responses to i. m. HAL (r = 0.8205, N = 15, p < 0.001) and not to the PRL responses to i. v. CMI (r = 0.1713, n. s.). Haloperidol 203-206 prolactin Homo sapiens 122-125 12242577-7 2002 Searching for correlations among the maximal PRL responses to the three stimuli in the patient"s group, we found that the PRL responses to ECT were significantly correlated to the PRL responses to i. m. HAL (r = 0.8205, N = 15, p < 0.001) and not to the PRL responses to i. v. CMI (r = 0.1713, n. s.). Haloperidol 203-206 prolactin Homo sapiens 122-125 12570066-7 2002 Quetiapine has a particularly favourable tolerability profile, with placebo-level extrapyramidal symptoms and prolactin levels across the entire dose range combined with a neutral effect on weight during long-term use, and may be a valuable treatment option in acute mania and bipolar disorder. Quetiapine Fumarate 0-10 prolactin Homo sapiens 110-119 12161478-9 2002 A periodic assessment of PRL levels during BRC (and other dopamine-agonist drugs) withdrawal is recommended to avoid the unnecessary maintenance of therapy in a subset of patients with prolactinomas. Dopamine 58-66 prolactin Homo sapiens 25-28 12570069-3 2002 Similarly, unlike risperidone and haloperidol, quetiapine treatment has been associated with a significant reduction in serum prolactin levels, and has normalized raised prolactin levels after discontinuation of previous treatment. Quetiapine Fumarate 47-57 prolactin Homo sapiens 126-135 12570069-3 2002 Similarly, unlike risperidone and haloperidol, quetiapine treatment has been associated with a significant reduction in serum prolactin levels, and has normalized raised prolactin levels after discontinuation of previous treatment. Quetiapine Fumarate 47-57 prolactin Homo sapiens 170-179 12185405-3 2002 OBJECTIVES: In the present investigation the influence of acute oral administration of 15 mg mirtazapine on the cortisol (COR), corticotropin (ACTH), growth hormone (GH), and prolactin (PRL) secretion was examined in six healthy male subjects, compared to placebo. Mirtazapine 93-104 prolactin Homo sapiens 175-184 12036601-6 2002 In the present study, we tested the effect of PRL on a U266 human myeloma cell line and demonstrated constitutive and melphalan-stimulated intracytoplasmic PRL in U266 cells. Melphalan 118-127 prolactin Homo sapiens 46-49 14764338-0 2002 Age related prolactin secretion in men after fentanyl anaesthesia. Fentanyl 45-53 prolactin Homo sapiens 12-21 14764338-6 2002 The study shows an age related increase of PRL concentrations after fentanyl administration. Fentanyl 68-76 prolactin Homo sapiens 43-46 12079993-3 2002 Release of pituitary PRL was blocked by daily treatment with bromocriptine (1 mg s.c. given at 1000 h) on Days 1-4 of pregnancy (PB group). Bromocriptine 61-74 prolactin Homo sapiens 21-24 12079993-3 2002 Release of pituitary PRL was blocked by daily treatment with bromocriptine (1 mg s.c. given at 1000 h) on Days 1-4 of pregnancy (PB group). Lead 129-131 prolactin Homo sapiens 21-24 12079993-4 2002 PRL withdrawal induced functional luteolysis, as evidenced by a precipitous drop in serum progesterone to background levels. Progesterone 90-102 prolactin Homo sapiens 0-3 12036601-6 2002 In the present study, we tested the effect of PRL on a U266 human myeloma cell line and demonstrated constitutive and melphalan-stimulated intracytoplasmic PRL in U266 cells. Melphalan 118-127 prolactin Homo sapiens 156-159 12036601-8 2002 Concerning etoposide-induced apoptosis, PRL had a double-faceted effect depending on the applied dose: high, pharmacological doses (corresponding to hyperprolactinemia), inhibited apoptosis, whereas near physiological doses exerted a pro-apoptotic effect. Etoposide 11-20 prolactin Homo sapiens 40-43 12111188-5 2002 The presence of anti-prolactin auto-antibodies was suspected because of low recovery of PRL after precipitation with polyethylene glycol and confirmed by immunoprecipitation with anti-human IgG-agarose. Polyethylene Glycols 117-136 prolactin Homo sapiens 21-30 12173917-11 2002 Dopamine agonist therapy was initiated, and the prolactin level and size of the tumor decreased substantially. Dopamine 0-8 prolactin Homo sapiens 48-57 12111188-5 2002 The presence of anti-prolactin auto-antibodies was suspected because of low recovery of PRL after precipitation with polyethylene glycol and confirmed by immunoprecipitation with anti-human IgG-agarose. Sepharose 194-201 prolactin Homo sapiens 21-30 12089361-9 2002 The cooperation depends on the PRL-induced phosphorylation on Tyr(694) in Stat5A and Tyr(699) in Stat5B, as demonstrated using the Stat5AY694F and Stat5BY699F proteins. Tyrosine 62-65 prolactin Homo sapiens 31-34 12087074-6 2002 Within the vas deferens, PRL induced rapid tyrosine phosphorylation of JAK 2 and STAT 5 (after 10 and 20 min respectively), and tyrosine and threonine phosphorylation of ERK 1 and 2 (after 5 min). Tyrosine 43-51 prolactin Homo sapiens 25-28 12087074-6 2002 Within the vas deferens, PRL induced rapid tyrosine phosphorylation of JAK 2 and STAT 5 (after 10 and 20 min respectively), and tyrosine and threonine phosphorylation of ERK 1 and 2 (after 5 min). Tyrosine 128-136 prolactin Homo sapiens 25-28 12188977-0 2002 Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Haloperidol 107-118 prolactin Homo sapiens 33-42 12188977-0 2002 Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Clozapine 120-129 prolactin Homo sapiens 33-42 12188977-0 2002 Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. Olanzapine 134-144 prolactin Homo sapiens 33-42 12188977-4 2002 Correlations between antipsychotic plasma concentration and serum prolactin concentration were significant only for the olanzapine treatment group (r = 0.80, p = 0.002). Olanzapine 120-130 prolactin Homo sapiens 66-75 12087074-6 2002 Within the vas deferens, PRL induced rapid tyrosine phosphorylation of JAK 2 and STAT 5 (after 10 and 20 min respectively), and tyrosine and threonine phosphorylation of ERK 1 and 2 (after 5 min). Threonine 141-150 prolactin Homo sapiens 25-28 12089361-9 2002 The cooperation depends on the PRL-induced phosphorylation on Tyr(694) in Stat5A and Tyr(699) in Stat5B, as demonstrated using the Stat5AY694F and Stat5BY699F proteins. Tyrosine 85-88 prolactin Homo sapiens 31-34 12171388-3 2002 Therefore, we tested whether subjects with BPD showed a blunted prolactin (PRL) response to flesinoxan, a highly potent and selective 5-HT1A agonist. flesinoxan 92-102 prolactin Homo sapiens 64-73 12171388-3 2002 Therefore, we tested whether subjects with BPD showed a blunted prolactin (PRL) response to flesinoxan, a highly potent and selective 5-HT1A agonist. flesinoxan 92-102 prolactin Homo sapiens 75-78 12084414-0 2002 Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine. Clomipramine 29-41 prolactin Homo sapiens 0-9 12171388-8 2002 Among the BPD in-patients, PRL responses to flesinoxan were lower in patients with past history of suicide attempts (N = 8) than in those with a negative history. flesinoxan 44-54 prolactin Homo sapiens 27-30 12084414-0 2002 Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine. Haloperidol 46-57 prolactin Homo sapiens 0-9 12050218-6 2002 The potential functional relevance of this increase in Stat5 is suggested by the ability of transiently transfected Stat5a or Stat5b to significantly enhance the response of the decidual PRL promoter to cAMP/MPA and attenuation of the response to cAMP/MPA by dominant negative Stat5. Cyclic AMP 203-207 prolactin Homo sapiens 187-190 12084414-0 2002 Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine. Clozapine 135-144 prolactin Homo sapiens 0-9 12084414-0 2002 Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine. Olanzapine 153-163 prolactin Homo sapiens 0-9 12084414-4 2002 We measured the prolactin responses to the acute administration of a serotonergic drug, clomipramine, and a dopaminergic one, haloperidol. Clomipramine 88-100 prolactin Homo sapiens 16-25 12084414-6 2002 Clomipramine administration induced significant increases of prolactin in the drug-free state. Clomipramine 0-12 prolactin Homo sapiens 61-70 12084414-8 2002 The prolactin responses to haloperidol were not altered after treatment with clozapine, but were significantly reduced after the olanzapine treatment. Haloperidol 27-38 prolactin Homo sapiens 4-13 12084414-8 2002 The prolactin responses to haloperidol were not altered after treatment with clozapine, but were significantly reduced after the olanzapine treatment. Olanzapine 129-139 prolactin Homo sapiens 4-13 12084414-9 2002 The baseline prolactin levels were not influenced by clozapine treatment, and were moderately but significantly increased after treatment with olanzapine. Olanzapine 143-153 prolactin Homo sapiens 13-22 12084422-1 2002 Recent studies suggest that altered serotonergic (5-HT) function, as assessed by lower prolactin (PRL) response to fenfluramine (FEN), a specific 5-HT releaser and uptake inhibitor, is associated with suicidal behavior in either depressed and personality disordered patients. Fenfluramine 115-127 prolactin Homo sapiens 98-101 12084422-1 2002 Recent studies suggest that altered serotonergic (5-HT) function, as assessed by lower prolactin (PRL) response to fenfluramine (FEN), a specific 5-HT releaser and uptake inhibitor, is associated with suicidal behavior in either depressed and personality disordered patients. Fenfluramine 129-132 prolactin Homo sapiens 98-101 12084422-2 2002 The purpose of this study was to investigate, in schizophrenic patients, the relationship between suicidal behavior and PRL response to D-fenfluramine (D-FEN). Dexfenfluramine 136-150 prolactin Homo sapiens 120-123 12084422-2 2002 The purpose of this study was to investigate, in schizophrenic patients, the relationship between suicidal behavior and PRL response to D-fenfluramine (D-FEN). Dexfenfluramine 152-157 prolactin Homo sapiens 120-123 12047930-2 2002 Two experiments were performed to test the hypothesis that blockade of glucose metabolism via administration of the glucose inhibitor 2-deoxy-D-glucose (2DG) to mares would cause a modification in gonadotropin and prolactin secretion. Glucose 71-78 prolactin Homo sapiens 214-223 12047930-2 2002 Two experiments were performed to test the hypothesis that blockade of glucose metabolism via administration of the glucose inhibitor 2-deoxy-D-glucose (2DG) to mares would cause a modification in gonadotropin and prolactin secretion. Glucose 116-123 prolactin Homo sapiens 214-223 12047930-2 2002 Two experiments were performed to test the hypothesis that blockade of glucose metabolism via administration of the glucose inhibitor 2-deoxy-D-glucose (2DG) to mares would cause a modification in gonadotropin and prolactin secretion. Deoxyglucose 134-151 prolactin Homo sapiens 214-223 12047930-2 2002 Two experiments were performed to test the hypothesis that blockade of glucose metabolism via administration of the glucose inhibitor 2-deoxy-D-glucose (2DG) to mares would cause a modification in gonadotropin and prolactin secretion. Deoxyglucose 153-156 prolactin Homo sapiens 214-223 12047930-7 2002 Mares treated with 100 mg 2DG/kg BW exhibited a significant increase in prolactin and mares treated with 100mg 2DG or 50mg 2DG/kg BW exhibited a significant increase in serum glucose concentrations, suggesting that glucoprivation was detected at these doses. Deoxyglucose 26-29 prolactin Homo sapiens 72-81 12114282-6 2002 PRL release after thyreoliberin stimulation (TRH, 200 g, i.v.) thyreoliberin 18-31 prolactin Homo sapiens 0-3 12050218-6 2002 The potential functional relevance of this increase in Stat5 is suggested by the ability of transiently transfected Stat5a or Stat5b to significantly enhance the response of the decidual PRL promoter to cAMP/MPA and attenuation of the response to cAMP/MPA by dominant negative Stat5. Cyclic AMP 247-251 prolactin Homo sapiens 187-190 12369265-2 2002 The aim of this study was to use fentanyl-induced prolactin response as an opiate receptor sensitivity test in patients with stereotypic movement disorder (SMD) manifesting SIB (skin picking). Fentanyl 33-41 prolactin Homo sapiens 50-59 12094689-16 2002 Postoperative serum PRL level remained high (66.9 ng/ml), but, subsequently, was normalized (9.5 ng/ml) with a bromocriptine therapy (15 mg daily). Bromocriptine 111-124 prolactin Homo sapiens 20-23 12369265-10 2002 Fentanyl elevated plasma prolactin in a dose-dependent manner. Fentanyl 0-8 prolactin Homo sapiens 25-34 12107619-0 2002 Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Haloperidol 47-58 prolactin Homo sapiens 14-23 12107619-7 2002 However, from a purely pharmacological point of view, prolactin response per drug concentration was more sensitive during haloperidol treatment than risperidone treatment, probably resulting from the potent and selective antagonistic effect of haloperidol on dopamine D(2) receptor, compared with the broader pharmacological spectrum of risperidone. Haloperidol 122-133 prolactin Homo sapiens 54-63 11968058-0 2002 Effects of prolactin on intracellular calcium concentration and cell proliferation in human glioma cells. Calcium 38-45 prolactin Homo sapiens 11-20 12107619-7 2002 However, from a purely pharmacological point of view, prolactin response per drug concentration was more sensitive during haloperidol treatment than risperidone treatment, probably resulting from the potent and selective antagonistic effect of haloperidol on dopamine D(2) receptor, compared with the broader pharmacological spectrum of risperidone. Haloperidol 244-255 prolactin Homo sapiens 54-63 12107619-7 2002 However, from a purely pharmacological point of view, prolactin response per drug concentration was more sensitive during haloperidol treatment than risperidone treatment, probably resulting from the potent and selective antagonistic effect of haloperidol on dopamine D(2) receptor, compared with the broader pharmacological spectrum of risperidone. Risperidone 337-348 prolactin Homo sapiens 54-63 12007589-3 2002 Prolactin responses to the administration of clomipramine (i.v.) Clomipramine 45-57 prolactin Homo sapiens 0-9 12007589-6 2002 In the drug-free state, schizophrenic patients exhibited significantly increased prolactin responses to clomipramine administration compared with both the healthy control subjects and the schizophreniform patients. Clomipramine 104-116 prolactin Homo sapiens 81-90 12007589-7 2002 Maximum prolactin responses to clomipramine in the total group of patients were positively correlated with the duration of psychotic illness and negatively correlated with changes in Positive and Negative Syndrome Scale (PANSS) total, negative symptoms and general psychopathology scores after 5 weeks of treatment with haloperidol. Clomipramine 31-43 prolactin Homo sapiens 8-17 12007589-7 2002 Maximum prolactin responses to clomipramine in the total group of patients were positively correlated with the duration of psychotic illness and negatively correlated with changes in Positive and Negative Syndrome Scale (PANSS) total, negative symptoms and general psychopathology scores after 5 weeks of treatment with haloperidol. Haloperidol 320-331 prolactin Homo sapiens 8-17 12007589-8 2002 Prolactin responses to haloperidol challenge in the drug-free state were lower in the schizophreniform group than in the control and the schizophrenic groups, but the differences did not reach statistical significance. Haloperidol 23-34 prolactin Homo sapiens 0-9 11983290-0 2002 The decline in serum choline concentration in humans during and after surgery is associated with the elevation of cortisol, adrenocorticotropic hormone, prolactin and beta-endorphin concentrations. Choline 21-28 prolactin Homo sapiens 153-162 11983290-5 2002 The decrease in serum choline was associated and inversely correlated with the increase in serum cortisol (P<0.001; r = -0.642), prolactin (P<0.001; r = -0.756), -endorphin (P<0.001; r = -0.726) and ACTH (P<0.01; r = -0.458). Choline 22-29 prolactin Homo sapiens 132-141 11983290-6 2002 In conclusion, we found that abdominal surgery induces a decline in serum choline associated with an increase in circulating cortisol, prolactin, ACTH and -endorphin. Choline 74-81 prolactin Homo sapiens 135-144 11983191-5 2002 Baseline prolactin and prolactin response to d-fenfluramine were associated with the extent of previous cannabis use. Dexfenfluramine 45-59 prolactin Homo sapiens 23-32 12012275-0 2002 Effect of ionotropic and metabotropic glutamate agonists and D-aspartate on prolactin release from anterior pituitary cells. Glutamic Acid 38-47 prolactin Homo sapiens 76-85 12012275-0 2002 Effect of ionotropic and metabotropic glutamate agonists and D-aspartate on prolactin release from anterior pituitary cells. D-Aspartic Acid 61-72 prolactin Homo sapiens 76-85 12107619-0 2002 Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Risperidone 63-74 prolactin Homo sapiens 14-23 12107619-1 2002 The present study aimed to investigate intraindividual changes in plasma prolactin concentrations by switching from haloperidol treatment to risperidone treatment. Haloperidol 116-127 prolactin Homo sapiens 73-82 12107619-1 2002 The present study aimed to investigate intraindividual changes in plasma prolactin concentrations by switching from haloperidol treatment to risperidone treatment. Risperidone 141-152 prolactin Homo sapiens 73-82 12107619-3 2002 Prolactin concentration in plasma during risperidone treatment (median 87.5 ng/ml, range 5.3-298.1 ng/ml) was significantly ( P<0.01) higher than during haloperidol treatment (median 50.7 ng/ml, range 11.6-226.6 ng/ml). Risperidone 41-52 prolactin Homo sapiens 0-9 11983191-2 2002 METHODS: Prolactin response to d-fenfluramine was assessed in abstinent ecstasy users with concomitant use of cannabis only (n = 24, male/female 13/11) and in two control groups: healthy nonusers (n = 13, female) and exclusive cannabis users (n = 7, male). Dexfenfluramine 31-45 prolactin Homo sapiens 9-18 11983191-3 2002 RESULTS: Prolactin response to d-fenfluramine was slightly blunted in female ecstasy users. Dexfenfluramine 31-45 prolactin Homo sapiens 9-18 11983191-4 2002 Both male user samples exhibited a weak prolactin response to d-fenfluramine, but this was weaker in the group of cannabis users. Dexfenfluramine 62-76 prolactin Homo sapiens 40-49 11968058-11 2002 Furthermore, PRL induced a dose-dependent increase in [3H]thymidine incorporation levels and in cellular growth and survival, detected by the MTT method. Tritium 55-57 prolactin Homo sapiens 13-16 11968058-11 2002 Furthermore, PRL induced a dose-dependent increase in [3H]thymidine incorporation levels and in cellular growth and survival, detected by the MTT method. Thymidine 58-67 prolactin Homo sapiens 13-16 11968058-11 2002 Furthermore, PRL induced a dose-dependent increase in [3H]thymidine incorporation levels and in cellular growth and survival, detected by the MTT method. monooxyethylene trimethylolpropane tristearate 142-145 prolactin Homo sapiens 13-16 11994384-4 2002 Western blot analysis performed on proteins, extracted after up to 30 min culture with PRL, demonstrated rapid tyrosine and threonine phosphorylation of ERK 1 and 2 MAPKs. Threonine 124-133 prolactin Homo sapiens 87-90 12063637-5 2002 These peptide hormones" ability to decrease circulating prolactin concentrations may be mediated in part by dopamine and in part by their demonstrated ability to decrease corticotropin-releasing hormone concentrations, which stimulate prolactin release. Dopamine 108-116 prolactin Homo sapiens 56-65 11994384-1 2002 Functional PRL receptors are expressed in the human endometrium during the secretory phase of the menstrual cycle in which PRL stimulates tyrosine phosphorylation of Janus kinase 2 and STAT (signal transducer and activator of transcription) 1 and 5. Tyrosine 138-146 prolactin Homo sapiens 11-14 11994384-1 2002 Functional PRL receptors are expressed in the human endometrium during the secretory phase of the menstrual cycle in which PRL stimulates tyrosine phosphorylation of Janus kinase 2 and STAT (signal transducer and activator of transcription) 1 and 5. Tyrosine 138-146 prolactin Homo sapiens 123-126 11994384-4 2002 Western blot analysis performed on proteins, extracted after up to 30 min culture with PRL, demonstrated rapid tyrosine and threonine phosphorylation of ERK 1 and 2 MAPKs. Tyrosine 111-119 prolactin Homo sapiens 87-90 12019665-0 2002 Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Olanzapine 11-21 prolactin Homo sapiens 25-34 12175775-3 2002 Assays of aggregation of human prolactin and growth hormone in neuroendocrine cells indicate that acidic intracellular compartments are necessary, and Zn2+ and Cu2+ may facilitate aggregation through low affinity binding sites. Zinc 151-155 prolactin Homo sapiens 31-40 12019665-0 2002 Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. Risperidone 93-104 prolactin Homo sapiens 25-34 12019665-6 2002 RESULTS: Serum prolactin levels decreased significantly (p < .01) following the switch from risperidone to olanzapine. Risperidone 95-106 prolactin Homo sapiens 15-24 12019665-6 2002 RESULTS: Serum prolactin levels decreased significantly (p < .01) following the switch from risperidone to olanzapine. Olanzapine 110-120 prolactin Homo sapiens 15-24 11927190-2 2002 In order to determine whether blunted prolactin responses to clomipramine challenge is a "state" vs. "trait" marker in depression, we applied this challenge paradigm to 20 patients with Major Depression prior to treatment and at three additional time points following response to desipramine: at the completion of acute treatment; at the end of the continuation phase of treatment; and after a minimum of three weeks "washout" following the discontinuation of treatment. Clomipramine 61-73 prolactin Homo sapiens 38-47 12175775-3 2002 Assays of aggregation of human prolactin and growth hormone in neuroendocrine cells indicate that acidic intracellular compartments are necessary, and Zn2+ and Cu2+ may facilitate aggregation through low affinity binding sites. cupric ion 160-164 prolactin Homo sapiens 31-40 11927190-3 2002 The prolactin response to clomipramine challenge was blunted in depressed patients compared with matched healthy control subjects, at each time point over the longitudinal course of their illness and recovery. Clomipramine 26-38 prolactin Homo sapiens 4-13 11927190-5 2002 Blunted prolactin response to clomipramine challenge persists in depressed patients after recovery from acute illness, and may reflect an underlying biological vulnerability. Clomipramine 30-42 prolactin Homo sapiens 8-17 12030773-6 2002 Our results show that endosulfan and chlordane are able to induce a substantial increase of PRL expression while these two chemicals do not increase cell growth. Endosulfan 22-32 prolactin Homo sapiens 92-95 11959366-10 2002 Risperidone treatment significantly increased the serum PRL levels of schizophrenic patients. Risperidone 0-11 prolactin Homo sapiens 56-59 11959366-11 2002 There was a close relationship between the improvement in positive symptoms and the change of serum PRL level before and after risperidone treatment. Risperidone 127-138 prolactin Homo sapiens 100-103 11959366-12 2002 The serum PRL levels at baseline could be used to predict the responses of schizophrenic patients to risperidone. Risperidone 101-112 prolactin Homo sapiens 10-13 11935401-1 2002 Prolactin secretion is controlled by the hypothalamus, and by circulating steroids; oestrogens stimulate, but glucocorticoids inhibit prolactin release. Steroids 74-82 prolactin Homo sapiens 0-9 11935401-5 2002 Oestradiol and testosterone can stimulate rapid release of prolactin selectively from type II lactotrophs characterised by small round vesicles. Estradiol 0-10 prolactin Homo sapiens 59-68 11935401-5 2002 Oestradiol and testosterone can stimulate rapid release of prolactin selectively from type II lactotrophs characterised by small round vesicles. Testosterone 15-27 prolactin Homo sapiens 59-68 11935401-12 2002 Both oestradiol and glucocorticoids therefore influence the secretion of prolactin by novel direct and indirect mechanisms, in addition to their much better understood effects on transcription via classical intracellular steroid receptors. Estradiol 5-15 prolactin Homo sapiens 73-82 11897686-2 2002 In transfected AtT20 cells, but not COS cells, Lubrol-insoluble aggregates of human prolactin (PRL) accumulated within 30 min after synthesis. lubrol 47-53 prolactin Homo sapiens 84-93 11897686-2 2002 In transfected AtT20 cells, but not COS cells, Lubrol-insoluble aggregates of human prolactin (PRL) accumulated within 30 min after synthesis. lubrol 47-53 prolactin Homo sapiens 95-98 11897686-5 2002 In solution, purified recombinant human PRL was precipitated by 20 microM Cu(2+) or Zn(2+). Copper 74-76 prolactin Homo sapiens 40-43 11897686-5 2002 In solution, purified recombinant human PRL was precipitated by 20 microM Cu(2+) or Zn(2+). Zinc 84-86 prolactin Homo sapiens 40-43 11897686-7 2002 In solution with polyethylene glycol, precipitation occurred with acidic pH, precipitation with Zn(2+) occurred effectively at acidic pH, and the ratio of Zn(2+) to PRL was less than 1. Polyethylene Glycols 17-36 prolactin Homo sapiens 165-168 11959366-0 2002 Risperidone-induced increase in serum prolactin is correlated with positive symptom improvement in chronic schizophrenia. Risperidone 0-11 prolactin Homo sapiens 38-47 11959366-2 2002 Recently, increased prolactin levels have been reported in patients taking risperidone. Risperidone 75-86 prolactin Homo sapiens 20-29 11959366-3 2002 The purpose of this study was to explore the effect of the atypical antipsychotic drug risperidone on serum prolactin, and to investigate the relationship between the change in PRL and the therapeutic outcome. Risperidone 87-98 prolactin Homo sapiens 108-117 11959366-8 2002 The results showed that risperidone treatment significantly increased the serum PRL. Risperidone 24-35 prolactin Homo sapiens 80-83 11925390-4 2002 This study aimed to evaluate PRL and GH secretion after metoclopramide and thyrotrophin-releasing hormone (TRH) infusion in infertile patients with minimal/mild endometriosis. Metoclopramide 56-70 prolactin Homo sapiens 29-32 12030773-6 2002 Our results show that endosulfan and chlordane are able to induce a substantial increase of PRL expression while these two chemicals do not increase cell growth. Chlordan 37-46 prolactin Homo sapiens 92-95 12030773-7 2002 Together, our results suggest that endosulfan and chlordane could indeed modulate an estrogen-inducible gene such as PRL, possibly acting via second messenger-mediated cellular mechanisms instead of solely competing with estrogens for the nuclear estrogen receptor sites. Endosulfan 35-45 prolactin Homo sapiens 117-120 12030773-7 2002 Together, our results suggest that endosulfan and chlordane could indeed modulate an estrogen-inducible gene such as PRL, possibly acting via second messenger-mediated cellular mechanisms instead of solely competing with estrogens for the nuclear estrogen receptor sites. Chlordan 50-59 prolactin Homo sapiens 117-120 11927145-0 2002 Prolactin but not ACTH increases during sodium lactate-induced panic attacks. Sodium Lactate 40-54 prolactin Homo sapiens 0-9 11943200-1 2002 p21-activated protein kinase gamma-PAK phosphorylates prolactin (PRL) in rat pituitary secretory granules on Ser-177 and on the equivalent site, Ser-179, in recombinant human PRL. Serine 109-112 prolactin Homo sapiens 65-68 11927145-2 2002 We measured the response of another stress-sensitive hormone, prolactin, to standard lactate and placebo infusion in a double-blind randomised design in eight patients with panic disorder and eight matched normal controls. Lactic Acid 85-92 prolactin Homo sapiens 62-71 12010287-0 2002 MR imaging of pituitary adenomas treated with the prolactin inhibitor quinagolide. quinagolide 70-81 prolactin Homo sapiens 50-59 11912073-4 2002 ACTH and prolactin correlated positively with cortisol, DHEAS and testosterone in women, which suggests that prolactin and ACTH could contribute to stimulated adrenal androgen production. Dehydroepiandrosterone Sulfate 56-61 prolactin Homo sapiens 9-18 11912073-4 2002 ACTH and prolactin correlated positively with cortisol, DHEAS and testosterone in women, which suggests that prolactin and ACTH could contribute to stimulated adrenal androgen production. Dehydroepiandrosterone Sulfate 56-61 prolactin Homo sapiens 109-118 11912073-4 2002 ACTH and prolactin correlated positively with cortisol, DHEAS and testosterone in women, which suggests that prolactin and ACTH could contribute to stimulated adrenal androgen production. Testosterone 66-78 prolactin Homo sapiens 9-18 11912073-4 2002 ACTH and prolactin correlated positively with cortisol, DHEAS and testosterone in women, which suggests that prolactin and ACTH could contribute to stimulated adrenal androgen production. Testosterone 66-78 prolactin Homo sapiens 109-118 12168912-2 2002 It has already been demonstrated that low-dose bromocriptine, an antiprolactinemic long-acting dopaminergic drug, normalizes PRL blood concentrations in metastatic breast cancer patients with abnormally elevated PRL levels. Bromocriptine 47-60 prolactin Homo sapiens 125-128 12168912-2 2002 It has already been demonstrated that low-dose bromocriptine, an antiprolactinemic long-acting dopaminergic drug, normalizes PRL blood concentrations in metastatic breast cancer patients with abnormally elevated PRL levels. Bromocriptine 47-60 prolactin Homo sapiens 212-215 12168912-9 2002 Bromocriptine therapy induced a significant decline in PRL mean blood concentrations compared to patients treated by chemotherapy alone. Bromocriptine 0-13 prolactin Homo sapiens 55-58 12168912-14 2002 This preliminary clinical study would suggest that the inhibition of PRL secretion by antiprolactinemic drugs such as bromocriptine may enhance the efficacy of chemotherapy for metastatic breast cancer. Bromocriptine 118-131 prolactin Homo sapiens 69-72 12010287-2 2002 MATERIAL AND METHODS: The effect of the prolactin inhibitor quinagolide on the volume of pituitary adenoma was evaluated retrospectively in 11 female patients. quinagolide 60-71 prolactin Homo sapiens 40-49 11914736-5 2002 Their DNA binding activity and their transactivating potency can be modified in response to nutrients (glucose, NEFA) or hormonal stimuli (insulin, leptin, glucagon like peptide-1, growth hormone, prolactin) through kinase-dependent signalling pathways (PI3-K, p38MAPK, PKA, CaMK) modulating their affinities for DNA and/or for each other. Fatty Acids, Nonesterified 112-116 prolactin Homo sapiens 197-206 11914736-5 2002 Their DNA binding activity and their transactivating potency can be modified in response to nutrients (glucose, NEFA) or hormonal stimuli (insulin, leptin, glucagon like peptide-1, growth hormone, prolactin) through kinase-dependent signalling pathways (PI3-K, p38MAPK, PKA, CaMK) modulating their affinities for DNA and/or for each other. Glucose 103-110 prolactin Homo sapiens 197-206 11861540-4 2002 Furthermore, we demonstrate a functional basis for these gene expression oscillations, inasmuch as PRL-GE pulses were sensitive to calcium-dependent modulation, which we show arose exclusively as changes in the shape of individual pulse episodes. Calcium 131-138 prolactin Homo sapiens 99-102 12008749-5 2002 Two-week treatment with cabergoline, a dopamine D2 receptor agonist, decreased serum PRL and GH levels, and size of the tumor. Cabergoline 24-35 prolactin Homo sapiens 85-88 11942771-1 2002 OBJECTIVE: To investigate whether the serum prolactin (PRL) response to a dopamine antagonist was different in nonobese, euthyroid women with malignant or benign breast tumors in comparison with healthy women, considering their age at first full-term pregnancy or their nulliparity. Dopamine 74-82 prolactin Homo sapiens 44-53 11942771-1 2002 OBJECTIVE: To investigate whether the serum prolactin (PRL) response to a dopamine antagonist was different in nonobese, euthyroid women with malignant or benign breast tumors in comparison with healthy women, considering their age at first full-term pregnancy or their nulliparity. Dopamine 74-82 prolactin Homo sapiens 55-58 11942771-4 2002 RESULTS: Early parous women with invasive breast cancer (both premenopausal and postmenopausal) and early parous premenopausal women with benign breast disease had significantly higher serum PRL concentrations in response to administration of metoclopramide (P<0.05) and a greater area under the PRL curve (P<0.05) than those observed in early parous healthy women. Metoclopramide 243-257 prolactin Homo sapiens 191-194 11942771-4 2002 RESULTS: Early parous women with invasive breast cancer (both premenopausal and postmenopausal) and early parous premenopausal women with benign breast disease had significantly higher serum PRL concentrations in response to administration of metoclopramide (P<0.05) and a greater area under the PRL curve (P<0.05) than those observed in early parous healthy women. Metoclopramide 243-257 prolactin Homo sapiens 299-302 11944969-2 2002 Recombinant goldfish prolactin was expressed mainly as insoluble inclusion bodies in the form of N-terminal 6x His-tagged fusion protein. Histidine 111-114 prolactin Homo sapiens 21-30 11944969-8 2002 In this case, the Ca(2+) ionophore A23187 and protein kinase C activator TPA were effective in elevating basal levels of prolactin secretion in perifused goldfish pituitary cells. Calcimycin 35-41 prolactin Homo sapiens 121-130 11944969-8 2002 In this case, the Ca(2+) ionophore A23187 and protein kinase C activator TPA were effective in elevating basal levels of prolactin secretion in perifused goldfish pituitary cells. Tetradecanoylphorbol Acetate 73-76 prolactin Homo sapiens 121-130 11944969-9 2002 In parallel studies using a static incubation approach, somatostatin and dopamine, but not vasoactive intestinal polypeptide, were inhibitory to basal prolactin release in goldfish pituitary cells. Dopamine 73-81 prolactin Homo sapiens 151-160 11944969-10 2002 These results suggest that somatostatin and dopamine may serve as negative regulators of basal prolactin secretion and that extracellular Ca(2+) influx and protein kinase C activation may be important signaling events mediating prolactin release in the goldfish. Dopamine 44-52 prolactin Homo sapiens 95-104 11949767-11 2002 Haloperidol, but not ketanserin, elevated serum prolactin level. Haloperidol 0-11 prolactin Homo sapiens 48-57 11836053-1 2002 Two spectrophotometric procedures are described for the determination of clobetasol propionate(I), halobetasol propionate(II) (corticosteroids) and quinagolide hydrochloride(III) (prolactin inhibitor). quinagolide 148-173 prolactin Homo sapiens 180-189 11985379-2 2002 Dopamine is the major inhibitory factor of prolactin release and also influences growth hormone (hGH) secretion. Dopamine 0-8 prolactin Homo sapiens 43-52 11846864-7 2002 From the marked increase in PRL level and the slight decrease in T/E2 ratio observed during sulpiride therapy, it is proposed that sulpiride may induce gynecomastia by inhibiting hypothalamic-pituitary function directly, and/or indirectly through hyperPRLemia. Sulpiride 131-140 prolactin Homo sapiens 28-31 11790522-0 2002 Retest reliability of prolactin response to dl-fenfluramine challenge in adults. Fenfluramine 44-59 prolactin Homo sapiens 22-31 11790522-4 2002 dl-Fenfluramine was administered here to 57 adults, aged 24-60 years, on two occasions 6 months apart, to examine the retest reliability of fenfluramine-induced prolactin [PRL] response to fenfluramine. Fenfluramine 140-152 prolactin Homo sapiens 161-170 11790522-4 2002 dl-Fenfluramine was administered here to 57 adults, aged 24-60 years, on two occasions 6 months apart, to examine the retest reliability of fenfluramine-induced prolactin [PRL] response to fenfluramine. Fenfluramine 140-152 prolactin Homo sapiens 172-175 11790522-5 2002 Baseline PRL concentration (i.e., before administration of fenfluramine) was highly stable over the 6 months (r = 0.88). Fenfluramine 59-71 prolactin Homo sapiens 9-12 11880864-3 2002 The present study was carried out to analyze the effects of the new antiandrogen agent bicalutamide on basal levels of PRL and on its response to L-dopa in metastatic prostate cancer patients. bicalutamide 87-99 prolactin Homo sapiens 119-122 11880864-0 2002 Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients. bicalutamide 10-22 prolactin Homo sapiens 34-43 11880864-10 2002 Mean PRL basal levels decreased after bicalutamide therapy, without, however, significant differences. bicalutamide 38-50 prolactin Homo sapiens 5-8 11880864-0 2002 Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients. Levodopa 56-62 prolactin Homo sapiens 34-43 11880864-1 2002 OBJECTIVES: The secretion of prolactin (PRL), which is a growth factor for prostate cancer cell proliferation, has been proven to present profound alterations in advanced prostate cancer patients, consisting of abnormally elevated baseline levels and paradoxical response to L-dopa. Levodopa 275-281 prolactin Homo sapiens 29-38 11880864-12 2002 Moreover, bicalutamide therapy significantly reduced PRL increase in response to L-dopa. bicalutamide 10-22 prolactin Homo sapiens 53-56 11880864-1 2002 OBJECTIVES: The secretion of prolactin (PRL), which is a growth factor for prostate cancer cell proliferation, has been proven to present profound alterations in advanced prostate cancer patients, consisting of abnormally elevated baseline levels and paradoxical response to L-dopa. Levodopa 275-281 prolactin Homo sapiens 40-43 11880864-12 2002 Moreover, bicalutamide therapy significantly reduced PRL increase in response to L-dopa. Levodopa 81-87 prolactin Homo sapiens 53-56 11854098-1 2002 Prolactin (PRL) is capable of stimulating both calcium and nitric oxide (NO) accumulation in mammary epithelial cells within 15min. Calcium 47-54 prolactin Homo sapiens 0-9 11880864-14 2002 Moreover, the study shows that the antitumor therapy with the new anti-androgen bicalutamide may reduce PRL secretion and improve its paradoxical secretion in response to L.-Dopa. bicalutamide 80-92 prolactin Homo sapiens 104-107 11854098-1 2002 Prolactin (PRL) is capable of stimulating both calcium and nitric oxide (NO) accumulation in mammary epithelial cells within 15min. Calcium 47-54 prolactin Homo sapiens 11-14 11854098-1 2002 Prolactin (PRL) is capable of stimulating both calcium and nitric oxide (NO) accumulation in mammary epithelial cells within 15min. Nitric Oxide 59-71 prolactin Homo sapiens 0-9 11755721-10 2002 GnRH-stimulated LH production was enhanced in PRL-treated sows compared to that of control sows (P<0.05). Luteinizing Hormone 16-18 prolactin Homo sapiens 46-49 11854098-1 2002 Prolactin (PRL) is capable of stimulating both calcium and nitric oxide (NO) accumulation in mammary epithelial cells within 15min. Nitric Oxide 59-71 prolactin Homo sapiens 11-14 11854098-3 2002 Furthermore, maximal concentrations of PRL and the ionophore were not additive, suggesting that they were both using the same pathway, i.e. calcium. Calcium 140-147 prolactin Homo sapiens 39-42 11854098-4 2002 Finally, the depletion of intracellular calcium completely abrogated the effect of PRL on NO production. Calcium 40-47 prolactin Homo sapiens 83-86 11854098-7 2002 Therefore, the ability of PRL to stimulate NO production at 15min can be completely explained by its ability to elevate intracellular calcium. Calcium 134-141 prolactin Homo sapiens 26-29 11817505-5 2002 The present study thus suggests that the spectrum of nemonapride-induced side effects is characterized by predominant extrapyramidal symptoms, and that prolactin response as an index of dopamine blockade reflects severity of EPS at least in male patients treated with nemonapride. Dopamine 186-194 prolactin Homo sapiens 152-161 11900622-0 2002 Serum prolactin and response to treatment among cocaine-dependent individuals. Cocaine 48-55 prolactin Homo sapiens 6-15 11904200-8 2002 Medical treatment with the dopamine agonist cabergoline was given; it was effective in normalizing prolactin levels and inducing tumor shrinkage. Dopamine 27-35 prolactin Homo sapiens 99-108 11904200-8 2002 Medical treatment with the dopamine agonist cabergoline was given; it was effective in normalizing prolactin levels and inducing tumor shrinkage. Cabergoline 44-55 prolactin Homo sapiens 99-108 11998830-0 2002 Administration of sulpiride to anovulatory mares in winter: effects on prolactin and gonadotropin concentrations, ovarian activity, ovulation and hair shedding. Sulpiride 18-27 prolactin Homo sapiens 71-80 11998830-2 2002 Sulpiride administration increased daily plasma prolactin concentrations (P < 0.05), although the prolactin response during the 6 h following sulpiride injections decreased markedly from the 1st to the 6th day of treatment (treatment by day, P < 0.0001). Sulpiride 0-9 prolactin Homo sapiens 48-57 11998830-2 2002 Sulpiride administration increased daily plasma prolactin concentrations (P < 0.05), although the prolactin response during the 6 h following sulpiride injections decreased markedly from the 1st to the 6th day of treatment (treatment by day, P < 0.0001). Sulpiride 145-154 prolactin Homo sapiens 101-110 11998830-4 2002 Injection of GnRH and TRH on 15 February showed that the response of plasma prolactin to secretagogue was increased in sulpiride-treated mares (P < 0.005), while there was no effect (P > 0.1) of sulpiride treatment on the response of LH or FSH. Sulpiride 119-128 prolactin Homo sapiens 76-85 11998830-4 2002 Injection of GnRH and TRH on 15 February showed that the response of plasma prolactin to secretagogue was increased in sulpiride-treated mares (P < 0.005), while there was no effect (P > 0.1) of sulpiride treatment on the response of LH or FSH. Sulpiride 201-210 prolactin Homo sapiens 76-85 11998830-9 2002 It was concluded that sulpiride administration to seasonally anovulatory mares under the conditions of our experiment increased daily plasma prolactin levels but did not stimulate gonadotropin secretion or ovarian activity. Sulpiride 22-31 prolactin Homo sapiens 141-150 11772702-4 2002 RESULTS: The baseline prolactin levels in patients receiving risperidone (mean=27 ng/ml, SD=14) were abnormally high, but baseline prolactin levels in patients receiving olanzapine (mean=9 ng/ml, SD=5) and clozapine (mean=9 ng/ml, SD=5) were not high. Risperidone 61-72 prolactin Homo sapiens 22-31 12613913-0 2002 Prolactin inhibits carbachol-dependent secretion by lacrimal acinar cells in vitro. Carbachol 19-28 prolactin Homo sapiens 0-9 11772702-4 2002 RESULTS: The baseline prolactin levels in patients receiving risperidone (mean=27 ng/ml, SD=14) were abnormally high, but baseline prolactin levels in patients receiving olanzapine (mean=9 ng/ml, SD=5) and clozapine (mean=9 ng/ml, SD=5) were not high. Olanzapine 170-180 prolactin Homo sapiens 131-140 11772477-2 2002 The relationship between years of excessive alcohol consumption and central serotonergic neurotransmission, as assessed by the prolactin (PRL) response to D-fenfluramine, was investigated in 22 male alcohol-dependent subjects. Dexfenfluramine 155-169 prolactin Homo sapiens 138-141 11772847-3 2002 METHOD: We used a double-blind, placebo-controlled design to measure the prolactin and cortisol responses to citalopram (10 mg intravenously) in patients with major depression, in unmedicated subjects recovered from depression and in healthy controls. Citalopram 109-119 prolactin Homo sapiens 73-82 11772847-4 2002 RESULTS: The prolactin responses to citalopram were blunted similarly in both acutely depressed and recovered subjects. Citalopram 36-46 prolactin Homo sapiens 13-22 11772477-2 2002 The relationship between years of excessive alcohol consumption and central serotonergic neurotransmission, as assessed by the prolactin (PRL) response to D-fenfluramine, was investigated in 22 male alcohol-dependent subjects. Alcohols 44-51 prolactin Homo sapiens 138-141 11772477-3 2002 A negative correlation was obtained, that is, the longer duration of excessive alcohol consumption the lower PRL response to D-fenfluramine. Dexfenfluramine 125-139 prolactin Homo sapiens 109-112 11772477-5 2002 The relationship between depressive and anxiety symptoms during on-going drinking and the PRL response to D-fenfluramine was also investigated. Dexfenfluramine 106-120 prolactin Homo sapiens 90-93 12207145-0 2002 Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. benzamide 37-46 prolactin Homo sapiens 97-106 11979064-0 2002 Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients. Sertraline 11-21 prolactin Homo sapiens 52-61 11979064-6 2002 The data show different and time-dependent effects of sertraline treatment on plasma cortisol, PRL and thyroid hormones in female depressed patients. Sertraline 54-64 prolactin Homo sapiens 95-98 12593790-0 2002 Ritonavir and Saquinavir directly stimulate anterior pituitary prolactin secretion, in vitro. Ritonavir 0-9 prolactin Homo sapiens 63-72 12593790-0 2002 Ritonavir and Saquinavir directly stimulate anterior pituitary prolactin secretion, in vitro. Saquinavir 14-24 prolactin Homo sapiens 63-72 12593790-2 2002 This could be explained by a direct effect of ritonavir and saquinavir on anterior pituitary prolactin (PRL) release, and/or an indirect effect of PIs on the secretion of hypothalamic dopamine, which is the main PRL inhibitory factor. Ritonavir 46-55 prolactin Homo sapiens 93-102 12593790-2 2002 This could be explained by a direct effect of ritonavir and saquinavir on anterior pituitary prolactin (PRL) release, and/or an indirect effect of PIs on the secretion of hypothalamic dopamine, which is the main PRL inhibitory factor. Saquinavir 60-70 prolactin Homo sapiens 93-102 12207145-0 2002 Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Amisulpride 58-69 prolactin Homo sapiens 97-106 12207145-1 2002 In the present study, we investigated the long-term effects of treatment with amisulpride, a substituted benzamide derivative, as compared with the effects of treatment with flupenthixol, a thioxanthene, on the prolactin levels in schizophrenic patients. Flupenthixol 174-186 prolactin Homo sapiens 211-220 14558674-8 2002 Six patients had normal L PRL levels, and their hyper PRL was due to excess BPRL or BB PRL. boeravinone B 84-86 prolactin Homo sapiens 54-57 14558674-8 2002 Six patients had normal L PRL levels, and their hyper PRL was due to excess BPRL or BB PRL. boeravinone B 84-86 prolactin Homo sapiens 54-57 14558674-11 2002 Furthermore in patients with clinically controlled prolactinomas the presence of PRL variants should be ruled out to avoid an unnecessary increase of dopamine agonist dosage. Dopamine 150-158 prolactin Homo sapiens 81-84 12397853-3 2002 Conventional antipsychotic medications and the atypical agent risperidone cause significant elevations in prolactin. Risperidone 62-73 prolactin Homo sapiens 106-115 12397853-4 2002 Clozapine, olanzapine, quetiapine, and ziprasidone cause minimal effects on prolactin levels in adults, which may be due to a higher 5-HT2A:D2 binding ratio and differential effects on dopamine neurotransmission, with less interference in the tuberoinfundibular pathway. ziprasidone 39-50 prolactin Homo sapiens 76-85 12207145-8 2002 Flupenthixol treatment initially raised the prolactin levels about two- or threefold, and a subsequent decline during months 3 and 6 occurred. Flupenthixol 0-12 prolactin Homo sapiens 44-53 12207145-10 2002 The prolactin secretion was initially increased over tenfold by amisulpride. Amisulpride 64-75 prolactin Homo sapiens 4-13 12207145-14 2002 Notably, in the amisulpride group, 3 months after cessation of treatment at month 12, the elevated levels of prolactin returned to baseline at month 15. Amisulpride 16-27 prolactin Homo sapiens 109-118 12207145-15 2002 In summary, amisulpride demonstrated more pronounced effects than flupenthixol on the prolactin levels. Amisulpride 12-23 prolactin Homo sapiens 86-95 12207145-15 2002 In summary, amisulpride demonstrated more pronounced effects than flupenthixol on the prolactin levels. Flupenthixol 66-78 prolactin Homo sapiens 86-95 12207145-16 2002 However, the findings indicate also that treatment with amisulpride at clinically effective doses can be achieved at significantly lower prolactin levels during the long-term maintenance phase than during the prior acute phase. Amisulpride 56-67 prolactin Homo sapiens 137-146 12557612-1 2002 We report on the occurrence of galactorrhea and amenorrhea associated with prolactin elevation after 6 months of treatment with risperidone. Risperidone 128-139 prolactin Homo sapiens 75-84 11739329-0 2001 Dopamine as a prolactin (PRL) inhibitor. Dopamine 0-8 prolactin Homo sapiens 25-28 11728119-2 2001 Pregnancy-related breast hypertrophy is often arrested or reversed by reducing serum prolactin levels with bromocriptine therapy. Bromocriptine 107-120 prolactin Homo sapiens 85-94 11793612-7 2001 RESULTS: Prolactin (PRL) increased significantly during risperidone administration. Risperidone 56-67 prolactin Homo sapiens 9-18 11739329-4 2001 Dopamine reaches the pituitary via hypophysial portal blood from several hypothalamic nerve tracts that are regulated by PRL itself, estrogens, and several neuropeptides and neurotransmitters. Dopamine 0-8 prolactin Homo sapiens 121-124 11739329-6 2001 In addition to inhibiting PRL release by controlling calcium fluxes, dopamine activates several interacting intracellular signaling pathways and suppresses PRL gene expression and lactotroph proliferation. Calcium 53-60 prolactin Homo sapiens 26-29 11739329-6 2001 In addition to inhibiting PRL release by controlling calcium fluxes, dopamine activates several interacting intracellular signaling pathways and suppresses PRL gene expression and lactotroph proliferation. Dopamine 69-77 prolactin Homo sapiens 26-29 11739329-6 2001 In addition to inhibiting PRL release by controlling calcium fluxes, dopamine activates several interacting intracellular signaling pathways and suppresses PRL gene expression and lactotroph proliferation. Dopamine 69-77 prolactin Homo sapiens 156-159 11739329-7 2001 Thus, PRL homeostasis should be viewed in the context of a fine balance between the action of dopamine as an inhibitor and the many hypothalamic, systemic, and local factors acting as stimulators, none of which has yet emerged as a primary PRL releasing factor. Dopamine 94-102 prolactin Homo sapiens 6-9 11739329-8 2001 The generation of transgenic animals with overexpressed or mutated genes expanded our understanding of dopamine-PRL interactions and the physiological consequences of their perturbations. Dopamine 103-111 prolactin Homo sapiens 112-115 11583917-0 2001 Prolactin induces calcium influx and release from intracellular pools in human T lymphocytes by activation of tyrosine kinases. Calcium 18-25 prolactin Homo sapiens 0-9 11769817-13 2001 Haloperidol, but not clozapine, elevated serum prolactin levels. Haloperidol 0-11 prolactin Homo sapiens 47-56 11782718-3 2001 This study reports our observations of the integrated 24-hour concentrations of GH, IGF-I and prolactin (PRL) in acromegalic patients treated with octreotide (OC) and octreotide LAR (OC-LAR), highlighting lower percentages of apparent remissions. Octreotide 159-161 prolactin Homo sapiens 94-103 11684336-3 2001 MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn antagonizes the release of prolactin (PL). Dopamine 27-35 prolactin Homo sapiens 111-120 11684336-3 2001 MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn antagonizes the release of prolactin (PL). Dopamine 27-35 prolactin Homo sapiens 122-124 11684336-3 2001 MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn antagonizes the release of prolactin (PL). Dopamine 61-69 prolactin Homo sapiens 111-120 11684336-3 2001 MPH blocks the reuptake of dopamine, thus enhancing synaptic dopamine which in turn antagonizes the release of prolactin (PL). Dopamine 61-69 prolactin Homo sapiens 122-124 11583917-15 2001 In summary, PRL induces calcium influx in normal T lymphocytes. Calcium 24-31 prolactin Homo sapiens 12-15 11726571-0 2001 Plasma prolactin/oestradiol ratio at 38 weeks gestation predicts the duration of lactational amenorrhoea. Estradiol 17-27 prolactin Homo sapiens 7-16 11739463-6 2001 We found a significant correlation between PRL values and ADP stimulation of platelets in pregnant women (r = 0.56; P < 0.0001) and patients with pituitary tumors (r = 0.57; P = 0.006). Adenosine Diphosphate 58-61 prolactin Homo sapiens 43-46 11740295-7 2001 Furthermore, although no differences in the GH response to exercise were shown, a significantly reduced total PRL response to stress condition was observed after ASA. Aspirin 162-165 prolactin Homo sapiens 110-113 11740295-8 2001 CONCLUSION: ASA influences ACTH, beta-endorphin, cortisol, GH, and PRL responses to exercise-related stress in humans (preexercise activation/exercise-linked response). Aspirin 12-15 prolactin Homo sapiens 67-70 11899856-2 2001 It is noted that sulpiride clearly increases the evolution of prolactin in both sexes. Sulpiride 17-26 prolactin Homo sapiens 62-71 11899856-7 2001 In the article the analysis has been carried out how wider and wider used neuroleptic-sulpiride--influences upon endocrine system and particularly upon the evaluation of prolactin. Sulpiride 86-95 prolactin Homo sapiens 170-179 11583917-2 2001 The aim of this work was to study the effect of PRL in cytosolic calcium levels in human T lymphocytes. Calcium 65-72 prolactin Homo sapiens 48-51 11583917-4 2001 Fifty nanograms per milliliter PRL induces a small increase in cytosolic calcium. Calcium 73-80 prolactin Homo sapiens 31-34 11583917-5 2001 When the cells are preincubated overnight (16-20 h) in the presence of PRL, the increase in calcium is higher. Calcium 92-99 prolactin Homo sapiens 71-74 11583917-7 2001 That is, after overnight incubation with PRL, calcium influx in T cells follows the capacitative model. Calcium 46-53 prolactin Homo sapiens 41-44 11583917-10 2001 The presence of genistein also completely blocks the increase in cytosolic calcium stimulated by PRL after overnight incubation with PRL. Calcium 75-82 prolactin Homo sapiens 97-100 11583917-10 2001 The presence of genistein also completely blocks the increase in cytosolic calcium stimulated by PRL after overnight incubation with PRL. Calcium 75-82 prolactin Homo sapiens 133-136 11583917-11 2001 In the presence of PRL and N,N-dimethyl-D-erythro-sphingosine (DMS), a stimulus that increases cytosolic calcium in T cells by tyrosine kinase stimulation, a high, even insignificant, calcium influx is induced. Calcium 105-112 prolactin Homo sapiens 19-22 11583917-11 2001 In the presence of PRL and N,N-dimethyl-D-erythro-sphingosine (DMS), a stimulus that increases cytosolic calcium in T cells by tyrosine kinase stimulation, a high, even insignificant, calcium influx is induced. Calcium 184-191 prolactin Homo sapiens 19-22 11583917-12 2001 However, when the cells are incubated overnight in the presence of PRL, and then DMS is added, a significant increase in cytosolic calcium levels takes place. Calcium 131-138 prolactin Homo sapiens 67-70 11583917-14 2001 Genistein reduces the influx of external calcium induced by DMS after short incubation with PRL and significantly inhibits both, calcium pools empty, and calcium influx is induced by DMS after overnight incubation with PRL. Genistein 0-9 prolactin Homo sapiens 92-95 11583917-14 2001 Genistein reduces the influx of external calcium induced by DMS after short incubation with PRL and significantly inhibits both, calcium pools empty, and calcium influx is induced by DMS after overnight incubation with PRL. Genistein 0-9 prolactin Homo sapiens 219-222 11583917-14 2001 Genistein reduces the influx of external calcium induced by DMS after short incubation with PRL and significantly inhibits both, calcium pools empty, and calcium influx is induced by DMS after overnight incubation with PRL. Calcium 41-48 prolactin Homo sapiens 92-95 11679501-3 2001 It is suggested that a reduction of the dopamine inhibitory effect might raise both prolactin (PRL) and LH. Dopamine 40-48 prolactin Homo sapiens 84-93 11704898-13 2001 Moderate increases of prolactin levels were detected during administration of olanzapine. Olanzapine 78-88 prolactin Homo sapiens 22-31 11694320-10 2001 Also, pretreatment of granulocytes with a p38 MAPK inhibitor (SB 203580) prevented in part PRL-induced iNOS and IRF-1 expression. SB 203580 62-71 prolactin Homo sapiens 91-94 11680780-5 2001 The dopamine agonist bromocriptine, which inhibits pituitary secretion of prolactin, has been shown in a variety of small animal and human trials to reduce disease activity in SLE. Dopamine 4-12 prolactin Homo sapiens 74-83 11713611-1 2001 RATIONALE: Buspirone is used as a neuroendocrine challenge in which the increase of circulating prolactin is taken as a measure of the sensitivity of central serotonergic (5-HT(1A)) pathways. Buspirone 11-20 prolactin Homo sapiens 96-105 11713611-2 2001 Interpretation of the test is complicated, however, by the fact that buspirone possesses D(2) antagonist and 5-HT(1A) agonist activity, both of which will result in the release of prolactin. Buspirone 69-78 prolactin Homo sapiens 180-189 11713611-3 2001 To understand the significance of prolactin secretion in response to buspirone, it is important to measure the differential actions of the two controlling pathways. Buspirone 69-78 prolactin Homo sapiens 34-43 11713611-4 2001 OBJECTIVE: To characterise the dual action of buspirone in stimulating the secretion of prolactin by blocking the 5-HT(1A) action with the 5-HT1A antagonist action of pindolol. Buspirone 46-55 prolactin Homo sapiens 88-97 11713611-7 2001 RESULTS: Pindolol alone caused a small but significant reduction (18%) in the tonic release of prolactin. Pindolol 9-17 prolactin Homo sapiens 95-104 11713611-8 2001 Buspirone alone produced a robust prolactin response which was reduced to approximately half by pindolol pre-treatment. Buspirone 0-9 prolactin Homo sapiens 34-43 11713611-8 2001 Buspirone alone produced a robust prolactin response which was reduced to approximately half by pindolol pre-treatment. Pindolol 96-104 prolactin Homo sapiens 34-43 11713611-9 2001 Pindolol pre-treatment also, on average, delayed the onset and peak of the prolactin response. Pindolol 0-8 prolactin Homo sapiens 75-84 11713611-12 2001 However, if two challenges are carried out, one with buspirone and the other with buspirone plus pindolol, quantitative measures can be made of the sensitivity of both the 5-HT(1A) and the putative D(2) pathways controlling prolactin release. Pindolol 97-105 prolactin Homo sapiens 224-233 11680780-5 2001 The dopamine agonist bromocriptine, which inhibits pituitary secretion of prolactin, has been shown in a variety of small animal and human trials to reduce disease activity in SLE. Bromocriptine 21-34 prolactin Homo sapiens 74-83 11579944-0 2001 Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Cabergoline 29-40 prolactin Homo sapiens 62-71 11561066-1 2001 Atypical antipsychotic drugs, which are distinguished from typical antipsychotic drugs by a lower incidence of extra-pyramidal side effects and less propensity to elevate serum prolactin levels (e.g., clozapine, olanzapine, risperidone, quetiapine, ziprasidone), have become the most widely used treatments for schizophrenia, although their precise mechanism of action remains controversial. Olanzapine 212-222 prolactin Homo sapiens 177-186 11500255-5 2001 Buspirone was found to consistently elevate PRL levels above those seen following placebo administration. Buspirone 0-9 prolactin Homo sapiens 44-47 11500255-6 2001 The PRL response as measured by area under the curve was highly correlated with the baseline cortisol level. Hydrocortisone 93-101 prolactin Homo sapiens 4-7 11560566-7 2001 Conversely, D(2) dopamine receptor blockade by haloperidol is likely to be responsible for the increase in prolactin secretion evoked by the drug. Haloperidol 47-58 prolactin Homo sapiens 107-116 11561213-0 2001 Growth hormone and prolactin secretion after metoclopramide administration (DA2 receptor blockade) in fertile women. Metoclopramide 45-59 prolactin Homo sapiens 19-28 11579944-1 2001 OBJECTIVE: It is well known that bromocriptine has a suppressive effect on the prolactin release in hyperprolactinemic patients. Bromocriptine 33-46 prolactin Homo sapiens 79-88 11579944-7 2001 RESULTS: At the end of the study, the prolactin reduction was significantly greater in the cabergoline group than in the bromocriptine group (-93 vs. -87.5 %, respectively, p < 0.05). Cabergoline 91-102 prolactin Homo sapiens 38-47 11579944-8 2001 Normalization of prolactin levels was achieved in 10 of 17 patients (59%) in the bromocriptine group, and in 14 of 17 patients (82%) in the cabergoline group (p = 0.13). Bromocriptine 81-94 prolactin Homo sapiens 17-26 11579944-11 2001 CONCLUSION: These data indicate that cabergoline is a very effective agent for lowering the prolactin levels in hyperprolactinemic patients and that it appears to offer considerable advantage over bromocriptine in terms of efficacy and tolerability. Cabergoline 37-48 prolactin Homo sapiens 92-101 11579944-0 2001 Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Bromocriptine 45-58 prolactin Homo sapiens 62-71 11761431-2 2001 However, their relative incidence in recent surgical series is much less impressive since medical treatment with dopamine agonists is routinely employed, which in many cases leads to tumor shrinkage and normalization of prolactin levels. Dopamine 113-121 prolactin Homo sapiens 220-229 11418230-3 2001 When the group of subjects were divided into those with high and low PRL response (above and below median, respectively) to fenfluramine, those with high PRL response had a significant reduction in alcohol intake during citalopram treatment, whereas those with low PRL response had no such effect. Fenfluramine 124-136 prolactin Homo sapiens 69-72 11522467-0 2001 Prolactin response to dl-fenfluramine challenge before and after treatment with paroxetine. Fenfluramine 22-37 prolactin Homo sapiens 0-9 11522467-1 2001 The prolactin response to dl-fenfluramine (an indirect central serotonin agonist) challenge has been used to assess serotonergic function and appears to be blunted in depressed patients. Fenfluramine 26-41 prolactin Homo sapiens 4-13 11522467-7 2001 Treatment with paroxetine significantly increased the baseline prolactin level independently of treatment response but positively correlated with paroxetine dose. Paroxetine 15-25 prolactin Homo sapiens 63-72 11522467-8 2001 We found that pre-treatment prolactin response to dl-fenfluramine challenge did not predict clinical response to paroxetine, nor did the prolactin response change significantly after treatment. Fenfluramine 50-65 prolactin Homo sapiens 28-37 11522467-10 2001 We found evidence of increased prolactin levels that may reflect effects of paroxetine in enhancing serotonin levels. Paroxetine 76-86 prolactin Homo sapiens 31-40 11522467-10 2001 We found evidence of increased prolactin levels that may reflect effects of paroxetine in enhancing serotonin levels. Serotonin 100-109 prolactin Homo sapiens 31-40 11522467-11 2001 Acute release of serotonin as measured by the prolactin response to fenfluramine is not altered by paroxetine treatment. Serotonin 17-26 prolactin Homo sapiens 46-55 11522467-11 2001 Acute release of serotonin as measured by the prolactin response to fenfluramine is not altered by paroxetine treatment. Fenfluramine 68-80 prolactin Homo sapiens 46-55 11577979-0 2001 The prolactin releasing peptides: RF-amide peptides. Amides 37-42 prolactin Homo sapiens 4-13 11577979-1 2001 Although dopamine is considered the major hypothalamic controller of prolactin release from the anterior pituitary gland, there is evidence that a yet to be discovered prolactin releasing factor (PRF) also exists in brain. Dopamine 9-17 prolactin Homo sapiens 69-78 11418230-3 2001 When the group of subjects were divided into those with high and low PRL response (above and below median, respectively) to fenfluramine, those with high PRL response had a significant reduction in alcohol intake during citalopram treatment, whereas those with low PRL response had no such effect. Alcohols 198-205 prolactin Homo sapiens 154-157 11418230-3 2001 When the group of subjects were divided into those with high and low PRL response (above and below median, respectively) to fenfluramine, those with high PRL response had a significant reduction in alcohol intake during citalopram treatment, whereas those with low PRL response had no such effect. Alcohols 198-205 prolactin Homo sapiens 154-157 11418230-4 2001 Thus, in subjects with evidence of unimpaired or only slightly impaired central serotonergic neurotransmission (high PRL response) citalopram may have beneficial effect on alcohol consumption, whereas in those with more evidently impaired serotonergic neurotransmission (low PRL response) citalopram treatment may have no effect on or may even increase the alcohol consumption. Citalopram 131-141 prolactin Homo sapiens 117-120 11418230-4 2001 Thus, in subjects with evidence of unimpaired or only slightly impaired central serotonergic neurotransmission (high PRL response) citalopram may have beneficial effect on alcohol consumption, whereas in those with more evidently impaired serotonergic neurotransmission (low PRL response) citalopram treatment may have no effect on or may even increase the alcohol consumption. Citalopram 131-141 prolactin Homo sapiens 275-278 11495699-8 2001 RESULTS: STAT-5 tyrosine phosphorylation was similarly induced by PRL and IL-3, with an additive effect detected in the presence of both stimuli. Tyrosine 16-24 prolactin Homo sapiens 66-69 11560097-1 2001 The aim of the study was to evaluate the potential of human breast cancer tissue to secrete growth hormone (GH), insulin-like growth factor I (IGF-I) and prolactin in response to 10(-7) M progesterone stimulation. Progesterone 188-200 prolactin Homo sapiens 154-163 11476769-10 2001 bTSH correlated significantly with PRL (P<.001). btsh 0-4 prolactin Homo sapiens 35-38 11561931-0 2001 Risperidone added to clozapine: impact on serum prolactin levels. Risperidone 0-11 prolactin Homo sapiens 48-57 11561931-2 2001 Risperidone, in general, is well tolerated when administered as monotherapy, but has been linked to a persistent elevation of serum prolactin and associated symptoms. Risperidone 0-11 prolactin Homo sapiens 132-141 11561931-3 2001 The goal of this study was to determine whether the addition of risperidone to clozapine results in an elevation of serum prolactin levels in patients with chronic schizophrenia or schizoaffective disorder. Risperidone 64-75 prolactin Homo sapiens 122-131 11561931-3 2001 The goal of this study was to determine whether the addition of risperidone to clozapine results in an elevation of serum prolactin levels in patients with chronic schizophrenia or schizoaffective disorder. Clozapine 79-88 prolactin Homo sapiens 122-131 11561931-8 2001 The mean +/- SD serum prolactin level was 8.42+/-4.17 ng/mL for clozapine monotherapy patients and 35.76+/-17.43 ng/mL for combination therapy patients. Clozapine 64-73 prolactin Homo sapiens 22-31 11561931-11 2001 CONCLUSION: The combination of risperidone and clozapine appears to result in a moderate elevation of serum prolactin levels. Risperidone 31-42 prolactin Homo sapiens 108-117 11561931-11 2001 CONCLUSION: The combination of risperidone and clozapine appears to result in a moderate elevation of serum prolactin levels. Clozapine 47-56 prolactin Homo sapiens 108-117 11560097-3 2001 Our results show distinct differences in cultured breast cancer tissue responses to progesterone stimulation with regard to secretion of proliferative agents such as GH, IGF-I and prolactin. Progesterone 84-96 prolactin Homo sapiens 180-189 11560097-6 2001 This study provides evidence for the first time that in PR(+) breast cancer tissue, progesterone may increase GH, prolactin and IGF-I secretion in both malignant and surrounding non-malignant tissue. Progesterone 84-96 prolactin Homo sapiens 114-123 11512043-2 2001 Treatment with risperidone, though, results in considerably elevated plasma prolactin (PRL) levels which are not observed with other atypical neuroleptics, such as clozapine, indicating a differentiated action on receptors that are involved in PRL release, mainly dopaminergic and serotonergic. Risperidone 15-26 prolactin Homo sapiens 76-85 11524630-1 2001 BACKGROUND: Serotonin (5-HT) agonists are reported to affect prolactin (PRL) and gonadotropin secretion. Serotonin 12-21 prolactin Homo sapiens 72-75 11403983-0 2001 Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Olanzapine 11-21 prolactin Homo sapiens 47-56 11403983-0 2001 Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients. Haloperidol 26-37 prolactin Homo sapiens 47-56 11403983-2 2001 The aim of this study was to compare the effects of olanzapine and haloperidol on PRL secretion in male schizophrenic patients. Olanzapine 52-62 prolactin Homo sapiens 82-85 11403983-2 2001 The aim of this study was to compare the effects of olanzapine and haloperidol on PRL secretion in male schizophrenic patients. Haloperidol 67-78 prolactin Homo sapiens 82-85 11403983-7 2001 At the end of the 6th week, the PRL values observed with olanzapine treatment were significantly less than those observed with haloperidol, but not different from those of the controls. Olanzapine 57-67 prolactin Homo sapiens 32-35 11403983-8 2001 There was a significant positive correlation between the PRL values and the severity of extrapyramidal side effects in only the haloperidol group after the six week"s treatment period. Haloperidol 128-139 prolactin Homo sapiens 57-60 11512043-2 2001 Treatment with risperidone, though, results in considerably elevated plasma prolactin (PRL) levels which are not observed with other atypical neuroleptics, such as clozapine, indicating a differentiated action on receptors that are involved in PRL release, mainly dopaminergic and serotonergic. Risperidone 15-26 prolactin Homo sapiens 87-90 11403983-9 2001 Our data indicate that short-term olanzapine treatment at doses of 10 mg/day PO causes minimal elevations in PRL secretion in male schizophrenic patients in contrast to haloperidol. Olanzapine 34-44 prolactin Homo sapiens 109-112 11512043-2 2001 Treatment with risperidone, though, results in considerably elevated plasma prolactin (PRL) levels which are not observed with other atypical neuroleptics, such as clozapine, indicating a differentiated action on receptors that are involved in PRL release, mainly dopaminergic and serotonergic. Risperidone 15-26 prolactin Homo sapiens 244-247 11512043-4 2001 METHODS: Two neuroendocrine challenge tests, measuring the PRL increases induced by acute administration of serotonergic (clomipramine, 25 mg i.v.) Clomipramine 122-134 prolactin Homo sapiens 59-62 11512043-8 2001 PRL was estimated in blood samples taken every 15 min for 1 h for clomipramine and every 30 min for 2 h for haloperidol. Clomipramine 66-78 prolactin Homo sapiens 0-3 11512043-8 2001 PRL was estimated in blood samples taken every 15 min for 1 h for clomipramine and every 30 min for 2 h for haloperidol. Haloperidol 108-119 prolactin Homo sapiens 0-3 12138991-7 2001 Bromocriptine was reinitiated and the patient responded initially with decreasing headaches and declining PRL concentrations to 1488 microg/L at 15 weeks gestation. Bromocriptine 0-13 prolactin Homo sapiens 106-109 11512043-11 2001 haloperidol caused significant elevations in plasma PRL, which were totally abolished after 6 weeks treatment with risperidone (mean dose 12.1 mg/day, range 8-16 mg/day), indicating complete D2 receptor blockade. Haloperidol 0-11 prolactin Homo sapiens 52-55 11512043-11 2001 haloperidol caused significant elevations in plasma PRL, which were totally abolished after 6 weeks treatment with risperidone (mean dose 12.1 mg/day, range 8-16 mg/day), indicating complete D2 receptor blockade. Risperidone 115-126 prolactin Homo sapiens 52-55 11512043-12 2001 In contrast, the PRL increases obtained after clomipramine administration during neuroleptic treatment were preserved after treatment with risperidone. Clomipramine 46-58 prolactin Homo sapiens 17-20 11512043-12 2001 In contrast, the PRL increases obtained after clomipramine administration during neuroleptic treatment were preserved after treatment with risperidone. Risperidone 139-150 prolactin Homo sapiens 17-20 11512043-13 2001 Both PRL response patterns to clomipramine were similar to that of healthy controls. Clomipramine 30-42 prolactin Homo sapiens 5-8 11512043-15 2001 CONCLUSIONS: During treatment with typical neuroleptics, the PRL responses to clomipramine are normal, and they are preserved after switch to risperidone in doses that cause complete dopamine receptor blockade. Clomipramine 78-90 prolactin Homo sapiens 61-64 11486861-0 2001 Ni(II)-based immobilized metal ion affinity chromatography of recombinant human prolactin from periplasmic Escherichia coli extracts. Nickel(2+) 0-6 prolactin Homo sapiens 80-89 11486861-0 2001 Ni(II)-based immobilized metal ion affinity chromatography of recombinant human prolactin from periplasmic Escherichia coli extracts. Metals 25-30 prolactin Homo sapiens 80-89 11486861-2 2001 The first step is based on immobilized metal ion affinity chromatography of periplasmic extract, using Ni(II) as a relatively specific ligand for hPRL in this system. Metals 39-44 prolactin Homo sapiens 146-150 11486861-2 2001 The first step is based on immobilized metal ion affinity chromatography of periplasmic extract, using Ni(II) as a relatively specific ligand for hPRL in this system. Nickel(2+) 103-109 prolactin Homo sapiens 146-150 11499189-5 2001 RESULTS: Baseline PRL correlated positively with DHEAS (r = .23, P = .03) and free testosterone (r = .36, P < .001). Testosterone 83-95 prolactin Homo sapiens 18-21 11499189-7 2001 The decline in free testosterone was higher when PRL was > or = 65 ng/mL than when PRL was < 65 (P = .03) and correlated positively with basal DHEAS (r = .40, P < .001). Testosterone 20-32 prolactin Homo sapiens 49-52 11499189-7 2001 The decline in free testosterone was higher when PRL was > or = 65 ng/mL than when PRL was < 65 (P = .03) and correlated positively with basal DHEAS (r = .40, P < .001). Testosterone 20-32 prolactin Homo sapiens 86-89 11418281-0 2001 The prolactin response to sulpiride in major depression: the role of the D2 receptor in depression. Sulpiride 26-35 prolactin Homo sapiens 4-13 11337133-0 2001 Prolactin response to d-fenfluramine in postmenopausal women on and off ERT: comparison with young women. Dexfenfluramine 22-36 prolactin Homo sapiens 0-9 11337133-4 2001 Prolactin (PRL) responses to the specific 5-HT releasing and re-uptake inhibiting agent, d-fenfluramine, were measured in three groups of healthy women: 11 young, 11 postmenopausal on long-term ERT, and 11 postmenopausal ERT naive. Dexfenfluramine 89-103 prolactin Homo sapiens 0-9 11337133-4 2001 Prolactin (PRL) responses to the specific 5-HT releasing and re-uptake inhibiting agent, d-fenfluramine, were measured in three groups of healthy women: 11 young, 11 postmenopausal on long-term ERT, and 11 postmenopausal ERT naive. Dexfenfluramine 89-103 prolactin Homo sapiens 11-14 11356701-4 2001 To achieve regulatable transgene expression within predetermined AP cells, the tetracycline-responsive transcriptional elements have been engineered to be under the control of human, lactotroph-specific PRL (hPRL) promoter elements within a dual adenoviral vector system. Tetracycline 79-91 prolactin Homo sapiens 203-206 11356701-4 2001 To achieve regulatable transgene expression within predetermined AP cells, the tetracycline-responsive transcriptional elements have been engineered to be under the control of human, lactotroph-specific PRL (hPRL) promoter elements within a dual adenoviral vector system. Tetracycline 79-91 prolactin Homo sapiens 208-212 11418281-6 2001 Significantly higher prolactin levels after sulpiride challenge were however found in depressed patients than controls at all time points after sulpiride administration. Sulpiride 44-53 prolactin Homo sapiens 21-30 11418281-6 2001 Significantly higher prolactin levels after sulpiride challenge were however found in depressed patients than controls at all time points after sulpiride administration. Sulpiride 144-153 prolactin Homo sapiens 21-30 11418281-7 2001 This neuroendocrine challenge paradigm suggests that the prolactin response to sulpiride, a D2 receptor antagonist, is enhanced in depression, which suggests that this receptor might be supersensitive in depression compared to controls. Sulpiride 79-88 prolactin Homo sapiens 57-66 11437600-3 2001 In the present work prolactin was expressed as a hexahistidine-tagged fusion protein and recombinant protein was purified by metal affinity resin. Metals 125-130 prolactin Homo sapiens 20-29 11422107-2 2001 DESIGN: In a cross-sectional study the effect of acute dopaminergic blockade with intravenous metoclopramide on serum PRL (both immunoreactive and biologically active), TSH and PRL circulating molecular isoforms was evaluated. Metoclopramide 94-108 prolactin Homo sapiens 118-121 11418281-2 2001 The aim of the study was to characterise the Dopamine D2 receptor sensitivity status in depressed patients versus controls by means of a novel neuro-endocrine challenge test, the prolactin response to sulpiride. Sulpiride 201-210 prolactin Homo sapiens 179-188 11685661-1 2001 The release of secretory granules outside the cells increased in frequency, in inverse proportion to the marked decrease in serum prolactin (PRL) levels in human prolactin-secreting adenomas (PRLomas) treated with bromocriptine (CB), a dopamine agonist. Bromocriptine 214-227 prolactin Homo sapiens 130-139 11447733-12 2001 Three factors might explain the higher amount of decidual prolactin in group 2 compared to group 1: (1) a higher serum progesterone concentration owing to an increased production by multiple corpora lutea, or because of the administered progesterone; (2) increased estradiol levels and thus progesterone receptors; and (3) direct stimulation of decidualization by gonadotropins. Progesterone 119-131 prolactin Homo sapiens 58-67 11447733-12 2001 Three factors might explain the higher amount of decidual prolactin in group 2 compared to group 1: (1) a higher serum progesterone concentration owing to an increased production by multiple corpora lutea, or because of the administered progesterone; (2) increased estradiol levels and thus progesterone receptors; and (3) direct stimulation of decidualization by gonadotropins. Progesterone 237-249 prolactin Homo sapiens 58-67 11397894-6 2001 Coincubation with estradiol resulted in enhanced fetal PRL response to PrRP, and GH release was only increased in the presence of estradiol. Estradiol 18-27 prolactin Homo sapiens 55-58 11434670-3 2001 Although her serum prolactin level decreased after the administration of bromocriptine mesilate, and the size of the two tumors remained unchanged, a malignant fibrous histiocytoma, which might have been induced by the irradiation 18 years before, grew rapidly in the right suprasellar-prepontine cistern to the right pedunculus cerebralis, leading to a poor prognosis. Bromocriptine 73-95 prolactin Homo sapiens 19-28 11685661-1 2001 The release of secretory granules outside the cells increased in frequency, in inverse proportion to the marked decrease in serum prolactin (PRL) levels in human prolactin-secreting adenomas (PRLomas) treated with bromocriptine (CB), a dopamine agonist. Bromocriptine 214-227 prolactin Homo sapiens 141-144 11685661-1 2001 The release of secretory granules outside the cells increased in frequency, in inverse proportion to the marked decrease in serum prolactin (PRL) levels in human prolactin-secreting adenomas (PRLomas) treated with bromocriptine (CB), a dopamine agonist. Bromocriptine 214-227 prolactin Homo sapiens 162-171 11413749-11 2001 Under dopamine agonist therapy prolactin levels rose to a maximum of 6460 ng/ml to decline thereafter to normal values, and the visual disturbances recovered. Dopamine 6-14 prolactin Homo sapiens 31-40 11380528-7 2001 In all subjects, PRL levels were stimulated by acute administration of 1 mg of exogenous melatonin, while the levels of other pituitary hormones were not affected. Melatonin 89-98 prolactin Homo sapiens 17-20 11396264-1 2001 In a 34-year-old woman with primary subfertility, a strongly increased serum concentration of prolactin was found in combination with normal levels of oestradiol, which is an indication for the presence of prolactin forms without clinical effect. Estradiol 151-161 prolactin Homo sapiens 206-215 11380528-8 2001 These results suggested that exogenous melatonin can affect the spontaneous release of LH and PRL in humans. Melatonin 39-48 prolactin Homo sapiens 94-97 11421571-0 2001 Effect of risperidone dose on serum prolactin level. Risperidone 10-21 prolactin Homo sapiens 36-45 11315926-4 2001 PRL concentrations in serum and fractions by gel filtration chromatography and affinity chromatography were characterized by immunoradiometric assay (IRMA), Nb2 bioassay, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting, and clearance studies. Sodium Dodecyl Sulfate 171-193 prolactin Homo sapiens 0-3 11329375-2 2001 We report that when PRL is added after disorganisation of the Golgi apparatus by brefeldin A treatment, prolactin signalling to expression of genes for milk proteins and prolactin endocytosis are not affected. Brefeldin A 81-92 prolactin Homo sapiens 20-23 11432696-1 2001 RATIONALE: Intravenous administration of the selective serotonin re-uptake inhibitor, citalopram (20 mg), is known to increase plasma prolactin (PRL) and cortisol in human subjects. Serotonin 55-64 prolactin Homo sapiens 134-143 11432696-1 2001 RATIONALE: Intravenous administration of the selective serotonin re-uptake inhibitor, citalopram (20 mg), is known to increase plasma prolactin (PRL) and cortisol in human subjects. Serotonin 55-64 prolactin Homo sapiens 145-148 11432696-1 2001 RATIONALE: Intravenous administration of the selective serotonin re-uptake inhibitor, citalopram (20 mg), is known to increase plasma prolactin (PRL) and cortisol in human subjects. Citalopram 86-96 prolactin Homo sapiens 134-143 11432696-1 2001 RATIONALE: Intravenous administration of the selective serotonin re-uptake inhibitor, citalopram (20 mg), is known to increase plasma prolactin (PRL) and cortisol in human subjects. Citalopram 86-96 prolactin Homo sapiens 145-148 11432696-3 2001 OBJECTIVE: To find out whether lower doses of intravenous citalopram would be sufficient to increase plasma prolactin and cortisol. Citalopram 58-68 prolactin Homo sapiens 108-117 11432696-7 2001 RESULTS: Citalopram increased plasma PRL and cortisol in a dose-related manner. Citalopram 9-19 prolactin Homo sapiens 37-40 11432696-8 2001 Cyproheptadine lowered baseline PRL and cortisol but did not attenuate the endocrine responses to citalopram. Cyproheptadine 0-14 prolactin Homo sapiens 32-35 11393578-5 2001 Treatment with bromocriptine and methimazole led to normalization of prolactin and thyroid hormone levels. Bromocriptine 15-28 prolactin Homo sapiens 69-78 11393578-5 2001 Treatment with bromocriptine and methimazole led to normalization of prolactin and thyroid hormone levels. Methimazole 33-44 prolactin Homo sapiens 69-78 11282259-0 2001 Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. Ketamine 29-37 prolactin Homo sapiens 55-64 11282259-0 2001 Comparison of the effects of ketamine and memantine on prolactin and cortisol release in men. Memantine 42-51 prolactin Homo sapiens 55-64 11282259-7 2001 Ketamine increased serum prolactin and cortisol levels (p < 0.001), whereas memantine and placebo did not affect hormone levels. Ketamine 0-8 prolactin Homo sapiens 25-34 11352361-1 2001 BACKGROUND: Chronic fatigue syndrome (CFS) has been associated with increased prolactin (PRL) responses to the serotonin (5-HT) releasing agent fenfluramine. Serotonin 111-120 prolactin Homo sapiens 78-87 11352361-1 2001 BACKGROUND: Chronic fatigue syndrome (CFS) has been associated with increased prolactin (PRL) responses to the serotonin (5-HT) releasing agent fenfluramine. Fenfluramine 144-156 prolactin Homo sapiens 78-87 11315926-4 2001 PRL concentrations in serum and fractions by gel filtration chromatography and affinity chromatography were characterized by immunoradiometric assay (IRMA), Nb2 bioassay, sodium dodecyl sulfate-polyacrylamide gel electrophoresis and Western blotting, and clearance studies. polyacrylamide 194-208 prolactin Homo sapiens 0-3 11335890-0 2001 A study of light/dark rhythm of melatonin in relation to cortisol and prolactin secretion in schizophrenia. Melatonin 32-41 prolactin Homo sapiens 70-79 11318782-1 2001 OBJECTIVE: GH and PRL cosecretion frequently occurs in acromegaly and the sensitivity of both hormones to somatostatin analogs (SA) and dopamine agonists (DA) alone or in combination, is still debated. sa 128-130 prolactin Homo sapiens 18-21 11318782-13 2001 Dopamine agonists (DA) significantly suppressed PRL release in all the cultures, while GH secretion was significantly suppressed in three out of four. Dopamine 0-8 prolactin Homo sapiens 48-51 11287025-11 2001 Prolactin levels decreased significantly in the group receiving lisuride, which correlated well with pain resolution. Lisuride 64-72 prolactin Homo sapiens 0-9 11570005-7 2001 Prolactin concentrations significantly (p < 0.01 to < 0.001) decreased with time postpartum in the SA group, but not in the LA group. sa 105-107 prolactin Homo sapiens 0-9 11223109-1 2001 BACKGROUND: Prolactin and cortisol responses to d-fenfluramine challenge of central serotonin are reduced in depressed and suicidal patients. Serotonin 84-93 prolactin Homo sapiens 12-21 11278160-7 2001 The differential response of adding 50mcg versus 100mcg estradiol on the types of symptom affected may be related to the estrogen effect on LH and prolactin. Estradiol 56-65 prolactin Homo sapiens 147-156 11167213-1 2001 BACKGROUND: We wanted to evaluate the very long-term effects of bromocriptine on prolactin (PRL) levels and pituitary tumor size in a large cohort of hyperprolactinemic patients. Bromocriptine 64-77 prolactin Homo sapiens 81-90 11167213-1 2001 BACKGROUND: We wanted to evaluate the very long-term effects of bromocriptine on prolactin (PRL) levels and pituitary tumor size in a large cohort of hyperprolactinemic patients. Bromocriptine 64-77 prolactin Homo sapiens 92-95 11167213-9 2001 In the bromocriptine group, PRL levels decreased from 99.6+/-7.9 to 20.0+/-1.5 ng/ml (p=0.00001). Bromocriptine 7-20 prolactin Homo sapiens 28-31 11156818-0 2001 Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Haloperidol 100-111 prolactin Homo sapiens 56-65 11156818-0 2001 Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Clozapine 115-124 prolactin Homo sapiens 56-65 11156818-3 2001 RESULTS: Adding haloperidol significantly increased D(2) receptor occupancy, from a mean of 55% to 79%, and significantly increased the prolactin level. Haloperidol 16-27 prolactin Homo sapiens 136-145 11156818-5 2001 CONCLUSIONS: Adding a modest dose of haloperidol to clozapine results in the high D(2) receptor occupancy and sustained prolactin elevation usually associated with typical antipsychotics. Haloperidol 37-48 prolactin Homo sapiens 120-129 11156818-5 2001 CONCLUSIONS: Adding a modest dose of haloperidol to clozapine results in the high D(2) receptor occupancy and sustained prolactin elevation usually associated with typical antipsychotics. Clozapine 52-61 prolactin Homo sapiens 120-129 11156818-6 2001 These findings suggest that the lack of prolactin elevation associated with clozapine derives mainly from low D(2) receptor occupancy and not from the medication"s effects on other receptors. Clozapine 76-85 prolactin Homo sapiens 40-49 11159845-0 2001 Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats. Steroids 125-132 prolactin Homo sapiens 80-83 11213313-2 2001 A 71-year-old woman taking estrogen replacement therapy developed galactorrhea after initiation of fluoxetine for depression and was found to have an elevated prolactin level. Fluoxetine 99-109 prolactin Homo sapiens 159-168 11159845-3 2001 The recent development of the PRL receptor antagonist S179D-PRL, a mutant of human PRL in which the serine residue at the 179 position is replaced with aspartate, provides a potentially useful tool to examine the role of PRL in neural processing. Serine 100-106 prolactin Homo sapiens 60-63 11159845-3 2001 The recent development of the PRL receptor antagonist S179D-PRL, a mutant of human PRL in which the serine residue at the 179 position is replaced with aspartate, provides a potentially useful tool to examine the role of PRL in neural processing. Serine 100-106 prolactin Homo sapiens 60-63 11159845-3 2001 The recent development of the PRL receptor antagonist S179D-PRL, a mutant of human PRL in which the serine residue at the 179 position is replaced with aspartate, provides a potentially useful tool to examine the role of PRL in neural processing. Serine 100-106 prolactin Homo sapiens 60-63 11159845-3 2001 The recent development of the PRL receptor antagonist S179D-PRL, a mutant of human PRL in which the serine residue at the 179 position is replaced with aspartate, provides a potentially useful tool to examine the role of PRL in neural processing. Aspartic Acid 152-161 prolactin Homo sapiens 60-63 11159845-3 2001 The recent development of the PRL receptor antagonist S179D-PRL, a mutant of human PRL in which the serine residue at the 179 position is replaced with aspartate, provides a potentially useful tool to examine the role of PRL in neural processing. Aspartic Acid 152-161 prolactin Homo sapiens 60-63 11159845-3 2001 The recent development of the PRL receptor antagonist S179D-PRL, a mutant of human PRL in which the serine residue at the 179 position is replaced with aspartate, provides a potentially useful tool to examine the role of PRL in neural processing. Aspartic Acid 152-161 prolactin Homo sapiens 60-63 11213313-0 2001 Reversible galactorrhea and prolactin elevation related to fluoxetine use. Fluoxetine 59-69 prolactin Homo sapiens 28-37 11213313-1 2001 Fluoxetine, an antidepressant of the selective serotonin reuptake inhibitor class, may stimulate prolactin release by pituitary lactotrophs. Fluoxetine 0-10 prolactin Homo sapiens 97-106 11158068-3 2001 Sera from 8 of the 209 women (3.8%) were found to have a significantly high proportion of precipitated PRL by PEG (macroprolactinemia); in these patients, gel filtration showed that a substantial amount of big big PRL (molecular mass >100 kDa) was present (19.0--78.2% vs. 3.8-4.9%, P = 0.009 in normal pregnant women with a normal proportion of precipitated PRL by PEG). Polyethylene Glycols 110-113 prolactin Homo sapiens 103-106 11158068-3 2001 Sera from 8 of the 209 women (3.8%) were found to have a significantly high proportion of precipitated PRL by PEG (macroprolactinemia); in these patients, gel filtration showed that a substantial amount of big big PRL (molecular mass >100 kDa) was present (19.0--78.2% vs. 3.8-4.9%, P = 0.009 in normal pregnant women with a normal proportion of precipitated PRL by PEG). Polyethylene Glycols 369-372 prolactin Homo sapiens 103-106 11158068-3 2001 Sera from 8 of the 209 women (3.8%) were found to have a significantly high proportion of precipitated PRL by PEG (macroprolactinemia); in these patients, gel filtration showed that a substantial amount of big big PRL (molecular mass >100 kDa) was present (19.0--78.2% vs. 3.8-4.9%, P = 0.009 in normal pregnant women with a normal proportion of precipitated PRL by PEG). Polyethylene Glycols 369-372 prolactin Homo sapiens 214-217 11158068-3 2001 Sera from 8 of the 209 women (3.8%) were found to have a significantly high proportion of precipitated PRL by PEG (macroprolactinemia); in these patients, gel filtration showed that a substantial amount of big big PRL (molecular mass >100 kDa) was present (19.0--78.2% vs. 3.8-4.9%, P = 0.009 in normal pregnant women with a normal proportion of precipitated PRL by PEG). Polyethylene Glycols 369-372 prolactin Homo sapiens 214-217 11213313-3 2001 Fluoxetine was discontinued with resolution of the patient"s galactorrhea and normalization of her prolactin level. Fluoxetine 0-10 prolactin Homo sapiens 99-108 11294478-0 2001 Effects of short and long-term lithium treatment on serum prolactin levels in patients with bipolar affective disorder. Lithium 31-38 prolactin Homo sapiens 58-67 11294478-2 2001 In this study, the authors sought to test the hypothesis that Li (lithium) treatment can induce alterations in PRL (prolactin) secretion in euthymic bipolar patients compared to controls and that short and long-term administration can lead to prolactin changes different from each other. Lithium 66-73 prolactin Homo sapiens 111-114 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Dopamine 169-177 prolactin Homo sapiens 76-79 11294478-2 2001 In this study, the authors sought to test the hypothesis that Li (lithium) treatment can induce alterations in PRL (prolactin) secretion in euthymic bipolar patients compared to controls and that short and long-term administration can lead to prolactin changes different from each other. Lithium 66-73 prolactin Homo sapiens 116-125 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Serotonin 179-188 prolactin Homo sapiens 13-16 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Serotonin 179-188 prolactin Homo sapiens 76-79 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Dopamine 169-177 prolactin Homo sapiens 13-16 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Serotonin 179-188 prolactin Homo sapiens 76-79 11294478-11 2001 Furthermore, PRL has wide intra-interindividual and circadian variations Li-PRL relationship seems to be very complex and probably depends on various interactions among dopamine, serotonin and PRL. Dopamine 169-177 prolactin Homo sapiens 76-79 11145594-4 2001 In addition, extracellular Ca(2+) (1.5 mmol/liter) increased the effect of PRL on human CG (hCG)-stimulated StAR messenger RNA expression and progesterone (P) production. Progesterone 142-154 prolactin Homo sapiens 75-78 11803861-2 2001 Dostinex is a dopamine ergoline derivation that strongly decrease the Prolactin secretion and has a long-lasting effect. Cabergoline 0-8 prolactin Homo sapiens 70-79 11803861-2 2001 Dostinex is a dopamine ergoline derivation that strongly decrease the Prolactin secretion and has a long-lasting effect. dopamine ergoline 14-31 prolactin Homo sapiens 70-79 11305486-17 2001 On the other hand, bitches in the high PRL group showed significantly (p < 0.01) lower serum LH levels than those in the low PRL group of animals. Luteinizing Hormone 96-98 prolactin Homo sapiens 39-42 11305486-18 2001 Serum PRL concentrations presented a significant inverse correlation with LH concentrations (r=-0.21, p < 0.03) and a significant positive correlation with P4 concentrations across the study (0.92, p < 0.01). Luteinizing Hormone 74-76 prolactin Homo sapiens 6-9 11305486-19 2001 It is concluded that in anoestrous crossbred bitches serum PRL is highly variable and inversely related to LH. Luteinizing Hormone 107-109 prolactin Homo sapiens 59-62 11202662-9 2001 The serum prolactin levels were similar in the 2 groups at baseline; by day 5 they were significantly higher in the domperidone group than in the placebo group, returning to baseline levels in both groups 3 days after the last dose of the study medication. Domperidone 116-127 prolactin Homo sapiens 10-19 11167186-2 2001 BACKGROUND: To investigate the role of dopamine on the mechanisms of maternal prolactin secretion during labor and in the first six hours following delivery. Dopamine 39-47 prolactin Homo sapiens 78-87 11832659-4 2001 Bromocriptine inhibited the basal secretion of PRL in a dose dependent manner, and completely abolished both the thyroliberin (TRH) and the vasoactive intestinal peptide (VIP) stimulated PRL secretion in GH(3) cells. Bromocriptine 0-13 prolactin Homo sapiens 47-50 11832659-4 2001 Bromocriptine inhibited the basal secretion of PRL in a dose dependent manner, and completely abolished both the thyroliberin (TRH) and the vasoactive intestinal peptide (VIP) stimulated PRL secretion in GH(3) cells. Bromocriptine 0-13 prolactin Homo sapiens 187-190 11832659-5 2001 Maximal inhibitory effect on PRL egress elicited by both hormones was obtained at 10-50 microM of bromocriptine. Bromocriptine 98-111 prolactin Homo sapiens 29-32 11847468-17 2001 As macroprolactin seems to have minimal clinical relevance, it would be important that the users of PRL assays be aware to what extent macroprolactin interferes with their assays, and have available a validated method, such as the PEG precipitation test, to confirm the presence of macroprolactin. Polyethylene Glycols 231-234 prolactin Homo sapiens 100-103 11838821-0 2001 Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. Risperidone 81-92 prolactin Homo sapiens 0-9 11115535-12 2001 Thirdly, we explored the additive effects of an anti-neoplastic drug, cisplatin, with the hPRL-G129R in T47D breast cancer cells. Cisplatin 70-79 prolactin Homo sapiens 90-94 11771778-7 2001 Daily prednisone doses higher than 5 mg were administered to 43% of the patients with elevated PRL, compared with 25% of patients with normal prolactin concentrations. Prednisone 6-16 prolactin Homo sapiens 95-98 11838821-2 2001 The aim of this study is to report on serum prolactin levels in 25 young autistic children (22 males and 3 females, age range 3.9-7 years, mean age 4.10 years) during treatment with risperidone (dosage range 0.25-0.90 mg/day, mean dosage 0.52 mg/day). Risperidone 182-193 prolactin Homo sapiens 44-53 11838821-9 2001 Dose reduction of risperidone resulted in a decrease of prolactin levels. Risperidone 18-29 prolactin Homo sapiens 56-65 11746508-3 2001 We have previously found that the minimal ECM- and Prl-responsive enhancer element BCE-1 was only active when stably integrated into chromatin, and that trichostatin A (TSA), a reagent that leads to alterations in chromatin structure, was able to activate the integrated enhancer element. trichostatin A 153-167 prolactin Homo sapiens 51-54 11746508-3 2001 We have previously found that the minimal ECM- and Prl-responsive enhancer element BCE-1 was only active when stably integrated into chromatin, and that trichostatin A (TSA), a reagent that leads to alterations in chromatin structure, was able to activate the integrated enhancer element. trichostatin A 169-172 prolactin Homo sapiens 51-54 11746508-4 2001 We now show that endogenous beta-casein gene, which is controlled by a genetic assembly that is highly similar to that of BCE-1 and which is also activated by incubation in ECM and Prl, is instead inhibited by TSA. trichostatin A 210-213 prolactin Homo sapiens 181-184 11838826-6 2001 RESULTS: Four males (age 6-11 years) with Diagnostic and Statistical Manual of Mental Disorders (fourth edition) bipolar disorder or psychoses, with risperidone-induced elevations in serum prolactin levels (57.5-129 ng/mL, normal 5-15 ng/mL), were treated with cabergoline (mean dose 2.13 +/- 0.09 mg/week). Risperidone 149-160 prolactin Homo sapiens 189-198 11721691-3 2001 Most cases of hyperprolactinemia are due to prolactin secreting pituitary tumors or to medications which alter dopamine production. Dopamine 111-119 prolactin Homo sapiens 19-28 11964017-7 2001 Cabergoline may normalize prolactin secretion, restore fertility in women and men. Cabergoline 0-11 prolactin Homo sapiens 26-35 11721702-11 2001 The interactions between PRL, cytoquines, autoantibodies and organ involvement suggest that PRL participates in local and generalized immune and inflammatory processes and acts as a bridge between the neuroendocrine and immune systems in SLE. cytoquines 30-40 prolactin Homo sapiens 92-95 11403264-1 2001 The objective of this study was to determine the diagnostic performance of the percentage of serum prolactin (PRL) precipitated with polyethylene glycol (PEG) for the detection of macroprolactinemia in systemic lupus erythematosus (SLE) patients with hyperprolactinemia. Polyethylene Glycols 133-152 prolactin Homo sapiens 99-108 11721704-2 2001 It has been hypothesized that bromocriptine, a dopamine analog that suppresses pituitary secretion of prolactin, suppresses circulating prolactin and, through this mechanism, has the potential to suppress autoimmune disease. Bromocriptine 30-43 prolactin Homo sapiens 102-111 11403264-1 2001 The objective of this study was to determine the diagnostic performance of the percentage of serum prolactin (PRL) precipitated with polyethylene glycol (PEG) for the detection of macroprolactinemia in systemic lupus erythematosus (SLE) patients with hyperprolactinemia. Polyethylene Glycols 133-152 prolactin Homo sapiens 110-113 11403264-1 2001 The objective of this study was to determine the diagnostic performance of the percentage of serum prolactin (PRL) precipitated with polyethylene glycol (PEG) for the detection of macroprolactinemia in systemic lupus erythematosus (SLE) patients with hyperprolactinemia. Polyethylene Glycols 154-157 prolactin Homo sapiens 99-108 11721704-2 2001 It has been hypothesized that bromocriptine, a dopamine analog that suppresses pituitary secretion of prolactin, suppresses circulating prolactin and, through this mechanism, has the potential to suppress autoimmune disease. Bromocriptine 30-43 prolactin Homo sapiens 136-145 11403264-1 2001 The objective of this study was to determine the diagnostic performance of the percentage of serum prolactin (PRL) precipitated with polyethylene glycol (PEG) for the detection of macroprolactinemia in systemic lupus erythematosus (SLE) patients with hyperprolactinemia. Polyethylene Glycols 154-157 prolactin Homo sapiens 110-113 11721704-2 2001 It has been hypothesized that bromocriptine, a dopamine analog that suppresses pituitary secretion of prolactin, suppresses circulating prolactin and, through this mechanism, has the potential to suppress autoimmune disease. Dopamine 47-55 prolactin Homo sapiens 102-111 11403264-8 2001 The best cut-off point for percentage of serum PRL precipitated with PEG for detection of macroprolactinemia was > or = 58.4%. Polyethylene Glycols 69-72 prolactin Homo sapiens 47-50 11335876-0 2001 Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Docetaxel 34-43 prolactin Homo sapiens 70-79 11335876-0 2001 Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Docetaxel 45-53 prolactin Homo sapiens 70-79 11335876-3 2001 The present study was performed to evaluate the efficacy of chemotherapy with taxanes in relation to PRL blood levels in metastatic breast cancer. Taxoids 78-85 prolactin Homo sapiens 101-104 11335876-10 2001 CONCLUSIONS: This study shows that the evidence of abnormally high serum levels of PRL correlates with resistance to chemotherapy with taxanes in metastatic breast cancer. Taxoids 135-142 prolactin Homo sapiens 83-86 11589129-5 2001 In the arcuate nucleus, mating is associated with Fos expression in beta-endorphin neurons, and infusion of naloxone blocks both mating-induced and diurnal prolactin surges. Naloxone 108-116 prolactin Homo sapiens 156-165 11521733-3 2001 Moreover, prolactin concentrations were more than twice the normal levels, this being an effect of propafol and the opiate fentanyl used for the general anesthesia. propafol 99-107 prolactin Homo sapiens 10-19 11521733-3 2001 Moreover, prolactin concentrations were more than twice the normal levels, this being an effect of propafol and the opiate fentanyl used for the general anesthesia. Fentanyl 123-131 prolactin Homo sapiens 10-19 11589129-12 2001 This may involve beta-endorphin-mediated inhibition of dopamine neurons, as naloxone causes a marked increase in tyrosine hydroxylase activity and suppression of circulating prolactin. Naloxone 76-84 prolactin Homo sapiens 174-183 11175925-0 2000 Prolactin secretion in response to haloperidol challenge in delusional (psychotic) and non-delusional depression. Haloperidol 35-46 prolactin Homo sapiens 0-9 11163716-0 2001 Synergetic effect of pimozide and thyrotropin releasing hormone on prolactin and thyrotropin release during the drying off of ewes. Pimozide 21-29 prolactin Homo sapiens 67-76 11163716-7 2001 TRH and pimozide both resulted in elevated plasma PRL levels and acted in a synergetic way. Pimozide 8-16 prolactin Homo sapiens 50-53 11163716-10 2001 The higher effect of pimozide upon TRH stimulated PRL and TSH release at day 8 compared to days 0 and 3 indicates a progressive involvement of dopamine on the inhibition of PRL and the sensitivity of the thyrotrophs to TRH during drying off. Pimozide 21-29 prolactin Homo sapiens 50-53 11163716-10 2001 The higher effect of pimozide upon TRH stimulated PRL and TSH release at day 8 compared to days 0 and 3 indicates a progressive involvement of dopamine on the inhibition of PRL and the sensitivity of the thyrotrophs to TRH during drying off. Pimozide 21-29 prolactin Homo sapiens 173-176 11163716-10 2001 The higher effect of pimozide upon TRH stimulated PRL and TSH release at day 8 compared to days 0 and 3 indicates a progressive involvement of dopamine on the inhibition of PRL and the sensitivity of the thyrotrophs to TRH during drying off. Dopamine 143-151 prolactin Homo sapiens 173-176 11813510-7 2001 Functional diversity among PRL cells is documented in vitro, in terms of basal and synthetic capacity and in respect to responsiveness to dopamine and oestrogen regulation. Dopamine 138-146 prolactin Homo sapiens 27-30 11175925-2 2000 A neuroendocrinologic method to check the degree of DA receptor responsivity is by measuring the prolactin responses to acute intramuscular administration of haloperidol. Haloperidol 158-169 prolactin Homo sapiens 97-106 11175925-8 2000 However, the prolactin responses to haloperidol did not differ significantly between the two patient groups (F = 0.12, P = 0.97). Haloperidol 36-47 prolactin Homo sapiens 13-22 11084179-1 2000 OBJECTIVE: To study the effect of depot medroxyprogesterone acetate on basal serum prolactin levels in lactating women. Medroxyprogesterone Acetate 40-67 prolactin Homo sapiens 83-92 11084179-9 2000 CONCLUSION: Contraception with depot medroxyprogesterone acetate in lactating women produced higher basal prolactin levels than contraception with copper T380A intrauterine device. Medroxyprogesterone Acetate 37-64 prolactin Homo sapiens 106-115 11155212-3 2000 RESULTS: The percentage of women with increased prolactin concentrations was significantly greater in the risperidone group (100%, 12 of 12 patients) than in the clozapine group (25%, 1 of 4) (P = 0.0071) but not in comparison with the typical antipsychotic agent group (83%, 5 of 6) (P = 0.333). Risperidone 106-117 prolactin Homo sapiens 48-57 11128236-6 2000 Prolactin level was related to administered dosage only in those who were taking haloperidol. Haloperidol 81-92 prolactin Homo sapiens 0-9 11128236-7 2000 For those taking haloperidol or thioridazine, prolactin levels decreased when participants were on placebo. Haloperidol 17-28 prolactin Homo sapiens 46-55 11128236-7 2000 For those taking haloperidol or thioridazine, prolactin levels decreased when participants were on placebo. Thioridazine 32-44 prolactin Homo sapiens 46-55 11084391-7 2000 RESULTS: The prolactin level returned to normal after a mean interval of 9.8 1.6 months (1-48) in 47 of the 107 patients (44%) using a mean dose of quinagolide of 259 32.7 microg/d (75-750). quinagolide 148-159 prolactin Homo sapiens 13-22 11084391-8 2000 The plasma prolactin concentration had already been normalized using bromocriptine in three patients. Bromocriptine 69-82 prolactin Homo sapiens 11-20 11084391-11 2000 The following predictive indicators were identified concerning the efficacy of quinagolide: a pre-quinagolide prolactin level of<300 ng/ml in the group of patients whose plasma prolactin concentration was normalized, and a mean decrease in prolactin of 619 ng/ml in the group of patients showing a reduction in tumor volume treated with quinagolide for 3 months. quinagolide 79-90 prolactin Homo sapiens 110-119 11084391-11 2000 The following predictive indicators were identified concerning the efficacy of quinagolide: a pre-quinagolide prolactin level of<300 ng/ml in the group of patients whose plasma prolactin concentration was normalized, and a mean decrease in prolactin of 619 ng/ml in the group of patients showing a reduction in tumor volume treated with quinagolide for 3 months. quinagolide 79-90 prolactin Homo sapiens 180-189 11084391-11 2000 The following predictive indicators were identified concerning the efficacy of quinagolide: a pre-quinagolide prolactin level of<300 ng/ml in the group of patients whose plasma prolactin concentration was normalized, and a mean decrease in prolactin of 619 ng/ml in the group of patients showing a reduction in tumor volume treated with quinagolide for 3 months. quinagolide 79-90 prolactin Homo sapiens 180-189 11155212-4 2000 The percentage of men with increased prolactin concentrations was significantly greater in the risperidone group (94%, 17 of 18) than in the clozapine group (18%, 3 of 17) (P<0.0001) and in comparison with the typical antipsychotic agent group (27%, 3 of 11) (P = 0.0003). Risperidone 95-106 prolactin Homo sapiens 37-46 11155212-5 2000 The mean prolactin concentration (all ng/mL +/- standard deviation) was also significantly higher in patients taking risperidone (women, 125.0 +/- 56.6; men, 37.3 +/- 23.9) than clozapine (women, 22.0 +/- 25.9; men, 13.3 +/- 22.4) (female patients, P = 0.0004; male patients, P<0.0001) or typical antipsychotic agents (women, 69.0 +/- 59.8; men, 13. Risperidone 117-128 prolactin Homo sapiens 9-18 11155212-5 2000 The mean prolactin concentration (all ng/mL +/- standard deviation) was also significantly higher in patients taking risperidone (women, 125.0 +/- 56.6; men, 37.3 +/- 23.9) than clozapine (women, 22.0 +/- 25.9; men, 13.3 +/- 22.4) (female patients, P = 0.0004; male patients, P<0.0001) or typical antipsychotic agents (women, 69.0 +/- 59.8; men, 13. Clozapine 178-187 prolactin Homo sapiens 9-18 11155212-7 2000 In the risperidone group, gender affected prolactin level, with women having higher concentrations than men, but the duration of therapy did not. Risperidone 7-18 prolactin Homo sapiens 42-51 11155212-11 2000 The higher and more frequently increased prolactin concentrations caused by risperidone could adversely affect patient health and compliance. Risperidone 76-87 prolactin Homo sapiens 41-50 10978848-3 2000 Prolactin induced the majority of astrocytes to incorporate bromodeoxyuridine (BrdU) with a four-fold increase over controls after 18 h of exposure. Bromodeoxyuridine 60-77 prolactin Homo sapiens 0-9 11106920-1 2000 OBJECTIVE: Cabergoline therapy normalizes prolactin levels and reduces the size of macroprolactinomas. Cabergoline 11-22 prolactin Homo sapiens 42-51 11106920-5 2000 RESULTS: Treatment with cabergoline was associated with a significant reduction in prolactin concentration (74341 +/- 31939 mU/l vs. 265.9 +/- 86.3, P = 0.009). Cabergoline 24-35 prolactin Homo sapiens 83-92 11106920-14 2000 CONCLUSION: These data indicate that growth hormone secretion may recover following successful reduction of prolactin levels after cabergoline therapy for a mean of 22 months (range 6-28 months) in most but not all subjects with a macroprolactinoma. Cabergoline 131-142 prolactin Homo sapiens 108-117 10978848-4 2000 Investigating possible mitogenic signaling pathways we show for the first time that prolactin is coupled to a sustained phospholipase D (PLD) activation, with an efficacy similar to the phorbol ester and astrocytic mitogen 12-tetradecanoylphorbol-13-acetate (TPA). Tetradecanoylphorbol Acetate 259-262 prolactin Homo sapiens 84-93 10978848-3 2000 Prolactin induced the majority of astrocytes to incorporate bromodeoxyuridine (BrdU) with a four-fold increase over controls after 18 h of exposure. Bromodeoxyuridine 79-83 prolactin Homo sapiens 0-9 10978848-6 2000 Staurosporine and calphostin C also inhibited the PRL effect by 50%, consistent with involvement of protein kinase C-(PKC)-alpha, the major PKC isoform in astrocytes. Staurosporine 0-13 prolactin Homo sapiens 50-53 11053497-3 2000 Arg exerts its vascular actions also through NO-independent effects, including membrane depolarization, syntheses of creatine, proline and polyamines, secretion of insulin, growth hormone, glucagon and prolactin, plasmin generation and fibrinogenolysis, superoxide scavenging and inhibition of leukocyte adhesion to nonendothelial matrix. Arginine 0-3 prolactin Homo sapiens 202-211 10978848-6 2000 Staurosporine and calphostin C also inhibited the PRL effect by 50%, consistent with involvement of protein kinase C-(PKC)-alpha, the major PKC isoform in astrocytes. calphostin C 18-30 prolactin Homo sapiens 50-53 10978848-11 2000 In exploring the signaling for prolactin-induced differentiation we found that prolactin activated the tyrosine kinase Janus kinase (JAK) 2 and significantly stimulated tyrosine, phosphorylation of the prolactin receptor. Tyrosine 103-111 prolactin Homo sapiens 31-40 10978848-11 2000 In exploring the signaling for prolactin-induced differentiation we found that prolactin activated the tyrosine kinase Janus kinase (JAK) 2 and significantly stimulated tyrosine, phosphorylation of the prolactin receptor. Tyrosine 103-111 prolactin Homo sapiens 79-88 10938266-0 2000 Constitutive tyrosine phosphorylation of ErbB-2 via Jak2 by autocrine secretion of prolactin in human breast cancer. Tyrosine 13-21 prolactin Homo sapiens 83-92 11383480-3 2000 In a 22-year-old man (case 1) with delayed puberty and low testosterone levels, mild hyperprolactinemia was diagnosed and treated with dopamine agonist therapy that reduced the prolactin (PRL) levels to normal. Dopamine 135-143 prolactin Homo sapiens 90-99 11383480-3 2000 In a 22-year-old man (case 1) with delayed puberty and low testosterone levels, mild hyperprolactinemia was diagnosed and treated with dopamine agonist therapy that reduced the prolactin (PRL) levels to normal. Dopamine 135-143 prolactin Homo sapiens 188-191 11049750-7 2000 Carbohydrate analysis of the purified protein indicated that a fraction of the recombinant prolactin made in insect cells appeared to be glycosylated. Carbohydrates 0-12 prolactin Homo sapiens 91-100 10938266-5 2000 By using a neutralizing antibody or dominant negative (DN) strategies or specific inhibitors, we also show that activation of Janus kinase Jak2 by autocrine secretion of PRL is one of the significant components of constitutive tyrosine phosphorylation of ErbB-2, its association with Grb2 and activation of mitogen-activated protein (MAP) kinase in human breast cancer cell lines that overexpress ErbB-2. Tyrosine 227-235 prolactin Homo sapiens 170-173 10938266-6 2000 Furthermore, the neutralizing anti-PRL antibody or erbB-2 antisense oligonucleotide or DN Jak2 or Jak2 inhibitor or DNRas or MAP kinase kinase inhibitor inhibits the proliferation of both untreated and PRL-treated cells. Oligonucleotides 68-83 prolactin Homo sapiens 202-205 10938266-7 2000 Our results indicate that autocrine secretion of PRL stimulates tyrosine phosphorylation of ErbB-2 by Jak2, provides docking sites for Grb2 and stimulates Ras-MAP kinase cascade, thereby causing unrestricted cellular proliferation. Tyrosine 64-72 prolactin Homo sapiens 49-52 11069474-2 2000 In all three patients, administration of bromocriptine, a dopamine agonist that suppresses the secretion of prolactin, improved the therapeutic response of the psoriasis. Bromocriptine 41-54 prolactin Homo sapiens 108-117 11001873-4 2000 Without methotrexate (MTX) amplification, p658-hPRL-transfected stable cell lines, secreting up to approximately 10 microg of hPRL/10(6) cells per day, could be rapidly obtained; production by pEDdc-hPRL-transfected cells was about 10-fold lower. peddc 193-198 prolactin Homo sapiens 47-51 11001873-5 2000 However, a three-step MTX amplification of the latter led to clones secreting up to approximately 30 microg of hPRL/10(6) cells per day. Methotrexate 22-25 prolactin Homo sapiens 111-115 11001873-7 2000 SDS/PAGE analysis indicated that recombinant hPRL contained approximately 10% glycosylated PRL. Sodium Dodecyl Sulfate 0-3 prolactin Homo sapiens 45-49 11001873-7 2000 SDS/PAGE analysis indicated that recombinant hPRL contained approximately 10% glycosylated PRL. Sodium Dodecyl Sulfate 0-3 prolactin Homo sapiens 46-49 11069474-2 2000 In all three patients, administration of bromocriptine, a dopamine agonist that suppresses the secretion of prolactin, improved the therapeutic response of the psoriasis. Dopamine 58-66 prolactin Homo sapiens 108-117 11048906-5 2000 RESULTS: PRL elevations were significantly greater with risperidone than with either olanzapine or haloperidol in study 2. and significantly greater than with olanzapine in study 3 (all, P < 0.001). Risperidone 56-67 prolactin Homo sapiens 9-12 11130286-10 2000 A safe exposure level was calculated on the basis of dose-response relationship with prolactin alteration, yielding a PbB value of 10 microg/dl. Polybrominated Biphenyls 118-121 prolactin Homo sapiens 85-94 11048906-0 2000 The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Olanzapine 15-25 prolactin Homo sapiens 66-75 11015620-7 2000 Finally, although it is well known that dopamine of hypothalamic origin provides inhibitory control over the secretion of prolactin, other factors within the brain, pituitary gland, and peripheral organs have been shown to inhibit or stimulate prolactin secretion as well. Dopamine 40-48 prolactin Homo sapiens 122-131 11015620-7 2000 Finally, although it is well known that dopamine of hypothalamic origin provides inhibitory control over the secretion of prolactin, other factors within the brain, pituitary gland, and peripheral organs have been shown to inhibit or stimulate prolactin secretion as well. Dopamine 40-48 prolactin Homo sapiens 244-253 10974357-6 2000 Analyses of the neuroendocrine hormones revealed that the depressed group had a higher baseline prolactin level and an augmented prolactin response to mCPP challenge than did the control group. 1-(3-chlorophenyl)piperazine 151-155 prolactin Homo sapiens 129-138 11048906-0 2000 The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Risperidone 27-38 prolactin Homo sapiens 66-75 11048906-5 2000 RESULTS: PRL elevations were significantly greater with risperidone than with either olanzapine or haloperidol in study 2. and significantly greater than with olanzapine in study 3 (all, P < 0.001). Olanzapine 85-95 prolactin Homo sapiens 9-12 11048906-0 2000 The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Haloperidol 44-55 prolactin Homo sapiens 66-75 11048906-2 2000 OBJECTIVE: This paper examines the comparative effects on PRL of olanzapine, risperidone, and haloperidol based on data from 3 multicenter, double-blind, randomized clinical trials. Olanzapine 65-75 prolactin Homo sapiens 58-61 11048906-5 2000 RESULTS: PRL elevations were significantly greater with risperidone than with either olanzapine or haloperidol in study 2. and significantly greater than with olanzapine in study 3 (all, P < 0.001). Haloperidol 99-110 prolactin Homo sapiens 9-12 11048906-6 2000 PRL elevations were significantly greater with haloperidol than with olanzapine in study 1 (P < 0.001 ). Haloperidol 47-58 prolactin Homo sapiens 0-3 11048906-6 2000 PRL elevations were significantly greater with haloperidol than with olanzapine in study 1 (P < 0.001 ). Olanzapine 69-79 prolactin Homo sapiens 0-3 11048906-8 2000 Risperidone-associated PRL elevations peaked relatively early in treatment. Risperidone 0-11 prolactin Homo sapiens 23-26 11048906-9 2000 In haloperidol- and risperidone-treated patients, the mean change in PRL was greater in women than in men. Haloperidol 3-14 prolactin Homo sapiens 69-72 11048906-9 2000 In haloperidol- and risperidone-treated patients, the mean change in PRL was greater in women than in men. Risperidone 20-31 prolactin Homo sapiens 69-72 11048906-10 2000 PRL decreased significantly when treatment was switched from haloperidol to olanzapine. Haloperidol 61-72 prolactin Homo sapiens 0-3 11048906-10 2000 PRL decreased significantly when treatment was switched from haloperidol to olanzapine. Olanzapine 76-86 prolactin Homo sapiens 0-3 11048906-11 2000 CONCLUSIONS: This side-by-side analysis of 3 independent studies suggests that with the 3 antipsychotic drugs studied, PRL is elevated moderately by olanzapine (mean change, 1-4 ng/mL), intermediately by haloperidol (mean change, approximately 17 ng/mL), and strongly by risperidone (mean change, 45-80 ng/mL). Olanzapine 149-159 prolactin Homo sapiens 119-122 11048906-11 2000 CONCLUSIONS: This side-by-side analysis of 3 independent studies suggests that with the 3 antipsychotic drugs studied, PRL is elevated moderately by olanzapine (mean change, 1-4 ng/mL), intermediately by haloperidol (mean change, approximately 17 ng/mL), and strongly by risperidone (mean change, 45-80 ng/mL). Haloperidol 204-215 prolactin Homo sapiens 119-122 11048906-11 2000 CONCLUSIONS: This side-by-side analysis of 3 independent studies suggests that with the 3 antipsychotic drugs studied, PRL is elevated moderately by olanzapine (mean change, 1-4 ng/mL), intermediately by haloperidol (mean change, approximately 17 ng/mL), and strongly by risperidone (mean change, 45-80 ng/mL). Risperidone 271-282 prolactin Homo sapiens 119-122 10999785-8 2000 All patients had at least one follow-up visit, and the most recent serum PRL measurement after initiating dopamine agonist therapy was reported. Dopamine 106-114 prolactin Homo sapiens 73-76 10965923-4 2000 Functionally, the restriction of expression of HSV1-TK to lactotrophic tumor cells, using the hPrl promoter, resulted in the cell type-specific induction of apoptosis in the lactotrophic GH3 tumor cell line, in the presence of ganciclovir (GCV). Ganciclovir 227-238 prolactin Homo sapiens 94-98 10965923-4 2000 Functionally, the restriction of expression of HSV1-TK to lactotrophic tumor cells, using the hPrl promoter, resulted in the cell type-specific induction of apoptosis in the lactotrophic GH3 tumor cell line, in the presence of ganciclovir (GCV). Ganciclovir 240-243 prolactin Homo sapiens 94-98 11020104-1 2000 OBJECTIVE: The case of a psychotic woman is described in which risperidone use was found to correspond with an increase in the size of a prolactinoma and prevented the return of serum prolactin level to baseline. Risperidone 63-74 prolactin Homo sapiens 137-146 11020104-2 2000 METHODS: Although the patient had been treated with a high dose of bromocriptine, her prolactin level remained elevated, causing persistent galactorrhea. Bromocriptine 67-80 prolactin Homo sapiens 86-95 11020104-4 2000 RESULTS: This case report highlights the role of risperidone on prolactin and discusses alternative methods of treating psychosis when the etiology is unclear, especially in younger patients. Risperidone 49-60 prolactin Homo sapiens 64-73 10969181-2 2000 Evidence from experimental models indicates that inhibition of PRL release by bromocriptine downregulates immune reactions and ameliorates autoimmune diseases in which Th1 responses are predominant. Bromocriptine 78-91 prolactin Homo sapiens 63-66 10969182-2 2000 The multiple cell function defects associated with hypophysectomy or bromocriptine treatment were reversed by administration of prolactin. Bromocriptine 69-82 prolactin Homo sapiens 128-137 10999785-12 2000 Although the majority of patients in both groups were treated with bromocriptine, a comparable number of patients with microprolactinomas vs. macroprolactinomas achieved a normal PRL level with cabergoline therapy. Cabergoline 194-205 prolactin Homo sapiens 179-182 10974487-0 2000 Prolactin and corticosterone secretion in response to acute stress after paraventricular nucleus lesion by ibotenic acid. Ibotenic Acid 107-120 prolactin Homo sapiens 0-9 10955855-6 2000 Antiemetic drugs such as metoclopramide and phenothiazines, known to enhance pituitary prolactin secretion, further elevated prolactin plasma levels (p < 0.00001). Metoclopramide 25-39 prolactin Homo sapiens 87-96 10955855-6 2000 Antiemetic drugs such as metoclopramide and phenothiazines, known to enhance pituitary prolactin secretion, further elevated prolactin plasma levels (p < 0.00001). Metoclopramide 25-39 prolactin Homo sapiens 125-134 10955855-6 2000 Antiemetic drugs such as metoclopramide and phenothiazines, known to enhance pituitary prolactin secretion, further elevated prolactin plasma levels (p < 0.00001). Phenothiazines 44-58 prolactin Homo sapiens 87-96 10955855-6 2000 Antiemetic drugs such as metoclopramide and phenothiazines, known to enhance pituitary prolactin secretion, further elevated prolactin plasma levels (p < 0.00001). Phenothiazines 44-58 prolactin Homo sapiens 125-134 10955855-9 2000 Further elevations of prolactin plasma levels are induced by metoclopramide and other antiemetic drugs. Metoclopramide 61-75 prolactin Homo sapiens 22-31 10935542-7 2000 The exogenous addition of CypB potentiated the 3H-thymidine incorporation of PRL-dependent cell lines up to 18-fold. 3h-thymidine 47-59 prolactin Homo sapiens 77-80 11051045-6 2000 Using rhodamine-labeled PRL, we observed specific PRL uptake by these cells that suggested the presence of a PRL receptor. Rhodamines 6-15 prolactin Homo sapiens 24-27 11051045-6 2000 Using rhodamine-labeled PRL, we observed specific PRL uptake by these cells that suggested the presence of a PRL receptor. Rhodamines 6-15 prolactin Homo sapiens 50-53 10837886-0 2000 The prolactin response to buspirone in poststroke depression: a preliminary report. Buspirone 26-35 prolactin Homo sapiens 4-13 10892620-7 2000 A significant negative correlation between Animal Naming Test scores and plasma prolactin suggests that a decrement in brain dopamine secretion is related to reduced animal naming ability. Dopamine 125-133 prolactin Homo sapiens 80-89 11951117-5 2000 Furthermore, RU486 dramatically inhibited PRL release, suggesting that the effect of progesterone was mediated, at least in part, through its receptor. Mifepristone 13-18 prolactin Homo sapiens 42-45 11951117-5 2000 Furthermore, RU486 dramatically inhibited PRL release, suggesting that the effect of progesterone was mediated, at least in part, through its receptor. Progesterone 85-97 prolactin Homo sapiens 42-45 11951117-6 2000 cAMP at concentration higher than 10( 5) mol/L significantly increased PRL secretion, suggesting that the cAMP signal pathway might be involved in decidualization. Cyclic AMP 0-4 prolactin Homo sapiens 72-75 11951117-6 2000 cAMP at concentration higher than 10( 5) mol/L significantly increased PRL secretion, suggesting that the cAMP signal pathway might be involved in decidualization. Cyclic AMP 107-111 prolactin Homo sapiens 72-75 10962898-1 2000 Quinagolide has a strong dopaminerg activity, suppresses prolactin secretion and restores gonadal function in women with hyperprolactinemic anovulation. quinagolide 0-11 prolactin Homo sapiens 57-66 10962898-6 2000 Serum prolactin levels decreased in most of the patients during the first month and only in one case remained in the pathological range after six months quinagolide++ treatment. quinagolide 153-166 prolactin Homo sapiens 6-15 10962898-10 2000 In conclusion, our results show that quinagolide has a good efficacy on regulation of prolactin secretion and it is a well tolerated dopamin-agonist drug. quinagolide 37-48 prolactin Homo sapiens 86-95 10859276-7 2000 An additional observation confirmed that the prolactin axis is responsive to continuous treatment with melatonin but that a suppression of prolactin secretion is limited to the spring months. Melatonin 103-112 prolactin Homo sapiens 45-54 10924001-1 2000 BACKGROUND: The prolactin response to serotonergic stimulation has been used as an index of central nervous system serotonin function. Serotonin 115-124 prolactin Homo sapiens 16-25 10924001-6 2000 RESULTS: Smokers had a blunted prolactin response to fenfluramine compared with nonsmokers without any alcoholism or antisocial personality effects. Fenfluramine 53-65 prolactin Homo sapiens 31-40 10924001-7 2000 Using a cutoff point of delta peak prolactin < 10 ng/ml, more smokers (41/76, 54%) had a dampened response to fenfluramine than did nonsmokers (7/34, 21%) [chi2(1) = 10.6, p < 0.003]. Fenfluramine 113-125 prolactin Homo sapiens 35-44 10924001-9 2000 Multiple regression revealed that three variables--(1) number of pack-years of smoking, (2) actual dosage of fenfluramine received, and (3) plasma norfenfluramine level obtained--explained 43% of the variance (R2 = 0.43) in delta prolactin area under the curve. Norfenfluramine 147-162 prolactin Homo sapiens 230-239 10968479-0 2000 Differences of hexarelin-induced prolactin and cortisol responses between prepubertal and early pubertal short children and lack of correlation with gonadotropin-releasing hormone-induced gonadotropin response. hexarelin 15-24 prolactin Homo sapiens 33-42 10924001-11 2000 CONCLUSIONS: Cigarette smoking blunted the prolactin response to a pharmacological challenge with d,l-fenfluramine. d,l-fenfluramine 98-114 prolactin Homo sapiens 43-52 10924001-12 2000 Pharmacodynamic and pharmacokinetic factors related to smoking both appear to influence fenfluramine-induced prolactin secretion. Fenfluramine 88-100 prolactin Homo sapiens 109-118 10931080-11 2000 RESULTS: After 12 months of quinagolide treatment, serum PRL levels normalized in all 23 patients with microprolactinoma (100%) and in 14 out of 16 with macroprolactinoma (87.5%). quinagolide 28-39 prolactin Homo sapiens 57-60 10931080-15 2000 After 12 months of CAB treatment, serum PRL levels normalized in 22 out of 23 patients with microprolactinoma (95.6%) and in 14 out of 16 with macroprolactinoma (87.5%). Cabergoline 19-22 prolactin Homo sapiens 40-43 10931080-21 2000 The withdrawal from CAB treatment, induced an increase in serum PRL levels in all macroprolactinomas between 15 and 30 days, in 15 out of 23 microprolactinoma after 30 days, and in four patients after 2-4 months. Cabergoline 20-23 prolactin Homo sapiens 64-67 10931080-26 2000 CONCLUSIONS: Both quinagolide and CAB treatments, induced the normalization of serum PRL levels in the great majority of patients with prolactinoma. quinagolide 18-29 prolactin Homo sapiens 85-88 10931080-26 2000 CONCLUSIONS: Both quinagolide and CAB treatments, induced the normalization of serum PRL levels in the great majority of patients with prolactinoma. Cabergoline 34-37 prolactin Homo sapiens 85-88 10968479-1 2000 Hexarelin (HEX), a synthetic hexapeptide with strong GH-stimulating activity, is known to induce the release of prolactin (PRL) and cortisol (F). hexarelin 0-9 prolactin Homo sapiens 112-121 10968479-1 2000 Hexarelin (HEX), a synthetic hexapeptide with strong GH-stimulating activity, is known to induce the release of prolactin (PRL) and cortisol (F). hexarelin 0-9 prolactin Homo sapiens 123-126 10968479-1 2000 Hexarelin (HEX), a synthetic hexapeptide with strong GH-stimulating activity, is known to induce the release of prolactin (PRL) and cortisol (F). hexarelin 11-14 prolactin Homo sapiens 112-121 10968479-1 2000 Hexarelin (HEX), a synthetic hexapeptide with strong GH-stimulating activity, is known to induce the release of prolactin (PRL) and cortisol (F). hexarelin 11-14 prolactin Homo sapiens 123-126 10968479-6 2000 HEX induced a strong GH and a slight PRL increase in prepubertal and early pubertal children, with no differences in the extent of the response, while F secretion was not affected in either group; these responses did not correlate with those of the gonadotropins to GnRH nor with basal T or E2. hexarelin 0-3 prolactin Homo sapiens 37-40 10818282-6 2000 Bromocriptine challenge induced a significant GH increase and a significant suppression of PRL. Bromocriptine 0-13 prolactin Homo sapiens 91-94 10818282-7 2000 D-fenfluramine test significantly increased PRL and cortisol plasma levels and Clonidine test induced a significant rise in GH values. Dexfenfluramine 0-14 prolactin Homo sapiens 44-47 10818282-9 2000 HA scores correlated significantly with D-fen-stimulated PRL and CORT AUCs, (PRL: r=0.424, P<0.05; CORT: r=0. d-fen 40-45 prolactin Homo sapiens 57-60 10818282-9 2000 HA scores correlated significantly with D-fen-stimulated PRL and CORT AUCs, (PRL: r=0.424, P<0.05; CORT: r=0. d-fen 40-45 prolactin Homo sapiens 77-80 10818282-11 2000 RD scores correlated positively with clon-stimulated GH values (r=0.55; F=8.6; P<0.01) and negatively with brom-inhibited-PRL AUCs (r=-0.439, P<0.05). Bromine 110-114 prolactin Homo sapiens 125-128 10963935-1 2000 Previous results from our laboratory have indicated that chronic (8 days) alcohol administration inhibits suckling-induced prolactin (PRL) release in response to 30 min of suckling. Alcohols 74-81 prolactin Homo sapiens 123-132 10838162-0 2000 Prolactin stimulation of tyrosyl phosphorylation of Shc proteins in Nb(2) lymphoma cells, but not mammary tissues. cyclo(tyrosyl-tyrosyl) 25-32 prolactin Homo sapiens 0-9 10838162-3 2000 In the present studies, PRL is shown to stimulate the tyrosyl phosphorylation of all three isoforms of Shc proteins in Nb(2) cells (mitogenesis), but not in the mammary gland. cyclo(tyrosyl-tyrosyl) 54-61 prolactin Homo sapiens 24-27 28796358-13 2000 CONCLUSION: The present study shows the presence of reduced LH pulsatility in hyperprolactinaemic women that recovers completely to within the physiological distribution when PRL levels are normalized by bromocriptine therapy. Luteinizing Hormone 60-62 prolactin Homo sapiens 175-178 10848874-12 2000 When PRL was normalized, the number of high-amplitude LH pulses (4.25 +/- 1.03 pulses/6 h), became statistically different from the pulse number before (P < 0.01) and during (P < 0.01) therapy; in particular the pulse frequency after therapy rose to a level not statistically different from that in controls. Luteinizing Hormone 54-56 prolactin Homo sapiens 5-8 10848874-13 2000 CONCLUSION: The present study shows the presence of reduced LH pulsatility in hyperprolactinaemic women that recovers completely to within the physiological distribution when PRL levels are normalized by bromocriptine therapy. Luteinizing Hormone 60-62 prolactin Homo sapiens 175-178 10848874-13 2000 CONCLUSION: The present study shows the presence of reduced LH pulsatility in hyperprolactinaemic women that recovers completely to within the physiological distribution when PRL levels are normalized by bromocriptine therapy. Bromocriptine 204-217 prolactin Homo sapiens 175-178 28796358-13 2000 CONCLUSION: The present study shows the presence of reduced LH pulsatility in hyperprolactinaemic women that recovers completely to within the physiological distribution when PRL levels are normalized by bromocriptine therapy. Bromocriptine 204-217 prolactin Homo sapiens 175-178 10852458-17 2000 At the multistep correlation analysis, nadir PRL levels were the strongest predictors of tumor shrinkage (r2 = 0.556; P < 0.0001), followed by CAB dose (r2 = 0.577; P < 0.0001). nadir 39-44 prolactin Homo sapiens 45-48 10869858-0 2000 Evidence for a seasonal variation in the ability of exogenous melatonin to suppress prolactin secretion in the mare. Melatonin 62-71 prolactin Homo sapiens 84-93 10788422-5 2000 Here we show that 16K-PRL, but not full-length PRL, acts to promote the expression of the inducible isoform of nitric oxide synthase (iNOS) and nitric oxide (*NO) production by pulmonary fibroblasts and alveolar type II cells with potency comparable with the proinflammatory cytokines interleukin-1beta, interferon gamma, and tumor necrosis factor alpha. Nitric Oxide 111-123 prolactin Homo sapiens 18-25 10788422-5 2000 Here we show that 16K-PRL, but not full-length PRL, acts to promote the expression of the inducible isoform of nitric oxide synthase (iNOS) and nitric oxide (*NO) production by pulmonary fibroblasts and alveolar type II cells with potency comparable with the proinflammatory cytokines interleukin-1beta, interferon gamma, and tumor necrosis factor alpha. Nitric Oxide 111-123 prolactin Homo sapiens 22-25 10928095-0 2000 Cyclosporine A inhibition of prolactin-dependent up-regulation of BRCA1 protein expression in human breast cell lines. Cyclosporine 0-14 prolactin Homo sapiens 29-38 10928095-5 2000 RESULTS AND CONCLUSION: We showed that Prolactin in presence of Cyclosporine A has no effect on BRCA1 protein expression in human breast cell lines. Cyclosporine 64-78 prolactin Homo sapiens 39-48 10869858-1 2000 In seasonally breeding species photoperiodic information is thought to be conveyed to the reproductive and prolactin axis via changes in circulating concentrations of melatonin. Melatonin 167-176 prolactin Homo sapiens 107-116 10869858-5 2000 In experiments 1-3, the effects of constant administration of melatonin on prolactin secretion were investigated. Melatonin 62-71 prolactin Homo sapiens 75-84 10869858-15 2000 In the presence of a continuous melatonin implant the circannual rhythm of prolactin secretion was not disturbed. Melatonin 32-41 prolactin Homo sapiens 75-84 10869858-16 2000 The results suggest that the prolactin axis of the mare is sensitive to an inhibitory melatonin signal during a restricted period of time and that at other times is refractory to this signal. Melatonin 86-95 prolactin Homo sapiens 29-38 10748449-4 2000 Immunohistochemical localization of PRL was performed on formalin-fixed paraffin-embedded tissue sections. Formaldehyde 57-65 prolactin Homo sapiens 36-39 10765095-0 2000 Paradoxical stimulation of prolactin secretion by L-dopa in metastatic prostate cancer and its possible role in prostate-cancer-related hyperprolactinemia. Levodopa 50-56 prolactin Homo sapiens 27-36 10765095-4 2000 This study was carried out to analyze PRL secretion in metastatic prostate cancer patients both at basal conditions and in response to L-Dopa and metoclopramide, which represents the most classical inhibitory and stimulatory tests for PRL secretion, respectively. Levodopa 135-141 prolactin Homo sapiens 38-41 10765095-4 2000 This study was carried out to analyze PRL secretion in metastatic prostate cancer patients both at basal conditions and in response to L-Dopa and metoclopramide, which represents the most classical inhibitory and stimulatory tests for PRL secretion, respectively. Metoclopramide 146-160 prolactin Homo sapiens 38-41 10765095-4 2000 This study was carried out to analyze PRL secretion in metastatic prostate cancer patients both at basal conditions and in response to L-Dopa and metoclopramide, which represents the most classical inhibitory and stimulatory tests for PRL secretion, respectively. Metoclopramide 146-160 prolactin Homo sapiens 235-238 10765095-6 2000 On separate occasions, PRL secretion was evaluated in response to L-Dopa (500 mg orally) and to metoclopramide (10 mg i.v. Levodopa 66-72 prolactin Homo sapiens 23-26 10765095-9 2000 RESULTS: Mean PRL concentrations significantly increased after metoclopramide administration, even though no PRL response occurred in 6 of 12 patients. Metoclopramide 63-77 prolactin Homo sapiens 14-17 10765095-11 2000 CONCLUSION: By showing a paradoxical stimulatory effect of L-Dopa on PRL secretion and a lack of response to metoclopramide in some patients, this study would suggest the existence of evident alterations in the neuroendocrine regulation of PRL release in advanced prostate cancer. Levodopa 59-65 prolactin Homo sapiens 69-72 10748449-4 2000 Immunohistochemical localization of PRL was performed on formalin-fixed paraffin-embedded tissue sections. Paraffin 72-80 prolactin Homo sapiens 36-39 10788673-9 2000 Depressed patients with anger attacks showed a significantly blunted prolactin response to fenfluramine challenge compared to patients without anger attacks. Fenfluramine 91-103 prolactin Homo sapiens 69-78 10870870-9 2000 Serum prolactin concentrations were elevated at the end of fluphenazine treatment in 73% of patients. Fluphenazine 59-71 prolactin Homo sapiens 6-15 10870870-10 2000 Between weeks 4 and 12, elevated serum prolactin concentrations significantly decreased in quetiapine-treated patients compared to those receiving haloperidol (P < 0.001). Quetiapine Fumarate 91-101 prolactin Homo sapiens 39-48 11081147-8 2000 An eight-week trial of relatively low dose dopamine agonists led to a reduction of PRL, while the GH- and IGF-1 levels remained unchanged; the tumor showed only little shrinkage. Dopamine 43-51 prolactin Homo sapiens 83-86 10788673-10 2000 As previous studies have shown blunted prolactin responses to fenfluramine in impulsive aggression among patients with personality disorders, our results support our hypothesis that depressed patients with anger attacks may have a relatively greater serotonergic dysregulation than depressed patients without these attacks. Fenfluramine 62-74 prolactin Homo sapiens 39-48 10823405-0 2000 Prolactin response to nemonapride, a selective antagonist for D2 like dopamine receptors, in schizophrenic patients in relation to Taq1A polymorphism of DRD2 gene. nemonapride 22-33 prolactin Homo sapiens 0-9 10746642-0 2000 Dexamethasone counteracts the effect of prolactin on islet function: implications for islet regulation in late pregnancy. Dexamethasone 0-13 prolactin Homo sapiens 40-49 11060712-2 2000 Clinical trials indicate that ziprasidone is effective against positive, negative and affective symptoms in schizophrenia and schizoaffective disorder with minimal motor, cognitive, weight gain, prolactin related, or anticholinergic side effects. ziprasidone 30-41 prolactin Homo sapiens 195-204 10933752-2 2000 Octreotide therapy is effective in suppressing the secretion of thyrotropin, prolactin, and thyroid hormones, and by this, renders relief of symptoms and complications of thyrotoxicosis. Octreotide 0-10 prolactin Homo sapiens 77-86 10760377-0 2000 Prolactin response to D-fenfluramine and suicidal behavior in depressed patients. Dexfenfluramine 22-36 prolactin Homo sapiens 0-9 10760377-1 2000 Previous studies of the prolactin response to D-fenfluramine in depressed patients have yielded inconsistent results. Dexfenfluramine 46-60 prolactin Homo sapiens 24-33 10760377-3 2000 We carried out this study to test the hypothesis that lower prolactin response to D-fenfluramine is more closely associated with suicidal behavior than with depression itself. Dexfenfluramine 82-96 prolactin Homo sapiens 60-69 10760377-5 2000 Depressed inpatients with a history of suicide attempt showed a significantly lower prolactin response to D-fenfluramine compared to depressed inpatients without such a history and compared to control subjects. Dexfenfluramine 106-120 prolactin Homo sapiens 84-93 10760377-6 2000 Healthy control subjects and depressed inpatients without a history of suicide attempt showed comparable levels of prolactin after D-fenfluramine. Dexfenfluramine 131-145 prolactin Homo sapiens 115-124 10760377-8 2000 Results show that in our depressed drug-free inpatient sample, prolactin response to D-fenfluramine seems to be a marker of suicidality, but not of depression itself. Dexfenfluramine 85-99 prolactin Homo sapiens 63-72 10725568-2 2000 Therefore, the relationship between CNV and serotonergic activity as reflected by prolactin (PRL) response to flesinoxan, a 5-HT(1A) full agonist, has been investigated in 28 healthy volunteers. flesinoxan 110-120 prolactin Homo sapiens 82-91 10760953-9 2000 In the presence of ethanol, however, PRL- and TNF-alpha-induced increases in all four immunoreactive ICAM-1 proteins were markedly inhibited. Ethanol 19-26 prolactin Homo sapiens 37-40 10760953-12 2000 Consistent with our Western blot analyses, ethanol significantly inhibited TNF-alpha- and PRL-induced cell surface ICAM-1 expression. Ethanol 43-50 prolactin Homo sapiens 90-93 10776662-4 2000 METHODS: The adrenocorticotropic hormone (ACTH), beta-endorphin (beta-E), cortisol (CORT), and prolactin (PRL) responses to alcohol were examined in male and female identical (monozygotic or MZ) and fraternal (dizygotic or DZ) twin pairs. Alcohols 124-131 prolactin Homo sapiens 106-109 10805609-0 2000 Impulsiveness and the prolactin response to d-fenfluramine. Dexfenfluramine 44-58 prolactin Homo sapiens 22-31 10805609-3 2000 METHOD: The prolactin response to d-fenfluramine was measured in subjects scoring high and low on a scale of impulsiveness selected from a panel of healthy volunteers screened for impulsiveness. Dexfenfluramine 34-48 prolactin Homo sapiens 12-21 26976681-0 2000 Serum prolactin levels and sexual dysfunctions in antipsychotic medication, such as risperidone: a review. Risperidone 84-95 prolactin Homo sapiens 6-15 26976681-2 2000 The atypical antipsychotic clozapine barely increases prolactin levels. Clozapine 27-36 prolactin Homo sapiens 54-63 26976681-4 2000 In the literature reviewed, risperidone is associated with higher prolactin levels in comparison to classical antipsychotics. Risperidone 28-39 prolactin Homo sapiens 66-75 26976681-5 2000 It is still unclear which mechanism is responsible for the increase of serum prolactin levels and sexual dysfunctions in patients using risperidone. Risperidone 136-147 prolactin Homo sapiens 77-86 10776662-11 2000 RESULTS: Resting plasma levels of all four hormones were within the expected range, and the beta-E, ACTH, and PRL responses to the alcohol challenge evidenced good test-retest reliability. Alcohols 131-138 prolactin Homo sapiens 110-113 10639190-5 2000 Previous animal studies demonstrated that testosterone and prolactin regulate the level of m-aconitase specifically in citrate-producing prostate cells. Citric Acid 119-126 prolactin Homo sapiens 59-68 10880731-2 2000 METHODS: Our group evaluated the response of pituitary PRL, LH, FSH, and TSH to the administration of a single 10-mg oral dose of the dopamine (DA) receptor antagonist metoclopramide in lean (n = 7) and obese (n = 8) PCOS women and in 11 regularly cycling age- and weight-matched controls (six lean and five obese). Metoclopramide 168-182 prolactin Homo sapiens 55-58 10880731-4 2000 RESULTS: Oral administration of metoclopramide resulted in a significant increase in serum PRL in all subjects; however, the highest increments, regardless of body mass index (BMI), were observed in control women (p <0.005). Metoclopramide 32-46 prolactin Homo sapiens 91-94 11249538-1 2000 Cabergoline (CAB) (1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea) is an ergoline derivative with potent, selective and long-lasting inhibitory activity on prolactin (PRL) secretion acting on dopamine receptors present in pituitary lactotrophes. Cabergoline 0-11 prolactin Homo sapiens 202-205 11249538-1 2000 Cabergoline (CAB) (1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea) is an ergoline derivative with potent, selective and long-lasting inhibitory activity on prolactin (PRL) secretion acting on dopamine receptors present in pituitary lactotrophes. Cabergoline 13-16 prolactin Homo sapiens 202-205 11249538-1 2000 Cabergoline (CAB) (1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea) is an ergoline derivative with potent, selective and long-lasting inhibitory activity on prolactin (PRL) secretion acting on dopamine receptors present in pituitary lactotrophes. 1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea 19-100 prolactin Homo sapiens 202-205 11249538-1 2000 Cabergoline (CAB) (1-[(6-allelylergolin-8 beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethyl-urea) is an ergoline derivative with potent, selective and long-lasting inhibitory activity on prolactin (PRL) secretion acting on dopamine receptors present in pituitary lactotrophes. Ergolines 3-11 prolactin Homo sapiens 202-205 10739497-0 2000 The effects of L-arginine on the release of prolactin from decidual explants in vitro. Arginine 15-25 prolactin Homo sapiens 44-53 10739497-1 2000 OBJECTIVE: Our aim was to elucidate a role for the L -arginine-nitric oxide-cyclic guanosine monophosphate pathway in the control of decidual prolactin release in vitro. Arginine 51-62 prolactin Homo sapiens 142-151 10739497-1 2000 OBJECTIVE: Our aim was to elucidate a role for the L -arginine-nitric oxide-cyclic guanosine monophosphate pathway in the control of decidual prolactin release in vitro. Nitric Oxide 63-75 prolactin Homo sapiens 142-151 10739497-1 2000 OBJECTIVE: Our aim was to elucidate a role for the L -arginine-nitric oxide-cyclic guanosine monophosphate pathway in the control of decidual prolactin release in vitro. Cyclic GMP 76-106 prolactin Homo sapiens 142-151 10739497-3 2000 RESULTS: L -arginine, at 100 micromol/L, produced an increase in medium prolactin concentration after a 2-hour exposure; however, its inactive isomer, D -arginine, at the same concentration, did not. Arginine 9-20 prolactin Homo sapiens 72-81 10739497-4 2000 The increase in prolactin release initiated by L -arginine was sustained after a 24-hour incubation. Arginine 47-58 prolactin Homo sapiens 16-25 10739497-5 2000 In addition, 8-bromo-cyclic guanosine monophosphate (10 micromol/L) stimulated prolactin release. 8-bromocyclic GMP 13-51 prolactin Homo sapiens 79-88 10739497-7 2000 Incubation of tissue with L -NAME for 24 hours inhibited prolactin secretion (24 hours; P <.05, vs control); however, L -NMMA was without effect. NG-Nitroarginine Methyl Ester 26-33 prolactin Homo sapiens 57-66 10739497-8 2000 CONCLUSIONS: These results suggest that the L -arginine-nitric oxide-cyclic guanosine monophosphate pathway is involved in the regulation of prolactin secretion by decidual tissue. Arginine 44-55 prolactin Homo sapiens 141-150 10739497-8 2000 CONCLUSIONS: These results suggest that the L -arginine-nitric oxide-cyclic guanosine monophosphate pathway is involved in the regulation of prolactin secretion by decidual tissue. Nitric Oxide 56-68 prolactin Homo sapiens 141-150 10739497-8 2000 CONCLUSIONS: These results suggest that the L -arginine-nitric oxide-cyclic guanosine monophosphate pathway is involved in the regulation of prolactin secretion by decidual tissue. Cyclic GMP 69-99 prolactin Homo sapiens 141-150 10785345-6 2000 Men with more pregnancy (couvade) symptoms and men who were most affected by the infant reactivity test had higher prolactin levels and greater post-test reduction in testosterone. couvade 25-32 prolactin Homo sapiens 115-124 10705038-2 2000 Although this pituitary hormone has been long suspected to be involved in the progression of human breast cancer, the failure of clinical improvement by treatment with dopamine agonists (which lower circulating levels of PRL) rapidly reduced the interest of oncologists concerning a potential role of PRL in the development of breast cancer. Dopamine 168-176 prolactin Homo sapiens 221-224 10671947-9 2000 However a reduction in prolactin level was evident with thyroxine replacement and a rise in free testosterone levels. Thyroxine 56-65 prolactin Homo sapiens 23-32 10671947-9 2000 However a reduction in prolactin level was evident with thyroxine replacement and a rise in free testosterone levels. Testosterone 97-109 prolactin Homo sapiens 23-32 10705038-4 2000 In agreement with a recent epidemiological study, these observations have led to a reconsideration of the role of PRL as an active participant in breast cancer, and are an impetus to redefine the molecular targets of anti-prolactin strategies since dopamine analogs are assumed to be inefficient on extrapituitary PRL synthesis. Dopamine 249-257 prolactin Homo sapiens 222-231 10746297-7 2000 On sulpiride, patients gained weight and exhibited fatigue and increased levels of prolactin. Sulpiride 3-12 prolactin Homo sapiens 83-92 11065057-4 2000 The component in beer responsible for the effect on prolactin secretion is not the alcohol content but apparently a polysaccharide from barley, which explains that the effect on prolactin can also be induced by non-alcoholic beer. Alcohols 83-90 prolactin Homo sapiens 52-61 10664829-3 2000 RESULTS: MDMA users showed significantly reduced PRL and CORT responses in comparison with control subjects at 3 weeks (respectively, p < .001; p < .005). N-Methyl-3,4-methylenedioxyamphetamine 9-13 prolactin Homo sapiens 49-52 10691808-1 2000 Dopamine modulates cardiovascular function by actions in the central and peripheral nervous system, by altering the secretion/release of prolactin, pro-opiomelanocortin, vasopressin, aldosterone, and renin, and by directly affecting renal function. Dopamine 0-8 prolactin Homo sapiens 137-146 10664829-8 2000 PRL AUCs at 12 months were inversely correlated with the measures of MDMA exposure (r = -.538). N-Methyl-3,4-methylenedioxyamphetamine 69-73 prolactin Homo sapiens 0-3 11261272-5 2000 CONCLUSION 1: Drug-induced pulsatile PRL elevation (by metoclopramid) enhancing NK-LAK activity could be an easily feasible bridging therapy for the early posttransplant period, when Il-2 production is impaired and high-dose IL-2 therapy is precluded because of side effects. Metoclopramide 55-68 prolactin Homo sapiens 37-40 11261272-7 2000 On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner). Cyclosporine 39-43 prolactin Homo sapiens 19-22 11261272-7 2000 On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner). Cyclosporine 100-104 prolactin Homo sapiens 19-22 11261272-7 2000 On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner). Cyclosporine 100-104 prolactin Homo sapiens 115-118 11261272-7 2000 On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner). Cyclosporine 100-104 prolactin Homo sapiens 115-118 11261272-7 2000 On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner). Cyclosporine 100-104 prolactin Homo sapiens 19-22 11261272-7 2000 On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner). Cyclosporine 100-104 prolactin Homo sapiens 115-118 11261272-7 2000 On NK- and T-cells PRL interferes with Cy-A in two different, dose-dependent ways (subtherapeutical Cy-A increases PRL-binding to its receptor 4 fold; therapeutical Cy-A competes with PRL for binding in a dose dependent manner). Cyclosporine 100-104 prolactin Homo sapiens 115-118 11261272-8 2000 Cy-A inhibits PRL-production on the transcriptional level in pituitary cells. Cyclosporine 0-4 prolactin Homo sapiens 14-17 11065057-4 2000 The component in beer responsible for the effect on prolactin secretion is not the alcohol content but apparently a polysaccharide from barley, which explains that the effect on prolactin can also be induced by non-alcoholic beer. Polysaccharides 116-130 prolactin Homo sapiens 52-61 11065057-4 2000 The component in beer responsible for the effect on prolactin secretion is not the alcohol content but apparently a polysaccharide from barley, which explains that the effect on prolactin can also be induced by non-alcoholic beer. Polysaccharides 116-130 prolactin Homo sapiens 178-187 10771448-10 2000 Ziprasidone was associated with transient prolactin elevation but levels of prolactin returned to baseline within the dosing interval at steady state. ziprasidone 0-11 prolactin Homo sapiens 42-51 10686432-19 2000 In E(2)-treated rats, a point mutation with a base substitution from cytidine (C) to adenine (A) was found at the -36-bp site of the proximal promoter of the prolactin gene in eutopic pituitary prolactinomas, but no change was observed in the same sequence of the prolactin gene in ectopic prolactinoma. Cytidine 69-77 prolactin Homo sapiens 158-167 10686432-19 2000 In E(2)-treated rats, a point mutation with a base substitution from cytidine (C) to adenine (A) was found at the -36-bp site of the proximal promoter of the prolactin gene in eutopic pituitary prolactinomas, but no change was observed in the same sequence of the prolactin gene in ectopic prolactinoma. Cytidine 69-77 prolactin Homo sapiens 194-203 10686432-19 2000 In E(2)-treated rats, a point mutation with a base substitution from cytidine (C) to adenine (A) was found at the -36-bp site of the proximal promoter of the prolactin gene in eutopic pituitary prolactinomas, but no change was observed in the same sequence of the prolactin gene in ectopic prolactinoma. Adenine 85-92 prolactin Homo sapiens 158-167 10686432-19 2000 In E(2)-treated rats, a point mutation with a base substitution from cytidine (C) to adenine (A) was found at the -36-bp site of the proximal promoter of the prolactin gene in eutopic pituitary prolactinomas, but no change was observed in the same sequence of the prolactin gene in ectopic prolactinoma. Adenine 85-92 prolactin Homo sapiens 194-203 10718101-8 2000 Dopamine agonists are very effective in the treatment of prolactin (PRL)-secreting tumours, with rates of control as high as 80 to 90% for microprolactinomas (< 10 mm) and 60 to 75% for macroprolactinomas (> or = 10 mm). Dopamine 0-8 prolactin Homo sapiens 57-66 10661677-6 2000 RESULTS: The prolactin responses to haloperidol increased significantly after detoxification compared to those during usual alcohol consumption (state x time interaction P < 0.01; planned comparisons for times 0 and 90 min between states P = 0.03). Haloperidol 36-47 prolactin Homo sapiens 13-22 10796498-3 2000 Whilst bromocriptine treatment for reducing prolactin levels in hyperprolactinaemic males (as in females), and, in the treatment of hypogonadotropic hypogonadism with hyperprolactinaemia, is beneficial, it has also been used for oligospermic men in the absence of any endocrinopathy. Bromocriptine 7-20 prolactin Homo sapiens 44-53 10796498-6 2000 It has been proposed that the administration of bromocriptine under these circumstances might counteract a prolactin-induced block on the action of gonadotrophins on the testicles and, subsequently, that the reduction in prolactin levels might lead to an improvement in semen parameters and fertility. Bromocriptine 48-61 prolactin Homo sapiens 107-116 10796498-6 2000 It has been proposed that the administration of bromocriptine under these circumstances might counteract a prolactin-induced block on the action of gonadotrophins on the testicles and, subsequently, that the reduction in prolactin levels might lead to an improvement in semen parameters and fertility. Bromocriptine 48-61 prolactin Homo sapiens 221-230 10796498-7 2000 Although it is not licensed for use in male infertility, bromocriptine has been used for normogonadotrophic individuals with oligospermia and normal or sligthly elevated prolactin levels. Bromocriptine 57-70 prolactin Homo sapiens 170-179 10796498-15 2000 Compared with placebo, bromocriptine was associated with a significant reduction in serum prolactin levels (weighted mean difference -195.3 micro international units per litre, 95% confidence interval -276.5 to -114). Bromocriptine 23-36 prolactin Homo sapiens 90-99 10796498-18 2000 REVIEWER"S CONCLUSIONS: Bromocriptine appears to reduce prolactin levels in subfertile men with normal gonadotrophic function. Bromocriptine 24-37 prolactin Homo sapiens 56-65 10661677-6 2000 RESULTS: The prolactin responses to haloperidol increased significantly after detoxification compared to those during usual alcohol consumption (state x time interaction P < 0.01; planned comparisons for times 0 and 90 min between states P = 0.03). Alcohols 124-131 prolactin Homo sapiens 13-22 10811239-4 2000 While increased prolactin levels have been reported in patients taking risperidone, little correlation has been found between prolactin levels and adverse events. Risperidone 71-82 prolactin Homo sapiens 16-25 11080913-0 2000 Placental lactogen not growth hormone and prolactin regulates secretion of progesterone in vitro by the 40-45 day ovine corpus luteum of pregnancy. Progesterone 75-87 prolactin Homo sapiens 42-51 11080913-4 2000 To determine to what extent growth hormone (GH), prolactin (PRL) and lactogen (PL) regulate the activity of 3 beta-HSD, an enzyme involved in progesterone synthesis, the classical steroidal competitive inhibitor of 3 beta-HSD trilostane, was investigated for its effects on basal and GH-, PRL-, and PL-stimulated progesterone biosynthesis since there is a possibility that the luteotropic effect of these hormones are mediated via 3 beta-HSD. Progesterone 142-154 prolactin Homo sapiens 49-58 10585595-9 2000 PRL protein in the immunoprecipitate of (35)S-methionine-labeled cell lysates and supernatants paralleled mRNA expression, and Western blotting analysis showed the presence of the pituitary/lymphocyte non-glycosylated (23.5 kDa) and glycosylated (25 kDa) isoforms. Methionine 46-56 prolactin Homo sapiens 0-3 10686483-6 2000 Testosterone levels appear to have an inverse relationship to prolactin levels during infant care in birds and rodents, but this relationship has not been examined for primates. Testosterone 0-12 prolactin Homo sapiens 62-71 10732318-0 2000 Effect of parity on pituitary prolactin response to metoclopramide and domperidone: implications for the enhancement of lactation. Metoclopramide 52-66 prolactin Homo sapiens 30-39 12845746-1 2000 Phorbol ester-induced release of growth hormone (GH) and prolactin (PRL) from human somatotrophic tumors was examined in vitro. Phorbol Esters 0-13 prolactin Homo sapiens 68-71 12845746-2 2000 12-O-tetradecanoyl-phorbol-13-acetate (TPA) strongly stimulated GH and PRL secretion and showed an additive effect on GH secretion if used in combination with GH releasing hormone (GHRH). Tetradecanoylphorbol Acetate 0-37 prolactin Homo sapiens 71-74 10732318-0 2000 Effect of parity on pituitary prolactin response to metoclopramide and domperidone: implications for the enhancement of lactation. Domperidone 71-82 prolactin Homo sapiens 30-39 12845746-2 2000 12-O-tetradecanoyl-phorbol-13-acetate (TPA) strongly stimulated GH and PRL secretion and showed an additive effect on GH secretion if used in combination with GH releasing hormone (GHRH). Tetradecanoylphorbol Acetate 39-42 prolactin Homo sapiens 71-74 10732318-1 2000 OBJECTIVE: The gastrointestinal motility agents metoclopramide and domperidone are known to increase pituitary prolactin (PRL) secretion and breast milk production. Metoclopramide 48-62 prolactin Homo sapiens 111-120 10732318-1 2000 OBJECTIVE: The gastrointestinal motility agents metoclopramide and domperidone are known to increase pituitary prolactin (PRL) secretion and breast milk production. Metoclopramide 48-62 prolactin Homo sapiens 122-125 10732318-1 2000 OBJECTIVE: The gastrointestinal motility agents metoclopramide and domperidone are known to increase pituitary prolactin (PRL) secretion and breast milk production. Domperidone 67-78 prolactin Homo sapiens 111-120 10732318-1 2000 OBJECTIVE: The gastrointestinal motility agents metoclopramide and domperidone are known to increase pituitary prolactin (PRL) secretion and breast milk production. Domperidone 67-78 prolactin Homo sapiens 122-125 20681130-8 2000 Domperidone administration resulted in significantly higher plasma prolactin concentrations measured at 0, 4, 8, 12 and 24 h on day 7 of treatment compared with untreated controls (25.5 +/- 15.8 versus 2.5 +/- 3.0 ng ml(-1)). Domperidone 0-11 prolactin Homo sapiens 67-76 10732318-2 2000 This study compared the effect of single doses of two strengths of metoclopramide and a single dose of domperidone on PRL secretion. Domperidone 103-114 prolactin Homo sapiens 118-121 20681131-7 2000 Sulpiride administration increased plasma prolactin concentrations at all times of the year and was most pronounced in cyclic mares, whereas naloxone administration did not affect prolactin secretion. Sulpiride 0-9 prolactin Homo sapiens 42-51 10732318-8 2000 Metoclopramide and domperidone both caused a significant increase in PRL. Metoclopramide 0-14 prolactin Homo sapiens 69-72 10732318-8 2000 Metoclopramide and domperidone both caused a significant increase in PRL. Domperidone 19-30 prolactin Homo sapiens 69-72 10732318-10 2000 Nulliparous women had the quickest and highest PRL secretion with metoclopramide 10 mg, compared with the PRL response with metoclopramide 5 mg and domperidone 10 mg. Conversely, multiparous women had PRL secretion patterns that were equivalent between the medications. Metoclopramide 66-80 prolactin Homo sapiens 47-50 10732318-10 2000 Nulliparous women had the quickest and highest PRL secretion with metoclopramide 10 mg, compared with the PRL response with metoclopramide 5 mg and domperidone 10 mg. Conversely, multiparous women had PRL secretion patterns that were equivalent between the medications. Metoclopramide 124-138 prolactin Homo sapiens 106-109 10732318-10 2000 Nulliparous women had the quickest and highest PRL secretion with metoclopramide 10 mg, compared with the PRL response with metoclopramide 5 mg and domperidone 10 mg. Conversely, multiparous women had PRL secretion patterns that were equivalent between the medications. Metoclopramide 124-138 prolactin Homo sapiens 106-109 11335865-8 2000 (3) The mean level of the serum prolactin in the group of patients without gynecomastia (n = 53) was significantly higher than that in the normal group (n = 35), but there was no significant difference in blood luteinizing hormone, follicle-stimulating hormone, testosterone (T), estradiol (E(2)) or T/E(2) ratio between the groups. Testosterone 262-274 prolactin Homo sapiens 32-41 11335865-8 2000 (3) The mean level of the serum prolactin in the group of patients without gynecomastia (n = 53) was significantly higher than that in the normal group (n = 35), but there was no significant difference in blood luteinizing hormone, follicle-stimulating hormone, testosterone (T), estradiol (E(2)) or T/E(2) ratio between the groups. Estradiol 280-289 prolactin Homo sapiens 32-41 16985734-2 2000 Men with erectile dysfunction who are found to have a low testosterone level should have a measurement of their prolactin level. Testosterone 58-70 prolactin Homo sapiens 112-121 16985734-4 2000 Bromocriptine, a dopamine agonist, is efficacious in lowering elevated prolactin levels and can simultaneously shrink these pituitary tumors. Bromocriptine 0-13 prolactin Homo sapiens 71-80 16985734-4 2000 Bromocriptine, a dopamine agonist, is efficacious in lowering elevated prolactin levels and can simultaneously shrink these pituitary tumors. Dopamine 17-25 prolactin Homo sapiens 71-80 10601959-7 1999 The girls receiving 0.2mg ethinyloestradiol daily had lower IGF-I levels after 12 months of therapy and had higher serum prolactin concentrations than the girls treated with 0.1mg daily. Ethinyl Estradiol 26-43 prolactin Homo sapiens 121-130 10687204-4 2000 Parlodel given in a daily dose 5 mg for 7 days in menopausal hypertensive women lowered a significant fall in arterial pressure, blood concentrations of aldosteron, prolactin, aroused dopamine and urinary sodium excretion (p < 0.01). Bromocriptine 0-8 prolactin Homo sapiens 165-174 10816735-1 1999 Previous in vitro studies have demonstrated zinc (Zn++) inhibition of basal and of potassium (K+) or thyrotropin-releasing hormone (TRH)-stimulated prolactin (PRL) secretion, in a selective, reversible, and dose-dependent manner. Zinc 50-54 prolactin Homo sapiens 148-157 10816735-1 1999 Previous in vitro studies have demonstrated zinc (Zn++) inhibition of basal and of potassium (K+) or thyrotropin-releasing hormone (TRH)-stimulated prolactin (PRL) secretion, in a selective, reversible, and dose-dependent manner. Zinc 50-54 prolactin Homo sapiens 159-162 10816735-2 1999 Thus, Zn++ may regulate physiologically pituitary PRL secretion. Zinc 6-10 prolactin Homo sapiens 50-53 10816735-4 1999 In normal individuals Zn++ administration produced controversial results on PRL secretion. Zinc 22-26 prolactin Homo sapiens 76-79 10646830-6 1999 Moderate PRL responses to the HAL test were found during haloperidol treatment and no responses at all during treatment with risperidone. hal 30-33 prolactin Homo sapiens 9-12 10646830-6 1999 Moderate PRL responses to the HAL test were found during haloperidol treatment and no responses at all during treatment with risperidone. Haloperidol 57-68 prolactin Homo sapiens 9-12 10646830-10 1999 This high potency of risperidone to increase PRL levels cannot be explained by the serotonergic blocking activity of the drug, and seems not to be restricted to its D2 receptor blocking capacity. Risperidone 21-32 prolactin Homo sapiens 45-48 10601959-9 1999 CONCLUSIONS: Therapy with pharmacological doses of ethinyloestradiol changes the levels of several hormones including IGF-I, testosterone, DHEA-S, prolactin and cortisol but the role of the respective changes in the inhibition of growth is not clear. Ethinyl Estradiol 51-68 prolactin Homo sapiens 147-156 10649820-6 1999 With the availability of safe dopamine agonists like bromocriptine and now cabergoline, it seems prudent to attempt to normalize serum prolactin levels early on, before long-term pathologies set in. Bromocriptine 53-66 prolactin Homo sapiens 135-144 10661600-5 1999 Response to treatment with mianserin (76% vs.18% for placebo) was closely linked to a high increase in PRL and COR following a fenfluramine challenge test (positive predictive power=72%). Mianserin 27-36 prolactin Homo sapiens 103-106 10661600-5 1999 Response to treatment with mianserin (76% vs.18% for placebo) was closely linked to a high increase in PRL and COR following a fenfluramine challenge test (positive predictive power=72%). Fenfluramine 127-139 prolactin Homo sapiens 103-106 10688158-7 1999 Prolactin (PRL) levels were elevated in the risperidone, but not in the olanzapine group, at comparable D2 receptor occupancy levels. Risperidone 44-55 prolactin Homo sapiens 0-9 10658257-10 1999 In the case of pituitary tumours responsible hyperprolactinaemia and erectile insufficiency: 1) plasma prolactin is greater than 30 ng/ml in 90% of cases and greater than 50 ng/ml in 83% of cases; 2) total plasma testosterone is less than 3 ng/ml in 88% of cases and less than 4 ng/ml in 96% of cases; 3) libido is decreased in 90% of cases. Testosterone 213-225 prolactin Homo sapiens 50-59 10622344-5 1999 Whereas significant differences in the secretion of prolactin and cortisol between citalopram and placebo challenge were observed in the control group, no differences were found in the group of depressed patients. Citalopram 83-93 prolactin Homo sapiens 52-61 10688158-7 1999 Prolactin (PRL) levels were elevated in the risperidone, but not in the olanzapine group, at comparable D2 receptor occupancy levels. Risperidone 44-55 prolactin Homo sapiens 11-14 10622345-1 1999 Serotonin (5-HT) dysregulation has been associated with major depressive disorder (MDD); a blunted prolactin (PRL) response to D,L-fenfluramine (FEN) has been associated with MDD. d,l-fenfluramine 127-143 prolactin Homo sapiens 99-108 10688158-8 1999 In the olanzapine group, PRL levels were correlated with [123I]IBZM binding ratio (r = -0.551; P < 0.01). Olanzapine 7-17 prolactin Homo sapiens 25-28 10622345-1 1999 Serotonin (5-HT) dysregulation has been associated with major depressive disorder (MDD); a blunted prolactin (PRL) response to D,L-fenfluramine (FEN) has been associated with MDD. fen 145-148 prolactin Homo sapiens 99-108 10688158-8 1999 In the olanzapine group, PRL levels were correlated with [123I]IBZM binding ratio (r = -0.551; P < 0.01). IBZM 63-67 prolactin Homo sapiens 25-28 10688158-10 1999 The lower incidence of prolactin elevation with olanzapine, compared to risperidone, may not be attributed to a lower D2 receptor occupancy. Olanzapine 48-58 prolactin Homo sapiens 23-32 10624504-8 1999 In infertile men who are mildly hyperprolactinemic, bromocriptine administration does not improve semen analysis, although it does normalize the PRL. Bromocriptine 52-65 prolactin Homo sapiens 145-148 10537136-2 1999 A molecular mimic of phosphorylated PRL, which substitutes an aspartate residue for the normally phosphorylated serine (serine 179), has the same properties. Aspartic Acid 62-71 prolactin Homo sapiens 36-39 10589775-8 1999 By using cell proliferation assays, we have demonstrated that: (a) hPRL and E2 exhibited an additive stimulatory effect on human breast cancer cell (T-47D) proliferation; (b) hPRL-G129R possessed an inhibitory effect on T-47D cell proliferation; and (c) when antiestrogen (4-OH-tamoxifen) and anti-PRL (hPRL-G129R) agents were added together, an additive inhibitory effect was observed. 4-oh-tamoxifen 273-287 prolactin Homo sapiens 67-71 10589775-8 1999 By using cell proliferation assays, we have demonstrated that: (a) hPRL and E2 exhibited an additive stimulatory effect on human breast cancer cell (T-47D) proliferation; (b) hPRL-G129R possessed an inhibitory effect on T-47D cell proliferation; and (c) when antiestrogen (4-OH-tamoxifen) and anti-PRL (hPRL-G129R) agents were added together, an additive inhibitory effect was observed. 4-oh-tamoxifen 273-287 prolactin Homo sapiens 175-179 10589775-8 1999 By using cell proliferation assays, we have demonstrated that: (a) hPRL and E2 exhibited an additive stimulatory effect on human breast cancer cell (T-47D) proliferation; (b) hPRL-G129R possessed an inhibitory effect on T-47D cell proliferation; and (c) when antiestrogen (4-OH-tamoxifen) and anti-PRL (hPRL-G129R) agents were added together, an additive inhibitory effect was observed. 4-oh-tamoxifen 273-287 prolactin Homo sapiens 68-71 10589775-8 1999 By using cell proliferation assays, we have demonstrated that: (a) hPRL and E2 exhibited an additive stimulatory effect on human breast cancer cell (T-47D) proliferation; (b) hPRL-G129R possessed an inhibitory effect on T-47D cell proliferation; and (c) when antiestrogen (4-OH-tamoxifen) and anti-PRL (hPRL-G129R) agents were added together, an additive inhibitory effect was observed. 4-oh-tamoxifen 273-287 prolactin Homo sapiens 175-179 10589775-10 1999 We report that hPRL-G129R is able to induce apoptosis in all four cell lines in a dose-dependent manner as determined by the Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. deoxyuridine triphosphate 172-176 prolactin Homo sapiens 15-19 10537179-2 1999 These effects are mediated by the PRL receptor (PRLr); when stimulated the PRL-PRLr complex activates several signaling cascades, including those involving the GTP-binding proteins Ras and Rac. Guanosine Triphosphate 160-163 prolactin Homo sapiens 34-37 10537179-2 1999 These effects are mediated by the PRL receptor (PRLr); when stimulated the PRL-PRLr complex activates several signaling cascades, including those involving the GTP-binding proteins Ras and Rac. Guanosine Triphosphate 160-163 prolactin Homo sapiens 48-51 10537179-8 1999 IF microscopy of filamentous actin using rhodamine-conjugated phalloidin revealed a significant and rapid generation of both membrane ruffling and stress fibers in response to PRL, an effect inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Rhodamines 41-50 prolactin Homo sapiens 176-179 10537179-8 1999 IF microscopy of filamentous actin using rhodamine-conjugated phalloidin revealed a significant and rapid generation of both membrane ruffling and stress fibers in response to PRL, an effect inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. Phalloidine 62-72 prolactin Homo sapiens 176-179 10537179-8 1999 IF microscopy of filamentous actin using rhodamine-conjugated phalloidin revealed a significant and rapid generation of both membrane ruffling and stress fibers in response to PRL, an effect inhibited by the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002. 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 255-263 prolactin Homo sapiens 176-179 10537136-2 1999 A molecular mimic of phosphorylated PRL, which substitutes an aspartate residue for the normally phosphorylated serine (serine 179), has the same properties. Serine 112-118 prolactin Homo sapiens 36-39 10537136-2 1999 A molecular mimic of phosphorylated PRL, which substitutes an aspartate residue for the normally phosphorylated serine (serine 179), has the same properties. Serine 120-126 prolactin Homo sapiens 36-39 10584673-5 1999 In patients with MSA, basal levels of prolactin were elevated (21.1 +/- 5.2 ng/mL [mean +/-standard error]) compared with control subjects (12.1 +/- 1.7, p <0.05), and after L-dopa there was increased variability in prolactin response with less suppression compared with control subjects. Levodopa 174-180 prolactin Homo sapiens 38-47 10525070-0 1999 Pharmacokinetic-pharmacodynamic modeling of tolerance to the prolactin-secreting effect of chlorprothixene after different modes of drug administration. Chlorprothixene 91-106 prolactin Homo sapiens 61-70 10525070-1 1999 The objective of this study was the construction of a pharmacokinetic-pharmacodynamic model to describe the effects of chlorprothixene on prolactin secretion and the time-dependent alterations in the concentration-effect relationship due to tolerance development. Chlorprothixene 119-134 prolactin Homo sapiens 138-147 10525070-3 1999 An integrated pharmacokinetic model and a physiological indirect pharmacodynamic/tolerance model were applied to describe the prolactin-secreting effect of chlorprothixene. Chlorprothixene 156-171 prolactin Homo sapiens 126-135 10559703-0 1999 Trait hostility and prolactin response to tryptophan enhancement/depletion. Tryptophan 42-52 prolactin Homo sapiens 20-29 10774572-11 1999 In addition, by showing a paradoxical rise of PRL in response to L-dopa, which inhibits PRL secretion in physiological conditions, this study would suggest that breast cancer-related hyperprolactinemia may depend at least in part on endogenous disease-related neuroendocrine alterations. Levodopa 65-71 prolactin Homo sapiens 46-49 10559703-1 1999 This study investigated the relationship between trait hostility and aspects of serotonergic function by assessing the prolactin (PRL) response to acute tryptophan depletion and enhancement in 28 healthy male volunteers. Tryptophan 153-163 prolactin Homo sapiens 119-128 10559703-1 1999 This study investigated the relationship between trait hostility and aspects of serotonergic function by assessing the prolactin (PRL) response to acute tryptophan depletion and enhancement in 28 healthy male volunteers. Tryptophan 153-163 prolactin Homo sapiens 130-133 10774572-11 1999 In addition, by showing a paradoxical rise of PRL in response to L-dopa, which inhibits PRL secretion in physiological conditions, this study would suggest that breast cancer-related hyperprolactinemia may depend at least in part on endogenous disease-related neuroendocrine alterations. Levodopa 65-71 prolactin Homo sapiens 88-91 10576237-12 1999 Increasing concentrations of FSH (P < 0.0045) and lower levels of prolactin (P < 0.0055) were only found in the group receiving 20 mg/day of TAM (group C). Tamoxifen 147-150 prolactin Homo sapiens 69-78 10499541-2 1999 Cotreatment with the progestin medroxyprogesterone acetate (MPA) enhanced decidual PRL gene activation in the presence of elevated intracellular cAMP levels. Medroxyprogesterone Acetate 31-58 prolactin Homo sapiens 83-86 10499541-2 1999 Cotreatment with the progestin medroxyprogesterone acetate (MPA) enhanced decidual PRL gene activation in the presence of elevated intracellular cAMP levels. Medroxyprogesterone Acetate 60-63 prolactin Homo sapiens 83-86 10499541-6 1999 The decline in PR levels was of functional relevance, as expression of PR-B or PR-A, by transient transfection, dramatically inhibited the activity of a decidual PRL promoter-reporter construct in response to cAMP. Cyclic AMP 209-213 prolactin Homo sapiens 162-165 10499541-7 1999 Furthermore, the expression of endogenous PRL protein in response to cAMP or cAMP plus MPA was substantially decreased by constitutive expression of green fluorescence protein-tagged PR, which was localized in the nucleus even in the absence of added ligand. Cyclic AMP 69-73 prolactin Homo sapiens 42-45 10499541-7 1999 Furthermore, the expression of endogenous PRL protein in response to cAMP or cAMP plus MPA was substantially decreased by constitutive expression of green fluorescence protein-tagged PR, which was localized in the nucleus even in the absence of added ligand. Cyclic AMP 77-81 prolactin Homo sapiens 42-45 10451911-1 1999 In the present study the effects of acute PO-administration of 15 mg mirtazapine on the growth hormone (GH), prolactin (PRL), and cortisol (COR) secretion were examined in eight physically and mentally healthy male subjects, compared to placebo. Mirtazapine 69-80 prolactin Homo sapiens 109-118 10473550-3 1999 We engineered in binding site 1 of hPRL a hGH-like zinc coordination site, by mutating Asp-183(hPRL) (homologous to Glu-174(hGH)) into Glu (D183E mutation). Aspartic Acid 87-90 prolactin Homo sapiens 35-39 10473550-3 1999 We engineered in binding site 1 of hPRL a hGH-like zinc coordination site, by mutating Asp-183(hPRL) (homologous to Glu-174(hGH)) into Glu (D183E mutation). Aspartic Acid 87-90 prolactin Homo sapiens 95-99 10473550-3 1999 We engineered in binding site 1 of hPRL a hGH-like zinc coordination site, by mutating Asp-183(hPRL) (homologous to Glu-174(hGH)) into Glu (D183E mutation). Glutamic Acid 116-119 prolactin Homo sapiens 35-39 10473550-3 1999 We engineered in binding site 1 of hPRL a hGH-like zinc coordination site, by mutating Asp-183(hPRL) (homologous to Glu-174(hGH)) into Glu (D183E mutation). Glutamic Acid 116-119 prolactin Homo sapiens 95-99 10473550-3 1999 We engineered in binding site 1 of hPRL a hGH-like zinc coordination site, by mutating Asp-183(hPRL) (homologous to Glu-174(hGH)) into Glu (D183E mutation). Glutamic Acid 135-138 prolactin Homo sapiens 35-39 10473550-3 1999 We engineered in binding site 1 of hPRL a hGH-like zinc coordination site, by mutating Asp-183(hPRL) (homologous to Glu-174(hGH)) into Glu (D183E mutation). Glutamic Acid 135-138 prolactin Homo sapiens 95-99 10493666-9 1999 Inhibitors of PRL release, such as bromocriptine, inhibited proliferation of proinflammatory cytokines and collagenases by RA synovial cells. Bromocriptine 35-48 prolactin Homo sapiens 14-17 10470826-4 1999 Although the patient"s prolactin level was lowered to 55 ng/ml by bromocriptine therapy, no tumor shrinkage occurred. Bromocriptine 66-79 prolactin Homo sapiens 23-32 10470826-8 1999 Subsequently, despite a fall in the serum prolactin concentration to less than 20 ng/ml in response to the course of bromocriptine, the mass displayed further extension into the temporal lobe. Bromocriptine 117-130 prolactin Homo sapiens 42-51 10470826-14 1999 Although exceedingly rare, this disease must be added to the differential diagnosis in cases of "prolactinoma" when bromocriptine therapy is followed by a marked decline in serum prolactin that is not accompanied by significant tumor shrinkage. Bromocriptine 116-129 prolactin Homo sapiens 97-106 10580837-0 1999 Prolactin and insulin synergize to regulate the translation modulator PHAS-I via mitogen-activated protein kinase-independent but wortmannin- and rapamycin-sensitive pathway. Wortmannin 130-140 prolactin Homo sapiens 0-9 10516853-8 1999 In addition, tamoxifen has been shown to act locally at the target tissue by binding directly to the PRL receptor and thus inhibiting PRL"s action. Tamoxifen 13-22 prolactin Homo sapiens 101-104 10516853-8 1999 In addition, tamoxifen has been shown to act locally at the target tissue by binding directly to the PRL receptor and thus inhibiting PRL"s action. Tamoxifen 13-22 prolactin Homo sapiens 134-137 10496143-1 1999 In a double blind and placebo controlled study designed to investigate the effect of melatonin administration at 13:00 hr on menstrual characteristics, prolactin, and premenstrual syndrome-like symptoms during simulated eastward travel, it was noted that melatonin reduces or alleviates the stress associated with the simulated travel. Melatonin 85-94 prolactin Homo sapiens 152-161 10496143-6 1999 The placebo group showed a prolactin peak at 13:00 hr (dose time) on the last dose day/blood draw, while the melatonin group showed a prolactin peak at 15:00 hr. Melatonin 109-118 prolactin Homo sapiens 134-143 10472432-13 1999 Our results suggest that both suppression tests with OCT and BCR, and scintigraphic studies in vivo with 123I-IBZM and 111In-OCT can be predictive for the effectiveness of therapies with dopamine agonists and/or SS-analogs in patients with mixed PRL/GH-secreting pituitary tumors. Dopamine 187-195 prolactin Homo sapiens 246-249 10459401-0 1999 The influence of prolactin response to d-fenfluramine on executive functioning in major depression. Dexfenfluramine 39-53 prolactin Homo sapiens 17-26 10459401-1 1999 BACKGROUND: The main purpose of this study was to assess the influence of serotonergic activity, as measured by prolactin response to d-fenfluramine, on executive functioning in major depression. Dexfenfluramine 134-148 prolactin Homo sapiens 112-121 10480671-0 1999 The prolactin response to fenfluramine in schizophrenia is associated with negative symptoms. Fenfluramine 26-38 prolactin Homo sapiens 4-13 10480671-3 1999 Response to fenfluramine as reflected by changes in serum prolactin and cortisol were examined by repeated measures ANOVA, as well as Area Under the Curves (AUCs). Fenfluramine 12-24 prolactin Homo sapiens 58-67 10428824-6 1999 Furthermore, overexpression of a dominant negative kinase-inactive mutant of JAK2 prevented prolactin-induced tyrosine phosphorylation and nuclear translocation of STAT5A and STAT5B but did not block src kinase activation and nuclear translocation of STAT5B. Tyrosine 110-118 prolactin Homo sapiens 92-101 10404396-0 1999 Ethanol inhibits prolactin-induced activation of the JAK/STAT pathway in cultured astrocytes. Ethanol 0-7 prolactin Homo sapiens 17-26 10404396-9 1999 In PRL-stimulated astrocytes, ethanol inhibited binding of nuclear proteins to oligonucleotides corresponding to the gamma-interferon activated sequence (GAS). Ethanol 30-37 prolactin Homo sapiens 3-6 10404396-4 1999 We have recently shown that whereas ethanol does not inhibit PRL receptor binding, it markedly inhibits PRL-induced mitogenesis and TNF alpha secretion in cultured astrocytes. Ethanol 36-43 prolactin Homo sapiens 104-107 10404396-9 1999 In PRL-stimulated astrocytes, ethanol inhibited binding of nuclear proteins to oligonucleotides corresponding to the gamma-interferon activated sequence (GAS). Oligonucleotides 79-95 prolactin Homo sapiens 3-6 10404396-10 1999 Further, ethanol blocked PRL-induced increases in interferon regulatory factor-1 (IRF-1) mRNA, a PRL/cytokine inducible transcription factor involved in the regulation of a number of cytokine inducible genes. Ethanol 9-16 prolactin Homo sapiens 25-28 10404396-5 1999 It is clear that PRL activates the tyrosine phosphorylation of several proteins, including members of a novel family of protein tyrosine kinases, the Janus Kinases (JAKs). Tyrosine 35-43 prolactin Homo sapiens 17-20 10404396-10 1999 Further, ethanol blocked PRL-induced increases in interferon regulatory factor-1 (IRF-1) mRNA, a PRL/cytokine inducible transcription factor involved in the regulation of a number of cytokine inducible genes. Ethanol 9-16 prolactin Homo sapiens 97-100 10404396-7 1999 We found that PRL specifically increases the tyrosine phosphorylation of JAK2, but not JAK1, JAK3, or Tyk2, and the subsequent phosphorylation of STAT1 alpha, STAT5a, and STAT5b. Tyrosine 45-53 prolactin Homo sapiens 14-17 10404396-12 1999 These data indicate that ethanol inhibits PRL-induced tyrosine phosphorylation of the JAK/STAT pathway resulting in decreased nuclear GAS DNA binding and inhibition of the PRL inducible gene, IRF-1. Ethanol 25-32 prolactin Homo sapiens 42-45 10404396-12 1999 These data indicate that ethanol inhibits PRL-induced tyrosine phosphorylation of the JAK/STAT pathway resulting in decreased nuclear GAS DNA binding and inhibition of the PRL inducible gene, IRF-1. Ethanol 25-32 prolactin Homo sapiens 172-175 10456673-1 1999 Prolactin (PRL) has been reported to inhibit dexamethasone (Dex) induced cell death. Dexamethasone 45-58 prolactin Homo sapiens 0-9 10404396-12 1999 These data indicate that ethanol inhibits PRL-induced tyrosine phosphorylation of the JAK/STAT pathway resulting in decreased nuclear GAS DNA binding and inhibition of the PRL inducible gene, IRF-1. Tyrosine 54-62 prolactin Homo sapiens 42-45 10404396-12 1999 These data indicate that ethanol inhibits PRL-induced tyrosine phosphorylation of the JAK/STAT pathway resulting in decreased nuclear GAS DNA binding and inhibition of the PRL inducible gene, IRF-1. Tyrosine 54-62 prolactin Homo sapiens 172-175 10456673-1 1999 Prolactin (PRL) has been reported to inhibit dexamethasone (Dex) induced cell death. Dexamethasone 45-58 prolactin Homo sapiens 11-14 10456673-1 1999 Prolactin (PRL) has been reported to inhibit dexamethasone (Dex) induced cell death. Dexamethasone 60-63 prolactin Homo sapiens 0-9 10456673-1 1999 Prolactin (PRL) has been reported to inhibit dexamethasone (Dex) induced cell death. Dexamethasone 60-63 prolactin Homo sapiens 11-14 10404830-8 1999 Treatment with cabergoline normalized serum PRL levels in 86% of all patients: in 92% of 244 patients with idiopathic hyperprolactinemia or a microprolactinoma and in 77% of 181 macroadenomas. Cabergoline 15-26 prolactin Homo sapiens 44-47 10468974-6 1999 MEASUREMENTS: Prolactin was measured in sera, fractions from gel filtration chromatography and supernatant obtained after PEG precipitation, by the DELFIA fluoroimmunoassay. Polyethylene Glycols 122-125 prolactin Homo sapiens 14-23 10468974-13 1999 Dopamine agonist therapy resulted in substantial falls in serum PRL and this was associated with improvement or resolution of symptoms in some patients. Dopamine 0-8 prolactin Homo sapiens 64-67 10468974-16 1999 CONCLUSIONS: The PEG precipitation test with assessment of "free" prolactin has been shown to be reproducible and sensitive for the detection of macroprolactinaemia. Polyethylene Glycols 17-20 prolactin Homo sapiens 66-75 10404830-2 1999 The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities. Cabergoline 134-145 prolactin Homo sapiens 118-121 10404830-15 1999 In the patients with bromocriptine intolerance, normalization of PRL was reached in 84% of cases, whereas in the bromocriptine-resistant patients, PRL could be normalized in 70%. Bromocriptine 21-34 prolactin Homo sapiens 65-68 10404830-15 1999 In the patients with bromocriptine intolerance, normalization of PRL was reached in 84% of cases, whereas in the bromocriptine-resistant patients, PRL could be normalized in 70%. Bromocriptine 113-126 prolactin Homo sapiens 147-150 10404830-18 1999 Cabergoline also normalized PRL in the majority of patients with known bromocriptine intolerance or -resistance. Cabergoline 0-11 prolactin Homo sapiens 28-31 10404830-18 1999 Cabergoline also normalized PRL in the majority of patients with known bromocriptine intolerance or -resistance. Bromocriptine 71-84 prolactin Homo sapiens 28-31 10475155-4 1999 The high serum level of hCG was unaffected by bromocriptine nor octreotide, while the PRL level (80.0 microg/L) was reduced only by bromocriptine. Bromocriptine 132-145 prolactin Homo sapiens 86-89 10404830-19 1999 Once PRL secretion was adequately controlled, the dose of cabergoline could often be significantly decreased, which further reduced costs of therapy. Cabergoline 58-69 prolactin Homo sapiens 5-8 10615249-9 1999 Morphine also significantly inhibited (P < 0.05) prolactin secretion in suckled sows. Morphine 0-8 prolactin Homo sapiens 52-61 10444306-9 1999 In the two mammosomatotrophs, the PRL response to MK-0677 and to GHRH was similar to the GH response. ibutamoren mesylate 50-57 prolactin Homo sapiens 34-37 10615249-12 1999 Furthermore, in suckled sows, morphine is stimulatory to systems that have an inhibitory effect on prolactin secretion. Morphine 30-38 prolactin Homo sapiens 99-108 10505482-14 1999 The laboratory parameters revealed no significant differences between the treatment groups, with the exception of prolactin which moderately exceeded the range of normal in 50% of the patients treated with sulpiride. Sulpiride 206-215 prolactin Homo sapiens 114-123 10424206-18 1999 However, dopamine agonist (DA) therapy, usually resulting in satisfactory control of PRL levels and in tumor shrinkage, progressively displaced surgery as primary treatment for prolactinomas throughout the study period. Dopamine 9-17 prolactin Homo sapiens 85-88 10420090-0 1999 Potentiation of prolactin secretion following lactotrope escape from dopamine action. Dopamine 69-77 prolactin Homo sapiens 16-25 10420090-3 1999 Hypothalamic dopamine (DA) tonically inhibits prolactin (PRL) release from the anterior pituitary gland. Dopamine 13-21 prolactin Homo sapiens 46-55 10420090-3 1999 Hypothalamic dopamine (DA) tonically inhibits prolactin (PRL) release from the anterior pituitary gland. Dopamine 13-21 prolactin Homo sapiens 57-60 10420090-7 1999 We initially found that in these cells, DA effectively and reversibly inhibited PRL secretion, and reversibly enhanced an inwardly rectifying K(+) current. Dopamine 40-42 prolactin Homo sapiens 80-83 10420090-12 1999 The present results directly demonstrate that dissociation of DA from D(2)-receptors expressed in GH(4)C(1) lactotrope cells causes an increase of high-voltage-activated Ca(2+) channel function, which may play an important role in the cross-talking amplification of endocrine cascades such as that involved in the TRH-induced PRL-release potentiating action of DA withdrawal. Dopamine 62-64 prolactin Homo sapiens 326-329 10420091-0 1999 Potentiation of prolactin secretion following lactotrope escape from dopamine action. Dopamine 69-77 prolactin Homo sapiens 16-25 10420091-5 1999 Prolactin (PRL) secretion is tonically inhibited by dopamine (DA), the escape from which triggers acute episodes of hormone secretion. Dopamine 52-60 prolactin Homo sapiens 0-9 10420091-5 1999 Prolactin (PRL) secretion is tonically inhibited by dopamine (DA), the escape from which triggers acute episodes of hormone secretion. Dopamine 52-60 prolactin Homo sapiens 11-14 10420091-5 1999 Prolactin (PRL) secretion is tonically inhibited by dopamine (DA), the escape from which triggers acute episodes of hormone secretion. Dopamine 62-64 prolactin Homo sapiens 0-9 10420091-5 1999 Prolactin (PRL) secretion is tonically inhibited by dopamine (DA), the escape from which triggers acute episodes of hormone secretion. Dopamine 62-64 prolactin Homo sapiens 11-14 10420091-9 1999 Here we show that the withdrawal from DA potentiates the PRL-releasing action of TRH in GH(4)C(1)/D(2)-DAR cells to the same extent as in enriched lactotropes in primary culture. Dopamine 38-40 prolactin Homo sapiens 57-60 10406465-3 1999 We have analyzed the role of GHF-1 and of the vitamin D receptor (VDR) to confer vitamin D responsiveness to the PRL promoter. Vitamin D 46-55 prolactin Homo sapiens 113-116 10406465-8 1999 Truncation of the last 12 C-terminal amino acids of VDR, which contain the ligand-dependent activation function (AF2), abolishes regulation by vitamin D, suggesting that binding of coactivators to this region mediates ligand-dependent stimulation of the PRL promoter by the receptor. Vitamin D 143-152 prolactin Homo sapiens 254-257 10397281-11 1999 A transient elevating effect of alcohol (0.5 g/kg) on prolactin levels was observed in both study groups. Alcohols 32-39 prolactin Homo sapiens 54-63 10376122-0 1999 Prolactin hyperresponsiveness to D-fenfluramine in drug-free schizophrenic patients: a placebo-controlled study. Dexfenfluramine 33-47 prolactin Homo sapiens 0-9 10376122-2 1999 In the present study, we investigated the prolactin (PRL) response to the selective serotonin (5-HT) releasing agent D-fenfluramine in both patients with schizophrenia and matched healthy subjects. Serotonin 84-93 prolactin Homo sapiens 42-51 10376122-2 1999 In the present study, we investigated the prolactin (PRL) response to the selective serotonin (5-HT) releasing agent D-fenfluramine in both patients with schizophrenia and matched healthy subjects. Serotonin 84-93 prolactin Homo sapiens 53-56 10376122-2 1999 In the present study, we investigated the prolactin (PRL) response to the selective serotonin (5-HT) releasing agent D-fenfluramine in both patients with schizophrenia and matched healthy subjects. Dexfenfluramine 117-131 prolactin Homo sapiens 42-51 10376122-2 1999 In the present study, we investigated the prolactin (PRL) response to the selective serotonin (5-HT) releasing agent D-fenfluramine in both patients with schizophrenia and matched healthy subjects. Dexfenfluramine 117-131 prolactin Homo sapiens 53-56 10376122-7 1999 The PRL response to D-fenfluramine was significantly enhanced in patients as compared to matched control subjects (p < .005). Dexfenfluramine 20-34 prolactin Homo sapiens 4-7 10376122-8 1999 Schizophrenics meeting Kane"s criteria for previous nonresponse to typical neuroleptics exhibited a PRL response to D-fenfluramine significantly higher than non-drug-resistant patients (p < .04). Dexfenfluramine 116-130 prolactin Homo sapiens 100-103 10397281-14 1999 The transient effect on prolactin levels may reflect acute changes in opioid and dopamine levels in the hypothalamus. Dopamine 81-89 prolactin Homo sapiens 24-33 10362440-2 1999 CASE REPORTS: On regimens of risperidone (1-8 mg/day), 5 psychiatric patients with various diagnoses developed amenorrhea with elevated serum prolactin levels (mean = 121.7 ng/mL; range, 61.2-229.8 ng/mL). Risperidone 29-40 prolactin Homo sapiens 142-151 10343287-0 1999 The human prolactin gene upstream promoter is regulated in lymphoid cells by activators of T-cells and by cAMP. Cyclic AMP 106-110 prolactin Homo sapiens 10-19 10343287-8 1999 A single point mutation in the CRE (cAMP response element) located at -25 bp in the PRL upstream promoter (TGACGT to TGCCGT) failed to reduce the response to cptAMP, while mutations or deletion of four nucleotides in the CRE to TACTCT diminished the response to cAMP by more than half. Cyclic AMP 36-40 prolactin Homo sapiens 84-87 10343287-8 1999 A single point mutation in the CRE (cAMP response element) located at -25 bp in the PRL upstream promoter (TGACGT to TGCCGT) failed to reduce the response to cptAMP, while mutations or deletion of four nucleotides in the CRE to TACTCT diminished the response to cAMP by more than half. Cyclic AMP 262-266 prolactin Homo sapiens 84-87 10343287-9 1999 We conclude that activity of the human PRL upstream extrapituitary promoter can be induced by activators of T-cells, as well as by a cAMP analogue. Cyclic AMP 133-137 prolactin Homo sapiens 39-42 10381045-6 1999 One of the patients developed primary SS after being treated with bromocriptine, an inhibitor of PRL synthesis, for 12 years. Bromocriptine 66-79 prolactin Homo sapiens 97-100 10411322-1 1999 Although prolactin (PRL) has been long suspected to be involved in the progression of human breast cancer, the failure of clinical improvement by treatment with dopamine agonists, which lower circulating levels of PRL, rapidly reduced the interest of oncologists concerning a potential role of this pituitary hormone in the development of breast cancer. Dopamine 161-169 prolactin Homo sapiens 214-217 10360922-1 1999 OBJECTIVE: To evaluate the influence of the menstrual cycle and the effects of medroxyprogesterone acetate (MPA) on the expression of the protooncogene c-fos and of prolactin (PRL) in the human endometrium in vivo. Medroxyprogesterone Acetate 79-106 prolactin Homo sapiens 165-174 10349036-0 1999 Serotonergic function in cocaine addicts: prolactin responses to sequential D,L-fenfluramine challenges. Cocaine 25-32 prolactin Homo sapiens 42-51 10349036-0 1999 Serotonergic function in cocaine addicts: prolactin responses to sequential D,L-fenfluramine challenges. d,l-fenfluramine 76-92 prolactin Homo sapiens 42-51 10349036-13 1999 The greater blunting of the prolactin response observed within days of cocaine discontinuation followed by a greater rebound of this response 2 weeks later could indicate an increased vulnerability to the disruptive effects of cocaine in these patients. Cocaine 71-78 prolactin Homo sapiens 28-37 15251686-11 1999 The prolactin levels eventually normalized after withdrawal of verapamil, prochlorperazine, and metoclopramide. Verapamil 63-72 prolactin Homo sapiens 4-13 15251686-11 1999 The prolactin levels eventually normalized after withdrawal of verapamil, prochlorperazine, and metoclopramide. Prochlorperazine 74-90 prolactin Homo sapiens 4-13 15251686-11 1999 The prolactin levels eventually normalized after withdrawal of verapamil, prochlorperazine, and metoclopramide. Metoclopramide 96-110 prolactin Homo sapiens 4-13 10401709-2 1999 We investigated the efficacy of 24-month treatment with CAB in 37 patients with previously untreated PRL-secreting pituitary adenoma and evaluated the hormonal and neuroradiological changes after the discontinuation of long-term therapy. Cabergoline 56-59 prolactin Homo sapiens 101-104 10362440-5 1999 CONCLUSION: These findings indicate that the occurrence of amenorrhea during risperidone treatment may be related to elevated serum prolactin levels. Risperidone 77-88 prolactin Homo sapiens 132-141 10401709-7 1999 In 3 cases PRL levels decreased but did not normalize because the appearance of side effects, such as nausea or hypotension, prevented the increase of the dose of CAB. Cabergoline 163-166 prolactin Homo sapiens 11-14 10401709-11 1999 CAB withdrawal was followed by serum PRL increase in 13 cases after 3 months, in 6 after 6 months, in 2 after 9 months, and in one patient at the 12th month. Cabergoline 0-3 prolactin Homo sapiens 37-40 10319320-4 1999 16K hPRL indirectly increased cAMP levels; however, the blockade of Raf-1 activation was not dependent on the stimulation of cAMP-dependent protein kinase (PKA), but rather on the inhibition of the GTP-bound Ras. Cyclic AMP 30-34 prolactin Homo sapiens 4-8 10319320-4 1999 16K hPRL indirectly increased cAMP levels; however, the blockade of Raf-1 activation was not dependent on the stimulation of cAMP-dependent protein kinase (PKA), but rather on the inhibition of the GTP-bound Ras. Guanosine Triphosphate 198-201 prolactin Homo sapiens 4-8 10319320-5 1999 The VEGF-induced tyrosine phosphorylation of the VEGF receptor, Flk-1, and its association with the Shc/Grb2/Ras-GAP (guanosine triphosphatase-activating protein) complex were unaffected by 16K hPRL treatment. Tyrosine 17-25 prolactin Homo sapiens 194-198 10342366-0 1999 Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. Cabergoline 65-76 prolactin Homo sapiens 15-18 11081212-17 1999 Administration of bromocriptine decreased blood PRL levels but it had a limited action on GH hypersecretion. Bromocriptine 18-31 prolactin Homo sapiens 48-51 10211930-0 1999 Prolactin levels in premenopausal women treated with risperidone compared with those of women treated with typical neuroleptics. Risperidone 53-64 prolactin Homo sapiens 0-9 10342366-1 1999 Cabergoline decreases both serum PRL levels and size of prolactinomas, including some tumors resistant to other dopamine-agonists. Cabergoline 0-11 prolactin Homo sapiens 33-36 10192175-0 1999 Blood oxygen partial pressure affects plasma prolactin concentration in humans. Oxygen 6-12 prolactin Homo sapiens 45-54 10192175-1 1999 Responses of plasma prolactin (PRL) concentration to acute and repeated changes in blood oxygen partial pressure (PO2a) at rest were investigated in two studies (A; B), with special reference to possible effects mediated via serotonin (5-HT) synthesis. Oxygen 89-95 prolactin Homo sapiens 20-29 10192175-1 1999 Responses of plasma prolactin (PRL) concentration to acute and repeated changes in blood oxygen partial pressure (PO2a) at rest were investigated in two studies (A; B), with special reference to possible effects mediated via serotonin (5-HT) synthesis. Oxygen 89-95 prolactin Homo sapiens 31-34 10192175-11 1999 A higher blood PO2a induced a higher plasma PRL secretion but also an earlier decline from peak plasma PRL value despite continued inhalation of the respective oxygen concentration. po2a 15-19 prolactin Homo sapiens 44-47 10192175-11 1999 A higher blood PO2a induced a higher plasma PRL secretion but also an earlier decline from peak plasma PRL value despite continued inhalation of the respective oxygen concentration. po2a 15-19 prolactin Homo sapiens 103-106 10338264-10 1999 In most cases, dopamine agonists (bromocriptine, pergolide, cabergoline) are extremely effective in lowering serum prolactin, restoring gonadal function, decreasing tumor size, and improving visual fields. Cabergoline 60-71 prolactin Homo sapiens 115-124 10338264-10 1999 In most cases, dopamine agonists (bromocriptine, pergolide, cabergoline) are extremely effective in lowering serum prolactin, restoring gonadal function, decreasing tumor size, and improving visual fields. Dopamine 15-23 prolactin Homo sapiens 115-124 10026105-1 1999 This study tested the hypothesis that prolactin (PRL) inhibits gonadotropin secretion in rams maintained under long days and that treatment with melatonin (s.c. continuous-release implant; MEL-IMP) reactivates the reproductive axis by suppressing PRL secretion. Melatonin 145-154 prolactin Homo sapiens 247-250 10226182-6 1999 The growth of the nipple and the rate of excretion of lactose were related to the concentration of prolactin in the plasma. Lactose 54-61 prolactin Homo sapiens 99-108 10476911-4 1999 As in primary cultures of endometrial stromal cells, treatment of N5 cells with progesterone and estradiol alone or in combination with prostaglandin E2 stimulated the synthesis and release of prolactin. Progesterone 80-92 prolactin Homo sapiens 193-202 10476911-4 1999 As in primary cultures of endometrial stromal cells, treatment of N5 cells with progesterone and estradiol alone or in combination with prostaglandin E2 stimulated the synthesis and release of prolactin. Estradiol 97-106 prolactin Homo sapiens 193-202 10476911-4 1999 As in primary cultures of endometrial stromal cells, treatment of N5 cells with progesterone and estradiol alone or in combination with prostaglandin E2 stimulated the synthesis and release of prolactin. Dinoprostone 136-152 prolactin Homo sapiens 193-202 10476911-5 1999 Transient transfection of the N5 cells with an expression vector containing - 2927/ + 66 bp of the decidual prolactin promoter coupled to a luciferase reporter gene resulted in a 20 to 25-fold increase in luciferase activity, a magnitude similar to that which occurs in primary cultures of endometrial stromal cells decidualized in vitro by treatment with progesterone and estradiol. Progesterone 356-368 prolactin Homo sapiens 108-117 10476911-5 1999 Transient transfection of the N5 cells with an expression vector containing - 2927/ + 66 bp of the decidual prolactin promoter coupled to a luciferase reporter gene resulted in a 20 to 25-fold increase in luciferase activity, a magnitude similar to that which occurs in primary cultures of endometrial stromal cells decidualized in vitro by treatment with progesterone and estradiol. Estradiol 373-382 prolactin Homo sapiens 108-117 10338264-10 1999 In most cases, dopamine agonists (bromocriptine, pergolide, cabergoline) are extremely effective in lowering serum prolactin, restoring gonadal function, decreasing tumor size, and improving visual fields. Bromocriptine 34-47 prolactin Homo sapiens 115-124 10338264-10 1999 In most cases, dopamine agonists (bromocriptine, pergolide, cabergoline) are extremely effective in lowering serum prolactin, restoring gonadal function, decreasing tumor size, and improving visual fields. Pergolide 49-58 prolactin Homo sapiens 115-124 10338264-12 1999 The newest dopamine agonist, cabergoline, can be given just once or twice a week, is more effective in normalizing prolactin and restoring menses than bromocriptine, and is significantly better tolerated. Dopamine 11-19 prolactin Homo sapiens 115-124 10338264-12 1999 The newest dopamine agonist, cabergoline, can be given just once or twice a week, is more effective in normalizing prolactin and restoring menses than bromocriptine, and is significantly better tolerated. Cabergoline 29-40 prolactin Homo sapiens 115-124 9989565-2 1999 The new antipsychotics clozapine, risperidone, and olanzapine obtain antipsychotic response with few extrapyramidal side effects and little prolactin elevation. Clozapine 23-32 prolactin Homo sapiens 140-149 10084599-5 1999 PRL concentrations correlated with serum testosterone (r = 0.473; P = 0.041), dehydroepiandrosteroen sulfate (r = +0.455, P = 0.05), and insulin-like growth factor I (r = 0.494; P = 0.032) levels. Testosterone 41-53 prolactin Homo sapiens 0-3 10219888-7 1999 PROL-CTK was the method less influenced by the presence of bb-PRL since most of the subjects with macroprolactinemia had PRL levels either within the normal range or only marginally elevated. boeravinone B 59-61 prolactin Homo sapiens 62-65 10190227-3 1999 These new antipsychotics appear to spare dopamine blockade within the brain"s tubero-infundibular tract, a dopamine pathway that also controls prolactin secretion. Dopamine 107-115 prolactin Homo sapiens 143-152 10190227-4 1999 Since the release of prolactin is tonically inhibited by the hypothalamus, with dopamine acting as the prolactin release-inhibiting factor, any disruption of the connection between the hypothalamus and the pituitary gland is associated with hyperprolactinemia. Dopamine 80-88 prolactin Homo sapiens 103-112 10190227-9 1999 Current data indicate that conventional antipsychotics, as well as high doses of risperidone (> 6 mg/day), increase prolactin levels to a range associated with sexual dysfunction in nonpsychiatric patients. Risperidone 81-92 prolactin Homo sapiens 119-128 9989565-2 1999 The new antipsychotics clozapine, risperidone, and olanzapine obtain antipsychotic response with few extrapyramidal side effects and little prolactin elevation. Risperidone 34-45 prolactin Homo sapiens 140-149 9989565-2 1999 The new antipsychotics clozapine, risperidone, and olanzapine obtain antipsychotic response with few extrapyramidal side effects and little prolactin elevation. Olanzapine 51-61 prolactin Homo sapiens 140-149 10426581-0 1999 Long-term treatment with bromocriptine of a plurihormonal pituitary adenoma secreting thyrotropin, growth hormone and prolactin. Bromocriptine 25-38 prolactin Homo sapiens 118-127 10023505-0 1999 Prolactin response to d-fenfluramine in major depression before and after treatment with serotonin reuptake inhibitors. Dexfenfluramine 22-36 prolactin Homo sapiens 0-9 10023505-3 1999 METHODS: The authors studied 19 outpatients with major depressive disorder using prolactin response to d-fenfluramine as a measure of central serotonergic functioning. Dexfenfluramine 103-117 prolactin Homo sapiens 81-90 10023505-6 1999 RESULTS: Unlike previous studies in which antidepressant treatment produced an enhanced prolactin response to fenfluramine, in this study there was no increase in prolactin response to d-fenfluramine following SSRI treatment. Fenfluramine 110-122 prolactin Homo sapiens 88-97 10023505-7 1999 In fact, prolactin response to d-fenfluramine was significantly diminished after treatment with fluvoxamine but not fluoxetine. Dexfenfluramine 31-45 prolactin Homo sapiens 9-18 10023505-7 1999 In fact, prolactin response to d-fenfluramine was significantly diminished after treatment with fluvoxamine but not fluoxetine. Fluvoxamine 96-107 prolactin Homo sapiens 9-18 10023517-2 1999 METHODS: The prolactin (PRL) response to fenfluramine (FEN) challenge was used to assess central serotonergic (5-HT) functioning in 10 8-11-year-old boys with ADHD. Fenfluramine 41-53 prolactin Homo sapiens 13-22 10023517-2 1999 METHODS: The prolactin (PRL) response to fenfluramine (FEN) challenge was used to assess central serotonergic (5-HT) functioning in 10 8-11-year-old boys with ADHD. Fenfluramine 55-58 prolactin Homo sapiens 13-22 9927340-0 1999 Heparin-binding property of human prolactin: a novel aspect of prolactin biology. Heparin 0-7 prolactin Homo sapiens 34-43 9927340-0 1999 Heparin-binding property of human prolactin: a novel aspect of prolactin biology. Heparin 0-7 prolactin Homo sapiens 63-72 9927340-2 1999 In this study we examined the heparin-binding properties of selected members of the PRL/GH family, using heparin affinity columns followed by gel electrophoresis/Western blotting. Heparin 30-37 prolactin Homo sapiens 84-87 9927340-2 1999 In this study we examined the heparin-binding properties of selected members of the PRL/GH family, using heparin affinity columns followed by gel electrophoresis/Western blotting. Heparin 105-112 prolactin Homo sapiens 84-87 9927340-3 1999 Purified human PRL and its cleaved 16K fragment, but not human GH or placental lactogen, were retained on the heparin column and were displaced by 0.5 M NaCl. Heparin 110-117 prolactin Homo sapiens 15-18 9927340-3 1999 Purified human PRL and its cleaved 16K fragment, but not human GH or placental lactogen, were retained on the heparin column and were displaced by 0.5 M NaCl. Sodium Chloride 153-157 prolactin Homo sapiens 15-18 9927340-4 1999 Native PRL in human pituitary extracts and amniotic fluid showed a similar binding affinity to heparin as the purified hormone. Heparin 95-102 prolactin Homo sapiens 7-10 9927340-6 1999 Two consensus heparin-binding sequences are present in human PRL but not in the other hormones included in this study. Heparin 14-21 prolactin Homo sapiens 61-64 9986923-4 1999 Melatonin was infused into the third brain ventricle (100 microgram/100 microliter/h) from 14.00 to 18.00 h. The concentration of prolactin increased significantly during the infusion of melatonin in late follicular-phase ewes, but not in luteal-phase ewes, as compared to the concentration before the infusion: range from 204.0 +/- 31.7 to 272.2 +/- 50.1 ng/ml vs. range from 68.2 +/- 31.8 to 94.7 +/- 33.1 ng/ml (mean +/- SEM, n = 4, p < 0.01) and to the concentration noted during control infusions: range from 130.0 +/- 58.0 to 179.3 +/- 55.6 ng/ml (mean +/- SEM, n = 4, p < 0.05). Melatonin 187-196 prolactin Homo sapiens 130-139 9927340-7 1999 We postulate that the heparin-binding capability of PRL affects its biological activity as a growth factor and the angiostatic actions of its 16K fragment. Heparin 22-29 prolactin Homo sapiens 52-55 9934942-7 1999 Prolactin response after 1 week of treatment as an index of dopamine blockade may reflect vulnerability to the development of acute dystonia at least in male patients treated with nemonapride. Dopamine 60-68 prolactin Homo sapiens 0-9 9934942-7 1999 Prolactin response after 1 week of treatment as an index of dopamine blockade may reflect vulnerability to the development of acute dystonia at least in male patients treated with nemonapride. nemonapride 180-191 prolactin Homo sapiens 0-9 9934944-0 1999 Prolactin levels and adverse events in patients treated with risperidone. Risperidone 61-72 prolactin Homo sapiens 0-9 9934944-6 1999 Both risperidone and haloperidol produced dose-related increases in plasma prolactin levels in men and women. Risperidone 5-16 prolactin Homo sapiens 75-84 9934944-6 1999 Both risperidone and haloperidol produced dose-related increases in plasma prolactin levels in men and women. Haloperidol 21-32 prolactin Homo sapiens 75-84 9934944-10 1999 Risperidone-associated increase in serum prolactin levels was not significantly correlated to the emergence of possible prolactin-related side effects. Risperidone 0-11 prolactin Homo sapiens 41-50 9986923-0 1999 Melatonin modulation of the daily prolactin secretion in intact and ovariectomized ewes. Melatonin 0-9 prolactin Homo sapiens 34-43 9986923-2 1999 The aim of this study was to investigate whether melatonin might modulate the daily prolactin secretion in the ewe during a period of ovarian activity and, if so, whether this modulatory action of melatonin was related to the presence of estradiol in the organism. Melatonin 49-58 prolactin Homo sapiens 84-93 9986923-4 1999 Melatonin was infused into the third brain ventricle (100 microgram/100 microliter/h) from 14.00 to 18.00 h. The concentration of prolactin increased significantly during the infusion of melatonin in late follicular-phase ewes, but not in luteal-phase ewes, as compared to the concentration before the infusion: range from 204.0 +/- 31.7 to 272.2 +/- 50.1 ng/ml vs. range from 68.2 +/- 31.8 to 94.7 +/- 33.1 ng/ml (mean +/- SEM, n = 4, p < 0.01) and to the concentration noted during control infusions: range from 130.0 +/- 58.0 to 179.3 +/- 55.6 ng/ml (mean +/- SEM, n = 4, p < 0.05). Melatonin 0-9 prolactin Homo sapiens 130-139 9885797-3 1999 Pre-CCK-4 neuropeptide Y (NPY) plasma levels were significantly higher and maximal changes in cortisol, growth hormone, and prolactin secretion from baseline (delta max) were significantly lower in the ondansetron group. Ondansetron 202-213 prolactin Homo sapiens 124-133 9986923-5 1999 In ovariectomized ewes, the concentration of prolactin during infusion of melatonin increased significantly, unrelated to the presence of estradiol, as compared to the concentration before infusion: range from 136.7 +/- 20.3 to 260.0 +/- 11.6 ng/ml vs. range from 41.6 +/- 2.6 to 152.3 +/- 14.6 ng/ml in OVX ewes (mean +/- SEM, n = 4, p < 0.01) and range from 161.5 +/- 66.5 to 250.2 +/- 24.3 ng/ml vs. range from 61.2 +/- 1.7 to 159.2 +/- 43.3 ng/ml in OVX+E2 ewes (mean +/- SEM, n = 4, p < 0.01). Melatonin 74-83 prolactin Homo sapiens 45-54 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Melatonin 28-37 prolactin Homo sapiens 72-81 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Melatonin 177-186 prolactin Homo sapiens 160-169 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Melatonin 177-186 prolactin Homo sapiens 160-169 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Steroids 276-284 prolactin Homo sapiens 160-169 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Steroids 276-284 prolactin Homo sapiens 160-169 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Estradiol 287-296 prolactin Homo sapiens 160-169 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Estradiol 287-296 prolactin Homo sapiens 160-169 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Progesterone 301-313 prolactin Homo sapiens 160-169 9986923-7 1999 These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor. Progesterone 301-313 prolactin Homo sapiens 160-169 10099857-2 1999 We have investigated the prolactin response to bromocriptine (BRC), a D2 dopamine receptor agonist in migrainous women before and after treatment with flunarizine. Bromocriptine 47-60 prolactin Homo sapiens 25-34 10101728-0 1999 Seasonal variation in plasma prolactin response to D-fenfluramine in healthy subjects. Dexfenfluramine 51-65 prolactin Homo sapiens 29-38 10101728-1 1999 To assess dynamically a seasonal variation in the functioning of the central serotonin (5-HT) system, we investigated the prolactin (PRL) response to the specific serotonergic agent D-fenfluramine (D-FEN) in the different seasons of the year. Dexfenfluramine 182-196 prolactin Homo sapiens 122-131 10101728-1 1999 To assess dynamically a seasonal variation in the functioning of the central serotonin (5-HT) system, we investigated the prolactin (PRL) response to the specific serotonergic agent D-fenfluramine (D-FEN) in the different seasons of the year. Dexfenfluramine 182-196 prolactin Homo sapiens 133-136 10101728-1 1999 To assess dynamically a seasonal variation in the functioning of the central serotonin (5-HT) system, we investigated the prolactin (PRL) response to the specific serotonergic agent D-fenfluramine (D-FEN) in the different seasons of the year. Dexfenfluramine 198-203 prolactin Homo sapiens 122-131 10102766-0 1999 Prolactin response to buspirone was reduced in violent compared to nonviolent parolees. Buspirone 22-31 prolactin Homo sapiens 0-9 10024465-7 1999 Human growth hormone, 22 kDa; human prolactin, 23 kDa; and bovine prolactin, 23 kDa, contain two, three, and three disulfides, respectively, and are folded correctly by air oxidation performed during renaturation under alkaline conditions. Disulfides 115-125 prolactin Homo sapiens 36-45 10099857-9 1999 The effect of flunarizine on PRL level was not related to the therapeutic efficacy of the drug. Flunarizine 14-25 prolactin Homo sapiens 29-32 10640900-3 1999 Treatment with cabergoline (CAB) resulted in rapid normalization of serum PRL (6 weeks after initiation of treatment) and reduction of tumor size. Cabergoline 15-26 prolactin Homo sapiens 74-77 10341859-0 1999 The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin. hexarelin 22-31 prolactin Homo sapiens 81-90 10341859-2 1999 More recent studies in humans have demonstrated acute increases in adrenocorticotrophic hormone (ACTH), cortisol and prolactin (PRL) after boluses of intravenous or subcutaneous GHRPs. gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide 178-183 prolactin Homo sapiens 117-126 10341859-2 1999 More recent studies in humans have demonstrated acute increases in adrenocorticotrophic hormone (ACTH), cortisol and prolactin (PRL) after boluses of intravenous or subcutaneous GHRPs. gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide 178-183 prolactin Homo sapiens 128-131 10341859-18 1999 CONCLUSION: The present study demonstrates clearly that in this hexarelin dosage regimen, over-stimulation of the pituitary adrenal axis and prolactin secretion do not occur. hexarelin 64-73 prolactin Homo sapiens 141-150 9949282-6 1999 We conclude that immunoreactive c-fos is found mostly in stromal cells during the proliferative phase of the menstrual cycle, and is sharply reduced during the secretory phase, when the endometrium is under progesterone stimulation - attested by PRL production. Progesterone 207-219 prolactin Homo sapiens 246-249 10352391-0 1999 Onapristone suppresses prolactin production in explant cultures of leiomyoma. onapristone 0-11 prolactin Homo sapiens 23-32 10352391-1 1999 OBJECTIVE: To assess the action of onapristone, a type I antiprogestin, on prolactin (PRL) production by explant cultures of leiomyoma and myometrium. onapristone 35-46 prolactin Homo sapiens 75-84 10640900-3 1999 Treatment with cabergoline (CAB) resulted in rapid normalization of serum PRL (6 weeks after initiation of treatment) and reduction of tumor size. Cabergoline 28-31 prolactin Homo sapiens 74-77 10221354-10 1999 Bromocriptine suppressed and haloperidol elevated serum prolactin levels, these changes being absent when the two drugs were given in combination. Haloperidol 29-40 prolactin Homo sapiens 56-65 10630453-5 1999 Prolactin was increased above the upper limit of normal for 100% of 10 patients on haloperidol, 70% of 10 patients on olanzapine, and 0% of 15 patients on clozapine (chi2 analyses: H > C, p = 0.004; O > C, p = 0.001). Haloperidol 83-94 prolactin Homo sapiens 0-9 10630453-5 1999 Prolactin was increased above the upper limit of normal for 100% of 10 patients on haloperidol, 70% of 10 patients on olanzapine, and 0% of 15 patients on clozapine (chi2 analyses: H > C, p = 0.004; O > C, p = 0.001). Olanzapine 118-128 prolactin Homo sapiens 0-9 10630453-5 1999 Prolactin was increased above the upper limit of normal for 100% of 10 patients on haloperidol, 70% of 10 patients on olanzapine, and 0% of 15 patients on clozapine (chi2 analyses: H > C, p = 0.004; O > C, p = 0.001). Clozapine 155-164 prolactin Homo sapiens 0-9 10630453-6 1999 Given the potential endocrine and possible cardiac correlates of hyperprolactinemia, these more robust prolactin elevations in pediatric patients after short-term exposure to olanzapine than those reported for adults justify longer observation intervals with bigger samples to establish treatment safety of atypical antipsychotics in adolescents. Olanzapine 175-185 prolactin Homo sapiens 70-79 10406072-5 1999 Replacing progestin by the antiprogestin, RU 486, causes a transient superinduction of PRL production followed by reduction to basal level of expression. Mifepristone 42-48 prolactin Homo sapiens 87-90 10447218-3 1999 A single and well-characterized dose of AM404, which presumably resulted in a significant elevation of the levels of endogenous cannabinoids, produced a marked decrease in plasma prolactin (PRL) levels, with no changes in luteinizing hormone (LH) levels. N-(4-hydroxyphenyl)arachidonylamide 40-45 prolactin Homo sapiens 179-188 10447218-3 1999 A single and well-characterized dose of AM404, which presumably resulted in a significant elevation of the levels of endogenous cannabinoids, produced a marked decrease in plasma prolactin (PRL) levels, with no changes in luteinizing hormone (LH) levels. N-(4-hydroxyphenyl)arachidonylamide 40-45 prolactin Homo sapiens 190-193 10447218-5 1999 Both decreased PRL secretion and increased hypothalamic TH activity have been reported to occur after the administration of anandamide. anandamide 124-134 prolactin Homo sapiens 15-18 18472906-1 1999 The inverse relationship between zinc (Zn(++)) and prolactin (PRL) was detected in in vitro studies, whereas in vivo results are contradictory. Zinc 39-45 prolactin Homo sapiens 62-65 18472906-3 1999 Basal serum Zn(++) levels and serum PRL response to acute and chronic oral Zn(++) administration were evaluated in seven patients with prolactinomas and one with idiopathic hyperprolactinemia. Zinc 75-81 prolactin Homo sapiens 36-39 18472906-5 1999 ZnZn(++) administration (47.7 mg daily) during 60 days increased serum Zn(++) levels from 1.11 +/- 0.15 to 1.59 +/- 0.58 mug/mL (p < 0.05) but caused no change in serum PRL levels. znzn(++) 0-8 prolactin Homo sapiens 172-175 18472906-5 1999 ZnZn(++) administration (47.7 mg daily) during 60 days increased serum Zn(++) levels from 1.11 +/- 0.15 to 1.59 +/- 0.58 mug/mL (p < 0.05) but caused no change in serum PRL levels. Zinc 2-8 prolactin Homo sapiens 172-175 10851292-1 1999 Prolactin stimulates citrate accumulation in prostate cells by increasing the expression of mitochondrial aspartate aminotransferase (mAAT). Citric Acid 21-28 prolactin Homo sapiens 0-9 10071177-2 1999 Since, furthermore, cortisol responses are more readily elicited by 5-HT1a challenges and prolactin responses by d-Fenfluramine or uptake inhibitors, these two types of drugs were used to answer the question if these hormone responses are suitable to differentiate between the two types of aggression. Dexfenfluramine 113-127 prolactin Homo sapiens 90-99 10027514-0 1999 Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. Haloperidol 11-22 prolactin Homo sapiens 36-45 10027514-0 1999 Effects of haloperidol treatment on prolactin response to D-fenfluramine challenge in acute schizophrenia. Dexfenfluramine 58-72 prolactin Homo sapiens 36-45 10027514-1 1999 We have previously described an association between higher serotonin (5-HT) responsivity, indexed by prolactin response to D-fenfluramine challenge, and poorer treatment response to haloperidol in non-medicated schizophrenics. Serotonin 59-68 prolactin Homo sapiens 101-110 10027514-1 1999 We have previously described an association between higher serotonin (5-HT) responsivity, indexed by prolactin response to D-fenfluramine challenge, and poorer treatment response to haloperidol in non-medicated schizophrenics. Dexfenfluramine 123-137 prolactin Homo sapiens 101-110 10027514-7 1999 An observed negative association between posttreatment prolactin response and therapeutic response to haloperidol did not reach statistical significance. Haloperidol 102-113 prolactin Homo sapiens 55-64 9893701-4 1998 MICROADENOMA: Small (< 10 mm) prolactin-secreting adenomas should be treated surgically, generally by transsphenoidal adenomectomy, or medically by dopaminergic agonists: bromocriptin, quinagolide or cabergolin (the two latter drugs are more effective and better tolerated than their parent compound bromocriptin). Bromocriptine 174-186 prolactin Homo sapiens 33-42 9851959-2 1998 The aim of the study was to investigate the responsiveness of the central serotonergic system by measuring the prolactin and cortisol responses to intravenous administration of the serotonin reuptake inhibitor clomipramine. Clomipramine 210-222 prolactin Homo sapiens 111-120 9851959-7 1998 During the clomipramine challenge, plasma prolactin levels increased in both groups. Clomipramine 11-23 prolactin Homo sapiens 42-51 9893701-4 1998 MICROADENOMA: Small (< 10 mm) prolactin-secreting adenomas should be treated surgically, generally by transsphenoidal adenomectomy, or medically by dopaminergic agonists: bromocriptin, quinagolide or cabergolin (the two latter drugs are more effective and better tolerated than their parent compound bromocriptin). quinagolide 188-199 prolactin Homo sapiens 33-42 9893701-4 1998 MICROADENOMA: Small (< 10 mm) prolactin-secreting adenomas should be treated surgically, generally by transsphenoidal adenomectomy, or medically by dopaminergic agonists: bromocriptin, quinagolide or cabergolin (the two latter drugs are more effective and better tolerated than their parent compound bromocriptin). cabergolin 203-213 prolactin Homo sapiens 33-42 9893701-4 1998 MICROADENOMA: Small (< 10 mm) prolactin-secreting adenomas should be treated surgically, generally by transsphenoidal adenomectomy, or medically by dopaminergic agonists: bromocriptin, quinagolide or cabergolin (the two latter drugs are more effective and better tolerated than their parent compound bromocriptin). Bromocriptine 303-315 prolactin Homo sapiens 33-42 9829650-0 1998 Change in plasma prolactin and clinical response to haloperidol in schizophrenia and schizoaffective disorder. Haloperidol 52-63 prolactin Homo sapiens 17-26 9833836-4 1998 Hyperprolactinemia, with levels of prolactin as high as 150 ng/ml, is commonly associated with sellar tumors and is attributed to disruption of the normal delivery of dopamine to the adenohypophysis. Dopamine 167-175 prolactin Homo sapiens 5-14 9833836-5 1998 The prolactin level found in this patient represents the highest level attributed to the stalk-section effect reported in the literature and underscores the need for repeated radiographic assessment of patients who are undergoing treatment with bromocriptine and have prolactin levels in the 25 to 1000 ng/ml range. Bromocriptine 245-258 prolactin Homo sapiens 4-13 9822660-3 1998 In non-pituitary cell lines, coexpression of ERF disrupts the cooperative interactions between Pit-1 and ETS-1 and blocks the induction of Pit-1-dependent prolactin promoter activity by cAMP. Cyclic AMP 186-190 prolactin Homo sapiens 155-164 9822660-4 1998 The potential role of ERF in the inhibitory response of the prolactin promoter to dopamine was examined using pituitary tumor cells stably expressing dopamine D2 receptors. Dopamine 82-90 prolactin Homo sapiens 60-69 9822660-5 1998 The inhibitory responses of the prolactin promoter to ERF and dopamine are additive, suggesting that ERF has a complementary role in this hormonal response. Dopamine 62-70 prolactin Homo sapiens 32-41 9822800-3 1998 As we have previously shown that vasoactive intestinal peptide (VIP) mediates through an autocrine or paracrine action the PRL release induced by insulin-like growth factor I, thyrotropin-releasing hormone (TRH) and dopamine withdrawal, the aim of the present work was to determine whether 5-HT has a direct action on pituitary secretion and to study the possible role of pituitary VIP in this situation. Dopamine 216-224 prolactin Homo sapiens 123-126 10224791-0 1998 [The influence of bromocriptine treatment on prolactin secretion in infertile women with suspicion of luteal phase insufficiency]. Bromocriptine 18-31 prolactin Homo sapiens 45-54 10224791-4 1998 During the treatment with Bromocorn it was observed earlier, independently from the prolactin level in blood serum. bromocorn 26-35 prolactin Homo sapiens 84-93 9829650-6 1998 Clinical symptoms at endpoint were related to both prolactin change and final prolactin level during haloperidol treatment. Haloperidol 101-112 prolactin Homo sapiens 78-87 9829650-8 1998 Thus, prolactin increase caused by low to moderate doses of haloperidol may be a correlate of endpoint symptomatology. Haloperidol 60-71 prolactin Homo sapiens 6-15 9814831-6 1998 In more than 80% of the patients with microprolactinoma, suppression of PRL levels and tumour shrinkage can be achieved with bromocriptine therapy given at doses of 2.5-5 mg per day. Bromocriptine 125-138 prolactin Homo sapiens 72-75 9814831-9 1998 Treatment with cabergoline, a selective and long-lasting dopamine 2-receptor agonist at weekly doses of 0.5-2 mg has been shown to be effective both in normalizing PRL levels and in inducing tumour shrinkage. Cabergoline 15-26 prolactin Homo sapiens 164-167 9840387-9 1998 Postoperatively, the patient was prescribed bromocriptine as maintenance therapy, and the serum prolactin level became normalized. Bromocriptine 44-57 prolactin Homo sapiens 96-105 9829289-2 1998 The study aimed to search for the effect of clozapine on the levels of the main metabolites of dopamine homovanillic acid (HVA), serotonin 5-hydroxyindoleacetic acid (5-HIAA) and norepinephrine 3-methoxy-4-hydroxyphenylglycol (MHPG) in urine as well as on plasma levels of HVA, 5-HIAA, prolactin (PRL) and cortisol. Clozapine 44-53 prolactin Homo sapiens 297-300 9812172-9 1998 CONCLUSION: Our data suggests that enhanced PRL levels have a direct effect on urinary steroid secretion and metabolism, probably due to lowered activities of 5 alpha-reductase and 3 beta-hydroxysteroid dehydrogenase in the patients with prolactinoma. Steroids 87-94 prolactin Homo sapiens 44-47 9845004-1 1998 Prolactin (PRL) has been reported to promote antidiuresis and increase intestinal water-electrolyte absorption, whereas osmolar changes have been shown to influence PRL secretion. Water 82-87 prolactin Homo sapiens 0-9 9845004-1 1998 Prolactin (PRL) has been reported to promote antidiuresis and increase intestinal water-electrolyte absorption, whereas osmolar changes have been shown to influence PRL secretion. Water 82-87 prolactin Homo sapiens 11-14 9845004-5 1998 In healthy women (21-39 y, n=6), an oral water load (OWL, 20 ml/bw) significantly suppressed the plasma levels of AVP, OXT and cortisol, and the PRL level too tended to decrease. Water 41-46 prolactin Homo sapiens 145-148 9845004-6 1998 In hyperprolactinaemic females (22-41 y, n=6, three with pituitary adenomas), water retention was registered following an OWL, together with paradoxical AVP and OXT level increases, whereas the cortisol response remained normal, and the PRL level did not change at all. Water 78-83 prolactin Homo sapiens 237-240 9696215-4 1998 PATIENT(S): From a group of 352 women with recurrent spontaneous abortion, we identified 64 patients with a prolactin disorder that was not associated with any other etiologic abnormalities, including ovarian or endocrinologic disturbances such as luteal phase dysfunction, polycystic ovaries, hypersecretion of LH, galactorrhea, or thyroid hormone disorders. Luteinizing Hormone 312-314 prolactin Homo sapiens 108-117 9751223-0 1998 Okadaic acid mimics several proximal effects of prolactin in Nb2 lymphoma cells. Okadaic Acid 0-12 prolactin Homo sapiens 48-57 9751223-3 1998 In the present study, okadaic acid, which inhibits serine/threonine protein phosphatase activity, was used to explore the linkage of MAPK and p70S6K activation to down-stream effects of prolactin in Nb2 cells. Okadaic Acid 22-34 prolactin Homo sapiens 186-195 9751223-4 1998 The results show that 1 nM okadaic acid augmented prolactin-stimulated mitogenesis and synthesis of protein and DNA 250%, 42%, and 70%, respectively. Okadaic Acid 27-39 prolactin Homo sapiens 50-59 9751223-5 1998 Addition of okadaic acid alone a) stimulated and sustained p70S6K activity (5- to 8-fold) and MAPK (3.5- to 5-fold); and b) increased protein synthesis with the maximum effect being about equal to that of prolactin (2.1-fold with 1 nMokadaic acid versus 2.3-fold with 0.2 nMprolactin). Okadaic Acid 12-24 prolactin Homo sapiens 205-214 9777316-13 1998 Although significant elevation of plasma prolactin levels (unrelated to dosage and duration of treatment) occurred in all domperidone recipients, prolactin-related adverse events were observed in only 10 to 20% of patients. Domperidone 122-133 prolactin Homo sapiens 41-50 9817624-5 1998 A significant elevation of baseline serum prolactin levels, consistent with dopaminergic antagonism was seen after risperidone treatment. Risperidone 115-126 prolactin Homo sapiens 42-51 9817624-6 1998 Significantly reduced 5-HT mediated serum prolactin responses were seen in risperidone treated patients. Risperidone 75-86 prolactin Homo sapiens 42-51 9817624-7 1998 D-fenfluramine evoked serum prolactin responses were positively correlated with positive but not negative schizophrenic symptoms for all 20 patients. Dexfenfluramine 0-14 prolactin Homo sapiens 28-37 9756145-11 1998 Serum prolactin was reduced equally by increasing (dopa) preoperatively and postoperatively. Dihydroxyphenylalanine 51-55 prolactin Homo sapiens 6-15 9696215-5 1998 INTERVENTION(S): Restoration of prolactin levels with bromocriptine. Bromocriptine 54-67 prolactin Homo sapiens 32-41 9769665-15 1998 GABA plays an important role in neuroendocrine regulation of the following hormones: LH, FSH, PRL, STH, SS, ACTH, TSH, TRH, MSH, VP and OX. gamma-Aminobutyric Acid 0-4 prolactin Homo sapiens 94-97 9717847-0 1998 Transcription factor AP1 is involved in basal and okadaic acid-stimulated activity of the human PRL promoter. Okadaic Acid 50-62 prolactin Homo sapiens 96-99 9717847-1 1998 The tumor promoter, okadaic acid (OA), an inhibitor of protein phosphatases, stimulates the activity of the human PRL (hPRL) proximal promoter. Okadaic Acid 20-32 prolactin Homo sapiens 114-117 9717847-1 1998 The tumor promoter, okadaic acid (OA), an inhibitor of protein phosphatases, stimulates the activity of the human PRL (hPRL) proximal promoter. Okadaic Acid 20-32 prolactin Homo sapiens 119-123 9717847-1 1998 The tumor promoter, okadaic acid (OA), an inhibitor of protein phosphatases, stimulates the activity of the human PRL (hPRL) proximal promoter. Okadaic Acid 34-36 prolactin Homo sapiens 114-117 9717847-1 1998 The tumor promoter, okadaic acid (OA), an inhibitor of protein phosphatases, stimulates the activity of the human PRL (hPRL) proximal promoter. Okadaic Acid 34-36 prolactin Homo sapiens 119-123 9727959-1 1998 The prolactin (PRL) response to the administration of serotonin (5HT) agonists is an index of central nervous system 5HT activity. Serotonin 117-120 prolactin Homo sapiens 4-13 9704866-0 1998 Prolactin response to D-fenfluramine in outpatients with major depression. Dexfenfluramine 22-36 prolactin Homo sapiens 0-9 11281951-3 1998 With regard to endocrine effects, risperidone causes an increase in prolactin levels similar to that of other neuroleptics (Claus et al., 1992). Risperidone 34-45 prolactin Homo sapiens 68-77 9711981-0 1998 Involvement of nitric oxide in vasoactive intestinal peptide-stimulated prolactin secretion in normal men. Nitric Oxide 15-27 prolactin Homo sapiens 72-81 9711981-4 1998 In contrast, L-NAME significantly enhanced the PRL increase induced by VIP. NG-Nitroarginine Methyl Ester 13-19 prolactin Homo sapiens 47-50 9711981-6 1998 In contrast, the stimulatory effect of L-NAME on VIP-induced PRL secretion suggests that NO exerts an inhibitory control of the PRL response to VIP. NG-Nitroarginine Methyl Ester 39-45 prolactin Homo sapiens 61-64 9711981-6 1998 In contrast, the stimulatory effect of L-NAME on VIP-induced PRL secretion suggests that NO exerts an inhibitory control of the PRL response to VIP. NG-Nitroarginine Methyl Ester 39-45 prolactin Homo sapiens 128-131 9727959-0 1998 Hostility is associated with a heightened prolactin response to meta-chlorophenylpiperazine in abstinent cocaine addicts. 1-(3-chlorophenyl)piperazine 64-91 prolactin Homo sapiens 42-51 9727959-0 1998 Hostility is associated with a heightened prolactin response to meta-chlorophenylpiperazine in abstinent cocaine addicts. Cocaine 105-112 prolactin Homo sapiens 42-51 9727959-1 1998 The prolactin (PRL) response to the administration of serotonin (5HT) agonists is an index of central nervous system 5HT activity. Serotonin 54-63 prolactin Homo sapiens 4-13 9727959-1 1998 The prolactin (PRL) response to the administration of serotonin (5HT) agonists is an index of central nervous system 5HT activity. Serotonin 65-68 prolactin Homo sapiens 4-13 9777574-8 1998 Bromocriptine suppressed serum prolactin level to normal in four cases, but in the girl with idiopathic hyperprolactinaemia, bromocriptine was not useful. Bromocriptine 0-13 prolactin Homo sapiens 31-40 9777574-10 1998 Nevertheless, in children and adolescents with prolactin-secreting pituitary adenoma, bromocriptine should be the first line of treatment. Bromocriptine 86-99 prolactin Homo sapiens 47-56 9625840-4 1998 Based on these data, we evaluated the clinical effect of prolactin suppression using bromocriptine in patients with androgen-independent prostate cancer. Bromocriptine 85-98 prolactin Homo sapiens 57-66 9625840-12 1998 The vast majority of patients (10 of 11) had suppression of prolactin with a bromocriptine dose of 2.5 mg three times a day. Bromocriptine 77-90 prolactin Homo sapiens 60-69 9625840-16 1998 Our data showed that 2.5 mg three times per day of bromocriptine suppressed prolactin in 90% of the patients. Bromocriptine 51-64 prolactin Homo sapiens 76-85 9660375-0 1998 Diminished serotonin-mediated prolactin responses in nondepressed stroke patients compared with healthy normal subjects. Serotonin 11-20 prolactin Homo sapiens 30-39 9694521-0 1998 Acute tryptophan depletion attenuates the prolactin response to d-fenfluramine challenge in healthy human subjects. Tryptophan 6-16 prolactin Homo sapiens 42-51 9712230-4 1998 RESULTS: Fenfluramine challenge induced an increase in mean prolactin and cortisol serum values in both patients and controls. Fenfluramine 9-21 prolactin Homo sapiens 60-69 9694521-0 1998 Acute tryptophan depletion attenuates the prolactin response to d-fenfluramine challenge in healthy human subjects. Dexfenfluramine 64-78 prolactin Homo sapiens 42-51 9694521-1 1998 Prolactin responses to d-fenfluramine (d-FEN) Challenge (0.5 mg/kg PO) were examined after pretreatment with and without acute tryptophan depletion (ATD) in six physically healthy male volunteers. Dexfenfluramine 23-37 prolactin Homo sapiens 0-9 9694521-1 1998 Prolactin responses to d-fenfluramine (d-FEN) Challenge (0.5 mg/kg PO) were examined after pretreatment with and without acute tryptophan depletion (ATD) in six physically healthy male volunteers. Dexfenfluramine 39-44 prolactin Homo sapiens 0-9 9694521-2 1998 Compared to pretreatment with SHAM-ATD, ATD pretreatment attenuated the PRL response to d-FEN Challenge in all subjects. Dexfenfluramine 88-93 prolactin Homo sapiens 72-75 9723152-0 1998 Plasma prolactin response to D-fenfluramine is blunted in bulimic patients with frequent binge episodes. Dexfenfluramine 29-43 prolactin Homo sapiens 7-16 9723152-2 1998 The purpose of this study was to assess 5-HT transmission via the measurement of the prolactin (PRL) response to the specific 5-HT releasing agent D-fenfluramine (D-FEN) in both patients with BN and comparison subjects. Dexfenfluramine 147-161 prolactin Homo sapiens 85-94 9712230-8 1998 CONCLUSIONS: The cortisol and prolactin responses to fenfluramine suggest a psychobiologic gender difference with a possible stress-induced central serotonergic dysfunction in female patients but not in male patients. Fenfluramine 53-65 prolactin Homo sapiens 30-39 9670230-2 1998 Prolactin provides us with a window to the brain in our quest for understanding the psychobiology of depression, since the regulation of its release involves some of the monamine neurotransmitter systems that have been implicated in the pathophysiology of depression. Meclizine 170-178 prolactin Homo sapiens 0-9 9636230-0 1998 Adenosine acts by A1 receptors to stimulate release of prolactin from anterior-pituitaries in vitro. Adenosine 0-9 prolactin Homo sapiens 55-64 9626142-2 1998 Here, we describe seven children with GH, PRL, and TSH deficiency from three, reportedly unrelated, Middle Eastern families, harboring a newly recognized Pro- > Ser recessive mutation in codon 239 of the Pit-1 gene. Proline 154-157 prolactin Homo sapiens 42-45 9626142-2 1998 Here, we describe seven children with GH, PRL, and TSH deficiency from three, reportedly unrelated, Middle Eastern families, harboring a newly recognized Pro- > Ser recessive mutation in codon 239 of the Pit-1 gene. Serine 161-164 prolactin Homo sapiens 42-45 9619161-2 1998 METHOD: Prolactin responses to the 5-HT releasing agent d-fenfluramine were measured in two groups of 10 schizophrenic subjects. Dexfenfluramine 56-70 prolactin Homo sapiens 8-17 9619161-5 1998 RESULTS: The prolactin response was significantly blunted in these 20 patients treated with clozapine. Clozapine 92-101 prolactin Homo sapiens 13-22 9619161-6 1998 There was a significant positive correlation between d-fenfluramine-evoked prolactin release and the overall positive symptom score and the hallucination and delusion subscores of the Scale for the Assessment of Positive Symptoms. Dexfenfluramine 53-67 prolactin Homo sapiens 75-84 9619161-7 1998 CONCLUSIONS: Blunted 5-HT-mediated prolactin responses in schizophrenic patients receiving clozapine monotherapy for up to 20 months were correlated with reductions in positive symptoms. Clozapine 91-100 prolactin Homo sapiens 35-44 9670230-4 1998 Further exploration of the precise mechanisms involved in serotonin-stimulated prolactin release should shed light on the pathophysiology of abnormal prolactin responsivity in depression, and by extension, the psychobiologic basis of depression. Serotonin 58-67 prolactin Homo sapiens 79-88 9670230-4 1998 Further exploration of the precise mechanisms involved in serotonin-stimulated prolactin release should shed light on the pathophysiology of abnormal prolactin responsivity in depression, and by extension, the psychobiologic basis of depression. Serotonin 58-67 prolactin Homo sapiens 150-159 9581833-10 1998 Instead, IFN alpha/beta- and PRL-induced tyrosine phosphorylation of Stat1 was additive and occurred without evidence of competition for limited concentrations of cytoplasmic Stat1. Tyrosine 41-49 prolactin Homo sapiens 29-32 9581833-11 1998 A similar additive relationship was observed on IFN alpha/beta- and PRL-induced Stat3 tyrosine phosphorylation. Tyrosine 86-94 prolactin Homo sapiens 68-71 9646575-2 1998 From the seric specimens obtained in 225 patients with LES, we found 37 (14.5%) with hyperprolactinemia and they were trated with polyethylenglicol, in 11 of 37 patients (29.7%) had a high significance of prolactin precipitation (PRL). polyethylenglicol 130-147 prolactin Homo sapiens 230-233 9741713-2 1998 The heavy metal excretion was correlated to different immunological (natural killer cells, T cell subpopulations) and hormonal (progesterone, oestradiol, prolactin, thyroid stimulating hormone) parameters. Metals 10-15 prolactin Homo sapiens 154-163 9747408-0 1998 Prolactin response to d-fenfluramine is blunted in people with anorexia nervosa. Dexfenfluramine 22-36 prolactin Homo sapiens 0-9 9747408-2 1998 METHOD: According to a double-blind placebo-controlled design, plasma prolactin response to the specific serotonergic probed d-fenfluramine was investigated in 10 under weight and two normal-weight women with anorexia, and in 12 age-matched healthy females. Dexfenfluramine 125-139 prolactin Homo sapiens 70-79 9747408-5 1998 The prolactin response to d-fenfluramine was blunted and did not correlate with psychopathological measures. Dexfenfluramine 26-40 prolactin Homo sapiens 4-13 9648050-1 1998 Dopamine in humans inhibits the secretion of luteinizing hormone (LH), follicular stimulating hormone (FSH), thyroid stimulating hormone (TSH) and prolactin (PRL), and is a stimulator of growth hormone (GH) secretion. Dopamine 0-8 prolactin Homo sapiens 158-161 9572212-1 1998 OBJECTIVE: To determine the time it takes for prolactin (PRL) levels to increase after initiation of therapy with haloperidol (a neuroleptic medication) and the pattern and extent of the increase. Haloperidol 114-125 prolactin Homo sapiens 46-55 9572212-1 1998 OBJECTIVE: To determine the time it takes for prolactin (PRL) levels to increase after initiation of therapy with haloperidol (a neuroleptic medication) and the pattern and extent of the increase. Haloperidol 114-125 prolactin Homo sapiens 57-60 9572212-11 1998 CONCLUSION: There is a distinct pattern of response of PRL to haloperidol. Haloperidol 62-73 prolactin Homo sapiens 55-58 9648050-2 1998 Dopamine-D1 receptor stimulation with fenoldopam increases basal PRL levels, suppresses TSH, and increases gonadotropin releasing hormone (LHRH) induced LH release. Fenoldopam 38-48 prolactin Homo sapiens 65-68 9593964-1 1998 Dopamine (DA), produced by tubero-infundibular dopaminergic (TIDA) neurons of the arcuate nucleus (ARN) is the established inhibitor of the secretion of prolactin (PRL). Dopamine 0-8 prolactin Homo sapiens 164-167 9630008-0 1998 Sumatriptan lowers plasma prolactin in healthy female volunteers. Sumatriptan 0-11 prolactin Homo sapiens 26-35 9593964-1 1998 Dopamine (DA), produced by tubero-infundibular dopaminergic (TIDA) neurons of the arcuate nucleus (ARN) is the established inhibitor of the secretion of prolactin (PRL). Dopamine 10-12 prolactin Homo sapiens 164-167 9593964-2 1998 Changes in dopaminergic (DAergic) neuronal activity in the median eminence-long portal vessels (ME-LPV) and/or the concentration of DA in the anterior lobe (AL) are inversely related to the secretion of PRL. Dopamine 25-27 prolactin Homo sapiens 203-206 9593964-12 1998 In addition TIDA and THDA neurons, but not PHDA neurons, regulate the control of the secretion of PRL in response to suckling. tida 12-16 prolactin Homo sapiens 98-101 9593964-12 1998 In addition TIDA and THDA neurons, but not PHDA neurons, regulate the control of the secretion of PRL in response to suckling. thda 21-25 prolactin Homo sapiens 98-101 9579292-0 1998 Pilot investigation of thyrotropin-releasing hormone-induced thyrotropin and prolactin release in anxious patients treated with diazepam. Diazepam 128-136 prolactin Homo sapiens 77-86 9561979-3 1998 Since gamma-aminobutyric acid also modulates the release of prolactin, we examined the possible association between alleles of the GABRA3 (gamma-aminobutyric acid A3 receptor) gene and MS. DESIGN: We examined the GABRA3 alleles of 189 subjects with MS who died of their disease. gamma-Aminobutyric Acid 6-29 prolactin Homo sapiens 60-69 9617019-1 1998 A young woman with amenorrhea-galactorrhea induced by a prolactin (PRL) secreting pituitary macroadenoma, was treated with bromocriptine 5 mg/day per os. Bromocriptine 123-136 prolactin Homo sapiens 56-65 9617019-1 1998 A young woman with amenorrhea-galactorrhea induced by a prolactin (PRL) secreting pituitary macroadenoma, was treated with bromocriptine 5 mg/day per os. Bromocriptine 123-136 prolactin Homo sapiens 67-70 9545000-8 1998 Conventional treatment of BH4 deficiency, i.e. BH4, 5-hydroxytryptophan, and L-DOPA/carbidopa (the last named given in three doses per day), suppresses prolactin levels merely for a few hours. sapropterin 26-29 prolactin Homo sapiens 152-161 9545000-8 1998 Conventional treatment of BH4 deficiency, i.e. BH4, 5-hydroxytryptophan, and L-DOPA/carbidopa (the last named given in three doses per day), suppresses prolactin levels merely for a few hours. 5-Hydroxytryptophan 52-71 prolactin Homo sapiens 152-161 9545000-8 1998 Conventional treatment of BH4 deficiency, i.e. BH4, 5-hydroxytryptophan, and L-DOPA/carbidopa (the last named given in three doses per day), suppresses prolactin levels merely for a few hours. Levodopa 77-83 prolactin Homo sapiens 152-161 9545000-8 1998 Conventional treatment of BH4 deficiency, i.e. BH4, 5-hydroxytryptophan, and L-DOPA/carbidopa (the last named given in three doses per day), suppresses prolactin levels merely for a few hours. Carbidopa 84-93 prolactin Homo sapiens 152-161 9545000-9 1998 L-DOPA/carbidopa given at shorter intervals or, even better, as a slow release preparation, is more effective in suppressing prolactin levels. Levodopa 0-6 prolactin Homo sapiens 125-134 9545000-9 1998 L-DOPA/carbidopa given at shorter intervals or, even better, as a slow release preparation, is more effective in suppressing prolactin levels. Carbidopa 7-16 prolactin Homo sapiens 125-134 9545000-11 1998 Prolactin secretion may serve as an extremely sensitive marker for the hypothalamic dopamine content under different therapeutic regimens. Dopamine 84-92 prolactin Homo sapiens 0-9 9545000-12 1998 Treatment with an L-DOPA/carbidopa slow release preparation produces virtually normal prolactin levels. Levodopa 18-24 prolactin Homo sapiens 86-95 9545000-12 1998 Treatment with an L-DOPA/carbidopa slow release preparation produces virtually normal prolactin levels. Carbidopa 25-34 prolactin Homo sapiens 86-95 9650316-4 1998 Medical treatment with bromocriptine reduced the prolactin level to 31 ng/ml and reduced the size of the tumor, although less than expected. Bromocriptine 23-36 prolactin Homo sapiens 49-58 9579292-1 1998 Benzodiazepines have been reported to inhibit thyrotropin (TSH) and prolactin (PRL) secretion in response to stressful and pharmacologic stimuli in experimental animals. Benzodiazepines 0-15 prolactin Homo sapiens 68-77 9539303-9 1998 After 1 month, serum PRL levels were significantly reduced in both groups of patients (20.6 +/- 6.6 microg/l during CAB and 256.3 +/- 115.1 microg/l during BRC treatment) and were normalized after 6 months in all patients (CAB: 7.9 +/- 2.2 microg/l; BRC: 16.7 +/- 1.8 microg/l). Cabergoline 116-119 prolactin Homo sapiens 21-24 9539303-16 1998 The treatment with CAB normalized PRL levels, improving gonadal and sexual function and fertility in males with prolactinoma, earlier than did BRC treatment, providing good tolerability and excellent patient compliance to medical treatment. Cabergoline 19-22 prolactin Homo sapiens 34-37 9551777-4 1998 These findings show that following 10 days administration of hydrocortisone, the prolactin responses to d-fenfluramine are not changed. Dexfenfluramine 104-118 prolactin Homo sapiens 81-90 9506725-6 1998 The 4 hyperprolactinemic acromegalics were treated with octreotide and cabergoline (1-2 mg/week) to suppress PRL levels. Cabergoline 71-82 prolactin Homo sapiens 109-112 9506725-19 1998 Serum PRL levels were suppressed after cabergoline treatment in all 4 hyperprolactinemic patients throughout the study period. Cabergoline 39-50 prolactin Homo sapiens 6-9 9506732-12 1998 In conclusion, treatment with bromocriptine, quinagolide, and cabergoline for 18 months, although successfull in suppressing serum PRL levels and restoring gonadal function, was unable to restore lumbar spine and femoral neck BMD and normalize Ntx levels. Bromocriptine 30-43 prolactin Homo sapiens 131-134 9506732-12 1998 In conclusion, treatment with bromocriptine, quinagolide, and cabergoline for 18 months, although successfull in suppressing serum PRL levels and restoring gonadal function, was unable to restore lumbar spine and femoral neck BMD and normalize Ntx levels. Cabergoline 62-73 prolactin Homo sapiens 131-134 9551777-0 1998 Lack of effect of hydrocortisone treatment on d-fenfluramine-mediated prolactin release. Dexfenfluramine 46-60 prolactin Homo sapiens 70-79 9551777-1 1998 The prolactin responses to the serotonin (5-HT) releasing agent d-fenfluramine (30 mg orally) were studied in 11 male normal volunteers after administration of hydrocortisone (20 mg orally, twice daily for 10 days) using a double-blind, placebo-controlled, cross-over design. Serotonin 31-40 prolactin Homo sapiens 4-13 9551777-1 1998 The prolactin responses to the serotonin (5-HT) releasing agent d-fenfluramine (30 mg orally) were studied in 11 male normal volunteers after administration of hydrocortisone (20 mg orally, twice daily for 10 days) using a double-blind, placebo-controlled, cross-over design. Dexfenfluramine 64-78 prolactin Homo sapiens 4-13 9551777-4 1998 These findings show that following 10 days administration of hydrocortisone, the prolactin responses to d-fenfluramine are not changed. Hydrocortisone 61-75 prolactin Homo sapiens 81-90 9678073-2 1998 The aim of this study was to determine the correlation between the duration of contraceptive pill intake, the dose of steroid contained in the contraceptive pills and the incidence and degree of serum prolactin level elevation in those women. Steroids 118-125 prolactin Homo sapiens 201-210 9678073-8 1998 CONCLUSIONS: There is a positive relationship between serum prolactin level and the duration of pill intake and their steroid content, and this relationship is not related to the age and parity of the women. Steroids 118-125 prolactin Homo sapiens 60-69 9553995-0 1998 Prolactin response to bromperidol treatment in schizophrenic patients. bromperidol 22-33 prolactin Homo sapiens 0-9 9553995-6 1998 Bromperidol treatment significantly (P < 0.01) increased plasma concentration of prolactin each week. bromperidol 0-11 prolactin Homo sapiens 84-93 9553995-9 1998 Multiple regression analysis showed that the delta-prolactin concentration was significantly greater in females than in males (P < 0.05) and correlated to plasma concentrations of bromperidol (P < 0.001) and reduced bromperidol (P < 0.0001). bromperidol 183-194 prolactin Homo sapiens 51-60 9553995-9 1998 Multiple regression analysis showed that the delta-prolactin concentration was significantly greater in females than in males (P < 0.05) and correlated to plasma concentrations of bromperidol (P < 0.001) and reduced bromperidol (P < 0.0001). bromperidol 222-233 prolactin Homo sapiens 51-60 9553995-10 1998 These results suggest that the prolactin response to bromperidol treatment depend on plasma concentrations of both bromperidol and reduced bromperidol and gender, and that reduced bromperidol is involved in the pharmacological effects during bromperidol treatment. bromperidol 53-64 prolactin Homo sapiens 31-40 9553995-10 1998 These results suggest that the prolactin response to bromperidol treatment depend on plasma concentrations of both bromperidol and reduced bromperidol and gender, and that reduced bromperidol is involved in the pharmacological effects during bromperidol treatment. bromperidol 115-126 prolactin Homo sapiens 31-40 9572087-1 1998 BACKGROUND: Sumatriptan, a specific agonist at 5-HT1D receptors, stimulates release of growth hormone (GH) and inhibits release of prolactin (PRL). Sumatriptan 12-23 prolactin Homo sapiens 131-140 9542792-0 1998 Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. Dexfenfluramine 22-36 prolactin Homo sapiens 0-9 9553995-10 1998 These results suggest that the prolactin response to bromperidol treatment depend on plasma concentrations of both bromperidol and reduced bromperidol and gender, and that reduced bromperidol is involved in the pharmacological effects during bromperidol treatment. bromperidol 115-126 prolactin Homo sapiens 31-40 9553995-10 1998 These results suggest that the prolactin response to bromperidol treatment depend on plasma concentrations of both bromperidol and reduced bromperidol and gender, and that reduced bromperidol is involved in the pharmacological effects during bromperidol treatment. bromperidol 115-126 prolactin Homo sapiens 31-40 9553995-10 1998 These results suggest that the prolactin response to bromperidol treatment depend on plasma concentrations of both bromperidol and reduced bromperidol and gender, and that reduced bromperidol is involved in the pharmacological effects during bromperidol treatment. bromperidol 115-126 prolactin Homo sapiens 31-40 9542792-0 1998 Prolactin response to D-fenfluramine challenge test as a predictor of treatment response to haloperidol in acute schizophrenia. Haloperidol 92-103 prolactin Homo sapiens 0-9 9542792-2 1998 The objective of our study was to investigate prolactin response to D-fenfluramine challenge in non-medicated, first episode schizophrenics. Dexfenfluramine 68-82 prolactin Homo sapiens 46-55 9542792-9 1998 A statistically significant negative correlation was found between prolactin response to the D-fenfluramine challenge and improvement of psychopathology measured by the change in total BPRS score (p = 0.0004), in positive (p = 0.0403), negative (p = 0.0267), and anxiety-depression symptoms of BPRS (p = 0.0014). Dexfenfluramine 93-107 prolactin Homo sapiens 67-76 9519076-0 1998 Increased prolactin responses to d-fenfluramine in obsessive-compulsive disorder. Dexfenfluramine 33-47 prolactin Homo sapiens 10-19 9449632-3 1998 In addition, because of the marked effect of phosphorylation on biological activity, we investigated the importance of the unmodified serine in the growth-promoting activity of PRL. Serine 134-140 prolactin Homo sapiens 177-180 9449632-4 1998 hPRL complementary DNA was obtained from the American Type Culture Collection and subcloned into pT7-SCII after site-directed mutagenesis using the deoxyuridine approach. Deoxyuridine 148-160 prolactin Homo sapiens 0-4 9449632-8 1998 The aspartate and glutamate mutants had no intrinsic agonist activity, but both antagonized the growth-promoting activity of wild-type PRL, with the aspartate mutant proving to be a very effective antagonist. Aspartic Acid 4-13 prolactin Homo sapiens 135-138 9449632-8 1998 The aspartate and glutamate mutants had no intrinsic agonist activity, but both antagonized the growth-promoting activity of wild-type PRL, with the aspartate mutant proving to be a very effective antagonist. Glutamic Acid 18-27 prolactin Homo sapiens 135-138 9449632-8 1998 The aspartate and glutamate mutants had no intrinsic agonist activity, but both antagonized the growth-promoting activity of wild-type PRL, with the aspartate mutant proving to be a very effective antagonist. Aspartic Acid 149-158 prolactin Homo sapiens 135-138 9449632-9 1998 Two hundred picograms per ml of the aspartate mutant negated 75% of the growth response to 400 pg/ml wild-type PRL. Aspartic Acid 36-45 prolactin Homo sapiens 111-114 9449632-11 1998 These results demonstrate 1) that molecular mimicry of the phosphorylated hormone does produce a PRL antagonist, and 2) that the serine at position 179 is crucial to the growth-promoting activity of PRL. Serine 129-135 prolactin Homo sapiens 199-202 9449632-12 1998 The aspartate mutant can now be used to study many aspects of the physiology of PRL. Aspartic Acid 4-13 prolactin Homo sapiens 80-83 9449632-2 1998 In this study our aim was to produce a molecular mimic of phosphorylated PRL by substituting a fairly bulky, negatively charged amino acid (glutamate or aspartate) for the normally phosphorylated serine [serine 179 in human PRL (hPRL)]. Glutamic Acid 140-149 prolactin Homo sapiens 73-76 9449632-2 1998 In this study our aim was to produce a molecular mimic of phosphorylated PRL by substituting a fairly bulky, negatively charged amino acid (glutamate or aspartate) for the normally phosphorylated serine [serine 179 in human PRL (hPRL)]. Aspartic Acid 153-162 prolactin Homo sapiens 73-76 9449632-2 1998 In this study our aim was to produce a molecular mimic of phosphorylated PRL by substituting a fairly bulky, negatively charged amino acid (glutamate or aspartate) for the normally phosphorylated serine [serine 179 in human PRL (hPRL)]. Serine 196-202 prolactin Homo sapiens 73-76 9449632-2 1998 In this study our aim was to produce a molecular mimic of phosphorylated PRL by substituting a fairly bulky, negatively charged amino acid (glutamate or aspartate) for the normally phosphorylated serine [serine 179 in human PRL (hPRL)]. Serine 204-210 prolactin Homo sapiens 73-76 9449660-6 1998 Further, PRL induced tyrosyl phosphorylation of ZAP-70 in each population of T-lymphocytes tested, demonstrating for the first time that ZAP-70 is a target of PRL action. cyclo(tyrosyl-tyrosyl) 21-28 prolactin Homo sapiens 9-12 9449660-6 1998 Further, PRL induced tyrosyl phosphorylation of ZAP-70 in each population of T-lymphocytes tested, demonstrating for the first time that ZAP-70 is a target of PRL action. cyclo(tyrosyl-tyrosyl) 21-28 prolactin Homo sapiens 159-162 9535530-0 1998 Developmental regulation of the inhibitory effect of dopamine on prolactin release in the preterm neonate. Dopamine 53-61 prolactin Homo sapiens 65-74 10099036-5 1998 Bromocriptine and the other dopaminergic agonists mentioned act over DA 2 receptors of the tuberoinfundibular system, inhibiting prolactin release and decreasing hyperprolactinemia and tumor size. Bromocriptine 0-13 prolactin Homo sapiens 129-138 9535530-6 1998 However, simple regression analysis of the individual data revealed that the magnitude of the dopamine-induced decrease in serum prolactin was significantly influenced by gestational age (p = 0.006) and birthweight (p = 0.037). Dopamine 94-102 prolactin Homo sapiens 129-138 9535530-1 1998 The secretion and release of prolactin from the anterior pituitary is under the tonic inhibitory control of endogenous dopamine produced in the central nervous system. Dopamine 119-127 prolactin Homo sapiens 29-38 9535530-2 1998 Exogenous dopamine inhibits prolactin secretion by reaching the pituitary via the portal circulation, and the hypolactotropic effect of dopamine infusion has been documented in all age groups in humans. Dopamine 10-18 prolactin Homo sapiens 28-37 9535530-5 1998 As expected, dopamine therapy resulted in a decrease in mean serum prolactin from 89.4+/-9.5 to 58.6+/-9.1 microg/l (p < 0.05) with a return of the serum prolactin concentration to the pretreatment level 2-6 h after discontinuation of drug administration (98.3+/-11.7 microg/l, p < 0.05). Dopamine 13-21 prolactin Homo sapiens 67-76 9535530-5 1998 As expected, dopamine therapy resulted in a decrease in mean serum prolactin from 89.4+/-9.5 to 58.6+/-9.1 microg/l (p < 0.05) with a return of the serum prolactin concentration to the pretreatment level 2-6 h after discontinuation of drug administration (98.3+/-11.7 microg/l, p < 0.05). Dopamine 13-21 prolactin Homo sapiens 157-166 9435450-12 1998 In particular, the normalization of serum alpha-subunit and PRL levels, respectively, was achieved in 3 patients with NFPA and in 2 patients with prolactinoma, who showed intense 123I-IBZM uptake in the pituitary region. 3-iodo-2-hydroxy-6-methoxy-N-((1-ethyl-2-pyrrolidinyl)methyl)benzamide 179-188 prolactin Homo sapiens 60-63 9509065-7 1998 RESULTS: The cortisol peak was advanced and prolactin release increased after melatonin administration, while growth hormone was not affected. Melatonin 78-87 prolactin Homo sapiens 44-53 9509065-9 1998 CONCLUSION: Altering the melatonin rhythm may affect neuroendocrine function, influencing the nocturnal pattern of neurohypophysial hormone secretion, augmenting prolactin release and advancing the peak of cortisol release. Melatonin 25-34 prolactin Homo sapiens 162-171 9509074-2 1998 We have therefore evaluated whether increased serum Phe concentrations lead to increased prolactin (PRL) secretion in phenylketonuria. Phenylalanine 52-55 prolactin Homo sapiens 89-98 9509074-2 1998 We have therefore evaluated whether increased serum Phe concentrations lead to increased prolactin (PRL) secretion in phenylketonuria. Phenylalanine 52-55 prolactin Homo sapiens 100-103 9509074-10 1998 Serum Phe in group B patients was significantly correlated to serum PRL (r = 0.59) and DA (r = -0.41). Phenylalanine 6-9 prolactin Homo sapiens 68-71 9509074-12 1998 CONCLUSION: High serum phenylalanine concentrations in phenylketonuric patients not strictly adhering to their diets are correlated with high serum PRL and low serum dopamine concentrations, and a high prevalence of menstrual irregularities. Phenylalanine 23-36 prolactin Homo sapiens 148-151 9988364-7 1998 Ipsapirone caused clear and significant elevations in adrenocorticotrophin (ACTH), cortisol (CORT), prolactin (PRL), and growth hormone (GH) release. ipsapirone 0-10 prolactin Homo sapiens 100-109 9988364-7 1998 Ipsapirone caused clear and significant elevations in adrenocorticotrophin (ACTH), cortisol (CORT), prolactin (PRL), and growth hormone (GH) release. ipsapirone 0-10 prolactin Homo sapiens 111-114 9736322-2 1998 The regulation of pituitary prolactin secretion is complex and involves a negative feedback process in the hypothalamus, in which dopamine plays the principal role. Dopamine 130-138 prolactin Homo sapiens 28-37 10958249-11 1998 Bromocriptine significantly suppressed and haloperidol significantly elevated serum prolactin levels, these changes being absent when the two drugs were given in combination. Haloperidol 43-54 prolactin Homo sapiens 84-93 9736322-15 1998 The relationship between HVA and PRL in healthy controls was r = 0.47, P = 0.08, and in patients was r = 0.04, P = 0.84. Homovanillic Acid 25-28 prolactin Homo sapiens 33-36 9524980-5 1998 The results indicated that +/- pindolol decreases PRL concentrations depending on personality. Pindolol 31-39 prolactin Homo sapiens 50-53 27406549-12 1998 Lower plasma free TRP/BCAA ratio induced by CHO occurred concomitant with reduced plasma PRL and HGH concentrations, suggesting that the brain monoaminergic system might be affected if CHO-containing drinks are consumed during tennis match play. CAV protocol 185-188 prolactin Homo sapiens 89-92 10806816-1 1998 Dopamine agonists effectively reduce the secretion of prolactin (PRL) in the great majority of prolactinomas and reduce the bulk of the adenomas, as well as have partial therapeutic effect on some patients with acromegaly. Dopamine 0-8 prolactin Homo sapiens 54-63 10806816-1 1998 Dopamine agonists effectively reduce the secretion of prolactin (PRL) in the great majority of prolactinomas and reduce the bulk of the adenomas, as well as have partial therapeutic effect on some patients with acromegaly. Dopamine 0-8 prolactin Homo sapiens 65-68 10806816-2 1998 The inhibitory effect of bromocriptine (BC), a dopamine agonist, on growth hormone (GH) and PRL secretion of dispersed cells from the pituitary adenomas of 16 cases of acromegaly, which secret GH and PRL simultaneously, were evaluated in vitro. Bromocriptine 40-42 prolactin Homo sapiens 92-95 10806816-3 1998 The significant inhibitory effects of BC on PRL secretion were found in 12 cases. Bromocriptine 38-40 prolactin Homo sapiens 44-47 9460182-1 1998 Increased serum prolactin (PRL) is a common finding among subjects exposed to styrene, perchloroethylene, lead (Pb), and manganese (Mn) at levels below the current threshold limit values. Styrene 78-85 prolactin Homo sapiens 16-25 9629752-4 1998 AIM AND METHODS: We studied immunological and clinical effects of PRL suppression in 9 RA patients with active disease, treated for 3 months with bromocriptine (BRC), an inhibitor of PRL secretion. Bromocriptine 146-159 prolactin Homo sapiens 183-186 9460182-1 1998 Increased serum prolactin (PRL) is a common finding among subjects exposed to styrene, perchloroethylene, lead (Pb), and manganese (Mn) at levels below the current threshold limit values. Tetrachloroethylene 87-104 prolactin Homo sapiens 16-25 9460182-1 1998 Increased serum prolactin (PRL) is a common finding among subjects exposed to styrene, perchloroethylene, lead (Pb), and manganese (Mn) at levels below the current threshold limit values. Tetrachloroethylene 87-104 prolactin Homo sapiens 27-30 9619713-0 1998 Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer. Anastrozole 45-56 prolactin Homo sapiens 72-81 9619713-3 1998 This phase II study was performed to evaluate the effects of the novel aromatase inhibitor anastrozole on PRL secretion in metastatic breast cancer and the possible influence of PRL pretreatment levels on the efficacy of therapy. Anastrozole 91-102 prolactin Homo sapiens 106-109 9460182-1 1998 Increased serum prolactin (PRL) is a common finding among subjects exposed to styrene, perchloroethylene, lead (Pb), and manganese (Mn) at levels below the current threshold limit values. Styrene 78-85 prolactin Homo sapiens 27-30 9616799-17 1997 Using a serotonergic probe of 5-HT1A receptors, several investigators examined ipsapirone-induced prolactin release in suicidal patients and did not find it different that that of control subjects. ipsapirone 79-89 prolactin Homo sapiens 98-107 9460182-1 1998 Increased serum prolactin (PRL) is a common finding among subjects exposed to styrene, perchloroethylene, lead (Pb), and manganese (Mn) at levels below the current threshold limit values. Lead 112-114 prolactin Homo sapiens 16-25 9460182-1 1998 Increased serum prolactin (PRL) is a common finding among subjects exposed to styrene, perchloroethylene, lead (Pb), and manganese (Mn) at levels below the current threshold limit values. Lead 112-114 prolactin Homo sapiens 27-30 9460182-1 1998 Increased serum prolactin (PRL) is a common finding among subjects exposed to styrene, perchloroethylene, lead (Pb), and manganese (Mn) at levels below the current threshold limit values. Manganese 121-130 prolactin Homo sapiens 16-25 9460182-1 1998 Increased serum prolactin (PRL) is a common finding among subjects exposed to styrene, perchloroethylene, lead (Pb), and manganese (Mn) at levels below the current threshold limit values. Manganese 121-130 prolactin Homo sapiens 27-30 9460182-2 1998 On a group basis, abnormally high basal PRL shows a dose-related distribution among workers exposed to styrene, Pb, and Mn. Styrene 103-110 prolactin Homo sapiens 40-43 9460182-2 1998 On a group basis, abnormally high basal PRL shows a dose-related distribution among workers exposed to styrene, Pb, and Mn. Lead 112-114 prolactin Homo sapiens 40-43 9460182-5 1998 A shift in the distribution but not in the prevalence of abnormally high values of serum PRL was observed among perchloroethylene-exposed dry cleaners, which makes interpretation in terms of risk difficult. Tetrachloroethylene 112-129 prolactin Homo sapiens 89-92 9616799-18 1997 On the other hand, fenfluramine, which causes release of serotonin and blocks serotonin uptake, causes a decreased release of prolactin in depressed patients compared to normal control subjects. Fenfluramine 19-31 prolactin Homo sapiens 126-135 9616799-19 1997 Furthermore it has been shown by some investigators that fenfluramine-induced prolactin release is also decreased in suicidal patients compared to normal control subjects. Fenfluramine 57-69 prolactin Homo sapiens 78-87 9451892-2 1997 Bromocriptine (BRC) is a dopamine agonist that suppresses secretion of PRL. Bromocriptine 0-13 prolactin Homo sapiens 71-74 10086082-1 1997 OBJECTIVE: To evaluate the long-term effects of pregnancy and bromocriptine treatment on prolactin-secreting pituitary tumors in women undergoing infertility treatment for prolactinomas. Bromocriptine 62-75 prolactin Homo sapiens 89-98 9426882-4 1997 We examined the relationship between the prolactin and cortisol responses to a 12.5-mg intravenous clomipramine challenge and these personality dimensions as measured by Cloninger"s Tridimensional Personality Questionnaire in 32 healthy subjects. Clomipramine 99-111 prolactin Homo sapiens 41-50 9437229-0 1997 The GH, prolactin, ACTH and cortisol responses to Hexarelin, a synthetic hexapeptide, undergo different age-related variations. hexarelin 50-59 prolactin Homo sapiens 8-17 9451892-2 1997 Bromocriptine (BRC) is a dopamine agonist that suppresses secretion of PRL. Dopamine 25-33 prolactin Homo sapiens 71-74 9387855-0 1997 Natural and melatonin-stimulated changes in the circadian rhythm of prolactin secretion in the ewe during seasonal anestrus. Melatonin 12-21 prolactin Homo sapiens 68-77 9415637-7 1997 Further analysis of the relationship of plasma PRL and therapy showed that patients with SLE selected by the attending physician for prednisone therapy in doses > or = 10 mg/day were more frequently hyperprolactinemic. Prednisone 133-143 prolactin Homo sapiens 47-50 9389815-9 1997 A statistically significant increase in serum prolactin was observed on the day of the LH surge (naltrexone: 22.6 +/- 3.7 micrograms/L; placebo: 21.7 +/- 2.7 micrograms/L; P < 0.05 versus early follicular phase), but no difference between treatments was observed. Naltrexone 97-107 prolactin Homo sapiens 46-55 9389815-10 1997 However, midluteal prolactin levels were statistically significantly lower in naltrexone cycles compared with placebo cycles (12.6 +/- 3.3 versus 15.4 +/- 3.0 micrograms/L; P < 0.05). Naltrexone 78-88 prolactin Homo sapiens 19-28 9399220-11 1997 Serum prolactin was elevated in all patients after domperidone therapy (p < 0.05). Domperidone 51-62 prolactin Homo sapiens 6-15 9547133-0 1997 Moclobemide effects on prolactin plasma levels in healthy individuals: the hormonal increase induced by a single dose is maintained during a 4-week period of drug intake. Moclobemide 0-11 prolactin Homo sapiens 23-32 9547133-6 1997 The present data show an acute and transitory increase of plasma prolactin levels after the single dose, and also during the long-term moclobemide administration. Moclobemide 135-146 prolactin Homo sapiens 65-74 9360509-1 1997 Cabergoline (CAB), a long-lasting dopamine-agonist, specific for the D2 receptor, is effective in normalizing serum PRL levels in most patients with microprolactinoma or idiopathic hyperprolactinemia. Cabergoline 0-11 prolactin Homo sapiens 116-119 9360509-1 1997 Cabergoline (CAB), a long-lasting dopamine-agonist, specific for the D2 receptor, is effective in normalizing serum PRL levels in most patients with microprolactinoma or idiopathic hyperprolactinemia. Cabergoline 13-16 prolactin Homo sapiens 116-119 9360514-0 1997 A therapeutic role of prolactin supplementation in ovarian stimulation for in vitro fertilization: the bromocriptine-rebound method. Bromocriptine 103-116 prolactin Homo sapiens 22-31 9334596-3 1997 Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire, gynecomastia or testosterone less than 4 ng./ml. Testosterone 131-143 prolactin Homo sapiens 70-79 9334596-12 1997 Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction (definite improvement in only 16 of 44 [36%] after androgen therapy, normal morning or nocturnal erections in 30% and definite vasculogenic contributions in 42%). Testosterone 22-34 prolactin Homo sapiens 148-157 9334596-19 1997 Bromocriptine was definitely effective in cases with prolactin greater than 35 ng./ml. Bromocriptine 0-13 prolactin Homo sapiens 53-62 9334596-21 1997 Testosterone was low in less than 50% of cases with prolactin greater than 35 ng./ml. Testosterone 0-12 prolactin Homo sapiens 52-61 9396279-3 1997 Dopamine is the major physiologic prolactin inhibiting factor (PIF). Dopamine 0-8 prolactin Homo sapiens 34-43 9387855-2 1997 The decreased amplitude and duration of nocturnal melatonin secretion were accompanied with changes in the daily pattern of prolactin secretion. Melatonin 50-59 prolactin Homo sapiens 124-133 9387855-4 1997 Melatonin infused into the third ventricle evoked an abrupt increase in the concentration of prolactin after 30 min, and the enhanced prolactin level was significantly higher than during the control infusion (range from 204 +/- 75 to 248 +/- 48 ng/ml vs. 128 +/- 68 to 149 +/- 93 ng/ml, mean +/- SD). Melatonin 0-9 prolactin Homo sapiens 93-102 9387855-4 1997 Melatonin infused into the third ventricle evoked an abrupt increase in the concentration of prolactin after 30 min, and the enhanced prolactin level was significantly higher than during the control infusion (range from 204 +/- 75 to 248 +/- 48 ng/ml vs. 128 +/- 68 to 149 +/- 93 ng/ml, mean +/- SD). Melatonin 0-9 prolactin Homo sapiens 134-143 9387855-6 1997 These data suggest that short-term infusions of melatonin stimulate the secretion of prolactin in the ewe under increasing daylength conditions, and that this effect is not mediated by changes in DA release. Melatonin 48-57 prolactin Homo sapiens 85-94 9326827-0 1997 Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Serotonin 8-17 prolactin Homo sapiens 69-78 9329339-0 1997 Effects of leuprolide-induced hypogonadism and testosterone replacement on sleep, melatonin, and prolactin secretion in men. Testosterone 47-59 prolactin Homo sapiens 97-106 9357442-7 1997 Depletion of medium PRL with two polyclonal anti-hPRL antisera inhibited the growth of Jurkat cells in a dose-dependent manner, as evaluated by cell number and 3H-TdR uptake. Tritium 160-162 prolactin Homo sapiens 20-23 9357442-7 1997 Depletion of medium PRL with two polyclonal anti-hPRL antisera inhibited the growth of Jurkat cells in a dose-dependent manner, as evaluated by cell number and 3H-TdR uptake. Tritium 160-162 prolactin Homo sapiens 49-53 9463181-4 1997 4) Evaluate the reduction rate of prolactin (PRL) at 4 and 14 days after cabergoline administration. Cabergoline 73-84 prolactin Homo sapiens 34-43 9463181-4 1997 4) Evaluate the reduction rate of prolactin (PRL) at 4 and 14 days after cabergoline administration. Cabergoline 73-84 prolactin Homo sapiens 45-48 9463181-11 1997 Mean levels of serum PRL at 4 and 14 days after cabergoline administration were respectively 12.5 and 18.2 ng/ml. Cabergoline 48-59 prolactin Homo sapiens 21-24 9463181-12 1997 CONCLUSIONS: Cabergoline, a new dopaminergic drug with long-term inhibition of PRL production and secretion, can inhibit lactogenesis and lactopoies in 92% of cases at a dose of 1 mg; it can reduce long-term PRL levels (18.2 ng/ml) and in 4% it is necessary to resort to symptomatic treatment of the undesirable effects caused. Cabergoline 13-24 prolactin Homo sapiens 79-82 9463181-12 1997 CONCLUSIONS: Cabergoline, a new dopaminergic drug with long-term inhibition of PRL production and secretion, can inhibit lactogenesis and lactopoies in 92% of cases at a dose of 1 mg; it can reduce long-term PRL levels (18.2 ng/ml) and in 4% it is necessary to resort to symptomatic treatment of the undesirable effects caused. Cabergoline 13-24 prolactin Homo sapiens 208-211 9299534-4 1997 PRL stimulated MAP kinase activity, as detected by 32P incorporation into MAP-2, in a dose-dependent manner. Phosphorus-32 51-54 prolactin Homo sapiens 0-3 9299534-5 1997 PRL also rapidly stimulated MAP kinase phosphorylation as detected by in vivo phosphorylation using 32P labeling and phosphotyrosine immunoblotting. Phosphorus-32 100-103 prolactin Homo sapiens 0-3 9299534-5 1997 PRL also rapidly stimulated MAP kinase phosphorylation as detected by in vivo phosphorylation using 32P labeling and phosphotyrosine immunoblotting. Phosphotyrosine 117-132 prolactin Homo sapiens 0-3 9294375-6 1997 RESULTS: Increasing degrees of aggressive behavior at either assessment were positively correlated with the prolactin response to fenfluramine challenge. Fenfluramine 130-142 prolactin Homo sapiens 108-117 9284727-5 1997 High-dose cabergoline administration resulted in a 30% decrease in serum PRL. Cabergoline 10-21 prolactin Homo sapiens 73-76 9232209-0 1997 Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment. Dexfenfluramine 29-43 prolactin Homo sapiens 7-16 9232209-0 1997 Plasma prolactin response to d-fenfluramine in obsessive-compulsive patients before and after fluvoxamine treatment. Fluvoxamine 94-105 prolactin Homo sapiens 7-16 9232209-1 1997 The prolactin (PRL) responses to oral d-fenfluramine (30 mg) and placebo were assessed in 13 patients with obsessive-compulsive disorder (OCD) and in matched healthy subjects. Dexfenfluramine 38-52 prolactin Homo sapiens 4-13 9232209-4 1997 In drug-free patients, the PRL response to d-fenfluramine was significantly lower than in the comparison group. Dexfenfluramine 43-57 prolactin Homo sapiens 27-30 9232209-5 1997 After 10-week fluvoxamine treatment, the PRL response to the serotonergic agent normalized. Fluvoxamine 14-25 prolactin Homo sapiens 41-44 9272110-4 1997 In decidualized endometrial cells induced by ovarian steroid hormones in vitro, PRL release increased and ET-1 release decreased in a time-dependent manner. Steroids 53-69 prolactin Homo sapiens 80-83 9241009-0 1997 The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status. Fluvoxamine 14-25 prolactin Homo sapiens 35-44 9241009-6 1997 Two subjects had substantial increases in serum prolactin levels (up to 35 microg/L) during fluvoxamine treatment, and these two subjects had higher Bmax for platelet [3H]LSD binding before fluvoxamine treatment than the six other subjects (32.7 vs. 23.1 fmol/mg protein). Fluvoxamine 92-103 prolactin Homo sapiens 48-57 9241009-9 1997 The results indicate that fluvoxamine affects serum prolactin as well as serum sodium concentrations and lend indirect support to the suggestion that 5-HT2A receptors might be involved in the mediation of these effects. Fluvoxamine 26-37 prolactin Homo sapiens 52-61 9639745-0 1997 [Responses of growth hormone and prolactin to L-Dopa in women with polycystic ovarian syndrome]. Levodopa 46-52 prolactin Homo sapiens 33-42 9639745-2 1997 METHODS: Responses of GH and PRL to L-Dopa (L-DA) (500 mg) were observed in two PCOS groups (LH/FSH > or = 3, Group I, n = 15, LH/FSH < 3, Group II, n = 15) and the control (n = 20). Levodopa 36-42 prolactin Homo sapiens 29-32 9639745-2 1997 METHODS: Responses of GH and PRL to L-Dopa (L-DA) (500 mg) were observed in two PCOS groups (LH/FSH > or = 3, Group I, n = 15, LH/FSH < 3, Group II, n = 15) and the control (n = 20). Levodopa 44-48 prolactin Homo sapiens 29-32 9639745-3 1997 RESULTS: Significantly lower GH (P < 0.01) and higher PRL levels (P < 0.05 in group I) in the basal state, and lower responses of GH and PRL to L-DA were found in two PCOS groups as compared with the control. Levodopa 150-154 prolactin Homo sapiens 143-146 9639745-4 1997 CONCLUSION: The altered basal levels and blunted L-DA evoked responses of GH and PRL suggest a relative decrease of the dopaminergic activity in PCOS patients. Levodopa 49-53 prolactin Homo sapiens 81-84 9228870-9 1997 RESULTS: Patients with SCI had significant suppression in PTH (p < .000009) and 1,25-D (p < .02) levels with elevated phosphorus (p < 0.03) and prolactin (p < .03) levels compared to patients with TBI. Phosphorus 124-134 prolactin Homo sapiens 153-162 9441209-0 1997 [Prolactin levels in pregnant women with glucose intolerance at full-term delivery]. Glucose 41-48 prolactin Homo sapiens 1-10 9441209-1 1997 A prospective study was carried out to establish the influence of deteriorated metabolism of glucose in mothers to the synthesis and secretion of prolactin during the pregnancy. Glucose 93-100 prolactin Homo sapiens 146-155 9441209-4 1997 The level of prolactin in the sera of mothers with glucose intolerance (205.7 +/- 66.4 micrograms/l) was significantly increased (p < 0.05) than in case of mothers with normal pregnancy (172.2 +/- 60.7 micrograms/l), probably due to the development of gestosis in a large number of pregnant women. Glucose 51-58 prolactin Homo sapiens 13-22 9441209-5 1997 The difference of prolactin level in pregnant women with glucose intolerance but without the elements of gestosis (167.3 +/- 35.7 micrograms/l) and in women with normal pregnancy was not important. Glucose 57-64 prolactin Homo sapiens 18-27 9209949-0 1997 Aetiopathogenesis of peripartum cardiomyopathy: prolactin-selenium interaction? Selenium 58-66 prolactin Homo sapiens 48-57 9209949-2 1997 Fragmentary evidence from the published literature are synthesised to suggest a hypothesis that prolactin-selenium interactions resulting in selenium deficiency and/or autoimmunity are responsible for peripartum cardiomyopathy. Selenium 106-114 prolactin Homo sapiens 96-105 9209949-2 1997 Fragmentary evidence from the published literature are synthesised to suggest a hypothesis that prolactin-selenium interactions resulting in selenium deficiency and/or autoimmunity are responsible for peripartum cardiomyopathy. Selenium 141-149 prolactin Homo sapiens 96-105 9209949-4 1997 The possible link between prolactin and selenium should be explored. Selenium 40-48 prolactin Homo sapiens 26-35 9248578-0 1997 The effect of microtubule and microfilament-disrupting drugs on prolactin-stimulated progesterone synthesis and secretion by cultured porcine theca cells. Progesterone 85-97 prolactin Homo sapiens 64-73 9248578-1 1997 The effect of microtubule- and microfilament-disrupting drugs (colchicine, cytochalasin B and D) on basal and prolactin (Prl)-stimulated progesterone synthesis and secretion was studied. Progesterone 137-149 prolactin Homo sapiens 110-119 9197946-4 1997 Flunarizine treatment increased basal prolactin levels, but it did not reduce the inhibitory response of prolactin to acute bromocriptine administration. Flunarizine 0-11 prolactin Homo sapiens 38-47 9376450-3 1997 METHODS: In this pilot study, we examined the relationship between: a) pretreatment prolactin responses to d-fenfluramine (PRL[d-FEN]) challenge; and b) antiaggressive responses to 12 weeks of treatment with either fluoxetine or placebo in 15 impulsively aggressive personality disordered subjects as observed in a 12-week, double-blind, placebo-controlled trial. Dexfenfluramine 107-121 prolactin Homo sapiens 84-93 9331518-7 1997 Plasma prolactin concentrations were increased by 40% after 10 days" treatment with citalopram (p = 0.03); this was not potentiated by concomitantly administered selegiline. Citalopram 84-94 prolactin Homo sapiens 7-16 9413808-1 1997 Cabergoline (Cab), a very potent and long-lasting dopaminergic compound, was administered to 26 women with pituitary microprolactinoma [mean serum PRL levels: 124.8 +/- 11.3 micrograms/l (+/- SE), range 62-300 micrograms/l] and 3 patients with GH-secreting pituitary adenoma (2 with associated PRL hypersecretion) for 12 and 24 months, respectively. Cabergoline 0-11 prolactin Homo sapiens 147-150 9413809-1 1997 Cabergoline (CAB), a new long-acting ergoline derivative, was shown to be very effective in reducing PRL levels in normal volunteers and in hyperprolactinemic patients. Cabergoline 0-11 prolactin Homo sapiens 101-104 9413809-1 1997 Cabergoline (CAB), a new long-acting ergoline derivative, was shown to be very effective in reducing PRL levels in normal volunteers and in hyperprolactinemic patients. Cabergoline 13-16 prolactin Homo sapiens 101-104 9413809-1 1997 Cabergoline (CAB), a new long-acting ergoline derivative, was shown to be very effective in reducing PRL levels in normal volunteers and in hyperprolactinemic patients. Ergolines 3-11 prolactin Homo sapiens 101-104 9413809-4 1997 After long-term treatment, CAB was withdrawn in 11 patients and PRL levels were persistently normal for almost 15 days and significantly lower (p < 0.05) than basal at 30, 45, 60, 90, 120 days. Cabergoline 27-30 prolactin Homo sapiens 64-67 9294375-3 1997 This study examines the prolactin response to fenfluramine hydrochloride challenge in young boys who show clinically significant aggressive behavior or who are raised in a social environment that is conducive to the development of chronic aggression. Fenfluramine 46-72 prolactin Homo sapiens 24-33 9241064-0 1997 Refractoriness to a static melatonin signal develops in the pituitary gland for the control of prolactin secretion in the ram. Melatonin 27-36 prolactin Homo sapiens 95-104 9241064-7 1997 Overall, the results support the conclusion that 1) melatonin acts primarily in the pituitary gland to affect prolactin secretion, and partial refractoriness develops at this level for control of prolactin; and 2) melatonin acts most probably in the hypothalamus to affect gonadotropin secretion, and refractoriness develops at the level of the neural tissue regulating GnRH release for control of gonadotropins. Melatonin 52-61 prolactin Homo sapiens 110-119 9282338-0 1997 Effect and mechanisms of the anti-prolactin drug cabergoline on pseudopregnancy in the bitch. Cabergoline 49-60 prolactin Homo sapiens 34-43 9282338-1 1997 A potent anti-prolactin drug, cabergoline, administered orally for five days, was clinically successful in treating three different clinical manifestations of pseudopregnancy in referred bitches. Cabergoline 30-41 prolactin Homo sapiens 14-23 9207433-6 1997 PAF-modulated release of PRL by BMSC was confirmed by an enzyme-linked-immunospot (Elispot) technique. Platelet Activating Factor 0-3 prolactin Homo sapiens 25-28 9207433-11 1997 In situ hybridization experiments with a rat PRL cDNA probe cross-reacting with human PRL mRNA confirmed its presence in a small fraction of unstimulated BMSC and in the majority of PAF-stimulated BMSC. Platelet Activating Factor 182-185 prolactin Homo sapiens 86-89 9212064-1 1997 Several different Janus kinases (JAKs) and signal transducers and activation of transcription (STATs) have been implicated in mediating the biological responses induced by PRL, based on their ligand-dependent tyrosine phosphorylation and activation. Tyrosine 209-217 prolactin Homo sapiens 172-175 9194044-0 1997 Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. Fluoxetine 0-10 prolactin Homo sapiens 124-133 9194044-0 1997 Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder. 5-Hydroxytryptophan 63-82 prolactin Homo sapiens 124-133 9194044-2 1997 The effects of chronic treatment with fluoxetine or tricyclic antidepressants on the L-5-hydroxytryptophan (200 mg, L-5-HTP; PO)-induced increases in plasma cortisol and prolactin (PRL) concentrations were studied in patients with major depression or obsessive compulsive disorder (OCD). 5-Hydroxytryptophan 85-106 prolactin Homo sapiens 170-179 9194044-2 1997 The effects of chronic treatment with fluoxetine or tricyclic antidepressants on the L-5-hydroxytryptophan (200 mg, L-5-HTP; PO)-induced increases in plasma cortisol and prolactin (PRL) concentrations were studied in patients with major depression or obsessive compulsive disorder (OCD). 5-Hydroxytryptophan 85-106 prolactin Homo sapiens 181-184 9194044-3 1997 Administration of L-5-HTP increased plasma cortisol and PRL levels in medicated and unmedicated patients with major depression or OCD. 5-Hydroxytryptophan 18-25 prolactin Homo sapiens 56-59 9194044-4 1997 The L-5-HTP-induced cortisol and PRL responses were significantly higher in fluoxetine-treated than in tricyclic-treated or unmedicated major depressed patients. 5-Hydroxytryptophan 4-11 prolactin Homo sapiens 33-36 9194044-4 1997 The L-5-HTP-induced cortisol and PRL responses were significantly higher in fluoxetine-treated than in tricyclic-treated or unmedicated major depressed patients. Fluoxetine 76-86 prolactin Homo sapiens 33-36 9194044-6 1997 The L-5-HTP-induced increases in cortisol and PRL in fluoxetine-treated patients with major depression or OCD were not significantly different. 5-Hydroxytryptophan 4-11 prolactin Homo sapiens 46-49 9194044-6 1997 The L-5-HTP-induced increases in cortisol and PRL in fluoxetine-treated patients with major depression or OCD were not significantly different. Fluoxetine 53-63 prolactin Homo sapiens 46-49 9194044-7 1997 The results suggest that fluoxetine, but not tricyclic antidepressants, potentiates 5-HT receptor-mediated stimulation of cortisol and PRL secretion in humans, consistent with available evidence that fluoxetine treatment, but not tricyclic antidepressants, increases central serotonergic activity in patients with MD or OCD by a presynaptic mechanism. Fluoxetine 25-35 prolactin Homo sapiens 135-138 9193193-6 1997 RESULTS: For patients with bulimia nervosa, the fenfluramine-stimulated increase in serum prolactin concentration was significantly less than for controls. Fenfluramine 48-60 prolactin Homo sapiens 90-99 9193193-7 1997 Within the patient group, the frequency of binge eating episodes during the 4 weeks prior to the study exhibited a significant inverse correlation with serotonin-stimulated prolactin secretion. Serotonin 152-161 prolactin Homo sapiens 173-182 9330023-0 1997 Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment. Dexfenfluramine 22-36 prolactin Homo sapiens 0-9 9330023-2 1997 METHOD: According to a double-blind placebo-controlled design, plasma prolactin (PRL) response to a specific serotonergic probe, d-fenfluramine, was measured in 20 drug-free obsessive-compulsive patients and in 20 matched healthy controls. Dexfenfluramine 129-143 prolactin Homo sapiens 70-79 9330023-2 1997 METHOD: According to a double-blind placebo-controlled design, plasma prolactin (PRL) response to a specific serotonergic probe, d-fenfluramine, was measured in 20 drug-free obsessive-compulsive patients and in 20 matched healthy controls. Dexfenfluramine 129-143 prolactin Homo sapiens 81-84 9330023-5 1997 RESULTS: PRL response in OCD patients was blunted under the drug-free condition; correlated inversely with pretreatment ratings of obsessive-compulsive and depressive symptomatology; and correlated inversely with the improvement in obsessive-compulsive score observed after fluvoxamine treatment. Fluvoxamine 274-285 prolactin Homo sapiens 9-12 9197946-0 1997 Prolactin response to bromocriptine in flunarizine-treated migrainous women. Bromocriptine 22-35 prolactin Homo sapiens 0-9 9197946-0 1997 Prolactin response to bromocriptine in flunarizine-treated migrainous women. Flunarizine 39-50 prolactin Homo sapiens 0-9 9197946-3 1997 We studied the inhibitory response of prolactin to acute administration of bromocriptine, a D2 dopamine receptor agonist, before and after 1 month of treatment with flunarizine in migrainous women. Bromocriptine 75-88 prolactin Homo sapiens 38-47 9368687-3 1997 In this article, we have used an in vitro culture model of progesterone-dependent decidualization of human endometrial stromal cells to examine whether progesterone-induced decidualization is associated with activation of the cAMP signal transduction pathway in which the prolactin gene expression is a marker of decidualization. Cyclic AMP 226-230 prolactin Homo sapiens 272-281 9368687-6 1997 Changes in cAMP levels showed a positive correlation with prolactin secretion. Cyclic AMP 11-15 prolactin Homo sapiens 58-67 9368687-7 1997 Prostaglandin E2 (PGE2), which enhances progesterone-dependent decidualization, also increased both prolactin secretion and cAMP levels approx two- to fourfold on d 15 compared with d 3, whereas PGE2 alone, which does not induce decidualization, did not stimulate prolactin secretion or intracellular cAMP accumulation. Dinoprostone 0-16 prolactin Homo sapiens 100-109 9368687-7 1997 Prostaglandin E2 (PGE2), which enhances progesterone-dependent decidualization, also increased both prolactin secretion and cAMP levels approx two- to fourfold on d 15 compared with d 3, whereas PGE2 alone, which does not induce decidualization, did not stimulate prolactin secretion or intracellular cAMP accumulation. Dinoprostone 0-16 prolactin Homo sapiens 264-273 9368687-7 1997 Prostaglandin E2 (PGE2), which enhances progesterone-dependent decidualization, also increased both prolactin secretion and cAMP levels approx two- to fourfold on d 15 compared with d 3, whereas PGE2 alone, which does not induce decidualization, did not stimulate prolactin secretion or intracellular cAMP accumulation. Dinoprostone 18-22 prolactin Homo sapiens 100-109 9368687-7 1997 Prostaglandin E2 (PGE2), which enhances progesterone-dependent decidualization, also increased both prolactin secretion and cAMP levels approx two- to fourfold on d 15 compared with d 3, whereas PGE2 alone, which does not induce decidualization, did not stimulate prolactin secretion or intracellular cAMP accumulation. Dinoprostone 18-22 prolactin Homo sapiens 264-273 9368687-8 1997 Conversely, all-trans retinoic acid, which attenuates progesterone-dependent decidualization, significantly (p < 0.05) decreased both prolactin secretion and cAMP levels. Tretinoin 12-35 prolactin Homo sapiens 137-146 9368687-8 1997 Conversely, all-trans retinoic acid, which attenuates progesterone-dependent decidualization, significantly (p < 0.05) decreased both prolactin secretion and cAMP levels. Progesterone 54-66 prolactin Homo sapiens 137-146 9368687-9 1997 Furthermore, the protein kinase A (PKA) inhibitor, 8-bromoadenosine-3",5"-cyclic monophosphorothioate, significantly (p < 0.05) suppressed progesterone-dependent prolactin expression. 8-bromoadenosine-3',5'-cyclic monophosphorothioate 51-101 prolactin Homo sapiens 165-174 9368687-9 1997 Furthermore, the protein kinase A (PKA) inhibitor, 8-bromoadenosine-3",5"-cyclic monophosphorothioate, significantly (p < 0.05) suppressed progesterone-dependent prolactin expression. Progesterone 142-154 prolactin Homo sapiens 165-174 9203990-7 1997 When human PRL was added to the culture medium, in doses ranging from 1 to 200 ng/ml, a dose-dependent stimulation of 3H-thymidine incorporation was observed only in PRL-receptor positive tumours. Tritium 118-120 prolactin Homo sapiens 11-14 9203990-7 1997 When human PRL was added to the culture medium, in doses ranging from 1 to 200 ng/ml, a dose-dependent stimulation of 3H-thymidine incorporation was observed only in PRL-receptor positive tumours. Tritium 118-120 prolactin Homo sapiens 166-169 9203990-7 1997 When human PRL was added to the culture medium, in doses ranging from 1 to 200 ng/ml, a dose-dependent stimulation of 3H-thymidine incorporation was observed only in PRL-receptor positive tumours. Thymidine 121-130 prolactin Homo sapiens 11-14 9203990-7 1997 When human PRL was added to the culture medium, in doses ranging from 1 to 200 ng/ml, a dose-dependent stimulation of 3H-thymidine incorporation was observed only in PRL-receptor positive tumours. Thymidine 121-130 prolactin Homo sapiens 166-169 9326827-0 1997 Central serotonin activity and aggression: inverse relationship with prolactin response to d-fenfluramine, but not CSF 5-HIAA concentration, in human subjects. Dexfenfluramine 91-105 prolactin Homo sapiens 69-78 9326827-1 1997 OBJECTIVE: This study compared the nature and magnitude of the relationship between aggression and CSF 5-hydroxyindoleacetic acid (5-HIAA) concentration with that between aggression and the prolactin response to d-fenfluramine challenge in human subjects. Dexfenfluramine 212-226 prolactin Homo sapiens 190-199 9326827-2 1997 METHOD: The Life History of Aggression assessment scores of 24 subjects with personality disorders were compared with their lumbar CSF 5-HIAA concentrations and with their prolactin responses to d-fenfluramine challenge. Dexfenfluramine 195-209 prolactin Homo sapiens 172-181 9326827-3 1997 RESULTS: Aggression was significantly and inversely correlated with prolactin responses to d-fenfluramine challenge but not with lumbar CSF 5-HIAA concentrations in these subjects. Dexfenfluramine 91-105 prolactin Homo sapiens 68-77 9326827-4 1997 CONCLUSIONS: Prolactin response to d-fenfluramine may be more sensitive than lumbar CSF 5-HIAA concentration in detecting a relationship between aggression and central serotonin activity in noncriminally violent human subjects. Dexfenfluramine 35-49 prolactin Homo sapiens 13-22 9202403-5 1997 Our data suggest that the Box 1 region of the PRL receptor and particularly the last proline is critical for JAK2 association and subsequent activation. Proline 85-92 prolactin Homo sapiens 46-49 9164861-1 1997 Treatment of T47-D human breast carcinoma cells with recombinant prolactin (rhPRL) induced a concentration- and time-dependent increase in the phosphotyrosine content of JAK2. Phosphotyrosine 143-158 prolactin Homo sapiens 65-74 9202399-0 1997 Involvement of nitric oxide in the interferon-gamma-induced inhibition of growth hormone and prolactin secretion in anterior pituitary cell cultures. Nitric Oxide 15-27 prolactin Homo sapiens 93-102 9202399-5 1997 L-N6-(1-iminoethyl)lysine (L-NIL), a NOS inhibitor with preferential affinity for iNOS, abrogated the IFN-gamma effect on GHRH-stimulated GH secretion and partially reversed IFN-gamma inhibition of PRL release. N(6)-(1-iminoethyl)lysine 0-25 prolactin Homo sapiens 198-201 9202399-5 1997 L-N6-(1-iminoethyl)lysine (L-NIL), a NOS inhibitor with preferential affinity for iNOS, abrogated the IFN-gamma effect on GHRH-stimulated GH secretion and partially reversed IFN-gamma inhibition of PRL release. N(6)-(1-iminoethyl)lysine 27-32 prolactin Homo sapiens 198-201 9202399-11 1997 The inhibition of PRL and GH release by IFN-gamma was markedly reduced in L-arginine-depleted medium. Arginine 74-84 prolactin Homo sapiens 18-21 9202399-12 1997 The NO donor sodium nitroprusside (SNP) mimicked the inhibitory action of IFN-gamma on GHRH-stimulated GH and basal PRL release. Nitroprusside 13-33 prolactin Homo sapiens 116-119 9202399-16 1997 Interestingly, in the absence of IFN-gamma L-NMMA strongly stimulated basal PRL release in the population most enriched in FS cells. omega-N-Methylarginine 43-49 prolactin Homo sapiens 76-79 9158821-4 1997 With the Delfia and Immuno 1 systems samples containing substantial quantities of macroprolactin showed low recovery of PRL after precipitation with polyethylene glycol 6000 (PEG 6000) and this technique can be used as a screening test for macroprolactinaemia. Polyethylene Glycol 6000 149-173 prolactin Homo sapiens 120-123 9158821-4 1997 With the Delfia and Immuno 1 systems samples containing substantial quantities of macroprolactin showed low recovery of PRL after precipitation with polyethylene glycol 6000 (PEG 6000) and this technique can be used as a screening test for macroprolactinaemia. Polyethylene Glycol 6000 175-183 prolactin Homo sapiens 120-123 9169300-8 1997 Although olanzapine was associated with some increase in prolactin concentrations, increases were transient, occurred less often, and were of lesser magnitude than those observed with haloperidol. Olanzapine 9-19 prolactin Homo sapiens 57-66 9258810-0 1997 Prolactin decrease and shift to a normal-like isoform profile during treatment with quinagolide in a patient affected by an invasive prolactinoma. quinagolide 84-95 prolactin Homo sapiens 0-9 9175708-7 1997 Immunofluorescence combined with detailed confocal laser microscopy showed that addition of PRL (0 to 12 hours) to COS-7, CHO and NIH-3T3 transfected fibroblasts induces rapid internalization of the receptor (long form), without any translocation to the nucleus. carbonyl sulfide 115-118 prolactin Homo sapiens 92-95 9175708-7 1997 Immunofluorescence combined with detailed confocal laser microscopy showed that addition of PRL (0 to 12 hours) to COS-7, CHO and NIH-3T3 transfected fibroblasts induces rapid internalization of the receptor (long form), without any translocation to the nucleus. CAV protocol 122-125 prolactin Homo sapiens 92-95 9258810-14 1997 These data show that quinagolide successfully reduced PRL levels, while inducing secretion of forms more similar to those found in women affected by pathological hyperprolactinaemia or in normal women. quinagolide 21-32 prolactin Homo sapiens 54-57 9109176-7 1997 There was also an inverse relation between basal cortisol levels and both prolactin and cortisol responses, but no relation between basal cortisol levels and aggressive measures. Hydrocortisone 49-57 prolactin Homo sapiens 74-83 9179513-0 1997 Effects of thyrotropin-releasing hormone and metoclopramide on PRL secretion in normally cycling and amenorrheic alcoholic women. Metoclopramide 45-59 prolactin Homo sapiens 63-66 9179513-9 1997 In contrast, the PRL response to MTC was significantly higher in cycling alcoholic patients than in normal controls and amenorrheic alcoholic subjects. Metoclopramide 33-36 prolactin Homo sapiens 17-20 9093196-11 1997 After treatment with bromocriptine, the PRL level decreased in all women to within normal limits. Bromocriptine 21-34 prolactin Homo sapiens 40-43 21584063-1 1997 This study was designed to assess the relationship between psychopathology and serotonin generated prolactin response to clomipramine and to assess the relationship between improvement in psychopathology and prolactin levels. Serotonin 79-88 prolactin Homo sapiens 99-108 21584063-1 1997 This study was designed to assess the relationship between psychopathology and serotonin generated prolactin response to clomipramine and to assess the relationship between improvement in psychopathology and prolactin levels. Clomipramine 121-133 prolactin Homo sapiens 99-108 9110224-1 1997 This experiment was designed to determine 1) the efficacy of daily s.c. injections of a dopamine antagonist, sulpiride, for increasing prolactin secretion in geldings in winter and 2) whether increasing prolactin concentrations would hasten the onset of hair shedding or enhance gonadotropin secretion. Dopamine 88-96 prolactin Homo sapiens 135-144 9110224-1 1997 This experiment was designed to determine 1) the efficacy of daily s.c. injections of a dopamine antagonist, sulpiride, for increasing prolactin secretion in geldings in winter and 2) whether increasing prolactin concentrations would hasten the onset of hair shedding or enhance gonadotropin secretion. Sulpiride 109-118 prolactin Homo sapiens 135-144 9141006-2 1997 As evidence suggests that prolactin has important immunostimulatory properties, we conducted a randomized, prospective open trial in which bromocriptine, a drug suppressing prolactin secretion, was administered as an additive immunosuppressive drug after first cadaver kidney transplantation. Bromocriptine 139-152 prolactin Homo sapiens 26-35 9141006-2 1997 As evidence suggests that prolactin has important immunostimulatory properties, we conducted a randomized, prospective open trial in which bromocriptine, a drug suppressing prolactin secretion, was administered as an additive immunosuppressive drug after first cadaver kidney transplantation. Bromocriptine 139-152 prolactin Homo sapiens 173-182 9141006-6 1997 RESULTS: Serum prolactin concentrations were slightly elevated above normal values before transplantation (32 +/- 5.3 ng/ml) and decreased to values between 13 and 16 ng/ml in the control group and were totally suppressed in the bromocriptine group. Bromocriptine 229-242 prolactin Homo sapiens 15-24 9141006-12 1997 CONCLUSIONS: Suppression of circulating prolactin concentration by bromocriptine did not improve the clinical outcome of patients after kidney transplantation receiving cyclosporin and prednisolone. Bromocriptine 67-80 prolactin Homo sapiens 40-49 9112362-4 1997 Through mechanisms only partially understood, calcium channel blockers and cyclosporine are reported to increase the serum prolactin level, producing gynecomastia in men. Cyclosporine 75-87 prolactin Homo sapiens 123-132 9196602-3 1997 We have therefore reviewed the efficiency and safety of cabergoline in the treatment of patients with prolactin-secreting macroadenomas treated on a compassionate basis. Cabergoline 56-67 prolactin Homo sapiens 102-111 9110224-5 1997 Over the 8-wk sampling period, prolactin response to sulpiride varied in a quadratic manner (P < .002). Sulpiride 53-62 prolactin Homo sapiens 31-40 9110224-10 1997 In conclusion, even though prolactin concentrations were increased by sulpiride, the effects on gonadotropin secretion and hair shedding were minor and opposite of those expected. Sulpiride 70-79 prolactin Homo sapiens 27-36 9192542-3 1997 We describe a case of attenuated serum prolactin levels after conversion to clozapine therapy in an adolescent. Clozapine 76-85 prolactin Homo sapiens 39-48 9192542-7 1997 Clozapine 150 mg twice daily improved her psychiatric status and corrected her serum prolactin concentrations after 2 weeks; bromocriptine was able to be discontinued. Clozapine 0-9 prolactin Homo sapiens 85-94 9066992-2 1997 This study assessed 5-HT function, using a fenfluramine (FEN) challenge procedure, in an attempt to replicate a previously reported enhancement of the prolactin (PRL) response to FEN in aggressive relative to nonaggressive ADHD boys. Fenfluramine 57-60 prolactin Homo sapiens 151-160 9071561-3 1997 Treatment with a dose of forskolin (5 microM), known to induce PRL gene transcription, significantly inhibited TGF-beta 1 levels in culture medium and TGF-beta 1 mRNA levels in cellular extracts. Colforsin 25-34 prolactin Homo sapiens 63-66 9156042-11 1997 Sixty-four patients had an abnormal PRL response to domperidone and 18 of these had a macrolesion (nine prolactinomas, nine other tumours). Domperidone 52-63 prolactin Homo sapiens 36-39 9156042-14 1997 CONCLUSIONS: The majority of patients with a normal dynamic response of PRL to domperidone had a normal or near normal pituitary MRI scan. Domperidone 79-90 prolactin Homo sapiens 72-75 9156042-15 1997 In the two cases where an abnormality was detected it could have been an incidental microadenoma or cyst, thus suggesting that pituitary scanning could normally be omitted in patients whose PRL response to domperidone is normal (24% of our total). Domperidone 206-217 prolactin Homo sapiens 190-193 9156042-16 1997 The group of patients with an abnormal dynamic response of PRL to domperidone was not generally amenable to further diagnostic refinement by considering the degree of hyperprolactinaemia or the TSH response to domperidone because of overlap of these parameters between the diagnostic subgroups. Domperidone 66-77 prolactin Homo sapiens 59-62 9156042-17 1997 Therefore any degree of hyperprolactinaemia associated with a blunted PRL response to domperidone warrants pituitary imaging. Domperidone 86-97 prolactin Homo sapiens 70-73 9364359-5 1997 On cabergoline treatment normal serum PRL levels were achieved within 3 months along with a marked shrinkage of the adenoma but growth rate did not increase nor did puberty start. Cabergoline 3-14 prolactin Homo sapiens 38-41 9015165-11 1997 A strong negative correlation between testosterone and prolactin serum concentrations was found during the first 18 hours. Testosterone 38-50 prolactin Homo sapiens 55-64 9015165-15 1997 The relation between testosterone and prolactin might be helpful for predicting the clinical course and trauma outcome. Testosterone 21-33 prolactin Homo sapiens 38-47 9099897-1 1997 Citrate production is a major physiological function of the prostate that is regulated by testosterone and prolactin. Citric Acid 0-7 prolactin Homo sapiens 107-116 9099897-9 1997 Treatment of LNCaP and PC-3 cells with the phorbol ester 12-O-tetradecanoylphorbol (TPA) caused the same effect on mAAT activity and mRNA level as prolactin. Phorbol Esters 43-56 prolactin Homo sapiens 147-156 9099897-9 1997 Treatment of LNCaP and PC-3 cells with the phorbol ester 12-O-tetradecanoylphorbol (TPA) caused the same effect on mAAT activity and mRNA level as prolactin. phorbol-12-myristate 57-82 prolactin Homo sapiens 147-156 9099897-9 1997 Treatment of LNCaP and PC-3 cells with the phorbol ester 12-O-tetradecanoylphorbol (TPA) caused the same effect on mAAT activity and mRNA level as prolactin. Tetradecanoylphorbol Acetate 84-87 prolactin Homo sapiens 147-156 9099897-10 1997 The results suggest that the diacylglycerol-PKC signal transduction system mediates the prolactin effect on mAAT. Diglycerides 29-43 prolactin Homo sapiens 88-97 9062500-1 1997 Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in tumoral hyperprolactinemia. Cabergoline 0-11 prolactin Homo sapiens 51-54 9062500-1 1997 Cabergoline (CAB), a new, potent, and long-lasting PRL-lowering agent, was shown to be effective in tumoral hyperprolactinemia. Cabergoline 13-16 prolactin Homo sapiens 51-54 9062500-8 1997 CAB treatment normalized serum PRL levels in 15 of 19 macroprolactinomas and in all 8 microprolactinomas. Cabergoline 0-3 prolactin Homo sapiens 31-34 9037573-7 1997 These results suggest that the drop in prolactin levels occurring when cimetidine and ranitidine are suspended may contribute to the development of this syndrome. Cimetidine 71-81 prolactin Homo sapiens 39-48 9037573-7 1997 These results suggest that the drop in prolactin levels occurring when cimetidine and ranitidine are suspended may contribute to the development of this syndrome. Ranitidine 86-96 prolactin Homo sapiens 39-48 8999900-1 1997 Prolactin (PRL) has been demonstrated to induce tyrosine phosphorylation and activation of the cytoplasmic tyrosine kinase JAK2. Tyrosine 48-56 prolactin Homo sapiens 0-9 9152619-5 1997 There was a close association between the increment in serum PRL and of free triiodothyronine above the basal level after TRH administration. Triiodothyronine 77-93 prolactin Homo sapiens 61-64 9070698-0 1997 Differences in the metoclopramide-induced prolactin release related to age at first full-term pregnancy or nulliparity. Metoclopramide 19-33 prolactin Homo sapiens 42-51 9070698-1 1997 To investigate if an association exists in parous women between metoclopramide-induced prolactin (PRL) release and chronological age at first full-term pregnancy and to compare their response to a group of non-parous women, we studied 139 healthy, non-lactating women, aged 15.8-48.2 years, on days 18-22 of their menstrual cycle (except two post-menopausal women). Metoclopramide 64-78 prolactin Homo sapiens 87-96 9070698-1 1997 To investigate if an association exists in parous women between metoclopramide-induced prolactin (PRL) release and chronological age at first full-term pregnancy and to compare their response to a group of non-parous women, we studied 139 healthy, non-lactating women, aged 15.8-48.2 years, on days 18-22 of their menstrual cycle (except two post-menopausal women). Metoclopramide 64-78 prolactin Homo sapiens 98-101 8999900-0 1997 Prolactin activates tyrosyl phosphorylation of insulin receptor substrate 1 and phosphatidylinositol-3-OH kinase. cyclo(tyrosyl-tyrosyl) 20-27 prolactin Homo sapiens 0-9 9149330-2 1997 As compared to placebo, D-fenfluramine significantly increased plasma PRL levels in both the morning and the afternoon, with no significant circadian difference. Dexfenfluramine 24-38 prolactin Homo sapiens 70-73 9239226-3 1997 In this situation, plasma prolactin levels are normalized in about 60% of patients and in about one third of those who are resistant to bromocriptine. Bromocriptine 136-149 prolactin Homo sapiens 26-35 9064619-9 1997 Our results suggest that continuation of the antiprolactinemic (bromocryptine) treatment following completion of child-bearing appears to be indicated in premenopausal women with increased levels of serum prolactin. Bromocriptine 64-77 prolactin Homo sapiens 49-58 9231238-0 1997 The circulating concentrations of FSH, LH and prolactin in the oestradiol-implanted ovariectomized ewe treated with caffeine. Estradiol 63-73 prolactin Homo sapiens 46-55 9231238-4 1997 Thus, an experiment was designed to determine the effect of acute caffeine administration on the circulating concentrations of gonadotrophins and prolactin in the ovariectomized oestradiol-implanted ewe. Caffeine 66-74 prolactin Homo sapiens 146-155 9231238-6 1997 Circulating prolactin levels, on the other hand, were significantly (P < 0.01) elevated following intravenous treatment with caffeine. Caffeine 128-136 prolactin Homo sapiens 12-21 9231238-9 1997 Furthermore, they show that acute administration of caffeine stimulates prolactin secretion via an action that is independent of oestradiol feedback and which we suggest, may involve the ACTH/adrenal axis. Caffeine 52-60 prolactin Homo sapiens 72-81 8989257-0 1997 Biological mechanisms underlying the clinical effects of RU 486: modulation of cultured endometrial stromal cell stromelysin-1 and prolactin expression. Mifepristone 57-63 prolactin Homo sapiens 131-140 9059216-0 1997 Effect of low-dose dopamine on serum concentrations of prolactin in critically ill patients. Dopamine 19-27 prolactin Homo sapiens 55-64 9059216-1 1997 Dopamine is a naturally occurring catecholamine with actions in the central nervous system and endocrine systems, including inhibition of prolactin release from the pituitary gland. Dopamine 0-8 prolactin Homo sapiens 138-147 9059216-1 1997 Dopamine is a naturally occurring catecholamine with actions in the central nervous system and endocrine systems, including inhibition of prolactin release from the pituitary gland. Catecholamines 34-47 prolactin Homo sapiens 138-147 9059216-3 1997 We have investigated the effects of low-dose infusion of dopamine 2.5 micrograms kg-1 min-1 on serum concentrations of prolactin in critically ill patients. Dopamine 57-65 prolactin Homo sapiens 119-128 9059216-4 1997 Six hours after commencing the dopamine infusion, mean serum prolactin concentration had decreased from 746.95 to 128.9 mu. Dopamine 31-39 prolactin Homo sapiens 61-70 9241488-2 1997 Lymphocytes taken from doves with increased plasma concentrations of prolactin demonstrated significantly increased 3H-thymidine incorporation. 3h-thymidine 116-128 prolactin Homo sapiens 69-78 18638926-0 1997 Prolactin secreting pituitary tumours with marked visual field impairment should be treated by bromocriptine. Bromocriptine 95-108 prolactin Homo sapiens 0-9 9265916-4 1997 Olanzapine has a favorable acute and tardive extrapyramidal symptom profile relative to haloperidol and caused substantially less elevation of serum prolactin. Olanzapine 0-10 prolactin Homo sapiens 149-158 18638928-0 1997 Prolactin secreting pituitary tumours with marked visual field impairment should be treated by early surgical decompression versus treatment by bromocriptine. Bromocriptine 144-157 prolactin Homo sapiens 0-9 10887516-2 1997 The cytoplasmic domain of the prolactin receptor (PrlR) displays no enzymatic activity yet prolactin treatment leads to the induction of protein tyrosine phosphorylation. Tyrosine 145-153 prolactin Homo sapiens 30-39 9104733-0 1997 Elevated serum levels of cyclo (His-Pro), an endogenous inhibitor of pituitary prolactin secretion, in systemic lupus erythematosus patients. emodepside 25-30 prolactin Homo sapiens 79-88 9443523-1 1997 We studied the effect of the selective serotonin reuptake inhibitor (SSRI), paroxetine, on basal plasma prolactin concentrations in 11 healthy subjects. Paroxetine 76-86 prolactin Homo sapiens 104-113 9443523-3 1997 On each test occasion prolactin levels were sampled before and following administration of a placebo capsule, for a total of 4 h. After 3 weeks paroxetine treatment plasma prolactin levels were significantly higher than those seen either pre-treatment or after 1 week of treatment. Paroxetine 144-154 prolactin Homo sapiens 172-181 9443523-6 1997 The secretion of plasma prolactin is, in part, under the tonic regulation of serotonergic pathways and the present results therefore support animal experimental data suggesting that SSRIs produce a delayed increase in some aspects of brain serotonin neurotransmission. Serotonin 240-249 prolactin Homo sapiens 24-33 9286726-0 1997 Suppression of serum prolactin levels after an oral glucose tolerance test in patients with polycystic ovarian syndrome. Glucose 52-59 prolactin Homo sapiens 21-30 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. cyclic 28-34 prolactin Homo sapiens 139-142 9104733-0 1997 Elevated serum levels of cyclo (His-Pro), an endogenous inhibitor of pituitary prolactin secretion, in systemic lupus erythematosus patients. histidylproline 32-39 prolactin Homo sapiens 79-88 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. Dipeptides 35-44 prolactin Homo sapiens 128-137 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. Dipeptides 35-44 prolactin Homo sapiens 139-142 9126866-0 1997 Octylphenol (OP), an environmental estrogen, stimulates prolactin (PRL) gene expression. octylphenol 0-11 prolactin Homo sapiens 56-65 9126866-0 1997 Octylphenol (OP), an environmental estrogen, stimulates prolactin (PRL) gene expression. octylphenol 0-11 prolactin Homo sapiens 67-70 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. Histidine 7-10 prolactin Homo sapiens 128-137 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. Histidine 7-10 prolactin Homo sapiens 139-142 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. Proline 11-14 prolactin Homo sapiens 128-137 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. Proline 11-14 prolactin Homo sapiens 139-142 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. chp 19-22 prolactin Homo sapiens 128-137 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. chp 19-22 prolactin Homo sapiens 139-142 9104733-1 1997 Cyclo (His-Pro) or CHP is a cyclic dipeptide that is known to elicit many biologic activities including inhibition of pituitary prolactin (PRL) secretion. cyclic 28-34 prolactin Homo sapiens 128-137 9211435-6 1997 In contrast, dopamine-induced PRL decrement was significantly lighter in alcoholics than in controls. Dopamine 13-21 prolactin Homo sapiens 30-33 8943229-3 1996 Prolactin induces a signaling event which involves tyrosine phosphorylation of the mammary gland factor, Stat5, a member of the family of signal transducers and activators of transcription (Stat). Tyrosine 51-59 prolactin Homo sapiens 0-9 9039343-5 1996 These results closely correlated with the response of plasma PRL levels to the dopamine D2 receptor agonist quinagolide. quinagolide 108-119 prolactin Homo sapiens 61-64 8931912-0 1996 Prolactin response to low-dose dexamethasone challenge in combat-exposed veterans with and without posttraumatic stress disorder and normal controls. Dexamethasone 31-44 prolactin Homo sapiens 0-9 8931912-4 1996 These findings suggest that the prolactin response to dexamethasone may reflect a feature of combat exposure rather than PTSD per se. Dexamethasone 54-67 prolactin Homo sapiens 32-41 9014831-8 1996 Up-modulation of a 32S-methionine-labelled 27,000 MW protein was detected in the lysates and supernatants of IL-2-stimulated PBMC immunoprecipitated with an anti-PRL antiserum. 32s-methionine 19-33 prolactin Homo sapiens 162-165 21153074-0 1996 Prolactin gene expression in human myometrial smooth muscle cells is induced by cyclic adenosine 3",5"-monophosphate. Cyclic AMP 80-116 prolactin Homo sapiens 0-9 21153074-4 1996 PRL secretion could be further simulated by the addition of PGE(2) or relaxin, both of which were also shown to increase cAMP formation in smooth muscle cells. Prostaglandins E 60-63 prolactin Homo sapiens 0-3 21153074-4 1996 PRL secretion could be further simulated by the addition of PGE(2) or relaxin, both of which were also shown to increase cAMP formation in smooth muscle cells. Cyclic AMP 121-125 prolactin Homo sapiens 0-3 21153074-5 1996 Likewise, treatment with 8-Br-cAMP led to an elevation of PRL secretion. 8-Bromo Cyclic Adenosine Monophosphate 25-34 prolactin Homo sapiens 58-61 21153074-10 1996 In parallel with the increase in PRL secretion, we detected an increase in cAMP formation and PGE(2) secretion in cultured smooth muscle cells. Cyclic AMP 75-79 prolactin Homo sapiens 33-36 21153074-10 1996 In parallel with the increase in PRL secretion, we detected an increase in cAMP formation and PGE(2) secretion in cultured smooth muscle cells. Dinoprostone 94-100 prolactin Homo sapiens 33-36 9032565-0 1996 Nasal spray administration of bromocriptine: pharmacology and effect on serum prolactin level in puerperal women. Bromocriptine 30-43 prolactin Homo sapiens 78-87 9032565-1 1996 This study was aimed at investigating the absorption of nasally administered bromocriptine and its effect on serum prolactin level. Bromocriptine 77-90 prolactin Homo sapiens 115-124 9032565-4 1996 Serum bromocriptine levels increased rapidly after administration, reached a maximum at 120 min and thereafter declined slowly over the subsequent 10 h. As the bromocriptine level increased there was a decline in the serum prolactin level. Bromocriptine 160-173 prolactin Homo sapiens 223-232 9032565-8 1996 Correlation analysis between serum bromocriptine and prolactin concentrations yielded a significant negative value between times 0 and 120 min after administration. Bromocriptine 35-48 prolactin Homo sapiens 53-62 9032565-12 1996 In conclusion, nasal administration of 0.8 mg bromocriptine was effective in reducing the serum prolactin level for more than 12 h after administration without inducing significant side-effects. Bromocriptine 46-59 prolactin Homo sapiens 96-105 10979048-3 1996 On the other hand, hyperinsulinaemia and disorders in GH, PRL and cortisol release were associated with lower levels of reverse triiodothyronine, gonadotropins, testosterone, 17-corticoids and SHBG and higher levels of triiodothyronine, estradiol, 17-hydroxycorticoids and IGF-I. Triiodothyronine 128-144 prolactin Homo sapiens 58-61 10979048-3 1996 On the other hand, hyperinsulinaemia and disorders in GH, PRL and cortisol release were associated with lower levels of reverse triiodothyronine, gonadotropins, testosterone, 17-corticoids and SHBG and higher levels of triiodothyronine, estradiol, 17-hydroxycorticoids and IGF-I. Testosterone 161-173 prolactin Homo sapiens 58-61 10979048-3 1996 On the other hand, hyperinsulinaemia and disorders in GH, PRL and cortisol release were associated with lower levels of reverse triiodothyronine, gonadotropins, testosterone, 17-corticoids and SHBG and higher levels of triiodothyronine, estradiol, 17-hydroxycorticoids and IGF-I. 17-corticoids 175-188 prolactin Homo sapiens 58-61 10979048-3 1996 On the other hand, hyperinsulinaemia and disorders in GH, PRL and cortisol release were associated with lower levels of reverse triiodothyronine, gonadotropins, testosterone, 17-corticoids and SHBG and higher levels of triiodothyronine, estradiol, 17-hydroxycorticoids and IGF-I. Triiodothyronine 219-235 prolactin Homo sapiens 58-61 10979048-3 1996 On the other hand, hyperinsulinaemia and disorders in GH, PRL and cortisol release were associated with lower levels of reverse triiodothyronine, gonadotropins, testosterone, 17-corticoids and SHBG and higher levels of triiodothyronine, estradiol, 17-hydroxycorticoids and IGF-I. Estradiol 237-246 prolactin Homo sapiens 58-61 8946434-2 1996 Prolactin (PRL) responses to d- and d,l-fenfluramine were significantly greater than those to placebo and were equivalent at both dose levels. d- and d,l-fenfluramine 29-52 prolactin Homo sapiens 0-9 8946434-2 1996 Prolactin (PRL) responses to d- and d,l-fenfluramine were significantly greater than those to placebo and were equivalent at both dose levels. d- and d,l-fenfluramine 29-52 prolactin Homo sapiens 11-14 8946434-5 1996 PRL responses to d-fenfluramine were higher than the PRL response to d,l-fenfluramine at either dose level. Dexfenfluramine 17-31 prolactin Homo sapiens 0-3 8946434-5 1996 PRL responses to d-fenfluramine were higher than the PRL response to d,l-fenfluramine at either dose level. d,l-fenfluramine 69-85 prolactin Homo sapiens 53-56 8946434-6 1996 The PRL response to d-fenfluramine at 0.5 mg/kg was very highly correlated with the PRL responses to d,l-fenfluramine at 1.0 mg/kg (r = 0.97, n = 10). Dexfenfluramine 20-34 prolactin Homo sapiens 4-7 8946434-6 1996 The PRL response to d-fenfluramine at 0.5 mg/kg was very highly correlated with the PRL responses to d,l-fenfluramine at 1.0 mg/kg (r = 0.97, n = 10). Dexfenfluramine 20-34 prolactin Homo sapiens 84-87 8946434-6 1996 The PRL response to d-fenfluramine at 0.5 mg/kg was very highly correlated with the PRL responses to d,l-fenfluramine at 1.0 mg/kg (r = 0.97, n = 10). d,l-fenfluramine 101-117 prolactin Homo sapiens 4-7 8946434-6 1996 The PRL response to d-fenfluramine at 0.5 mg/kg was very highly correlated with the PRL responses to d,l-fenfluramine at 1.0 mg/kg (r = 0.97, n = 10). d,l-fenfluramine 101-117 prolactin Homo sapiens 84-87 8946434-9 1996 These data suggest that the PRL response evoked by d-fenfluramine is quantitatively very similar to that evoked by d,l-fenfluramine. Dexfenfluramine 51-65 prolactin Homo sapiens 28-31 8946434-9 1996 These data suggest that the PRL response evoked by d-fenfluramine is quantitatively very similar to that evoked by d,l-fenfluramine. d,l-fenfluramine 115-131 prolactin Homo sapiens 28-31 9055023-5 1996 This represents one of the highest serum prolactin levels reported in the literature in a patient with a prolactin-secreting pituitary tumour and illustrates the remarkable efficacy of dopamine agonist therapy in patients with large macroprolactinomas. Dopamine 185-193 prolactin Homo sapiens 41-50 9011126-8 1996 The results show that all of the three medicines cause elevation of prolactin level in serum, and sulpiride causes the highest elevation of prolactin level in this study. Sulpiride 98-107 prolactin Homo sapiens 140-149 8915564-0 1996 Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette"s syndrome. Haloperidol 24-35 prolactin Homo sapiens 0-9 8915564-0 1996 Prolactin monitoring of haloperidol and pimozide treatment in children with Tourette"s syndrome. Pimozide 40-48 prolactin Homo sapiens 0-9 8915564-6 1996 Prolactin may be a marker for tic response to pimozide, and conversely, a potential marker for haloperidol-related incidence of extrapyramidal symptoms during haloperidol therapy. Pimozide 46-54 prolactin Homo sapiens 0-9 8890681-0 1996 d-fenfluramine-induced prolactin responses in mania: evidence for serotonergic subsensitivity. Dexfenfluramine 0-14 prolactin Homo sapiens 23-32 8890681-8 1996 The plasma prolactin responses to d-fenfluramine of the bipolar manic subjects were significantly lower than those of the comparison subjects. Dexfenfluramine 34-48 prolactin Homo sapiens 11-20 9055023-5 1996 This represents one of the highest serum prolactin levels reported in the literature in a patient with a prolactin-secreting pituitary tumour and illustrates the remarkable efficacy of dopamine agonist therapy in patients with large macroprolactinomas. Dopamine 185-193 prolactin Homo sapiens 105-114 9010834-3 1996 The prolactin response to metoclopramide was blunted in hyperprolactinemic patients in comparison with controls. Metoclopramide 26-40 prolactin Homo sapiens 4-13 8977754-9 1996 The mean (+/- SD) serum PRL levels were 267 +/- 205 and 203 +/- 118 mU/l in the verapamil and control groups, respectively (P < 0.001, independent t-test). Verapamil 80-89 prolactin Homo sapiens 24-27 8973993-12 1996 Serum prolactin levels were inversely associated with the amount of dextroamphetamine administered, with the largest decrease in serum prolactin levels observed after the 5-mg dose, and this finding was statistically significant. Dextroamphetamine 68-85 prolactin Homo sapiens 6-15 8973993-12 1996 Serum prolactin levels were inversely associated with the amount of dextroamphetamine administered, with the largest decrease in serum prolactin levels observed after the 5-mg dose, and this finding was statistically significant. Dextroamphetamine 68-85 prolactin Homo sapiens 135-144 8973993-16 1996 Serum prolactin concentration was the most sensitive measure of central nervous system stimulation on EEG produced by dextroamphetamine under these study conditions. Dextroamphetamine 118-135 prolactin Homo sapiens 6-15 8931651-7 1996 The plasma glucose threshold required for stimulation of prolactin secretion was 2.2 +/- 0.1 mmol/L in well-controlled IDDM, 3.0 +/- 0.4 mmol/L in poorly controlled IDDM, and 2.4 +/- 0.1 mmol/L in healthy subjects (P < .05 between IDDM groups). Glucose 11-18 prolactin Homo sapiens 57-66 8931651-11 1996 In conclusion, prolactin and beta-endorphin responses to a standardized hypoglycemic stimulus (plasma glucose, 2.2 mmol/L) are reduced and plasma glucose levels required to stimulate release of prolactin and beta-endorphin are lower in well-controlled IDDM compared with poorly controlled IDDM and healthy subjects. Glucose 102-109 prolactin Homo sapiens 15-24 9010834-6 1996 for 5 days) in patients with prolactinoma completely suppressed the prolactin response to metoclopramide and the aldosterone response curve was very similar to that of controls. Metoclopramide 90-104 prolactin Homo sapiens 29-38 8931651-11 1996 In conclusion, prolactin and beta-endorphin responses to a standardized hypoglycemic stimulus (plasma glucose, 2.2 mmol/L) are reduced and plasma glucose levels required to stimulate release of prolactin and beta-endorphin are lower in well-controlled IDDM compared with poorly controlled IDDM and healthy subjects. Glucose 146-153 prolactin Homo sapiens 194-203 8889285-2 1996 Apomorphine did not change BP and HR but significantly decreased PRL plasma levels in controls as well as in the two groups of PD patients. Apomorphine 0-11 prolactin Homo sapiens 65-68 8944409-4 1996 Buspirone significantly elevated plasma prolactin (PRL) and growth hormone (GH) concentrations but had no significant effect on cortisol (CORT) or temperature. Buspirone 0-9 prolactin Homo sapiens 40-49 8912811-9 1996 Overall these findings do not support the possibility of direct effects of melatonin on the adult PD, and by implication they reinforce the view that the melatonin-responsive PT is an intermediary in the control of PRL secretion. Melatonin 154-163 prolactin Homo sapiens 215-218 8894070-2 1996 To evaluate central serotonergic function in Parkinson"s disease in relation to depression, we examined prolactin and cortisol responses to a single-dose challenge with fenfluramine (60 mg orally), a serotonin releasing/uptake-inhibiting agent, in the course of 5 hours in 11 patients with Parkinson"s disease associated with major depression (SADS-RDC), 22 nondepressed parkinsonians, and 20 age- and gender-matched healthy controls. Fenfluramine 169-181 prolactin Homo sapiens 104-113 8894070-3 1996 No difference in cortisol responses were observed between the groups; however, prolactin responses to fenfluramine were significantly impaired in patients with Parkinson"s disease compared to controls, and the response was significantly more blunted in parkinsonian patients with major depression in comparison with the nondepressed ones. Fenfluramine 102-114 prolactin Homo sapiens 79-88 8889285-6 1996 These results show that hypothalamic dopaminergic sensitivity (studied through GH and PRL responses to apomorphine) is normal in PD. Apomorphine 103-114 prolactin Homo sapiens 86-89 8921822-1 1996 Resistance to bromocriptine, defined as the absence of normalization of prolactin (PRL) levels despite a 15-30 mg daily dose of bromocriptine during at least 6 months, has been observed in 5-17% of the prolactinomas according to the literature. Bromocriptine 14-27 prolactin Homo sapiens 72-81 8921822-1 1996 Resistance to bromocriptine, defined as the absence of normalization of prolactin (PRL) levels despite a 15-30 mg daily dose of bromocriptine during at least 6 months, has been observed in 5-17% of the prolactinomas according to the literature. Bromocriptine 14-27 prolactin Homo sapiens 83-86 8921822-5 1996 Subsequently, after 1 year of 150-300 micrograms/day quinagolide, 12/28 patients of the present series recovered normal gonadal function and their initial mean baseline PRL value (404 +/- 180 micrograms/l) was 16 +/- 2 micrograms/l after 1 year of treatment. quinagolide 53-64 prolactin Homo sapiens 169-172 21153106-5 1996 Progesterone-dependent PRL-R and PRL expression were stimulated by 1 mu/M prostaglandin E(2). Dinoprostone 74-92 prolactin Homo sapiens 23-26 8921822-7 1996 During the 3-year follow-up period under quinagolide, a similar good control was achieved in these patients, with the exception of one man presenting with a secondary rise of PRL under quinagolide. quinagolide 185-196 prolactin Homo sapiens 175-178 8921822-12 1996 Three patients even presented, after 2 years of quinagolide treatment, with a secondary rise of PRL values associated with a further tumor growth in two patients. quinagolide 48-59 prolactin Homo sapiens 96-99 8816612-8 1996 RESULTS: Both in controls and in PCOS-affected women, cabergoline administration blunted plasma PRL levels without affecting LH pulsatility. Cabergoline 54-65 prolactin Homo sapiens 96-99 8904716-3 1996 Prolactin concentrations in plasma were increased by sexual stimulation (P < .01) and sulpiride (P < .001) administration and were decreased (P < .01) when bromocriptine was administered before sexual stimulation. Sulpiride 89-98 prolactin Homo sapiens 0-9 8904716-3 1996 Prolactin concentrations in plasma were increased by sexual stimulation (P < .01) and sulpiride (P < .001) administration and were decreased (P < .01) when bromocriptine was administered before sexual stimulation. Bromocriptine 165-178 prolactin Homo sapiens 0-9 9086498-7 1996 Serum PRL was higher both in male (GM: 8.90 ng/ml vs. 6.05 ng/ml; p < 0.01) and female (GM: 12.6 ng/ml vs. 9.33 ng/ml; p < 0.05) styrene-exposed workers as compared to their respective controls. gm 35-37 prolactin Homo sapiens 6-9 9080251-0 1996 Role of prolactin in the modulation of NK and LAK cell activity after short- or long-term morphine administration in neoplastic patients. Morphine 90-98 prolactin Homo sapiens 8-17 9080251-3 1996 An intravenous morphine injection (10 mg) significantly increased the plasma levels of PRL, reduced the cytotoxic activity of NK cells, and increased the development of LAK cell activity 30 min after drug injection in neoplastic patients. Morphine 15-23 prolactin Homo sapiens 87-90 9080251-4 1996 The administration of bromocriptine before the injection of morphine prevented both PRL augmentation and the increase in LAK cell activation, although it did not prevent the inhibition of NK cytotoxicity. Bromocriptine 22-35 prolactin Homo sapiens 84-87 9080251-5 1996 The chronic oral administration of morphine (90 +/- 30 mg/day for 1 month) also resulted in higher PRL levels; the NK and LAK cell activities were, respectively, lower than or higher than those found in neoplastic patients untreated with morphine. Morphine 35-43 prolactin Homo sapiens 99-102 9080251-10 1996 The effect of morphine on LAK cell activation but not on NK cell reduction is related to the modulation of PRL levels determined by the opioid drug. Morphine 14-22 prolactin Homo sapiens 107-110 8914150-0 1996 [Seizures as a late complication of bromocriptine therapy in patients with prolactin-producing macroadenomas: correlation between lateral extension of the adenoma and seizure onset]. Bromocriptine 36-49 prolactin Homo sapiens 75-84 9086498-7 1996 Serum PRL was higher both in male (GM: 8.90 ng/ml vs. 6.05 ng/ml; p < 0.01) and female (GM: 12.6 ng/ml vs. 9.33 ng/ml; p < 0.05) styrene-exposed workers as compared to their respective controls. gm 91-93 prolactin Homo sapiens 6-9 9086498-7 1996 Serum PRL was higher both in male (GM: 8.90 ng/ml vs. 6.05 ng/ml; p < 0.01) and female (GM: 12.6 ng/ml vs. 9.33 ng/ml; p < 0.05) styrene-exposed workers as compared to their respective controls. Styrene 135-142 prolactin Homo sapiens 6-9 9086498-8 1996 Dose-response relationships were found for abnormally low DBH and abnormally high PRL values, with a threshold occurring at metabolite levels corresponding to 8h-TWA styrene concentrations in air around 25 ppm. Styrene 166-173 prolactin Homo sapiens 82-85 9086498-9 1996 In summary, this study shows that long-term exposure to relatively low levels of styrene can affect DBH activity and basal serum PRL. Styrene 81-88 prolactin Homo sapiens 129-132 8906007-0 1996 Nasal spray bromocriptine: effects on serum prolactin in puerperal women. Bromocriptine 12-25 prolactin Homo sapiens 44-53 8808687-6 1996 We also showed a rapid and transient tyrosine phosphorylation of STAT5 in proliferating T47D cells which reached its peak after 30 min of Prl treatment. Tyrosine 37-45 prolactin Homo sapiens 138-141 9239689-2 1996 In this study, the mechanisms of the in-vitro effects of human prolactin (hPRL) on human follicle stimulating hormone (hFSH)-induced aromatase activity were determined using cultured granulosa cells from diethylstilboestrol (DES)-primed immature rats. diethylstilboestrol 204-223 prolactin Homo sapiens 63-72 9239689-2 1996 In this study, the mechanisms of the in-vitro effects of human prolactin (hPRL) on human follicle stimulating hormone (hFSH)-induced aromatase activity were determined using cultured granulosa cells from diethylstilboestrol (DES)-primed immature rats. diethylstilboestrol 204-223 prolactin Homo sapiens 74-78 9239689-2 1996 In this study, the mechanisms of the in-vitro effects of human prolactin (hPRL) on human follicle stimulating hormone (hFSH)-induced aromatase activity were determined using cultured granulosa cells from diethylstilboestrol (DES)-primed immature rats. desacetyluvaricin 225-228 prolactin Homo sapiens 63-72 9239689-2 1996 In this study, the mechanisms of the in-vitro effects of human prolactin (hPRL) on human follicle stimulating hormone (hFSH)-induced aromatase activity were determined using cultured granulosa cells from diethylstilboestrol (DES)-primed immature rats. desacetyluvaricin 225-228 prolactin Homo sapiens 74-78 9239689-3 1996 Human PRL caused a dose-dependent decrease in hFSH-induced 17 beta-oestradiol production, even when cells were cultured in the presence of a cAMP analogue (8-Br-cAMP). Estradiol 59-77 prolactin Homo sapiens 6-9 9239689-3 1996 Human PRL caused a dose-dependent decrease in hFSH-induced 17 beta-oestradiol production, even when cells were cultured in the presence of a cAMP analogue (8-Br-cAMP). Cyclic AMP 141-145 prolactin Homo sapiens 6-9 9239689-3 1996 Human PRL caused a dose-dependent decrease in hFSH-induced 17 beta-oestradiol production, even when cells were cultured in the presence of a cAMP analogue (8-Br-cAMP). 8-Bromo Cyclic Adenosine Monophosphate 156-165 prolactin Homo sapiens 6-9 9239689-6 1996 The results showed that addition of genistein or staurosporine (a tyrosine kinase and protein kinase-C antagonist respectively) to cultured granulosa cells resulted in potent inhibition of hPRL actions upon hFSH-induced aromatization in a dose-dependent manner. Genistein 36-45 prolactin Homo sapiens 189-193 9239689-6 1996 The results showed that addition of genistein or staurosporine (a tyrosine kinase and protein kinase-C antagonist respectively) to cultured granulosa cells resulted in potent inhibition of hPRL actions upon hFSH-induced aromatization in a dose-dependent manner. Staurosporine 49-62 prolactin Homo sapiens 189-193 8853619-0 1996 Gender differences in the prolactin response to fenfluramine challenge in children with disruptive behavior disorders. Fenfluramine 48-60 prolactin Homo sapiens 26-35 8906007-1 1996 BACKGROUND: The objective of this study was to investigate the effectiveness of a single nasal spray administration of 0.8 mg bromocriptine in reducing PRL serum levels. Bromocriptine 126-139 prolactin Homo sapiens 152-155 8906007-3 1996 RESULTS: After the administration of bromocriptine serum levels of PRL decreased rapidly; the reduction was statistically significant after 45 minutes. Bromocriptine 37-50 prolactin Homo sapiens 67-70 9414453-5 1996 These data in conjunction with physiological studies, which show that photoperiodically driven cycles in prolactin secretion can occur in the absence of an intact hypothalamic-pituitary axis, suggest that the function of the pars tuberalis is to act as an endocrine intermediate in the photoperiodic effects of melatonin on prolactin secretion. Melatonin 311-320 prolactin Homo sapiens 105-114 15251513-3 1996 RESULTS: In patients with prolactinomas, medical therapy with a dopamine agonist constitutes the primary treatment and is usually associated with normalization of prolactin levels, tumor shrinkage, and resolution of clinical symptoms. Dopamine 64-72 prolactin Homo sapiens 26-35 8918686-12 1996 Both cortisol and prolactin were elevated following capture and injection of saline or a dopaminergic receptor antagonist, indicating that prolactin does respond to acute stress. Sodium Chloride 77-83 prolactin Homo sapiens 18-27 8918686-12 1996 Both cortisol and prolactin were elevated following capture and injection of saline or a dopaminergic receptor antagonist, indicating that prolactin does respond to acute stress. Sodium Chloride 77-83 prolactin Homo sapiens 139-148 8897119-1 1996 OBJECTIVE: The objective of our study was to explore the effect of dexamethasone (DEX), a highly potent, long-acting glucocorticoid, on the treatment outcome of 74 anovulatory women aged 21 to 29 years, with normal gonadotropins, androgen, and prolactin (PRL) serum levels who failed to conceive on antiestrogen therapy. Dexamethasone 82-85 prolactin Homo sapiens 244-253 8888375-1 1996 Prolactin responses to d-fenfluramine (d-FEN) challenge (0.5 mg/kg PO) were examined after pre-treatment with and without the 5-HT3 receptor antagonist ondansetron (16 mg PO) in 11 physically healthy male volunteers. Dexfenfluramine 23-37 prolactin Homo sapiens 0-9 8888375-1 1996 Prolactin responses to d-fenfluramine (d-FEN) challenge (0.5 mg/kg PO) were examined after pre-treatment with and without the 5-HT3 receptor antagonist ondansetron (16 mg PO) in 11 physically healthy male volunteers. Dexfenfluramine 39-44 prolactin Homo sapiens 0-9 9414453-7 1996 On the basis of these physiological and biochemical studies, a hypothetical model is proposed to account for the mechanism of photoperiodic regulation of prolactin secretion by melatonin. Melatonin 177-186 prolactin Homo sapiens 154-163 9122001-0 1996 [Effects of opiate receptor blockade with naloxone on prolactin (PRL) secretion in patients with diabetes type I (IDDM) with chronic renal failure treated with hemodialysis (HD)]. Naloxone 42-50 prolactin Homo sapiens 54-63 8830948-1 1996 Prolactin (PRL) responses to acute challenge with the serotonin (5-HT) releaser/uptake inhibitor, d-fenfluramine (PRL[d-FEN]), were correlated with three different measures of aggression in 14 male personality-disordered subjects. Serotonin 54-63 prolactin Homo sapiens 0-9 8830948-1 1996 Prolactin (PRL) responses to acute challenge with the serotonin (5-HT) releaser/uptake inhibitor, d-fenfluramine (PRL[d-FEN]), were correlated with three different measures of aggression in 14 male personality-disordered subjects. Serotonin 54-63 prolactin Homo sapiens 11-14 8830948-1 1996 Prolactin (PRL) responses to acute challenge with the serotonin (5-HT) releaser/uptake inhibitor, d-fenfluramine (PRL[d-FEN]), were correlated with three different measures of aggression in 14 male personality-disordered subjects. Dexfenfluramine 98-112 prolactin Homo sapiens 0-9 8830948-1 1996 Prolactin (PRL) responses to acute challenge with the serotonin (5-HT) releaser/uptake inhibitor, d-fenfluramine (PRL[d-FEN]), were correlated with three different measures of aggression in 14 male personality-disordered subjects. Dexfenfluramine 98-112 prolactin Homo sapiens 11-14 8830948-1 1996 Prolactin (PRL) responses to acute challenge with the serotonin (5-HT) releaser/uptake inhibitor, d-fenfluramine (PRL[d-FEN]), were correlated with three different measures of aggression in 14 male personality-disordered subjects. Dexfenfluramine 98-112 prolactin Homo sapiens 114-117 8828835-1 1996 This study determined effects of treatment with the endogenous opioid peptide (EOP) antagonist naloxone on LH and prolactin (PRL) secretion in late gestation, as well as possible relationships between LH and progesterone secretion. Naloxone 95-103 prolactin Homo sapiens 114-123 8930531-2 1996 35S-labeled PRLs produced by the cells were immunoprecipitated with anti-human PRL antiserum, and the ratios of G-PRL to total PRL were compared. Sulfur-35 0-3 prolactin Homo sapiens 12-15 8930531-2 1996 35S-labeled PRLs produced by the cells were immunoprecipitated with anti-human PRL antiserum, and the ratios of G-PRL to total PRL were compared. Sulfur-35 0-3 prolactin Homo sapiens 79-82 8930531-2 1996 35S-labeled PRLs produced by the cells were immunoprecipitated with anti-human PRL antiserum, and the ratios of G-PRL to total PRL were compared. Sulfur-35 0-3 prolactin Homo sapiens 79-82 8880220-0 1996 Recombinant human prolactin induces protection against Salmonella typhimurium infection in the mouse: role of nitric oxide. Nitric Oxide 110-122 prolactin Homo sapiens 18-27 9122001-10 1996 3) TRH and TRH with naloxone caused significant increase of prolactin secretion in all investigated groups, but the increase is significantly lower in chronic renal failure patients than in healthy subjects. Naloxone 20-28 prolactin Homo sapiens 60-69 9122001-11 1996 4) Naloxone decreases significantly the prolactin secretion during TRH test only in haemodialyzed patients with chronic renal failure of non-diabetic etiology. Naloxone 3-11 prolactin Homo sapiens 40-49 8844112-7 1996 The other three patients were diagnosed as having pituitary microadenomas and received bromocriptine treatment; the serum prolactin levels normalized within 1 month. Bromocriptine 87-100 prolactin Homo sapiens 122-131 8843016-4 1996 Melatonin is thought to act through hypothalamic sites to control the gonadotrophic axis (4-6), but the sites through which melatonin modulates prolactin remain to be established. Melatonin 124-133 prolactin Homo sapiens 144-153 8712744-9 1996 The maximum PRL level in the NC and the PD group was higher than that in the PR group (p < 0.05, p < 0.01, respectively). Palladium 40-42 prolactin Homo sapiens 12-15 8884536-0 1996 Nasal spray vs oral administration of bromocriptine: pharmacology and effect on serum prolactin in puerperal women. Bromocriptine 38-51 prolactin Homo sapiens 86-95 8770934-3 1996 Both the short and the long PRL receptor proteins were detected in DP and LP by Western blot analysis and cross-linking of [125I]human PRL to membrane preparations of DP and LP. dp 67-69 prolactin Homo sapiens 28-31 8770934-3 1996 Both the short and the long PRL receptor proteins were detected in DP and LP by Western blot analysis and cross-linking of [125I]human PRL to membrane preparations of DP and LP. dp 167-169 prolactin Homo sapiens 28-31 8770934-8 1996 Furthermore, the hormonal responses of the different mRNA splicing variants of the long PRL receptor were not all similar; T, E, and PRL each increased the expression of 1.3- to 1.7-kb and 9.5- to 10-kb transcripts in DP, but only T did so in LP, whereas no clear regulation for the 2.5-kb mRNA could be observed in either tissue. dp 218-220 prolactin Homo sapiens 88-91 21584119-6 1996 Status of prolactin - dopamine relationship and its correlation to neuro - cognition may be another pointer in guiding some of these complex issues. Dopamine 22-30 prolactin Homo sapiens 10-19 8843016-5 1996 One possibility is that melatonin acts at the level of the hypothalamus to modulate the release of the hypothalamic prolactin inhibitory factor, dopamine (7). Melatonin 24-33 prolactin Homo sapiens 116-125 8843016-5 1996 One possibility is that melatonin acts at the level of the hypothalamus to modulate the release of the hypothalamic prolactin inhibitory factor, dopamine (7). Dopamine 145-153 prolactin Homo sapiens 116-125 8843016-6 1996 However, recent evidence from hypothalamo-pituitary disconnection experiments performed in the ram suggests that the photoperiodic modulation of prolactin secretion can occur independently of the hypothalamus, presumably due to direct effects of melatonin on the anterior pituitary (8). Melatonin 246-255 prolactin Homo sapiens 145-154 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Dopamine 61-69 prolactin Homo sapiens 0-9 8853213-0 1996 5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects. Dexfenfluramine 81-95 prolactin Homo sapiens 59-68 8853213-1 1996 Prolactin responses to d-fenfluramine (d-FEN) challenge (0.5 mg/kg PO) were examined after pre-treatment with and without the 5-HT2a/2c receptor antagonist amesergide in eight physically healthy male volunteers. Dexfenfluramine 23-37 prolactin Homo sapiens 0-9 8853213-1 1996 Prolactin responses to d-fenfluramine (d-FEN) challenge (0.5 mg/kg PO) were examined after pre-treatment with and without the 5-HT2a/2c receptor antagonist amesergide in eight physically healthy male volunteers. Dexfenfluramine 39-44 prolactin Homo sapiens 0-9 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Dopamine 61-69 prolactin Homo sapiens 11-14 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Dopamine 71-73 prolactin Homo sapiens 0-9 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Dopamine 71-73 prolactin Homo sapiens 11-14 8853213-2 1996 Compared to pretreatment with placebo, pre-treatment with amesergide completely blocked the prolactin (PRL) response to d-FEN challenge in all subjects. amesergide 58-68 prolactin Homo sapiens 92-101 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Norepinephrine 79-93 prolactin Homo sapiens 0-9 8853213-2 1996 Compared to pretreatment with placebo, pre-treatment with amesergide completely blocked the prolactin (PRL) response to d-FEN challenge in all subjects. amesergide 58-68 prolactin Homo sapiens 103-106 8853213-2 1996 Compared to pretreatment with placebo, pre-treatment with amesergide completely blocked the prolactin (PRL) response to d-FEN challenge in all subjects. Dexfenfluramine 120-125 prolactin Homo sapiens 92-101 8853213-2 1996 Compared to pretreatment with placebo, pre-treatment with amesergide completely blocked the prolactin (PRL) response to d-FEN challenge in all subjects. Dexfenfluramine 120-125 prolactin Homo sapiens 103-106 8888369-1 1996 Prolactin (PRL) and melatonin (ML) secretion are mediated by dopamine (DA) and norepinephrine (NE), respectively. Norepinephrine 79-93 prolactin Homo sapiens 11-14 8888369-15 1996 The pre and post AMPT-induced changes in 6-MS are not gender dependent, dissimilar to the AMPT-induced changes in PRL secretion. alpha-Methyltyrosine 90-94 prolactin Homo sapiens 114-117 8752665-3 1996 Medroxyprogesterone acetate and estradiol (E2) had no effect on PRL release, but prostaglandin E2 (PGE2) reduced the time required for PRL induction to 6-9 days. Dinoprostone 81-97 prolactin Homo sapiens 135-138 8881162-4 1996 Treatment modalities include dopamine agonist therapy such as bromocriptine which allows normalization of prolactin levels, restoration of gonadal functions and tumor shrinkage in most cases. Dopamine 29-37 prolactin Homo sapiens 106-115 8881162-4 1996 Treatment modalities include dopamine agonist therapy such as bromocriptine which allows normalization of prolactin levels, restoration of gonadal functions and tumor shrinkage in most cases. Bromocriptine 62-75 prolactin Homo sapiens 106-115 8736617-14 1996 Bromocriptine, the most common drug used in this condition, is a semisynthetic ergot alkaloid that directly stimulates specific pituitary cell membrane dopamine D2 receptors and inhibits prolactin synthesis and secretion. Bromocriptine 0-13 prolactin Homo sapiens 187-196 8736617-14 1996 Bromocriptine, the most common drug used in this condition, is a semisynthetic ergot alkaloid that directly stimulates specific pituitary cell membrane dopamine D2 receptors and inhibits prolactin synthesis and secretion. Ergot Alkaloids 79-93 prolactin Homo sapiens 187-196 8964874-0 1996 Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Dopamine 68-76 prolactin Homo sapiens 13-22 8964874-0 1996 Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. Cabergoline 85-96 prolactin Homo sapiens 13-22 8662911-3 1996 In an earlier alanine-scanning mutational study, we identified three major binding determinants in loop 1 of human PRL (hPRL) (Goffin, V., Norman, M. & Martial, J. Alanine 14-21 prolactin Homo sapiens 115-118 8662911-3 1996 In an earlier alanine-scanning mutational study, we identified three major binding determinants in loop 1 of human PRL (hPRL) (Goffin, V., Norman, M. & Martial, J. Alanine 14-21 prolactin Homo sapiens 120-124 8641169-2 1996 Biochemical differentiation of this cell line has been demonstrated by the ability of a decidualizing stimulus, 8-bromo-cAMP plus medroxyprogesterone acetate (MPA), to induce PRL secretion and increase the enzymatic activity of estrone sulfatase. 8-Bromo Cyclic Adenosine Monophosphate 112-124 prolactin Homo sapiens 175-178 8641169-2 1996 Biochemical differentiation of this cell line has been demonstrated by the ability of a decidualizing stimulus, 8-bromo-cAMP plus medroxyprogesterone acetate (MPA), to induce PRL secretion and increase the enzymatic activity of estrone sulfatase. Medroxyprogesterone Acetate 130-157 prolactin Homo sapiens 175-178 8641169-2 1996 Biochemical differentiation of this cell line has been demonstrated by the ability of a decidualizing stimulus, 8-bromo-cAMP plus medroxyprogesterone acetate (MPA), to induce PRL secretion and increase the enzymatic activity of estrone sulfatase. Medroxyprogesterone Acetate 159-162 prolactin Homo sapiens 175-178 8641169-3 1996 MPA, alone or in combination with estradiol, was unable to elicit this response, but potentiated the effect of 8-bromo-cAMP on PRL production and estrone sulfatase activity. 8-Bromo Cyclic Adenosine Monophosphate 111-123 prolactin Homo sapiens 127-130 8641169-7 1996 Transient transfection of a reporter construct containing 3000 bp of DNA 5" to the decidual-specific promoter of the human PRL gene demonstrated that cAMP was capable of activating this distal promoter in St-2 cells. Cyclic AMP 150-154 prolactin Homo sapiens 123-126 8752665-3 1996 Medroxyprogesterone acetate and estradiol (E2) had no effect on PRL release, but prostaglandin E2 (PGE2) reduced the time required for PRL induction to 6-9 days. Dinoprostone 99-103 prolactin Homo sapiens 135-138 8752665-5 1996 Dibutyryl-cyclic AMP, a second messenger in prostaglandin signal transduction, was also synergistic with medroxyprogesterone acetate and E2, but induced significant PRL expression in the absence of the steroids (28 and 12 ng/72 h, respectively). Bucladesine 0-20 prolactin Homo sapiens 165-168 8752665-6 1996 The increase in PRL release was not a result of increased cell proliferation, because the PRL-secreting cultures had 32.2 +/- 8.8% less DNA (N = 3 individuals, 93% confidence limit) than control cultures after 3 weeks of treatment with dibutyryl-cyclic AMP, medroxyprogesterone acetate, and E2. Bucladesine 236-256 prolactin Homo sapiens 16-19 8752665-6 1996 The increase in PRL release was not a result of increased cell proliferation, because the PRL-secreting cultures had 32.2 +/- 8.8% less DNA (N = 3 individuals, 93% confidence limit) than control cultures after 3 weeks of treatment with dibutyryl-cyclic AMP, medroxyprogesterone acetate, and E2. Bucladesine 236-256 prolactin Homo sapiens 90-93 8752665-6 1996 The increase in PRL release was not a result of increased cell proliferation, because the PRL-secreting cultures had 32.2 +/- 8.8% less DNA (N = 3 individuals, 93% confidence limit) than control cultures after 3 weeks of treatment with dibutyryl-cyclic AMP, medroxyprogesterone acetate, and E2. Medroxyprogesterone Acetate 258-285 prolactin Homo sapiens 90-93 8703557-10 1996 Preoperative bromocriptine therapy proved effective in reducing tumor size and serum PRL levels, but had no effect on the MIB-1 positive rate. Bromocriptine 13-26 prolactin Homo sapiens 85-88 8731516-1 1996 The plasma prolactin response to a single-dose fenfluramine challenge is increasingly utilized in psychiatric research as an indirect and noninvasive measure of central serotonergic activity. Fenfluramine 47-59 prolactin Homo sapiens 11-20 8803308-2 1996 Because of its central dopamine antagonist property, it can be a potent stimulant of prolactin release and cause extrapyramidal movement disorders. Dopamine 23-31 prolactin Homo sapiens 85-94 8803308-6 1996 Prolactin level mildly elevated during metoclopramide treatment. Metoclopramide 39-53 prolactin Homo sapiens 0-9 8803308-8 1996 The characters of these adverse effects of metoclopramide and the prolactin levels of long-term metoclopramide treatment will be discussed. Metoclopramide 96-110 prolactin Homo sapiens 66-75 8731516-9 1996 We conclude that fenfluramine challenge results should be reported as change in plasma prolactin relative to dose, and that in nonpatient samples the test is associated with frequent side effects. Fenfluramine 17-29 prolactin Homo sapiens 87-96 8728009-9 1996 Combinations (10 ng/mL each hormone) of GH and IGF-I or PRL and IGF-I increased progesterone secretion by LLC compared with control, GH, PRL, or IGF-I alone (P < .05). Progesterone 80-92 prolactin Homo sapiens 56-59 8796337-3 1996 The TSH response to domperidone was significantly elevated in patients with PES and either normal or elevated PRL, as in patients with prolactinoma. Domperidone 20-31 prolactin Homo sapiens 110-113 8796337-4 1996 The PRL response to domperidone was significantly reduced in patients with PES and hyperprolactinemia as in patients with prolactionoma. Domperidone 20-31 prolactin Homo sapiens 4-7 8630038-1 1996 In the present studies, using anti-phosphotyrosine (PY20) and PI3-kinase (p85) antibodies, we have shown that PRL causes activation of phosphatidyl inositol 3-kinase (PI3-kinase) in vitro in a dose- and time-dependent manner in Nb2 cells. Phosphotyrosine 35-50 prolactin Homo sapiens 110-113 8630038-2 1996 PRL activated PI3-kinase was completely inhibited by LY294002 (1 microgram/ml). 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one 53-61 prolactin Homo sapiens 0-3 8630038-3 1996 Stimulation of the cells with PRL also increased tyrosine phosphorylation of the 85-kDa regulatory subunit. Tyrosine 49-57 prolactin Homo sapiens 30-33 8625908-6 1996 We found that alpha subunit acted synergistically with progesterone (P) to induce more rapid decidualization with higher output (2- to 6-fold) of PRL and IGFBP-1, compared with P alone (P < 0.01). Progesterone 55-67 prolactin Homo sapiens 146-149 8701791-0 1996 Prolactin response to metoclopramide and thyrotropin-releasing hormone in normoprolactinemic and hyperprolactinemic women: a comparison of diagnostic validity. Metoclopramide 22-36 prolactin Homo sapiens 0-9 8701791-1 1996 The objective was to define the diagnostic validity of prolactin response tests by comparing the stimulating effect of thyrotropin-releasing hormone (TRH) and metoclopramide on prolactin secretion in patients with and without functional hyperprolactinemia. Metoclopramide 159-173 prolactin Homo sapiens 55-64 8701791-1 1996 The objective was to define the diagnostic validity of prolactin response tests by comparing the stimulating effect of thyrotropin-releasing hormone (TRH) and metoclopramide on prolactin secretion in patients with and without functional hyperprolactinemia. Metoclopramide 159-173 prolactin Homo sapiens 177-186 8701791-4 1996 After metoclopramide, higher maximal prolactin levels were observed in the study group as well as in the control group than after TRH (metoclopramide mean: 243 +/- 62 ng/ml vs. 181 +/- 100 ng/ml, U-test: p = 0.0019; TRH mean: 101 +/- 23 ng/ml vs. 41 +/- 20 ng/ml, U-test: p = 0.0001). Metoclopramide 6-20 prolactin Homo sapiens 37-46 8701791-7 1996 While significantly higher prolactin peaks were recorded after metoclopramide than after TRH in both groups, no difference in the response to TRH and metoclopramide, regarding absolute and relative increment, could be found. Metoclopramide 63-77 prolactin Homo sapiens 27-36 8796337-1 1996 The aim of this study was to investigate TSH and PRL response to TRH and domperidone, an antidopaminergic drug which does not cross the blood-brain barrier, in 16 patients with primary empty sella (PES) and either normal or elevated plasma PRL level and to compare it with the response observed in 8 patients with prolactinoma. Domperidone 73-84 prolactin Homo sapiens 49-52 8796337-2 1996 In the patients with PES and hyperprolactinemia, the PRL response to TRH was significantly lower than in the controls and the patients with PES and normal PRL, which suggests there is impaired PRL synthesis and release in cases of PES with hyperprolactinemia. polyether sulfone 21-24 prolactin Homo sapiens 53-56 8796337-2 1996 In the patients with PES and hyperprolactinemia, the PRL response to TRH was significantly lower than in the controls and the patients with PES and normal PRL, which suggests there is impaired PRL synthesis and release in cases of PES with hyperprolactinemia. polyether sulfone 21-24 prolactin Homo sapiens 155-158 8796337-2 1996 In the patients with PES and hyperprolactinemia, the PRL response to TRH was significantly lower than in the controls and the patients with PES and normal PRL, which suggests there is impaired PRL synthesis and release in cases of PES with hyperprolactinemia. polyether sulfone 21-24 prolactin Homo sapiens 155-158 8739113-3 1996 AN patients had blunted prolactin (PRL) responses to both m-CPP and L-TRP at low-weight and at goal-weight in comparison to controls, although there was a tendency toward normalization with weight gain. Tryptophan 68-73 prolactin Homo sapiens 24-33 8728009-6 1996 Growth hormone, PRL, and IGF-I increased (P < .05; 100 ng/mL dose) concentrations of progesterone in media of LLC. Progesterone 88-100 prolactin Homo sapiens 16-19 8728009-11 1996 Conclusions are that GH and PRL are stimulatory to progesterone secretion by LLC (location of GH receptor) and SLC are responsive to LH during mid-pregnancy. Luteinizing Hormone 133-135 prolactin Homo sapiens 28-31 8728009-12 1996 Both GH and PRL are synergistic with IGF-I for increased progesterone secretion. Progesterone 57-69 prolactin Homo sapiens 12-15 8901020-0 1996 The sigma receptor ligand rimcazole alters secretion of prolactin and alpha-melanocyte stimulating hormone by dopaminergic and non-dopaminergic mechanisms. rimcazole 26-35 prolactin Homo sapiens 56-65 8676055-4 1996 The intravenous injection of NMA into cycling ewes resulted in an immediate (within 15 min) release of a pulse of LH and of GH and a prolonged (up to 1 h) suppression of prolactin secretion. nma 29-32 prolactin Homo sapiens 170-179 8862501-0 1996 Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity. Bromocriptine 10-23 prolactin Homo sapiens 55-64 8862501-0 1996 Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity. Arginine 78-86 prolactin Homo sapiens 55-64 8862501-10 1996 Our results show that in obese patients the acute activation of dopaminergic receptors by bromocriptine fails to modify both basal and ARG-induced insulin release, while inhibits spontaneous and stimulated PRL secretion. Bromocriptine 90-103 prolactin Homo sapiens 206-209 8739554-0 1996 Paroxetine treatment and the prolactin response to sumatriptan. Sumatriptan 51-62 prolactin Homo sapiens 29-38 8739554-2 1996 Compared to placebo injection, sumatriptan lowered plasma prolactin and oral temperature and increased diastolic blood pressure. Sumatriptan 31-42 prolactin Homo sapiens 58-67 8739554-3 1996 While paroxetine increased baseline prolactin concentration, it had no effect on any of the responses to sumatriptan. Paroxetine 6-16 prolactin Homo sapiens 36-45 8740053-3 1996 This study investigated the relationship between receptor occupancy and plasma prolactin levels in 12 male patients treated with haloperidol, benperidol or clozapine. Haloperidol 129-140 prolactin Homo sapiens 79-88 8740053-3 1996 This study investigated the relationship between receptor occupancy and plasma prolactin levels in 12 male patients treated with haloperidol, benperidol or clozapine. Benperidol 142-152 prolactin Homo sapiens 79-88 8740053-3 1996 This study investigated the relationship between receptor occupancy and plasma prolactin levels in 12 male patients treated with haloperidol, benperidol or clozapine. Clozapine 156-165 prolactin Homo sapiens 79-88 8737372-3 1996 On the other hand, tyrosine phosphorylation analysis and electrophoretic mobility shift assays showed that receptor mutant G328, which lacks four of the five conserved cytoplasmic tyrosine residues of PRL receptors, retained the ability to activate JAK2 and STAT1, STAT3 and STAT5. Tyrosine 180-188 prolactin Homo sapiens 201-204 8901020-1 1996 The role of tuberoinfundibular and periventricular-hypophysial dopaminergic neurons in mediating rimcazole-induced decreases in plasma concentrations of prolactin and alpha-melanocyte stimulating hormone was assessed. rimcazole 97-106 prolactin Homo sapiens 153-162 8901020-3 1996 Rimcazole decreased plasma concentrations of both prolactin and alpha-melanocyte stimulating hormone, increased the concentration of DOPAC in median eminence, but did not alter DOPAC concentrations in the intermediate lobe of the pituitary. rimcazole 0-9 prolactin Homo sapiens 50-59 8901020-4 1996 Pretreatment with a "putative" sigma receptor agonist, pentazocine, prevented the rimcazole-induced increase of the concentration of DOPAC in the median eminence, but did not block the ability of rimcazole to decrease plasma concentrations of prolactin. Pentazocine 55-66 prolactin Homo sapiens 243-252 8901020-5 1996 The results of this study reveal that the ability of rimcazole to decrease alpha-melanocyte stimulating hormone secretion is not mediated by a dopaminergic mechanism, whereas the ability of rimcazole to decrease prolactin secretion appears to be mediated by both dopaminergic and non-dopaminergic mechanisms. rimcazole 190-199 prolactin Homo sapiens 212-221 8737233-5 1996 Plasma levels of prolactin were found to decrease after glucocorticoid, mineralocorticoid and bromocriptine therapy. Bromocriptine 94-107 prolactin Homo sapiens 17-26 9363201-2 1996 The present study was undertaken to examine the relationship of DCIP production to that of cell protein, prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1). dcip 64-68 prolactin Homo sapiens 105-114 9363201-2 1996 The present study was undertaken to examine the relationship of DCIP production to that of cell protein, prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1). dcip 64-68 prolactin Homo sapiens 116-119 15251546-7 1996 Discontinuing the thioridazine therapy resulted in normalization of the serum PRL and resolution of the pituitary abnormality. Thioridazine 18-30 prolactin Homo sapiens 78-81 9238678-6 1996 RA treatment significantly (P < 0.05) suppressed prolactin and IGFBP-1 production associated with stromal cells decidualization. Tretinoin 0-2 prolactin Homo sapiens 52-61 9238678-12 1996 Addition of 50 microM dibutyryl cAMP to stromal cells treated with MPA and oestradiol only partially reversed the suppression of decidualization and prolactin release by RA. dibutyryl 22-31 prolactin Homo sapiens 149-158 9238678-12 1996 Addition of 50 microM dibutyryl cAMP to stromal cells treated with MPA and oestradiol only partially reversed the suppression of decidualization and prolactin release by RA. Cyclic AMP 32-36 prolactin Homo sapiens 149-158 9238678-12 1996 Addition of 50 microM dibutyryl cAMP to stromal cells treated with MPA and oestradiol only partially reversed the suppression of decidualization and prolactin release by RA. Medroxyprogesterone Acetate 67-70 prolactin Homo sapiens 149-158 9238678-12 1996 Addition of 50 microM dibutyryl cAMP to stromal cells treated with MPA and oestradiol only partially reversed the suppression of decidualization and prolactin release by RA. Estradiol 75-85 prolactin Homo sapiens 149-158 9238678-12 1996 Addition of 50 microM dibutyryl cAMP to stromal cells treated with MPA and oestradiol only partially reversed the suppression of decidualization and prolactin release by RA. Tretinoin 170-172 prolactin Homo sapiens 149-158 8833686-0 1996 Prolactin response to fenfluramine and suicide attempt lethality in major depression. Fenfluramine 22-34 prolactin Homo sapiens 0-9 8833686-3 1996 Fenfluramine challenge test outcome was defined as the maximum prolactin response in the five hours following fenfluramine. Fenfluramine 0-12 prolactin Homo sapiens 63-72 8833686-3 1996 Fenfluramine challenge test outcome was defined as the maximum prolactin response in the five hours following fenfluramine. Fenfluramine 110-122 prolactin Homo sapiens 63-72 8833686-4 1996 RESULTS: Patients with a history of a higher lethality suicide attempt had a significantly lower prolactin response to fenfluramine, even when controlling for cortisol, age, sex, weight, comorbid cluster B personality disorder, pharmacokinetic and menstrual cycle effects. Fenfluramine 119-131 prolactin Homo sapiens 97-106 8833655-2 1996 Human PRL bound (65)Zn++; the Scatchard analysis was convex up, and limited by the solubility of PRL, but at least 0.7 mole Zn++ bound per mole of PRL. Zinc 20-24 prolactin Homo sapiens 6-9 8833655-2 1996 Human PRL bound (65)Zn++; the Scatchard analysis was convex up, and limited by the solubility of PRL, but at least 0.7 mole Zn++ bound per mole of PRL. Zinc 124-128 prolactin Homo sapiens 6-9 8833655-3 1996 Binding of (65)Zn++ to H27A-PRL was greatly reduced. Zinc 15-19 prolactin Homo sapiens 28-31 8833655-4 1996 The biological activity in an Nb2 cell assay and the circular dichroism spectrum of wild type and H27A-PRL were similar, indicating the H27A mutant folded correctly, and the binding of Zn++ to the high affinity site is not essential for biological activity. Zinc 185-189 prolactin Homo sapiens 103-106 8833655-5 1996 Dynamic light scattering measurements indicated 10 and 20 mu M Zn++ caused some aggregation of both wild type and H27A-PRL. Zinc 63-67 prolactin Homo sapiens 119-122 8833655-6 1996 Sedimentation equilibrium analysis indicated that PRL is primarily a monomer in the absence of Zn++ and that there is increasing self-association in the presence of 5 and 10 mu M Zn++. Zinc 95-99 prolactin Homo sapiens 50-53 8833655-8 1996 Although human PRL binds Zn++ as human GH does, it differs in that the ability to bind Zn++ and to self-associate were decoupled in PRL. Zinc 25-29 prolactin Homo sapiens 15-18 8833655-8 1996 Although human PRL binds Zn++ as human GH does, it differs in that the ability to bind Zn++ and to self-associate were decoupled in PRL. Zinc 87-91 prolactin Homo sapiens 15-18 8833655-9 1996 Human PRL must have two types of interactions with Zn++; one is binding to a site involving histidine 27, and the other is weaker interactions that induce self-association of PRL. Zinc 51-55 prolactin Homo sapiens 6-9 8833655-9 1996 Human PRL must have two types of interactions with Zn++; one is binding to a site involving histidine 27, and the other is weaker interactions that induce self-association of PRL. Histidine 92-101 prolactin Homo sapiens 6-9 21153290-7 1996 Colchicine (1 muM) and taxol (1 muM) inhibited the basal PRL secretion by 38 and 44%, respectively. Colchicine 0-10 prolactin Homo sapiens 57-60 8852866-0 1996 Role of serotonin3 receptors in prolactin release induced by electroconvulsive therapy: a study with ondansetron. Ondansetron 101-112 prolactin Homo sapiens 32-41 8852866-1 1996 The effect of pretreatment with odansetron on prolactin (PRL) release induced by electroconvulsive therapy (ECT) was examined in 16 depressive patients in a double-blind, placebo-controlled crossover study. odansetron 32-42 prolactin Homo sapiens 46-55 8867898-0 1996 Production and characterization of biologically active Ala-Ser-(His)6-Ile-Glu-Gly-Arg-human prolactin (tag-hPRL) secreted in the periplasmic space of Escherichia coli. Ala-Ser 55-62 prolactin Homo sapiens 92-101 8867898-0 1996 Production and characterization of biologically active Ala-Ser-(His)6-Ile-Glu-Gly-Arg-human prolactin (tag-hPRL) secreted in the periplasmic space of Escherichia coli. Ala-Ser 55-62 prolactin Homo sapiens 107-111 8867898-1 1996 Human prolactin (hPRL) cDNA was obtained by screening of a pituitary cDNA library with a synthetic 21-mer oligonucleotide and with rat PRL cDNA. 21-mer oligonucleotide 99-121 prolactin Homo sapiens 17-21 8867898-4 1996 Expression in Escherichia coli led to secretion in the periplasmic space of a fully bioactive hPRL variant constituting authentic hPRL with a peptide tag, i.e. Ala-Ser-(His)6-Ile-Glu-Gly-Arg, at its N-terminal. Ala-Ser 160-167 prolactin Homo sapiens 94-98 8867898-4 1996 Expression in Escherichia coli led to secretion in the periplasmic space of a fully bioactive hPRL variant constituting authentic hPRL with a peptide tag, i.e. Ala-Ser-(His)6-Ile-Glu-Gly-Arg, at its N-terminal. Glutamic Acid 179-182 prolactin Homo sapiens 94-98 8867898-4 1996 Expression in Escherichia coli led to secretion in the periplasmic space of a fully bioactive hPRL variant constituting authentic hPRL with a peptide tag, i.e. Ala-Ser-(His)6-Ile-Glu-Gly-Arg, at its N-terminal. Glycine 183-186 prolactin Homo sapiens 94-98 8867898-4 1996 Expression in Escherichia coli led to secretion in the periplasmic space of a fully bioactive hPRL variant constituting authentic hPRL with a peptide tag, i.e. Ala-Ser-(His)6-Ile-Glu-Gly-Arg, at its N-terminal. Arginine 187-190 prolactin Homo sapiens 94-98 8867898-5 1996 This tag-hPRL could be rapidly and efficiently purified by metal-chelate affinity chromatography. Metals 59-64 prolactin Homo sapiens 9-13 8867898-6 1996 The correct processing and quality of tag-hPRL was monitored by SDS/PAGE, Western-blot analysis, immunoassay and Nb2-lymphoma-cell bioassay. Sodium Dodecyl Sulfate 64-67 prolactin Homo sapiens 42-46 8624588-0 1996 [The effect of diazepam and flumazenil on pulsatile secretion of prolactin and LH in women]. Diazepam 15-23 prolactin Homo sapiens 65-74 8624588-0 1996 [The effect of diazepam and flumazenil on pulsatile secretion of prolactin and LH in women]. Flumazenil 28-38 prolactin Homo sapiens 65-74 8624588-1 1996 The authors examined the effect of diazepam and flumazenil on prolactin and LH secretion in women. Flumazenil 48-58 prolactin Homo sapiens 62-71 8624588-7 1996 Diazepam caused in 3 of 4 women in the luteal phase of the cycle a significant rise of the prolactin secretion (p < 0.001), in the remaining women in the luteal phase and 3 women in the follicular stage a rise of prolactin was recorded but it did not reach statistical significance. Diazepam 0-8 prolactin Homo sapiens 91-100 8624588-7 1996 Diazepam caused in 3 of 4 women in the luteal phase of the cycle a significant rise of the prolactin secretion (p < 0.001), in the remaining women in the luteal phase and 3 women in the follicular stage a rise of prolactin was recorded but it did not reach statistical significance. Diazepam 0-8 prolactin Homo sapiens 216-225 8867520-5 1996 At the beginning of the study, basal hormonal levels were within normal limits, and levodopa administration induced a significant suppression in PRL and TSH levels (both p < 0.01)) and a significant increase in GH (p < 0.01). Levodopa 84-92 prolactin Homo sapiens 145-148 8867520-7 1996 Addition of terguride induced a significant suppression in basal PRL levels (p < 0.01), whereas levodopa-induced hormonal changes were unaffected. dironyl 12-21 prolactin Homo sapiens 65-68 8867520-9 1996 The strong additional prolactin-lowering effect of terguride indicates long-lasting dopaminergic effects, as is already known from hyperprolactinemic conditions. dironyl 51-60 prolactin Homo sapiens 22-31 21153290-7 1996 Colchicine (1 muM) and taxol (1 muM) inhibited the basal PRL secretion by 38 and 44%, respectively. Paclitaxel 23-28 prolactin Homo sapiens 57-60 21153290-8 1996 In addition, colchicine (1 muM) and taxol (1 muM) significantly inhibited TRH-stimulated PRL secretion. Colchicine 13-23 prolactin Homo sapiens 89-92 21153290-8 1996 In addition, colchicine (1 muM) and taxol (1 muM) significantly inhibited TRH-stimulated PRL secretion. Paclitaxel 36-41 prolactin Homo sapiens 89-92 21153290-9 1996 TRH-stimulated PRL secretion in control, colchicine-, and taxol-treated cells was 13.9, 9.1, and 6 ng/mL, respectively. Colchicine 41-51 prolactin Homo sapiens 15-18 21153290-9 1996 TRH-stimulated PRL secretion in control, colchicine-, and taxol-treated cells was 13.9, 9.1, and 6 ng/mL, respectively. Paclitaxel 58-63 prolactin Homo sapiens 15-18 8737186-6 1996 In prolactinoma patients, administration of metoclopramide induced a significant rise in plasma prolactin which, however, was significantly lower than the one displayed by controls. Metoclopramide 44-58 prolactin Homo sapiens 3-12 8737186-5 1996 Dopamine infusion, compared to saline, caused a significant prolactin decrease in all the three groups of subjects, without significant difference between micro- and macroprolactinoma patients. Dopamine 0-8 prolactin Homo sapiens 60-69 8566276-7 1996 RESULTS: A single vaginal dose of 0.5 mg cabergoline reduced serum PRL levels by approximately 50% to 85% of basal values over a period of 4 to 5 hours. Cabergoline 41-52 prolactin Homo sapiens 67-70 8737186-8 1996 Dopamine infusion induced a significant and comparable increase in the prolactin response to metoclopramide in micro- and macroprolactinoma patients, while it was ineffective in control subjects. Dopamine 0-8 prolactin Homo sapiens 71-80 8737186-5 1996 Dopamine infusion, compared to saline, caused a significant prolactin decrease in all the three groups of subjects, without significant difference between micro- and macroprolactinoma patients. Sodium Chloride 31-37 prolactin Homo sapiens 60-69 8737186-8 1996 Dopamine infusion induced a significant and comparable increase in the prolactin response to metoclopramide in micro- and macroprolactinoma patients, while it was ineffective in control subjects. Metoclopramide 93-107 prolactin Homo sapiens 71-80 8772480-1 1996 Verapamil, a phenylalkylamine calcium channel blocker, causes a doubling of serum prolactin (PRL) levels in humans. Verapamil 0-9 prolactin Homo sapiens 82-91 8636272-7 1996 A significantly high proportion of PRL was absorbed to a concanavalin A column (41.1% vs. 4.0 +/- 2.1% in normal pregnant women), repetitive freezing and thawing of isolated big-big PRL resulted in a partial conversion to big and little PRL, and reduction of the isolated big-big PRL with 2-mercaptoethanol almost completely converted big-big PRL to little PRL in this woman. Mercaptoethanol 289-306 prolactin Homo sapiens 35-38 8636272-7 1996 A significantly high proportion of PRL was absorbed to a concanavalin A column (41.1% vs. 4.0 +/- 2.1% in normal pregnant women), repetitive freezing and thawing of isolated big-big PRL resulted in a partial conversion to big and little PRL, and reduction of the isolated big-big PRL with 2-mercaptoethanol almost completely converted big-big PRL to little PRL in this woman. Mercaptoethanol 289-306 prolactin Homo sapiens 182-185 8636272-7 1996 A significantly high proportion of PRL was absorbed to a concanavalin A column (41.1% vs. 4.0 +/- 2.1% in normal pregnant women), repetitive freezing and thawing of isolated big-big PRL resulted in a partial conversion to big and little PRL, and reduction of the isolated big-big PRL with 2-mercaptoethanol almost completely converted big-big PRL to little PRL in this woman. Mercaptoethanol 289-306 prolactin Homo sapiens 182-185 8636272-7 1996 A significantly high proportion of PRL was absorbed to a concanavalin A column (41.1% vs. 4.0 +/- 2.1% in normal pregnant women), repetitive freezing and thawing of isolated big-big PRL resulted in a partial conversion to big and little PRL, and reduction of the isolated big-big PRL with 2-mercaptoethanol almost completely converted big-big PRL to little PRL in this woman. Mercaptoethanol 289-306 prolactin Homo sapiens 182-185 8636272-7 1996 A significantly high proportion of PRL was absorbed to a concanavalin A column (41.1% vs. 4.0 +/- 2.1% in normal pregnant women), repetitive freezing and thawing of isolated big-big PRL resulted in a partial conversion to big and little PRL, and reduction of the isolated big-big PRL with 2-mercaptoethanol almost completely converted big-big PRL to little PRL in this woman. Mercaptoethanol 289-306 prolactin Homo sapiens 182-185 8636272-7 1996 A significantly high proportion of PRL was absorbed to a concanavalin A column (41.1% vs. 4.0 +/- 2.1% in normal pregnant women), repetitive freezing and thawing of isolated big-big PRL resulted in a partial conversion to big and little PRL, and reduction of the isolated big-big PRL with 2-mercaptoethanol almost completely converted big-big PRL to little PRL in this woman. Mercaptoethanol 289-306 prolactin Homo sapiens 182-185 8833706-1 1996 It has been hypothesized that fatigue and prolactin (PRL) changes during endurance exercise are influenced by serotonin synthesis, and in turn, release. Serotonin 110-119 prolactin Homo sapiens 42-51 8833706-1 1996 It has been hypothesized that fatigue and prolactin (PRL) changes during endurance exercise are influenced by serotonin synthesis, and in turn, release. Serotonin 110-119 prolactin Homo sapiens 53-56 9222386-3 1996 The interaction between hormones (androgens, LH, FSH and PRL) and the main enzymes involved on the polyamine biosynthesis, and the relationship of these compounds on cell growth and differentiation, are also discussed. Polyamines 99-108 prolactin Homo sapiens 57-60 8834356-0 1996 Serum prolactin in subjects occupationally exposed to manganese. Manganese 54-63 prolactin Homo sapiens 6-15 8772480-1 1996 Verapamil, a phenylalkylamine calcium channel blocker, causes a doubling of serum prolactin (PRL) levels in humans. Verapamil 0-9 prolactin Homo sapiens 93-96 8772480-2 1996 To determine whether the mechanism involved a decrease in the PRL response to dopamine (DA), we infused low doses of DA, finding that the percent inhibition of PRL was not affected by verapamil (max %decrements for 0.003, 0.01, and 0.03 microgram.kg-1.min-1 doses of DA, respectively, 86.7 +/- 19.1, 73.2 +/- 24.8, and 65.2 +/- 20.0% without verapamil and 93.4 +/- 24.6, 79.7 +/- 14.9, and 58.0 +/- 18.1% with verapamil). Dopamine 78-86 prolactin Homo sapiens 62-65 8772480-2 1996 To determine whether the mechanism involved a decrease in the PRL response to dopamine (DA), we infused low doses of DA, finding that the percent inhibition of PRL was not affected by verapamil (max %decrements for 0.003, 0.01, and 0.03 microgram.kg-1.min-1 doses of DA, respectively, 86.7 +/- 19.1, 73.2 +/- 24.8, and 65.2 +/- 20.0% without verapamil and 93.4 +/- 24.6, 79.7 +/- 14.9, and 58.0 +/- 18.1% with verapamil). Dopamine 88-90 prolactin Homo sapiens 62-65 8952744-4 1996 Suppression of physiologic levels of prolactin by bromocriptine administration was associated with improvement in SLE in a preliminary study. Bromocriptine 50-63 prolactin Homo sapiens 37-46 8772480-3 1996 To determine whether the PRL elevation was due to a decrease in hypothalamic generation of DA, we measured the inhibition of PRL by L-dopa before and after inhibition of peripheral decarboxylase activity with carbidopa. Levodopa 132-138 prolactin Homo sapiens 125-128 8772480-4 1996 Without verapamil, L-dopa alone and carbidopa-L-dopa caused similar maximum decreases in PRL levels of 83.2 +/- 2.5 and 80.3 +/- 2.0%, respectively. Levodopa 19-25 prolactin Homo sapiens 89-92 8772480-4 1996 Without verapamil, L-dopa alone and carbidopa-L-dopa caused similar maximum decreases in PRL levels of 83.2 +/- 2.5 and 80.3 +/- 2.0%, respectively. carbidopa-l-dopa 36-52 prolactin Homo sapiens 89-92 8772480-5 1996 With verapamil, the PRL maximum decrement with L-dopa was 85.2 +/- 2.7% and with carbidopa-L-dopa was 76.3 +/- 1.9% (P < 0.01). Verapamil 5-14 prolactin Homo sapiens 20-23 8772480-5 1996 With verapamil, the PRL maximum decrement with L-dopa was 85.2 +/- 2.7% and with carbidopa-L-dopa was 76.3 +/- 1.9% (P < 0.01). Levodopa 47-53 prolactin Homo sapiens 20-23 9160649-7 1996 In contrast to imipramine, trimipramine induced an increase in prolactin secretion compatible with its known antagonism at dopamine (D2) receptors. Trimipramine 27-39 prolactin Homo sapiens 63-72 8770429-0 1996 Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients. Dexfenfluramine 41-55 prolactin Homo sapiens 19-28 8706295-3 1996 We have therefore evaluated the effect of hexarelin on PRL and GH secretion in patients with active acromegaly or pathological hyperprolactinaemia. hexarelin 42-51 prolactin Homo sapiens 55-58 8706295-13 1996 CONCLUSIONS: Our data show that the PRL releasing effect of hexarelin is preserved in acromegaly but lost in pathological hyperprolactinaemia. hexarelin 60-69 prolactin Homo sapiens 36-39 9026379-5 1996 Pindolol significantly increased basal plasma cortisol concentrations, whereas it decreased plasma prolactin (PRL) concentrations and body temperature. Pindolol 0-8 prolactin Homo sapiens 99-108 8954292-0 1996 Effect of O2 availability on neuroendocrine variables at rest and during exercise: O2 breathing increases plasma prolactin. Oxygen 10-12 prolactin Homo sapiens 113-122 8954292-0 1996 Effect of O2 availability on neuroendocrine variables at rest and during exercise: O2 breathing increases plasma prolactin. Oxygen 83-85 prolactin Homo sapiens 113-122 8750573-0 1996 Naloxone influence on the growth hormone, prolactin and thyrotropin response to thyrotropin releasing hormone in acromegalic patients. Naloxone 0-8 prolactin Homo sapiens 42-51 8739973-0 1996 Monitoring treatment in tetrahydrobiopterin deficiency by serum prolactin. sapropterin 24-43 prolactin Homo sapiens 64-73 8836934-5 1996 Entacapone had no effect on resting levels of GH, but PRL concentrations in plasma were slightly lower after entacapone than after placebo. entacapone 109-119 prolactin Homo sapiens 54-57 8836934-6 1996 As expected, LD/carbidopa increased the concentration of GH and decreased that of PRL. Levodopa 13-15 prolactin Homo sapiens 82-85 8836934-6 1996 As expected, LD/carbidopa increased the concentration of GH and decreased that of PRL. Carbidopa 16-25 prolactin Homo sapiens 82-85 9026379-5 1996 Pindolol significantly increased basal plasma cortisol concentrations, whereas it decreased plasma prolactin (PRL) concentrations and body temperature. Pindolol 0-8 prolactin Homo sapiens 110-113 8761011-6 1996 The effects of Cyclosporin (CsA) on IL-2 and PRL gene activation and the analysis of the intracellular signaling events downstream IL-2 and PRL receptors suggest coordinate actions of these two cytokines during T cell activation. Cyclosporine 28-31 prolactin Homo sapiens 45-48 8519656-0 1995 Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Melatonin 0-9 prolactin Homo sapiens 44-53 8927658-0 1996 Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636). Quetiapine Fumarate 56-64 prolactin Homo sapiens 7-16 8927658-7 1996 A significant difference was found, however, between ICI 204,636- and chlorpromazine-treated subjects; prolactin levels in ICI 204,636-treated subjects fell to a greater degree than they did in chlorpromazine-treated subjects, however in all three trials, ICI 204,636 did not cause sustained elevation of prolactin. Chlorpromazine 70-84 prolactin Homo sapiens 103-112 8519656-4 1995 Melatonin, at concentrations between 10(-12) M and 10(-5)M, diminished and at physiological levels completely abolished PRL"s mitogenic activity, but had no effect on growth in the absence of PRL. Melatonin 0-9 prolactin Homo sapiens 120-123 8548056-4 1995 Responsivity of the corpus luteum to LH episodes developed during the second half of the luteal phase and was most marked in cases where LH episodes were accompanied by prolactin episodes. Luteinizing Hormone 37-39 prolactin Homo sapiens 169-178 8580229-0 1995 Effects of intravenous cocaine on plasma cortisol and prolactin in human cocaine abusers. Cocaine 23-30 prolactin Homo sapiens 54-63 8580229-1 1995 The aim of the present work was to examine the cortisol and prolactin responses to acute cocaine administration in human cocaine users. Cocaine 89-96 prolactin Homo sapiens 60-69 8530591-16 1995 The mild increase in serum PRL levels in hypopituitary patients and the discordant responses to stimulation with TRH and PZ suggest dopamine deficiency as a cause of hyperprolactinemia. Dopamine 132-140 prolactin Homo sapiens 27-30 7589658-5 1995 MAIN OUTCOME MEASURE: Basal PRL levels and PRL increase induced by sulpiride. Sulpiride 67-76 prolactin Homo sapiens 43-46 7589658-6 1995 RESULTS: Basal PRL levels and the PRL response to sulpiride were increased in women with PCOS. Sulpiride 50-59 prolactin Homo sapiens 34-37 7589658-7 1995 In women with PCOS medical ovariectomy induced by GnRH-a administration reversed to normal both basal and sulpiride-stimulated PRL levels. gnrh-a 50-56 prolactin Homo sapiens 127-130 7589658-7 1995 In women with PCOS medical ovariectomy induced by GnRH-a administration reversed to normal both basal and sulpiride-stimulated PRL levels. Sulpiride 106-115 prolactin Homo sapiens 127-130 8530591-5 1995 To test these hypotheses, we examined PRL responsiveness to TRH and the dopamine antagonist, perphenazine (PZ), in patients with pituitary macroadenomas who had hypopituitarism and others with intact pituitary function (controls). Dopamine 72-80 prolactin Homo sapiens 38-41 8568352-12 1995 The results of this study show that the BR regimen increases the developmental potential of oocytes and the pregnancy rate, probably because of increasing serum PRL levels to within the normal range. Bromine 40-42 prolactin Homo sapiens 161-164 8530591-5 1995 To test these hypotheses, we examined PRL responsiveness to TRH and the dopamine antagonist, perphenazine (PZ), in patients with pituitary macroadenomas who had hypopituitarism and others with intact pituitary function (controls). Perphenazine 93-105 prolactin Homo sapiens 38-41 8778155-0 1995 Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients. Octreotide 21-31 prolactin Homo sapiens 45-54 8778155-2 1995 We aimed to test the hypothesis, that octreotide has a suppressive effect on unstimulated and TRH-stimulated PRL levels in both normo- and hyperprolactinaemic acromegalic patients, and besides to evaluate the effect of octreotide on unstimulated TSH and thyroid hormones. Octreotide 38-48 prolactin Homo sapiens 109-112 8778155-6 1995 In the whole group unstimulated PRL levels were 18 micrograms/l +/- 5 before and 7 micrograms/l +/- 1 during octreotide treatment (p < 0.01). Octreotide 109-119 prolactin Homo sapiens 32-35 8778155-7 1995 The PRL lowering effect of octreotide was significantly more pronounced in hyperprolactinemic patients compared to normoprolactinaemic patients (p < 0.05). Octreotide 27-37 prolactin Homo sapiens 4-7 8778155-8 1995 Patients with the highest pretreatment PRL levels had the most pronounced percentage suppression of unstimulated PRL levels during octreotide treatment. Octreotide 131-141 prolactin Homo sapiens 39-42 8778155-8 1995 Patients with the highest pretreatment PRL levels had the most pronounced percentage suppression of unstimulated PRL levels during octreotide treatment. Octreotide 131-141 prolactin Homo sapiens 113-116 8778155-9 1995 Eight out of 12 patients had a TRH-stimulated PRL response > or = 100%, both during placebo and octreotide treatment, but in the group as a whole maximal TRH-stimulated PRL levels were suppressed during octreotide treatment, PRL levels were 50 micrograms/l +/- 20 before and 18 micrograms/l +/- 3 during octreotide treatment (p < 0.05). Octreotide 99-109 prolactin Homo sapiens 46-49 8548944-16 1995 PRL pulse characteristics were modified significantly by naloxone only in the control group. Naloxone 57-65 prolactin Homo sapiens 0-3 8625053-10 1995 CONCLUSION: Tamoxifen may have efficacy in the treatment of prolactin-secreting pituitary carcinomas. Tamoxifen 12-21 prolactin Homo sapiens 60-69 8548944-21 1995 These data, along with those previously reported in normal women throughout the menstrual cycle, are consistent with the concept that sex steroid hormones contribute to the underlying mechanisms involved in the opioidergic control of LH and PRL release. Steroids 138-154 prolactin Homo sapiens 241-244 7588233-6 1995 The immunological properties of des(3-11)-PRL were reduced 10-fold compared to those of wildtype human PRL in a RIA using NIH antihuman PRL-3, AFP C11580; the others were similar to those of wild-type PRL. des(3-11) 32-41 prolactin Homo sapiens 42-45 8835242-10 1995 In DR4+ RA patients, the overall prolactin secretion reflected by the AUC is increased compared to DR4- patients. Radium 8-10 prolactin Homo sapiens 33-42 7581993-8 1995 The detrimental effect of bromocriptine on the mammary glands, assessed by both weight and histological appearance, was reversed by administration of r-hPRL. Bromocriptine 26-39 prolactin Homo sapiens 152-156 7581993-9 1995 These results demonstrate that r-hPRL is biologically active in vivo and replacement therapy of r-hPRL is effective in improving the lactational performance in bromocriptine-treated rats, and also that r-hPRL may be useful for the treatment of women with poor lactation. Bromocriptine 160-173 prolactin Homo sapiens 33-37 7581993-9 1995 These results demonstrate that r-hPRL is biologically active in vivo and replacement therapy of r-hPRL is effective in improving the lactational performance in bromocriptine-treated rats, and also that r-hPRL may be useful for the treatment of women with poor lactation. Bromocriptine 160-173 prolactin Homo sapiens 98-102 7581993-9 1995 These results demonstrate that r-hPRL is biologically active in vivo and replacement therapy of r-hPRL is effective in improving the lactational performance in bromocriptine-treated rats, and also that r-hPRL may be useful for the treatment of women with poor lactation. Bromocriptine 160-173 prolactin Homo sapiens 98-102 7588213-3 1995 The predominant PRL forms were identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting as being 23 and 25 kilodaltons (kDa). Sodium Dodecyl Sulfate 45-67 prolactin Homo sapiens 16-19 7588213-3 1995 The predominant PRL forms were identified by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotting as being 23 and 25 kilodaltons (kDa). polyacrylamide 68-82 prolactin Homo sapiens 16-19 7588213-5 1995 Glycosidase digestions indicated that the 25-kDa PRL is N-glycosylated and sialylated, whereas 23-kDa PRL is nonglycosylated. Nitrogen 56-57 prolactin Homo sapiens 49-52 7589644-11 1995 The level of endogenous gonadotropins as well as the steroid milieu may modulate myometrial PRL secretion. Steroids 53-60 prolactin Homo sapiens 92-95 7588233-7 1995 The biological activity of des(3-11)-PRL was the most affected; activity was reduced about 8-fold compared to that of wild-type PRL in the Nb2 cell assay. des(3-11) 27-36 prolactin Homo sapiens 37-40 8582329-1 1995 We have developed a novel vector-free method for the synthesis of nonisotopic (digoxigenin) labeled prolactin (PRL)-gene specific cRNA probe based on the direct in vitro transcription of DNA template amplified by polymerase chain reaction (PCR). Digoxigenin 79-90 prolactin Homo sapiens 100-109 7588233-7 1995 The biological activity of des(3-11)-PRL was the most affected; activity was reduced about 8-fold compared to that of wild-type PRL in the Nb2 cell assay. des(3-11) 27-36 prolactin Homo sapiens 128-131 8582329-1 1995 We have developed a novel vector-free method for the synthesis of nonisotopic (digoxigenin) labeled prolactin (PRL)-gene specific cRNA probe based on the direct in vitro transcription of DNA template amplified by polymerase chain reaction (PCR). Digoxigenin 79-90 prolactin Homo sapiens 111-114 7588233-12 1995 The N-terminal cystine loop may be conserved because it is needed for biological activity, but the conservation of serine 90 in GH and PRL must be determined by other properties, such as spacial requirements. Serine 115-121 prolactin Homo sapiens 135-138 8559274-0 1995 Does melatonin act on dopaminergic pathways in the mediobasal hypothalamus to mediate effects of photoperiod on prolactin secretion in the ram? Melatonin 5-14 prolactin Homo sapiens 112-121 8559274-1 1995 Previous studies have shown that the chronic administration of melatonin in the mediobasal hypothalamus (MBH) using micro-implants in Soay rams housed under long days causes a sustained decrease in the secretion of prolactin as occurs in response to short days. Melatonin 63-72 prolactin Homo sapiens 215-224 8559274-10 1995 There were changes in growth and moulting of the pelage correlated with the marked changes in the secretion of prolactin induced by MEL, but not related to the lesser effects of BROM and SULP. Melatonin 132-135 prolactin Homo sapiens 111-120 8559274-13 1995 However, since the administration of the D2 antagonist in the MBH did influence the response to MEL, it is probable that DA pathways are involved in relaying the effects of MEL on the long-term cycle in the secretion of prolactin in the ram. Melatonin 96-99 prolactin Homo sapiens 220-229 8559274-13 1995 However, since the administration of the D2 antagonist in the MBH did influence the response to MEL, it is probable that DA pathways are involved in relaying the effects of MEL on the long-term cycle in the secretion of prolactin in the ram. Melatonin 173-176 prolactin Homo sapiens 220-229 8539309-4 1995 Dexamethasone administration resulted in a significant decrease in plasma levels of ACTH, 11-desoxycortisol, and cortisol at all time points and to a significant decrease in PRL secretion in the early morning. Dexamethasone 0-13 prolactin Homo sapiens 174-177 8848526-7 1995 Bretazenil prompted a significant decrease in cortisol secretion and a significant increase in prolactin release. bretazenil 0-10 prolactin Homo sapiens 95-104 8570767-0 1995 Serotonin function in detoxified heroin abusers: prolactin and cortisol responses to fenfluramine challenge. Serotonin 0-9 prolactin Homo sapiens 49-58 17590643-2 1995 In the patients who received adjuvant CMF-chemotherapy, there was a significant decrease in the circulating FSH, LH and PRL levels compared to healthy age-matched controls. CMF regimen 38-41 prolactin Homo sapiens 120-123 8539309-8 1995 These results are discussed in relation to the neurochemical and behavioral changes associated with steroid administration and interpreted with regard to a possible association between HVA and PRL in the effects of corticosteroids on dopaminergic activity. Homovanillic Acid 185-188 prolactin Homo sapiens 193-196 7658481-0 1995 Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. Alcohols 0-7 prolactin Homo sapiens 59-68 7495925-3 1995 MK-212 induced a significant increase in plasma concentrations of cortisol and PRL. 6-chloro-2-(1-piperazinyl)pyrazine 0-6 prolactin Homo sapiens 79-82 7495925-1 1995 Previous reports based on studies with serotonin (5-HT) precursors or direct acting agonists have suggested that postsynaptic 5-HT1A and 5-HT2A/5-HT2C receptors may stimulate cortisol and prolactin (PRL) secretion in man. Serotonin 39-48 prolactin Homo sapiens 188-197 7495925-0 1995 Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. Pindolol 10-18 prolactin Homo sapiens 70-79 7495925-4 1995 The MK-212-induced response in plasma cortisol was not diminished by pindolol pretreatment, whereas the MK-212-induced PRL response was significantly inhibited by pindolol pretreatment. 6-chloro-2-(1-piperazinyl)pyrazine 104-110 prolactin Homo sapiens 119-122 7495925-0 1995 Effect of pindolol pretreatment on MK-212-induced plasma cortisol and prolactin responses in normal men. 6-chloro-2-(1-piperazinyl)pyrazine 35-41 prolactin Homo sapiens 70-79 7495925-4 1995 The MK-212-induced response in plasma cortisol was not diminished by pindolol pretreatment, whereas the MK-212-induced PRL response was significantly inhibited by pindolol pretreatment. Pindolol 163-171 prolactin Homo sapiens 119-122 7495925-1 1995 Previous reports based on studies with serotonin (5-HT) precursors or direct acting agonists have suggested that postsynaptic 5-HT1A and 5-HT2A/5-HT2C receptors may stimulate cortisol and prolactin (PRL) secretion in man. Serotonin 39-48 prolactin Homo sapiens 199-202 7495925-5 1995 These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212. 6-chloro-2-(1-piperazinyl)pyrazine 28-34 prolactin Homo sapiens 163-166 7495925-5 1995 These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212. 6-chloro-2-(1-piperazinyl)pyrazine 28-34 prolactin Homo sapiens 321-324 7495925-5 1995 These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212. 6-chloro-2-(1-piperazinyl)pyrazine 180-186 prolactin Homo sapiens 163-166 7495925-5 1995 These data suggest that the MK-212-induced cortisol response may be mediated by 5-HT2A or 5-HT2C receptor activation, or both, despite 5-HT1A inhibition; however, PRL secretion by MK-212 requires 5-HT1A receptor availability as well as 5-HT2A/5-HT2C receptor activation, since blockade of the former appears to blunt the PRL responses to MK-212. 6-chloro-2-(1-piperazinyl)pyrazine 180-186 prolactin Homo sapiens 163-166 7586610-2 1995 Bromocriptine normalized PRL levels but failed to suppress tumour growth. Bromocriptine 0-13 prolactin Homo sapiens 25-28 8675971-2 1995 Prolactin responses to d-fenfluramine and cortisol responses to ipsapirone challenge were inversely correlated with self-reported assaultiveness. Dexfenfluramine 23-37 prolactin Homo sapiens 0-9 8540286-2 1995 This postpartum prolactin rise can be prevented by administration of dopamine agonists. Dopamine 69-77 prolactin Homo sapiens 16-25 8540294-9 1995 As a consequence, the fraction of LH pulses that were co-secreted with prolactin episodes decreased with higher LH pulse frequencies, while the fraction of prolactin pulses concomitant with LH pulses increased. Luteinizing Hormone 34-36 prolactin Homo sapiens 71-80 8540294-9 1995 As a consequence, the fraction of LH pulses that were co-secreted with prolactin episodes decreased with higher LH pulse frequencies, while the fraction of prolactin pulses concomitant with LH pulses increased. Luteinizing Hormone 112-114 prolactin Homo sapiens 71-80 8540294-9 1995 As a consequence, the fraction of LH pulses that were co-secreted with prolactin episodes decreased with higher LH pulse frequencies, while the fraction of prolactin pulses concomitant with LH pulses increased. Luteinizing Hormone 112-114 prolactin Homo sapiens 71-80 7554710-0 1995 Restoration of normal sperm characteristics in hypoprolactinemic infertile men treated with metoclopramide and exogenous human prolactin. Metoclopramide 92-106 prolactin Homo sapiens 51-60 7577707-6 1995 The effect of CRF on stromal cells and on prolactin release was significantly augmented by the coincubation in the presence of medroxyprogesterone acetate. Medroxyprogesterone Acetate 127-154 prolactin Homo sapiens 42-51 8562282-6 1995 Zn2+ is closely related to the thyroid and steroid hormones, insulin, parathormone, and pituitary hormones, particularly prolactin (PRL). Zinc 0-4 prolactin Homo sapiens 121-130 8547445-3 1995 The prolactin response to buspirone in the presence of metoclopramide was not statistically different from that to placebo under the same conditions. Buspirone 26-35 prolactin Homo sapiens 4-13 8547445-3 1995 The prolactin response to buspirone in the presence of metoclopramide was not statistically different from that to placebo under the same conditions. Metoclopramide 55-69 prolactin Homo sapiens 4-13 8547445-5 1995 These results lend further support to a dopaminergic mechanism in buspirone-induced prolactin secretion; therefore, further caution is warranted in interpreting the results of this challenge test as a measure of serotonergic activity in the brain. Buspirone 66-75 prolactin Homo sapiens 84-93 8570574-0 1995 Long-term effects of calcium availability on prolactin and protein synthesis in human decidual cells. Calcium 21-28 prolactin Homo sapiens 45-54 8547445-0 1995 Prolactin response to buspirone challenge in the presence of dopaminergic blockade. Buspirone 22-31 prolactin Homo sapiens 0-9 8547445-1 1995 Buspirone-stimulated prolactin release has been employed as an indirect measure of central serotonin activity; however, it is not clear whether serotonergic or dopaminergic systems are responsible for this response. Buspirone 0-9 prolactin Homo sapiens 21-30 8547445-1 1995 Buspirone-stimulated prolactin release has been employed as an indirect measure of central serotonin activity; however, it is not clear whether serotonergic or dopaminergic systems are responsible for this response. Serotonin 91-100 prolactin Homo sapiens 21-30 8547445-2 1995 In an attempt to further elucidate the mechanism, we studied the prolactin response to buspirone in eight subjects in the presence of maximal dopaminergic receptor blockade with metoclopramide under placebo-controlled, double-blind conditions. Buspirone 87-96 prolactin Homo sapiens 65-74 7628388-10 1995 Moreover, PRL induced tyrosine phosphorylation of SHC in two of three PRL-responsive human breast cancer cell lines, suggesting that SHC-mediated Ras activation is a commonly used signaling strategy by PRL. Tyrosine 22-30 prolactin Homo sapiens 10-13 7582676-0 1995 Effect of valine on 5-HT-mediated prolactin release in healthy volunteers, and on mood in remitted depressed patients. Valine 10-16 prolactin Homo sapiens 34-43 7582676-3 1995 METHOD: We studied the effect of valine (30 g) on the prolactin (PRL) response to the 5-HT releasing agent, D-fenfluramine, in healthy male subjects and on the mood of 12 remitted depressed patients taking either selective serotonin re-uptake inhibitors (n = 10) or lithium and amitriptyline (n = 2). Valine 33-39 prolactin Homo sapiens 54-63 7582676-3 1995 METHOD: We studied the effect of valine (30 g) on the prolactin (PRL) response to the 5-HT releasing agent, D-fenfluramine, in healthy male subjects and on the mood of 12 remitted depressed patients taking either selective serotonin re-uptake inhibitors (n = 10) or lithium and amitriptyline (n = 2). Valine 33-39 prolactin Homo sapiens 65-68 7582676-3 1995 METHOD: We studied the effect of valine (30 g) on the prolactin (PRL) response to the 5-HT releasing agent, D-fenfluramine, in healthy male subjects and on the mood of 12 remitted depressed patients taking either selective serotonin re-uptake inhibitors (n = 10) or lithium and amitriptyline (n = 2). Dexfenfluramine 108-122 prolactin Homo sapiens 54-63 7582676-3 1995 METHOD: We studied the effect of valine (30 g) on the prolactin (PRL) response to the 5-HT releasing agent, D-fenfluramine, in healthy male subjects and on the mood of 12 remitted depressed patients taking either selective serotonin re-uptake inhibitors (n = 10) or lithium and amitriptyline (n = 2). Dexfenfluramine 108-122 prolactin Homo sapiens 65-68 7582676-4 1995 RESULTS: Valine significantly lowered the PRL response to D-fenfluramine in healthy subjects. Valine 9-15 prolactin Homo sapiens 42-45 7582676-4 1995 RESULTS: Valine significantly lowered the PRL response to D-fenfluramine in healthy subjects. Dexfenfluramine 58-72 prolactin Homo sapiens 42-45 21153137-0 1995 Vinblastine and nocodazole inhibit basal and thyrotropin-releasing hormone-stimulated prolactin secretion in GH(3) cells. Vinblastine 0-11 prolactin Homo sapiens 86-95 21153137-0 1995 Vinblastine and nocodazole inhibit basal and thyrotropin-releasing hormone-stimulated prolactin secretion in GH(3) cells. Nocodazole 16-26 prolactin Homo sapiens 86-95 21153137-4 1995 In cells treated with 0.1, 1 and 10muM: nocodazole for 24 h, PRL secretion was reduced to 200+-30 ng/ml. Nocodazole 40-50 prolactin Homo sapiens 61-64 21153137-6 1995 TRH-stimulated PRL secretion was 35+-7 ng/ml in control cells, 14+-0.5 ng/ml in vinblastine-treated cells and 8.8+-0.1 ng/ml in nocodazole-treated cells. Vinblastine 80-91 prolactin Homo sapiens 15-18 21153137-6 1995 TRH-stimulated PRL secretion was 35+-7 ng/ml in control cells, 14+-0.5 ng/ml in vinblastine-treated cells and 8.8+-0.1 ng/ml in nocodazole-treated cells. Nocodazole 128-138 prolactin Homo sapiens 15-18 21153137-9 1995 These observations that vinblastine suppresses PRL secretion by GH(3) cells suggest that this drug might be useful as a therapeutic agent for prolactinomas. Vinblastine 24-35 prolactin Homo sapiens 47-50 7615104-5 1995 RESULTS: Hyperprolactinemia developed in 5 of 13 girls after treatment with long-acting GnRH-a; mean blood PRL in all 13 girls rose significantly from 11.9 +/- 5.6 to 21.5 +/- 12.5 micrograms/L (mean +/- SD). gnrh-a 88-94 prolactin Homo sapiens 107-110 8556061-5 1995 Sections of these tissues were hybridized with 35S-labeled RNA probe complementary to human PRL mRNA. Sulfur-35 47-50 prolactin Homo sapiens 92-95 7628388-10 1995 Moreover, PRL induced tyrosine phosphorylation of SHC in two of three PRL-responsive human breast cancer cell lines, suggesting that SHC-mediated Ras activation is a commonly used signaling strategy by PRL. Tyrosine 22-30 prolactin Homo sapiens 70-73 7649494-6 1995 Furthermore, lipoate can function as a redox regulator of proteins such as myoglobin, prolactin, thioredoxin and NF-kappa B transcription factor. dl-Thioctic acid 13-20 prolactin Homo sapiens 86-95 7628388-10 1995 Moreover, PRL induced tyrosine phosphorylation of SHC in two of three PRL-responsive human breast cancer cell lines, suggesting that SHC-mediated Ras activation is a commonly used signaling strategy by PRL. Tyrosine 22-30 prolactin Homo sapiens 70-73 7636755-0 1995 Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. Remoxipride 24-35 prolactin Homo sapiens 0-9 7629253-5 1995 We conclude that, in these two patients, the pituitary scintigraphy with IBZM has given information on the density of dopamine receptors on the adenoma and has correlated with the inhibitory effect of Br on PRL secretion. IBZM 73-77 prolactin Homo sapiens 207-210 7629253-5 1995 We conclude that, in these two patients, the pituitary scintigraphy with IBZM has given information on the density of dopamine receptors on the adenoma and has correlated with the inhibitory effect of Br on PRL secretion. Bromocriptine 201-203 prolactin Homo sapiens 207-210 7636755-1 1995 An integrated pharmacokinetic-pharmacodynamic model is suggested for remoxipride and its effect on prolactin (PRL) release acting by preventing the inhibitory effect of dopamine D2 receptors in the anterior pituitary. Remoxipride 69-80 prolactin Homo sapiens 99-108 7636755-1 1995 An integrated pharmacokinetic-pharmacodynamic model is suggested for remoxipride and its effect on prolactin (PRL) release acting by preventing the inhibitory effect of dopamine D2 receptors in the anterior pituitary. Remoxipride 69-80 prolactin Homo sapiens 110-113 7636755-2 1995 The model was implemented to describe the time course of PRL plasma levels after administration of two consecutive doses of remoxipride at 5 different time intervals, 2, 8, 12, 24 and 48 hr. Remoxipride 124-135 prolactin Homo sapiens 57-60 7636755-6 1995 The limitation in the PRL release is the amount available in the pool, which takes 24 to 48 hr to fully restore, rather than a maximal effect of remoxipride. Remoxipride 145-156 prolactin Homo sapiens 22-25 7540803-0 1995 Risperidone-induced prolactin elevations in premenopausal women with schizophrenia. Risperidone 0-11 prolactin Homo sapiens 20-29 7589185-3 1995 Under non-stress conditions, injection of 3 mg/kg flesinoxan significantly enhanced plasma corticosterone and glucose levels, whereas prolactin secretion was significantly enhanced after both 1 mg/kg and 3 mg/kg flesinoxan. flesinoxan 212-222 prolactin Homo sapiens 134-143 7589185-5 1995 The enhanced plasma prolactin levels induced by flesinoxan were not further affected by shock-probe exposure. flesinoxan 48-58 prolactin Homo sapiens 20-29 8526971-1 1995 We found a 38% lower maximal prolactin response to an oral challenge dose of 60 mg of dl-fenfluramine relative to placebo in younger (< 30 years) depressed inpatients compared with the response in age-matched healthy controls (p < .03). Fenfluramine 86-101 prolactin Homo sapiens 29-38 8526971-5 1995 A blunted prolactin response to fenfluramine may be interpreted as evidence for reduced serotonergic function in younger depressed patients and may underlie their observed greater suicidality and hopelessness. Fenfluramine 32-44 prolactin Homo sapiens 10-19 8582955-3 1995 In the treatment of hyperprolactinaemic amenorrhoea, 1-2 mg weekly doses of cabergoline (given on a twice weekly schedule) compare favourably with 5-10 mg daily bromocriptine (given on a twice daily schedule) both for biochemical (normalization of serum prolactin concentrations) and clinical efficacy (resumption of ovulatory cycles) as well as for tolerability. Cabergoline 76-87 prolactin Homo sapiens 25-34 7481412-8 1995 In contrast, though remaining in the normal range, the nocturnal elevation of prolactin was enhanced two-fold in all subjects after zolpidem during early sleep, and prolactin levels were still 50% higher than baseline in late sleep. Zolpidem 132-140 prolactin Homo sapiens 78-87 7476971-10 1995 The low response of hPRL/luciferase fusion genes to phorbol ester was greatly enhanced by cotransfected Pit-1 and was mediated by the proximal region between -250 and -38. Phorbol Esters 52-65 prolactin Homo sapiens 20-24 7777588-14 1995 Prolactin action and DEX-induced apoptosis both occurred in calcium-free PBS. Calcium 60-67 prolactin Homo sapiens 0-9 7777588-14 1995 Prolactin action and DEX-induced apoptosis both occurred in calcium-free PBS. Lead 73-76 prolactin Homo sapiens 0-9 7780973-7 1995 A single M(r) 22,000 band, the dominant size of monomeric pituitary Prl, was found in immunoprecipitates of both cell extracts and conditioned medium from T47Dco cells labeled metabolically with [35S]cysteine. Sulfur-35 196-199 prolactin Homo sapiens 68-71 7780973-7 1995 A single M(r) 22,000 band, the dominant size of monomeric pituitary Prl, was found in immunoprecipitates of both cell extracts and conditioned medium from T47Dco cells labeled metabolically with [35S]cysteine. Cysteine 200-208 prolactin Homo sapiens 68-71 7670147-6 1995 High levels of prolactin have been shown to suppress production of estrogen and progesterone. Progesterone 80-92 prolactin Homo sapiens 15-24 7597365-5 1995 Drug therapy with dopamine agonists will almost always decrease prolactin levels, but will rarely cure the disease. Dopamine 18-26 prolactin Homo sapiens 64-73 7768923-8 1995 Treatment of Nb2 cells with antisense Vav oligonucleotide ablated Vav expression and blocked PRL-driven proliferation, but failed to inhibit PRL-induced GEF activation within Nb2 lysates. Oligonucleotides 42-57 prolactin Homo sapiens 93-96 7670564-1 1995 The responsiveness in vivo to dopamine of prolactin (PRL) secretion in patients with prolactinoma was compared with that in vitro of single cells obtained from the same prolactinomas by surgical operations. Dopamine 30-38 prolactin Homo sapiens 42-51 7634499-8 1995 RESULTS: In all patients with macroprolactinomas, serum PRL levels decreased significantly after their first 50-mg injection with nadir levels obtained by 24-48 hours post injection (12815 +/- 8704 vs 1480 +/- 1859 mU/l; mean +/- SD, P < 0.01). nadir 130-135 prolactin Homo sapiens 56-59 7670564-1 1995 The responsiveness in vivo to dopamine of prolactin (PRL) secretion in patients with prolactinoma was compared with that in vitro of single cells obtained from the same prolactinomas by surgical operations. Dopamine 30-38 prolactin Homo sapiens 53-56 7646913-2 1995 The efficacy of oral hydrocortisone as an alternative to commercial anti-androgens in reducing the adrenal androgens, and of bromocriptine in reducing the prolactin level were also examined. Bromocriptine 125-138 prolactin Homo sapiens 155-164 7670564-3 1995 Bromocriptine administration caused a decrease in the serum PRL concentration ranging 24-95% and there was no correlation between the basal PRL level and bromocriptine-induced inhibition. Bromocriptine 0-13 prolactin Homo sapiens 60-63 7670564-7 1995 When the inhibition rates in vitro due to 10(-5) M dopamine in these two parameters were compared with the inhibition rate in vivo in the serum PRL concentration due to bromocriptine, it was found that there was a significant correlation between them. Dopamine 51-59 prolactin Homo sapiens 144-147 7670564-7 1995 When the inhibition rates in vitro due to 10(-5) M dopamine in these two parameters were compared with the inhibition rate in vivo in the serum PRL concentration due to bromocriptine, it was found that there was a significant correlation between them. Bromocriptine 169-182 prolactin Homo sapiens 144-147 7670564-8 1995 These results show that the reverse hemolytic plaque assay can be used to determine in vitro responsiveness to dopamine of PRL secretion from single prolactinoma cells. Dopamine 111-119 prolactin Homo sapiens 123-126 8531896-2 1995 We studied the effects of sumatriptan, a new 5-HT1D receptor agonist, on PRL and GH secretion in active acromegaly. Sumatriptan 26-37 prolactin Homo sapiens 73-76 9363245-0 1995 Production of endometrial placental protein 14 and prolactin by cultured endometrial explants after collagenase and freeze/thaw treatment, and in response to progesterone. Progesterone 158-170 prolactin Homo sapiens 51-60 9363245-6 1995 RESULTS: Production of prolactin, but not PP14, was increased by 200 nmol/l progesterone, 2-8-fold after 4 days and 1.5-700-fold after 7 days in culture. Progesterone 76-88 prolactin Homo sapiens 23-32 7594236-1 1995 The role of serotonin in the insulin hypoglycemia (IH) stimulated secretion of prolactin (PRL), growth hormone (GH), adrenocorticotropin (ACTH) and cortisol (F) was studied in a group of 12 normal subjects during the control period after placebo and a consecutive six-day treatment with 20 mg ritanserin (RIT) per day. Serotonin 12-21 prolactin Homo sapiens 79-88 7673654-0 1995 Trazodone treatment increases plasma prolactin concentrations in depressed patients. Trazodone 0-9 prolactin Homo sapiens 37-46 7673654-2 1995 To examine for the possibility that m-CPP is involved in biochemical effects during treatment with the parent compound, prolactin response to trazodone treatment (150 mg at bedtime for 3 weeks) was studied in 12 depressed patients. Trazodone 142-151 prolactin Homo sapiens 120-129 7673654-6 1995 The present study thus shows that trazodone treatment increases prolactin concentrations, suggesting that m-CPP is involved in biochemical effects during treatment with the parent compound. Trazodone 34-43 prolactin Homo sapiens 64-73 7675967-2 1995 Pindolol pretreatment attenuated the (+)-fenfluramine-induced increase in prolactin concentrations but failed to affect the (+)-fenfluramine-induced cortisol increase. Pindolol 0-8 prolactin Homo sapiens 74-83 7675967-2 1995 Pindolol pretreatment attenuated the (+)-fenfluramine-induced increase in prolactin concentrations but failed to affect the (+)-fenfluramine-induced cortisol increase. Fenfluramine 37-53 prolactin Homo sapiens 74-83 7640329-1 1995 We report on the plasma cortisol and prolactin responses to the serotonergic agonist m-CPP (0.1 mg/kg) in 10 patients with winter seasonal affective disorder (SAD) and 10 controls during the winter, in both untreated and bright light-treated conditions; and on 8 other SAD patients and 8 other controls during the summer. 1-(3-chlorophenyl)piperazine 85-90 prolactin Homo sapiens 37-46 8585180-2 1995 Radioimmunoassay of blood prolactin enabled the state of these receptors to be evaluated before and after loading with D2-receptor agonist (bromocriptine) and antagonist (metoclopramide). Bromocriptine 140-153 prolactin Homo sapiens 26-35 9098469-5 1995 The patient started Cabergoline treatment with good results: normalization of PRL levels after 5 days, of the visual field after 58 days and complete disappearance of prolactinoma within 180 days from the beginning of treatment. Cabergoline 20-31 prolactin Homo sapiens 78-81 7714616-0 1995 Prolactin-producing pituitary tumor: resistance to dopamine agonist therapy. Dopamine 51-59 prolactin Homo sapiens 0-9 7744007-8 1995 The activation of DNA binding by prolactin, EPO and GH requires the phosphorylation of tyrosine residue 694 of MGF-Stat5. Tyrosine 87-95 prolactin Homo sapiens 33-42 7594225-11 1995 Elevated PRL levels also declined with the use of higher doses of octreotide. Octreotide 66-76 prolactin Homo sapiens 9-12 8585180-2 1995 Radioimmunoassay of blood prolactin enabled the state of these receptors to be evaluated before and after loading with D2-receptor agonist (bromocriptine) and antagonist (metoclopramide). Metoclopramide 171-185 prolactin Homo sapiens 26-35 8585180-3 1995 In all forms of SCD, the rate of blood prolactin decrease in response to bromocriptine, was significantly lower than control values, which demonstrated the lower sensitivity of D2-receptors in the hypothalamic tubero-infundibular region to agonists. Bromocriptine 73-86 prolactin Homo sapiens 39-48 8585180-4 1995 Metoclopramide caused a higher increase in blood prolactin levels than in the controls. Metoclopramide 0-14 prolactin Homo sapiens 49-58 7568634-0 1995 Effect of pindolol on the prolactin response to d-fenfluramine. Pindolol 10-18 prolactin Homo sapiens 26-35 7619973-1 1995 In response to the partial serotonin agonist meta-chlorophenylpiperazine (metaCPP), patients with obsessive-compulsive disorder have been reported to exhibit an increase in obsessive symptoms and a diminished release of prolactin and/or cortisol compared to controls. 1-(3-chlorophenyl)piperazine 45-72 prolactin Homo sapiens 220-229 7619973-1 1995 In response to the partial serotonin agonist meta-chlorophenylpiperazine (metaCPP), patients with obsessive-compulsive disorder have been reported to exhibit an increase in obsessive symptoms and a diminished release of prolactin and/or cortisol compared to controls. 1-(3-chlorophenyl)piperazine 74-81 prolactin Homo sapiens 220-229 7534770-8 1995 PGE2 stimulated the release of PRL and IGFBP-1 from cells cultured on laminin to levels comparable to those from cells cultured on plastic or other ECM proteins. Dinoprostone 0-4 prolactin Homo sapiens 31-34 7568634-0 1995 Effect of pindolol on the prolactin response to d-fenfluramine. Dexfenfluramine 48-62 prolactin Homo sapiens 26-35 7568634-1 1995 We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers. Pindolol 57-65 prolactin Homo sapiens 74-83 7568634-1 1995 We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers. Pindolol 57-65 prolactin Homo sapiens 85-88 7568634-1 1995 We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers. Dexfenfluramine 128-142 prolactin Homo sapiens 74-83 7568634-1 1995 We studied the effect of the 5-HT1A receptor antagonist, pindolol, on the prolactin (PRL) response to the 5-HT releasing agent, d-fenfluramine (d-FEN), in ten healthy male volunteers. Dexfenfluramine 128-142 prolactin Homo sapiens 85-88 7568634-2 1995 Pindolol pretreatment lowered baseline PRL levels but, when this effect was taken into account, did not significantly attenuate the PRL response to d-FEN. Pindolol 0-8 prolactin Homo sapiens 39-42 7568634-4 1995 We propose that the PRL response to d-FEN may involve selective activation of postsynaptic 5-HT2 receptors. Dexfenfluramine 36-41 prolactin Homo sapiens 20-23 7772644-2 1995 Using the cortisol synthesis inhibitor ketoconazole, we investigated the effects of directly lowering cortisol on the symptoms and the response of prolactin (PRL) to d-fenfluramine in eight patients suffering from major depression. Dexfenfluramine 166-180 prolactin Homo sapiens 147-156 7750626-8 1995 Treatment with 50-100 micrograms of levothyroxine sodium normalized her thyroid function and secretion of GH and prolactin. Thyroxine 36-56 prolactin Homo sapiens 113-122 7772644-2 1995 Using the cortisol synthesis inhibitor ketoconazole, we investigated the effects of directly lowering cortisol on the symptoms and the response of prolactin (PRL) to d-fenfluramine in eight patients suffering from major depression. Dexfenfluramine 166-180 prolactin Homo sapiens 158-161 7772644-3 1995 Prolactin responses to d-fenfluramine were measured, and patients were treated with 400-600 mg of ketoconazole for 4 weeks, after which they were retested. Dexfenfluramine 23-37 prolactin Homo sapiens 0-9 7772644-5 1995 Posttreatment prolactin responses to d-fenfluramine were higher than pretreatment values. Dexfenfluramine 37-51 prolactin Homo sapiens 14-23 7772644-6 1995 Ketoconazole normalizes the blunted prolactin responses to d-fenfluramine and may be an effective method by which to treat depression. Ketoconazole 0-12 prolactin Homo sapiens 36-45 7772644-6 1995 Ketoconazole normalizes the blunted prolactin responses to d-fenfluramine and may be an effective method by which to treat depression. Dexfenfluramine 59-73 prolactin Homo sapiens 36-45 7537011-3 1995 The influence exerted by the EGF, the DHT and the PRL on the BPH cell proliferation was characterized by adding these compounds alone or in combination to the culture media. 1-Benzyl-1-phenylhydrazine hydrochloride 61-64 prolactin Homo sapiens 50-53 8614237-0 1995 A possible role for nitric oxide but not for prostaglandin E2 in basal and interleukin-1-beta-induced PRL release in vitro. Nitric Oxide 20-32 prolactin Homo sapiens 102-105 7537011-5 1995 The results show that of the DHT, EGF and PRL, the first two induced a statistically significant increase in the cell proliferation rate in a proportion of BPH significantly higher than the proportion of BPHs whose cell proliferation was increased significantly by the PRL. 1-Benzyl-1-phenylhydrazine hydrochloride 156-159 prolactin Homo sapiens 42-45 8614237-3 1995 L-NG-nitro-arginine, an inhibitor of nitric oxide synthetase, and hemoglobin, a NO scavenger, impaired basal and interleukin-1-beta-induced PRL release, while molsidomine, a NO donor, was able to release PRL and to amplify interleukin-1-beta-induced PRL release, confirming a modulatory role for nitric oxide in pituitary hormone secretion. Nitroarginine 0-19 prolactin Homo sapiens 140-143 7756454-6 1995 As with endometrial stromal cells, continuous treatment of the decidual fibroblast cells with the progesterone analog medroxyprogesterone acetate and estradiol in combination with either dibutyryl-cAMP or prostaglandin E2 induced cell aggregation and the expression of prolactin (PRL) and insulin-like growth factor-binding protein-1 (IGFBP-1). Medroxyprogesterone Acetate 118-145 prolactin Homo sapiens 269-278 7613098-0 1995 Effects of methysergide and ritanserin on the prolactin and thyrotropin responses to TRH in depressed patients. Ritanserin 28-38 prolactin Homo sapiens 46-55 7613098-3 1995 Methysergide was found to decrease significantly the PRL response to TRH, while ritanserin had no effect. Methysergide 0-12 prolactin Homo sapiens 53-56 7613098-6 1995 The reduction in PRL observed after methysergide is probably due to either 5-HT1 or dopaminergic mechanisms. Methysergide 36-48 prolactin Homo sapiens 17-20 7789747-2 1995 Injections of ovine prolactin (oPRL) or homologous fish pituitary extract or partially purified prolactin of murrel, Channa punctatus pituitary (mPRL), caused significant increases in total and ultrafiltrable plasma calcium. Calcium 216-223 prolactin Homo sapiens 20-29 7789747-2 1995 Injections of ovine prolactin (oPRL) or homologous fish pituitary extract or partially purified prolactin of murrel, Channa punctatus pituitary (mPRL), caused significant increases in total and ultrafiltrable plasma calcium. Calcium 216-223 prolactin Homo sapiens 96-105 7789747-7 1995 These results indicate that PRL may be involved in regulating plasma calcium levels in fish. Calcium 69-76 prolactin Homo sapiens 28-31 7756454-6 1995 As with endometrial stromal cells, continuous treatment of the decidual fibroblast cells with the progesterone analog medroxyprogesterone acetate and estradiol in combination with either dibutyryl-cAMP or prostaglandin E2 induced cell aggregation and the expression of prolactin (PRL) and insulin-like growth factor-binding protein-1 (IGFBP-1). Medroxyprogesterone Acetate 118-145 prolactin Homo sapiens 280-283 7759666-2 1995 In women, dieting significantly lowered plasma total and free tryptophan (TRP) and increased the PRL response to d-fenfluramine. Dexfenfluramine 113-127 prolactin Homo sapiens 97-100 7759666-0 1995 Dieting decreases plasma tryptophan and increases the prolactin response to d-fenfluramine in women but not men. Dexfenfluramine 76-90 prolactin Homo sapiens 54-63 7852536-4 1995 Pit-1 is also important for hormonal regulation of the PRL and TSH-beta genes by TRH and cAMP. Cyclic AMP 89-93 prolactin Homo sapiens 55-58 7711159-1 1995 The prolactin (PRL) response to 0.5 mg of intravenous haloperidol (HPL) IV may be a measure of tuberoinfundibular dopaminergic activity. Haloperidol 54-65 prolactin Homo sapiens 15-18 7711159-1 1995 The prolactin (PRL) response to 0.5 mg of intravenous haloperidol (HPL) IV may be a measure of tuberoinfundibular dopaminergic activity. Haloperidol 67-70 prolactin Homo sapiens 15-18 7729332-5 1995 In the only comparative study to date, cabergoline 0.5 to 1.0 mg twice weekly was more effective than bromocriptine 2.5 to 5.0 mg twice daily in the treatment of hyperprolactinaemic amenorrhoea, restoring ovulatory cycles in 72% of women and normalising plasma prolactin levels in 83%, compared with 52 and 58%, respectively, for bromocriptine. Cabergoline 39-50 prolactin Homo sapiens 167-176 7852517-12 1995 PRL levels did not change on the first NTX day vs. the control day (166 +/- 79 vs. 167 +/- 67 micrograms/L); however, PRL did increase over time with continued NTX treatment (P < 0.05). Naltrexone 160-163 prolactin Homo sapiens 118-121 7852517-13 1995 The mean PRL level during chronic NTX treatment was 255 +/- 121 micrograms/L. Naltrexone 34-37 prolactin Homo sapiens 9-12 7604150-4 1995 Both basal and thyrotropin releasing hormone (TRH) -induced prolactin secretion diminished significantly to 26.4% and 22.8% of baseline levels, respectively, under roxindole. roxindole 164-173 prolactin Homo sapiens 60-69 7716193-2 1995 Prolactin response to fenfluramine was distributed bimodally with 24 monkeys displaying a "low" prolactin response and 15 showing a "high" prolactin response to the fenfluramine challenge. Fenfluramine 22-34 prolactin Homo sapiens 0-9 7716193-2 1995 Prolactin response to fenfluramine was distributed bimodally with 24 monkeys displaying a "low" prolactin response and 15 showing a "high" prolactin response to the fenfluramine challenge. Fenfluramine 165-177 prolactin Homo sapiens 0-9 7530217-0 1995 Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. Sirolimus 0-9 prolactin Homo sapiens 49-58 7530217-0 1995 Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. Tacrolimus 11-16 prolactin Homo sapiens 49-58 7530217-0 1995 Rapamycin, FK506 and cyclosporin A inhibit human prolactin gene expression. Cyclosporine 21-34 prolactin Homo sapiens 49-58 7530217-1 1995 In this work we demonstrate that transcription of the human prolactin gene is inhibited by the immunosuppressants FK506 (IC50 = 25 nM), cyclosporin A (IC50 = 190 nM) and rapamycin (IC50 = 25 nM). Tacrolimus 114-119 prolactin Homo sapiens 60-69 7530217-1 1995 In this work we demonstrate that transcription of the human prolactin gene is inhibited by the immunosuppressants FK506 (IC50 = 25 nM), cyclosporin A (IC50 = 190 nM) and rapamycin (IC50 = 25 nM). Cyclosporine 136-149 prolactin Homo sapiens 60-69 7530217-1 1995 In this work we demonstrate that transcription of the human prolactin gene is inhibited by the immunosuppressants FK506 (IC50 = 25 nM), cyclosporin A (IC50 = 190 nM) and rapamycin (IC50 = 25 nM). Sirolimus 170-179 prolactin Homo sapiens 60-69 7530217-2 1995 Whereas the effect of FK506 and cyclosporin A is specific for prolactin gene transcription, rapamycin has a more general effect on transcription and/or translation in pituitary cells. Tacrolimus 22-27 prolactin Homo sapiens 62-71 7530217-2 1995 Whereas the effect of FK506 and cyclosporin A is specific for prolactin gene transcription, rapamycin has a more general effect on transcription and/or translation in pituitary cells. Cyclosporine 32-45 prolactin Homo sapiens 62-71 7840614-4 1995 The results show that MAPK stimulation is transient (peak activity, 30 min) and precedes that of S6K, which reaches a maximum at 1.5-2 h, and slowly returns towards control levels at 6 h. Both staurosporine which inhibits GH receptor-associated kinase (JAK2) and genistein (GEN), an inhibitor of membrane-associated and cytoplasmic TKs, abrogate Prl-stimulated TK, MAPK, and S6K. Staurosporine 193-206 prolactin Homo sapiens 346-349 7755189-8 1995 Presumably, in Klinefelter"s syndrome both alterations--of prolactin and thyrotrophin secretion--may be caused by decrease of testosterone levels or they could reflect a disturbance in neuroendocrine regulation with some neurotransmitter imbalance. Testosterone 126-138 prolactin Homo sapiens 59-68 7529411-21 1995 NO appears to play little role in the prolactin-releasing action of vasoactive intestinal polypeptide and substance P, but mediates the prolactin-inhibiting activity of dopamine and atrial natriuretic factor. Dopamine 169-177 prolactin Homo sapiens 136-145 8744700-1 1995 Domperidone, anti-emetic drug, given to healthy female volunteers, induced an elevation of plasma prolactin (PRL) concentration with the peak in 1-4 h. The release of prolactin had a transient stimulating effect on theophylline sensitive T lymphocytes and on concanavalin A induced mitogenic activity, suggesting an enhanced activity of T suppressor lymphocytes. Domperidone 0-11 prolactin Homo sapiens 98-107 8744700-1 1995 Domperidone, anti-emetic drug, given to healthy female volunteers, induced an elevation of plasma prolactin (PRL) concentration with the peak in 1-4 h. The release of prolactin had a transient stimulating effect on theophylline sensitive T lymphocytes and on concanavalin A induced mitogenic activity, suggesting an enhanced activity of T suppressor lymphocytes. Domperidone 0-11 prolactin Homo sapiens 167-176 8744700-1 1995 Domperidone, anti-emetic drug, given to healthy female volunteers, induced an elevation of plasma prolactin (PRL) concentration with the peak in 1-4 h. The release of prolactin had a transient stimulating effect on theophylline sensitive T lymphocytes and on concanavalin A induced mitogenic activity, suggesting an enhanced activity of T suppressor lymphocytes. Theophylline 215-227 prolactin Homo sapiens 98-107 8744700-1 1995 Domperidone, anti-emetic drug, given to healthy female volunteers, induced an elevation of plasma prolactin (PRL) concentration with the peak in 1-4 h. The release of prolactin had a transient stimulating effect on theophylline sensitive T lymphocytes and on concanavalin A induced mitogenic activity, suggesting an enhanced activity of T suppressor lymphocytes. Theophylline 215-227 prolactin Homo sapiens 167-176 7776178-0 1995 Circadian and ultradian variations of pituitary and pineal hormones in normal men: evidence for a link between melatonin, gonadotropin, and prolactin secretion. Melatonin 111-120 prolactin Homo sapiens 140-149 7529411-0 1995 Role of nitric oxide in control of prolactin release by the adenohypophysis. Nitric Oxide 8-20 prolactin Homo sapiens 35-44 7529411-4 1995 When hemipituitaries were incubated for 30 min in the presence of sodium nitroprusside, a releaser of NO, prolactin release was inhibited. Nitroprusside 66-86 prolactin Homo sapiens 106-115 7529411-8 1995 Since in other tissues most of the actions of NO are mediated by activation of soluble guanylate cyclase with the formation of cyclic GMP, we evaluated the effects of cyclic GMP on prolactin release. Cyclic GMP 167-177 prolactin Homo sapiens 181-190 7529411-9 1995 Cyclic GMP (10 mM) produced an approximately 40% reduction in prolactin release. Cyclic GMP 0-10 prolactin Homo sapiens 62-71 7529411-12 1995 In the case of vasoactive intestinal polypeptide, the significant stimulation of prolactin release was augmented by NMMA to give an additive effect. omega-N-Methylarginine 116-120 prolactin Homo sapiens 81-90 7529411-15 1995 Dopamine (0.1 microM), an inhibitor of prolactin release, reduced prolactin release, and this inhibitory action was significantly blocked by either hemoglobin (20 micrograms/ml) or NMMA and was completely blocked by 1 mM nitroarginine methyl ester. Dopamine 0-8 prolactin Homo sapiens 39-48 7529411-15 1995 Dopamine (0.1 microM), an inhibitor of prolactin release, reduced prolactin release, and this inhibitory action was significantly blocked by either hemoglobin (20 micrograms/ml) or NMMA and was completely blocked by 1 mM nitroarginine methyl ester. Dopamine 0-8 prolactin Homo sapiens 66-75 7529411-17 1995 In contrast to these results with prolactin, luteinizing hormone (LH) was measured in the same medium in which the effect of nitroprusside was tested on prolactin release, there was no effect of nitroprusside, hemoglobin, or the combination of nitroprusside and hemoglobin on luteinizing hormone release. Nitroprusside 125-138 prolactin Homo sapiens 153-162 7890253-0 1995 Effect of acute ethanol ingestion on prolactin in menopausal women using estradiol replacement. Ethanol 16-23 prolactin Homo sapiens 37-46 7890253-0 1995 Effect of acute ethanol ingestion on prolactin in menopausal women using estradiol replacement. Estradiol 73-82 prolactin Homo sapiens 37-46 7890253-2 1995 Two randomized, crossover studies were performed to examine the effects of ethanol on prolactin in menopausal women using transdermal estradiol. Ethanol 75-82 prolactin Homo sapiens 86-95 7890253-5 1995 Prolactin levels were measured frequently for 6.3 h. Serum ethanol levels reached a broad peak from 40 to 100 min after initiation of ethanol ingestion. Ethanol 59-66 prolactin Homo sapiens 0-9 7890253-6 1995 Serum prolactin levels were significantly higher after ethanol ingestion than after the isocaloric carbohydrate drink ingestion (p < 0.03). Ethanol 55-62 prolactin Homo sapiens 6-15 7890253-6 1995 Serum prolactin levels were significantly higher after ethanol ingestion than after the isocaloric carbohydrate drink ingestion (p < 0.03). Carbohydrates 99-111 prolactin Homo sapiens 6-15 7890253-8 1995 In study 2, serum prolactin was greater after ethanol ingestion than after carbohydrate ingestion (p < 0.001). Ethanol 46-53 prolactin Homo sapiens 18-27 7890253-8 1995 In study 2, serum prolactin was greater after ethanol ingestion than after carbohydrate ingestion (p < 0.001). Carbohydrates 75-87 prolactin Homo sapiens 18-27 7890253-9 1995 In menopausal women using transdermal estradiol, acute ethanol ingestion is associated with an increase in serum prolactin. Estradiol 38-47 prolactin Homo sapiens 113-122 7890253-9 1995 In menopausal women using transdermal estradiol, acute ethanol ingestion is associated with an increase in serum prolactin. Ethanol 55-62 prolactin Homo sapiens 113-122 8852276-0 1995 The influence of calcium infusion on serum prolactin in hyperprolactinemic women. Calcium 17-24 prolactin Homo sapiens 43-52 8852276-1 1995 This study investigated the influence of calcium on serum prolactin (PRL) in hyperprolactinemic and healthy women. Calcium 41-48 prolactin Homo sapiens 58-67 8852276-1 1995 This study investigated the influence of calcium on serum prolactin (PRL) in hyperprolactinemic and healthy women. Calcium 41-48 prolactin Homo sapiens 69-72 8852276-4 1995 Serum PRL level was significantly decreased by calcium injection in hyperprolactinemic women (89.2 +/- 29.1 and 63.3 +/- 35.8 ng/ml; p < 0.01) while it was not significant (p > 0.05) in women with normal PRL levels (12.6 +/- 5.1 ng/ml and 11.3 +/- 4.0 ng/ml). Calcium 47-54 prolactin Homo sapiens 6-9 8852276-4 1995 Serum PRL level was significantly decreased by calcium injection in hyperprolactinemic women (89.2 +/- 29.1 and 63.3 +/- 35.8 ng/ml; p < 0.01) while it was not significant (p > 0.05) in women with normal PRL levels (12.6 +/- 5.1 ng/ml and 11.3 +/- 4.0 ng/ml). Calcium 47-54 prolactin Homo sapiens 210-213 8852276-5 1995 These results indicate that acute alterations in serum calcium levels affect PRL secretion in hyperprolactinemic women. Calcium 55-62 prolactin Homo sapiens 77-80 7889620-1 1994 OBJECTIVE: To audit the efficacy of quinagolide (CV205-502, Norprolac, Sandoz) in lowering prolactin, and its tolerability, in patients with bromocriptine resistance (BCR) or bromocriptine intolerance (BCI), in view of the paucity of results published in patients specifically with BCR or BCI, by collating results in our own patients with the reports in the literature. quinagolide 36-47 prolactin Homo sapiens 91-100 7565071-0 1995 [The linear correlation coefficient of serotonin and prolactin concentrations in plasma of women chronically exposed to carbon disulfide]. Carbon Disulfide 120-136 prolactin Homo sapiens 53-62 7565071-5 1995 The linear correlation between serotonin and prolactin concentrations was also significantly positive (r = 0.44; p 0.01) in women expose to carbon disulfide. Serotonin 31-40 prolactin Homo sapiens 45-54 7565071-5 1995 The linear correlation between serotonin and prolactin concentrations was also significantly positive (r = 0.44; p 0.01) in women expose to carbon disulfide. Carbon Disulfide 140-156 prolactin Homo sapiens 45-54 8851636-3 1995 We examined the PRL response to intravenous perphenazine (PZ) in 11 elderly patients with psychotic symptoms complicating either a major depression (MD-P) or a dementia. Perphenazine 44-56 prolactin Homo sapiens 16-19 7893848-2 1994 In order to evaluate whether sleep deprivation (SD) produces alterations in 5-HT function, the increase in prolactin (PRL) produced by intravenous tryptophan (TRP) was assessed in depressed patients following SD and undisturbed sleep (US). Tryptophan 147-157 prolactin Homo sapiens 107-116 7893848-2 1994 In order to evaluate whether sleep deprivation (SD) produces alterations in 5-HT function, the increase in prolactin (PRL) produced by intravenous tryptophan (TRP) was assessed in depressed patients following SD and undisturbed sleep (US). Tryptophan 159-162 prolactin Homo sapiens 107-116 7810625-6 1994 However, PMA inhibited basal PRL release and also enhanced the inhibitory effect of ET-1. Tetradecanoylphorbol Acetate 9-12 prolactin Homo sapiens 29-32 7810625-7 1994 The PKC inhibitor staurosporine increased basal PRL release and completely reversed the inhibitory effect of ET on PRL release. Staurosporine 18-31 prolactin Homo sapiens 48-51 7810625-7 1994 The PKC inhibitor staurosporine increased basal PRL release and completely reversed the inhibitory effect of ET on PRL release. Staurosporine 18-31 prolactin Homo sapiens 115-118 7859890-13 1994 By the administration of bromocriptine, serum prolactin levels decreased both in group A and B, and the elevated serum LH/FSH ratio (1.0 +/- 0.4, p < = 0.02), LH30 (46.1 +/- 37.0mIU/ml, p < 0.005) also decreased significantly. Bromocriptine 25-38 prolactin Homo sapiens 46-55 7859890-16 1994 From these facts, it was concluded that FSH secretion was suppressed even by a slight increase of serum prolactin levels which was usually seen in the OHP, and bromocriptine administration was effective not only for the suppression of serum prolactin and LH levels, but also for the improvement of FSH secretion in the OHP patients. Bromocriptine 160-173 prolactin Homo sapiens 241-250 7889620-8 1994 In bromocriptine intolerance, prolactin was normalized by quinagolide in doses of 225 micrograms or less in 58% of published cases and in 3 more patients by higher doses up to 1050 micrograms. Bromocriptine 3-16 prolactin Homo sapiens 30-39 7889620-8 1994 In bromocriptine intolerance, prolactin was normalized by quinagolide in doses of 225 micrograms or less in 58% of published cases and in 3 more patients by higher doses up to 1050 micrograms. quinagolide 58-69 prolactin Homo sapiens 30-39 7889620-1 1994 OBJECTIVE: To audit the efficacy of quinagolide (CV205-502, Norprolac, Sandoz) in lowering prolactin, and its tolerability, in patients with bromocriptine resistance (BCR) or bromocriptine intolerance (BCI), in view of the paucity of results published in patients specifically with BCR or BCI, by collating results in our own patients with the reports in the literature. quinagolide 60-69 prolactin Homo sapiens 91-100 7889620-2 1994 DESIGN: Open prospective, uncontrolled administration of quinagolide in patients with BCR (defined for this report as failure to attain normal prolactin levels after 4 months of bromocriptine at maximum tolerated doses), or BCI (defined as a patient request to cease bromocriptine treatment because of side-effects at doses that were required, or failed, to normalize PRL levels). quinagolide 57-68 prolactin Homo sapiens 143-152 7889620-7 1994 CONCLUSIONS: Results in our 12 patients are broadly in line with those in 51 patients with bromocriptine resistance and 39 with bromocriptine intolerance extracted from various published reports, which together suggest that prolactin can be normalized in 16% of patients with bromocriptine resistance by quinagolide in doses of 225 micrograms or less, and in a further 20% by higher doses up to 600 micrograms. Bromocriptine 91-104 prolactin Homo sapiens 224-233 7889620-7 1994 CONCLUSIONS: Results in our 12 patients are broadly in line with those in 51 patients with bromocriptine resistance and 39 with bromocriptine intolerance extracted from various published reports, which together suggest that prolactin can be normalized in 16% of patients with bromocriptine resistance by quinagolide in doses of 225 micrograms or less, and in a further 20% by higher doses up to 600 micrograms. Bromocriptine 128-141 prolactin Homo sapiens 224-233 7889620-7 1994 CONCLUSIONS: Results in our 12 patients are broadly in line with those in 51 patients with bromocriptine resistance and 39 with bromocriptine intolerance extracted from various published reports, which together suggest that prolactin can be normalized in 16% of patients with bromocriptine resistance by quinagolide in doses of 225 micrograms or less, and in a further 20% by higher doses up to 600 micrograms. Bromocriptine 128-141 prolactin Homo sapiens 224-233 7889620-7 1994 CONCLUSIONS: Results in our 12 patients are broadly in line with those in 51 patients with bromocriptine resistance and 39 with bromocriptine intolerance extracted from various published reports, which together suggest that prolactin can be normalized in 16% of patients with bromocriptine resistance by quinagolide in doses of 225 micrograms or less, and in a further 20% by higher doses up to 600 micrograms. quinagolide 304-315 prolactin Homo sapiens 224-233 21559725-0 1994 Prolactin receptor-linked tyrosine-phosphorylation of membrane-proteins is mediated by GTP-binding protein in endometrial carcinoma and endometrium. Tyrosine 26-34 prolactin Homo sapiens 0-9 21559725-0 1994 Prolactin receptor-linked tyrosine-phosphorylation of membrane-proteins is mediated by GTP-binding protein in endometrial carcinoma and endometrium. Guanosine Triphosphate 87-90 prolactin Homo sapiens 0-9 21559725-9 1994 PRL may decrease the phosphotyrosine level in protein substrates through block of tyrosine kinase. Phosphotyrosine 21-36 prolactin Homo sapiens 0-3 7715466-0 1994 Antagonism of oestrogen-induced prolactin release by medroxyprogesterone acetate. Medroxyprogesterone Acetate 53-80 prolactin Homo sapiens 32-41 7886088-1 1994 Exposure to ethanol is followed by changes in reproductive function in man and animals, characterized by modifications in the secretion patterns of prolactin and luteinizing hormone (LH). Ethanol 12-19 prolactin Homo sapiens 148-157 7704434-3 1994 In intact cells, the AT1 antagonist DuP753 blocked Ang II-induced PRL release, reversed in a dose dependent manner Ang II-evoked inositol phosphates production, and inhibited completely the PLC and protein kinase C (PKC) dependent cAMP accumulation induced by Ang II. Losartan 36-42 prolactin Homo sapiens 66-69 7977731-0 1994 Stimulation of prolactin release by dopamine withdrawal: role of membrane hyperpolarization. Dopamine 36-44 prolactin Homo sapiens 15-24 7977731-1 1994 Hypothalamic dopamine (DA) tonically inhibits prolactin (PRL) release from the anterior pituitary gland, whereas removal of DA markedly augments its release to values exceeding pre-DA rates. Dopamine 13-21 prolactin Homo sapiens 46-55 7977731-1 1994 Hypothalamic dopamine (DA) tonically inhibits prolactin (PRL) release from the anterior pituitary gland, whereas removal of DA markedly augments its release to values exceeding pre-DA rates. Dopamine 23-25 prolactin Homo sapiens 46-55 7929252-0 1994 The insulin and cAMP response elements of the prolactin gene are overlapping sequences. Cyclic AMP 16-20 prolactin Homo sapiens 46-55 7926136-1 1994 OBJECTIVE: To study the efficacy of long-acting repeatable bromocriptine in suppressing abnormal PRL secretion in microprolactinoma patients. Bromocriptine 59-72 prolactin Homo sapiens 97-100 7943465-1 1994 The prolactin response to oral d-fenfluramine (30 mg) was measured in nine patients with late-onset Alzheimer"s disease and in an elderly comparison group. Dexfenfluramine 31-45 prolactin Homo sapiens 4-13 7943465-2 1994 The serotonin-mediated prolactin response was significantly greater in the patients with Alzheimer"s disease than in the comparison group. Serotonin 4-13 prolactin Homo sapiens 23-32 7962804-6 1994 Case 1 was treated with bromocriptine, leading to marked decrease in serum PRL levels and reduction of tumor size. Bromocriptine 24-37 prolactin Homo sapiens 75-78 7929252-2 1994 This report identifies sequences within the prolactin gene promoter that are required for the responses to cAMP and insulin. Cyclic AMP 107-111 prolactin Homo sapiens 44-53 7929252-5 1994 This is characteristic of cAMP response elements, but the importance of this element to basal prolactin gene transcription was previously unrecognized. Cyclic AMP 26-30 prolactin Homo sapiens 94-103 7929252-8 1994 Together, insulin and cAMP increase prolactin gene expression additively. Cyclic AMP 22-26 prolactin Homo sapiens 36-45 7994262-6 1994 In allogeneic recipients exhibiting no GVHD, serum prolactin levels were positively correlated with serum cyclosporin levels (p < 0.05). Cyclosporine 106-117 prolactin Homo sapiens 51-60 7851873-2 1994 In the normal group a non-significant increase in PRL levels occurred (mean +/- SEM = 11.7 +/- 2.9 micrograms/l verapamil vs. 8.5 +/- 1.4 micrograms/l saline). Verapamil 112-121 prolactin Homo sapiens 50-53 7851873-4 1994 In the hyperprolactinemic subjects verapamil induced opposite effects on PRL levels, the prolactinoma group exhibiting an increase in the mean values (168.5 +/- 22.3 micrograms/l vs. 150.8 +/- 23.6 micrograms/l on saline, p = 0.04) whereas in the sulpiride-induced there was a reduction in the mean PRL levels (61.1 +/- 13.8 micrograms/l vs. 78.5 +/- 19.3 micrograms/l on saline, p = 0.002). Verapamil 35-44 prolactin Homo sapiens 73-76 7925280-12 1994 Prolactin stimulation of transfected cells induces Stat5 phosphorylation on tyrosine. Tyrosine 76-84 prolactin Homo sapiens 0-9 7955444-1 1994 OBJECTIVE: Reduced PRL responses to TRH or dopamine antagonists have been described in hyperthyroid patients. Dopamine 43-51 prolactin Homo sapiens 19-22 7955444-2 1994 Arginine stimulates PRL secretion through pathways other than the activation of TRH receptors or dopamine-dependent mechanisms. Arginine 0-8 prolactin Homo sapiens 20-23 7955444-3 1994 We therefore investigated PRL responses to arginine in patients with hyperthyroidism. Arginine 43-51 prolactin Homo sapiens 26-29 7955444-9 1994 PRL responses to arginine, small but clearly detectable in normal men, were completely abolished in hyperthyroid men (peak PRL levels, 248 +/- 48 mU/l, vs 112 +/- 14, P < 0.01). Arginine 17-25 prolactin Homo sapiens 0-3 7955444-9 1994 PRL responses to arginine, small but clearly detectable in normal men, were completely abolished in hyperthyroid men (peak PRL levels, 248 +/- 48 mU/l, vs 112 +/- 14, P < 0.01). Arginine 17-25 prolactin Homo sapiens 123-126 7955444-10 1994 CONCLUSIONS: PRL responses to arginine are impaired in hyperthyroid patients. Arginine 30-38 prolactin Homo sapiens 13-16 7955444-11 1994 Therefore, arginine should be added to the list of PRL stimuli whose responses are blunted in hyperthyroidism. Arginine 11-19 prolactin Homo sapiens 51-54 7814826-4 1994 The results confirm previous findings that in humans mCPP causes significant increases in the symptoms of anxiety, and in the plasma concentrations of cortisol, prolactin and growth hormone. 1-(3-chlorophenyl)piperazine 53-57 prolactin Homo sapiens 161-170 7836703-0 1994 Indirect evidence to suggest that prolactin induces salt retention in cirrhosis. Salts 52-56 prolactin Homo sapiens 34-43 7836703-1 1994 Prolactin is known to have renal sodium retention properties in animals. Sodium 33-39 prolactin Homo sapiens 0-9 7836703-5 1994 The effect of serum prolactin elevation on renal sodium and potassium excretion was studied in all patients after thyrotropin-releasing hormone stimulation (200 micrograms), with seven consecutive hourly urinary samples. Sodium 49-55 prolactin Homo sapiens 20-29 7836703-5 1994 The effect of serum prolactin elevation on renal sodium and potassium excretion was studied in all patients after thyrotropin-releasing hormone stimulation (200 micrograms), with seven consecutive hourly urinary samples. Potassium 60-69 prolactin Homo sapiens 20-29 7836703-8 1994 In contrast, in group II with a "high PRL release" (delta prolactin > 1000 mu u/ml, n = 11), significant reductions in urinary sodium (p < 0.01) and potassium (p < 0.02) excretion were observed, which lasted until the third hour after thyrotropin-releasing hormone injection. Sodium 130-136 prolactin Homo sapiens 58-67 7836703-10 1994 The pattern of urinary electrolyte changes and the stability of the ratio UK/UK+Na suggest a possible sodium-retaining effect of prolactin localized proximally to the distal tubule. Sodium 102-108 prolactin Homo sapiens 129-138 7870845-1 1994 Growth hormone (GH) and prolactin (PRL) responses to the acute administration of clonidine (150 micrograms) and apomorphine (0.5 mg) were investigated in parallel in 20 drug-free subchronic and chronic schizophrenic patients and in nine control subjects. Clonidine 81-90 prolactin Homo sapiens 35-38 7870845-6 1994 Significant correlations were observed between negative symptoms and GH responses to clonidine (negative), between negative symptoms and PRL responses to apomorphine (positive), and between positive symptoms and PRL responses to apomorphine (negative). Apomorphine 154-165 prolactin Homo sapiens 137-140 7870845-6 1994 Significant correlations were observed between negative symptoms and GH responses to clonidine (negative), between negative symptoms and PRL responses to apomorphine (positive), and between positive symptoms and PRL responses to apomorphine (negative). Apomorphine 229-240 prolactin Homo sapiens 212-215 7765089-1 1994 Human prolactin was partially purified from pituitary glands by a combination of alkaline extraction, ammonium sulphate precipitation, hydrophobic interaction chromatography and gel filtration. Ammonium Sulfate 102-119 prolactin Homo sapiens 6-15 7765089-4 1994 During chromatography on phenyl-Sepharose, it was found that bound prolactin could be eluted with aqueous buffer, in contrast to the organic solvents used by previous investigators. phenyl-sepharose 25-41 prolactin Homo sapiens 67-76 8041708-6 1994 The PRL-receptor complex signals tyrosine phosphorylation of JAK2, a nonreceptor tyrosine kinase, which may lead to activation of PRLIF. Tyrosine 33-41 prolactin Homo sapiens 4-7 7979805-7 1994 Seminal prolactin levels in leucocytospermic subjects were more associated with citric acid concentration than with corrected fructose, suggesting that prolactin is also secreted by the prostate. Citric Acid 80-91 prolactin Homo sapiens 8-17 7969823-1 1994 The most prominent previously reported clinical features of growth hormone (GH) and prolactin (PRL)-secreting pituitary adenomas associated with acromegaly have included the high incidence of galactorrhea in women and a generally more favorable response to dopamine agonist therapy. Dopamine 257-265 prolactin Homo sapiens 84-93 7941955-0 1994 Neuroendocrine studies in dementia patients: responses of plasma GH and PRL following bromocriptine administration. Bromocriptine 86-99 prolactin Homo sapiens 72-75 7941955-1 1994 Bromocriptine stimulates growth hormone (GH) secretion at the hypothalamus and suppresses prolactin (PRL) secretion at the pituitary level. Bromocriptine 0-13 prolactin Homo sapiens 90-99 7941955-1 1994 Bromocriptine stimulates growth hormone (GH) secretion at the hypothalamus and suppresses prolactin (PRL) secretion at the pituitary level. Bromocriptine 0-13 prolactin Homo sapiens 101-104 7979805-7 1994 Seminal prolactin levels in leucocytospermic subjects were more associated with citric acid concentration than with corrected fructose, suggesting that prolactin is also secreted by the prostate. Citric Acid 80-91 prolactin Homo sapiens 152-161 7979805-7 1994 Seminal prolactin levels in leucocytospermic subjects were more associated with citric acid concentration than with corrected fructose, suggesting that prolactin is also secreted by the prostate. Fructose 126-134 prolactin Homo sapiens 8-17 7950157-3 1994 Ten patients with prolactin-secreting pituitary adenomas received roxindol three times daily at a dosage of 7.5-30 mg/day for at least 4 weeks according to a prospective protocol. roxindole 66-74 prolactin Homo sapiens 18-27 8038904-0 1994 Opioid modulation of the gamma-aminobutyric acid-controlled inhibition of exercise-stimulated growth hormone and prolactin secretion in normal men. gamma-Aminobutyric Acid 25-48 prolactin Homo sapiens 113-122 8038904-1 1994 The possible involvement of endogenous opioids in the gamma-aminobutyric acid-controlled (GABAergic) inhibition of growth hormone (GH) and prolactin (PRL) during physical exercise was evaluated in normal men. gamma-Aminobutyric Acid 54-77 prolactin Homo sapiens 139-148 8038904-1 1994 The possible involvement of endogenous opioids in the gamma-aminobutyric acid-controlled (GABAergic) inhibition of growth hormone (GH) and prolactin (PRL) during physical exercise was evaluated in normal men. gamma-Aminobutyric Acid 54-77 prolactin Homo sapiens 150-153 8038904-7 1994 The administration of naloxone did not modify, whereas sodium valproate significantly reduced the plasma GH and PRL rise during exercise. Valproic Acid 55-71 prolactin Homo sapiens 112-115 8038904-8 1994 In the presence of sodium valproate, GH and PRL levels rose 3- and 1.5-fold, respectively, in response to exercise. Valproic Acid 19-35 prolactin Homo sapiens 44-47 8038904-9 1994 When naloxone was given together with sodium valproate, both GH and PRL responses to exercise were abolished completely. Naloxone 5-13 prolactin Homo sapiens 68-71 8038904-9 1994 When naloxone was given together with sodium valproate, both GH and PRL responses to exercise were abolished completely. Valproic Acid 38-54 prolactin Homo sapiens 68-71 7517048-6 1994 Finally, GH and PRL have been shown to induce the rapid tyrosine phosphorylation of an associated kinase, Janus kinase 2, and of the receptor itself. Tyrosine 56-64 prolactin Homo sapiens 16-19 8053078-3 1994 This study was performed to analyze PRL response to the serotonin-type 3 receptor antagonist ondansetron, a new active drug in the treatment of vomiting due to chemotherapy, in cancer patients. Ondansetron 93-104 prolactin Homo sapiens 36-39 8053078-8 1994 RESULTS: PRL mean levels significantly increased in response to metoclopramide. Metoclopramide 64-78 prolactin Homo sapiens 9-12 8051973-5 1994 PRL was determined prior to the study, 1, 3, 7, 14, and 28 days following the initial dose of bromocriptine and thereafter with monthly periodicity. Bromocriptine 94-107 prolactin Homo sapiens 0-3 8051973-6 1994 RESULTS: The PRL values decreased in those patients with macroprolactinomas following the administration of bromocriptine LAR; in 2 patients the monthly doses of bromocriptine LAR was increased to 100 mg since the month after the initial dose PRL remained greater than 200 ng/ml with serum RPL normalizing in most of the patients at 6 months of treatment. Bromocriptine 108-121 prolactin Homo sapiens 13-16 8051973-6 1994 RESULTS: The PRL values decreased in those patients with macroprolactinomas following the administration of bromocriptine LAR; in 2 patients the monthly doses of bromocriptine LAR was increased to 100 mg since the month after the initial dose PRL remained greater than 200 ng/ml with serum RPL normalizing in most of the patients at 6 months of treatment. Bromocriptine 162-175 prolactin Homo sapiens 243-246 7956751-5 1994 However, the plasma cortisol and PRL responses to MK-212 did not differ between the two groups. 6-chloro-2-(1-piperazinyl)pyrazine 50-56 prolactin Homo sapiens 33-36 7950157-13 1994 Thus, for the first time we could show a suppressive effect of roxindol on prolactin secretion in human prolactinomas. roxindole 63-71 prolactin Homo sapiens 75-84 8194638-3 1994 Patients with menstrual disturbances, galactorrhea, and confirmed elevations in serum PRL should have a screening TSH to rule out primary hypothyroidism (5). Thyrotropin 114-117 prolactin Homo sapiens 86-89 8077999-8 1994 Cost of selective prolactin estimation in patients with low testosterone levels resulted in a net saving of $2,574 per case detected. Testosterone 60-72 prolactin Homo sapiens 18-27 7942085-8 1994 In conclusion, in amenorrhea associated with weight loss the chronobiological organization of prolactin secretion is deranged, both as a result of a neuroendocrine alteration and as a result of low plasma levels of gonadal steroids. Steroids 223-231 prolactin Homo sapiens 94-103 7930386-1 1994 The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect. Clomipramine 86-98 prolactin Homo sapiens 140-149 7930386-1 1994 The present study was undertaken to examine the role of sleep disturbance, induced by clomipramine administration, on the secretory rate of prolactin (PRL) in addition to the direct drug effect. Clomipramine 86-98 prolactin Homo sapiens 151-154 8087709-7 1994 RESULTS: Five patients needed bromocriptine treatment of more than 12.5mg/day to decrease the serum prolactin level. Bromocriptine 30-43 prolactin Homo sapiens 100-109 8180669-2 1994 Diagnosis of possessing the anti-PRL autoantibody was based on the polyethylene glycol method, displacement of the binding of [125I]PRL with the serum by unlabeled PRL and the binding of PRL to protein G, the affinity gel for immunoglobulin G. Prolactin was measured by an immunoradiometric assay that we found was not affected by the anti-PRL autoantibody. Polyethylene Glycols 67-86 prolactin Homo sapiens 33-36 8188682-0 1994 Prolactin-induced proliferation of Nb2 cells involves tyrosine phosphorylation of the prolactin receptor and its associated tyrosine kinase JAK2. Tyrosine 54-62 prolactin Homo sapiens 0-9 8038299-0 1994 Buspirone induced prolactin release in mania. Buspirone 0-9 prolactin Homo sapiens 18-27 7855226-0 1994 Effect of pindolol on the L-5-HTP-induced increase in plasma prolactin and cortisol concentrations in man. Pindolol 10-18 prolactin Homo sapiens 61-70 7855226-1 1994 Previous studies with direct-acting serotonin (5-HT) agonists and antagonists have demonstrated that stimulation of 5-HT1A, 5-HT1C and 5-HT2 receptors may promote cortisol and prolactin (PRL) secretion in man. Serotonin 36-45 prolactin Homo sapiens 176-185 7855226-1 1994 Previous studies with direct-acting serotonin (5-HT) agonists and antagonists have demonstrated that stimulation of 5-HT1A, 5-HT1C and 5-HT2 receptors may promote cortisol and prolactin (PRL) secretion in man. Serotonin 36-45 prolactin Homo sapiens 187-190 7855226-4 1994 Pretreatment with pindolol, 30 mg orally, significantly inhibited the PRL but not the cortisol response to L-5-HTP, 200 mg PO. Pindolol 18-26 prolactin Homo sapiens 70-73 7855226-5 1994 Pindolol alone decreased basal plasma PRL levels and increased basal plasma cortisol levels, possibly due to 5-HT1A antagonist and agonists effects, respectively. Pindolol 0-8 prolactin Homo sapiens 38-41 8038299-4 1994 Lithium treatment led to a large reduction in delta (delta) prolactin levels, which did not correlate with changes in symptom severity. Lithium 0-7 prolactin Homo sapiens 60-69 8038299-1 1994 Prolactin responses to buspirone challenge were examined in 11 manic patients and 11 healthy controls. Buspirone 23-32 prolactin Homo sapiens 0-9 8019107-5 1994 Lisuride was administered instead resulting in a new decrease in PRL serum levels, disappearance of galactorrhea and beginning of regular menses. Lisuride 0-8 prolactin Homo sapiens 65-68 8019107-9 1994 With these chromatographic patterns it is concluded that the pituitary macroprolactinoma secreted different molecular forms of PRL and treatment with lisuride appeared to exert some effect on the PRL molecular size secreted by the pituitary. Lisuride 150-158 prolactin Homo sapiens 196-199 8137767-5 1994 Considering that the prolactin-regulated factors might be related to the p91 component of IFN gamma-activated factor, we used immunoassays to show that prolactin induced tyrosine phosphorylation of a protein that comigrated with immunoreactive relatives of p91, and that antibody to p91 specifically interfered with the prolactin-induced binding activity on the annexin Icp35 gene. Tyrosine 170-178 prolactin Homo sapiens 21-30 8000909-2 1994 We have recently shown that PRL was able to bind to a protein of high molecular weight in plasma obtained from estradiol treated ovariectomized females rats. Estradiol 111-120 prolactin Homo sapiens 28-31 8137767-5 1994 Considering that the prolactin-regulated factors might be related to the p91 component of IFN gamma-activated factor, we used immunoassays to show that prolactin induced tyrosine phosphorylation of a protein that comigrated with immunoreactive relatives of p91, and that antibody to p91 specifically interfered with the prolactin-induced binding activity on the annexin Icp35 gene. Tyrosine 170-178 prolactin Homo sapiens 152-161 8137767-0 1994 Prolactin induces rapid p95/p70 tyrosine phosphorylation, and protein binding to GAS-like sites in the anx Icp35 and c-fos genes. Tyrosine 32-40 prolactin Homo sapiens 0-9 8181575-0 1994 Can plasma prolactin predict tamoxifen resistance in patients with advanced breast cancer? Tamoxifen 29-38 prolactin Homo sapiens 11-20 8137767-5 1994 Considering that the prolactin-regulated factors might be related to the p91 component of IFN gamma-activated factor, we used immunoassays to show that prolactin induced tyrosine phosphorylation of a protein that comigrated with immunoreactive relatives of p91, and that antibody to p91 specifically interfered with the prolactin-induced binding activity on the annexin Icp35 gene. Tyrosine 170-178 prolactin Homo sapiens 152-161 7907340-1 1994 Dopamine, acting via its specific receptor (DRD2) in the anterior pituitary, tonically inhibits pituitary prolactin secretion and lactotroph proliferation. Dopamine 0-8 prolactin Homo sapiens 106-115 8162255-0 1994 Growth hormone and prolactin gene expression in human densely and sparsely granulated somatotroph adenomas by in situ hybridization with digoxigenin-labeled probes. Digoxigenin 137-148 prolactin Homo sapiens 19-28 8024675-2 1994 The primary hypothesis of the study was that the prolactin response to buspirone would be blunted in the depressed patients. Buspirone 71-80 prolactin Homo sapiens 49-58 8011800-0 1994 Effects of buspirone on plasma prolactin and cortisol levels in major depressed and normal subjects. Buspirone 11-20 prolactin Homo sapiens 31-40 8011800-3 1994 This study investigated cortisol and prolactin (PRL) responses to buspirone (30 mg orally) in 45 major depressed subjects and 28 normal controls. Buspirone 66-75 prolactin Homo sapiens 37-46 8011800-3 1994 This study investigated cortisol and prolactin (PRL) responses to buspirone (30 mg orally) in 45 major depressed subjects and 28 normal controls. Buspirone 66-75 prolactin Homo sapiens 48-51 8011800-4 1994 Buspirone administration yielded a significant increase in cortisol and PRL levels in both normal controls and depressed subjects. Buspirone 0-9 prolactin Homo sapiens 72-75 8011800-7 1994 PRL responses to buspirone were significantly higher in women than in men. Buspirone 17-26 prolactin Homo sapiens 0-3 7907340-2 1994 In addition, dopamine agonist therapy for pituitary prolactinomas results in reduction of prolactin secretion and tumor regression. Dopamine 13-21 prolactin Homo sapiens 52-61 7907340-3 1994 These observations lead to the speculation that functional dopamine uncoupling may release lactotrophs from the inhibitory effects of dopamine and contribute to the development of prolactin (PRL)-secreting pituitary tumors. Dopamine 59-67 prolactin Homo sapiens 180-189 8299792-4 1994 Bromocriptine treatment, which significantly suppressed circulating PRL levels, continued through the day of peritoneal macrophage collection. Bromocriptine 0-13 prolactin Homo sapiens 68-71 8137548-1 1994 Bromocriptine (BRC), a dopamine type 2 agonist, prevents secretion of pituitary prolactin (PRL). Bromocriptine 0-13 prolactin Homo sapiens 91-94 8137548-1 1994 Bromocriptine (BRC), a dopamine type 2 agonist, prevents secretion of pituitary prolactin (PRL). Dopamine 23-31 prolactin Homo sapiens 91-94 8015553-9 1994 Activation of the dPRL promoter construct in these undifferentiated cells could however be induced by the addition of cAMP, in the absence of progesterone, suggesting that a signal transduced through the cAMP signaling pathway is a primary inducer of decidual PRL gene expression. Cyclic AMP 118-122 prolactin Homo sapiens 19-22 8015553-9 1994 Activation of the dPRL promoter construct in these undifferentiated cells could however be induced by the addition of cAMP, in the absence of progesterone, suggesting that a signal transduced through the cAMP signaling pathway is a primary inducer of decidual PRL gene expression. Cyclic AMP 204-208 prolactin Homo sapiens 19-22 8035765-4 1994 The objective of this study was to verify how treatment with L-thyroxine modifies the enhanced PRL response to TRH administration in a group of patients with primary hypothyroidism. Thyroxine 61-72 prolactin Homo sapiens 95-98 8296897-2 1994 METHOD: Prolactin response to a challenge dose of the 5-HT agonist d,l-fenfluramine was assessed in 25 7-11-year-old boys with attention deficit hyperactivity disorder who were divided into aggressive and nonaggressive subgroups. d,l-fenfluramine 67-83 prolactin Homo sapiens 8-17 8296897-4 1994 RESULTS: The aggressive group had a significantly greater prolactin response to the fenfluramine challenge than the nonaggressive subgroup. Fenfluramine 84-96 prolactin Homo sapiens 58-67 8296905-4 1994 Compared with the normal male subjects, the male patients with borderline personality disorder had higher cortisol levels and marginally blunted prolactin responses after receiving m-CPP. 1-(3-chlorophenyl)piperazine 181-186 prolactin Homo sapiens 145-154 8190778-2 1994 Sexually inert newts injected with prolactin (PRL) and human chorionic gonadotropin (HCG) in combination preferred the water in which newts of the opposite sex had been kept, whereas saline-injected specimens did not. Water 119-124 prolactin Homo sapiens 35-44 8190778-4 1994 The water in which PRL plus HCG-treated newts had been kept attracted the opposite sex more intensely than the water in which PRL-, HCG-, or saline-injected newts had been kept. Water 4-9 prolactin Homo sapiens 19-22 8119890-8 1994 In contrast to the PRL-dependent Nb2 cells, phosphorylation and activation of Raf-1 were constitutive in the Nb2-derived, PRL-independent, T-cell line Sp. TFF2 protein, human 151-153 prolactin Homo sapiens 122-125 8070714-4 1994 Therefore, in order to select a group of patients with hyperprolactinemia qualified for Bromocriptine treatment it was necessary to test them for prolactin. Bromocriptine 88-101 prolactin Homo sapiens 60-69 8108463-7 1994 Concomitant exposure of the membrane preparations to PRL led to a remarkable inhibition of the vanadate-responsive PtdIns phosphorylation and protein autophosphorylation. Vanadates 95-103 prolactin Homo sapiens 53-56 8187962-5 1994 The short-term inhibitory effect of PRL was also observed on ovarian immunoreactive 3 beta-HSD protein, as measured by Western blot analysis, and on 3 beta-HSD activity measured by the conversion of [14C]dehydroepiandrosterone into [14C]androstenedione. [14c]dehydroepiandrosterone 199-226 prolactin Homo sapiens 36-39 8187962-5 1994 The short-term inhibitory effect of PRL was also observed on ovarian immunoreactive 3 beta-HSD protein, as measured by Western blot analysis, and on 3 beta-HSD activity measured by the conversion of [14C]dehydroepiandrosterone into [14C]androstenedione. Carbon-14 200-203 prolactin Homo sapiens 36-39 8187962-5 1994 The short-term inhibitory effect of PRL was also observed on ovarian immunoreactive 3 beta-HSD protein, as measured by Western blot analysis, and on 3 beta-HSD activity measured by the conversion of [14C]dehydroepiandrosterone into [14C]androstenedione. Androstenedione 237-252 prolactin Homo sapiens 36-39 8108463-7 1994 Concomitant exposure of the membrane preparations to PRL led to a remarkable inhibition of the vanadate-responsive PtdIns phosphorylation and protein autophosphorylation. Phosphatidylinositols 115-121 prolactin Homo sapiens 53-56 8108463-12 1994 The inhibition of vanadate-responsive PtdIns kinase by PRL suggests an involvement of this enzyme in the antimitogenic action of the hormone on human endometrial fibroblasts. Vanadates 18-26 prolactin Homo sapiens 55-58 8167201-3 1994 More severe impairment on these summary measures was significantly associated with greater biological evidence of dopamine blockade (more severe extrapyramidal side effects and higher serum prolactin levels). Dopamine 114-122 prolactin Homo sapiens 190-199 8167207-2 1994 Serotonergic responsivity was assessed in 20 psychiatric patients by the prolactin response to a fenfluramine challenge test. Fenfluramine 97-109 prolactin Homo sapiens 73-82 8167207-5 1994 Abnormal behavioral responders had statistically significant greater increases in prolactin 1 to 4 hr after fenfluramine when compared to normal responders. Fenfluramine 108-120 prolactin Homo sapiens 82-91 7638039-4 1994 Nadir plasma PRL levels during levodopa tests were significantly increased before and during treatment. Levodopa 31-39 prolactin Homo sapiens 13-16 7638039-6 1994 Peak plasma PRL levels during TRH tests and nadir plasma PRL levels during levodopa tests were also significantly increased. Levodopa 75-83 prolactin Homo sapiens 57-60 8166945-1 1994 PROBLEM: Experimental and clinical evidence has suggested an immunostimulatory effect of prolactin and that bromocriptine, an inhibitor of prolactin release, counteracts the actions of prolactin on the immune system. Bromocriptine 108-121 prolactin Homo sapiens 139-148 8166945-1 1994 PROBLEM: Experimental and clinical evidence has suggested an immunostimulatory effect of prolactin and that bromocriptine, an inhibitor of prolactin release, counteracts the actions of prolactin on the immune system. Bromocriptine 108-121 prolactin Homo sapiens 139-148 8166945-4 1994 Studies were performed when serum prolactin concentrations were high as well as during different phases of the menstrual cycle when prolactin levels had been normalized through treatment with bromocriptine. Bromocriptine 192-205 prolactin Homo sapiens 132-141 7864512-14 1994 Also, in both groups of women on steroid treatment, a decrease of PRL was observed compared to the controls. Steroids 33-40 prolactin Homo sapiens 66-69 7765932-1 1994 The relationship between synthesis and N-linked glycosylation site occupancy of recombinant human prolactin produced from C127 cells was studied with the aid of a battery of protein synthesis inhibitors. Nitrogen 39-40 prolactin Homo sapiens 98-107 7506205-10 1994 These results indicate that there are synergistic effects among PGE2, estradiol, and MPA, resulting in acceleration of endometrial stromal cell differentiation and enhanced PRL expression. Dinoprostone 64-68 prolactin Homo sapiens 173-176 7506205-10 1994 These results indicate that there are synergistic effects among PGE2, estradiol, and MPA, resulting in acceleration of endometrial stromal cell differentiation and enhanced PRL expression. Estradiol 70-79 prolactin Homo sapiens 173-176 7506205-6 1994 In contrast, PRL was detected on day 3 in the PGE2-treated cells, and the magnitude of stimulation in these cells on days 9-12 was 1300-1400% of that in control cells. Dinoprostone 46-50 prolactin Homo sapiens 13-16 7957540-0 1994 Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine. Dexfenfluramine 0-15 prolactin Homo sapiens 24-33 7506205-7 1994 Furthermore, the PRL mRNA content of the PGE2-treated cells on day 12 was 4.6-fold greater than that in the control cells. Dinoprostone 41-45 prolactin Homo sapiens 17-20 7506205-8 1994 The effect of PGE2 on PRL production was dose dependent, with a minimal effective dose of 10(-10) M. PGE2 in the absence of steroids had a minimal effect on PRL production. Dinoprostone 14-18 prolactin Homo sapiens 22-25 8155388-10 1994 The TRH-induced PRL release was suppressed by both doses of TOR. Thyrotropin-Releasing Hormone 4-7 prolactin Homo sapiens 16-19 8155388-10 1994 The TRH-induced PRL release was suppressed by both doses of TOR. Toremifene 60-63 prolactin Homo sapiens 16-19 7957540-0 1994 Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine. Serotonin 78-97 prolactin Homo sapiens 24-33 7957540-0 1994 Dexfenfluramine-induced prolactin release as an index of central synaptosomal 5-hydroxytryptamine during treatment with fluoxetine. Fluoxetine 120-130 prolactin Homo sapiens 24-33 7957540-1 1994 Serotonin (5-HT) stimulates prolactin release. Serotonin 0-9 prolactin Homo sapiens 28-37 8018567-3 1994 Serum prolactin levels decreased in a log-linear fashion with time, both in the patients who never received bromocriptine and those who were treated with this drug. Bromocriptine 108-121 prolactin Homo sapiens 6-15 7957540-2 1994 In the present study the ability of dexfenfluramine to increase serum prolactin was used as an index of central 5-HT function after acute and chronic pretreatment of volunteers with fluoxetine. Dexfenfluramine 36-51 prolactin Homo sapiens 70-79 7957540-7 1994 The reduction in the median basal serum prolactin level by almost two-thirds after 14 days of fluoxetine treatment suggests a decrease in 5-HT turnover. Fluoxetine 94-104 prolactin Homo sapiens 40-49 7957540-8 1994 Furthermore, the delayed surge in prolactin release produced by dexfenfluramine with this regimen suggests 5-HT release from a less accessible pool or accumulation of fluoxetine in the neuronal cytosol and consequent competitive inhibition of 5-HT transport out of the nerve terminal. Dexfenfluramine 64-79 prolactin Homo sapiens 34-43 8070116-0 1994 Shrinkage of pituitary PRL-secernent adenoma after short-term treatment with bromocriptine long-acting repeatable injections. Bromocriptine 77-90 prolactin Homo sapiens 23-26 7957540-8 1994 Furthermore, the delayed surge in prolactin release produced by dexfenfluramine with this regimen suggests 5-HT release from a less accessible pool or accumulation of fluoxetine in the neuronal cytosol and consequent competitive inhibition of 5-HT transport out of the nerve terminal. Fluoxetine 167-177 prolactin Homo sapiens 34-43 7911813-11 1994 Nine patients completed both treatment cycles and PRL levels were lower under cabergoline (10.7 +/- 3.7 micrograms/L) than under quinagolide (25.0 +/- 7.7 micrograms/L; p < 0.05). Cabergoline 78-89 prolactin Homo sapiens 50-53 7890021-2 1994 Pharmacological reduction of Prl release by dopamine agonists or treatment with extracts of Agnus castus (AC) improve the clinical situation of patients with such premenstrual symptoms. Dopamine 44-52 prolactin Homo sapiens 29-32 8013942-0 1994 Stimulation of prolactin secretion by melatonin is not mediated by opioids. Melatonin 38-47 prolactin Homo sapiens 15-24 8013942-1 1994 To clarify the role the opioid system plays in mediating the stimulation of prolactin release by melatonin, we performed two separate studies between the 6th and 8th days of the follicular phase in normal young women. Melatonin 97-106 prolactin Homo sapiens 76-85 8013942-4 1994 Oral melatonin administration alone induced a significant increase in serum prolactin concentration, which was maximal 3 h after melatonin administration. Melatonin 5-14 prolactin Homo sapiens 76-85 8013942-4 1994 Oral melatonin administration alone induced a significant increase in serum prolactin concentration, which was maximal 3 h after melatonin administration. Melatonin 129-138 prolactin Homo sapiens 76-85 8013942-5 1994 Prolactin release following melatonin administration was not affected by continuous intravenous infusion of naloxone. Melatonin 28-37 prolactin Homo sapiens 0-9 8013942-7 1994 These findings strongly suggest that the stimulation of prolactin release by melatonin is not mediated by opioids. Melatonin 77-86 prolactin Homo sapiens 56-65 7868851-0 1994 Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients. zotepine 66-74 prolactin Homo sapiens 20-29 7868851-4 1994 Thus, prolactin response may reflect therapeutic effects of zotepine, at least in males. zotepine 60-68 prolactin Homo sapiens 6-15 7911813-14 1994 At week 12, normal PRL levels (< 20 micrograms/L) were observed in 10 and 6 women during cabergoline and quinagolide, respectively. quinagolide 108-119 prolactin Homo sapiens 19-22 8107524-0 1994 Endogenous opioid mediation of the inhibitory effect of ethanol on the prolactin response to breast stimulation in normal women. Ethanol 56-63 prolactin Homo sapiens 71-80 7698720-0 1994 Prolactin responsiveness to peptide histidine methionine-27 in normal subjects and hyperprolactinemic patients. Histidine 36-45 prolactin Homo sapiens 0-9 7698720-0 1994 Prolactin responsiveness to peptide histidine methionine-27 in normal subjects and hyperprolactinemic patients. Methionine 46-56 prolactin Homo sapiens 0-9 7698720-1 1994 In order to verify whether synthetic peptide histidine methionine (PHM-27) is able to induce serum prolactin (PRL) rise in normal subjects and to investigate its effect on PRL secretion in hyperprolactinemic conditions, PHM-27 (100 micrograms i.v. Histidine 45-54 prolactin Homo sapiens 99-108 7698720-1 1994 In order to verify whether synthetic peptide histidine methionine (PHM-27) is able to induce serum prolactin (PRL) rise in normal subjects and to investigate its effect on PRL secretion in hyperprolactinemic conditions, PHM-27 (100 micrograms i.v. Histidine 45-54 prolactin Homo sapiens 110-113 7698720-1 1994 In order to verify whether synthetic peptide histidine methionine (PHM-27) is able to induce serum prolactin (PRL) rise in normal subjects and to investigate its effect on PRL secretion in hyperprolactinemic conditions, PHM-27 (100 micrograms i.v. Methionine 55-65 prolactin Homo sapiens 99-108 7698720-1 1994 In order to verify whether synthetic peptide histidine methionine (PHM-27) is able to induce serum prolactin (PRL) rise in normal subjects and to investigate its effect on PRL secretion in hyperprolactinemic conditions, PHM-27 (100 micrograms i.v. Methionine 55-65 prolactin Homo sapiens 110-113 8107524-1 1994 The effect of ethanol on the prolactin (PRL) response to breast stimulation was tested in normal women. Ethanol 14-21 prolactin Homo sapiens 29-38 8107524-9 1994 The PRL response to breast stimulation was not changed by the treatment with the lower (2 plus 10 mg) or the higher (4 plus 20 mg) dose of naloxone, whereas it was strikingly decreased by ethanol (mean peak was 25% higher than baseline). Ethanol 188-195 prolactin Homo sapiens 4-7 8107524-10 1994 However, when ethanol was given together with naloxone, the peak rise induced by breast stimulation was only partially inhibited by ethanol (the mean PRL peak was 46.2% higher than baseline). Ethanol 14-21 prolactin Homo sapiens 150-153 8107524-10 1994 However, when ethanol was given together with naloxone, the peak rise induced by breast stimulation was only partially inhibited by ethanol (the mean PRL peak was 46.2% higher than baseline). Naloxone 46-54 prolactin Homo sapiens 150-153 8107524-10 1994 However, when ethanol was given together with naloxone, the peak rise induced by breast stimulation was only partially inhibited by ethanol (the mean PRL peak was 46.2% higher than baseline). Ethanol 132-139 prolactin Homo sapiens 150-153 8107524-12 1994 These data demonstrate that ethanol inhibits the PRL response to breast stimulation. Ethanol 28-35 prolactin Homo sapiens 49-52 8115281-4 1994 Citrate production, the major function of prostate, is directly regulated by prolactin. Citric Acid 0-7 prolactin Homo sapiens 77-86 7711007-1 1994 Glucose was found to exert an In vitro regulatory effect on prolactin secretion. Glucose 0-7 prolactin Homo sapiens 60-69 8115356-9 1994 The mechanism of the effect was investigated, and genistein, a tyrosine kinase inhibitor, was found to abort the influence of prolactin on gamma IFN production. Genistein 50-59 prolactin Homo sapiens 126-135 8115281-6 1994 The mechanisms of prolactin regulation of citrate production by prostate epithelial cells include a. Citric Acid 42-49 prolactin Homo sapiens 18-27 8115281-7 1994 Regulation of the pmAAT gene, which results in an increase in the biosynthesis of mAAT and, ultimately, an increase in citrate synthesis (the prolactin regulation of gene transcription is mediated via PKC). Citric Acid 119-126 prolactin Homo sapiens 142-151 8115281-14 1994 The regulation of prostate citrate production is the reproductive function of prolactin in males. prostate citrate 18-34 prolactin Homo sapiens 78-87 8292678-1 1993 The effects of fenfluramine, an indirect serotonergic agonist, on electroencephalographic sleep and prolactin secretion were assessed in 12 unmedicated inpatients with a primary diagnosis of major depressive episode. Fenfluramine 15-27 prolactin Homo sapiens 100-109 7906538-0 1993 Ophthalmic results in patients with macroprolactinomas treated with a new prolactin inhibitor CV 205-502. quinagolide 94-104 prolactin Homo sapiens 41-50 7906538-2 1993 The visual function of 13 patients treated with a new prolactin (PRL) inhibitor CV 205-502 (Sandoz Basle), a potent and selective dopamine D2 receptor agonist, was evaluated. quinagolide 80-90 prolactin Homo sapiens 54-63 8313305-2 1993 Prolactin responses to buspirone challenges were examined in seven women with late luteal phase dysphoric disorder and the same number of healthy controls. Buspirone 23-32 prolactin Homo sapiens 0-9 8143909-2 1993 It is through this site that TAM inhibits lactogen binding to the prolactin (Prl) receptor and subsequent Prl induced growth and differentiation in target tissues. Tamoxifen 29-32 prolactin Homo sapiens 77-80 8266982-2 1993 Inhibition of prolactin secretion by a dopamine agonist restores menses and reduces tumor size. Dopamine 39-47 prolactin Homo sapiens 14-23 8148042-8 1993 This finding suggests that the increases in plasma and pituitary prolactin levels in larvae at metamorphic climax and in adults that remain in or migrate into water, as reported previously, accompany the increase in prolactin synthesis. Water 159-164 prolactin Homo sapiens 65-74 8148042-8 1993 This finding suggests that the increases in plasma and pituitary prolactin levels in larvae at metamorphic climax and in adults that remain in or migrate into water, as reported previously, accompany the increase in prolactin synthesis. Water 159-164 prolactin Homo sapiens 216-225 8274425-4 1993 This finding suggests that the mechanism by which gonadotropins promote decidualization of human endometrial stromal cells in vitro involves the introduction of cAMP, a compound that we have found to elicit the expression of PRL in this system. Cyclic AMP 161-165 prolactin Homo sapiens 225-228 8143909-3 1993 Binding of lactogens to the Prl receptor is inhibited by TAM or 4-hydroxy-TAM at 4 degrees C as well as room temperature, thus suggesting that the ALBS is not an enzyme. Tamoxifen 57-60 prolactin Homo sapiens 28-31 8143909-3 1993 Binding of lactogens to the Prl receptor is inhibited by TAM or 4-hydroxy-TAM at 4 degrees C as well as room temperature, thus suggesting that the ALBS is not an enzyme. 4-hydroxy-tam 64-77 prolactin Homo sapiens 28-31 8288699-4 1994 T induced PRL production in a time- and dose-dependent manner, as reported previously for progesterone (P) stimulation. Progesterone 90-102 prolactin Homo sapiens 10-13 8143909-3 1993 Binding of lactogens to the Prl receptor is inhibited by TAM or 4-hydroxy-TAM at 4 degrees C as well as room temperature, thus suggesting that the ALBS is not an enzyme. albs 147-151 prolactin Homo sapiens 28-31 8288699-5 1994 In addition, 5 alpha-dihydrotestosterone, which cannot be converted to estrogens, similarly induced PRL production. Dihydrotestosterone 13-40 prolactin Homo sapiens 100-103 8143909-7 1993 Re-isolation of the affinity purified Prl receptor on a TAM-Sepharose affinity resin again resulted in co-elution of both binding activities. tam-sepharose 56-69 prolactin Homo sapiens 38-41 8288699-7 1994 A specific androgen receptor blocker, flutamide, when added to cultures containing T, inhibited PRL production in a dose-dependent manner, but did not affect the production of PRL induced by P. These results indicate that in vitro PRL production by human ESC is induced not only by P, but also by androgens through specific receptors and further suggest that androgens play an important role in human endometrial differentiation. Flutamide 38-47 prolactin Homo sapiens 96-99 8143909-9 1993 This band was precipitated with the anti-Prl receptor antibody and specifically bound the affinity label ring-3H-TAM aziridine. 3h-tam aziridine 110-126 prolactin Homo sapiens 41-44 8116455-0 1993 [Clinico-pharmacological investigation of drugs (domperidone, bromocriptine) influencing human prolactin levels from pregnancy to menopause]. Domperidone 49-60 prolactin Homo sapiens 95-104 8116455-0 1993 [Clinico-pharmacological investigation of drugs (domperidone, bromocriptine) influencing human prolactin levels from pregnancy to menopause]. Bromocriptine 62-75 prolactin Homo sapiens 95-104 8116455-1 1993 The influence of Motilium (domperidone) tablet on the increase of human prolactin level was investigated in the first and second trimester of pregnancy, in confinement and menopause. Domperidone 17-25 prolactin Homo sapiens 72-81 8116455-1 1993 The influence of Motilium (domperidone) tablet on the increase of human prolactin level was investigated in the first and second trimester of pregnancy, in confinement and menopause. Domperidone 27-38 prolactin Homo sapiens 72-81 8116455-2 1993 It has been stated that domperidone causes the serum prolactin level to increase not only in pregnancy and confinement but in menopause, too, not depending on whether it was spontaneous or it took place after castration. Domperidone 24-35 prolactin Homo sapiens 53-62 8116455-4 1993 The decrease of the prolactin level effected by bromocriptine tablet in physiological and pathological galactorrhoea and in hyperprolactinaemia associated with infertility has also been investigated. Bromocriptine 48-61 prolactin Homo sapiens 20-29 8287640-9 1993 In the second hour, adrenaline rose significantly (P < 0.05, analysis of variance) with a blood glucose of 3.3 and 3.7 mmol/l, as did cortisol and heart rate at 3.3 mmol/l, but glucagon, prolactin, sweating rate, symptom score and blood pressure were the same during the second hour on all three visits. Epinephrine 20-30 prolactin Homo sapiens 190-199 8144855-2 1993 These lectins allowed the isolation of PRL glycoforms containing either biantennary, mannose-rich or fucosylated complex carbohydrate structures, respectively. Mannose 85-92 prolactin Homo sapiens 39-42 8404671-0 1993 Cyclic adenosine 3",5"-monophosphate induces prolactin expression in stromal cells isolated from human proliferative endometrium. Cyclic AMP 0-36 prolactin Homo sapiens 45-54 8404671-2 1993 PRL production under these conditions was demonstrated by documenting the synthesis of PRL mRNA (approximately 1.1 kilobase), the output of immunoprecipitable [35S]methionine-labeled PRL migrating as a single 23-kilodalton band during gel electrophoresis, and the time- and concentration-dependent secretion of PRL into the medium, measured by RIA (maximal on days 4-5 using 0.5 mM db-cAMP). Sulfur-35 160-163 prolactin Homo sapiens 0-3 8404671-2 1993 PRL production under these conditions was demonstrated by documenting the synthesis of PRL mRNA (approximately 1.1 kilobase), the output of immunoprecipitable [35S]methionine-labeled PRL migrating as a single 23-kilodalton band during gel electrophoresis, and the time- and concentration-dependent secretion of PRL into the medium, measured by RIA (maximal on days 4-5 using 0.5 mM db-cAMP). Methionine 164-174 prolactin Homo sapiens 0-3 8404671-2 1993 PRL production under these conditions was demonstrated by documenting the synthesis of PRL mRNA (approximately 1.1 kilobase), the output of immunoprecipitable [35S]methionine-labeled PRL migrating as a single 23-kilodalton band during gel electrophoresis, and the time- and concentration-dependent secretion of PRL into the medium, measured by RIA (maximal on days 4-5 using 0.5 mM db-cAMP). Bucladesine 382-389 prolactin Homo sapiens 0-3 8404671-3 1993 Medroxyprogesterone acetate (1 microM) enhanced (1.7- to 2.5-fold) the effect of db-cAMP, 8-bromo-cAMP, or forskolin on PRL production, as evaluated by Western blotting analysis. Medroxyprogesterone Acetate 0-27 prolactin Homo sapiens 120-123 8404671-3 1993 Medroxyprogesterone acetate (1 microM) enhanced (1.7- to 2.5-fold) the effect of db-cAMP, 8-bromo-cAMP, or forskolin on PRL production, as evaluated by Western blotting analysis. Bucladesine 81-88 prolactin Homo sapiens 120-123 8404671-3 1993 Medroxyprogesterone acetate (1 microM) enhanced (1.7- to 2.5-fold) the effect of db-cAMP, 8-bromo-cAMP, or forskolin on PRL production, as evaluated by Western blotting analysis. 8-Bromo Cyclic Adenosine Monophosphate 90-102 prolactin Homo sapiens 120-123 8404671-3 1993 Medroxyprogesterone acetate (1 microM) enhanced (1.7- to 2.5-fold) the effect of db-cAMP, 8-bromo-cAMP, or forskolin on PRL production, as evaluated by Western blotting analysis. Colforsin 107-116 prolactin Homo sapiens 120-123 8404671-5 1993 The induction of PRL by cAMP may be a key step in the process of differentiation of fibroblast-like stromal cells to the decidual phenotype, as it has been previously reported by this laboratory that, under similar culture conditions, PRL itself is capable of inducing the production of heat shock protein-27, insulin-like growth factor-binding protein-1, desmin, and laminin in stromal cells isolated from proliferative endometrium. Cyclic AMP 24-28 prolactin Homo sapiens 17-20 8404671-5 1993 The induction of PRL by cAMP may be a key step in the process of differentiation of fibroblast-like stromal cells to the decidual phenotype, as it has been previously reported by this laboratory that, under similar culture conditions, PRL itself is capable of inducing the production of heat shock protein-27, insulin-like growth factor-binding protein-1, desmin, and laminin in stromal cells isolated from proliferative endometrium. Cyclic AMP 24-28 prolactin Homo sapiens 235-238 8144855-9 1993 In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. Carbohydrates 298-310 prolactin Homo sapiens 208-211 8144855-9 1993 In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. mannose-rich oligosaccharides 362-391 prolactin Homo sapiens 16-19 8144855-9 1993 In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. mannose-rich oligosaccharides 362-391 prolactin Homo sapiens 208-211 8144855-9 1993 In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. mannose-rich oligosaccharides 362-391 prolactin Homo sapiens 208-211 8144855-9 1993 In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. mannose-rich oligosaccharides 362-391 prolactin Homo sapiens 208-211 8144855-10 1993 The distribution of PRL to target and elimination organs was also found to be different according to the carbohydrate structure present in the hormone. Carbohydrates 105-117 prolactin Homo sapiens 20-23 8144855-2 1993 These lectins allowed the isolation of PRL glycoforms containing either biantennary, mannose-rich or fucosylated complex carbohydrate structures, respectively. Carbohydrates 121-133 prolactin Homo sapiens 39-42 8144855-11 1993 NG-PRL and mannose-rich G-PRL showed higher incorporation in liver than biantennary G-PRL which was preferentially eliminated by the kidney. Mannose 11-18 prolactin Homo sapiens 26-29 8144855-11 1993 NG-PRL and mannose-rich G-PRL showed higher incorporation in liver than biantennary G-PRL which was preferentially eliminated by the kidney. Mannose 11-18 prolactin Homo sapiens 26-29 8144855-3 1993 Endoglycosidase treatment and carbohydrate content of PRL was found to be consistent with N-linked oligosaccharides of mannose-rich structure and complex units terminated in sialic acid. Carbohydrates 30-42 prolactin Homo sapiens 54-57 8144855-12 1993 Altogether, the current data show that addition of oligosaccharides to PRL as well as carbohydrate structure contribute to modulate both the duration of the hormone in the blood and its distribution to different organs. Oligosaccharides 51-67 prolactin Homo sapiens 71-74 8144855-3 1993 Endoglycosidase treatment and carbohydrate content of PRL was found to be consistent with N-linked oligosaccharides of mannose-rich structure and complex units terminated in sialic acid. n-linked oligosaccharides 90-115 prolactin Homo sapiens 54-57 8144855-3 1993 Endoglycosidase treatment and carbohydrate content of PRL was found to be consistent with N-linked oligosaccharides of mannose-rich structure and complex units terminated in sialic acid. Mannose 119-126 prolactin Homo sapiens 54-57 8144855-3 1993 Endoglycosidase treatment and carbohydrate content of PRL was found to be consistent with N-linked oligosaccharides of mannose-rich structure and complex units terminated in sialic acid. N-Acetylneuraminic Acid 174-185 prolactin Homo sapiens 54-57 8144855-4 1993 Mannose-rich PRL and PRL with biantennary oligosaccharides promoted cell growth of rat lymphoma cells to a diminished extent compared to non-glycosylated PRL (NG-PRL), indicating that the two major types of carbohydrate structure are able to decrease the intrinsic bioactivity of PRL. Oligosaccharides 42-58 prolactin Homo sapiens 21-24 8144855-4 1993 Mannose-rich PRL and PRL with biantennary oligosaccharides promoted cell growth of rat lymphoma cells to a diminished extent compared to non-glycosylated PRL (NG-PRL), indicating that the two major types of carbohydrate structure are able to decrease the intrinsic bioactivity of PRL. Oligosaccharides 42-58 prolactin Homo sapiens 21-24 8144855-4 1993 Mannose-rich PRL and PRL with biantennary oligosaccharides promoted cell growth of rat lymphoma cells to a diminished extent compared to non-glycosylated PRL (NG-PRL), indicating that the two major types of carbohydrate structure are able to decrease the intrinsic bioactivity of PRL. Carbohydrates 207-219 prolactin Homo sapiens 21-24 8144855-4 1993 Mannose-rich PRL and PRL with biantennary oligosaccharides promoted cell growth of rat lymphoma cells to a diminished extent compared to non-glycosylated PRL (NG-PRL), indicating that the two major types of carbohydrate structure are able to decrease the intrinsic bioactivity of PRL. Carbohydrates 207-219 prolactin Homo sapiens 21-24 8144855-9 1993 In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. Carbohydrates 298-310 prolactin Homo sapiens 16-19 8144855-9 1993 In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. Carbohydrates 298-310 prolactin Homo sapiens 208-211 8144855-9 1993 In contrast, NG-PRL was eliminated with a half-time of approximately 5 min, followed by a very slow disappearance over several h. It thus appeared that glycosylation increased the metabolic clearance rate of PRL from 0.13 +/- 0.07 ml/min for NG-PRL to 0.47 +/- 0.12 ml/min for PRL with biantennary carbohydrate chains and 0.8 +/- 0.2 ml/min for the hormone with mannose-rich oligosaccharides. Carbohydrates 298-310 prolactin Homo sapiens 208-211 8284103-0 1993 Dopamine inhibits growth hormone and prolactin secretion in the human newborn. Dopamine 0-8 prolactin Homo sapiens 37-46 7511776-4 1993 An especially novel aspect of this study is the recognition of the presence and androgen- and prolactin-dependent concentration of the tripeptide, thyrotropin-releasing hormone (TRH) in prostatic tissue. tripeptide K-26 135-145 prolactin Homo sapiens 94-103 8284103-4 1993 We observed strikingly low serum concentrations of growth hormone (GH) and prolactin (PRL) during a therapeutic, standardized, isovolumetric, partial exchange transfusion (blood sampling every 20 min for 6 h) in two polycythemic neonates requiring intensive therapy, including continuous dopamine infusion. Dopamine 288-296 prolactin Homo sapiens 86-89 8284103-9 1993 During the dopamine infusion, GH secretion was virtually abolished and PRL release was reduced by at least 50%. Dopamine 11-19 prolactin Homo sapiens 71-74 8284103-10 1993 Dopamine withdrawal was associated with a rebound release of GH and PRL. Dopamine 0-8 prolactin Homo sapiens 68-71 8284103-13 1993 Within 2 h after dopamine withdrawal, GH and PRL levels increased a median 3-fold and 10-fold respectively. Dopamine 17-25 prolactin Homo sapiens 45-48 8284103-14 1993 These data concord to indicate that dopamine is a potent inhibitor of GH and PRL secretion in the human newborn. Dopamine 36-44 prolactin Homo sapiens 77-80 8213676-2 1993 OBJECTIVE: To report five cases of prolactin (PRL)-secreting macroadenomas in adolescents, including their presentations and responses to bromocriptine mesylate treatment. Bromocriptine 138-160 prolactin Homo sapiens 35-44 8266806-6 1993 The 5-HT1+2 receptor antagonist methysergide did not significantly interfere with cardiovascular variables but attenuated the response of NA, prolactin (PRL), beta-endorphin (beta-END) and PRA (P < 0.02). Methysergide 32-44 prolactin Homo sapiens 142-151 8266806-6 1993 The 5-HT1+2 receptor antagonist methysergide did not significantly interfere with cardiovascular variables but attenuated the response of NA, prolactin (PRL), beta-endorphin (beta-END) and PRA (P < 0.02). Methysergide 32-44 prolactin Homo sapiens 153-156 8213676-2 1993 OBJECTIVE: To report five cases of prolactin (PRL)-secreting macroadenomas in adolescents, including their presentations and responses to bromocriptine mesylate treatment. Bromocriptine 138-160 prolactin Homo sapiens 46-49 8213676-17 1993 CONCLUSIONS: Bromocriptine was quite effective in the shrinkage of PRL-secreting macroadenomas in all our patients. Bromocriptine 13-26 prolactin Homo sapiens 67-70 8213676-19 1993 Bromocriptine is preferable to surgery or radiation in the treatment of PRL-secreting macroadenomas in the adolescent. Bromocriptine 0-13 prolactin Homo sapiens 72-75 8300813-0 1993 The effect of nalmefene on pulsatile secretion of luteinizing hormone and prolactin in men. nalmefene 14-23 prolactin Homo sapiens 74-83 8300813-3 1993 The objectives of this study were firstly to determine whether LH and prolactin pulses are synchronous in men, and secondly to examine the effects of naloxone and a new orally active opiate antagonist, nalmefene, on LH and prolactin release in men. nalmefene 202-211 prolactin Homo sapiens 223-232 8300813-9 1993 There was a decrease in concomitance of LH and prolactin pulses with naloxone (48%) and nalmefene (24%; P < 0.025) administration. Naloxone 69-77 prolactin Homo sapiens 47-56 8300813-9 1993 There was a decrease in concomitance of LH and prolactin pulses with naloxone (48%) and nalmefene (24%; P < 0.025) administration. nalmefene 88-97 prolactin Homo sapiens 47-56 8300813-11 1993 The difference observed between naloxone and nalmefene on prolactin--LH pulse synchrony is probably due to differential opioid receptor activity at the pituitary and hypothalamic level. Naloxone 32-40 prolactin Homo sapiens 58-67 8300813-11 1993 The difference observed between naloxone and nalmefene on prolactin--LH pulse synchrony is probably due to differential opioid receptor activity at the pituitary and hypothalamic level. nalmefene 45-54 prolactin Homo sapiens 58-67 8300816-2 1993 Lectin affinity chromatography and denaturing polyacrylamide gel electrophoresis under reducing and non-reducing conditions, followed by Western blotting and immunostaining were used to resolve and identify the molecular variants of prolactin. polyacrylamide 46-60 prolactin Homo sapiens 233-242 8254926-6 1993 Estrogen coupled with the receptors in the cytoplasma goes directly to the DNA region -1713-->-1495 being upstream to the starting site of prolactin transcription and differing from the region on which dopamine acts. Dopamine 205-213 prolactin Homo sapiens 142-151 8221107-2 1993 In an attempt to corroborate these results and to provide a more complete map of PRL-sensitive brain sites mediating the orexigenic action of PRL, a microinjection procedure was employed in the present study that delivered PRL or saline vehicle in extremely small volumes (10 nl/injection) to a variety of diencephalic sites in dove brain that had been previously demonstrated to contain high concentrations of PRL receptors. Sodium Chloride 230-236 prolactin Homo sapiens 81-84 8221107-2 1993 In an attempt to corroborate these results and to provide a more complete map of PRL-sensitive brain sites mediating the orexigenic action of PRL, a microinjection procedure was employed in the present study that delivered PRL or saline vehicle in extremely small volumes (10 nl/injection) to a variety of diencephalic sites in dove brain that had been previously demonstrated to contain high concentrations of PRL receptors. Sodium Chloride 230-236 prolactin Homo sapiens 142-145 8221107-2 1993 In an attempt to corroborate these results and to provide a more complete map of PRL-sensitive brain sites mediating the orexigenic action of PRL, a microinjection procedure was employed in the present study that delivered PRL or saline vehicle in extremely small volumes (10 nl/injection) to a variety of diencephalic sites in dove brain that had been previously demonstrated to contain high concentrations of PRL receptors. Sodium Chloride 230-236 prolactin Homo sapiens 142-145 8221107-2 1993 In an attempt to corroborate these results and to provide a more complete map of PRL-sensitive brain sites mediating the orexigenic action of PRL, a microinjection procedure was employed in the present study that delivered PRL or saline vehicle in extremely small volumes (10 nl/injection) to a variety of diencephalic sites in dove brain that had been previously demonstrated to contain high concentrations of PRL receptors. Sodium Chloride 230-236 prolactin Homo sapiens 142-145 7823004-0 1993 Prolactin (PRL) release in normal and growth hormone deficient children after oral metoclopramide. Metoclopramide 83-97 prolactin Homo sapiens 0-9 7823004-0 1993 Prolactin (PRL) release in normal and growth hormone deficient children after oral metoclopramide. Metoclopramide 83-97 prolactin Homo sapiens 11-14 7823004-1 1993 Studies were done to determine plasma PRL in response to oral MC 0.2 mg/kg in 17 normal children (NC), 12 males and 5 females aged between 4.7-12.8 years and in 26 idiopathic growth hormone deficient children (IGHD), 15 M, 11 F, between 1.5-14.7 years old. Methylcholanthrene 62-64 prolactin Homo sapiens 38-41 7823004-8 1993 The peak serum PRL response to MC ranges were from 33 to 127 ng/ml with the mean +/- SD and +/- SE of 64.45 +/- 24.22 and +/- 5.88 ng/ml respectively giving the cut point-2SD value of 16.01 ng/ml. Methylcholanthrene 31-33 prolactin Homo sapiens 15-18 7823004-9 1993 Among 26I GHD, only 2 patients (7.69%) being all male, had peak PRL response to MC below 16.01 ng/ml, whereas, the rest (92.31%) had peak PRL levels above it. Methylcholanthrene 80-82 prolactin Homo sapiens 64-67 7823004-10 1993 It is concluded that oral MC 0.2 mg/kg is the potent PRL stimulator in children, which can be safely used to test pituitary PRL secretion effectively. Methylcholanthrene 26-28 prolactin Homo sapiens 53-56 7823004-10 1993 It is concluded that oral MC 0.2 mg/kg is the potent PRL stimulator in children, which can be safely used to test pituitary PRL secretion effectively. Methylcholanthrene 26-28 prolactin Homo sapiens 124-127 7823004-11 1993 The majority (92.31%) of idiopathic GH deficient children had adequate serum PRL response to oral MC, whilst 7.69 per cent disclosed inadequate response which might indicate different etiologies. Methylcholanthrene 98-100 prolactin Homo sapiens 77-80 7902959-7 1993 By contrast, plasma PRL levels increased when THC was administered on the afternoon of estrus, in parallel with a significant reduction in the number of D2 receptors in the anterior pituitary gland and no effects on TIDA activity. Dronabinol 46-49 prolactin Homo sapiens 20-23 8276123-1 1993 We have previously shown that a human mammotropic polypeptide hormone, prolactin (PRL) can act synergistically with steroid hormones to regulate gene expression directed by the long terminal repeat of mouse mammary tumor virus (MMTV LTR) in a human ductal carcinoma cell line T47D cells using a chloramphenicol acetyltransferase reporter gene system and gene transfection methods. Steroids 116-123 prolactin Homo sapiens 71-80 8276123-1 1993 We have previously shown that a human mammotropic polypeptide hormone, prolactin (PRL) can act synergistically with steroid hormones to regulate gene expression directed by the long terminal repeat of mouse mammary tumor virus (MMTV LTR) in a human ductal carcinoma cell line T47D cells using a chloramphenicol acetyltransferase reporter gene system and gene transfection methods. Steroids 116-123 prolactin Homo sapiens 82-85 7985467-3 1993 The cAMP effect on PRL production is enhanced by progestins, which by themselves are weak PRL inducers under similar experimental conditions. Cyclic AMP 4-8 prolactin Homo sapiens 19-22 7985467-3 1993 The cAMP effect on PRL production is enhanced by progestins, which by themselves are weak PRL inducers under similar experimental conditions. Cyclic AMP 4-8 prolactin Homo sapiens 90-93 7985467-4 1993 As expected from previous findings in our laboratory, showing that addition of PRL to the culture medium induces decidualization of endometrial stromal cells, cAMP derivatives not only induce PRL but also provoke differentiation of the fibroblast-like stromal cells to the decidual phenotype, as evident from morphologic changes and by the expression of products characteristic of decidual cells, e.g. IGFBP-1, desmin, hsp 27 and laminin. Cyclic AMP 159-163 prolactin Homo sapiens 192-195 7985467-5 1993 These findings suggest a PRL-mediated, progesterone-enhanced decidualization mechanism initiated by physiologic agents increasing cAMP levels in stromal cells. Cyclic AMP 130-134 prolactin Homo sapiens 25-28 8258642-1 1993 To test the hypothesis that PRL is able to feedback negatively on its own secretion (short-loop feedback) in humans via augmentation of the turnover of tuberoinfundibular dopamine (TIDA), the effects of the administration of purified hPRL on endogenous LH, FSH and TSH were assessed. Dopamine 171-179 prolactin Homo sapiens 28-31 8258642-1 1993 To test the hypothesis that PRL is able to feedback negatively on its own secretion (short-loop feedback) in humans via augmentation of the turnover of tuberoinfundibular dopamine (TIDA), the effects of the administration of purified hPRL on endogenous LH, FSH and TSH were assessed. tida 181-185 prolactin Homo sapiens 28-31 7690693-8 1993 It is concluded that risperidone metabolic polymorphism on increased plasma prolactin is minimal and that the active moiety is clinically relevant. Risperidone 21-32 prolactin Homo sapiens 76-85 8270182-4 1993 A bromocriptine induced decrease in plasma prolactin was not accompanied by a decrease in beta-endorphin. Bromocriptine 2-15 prolactin Homo sapiens 43-52 8291452-4 1993 Blood samples for the determination of luteinizing hormone (LH), follicle stimulating hormone (FSH) and prolactin were frequently obtained following opioidergic and/or dopaminergic antagonism affected by naloxone (4 mg i.v.) Naloxone 204-212 prolactin Homo sapiens 104-113 8291452-8 1993 Prolactin release in response to metoclopramide was markedly (p < 0.01) higher following ovarian surgery than before. Metoclopramide 33-47 prolactin Homo sapiens 0-9 7688676-1 1993 Bromocriptine (BRC), a dopamine ergot alkaloid, inhibits the release of pituitary prolactin (PRL). Bromocriptine 0-13 prolactin Homo sapiens 82-91 8162388-4 1993 Among several possible regulators, inhibitory dopamine and stimulatory thyrotropin-releasing hormone (TRH) may take part in the regulation of prolactin levels in connection with epileptic activity. Dopamine 46-54 prolactin Homo sapiens 142-151 16727343-4 1993 Bromocriptine treatment (2.5 mg/day/ewe) reduced plasma PRL levels (P < 0.0001) but had no effect on ovarian activity as evidenced by P(4) and resumption of estrus or on either the frequency or amplitude of the LH pulse. Bromocriptine 0-13 prolactin Homo sapiens 56-59 7690312-14 1993 The PRL response to TRH and, much more so, to metoclopramide was significantly lower in patients with Cushing"s disease than in normal subjects (42125 +/- 8000 vs 73181 +/- 7246 mU/l/90 min, P < 0.01 after TRH and 79095 +/- 27265 vs 229049 +/- 10602 mU/l/90 min, P < 0.01 after metoclopramide). Metoclopramide 46-60 prolactin Homo sapiens 4-7 8370131-1 1993 OBJECTIVE: The aim of the study was to evaluate the effects of exogenous melatonin on the spontaneous pulsatile release of PRL, TSH and LH in normal women. Melatonin 73-82 prolactin Homo sapiens 123-126 8370131-4 1993 RESULTS: Melatonin treatment caused a significant upward resetting of the pulsatile pattern of PRL in six out of seven subjects. Melatonin 9-18 prolactin Homo sapiens 95-98 7690312-14 1993 The PRL response to TRH and, much more so, to metoclopramide was significantly lower in patients with Cushing"s disease than in normal subjects (42125 +/- 8000 vs 73181 +/- 7246 mU/l/90 min, P < 0.01 after TRH and 79095 +/- 27265 vs 229049 +/- 10602 mU/l/90 min, P < 0.01 after metoclopramide). Metoclopramide 284-298 prolactin Homo sapiens 4-7 8370131-8 1993 CONCLUSIONS: Exogenous melatonin has a stimulatory effect on PRL release without affecting the temporal pattern of its pulsatile secretion in normal women. Melatonin 23-32 prolactin Homo sapiens 61-64 7690312-18 1993 This finding together with the impaired PRL responsiveness to TRH and metoclopramide, also observed in this study, is a further example of a dysregulation of PRL secretion in patients with Cushing"s disease. Metoclopramide 70-84 prolactin Homo sapiens 40-43 7690312-18 1993 This finding together with the impaired PRL responsiveness to TRH and metoclopramide, also observed in this study, is a further example of a dysregulation of PRL secretion in patients with Cushing"s disease. Metoclopramide 70-84 prolactin Homo sapiens 158-161 8232316-0 1993 Okadaic acid, a protein phosphatase inhibitor, enhances transcription of a receptor gene containing sequence A of the human prolactin promoter. Okadaic Acid 0-12 prolactin Homo sapiens 124-133 8344196-4 1993 ET-1-exposed cells incubated with [35S]methionine between 72-96 h also released less [35S] PRL than control cells. Sulfur-35 35-38 prolactin Homo sapiens 91-94 8344196-4 1993 ET-1-exposed cells incubated with [35S]methionine between 72-96 h also released less [35S] PRL than control cells. Methionine 39-49 prolactin Homo sapiens 91-94 8344196-4 1993 ET-1-exposed cells incubated with [35S]methionine between 72-96 h also released less [35S] PRL than control cells. Sulfur-35 86-89 prolactin Homo sapiens 91-94 8344196-5 1993 Sarafotoxin S6C, an ETB receptor agonist, also inhibited basal PRL release, whereas BQ-123, an ETA receptor antagonist, had no effect on basal or on ET-1-mediated inhibition of PRL release. sarafotoxin 0-11 prolactin Homo sapiens 63-66 8344196-5 1993 Sarafotoxin S6C, an ETB receptor agonist, also inhibited basal PRL release, whereas BQ-123, an ETA receptor antagonist, had no effect on basal or on ET-1-mediated inhibition of PRL release. s6c 12-15 prolactin Homo sapiens 63-66 8355506-5 1993 Simultaneous addition of an irreversible inhibitor of ODC, difluoromethyl ornithine (DFMO), also abolished the inductions of ODC and DNA synthesis by hPRL. Eflornithine 59-83 prolactin Homo sapiens 150-154 8355506-5 1993 Simultaneous addition of an irreversible inhibitor of ODC, difluoromethyl ornithine (DFMO), also abolished the inductions of ODC and DNA synthesis by hPRL. Eflornithine 85-89 prolactin Homo sapiens 150-154 8355506-6 1993 The inhibitory effect of DFMO on hPRL-induced DNA synthesis was reversed by the addition of putrescine to the culture medium. Eflornithine 25-29 prolactin Homo sapiens 33-37 8355506-6 1993 The inhibitory effect of DFMO on hPRL-induced DNA synthesis was reversed by the addition of putrescine to the culture medium. Putrescine 92-102 prolactin Homo sapiens 33-37 8355506-7 1993 These results suggest that hPRL binds to the prolactin receptor on HL60 cells and induces ODC activity to increase cellular polyamine levels, which eventually stimulates DNA synthesis and cellular proliferation. Polyamines 124-133 prolactin Homo sapiens 27-31 8232316-1 1993 Human PRL (hPRL) gene expression is controlled by cAMP and Ca2+. Cyclic AMP 50-54 prolactin Homo sapiens 6-9 8232316-1 1993 Human PRL (hPRL) gene expression is controlled by cAMP and Ca2+. Cyclic AMP 50-54 prolactin Homo sapiens 11-15 8232316-9 1993 Synergism is observed between cAMP and OA in activating PRL gene transcription. Cyclic AMP 30-34 prolactin Homo sapiens 56-59 8372607-5 1993 The portal concentration of dopamine and oxytocin (a prolactin stimulatory substance) may be increased in hyperprolactinaemia. Dopamine 28-36 prolactin Homo sapiens 53-62 8329446-5 1993 Moreover, the PRL contains three disulfide bonds homologous to those of tetrapod PRLs and differs from teleost PRLs which lack the amino-terminal disulfide bond. Disulfides 33-42 prolactin Homo sapiens 14-17 8329446-5 1993 Moreover, the PRL contains three disulfide bonds homologous to those of tetrapod PRLs and differs from teleost PRLs which lack the amino-terminal disulfide bond. Disulfides 146-155 prolactin Homo sapiens 14-17 8103956-2 1993 True prolactinomas, usually characterized by pituitary lesions and circulating levels of prolactin in excess of 2 U/l (100 micrograms/l), are best treated with a dopamine agonist such as bromocriptine. Dopamine 162-170 prolactin Homo sapiens 5-14 8372607-6 1993 In mammals, prolactin is associated with learning, stimulation of the immune response, reduction of body temperature and increased corticosterone secretion. Corticosterone 131-145 prolactin Homo sapiens 12-21 8103956-2 1993 True prolactinomas, usually characterized by pituitary lesions and circulating levels of prolactin in excess of 2 U/l (100 micrograms/l), are best treated with a dopamine agonist such as bromocriptine. Bromocriptine 187-200 prolactin Homo sapiens 5-14 8508278-6 1993 Since PL has a diurnal rhythm of secretion in man with a peak at about 02.00 hours, it may contribute to the nocturnal worsening of RA. Radium 132-134 prolactin Homo sapiens 6-8 8103956-3 1993 Administration of 50 mg of a repeatable bromocriptine depot preparation (Parlodel-LAR, Sandoz, Basel, Switzerland), results in a prompt reduction of circulating prolactin levels to within normal limits over 48 h in a patient with macroadenoma. Bromocriptine 40-53 prolactin Homo sapiens 161-170 8103956-4 1993 Bromocriptine treatment results in a reduction of circulating prolactin in 80% of patients and tumour shrinkage in about two-thirds. Bromocriptine 0-13 prolactin Homo sapiens 62-71 8103956-5 1993 Patients with macroadenomas treated successfully with dopamine agonists should be given pituitary radiotherapy to provide long-term ablation of the prolactin-secreting cells and facilitate a gradual cessation of drug. Dopamine 54-62 prolactin Homo sapiens 148-157 8103956-7 1993 Pseudoprolactinomas usually associated with circulating prolactin levels < 2 U/l (100 micrograms/l) are caused by a peripituitary tumour which obstructs the flow of dopamine into the pituitary. Dopamine 168-176 prolactin Homo sapiens 6-15 8103956-8 1993 Treatment with dopamine agonists reduces prolactin levels but does not result in tumour shrinkage and so the treatment of choice is trans-sphenoidal surgery. Dopamine 15-23 prolactin Homo sapiens 41-50 8103957-1 1993 Bromocriptine therapy normalizes prolactin levels and restores fertility in 82 to 90% of patients with prolactinoma. Bromocriptine 0-13 prolactin Homo sapiens 33-42 8323298-0 1993 Identification and characterization of a nucleotide binding site of ovine prolactin with 2-azido-NAD. nicotinamide 2-azidoadenine dinucleotide 89-100 prolactin Homo sapiens 74-83 8323298-1 1993 Photoaffinity labeling of ovine prolactin with the NAD+ photoaffinity analog [alpha-32P]nicotinamide-2-azidoadenine dinucleotide has been used to identify an NADH/NADPH binding site. NAD 51-55 prolactin Homo sapiens 32-41 8323298-1 1993 Photoaffinity labeling of ovine prolactin with the NAD+ photoaffinity analog [alpha-32P]nicotinamide-2-azidoadenine dinucleotide has been used to identify an NADH/NADPH binding site. [alpha-32p]nicotinamide-2-azidoadenine dinucleotide 77-128 prolactin Homo sapiens 32-41 8323298-1 1993 Photoaffinity labeling of ovine prolactin with the NAD+ photoaffinity analog [alpha-32P]nicotinamide-2-azidoadenine dinucleotide has been used to identify an NADH/NADPH binding site. NAD 158-162 prolactin Homo sapiens 32-41 8323298-1 1993 Photoaffinity labeling of ovine prolactin with the NAD+ photoaffinity analog [alpha-32P]nicotinamide-2-azidoadenine dinucleotide has been used to identify an NADH/NADPH binding site. NADP 163-168 prolactin Homo sapiens 32-41 8323298-7 1993 The adenine ring binding domain of NADH/NADPH binding site was identified by trypsin and chymotrypsin digestion of the photolabeled prolactin and purification of the photolabeled peptide by boronate affinity chromatography and immobilized Fe3+ affinity chromatography. Adenine 4-11 prolactin Homo sapiens 132-141 8323298-7 1993 The adenine ring binding domain of NADH/NADPH binding site was identified by trypsin and chymotrypsin digestion of the photolabeled prolactin and purification of the photolabeled peptide by boronate affinity chromatography and immobilized Fe3+ affinity chromatography. NAD 35-39 prolactin Homo sapiens 132-141 8323298-7 1993 The adenine ring binding domain of NADH/NADPH binding site was identified by trypsin and chymotrypsin digestion of the photolabeled prolactin and purification of the photolabeled peptide by boronate affinity chromatography and immobilized Fe3+ affinity chromatography. NADP 40-45 prolactin Homo sapiens 132-141 8323298-7 1993 The adenine ring binding domain of NADH/NADPH binding site was identified by trypsin and chymotrypsin digestion of the photolabeled prolactin and purification of the photolabeled peptide by boronate affinity chromatography and immobilized Fe3+ affinity chromatography. glutamyl-gamma-boronate 190-198 prolactin Homo sapiens 132-141 8323298-7 1993 The adenine ring binding domain of NADH/NADPH binding site was identified by trypsin and chymotrypsin digestion of the photolabeled prolactin and purification of the photolabeled peptide by boronate affinity chromatography and immobilized Fe3+ affinity chromatography. ferric sulfate 239-243 prolactin Homo sapiens 132-141 8323298-9 1993 These studies demonstrate that prolactin contains an NADH/NADPH binding site which may be significant in the mechanism of action of this hormone. NAD 53-57 prolactin Homo sapiens 31-40 8323298-9 1993 These studies demonstrate that prolactin contains an NADH/NADPH binding site which may be significant in the mechanism of action of this hormone. NADP 58-63 prolactin Homo sapiens 31-40 8393895-4 1993 Following d-fenfluramine there was a rise in plasma prolactin, but no ACTH response. Dexfenfluramine 10-24 prolactin Homo sapiens 52-61 8327599-2 1993 Previously, we have shown that lesions of the suprachiasmatic nucleus of the hypothalamus (SCNx) block regression of the testes and decreases in body weight and EWAT caused by short day-like, timed daily subcutaneous melatonin infusions in pinealectomized Siberian hamsters and elevate dramatically serum PRL concentrations. Melatonin 217-226 prolactin Homo sapiens 305-308 8373918-0 1993 Effect of lithium on the prolactin response to D-fenfluramine in healthy subjects. Lithium 10-17 prolactin Homo sapiens 25-34 8373918-0 1993 Effect of lithium on the prolactin response to D-fenfluramine in healthy subjects. Dexfenfluramine 47-61 prolactin Homo sapiens 25-34 8317389-4 1993 During the first postnatal week, milk immunoreactive prolactin concentrations were lower for women with IDDM than for control and reference women and the inverse relationship between lactose and milk prolactin, which was significant at day 2 postpartum for reference women, was delayed until day 14 postpartum for women with IDDM. Lactose 183-190 prolactin Homo sapiens 53-62 8317389-4 1993 During the first postnatal week, milk immunoreactive prolactin concentrations were lower for women with IDDM than for control and reference women and the inverse relationship between lactose and milk prolactin, which was significant at day 2 postpartum for reference women, was delayed until day 14 postpartum for women with IDDM. Lactose 183-190 prolactin Homo sapiens 200-209 8370641-0 1993 Chemical modification of ovine prolactin with N-acetylimidazole. N-acetylimidazole 46-63 prolactin Homo sapiens 31-40 8370641-1 1993 Reaction of ovine prolactin (oPRL) with a 150-fold molar excess of N-acetylimidazole over protein content resulted in the modification of 2.5 tyrosine residues and 1.2 lysine residues. N-acetylimidazole 67-84 prolactin Homo sapiens 18-27 8370641-1 1993 Reaction of ovine prolactin (oPRL) with a 150-fold molar excess of N-acetylimidazole over protein content resulted in the modification of 2.5 tyrosine residues and 1.2 lysine residues. Tyrosine 142-150 prolactin Homo sapiens 18-27 8370641-1 1993 Reaction of ovine prolactin (oPRL) with a 150-fold molar excess of N-acetylimidazole over protein content resulted in the modification of 2.5 tyrosine residues and 1.2 lysine residues. Lysine 168-174 prolactin Homo sapiens 18-27 8410056-0 1993 Serum prolactin levels in active multiple sclerosis and during cyclosporin treatment. Cyclosporine 63-74 prolactin Homo sapiens 6-15 8410056-6 1993 Acute cyclosporin A (CsA) administration increases circulating prolactin levels in animals and might paradoxically augment some immune reactions. Cyclosporine 21-24 prolactin Homo sapiens 63-72 8508278-7 1993 We show that patients with RA secrete an excess of prolactin as evidenced by an upregulated diurnal periodicity and an abnormal increase in plasma prolactin concentration following surgery. Radium 27-29 prolactin Homo sapiens 51-60 8508278-7 1993 We show that patients with RA secrete an excess of prolactin as evidenced by an upregulated diurnal periodicity and an abnormal increase in plasma prolactin concentration following surgery. Radium 27-29 prolactin Homo sapiens 147-156 8329652-2 1993 Control of prolactin secretion is complex and involves inhibition by dopamine and possibly endothelins, as well as stimulation by serotoninergic and opioidergic pathways, gonadotropin-releasing hormone, and possibly galanin. Dopamine 69-77 prolactin Homo sapiens 11-20 32370447-0 1993 Short-term morphologic and functional effects of bromocriptine on pituitary prolactin cell adenomas in vitro. Bromocriptine 49-62 prolactin Homo sapiens 76-85 8213227-0 1993 Effect of dihydroergocryptine on serum prolactin levels and milk secretion in puerperal women. Dihydroergocryptine 10-29 prolactin Homo sapiens 39-48 8213227-5 1993 With acute administration, dihydroergocryptine significantly reduced prolactin levels only at the dose of 10 mg and not at 5 mg. With repeated administration, a daily dose of 15 mg was more effective than 10 mg in reducing prolactin levels and in suppressing puerperal lactation. Dihydroergocryptine 27-46 prolactin Homo sapiens 69-78 8213227-5 1993 With acute administration, dihydroergocryptine significantly reduced prolactin levels only at the dose of 10 mg and not at 5 mg. With repeated administration, a daily dose of 15 mg was more effective than 10 mg in reducing prolactin levels and in suppressing puerperal lactation. Dihydroergocryptine 27-46 prolactin Homo sapiens 223-232 8481484-0 1993 Luteinizing hormone and prolactin responses to naloxone vary with stage of lactation in the sow. Naloxone 47-55 prolactin Homo sapiens 24-33 7688829-14 1993 The serum prolactin level decreased significantly in the flutamide group, but increased significantly in the CMA group. Flutamide 57-66 prolactin Homo sapiens 10-19 7688829-14 1993 The serum prolactin level decreased significantly in the flutamide group, but increased significantly in the CMA group. Chlormadinone Acetate 109-112 prolactin Homo sapiens 10-19 8481484-6 1993 Naloxone decreased (p < 0.05) plasma prolactin at Day 10 of lactation; but again during the first 78 h after farrowing, chronic naloxone treatment did not affect plasma prolactin. Naloxone 0-8 prolactin Homo sapiens 40-49 8315550-0 1993 Ranitidine treatment in newborn infants: effects on gastric acidity and serum prolactin levels. Ranitidine 0-10 prolactin Homo sapiens 78-87 8317189-4 1993 The calcium-stimulated C-cell reactivity was studied by measuring calcitonin in plasma during a calcium clamp before and after normalization of serum prolactin during treatment with bromocriptine. Calcium 4-11 prolactin Homo sapiens 150-159 8317189-11 1993 In addition, bromocriptine treatment with normalization of prolactin levels is beneficial for the bone mineral content in this condition. Bromocriptine 13-26 prolactin Homo sapiens 59-68 8330859-2 1993 Orthovanadate (0.1-0.25 microM), an inhibitor of specific phosphatases, was found to stimulate cell division as well as potentiate the mitogenic effect of prolactin on Nb2 cells when prolactin was employed at a less than maximum stimulatory concentration. Vanadates 0-13 prolactin Homo sapiens 155-164 8330859-2 1993 Orthovanadate (0.1-0.25 microM), an inhibitor of specific phosphatases, was found to stimulate cell division as well as potentiate the mitogenic effect of prolactin on Nb2 cells when prolactin was employed at a less than maximum stimulatory concentration. Vanadates 0-13 prolactin Homo sapiens 183-192 8330859-3 1993 Genistein, an inhibitor of tyrosine kinase, was found to inhibit the prolactin stimulation of cell division. Genistein 0-9 prolactin Homo sapiens 69-78 8330859-4 1993 Since prolactin was shown in earlier studies to stimulate the phosphorylation of tyrosyl residues in specific Nb2 cell proteins, these results suggest that the signal transduction pathway for the prolactin stimulation of cell division in the Nb2 node lymphoma cells likely involves the participation of tyrosine kinase(s). cyclo(tyrosyl-tyrosyl) 81-88 prolactin Homo sapiens 6-15 8330859-4 1993 Since prolactin was shown in earlier studies to stimulate the phosphorylation of tyrosyl residues in specific Nb2 cell proteins, these results suggest that the signal transduction pathway for the prolactin stimulation of cell division in the Nb2 node lymphoma cells likely involves the participation of tyrosine kinase(s). cyclo(tyrosyl-tyrosyl) 81-88 prolactin Homo sapiens 196-205 8341771-10 1993 These data confirm the indirect pharmacologic evidence of increased dopaminergic activity in schizophrenic patients that relates to dopamine"s precursors and to the neuroendocrine regulation of prolactin. Dopamine 68-76 prolactin Homo sapiens 194-203 8326259-0 1993 Protein kinase C activation and calcium mobilization decrease prolactin release from human decidual cells in early pregnancy. Calcium 32-39 prolactin Homo sapiens 62-71 8326259-1 1993 The present study was undertaken to investigate the effects of protein kinase C (PKC) activation and calcium mobilization on the release of prolactin from human decidual cells in early pregnancy. Calcium 101-108 prolactin Homo sapiens 140-149 8326259-4 1993 PMA, a PKC activator, dose-dependently attenuated the release of prolactin from cultured decidual cells, while a PKC inhibitor, H7, significantly (P < 0.001) diminished the effect of PMA on prolactin release. Tetradecanoylphorbol Acetate 0-3 prolactin Homo sapiens 65-74 8326259-4 1993 PMA, a PKC activator, dose-dependently attenuated the release of prolactin from cultured decidual cells, while a PKC inhibitor, H7, significantly (P < 0.001) diminished the effect of PMA on prolactin release. Tetradecanoylphorbol Acetate 0-3 prolactin Homo sapiens 193-202 8326259-7 1993 Calcium ionophore A23187, a Ca(2+)-mobilizing agent, also significantly (P < 0.001) attenuated the release of prolactin and potentiated the PMA-induced suppression of prolactin release from decidual cells. Calcium 0-7 prolactin Homo sapiens 113-122 8326259-7 1993 Calcium ionophore A23187, a Ca(2+)-mobilizing agent, also significantly (P < 0.001) attenuated the release of prolactin and potentiated the PMA-induced suppression of prolactin release from decidual cells. Calcium 0-7 prolactin Homo sapiens 170-179 8326259-7 1993 Calcium ionophore A23187, a Ca(2+)-mobilizing agent, also significantly (P < 0.001) attenuated the release of prolactin and potentiated the PMA-induced suppression of prolactin release from decidual cells. Calcimycin 18-24 prolactin Homo sapiens 113-122 8326259-7 1993 Calcium ionophore A23187, a Ca(2+)-mobilizing agent, also significantly (P < 0.001) attenuated the release of prolactin and potentiated the PMA-induced suppression of prolactin release from decidual cells. Calcimycin 18-24 prolactin Homo sapiens 170-179 8326259-7 1993 Calcium ionophore A23187, a Ca(2+)-mobilizing agent, also significantly (P < 0.001) attenuated the release of prolactin and potentiated the PMA-induced suppression of prolactin release from decidual cells. Tetradecanoylphorbol Acetate 143-146 prolactin Homo sapiens 170-179 8329499-0 1993 Prolactin response to sulpiride before and after sleep deprivation in depression. Sulpiride 22-31 prolactin Homo sapiens 0-9 8098604-0 1993 Treatment of macroprolactinoma with the new potent non-ergot D2-dopamine agonist quinagolide and effects on prolactin levels, pituitary function, an the renin-aldosterone system. quinagolide 81-92 prolactin Homo sapiens 18-27 8475132-8 1993 The rapid growth-inhibitory effect of PRL was mimicked by prostaglandin E1, but the combination of both types of ligand was not additive in the inhibitory action on growth. Alprostadil 58-74 prolactin Homo sapiens 38-41 8475132-12 1993 These findings would suggest that PRL may block the mitogenic activity of the fibroblasts stimulated by the endometrial carcinoma-derived mitogen via a PRL receptor-mediated mechanism, perhaps prostaglandin production. Prostaglandins 193-206 prolactin Homo sapiens 34-37 8475132-12 1993 These findings would suggest that PRL may block the mitogenic activity of the fibroblasts stimulated by the endometrial carcinoma-derived mitogen via a PRL receptor-mediated mechanism, perhaps prostaglandin production. Prostaglandins 193-206 prolactin Homo sapiens 152-155 8498149-0 1993 Different responses in little and bigbig prolactin to metoclopramide in subjects with hyperprolactinemia due to 150-170 kD (bigbig) prolactin. Metoclopramide 54-68 prolactin Homo sapiens 41-50 8498149-0 1993 Different responses in little and bigbig prolactin to metoclopramide in subjects with hyperprolactinemia due to 150-170 kD (bigbig) prolactin. Metoclopramide 54-68 prolactin Homo sapiens 91-100 8498149-2 1993 Metoclopramide (MTC) iv induced a 4-29-fold increase in little PRL (25 kD PRL) at 30 min, while the increase in 150-170 kD PRL was 1.1-2.2-fold. Metoclopramide 0-14 prolactin Homo sapiens 63-66 8498149-2 1993 Metoclopramide (MTC) iv induced a 4-29-fold increase in little PRL (25 kD PRL) at 30 min, while the increase in 150-170 kD PRL was 1.1-2.2-fold. Metoclopramide 0-14 prolactin Homo sapiens 74-77 8498149-2 1993 Metoclopramide (MTC) iv induced a 4-29-fold increase in little PRL (25 kD PRL) at 30 min, while the increase in 150-170 kD PRL was 1.1-2.2-fold. Metoclopramide 0-14 prolactin Homo sapiens 74-77 8498149-2 1993 Metoclopramide (MTC) iv induced a 4-29-fold increase in little PRL (25 kD PRL) at 30 min, while the increase in 150-170 kD PRL was 1.1-2.2-fold. Metoclopramide 16-19 prolactin Homo sapiens 63-66 8498149-2 1993 Metoclopramide (MTC) iv induced a 4-29-fold increase in little PRL (25 kD PRL) at 30 min, while the increase in 150-170 kD PRL was 1.1-2.2-fold. Metoclopramide 16-19 prolactin Homo sapiens 74-77 8498149-2 1993 Metoclopramide (MTC) iv induced a 4-29-fold increase in little PRL (25 kD PRL) at 30 min, while the increase in 150-170 kD PRL was 1.1-2.2-fold. Metoclopramide 16-19 prolactin Homo sapiens 74-77 8098604-2 1993 The oral non-ergot D2-dopamine agonist quinagolide (CV 205-502, CAS 87056-78-8) has proven to be highly effective in suppressing elevated prolactin (PRL) levels. quinagolide 39-50 prolactin Homo sapiens 138-147 8098604-2 1993 The oral non-ergot D2-dopamine agonist quinagolide (CV 205-502, CAS 87056-78-8) has proven to be highly effective in suppressing elevated prolactin (PRL) levels. quinagolide 39-50 prolactin Homo sapiens 149-152 8513038-0 1993 Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Fenfluramine 22-34 prolactin Homo sapiens 0-9 8485239-8 1993 Similarly, melatonin caused only a reduction of prolactin secretion in the mediobasal, s.c., and short-day groups. Melatonin 11-20 prolactin Homo sapiens 48-57 8513038-1 1993 Plasma prolactin (PRL) response to fenfluramine (FF) (60 mg orally) and placebo challenge was examined in eight remitted depressed patients who were withdrawn for 14 days from maintenance pharmacotherapy with clomipramine (CMI) plus lithium carbonate (Li) (n = 6) or Li alone (n = 2), 6 months after recovering from their major depressive episode. Fenfluramine 35-47 prolactin Homo sapiens 7-16 8473721-0 1993 The prolactin response to d- and l-fenfluramine and to d-amphetamine in human subjects. d- and l-fenfluramine 26-47 prolactin Homo sapiens 4-13 8473721-2 1993 Both isomers of fenfluramine were found to differ significantly in their effects from d-amphetamine, and from placebo, causing prolactin levels to rise. Fenfluramine 16-28 prolactin Homo sapiens 127-136 8473721-5 1993 d-Amphetamine produced a non-significant reduction in prolactin secretion. Dextroamphetamine 0-13 prolactin Homo sapiens 54-63 8406122-0 1993 [Serum prolactin during oral metoclopramide in normal nulliparous women]. Metoclopramide 29-43 prolactin Homo sapiens 7-16 8406122-1 1993 As a first step in an extensive project planned to determine serum PRL levels in response to oral metoclopramide in women with a diverse gyneco-obstetric history, it was decided to study 51 clinically healthy nulliparous women, aged 15.8 to 48.2 years, with history of regular menses at least one year before the study (except the three postmenopausal women), with no regular drug ingestion during the last six months. Metoclopramide 98-112 prolactin Homo sapiens 67-70 8474497-0 1993 Function of dopamine receptors in young-onset Parkinson"s disease: prolactin response. Dopamine 12-20 prolactin Homo sapiens 67-76 8473721-0 1993 The prolactin response to d- and l-fenfluramine and to d-amphetamine in human subjects. Dextroamphetamine 55-68 prolactin Homo sapiens 4-13 8473721-1 1993 Twelve normal male volunteers took part in a double-blind placebo-controlled study to measure the effects of d- and l-fenfluramine singly and in combination with d-amphetamine on plasma prolactin levels. d- and l-fenfluramine 109-130 prolactin Homo sapiens 186-195 8473721-1 1993 Twelve normal male volunteers took part in a double-blind placebo-controlled study to measure the effects of d- and l-fenfluramine singly and in combination with d-amphetamine on plasma prolactin levels. Dextroamphetamine 162-175 prolactin Homo sapiens 186-195 8456892-0 1993 Role of melatonin in nocturnal prolactin secretion in women with normoprolactinemia and mild hyperprolactinemia. Melatonin 8-17 prolactin Homo sapiens 31-40 8456892-8 1993 Oral administration (1 mg) of melatonin to normoprolactinemia and mild hyperprolactinemia in the daytime resulted in release of prolactin in a fashion similar to that observed during the night. Melatonin 30-39 prolactin Homo sapiens 48-57 8456892-9 1993 CONCLUSION: Melatonin can regulate nocturnal prolactin secretion independent of sleep-related factors. Melatonin 12-21 prolactin Homo sapiens 45-54 8471832-0 1993 Prolactin and thyrotropin responses to ECT after pindolol administration. Pindolol 49-57 prolactin Homo sapiens 0-9 8094329-16 1993 Thus, sex steroids and adenohypophyseal hormones (PRL, FSH, and LH) have subset-specific effects on T-cell activation which may influence sex-related differences in immune response. Steroids 10-18 prolactin Homo sapiens 50-53 8097192-6 1993 This article discusses behavioral response to psychostimulant tests and pituitary hormone levels, particularly growth hormone and prolactin response to dopamine antagonist stimulation. Dopamine 152-160 prolactin Homo sapiens 130-139 8470947-7 1993 In one patient who showed an increase of plasma prolactin level, associated with low testosterone and LH, a microadenoma of the pituitary gland (prolactinoma) was detected. Testosterone 85-97 prolactin Homo sapiens 48-57 8436973-8 1993 Incubation of astrocytes with PRL in the presence of the PKC inhibitors staurosporine, 1-(-5-isoquinolinesulfonyl)-2-methylpiperazine, or polymyxin B blocked the PRL-induced increase in cell number with IC50 values of approximately 2 nM, 10 microM, and 6 microM, respectively. Staurosporine 72-85 prolactin Homo sapiens 30-33 8436973-8 1993 Incubation of astrocytes with PRL in the presence of the PKC inhibitors staurosporine, 1-(-5-isoquinolinesulfonyl)-2-methylpiperazine, or polymyxin B blocked the PRL-induced increase in cell number with IC50 values of approximately 2 nM, 10 microM, and 6 microM, respectively. Staurosporine 72-85 prolactin Homo sapiens 162-165 8436973-8 1993 Incubation of astrocytes with PRL in the presence of the PKC inhibitors staurosporine, 1-(-5-isoquinolinesulfonyl)-2-methylpiperazine, or polymyxin B blocked the PRL-induced increase in cell number with IC50 values of approximately 2 nM, 10 microM, and 6 microM, respectively. 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine 87-133 prolactin Homo sapiens 30-33 8436973-8 1993 Incubation of astrocytes with PRL in the presence of the PKC inhibitors staurosporine, 1-(-5-isoquinolinesulfonyl)-2-methylpiperazine, or polymyxin B blocked the PRL-induced increase in cell number with IC50 values of approximately 2 nM, 10 microM, and 6 microM, respectively. 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine 87-133 prolactin Homo sapiens 162-165 8471832-2 1993 The effect of pindolol, a beta-receptor blocker with potent 5-HT1 receptor antagonistic properties, on the prolactin (PRL) and thyrotropin (TSH) responses to electroconvulsive therapy (ECT) was systematically studied in 12 female depressed patients. Pindolol 14-22 prolactin Homo sapiens 107-116 7678802-6 1993 In contrast, it significantly reduced the dose-dependent inhibition of PRL mRNA induced by 1 nM bromocriptine after a 4-day incubation period. Bromocriptine 96-109 prolactin Homo sapiens 71-74 8097570-0 1993 Inhibition of recombinant human growth hormone-induced and prolactin-induced activation of neutrophils by octreotide. Octreotide 106-116 prolactin Homo sapiens 59-68 8097570-9 1993 The present study suggests that octreotide may act on neutrophils directly by antagonizing growth hormone or prolactin at the cellular level. Octreotide 32-42 prolactin Homo sapiens 109-118 8386115-5 1993 We have previously shown that sequence A (-115 to -85) is needed together with Pit-1 binding sites for full cyclic AMP response of hPRL-CAT. Cyclic AMP 108-118 prolactin Homo sapiens 131-135 7678802-1 1993 The role of protein kinase C (PKC) on dopamine inhibition of PRL messenger RNA (mRNA) levels was studied in anterior pituitary cells kept in primary culture. Dopamine 38-46 prolactin Homo sapiens 61-64 7678802-7 1993 Since dopamine inhibition of PRL release is mediated by several second messager pathways, including cAMP, inositol phosphates, and Ca2+, we investigated whether PKC depletion was able to interact with direct stimulation of these pathways. Dopamine 6-14 prolactin Homo sapiens 29-32 7678802-3 1993 Effectiveness of PKC desensitization was confirmed by the fact that after TPA pretreatment, short-term (1-h) exposure to TPA was no longer able to trigger PRL release. Tetradecanoylphorbol Acetate 121-124 prolactin Homo sapiens 155-158 7678802-8 1993 Pretreatment with PKC suppressed stimulation of PRL mRNA levels induced by either Forskolin (FK) or 8Br-cAMP. Colforsin 82-91 prolactin Homo sapiens 48-51 7678802-8 1993 Pretreatment with PKC suppressed stimulation of PRL mRNA levels induced by either Forskolin (FK) or 8Br-cAMP. 8-Bromo Cyclic Adenosine Monophosphate 100-108 prolactin Homo sapiens 48-51 7678802-10 1993 In addition, chronic exposure to TPA completely suppressed PRL mRNA inhibition induced by nifedipine, a dihydropyridine antagonist which blocks voltage-dependent Ca2+ channels. Tetradecanoylphorbol Acetate 33-36 prolactin Homo sapiens 59-62 7678802-10 1993 In addition, chronic exposure to TPA completely suppressed PRL mRNA inhibition induced by nifedipine, a dihydropyridine antagonist which blocks voltage-dependent Ca2+ channels. Nifedipine 90-100 prolactin Homo sapiens 59-62 7678802-10 1993 In addition, chronic exposure to TPA completely suppressed PRL mRNA inhibition induced by nifedipine, a dihydropyridine antagonist which blocks voltage-dependent Ca2+ channels. 1,4-dihydropyridine 104-119 prolactin Homo sapiens 59-62 7678802-11 1993 TPA desensitization also affected the action of bromocriptine, FK or nifedipine on PRL release measured under the same conditions. Tetradecanoylphorbol Acetate 0-3 prolactin Homo sapiens 83-86 7678802-11 1993 TPA desensitization also affected the action of bromocriptine, FK or nifedipine on PRL release measured under the same conditions. Bromocriptine 48-61 prolactin Homo sapiens 83-86 7678802-11 1993 TPA desensitization also affected the action of bromocriptine, FK or nifedipine on PRL release measured under the same conditions. Nifedipine 69-79 prolactin Homo sapiens 83-86 7678802-12 1993 The data indicate that endogenous PKC can interfere with the regulation of PRL gene expression induced by both cAMP and Ca2+ pathways, two second messengers associated with the action of dopamine in lactotroph cells. Cyclic AMP 111-115 prolactin Homo sapiens 75-78 7678802-12 1993 The data indicate that endogenous PKC can interfere with the regulation of PRL gene expression induced by both cAMP and Ca2+ pathways, two second messengers associated with the action of dopamine in lactotroph cells. Dopamine 187-195 prolactin Homo sapiens 75-78 8502593-1 1993 UNLABELLED: The influence of prazosin treatment for 12 months on basal and LH-RH stimulated FSH, LH, estradiol and testosterone secretion and basal and chlorpromazine stimulated prolactin secretion was estimated in 15 male patients with essential hypertension. Chlorpromazine 152-166 prolactin Homo sapiens 178-187 8453823-11 1993 Clozapine transiently increases serum prolactin levels with minimal changes in homovanillic acid plasma levels. Clozapine 0-9 prolactin Homo sapiens 38-47 8502593-4 1993 After 12 months of prazosin treatment basal and stimulated LH and prolactin secretion significantly decreased while estradiol secretion significantly increased. Prazosin 19-27 prolactin Homo sapiens 66-75 8502593-9 1993 Long-term prazosin treatment shows an inhibitory effect on FSH and prolactin secretion but stimulatory one on estrogens secretion in male hypertensive patients. Prazosin 10-18 prolactin Homo sapiens 67-76 8267897-3 1993 In both patients, oral bromocriptine normalized prolactin levels and menstruation resumed. Bromocriptine 23-36 prolactin Homo sapiens 48-57 8382534-2 1993 Nefazodone significantly increased plasma levels of prolactin (PRL) and raised oral temperature. nefazodone 0-10 prolactin Homo sapiens 52-61 8382534-2 1993 Nefazodone significantly increased plasma levels of prolactin (PRL) and raised oral temperature. nefazodone 0-10 prolactin Homo sapiens 63-66 8397670-0 1993 [The behavior of the stress hormones cortisol, somatotropin (STH) and prolactin during anesthesia induction with midazolam-alfentanil in comparison with thiopental]. Midazolam 113-122 prolactin Homo sapiens 70-79 8397670-0 1993 [The behavior of the stress hormones cortisol, somatotropin (STH) and prolactin during anesthesia induction with midazolam-alfentanil in comparison with thiopental]. Alfentanil 123-133 prolactin Homo sapiens 70-79 8397670-6 1993 After alfentanil a slight, insignificant rise in the prolactin level occurred. Alfentanil 6-16 prolactin Homo sapiens 53-62 8130181-2 1993 Plasma prolactin elevation was induced by administration of a dopamine antagonist drug domperidone (Motilium 10 mg orally, 9 subjects) and 2 h later the oral glucose tolerance test was performed. Dopamine 62-70 prolactin Homo sapiens 7-16 8299703-2 1993 Since it is known that endogenous opiates and dopamine interact in modulating PRL secretion, we have studied the effect of an opiate receptor blockade (with Naloxone, NAL, 1.6 mg/h as a continuous infusion) on anterior pituitary hormones and on PRL responsiveness to metoclopramide (MCP), in 10 premenopausal normoprolactinemic patients with PES, studied in follicular phase, in order to investigate neurotransmitter abnormalities present in such a syndrome. Dopamine 46-54 prolactin Homo sapiens 78-81 8299703-6 1993 The infusion of NAL induced a "paradoxical" increase in hormones (PRL and GH) which are normally stimulated by endogenous opiates; but, on the other side, it blocked the marked PRL responsiveness to the dopaminergic blockade, which is characteristic of PES syndrome. acetylleucine 16-19 prolactin Homo sapiens 66-69 8299703-6 1993 The infusion of NAL induced a "paradoxical" increase in hormones (PRL and GH) which are normally stimulated by endogenous opiates; but, on the other side, it blocked the marked PRL responsiveness to the dopaminergic blockade, which is characteristic of PES syndrome. acetylleucine 16-19 prolactin Homo sapiens 177-180 8503984-1 1993 Because increased prolactin levels and hyperprolactinemia in the presence of encephalopathy in males with cirrhosis (alcohol-induced cirrhosis in particular) are associated with statistically increased mortality, we have examined pre-surgical levels of prolactin and other hormones, as well as the presence of encephalopathy, in 12 postmenopausal women with end-stage alcohol-induced cirrhosis in relation to liver transplant survival. Alcohols 117-124 prolactin Homo sapiens 44-53 8130181-2 1993 Plasma prolactin elevation was induced by administration of a dopamine antagonist drug domperidone (Motilium 10 mg orally, 9 subjects) and 2 h later the oral glucose tolerance test was performed. Domperidone 87-98 prolactin Homo sapiens 7-16 8130181-2 1993 Plasma prolactin elevation was induced by administration of a dopamine antagonist drug domperidone (Motilium 10 mg orally, 9 subjects) and 2 h later the oral glucose tolerance test was performed. Domperidone 100-108 prolactin Homo sapiens 7-16 7831446-2 1993 Cimetidine, an H2 antagonist, produces robust, transient increase in plasma prolactin (PRL) levels in man following intravenous administration. Cimetidine 0-10 prolactin Homo sapiens 76-85 7831446-0 1993 The cimetidine-induced increase in prolactin secretion in schizophrenia: effect of clozapine. Cimetidine 4-14 prolactin Homo sapiens 35-44 7831446-2 1993 Cimetidine, an H2 antagonist, produces robust, transient increase in plasma prolactin (PRL) levels in man following intravenous administration. Cimetidine 0-10 prolactin Homo sapiens 87-90 7831446-4 1993 This study investigated the effects of cimetidine on plasma PRL levels in unmedicated schizophrenic patients versus normal controls and the effect of chronic treatment with clozapine on the cimetidine-induced PRL response. Clozapine 173-182 prolactin Homo sapiens 209-212 7831446-4 1993 This study investigated the effects of cimetidine on plasma PRL levels in unmedicated schizophrenic patients versus normal controls and the effect of chronic treatment with clozapine on the cimetidine-induced PRL response. Cimetidine 190-200 prolactin Homo sapiens 209-212 7870880-4 1993 SDZ HDC-912 significantly decreased Apo-induced PRL inhibition, and tended to decrease PRL secretion and Apo-induced GH stimulation. Sulfadiazine 0-3 prolactin Homo sapiens 48-51 7870880-4 1993 SDZ HDC-912 significantly decreased Apo-induced PRL inhibition, and tended to decrease PRL secretion and Apo-induced GH stimulation. Sulfadiazine 0-3 prolactin Homo sapiens 87-90 7831446-5 1993 The PRL response to cimetidine was significantly blunted in male but not female schizophrenic patients. Cimetidine 20-30 prolactin Homo sapiens 4-7 7831446-7 1993 Chronic treatment with clozapine completely suppressed the plasma PRL response following cimetidine. Clozapine 23-32 prolactin Homo sapiens 66-69 7831446-7 1993 Chronic treatment with clozapine completely suppressed the plasma PRL response following cimetidine. Cimetidine 89-99 prolactin Homo sapiens 66-69 8416044-0 1993 Prolactin response to dl-fenfluramine in panic disorder. Fenfluramine 22-37 prolactin Homo sapiens 0-9 7870930-5 1993 Prolactin levels were unaffected by biperiden but increased following remoxipride administration. Remoxipride 70-81 prolactin Homo sapiens 0-9 7871058-7 1993 The results suggest that 5-HT2 or 5-HT1C receptors mediate the effects of d-fenfluramine on appetite, prolactin secretion and temperature in humans. Dexfenfluramine 74-88 prolactin Homo sapiens 102-111 8416044-4 1993 In both groups, fenfluramine induced a rise in the plasma prolactin concentration from baseline. Fenfluramine 16-28 prolactin Homo sapiens 58-67 8127946-1 1993 The effects of the serotonergic agent d,l-fenfluramine (60 mg PO) or a placebo on serum prolactin (PRL) and cortisol levels were evaluated in seven patients (five men and two women) with seasonal affective disorders (SAD) and in eight normal controls (eight men and two women). d,l-fenfluramine 38-54 prolactin Homo sapiens 88-97 8128789-6 1993 The persistence of elevated prolactin serum level gave necessity of dopamine agonist therapy postoperatively. Dopamine 68-76 prolactin Homo sapiens 28-37 8290659-2 1993 We compared the maximum prolactin response to intravenous clomipramine (CMI) in depressed patients who responded to antidepressant treatment to that of nonresponders. Clomipramine 58-70 prolactin Homo sapiens 24-33 8290659-3 1993 Pretreatment baseline prolactin concentrations and pretreatment prolactin responses to clomipramine challenge were not different in responders compared to non-responders. Clomipramine 87-99 prolactin Homo sapiens 64-73 8290659-4 1993 However, following antidepressant treatment, the 6 responders demonstrated a significant change in their clomipramine challenge test results, as indicated by an increase in prolactin responses. Clomipramine 105-117 prolactin Homo sapiens 173-182 8290659-6 1993 These data support the hypothesis that serotonergic system dysfunction, as manifested by blunted prolactin response to clomipramine challenge, tends to normalize after successful treatment for depression, and that abnormal serotonergic function may be a state-dependent characteristic. Clomipramine 119-131 prolactin Homo sapiens 97-106 1286524-0 1992 Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Cabergoline 49-60 prolactin Homo sapiens 36-45 1286524-3 1992 We have investigated the biochemical efficacy and side-effect profile of a range of doses of the novel, long-acting dopamine agonist, cabergoline, in suppressing prolactin (PRL) in hyperprolactinaemic women. Cabergoline 134-145 prolactin Homo sapiens 162-171 1286524-3 1992 We have investigated the biochemical efficacy and side-effect profile of a range of doses of the novel, long-acting dopamine agonist, cabergoline, in suppressing prolactin (PRL) in hyperprolactinaemic women. Cabergoline 134-145 prolactin Homo sapiens 173-176 1286524-9 1992 PRL was suppressed to below half the pretreatment level in 5, 60, 90, 95 and 98% and normalized in 0, 30, 74, 74 and 95% of patients taking placebo or cabergoline 0.125, 0.5, 0.75 or 1.0 mg twice weekly respectively (Armitage"s test, chi 2 = 39.3, P < 0.01). Cabergoline 151-162 prolactin Homo sapiens 0-3 1286524-15 1992 CONCLUSIONS: We have shown a linear dose-response relationship for cabergoline in the treatment of hyperprolactinaemia in the range 0.125-1.0 mg twice weekly, with normalization of PRL in up to 95% of cases and acceptable tolerability throughout the dose range. Cabergoline 67-78 prolactin Homo sapiens 181-184 1458939-12 1992 MAIN RESULTS: Serum prolactin concentrations decreased > 90% (p < .001) within hours in all patients receiving dopamine infusions at study dose limit or above. Dopamine 117-125 prolactin Homo sapiens 20-29 1477608-2 1992 Here we show that the supernatant and the cell lysate of NK cells express a 35S-labelled 50 kDa peptide specifically immunostained by two different PRL-antisera. Sulfur-35 76-79 prolactin Homo sapiens 148-151 1458939-14 1992 Dopamine infusions in medical ICU patients produced an immediate and profound reduction in serum prolactin concentrations in both males and females. Dopamine 0-8 prolactin Homo sapiens 97-106 1369592-1 1992 In this study we have examined the direct glucoregulation of prolactin secretion from normal anterior pituitary cells in vitro and have found that changes in medium glucose concentration regulate the amount of prolactin released. Glucose 165-172 prolactin Homo sapiens 61-70 1294377-3 1992 The FF PRL concentration was correlated positively with plasma PRL and highest estradiol levels during the stimulatory cycle. Estradiol 79-88 prolactin Homo sapiens 7-10 1369592-1 1992 In this study we have examined the direct glucoregulation of prolactin secretion from normal anterior pituitary cells in vitro and have found that changes in medium glucose concentration regulate the amount of prolactin released. Glucose 165-172 prolactin Homo sapiens 210-219 1369592-3 1992 When the cells were derived from animals with mean low-normal serum insulin levels, there was a stimulation of prolactin secretion by hypoglycemia, the response was rapid, transient, dose-dependent, and could be duplicated by 2-deoxyglucose. Deoxyglucose 226-240 prolactin Homo sapiens 111-120 1369592-5 1992 Conversely, elevated glucose caused a depression in prolactin secretion in the first group and a stimulation of prolactin secretion in the second. Glucose 21-28 prolactin Homo sapiens 52-61 1369592-5 1992 Conversely, elevated glucose caused a depression in prolactin secretion in the first group and a stimulation of prolactin secretion in the second. Glucose 21-28 prolactin Homo sapiens 112-121 1369592-6 1992 We conclude (1) that modulation of glucose levels in vitro regulates prolactin release from pituitary mammotrophs and (2) that this glucose regulation of prolactin release is in turn coregulated with or regulated by insulin. Glucose 35-42 prolactin Homo sapiens 69-78 1369592-6 1992 We conclude (1) that modulation of glucose levels in vitro regulates prolactin release from pituitary mammotrophs and (2) that this glucose regulation of prolactin release is in turn coregulated with or regulated by insulin. Glucose 35-42 prolactin Homo sapiens 154-163 1369592-6 1992 We conclude (1) that modulation of glucose levels in vitro regulates prolactin release from pituitary mammotrophs and (2) that this glucose regulation of prolactin release is in turn coregulated with or regulated by insulin. Glucose 132-139 prolactin Homo sapiens 69-78 1369592-6 1992 We conclude (1) that modulation of glucose levels in vitro regulates prolactin release from pituitary mammotrophs and (2) that this glucose regulation of prolactin release is in turn coregulated with or regulated by insulin. Glucose 132-139 prolactin Homo sapiens 154-163 1369597-0 1992 Influence of dopamine on the altered release of prolactin, luteinizing hormone, and follicle-stimulating hormone induced by interleukin-2 in vitro. Dopamine 13-21 prolactin Homo sapiens 48-57 1369597-3 1992 Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Dopamine 6-14 prolactin Homo sapiens 47-50 1369597-3 1992 Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Dopamine 6-14 prolactin Homo sapiens 186-189 1369597-3 1992 Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Dopamine 16-18 prolactin Homo sapiens 47-50 1369597-3 1992 Since dopamine (DA) is a powerful inhibitor of PRL release, in the present experiments were evaluated possible dose dependent effects of DA on IL-2-induced alterations of the release of PRL, LH, and FSH. Dopamine 137-139 prolactin Homo sapiens 186-189 1369597-5 1992 DA induced a dose-related, significant lowering of the basal PRL release with a minimal effective dose (MED) of less than 19 nM. Dopamine 0-2 prolactin Homo sapiens 61-64 1369597-14 1992 The effects of DA on PRL, LH, and FSH at all doses tested were blocked by the DA receptor blocker, haloperidol which by itself at the concentration tested (1 x 10(-5) M) had no effect. Dopamine 15-17 prolactin Homo sapiens 21-24 1369597-14 1992 The effects of DA on PRL, LH, and FSH at all doses tested were blocked by the DA receptor blocker, haloperidol which by itself at the concentration tested (1 x 10(-5) M) had no effect. Haloperidol 99-110 prolactin Homo sapiens 21-24 1304992-7 1992 Detecting serum prolactin before and after treatment in 6 cases of metoclopramide therapy and 5 cases of haloperidol therapy. Metoclopramide 67-81 prolactin Homo sapiens 16-25 1304992-7 1992 Detecting serum prolactin before and after treatment in 6 cases of metoclopramide therapy and 5 cases of haloperidol therapy. Haloperidol 105-116 prolactin Homo sapiens 16-25 1332868-1 1992 cAMP strongly stimulates the activity of the human prolactin (hPRL) promoter. Cyclic AMP 0-4 prolactin Homo sapiens 51-60 1332868-1 1992 cAMP strongly stimulates the activity of the human prolactin (hPRL) promoter. Cyclic AMP 0-4 prolactin Homo sapiens 62-66 1332868-4 1992 In this study, we show that a mutation in the TGACG motif of sequence A strongly reduces not only the cAMP regulation but also the Ca2+ regulation and basal activity of the hPRL promoter. Cyclic AMP 102-106 prolactin Homo sapiens 173-177 1332473-0 1992 Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine. Verapamil 41-50 prolactin Homo sapiens 58-67 1330488-0 1992 The effect of "binge" ethanol exposure on growth hormone and prolactin gene expression and secretion. Ethanol 22-29 prolactin Homo sapiens 61-70 1332473-0 1992 Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine. Levodopa 86-92 prolactin Homo sapiens 58-67 1332473-0 1992 Effects of calcium channel blockade with verapamil on the prolactin responses to TRH, L-dopa, and bromocriptine. Bromocriptine 98-111 prolactin Homo sapiens 58-67 1332473-1 1992 To determine the mechanisms by which calcium channel blockade with verapamil causes hyperprolactinemia, the authors investigated the effects of this blockade on the prolactin (PRL) responses to stimulation by thyrotropin releasing hormone (TRH) and inhibition by dopamine, using L-dopa and bromocriptine. Verapamil 67-76 prolactin Homo sapiens 89-98 1332473-2 1992 Verapamil, given for 1 week at a dosage of 240 mg orally to eight healthy volunteers, induced a significant elevation of basal PRL levels (17.3 +/- 1.8 ng/ml to 30.9 +/- 4.3 ng/ml, p < 0.005). Verapamil 0-9 prolactin Homo sapiens 127-130 1332473-3 1992 Verapamil also caused an increase in the PRL response to a TRH (100 micrograms). Verapamil 0-9 prolactin Homo sapiens 41-44 1332473-6 1992 In these same volunteers, PRL levels decreased from 13.2 +/- 2.5 ng/ml to a nadir of 5.5 +/- 1.6 ng/ml in response to L-dopa. Levodopa 118-124 prolactin Homo sapiens 26-29 1332473-7 1992 After 1 week of verapamil 240 mg, basal PRL levels were elevated to 21.5 +/- 3.1 ng/ml, then decreased to 8.2 +/- 1.8 ng/ml with L-dopa. Verapamil 16-25 prolactin Homo sapiens 40-43 1332473-8 1992 The percentage decreased in PRL in response to L-dopa (60 +/- 5% versus 62 +/- 3%) were not significantly different (p > 0.05). Levodopa 47-53 prolactin Homo sapiens 28-31 1332473-10 1992 Bromocriptine 2.5 mg given to five volunteers twice daily caused PRL levels to fall from 13.3 +/- 1.6 ng/ml to 5.0 +/- 0.9 ng/ml. Bromocriptine 0-13 prolactin Homo sapiens 65-68 1330488-3 1992 We have attempted to expand these studies by examining the impact of acute or "binge" EtOH in vivo on GH and PRL synthesis and secretion. Ethanol 86-90 prolactin Homo sapiens 109-112 1330488-10 1992 In summary, acute EtOH exposure in vivo appears to dampen both GH and PRL synthesis, while serum levels behave dissimilarily. Ethanol 18-22 prolactin Homo sapiens 70-73 1341480-0 1992 A clinical study of the pineal hormone melatonin in patients with growth hormone or prolactin secreting pituitary tumours. Melatonin 39-48 prolactin Homo sapiens 84-93 1460163-0 1992 D-fenfluramine-induced prolactin and cortisol release in major depression: response to treatment. Dexfenfluramine 0-14 prolactin Homo sapiens 23-32 1490755-4 1992 After the vitamin E treatment serum prolactin levels were significantly decreased (50.8 vs 15.4 ng/ml, p < 0.01). Vitamin E 10-19 prolactin Homo sapiens 36-45 1490755-8 1992 These results show that vitamin E treatment lowers prolactin levels in uremic hemodialysis patients. Vitamin E 24-33 prolactin Homo sapiens 51-60 1341021-3 1992 Serum prolactin levels were reduced during the use of bromocriptine. Bromocriptine 54-67 prolactin Homo sapiens 6-15 1331401-0 1992 Acute effects of cocaine on plasma adrenocorticotropic hormone, luteinizing hormone and prolactin levels in cocaine-dependent men. Cocaine 17-24 prolactin Homo sapiens 88-97 1336817-1 1992 Previous work from our laboratory showed that baclofen could lower serum prolactin (PRL) levels acting at the central nervous system. Baclofen 46-54 prolactin Homo sapiens 73-82 1490255-2 1992 Using bromocriptine, a potent inhibitor of PRL secretion, this study established the proper experimental conditions whereby any significant increase in plasma PRL level can be prevented and basal circulating levels maintained during physical exercise. Bromocriptine 6-19 prolactin Homo sapiens 43-46 1393339-0 1992 Cortisol and prolactin responses to d-fenfluramine in non-depressed patients with obsessive-compulsive disorder: a comparison with depressed and healthy controls. Dexfenfluramine 36-50 prolactin Homo sapiens 13-22 1393339-1 1992 Cortisol and prolactin responses to d-fenfluramine were measured in 10 drug-free normothymic patients with obsessive-compulsive disorder (OCD). Dexfenfluramine 36-50 prolactin Homo sapiens 13-22 1490255-2 1992 Using bromocriptine, a potent inhibitor of PRL secretion, this study established the proper experimental conditions whereby any significant increase in plasma PRL level can be prevented and basal circulating levels maintained during physical exercise. Bromocriptine 6-19 prolactin Homo sapiens 159-162 1490255-4 1992 Under all conditions, the plasma PRL elevation observed during exercise after placebo was prevented by the administration of bromocriptine. Bromocriptine 125-138 prolactin Homo sapiens 33-36 1490255-5 1992 Resting plasma PRL levels were maintained when exercise was performed 1 h after bromocriptine ingestion, but were significantly reduced when exercise was performed 3 h after administration of either bromocriptine dosages. Bromocriptine 80-93 prolactin Homo sapiens 15-18 1490255-6 1992 Considering the primary and secondary effects observed, 1.25 mg of bromocriptine administered 1 h before exercise provides suitable experimental conditions to investigate the role of the increase in plasma PRL during physical exercise. Bromocriptine 67-80 prolactin Homo sapiens 206-209 1330472-8 1992 The results on the 1st day reconfirmed the findings in the first experiment and on the 7th day, the last alcohol ingestion produced increases in prolactin levels and decreases in testosterone levels at 30 and 60 min, but did not change other hormone levels. Alcohols 105-112 prolactin Homo sapiens 145-154 1483294-3 1992 The bioactivity of sera and fractions containing BB-PRL was evaluated and the fractions analysed by affinity chromatography and electrophoresis. boeravinone B 49-51 prolactin Homo sapiens 52-55 1483294-14 1992 During gel chromatography either a change in the structure of BB-PRL and/or a removal of substances which potentiate the bioactivity of PRL occurs, explaining the lower bioactivity of fractions containing BB-PRL in comparison with the serum. boeravinone B 62-64 prolactin Homo sapiens 65-68 1411301-1 1992 Dopamine inhibits prolactin release from pituitary cells and seems to affect the release of several other hormones as well. Dopamine 0-8 prolactin Homo sapiens 18-27 1407345-2 1992 BC is known to be effective for reducing the volume of a prolactinoma and for decreasing the serum level of prolactin (PRL). Bromocriptine 0-2 prolactin Homo sapiens 57-66 1407345-2 1992 BC is known to be effective for reducing the volume of a prolactinoma and for decreasing the serum level of prolactin (PRL). Bromocriptine 0-2 prolactin Homo sapiens 119-122 8382895-9 1993 GH and PRL release was significantly inhibited by bromocriptine. Bromocriptine 50-63 prolactin Homo sapiens 7-10 1411301-5 1992 When two of the hormones known to be under dopamine control, i.e. prolactin (PRL) and thyrotropin (TSH), were tested, they were able to prevent dopamine-induced cell death if combined with heparin. Dopamine 43-51 prolactin Homo sapiens 66-75 1296388-5 1992 Control investigation done after 18 months showed that the concentration of prolactin after administration of metoclopramide was slightly lower than before, but was still high. Metoclopramide 110-124 prolactin Homo sapiens 76-85 1411301-5 1992 When two of the hormones known to be under dopamine control, i.e. prolactin (PRL) and thyrotropin (TSH), were tested, they were able to prevent dopamine-induced cell death if combined with heparin. Dopamine 144-152 prolactin Homo sapiens 66-75 1411301-5 1992 When two of the hormones known to be under dopamine control, i.e. prolactin (PRL) and thyrotropin (TSH), were tested, they were able to prevent dopamine-induced cell death if combined with heparin. Heparin 189-196 prolactin Homo sapiens 66-75 1358652-1 1992 Somatostatin-induced inhibition of prolactin secretion from adenohypophysis cells in culture is antagonized by the sulfonylurea glipizide, a specific blocker of ATP-sensitive K+ channels. Glipizide 128-137 prolactin Homo sapiens 35-44 1324146-0 1992 Posttranscriptional regulation of the human prolactin gene in IM-9-P3 cells by retinoic acid. Tretinoin 79-92 prolactin Homo sapiens 44-53 1323933-4 1992 RESULTS: The depressed patients demonstrated significant blunting of prolactin responses to clomipramine, as well as trends toward blunted ACTH and cortisol responses. Clomipramine 92-104 prolactin Homo sapiens 69-78 1380842-9 1992 Replacing MPA by RU486 caused a rapid increase of PRL mRNA (2-3-fold) in 2-3 days followed by a gradual reduction to less than 20% of peak levels over the next 3 days. Mifepristone 17-22 prolactin Homo sapiens 50-53 1324146-3 1992 When cells were incubated in medium supplemented with fetal calf serum that had been treated with dextran-coated charcoal, the addition of RA caused a 2-fold stimulation of hPRL secretion in the low hPRL-producing clone IM-9-P31 and the moderate producer IM-9-P32 (ED50, 0.53 and 0.13 nM, respectively), but not in the high hPRL-producing IM-9-P33 clone. Dextrans 98-105 prolactin Homo sapiens 173-177 1324146-3 1992 When cells were incubated in medium supplemented with fetal calf serum that had been treated with dextran-coated charcoal, the addition of RA caused a 2-fold stimulation of hPRL secretion in the low hPRL-producing clone IM-9-P31 and the moderate producer IM-9-P32 (ED50, 0.53 and 0.13 nM, respectively), but not in the high hPRL-producing IM-9-P33 clone. Tretinoin 139-141 prolactin Homo sapiens 173-177 1486148-0 1992 Multidiagnostic evaluation of prolactin response to haloperidol challenge in schizophrenia: maximal blunting in Kraepelinian patients. Haloperidol 52-63 prolactin Homo sapiens 30-39 1486148-1 1992 We have previously reported that prolactin (PRL) responses to haloperidol 0.5 mg IV were blunted in subjects characterized by several diagnostic systems of schizophrenia compared to controls (Keks et al 1990). Haloperidol 62-73 prolactin Homo sapiens 33-42 1486148-1 1992 We have previously reported that prolactin (PRL) responses to haloperidol 0.5 mg IV were blunted in subjects characterized by several diagnostic systems of schizophrenia compared to controls (Keks et al 1990). Haloperidol 62-73 prolactin Homo sapiens 44-47 1324146-3 1992 When cells were incubated in medium supplemented with fetal calf serum that had been treated with dextran-coated charcoal, the addition of RA caused a 2-fold stimulation of hPRL secretion in the low hPRL-producing clone IM-9-P31 and the moderate producer IM-9-P32 (ED50, 0.53 and 0.13 nM, respectively), but not in the high hPRL-producing IM-9-P33 clone. Tretinoin 139-141 prolactin Homo sapiens 199-203 1324146-2 1992 Here we describe regulation of hPRL gene expression in members of the IM-9-P3 family by retinoic acid (RA). Tretinoin 88-101 prolactin Homo sapiens 31-35 1324146-3 1992 When cells were incubated in medium supplemented with fetal calf serum that had been treated with dextran-coated charcoal, the addition of RA caused a 2-fold stimulation of hPRL secretion in the low hPRL-producing clone IM-9-P31 and the moderate producer IM-9-P32 (ED50, 0.53 and 0.13 nM, respectively), but not in the high hPRL-producing IM-9-P33 clone. Tretinoin 139-141 prolactin Homo sapiens 199-203 1324146-9 1992 This receptor subtype was absent from hPRL-negative members of the IM-9-P family, strongly induced by RA in the RA-responsive IM-9-P31 and IM-9-P32 cell lines via rapid transcriptional up-regulation, and only slightly induced in the RA-resistant IM-9-P33 cell line, suggesting a function in mediation of the effect of RA on hPRL gene expression. Tretinoin 102-104 prolactin Homo sapiens 38-42 1324146-2 1992 Here we describe regulation of hPRL gene expression in members of the IM-9-P3 family by retinoic acid (RA). Tretinoin 103-105 prolactin Homo sapiens 31-35 1324146-9 1992 This receptor subtype was absent from hPRL-negative members of the IM-9-P family, strongly induced by RA in the RA-responsive IM-9-P31 and IM-9-P32 cell lines via rapid transcriptional up-regulation, and only slightly induced in the RA-resistant IM-9-P33 cell line, suggesting a function in mediation of the effect of RA on hPRL gene expression. Tretinoin 112-114 prolactin Homo sapiens 38-42 1324146-9 1992 This receptor subtype was absent from hPRL-negative members of the IM-9-P family, strongly induced by RA in the RA-responsive IM-9-P31 and IM-9-P32 cell lines via rapid transcriptional up-regulation, and only slightly induced in the RA-resistant IM-9-P33 cell line, suggesting a function in mediation of the effect of RA on hPRL gene expression. Tretinoin 112-114 prolactin Homo sapiens 324-328 1525801-0 1992 Effect of sodium valproate on the secretion of prolactin, cortisol and growth hormone in migraine patients. Valproic Acid 10-26 prolactin Homo sapiens 47-56 1521641-13 1992 With multiple bromocriptine induced pregnancies, PRL levels and tumor size may progressively decrease with the eventual development of an empty sella. Bromocriptine 14-27 prolactin Homo sapiens 49-52 1395069-10 1992 An elevated serum PRL level predicted a stronger inhibitory response of bromocriptine on GH. Bromocriptine 72-85 prolactin Homo sapiens 18-21 1435787-0 1992 Alanine-scanning mutagenesis of human prolactin: importance of the 58-74 region for bioactivity. Alanine 0-7 prolactin Homo sapiens 38-47 1357683-1 1992 Bromocriptine, the ergotamine alkaloid 2-bromo-alpha-ergocriptine, is known as a dopamine D-2 receptor agonist with strong prolactin-lowering actions and potential mental side-effects. Bromocriptine 0-13 prolactin Homo sapiens 123-132 1357683-1 1992 Bromocriptine, the ergotamine alkaloid 2-bromo-alpha-ergocriptine, is known as a dopamine D-2 receptor agonist with strong prolactin-lowering actions and potential mental side-effects. ergotamine alkaloid 19-38 prolactin Homo sapiens 123-132 1357683-1 1992 Bromocriptine, the ergotamine alkaloid 2-bromo-alpha-ergocriptine, is known as a dopamine D-2 receptor agonist with strong prolactin-lowering actions and potential mental side-effects. 2-bromo-alpha-ergocriptine 39-65 prolactin Homo sapiens 123-132 1357683-5 1992 The high prolactin plasma levels that persisted in spite of treatment with bromocriptine would seem to be a reason to carry out further research into the mechanism of action of the drug. Bromocriptine 75-88 prolactin Homo sapiens 9-18 1430126-5 1992 Following a 60 mg oral dose of buspirone hydrochloride on day 22 of the menstrual cycle, patients in group A had a greater increase in prolactin levels than patients in group B (P less than 0.01). Buspirone 31-54 prolactin Homo sapiens 135-144 1527538-0 1992 Serum prolactin response to metoclopramide during status epilepticus. Metoclopramide 28-42 prolactin Homo sapiens 6-15 1323636-5 1992 Prolactin levels increased 10-fold after metoclopramide with placebo infusion, and about 50% of this stimulation was abolished by preinfusion with dopamine. Metoclopramide 41-55 prolactin Homo sapiens 0-9 1323636-5 1992 Prolactin levels increased 10-fold after metoclopramide with placebo infusion, and about 50% of this stimulation was abolished by preinfusion with dopamine. Dopamine 147-155 prolactin Homo sapiens 0-9 1527538-7 1992 Metoclopramide raised the mean (SD) prolactin levels at least five-fold in all patients, from 5.8 (8.0) micrograms/l to 87.0 (39.0) micrograms/l, within 60 minutes after the injection. Metoclopramide 0-14 prolactin Homo sapiens 36-45 1407377-6 1992 Following solubilization with Triton X-100 the PRL receptor fraction retained its hormone-binding properties and upon molecular sieve chromatography it behaved as a protein with a molecular mass of approximately 250,000. Octoxynol 30-42 prolactin Homo sapiens 47-50 1407377-7 1992 Cross-linking of 125I-hPRL to receptors from choroid plexus and subsequent sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis indicated a major hormone-binding unit of M(r) 44,000. Sodium Dodecyl Sulfate 75-97 prolactin Homo sapiens 22-26 1410069-1 1992 Plasma prolactin and cortisol levels after oral administration of d-l fenfluramine hydrochloride (60 mg) and placebo were examined in 24 endogenously depressed patients and 21 age- and sex-matched normal control subjects in a randomized, double-blind study. d-l fenfluramine hydrochloride 66-96 prolactin Homo sapiens 7-16 1410069-2 1992 Prolactin levels were significantly increased by fenfluramine in both groups, but the response was significantly blunted in the depressed patients compared with the controls. Fenfluramine 49-61 prolactin Homo sapiens 0-9 1410071-0 1992 Blood levels of melatonin, serotonin, cortisol, and prolactin in relation to the circadian rhythm of platelet serotonin uptake. Serotonin 110-119 prolactin Homo sapiens 52-61 1424194-8 1992 The testosterone treatment in agonadal men significantly reduced luteinizing hormone pulse frequency (baseline: 27.5 +/- 2, testosterone administration: 18 +/- 1.3 peaks/12h, P < 0.01) but did not affect pulsatile prolactin release. Testosterone 4-16 prolactin Homo sapiens 217-226 1446915-4 1992 Activation of phosphoinositide turnover and subsequent increase in protein kinase-C activity seems to be a possible mechanism acting in the regulatory influence of PRL on mammalian immune cells. Phosphatidylinositols 14-30 prolactin Homo sapiens 164-167 1351839-1 1992 Progesterone (P)-induced PRL secretion in estradiol (E)-primed monkeys is not due to direct pituitary stimulation, because lactotropes do not express progestin receptors (PR). Progesterone 0-12 prolactin Homo sapiens 25-28 1351839-20 1992 Therefore, the contribution of the PR-positive periventricular dopamine neurons to progestin-stimulated PRL secretion may be important. Dopamine 63-71 prolactin Homo sapiens 104-107 1624027-8 1992 Immunoprecipitation and polyacrylamide gel electrophoresis under reducing and denaturing conditions revealed that the largest form of PRL (MW 669 kd) was composed mostly of 25 kd glycosylated PRL; intermediate forms (171 kd and 291 kd) were composed of roughly equal portions of 25 kd glycosylated PRL and 23 kd nonglycosylated PRL, whereas "little" PRL in these patients was composed primarily of 23 kd nonglycosylated PRL. polyacrylamide 24-38 prolactin Homo sapiens 134-137 1352308-9 1992 Bromocriptine inhibited GH, PRL, and alpha-subunit release by most MSAs and mixed tumors but did not inhibit GH or PRL release by ASCAs. Bromocriptine 0-13 prolactin Homo sapiens 28-31 1352308-12 1992 The dynamic studies indicate that regulation of GH, PRL, and alpha-subunit release can be affected by GHRH, TRH, SRIH, and bromocriptine in these adenomas and suggest differences in receptor status. srih 113-117 prolactin Homo sapiens 52-55 1320050-1 1992 The secretion of PTH(1-84) and PRL over a 24-h period in normal subjects has been shown to be highly correlated, with changes in PRL occurring approximately 2 h after those in PTH(1-84). pth 17-20 prolactin Homo sapiens 129-132 1352308-12 1992 The dynamic studies indicate that regulation of GH, PRL, and alpha-subunit release can be affected by GHRH, TRH, SRIH, and bromocriptine in these adenomas and suggest differences in receptor status. Bromocriptine 123-136 prolactin Homo sapiens 52-55 1597150-0 1992 Voltage-dependent calcium current in human decidual cells and its relation to prolactin secretion. Calcium 18-25 prolactin Homo sapiens 78-87 1641069-0 1992 Plasma growth hormone and prolactin responses to graded levels of acute exercise and to a lactate infusion. Lactic Acid 90-97 prolactin Homo sapiens 26-35 1641069-6 1992 To examine a potential causative role of lactate in inducing the GH and PRL responses, sodium L-lactate was infused intravenously to normal sedentary volunteers at doses producing plasma lactate concentrations within the range of those seen between 70 and 90% VO2max. Lactic Acid 41-48 prolactin Homo sapiens 72-75 1641069-9 1992 Lactate may be involved in the exercise-induced GH and PRL response; however, it does not appear to play an exclusive role. Lactic Acid 0-7 prolactin Homo sapiens 55-58 1504133-3 1992 Fenfluramine stimulates the brain serotonin neurosystem, producing an increase in systemic prolactin. Fenfluramine 0-12 prolactin Homo sapiens 91-100 1504133-3 1992 Fenfluramine stimulates the brain serotonin neurosystem, producing an increase in systemic prolactin. Serotonin 34-43 prolactin Homo sapiens 91-100 1618918-3 1992 K-current blockers tested (quinidine, 4-aminopyridine, barium, and tetraethylammonium) exhibited similar rank order potency for K-current block and inhibition of prolactin-induced proliferation of malignant lymphocytes. Quinidine 27-36 prolactin Homo sapiens 162-171 1618918-3 1992 K-current blockers tested (quinidine, 4-aminopyridine, barium, and tetraethylammonium) exhibited similar rank order potency for K-current block and inhibition of prolactin-induced proliferation of malignant lymphocytes. 4-Aminopyridine 38-53 prolactin Homo sapiens 162-171 1618918-3 1992 K-current blockers tested (quinidine, 4-aminopyridine, barium, and tetraethylammonium) exhibited similar rank order potency for K-current block and inhibition of prolactin-induced proliferation of malignant lymphocytes. Barium 55-61 prolactin Homo sapiens 162-171 1618918-3 1992 K-current blockers tested (quinidine, 4-aminopyridine, barium, and tetraethylammonium) exhibited similar rank order potency for K-current block and inhibition of prolactin-induced proliferation of malignant lymphocytes. Tetraethylammonium 67-85 prolactin Homo sapiens 162-171 1298871-0 1992 [Effect of 5-hydroxytryptophan on the secretion of PRL, GH, TSH and cortisol in obesity]. 5-Hydroxytryptophan 11-30 prolactin Homo sapiens 51-54 1642081-11 1992 Following cabergoline discontinuation, prolactin levels increased slowly, being still markedly lower than pretreatment values after three months; 10 patients out of 32 had persistently normal prolactin levels during one year of follow-up. Cabergoline 10-21 prolactin Homo sapiens 39-48 1534540-4 1992 This rapid effect of estradiol also enhanced PRL mRNA, but did not affect other species of mRNA encoding for proenkephalin, D2 receptor mRNA, or hexosaminidase-A. Estradiol 21-30 prolactin Homo sapiens 45-48 1511080-3 1992 PRL response to fenfluramine (minus elevated baseline PRL levels) but not to placebo, was significantly increased by CMI administration, reflected over the 6-hr time course examined and in peak minus baseline values. Fenfluramine 16-28 prolactin Homo sapiens 0-3 1525456-8 1992 RESULTS: Higher serum prolactin was associated with both higher estradiol levels and use of LA but did not have any effects on fertilization rate, embryo quality, or occurrence of pregnancy. Estradiol 64-73 prolactin Homo sapiens 22-31 1320162-6 1992 We examined the effect of ketamine HCl, an anesthetic that has been shown to elevate serum prolactin levels in other primates, on prolactin secretion in squirrel monkeys. Ketamine 26-38 prolactin Homo sapiens 91-100 1320162-6 1992 We examined the effect of ketamine HCl, an anesthetic that has been shown to elevate serum prolactin levels in other primates, on prolactin secretion in squirrel monkeys. Ketamine 26-38 prolactin Homo sapiens 130-139 1320162-7 1992 Serum prolactin levels increased greater than fourfold after the administration of ketamine HCl (30 mg/kg b.w., i.m.) Ketamine 83-95 prolactin Homo sapiens 6-15 1511080-3 1992 PRL response to fenfluramine (minus elevated baseline PRL levels) but not to placebo, was significantly increased by CMI administration, reflected over the 6-hr time course examined and in peak minus baseline values. Fenfluramine 16-28 prolactin Homo sapiens 54-57 1438649-1 1992 An investigation of the cortisol and prolactin responses accompanying acute melatonin suppression by light (600 lux) in humans is described. Melatonin 76-85 prolactin Homo sapiens 37-46 1375019-6 1992 Clozapine and fluphenazine equally reduced plasma homovanillic acid levels in comparison with placebo, although fluphenazine but not clozapine increased plasma prolactin level. Fluphenazine 112-124 prolactin Homo sapiens 160-169 1618163-0 1992 Dissociation of dopamine from its receptor as a signal in the pleiotropic hypothalamic regulation of prolactin secretion. Dopamine 16-24 prolactin Homo sapiens 101-110 1618163-1 1992 We have reviewed the literature, which supports an important role for dopamine withdrawal in the regulation of PRL secretion. Dopamine 70-78 prolactin Homo sapiens 111-114 1618163-2 1992 Concentrations of dopamine in the hypophyseal portal circulation are sufficient to occupy the majority of dopamine receptors (1) and tonically suppress PRL secretion (20-26). Dopamine 18-26 prolactin Homo sapiens 152-155 1618163-4 1992 Therefore, dopamine regulates secretion of PRL both by occupancy of, as well as dissociation from, specific D2 dopamine receptors. Dopamine 11-19 prolactin Homo sapiens 43-46 1618163-7 1992 The removal of dopamine results directly in the release of PRL (37-41). Dopamine 15-23 prolactin Homo sapiens 59-62 1618163-8 1992 Furthermore, the brief removal of dopamine results in the long-term potentiation of the PRL-releasing action of TRH (38-40). Dopamine 34-42 prolactin Homo sapiens 88-91 1534990-3 1992 Incubation of stromal cells with a mixture of estradiol, medroxyprogesterone acetate and relaxin, at a concentration reported to yield maximal stimulation of PRL production, resulted in changes from elongated to rounder cells, approx. Estradiol 46-55 prolactin Homo sapiens 158-161 1534990-3 1992 Incubation of stromal cells with a mixture of estradiol, medroxyprogesterone acetate and relaxin, at a concentration reported to yield maximal stimulation of PRL production, resulted in changes from elongated to rounder cells, approx. Medroxyprogesterone Acetate 57-84 prolactin Homo sapiens 158-161 1590489-5 1992 Ovine prolactin resulted in an elevation of plasma urate concentration but had no significant effects on other plasma parameters or on the concentration of the various ions in tubular fluid samples. Uric Acid 51-56 prolactin Homo sapiens 6-15 1590489-7 1992 The whole animal fractional excretions of sodium and chloride were significantly higher, those of magnesium and potassium were significantly lower, and the fractional excretion of phosphate tended to be lower during prolactin infusion. Phosphates 180-189 prolactin Homo sapiens 216-225 1590489-8 1992 At the level of the proximal tubules of the reptilian-type nephrons, prolactin infusion caused a slight reduction in the net reabsorption of sodium and chloride. Sodium 141-147 prolactin Homo sapiens 69-78 1590489-8 1992 At the level of the proximal tubules of the reptilian-type nephrons, prolactin infusion caused a slight reduction in the net reabsorption of sodium and chloride. Chlorides 152-160 prolactin Homo sapiens 69-78 1591573-0 1992 Blunted prolactin responses to d-fenfluramine in sociopathy. Dexfenfluramine 31-45 prolactin Homo sapiens 8-17 1350237-3 1992 Pramipexole decreased serum prolactin levels in a dose-dependent manner, with a maximum effect after 2 to 4 hours. Pramipexole 0-11 prolactin Homo sapiens 28-37 1350936-1 1992 We report the case of a 27-year-old woman with a prolactin-secreting macroadenoma of the pituitary gland who was under treatment with a new dopamine agonist, Sandoz CV 205-502. Dopamine 140-148 prolactin Homo sapiens 49-58 1588831-0 1992 Prolactin responses to phenylalanine and tyrosine in phenylketonuria. Phenylalanine 23-36 prolactin Homo sapiens 0-9 1588831-0 1992 Prolactin responses to phenylalanine and tyrosine in phenylketonuria. Tyrosine 41-49 prolactin Homo sapiens 0-9 1588831-1 1992 In normal subjects, ingestion of tyrosine or phenylalanine stimulates prolactin (PRL) secretion. Tyrosine 33-41 prolactin Homo sapiens 70-79 1588831-1 1992 In normal subjects, ingestion of tyrosine or phenylalanine stimulates prolactin (PRL) secretion. Tyrosine 33-41 prolactin Homo sapiens 81-84 1588831-1 1992 In normal subjects, ingestion of tyrosine or phenylalanine stimulates prolactin (PRL) secretion. Phenylalanine 45-58 prolactin Homo sapiens 70-79 1588831-1 1992 In normal subjects, ingestion of tyrosine or phenylalanine stimulates prolactin (PRL) secretion. Phenylalanine 45-58 prolactin Homo sapiens 81-84 1588831-3 1992 PKU patients also showed greater PRL responses to tyrosine during dietary phenylalanine restriction than when consuming an unrestricted diet; this finding is consistent with inhibition by phenylalanine of tyrosine transport across the blood-brain barrier. Tyrosine 50-58 prolactin Homo sapiens 33-36 1588831-3 1992 PKU patients also showed greater PRL responses to tyrosine during dietary phenylalanine restriction than when consuming an unrestricted diet; this finding is consistent with inhibition by phenylalanine of tyrosine transport across the blood-brain barrier. Phenylalanine 74-87 prolactin Homo sapiens 33-36 1588831-3 1992 PKU patients also showed greater PRL responses to tyrosine during dietary phenylalanine restriction than when consuming an unrestricted diet; this finding is consistent with inhibition by phenylalanine of tyrosine transport across the blood-brain barrier. Phenylalanine 188-201 prolactin Homo sapiens 33-36 1413649-1 1992 Highly purified preparation of prolactin with molecular mass 23 kDa, which is the main form of the hormone in human amnionic fluid, was isolated from the fluid using gel filtration on Sephadex G-100, chromatography on DEAE-Sepharose, concanavalin A Sepharose, CM-cellulose. sephadex 184-198 prolactin Homo sapiens 31-40 1441548-8 1992 Moreover, it was found that prolactin affects the synthesis of fetal surfactant, influences calcium absorption in the fetal intestine. Calcium 92-99 prolactin Homo sapiens 28-37 1413649-1 1992 Highly purified preparation of prolactin with molecular mass 23 kDa, which is the main form of the hormone in human amnionic fluid, was isolated from the fluid using gel filtration on Sephadex G-100, chromatography on DEAE-Sepharose, concanavalin A Sepharose, CM-cellulose. deae-sepharose 218-232 prolactin Homo sapiens 31-40 1413649-1 1992 Highly purified preparation of prolactin with molecular mass 23 kDa, which is the main form of the hormone in human amnionic fluid, was isolated from the fluid using gel filtration on Sephadex G-100, chromatography on DEAE-Sepharose, concanavalin A Sepharose, CM-cellulose. Sepharose 223-232 prolactin Homo sapiens 31-40 1413649-1 1992 Highly purified preparation of prolactin with molecular mass 23 kDa, which is the main form of the hormone in human amnionic fluid, was isolated from the fluid using gel filtration on Sephadex G-100, chromatography on DEAE-Sepharose, concanavalin A Sepharose, CM-cellulose. 7,8-diacetoxy-3-(4-nitrophenyl)coumarin 260-272 prolactin Homo sapiens 31-40 1441548-7 1992 The most important biological function of decidual prolactin is its effect on water and electrolyte transport for the needs of the fetus, and this transport takes place mainly across the fetal membranes. Water 78-83 prolactin Homo sapiens 51-60 1587385-8 1992 Moreover, these observations further extended and supported the concept that the occurrence of PRL size heterogeneity depends mainly on thiol-disulfide interchange mechanisms, among PRL molecules, at the pituitary level. thiol-disulfide 136-151 prolactin Homo sapiens 95-98 1587385-8 1992 Moreover, these observations further extended and supported the concept that the occurrence of PRL size heterogeneity depends mainly on thiol-disulfide interchange mechanisms, among PRL molecules, at the pituitary level. thiol-disulfide 136-151 prolactin Homo sapiens 182-185 1559983-3 1992 We have recently shown the 4 cysteines to be critical to the maintenance of the structural and functional integrity of the PRL-receptor. Cysteine 29-38 prolactin Homo sapiens 123-126 1559983-6 1992 Binding of 125I-labeled ovine PRL or human GH to membrane preparations from COS-7 cells transiently expressing the mutant receptors have defined a region within the first disulfide loop (residues Arg13, Asp16, Glu18) and the set of lactogen-specific sequences between the two pairs of cysteines as key determinants of PRL-binding specificity, which converge to form a patch on a two-dimensional model of the PRL receptor. Iodine-125 11-15 prolactin Homo sapiens 30-33 1559983-6 1992 Binding of 125I-labeled ovine PRL or human GH to membrane preparations from COS-7 cells transiently expressing the mutant receptors have defined a region within the first disulfide loop (residues Arg13, Asp16, Glu18) and the set of lactogen-specific sequences between the two pairs of cysteines as key determinants of PRL-binding specificity, which converge to form a patch on a two-dimensional model of the PRL receptor. Disulfides 171-180 prolactin Homo sapiens 30-33 1559983-8 1992 Finally, substitution of the WS motif with alanine residues precludes high affinity binding to ovine PRL and human GH and suggests that this structural element may provide a target site for the interaction of an accessory protein necessary for the formation of a high-affinity receptor complex. H-TRP-SER-OH 29-31 prolactin Homo sapiens 101-104 1559983-8 1992 Finally, substitution of the WS motif with alanine residues precludes high affinity binding to ovine PRL and human GH and suggests that this structural element may provide a target site for the interaction of an accessory protein necessary for the formation of a high-affinity receptor complex. Alanine 43-50 prolactin Homo sapiens 101-104 1396349-3 1992 A bolus of 10 mg of metoclopramide significantly increased plasma PRL in 6 normal subjects and in 4 patients with APA, whereas the responses were blunted in 7 patients with prolactinoma and in our patient. Metoclopramide 20-34 prolactin Homo sapiens 66-69 1424170-1 1992 OBJECTIVE: The objective of this study was to assess the relationship of different doses of a long-acting bromocriptine preparation (Parlodel LAR) to the degree and duration of PRL suppression. Bromocriptine 106-119 prolactin Homo sapiens 177-180 1631251-0 1992 Prolactin responses to domperidone in chronic schizophrenia. Domperidone 23-34 prolactin Homo sapiens 0-9 1631251-1 1992 The prolactin response to 20 mg of domperidone, a peripheral dopamine receptor antagonist, was evaluated in a group of 17 male, drug-free, elderly, chronic schizophrenic patients and 8 age-matched male normal control subjects. Domperidone 35-46 prolactin Homo sapiens 4-13 1631251-4 1992 However, the prolactin response following domperidone was significantly greater in the schizophrenic patients, although plasma domperidone levels did not differ between the two groups. Domperidone 42-53 prolactin Homo sapiens 13-22 1631251-6 1992 The prolactin response to domperidone was markedly smaller in the old compared with the young normal control subjects, whereas the young and old schizophrenic patients had identical responses. Domperidone 26-37 prolactin Homo sapiens 4-13 1396349-5 1992 Oral administration of 2.5 mg of bromocriptine suppressed plasma PRL significantly in all the subjects studied, but did not produce any consistent changes in PAC. Bromocriptine 33-46 prolactin Homo sapiens 65-68 1396349-6 1992 Discrepancies in the response of PRL and aldosterone to metoclopramide and to bromocriptine suggest a difference in the dopaminergic regulation of PRL and aldosterone secretion in both normal subjects and patients with prolactinoma and APA. Metoclopramide 56-70 prolactin Homo sapiens 33-36 1396349-6 1992 Discrepancies in the response of PRL and aldosterone to metoclopramide and to bromocriptine suggest a difference in the dopaminergic regulation of PRL and aldosterone secretion in both normal subjects and patients with prolactinoma and APA. Metoclopramide 56-70 prolactin Homo sapiens 147-150 1396349-6 1992 Discrepancies in the response of PRL and aldosterone to metoclopramide and to bromocriptine suggest a difference in the dopaminergic regulation of PRL and aldosterone secretion in both normal subjects and patients with prolactinoma and APA. Bromocriptine 78-91 prolactin Homo sapiens 147-150 1532567-4 1992 A direct link between nutritional factors and secretion of the hormones prolactin and dehydroepiandrosterone sulfate is proposed. Dehydroepiandrosterone Sulfate 86-116 prolactin Homo sapiens 72-81 1574954-0 1992 Bromocriptine treatment over 12 years in acromegaly: effect on growth hormone and prolactin secretion. Bromocriptine 0-13 prolactin Homo sapiens 82-91 1624756-0 1992 Buspirone induced prolactin responses in obsessive-compulsive disorder (OCD): is OCD a 5-HT2 receptor disorder? Buspirone 0-9 prolactin Homo sapiens 18-27 1603882-3 1992 Two acute administrations of fenfluramine produced consistent and predictable effects on net prolactin responses (peak delta PRL, area under the curve delta PRL), but variable and unpredictable effects on net cortisol responses. Fenfluramine 29-41 prolactin Homo sapiens 93-102 1603882-3 1992 Two acute administrations of fenfluramine produced consistent and predictable effects on net prolactin responses (peak delta PRL, area under the curve delta PRL), but variable and unpredictable effects on net cortisol responses. Fenfluramine 29-41 prolactin Homo sapiens 125-128 1603882-3 1992 Two acute administrations of fenfluramine produced consistent and predictable effects on net prolactin responses (peak delta PRL, area under the curve delta PRL), but variable and unpredictable effects on net cortisol responses. Fenfluramine 29-41 prolactin Homo sapiens 157-160 1603882-4 1992 The time course and magnitude of fenfluramine blood levels, not nor-fenfluramine, paralleled net PRL responses to fenfluramine. Fenfluramine 33-45 prolactin Homo sapiens 97-100 1603882-5 1992 These data indicate that the PRL response to fenfluramine shows continuity within individuals over the course of 1 week, providing a reliable index to reflect the overall function of the serotonin system in the limbic-hypothalamus. Fenfluramine 45-57 prolactin Homo sapiens 29-32 1603882-5 1992 These data indicate that the PRL response to fenfluramine shows continuity within individuals over the course of 1 week, providing a reliable index to reflect the overall function of the serotonin system in the limbic-hypothalamus. Serotonin 187-196 prolactin Homo sapiens 29-32 1603884-0 1992 Fenfluramine stimulation of prolactin in obsessive-compulsive disorder. Fenfluramine 0-12 prolactin Homo sapiens 28-37 1603884-2 1992 Prolactin responses to a 60-mg oral dose of fenfluramine in 26 medication-free patients with a DSM-III-R diagnosis of OCD were compared with those of 20 controls subjects. Fenfluramine 44-56 prolactin Homo sapiens 0-9 1603884-3 1992 Fenfluramine produced a significant elevation of prolactin levels in both OCD patients and controls. Fenfluramine 0-12 prolactin Homo sapiens 49-58 1603884-5 1992 Female subjects in both groups showed greater prolactin responses to fenfluramine than did their male counterparts. Fenfluramine 69-81 prolactin Homo sapiens 46-55 1508425-1 1992 The hypothesis that long-term low-level exposure to perchloroethylene (PERC) may impair the dopaminergic control of prolactin (PRL) secretion and negatively affect neurobehavioral performance, was tested in a cross-sectional survey of dry-cleaners. Tetrachloroethylene 52-69 prolactin Homo sapiens 116-125 1508425-1 1992 The hypothesis that long-term low-level exposure to perchloroethylene (PERC) may impair the dopaminergic control of prolactin (PRL) secretion and negatively affect neurobehavioral performance, was tested in a cross-sectional survey of dry-cleaners. Tetrachloroethylene 52-69 prolactin Homo sapiens 127-130 1508425-1 1992 The hypothesis that long-term low-level exposure to perchloroethylene (PERC) may impair the dopaminergic control of prolactin (PRL) secretion and negatively affect neurobehavioral performance, was tested in a cross-sectional survey of dry-cleaners. Tetrachloroethylene 71-75 prolactin Homo sapiens 116-125 1508425-1 1992 The hypothesis that long-term low-level exposure to perchloroethylene (PERC) may impair the dopaminergic control of prolactin (PRL) secretion and negatively affect neurobehavioral performance, was tested in a cross-sectional survey of dry-cleaners. Tetrachloroethylene 71-75 prolactin Homo sapiens 127-130 1518496-0 1992 [The effects of l-dopa administration on the prolactin levels in short-stature subjects]. Levodopa 16-22 prolactin Homo sapiens 45-54 17589148-0 1992 The effect of prolactin on cyclosporin in renal transplant patients. Cyclosporine 27-38 prolactin Homo sapiens 14-23 17589148-2 1992 This study demonstrates a significant difference in the magnitude and fluctuation in prolactin and cyclosporin concentrations between males and females receiving cyclosporin as the single immunosuppressant. Cyclosporine 162-173 prolactin Homo sapiens 85-94 17589148-4 1992 It is proposed that prolactin levels should be taken into account when determining the appropriate dosage regimen of cyclosporin in those patients receiving cyclosporin alone as immunosuppressant therapy. Cyclosporine 117-128 prolactin Homo sapiens 20-29 17589148-4 1992 It is proposed that prolactin levels should be taken into account when determining the appropriate dosage regimen of cyclosporin in those patients receiving cyclosporin alone as immunosuppressant therapy. Cyclosporine 157-168 prolactin Homo sapiens 20-29 1564425-0 1992 Differential dopamine-induced prolactin mRNA levels in various prolactin-secreting cell (sub)populations. Dopamine 13-21 prolactin Homo sapiens 30-39 1564425-0 1992 Differential dopamine-induced prolactin mRNA levels in various prolactin-secreting cell (sub)populations. Dopamine 13-21 prolactin Homo sapiens 63-72 1564425-1 1992 We have examined the effects of dopamine on prolactin gene expression using quantitative in-situ hybridization histochemistry in different pituitary cell (sub)populations separated according to their density on a discontinuous Percoll gradient. Dopamine 32-40 prolactin Homo sapiens 44-53 1564425-2 1992 Administration of dopamine resulted in a drastic reduction in hybridization of 35S-labelled DNA probe complementary to prolactin mRNA in total pituitary cells and in lactotrophs with low density. Dopamine 18-26 prolactin Homo sapiens 119-128 1564425-2 1992 Administration of dopamine resulted in a drastic reduction in hybridization of 35S-labelled DNA probe complementary to prolactin mRNA in total pituitary cells and in lactotrophs with low density. Sulfur-35 79-82 prolactin Homo sapiens 119-128 1564425-3 1992 In contrast, dopamine significantly stimulated mRNA accumulation in prolactin-secreting cells with high density compared with other cell layers. Dopamine 13-21 prolactin Homo sapiens 68-77 1564425-5 1992 Prolactin-secreting cells with high and low density clearly show functional heterogeneity in their response to dopamine. Dopamine 111-119 prolactin Homo sapiens 0-9 1405209-2 1992 Prazosin monotherapy resulted in a significant decrease in prolactin levels, followed by inhibited elaboration of luteinizing, follicle-stimulating, and testicular hormones in the first 6 months of therapy without changing estradiol levels. Prazosin 0-8 prolactin Homo sapiens 59-68 1405209-3 1992 The hypoprolactinemic effect of prazosin was significantly enhanced with an increase in therapy duration and more profound in patients who had high baseline prolactin levels and in younger patients. Prazosin 32-40 prolactin Homo sapiens 8-17 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 210-216 prolactin Homo sapiens 165-168 1518496-5 1992 PRL levels significantly decreased in all groups, also in those with a deficient response to l-dopa (1 and 2a); furthermore no significant correlation between PRL and GH levels was demonstrated. Levodopa 93-99 prolactin Homo sapiens 0-3 1352703-0 1992 The effects of a dopamine antagonist on luteinizing hormone and prolactin release in women with anorexia nervosa and in normal controls. Dopamine 17-25 prolactin Homo sapiens 64-73 1352703-6 1992 The prolactin response to metoclopramide was significantly impaired in women with anorexia nervosa. Metoclopramide 26-40 prolactin Homo sapiens 4-13 1352703-8 1992 Basal and post-stimulation prolactin levels were correlated with estradiol levels. Estradiol 65-74 prolactin Homo sapiens 27-36 1573708-0 1992 Effects of metoclopramide and quipazine on serum prolactin concentrations in steers. Metoclopramide 11-25 prolactin Homo sapiens 49-58 1573708-0 1992 Effects of metoclopramide and quipazine on serum prolactin concentrations in steers. Quipazine 30-39 prolactin Homo sapiens 49-58 1573708-5 1992 At 1, 4, and 8 mg/kg i.v., and at 15, 30, 45, and 60 mg/kg orally, MC increased (P less than 0.05) serum PRL concentrations (difference between maximal and basal serum PRL concentrations) and increased (P less than 0.05) areas under the PRL response curves except for 1.0 mg/kg i.v. Methylcholanthrene 67-69 prolactin Homo sapiens 105-108 1573708-5 1992 At 1, 4, and 8 mg/kg i.v., and at 15, 30, 45, and 60 mg/kg orally, MC increased (P less than 0.05) serum PRL concentrations (difference between maximal and basal serum PRL concentrations) and increased (P less than 0.05) areas under the PRL response curves except for 1.0 mg/kg i.v. Methylcholanthrene 67-69 prolactin Homo sapiens 168-171 1573708-5 1992 At 1, 4, and 8 mg/kg i.v., and at 15, 30, 45, and 60 mg/kg orally, MC increased (P less than 0.05) serum PRL concentrations (difference between maximal and basal serum PRL concentrations) and increased (P less than 0.05) areas under the PRL response curves except for 1.0 mg/kg i.v. Methylcholanthrene 67-69 prolactin Homo sapiens 168-171 1573708-7 1992 These studies determined a dose-response to MC in terms of serum PRL concentration and indicate that MC is well tolerated and effective for elevating serum PRL concentrations in steers. Methylcholanthrene 44-46 prolactin Homo sapiens 65-68 1573708-7 1992 These studies determined a dose-response to MC in terms of serum PRL concentration and indicate that MC is well tolerated and effective for elevating serum PRL concentrations in steers. Methylcholanthrene 101-103 prolactin Homo sapiens 156-159 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 56-62 prolactin Homo sapiens 81-90 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 56-62 prolactin Homo sapiens 92-95 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 56-62 prolactin Homo sapiens 165-168 1518496-1 1992 In this study, on the basis of the inhibiting action of l-dopa administration on prolactin (PRL) secretion, we evaluated in a number of short children the levels of PRL during the provocative stimuli test with l-dopa in order to identify an index able to give reliability to the test and to investigate whether some differences may exist among the subjects showing a different response in growth hormone (GH) secretion to l-dopa. Levodopa 210-216 prolactin Homo sapiens 165-168 1591141-5 1992 The rise of serum prolactin in response to the increase in PTH was blunted or absent, and is a further example of a transient PTH resistance during the phase of magnesium replenishment. Magnesium 161-170 prolactin Homo sapiens 18-27 1594706-5 1992 Twelve patients received an apomorphine challenge; a trend toward a significant inverse relationship was found between baseline dyskinesia and apomorphine-induced decreases in plasma PRL. Apomorphine 28-39 prolactin Homo sapiens 183-186 1594706-5 1992 Twelve patients received an apomorphine challenge; a trend toward a significant inverse relationship was found between baseline dyskinesia and apomorphine-induced decreases in plasma PRL. Apomorphine 143-154 prolactin Homo sapiens 183-186 1594706-6 1992 Plasma PRL and plasma HVA may reflect different elements of dopamine function in the central nervous system during maintenance treatment; plasma PRL may be the useful marker under these conditions. Dopamine 60-68 prolactin Homo sapiens 7-10 1594711-5 1992 The results also suggest that drug-free schizophrenic patients may have a different pattern of prolactin variants than normal subjects and that this difference could be secondary to a disordered tuberoinfundibular dopamine system or long-term effects of neuroleptic drugs. Dopamine 214-222 prolactin Homo sapiens 95-104 1550467-0 1992 Effect of buspirone on prolactin secretion is not mediated by 5-HT-1a receptor stimulation. Buspirone 10-19 prolactin Homo sapiens 23-32 1543025-0 1992 Invasive mixed growth hormone/prolactin secreting pituitary tumour: complete shrinking by octreotide and bromocriptine, and lack of tumour growth relapse 20 months after octreotide withdrawal. Octreotide 90-100 prolactin Homo sapiens 30-39 1543025-1 1992 Octreotide and bromocriptine were used to treat an acromegalic patient harbouring an invasive pituitary tumour secreting growth hormone and prolactin. Octreotide 0-10 prolactin Homo sapiens 140-149 1543025-1 1992 Octreotide and bromocriptine were used to treat an acromegalic patient harbouring an invasive pituitary tumour secreting growth hormone and prolactin. Bromocriptine 15-28 prolactin Homo sapiens 140-149 1543025-8 1992 These findings suggest that combination therapy with octreotide and bromocriptine may be considered in pituitary macroadenomas secreting growth hormone and prolactin. Octreotide 53-63 prolactin Homo sapiens 156-165 1543025-8 1992 These findings suggest that combination therapy with octreotide and bromocriptine may be considered in pituitary macroadenomas secreting growth hormone and prolactin. Bromocriptine 68-81 prolactin Homo sapiens 156-165 1586397-4 1992 The failure of clozapine to elevate serum prolactin concentrations may be related to the stimulatory effect of clozapine on tuberoinfundibular dopamine neurons and/or the failure of clozapine to achieve effective blockade of pituitary dopamine D2 receptors. Clozapine 15-24 prolactin Homo sapiens 42-51 1415282-4 1992 There was a negative association between blood toluene and plasma levels of prolactin. Toluene 47-54 prolactin Homo sapiens 76-85 1540763-1 1992 Prolactin release in response to fenfluramine hydrochloride (60 mg orally) and placebo was evaluated in 18 medication-free patients with RDC major depressive disorder, endogenous subtype, before and after a series of bilateral treatments with ECT. Fenfluramine 33-59 prolactin Homo sapiens 0-9 1540763-2 1992 Before ECT, fenfluramine induced a twofold increase in plasma prolactin levels. Fenfluramine 12-24 prolactin Homo sapiens 62-71 1340555-2 1992 Bromocriptine was used to treat 3 patients with prolactin secreting pituitary adenoma. Bromocriptine 0-13 prolactin Homo sapiens 48-57 1304187-2 1992 Because PRL is thought to be involved in the regulation of brain water and electrolyte content attempt has been made to determine CSF and plasma PRL and dopamine (DA) concentrations, osmolality, and sodium level in 21 newborn infants undergoing lumbar punction because of apneic spells, fever, or perinatal asphyxia. Water 65-70 prolactin Homo sapiens 8-11 1304187-2 1992 Because PRL is thought to be involved in the regulation of brain water and electrolyte content attempt has been made to determine CSF and plasma PRL and dopamine (DA) concentrations, osmolality, and sodium level in 21 newborn infants undergoing lumbar punction because of apneic spells, fever, or perinatal asphyxia. Electrolytes 75-86 prolactin Homo sapiens 8-11 1314018-0 1992 Serum prolactin level, craving, and early discharge from treatment in cocaine-dependent patients. Cocaine 70-77 prolactin Homo sapiens 6-15 1310696-1 1992 Recombinant human growth hormone (HuGH) and human prolactin (HuPRL), but not GH of bovine or porcine origin, prime human neutrophils for enhanced superoxide anion (O2-) secretion. Superoxides 146-162 prolactin Homo sapiens 50-59 1310696-1 1992 Recombinant human growth hormone (HuGH) and human prolactin (HuPRL), but not GH of bovine or porcine origin, prime human neutrophils for enhanced superoxide anion (O2-) secretion. Superoxides 164-166 prolactin Homo sapiens 50-59 1617425-1 1992 We have studied the binding of 125I-labeled human prolactin (PRL) to membranes from various regions of the human brain (hypothalamus, cerebral cortex, cerebellum and choroid plexus) derived from autopsy specimens. Iodine-125 31-35 prolactin Homo sapiens 50-59 1617425-1 1992 We have studied the binding of 125I-labeled human prolactin (PRL) to membranes from various regions of the human brain (hypothalamus, cerebral cortex, cerebellum and choroid plexus) derived from autopsy specimens. Iodine-125 31-35 prolactin Homo sapiens 61-64 1617425-6 1992 The binding of 125I-labeled human PRL to hypothalamus and choroid plexus membranes from female specimens was inhibited in a dose-dependent manner by both unlabeled human and ovine PRL and by human growth hormone (GH), but not by other polypeptide hormones. Iodine-125 15-19 prolactin Homo sapiens 34-37 1617425-6 1992 The binding of 125I-labeled human PRL to hypothalamus and choroid plexus membranes from female specimens was inhibited in a dose-dependent manner by both unlabeled human and ovine PRL and by human growth hormone (GH), but not by other polypeptide hormones. Iodine-125 15-19 prolactin Homo sapiens 180-183 1519463-0 1992 Monoamine regulation of prolactin and TSH secretion in hypothyroidism. monoamine 0-9 prolactin Homo sapiens 24-33 1312904-4 1992 Prolactin (PRL) suppression in women with BBD receiving bromocriptine treatment was associated with a significant (p less than 0.02) decrease of baseline DHAS plasma levels and of stimulated ACTH response curve (p less than 0.02). Bromocriptine 56-69 prolactin Homo sapiens 0-9 1311964-2 1992 Net fenfluramine-induced prolactin release did not differ significantly between OCD patients and normal controls. Fenfluramine 4-16 prolactin Homo sapiens 25-34 1340688-3 1992 In the remaining 6 patients the serum prolactin levels fell to normal on thyroxine replacement therapy and reduction in size of the pituitary gland was demonstrated by neuroradiological imaging in the 3 documented cases. Thyroxine 73-82 prolactin Homo sapiens 38-47 1312904-4 1992 Prolactin (PRL) suppression in women with BBD receiving bromocriptine treatment was associated with a significant (p less than 0.02) decrease of baseline DHAS plasma levels and of stimulated ACTH response curve (p less than 0.02). Bromocriptine 56-69 prolactin Homo sapiens 11-14 1312904-4 1992 Prolactin (PRL) suppression in women with BBD receiving bromocriptine treatment was associated with a significant (p less than 0.02) decrease of baseline DHAS plasma levels and of stimulated ACTH response curve (p less than 0.02). Dehydroepiandrosterone Sulfate 154-158 prolactin Homo sapiens 0-9 1312904-4 1992 Prolactin (PRL) suppression in women with BBD receiving bromocriptine treatment was associated with a significant (p less than 0.02) decrease of baseline DHAS plasma levels and of stimulated ACTH response curve (p less than 0.02). Dehydroepiandrosterone Sulfate 154-158 prolactin Homo sapiens 11-14 1312904-5 1992 These data suggest a possible relationship between PRL and DHAS secretion in women with BBD. Dehydroepiandrosterone Sulfate 59-63 prolactin Homo sapiens 51-54 1559298-4 1992 MEASUREMENTS: TSH and PRL responses to domperidone (10 mg i.v.) Domperidone 39-50 prolactin Homo sapiens 22-25 1294345-6 1992 A statistically significant improvement due to the administration of Bromergon was observed in symptoms associated with overreactiveness to normal prolactin levels, i.e. abdominal tension, edema, weight gain and breast tenderness. Bromocriptine 69-78 prolactin Homo sapiens 147-156 1559298-10 1992 Preoperatively, normal responses of both TSH (incremental rise less than 2.0 mU/l) and PRL (greater than 100% rise) to domperidone were observed in two patients only: both had an abnormal vascular supply to the pituitary rather than an adenoma. Domperidone 119-130 prolactin Homo sapiens 87-90 1559298-17 1992 An abnormal response of TSH to domperidone was documented 2 months post-operatively in 11/60 patients with normal basal PRL, and preceded all three late recurrences. Domperidone 31-42 prolactin Homo sapiens 120-123 1730334-0 1992 A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study. Bromocriptine 33-46 prolactin Homo sapiens 73-82 11941158-0 1992 The Role of Dopamine in Seizure-Induced Prolactin Release in Humans. Dopamine 12-20 prolactin Homo sapiens 40-49 1345529-2 1992 The isolation method consisted in the extraction of crude pituitary preparation with acidified acetone followed by precipitation of crude prolactin preparation (acid acetone powder) by increasing the concentration of acetone in the extract to 92%. acid acetone 161-173 prolactin Homo sapiens 138-147 1345529-2 1992 The isolation method consisted in the extraction of crude pituitary preparation with acidified acetone followed by precipitation of crude prolactin preparation (acid acetone powder) by increasing the concentration of acetone in the extract to 92%. Acetone 166-173 prolactin Homo sapiens 138-147 1345529-3 1992 Further purification of prolactin was achieved by fractional precipitation at varying pH values and gel filtration on Sephadex G-75 column in a pH 7.5 phosphate buffer. sephadex 118-126 prolactin Homo sapiens 24-33 1345529-3 1992 Further purification of prolactin was achieved by fractional precipitation at varying pH values and gel filtration on Sephadex G-75 column in a pH 7.5 phosphate buffer. Phosphates 151-160 prolactin Homo sapiens 24-33 11941158-6 1992 The administration of metoclopramide produced a large increase in PRL plasma levels, with no further increase in PRL concentrations after ECT. Metoclopramide 22-36 prolactin Homo sapiens 66-69 11941158-7 1992 The data suggest that the PRL plasma rise after ECT involves dopamine as it is not seen when the dopaminergic inhibitory tone, exerted by the hypothalamus on the pituitary lactotroph, has been removed. Dopamine 61-69 prolactin Homo sapiens 26-29 1419076-0 1992 Effect of prostaglandin E2 or prostaglandin synthesis inhibitors on human gonadotrophins and prolactin. Dinoprostone 10-26 prolactin Homo sapiens 93-102 1419076-6 1992 PGE2 infusions in males depressed PRL levels significantly two hours after the onset of infusions. Dinoprostone 0-4 prolactin Homo sapiens 34-37 1419076-7 1992 Indomethacin raised PRL levels while Naproxen did not. Indomethacin 0-12 prolactin Homo sapiens 20-23 1419076-8 1992 In women, a similar response was also observed but prolactin levels decreased earlier (30 min from the PGE2 infusion). Dinoprostone 103-107 prolactin Homo sapiens 51-60 1419076-9 1992 These data indicate a probable role for PGE2 or other prostanoids as well in the regulation of human PRL release but not in gonadotrophin secretion. Dinoprostone 40-44 prolactin Homo sapiens 101-104 1427628-3 1992 In transient hyperprolactinemia, there was a significant inverse correlation between serum prolactin (PRL) 30 min after the 500-micrograms intravenous loading of thyrotropin-releasing hormone TRH (PRL30) and progesterone (P4) in the luteal phase (r = -0.67, p less than 0.005). Progesterone 208-220 prolactin Homo sapiens 18-27 1552819-1 1992 The effect of cyclosporin A (CsA) treatment on LH and prolactin was investigated. Cyclosporine 29-32 prolactin Homo sapiens 54-63 1490655-0 1992 Effects of prolonged treatment with diltiazem on pituitary secretion of luteinizing hormone, follicle-stimulating hormone, thyrotropin and prolactin. Diltiazem 36-45 prolactin Homo sapiens 139-148 23967857-7 1992 As a means of providing validation of bromocriptine"s D2 receptor effect, maximum inhibition of prolactin (PRL) secretion, which is inhibited specifically by activation of D2 receptor sites, was determined. Bromocriptine 38-51 prolactin Homo sapiens 96-105 22291398-2 1992 Low dose intravenous chlorimipramine (CMI) challenge produced a modest release of prolactin and significant increases in plasma adrenocorticotrophic hormone (ACTH) and cortisol. Clomipramine 21-36 prolactin Homo sapiens 82-91 22291398-2 1992 Low dose intravenous chlorimipramine (CMI) challenge produced a modest release of prolactin and significant increases in plasma adrenocorticotrophic hormone (ACTH) and cortisol. Clomipramine 38-41 prolactin Homo sapiens 82-91 1552819-0 1992 Effect of cyclosporin treatment on luteinizing hormone and prolactin. Cyclosporine 10-21 prolactin Homo sapiens 59-68 1796748-0 1991 Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety. Bromocriptine 33-46 prolactin Homo sapiens 68-77 1410150-2 1992 One measure of central serotonergic function is the prolactin (PRL) response to IV L-tryptophan (L-TRP). Tryptophan 83-95 prolactin Homo sapiens 63-66 1410150-2 1992 One measure of central serotonergic function is the prolactin (PRL) response to IV L-tryptophan (L-TRP). Tryptophan 97-102 prolactin Homo sapiens 63-66 1410150-5 1992 Primary antidepressant treatment did not increase the PRL response, but lithium augmentation resulted in a statistically significant increase in PRL response as compared to both placebo pretreatment (P less than 0.04) and antidepressant treatment alone (P less than 0.025). Lithium 72-79 prolactin Homo sapiens 145-148 1688013-0 1991 Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients. Remoxipride 25-36 prolactin Homo sapiens 68-77 1688013-0 1991 Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients. Haloperidol 41-52 prolactin Homo sapiens 68-77 1688013-5 1991 In the haloperidol group this was associated with a clearcut elevation of plasma PRL, whereas in the remoxipride group after an initial rise for 4 weeks, the mean PRL level returned to baseline at the end of the study. Haloperidol 7-18 prolactin Homo sapiens 81-84 1625777-5 1992 Also, prolactin response to glucose was attenuated relative to baseline levels in the more antisocial and aggressive subjects. Glucose 28-35 prolactin Homo sapiens 6-15 1329402-3 1992 The mean values of all but one (PRL) of the hormone and protein levels varied significantly from the controls, T, DHEAS, FAI and ALG showing the greatest differences. Dehydroepiandrosterone Sulfate 114-119 prolactin Homo sapiens 32-35 1688013-5 1991 In the haloperidol group this was associated with a clearcut elevation of plasma PRL, whereas in the remoxipride group after an initial rise for 4 weeks, the mean PRL level returned to baseline at the end of the study. Remoxipride 101-112 prolactin Homo sapiens 163-166 1796748-1 1991 Bromocriptine, a D2 receptor agonist, has been widely used in tumoral and non-tumoral hyperprolactinemia, in reducing both plasma prolactin levels and in restoring fertility and/or menses in most patients. Bromocriptine 0-13 prolactin Homo sapiens 91-100 1744458-7 1991 However, the other patient, whose prolactin secreting capacity was aggravated after the first puerperium, became pregnant the second time through bromocriptine treatment. Bromocriptine 146-159 prolactin Homo sapiens 34-43 1770154-0 1991 Serum prolactin as a correlate of clinical response to haloperidol. Haloperidol 55-66 prolactin Homo sapiens 6-15 1770154-5 1991 A serum prolactin level may be a useful guide to the lowest effective dose of haloperidol in newly treated schizophrenic men. Haloperidol 78-89 prolactin Homo sapiens 8-17 1770154-7 1991 Patients on the 5, 10, and 20 mg daily haloperidol doses had mean prolactin levels of 16, 32, and 34 ng/ml, respectively. Haloperidol 39-50 prolactin Homo sapiens 66-75 1778595-0 1991 Dissociated response of thyrotropin and prolactin to dopamine receptor blockade with domperidone in hypothyroid subjects. Domperidone 85-96 prolactin Homo sapiens 40-49 1753713-1 1991 Treatment with bromocriptine (CB) stimulates the release of secretory granules from human prolactinomas by exocytosis in spite of a remarkable decrease in serum prolactin (PRL) levels. Bromocriptine 15-28 prolactin Homo sapiens 90-99 1753713-1 1991 Treatment with bromocriptine (CB) stimulates the release of secretory granules from human prolactinomas by exocytosis in spite of a remarkable decrease in serum prolactin (PRL) levels. Bromocriptine 15-28 prolactin Homo sapiens 172-175 1797468-0 1991 Basal and metoclopramide-stimulated prolactin (PRL) serum levels in users and non-users of a copper intrauterine device (TCu-380 IUD). Metoclopramide 10-24 prolactin Homo sapiens 47-50 1756196-4 1991 The plasma PRL, but not the plasma cortisol response, following MK-212 was also significantly lower in the alcoholics. 6-chloro-2-(1-piperazinyl)pyrazine 64-70 prolactin Homo sapiens 11-14 1724345-1 1991 The relationship between prolactin in NH and prostate carcinoma has several aspects: under normal conditions, prolactin enhances androgens output, increasing the Leydig cell susceptibility to LH. Luteinizing Hormone 192-194 prolactin Homo sapiens 25-34 1724345-1 1991 The relationship between prolactin in NH and prostate carcinoma has several aspects: under normal conditions, prolactin enhances androgens output, increasing the Leydig cell susceptibility to LH. Luteinizing Hormone 192-194 prolactin Homo sapiens 110-119 1724345-7 1991 Also, prolactin itself stimulates the growth and development of carcinomatous human cell lines, increasing its effect in the presence of testosterone. Testosterone 137-149 prolactin Homo sapiens 6-15 1776854-0 1991 Antagonism of prolactin binding by cyclosporine A on MCF7 breast tumour cell line. Cyclosporine 35-49 prolactin Homo sapiens 14-23 1776854-1 1991 Cyclosporine A (an immunosuppressive cyclic undercapeptide) acts as an antagonist to prolactin receptors on a breast tumour cell line (MCF7) which is known to express specific prolactin receptors. Cyclosporine 0-14 prolactin Homo sapiens 85-94 1776854-1 1991 Cyclosporine A (an immunosuppressive cyclic undercapeptide) acts as an antagonist to prolactin receptors on a breast tumour cell line (MCF7) which is known to express specific prolactin receptors. Cyclosporine 0-14 prolactin Homo sapiens 176-185 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Cyclosporine 24-38 prolactin Homo sapiens 56-65 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Cyclosporine 24-38 prolactin Homo sapiens 56-65 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Cyclosporine 24-38 prolactin Homo sapiens 56-65 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Iodine-125 129-133 prolactin Homo sapiens 43-52 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Iodine-125 129-133 prolactin Homo sapiens 56-65 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Iodine-125 129-133 prolactin Homo sapiens 56-65 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Iodine-125 129-133 prolactin Homo sapiens 56-65 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Cyclosporine 231-245 prolactin Homo sapiens 43-52 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Cyclosporine 231-245 prolactin Homo sapiens 56-65 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Cyclosporine 231-245 prolactin Homo sapiens 56-65 1776854-2 1991 The competition between cyclosporine A and prolactin to prolactin receptors was demonstrated by measuring the decreased specific 125I-labeled prolactin-binding to prolactin receptors in the presence of increasing concentrations of cyclosporine A. Cyclosporine 231-245 prolactin Homo sapiens 56-65 1797468-0 1991 Basal and metoclopramide-stimulated prolactin (PRL) serum levels in users and non-users of a copper intrauterine device (TCu-380 IUD). Copper 93-99 prolactin Homo sapiens 47-50 1797468-1 1991 The study was undertaken to analyze the basal and metoclopramide-stimulated serum PRL levels in healthy parous women users (group 1, n = 12) and non-users (group 2, n = 12) of a TCu-380 IUD. Metoclopramide 50-64 prolactin Homo sapiens 82-85 1682138-13 1991 Okadaic acid, a protein phosphatase inhibitor, reversed the reduction in TH activity during the nocturnal and diurnal PRL surges, but did not significantly alter TH activity during the intersurge period on day 7. Okadaic Acid 0-12 prolactin Homo sapiens 118-121 1940822-3 1991 Here, we expand these results to show that 1) a higher dose of VML (50 microM) produces an additive effect with PRL; 2) addition of small amounts of calcium (0.1 mM) to the liver culture medium blocks PRL action; 3) neither nifedipine (NIF), a different type of calcium channel blocker, nor EDTA alter PRL action; and 4) gossypol, a reported inhibitor of protein kinase C, mimics PRL action. Calcium 149-156 prolactin Homo sapiens 201-204 1940822-3 1991 Here, we expand these results to show that 1) a higher dose of VML (50 microM) produces an additive effect with PRL; 2) addition of small amounts of calcium (0.1 mM) to the liver culture medium blocks PRL action; 3) neither nifedipine (NIF), a different type of calcium channel blocker, nor EDTA alter PRL action; and 4) gossypol, a reported inhibitor of protein kinase C, mimics PRL action. Calcium 149-156 prolactin Homo sapiens 201-204 1940822-3 1991 Here, we expand these results to show that 1) a higher dose of VML (50 microM) produces an additive effect with PRL; 2) addition of small amounts of calcium (0.1 mM) to the liver culture medium blocks PRL action; 3) neither nifedipine (NIF), a different type of calcium channel blocker, nor EDTA alter PRL action; and 4) gossypol, a reported inhibitor of protein kinase C, mimics PRL action. Calcium 149-156 prolactin Homo sapiens 201-204 1779976-0 1991 Pit-1 binding sequences permit calcium regulation of human prolactin gene expression. Calcium 31-38 prolactin Homo sapiens 59-68 1779976-1 1991 This study examines the regulation of the human PRL (hPRL) gene promoter by intracellular calcium. Calcium 90-97 prolactin Homo sapiens 48-51 1779976-1 1991 This study examines the regulation of the human PRL (hPRL) gene promoter by intracellular calcium. Calcium 90-97 prolactin Homo sapiens 53-57 1779976-3 1991 With the complete 5-kilobase pair (kbp) hPRL promoter sequence the calcium channel agonist Bay K8644 induced a significant 2-fold increase in CAT reporter gene expression and the antagonist verapamil a 4.5-fold reduction, using GH3 cells cultured in physiological levels of calcium. k8644 95-100 prolactin Homo sapiens 40-44 1779976-3 1991 With the complete 5-kilobase pair (kbp) hPRL promoter sequence the calcium channel agonist Bay K8644 induced a significant 2-fold increase in CAT reporter gene expression and the antagonist verapamil a 4.5-fold reduction, using GH3 cells cultured in physiological levels of calcium. Verapamil 190-199 prolactin Homo sapiens 40-44 1779976-3 1991 With the complete 5-kilobase pair (kbp) hPRL promoter sequence the calcium channel agonist Bay K8644 induced a significant 2-fold increase in CAT reporter gene expression and the antagonist verapamil a 4.5-fold reduction, using GH3 cells cultured in physiological levels of calcium. Calcium 67-74 prolactin Homo sapiens 40-44 1779976-4 1991 The transcriptional response to calcium influx was similar with a series of 5"-deleted hPRL-CAT constructs including those that comprised the proximal (up to 740 bp) or distal (-1300- to -1700-bp) sequences alone. Calcium 32-39 prolactin Homo sapiens 87-91 1779976-5 1991 When treating cells cultured in low calcium conditions the induction with the hPRL promoter increased to 5-fold on the addition of exogenous calcium and Bay K8644. Calcium 36-43 prolactin Homo sapiens 78-82 1779976-5 1991 When treating cells cultured in low calcium conditions the induction with the hPRL promoter increased to 5-fold on the addition of exogenous calcium and Bay K8644. Calcium 141-148 prolactin Homo sapiens 78-82 1684803-1 1991 CV 205-502, a benzoquinoline, is a new nonergot dopamine agonist compound which has been shown to be effective in lowering PRL levels in normal volunteers and in hyperprolactinemic women. benzo(h)quinoline 14-28 prolactin Homo sapiens 123-126 1742750-0 1991 Interactions of sleep and clonidine on daytime prolactin secretion in humans. Clonidine 26-35 prolactin Homo sapiens 47-56 1742750-8 1991 PRL concentrations increased in placebo and clonidine groups during sleep. Clonidine 44-53 prolactin Homo sapiens 0-3 1717245-4 1991 Incubation of decidual cells with a reference preparation of intact hCG (CR123) at a concentration of 260 ng/ml resulted in stimulated secretion of prolactin, however, the observed stimulation could be attributed to contamination of the preparation with free alpha or dissociated hCG alpha subunit. cr123 73-78 prolactin Homo sapiens 148-157 1686811-2 1991 As compared with placebo, D,L-fenfluramine significantly increased both prolactin and cortisol. d,l-fenfluramine 26-42 prolactin Homo sapiens 72-81 1686811-6 1991 These findings are consistent with recent animal studies suggesting that D,L-fenfluramine-induced prolactin and cortisol release may be mediated, at least in part, by catecholaminergic systems. d,l-fenfluramine 73-89 prolactin Homo sapiens 98-107 1687293-2 1991 Consequently new dopamine agonists have been developed, including the long acting non-ergot agonist CV205-502 which has been shown to date to be consistently effective in reducing serum PRL levels and causing tumour shrinkage. Dopamine 17-25 prolactin Homo sapiens 186-189 1683559-13 1991 Domperidone increased the plasma concentrations of prolactin whereas ropinirole administered alone reduced them. Domperidone 0-11 prolactin Homo sapiens 51-60 1684803-1 1991 CV 205-502, a benzoquinoline, is a new nonergot dopamine agonist compound which has been shown to be effective in lowering PRL levels in normal volunteers and in hyperprolactinemic women. Dopamine 48-56 prolactin Homo sapiens 123-126 1891468-3 1991 Animals administered bromocryptine, a drug that specifically blocks PRL release, have impaired immune responses similar to hypophysectomized animals, and again both PRL and GH correct these deficiencies. Bromocriptine 21-34 prolactin Homo sapiens 68-71 1752717-0 1991 Exercise changes in plasma tryptophan fractions and relationship with prolactin. Tryptophan 27-37 prolactin Homo sapiens 70-79 1752717-7 1991 Prolactin levels correlated with free plasma tryptophan throughout the test (r = 0.77, p less than 0.001, all measured values) and during recovery (10 minutes: r = 0.88, p less than 0.05; 20 minutes: r = 0.86, p less than 0.05). Tryptophan 45-55 prolactin Homo sapiens 0-9 1722339-5 1991 In the patients, weak positive and negative relationships were found between homovanillic acid in CSF and prolactin in serum, respectively, and regional metabolic rates. Homovanillic Acid 77-94 prolactin Homo sapiens 106-115 19215496-7 1991 NMDA injected intravenously also caused a dose-dependent increase in the blood plasma concentrations of prolactin but this only occurred following exposure to long days when the endogenous secretion of prolactin was high. N-Methylaspartate 0-4 prolactin Homo sapiens 104-113 19215496-7 1991 NMDA injected intravenously also caused a dose-dependent increase in the blood plasma concentrations of prolactin but this only occurred following exposure to long days when the endogenous secretion of prolactin was high. N-Methylaspartate 0-4 prolactin Homo sapiens 202-211 19215496-8 1991 At this time the initial increase in prolactin concentrations occurred within 2 to 4 min after the injection of NMDA as for beta-endorphin but the values continued to increase for 2 to 4 h. In a separate experiment, it was shown that pretreatment of the rams with dexamethasone (synthetic glucocorticoid, 133.4 mug/kg iv) blocked the beta-endorphin response to NMDA but had no effect on the prolactin response. N-Methylaspartate 112-116 prolactin Homo sapiens 37-46 19215496-8 1991 At this time the initial increase in prolactin concentrations occurred within 2 to 4 min after the injection of NMDA as for beta-endorphin but the values continued to increase for 2 to 4 h. In a separate experiment, it was shown that pretreatment of the rams with dexamethasone (synthetic glucocorticoid, 133.4 mug/kg iv) blocked the beta-endorphin response to NMDA but had no effect on the prolactin response. Dexamethasone 264-277 prolactin Homo sapiens 37-46 19215496-8 1991 At this time the initial increase in prolactin concentrations occurred within 2 to 4 min after the injection of NMDA as for beta-endorphin but the values continued to increase for 2 to 4 h. In a separate experiment, it was shown that pretreatment of the rams with dexamethasone (synthetic glucocorticoid, 133.4 mug/kg iv) blocked the beta-endorphin response to NMDA but had no effect on the prolactin response. N-Methylaspartate 361-365 prolactin Homo sapiens 37-46 19215496-9 1991 This indicates that NMDA stimulates the secretion of beta-endorphin from the corticotrophs probably acting centrally to induce the release of corticotrophin-releasing hormone and/or arginine vasopressin, while NMDA acts through separate mechanisms to affect the secretion of prolactin. N-Methylaspartate 20-24 prolactin Homo sapiens 275-284 19215496-10 1991 The overall results show that NMDA can be used as a probe to investigate the neuroendocrine control of beta-endorphin and prolactin in addition to luteinizing hormone as described previously. N-Methylaspartate 30-34 prolactin Homo sapiens 122-131 1661859-4 1991 The luteinizing hormone (LH) suppression and prolactin (PRL) secretion induced by morphine was blocked by both nalmefene HCl and its methyliodide analogue, indicating that the opioid receptor type which mediates both responses is located outside the BBB. Morphine 82-90 prolactin Homo sapiens 45-54 1661859-4 1991 The luteinizing hormone (LH) suppression and prolactin (PRL) secretion induced by morphine was blocked by both nalmefene HCl and its methyliodide analogue, indicating that the opioid receptor type which mediates both responses is located outside the BBB. nalmefene 111-124 prolactin Homo sapiens 45-54 1661859-4 1991 The luteinizing hormone (LH) suppression and prolactin (PRL) secretion induced by morphine was blocked by both nalmefene HCl and its methyliodide analogue, indicating that the opioid receptor type which mediates both responses is located outside the BBB. methyl iodide 133-145 prolactin Homo sapiens 45-54 1923170-7 1991 All 33 luteal phase deficiency subjects with transient hyperprolactinemia were treated with bromocriptine at a dose ranging from 1.25-5 mg/day to maintain mid-cycle PRL levels between 5-15 ng/mL. Bromocriptine 92-105 prolactin Homo sapiens 165-168 1798861-5 1991 All subjects had a significant increase in serum PRL levels after 90 min of domperidone administration. Domperidone 76-87 prolactin Homo sapiens 49-52 1891468-3 1991 Animals administered bromocryptine, a drug that specifically blocks PRL release, have impaired immune responses similar to hypophysectomized animals, and again both PRL and GH correct these deficiencies. Bromocriptine 21-34 prolactin Homo sapiens 165-168 1681822-3 1991 The change of central dopaminergic activity by salt load was evaluated as the percentage change of plasma prolactin (PRL) response to a small dose (25 micrograms) of thyrotropin-releasing hormone (TRH) administered intravenously. Salts 47-51 prolactin Homo sapiens 106-115 1950339-3 1991 Thirteen patients with persistent hyperprolactinemia after surgery achieved one pregnancy with or without bromocriptine treatment, but did not achieve a second one owing to an increase in the prolactin level after delivery. Bromocriptine 106-119 prolactin Homo sapiens 39-48 1797033-0 1991 Prolactin and cortisol levels following acute alcohol challenges in women with and without a family history of alcoholism. Alcohols 46-53 prolactin Homo sapiens 0-9 1681822-3 1991 The change of central dopaminergic activity by salt load was evaluated as the percentage change of plasma prolactin (PRL) response to a small dose (25 micrograms) of thyrotropin-releasing hormone (TRH) administered intravenously. Salts 47-51 prolactin Homo sapiens 117-120 1950339-5 1991 In these 13 patients, the mean increase from the postoperative to the post-delivery prolactin level was less for the patients with bromocriptine-induced pregnancy than for those with spontaneous pregnancy. Bromocriptine 131-144 prolactin Homo sapiens 84-93 1681822-4 1991 The mean percentage change of PRL response by salt load in the SS group was -9.4 +/- 8.5% (mean +/- SEM), which was remarkably lower than the 26.8 +/- 5.5% in the NSS group (P less than .01). Salts 46-50 prolactin Homo sapiens 30-33 1681822-4 1991 The mean percentage change of PRL response by salt load in the SS group was -9.4 +/- 8.5% (mean +/- SEM), which was remarkably lower than the 26.8 +/- 5.5% in the NSS group (P less than .01). H-SER-SER-OH 63-65 prolactin Homo sapiens 30-33 1743613-3 1991 Cells released from the hydroxyurea induced synchrony exhibited an increased rate of [3H] leucine incorporation in response to prolactin when ornithine, putrescine, or spermidine were present. Tritium 86-88 prolactin Homo sapiens 127-136 1743613-0 1991 Polyamine influences on the prolactin stimulation of phosphoprotein synthesis in hydroxyurea synchronized MCF-7 human mammary epithelial cells. Polyamines 0-9 prolactin Homo sapiens 28-37 1743613-3 1991 Cells released from the hydroxyurea induced synchrony exhibited an increased rate of [3H] leucine incorporation in response to prolactin when ornithine, putrescine, or spermidine were present. Leucine 90-97 prolactin Homo sapiens 127-136 1743613-2 1991 Cells not allowed to enter the S-phase of DNA replication, by maintaining hydroxyurea in the incubation medium, exhibited an increased rate of [3H] leucine incorporation into the isoelectrically precipitable phosphoprotein fraction when exposed to prolactin and 1-5 mM spermidine. Tritium 144-146 prolactin Homo sapiens 248-257 1743613-3 1991 Cells released from the hydroxyurea induced synchrony exhibited an increased rate of [3H] leucine incorporation in response to prolactin when ornithine, putrescine, or spermidine were present. Ornithine 142-151 prolactin Homo sapiens 127-136 1743613-3 1991 Cells released from the hydroxyurea induced synchrony exhibited an increased rate of [3H] leucine incorporation in response to prolactin when ornithine, putrescine, or spermidine were present. Hydroxyurea 24-35 prolactin Homo sapiens 127-136 1743613-3 1991 Cells released from the hydroxyurea induced synchrony exhibited an increased rate of [3H] leucine incorporation in response to prolactin when ornithine, putrescine, or spermidine were present. Putrescine 153-163 prolactin Homo sapiens 127-136 1743613-3 1991 Cells released from the hydroxyurea induced synchrony exhibited an increased rate of [3H] leucine incorporation in response to prolactin when ornithine, putrescine, or spermidine were present. Spermidine 168-178 prolactin Homo sapiens 127-136 1938655-8 1991 Sulpiride treatment resulted in (P less than .05) a six- to eightfold increase in daily PRL secretion. Sulpiride 0-9 prolactin Homo sapiens 88-91 1937422-1 1991 The effects of a brief exposure to newly hatched squabs upon the concentrations of plasma prolactin and LH secretion and length of incubation time in ring doves were investigated using a novel experimental procedure. squabs 49-55 prolactin Homo sapiens 90-99 1937430-10 1991 Empty crop sac weights of freely fed and food-deprived PRL-treated birds were not increased above control values, thus indicating that ICV PRL treatment did not result in significant stimulation of peripheral target organs. icv 135-138 prolactin Homo sapiens 139-142 1938655-9 1991 The PRL response to TRH increased (P less than .05) fourfold in stallions treated with sulpiride but was unchanged in control stallions. Sulpiride 87-96 prolactin Homo sapiens 4-7 1883854-7 1991 Cytosolic protein phosphorylation in the presence of EGTA resulted in phosphorylation of proteins of 68 kDa and 19 kDa which was increased by prolactin. Egtazic Acid 53-57 prolactin Homo sapiens 142-151 29783610-6 1991 Evidence from these studies indicates that post-ictal hyperprolactinaemia is caused by involvement of medial temporal structures, especially the amygdala and hippocampus, by ictal discharges and the resultant disruption of tonic dopaminergic inhibition of prolactin release and/or stimulation of serotonin, rather than due to non-specific influences. Serotonin 296-305 prolactin Homo sapiens 59-68 1776507-2 1991 Prior to the treatment, serum prolactin (PRL) levels ranged from 45 ng/ml to 7000 ng/ml and they decreased to within the normal range in all but one patient after 7 days-1 year of treatment with this new formulation of bromocriptine. Bromocriptine 219-232 prolactin Homo sapiens 30-39 1776507-5 1991 In conclusion, Parlodel SRO administered as a single daily dose resulted in very effective lowering of serum PRL in patients with hyperprolactinemic disorders. Bromocriptine 15-23 prolactin Homo sapiens 109-112 1776507-5 1991 In conclusion, Parlodel SRO administered as a single daily dose resulted in very effective lowering of serum PRL in patients with hyperprolactinemic disorders. sro 24-27 prolactin Homo sapiens 109-112 1912121-0 1991 Prolactin response to the dopamine antagonist, metoclopramide, in depression. Dopamine 26-34 prolactin Homo sapiens 0-9 18411177-1 1991 Macroprolactinomas will usually shrink with dopamine agonist therapy, often to within the pituitary fossa; definitive treatment with radiotherapy can then achieve eventual normalization of serum prolactin in the majority of patients. Dopamine 44-52 prolactin Homo sapiens 5-14 1912121-0 1991 Prolactin response to the dopamine antagonist, metoclopramide, in depression. Metoclopramide 47-61 prolactin Homo sapiens 0-9 1742605-7 1991 Melatonin administration produced robust nocturnal peaks in serum growth hormone and prolactin levels immediately following ingestion of the hormone, while serum cortisol and testosterone rhythms were not influenced. Melatonin 0-9 prolactin Homo sapiens 85-94 1886657-7 1991 After withdrawal of bromocriptine in 13 of these patients an average of 7 years after radiotherapy, the median serum PRL value had further decreased by 95%. Bromocriptine 20-33 prolactin Homo sapiens 117-120 1886657-9 1991 After withdrawal of bromocriptine in 8 patients not receiving radiotherapy an average of 7 years after operation, the median serum PRL level had further decreased by 75%. Bromocriptine 20-33 prolactin Homo sapiens 131-134 1685014-1 1991 The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. Dopamine 37-45 prolactin Homo sapiens 81-90 1685014-1 1991 The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. Dopamine 37-45 prolactin Homo sapiens 92-95 1886657-11 1991 Thus, because bromocriptine has a long-standing effect on prolactin secretion, and radiotherapy is associated with a notably high incidence of pituitary insufficiency, we propose that photon irradiation should be considered mainly for patients who are not candidates for surgical or medical treatment. Bromocriptine 14-27 prolactin Homo sapiens 58-67 1685014-1 1991 The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. Dopamine 47-49 prolactin Homo sapiens 81-90 1794350-4 1991 Serum basal prolactin (PRL) levels remain unchanged, but the PRL responses to thyrotropin-releasing hormone and metoclopramide increase slightly during the first year of CBZ medication. Metoclopramide 112-126 prolactin Homo sapiens 61-64 1685014-1 1991 The ability of low concentrations of dopamine (DA) to stimulate the secretion of prolactin (PRL) was examined in perifused or monolayer cultures of anterior pituitary cells. Dopamine 47-49 prolactin Homo sapiens 92-95 1685014-2 1991 In cultures perifused with media containing 100 nM DA, changing the DA concentration to either 1 or 100 pM caused a significant dose-dependent stimulatory PRL secretory response within 6 min when compared to the PRL secretory response to removal of DA altogether. Dopamine 51-53 prolactin Homo sapiens 155-158 1685014-2 1991 In cultures perifused with media containing 100 nM DA, changing the DA concentration to either 1 or 100 pM caused a significant dose-dependent stimulatory PRL secretory response within 6 min when compared to the PRL secretory response to removal of DA altogether. Dopamine 68-70 prolactin Homo sapiens 155-158 1685014-2 1991 In cultures perifused with media containing 100 nM DA, changing the DA concentration to either 1 or 100 pM caused a significant dose-dependent stimulatory PRL secretory response within 6 min when compared to the PRL secretory response to removal of DA altogether. Dopamine 68-70 prolactin Homo sapiens 212-215 1685014-3 1991 Picomolar concentrations of DA caused a biphasic PRL secretory response. Dopamine 28-30 prolactin Homo sapiens 49-52 1685014-7 1991 Although the D2 agonists, bromocriptine and 2-(N-phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride (PPHT) caused significant (p less than 0.05) inhibition of PRL secretion at nanomolar concentrations and above, neither had stimulatory activity. Bromocriptine 26-39 prolactin Homo sapiens 166-169 1685014-7 1991 Although the D2 agonists, bromocriptine and 2-(N-phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride (PPHT) caused significant (p less than 0.05) inhibition of PRL secretion at nanomolar concentrations and above, neither had stimulatory activity. 2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin 44-106 prolactin Homo sapiens 166-169 1685014-7 1991 Although the D2 agonists, bromocriptine and 2-(N-phenethyl-N-propyl)-amino-5-hydroxytetralin hydrochloride (PPHT) caused significant (p less than 0.05) inhibition of PRL secretion at nanomolar concentrations and above, neither had stimulatory activity. 2-(N-phenethyl-N-propyl)amino-5-hydroxytetralin 108-112 prolactin Homo sapiens 166-169 1676973-4 1991 81% of the patients in the CV 205-502 group and 70% of the patients in the bromocriptine group normalized their prolactin levels within the study period with a treatment dose as permitted in this protocol. Bromocriptine 75-88 prolactin Homo sapiens 112-121 1794350-4 1991 Serum basal prolactin (PRL) levels remain unchanged, but the PRL responses to thyrotropin-releasing hormone and metoclopramide increase slightly during the first year of CBZ medication. Carbamazepine 170-173 prolactin Homo sapiens 61-64 1774132-1 1991 Several studies have demonstrated zinc (Zn), prolactin (PRL) and thymulin (Zn-FTS) interplay: Zn inhibits, in a dose related manner, PRL release from lactotropes in vitro and stimulates thymulin synthesis in vivo both in humans and in animals. Thymic Factor, Circulating 65-73 prolactin Homo sapiens 133-136 1860893-4 1991 PRL caused activation of PKC from 10(-12) to 10(-8) M. Antiserum to PRL, a monoclonal antibody directed against the PRL receptor and the immunosuppressive agent cyclosporine A, were able to inhibit PRL-induced proliferation and activation of PKC. Cyclosporine 161-175 prolactin Homo sapiens 0-3 1860893-4 1991 PRL caused activation of PKC from 10(-12) to 10(-8) M. Antiserum to PRL, a monoclonal antibody directed against the PRL receptor and the immunosuppressive agent cyclosporine A, were able to inhibit PRL-induced proliferation and activation of PKC. Cyclosporine 161-175 prolactin Homo sapiens 68-71 1860893-4 1991 PRL caused activation of PKC from 10(-12) to 10(-8) M. Antiserum to PRL, a monoclonal antibody directed against the PRL receptor and the immunosuppressive agent cyclosporine A, were able to inhibit PRL-induced proliferation and activation of PKC. Cyclosporine 161-175 prolactin Homo sapiens 68-71 1860893-4 1991 PRL caused activation of PKC from 10(-12) to 10(-8) M. Antiserum to PRL, a monoclonal antibody directed against the PRL receptor and the immunosuppressive agent cyclosporine A, were able to inhibit PRL-induced proliferation and activation of PKC. Cyclosporine 161-175 prolactin Homo sapiens 68-71 1945013-0 1991 [Correlations between urinary prostaglandins, placental hormones and prolactin in the first pregnancy trimester]. Prostaglandins 30-44 prolactin Homo sapiens 69-78 1880474-1 1991 Prolactin is known to inhibit the production of prostaglandins, key substances in the initiation of labour. Prostaglandins 48-62 prolactin Homo sapiens 0-9 2055179-9 1991 hPRL secretion and hPRL mRNA abundance were not affected by estrogen but were markedly reduced by medroxy-progesterone acetate, which was maximally effective at a dose as low as 10(-10) M. Medroxyprogesterone Acetate 98-126 prolactin Homo sapiens 0-4 2055179-9 1991 hPRL secretion and hPRL mRNA abundance were not affected by estrogen but were markedly reduced by medroxy-progesterone acetate, which was maximally effective at a dose as low as 10(-10) M. Medroxyprogesterone Acetate 98-126 prolactin Homo sapiens 19-23 2068891-3 1991 Histamine stimulates the secretion of ACTH, beta-endorphin (mediated by CRH and AVP), alpha-MSH (mediated by dopamine and peripheral catecholamines), and PRL (mediated by dopamine, serotonin and AVP), and participates in the stress-induced release of these hormones and possibly in the suckling- and estrogen-induced PRL release. Histamine 0-9 prolactin Homo sapiens 154-157 2068891-3 1991 Histamine stimulates the secretion of ACTH, beta-endorphin (mediated by CRH and AVP), alpha-MSH (mediated by dopamine and peripheral catecholamines), and PRL (mediated by dopamine, serotonin and AVP), and participates in the stress-induced release of these hormones and possibly in the suckling- and estrogen-induced PRL release. Histamine 0-9 prolactin Homo sapiens 317-320 2068891-3 1991 Histamine stimulates the secretion of ACTH, beta-endorphin (mediated by CRH and AVP), alpha-MSH (mediated by dopamine and peripheral catecholamines), and PRL (mediated by dopamine, serotonin and AVP), and participates in the stress-induced release of these hormones and possibly in the suckling- and estrogen-induced PRL release. Dopamine 171-179 prolactin Homo sapiens 154-157 2068891-3 1991 Histamine stimulates the secretion of ACTH, beta-endorphin (mediated by CRH and AVP), alpha-MSH (mediated by dopamine and peripheral catecholamines), and PRL (mediated by dopamine, serotonin and AVP), and participates in the stress-induced release of these hormones and possibly in the suckling- and estrogen-induced PRL release. Serotonin 181-190 prolactin Homo sapiens 154-157 1794332-2 1991 In this study, we examined the responses of serum prolactin (PRL) to hypertonic saline infusion and TRH injection in 11 patients with idiopathic DI diagnosed by clinical examinations. Sodium Chloride 80-86 prolactin Homo sapiens 50-59 1794332-2 1991 In this study, we examined the responses of serum prolactin (PRL) to hypertonic saline infusion and TRH injection in 11 patients with idiopathic DI diagnosed by clinical examinations. Sodium Chloride 80-86 prolactin Homo sapiens 61-64 2032589-5 1991 During treatment with metoclopramide, all the women showed nocturnal hyperprolactinemia, but their diurnal PRL levels remained within the normal range. Metoclopramide 22-36 prolactin Homo sapiens 107-110 1676318-11 1991 Serum prolactin concentrations dropped considerably with both drugs from day 2 to day 15; a prolactin secretion rebound effect was observed in women treated with bromocriptine. Bromocriptine 162-175 prolactin Homo sapiens 92-101 1923955-7 1991 The surgical cure rates (serum PRL level less than 30 micrograms/l) of the bromocriptine-treated group were higher than those of the control group, both in microprolactinomas (87.5% vs 50%) and macroprolactinomas (33% vs 17%). Bromocriptine 75-88 prolactin Homo sapiens 31-34 1791916-6 1991 Thus: (i) depletion of the melatonin-synthesizing capability of the ovine pineal gland by prolonged exposure to long nights is not completely reversed after 3 months of continuous long day exposure, and (ii) a nocturnal melatonin peak is not essential for maintenance of plasma prolactin levels under these conditions. Melatonin 220-229 prolactin Homo sapiens 278-287 2068574-8 1991 Cyclosporine A interferes with prolactin binding to its receptors on lymphocytes. Cyclosporine 0-14 prolactin Homo sapiens 31-40 2060147-7 1991 Five out of 13 adenomas secreted detectable amount of PRL into the medium and these five adenomas (100%) responded to TPA (16.0 nmol/l) with a two- to six-fold increase. Tetradecanoylphorbol Acetate 118-121 prolactin Homo sapiens 54-57 1752237-3 1991 Bromocriptine therapy normalized serum PRL and made the paradoxical response to GHRH disappear. Bromocriptine 0-13 prolactin Homo sapiens 39-42 2034342-1 1991 The ability of surgery or bromocriptine to produce endocrine control of a prolactin macroadenoma decreases as the prolactin level increases. Bromocriptine 26-39 prolactin Homo sapiens 74-83 2034342-1 1991 The ability of surgery or bromocriptine to produce endocrine control of a prolactin macroadenoma decreases as the prolactin level increases. Bromocriptine 26-39 prolactin Homo sapiens 114-123 1747407-4 1991 The experimental data suggest that prolactin molecules are protected from exopeptidase influence by their terminal cyclic peptides. cyclic 115-121 prolactin Homo sapiens 35-44 1747407-7 1991 A structural analysis of the N-terminal domain of mammalian prolactin revealed the important role of Pro-2 and Pro-4 residues at positions adjacent with and inside the disulfide moiety. Disulfides 168-177 prolactin Homo sapiens 60-69 1747407-8 1991 It is assumed that these proline residues and the cyclic structure are necessary for the manifestation of the inhibiting effect of the mammalian prolactin N-terminal dodecapeptide on proline-specific proteinases. Proline 25-32 prolactin Homo sapiens 145-154 1850347-4 1991 In addition, anti-hPRL IgG identified a single band (29 kDa) in sfRamos spent medium, but not in fresh serum-free medium or in human transferrin, as demonstrated by sodium dodecyl sulfate-reducing polyacrylamide gel electrophoresis and Western immunoblot analysis. Sodium Dodecyl Sulfate 165-187 prolactin Homo sapiens 18-22 1850347-4 1991 In addition, anti-hPRL IgG identified a single band (29 kDa) in sfRamos spent medium, but not in fresh serum-free medium or in human transferrin, as demonstrated by sodium dodecyl sulfate-reducing polyacrylamide gel electrophoresis and Western immunoblot analysis. polyacrylamide gels 197-215 prolactin Homo sapiens 18-22 2022267-0 1991 Differential prolactin response to oral metoclopramide in nulliparous versus parous women throughout the menstrual cycle. Metoclopramide 40-54 prolactin Homo sapiens 13-22 1674531-1 1991 The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). Dopamine 9-17 prolactin Homo sapiens 117-126 1674531-1 1991 The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). Dopamine 9-17 prolactin Homo sapiens 128-131 1674531-1 1991 The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). r-(-)-n-n-propylnorapomorphine 26-56 prolactin Homo sapiens 117-126 1674531-1 1991 The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). r-(-)-n-n-propylnorapomorphine 26-56 prolactin Homo sapiens 128-131 1674531-1 1991 The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). NAPTALAM 58-61 prolactin Homo sapiens 117-126 1674531-1 1991 The full dopamine agonist R-(-)-N-n-propylnorapomorphine (NPA) completely suppressed (ED50 0.12 micrograms/kg) serum prolactin (PRL) levels elevated by pretreatment with gamma-butyrolactone (750 mg/kg). NAPTALAM 58-61 prolactin Homo sapiens 128-131 1821983-2 1991 Recent studies suggest that low prolactin secretion may be a trait characteristic in SAD and this hormone is known to influence on transport mechanism of water and electrolytes from blood to aqueous humor. Water 154-159 prolactin Homo sapiens 32-41 1821983-4 1991 The authors discuss the implications of the finding of lowered IOP in relation to opposing roles of dopamine and serotonin in prolactin secretion in SAD. Serotonin 113-122 prolactin Homo sapiens 126-135 1879060-1 1991 The prolactin (PRL) response to fenfluramine (FEN), a serotonin (5-HT) releasing agent, is used as an index of 5-HT sensitivity in studying disorders associated with central 5-HT abnormality. Fenfluramine 32-44 prolactin Homo sapiens 4-13 1879060-1 1991 The prolactin (PRL) response to fenfluramine (FEN), a serotonin (5-HT) releasing agent, is used as an index of 5-HT sensitivity in studying disorders associated with central 5-HT abnormality. Fenfluramine 32-44 prolactin Homo sapiens 15-18 1879060-1 1991 The prolactin (PRL) response to fenfluramine (FEN), a serotonin (5-HT) releasing agent, is used as an index of 5-HT sensitivity in studying disorders associated with central 5-HT abnormality. Fenfluramine 46-49 prolactin Homo sapiens 4-13 1879060-1 1991 The prolactin (PRL) response to fenfluramine (FEN), a serotonin (5-HT) releasing agent, is used as an index of 5-HT sensitivity in studying disorders associated with central 5-HT abnormality. Fenfluramine 46-49 prolactin Homo sapiens 15-18 1879060-1 1991 The prolactin (PRL) response to fenfluramine (FEN), a serotonin (5-HT) releasing agent, is used as an index of 5-HT sensitivity in studying disorders associated with central 5-HT abnormality. Serotonin 54-63 prolactin Homo sapiens 4-13 1879060-1 1991 The prolactin (PRL) response to fenfluramine (FEN), a serotonin (5-HT) releasing agent, is used as an index of 5-HT sensitivity in studying disorders associated with central 5-HT abnormality. Serotonin 54-63 prolactin Homo sapiens 15-18 2068574-12 1991 Suppression of circulating prolactin by bromocriptine appears to improve the immunosuppressive effect of cyclosporine A with significantly less toxicity. Bromocriptine 40-53 prolactin Homo sapiens 27-36 2068574-12 1991 Suppression of circulating prolactin by bromocriptine appears to improve the immunosuppressive effect of cyclosporine A with significantly less toxicity. Cyclosporine 105-119 prolactin Homo sapiens 27-36 1903236-4 1991 Patients showing a therapeutic motor improvement over 50% on the WRS (dopamine-dependent or "responder") showed lower PRL and TSH and higher GH responses than the non-responders. Dopamine 70-78 prolactin Homo sapiens 118-121 1829742-0 1991 Blunted growth hormone and prolactin responses to L-tryptophan in depression; a state-dependent abnormality. Tryptophan 50-62 prolactin Homo sapiens 27-36 1855345-9 1991 Progesterone and calcium both appear to stimulate pituitary and decidual prolactin secretion, while arachidonic acid seems to inhibit decidual prolactin release. Progesterone 0-12 prolactin Homo sapiens 73-82 1855345-9 1991 Progesterone and calcium both appear to stimulate pituitary and decidual prolactin secretion, while arachidonic acid seems to inhibit decidual prolactin release. Calcium 17-24 prolactin Homo sapiens 73-82 1855345-9 1991 Progesterone and calcium both appear to stimulate pituitary and decidual prolactin secretion, while arachidonic acid seems to inhibit decidual prolactin release. Arachidonic Acid 100-116 prolactin Homo sapiens 143-152 1829742-1 1991 We have investigated whether attenuated growth hormone (GH) and prolactin (PRL) responses to L-tryptophan in depression return to normal with clinical recovery. Tryptophan 93-105 prolactin Homo sapiens 64-73 2016218-0 1991 Prolactin in childhood obsessive-compulsive disorder: clinical correlates and response to clomipramine. Clomipramine 90-102 prolactin Homo sapiens 0-9 1829742-1 1991 We have investigated whether attenuated growth hormone (GH) and prolactin (PRL) responses to L-tryptophan in depression return to normal with clinical recovery. Tryptophan 93-105 prolactin Homo sapiens 75-78 1829742-6 1991 The results suggest that GH and PRL responses to tryptophan are state-dependent abnormalities rather than indicators of predisposition to depression. Tryptophan 49-59 prolactin Homo sapiens 32-35 2016218-3 1991 Clomipramine administration significantly increased basal prolactin levels. Clomipramine 0-12 prolactin Homo sapiens 58-67 1842116-4 1991 Bromocriptine induced a similar reduction of about 60% in prolactin levels in all groups (3.28, 11.5 and 5.95 ng/ml, respectively). Bromocriptine 0-13 prolactin Homo sapiens 58-67 2016218-4 1991 A slight decline in prolactin levels during the last 4 weeks of clomipramine treatment was positively correlated with a favorable treatment response and negatively correlated with duration of illness. Clomipramine 64-76 prolactin Homo sapiens 20-29 2016218-5 1991 If the changes in prolactin levels observed during clomipramine treatment are due primarily to changes in serotonergic neurotransmission, these data suggest that clomipramine treatment of obsessive-compulsive disorder produces an adaptive decrease in the responsiveness of serotonergic receptors. Clomipramine 51-63 prolactin Homo sapiens 18-27 2016218-5 1991 If the changes in prolactin levels observed during clomipramine treatment are due primarily to changes in serotonergic neurotransmission, these data suggest that clomipramine treatment of obsessive-compulsive disorder produces an adaptive decrease in the responsiveness of serotonergic receptors. Clomipramine 162-174 prolactin Homo sapiens 18-27 2013883-10 1991 Reduction of prolactin secretion by injections of bromocriptine from Days 3 to 5 post-partum terminated lactation. Bromocriptine 50-63 prolactin Homo sapiens 13-22 1997518-1 1991 UNLABELLED: Pergolide is a synthetic ergoline derivative with highly potent long-acting PRL-lowering activity, allowing therapy of hyperprolactinemia with a once daily administration of the drug. Pergolide 12-21 prolactin Homo sapiens 88-91 1997518-5 1991 A median optimal dose of 50 micrograms pergolide and 5 mg bromocriptine/day suppressed PRL levels in the 61 patients of trial I by more than 80%. Pergolide 39-48 prolactin Homo sapiens 87-90 1997518-5 1991 A median optimal dose of 50 micrograms pergolide and 5 mg bromocriptine/day suppressed PRL levels in the 61 patients of trial I by more than 80%. Bromocriptine 58-71 prolactin Homo sapiens 87-90 1842116-5 1991 After TRH, prolactin levels increased to 13.8 ng/ml in controls and 15.2 ng/ml in patients treated with levo-DOPA. Levodopa 104-113 prolactin Homo sapiens 11-20 1842116-7 1991 We postulate that low basal levels of prolactin in patients treated with levo-DOPA reveal a residual suppressing effect of the drug. Levodopa 73-82 prolactin Homo sapiens 38-47 1899397-1 1991 To study the role played by normal levels of plasma prolactin (PRL) in the secretion of testosterone (T) in the testes, we induced hypoprolactinemia with a daily dose of 5 mg bromocriptine administered orally in five normal men 20 to 35 years of age for 8 weeks. Testosterone 88-100 prolactin Homo sapiens 52-61 1831261-10 1991 However, recent studies implicate activation of adenylate cyclase, phospholipase C-mediated phosphoinositide hydrolysis and phospholipase A2-mediated arachidonic acid release in the regulation of prolactin release. Arachidonic Acid 150-166 prolactin Homo sapiens 196-205 1824932-7 1991 Hydrocortisone and dexamethasone (0.1-10 microM) had no effect on PRL release, and arachidonic acid (2-100 microM) inhibited rather than stimulated PRL release. Arachidonic Acid 83-99 prolactin Homo sapiens 148-151 2042357-4 1991 It is suggested that increased secretion of testosterone, progesterone and cortisol inhibits the production of gonadotropins and prolactin-inhibiting factor in the pituitary and leads to an increased prolactin level. Testosterone 44-56 prolactin Homo sapiens 129-138 2042357-4 1991 It is suggested that increased secretion of testosterone, progesterone and cortisol inhibits the production of gonadotropins and prolactin-inhibiting factor in the pituitary and leads to an increased prolactin level. Testosterone 44-56 prolactin Homo sapiens 200-209 2042357-4 1991 It is suggested that increased secretion of testosterone, progesterone and cortisol inhibits the production of gonadotropins and prolactin-inhibiting factor in the pituitary and leads to an increased prolactin level. Hydrocortisone 75-83 prolactin Homo sapiens 129-138 2042357-4 1991 It is suggested that increased secretion of testosterone, progesterone and cortisol inhibits the production of gonadotropins and prolactin-inhibiting factor in the pituitary and leads to an increased prolactin level. Hydrocortisone 75-83 prolactin Homo sapiens 200-209 1674920-4 1991 Br or L-Dopa was considered to be effective when serum GH or PRL levels were suppressed more than 50% of the basal value. Bromocriptine 0-2 prolactin Homo sapiens 61-64 1674920-4 1991 Br or L-Dopa was considered to be effective when serum GH or PRL levels were suppressed more than 50% of the basal value. Levodopa 6-12 prolactin Homo sapiens 61-64 1674920-10 1991 In contrast to the difference in the response of GH, serum PRL level was equally suppressed by Br or L-Dopa in each group. Bromocriptine 95-97 prolactin Homo sapiens 59-62 1674920-10 1991 In contrast to the difference in the response of GH, serum PRL level was equally suppressed by Br or L-Dopa in each group. Levodopa 101-107 prolactin Homo sapiens 59-62 1671361-7 1991 Prolactin levels increased significantly during Fenoldopam (24 +/- 2 micrograms/L) compared with placebo (16 +/- 2). Fenoldopam 48-58 prolactin Homo sapiens 0-9 1671361-9 1991 Additionally, dopamine and Fenoldopam have opposite effects on PRL secretion, the latter increasing PRL levels. Dopamine 14-22 prolactin Homo sapiens 63-66 1671361-9 1991 Additionally, dopamine and Fenoldopam have opposite effects on PRL secretion, the latter increasing PRL levels. Dopamine 14-22 prolactin Homo sapiens 100-103 1671361-9 1991 Additionally, dopamine and Fenoldopam have opposite effects on PRL secretion, the latter increasing PRL levels. Fenoldopam 27-37 prolactin Homo sapiens 63-66 1671361-9 1991 Additionally, dopamine and Fenoldopam have opposite effects on PRL secretion, the latter increasing PRL levels. Fenoldopam 27-37 prolactin Homo sapiens 100-103 1899397-1 1991 To study the role played by normal levels of plasma prolactin (PRL) in the secretion of testosterone (T) in the testes, we induced hypoprolactinemia with a daily dose of 5 mg bromocriptine administered orally in five normal men 20 to 35 years of age for 8 weeks. Testosterone 88-100 prolactin Homo sapiens 63-66 1678223-7 1991 Acute (1 mg dexamethasone) or prolonged (40 mg methylprednisolone over 6 days) intake of glucocorticoids suppressed prolactin levels in both groups, demonstrating that the effect of glucocorticoids on the hormone system is not restricted to the hypothalamic-pituitary-adrenal axis. Dexamethasone 12-25 prolactin Homo sapiens 116-125 1790024-7 1991 On the 5th postnatal day the plasma PRL of the newborns of mothers treated with metoclopramide does not differ from the values of the control babies (29.8 +/- 2.6 vs 30.7 +/- 2.4 ng/ml) indicating that the amount of metoclopramide transferred into the milk has no apparent influence on the hypothalamo-hypophyseal axis of the neonate. Metoclopramide 80-94 prolactin Homo sapiens 36-39 1818531-16 1991 In macroprolactinoma patients, a single 50 mg injection of bromocriptine LAR was thus able to achieve in the short-term a clear cut reduction in tumor size in 2/5 patients and normalization of PRL levels in 1/10 of patients. Bromocriptine 59-72 prolactin Homo sapiens 193-196 1905310-8 1991 In the latter cycles, LHRH induced a significant increase in serum PRL and LH levels, while the FSH cycles, the prolactin (PRL) response to LHRH was blunted and LH response markedly attenuated. Luteinizing Hormone 22-24 prolactin Homo sapiens 67-70 1905310-8 1991 In the latter cycles, LHRH induced a significant increase in serum PRL and LH levels, while the FSH cycles, the prolactin (PRL) response to LHRH was blunted and LH response markedly attenuated. Luteinizing Hormone 22-24 prolactin Homo sapiens 123-126 19215442-1 1991 Abstract The relative potencies of dopamine and somatostatin to inhibit prolactin secretion by pituitary cells in primary culture were compared. Dopamine 35-43 prolactin Homo sapiens 72-81 19215442-4 1991 Dopamine markedly inhibited basal as well as thyrotropin-releasing hormone-, vasoactive intestinal peptide-, forskolin- and BAY-K-8644-stimulated release of prolactin. Dopamine 0-8 prolactin Homo sapiens 157-166 19215442-4 1991 Dopamine markedly inhibited basal as well as thyrotropin-releasing hormone-, vasoactive intestinal peptide-, forskolin- and BAY-K-8644-stimulated release of prolactin. Colforsin 109-118 prolactin Homo sapiens 157-166 19215442-4 1991 Dopamine markedly inhibited basal as well as thyrotropin-releasing hormone-, vasoactive intestinal peptide-, forskolin- and BAY-K-8644-stimulated release of prolactin. 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester 124-134 prolactin Homo sapiens 157-166 19215442-12 1991 In contrast, the amine is only a partial inhibitor of exocytosis resulting from non-voltage-sensitive Ca(2+) channel-gated increase in Ca(2+) or direct activation of protein kinase C. 2) Somatostatin is a partial inhibitor of prolactin under all conditions tested. Amines 17-22 prolactin Homo sapiens 226-235 1838876-1 1991 Afternoon serum PRL levels and PRL responsiveness to metoclopramide (MCP) were determined in 36 women, aged 30.5 +/- 4.5, with normoprolactinemic anovulation. Metoclopramide 53-67 prolactin Homo sapiens 31-34 1986602-0 1991 A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women. Fluoxetine 42-66 prolactin Homo sapiens 103-112 1986602-3 1991 Mean 24-hour serum prolactin concentrations increased significantly in response to fluoxetine. Fluoxetine 83-93 prolactin Homo sapiens 19-28 1986602-5 1991 Multiple-parameter deconvolution disclosed no change in prolactin half-life, but a significant increase in the total mass of prolactin secreted per 24 hours during fluoxetine administration. Fluoxetine 164-174 prolactin Homo sapiens 125-134 1986602-6 1991 Cosinor analysis of the prolactin time series showed a significant increase in the circadian amplitude and mean without any change in the time of maximal concentration during treatment with fluoxetine. Fluoxetine 190-200 prolactin Homo sapiens 24-33 2058946-7 1991 Prolactin increases in response to suckling and postsuckling PRL levels were higher, E2 levels were lower, and follicular growth was arrested at earlier stages in progesterone-treated than in untreated women. Progesterone 163-175 prolactin Homo sapiens 0-9 1678223-7 1991 Acute (1 mg dexamethasone) or prolonged (40 mg methylprednisolone over 6 days) intake of glucocorticoids suppressed prolactin levels in both groups, demonstrating that the effect of glucocorticoids on the hormone system is not restricted to the hypothalamic-pituitary-adrenal axis. Methylprednisolone 47-65 prolactin Homo sapiens 116-125 2001445-5 1991 Under these conditions, 12.5 mg clomipramine stimulates the secretion of both cortisol and prolactin, but unlike studies conducted in the morning, clomipramine suppresses the secretion of growth hormone in both groups. Clomipramine 32-44 prolactin Homo sapiens 91-100 1672268-5 1991 Bromocriptine reduced significantly (P less than 0.001) plasma prolactin levels (from 2307 +/- 518 to 568 +/- 279 micrograms/l) (conversion to Sl units: 1 microgram/l = 20 mU/l). Bromocriptine 0-13 prolactin Homo sapiens 63-72 1901539-6 1991 Secretion of PRL was reduced (P less than .05) by treatment with DA and NE but not 5-HT. Dopamine 65-67 prolactin Homo sapiens 13-16 1901539-7 1991 Each amine reduced (P less than .05) the release of PRL in response to thyrotropin-releasing hormone (TRH; 3 micrograms, im). Amines 5-10 prolactin Homo sapiens 52-55 2022198-4 1991 The concentrations of plasma lactate and counterregulatory hormones at rest were similar at warm and cool temperature, whereas prolactin concentration was higher (P less than 0.01) at +30 degrees C. Exercise resulted in an increase in noradrenaline, growth hormone and prolactin (P less than 0.01), prevented the diurnal decrease in cortisol, but had no effect on glucagon. Norepinephrine 235-248 prolactin Homo sapiens 127-136 1915472-4 1991 A correlation analysis of the bromocriptine-induced decrease in L-[1-11C]tyrosine uptake and the reduction of serum prolactin levels indicated that the action of bromocriptine on prolactin synthesis and prolactin release is not coupled. Bromocriptine 30-43 prolactin Homo sapiens 116-125 1915472-4 1991 A correlation analysis of the bromocriptine-induced decrease in L-[1-11C]tyrosine uptake and the reduction of serum prolactin levels indicated that the action of bromocriptine on prolactin synthesis and prolactin release is not coupled. Bromocriptine 30-43 prolactin Homo sapiens 179-188 1915472-4 1991 A correlation analysis of the bromocriptine-induced decrease in L-[1-11C]tyrosine uptake and the reduction of serum prolactin levels indicated that the action of bromocriptine on prolactin synthesis and prolactin release is not coupled. Bromocriptine 30-43 prolactin Homo sapiens 179-188 1915472-4 1991 A correlation analysis of the bromocriptine-induced decrease in L-[1-11C]tyrosine uptake and the reduction of serum prolactin levels indicated that the action of bromocriptine on prolactin synthesis and prolactin release is not coupled. Bromocriptine 162-175 prolactin Homo sapiens 116-125 1915472-4 1991 A correlation analysis of the bromocriptine-induced decrease in L-[1-11C]tyrosine uptake and the reduction of serum prolactin levels indicated that the action of bromocriptine on prolactin synthesis and prolactin release is not coupled. Bromocriptine 162-175 prolactin Homo sapiens 179-188 1915472-4 1991 A correlation analysis of the bromocriptine-induced decrease in L-[1-11C]tyrosine uptake and the reduction of serum prolactin levels indicated that the action of bromocriptine on prolactin synthesis and prolactin release is not coupled. Bromocriptine 162-175 prolactin Homo sapiens 179-188 1782981-1 1991 Serum prolactin is increased during chronic flunarizine treatment of patients suffering from migraine. Flunarizine 44-55 prolactin Homo sapiens 6-15 2037265-8 1991 Maximum decrease of serum prolactin was -89.7% at 5 days, and the prolactin-lowering effect of cabergoline was still present at 14 days. Cabergoline 95-106 prolactin Homo sapiens 66-75 2018629-0 1991 Prolactin responses to haloperidol in drug-free and treated schizophrenic patients. Haloperidol 23-34 prolactin Homo sapiens 0-9 1916652-4 1991 After sulpiride administration the incremental area under the PRL profile in PCOS was significantly lower than in normal subjects (p less than 0.01). Sulpiride 6-15 prolactin Homo sapiens 62-65 1986014-7 1991 While the PRL concentrations were significantly lower in the FHA group during the infusion of saline (P less than 0.001) and MCP (P less than 0.005), the relative increases in PRL during MCP were similar in both groups. Sodium Chloride 94-100 prolactin Homo sapiens 10-13 1930878-3 1991 cis-Fx (1 mg six hourly times four doses) antagonized the GH response to Apo HCl (0.5 mg sc) and increased basal serum PRL concentrations whereas the trans-isomer showed no effect. Flupenthixol 0-6 prolactin Homo sapiens 119-122 1752603-4 1991 PRL levels in the hMG cycle increased according to estradiol levels. Estradiol 51-60 prolactin Homo sapiens 0-3 1752604-2 1991 A transient increase in serum PRL at the ovulatory phase was found in about half of the IVF-ET patients during clomiphene stimulation, and increased levels of PRL in serum and follicular fluid at the ovulatory phase may suppress the fertilization and cleavage of oocytes. Clomiphene 111-121 prolactin Homo sapiens 30-33 1806471-1 1991 The role of bromocriptine as primary therapy for prolactin-producing tumors is currently well accepted in the literature. Bromocriptine 12-25 prolactin Homo sapiens 49-58 1806471-2 1991 Bromocriptine decreases the concentration of serum prolactin and this decrease precludes tumor shrinkage, despite the lack of correlation between amount of decrease in tumor size and baseline serum prolactin. Bromocriptine 0-13 prolactin Homo sapiens 51-60 1806471-4 1991 Bromocriptine affects both release and storage of prolactin. Bromocriptine 0-13 prolactin Homo sapiens 50-59 1806471-10 1991 Because of the time difference between the baseline and TRH-stimulated prolactin levels, we conclude that clinically bromocriptine affects primarily secretion of prolactin and secondarily storage and synthesis. Bromocriptine 117-130 prolactin Homo sapiens 71-80 1806471-10 1991 Because of the time difference between the baseline and TRH-stimulated prolactin levels, we conclude that clinically bromocriptine affects primarily secretion of prolactin and secondarily storage and synthesis. Bromocriptine 117-130 prolactin Homo sapiens 162-171 2018629-1 1991 The prolactin response to 5 mg haloperidol i.m. Haloperidol 31-42 prolactin Homo sapiens 4-13 2018629-9 1991 It is suggested that the prolactin response to haloperidol is an index of the occupancy of receptors that are involved in the PRL releasing mechanisms, and could be used to verify their blockade by the neuroleptics, especially in patients that do not respond positively to drug treatment. Haloperidol 47-58 prolactin Homo sapiens 25-34 1795298-0 1991 Prolactin secretion in lactating mares before and after treatment with bromocriptine. Bromocriptine 71-84 prolactin Homo sapiens 0-9 1941707-1 1991 Recently, some researchers noted significant positive relationships between postdexamethasone serum cortisol and prolactin levels, whilst endogenous depressives exhibited a significantly lower suppression of prolactin by dexamethasone than non-endogenous patients or normal controls. postdexamethasone 76-93 prolactin Homo sapiens 113-122 1941707-2 1991 To ascertain the extent of prolactin responses to dexamethasone in severely depressed patients, we measured 8 a.m. pre- and postdexamethasone prolactin levels in 104 depressed and 42 normal subjects. Dexamethasone 50-63 prolactin Homo sapiens 27-36 1941707-4 1991 We found a significant suppressive effect of dexamethasone on prolactin levels. Dexamethasone 45-58 prolactin Homo sapiens 62-71 2051714-0 1991 [Effect of water immersion on the cortisol, glucose, growth hormone and prolactin levels in patients with transplanted heart]. Water 11-16 prolactin Homo sapiens 72-81 1813709-4 1991 Evidence will be presented to demonstrate that the immunosuppressive effects of hypoprolactinemia, chronic morphine treatment and chronic glucocorticoid administration are reversed by prolactin or by drugs that stimulate endogenous prolactin release. Morphine 107-115 prolactin Homo sapiens 184-193 1795298-3 1991 injection of 100 mg bromocriptine between Days 18 and 28 after foaling when the secretion rate of prolactin was elevated. Bromocriptine 20-33 prolactin Homo sapiens 98-107 1895690-0 1991 [A comparative study of the level of plasma prolactin in women and men undergoing operations under halothane and neuroleptanesthesia]. Halothane 99-108 prolactin Homo sapiens 44-53 1662403-0 1991 HPA-axis hormones and prolactin responses to dextro-fenfluramine in depressed patients and healthy controls. dextro-fenfluramine 45-64 prolactin Homo sapiens 22-31 1895690-6 1991 In women, the rise in plasma prolactin was greater during operations performed under halothane anesthesia and in men--under neuroleptanesthesia. Halothane 85-94 prolactin Homo sapiens 29-38 1944011-1 1991 Cabergoline is a new ergot derivative with long-lasting PRL lowering effect. Cabergoline 0-11 prolactin Homo sapiens 56-59 1662403-2 1991 Like other authors we have established disturbances in central serotonergic neurotransmission in severely depressed patients by implementing hypothalamic pituitary adrenal (HPA)-axis hormones and prolactin responses to serotonin agonists or precursors. Serotonin 219-228 prolactin Homo sapiens 196-205 1805295-0 1991 Serum prolactin increase induced by ethanol--a dose-dependent effect not related to stress. Ethanol 36-43 prolactin Homo sapiens 6-15 1805295-1 1991 The effect of moderate ethanol doses (0.5 and 1 g/kg body weight) on serum prolactin (PRL), cortisol, epinephrine and norepinephrine concentrations was measured in a double-blind, placebo-controlled study. Ethanol 23-30 prolactin Homo sapiens 75-84 1805295-4 1991 The higher ethanol dose, but not the lower dose, significantly increased PRL concentrations. Ethanol 11-18 prolactin Homo sapiens 73-76 1805295-6 1991 Thus, the effect of ethanol on PRL appears to be dose-dependent and not stress-related. Ethanol 20-27 prolactin Homo sapiens 31-34 1811245-0 1991 Influence of naloxone infusion on prolactin and growth hormone response to growth hormone-releasing hormone in anorexia nervosa. Naloxone 13-21 prolactin Homo sapiens 34-43 1811245-5 1991 PRL levels showed a significant increment after GHRH alone and a slight, nonsignificant, PRL increment after GHRH during naloxone infusion in AN patients. Naloxone 121-129 prolactin Homo sapiens 0-3 1811245-6 1991 In contrast a slight PRL decrease was observed after GHRH, both before and during naloxone infusion, in the normal subjects. Naloxone 82-90 prolactin Homo sapiens 21-24 1851310-0 1991 Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. Ritanserin 21-31 prolactin Homo sapiens 87-96 1923547-1 1991 Some experimental data from animals suggest that prolactin (PROL) is involved in sweat production and modulates the chloride concentration of sweat. Chlorides 116-124 prolactin Homo sapiens 49-58 1923547-1 1991 Some experimental data from animals suggest that prolactin (PROL) is involved in sweat production and modulates the chloride concentration of sweat. Chlorides 116-124 prolactin Homo sapiens 60-64 1676524-3 1991 Remoxipride and sulpiride increased the serum levels of prolactin to similar peak levels. Remoxipride 0-11 prolactin Homo sapiens 56-65 1676524-3 1991 Remoxipride and sulpiride increased the serum levels of prolactin to similar peak levels. Sulpiride 16-25 prolactin Homo sapiens 56-65 1676524-5 1991 Sulpiride increased prolactin levels at much lower plasma concentrations than remoxipride, and sulpiride"s effect on prolactin lasted for considerably longer than remoxipride"s. Sulpiride 0-9 prolactin Homo sapiens 20-29 1676524-5 1991 Sulpiride increased prolactin levels at much lower plasma concentrations than remoxipride, and sulpiride"s effect on prolactin lasted for considerably longer than remoxipride"s. Sulpiride 95-104 prolactin Homo sapiens 117-126 1851310-0 1991 Inhibitory effect of ritanserin on the 5-hydroxytryptophan-mediated cortisol, ACTH and prolactin secretion in humans. 5-Hydroxytryptophan 39-58 prolactin Homo sapiens 87-96 2035258-0 1991 Effect of dopamine agonist medication on prolactin producing pituitary adenomas. Dopamine 10-18 prolactin Homo sapiens 41-50 2006240-0 1991 Pindolol decreases prolactin and growth hormone responses to intravenous L-tryptophan. Pindolol 0-8 prolactin Homo sapiens 19-28 1701125-9 1990 In situ hybridization experiments using the 35S-labeled rat ovary 3 beta-HSD cDNA probe show that the inhibitory effect of PRL is exerted primarily on luteal cell 3 beta-HSD expression and activity. Sulfur-35 44-47 prolactin Homo sapiens 123-126 2006240-2 1991 Pindolol pretreatment (40 mg over 48 h) markedly attenuated the GH response to LTP and modestly, but significantly, reduced the LTP-induced increase in plasma PRL. Pindolol 0-8 prolactin Homo sapiens 159-162 2035258-2 1991 Conventional light microscopy, immunocytochemistry, electron microscopy and in situ hybridization were used to evaluate the effect of dopamine agonists (bromocriptine-LAR and bromocriptine) on the morphology of surgically removed prolactin (PRL)-producing pituitary adenomas. bromocriptine-lar 153-170 prolactin Homo sapiens 230-239 2035258-2 1991 Conventional light microscopy, immunocytochemistry, electron microscopy and in situ hybridization were used to evaluate the effect of dopamine agonists (bromocriptine-LAR and bromocriptine) on the morphology of surgically removed prolactin (PRL)-producing pituitary adenomas. Bromocriptine 153-166 prolactin Homo sapiens 230-239 2035258-3 1991 Dopamine agonist therapy resulted in decrease of serum PRL, clinical improvement and tumour shrinkage. Dopamine 0-8 prolactin Homo sapiens 55-58 2035258-7 1991 The large cells contained immunoreactive PRL and expressed the PRL gene indicating resistance to dopamine agonists. Dopamine 97-105 prolactin Homo sapiens 63-66 2035258-11 1991 The formation of irreversibly suppressed PRL cells may explain why some PRL-producing adenomas do not recur after withdrawal of dopamine agonists. Dopamine 128-136 prolactin Homo sapiens 41-44 2270485-6 1990 Mutational analysis showed that a cluster of three residues (His18, His21, and Glu174) in hGH and His188 from the hPRLbp (conserved in all PRL receptors but not GH receptors) are probable Zn2+ ligands. Zinc 188-192 prolactin Homo sapiens 115-118 2147816-0 1990 Comparison of norethindrone and medroxyprogesterone acetate with natural progesterone and estradiol in stimulating prolactin production from cultured endometrial stromal cells. Norethindrone 14-27 prolactin Homo sapiens 115-124 2147816-0 1990 Comparison of norethindrone and medroxyprogesterone acetate with natural progesterone and estradiol in stimulating prolactin production from cultured endometrial stromal cells. Medroxyprogesterone Acetate 32-59 prolactin Homo sapiens 115-124 2147816-0 1990 Comparison of norethindrone and medroxyprogesterone acetate with natural progesterone and estradiol in stimulating prolactin production from cultured endometrial stromal cells. Progesterone 39-51 prolactin Homo sapiens 115-124 2147816-0 1990 Comparison of norethindrone and medroxyprogesterone acetate with natural progesterone and estradiol in stimulating prolactin production from cultured endometrial stromal cells. Estradiol 90-99 prolactin Homo sapiens 115-124 2147816-2 1990 We compared the potencies of the synthetic progestins norethindrone and medroxyprogesterone acetate to natural progesterone in inducing stromal prolactin production. Norethindrone 54-67 prolactin Homo sapiens 144-153 2147816-2 1990 We compared the potencies of the synthetic progestins norethindrone and medroxyprogesterone acetate to natural progesterone in inducing stromal prolactin production. Medroxyprogesterone Acetate 72-99 prolactin Homo sapiens 144-153 2147816-2 1990 We compared the potencies of the synthetic progestins norethindrone and medroxyprogesterone acetate to natural progesterone in inducing stromal prolactin production. Progesterone 79-91 prolactin Homo sapiens 144-153 2229312-2 1990 PTH-(1-84) and PRL both exhibited two peaks of increased secretion [1600-1900 and 0200-0600 h for PTH-(1-84); 2000-2200 and 0400-0800 h for PRL]. pth 0-3 prolactin Homo sapiens 140-143 2083565-0 1990 Effect of oxytocin and PGF2 alpha on prolactin release in sows. Dinoprost 23-27 prolactin Homo sapiens 37-46 2128051-4 1990 Normal prolactin response in a group of normoprolactinaemic as well as in hyperprolactinaemic patients have been observed following metoclopramide bolus injection. Metoclopramide 132-146 prolactin Homo sapiens 7-16 2128051-5 1990 Following bromocriptine administration, maximal net decrease in prolactin levels has been found to be greater in normoprolactinaemic patients compared to healthy subjects, although the difference was statistically insignificant. Bromocriptine 10-23 prolactin Homo sapiens 64-73 2126309-15 1990 Hypothalamic regulation of prolactin mainly involves tonic inhibition via portal dopamine. Dopamine 81-89 prolactin Homo sapiens 27-36 2280212-3 1990 The role of dopamine in the control of beta-endorphin and prolactin was investigated in a series of experiments, conducted under both long and short days, in which rams were treated with dopamine receptor agonists (dopamine and bromocriptine) and antagonists (pimozide and sulpiride). Dopamine 12-20 prolactin Homo sapiens 58-67 2229312-2 1990 PTH-(1-84) and PRL both exhibited two peaks of increased secretion [1600-1900 and 0200-0600 h for PTH-(1-84); 2000-2200 and 0400-0800 h for PRL]. pth 98-101 prolactin Homo sapiens 15-18 2148756-0 1990 Prolactin response to thyrotropin-releasing hormone in normoprolactinemic patients with ovulatory dysfunction and its use for selection of candidates for bromocriptine therapy. Bromocriptine 154-167 prolactin Homo sapiens 0-9 2174755-0 1990 Dopamine-mediated effects induced by metoclopramide simultaneously on adrenocorticotropic hormone and prolactin in patients with pituitary and/or hypothalamic disorders. Dopamine 0-8 prolactin Homo sapiens 102-111 2174755-0 1990 Dopamine-mediated effects induced by metoclopramide simultaneously on adrenocorticotropic hormone and prolactin in patients with pituitary and/or hypothalamic disorders. Metoclopramide 37-51 prolactin Homo sapiens 102-111 2078111-2 1990 Sephadex G 100 exclusion chromatography showed that the predominating form of immunoreactive prolactin levels ranging from 41 to 135 ng/ml was found to be weight, differing from the regular occurrence of a 22 kilodalton major variant. sephadex 0-14 prolactin Homo sapiens 93-102 2175851-1 1990 Previous work established that intravenous administration of the opioid receptor antagonist naloxone abruptly increased release of luteinizing hormone (LH) and decreased release of prolactin (PRL) in suckled anestrous ewes and also increased LH release in cyclic luteal ewes. Naloxone 92-100 prolactin Homo sapiens 181-190 1697858-5 1990 The protein coding sequence of the IM-9-P and decidual PRL cDNAs is identical to the pituitary PRL message, and the 3"-untranslated region (UTR) exhibited a 7-14-nucleotide elongation. im-9-p 35-41 prolactin Homo sapiens 95-98 1697858-5 1990 The protein coding sequence of the IM-9-P and decidual PRL cDNAs is identical to the pituitary PRL message, and the 3"-untranslated region (UTR) exhibited a 7-14-nucleotide elongation. 7-14-nucleotide 157-172 prolactin Homo sapiens 55-58 1697858-6 1990 The 5"-UTR of IM-9-P and decidual PRL cDNAs revealed an extension of 41 base pairs upstream of the normal transcription start site for the human pituitary PRL gene. im-9-p 14-20 prolactin Homo sapiens 155-158 1697858-9 1990 The decidual/IM-9-P-specific segment of the 5"-UTR is located as a new 5"-noncoding exon 5-7 kilobase pairs upstream of the human pituitary PRL gene, exon 1. im-9-p 13-19 prolactin Homo sapiens 140-143 2118537-4 1990 PRL variants were identified and semiquantitated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblotting and autoradiography. Sodium Dodecyl Sulfate 55-77 prolactin Homo sapiens 0-3 2118537-4 1990 PRL variants were identified and semiquantitated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis, followed by immunoblotting and autoradiography. polyacrylamide 78-92 prolactin Homo sapiens 0-3 2118537-11 1990 During metaclopramide infusion, a similar increment in hPRL was observed during acute PRL release. Metoclopramide 7-21 prolactin Homo sapiens 55-59 2118537-12 1990 Administration of the opiate agonist morphine was associated with a small increment in PRL release and did not alter the proportions of PRL variants in the circulation. Morphine 37-45 prolactin Homo sapiens 87-90 1707126-2 1990 To elucidate the mechanisms underlying the different levels of hPRL gene activity in these cell lines, we investigated the methylation status of the gene, since the methylation pattern of cytosine-residues in CpG dinucleotides has been implicated with the transcriptional activity of eukaryotic genes. Cytosine 188-196 prolactin Homo sapiens 63-67 1707126-5 1990 Exposure of the cells to the nucleoside 1-beta-D-arabinofuranosylcytosine, which has been reported to increase enzymatic DNA-methylation, led to an elevation of hPRL production that persisted after removal of the drug. nucleoside 1-beta-d-arabinofuranosylcytosine 29-73 prolactin Homo sapiens 161-165 1707126-6 1990 However, treatment of PRL-positive cells with the demethylating cytidine analog, 5-azacytidine, caused a distinct and heritable reduction of hPRL secretion and hPRL mRNA abundance, concurrent with hypomethylation of the specific MspI site that is hypomethylated in PRL-negative cell lines of the IM-9-P family. Cytidine 64-72 prolactin Homo sapiens 22-25 1707126-6 1990 However, treatment of PRL-positive cells with the demethylating cytidine analog, 5-azacytidine, caused a distinct and heritable reduction of hPRL secretion and hPRL mRNA abundance, concurrent with hypomethylation of the specific MspI site that is hypomethylated in PRL-negative cell lines of the IM-9-P family. Cytidine 64-72 prolactin Homo sapiens 141-145 1707126-6 1990 However, treatment of PRL-positive cells with the demethylating cytidine analog, 5-azacytidine, caused a distinct and heritable reduction of hPRL secretion and hPRL mRNA abundance, concurrent with hypomethylation of the specific MspI site that is hypomethylated in PRL-negative cell lines of the IM-9-P family. Cytidine 64-72 prolactin Homo sapiens 160-164 1707126-6 1990 However, treatment of PRL-positive cells with the demethylating cytidine analog, 5-azacytidine, caused a distinct and heritable reduction of hPRL secretion and hPRL mRNA abundance, concurrent with hypomethylation of the specific MspI site that is hypomethylated in PRL-negative cell lines of the IM-9-P family. Cytidine 64-72 prolactin Homo sapiens 142-145 1707126-6 1990 However, treatment of PRL-positive cells with the demethylating cytidine analog, 5-azacytidine, caused a distinct and heritable reduction of hPRL secretion and hPRL mRNA abundance, concurrent with hypomethylation of the specific MspI site that is hypomethylated in PRL-negative cell lines of the IM-9-P family. Azacitidine 81-94 prolactin Homo sapiens 22-25 1707126-6 1990 However, treatment of PRL-positive cells with the demethylating cytidine analog, 5-azacytidine, caused a distinct and heritable reduction of hPRL secretion and hPRL mRNA abundance, concurrent with hypomethylation of the specific MspI site that is hypomethylated in PRL-negative cell lines of the IM-9-P family. Azacitidine 81-94 prolactin Homo sapiens 141-145 1707126-6 1990 However, treatment of PRL-positive cells with the demethylating cytidine analog, 5-azacytidine, caused a distinct and heritable reduction of hPRL secretion and hPRL mRNA abundance, concurrent with hypomethylation of the specific MspI site that is hypomethylated in PRL-negative cell lines of the IM-9-P family. Azacitidine 81-94 prolactin Homo sapiens 160-164 1707126-6 1990 However, treatment of PRL-positive cells with the demethylating cytidine analog, 5-azacytidine, caused a distinct and heritable reduction of hPRL secretion and hPRL mRNA abundance, concurrent with hypomethylation of the specific MspI site that is hypomethylated in PRL-negative cell lines of the IM-9-P family. Azacitidine 81-94 prolactin Homo sapiens 142-145 2286281-16 1990 These results indicated that the pulsatility and circadian secretion of prolactin were preserved during pregnancy and puerperium and also suggested that prolactin secretion during pregnancy, delivery and puerperium was regulated by at least 3 factors: estradiol, dopamine and LH-hCG. Estradiol 252-261 prolactin Homo sapiens 72-81 2286281-16 1990 These results indicated that the pulsatility and circadian secretion of prolactin were preserved during pregnancy and puerperium and also suggested that prolactin secretion during pregnancy, delivery and puerperium was regulated by at least 3 factors: estradiol, dopamine and LH-hCG. Estradiol 252-261 prolactin Homo sapiens 153-162 2286281-16 1990 These results indicated that the pulsatility and circadian secretion of prolactin were preserved during pregnancy and puerperium and also suggested that prolactin secretion during pregnancy, delivery and puerperium was regulated by at least 3 factors: estradiol, dopamine and LH-hCG. Dopamine 263-271 prolactin Homo sapiens 72-81 2286281-16 1990 These results indicated that the pulsatility and circadian secretion of prolactin were preserved during pregnancy and puerperium and also suggested that prolactin secretion during pregnancy, delivery and puerperium was regulated by at least 3 factors: estradiol, dopamine and LH-hCG. Dopamine 263-271 prolactin Homo sapiens 153-162 2286281-16 1990 These results indicated that the pulsatility and circadian secretion of prolactin were preserved during pregnancy and puerperium and also suggested that prolactin secretion during pregnancy, delivery and puerperium was regulated by at least 3 factors: estradiol, dopamine and LH-hCG. lh-hcg 276-282 prolactin Homo sapiens 72-81 2286281-16 1990 These results indicated that the pulsatility and circadian secretion of prolactin were preserved during pregnancy and puerperium and also suggested that prolactin secretion during pregnancy, delivery and puerperium was regulated by at least 3 factors: estradiol, dopamine and LH-hCG. lh-hcg 276-282 prolactin Homo sapiens 153-162 2149613-0 1990 Plasma prolactin response to domperidone in acute schizophrenia and schizophreniform illness. Domperidone 29-40 prolactin Homo sapiens 7-16 2149613-1 1990 The prolactin (PRL) response to 20 mg of domperidone, a peripheral dopamine (DA) blocking agent, was evaluated in a group of 16 drug-free, acute, young schizophreniform and schizophrenic males and in a group of age-matched normal males. Domperidone 41-52 prolactin Homo sapiens 4-13 2149613-2 1990 Although basal plasma PRL levels were normal, the PRL responses following domperidone were blunted in both patient groups. Domperidone 74-85 prolactin Homo sapiens 50-53 2215338-7 1990 Our study supports the concept that parity, menstrual status, and saturated fat consumption influence a woman"s exposure to prolactin and therefore the risk of developing breast cancer. saturated fat 66-79 prolactin Homo sapiens 124-133 2260483-0 1990 Prolactin responses in dexamethasone suppression test in patients with anorexia nervosa. Dexamethasone 23-36 prolactin Homo sapiens 0-9 2260483-1 1990 In anorexia nervosa (AN), abnormalities are present in the hypothalamic-pituitary-adrenal axis, but the prolactin (PRL) response to dexamethasone suppression test (DST) has not yet been studied. Dexamethasone 132-145 prolactin Homo sapiens 104-113 2260483-1 1990 In anorexia nervosa (AN), abnormalities are present in the hypothalamic-pituitary-adrenal axis, but the prolactin (PRL) response to dexamethasone suppression test (DST) has not yet been studied. Dexamethasone 132-145 prolactin Homo sapiens 115-118 2203327-0 1990 Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder. Serotonin 46-55 prolactin Homo sapiens 0-9 2118537-11 1990 During metaclopramide infusion, a similar increment in hPRL was observed during acute PRL release. Metoclopramide 7-21 prolactin Homo sapiens 56-59 2148756-5 1990 Only those patients showing a peak prolactin response after TRH which exceeded 40 ng/ml were treated with bromocriptine. Bromocriptine 106-119 prolactin Homo sapiens 35-44 2148756-9 1990 This study suggests that incidence of beneficial response to bromocriptine therapy in normoprolactinemic women with ovulatory dysfunction is significantly higher in subjects exhibiting excessive prolactin response to TRH stimulation. Bromocriptine 61-74 prolactin Homo sapiens 91-100 2386133-2 1990 Bromocriptine (7.5 mg per day) corrected visual field defects and suppressed prolactin secretion but did not reduce fasting growth hormone levels. Bromocriptine 0-13 prolactin Homo sapiens 77-86 2234477-3 1990 In fact many neurotransmitters (dopamine) and peptides can modulate prolactin release from anterior pituitary lactotrophs. Dopamine 32-40 prolactin Homo sapiens 68-77 2234477-5 1990 On the basis of these data we have studied the effects of enalapril (ACE-Inhibitor) on baseline plasma prolactin in nine hypertensive post-menopausal women. Enalapril 58-67 prolactin Homo sapiens 103-112 2234477-6 1990 The results indicate that 15-day inhibition of angiotensin-converting enzyme by enalapril significantly reduced serum prolactin levels. Enalapril 80-89 prolactin Homo sapiens 118-127 2169258-2 1990 This protein, comigrating with human Prl on sodium dodecyl sulfate (SDS)-polyacrylamide gels, represented 50% of the total bacterial extract. Sodium Dodecyl Sulfate 44-66 prolactin Homo sapiens 37-40 2169258-2 1990 This protein, comigrating with human Prl on sodium dodecyl sulfate (SDS)-polyacrylamide gels, represented 50% of the total bacterial extract. Sodium Dodecyl Sulfate 68-71 prolactin Homo sapiens 37-40 2169258-2 1990 This protein, comigrating with human Prl on sodium dodecyl sulfate (SDS)-polyacrylamide gels, represented 50% of the total bacterial extract. polyacrylamide 73-87 prolactin Homo sapiens 37-40 2169258-3 1990 Immunoprecipitation of [35S]methionine-labeled bacterial lysate with a rabbit antiserum to hPrl followed by SDS-polyacrylamide gel electrophoresis (PAGE) analysis showed that the major component had a Mr identical to that of standard hPrl. Sulfur-35 24-27 prolactin Homo sapiens 91-95 2169258-3 1990 Immunoprecipitation of [35S]methionine-labeled bacterial lysate with a rabbit antiserum to hPrl followed by SDS-polyacrylamide gel electrophoresis (PAGE) analysis showed that the major component had a Mr identical to that of standard hPrl. Methionine 28-38 prolactin Homo sapiens 91-95 2169258-13 1990 Recombinant hPrl is identical to natural hPrl except for an additional methionine group at the amino terminal end. Methionine 71-81 prolactin Homo sapiens 12-16 2225475-1 1990 Five patients with PRL-secreting macroadenoma and nine patients with PRL-secreting microadenoma or idiopathic hyperprolactinaemia were treated with monthly administrations of long-acting bromocriptine suitable for repeatable injections (Parlodel LAR) for 1-12 cycles of treatment. Bromocriptine 187-200 prolactin Homo sapiens 69-72 2245821-5 1990 The prolactin response to metoclopramide was blunted in acromegalics in comparison with normal subjects but the difference was statistically significant only in hypertensive patients. Metoclopramide 26-40 prolactin Homo sapiens 4-13 2245821-6 1990 The blunted aldosterone and prolactin responses to metoclopramide in hypertensive acromegalics suggest that there is a dopamine deficiency at central and adrenal level in these patients. Metoclopramide 51-65 prolactin Homo sapiens 28-37 2395335-1 1990 A technique for the subcellular localization of prolactin and chromogranin B messenger RNAs (mRNA) in pituitary adenomas by in situ hybridization with biotinylated oligonucleotide probes is described. Oligonucleotides 164-179 prolactin Homo sapiens 48-57 2209924-0 1990 [The effect of epidermal growth factor (EGF) with estradiol and progesterone on prolactin secretion from cultured human decidual tissues of early pregnancy]. Progesterone 64-76 prolactin Homo sapiens 80-89 2209924-2 1990 We investigated the effect of epidermal growth factor (EGF) with estradiol and progesterone on prolactin secretion by the decidual tissues from the early pregnant endometrium. Progesterone 79-91 prolactin Homo sapiens 95-104 2209924-9 1990 An increase in prolactin secretion was found after the tissues were treated with a combination of 10(-8)M estradiol and 10(-6)M progesterone or 10(-6)M progesterone alone. Estradiol 106-115 prolactin Homo sapiens 15-24 2209924-9 1990 An increase in prolactin secretion was found after the tissues were treated with a combination of 10(-8)M estradiol and 10(-6)M progesterone or 10(-6)M progesterone alone. Progesterone 128-140 prolactin Homo sapiens 15-24 2209924-9 1990 An increase in prolactin secretion was found after the tissues were treated with a combination of 10(-8)M estradiol and 10(-6)M progesterone or 10(-6)M progesterone alone. Progesterone 152-164 prolactin Homo sapiens 15-24 2209924-15 1990 The secretion of prolactin in the group treated with progesterone alone decreased dose-dependently responding to added EGF on the 8th day of culture. Progesterone 53-65 prolactin Homo sapiens 17-26 2209924-16 1990 In the presence of estradiol and progesterone, the secretion rate decreased to the values similar to the progesterone alone group with the addition of 0.1, 1 ng/ml EGF, and the decrease in prolactin secretion was less with the addition of 10 ng/ml EGF. Progesterone 33-45 prolactin Homo sapiens 189-198 2209924-17 1990 Mixed cultures of the decidual tissues and villi showed that the prolactin secretion rate increased in all groups treated with/without estradiol and/or progesterone. Estradiol 135-144 prolactin Homo sapiens 65-74 2209924-17 1990 Mixed cultures of the decidual tissues and villi showed that the prolactin secretion rate increased in all groups treated with/without estradiol and/or progesterone. Progesterone 152-164 prolactin Homo sapiens 65-74 2209924-20 1990 These results suggest that decidual prolactin secretion is regulated by the combined effects of steroids and EGF. Steroids 96-104 prolactin Homo sapiens 36-45 2225475-6 1990 In conclusion, its effectiveness and the fact that it is well tolerated, may suggest that this form of bromocriptine may be used as a first therapeutic approach for patients with PRL-secreting adenomas, particularly when shrinkage of a macroadenoma is urgently required. Bromocriptine 103-116 prolactin Homo sapiens 179-182 2146299-3 1990 Prolactin response to buspirone was examined in these patients, in eight male head-injured patients without depression and 10 age-matched male healthy controls. Buspirone 22-31 prolactin Homo sapiens 0-9 19215372-0 1990 Arachidonate Metabolism in the Anterior Pituitary: Effect of Arachidonate Inhibitors on Basal and Stimulated Secretion of Prolactin, Growth Hormone and Luteinizing Hormone. Arachidonic Acid 0-12 prolactin Homo sapiens 122-131 2223270-7 1990 And in 7 patients whose basal PRL levels were between 23 and 41 ng/ml after surgery, hyperprolactinemia was cured still after withdrawal of bromocriptine. Bromocriptine 140-153 prolactin Homo sapiens 30-33 2223270-8 1990 During pregnancy, PRL levels were relatively low in surgically cured patients, but in most of others they became over 200 ng/ml promptly after withdrawal of bromocriptine. Bromocriptine 157-170 prolactin Homo sapiens 18-21 2223270-10 1990 Even if it is not cured surgically, lowered PRL levels have a good effect on the additional bromocriptine therapy. Bromocriptine 92-105 prolactin Homo sapiens 44-47 2243892-1 1990 Plasma prolactin (PRL) and growth hormone (GH) levels are determined, in part, by the effects of dopamine (DA) at pituitary and hypothalamic DA receptors, respectively. Dopamine 97-105 prolactin Homo sapiens 18-21 2243892-3 1990 In addition, the functional responsivity of DA receptors was assessed in the same group of patients by measuring the change in plasma PRL and GH concentrations following the administration of the direct-acting DA agonist, apomorphine (0.01 mg/kg, s.c.) or saline. Apomorphine 222-233 prolactin Homo sapiens 134-137 2230414-3 1990 Despite high PRL level, milk secretion does not appear during pregnancy, because the sex steroid hormones suppress binding of PRL to the receptor in the mammary gland. Steroids 89-105 prolactin Homo sapiens 126-129 19215372-0 1990 Arachidonate Metabolism in the Anterior Pituitary: Effect of Arachidonate Inhibitors on Basal and Stimulated Secretion of Prolactin, Growth Hormone and Luteinizing Hormone. Arachidonic Acid 61-73 prolactin Homo sapiens 122-131 19215372-3 1990 Abstract In the accompanying study, we reported the effects of inhibitors of arachidonic acid metabolism on the regulation of prolactin, growth hormone (GH) and luteinizing hormone secretion by male hemipituitaries. Arachidonic Acid 77-93 prolactin Homo sapiens 126-135 19215372-10 1990 Basal prolactin secretion was reduced by 30% in the presence of ETYA and unaffected by cyclooxygenase inhibitors. ETYA 64-68 prolactin Homo sapiens 6-15 19215372-12 1990 However, in contrast to growth hormone-releasing factor-stimulated GH secretion, thyrotropin-releasing hormone stimulation of prolactin release was able to overcome the inhibition by ETYA in a dose-dependent manner. ETYA 183-187 prolactin Homo sapiens 126-135 19215372-16 1990 Intracellular accumulation of Ca(2+) by the ionophore A23187 and protein kinase C stimulation by the phorbol ester 12-O- tetradecanoyl phorbol acetate (TPA), strongly stimulated GH and prolactin release. Calcimycin 54-60 prolactin Homo sapiens 185-194 19215372-16 1990 Intracellular accumulation of Ca(2+) by the ionophore A23187 and protein kinase C stimulation by the phorbol ester 12-O- tetradecanoyl phorbol acetate (TPA), strongly stimulated GH and prolactin release. Phorbol Esters 101-114 prolactin Homo sapiens 185-194 19215372-16 1990 Intracellular accumulation of Ca(2+) by the ionophore A23187 and protein kinase C stimulation by the phorbol ester 12-O- tetradecanoyl phorbol acetate (TPA), strongly stimulated GH and prolactin release. Tetradecanoylphorbol Acetate 115-150 prolactin Homo sapiens 185-194 19215372-16 1990 Intracellular accumulation of Ca(2+) by the ionophore A23187 and protein kinase C stimulation by the phorbol ester 12-O- tetradecanoyl phorbol acetate (TPA), strongly stimulated GH and prolactin release. Tetradecanoylphorbol Acetate 152-155 prolactin Homo sapiens 185-194 19215372-19 1990 It is concluded that blockade of the arachidonic acid cascade interferes with a secretory pathway involved mainly with basal release of prolactin and GH, but not luteinizing hormone. Arachidonic Acid 37-53 prolactin Homo sapiens 136-145 2115046-2 1990 The quantitative response of TRH-Gly-stimulated PRL, TSH, and GH was evaluated in nine patients with anorexia nervosa, six age-matched normal women, eight patients with uremia, five patients with acromegaly, and two patients with prolactinoma. Glycine 33-36 prolactin Homo sapiens 48-51 2198504-9 1990 Acute stimulation with metoclopramide, TRH, or suckling favors the production of PRL, although BBPRL also rises to a small extent. Metoclopramide 23-37 prolactin Homo sapiens 81-84 2198504-10 1990 During treatment with bromocriptine the proportion of PRL in the circulation is markedly reduced, while BBPRL falls to a much lesser extent. Bromocriptine 22-35 prolactin Homo sapiens 54-57 2229238-3 1990 The equilibrium refolding of bovine, porcine and human growth hormone and ovine prolactin in guanidine hydrochloride has been investigated using high-performance size-exclusion chromatography (HPSEC). Guanidine 93-116 prolactin Homo sapiens 80-89 2118609-5 1990 IAP also blocked the inhibitions by DA of the releases of PRL by 5 microM AA and by 5 microM 5-hydroxyeicosatetraenoic acid. Dopamine 36-38 prolactin Homo sapiens 58-61 2195410-0 1990 Opioid, catecholamine, and steroid interaction in prolactin and gonadotropin regulation. Catecholamines 8-21 prolactin Homo sapiens 50-59 2195410-0 1990 Opioid, catecholamine, and steroid interaction in prolactin and gonadotropin regulation. Steroids 27-34 prolactin Homo sapiens 50-59 2356188-0 1990 Beta-glucan and pectin derivatives stimulate prolactin secretion from hypophysis in vitro. Glucans 4-11 prolactin Homo sapiens 45-54 2356188-3 1990 In this work, it is shown that beta-glucan and several pectin derivatives are able to stimulate prolactin secretion from hypophysis fragments incubated for 2 hr in a synthetic medium. beta-Glucans 31-42 prolactin Homo sapiens 96-105 18411139-0 1990 Calcium and calmodulin regulation of prolactin gene expression. Calcium 0-7 prolactin Homo sapiens 37-46 18411139-1 1990 Prolactin gene transcription is critically dependent upon intracellular calcium and the calcium-binding protein calmodulin. Calcium 72-79 prolactin Homo sapiens 0-9 2355177-2 1990 First, histochemical detection was accomplished by using an aminomethyl coumarin-acetic acid-conjugated ovine prolactin molecule (AMCA-oPRL) on both glutaraldehyde-fixed and unfixed Nb2 lymphoma cells. 2H-1-Benzopyran-2-one, aminomethyl- 60-80 prolactin Homo sapiens 110-119 2355177-2 1990 First, histochemical detection was accomplished by using an aminomethyl coumarin-acetic acid-conjugated ovine prolactin molecule (AMCA-oPRL) on both glutaraldehyde-fixed and unfixed Nb2 lymphoma cells. Acetic Acid 81-92 prolactin Homo sapiens 110-119 2355177-2 1990 First, histochemical detection was accomplished by using an aminomethyl coumarin-acetic acid-conjugated ovine prolactin molecule (AMCA-oPRL) on both glutaraldehyde-fixed and unfixed Nb2 lymphoma cells. Glutaral 149-163 prolactin Homo sapiens 110-119 2118609-2 1990 The inhibitions by 1 microM DA of the stimulations of prolactin (PRL) release by 100 nM thyrotropin-releasing hormone and by 10 microM calcium ionophore A23187 were blocked by 100 ng/ml IAP. Dopamine 28-30 prolactin Homo sapiens 65-68 2118609-2 1990 The inhibitions by 1 microM DA of the stimulations of prolactin (PRL) release by 100 nM thyrotropin-releasing hormone and by 10 microM calcium ionophore A23187 were blocked by 100 ng/ml IAP. Calcium 135-142 prolactin Homo sapiens 65-68 2118609-2 1990 The inhibitions by 1 microM DA of the stimulations of prolactin (PRL) release by 100 nM thyrotropin-releasing hormone and by 10 microM calcium ionophore A23187 were blocked by 100 ng/ml IAP. Calcimycin 153-159 prolactin Homo sapiens 65-68 2118609-5 1990 IAP also blocked the inhibitions by DA of the releases of PRL by 5 microM AA and by 5 microM 5-hydroxyeicosatetraenoic acid. 5-hydroxy-6,8,11,14-eicosatetraenoic acid 93-123 prolactin Homo sapiens 58-61 1973867-6 1990 Both dopamine agonists adequately suppressed PRL. Dopamine 5-13 prolactin Homo sapiens 45-48 2343924-0 1990 Serum prolactin levels during extended cocaine abstinence. Cocaine 39-46 prolactin Homo sapiens 6-15 2354227-0 1990 Basal and haloperidol-stimulated prolactin in neuroleptic-free men with schizophrenia defined by 11 diagnostic systems. Haloperidol 10-21 prolactin Homo sapiens 33-42 2354227-3 1990 Compared with the controls, the PRL response to haloperidol was lower in the patients with schizophrenia defined by all diagnostic systems except those of Schneider and M. Bleuler. Haloperidol 48-59 prolactin Homo sapiens 32-35 2378830-9 1990 We conclude that this new depot-bromocriptine is a safe, well tolerated and effective drug in the suppression of prolactin and the prevention of post-partum lactation. Bromocriptine 32-45 prolactin Homo sapiens 113-122 2383926-0 1990 Prolactin secretion in women during the oestradiol-induced luteinizing hormone surge with or without progesterone. Estradiol 40-50 prolactin Homo sapiens 0-9 2384365-0 1990 Serum prolactin and growth hormone responses to naloxone and intracerebral ventricle morphine administration in heifers. Naloxone 48-56 prolactin Homo sapiens 6-15 2360588-1 1990 Elevated levels of serum and follicular fluid prolactin occur in women undergoing ovulation induction with both clomiphene citrate and gonadotropin therapy. Clomiphene 112-130 prolactin Homo sapiens 46-55 2384365-3 1990 Increasing doses of morphine (M) from 2 to 1,500 micrograms injected into the third cerebral ventricle increased (P less than .001) serum PRL concentrations in a dose-related manner. Morphine 20-28 prolactin Homo sapiens 138-141 2384365-6 1990 Naloxone at doses of 1, 2 and 4 mg/kg reduced (P less than .05) serum concentrations of PRL for 45 to 60 min. Naloxone 0-8 prolactin Homo sapiens 88-91 2112150-10 1990 Progesterone supplementation in vitro inhibited fibroid PRL secretion; estrogen and GnRH-a in vitro had a minimal effect. Progesterone 0-12 prolactin Homo sapiens 56-59 2356395-11 1990 Irrespective of the magnitude of the nocturnal elevation, morning PRL levels were slightly but consistently higher after triazolam treatment than under basal conditions. Triazolam 121-130 prolactin Homo sapiens 66-69 2112150-12 1990 These results demonstrate: 1) PRL secretion is greater from fibroids than myometrium; 2) fibroid PRL secretion in vitro is specifically reduced after 24 h after in vivo treatment with GnRH-a; 3) estrogen or progesterone in vitro does not reverse the suppression by in vivo administration of GnRH-a; and 4) GnRH-a in vitro has no effect on fibroid PRL secretion. Progesterone 207-219 prolactin Homo sapiens 97-100 2112150-12 1990 These results demonstrate: 1) PRL secretion is greater from fibroids than myometrium; 2) fibroid PRL secretion in vitro is specifically reduced after 24 h after in vivo treatment with GnRH-a; 3) estrogen or progesterone in vitro does not reverse the suppression by in vivo administration of GnRH-a; and 4) GnRH-a in vitro has no effect on fibroid PRL secretion. Progesterone 207-219 prolactin Homo sapiens 97-100 2340323-2 1990 Subjects greater than or equal to 30 years of age, compared with younger subjects, exhibited decreased prolactin secretion in response to a 60-mg oral dose of dl-fenfluramine hydrochloride, an indirect serotonin agonist. Fenfluramine 159-188 prolactin Homo sapiens 103-112 2114008-2 1990 In order to gain insight into the mechanism of this response, we have tested the effect of a naloxone infusion (1.6 mg/h) on the PRL response to GnRH in 5 normal females, aged 20-27 years, tested during the periovulatory period. Naloxone 93-101 prolactin Homo sapiens 129-132 2114008-5 1990 Naloxone clearly blunted the PRL response (basal 10.7 +/- 1.7 ng/ml, peak 11.8 +/- 0.2 ng/ml at 30 min, versus: basal 9.0 +/- 0.5 ng/ml, peak 20.6 +/- 3.9 ng/ml at 45 min after GnRH alone; significance of difference between peaks: p less than 0.05). Naloxone 0-8 prolactin Homo sapiens 29-32 2114008-7 1990 These data indicate that periovulatory PRL dynamics are altered by naloxone administration and suggest a possible involvement of opioid peptides in the "paradoxical" PRL response to GnRH in normal subjects. Naloxone 67-75 prolactin Homo sapiens 39-42 1973937-1 1990 In healthy volunteers, the azapirones--buspirone, ipsapirone, and gepirone--increase plasma cortisol and decrease body temperature; buspirone and gepirone also increase plasma prolactin and growth hormone. azapirones 27-37 prolactin Homo sapiens 176-185 1973937-1 1990 In healthy volunteers, the azapirones--buspirone, ipsapirone, and gepirone--increase plasma cortisol and decrease body temperature; buspirone and gepirone also increase plasma prolactin and growth hormone. Buspirone 39-48 prolactin Homo sapiens 176-185 1973937-1 1990 In healthy volunteers, the azapirones--buspirone, ipsapirone, and gepirone--increase plasma cortisol and decrease body temperature; buspirone and gepirone also increase plasma prolactin and growth hormone. ipsapirone 50-60 prolactin Homo sapiens 176-185 1973937-1 1990 In healthy volunteers, the azapirones--buspirone, ipsapirone, and gepirone--increase plasma cortisol and decrease body temperature; buspirone and gepirone also increase plasma prolactin and growth hormone. gepirone 66-74 prolactin Homo sapiens 176-185 1973937-1 1990 In healthy volunteers, the azapirones--buspirone, ipsapirone, and gepirone--increase plasma cortisol and decrease body temperature; buspirone and gepirone also increase plasma prolactin and growth hormone. Buspirone 132-141 prolactin Homo sapiens 176-185 1973937-1 1990 In healthy volunteers, the azapirones--buspirone, ipsapirone, and gepirone--increase plasma cortisol and decrease body temperature; buspirone and gepirone also increase plasma prolactin and growth hormone. gepirone 146-154 prolactin Homo sapiens 176-185 2340323-4 1990 As prolactin secretory capacity appears to be stable through midlife, the age-associated decrease in fenfluramine-induced prolactin release suggests a decline in CNS serotonergic responsivity. Fenfluramine 101-113 prolactin Homo sapiens 122-131 2192585-0 1990 Effect of captopril on plasma prolactin in patients with essential hypertension. Captopril 10-19 prolactin Homo sapiens 30-39 2112813-4 1990 Dopamine infusion (4 micrograms.kg-1.min-1 for 180 min) did not affect gonadotropins and greatly reduced serum PRL. Dopamine 0-8 prolactin Homo sapiens 111-114 2333989-6 1990 We examined endogenous prolactin secretion after administration of the dopamine antagonist metoclopramide. Dopamine 71-79 prolactin Homo sapiens 23-32 2333989-6 1990 We examined endogenous prolactin secretion after administration of the dopamine antagonist metoclopramide. Metoclopramide 91-105 prolactin Homo sapiens 23-32 2192585-3 1990 Captopril decreased mean plasma prolactin from 17.5 +/- 1.4 ng/mL to 9.1 +/- 1.0 ng/mL (p less than 0.001). Captopril 0-9 prolactin Homo sapiens 32-41 2333989-7 1990 Metoclopramide significantly increased mean serum prolactin concentration and prolactin pulse height and amplitude in all subjects during the day and night. Metoclopramide 0-14 prolactin Homo sapiens 50-59 2192585-4 1990 Significant correlation was found between captopril-induced change from control values of plasma prolactin (delta plasma prolactin) vs delta plasma renin activity (r = -0.688, p less than 0.001). Captopril 42-51 prolactin Homo sapiens 97-106 2333989-7 1990 Metoclopramide significantly increased mean serum prolactin concentration and prolactin pulse height and amplitude in all subjects during the day and night. Metoclopramide 0-14 prolactin Homo sapiens 78-87 2333989-8 1990 However, net prolactin pulse amplitude after metoclopramide stimulation at night was significantly higher in older subjects compared with younger subjects. Metoclopramide 45-59 prolactin Homo sapiens 13-22 2110485-11 1990 Bulimics with high BHBA levels had significantly reduced nocturnal prolactin plasma levels. 3-Hydroxybutyric Acid 19-23 prolactin Homo sapiens 67-76 2192585-4 1990 Significant correlation was found between captopril-induced change from control values of plasma prolactin (delta plasma prolactin) vs delta plasma renin activity (r = -0.688, p less than 0.001). Captopril 42-51 prolactin Homo sapiens 121-130 2192585-5 1990 These results suggest that acute administration of captopril was accompanied by a reduction in plasma prolactin and that this reduction may be of clinical significance during therapy of hypertension. Captopril 51-60 prolactin Homo sapiens 102-111 2115483-2 1990 Prolactin responsiveness after metoclopramide- and TRH-injection and the nocturnal profile of serum prolactin were examined in 25 women. Metoclopramide 31-45 prolactin Homo sapiens 0-9 2350650-3 1990 Bromocriptine, an ergot derivative, was used to suppress a pathologically elevated prolactin level and successfully effect a rapid resolution of lactation. Bromocriptine 0-13 prolactin Homo sapiens 83-92 2110572-1 1990 The effects of the calcium entry blocker verapamil on the 24-h profile of PRL secretion and on the PRL response to TRH were investigated in six healthy volunteers. Verapamil 41-50 prolactin Homo sapiens 74-77 2110572-3 1990 In all subjects both basal and TRH-stimulated PRL levels were markedly elevated by verapamil. Verapamil 83-92 prolactin Homo sapiens 46-49 2110572-5 1990 Diurnal rhythm and pulsatility of PRL secretion were seen both before and during verapamil administration. Verapamil 81-90 prolactin Homo sapiens 34-37 2110572-8 1990 Interference with other PRL-regulating mechanisms may account for the demonstrated verapamil-induced PRL secretion in vivo. Verapamil 83-92 prolactin Homo sapiens 24-27 2110572-8 1990 Interference with other PRL-regulating mechanisms may account for the demonstrated verapamil-induced PRL secretion in vivo. Verapamil 83-92 prolactin Homo sapiens 101-104 2359983-2 1990 Buspirone stimulates central 5-hydroxytryptamine (5HT) receptors and brings about the release of prolactin, and there is evidence to suggest that the extent of prolactin release after a challenge with buspirone is an indicator of the sensitivity of central 5HT receptors. Buspirone 0-9 prolactin Homo sapiens 97-106 1974270-5 1990 There were no significant differences in both basal and after treatment PRL levels among patients treated with different drugs, although a greater PRL decrease was induced by cabergoline. Cabergoline 175-186 prolactin Homo sapiens 147-150 2125674-3 1990 The mean values of gonadotrophins and estradiol were characteristic of hypogonadotropic hypogonadism when the concentration of prolactin was higher than 4000 mIU/l. Estradiol 38-47 prolactin Homo sapiens 127-136 2204052-0 1990 [The effect of luliberin and sulpiride on the secretion of gonadotropic hormones and prolactin in patients with obesity]. Sulpiride 29-38 prolactin Homo sapiens 85-94 2359983-2 1990 Buspirone stimulates central 5-hydroxytryptamine (5HT) receptors and brings about the release of prolactin, and there is evidence to suggest that the extent of prolactin release after a challenge with buspirone is an indicator of the sensitivity of central 5HT receptors. Buspirone 201-210 prolactin Homo sapiens 160-169 2188799-1 1990 Histamine (HA), which acts as a neurotransmitter in the central nervous system, participates in the neuroendocrine regulation of prolactin (PRL) secretion. Histamine 11-13 prolactin Homo sapiens 129-138 2188044-8 1990 All 5 patients had a marked initial decrease of elevated prolactin levels 8 h after administration of 0.25 mg terguride orally. dironyl 110-119 prolactin Homo sapiens 57-66 2188044-13 1990 Tergurid as a dopaminagonist is an effective inhibitor of prolactin with little side effects and thus a useful drug in the treatment of hyperprolactinemia. dironyl 0-8 prolactin Homo sapiens 58-67 2327450-0 1990 In vitro induction of prolactin production and aromatase activity by gonadal steroids exclusively in the stroma of separated proliferative human endometrium. Steroids 77-85 prolactin Homo sapiens 22-31 2327450-8 1990 Stromal cell cultures demonstrated increasing prolactin with continuous incubation with progesterone (15-day control: 11.28 +/- 0.91 ng/100 micrograms deoxyribonucleic acid versus 15-day progesterone: 245.8 +/- 4.24 ng/100 micrograms). Progesterone 88-100 prolactin Homo sapiens 46-55 2327450-10 1990 Estradiol induced a sustained increase in prolactin production even after withdrawal of steroids. Estradiol 0-9 prolactin Homo sapiens 42-51 2327450-13 1990 These studies support these conclusions: (1) nongestational endometrial prolactin is of stromal, not glandular origin; (2) stromal prolactin production is induced and maintained by progesterone: (3) stromal prolactin production is induced by estradiol but does not require continued exposure for maintenance; (4) aromatase activity is increased by long-term exposure to progesterone and estradiol in stroma but not in glands. Progesterone 181-193 prolactin Homo sapiens 131-140 2327450-13 1990 These studies support these conclusions: (1) nongestational endometrial prolactin is of stromal, not glandular origin; (2) stromal prolactin production is induced and maintained by progesterone: (3) stromal prolactin production is induced by estradiol but does not require continued exposure for maintenance; (4) aromatase activity is increased by long-term exposure to progesterone and estradiol in stroma but not in glands. Progesterone 181-193 prolactin Homo sapiens 131-140 2188799-1 1990 Histamine (HA), which acts as a neurotransmitter in the central nervous system, participates in the neuroendocrine regulation of prolactin (PRL) secretion. Histamine 0-9 prolactin Homo sapiens 129-138 2188799-1 1990 Histamine (HA), which acts as a neurotransmitter in the central nervous system, participates in the neuroendocrine regulation of prolactin (PRL) secretion. Histamine 0-9 prolactin Homo sapiens 140-143 2188799-1 1990 Histamine (HA), which acts as a neurotransmitter in the central nervous system, participates in the neuroendocrine regulation of prolactin (PRL) secretion. Histamine 11-13 prolactin Homo sapiens 140-143 2188799-6 1990 However, high doses of CIM possess an additional PRL stimulatory action not related to blockade of H2-receptors. Cimetidine 23-26 prolactin Homo sapiens 49-52 2188799-8 1990 Since HA has no effect directly at the pituitary level, the actions of the amine may occur at different sites within the hypothalamus by an effect on hypothalamic transmitters regulating PRL secretion. Amines 75-80 prolactin Homo sapiens 187-190 2380543-0 1990 The reproducibility of the prolactin response to buspirone: relationship to the menstrual cycle. Buspirone 49-58 prolactin Homo sapiens 27-36 2354952-2 1990 We investigated the prolactin response to domperidone, a dopamine receptor blocker. Domperidone 42-53 prolactin Homo sapiens 20-29 2354952-4 1990 Domperidone produced a significant rise of serum prolactin (p less than 0.01) in migrainous patients (7.77 +/- 3.09 vs 71.06 +/- 9.97 in men, 7.05 +/- 2.3 vs 129.58 +/- 14.15 in women in the follicular phase of the menstrual cycle, and 14.28 +/- 3.51 vs 169.71 +/- 16.63 in women in the luteal phase) and control subjects. Domperidone 0-11 prolactin Homo sapiens 49-58 2380543-1 1990 Prolactin response to buspirone challenge was examined in eight normal healthy male and six healthy female volunteers. Buspirone 22-31 prolactin Homo sapiens 0-9 2380543-2 1990 A significant increase in prolactin levels was noted around 90 min following oral administration of buspirone hydrochloride. Buspirone 100-123 prolactin Homo sapiens 26-35 2161088-10 1990 This cAMP-independent PRL release was blocked by preincubation of the cells with 1 microgram/ml pertussis toxin. Cyclic AMP 5-9 prolactin Homo sapiens 22-25 2182616-4 1990 Most frequently used in these studies has been intravenous L-tryptophan (L-TRP), which increases serum prolactin (PRL). Tryptophan 59-71 prolactin Homo sapiens 103-112 2182616-4 1990 Most frequently used in these studies has been intravenous L-tryptophan (L-TRP), which increases serum prolactin (PRL). Tryptophan 73-78 prolactin Homo sapiens 103-112 2321008-2 1990 The complementary DNA for hPRL was cloned, expressed in Escherichia coli, and mutated to introduce sequentially those substitutions from hGH that were predicted by alanine-scanning mutagenesis and other studies to be most critical for binding to the hGH receptor from human liver. Alanine 164-171 prolactin Homo sapiens 26-30 2111223-1 1990 The authors examined the prolactin (PRL) and thyrotropin (TSH) response to stimulation with chloropromazine and thyreoliberin in 10 patients with pituitary tumours. Chlorpromazine 92-107 prolactin Homo sapiens 25-34 2307734-0 1990 Evidence for an intracerebral action of phenylalanine in stimulation of prolactin secretion: interaction of large neutral amino acids. Phenylalanine 40-53 prolactin Homo sapiens 72-81 2186960-2 1990 The release of the two forms of PRL in tilapia into the medium was measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by densitometry. Sodium Dodecyl Sulfate 79-101 prolactin Homo sapiens 32-35 2186960-2 1990 The release of the two forms of PRL in tilapia into the medium was measured by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by densitometry. polyacrylamide 102-116 prolactin Homo sapiens 32-35 2186960-4 1990 Newly synthesized PRL was detected by incorporation of [35S]methionine, introduced into the culture medium, by the PRL molecules. Sulfur-35 55-60 prolactin Homo sapiens 18-21 2186960-4 1990 Newly synthesized PRL was detected by incorporation of [35S]methionine, introduced into the culture medium, by the PRL molecules. Sulfur-35 55-60 prolactin Homo sapiens 115-118 2186960-4 1990 Newly synthesized PRL was detected by incorporation of [35S]methionine, introduced into the culture medium, by the PRL molecules. Methionine 60-70 prolactin Homo sapiens 18-21 2186960-4 1990 Newly synthesized PRL was detected by incorporation of [35S]methionine, introduced into the culture medium, by the PRL molecules. Methionine 60-70 prolactin Homo sapiens 115-118 2114023-2 1990 injection of metoclopramide (10 mg) and thyroliberin (200 micrograms) with a record of PRL and TSH levels for 120 min. Metoclopramide 13-27 prolactin Homo sapiens 87-90 2139693-13 1990 In both groups of sows, the timing of the initial increase in the concentration of plasma prolactin coincided with a similar rise in plasma lactose (P less than 0.01). Lactose 140-147 prolactin Homo sapiens 90-99 2157998-3 1990 Infusion of fructose, which is known not to cross the blood-brain barrier (BBB), did not influence the GH release during hypoglycemia; however, it inhibited PRL secretion. Fructose 12-20 prolactin Homo sapiens 157-160 2339765-6 1990 The neuroendocrine disorders were most severe in patients with macroprolactinoma who showed a refractory prolactin secretory response to dopaminergic metoclopramide inhibition. Metoclopramide 150-164 prolactin Homo sapiens 68-77 2168264-0 1990 Thyrotropin-and prolactin--secreting pituitary tumor dissociated hormonal response to bromocriptine. Bromocriptine 86-99 prolactin Homo sapiens 16-25 2168264-6 1990 After bromocriptine administration (2.5 mg daily), the suppressibility of serum TSH level was found better than that of prolactin level. Bromocriptine 6-19 prolactin Homo sapiens 120-129 2385731-3 1990 Bromocriptine induced only transient suppression of serum prolactin. Bromocriptine 0-13 prolactin Homo sapiens 58-67 2385731-4 1990 In vitro studies of tissue from this prolactinoma showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of prolactin mRNA, suggesting relative autonomy of prolactin synthesis. Bromocriptine 111-124 prolactin Homo sapiens 37-46 2385731-4 1990 In vitro studies of tissue from this prolactinoma showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of prolactin mRNA, suggesting relative autonomy of prolactin synthesis. Bromocriptine 111-124 prolactin Homo sapiens 71-80 2385731-4 1990 In vitro studies of tissue from this prolactinoma showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of prolactin mRNA, suggesting relative autonomy of prolactin synthesis. Bromocriptine 111-124 prolactin Homo sapiens 71-80 2385731-4 1990 In vitro studies of tissue from this prolactinoma showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of prolactin mRNA, suggesting relative autonomy of prolactin synthesis. Dopamine 129-137 prolactin Homo sapiens 71-80 2385731-4 1990 In vitro studies of tissue from this prolactinoma showed that although prolactin secretion was reduced by both bromocriptine and dopamine, neither agent affected cytoplasmic levels of prolactin mRNA, suggesting relative autonomy of prolactin synthesis. Dopamine 129-137 prolactin Homo sapiens 71-80 2385731-11 1990 Cases of apparent bromocriptine resistance may reflect abnormal regulation of prolactin gene expression. Bromocriptine 18-31 prolactin Homo sapiens 78-87 2107654-0 1990 Effects of a dopamine antagonist (metoclopramide) on the release of LH, FSH, TSH and PRL in normal women throughout the menstrual cycle. Metoclopramide 34-48 prolactin Homo sapiens 85-88 2339765-7 1990 The patients with microprolactinomas had a low prolactin response (increments less than 300-400%) and delayed TSH response. Thyrotropin 110-113 prolactin Homo sapiens 23-32 1968102-6 1990 The patient was started on bromocriptine, and her bone density, serum prolactin, dehydroepiandrosterone sulfate, and free and total testosterone improved. Bromocriptine 27-40 prolactin Homo sapiens 70-79 2105705-2 1990 After carbamazepine treatment, the prolactin response to intravenous administration of the serotonin precursor tryptophan (5 g) was significantly enhanced, but there was no change in basal plasma tryptophan level or in tryptophan disposition after infusion. Carbamazepine 6-19 prolactin Homo sapiens 35-44 2105705-2 1990 After carbamazepine treatment, the prolactin response to intravenous administration of the serotonin precursor tryptophan (5 g) was significantly enhanced, but there was no change in basal plasma tryptophan level or in tryptophan disposition after infusion. Serotonin 91-100 prolactin Homo sapiens 35-44 2105705-2 1990 After carbamazepine treatment, the prolactin response to intravenous administration of the serotonin precursor tryptophan (5 g) was significantly enhanced, but there was no change in basal plasma tryptophan level or in tryptophan disposition after infusion. Tryptophan 111-121 prolactin Homo sapiens 35-44 2404742-7 1990 Incubation of the cells with 8-chloroadenosine-cAMP during a 2-h chase period resulted in a 3.6-fold increase in the release of newly synthesized NG-hPRL and had only a slight effect on newly synthesized G-hPRL release (1.7-fold increase). 8-chloroadenosine-camp 29-51 prolactin Homo sapiens 149-153 2404742-7 1990 Incubation of the cells with 8-chloroadenosine-cAMP during a 2-h chase period resulted in a 3.6-fold increase in the release of newly synthesized NG-hPRL and had only a slight effect on newly synthesized G-hPRL release (1.7-fold increase). 8-chloroadenosine-camp 29-51 prolactin Homo sapiens 206-210 2311021-8 1990 It is concluded that in the medical treatment of macroprolactinomas 10-20 mg bromocriptine in four divided doses effectively reduces both plasma prolactin level and tumor size. Bromocriptine 77-90 prolactin Homo sapiens 54-63 2341064-0 1990 [Treatment of prolactin-secreting pituitary tumors with bromocriptine]. Bromocriptine 56-69 prolactin Homo sapiens 14-23 2329263-0 1990 A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia. Melatonin 72-81 prolactin Homo sapiens 18-27 2329263-0 1990 A study of pineal-prolactin interaction: prolactin response to an acute melatonin injection in patients with hyperprolactinemia. Melatonin 72-81 prolactin Homo sapiens 41-50 2329263-5 1990 A normalization of PRL levels was achieved after melatonin injection in 3/8 patients with idiopathic hyperprolactinemia, while no effect was seen in patients with prolactinoma. Melatonin 49-58 prolactin Homo sapiens 19-22 2329263-6 1990 Further studies, by evaluating the effect of a chronic treatment, will be required to define which is the action of melatonin on PRL release in PRL secretion disorders, and to evaluate its possible therapeutic role. Melatonin 116-125 prolactin Homo sapiens 129-132 2329263-6 1990 Further studies, by evaluating the effect of a chronic treatment, will be required to define which is the action of melatonin on PRL release in PRL secretion disorders, and to evaluate its possible therapeutic role. Melatonin 116-125 prolactin Homo sapiens 144-147 2351912-14 1990 In conclusion, this study demonstrated that lisuride is another effective prolactin inhibiting agent even at low dose. Lisuride 44-52 prolactin Homo sapiens 74-83 1695330-0 1990 Effects of naloxone on prolactin-secreting pituitary adenomas. Naloxone 11-19 prolactin Homo sapiens 23-32 2220345-6 1990 Compared with placebo, bromocriptine caused a significant reduction in the objective assessment score of breast tenderness (p less than 0.05) and milk secretion (p less than 0.01), in serum prolactin (PRL) (p less than 0.001) and in the subjective assessment score of breast pain (p less than 0.01) and milk secretion (p less than 0.01). Bromocriptine 23-36 prolactin Homo sapiens 190-199 2326398-3 1990 When three subjects with severe pretreatment weight loss were excluded, however, the remaining seven patients showed a significant increase in the prolactin response to L-tryptophan, consistent with other published studies. Tryptophan 169-181 prolactin Homo sapiens 147-156 2326398-4 1990 The findings suggest that severe recent weight loss may alter the effects of tricyclic antidepressants on 5HT-mediated prolactin release. Serotonin 106-109 prolactin Homo sapiens 119-128 2305604-7 1990 The results indicate that prolactin synthesis in the endometrium is regulated directly by progesterone, and indirectly by estradiol. Progesterone 90-102 prolactin Homo sapiens 26-35 2305604-7 1990 The results indicate that prolactin synthesis in the endometrium is regulated directly by progesterone, and indirectly by estradiol. Estradiol 122-131 prolactin Homo sapiens 26-35 2305604-8 1990 We suggest that prolactin production in primary stromal cell cultures could serve as a bioassay for progestational activity of steroid hormones in the human endometrium. Steroids 127-143 prolactin Homo sapiens 16-25 1967667-4 1990 Reduction in breast pain, heaviness, tenderness, and serum prolactin after 3 and 6 months" therapy were significantly greater with bromocriptine than with placebo. Bromocriptine 131-144 prolactin Homo sapiens 59-68 1978478-4 1990 Compared to those on haloperidol, fewer patients on remoxipride had trough plasma prolactin levels above the normal range in short-term treatment. Remoxipride 52-63 prolactin Homo sapiens 82-91 1978492-6 1990 The effect of remoxipride on the elevation of plasma prolactin levels was not modified by biperiden and the effect of warfarin on the prolongation of prothrombin time was uninfluened by remoxipride. Remoxipride 14-25 prolactin Homo sapiens 53-62 2220345-6 1990 Compared with placebo, bromocriptine caused a significant reduction in the objective assessment score of breast tenderness (p less than 0.05) and milk secretion (p less than 0.01), in serum prolactin (PRL) (p less than 0.001) and in the subjective assessment score of breast pain (p less than 0.01) and milk secretion (p less than 0.01). Bromocriptine 23-36 prolactin Homo sapiens 201-204 2297260-5 1990 Thirty patients (group 1) were administered cyclosporine, azathioprine, and prednisone and 24 patients (group 2), a modified protocol aimed at decreasing the level of circulating prolactin by adding bromocriptine to the immunosuppression regimen. Bromocriptine 199-212 prolactin Homo sapiens 179-188 2129295-5 1990 Many evidences indicate that dopamine acts as a physiological inhibitor on mammalian PRL secreting cells. Dopamine 29-37 prolactin Homo sapiens 85-88 2173365-0 1990 Differences in the effects of acute and chronic administration of dexfenfluramine on cortisol and prolactin secretion. Dexfenfluramine 66-81 prolactin Homo sapiens 98-107 2297260-10 1990 In conclusion, suppression of circulating prolactin by bromocriptine appears to improve the immunosuppressive effect of cyclosporine, at least during the early postoperative period when the risk of rejection and infection is higher, and could be a promising avenue to successful hormonal manipulations of the immune process after organ transplantation. Bromocriptine 55-68 prolactin Homo sapiens 42-51 2297260-2 1990 Prolactin receptors have been described on the membrane of lymphocyte cells, and competitive binding to these receptors by cyclosporine and circulating prolactin has been demonstrated. Cyclosporine 123-135 prolactin Homo sapiens 0-9 2297260-3 1990 Experimental evidence suggests a synergistic effect of cyclosporine and bromocriptine, an inhibitor of pituitary release of prolactin, on immunosuppression. Cyclosporine 55-67 prolactin Homo sapiens 124-133 2297260-10 1990 In conclusion, suppression of circulating prolactin by bromocriptine appears to improve the immunosuppressive effect of cyclosporine, at least during the early postoperative period when the risk of rejection and infection is higher, and could be a promising avenue to successful hormonal manipulations of the immune process after organ transplantation. Cyclosporine 120-132 prolactin Homo sapiens 42-51 2297260-3 1990 Experimental evidence suggests a synergistic effect of cyclosporine and bromocriptine, an inhibitor of pituitary release of prolactin, on immunosuppression. Bromocriptine 72-85 prolactin Homo sapiens 124-133 2093405-9 1990 Prolactin secreting pituitary adenomas shrink with bromocriptine treatment. Bromocriptine 51-64 prolactin Homo sapiens 0-9 2347321-10 1990 We hypothesize that immersion in water caused prolactin levels to decline. Water 33-38 prolactin Homo sapiens 46-55 2302549-1 1990 Immunoreactive prolactin has been recovered from human cerebrospinal fluid (CSF) by hydrophobic interaction chromatography on Phenyl-Sepharose CL-4B and molecular sieving on Sephadex G-100. Phenyl-Sepharose CL-4B 126-148 prolactin Homo sapiens 15-24 2302549-1 1990 Immunoreactive prolactin has been recovered from human cerebrospinal fluid (CSF) by hydrophobic interaction chromatography on Phenyl-Sepharose CL-4B and molecular sieving on Sephadex G-100. sephadex 174-188 prolactin Homo sapiens 15-24 2302549-4 1990 Upon chromatography on Sephadex G-100, the CSF prolactin coeluted with a pituitary reference preparation (molecular weight, 22,000 Da). sephadex 23-37 prolactin Homo sapiens 47-56 2253662-0 1990 Ibopamine-induced reduction of serum prolactin level and milk secretion in puerperal women. ibopamine 0-9 prolactin Homo sapiens 37-46 2253662-1 1990 Ibopamine, a peripheral dopamine agonist, was administered to 80 postpartum women to assess its effect on prolactin (PRL) and milk production. ibopamine 0-9 prolactin Homo sapiens 106-115 2352119-0 1990 Influence of melatonin on the sleep-independent component of prolactin secretion. Melatonin 13-22 prolactin Homo sapiens 61-70 2093697-3 1990 In contrast, administration of chlorpromazine was followed by an exaggerated response of prolactin secretion in KTP as compared with normals. Chlorpromazine 31-45 prolactin Homo sapiens 89-98 2126039-5 1990 The possibilities that an increase in melatonin concentrations is either the primary feature that leads to the regression of the seminiferous epithelium or is secondary and depends on elevated gonadotropins and/or prolactin levels are discussed. Melatonin 38-47 prolactin Homo sapiens 214-223 2352119-2 1990 Recent studies in the human suggest the hypothesis that prolactin has also an endogenous sleep-independent rhythm, which can be influenced by endogenous melatonin. Melatonin 153-162 prolactin Homo sapiens 56-65 2352119-7 1990 Fall and rise of prolactin secretion under these conditions were always preceded by decrease and rise in melatonin levels in all eight women studied. Melatonin 105-114 prolactin Homo sapiens 17-26 2352119-8 1990 Based on these observations, it is concluded that melatonin is associated with an endogenous circadian component of prolactin secretion. Melatonin 50-59 prolactin Homo sapiens 116-125 2352119-10 1990 An alternative explanation of our findings could be based on the fact that melatonin influences dopamine metabolism, which in turn alters prolactin secretion. Melatonin 75-84 prolactin Homo sapiens 138-147 2352119-10 1990 An alternative explanation of our findings could be based on the fact that melatonin influences dopamine metabolism, which in turn alters prolactin secretion. Dopamine 96-104 prolactin Homo sapiens 138-147 2352119-11 1990 It can also not be ruled out that melatonin might act via the opioid system, which then could affect prolactin secretion. Melatonin 34-43 prolactin Homo sapiens 101-110 2352119-16 1990 It is concluded that melatonin through its external modulator light might entrain the circadian sleep-independent component of prolactin secretion and via its action on prolactin could modulate reproductive processes. Melatonin 21-30 prolactin Homo sapiens 127-136 2352119-16 1990 It is concluded that melatonin through its external modulator light might entrain the circadian sleep-independent component of prolactin secretion and via its action on prolactin could modulate reproductive processes. Melatonin 21-30 prolactin Homo sapiens 169-178 2308471-0 1990 Growth hormone and prolactin response to methylphenidate in children with attention deficit disorder. Methylphenidate 41-56 prolactin Homo sapiens 19-28 2214676-5 1990 When the serum prolactin increases after child birth or renal insufficiency, the image from the accumulation of Ga-67 citrate in the breast may have a "doughnut" pattern. gallium citrate 112-125 prolactin Homo sapiens 15-24 2308471-1 1990 Utilizing a double-blind, drug-placebo design, we examined growth hormone (GH) and prolactin (Pro) response to oral administration of methylphenidate (MPH) in 14 boys (ages 7.0-12.4 years) with Attention Deficit Disorder (ADD). Methylphenidate 134-149 prolactin Homo sapiens 83-92 2250565-0 1990 Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers. Moclobemide 45-56 prolactin Homo sapiens 67-76 2250565-1 1990 The serotonin receptor antagonist methysergide was used to investigate the mechanism mediating stimulation of prolactin release after single doses of the reversible MAO-A inhibitor moclobemide. Moclobemide 181-192 prolactin Homo sapiens 110-119 2325501-12 1990 These observations suggest that the transient PRL-releasing effects which have been observed in both animal and human studies after clozapine administration are mediated via supra-pituitary actions of the drug. Clozapine 132-141 prolactin Homo sapiens 46-49 2250565-2 1990 Eight healthy male volunteers participated in a placebo-controlled cross-over study, where pretreatment with methysergide almost totally prevented the moclobemide-induced increase in plasma prolactin levels. Methysergide 109-121 prolactin Homo sapiens 190-199 2250565-2 1990 Eight healthy male volunteers participated in a placebo-controlled cross-over study, where pretreatment with methysergide almost totally prevented the moclobemide-induced increase in plasma prolactin levels. Moclobemide 151-162 prolactin Homo sapiens 190-199 2250565-4 1990 This result suggests that moclobemide stimulates prolactin release through activation of serotonergic receptors, and provides evidence that the drug is capable of augmenting central serotonergic neurotransmission in humans. Moclobemide 26-37 prolactin Homo sapiens 49-58 2250565-1 1990 The serotonin receptor antagonist methysergide was used to investigate the mechanism mediating stimulation of prolactin release after single doses of the reversible MAO-A inhibitor moclobemide. Methysergide 34-46 prolactin Homo sapiens 110-119 2149882-0 1990 Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. Remoxipride 93-104 prolactin Homo sapiens 37-46 2092340-3 1990 However, prolactin is prevented from exerting its effect on milk secretion by elevated levels of progesterone. Progesterone 97-109 prolactin Homo sapiens 9-18 2149882-3 1990 In a double-blind dose finding study prolactin was assessed at baseline and end of treatment in three groups of acute schizophrenics receiving low, intermediate and high doses of remoxipride as compared to a controlled group that received haloperidol. Remoxipride 179-190 prolactin Homo sapiens 37-46 2149882-5 1990 Remoxipride only in high doses (300-600 mg daily) has produced a modest increase in prolactin levels at endpoint as compared to the much higher increase in prolactin secretion that accompanied haloperidol treatment. Remoxipride 0-11 prolactin Homo sapiens 84-93 2156277-8 1990 Prolactin and growth hormone levels increased in both patients and controls following tryptophan. Tryptophan 86-96 prolactin Homo sapiens 0-9 2149882-5 1990 Remoxipride only in high doses (300-600 mg daily) has produced a modest increase in prolactin levels at endpoint as compared to the much higher increase in prolactin secretion that accompanied haloperidol treatment. Haloperidol 193-204 prolactin Homo sapiens 156-165 2149882-7 1990 The weak effects on prolactin as well as the previously reported low incidence of extrapyramidal side effects confirm the profile of remoxipride as a selective dopamine D2 antagonist with preferential effects on the mesolimbic and mesocortical tracts. Remoxipride 133-144 prolactin Homo sapiens 20-29 2149882-9 1990 Male responders to either remoxipride or haloperidol treatment had significantly higher baseline prolactin levels regardless of dose and drug used. Remoxipride 26-37 prolactin Homo sapiens 97-106 2163062-2 1990 HGH, PRL and TSH responses to clonidine. Clonidine 30-39 prolactin Homo sapiens 5-8 2149882-9 1990 Male responders to either remoxipride or haloperidol treatment had significantly higher baseline prolactin levels regardless of dose and drug used. Haloperidol 41-52 prolactin Homo sapiens 97-106 1966302-2 1990 Measurement of plasma ACTH, cortisol, and prolactin showed that nicotine produced in both groups a dose-dependent increase in cortisol, with ACTH in both groups and prolactin in the Alzheimer"s group significantly elevated only by the 0.5 micrograms dose. Nicotine 64-72 prolactin Homo sapiens 42-51 2235732-11 1990 Br counteracted the effects of androgens and prolactin. Bromocriptine 0-2 prolactin Homo sapiens 45-54 2236580-10 1990 L-TRP increases serum prolactin (PRL) in humans, probably via 5-HT mechanisms. Tryptophan 0-5 prolactin Homo sapiens 22-31 1966302-2 1990 Measurement of plasma ACTH, cortisol, and prolactin showed that nicotine produced in both groups a dose-dependent increase in cortisol, with ACTH in both groups and prolactin in the Alzheimer"s group significantly elevated only by the 0.5 micrograms dose. Nicotine 64-72 prolactin Homo sapiens 165-174 2277850-2 1990 Cysteamine is formed by degradation of coenzyme A (CoA) and causes somatostatin (SS), prolactin and noradrenaline depletion in the brain and peripheral tissues. Cysteamine 0-10 prolactin Homo sapiens 86-95 2277850-6 1990 Cysteamine has several established (cystinosis, radioprotection, acetaminophen poisoning) and theoretical (Huntington"s disease, prolactin-secreting adenomas) indications in clinical practice. Cysteamine 0-10 prolactin Homo sapiens 129-138 2277850-10 1990 Pantethine depletes SS, prolactin and noradrenaline with lower efficacy compared to that of cysteamine. pantethine 0-10 prolactin Homo sapiens 24-33 2101962-0 1990 Influence of clenbuterol, a beta-adrenergic agonist, on desipramine induced growth hormone, prolactin and cortisol stimulation. Clenbuterol 13-24 prolactin Homo sapiens 92-101 2101962-0 1990 Influence of clenbuterol, a beta-adrenergic agonist, on desipramine induced growth hormone, prolactin and cortisol stimulation. Desipramine 56-67 prolactin Homo sapiens 92-101 2101962-1 1990 We report herein the effects of the beta-adrenergic agonist clenbuterol on desipramine (DMI)-induced growth hormone (GH), prolactin (PRL) and cortisol secretion in healthy male subjects. Clenbuterol 60-71 prolactin Homo sapiens 122-131 2128415-1 1990 To evaluate whether the inhibitory control of TSH and the stimulatory control of prolactin (PRL) secretion exerted by endogenous serotonin was altered in obesity, 22 obese men and 10 normal controls were tested with TRH (200 micrograms IV bolus) in the presence (experimental test) and absence (control test) of the serotonergic agonist fenfluramine (60 mg PO 90 min before TRH). Serotonin 129-138 prolactin Homo sapiens 92-95 2106150-1 1990 The effect of pretreatment with ritanserin, a potent and selective serotonin-S2 (5-HT2) receptor antagonist, on the prolactin (PRL) response to electroconvulsive therapy (ECT) was studied in seven female patients suffering from major depressive disorder. Ritanserin 32-42 prolactin Homo sapiens 127-130 2128416-1 1990 The pituitary prolactin (PRL) response to domperidone (DOM; a dopaminergic antagonist) and TRH administration in human males during different stages of sexual maturation was investigated. Domperidone 42-53 prolactin Homo sapiens 14-23 2098668-3 1990 Prolactin levels were elevated by 100% from 2 to 8 h after alprazolam administration. Alprazolam 59-69 prolactin Homo sapiens 0-9 2128416-1 1990 The pituitary prolactin (PRL) response to domperidone (DOM; a dopaminergic antagonist) and TRH administration in human males during different stages of sexual maturation was investigated. Domperidone 42-53 prolactin Homo sapiens 25-28 2098668-4 1990 The robust increase in prolactin levels is less consistent with previously reported data on traditional benzodiazepines. Benzodiazepines 104-119 prolactin Homo sapiens 23-32 2125736-2 1990 In two studies conducted at different sites, depressed patients consistently demonstrated blunted prolactin responses to clomipramine, compared with healthy control subjects. Clomipramine 121-133 prolactin Homo sapiens 98-107 2128416-4 1990 Significant positive correlations also were found between the serum sex steroid hormone concentrations and the PRL response to dopaminergic blockade (r = 0.774, p = 0.02 and r = 0.554, p = 0.01, respectively). Steroids 72-87 prolactin Homo sapiens 111-114 2125736-4 1990 Although these patients demonstrated blunted prolactin responses to clomipramine, their prolactin responses to TRH were robust. Clomipramine 68-80 prolactin Homo sapiens 45-54 2128416-6 1990 The different patterns of PRL response to DOM and TRH throughout male puberty might be due to differences in pituitary thresholds for sex steroids between the dopamine- and TRH-dependent intracellular pools. Steroids 138-146 prolactin Homo sapiens 26-29 2125736-5 1990 These observations suggest that the blunted prolactin response to clomipramine in depression is not attributable to diminished hormonal secretory capacity in anterior pituitary lactotrophs and may be a reflection of dysregulation in central serotonergic systems. Clomipramine 66-78 prolactin Homo sapiens 44-53 2128415-1 1990 To evaluate whether the inhibitory control of TSH and the stimulatory control of prolactin (PRL) secretion exerted by endogenous serotonin was altered in obesity, 22 obese men and 10 normal controls were tested with TRH (200 micrograms IV bolus) in the presence (experimental test) and absence (control test) of the serotonergic agonist fenfluramine (60 mg PO 90 min before TRH). Serotonin 129-138 prolactin Homo sapiens 81-90 2128416-6 1990 The different patterns of PRL response to DOM and TRH throughout male puberty might be due to differences in pituitary thresholds for sex steroids between the dopamine- and TRH-dependent intracellular pools. Dopamine 159-167 prolactin Homo sapiens 26-29 2236457-2 1990 An example is the association between blood levels of prolactin and a drug (e.g., methylphenidate) measured at multiple time-points across study subjects. Methylphenidate 82-97 prolactin Homo sapiens 54-63 2129312-0 1990 Thyrotropin and prolactin responses to protirelin (TRH) prior to and during chronic imipramine treatment in patients with panic disorder. Imipramine 84-94 prolactin Homo sapiens 16-25 2291808-0 1990 Prolactin release and milk removal induced by suckling and milking in lactating ewes is prevented by L-dopa treatment. Levodopa 101-107 prolactin Homo sapiens 0-9 2255750-0 1990 Prolactin response to low-dose haloperidol challenge in schizophrenic, non-schizophrenic psychotic, and control subjects. Haloperidol 31-42 prolactin Homo sapiens 0-9 2255750-2 1990 A two-way analysis of covariance, with age as the covariate, revealed that DSM-III schizophrenics (n = 27) had a lower prolactin response to haloperidol than did the controls (n = 28). Haloperidol 141-152 prolactin Homo sapiens 119-128 2274628-6 1990 The cortisol and prolactin responses to tryptophan were blunted during the late luteal phase compared with the midfollicular phase, and the cortisol, but not prolactin, responses to the serotonergic agonist 1-(m-chlorophenyl) piperazine, (mCPP) was also blunted during that period. Tryptophan 40-50 prolactin Homo sapiens 17-26 2274641-1 1990 The prolactin (PRL) response to challenge with buspirone hydrochloride, a serotonin1a (5-HT1a) receptor agonist, was examined in 5 healthy male volunteers and in 10 healthy male and female patients with primary DSM-III personality disorder. Buspirone 47-70 prolactin Homo sapiens 4-13 2274641-1 1990 The prolactin (PRL) response to challenge with buspirone hydrochloride, a serotonin1a (5-HT1a) receptor agonist, was examined in 5 healthy male volunteers and in 10 healthy male and female patients with primary DSM-III personality disorder. Buspirone 47-70 prolactin Homo sapiens 15-18 2274641-3 1990 completely suppressed the maximal PRL response to buspirone challenge. Buspirone 50-59 prolactin Homo sapiens 34-37 2343077-8 1990 However, basal cortisol concentrations, which were raised in depressives with chronic psychosocial difficulties, were strongly and inversely predictive of PRL responses in depressives and controls. Hydrocortisone 15-23 prolactin Homo sapiens 155-158 2349370-8 1990 Drug injections at steady state induced an increase in prolactin secretion in all of the fluphenazine sub-group and in half of those receiving haloperidol. Fluphenazine 89-101 prolactin Homo sapiens 55-64 2349370-8 1990 Drug injections at steady state induced an increase in prolactin secretion in all of the fluphenazine sub-group and in half of those receiving haloperidol. Haloperidol 143-154 prolactin Homo sapiens 55-64 2349370-10 1990 Fluphenazine appeared more potent than haloperidol in provoking prolactin secretion. Fluphenazine 0-12 prolactin Homo sapiens 64-73 2349370-10 1990 Fluphenazine appeared more potent than haloperidol in provoking prolactin secretion. Haloperidol 39-50 prolactin Homo sapiens 64-73 2274641-4 1990 Pretreatment with the nonselective beta-adrenergic/5-HT1-like antagonist, pindolol suppressed the maximal PRL response to buspirone challenge depending upon dose (i.e., between 49 to 90% suppression at best dose). Pindolol 74-82 prolactin Homo sapiens 106-109 2274641-4 1990 Pretreatment with the nonselective beta-adrenergic/5-HT1-like antagonist, pindolol suppressed the maximal PRL response to buspirone challenge depending upon dose (i.e., between 49 to 90% suppression at best dose). Buspirone 122-131 prolactin Homo sapiens 106-109 2274641-5 1990 In personality disorder patients, PRL responses to buspirone challenge correlated inversely with self-assessed "irritability" (r = -.76, n = 10, p less than .01). Buspirone 51-60 prolactin Homo sapiens 34-37 2274641-6 1990 These data suggest that the PRL response to buspirone challenge reflects the responsivity of 5-HT1a receptors in the limbic-hypothalamus in humans and that reduced sensitivity of these receptors is associated with an important component of impulsive aggressive behaviors in personality disorder patients. Buspirone 44-53 prolactin Homo sapiens 28-31 2291808-7 1990 The inhibitory effect of 200 mg of L-DOPA on the secretion of prolactin after milking lasted for about 120 min, and thereafter a significant increase in serum prolactin level occurred. Levodopa 35-41 prolactin Homo sapiens 62-71 2291808-7 1990 The inhibitory effect of 200 mg of L-DOPA on the secretion of prolactin after milking lasted for about 120 min, and thereafter a significant increase in serum prolactin level occurred. Levodopa 35-41 prolactin Homo sapiens 159-168 2291808-9 1990 Doses of 25 or 50 mg of L-DOPA prevented the surge of prolactin observed immediately after milking, but a long-lasting release of prolactin was obtained thereafter. Levodopa 24-30 prolactin Homo sapiens 54-63 2291808-10 1990 The inhibitory effect of L-DOPA on prolactin release could be overridden by the suckling or milking stimuli according to the dose administered. Levodopa 25-31 prolactin Homo sapiens 35-44 2291808-12 1990 The results indicate that milk removal and prolactin release induced by milking or suckling in lactating ewes is inhibited by an increase in monoamines at the hypothalamic-hypophyseal level. monoamines 141-151 prolactin Homo sapiens 43-52 6787487-0 1981 Feedback effects of estradiol and progesterone upon gonadotropin and prolactin release. Estradiol 20-29 prolactin Homo sapiens 69-78 2374967-3 1990 Measurements of basal prolactin levels and of its secretion in metoclopramide test helped distinguish two types of hyperprolactinemia syndrome, differing in the pattern of spermatogenesis disorders. Metoclopramide 63-77 prolactin Homo sapiens 22-31 2374967-5 1990 Therapy with dopamine agonists (lisenyl, parlodel) was found most effective in Type I hyperprolactinemia syndrome, associated with essential prolactin hypersecretion and oligospermia. Dopamine 13-21 prolactin Homo sapiens 91-100 6787487-1 1981 The relationship between estradiol- and progesterone-mediated gonadotropin release and steroid-induced changes in prolactin levels was investigated in an improved human experimental model. Estradiol 25-34 prolactin Homo sapiens 114-123 6787487-1 1981 The relationship between estradiol- and progesterone-mediated gonadotropin release and steroid-induced changes in prolactin levels was investigated in an improved human experimental model. Steroids 87-94 prolactin Homo sapiens 114-123 7410533-3 1980 In group 1, discontinuation of bromocriptine resulted in elevated serum PRL concentrations, but this was not associated with any significant changes in the circulating levels of estradiol, progesterone, and hCG. Bromocriptine 31-44 prolactin Homo sapiens 72-75 33942735-6 2021 RESULTS: PRL was expressed diffusely and with a mild intensity in the cytoplasm of normal and tumor prostate luminal cells. Phenobarbital 109-116 prolactin Homo sapiens 9-12 7410533-4 1980 In group 2, chlorpromazine increased the serum PRL concentration but had no effect on serum estradiol, progesterone, or hCG concentrations. Chlorpromazine 12-26 prolactin Homo sapiens 47-50 7410533-5 1980 In group 3, bromocriptine decreased the serum PRL level, but this was not associated with any alteration in steroid hormone or hCG levels. Bromocriptine 12-25 prolactin Homo sapiens 46-49 401886-1 1977 Infertile men with azoospermia and low testosterone levels because of Klinefelter"s or Sertoli cell-only syndrome responded to a single injection of TRH by an increase in serum prolactin levels. Testosterone 39-51 prolactin Homo sapiens 177-186 401886-3 1977 The results demonstrate a link between testosterone and prolactin levels in fertile and infertile men. Testosterone 39-51 prolactin Homo sapiens 56-65 33812218-7 2021 Baseline body mass index and serum prolactin concentration could predict the effect of berberine on insulin resistance. Berberine 87-96 prolactin Homo sapiens 35-44 33794504-8 2021 Multivariate linear regression analysis indicated that fasting plasma glucose (FBG) and adipo-IR were significantly associated with PRL (FBG: beta = -0.263, P < 0.05; adipo-IR: beta = -0.464, P < 0.01). Glucose 70-77 prolactin Homo sapiens 132-135 33589921-6 2021 The selective HDAC6 inhibitor, ACY-241, blocks prolactin induced STAT5A chromatin engagement at cis-regulatory elements as well as a significant proportion of prolactin stimulated gene expression. Citarinostat 31-38 prolactin Homo sapiens 47-56 33589921-6 2021 The selective HDAC6 inhibitor, ACY-241, blocks prolactin induced STAT5A chromatin engagement at cis-regulatory elements as well as a significant proportion of prolactin stimulated gene expression. Citarinostat 31-38 prolactin Homo sapiens 159-168 33589921-7 2021 We identify functional pathways known to contribute to the development and/or progression of breast cancer that are activated by prolactin and inhibited by ACY-241. Citarinostat 156-163 prolactin Homo sapiens 129-138 33770166-13 2021 Prolactin secretion was also impaired by a PRL stop gain mutation deleting both of the terminal cysteine amino acids (c.652A>T; p.Lys218Ter). cysteine amino acids 96-116 prolactin Homo sapiens 0-9 33770166-13 2021 Prolactin secretion was also impaired by a PRL stop gain mutation deleting both of the terminal cysteine amino acids (c.652A>T; p.Lys218Ter). cysteine amino acids 96-116 prolactin Homo sapiens 43-46 33770166-15 2021 The loss of the terminal cysteine resulted in failure of prolactin secretion. Cysteine 25-33 prolactin Homo sapiens 57-66 33234470-13 2020 Prolactin (whose secretion is inhibited by dopamine) levels were elevated in several patients with PTPS deficiency and inversely correlated with the z-scores for height (p < 0.01) and weight (p < 0.05). Dopamine 43-51 prolactin Homo sapiens 0-9 33235024-0 2021 Relationship of Prolactin Concentrations to Steady-state Plasma Concentrations of Aripiprazole in Schizophrenia Patients. Aripiprazole 82-94 prolactin Homo sapiens 16-25 33235024-8 2021 There were significant inverse correlations between plasma prolactin levels and plasma concentrations of aripiprazole (rs = -0.447, p < 0.001) and the active moiety (aripiprazole plus dehydroaripiprazole) (rs = -0.429, p < 0.001) in males. Aripiprazole 105-117 prolactin Homo sapiens 59-68 33235024-9 2021 In females, significant inverse correlations were also found between plasma prolactin levels and plasma concentrations of aripiprazole (rs = -0.273, p < 0.01) and the active moiety (rs = -0.275, p < 0.01). Aripiprazole 122-134 prolactin Homo sapiens 76-85 33235024-10 2021 CONCLUSIONS: These findings suggest that lower prolactin levels are, to some extent, associated with higher plasma drug concentrations in male and female patients with schizophrenia treated with aripiprazole. Aripiprazole 195-207 prolactin Homo sapiens 47-56 33776913-3 2021 Here we report a patient with prolactinoma who was resistant to high-dose cabergoline (CAB) treatment, demonstrating a continuous increase in both the tumor volume and the prolactin (PRL) level. Cabergoline 74-85 prolactin Homo sapiens 30-39 34563856-0 2022 Disposable and cost-effective label-free electrochemical immunosensor for prolactin based on bismuth sulfide nanorods with polypyrrole. bismuth sulfide 93-108 prolactin Homo sapiens 74-83 34563856-0 2022 Disposable and cost-effective label-free electrochemical immunosensor for prolactin based on bismuth sulfide nanorods with polypyrrole. polypyrrole 123-134 prolactin Homo sapiens 74-83 34563856-3 2022 Accordingly, herein, a novel label-free immunosensor using a bismuth sulfide/polypyrrole (Bi2S3/PPy)-modified screen-printed electrode (SPE) for the fast and facile detection of the peptide hormone PRL. bismuth sulfide 61-76 prolactin Homo sapiens 198-201 34563856-3 2022 Accordingly, herein, a novel label-free immunosensor using a bismuth sulfide/polypyrrole (Bi2S3/PPy)-modified screen-printed electrode (SPE) for the fast and facile detection of the peptide hormone PRL. polypyrrole 77-88 prolactin Homo sapiens 198-201 34563856-3 2022 Accordingly, herein, a novel label-free immunosensor using a bismuth sulfide/polypyrrole (Bi2S3/PPy)-modified screen-printed electrode (SPE) for the fast and facile detection of the peptide hormone PRL. Bismuth sulfide (Bi2S3) 90-95 prolactin Homo sapiens 198-201 34934445-7 2022 A fourth-line therapy is necessary with temozolomide, an oral alkylating chemotherapeutic agent, that may induce tumor reduction and serum prolactin reduction in 75% of cases but only 8% have a normalization of prolactin levels. Temozolomide 40-52 prolactin Homo sapiens 139-148 34420839-10 2022 In addition, lurasidone was associated with smaller change in prolactin levels compared to OFC but not quetiapine. Lurasidone Hydrochloride 13-23 prolactin Homo sapiens 62-71 34587362-5 2022 In addition, one study investigated the impact of chlorpheniramine or promethazine on prolactin levels among 17 women, and one study investigated possible adverse drug reactions in 85 breastfed infants exposed to various antihistamines. Promethazine 70-82 prolactin Homo sapiens 86-95 34967003-6 2022 Dopamine receptor agonists, which suppress pituitary prolactin release, are an effective migraine treatment in a subset of patients. Dopamine 0-8 prolactin Homo sapiens 53-62 34934445-7 2022 A fourth-line therapy is necessary with temozolomide, an oral alkylating chemotherapeutic agent, that may induce tumor reduction and serum prolactin reduction in 75% of cases but only 8% have a normalization of prolactin levels. Temozolomide 40-52 prolactin Homo sapiens 211-220 34967147-8 2021 Serum prolactin increased with trazpiroben treatment (mean maximum serum concentration 93.32 ng/mL (10 mg) vs. 10.83 ng/mL (placebo)), illustrating receptor target engagement. Trazpiroben 31-42 prolactin Homo sapiens 6-15 34950736-12 2021 Metformin use resulted in significant increase in luteinizing hormone (LH) and progesterone levels in males, while it was associated with significant increase in prolactin, follicular stimulating hormone (FSH), and dehydroepiandrostenedione-sulphate (DHEA-S) levels and significant decrease in total testosterone level in females. Metformin 0-9 prolactin Homo sapiens 162-171 34968572-8 2022 FSH, LH, and prolactin levels were higher in m-TESE-negative patients compared to micro-TESE-positive patients, and testosterone levels and testicular volume were lower in micro-TESE-negative patients compared to micro-TESE-positive patients. m-tese 45-51 prolactin Homo sapiens 13-22 34173929-0 2021 Anastrozole as add-on therapy for cabergoline-resistant prolactin-secreting pituitary adenomas: real-life experience in male patients. Cabergoline 34-45 prolactin Homo sapiens 56-65 34876549-12 2021 CONCLUSIONS Stinging nettle (Urtica dioica) is a common supplement and has effects on (1) sex hormone-binding globulin, (2) histamine-induced prolactin release, and (3) serotonin-induced release of thyrotropin-releasing hormone. Histamine 124-133 prolactin Homo sapiens 142-151 34871603-6 2022 Prolactin (PRL) and testosterone (T) levels were evaluated. Prolactin 11-14 prolactin Homo sapiens 0-9 34173929-6 2021 They were resistant to cabergoline (CAB, > 2 mg/week) in terms of PRL secretion and tumor size reduction. Cabergoline 23-34 prolactin Homo sapiens 66-69 34173929-12 2021 CONCLUSIONS: Addition of an aromatase inhibitor (ANA) to the dopamine agonist therapy improved the control of prolactin levels and induced tumour regression. Dopamine 61-69 prolactin Homo sapiens 110-119 34917030-10 2021 Conclusions: The rapid decrease in PRL levels induced by PS might improve lipid metabolism, whereas HD-CAB might exert a beneficial impact on both insulin secretion and peripheral sensitivity, thus inducing a global metabolic improvement. ps 57-59 prolactin Homo sapiens 35-38 34787912-0 2022 Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3-monthly from paliperidone palmitate 1-monthly: Preliminary findings of the first 3 months. Paliperidone Palmitate 136-158 prolactin Homo sapiens 30-39 34787912-0 2022 Prospective analysis of serum prolactin levels, clinical symptomatology and sexual functions in patients with schizophrenia switched to paliperidone palmitate 3-monthly from paliperidone palmitate 1-monthly: Preliminary findings of the first 3 months. Paliperidone Palmitate 174-196 prolactin Homo sapiens 30-39 34450525-3 2021 However, testosterone also plays a key factor in male sexual function and may be affected by abnormal prolactin levels through gonadotropin-releasing hormone inhibition. Testosterone 9-21 prolactin Homo sapiens 102-111 34833125-7 2021 HD-C, progesterone and myo-inositol resulted in increased motility, kinematic and hyperactivation parameters, whereas prolactin and myo-inositol improved the LM subpopulations" MMP intactness and reduced ROS. Reactive Oxygen Species 204-207 prolactin Homo sapiens 118-127 34773564-6 2022 The effects of TMZ were assessed based on its suppression of cell viability and reduction of prolactin (PRL) levels. Temozolomide 15-18 prolactin Homo sapiens 93-102 34738596-9 2021 Further, higher levels of LH and LH/FSH ratio and lower estradiol levels were observed in patients with normal prolactin levels. Estradiol 56-65 prolactin Homo sapiens 111-120 34581701-7 2021 High-density lipoprotein cholesterol levels were negatively correlated with prolactin levels in female subjects, and glucose levels were positively correlated with prolactin levels in male subjects, although clozapine doses showed no such correlations. Glucose 117-124 prolactin Homo sapiens 164-173 34261980-1 2021 BACKGROUND: Dopamine agonists such as bromocriptine and cabergoline have been found to be an effective treatment for hyperprolactinemia, not only inducing adenoma shrinkage but also lowering serum prolactin levels. Dopamine 12-20 prolactin Homo sapiens 197-206 34261980-1 2021 BACKGROUND: Dopamine agonists such as bromocriptine and cabergoline have been found to be an effective treatment for hyperprolactinemia, not only inducing adenoma shrinkage but also lowering serum prolactin levels. Bromocriptine 38-51 prolactin Homo sapiens 197-206 34261980-1 2021 BACKGROUND: Dopamine agonists such as bromocriptine and cabergoline have been found to be an effective treatment for hyperprolactinemia, not only inducing adenoma shrinkage but also lowering serum prolactin levels. Cabergoline 56-67 prolactin Homo sapiens 197-206 34623593-10 2021 This review intends to summarize the therapeutic mechanisms of renin-angiotensin inhibitors, matrix metalloproteinase-9 inhibitors and protein hormones (prolactin) on methamphetamine neurotoxicity. Methamphetamine 167-182 prolactin Homo sapiens 153-162 34581701-0 2021 Metabolic Effects of Clozapine Administration Based on Sex Differences and the Relationships Between Dosage and Prolactin Levels: An Observational Study. Clozapine 21-30 prolactin Homo sapiens 112-121 34581701-3 2021 This study aimed to investigate the effects of clozapine treatment on metabolic and neuroendocrine parameters, and the relationships between prescribed clozapine dosage and prolactin levels that may be associated with plasma clozapine concentrations, in 24 female and 24 male Japanese schizophrenia inpatients switched to clozapine. Clozapine 152-161 prolactin Homo sapiens 173-182 34581701-3 2021 This study aimed to investigate the effects of clozapine treatment on metabolic and neuroendocrine parameters, and the relationships between prescribed clozapine dosage and prolactin levels that may be associated with plasma clozapine concentrations, in 24 female and 24 male Japanese schizophrenia inpatients switched to clozapine. Clozapine 225-234 prolactin Homo sapiens 173-182 34581701-7 2021 High-density lipoprotein cholesterol levels were negatively correlated with prolactin levels in female subjects, and glucose levels were positively correlated with prolactin levels in male subjects, although clozapine doses showed no such correlations. Cholesterol 25-36 prolactin Homo sapiens 76-85 34871486-8 2021 There was a significant increase in the serum concentrations of prolactin when the mothers were administered metoclopramide. Metoclopramide 109-123 prolactin Homo sapiens 64-73 34690776-0 2021 Pharmacogenomics Factors Influencing the Effect of Risperidone on Prolactin Levels in Thai Pediatric Patients With Autism Spectrum Disorder. Risperidone 51-62 prolactin Homo sapiens 66-75 34481200-9 2021 Newer antipsychotics (risperidone, amisulpride and paliperidone) and older antipsychotics (chlorpromazine, haloperidol and sulpride) increase prolactin levels with large effect sizes. Risperidone 22-33 prolactin Homo sapiens 142-151 34481200-9 2021 Newer antipsychotics (risperidone, amisulpride and paliperidone) and older antipsychotics (chlorpromazine, haloperidol and sulpride) increase prolactin levels with large effect sizes. Amisulpride 35-46 prolactin Homo sapiens 142-151 34481200-9 2021 Newer antipsychotics (risperidone, amisulpride and paliperidone) and older antipsychotics (chlorpromazine, haloperidol and sulpride) increase prolactin levels with large effect sizes. Paliperidone Palmitate 51-63 prolactin Homo sapiens 142-151 34481200-9 2021 Newer antipsychotics (risperidone, amisulpride and paliperidone) and older antipsychotics (chlorpromazine, haloperidol and sulpride) increase prolactin levels with large effect sizes. Chlorpromazine 91-105 prolactin Homo sapiens 142-151 34481200-9 2021 Newer antipsychotics (risperidone, amisulpride and paliperidone) and older antipsychotics (chlorpromazine, haloperidol and sulpride) increase prolactin levels with large effect sizes. Haloperidol 107-118 prolactin Homo sapiens 142-151 34481200-9 2021 Newer antipsychotics (risperidone, amisulpride and paliperidone) and older antipsychotics (chlorpromazine, haloperidol and sulpride) increase prolactin levels with large effect sizes. sulpride 123-131 prolactin Homo sapiens 142-151 34481200-12 2021 In contrast to a previous review clozapine and zotepine were no longer associated with decreased prolactin levels compared to placebo. zotepine 47-55 prolactin Homo sapiens 97-106 34620143-2 2021 We aimed to determine the frequency of macroprolactinemia in Chinese hyperprolactinemic patients using monomeric prolactin discriminated by precipitation with polyethylene glycol (PEG). Polyethylene Glycols 159-178 prolactin Homo sapiens 113-122 34620143-2 2021 We aimed to determine the frequency of macroprolactinemia in Chinese hyperprolactinemic patients using monomeric prolactin discriminated by precipitation with polyethylene glycol (PEG). Polyethylene Glycols 180-183 prolactin Homo sapiens 113-122 34690776-1 2021 We investigated the association between genetic variations in pharmacodynamic genes and risperidone-induced increased prolactin levels in children and adolescents with autism spectrum disorder (ASD). Risperidone 88-99 prolactin Homo sapiens 118-127 34690776-6 2021 As the dose-corrected plasma levels of risperidone, 9-OH-risperidone, and the active moiety increased, prolactin levels in patients carrying the H1/H3 diplotype were significantly higher than those of the other diplotypes. Risperidone 39-50 prolactin Homo sapiens 103-112 34690776-6 2021 As the dose-corrected plasma levels of risperidone, 9-OH-risperidone, and the active moiety increased, prolactin levels in patients carrying the H1/H3 diplotype were significantly higher than those of the other diplotypes. Paliperidone Palmitate 52-68 prolactin Homo sapiens 103-112 34690776-7 2021 DRD2 diplotypes showed significantly high prolactin levels as plasma risperidone levels increased. Risperidone 69-80 prolactin Homo sapiens 42-51 34690776-8 2021 Lower levels of prolactin were detected in patients who responded to risperidone. Risperidone 69-80 prolactin Homo sapiens 16-25 34160838-7 2021 After excluding patients that underwent surgery and radiotherapy, cabergoline suppressed prolactin to below 3 x ULN in 32/35 (91%), 29/37 (78%), and 11/14 (79%) men in group A, B, and C, respectively (P = 0.27). Cabergoline 66-77 prolactin Homo sapiens 89-98 34076286-0 2021 Vitamin D status determines the impact of metformin on circulating prolactin levels in premenopausal women. Vitamin D 0-9 prolactin Homo sapiens 67-76 34076286-0 2021 Vitamin D status determines the impact of metformin on circulating prolactin levels in premenopausal women. Metformin 42-51 prolactin Homo sapiens 67-76 34076286-3 2021 The aim of the current study was to investigate whether vitamin D status determines the impact of metformin on prolactin levels in premenopausal women with hyperprolactinaemia. Vitamin D 56-65 prolactin Homo sapiens 111-120 34076286-3 2021 The aim of the current study was to investigate whether vitamin D status determines the impact of metformin on prolactin levels in premenopausal women with hyperprolactinaemia. Metformin 98-107 prolactin Homo sapiens 111-120 34076286-9 2021 Only in subjects with 25-hydroxyvitamin D levels within the reference range, metformin reduced prolactin levels. Metformin 77-86 prolactin Homo sapiens 95-104 34076286-10 2021 The impact on prolactin levels correlated with 25-hydroxyvitamin D levels and with the improvement in insulin sensitivity. 25-hydroxyvitamin D 47-66 prolactin Homo sapiens 14-23 34216041-0 2021 The impact of metformin on prolactin levels in postmenopausal women. Metformin 14-23 prolactin Homo sapiens 27-36 34216041-1 2021 WHAT IS KNOWN AND OBJECTIVE: Metformin-induced reduction in prolactin levels is more pronounced in users of hormonal contraception than in non-users. Metformin 29-38 prolactin Homo sapiens 60-69 34216041-8 2021 Although metformin reduced monomeric prolactin levels in both study groups, this effect was more pronounced in group 1 than in group 2. Metformin 9-18 prolactin Homo sapiens 37-46 34216041-9 2021 Only in group 1, metformin decreased total prolactin levels, while only in group 2 the drug reduced FSH levels. Metformin 17-26 prolactin Homo sapiens 43-52 34216041-11 2021 The impact of metformin on total and monomeric prolactin levels correlated with baseline prolactin levels and with the degree of improvement in insulin sensitivity. Metformin 14-23 prolactin Homo sapiens 47-56 34216041-11 2021 The impact of metformin on total and monomeric prolactin levels correlated with baseline prolactin levels and with the degree of improvement in insulin sensitivity. Metformin 14-23 prolactin Homo sapiens 89-98 34086261-6 2021 Plasma lipid levels, glucose homeostasis markers, as well as circulating levels of gonadotropins, testosterone, bioavailable testosterone, dehydroepiandrosterone-sulfate, prolactin, estradiol and creatinine were measured at the beginning of the study and 4 months later in 28 individuals in whom rosuvastatin reduced LDL cholesterol levels to below 70 mg/dL. Rosuvastatin Calcium 296-308 prolactin Homo sapiens 171-180